nct_id,start_year,agency_class,lead_or_collaborator,sponsor_name,phase
NCT00000117,1995.0,NIH,lead,National Eye Institute (NEI),Phase 3
NCT00000146,1988.0,NIH,lead,National Eye Institute (NEI),Phase 3
NCT00000147,1988.0,NIH,lead,National Eye Institute (NEI),Not Applicable
NCT00000151,1979.0,NIH,lead,National Eye Institute (NEI),Phase 3
NCT00000170,1999.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00000170,1999.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00000171,,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000172,,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00000173,1999.0,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000173,1999.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 3
NCT00000174,,INDUSTRY,lead,Novartis,Phase 3
NCT00000175,,NIH,lead,National Institute on Aging (NIA),Not Applicable
NCT00000176,,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000177,1995.0,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000178,,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000179,,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00000180,,NIH,lead,National Institute on Aging (NIA),Phase 1
NCT00000187,1992.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00000187,1992.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000188,1994.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00000188,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000189,1990.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00000189,1990.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000190,1991.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT00000190,1991.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000191,1991.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00000191,1991.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000197,1987.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000197,1987.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00000198,1996.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT00000198,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000199,,OTHER,lead,University of Pennsylvania,Phase 1
NCT00000199,,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000200,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000200,1997.0,OTHER,collaborator,Columbia University,Phase 2
NCT00000201,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000201,,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00000210,1989.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000210,1989.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT00000211,1989.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000211,1989.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT00000212,1987.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000212,1987.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000212,1987.0,OTHER,collaborator,Columbia University,Phase 2
NCT00000213,1990.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000213,1990.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000213,1990.0,OTHER,collaborator,Columbia University,Phase 2
NCT00000214,1992.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000214,1992.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000214,1992.0,OTHER,collaborator,Columbia University,Phase 2
NCT00000215,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000215,,OTHER,collaborator,Columbia University,Phase 2
NCT00000216,,OTHER,lead,Yale University,Phase 3
NCT00000216,,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00000217,1990.0,OTHER,lead,University of Kansas,Phase 2
NCT00000217,1990.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000217,1990.0,FED,collaborator,US Department of Veterans Affairs,Phase 2
NCT00000218,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00000218,,FED,collaborator,VA Office of Research and Development,Phase 4
NCT00000240,1999.0,OTHER,lead,University of Vermont,Phase 2
NCT00000240,1999.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000241,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000241,1994.0,OTHER,collaborator,"Friends Research Institute, Inc.",Phase 2
NCT00000242,1992.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00000242,1992.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000244,1994.0,OTHER,lead,University of Minnesota,Phase 2
NCT00000244,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000245,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000245,1994.0,OTHER,collaborator,"Friends Research Institute, Inc.",Phase 2
NCT00000246,1993.0,OTHER,lead,Yale University,Phase 2
NCT00000246,1993.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000248,1996.0,OTHER,lead,Medical University of South Carolina,Phase 3
NCT00000248,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00000249,1993.0,OTHER,lead,University of Chicago,Phase 2
NCT00000249,1993.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000250,1993.0,OTHER,lead,University of Chicago,Phase 2
NCT00000250,1993.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000251,1994.0,OTHER,lead,University of Chicago,Phase 2
NCT00000251,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000252,1994.0,OTHER,lead,University of Chicago,Phase 2
NCT00000252,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000253,1994.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000253,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000254,1995.0,OTHER,lead,University of Chicago,Phase 2
NCT00000254,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000255,1995.0,OTHER,lead,University of Chicago,Phase 2
NCT00000255,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000256,1995.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000256,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000257,1995.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000257,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000259,1996.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000259,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000260,1997.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000260,1997.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000261,1997.0,OTHER,lead,University of Chicago,Phase 2
NCT00000261,1997.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000262,1996.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000262,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000263,1997.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000263,1997.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000264,1997.0,OTHER,lead,University of Chicago,Not Applicable
NCT00000264,1997.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000266,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000266,1994.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT00000267,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000267,,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT00000268,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00000268,1995.0,OTHER,collaborator,New York State Psychiatric Institute,Not Applicable
NCT00000269,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000269,1995.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT00000270,1995.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00000270,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00000271,1995.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000271,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000273,1995.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000273,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000274,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000274,1997.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT00000275,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000275,1996.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT00000276,1994.0,OTHER,lead,Yale University,Phase 1
NCT00000276,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000276,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 1
NCT00000277,1994.0,OTHER,lead,Yale University,Phase 2
NCT00000277,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000277,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 2
NCT00000278,1994.0,OTHER,lead,Yale University,Phase 2
NCT00000278,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000278,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 2
NCT00000279,1994.0,OTHER,lead,Yale University,Phase 2
NCT00000279,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000279,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 2
NCT00000280,1994.0,OTHER,lead,Yale University,Phase 1
NCT00000280,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000280,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 1
NCT00000282,1994.0,OTHER,lead,Yale University,Phase 2
NCT00000282,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000282,1994.0,FED,collaborator,VA Connecticut Healthcare System,Phase 2
NCT00000284,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000284,1995.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000285,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000285,1996.0,OTHER,collaborator,University of Minnesota,Phase 1
NCT00000286,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000286,1996.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000288,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000288,1995.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000289,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000289,1998.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000290,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000290,1997.0,OTHER,collaborator,University of Minnesota,Phase 1
NCT00000291,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000291,1997.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000292,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000292,1996.0,OTHER,collaborator,University of Minnesota,Phase 1
NCT00000293,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00000293,1999.0,OTHER,collaborator,University of Minnesota,Phase 3
NCT00000294,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000294,1998.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000295,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000295,1999.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000296,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000296,1997.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000297,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000297,1998.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00000301,1996.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00000301,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000303,1997.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00000303,1997.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000304,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000304,1997.0,OTHER,collaborator,University of Texas,Phase 2
NCT00000305,,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT00000305,,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000305,,OTHER,collaborator,University of Texas,Phase 1
NCT00000306,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000306,1994.0,OTHER,collaborator,University of Texas,Phase 2
NCT00000307,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000307,2003.0,OTHER,collaborator,University of Texas,Phase 2
NCT00000308,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000308,1995.0,OTHER,collaborator,University of Texas,Phase 2
NCT00000309,1994.0,OTHER,lead,Butler Hospital,Phase 2
NCT00000309,1994.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000309,1994.0,FED,collaborator,VA Boston Healthcare System,Phase 2
NCT00000310,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000310,1996.0,FED,collaborator,VA Boston Healthcare System,Phase 2
NCT00000311,1995.0,OTHER,lead,Yale University,Phase 3
NCT00000311,1995.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00000312,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000312,,FED,collaborator,US Department of Veterans Affairs,Phase 1
NCT00000313,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000313,,FED,collaborator,VA Office of Research and Development,Phase 1
NCT00000314,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000314,1994.0,FED,collaborator,VA Office of Research and Development,Phase 2
NCT00000315,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000315,1996.0,OTHER,collaborator,Johns Hopkins University,Phase 1
NCT00000316,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000316,1996.0,OTHER,collaborator,Johns Hopkins University,Phase 1
NCT00000317,1996.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00000317,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000317,1996.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT00000318,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000318,1994.0,OTHER,collaborator,Yale University,Phase 2
NCT00000319,1996.0,OTHER,lead,Yale University,Phase 2
NCT00000319,1996.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000321,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00000321,1996.0,OTHER,collaborator,"Friends Research Institute, Inc.",Phase 4
NCT00000322,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000324,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000324,1997.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00000332,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000332,1998.0,FED,collaborator,Washington D.C. Veterans Affairs Medical Center,Phase 2
NCT00000333,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000333,2001.0,FED,collaborator,Washington D.C. Veterans Affairs Medical Center,Phase 2
NCT00000336,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000337,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000338,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000339,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000340,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000342,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000346,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00000347,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000348,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000349,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000352,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000352,1996.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00000353,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000353,1996.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00000354,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000354,1996.0,OTHER,collaborator,University of Pennsylvania,Phase 1
NCT00000355,1994.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000355,1994.0,OTHER,collaborator,University of Pennsylvania,Phase 1
NCT00000356,1991.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000356,1991.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00000357,1992.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00000357,1992.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00000358,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00000358,,OTHER,collaborator,University of Pennsylvania,Phase 1
NCT00000361,1998.0,NIH,lead,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 3
NCT00000367,1998.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT00000367,1998.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00000368,1999.0,OTHER,lead,New York State Psychiatric Institute,Phase 3
NCT00000368,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00000369,1997.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00000371,1996.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00000372,1998.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00000373,1992.0,OTHER,lead,University of Florida,Phase 4
NCT00000373,1992.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00000374,1998.0,OTHER,lead,Northwell Health,Phase 4
NCT00000374,1998.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00000374,1998.0,OTHER,collaborator,The Zucker Hillside Hospital,Phase 4
NCT00000376,1996.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT00000376,1996.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00000377,1989.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00000377,1989.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00000378,1997.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00000378,1997.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00000379,1999.0,OTHER,lead,Boston University,Phase 3
NCT00000379,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00000380,1996.0,OTHER,lead,University of Washington,Not Applicable
NCT00000380,1996.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00000381,1997.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00000381,1997.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00000384,1997.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT00000384,1997.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00000385,1997.0,OTHER,lead,Drexel University,Phase 3
NCT00000385,1997.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00000388,1998.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00000388,1998.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00000389,1996.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00000390,,INDUSTRY,lead,GEIGY Pharmaceuticals,Phase 2
NCT00000392,1990.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00000393,1988.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00000428,2000.0,OTHER,lead,Tufts Medical Center,Phase 4
NCT00000428,2000.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 4
NCT00000439,2000.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00000439,2000.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT00000446,,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00000448,1995.0,OTHER,lead,Yale University,Phase 4
NCT00000448,1995.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00000458,,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00000469,1988.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00000479,1992.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT00000479,1992.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00000479,1992.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00000514,1984.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00000514,1984.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00000517,1985.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00000517,1985.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00000527,1986.0,OTHER,lead,Emory University,Phase 2
NCT00000527,1986.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00000599,1980.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00000600,1995.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00000613,1997.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00000639,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000639,,OTHER,collaborator,Washington University School of Medicine,Not Applicable
NCT00000643,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000648,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000648,,INDUSTRY,collaborator,Hoffmann-La Roche,Not Applicable
NCT00000657,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000657,,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT00000657,,INDUSTRY,collaborator,Glaxo Wellcome,Phase 2
NCT00000666,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000674,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000674,,INDUSTRY,collaborator,Upjohn,Not Applicable
NCT00000674,,INDUSTRY,collaborator,Glaxo Wellcome,Not Applicable
NCT00000677,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00000677,,INDUSTRY,collaborator,Schering-Plough,Phase 1
NCT00000702,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00000708,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000709,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00000738,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00000738,,INDUSTRY,collaborator,Miles,Phase 1
NCT00000738,,INDUSTRY,collaborator,Glaxo Wellcome,Phase 1
NCT00000776,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000793,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000793,,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 2
NCT00000794,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000817,1994.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000842,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000867,1996.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00000945,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00000966,,INDUSTRY,lead,Pfizer,Phase 1
NCT00000966,,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00000973,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00000973,,INDUSTRY,collaborator,Glaxo Wellcome,Phase 1
NCT00001017,,INDUSTRY,lead,Pfizer,Phase 3
NCT00001017,,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00001048,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00001048,,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT00001048,,INDUSTRY,collaborator,Upjohn,Phase 2
NCT00001146,1999.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00001234,1988.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00001251,1989.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00001261,1990.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001262,1990.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00001287,1990.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001328,1992.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00001333,1993.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00001344,1993.0,NIH,lead,National Institute of Dental and Craniofacial Research (NIDCR),Phase 2
NCT00001365,1993.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001410,1993.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00001416,1993.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001421,1995.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00001482,1995.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00001483,1995.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00001487,1995.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00001502,1996.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00001520,1996.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 4
NCT00001550,1996.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00001565,1996.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00001656,1997.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00001658,1997.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00001662,1996.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001669,1997.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001723,1998.0,NIH,lead,Jack Yanovski,Phase 2
NCT00001723,1998.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00001723,1998.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 2
NCT00001725,1997.0,NIH,lead,National Institute of Dental and Craniofacial Research (NIDCR),Phase 2
NCT00001768,1997.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00001777,1997.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00001781,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001783,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001784,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001785,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001860,1999.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT00001864,1999.0,NIH,lead,National Eye Institute (NEI),Phase 3
NCT00001925,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001929,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001930,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001931,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001933,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001934,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00001956,2000.0,NIH,lead,National Institute of Dental and Craniofacial Research (NIDCR),Phase 2
NCT00001986,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00001994,,INDUSTRY,lead,Glaxo Wellcome,Not Applicable
NCT00002010,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002019,,INDUSTRY,lead,Liposome,Not Applicable
NCT00002040,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002044,,INDUSTRY,lead,Glaxo Wellcome,Not Applicable
NCT00002064,,OTHER,lead,Palo Alto Medical Foundation,Not Applicable
NCT00002068,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002074,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002075,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002076,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002077,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002083,,INDUSTRY,lead,Advanced Peptides,Not Applicable
NCT00002113,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002163,,INDUSTRY,lead,Glaxo Wellcome,Phase 3
NCT00002209,,INDUSTRY,lead,Centaur Pharmaceuticals,Phase 1
NCT00002246,1997.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 3
NCT00002270,,OTHER,lead,University of Miami,Not Applicable
NCT00002274,,INDUSTRY,lead,Bristol-Myers Squibb,Not Applicable
NCT00002294,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002305,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002306,,INDUSTRY,lead,Pfizer,Not Applicable
NCT00002316,,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT00002395,,INDUSTRY,lead,SmithKline Beecham,Phase 2
NCT00002520,1990.0,NETWORK,lead,Eastern Cooperative Oncology Group,Not Applicable
NCT00002520,1990.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00002594,1994.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00002594,1994.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00002875,1996.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT00002875,1996.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00002875,1996.0,OTHER,collaborator,Pediatric Oncology Group,Phase 3
NCT00002944,1997.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT00002944,1997.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00003141,1998.0,NETWORK,lead,Children's Oncology Group,Phase 1
NCT00003141,1998.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00003203,1998.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00003203,1998.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00003483,1998.0,OTHER,lead,Burzynski Research Institute,Phase 2
NCT00003514,,OTHER,lead,Burzynski Research Institute,Phase 2
NCT00003573,1998.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00003573,1998.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00003625,1998.0,NETWORK,lead,Children's Oncology Group,Phase 1
NCT00003625,1998.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00003935,1999.0,NETWORK,lead,Children's Oncology Group,Phase 1
NCT00003935,1999.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00004268,2001.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004268,2001.0,INDUSTRY,collaborator,Roberts Pharmaceutical,Phase 2
NCT00004286,1996.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004286,1996.0,OTHER,collaborator,University of Vermont,Phase 3
NCT00004293,1999.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004293,1999.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT00004294,1999.0,NIH,lead,National Center for Research Resources (NCRR),Phase 1
NCT00004294,1999.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1
NCT00004294,1999.0,OTHER,collaborator,University of Pittsburgh,Phase 1
NCT00004297,1995.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004297,1995.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT00004300,,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00004300,,OTHER,collaborator,University of Florida,Phase 2
NCT00004310,1999.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004310,1999.0,OTHER,collaborator,Stanford University,Phase 2
NCT00004314,1996.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004314,1996.0,OTHER,collaborator,"University of California, San Diego",Phase 2
NCT00004338,1993.0,NIH,lead,National Center for Research Resources (NCRR),Phase 4
NCT00004338,1993.0,OTHER,collaborator,University of Michigan,Phase 4
NCT00004339,1994.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004339,1994.0,OTHER,collaborator,University of Michigan,Phase 3
NCT00004357,1997.0,OTHER,lead,Northwestern University,Phase 2
NCT00004357,1997.0,OTHER,collaborator,Ann & Robert H Lurie Children's Hospital of Chicago,Phase 2
NCT00004373,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00004373,1997.0,OTHER,collaborator,University of Texas,Phase 2
NCT00004376,1994.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004376,1994.0,OTHER,collaborator,Yale University,Phase 3
NCT00004386,1995.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT00004386,1995.0,OTHER,collaborator,Children's National Research Institute,Phase 1
NCT00004393,1997.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004393,1997.0,OTHER,collaborator,Yale University,Phase 2
NCT00004401,1998.0,OTHER,lead,California Department of Health Services,Not Applicable
NCT00004403,2000.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00004407,1998.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT00004418,1998.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT00004431,1998.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00004433,1994.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT00004442,,OTHER,lead,University of Cincinnati,Not Applicable
NCT00004442,,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT00004446,1998.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00004446,1998.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00004450,1998.0,FED,lead,FDA Office of Orphan Products Development,Not Applicable
NCT00004450,1998.0,OTHER,collaborator,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Not Applicable
NCT00004451,1998.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00004451,1998.0,OTHER,collaborator,University of Virginia,Not Applicable
NCT00004454,1996.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00004454,1996.0,OTHER,collaborator,University of Minnesota,Phase 1/Phase 2
NCT00004478,1999.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00004479,1999.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00004480,1999.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00004488,1998.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00004498,1998.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT00004554,2000.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00004576,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00004637,,NIH,lead,National Center for Research Resources (NCRR),Phase 4
NCT00004646,1995.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004646,1995.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004646,1995.0,OTHER,collaborator,University of Rochester,Phase 3
NCT00004647,1993.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004647,1993.0,OTHER,collaborator,University of Tennessee,Phase 3
NCT00004652,1993.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004652,1993.0,OTHER,collaborator,University of Rochester,Phase 2
NCT00004682,1995.0,OTHER,lead,University of Texas,Not Applicable
NCT00004685,1998.0,OTHER,lead,Ohio State University,Not Applicable
NCT00004686,1994.0,OTHER,lead,The Cleveland Clinic,Phase 2
NCT00004727,,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00004728,,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004730,1998.0,OTHER,lead,University of Washington,Phase 3
NCT00004731,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00004733,1998.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004734,1996.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004744,1993.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004744,1993.0,OTHER,collaborator,Mayo Clinic,Phase 3
NCT00004758,1993.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004758,1993.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00004758,1993.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT00004759,1991.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004759,1991.0,OTHER,collaborator,Yale University,Phase 3
NCT00004770,1995.0,NIH,lead,National Center for Research Resources (NCRR),Not Applicable
NCT00004770,1995.0,OTHER,collaborator,University of Rochester,Not Applicable
NCT00004771,1992.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004771,1992.0,OTHER,collaborator,Ohio State University,Phase 2
NCT00004772,1992.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004772,1992.0,OTHER,collaborator,Ohio State University,Phase 3
NCT00004776,1993.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004776,1993.0,OTHER,collaborator,"University of California, Los Angeles",Phase 3
NCT00004796,1994.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00004796,1994.0,OTHER,collaborator,Northwestern University,Phase 2
NCT00004802,1992.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004802,1992.0,OTHER,collaborator,Ohio State University,Phase 3
NCT00004807,1995.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00004807,1995.0,OTHER,collaborator,Johns Hopkins University,Not Applicable
NCT00004814,1991.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004814,1991.0,OTHER,collaborator,University of Maryland,Phase 3
NCT00004816,1995.0,NIH,lead,National Center for Research Resources (NCRR),Phase 1
NCT00004816,1995.0,OTHER,collaborator,Stanford University,Phase 1
NCT00004817,1991.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00004817,1991.0,OTHER,collaborator,Harborview Injury Prevention and Research Center,Phase 3
NCT00004826,1993.0,OTHER,lead,Memorial Hospital of Rhode Island,Not Applicable
NCT00004833,1995.0,OTHER,lead,Emory University,Not Applicable
NCT00004834,1998.0,OTHER,lead,Northwell Health,Not Applicable
NCT00004834,1998.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00004834,1998.0,OTHER,collaborator,Long Island Jewish Medical Center,Not Applicable
NCT00004845,,NIH,lead,National Institute on Aging (NIA),Phase 2/Phase 3
NCT00004845,,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2/Phase 3
NCT00004939,1996.0,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00004939,1996.0,OTHER,collaborator,Mayo Clinic,Phase 3
NCT00005015,,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00005571,2000.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00005574,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00005658,2000.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00005674,,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00005674,,OTHER,collaborator,Muscular Dystrophy Association,Phase 2
NCT00005766,,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00005812,2000.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 2
NCT00005812,2000.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00005850,2001.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 2
NCT00005850,2001.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00005903,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00005925,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00006024,2000.0,NETWORK,lead,Children's Oncology Group,Phase 1
NCT00006024,2000.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00006055,2000.0,OTHER,lead,Fairview University Medical Center,Not Applicable
NCT00006072,,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00006072,,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00006077,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00006170,2000.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00006170,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00006180,2000.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00006187,,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00006195,,NIH,lead,National Center for Research Resources (NCRR),Not Applicable
NCT00006195,,INDUSTRY,collaborator,"Janssen, LP",Not Applicable
NCT00006195,,OTHER,collaborator,Washington University School of Medicine,Not Applicable
NCT00006204,2000.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00006286,1998.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00006289,2000.0,NIH,lead,National Institute of Nursing Research (NINR),Phase 2
NCT00006289,2000.0,NIH,collaborator,National Institutes of Health Clinical Center (CC),Phase 2
NCT00006289,2000.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00006289,2000.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00006337,2000.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00006349,2001.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 3
NCT00006349,2001.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00006399,1999.0,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00006399,1999.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT00006399,1999.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00006399,1999.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2
NCT00006428,1996.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT00006448,1996.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00006450,2000.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00006488,,NIH,lead,National Center for Research Resources (NCRR),Phase 1
NCT00006489,2000.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00006489,2000.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00007020,1992.0,INDUSTRY,lead,"Mirum Pharmaceuticals, Inc.",Phase 3
NCT00007020,1992.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT00007189,2001.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 3
NCT00007189,2001.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00007189,2001.0,FED,collaborator,VA Puget Sound Health Care System,Phase 3
NCT00007189,2001.0,OTHER,collaborator,University of Washington,Phase 3
NCT00007189,2001.0,OTHER,collaborator,Johns Hopkins University,Phase 3
NCT00007501,1998.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00007501,1998.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 3
NCT00007501,1998.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00007605,1998.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00007670,1998.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00007670,1998.0,INDUSTRY,collaborator,Parke-Davis,Phase 3
NCT00007670,1998.0,INDUSTRY,collaborator,Glaxo Wellcome,Phase 3
NCT00007774,1998.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00007774,1998.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00009048,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00009178,1998.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT00009191,2005.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT00009191,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00009204,1995.0,OTHER,lead,Bruce Pollock,Phase 3
NCT00009204,1995.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00009217,1999.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00009217,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00009230,2000.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00009230,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00009620,1993.0,NETWORK,lead,NICHD Neonatal Research Network,Phase 3
NCT00009620,1993.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 3
NCT00009672,2001.0,NIH,lead,National Institute of Dental and Craniofacial Research (NIDCR),Phase 2
NCT00010335,2000.0,OTHER,lead,Fred Hutchinson Cancer Center,Phase 1
NCT00010803,2000.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00010803,2000.0,NIH,collaborator,Office of Dietary Supplements (ODS),Phase 3
NCT00010803,2000.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00010803,2000.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00010803,2000.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00010842,1999.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00010868,2000.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00010868,2000.0,INDUSTRY,collaborator,Pronova BioPharma,Phase 2
NCT00010881,1999.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00010920,1999.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00011375,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00011804,2001.0,NIH,lead,National Institute of Dental and Craniofacial Research (NIDCR),Phase 2
NCT00012454,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00012467,2000.0,INDUSTRY,lead,InterMune,Phase 2
NCT00012558,1998.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00012584,2000.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00013182,,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00013182,,FED,collaborator,Central Arkansas Veterans Healthcare System,Not Applicable
NCT00013182,,OTHER,collaborator,University of Arkansas,Not Applicable
NCT00013585,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00013585,,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00013585,,OTHER,collaborator,Neurologic AIDS Research Consortium (NARC),Phase 2
NCT00013624,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00013650,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00013923,,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT00013923,,OTHER,collaborator,Burke Medical Research Institute,Phase 2
NCT00014001,2000.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00014755,1997.0,OTHER,lead,Fred Hutchinson Cancer Center,Phase 1
NCT00014989,1997.0,OTHER,lead,The George Washington University Biostatistics Center,Phase 3
NCT00014989,1997.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00014989,1997.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00015028,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015028,1996.0,OTHER,collaborator,Cincinnati MDRU,Phase 2
NCT00015041,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00015041,1996.0,OTHER,collaborator,Cincinnati MDRU,Phase 1
NCT00015054,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015054,1998.0,OTHER,collaborator,Cincinnati MDRU,Phase 2
NCT00015067,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00015067,1997.0,OTHER,collaborator,Cincinnati MDRU,Phase 1
NCT00015080,1995.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015080,1995.0,OTHER,collaborator,Cincinnati MDRU,Phase 2
NCT00015106,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015132,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015171,1996.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00015171,1996.0,OTHER,collaborator,New York MDRU,Phase 3
NCT00015210,1997.0,OTHER,lead,Boston Medical Center,Phase 2
NCT00015210,1997.0,OTHER,collaborator,Boston University,Phase 2
NCT00015223,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00015223,1997.0,OTHER,collaborator,Cincinnati MDRU,Phase 2
NCT00015249,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00015249,1997.0,OTHER,collaborator,New York MDRU,Phase 1
NCT00015301,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00015301,2003.0,OTHER,collaborator,New York MDRU,Phase 4
NCT00015340,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00015340,1999.0,OTHER,collaborator,New York MDRU,Phase 4
NCT00015548,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00015769,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00015808,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00016653,2000.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 2/Phase 3
NCT00016679,2001.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00017628,2001.0,OTHER,lead,Northwestern Memorial Hospital,Phase 1
NCT00017940,,OTHER,lead,The Shiley Family Trust,Phase 1
NCT00017940,,OTHER,collaborator,Institute for the Study of Aging (ISOA),Phase 1
NCT00017940,,OTHER,collaborator,"University of California, San Diego",Phase 1
NCT00018057,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00018057,2001.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00018057,2001.0,OTHER,collaborator,University of Oregon,Phase 2
NCT00018057,2001.0,OTHER,collaborator,University of Maryland,Phase 2
NCT00018109,,NIH,lead,National Center for Research Resources (NCRR),Phase 3
NCT00018109,,OTHER,collaborator,Children's National Research Institute,Phase 3
NCT00018174,1998.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00018174,1998.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00018200,1999.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00018278,1998.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00018291,2001.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00018343,1998.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00018356,1999.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00018382,1999.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00018564,2000.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00018603,1999.0,FED,lead,US Department of Veterans Affairs,Phase 1
NCT00018642,1997.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00018668,2000.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00018733,1996.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00018759,2001.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00018759,2001.0,INDUSTRY,collaborator,SmithKline Beecham,Phase 4
NCT00018824,1999.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00018850,1998.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00018902,2001.0,OTHER,lead,University of Pittsburgh,Phase 2/Phase 3
NCT00018902,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00019630,1999.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00021528,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00021541,2001.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00021697,2001.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 3
NCT00021723,2001.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00021723,2001.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00022074,2001.0,OTHER,lead,Gary Morrow,Not Applicable
NCT00022074,2001.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00023283,2000.0,OTHER,lead,Yale University,Phase 2
NCT00023283,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00023634,2001.0,NETWORK,lead,SWOG Cancer Research Network,Phase 1
NCT00023634,2001.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00024531,2000.0,OTHER,lead,Institute for the Study of Aging (ISOA),Phase 2
NCT00024531,2000.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00025740,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00025779,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00025792,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00025896,2001.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00026039,1993.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00026052,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00026585,2001.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00026637,2001.0,OTHER,lead,Columbia University,Phase 3
NCT00026637,2001.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00026988,2001.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00027066,1993.0,OTHER,lead,Columbia University,Phase 3
NCT00027066,1993.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00027209,,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00027300,2001.0,INDUSTRY,lead,Biogen,Phase 3
NCT00027300,2001.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 3
NCT00027378,2001.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00027378,2001.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00027391,2001.0,FED,lead,FDA Office of Orphan Products Development,Not Applicable
NCT00027430,2001.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00027846,2003.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00027846,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00029146,2002.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 3
NCT00029146,2002.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00029146,2002.0,OTHER,collaborator,Washington University School of Medicine,Phase 3
NCT00029146,2002.0,OTHER,collaborator,University of Iowa,Phase 3
NCT00029315,2001.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00029458,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00029497,,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00029523,2001.0,INDUSTRY,lead,"Pacira Pharmaceuticals, Inc",Phase 4
NCT00029536,2000.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Columbia University,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Emory University,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Johns Hopkins University,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Montreal Neurological Institute and Hospital,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Ohio State University,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Thomas Jefferson University,Phase 3
NCT00029536,2000.0,OTHER,collaborator,University of Maryland,Phase 3
NCT00029536,2000.0,OTHER,collaborator,University of Southern California,Phase 3
NCT00029536,2000.0,OTHER,collaborator,University of Virginia,Phase 3
NCT00029536,2000.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 3
NCT00029536,2000.0,UNKNOWN,collaborator,Minnesota Comprehensive Epilepsy Program,Phase 3
NCT00029614,2006.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00029614,2006.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00029874,2001.0,FED,lead,FDA Office of Orphan Products Development,Phase 1/Phase 2
NCT00030147,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00030264,2001.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT00030966,2002.0,INDUSTRY,lead,Biogen,Phase 3
NCT00030966,2002.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 3
NCT00030979,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00031018,,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00031018,,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00031317,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00031486,2000.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00031590,2001.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT00031590,2001.0,OTHER,collaborator,Stanford University,Phase 2
NCT00031590,2001.0,OTHER,collaborator,Emory University,Phase 2
NCT00031798,2002.0,OTHER,lead,Wake Forest University Health Sciences,Phase 3
NCT00031798,2002.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00032695,,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00032734,2001.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00032916,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00032929,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00032929,2001.0,INDUSTRY,collaborator,Somerset Pharmaceuticals,Phase 3
NCT00032955,2001.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00032968,2001.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00033033,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00033033,2001.0,OTHER_GOV,collaborator,Cincinnati VA Medical Center,Phase 2
NCT00033046,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00033059,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00033072,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00033085,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00033085,2001.0,OTHER,collaborator,University of Texas,Phase 2
NCT00033098,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00033098,2001.0,OTHER_GOV,collaborator,Cincinnati VA Medical Center,Phase 1
NCT00033111,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00033111,2001.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT00033189,2001.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 2
NCT00033813,2002.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 2
NCT00033891,2002.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00034021,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00034229,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00034242,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00034580,2001.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00034697,2001.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00034710,2002.0,INDUSTRY,lead,NeurogesX,Phase 2
NCT00034749,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00034762,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00034775,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00034788,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00034801,2001.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00034814,2002.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00034892,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00034892,2002.0,OTHER,collaborator,University of North Carolina,Phase 3
NCT00034905,2001.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00035139,,NIH,lead,National Center for Research Resources (NCRR),Phase 4
NCT00035139,,OTHER,collaborator,Murray Fellowship,Phase 4
NCT00035191,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00035204,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00035204,,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00035230,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00035412,2001.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00035438,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00035529,2001.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT00035802,2002.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00035815,2003.0,OTHER,lead,Mayo Clinic,Phase 3
NCT00035815,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00035815,2003.0,OTHER,collaborator,ALS Association,Phase 3
NCT00035815,2003.0,INDUSTRY,collaborator,Cephalon,Phase 3
NCT00035958,2002.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2/Phase 3
NCT00035958,2002.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2/Phase 3
NCT00035958,2002.0,INDUSTRY,collaborator,Immunex Corporation,Phase 2/Phase 3
NCT00036088,2001.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00036101,2002.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00036114,2000.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00036127,2002.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2/Phase 3
NCT00036205,2000.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00036218,2001.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00036296,2006.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 1/Phase 2
NCT00036309,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00036335,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00036348,2000.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00036361,2002.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00036361,2002.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00036413,2002.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00036582,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00036881,2002.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 3
NCT00036881,2002.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00037102,2001.0,OTHER,lead,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,Phase 4
NCT00037102,2001.0,INDUSTRY,collaborator,Consultants in Neurology,Phase 4
NCT00037102,2001.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT00037115,2002.0,OTHER,lead,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,Phase 4
NCT00037115,2002.0,INDUSTRY,collaborator,Consultants in Neurology,Phase 4
NCT00037479,1999.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00037674,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00037830,1999.0,OTHER,lead,Thomas Jefferson University,Phase 2
NCT00037830,1999.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00038389,2001.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT00038441,1995.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1/Phase 2
NCT00038441,1995.0,INDUSTRY,collaborator,Direct Therapeutics,Phase 1/Phase 2
NCT00038896,2001.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00039832,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00039988,2001.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00039988,2001.0,OTHER,collaborator,Autoimmunity Centers of Excellence,Not Applicable
NCT00040040,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00040040,2002.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1
NCT00040053,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00040053,2002.0,OTHER,collaborator,University of Texas,Phase 2
NCT00040209,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00040261,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT00040326,2002.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00040404,2002.0,INDUSTRY,lead,Cephalon,Phase 2/Phase 3
NCT00040404,2002.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2/Phase 3
NCT00040404,2002.0,NETWORK,collaborator,The Parkinson Study Group,Phase 2/Phase 3
NCT00040482,1999.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00040482,1999.0,OTHER,collaborator,The Methodist Hospital Research Institute,Phase 2
NCT00040482,1999.0,OTHER,collaborator,"Center for Cell and Gene Therapy, Baylor College of Medicine",Phase 2
NCT00040560,,INDUSTRY,lead,Copharos,Phase 1
NCT00040573,2002.0,INDUSTRY,lead,TransMolecular,Phase 1/Phase 2
NCT00041392,2001.0,OTHER,lead,Duke University,Phase 2
NCT00041392,2001.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00041535,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00041678,2000.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00041717,2002.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00041795,2002.0,INDUSTRY,lead,NeoTherapeutics,Phase 2
NCT00041938,2002.0,OTHER,lead,Columbia University,Phase 3
NCT00041938,2002.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00042146,2001.0,OTHER,lead,Laval University,Phase 4
NCT00042146,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00042172,2002.0,OTHER,lead,University of Iowa,Phase 4
NCT00042172,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00042224,2000.0,OTHER,lead,Northwell Health,Phase 1/Phase 2
NCT00042224,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT00042237,2001.0,OTHER,lead,Butler Hospital,Phase 1
NCT00042237,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00042367,2000.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,Duke University,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,St. Jude Children's Research Hospital,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,Children's National Research Institute,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,Seattle Children's Hospital,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,Dana-Farber Cancer Institute,Not Applicable
NCT00042367,2000.0,OTHER,collaborator,"University of California, San Francisco",Not Applicable
NCT00042380,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00043264,,NIH,lead,National Center for Research Resources (NCRR),Phase 2
NCT00043264,,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT00043550,2001.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT00043550,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00043589,2002.0,OTHER,lead,Stanford University,Not Applicable
NCT00043589,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00043654,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00043849,2002.0,NIH,lead,National Institute on Aging (NIA),Phase 4
NCT00043875,2000.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00043901,2000.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00043914,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00044005,2002.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00044044,2002.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00044070,2000.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 2
NCT00044070,2000.0,INDUSTRY,collaborator,"Astellas Pharma US, Inc.",Phase 2
NCT00044083,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00044187,2001.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00044278,2000.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00044395,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00044408,2002.0,INDUSTRY,lead,"Chromaderm, Inc.",Phase 3
NCT00044421,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00044616,2001.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00044616,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00044629,2001.0,OTHER,lead,Duke University,Phase 2
NCT00044629,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00044642,2000.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00044642,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00044655,2001.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00044655,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00044681,2002.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00044681,2002.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00044772,2001.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00044798,2001.0,OTHER,lead,University of Iowa,Phase 3
NCT00044798,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00044915,2000.0,INDUSTRY,lead,Bayer,Phase 2
NCT00045916,2001.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00045916,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00045968,2006.0,INDUSTRY,lead,Northwest Biotherapeutics,Phase 3
NCT00046163,2002.0,INDUSTRY,lead,Shire,Phase 4
NCT00046293,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00046358,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00046475,1997.0,INDUSTRY,lead,Shire,Phase 4
NCT00046722,2003.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00046761,2002.0,INDUSTRY,lead,Ono Pharma USA Inc,Phase 2/Phase 3
NCT00046813,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00047320,2004.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00047320,2004.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00047450,2001.0,OTHER,lead,Veterans Medical Research Foundation,Not Applicable
NCT00047450,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00047567,2002.0,INDUSTRY,lead,Elan Pharmaceuticals,Phase 4
NCT00047580,2002.0,INDUSTRY,lead,Elan Pharmaceuticals,Phase 3
NCT00047671,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00047723,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00048646,2002.0,OTHER,lead,David Wright,Phase 1/Phase 2
NCT00048646,2002.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00048802,2002.0,OTHER,lead,Northwell Health,Phase 4
NCT00048802,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00048815,2003.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00048815,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00048815,2003.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00048815,2003.0,NIH,collaborator,Office of Dietary Supplements (ODS),Not Applicable
NCT00048828,2001.0,OTHER,lead,Northwell Health,Phase 4
NCT00048828,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00048906,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00049803,2000.0,INDUSTRY,lead,Orphan Medical,Phase 3
NCT00049946,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00050206,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00050232,2002.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 3
NCT00050245,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00050271,,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Not Applicable
NCT00050271,,OTHER,collaborator,Neurologic AIDS Research Consortium (NARC),Not Applicable
NCT00050778,2002.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00050778,2002.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT00050804,2002.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00050934,2002.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00050947,2002.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00051298,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00051402,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00051896,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00051909,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00051935,2003.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00052078,2003.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT00052078,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00053417,2003.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT00053573,2003.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1/Phase 2
NCT00053599,2002.0,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00053599,2002.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 3
NCT00053677,2002.0,OTHER,lead,University of Chicago,Phase 3
NCT00053677,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00053703,2002.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT00053703,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00053937,2002.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00054704,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00054730,2002.0,INDUSTRY,lead,RespireRx,Phase 2
NCT00054730,2002.0,OTHER,collaborator,FRAXA Research Foundation,Phase 2
NCT00054756,2003.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT00054795,,INDUSTRY,lead,Pharmacyclics LLC.,Phase 3
NCT00055393,2002.0,OTHER,lead,University of Iowa,Not Applicable
NCT00055393,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00055484,2002.0,INDUSTRY,lead,Elan Pharmaceuticals,Phase 2
NCT00055549,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00055575,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00056199,2003.0,NIH,lead,National Eye Institute (NEI),Phase 1
NCT00056225,2003.0,NIH,lead,National Institute on Aging (NIA),Phase 3
NCT00056225,2003.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 3
NCT00056238,2003.0,INDUSTRY,lead,Bellus Health Inc. - a GSK company,Phase 2
NCT00056238,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00056277,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00056290,2002.0,INDIV,lead,"Losordo, Douglas, M.D.",Phase 1/Phase 2
NCT00056329,2002.0,OTHER_GOV,lead,New York State Institute for Basic Research,Phase 3
NCT00056329,2002.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00056329,2002.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00056329,2002.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00056498,2001.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00056498,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00056498,2001.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00056524,2003.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 3
NCT00056576,2002.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00056810,2002.0,FED,lead,FDA Office of Orphan Products Development,Phase 2
NCT00057278,2003.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2/Phase 3
NCT00057551,2003.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00057551,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00057577,2002.0,OTHER,lead,Vanderbilt University,Phase 4
NCT00057577,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00057642,2002.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00057642,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00057681,2003.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT00057681,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00057707,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00058071,2003.0,NETWORK,lead,Gynecologic Oncology Group,Phase 3
NCT00058071,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00058838,2003.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00059228,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00059280,2003.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2/Phase 3
NCT00059306,2003.0,OTHER,lead,University of British Columbia,Phase 3
NCT00059306,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00059332,2005.0,OTHER,lead,Jeffrey L. Saver,Phase 3
NCT00059332,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00060489,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00060866,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00060905,2003.0,INDUSTRY,lead,Abbott,Phase 3
NCT00060957,1997.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00061022,2003.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00061074,1993.0,OTHER,lead,University of Minnesota,Phase 1
NCT00061074,1993.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00061087,1998.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT00061087,1998.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00061113,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00061776,,INDUSTRY,lead,NeurogesX,Phase 2/Phase 3
NCT00061789,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00061802,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00061802,2003.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00062478,2001.0,INDUSTRY,lead,"BioNumerik Pharmaceuticals, Inc.",Phase 2
NCT00062478,2001.0,INDUSTRY,collaborator,Crown Bioscience,Phase 2
NCT00062673,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00062738,2003.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 2
NCT00062738,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00062972,1999.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00062972,1999.0,FED,collaborator,U.S. Department of Education,Phase 3
NCT00063193,2003.0,OTHER,lead,University of Rochester,Phase 2
NCT00063193,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00063297,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00063310,2003.0,INDUSTRY,lead,Voyager Pharmaceutical Corporation,Phase 2
NCT00063323,2000.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00063323,2000.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 3
NCT00063362,2002.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00063362,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00064467,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00064623,2003.0,INDUSTRY,lead,NeurogesX,Phase 3
NCT00065169,2000.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT00065169,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00065273,1998.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00065702,2000.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00065767,2001.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2/Phase 3
NCT00065767,2001.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT00065923,2002.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00065936,1997.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00065949,1987.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00066157,2001.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2/Phase 3
NCT00066157,2001.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT00066170,2003.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00066248,2003.0,OTHER,lead,University of South Florida,Phase 2
NCT00066248,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00066859,2004.0,OTHER,lead,Wake Forest University Health Sciences,Phase 3
NCT00066859,2004.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00067158,2003.0,OTHER,lead,New York University,Phase 3
NCT00067262,2003.0,INDUSTRY,lead,Abbott,Phase 3
NCT00067327,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00067405,2004.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00067431,2003.0,INDUSTRY,lead,Abbott,Phase 3
NCT00067496,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00067535,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00067912,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00067938,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00068029,2003.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00068042,2003.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00068081,,INDUSTRY,lead,NeurogesX,Phase 3
NCT00068107,2003.0,OTHER,lead,Baylor Research Institute,Phase 2
NCT00068107,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00068458,2003.0,OTHER,lead,Duke University,Phase 2
NCT00068458,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00068913,2000.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00069069,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00069251,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00069329,2003.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 1/Phase 2
NCT00069459,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00069550,2004.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00069641,2003.0,INDUSTRY,lead,Shire,Phase 2/Phase 3
NCT00069849,2003.0,INDUSTRY,lead,Abbott,Phase 2
NCT00069927,2003.0,OTHER,lead,University of South Florida,Phase 2
NCT00069927,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00070694,2003.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00070928,2000.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00070941,2003.0,OTHER,lead,NYU Langone Health,Phase 2/Phase 3
NCT00070941,2003.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2/Phase 3
NCT00070941,2003.0,NIH,collaborator,Office of Dietary Supplements (ODS),Phase 2/Phase 3
NCT00070993,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00070993,2002.0,NIH,collaborator,Office of Dietary Supplements (ODS),Phase 2
NCT00071032,2003.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 3
NCT00071032,2003.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00071253,2003.0,INDUSTRY,lead,Abbott,Phase 4
NCT00071643,2002.0,OTHER,lead,Robert G. Robinson,Not Applicable
NCT00071643,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00071695,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00071721,2003.0,OTHER,lead,Alzheimer's Disease Cooperative Study (ADCS),Phase 3
NCT00071721,2003.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00071747,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00071838,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00071877,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00072683,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00072683,2003.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00072709,2003.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00072735,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00073164,2003.0,INDUSTRY,lead,Abbott,Phase 2
NCT00073320,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00073372,2003.0,INDUSTRY,lead,"Centocor, Inc.",Phase 3
NCT00073372,2003.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00073411,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00073476,2003.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00073658,2000.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00073658,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00073697,2003.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00073697,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00074477,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00074529,2003.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00074607,2001.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT00074607,2001.0,OTHER,collaborator,University of Pittsburgh,Phase 1
NCT00074607,2001.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00074607,2001.0,UNKNOWN,collaborator,Children's Hospital of Pittsburg,Phase 1
NCT00074607,2001.0,OTHER,collaborator,Seattle Children's Hospital,Phase 1
NCT00074607,2001.0,OTHER,collaborator,Mayo Clinic,Phase 1
NCT00074607,2001.0,OTHER,collaborator,Brown University,Phase 1
NCT00074776,2003.0,OTHER,lead,Stanford University,Phase 3
NCT00074776,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00074815,2003.0,OTHER,lead,Duke University,Phase 3
NCT00074815,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00074932,2004.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Not Applicable
NCT00074958,2002.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00074971,1999.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00074984,2001.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00075244,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00075842,2003.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 3
NCT00075842,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00075959,2004.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00076102,2004.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00076115,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00076440,2003.0,INDUSTRY,lead,Voyager Pharmaceutical Corporation,Phase 2
NCT00076492,2004.0,OTHER,lead,University of Rochester,Phase 2
NCT00076492,2004.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00076674,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00076687,2003.0,INDUSTRY,lead,Allergan,Phase 2
NCT00076726,2003.0,INDUSTRY,lead,"Centocor, Inc.",Phase 2
NCT00076726,2003.0,OTHER,collaborator,The Cleveland Clinic,Phase 2
NCT00076856,2004.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00076934,2003.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00076934,2003.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 1
NCT00076934,2003.0,INDUSTRY,collaborator,Repligen Corporation,Phase 1
NCT00077207,2004.0,NETWORK,lead,Children's Oncology Group,Not Applicable
NCT00077207,2004.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00077714,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00077727,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00078039,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00078286,2003.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00078286,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00078312,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00078325,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00078377,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00078481,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00078754,2003.0,OTHER,lead,University of Chicago,Phase 2
NCT00078754,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00078767,2001.0,OTHER,lead,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),Phase 3
NCT00078767,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00078988,2004.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT00078988,2004.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00079495,2003.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT00079495,2003.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 2
NCT00079638,2004.0,INDUSTRY,lead,Kos Pharmaceuticals,Phase 4
NCT00079677,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00079768,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00079807,2003.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00080054,,INDUSTRY,lead,Pharmacyclics LLC.,Phase 1
NCT00080145,2004.0,OTHER,lead,Yale University,Not Applicable
NCT00080145,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00080158,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT00080158,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00080314,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00080314,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00080327,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00080327,2003.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00080366,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00080483,2004.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00080483,2004.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00081380,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00081497,2004.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00082043,2004.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00082316,,INDUSTRY,lead,NeurogesX,Phase 2
NCT00082485,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00082602,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00082602,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00083421,2004.0,INDUSTRY,lead,Ono Pharma USA Inc,Phase 2
NCT00083590,2004.0,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT00083590,2004.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT00083590,2004.0,INDUSTRY,collaborator,Neuro-Hitech,Phase 2
NCT00083668,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00083954,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00083980,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00084084,2004.0,INDUSTRY,lead,Shire,Phase 2
NCT00084669,2004.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00085098,2007.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT00085098,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00085748,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00085761,,INDUSTRY,lead,NeurogesX,Phase 3
NCT00085891,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00086112,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00086112,,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00086138,2004.0,OTHER,lead,Johns Hopkins University,Phase 2/Phase 3
NCT00086138,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00086190,2005.0,OTHER,lead,University of Rochester,Phase 3
NCT00086190,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00086255,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00086255,2002.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT00086281,2003.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT00086294,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00086320,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00086385,2001.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT00086385,2001.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00086411,2003.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00086411,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00086593,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00086671,2004.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT00087529,2004.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2/Phase 3
NCT00087542,2004.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2
NCT00087555,2004.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT00087724,2004.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 2
NCT00087724,2004.0,INDUSTRY,collaborator,"Astellas Pharma US, Inc.",Phase 2
NCT00087750,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00087789,2004.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1
NCT00087789,2004.0,INDUSTRY,collaborator,Ceregene,Phase 1
NCT00087880,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00088036,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00088049,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00088075,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00088153,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT00088153,2003.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT00088153,2003.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2/Phase 3
NCT00088166,2004.0,INDUSTRY,lead,Celtic Pharma Development Services,Phase 3
NCT00088166,2004.0,INDUSTRY,collaborator,Neurobiological Technologies,Phase 3
NCT00088374,2004.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00088387,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00088452,2004.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT00088452,2004.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00088465,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00088478,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00088491,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00088582,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00088621,2004.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00088634,2004.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00088673,2004.0,INDUSTRY,lead,Bellus Health Inc. - a GSK company,Phase 3
NCT00088699,2004.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT00088738,2004.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00089414,2004.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00089440,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00089557,,INDUSTRY,lead,NeurogesX,Phase 2
NCT00089622,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00089687,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00089843,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT00089843,2003.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT00089843,2003.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2/Phase 3
NCT00089869,,INDUSTRY,lead,Eli Lilly and Company,Phase 1/Phase 2
NCT00090012,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00090064,2004.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT00090116,2003.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00090311,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00090324,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00090376,2003.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00090376,2003.0,INDUSTRY,collaborator,Symphony Neuro Development Company,Phase 2
NCT00090402,2004.0,OTHER,lead,Oregon Health and Science University,Phase 1/Phase 2
NCT00090402,2004.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1/Phase 2
NCT00090402,2004.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 1/Phase 2
NCT00091468,2003.0,NIH,lead,National Institute on Aging (NIA),Phase 1
NCT00091650,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00091845,2004.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT00091897,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00091949,2005.0,OTHER,lead,Yale University,Phase 3
NCT00091949,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00091949,2005.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 3
NCT00091962,2003.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00091962,2003.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00092469,2002.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00092911,,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00092963,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00093275,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00093847,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00093847,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00093860,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00093951,2004.0,INDUSTRY,lead,Saegis Pharmaceuticals,Phase 2
NCT00094172,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00094172,2005.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 2
NCT00094289,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00094315,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00094549,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00094614,2002.0,OTHER,lead,Jaeb Center for Health Research,Phase 4
NCT00094614,2002.0,NIH,collaborator,National Eye Institute (NEI),Phase 4
NCT00094640,,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT00094692,2002.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00094692,2002.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00094926,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00094926,2004.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00095004,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00095251,2004.0,OTHER,lead,Vanderbilt University,Phase 2
NCT00095355,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00095511,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00095511,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00095524,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00095524,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00095719,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00095719,2003.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00095810,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00095810,2003.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00096473,2001.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00096473,2001.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00096720,2004.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00096720,2004.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 2
NCT00096720,2004.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00096798,2001.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00096863,2004.0,OTHER,lead,Vanderbilt University,Phase 2
NCT00097032,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00097032,2004.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00097188,2004.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT00097266,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00097266,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00097318,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00097331,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00097474,2004.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00097604,2004.0,OTHER,lead,University of Washington,Phase 2
NCT00097604,2004.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00097669,1998.0,OTHER_GOV,lead,VITATOPS,Not Applicable
NCT00097669,1998.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Not Applicable
NCT00097669,1998.0,OTHER,collaborator,"National Heart Foundation, Australia",Not Applicable
NCT00097669,1998.0,OTHER,collaborator,"Medical Health Research Infrastructure Council, Australia",Not Applicable
NCT00097708,2004.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00097760,2003.0,INDUSTRY,lead,Biogen,Phase 2
NCT00097760,2003.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT00097890,2004.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00097916,2004.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00097942,2004.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00098124,2004.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00099216,2001.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00099229,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00099242,2003.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00099268,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00099268,2004.0,INDUSTRY,collaborator,"Orion Corporation, Orion Pharma",Phase 3
NCT00099489,2004.0,INDUSTRY,lead,Biogen,Phase 2
NCT00099502,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00099528,2003.0,INDUSTRY,lead,Renovis,Phase 2
NCT00099710,2003.0,OTHER,lead,John Douglas French Foundation,Phase 2
NCT00099710,2003.0,OTHER,collaborator,Institute for the Study of Aging (ISOA),Phase 2
NCT00100074,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00100100,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00100113,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00100165,2005.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT00100165,2005.0,FED,collaborator,VA Office of Research and Development,Phase 2
NCT00100282,2003.0,INDUSTRY,lead,PRAECIS Pharmaceuticals Inc.,Phase 1
NCT00100334,2004.0,INDUSTRY,lead,PRAECIS Pharmaceuticals Inc.,Phase 1/Phase 2
NCT00100412,1999.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00100464,2000.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00100776,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00100802,2005.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT00100802,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00101426,2004.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT00101452,2005.0,OTHER,lead,"Maurizio Fava, MD",Not Applicable
NCT00101452,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00101569,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00101569,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00101634,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00101959,2004.0,INDUSTRY,lead,EMD Serono,Phase 4
NCT00102063,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00102258,2005.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00102453,2002.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 1/Phase 2
NCT00102479,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT00102518,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00102596,2005.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00102817,2003.0,INDUSTRY,lead,Novo Nordisk A/S,Phase 3
NCT00102869,2005.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT00102869,2005.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00103571,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00103597,2005.0,OTHER_GOV,lead,Royal Brisbane and Women's Hospital,Phase 1
NCT00103649,2003.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00103727,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00103974,2004.0,INDUSTRY,lead,Bayhill Therapeutics,Phase 1
NCT00104013,2003.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00104078,2005.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1/Phase 2
NCT00104143,2007.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT00104247,2005.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT00104260,2004.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT00104273,2004.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00104273,2004.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2
NCT00104299,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2/Phase 3
NCT00104299,2005.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 2/Phase 3
NCT00104299,2005.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2/Phase 3
NCT00104416,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00104442,2003.0,INDUSTRY,lead,Novartis,Phase 4
NCT00104572,2004.0,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT00104598,2000.0,OTHER,lead,Yale University,Not Applicable
NCT00104598,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00104663,2004.0,OTHER_GOV,lead,Medical Research Council,Not Applicable
NCT00105040,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00105105,2003.0,INDUSTRY,lead,Corcept Therapeutics,Phase 2
NCT00105105,2003.0,OTHER,collaborator,Institute for the Study of Aging (ISOA),Phase 2
NCT00105326,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00105482,2005.0,OTHER,lead,Yale University,Phase 2
NCT00105482,2005.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00105508,2004.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00105521,2004.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00105547,2005.0,INDUSTRY,lead,Myrexis Inc.,Phase 3
NCT00105586,2004.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00105586,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00106106,2005.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 2
NCT00106106,2005.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00106184,2006.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00106184,2006.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00106184,2006.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00106184,2006.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT00106197,2004.0,OTHER,lead,Uma Rao,Phase 4
NCT00106197,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00106392,2005.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT00106405,2005.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00106769,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00106860,2005.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00107003,2005.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00107055,2003.0,INDUSTRY,lead,Renovis,Phase 2
NCT00107471,2005.0,NETWORK,lead,Children's Oncology Group,Phase 1/Phase 2
NCT00107471,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1/Phase 2
NCT00107770,2005.0,FED,lead,US Department of Veterans Affairs,Phase 1/Phase 2
NCT00107770,2005.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 1/Phase 2
NCT00107796,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00107809,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00107848,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00107926,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00107939,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00108173,2002.0,FED,lead,US Department of Veterans Affairs,Phase 1
NCT00108316,2004.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00108368,2003.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00108368,2003.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00108420,2003.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00108498,2003.0,FED,lead,US Department of Veterans Affairs,Phase 1
NCT00108537,2003.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00108576,2003.0,FED,lead,VA Office of Research and Development,Phase 3
NCT00108602,2007.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00108667,2005.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00108706,2004.0,OTHER,lead,City Hospitals Sunderland NHS Foundation Trust,Phase 4
NCT00108706,2004.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT00108836,2005.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00109083,2002.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00109161,2005.0,INDUSTRY,lead,"PDL BioPharma, Inc.",Phase 2
NCT00109304,2005.0,INDUSTRY,lead,"DynPort Vaccine Company LLC, A GDIT Company",Phase 1
NCT00109382,2003.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT00109382,2003.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2/Phase 3
NCT00109382,2003.0,OTHER,collaborator,Canadian Stroke Consortium (CSC),Phase 2/Phase 3
NCT00109564,2005.0,INDUSTRY,lead,Targacept Inc.,Phase 2
NCT00109577,2005.0,OTHER,lead,University of Calgary,Phase 2
NCT00109577,2005.0,OTHER,collaborator,Alberta Innovation and Science,Phase 2
NCT00109733,2005.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00109772,2005.0,INDUSTRY,lead,Celgene Corporation,Phase 2
NCT00109798,2005.0,OTHER,lead,The Methodist Hospital Research Institute,Not Applicable
NCT00109798,2005.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT00110396,2005.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00110396,2005.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00110461,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00110500,2005.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1
NCT00110552,2005.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT00110552,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 1
NCT00110604,2000.0,OTHER,lead,Wageningen University,Not Applicable
NCT00110604,2000.0,OTHER,collaborator,Wageningen Centre for Food Sciences,Not Applicable
NCT00110604,2000.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Not Applicable
NCT00110669,2004.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 3
NCT00110708,2005.0,INDUSTRY,lead,PediaMed Pharmaceuticals,Phase 2
NCT00111189,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00111189,2005.0,INDUSTRY,collaborator,Janssen-Cilag International NV,Phase 3
NCT00111267,2003.0,OTHER,lead,Wageningen University,Not Applicable
NCT00111267,2003.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Not Applicable
NCT00111371,2005.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT00111709,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00111722,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00111852,2005.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00111982,2003.0,INDUSTRY,lead,Amgen,Phase 1/Phase 2
NCT00111982,2003.0,INDUSTRY,collaborator,Medtronic,Phase 1/Phase 2
NCT00112034,2003.0,INDUSTRY,lead,Biogen,Phase 4
NCT00112073,2005.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00112073,2005.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00112385,2006.0,OTHER,lead,Brigham and Women's Hospital,Phase 1
NCT00112385,2006.0,INDUSTRY,collaborator,Amgen,Phase 1
NCT00112515,2004.0,OTHER,lead,University of Virginia,Not Applicable
NCT00112515,2004.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00113022,2005.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00113165,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00113295,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00113594,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00113620,2005.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 3
NCT00113685,2003.0,OTHER,lead,University of Washington,Not Applicable
NCT00113685,2003.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00113815,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00113854,2004.0,OTHER,lead,Makerere University,Phase 3
NCT00113906,2005.0,OTHER,lead,"University Hospital, Gentofte, Copenhagen",Phase 2/Phase 3
NCT00114127,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00114374,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00114439,2005.0,OTHER_GOV,lead,Sydney South West Area Health Service,Phase 2
NCT00114439,2005.0,OTHER,collaborator,The University of New South Wales,Phase 2
NCT00114569,2005.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT00114569,2005.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 1
NCT00114595,2003.0,OTHER,lead,University of Stellenbosch,Phase 4
NCT00114595,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00115011,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00115011,2002.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00115310,2005.0,INDUSTRY,lead,NeurogesX,Phase 3
NCT00115427,2003.0,INDUSTRY,lead,Amgen,Phase 1
NCT00115687,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00115804,2005.0,OTHER,lead,University of Cincinnati,Phase 3
NCT00116064,2004.0,OTHER,lead,Kamuzu University of Health Sciences,Phase 3
NCT00116129,2005.0,INDIV,lead,"Bennett, Robert, M.D.",Phase 2
NCT00116129,2005.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00116259,2005.0,OTHER,lead,Federal University of Rio Grande do Sul,Not Applicable
NCT00116259,2005.0,OTHER,collaborator,Hospital de Clinicas de Porto Alegre,Not Applicable
NCT00116532,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00116532,2002.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00116857,2005.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT00116857,2005.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00117403,2006.0,NIH,lead,National Institute on Aging (NIA),Phase 1
NCT00117403,2006.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 1
NCT00117585,2005.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT00117819,2001.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00117819,2001.0,OTHER,collaborator,Indiana University,Phase 2
NCT00117819,2001.0,OTHER,collaborator,Albany Medical College,Phase 2
NCT00118014,2000.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00118014,2000.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00118404,2000.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 3
NCT00118404,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00118417,1999.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT00118417,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00118430,2004.0,OTHER,lead,Indiana University,Phase 4
NCT00118430,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00118482,2005.0,OTHER,lead,University of Calgary,Phase 4
NCT00118482,2005.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 4
NCT00118495,2006.0,INDUSTRY,lead,QualiLife Pharmaceuticals,Phase 3
NCT00118833,2002.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2/Phase 3
NCT00118924,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00118924,2005.0,OTHER,collaborator,Johns Hopkins Bloomberg School of Public Health,Phase 1
NCT00119080,2006.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT00119080,2006.0,OTHER_GOV,collaborator,Georgia Department of Human Resources,Phase 4
NCT00119080,2006.0,OTHER_GOV,collaborator,Maryland Department of Health and Mental Hygiene,Phase 4
NCT00119080,2006.0,OTHER,collaborator,Johns Hopkins University,Phase 4
NCT00119080,2006.0,OTHER,collaborator,University of Pittsburgh,Phase 4
NCT00119210,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00119210,2005.0,OTHER,collaborator,Robert Wood Johnson Foundation,Phase 4
NCT00119626,2003.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00119652,2005.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00119756,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00120003,2005.0,OTHER,lead,Ullevaal University Hospital,Phase 3
NCT00120003,2005.0,UNKNOWN,collaborator,Southern-Eastern Norway Health Authorities RHF,Phase 3
NCT00120003,2005.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00120003,2005.0,INDUSTRY,collaborator,Takeda,Phase 3
NCT00120055,2005.0,OTHER,lead,University of Oslo School of Pharmacy,Phase 4
NCT00120120,2005.0,INDUSTRY,lead,Celgene Corporation,Phase 2/Phase 3
NCT00120250,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00120289,2005.0,INDUSTRY,lead,Axio Research. LLC,Phase 3
NCT00120289,2005.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00120289,2005.0,INDUSTRY,collaborator,Abbott,Phase 3
NCT00120367,2005.0,OTHER_GOV,lead,French National Agency for Research on AIDS and Viral Hepatitis,Phase 2
NCT00120367,2005.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2
NCT00120367,2005.0,INDUSTRY,collaborator,Gilead Sciences,Phase 2
NCT00120484,2005.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT00120484,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00120588,1997.0,OTHER,lead,"University Hospital, Rouen",Phase 4
NCT00120588,1997.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 4
NCT00120874,2006.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00120874,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00120874,2006.0,OTHER,collaborator,Fisher Center for Alzheimer's Research Foundation,Phase 4
NCT00121069,2002.0,INDIV,lead,"Connor, Kathryn M., M.D.",Phase 2/Phase 3
NCT00121069,2002.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2/Phase 3
NCT00121420,,INDUSTRY,lead,Pharmacyclics LLC.,Phase 2
NCT00121888,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT00122044,2003.0,OTHER,lead,University of Southern California,Phase 2
NCT00122044,2003.0,OTHER,collaborator,United Cerebral Palsy Foundation,Phase 2
NCT00122044,2003.0,OTHER,collaborator,Don and Linda Carter Foundation,Phase 2
NCT00122044,2003.0,OTHER,collaborator,Crowley Carter Foundation,Phase 2
NCT00122070,2005.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 3
NCT00122070,2005.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00122278,2005.0,OTHER,lead,Montefiore Medical Center,Phase 3
NCT00122499,2003.0,OTHER,lead,Erasmus Medical Center,Phase 3
NCT00122733,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT00122759,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT00122824,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00122824,2004.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00122837,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00122837,2005.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00122850,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00122850,2004.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00122863,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00122863,2005.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00122954,2005.0,OTHER,lead,Oregon Health and Science University,Phase 1/Phase 2
NCT00122954,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 1/Phase 2
NCT00122980,2006.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 3
NCT00122980,2006.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00123214,2004.0,UNKNOWN,lead,St. Vincent's Medical Center,Not Applicable
NCT00123214,2004.0,UNKNOWN,collaborator,"Inflammation Research Foundation, Marblehead, MA.",Not Applicable
NCT00123214,2004.0,INDUSTRY,collaborator,"NeuroScience, Inc., Osceola, WI.",Not Applicable
NCT00123266,2006.0,INDUSTRY,lead,ThromboGenics,Phase 2
NCT00123305,2005.0,INDUSTRY,lead,ThromboGenics,Phase 2
NCT00123370,2006.0,OTHER,lead,The University of New South Wales,Phase 2
NCT00123370,2006.0,OTHER_GOV,collaborator,Australian Government Department of Health and Ageing,Phase 2
NCT00123370,2006.0,UNKNOWN,collaborator,"Kirketon Road Centre, Sydney Hospital",Phase 2
NCT00123370,2006.0,OTHER,collaborator,"St Vincent's Hospital, Sydney",Phase 2
NCT00123383,2005.0,OTHER,lead,The University of New South Wales,Phase 2
NCT00123383,2005.0,OTHER_GOV,collaborator,Australian Government Department of Health and Ageing,Phase 2
NCT00123383,2005.0,UNKNOWN,collaborator,"Kirketon Road Centre, Sydney Hospital",Phase 2
NCT00123383,2005.0,OTHER,collaborator,"St Vincent's Hospital, Sydney",Phase 2
NCT00123539,2001.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00123578,2004.0,OTHER,lead,"University of California, Los Angeles",Phase 1/Phase 2
NCT00123578,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00123760,2004.0,OTHER,lead,AHS Cancer Control Alberta,Phase 2/Phase 3
NCT00123760,2004.0,OTHER,collaborator,Cross Cancer Institute,Phase 2/Phase 3
NCT00124150,2002.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT00124267,2003.0,OTHER,lead,Makerere University,Phase 3
NCT00124267,2003.0,INDUSTRY,collaborator,Sanofi-Synthelabo,Phase 3
NCT00124267,2003.0,OTHER_GOV,collaborator,"Ministry of Health, Uganda",Phase 3
NCT00124683,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00124696,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00124826,2004.0,OTHER,lead,University of Glasgow,Phase 2
NCT00124826,2004.0,OTHER,collaborator,South Glasgow University Hospitals NHS Trust,Phase 2
NCT00124826,2004.0,OTHER,collaborator,"The Stroke Association, United Kingdom",Phase 2
NCT00124839,2005.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 3
NCT00124852,2005.0,OTHER,lead,ZonMw: The Netherlands Organisation for Health Research and Development,Not Applicable
NCT00125138,2005.0,INDUSTRY,lead,Lundbeck LLC,Phase 2
NCT00125203,2003.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2/Phase 3
NCT00125203,2003.0,OTHER,collaborator,ALS Association,Phase 2/Phase 3
NCT00125203,2003.0,OTHER,collaborator,University of Kansas,Phase 2/Phase 3
NCT00125203,2003.0,UNKNOWN,collaborator,Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System,Phase 2/Phase 3
NCT00125567,2005.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 4
NCT00125879,2005.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2/Phase 3
NCT00125892,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00125892,2005.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00125931,2005.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00125931,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00125957,2005.0,OTHER,lead,Mclean Hospital,Phase 3
NCT00125957,2005.0,UNKNOWN,collaborator,National Association for Research on Schizophrenia and Affective Disorders.,Phase 3
NCT00126009,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00126087,2005.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT00126139,2004.0,OTHER,lead,University of Zurich,Phase 3
NCT00126139,2004.0,OTHER,collaborator,Schweizerische Herzstiftung,Phase 3
NCT00126139,2004.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00126282,2003.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00126516,2004.0,OTHER,lead,Nara Medical University,Phase 4
NCT00126672,2005.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 2
NCT00126672,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00126672,2005.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00126672,2005.0,OTHER,collaborator,Tuberous Sclerosis Alliance,Phase 2
NCT00127075,2005.0,OTHER,lead,Hospices Civils de Lyon,Phase 3
NCT00127114,2005.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT00127530,2005.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00127673,2004.0,OTHER,lead,Case Western Reserve University,Phase 3
NCT00127673,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00128050,2005.0,OTHER,lead,IRCCS Policlinico S. Matteo,Phase 2
NCT00128232,2002.0,INDUSTRY,lead,Novartis,Phase 3
NCT00128401,2005.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00128479,2004.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT00128505,2005.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT00129181,2005.0,OTHER,lead,Institute for Neurodegenerative Disorders,Not Applicable
NCT00129181,2005.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00129181,2005.0,INDUSTRY,collaborator,GE Healthcare,Not Applicable
NCT00129220,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00129246,2004.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT00129246,2004.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1/Phase 2
NCT00129272,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00129285,2004.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00129285,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00129298,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00129441,2005.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00129441,2005.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00129467,2005.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00129467,2005.0,OTHER,collaborator,Oregon Health and Science University,Not Applicable
NCT00129545,2005.0,INDUSTRY,lead,Boston Scientific Corporation,Phase 2/Phase 3
NCT00129675,2003.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00129675,2003.0,OTHER,collaborator,Molecular NeuroImaging,Phase 2
NCT00129805,2001.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT00129857,2001.0,INDUSTRY,lead,Pharmos,Phase 3
NCT00130039,2005.0,OTHER,lead,Asan Medical Center,Phase 4
NCT00130039,2005.0,INDUSTRY,collaborator,Korea Otsuka International Asia Arab,Phase 4
NCT00130338,2002.0,INDUSTRY,lead,Novartis,Phase 3
NCT00130429,2004.0,INDUSTRY,lead,Phytopharm,Phase 2
NCT00130455,2006.0,OTHER,lead,"Psychiatric Hospital, Hillerod",Phase 4
NCT00130455,2006.0,UNKNOWN,collaborator,"Psychogeriatric Unit, CU Hospital, Frederiksberg",Phase 4
NCT00130455,2006.0,OTHER,collaborator,Amager Hospital,Phase 4
NCT00130455,2006.0,OTHER,collaborator,Psychiatric Center Ballerup,Phase 4
NCT00130455,2006.0,UNKNOWN,collaborator,"Geriatric Department,Korsør, Vestsjælland",Phase 4
NCT00130676,2004.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT00130923,2005.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00130923,2005.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00131339,2004.0,OTHER,lead,Hartford Hospital,Not Applicable
NCT00131456,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00131456,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00131495,2004.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00132119,2005.0,INDUSTRY,lead,Somaxon Pharmaceuticals,Phase 2/Phase 3
NCT00132223,2005.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT00132314,2006.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00132470,2004.0,INDUSTRY,lead,Axaron Bioscience AG,Phase 2
NCT00132509,2001.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT00132626,1992.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00132626,1992.0,OTHER,collaborator,Molecular NeuroImaging,Phase 2
NCT00132626,1992.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00132678,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00132821,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00132873,2004.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00133081,2002.0,OTHER,lead,UMC Utrecht,Phase 4
NCT00133081,2002.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00133198,2004.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00133354,2001.0,OTHER,lead,Nemours Children's Clinic,Phase 2/Phase 3
NCT00133354,2001.0,INDUSTRY,collaborator,AstraZeneca,Phase 2/Phase 3
NCT00133354,2001.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2/Phase 3
NCT00133354,2001.0,INDUSTRY,collaborator,EMD Serono,Phase 2/Phase 3
NCT00133445,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00133757,2005.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 1
NCT00133757,2005.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 1
NCT00133822,2004.0,OTHER,lead,Emory University,Phase 1/Phase 2
NCT00133822,2004.0,INDUSTRY,collaborator,"Janssen, LP",Phase 1/Phase 2
NCT00133861,2005.0,OTHER,lead,Hospices Civils de Lyon,Phase 2/Phase 3
NCT00134251,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 3
NCT00134459,2005.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00134459,2005.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 3
NCT00134563,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00134784,2000.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00134784,2000.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00134901,2003.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00134901,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00134901,2003.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT00134953,2003.0,INDUSTRY,lead,Novartis,Phase 3
NCT00134966,2005.0,INDUSTRY,lead,Novartis,Phase 3
NCT00135109,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00135512,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00135525,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00135746,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00135746,2004.0,OTHER,collaborator,Virginia Commonwealth University,Not Applicable
NCT00135759,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00135876,2002.0,OTHER,lead,Ontario Clinical Oncology Group (OCOG),Phase 3
NCT00135876,2002.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00135993,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00136019,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00136045,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00136110,2005.0,OTHER,lead,UMC Utrecht,Phase 3
NCT00136110,2005.0,OTHER,collaborator,Princess Beatrix Muscle Foundation,Phase 3
NCT00136240,2003.0,OTHER,lead,Boston Medical Center,Not Applicable
NCT00136240,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00136318,2004.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 3
NCT00136383,2005.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00136383,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00136734,1998.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT00136734,1998.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00136747,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT00136747,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00136760,2003.0,OTHER,lead,Brown University,Phase 2
NCT00136760,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00136786,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT00136786,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00136825,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00136994,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00137020,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00137072,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00137085,2004.0,OTHER,lead,Queen's University,Not Applicable
NCT00137085,2004.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Not Applicable
NCT00137176,2004.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT00137306,2004.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00137696,2002.0,FED,lead,Centers for Disease Control and Prevention,Not Applicable
NCT00137696,2002.0,UNKNOWN,collaborator,Ponce School of Medicine,Not Applicable
NCT00137709,2004.0,OTHER,lead,Chinese University of Hong Kong,Phase 4
NCT00137735,2003.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT00137735,2003.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00138775,2004.0,OTHER_GOV,lead,Sheba Medical Center,Phase 2
NCT00138775,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00138801,2004.0,OTHER_GOV,lead,Sorlandet Hospital HF,Phase 3
NCT00138983,2000.0,OTHER,lead,UMC Utrecht,Phase 3
NCT00138983,2000.0,OTHER,collaborator,Dutch Health Care Insurance Board,Phase 3
NCT00139074,2005.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00139373,,OTHER,lead,Groupe Hospitalier Pitie-Salpetriere,Phase 2
NCT00139373,,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT00139594,2004.0,INDUSTRY,lead,Novartis,Phase 4
NCT00139737,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00139789,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00139867,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00139880,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00139906,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 2
NCT00139906,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT00139906,2005.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00139919,2006.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 2
NCT00139919,2006.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT00139919,2006.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00139945,2005.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00140153,2005.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00140179,2004.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00140179,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00140192,2004.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00140192,2004.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00140218,2005.0,INDIV,lead,"Bennett, James P., Jr., M.D., Ph.D.",Phase 1/Phase 2
NCT00140218,2005.0,OTHER,collaborator,University of Pittsburgh,Phase 1/Phase 2
NCT00140257,2004.0,OTHER,lead,Bispebjerg Hospital,Phase 4
NCT00140257,2004.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00140257,2004.0,OTHER,collaborator,Danish Heart Foundation,Phase 4
NCT00140257,2004.0,OTHER,collaborator,The Danish Medical Research Council,Phase 4
NCT00140413,2004.0,OTHER,lead,Children's Hospital Los Angeles,Phase 4
NCT00140413,2004.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT00140426,2004.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT00140426,2004.0,INDUSTRY,collaborator,Janssen Pharmaceuticals,Phase 4
NCT00140426,2004.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 4
NCT00140452,2005.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 2
NCT00140452,2005.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT00140621,2005.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00140712,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00141011,2005.0,INDUSTRY,lead,Neurobiological Technologies,Phase 3
NCT00141115,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00141115,2004.0,INDUSTRY,collaborator,UCB Pharma,Phase 2
NCT00141219,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00141245,1998.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00141271,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00141336,1999.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00141349,2005.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00141375,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00141388,1998.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00141414,1997.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00141427,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00141479,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 2
NCT00141479,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT00141479,2005.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00141661,2005.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00141661,2005.0,UNKNOWN,collaborator,Trans Tech Pharmaceuticals,Phase 2
NCT00141947,2005.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00141947,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00142090,2004.0,OTHER,lead,"Rady Children's Hospital, San Diego",Not Applicable
NCT00142324,2003.0,OTHER,lead,"Institute of Psychiatry, London",Phase 4
NCT00142324,2003.0,OTHER_GOV,collaborator,Medical Research Council,Phase 4
NCT00142324,2003.0,OTHER,collaborator,Alzheimer's Society,Phase 4
NCT00142402,2003.0,OTHER,lead,Kessler Foundation,Not Applicable
NCT00142402,2003.0,OTHER,collaborator,National Multiple Sclerosis Society,Not Applicable
NCT00142493,2004.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 1
NCT00142506,2005.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 3
NCT00142506,2005.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 3
NCT00142506,2005.0,OTHER,collaborator,Beth Israel Medical Center,Phase 3
NCT00142506,2005.0,OTHER,collaborator,St. Luke's-Roosevelt Hospital Center,Phase 3
NCT00142545,1999.0,INDUSTRY,lead,Mylan Bertek Pharmaceuticals,Phase 3
NCT00142779,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00142805,2004.0,INDUSTRY,lead,Cerecin,Phase 2
NCT00142818,2006.0,OTHER,lead,Kyle Kampman,Phase 2
NCT00142818,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00142831,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00142844,1999.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00142844,1999.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00142870,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00142883,2004.0,OTHER,lead,Yale University,Not Applicable
NCT00142883,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00142961,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00142961,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00143026,2005.0,INDUSTRY,lead,Novartis,Phase 4
NCT00143130,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00143143,2001.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00143156,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00143182,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00143182,2005.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00143221,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00143260,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00143351,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00143416,2004.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00144014,2005.0,INDUSTRY,lead,Vernalis (R&D) Ltd,Phase 2
NCT00144209,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00144235,2005.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00144300,2005.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00144690,2005.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00145132,2005.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00145132,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00145171,2001.0,INDUSTRY,lead,Mylan Bertek Pharmaceuticals,Phase 3
NCT00145249,2005.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00145405,2002.0,OTHER,lead,Odense University Hospital,Phase 4
NCT00145444,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00145470,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00145496,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00145509,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00146068,2004.0,OTHER,lead,University of North Carolina,Phase 4
NCT00146211,2005.0,INDUSTRY,lead,Amarin Neuroscience Ltd,Phase 3
NCT00146211,2005.0,NETWORK,collaborator,Huntington Study Group,Phase 3
NCT00146237,2003.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 4
NCT00146237,2003.0,OTHER,collaborator,The Rogosin Institute,Phase 4
NCT00147303,2004.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT00147316,2002.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT00147316,2002.0,INDUSTRY,collaborator,"Kyowa Hakko Kogyo Co., Ltd.",Phase 3
NCT00147394,2001.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1
NCT00147628,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00148031,2003.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 4
NCT00148083,2005.0,OTHER,lead,University of Illinois at Chicago,Phase 3
NCT00148083,2005.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00148083,2005.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 3
NCT00148447,2004.0,OTHER_GOV,lead,BeerYaakov Mental Health Center,Phase 3
NCT00148447,2004.0,INDUSTRY,collaborator,Lundbeck Israel,Phase 3
NCT00148486,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00148512,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00148564,2004.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 4
NCT00148590,2005.0,OTHER,lead,"M. Schaefer, MD",Phase 3
NCT00148590,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00149188,2004.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00149227,2004.0,OTHER,lead,Kyoto Prefectural University of Medicine,Phase 4
NCT00149292,2005.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 2
NCT00149552,2001.0,OTHER,lead,Florida International University,Not Applicable
NCT00149552,2001.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00149617,2004.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00149617,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00149630,2005.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00149630,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00149630,2005.0,OTHER,collaborator,Yale University,Phase 2
NCT00149643,2004.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00149643,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00149656,2003.0,OTHER,lead,Florida International University,Not Applicable
NCT00149656,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00149669,2005.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00149669,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00149799,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00149799,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00149799,2005.0,OTHER,collaborator,Rhode Island Hospital,Phase 3
NCT00149838,2005.0,OTHER,lead,Medical University of South Carolina,Phase 2/Phase 3
NCT00149838,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00150176,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00150215,2005.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00150215,2005.0,INDUSTRY,collaborator,PPD,Phase 1
NCT00150293,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00150306,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00150358,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00150436,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00150449,2001.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00150553,2005.0,INDUSTRY,lead,Validus Pharmaceuticals,Phase 3
NCT00150605,2005.0,INDUSTRY,lead,Validus Pharmaceuticals,Phase 3
NCT00150709,1998.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00150735,2002.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00150748,2001.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT00150800,2006.0,INDUSTRY,lead,UCB PHARMA Inc. (US),Phase 3
NCT00151294,2004.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00151294,2004.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00151333,2005.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00151398,2005.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00151424,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00151437,2004.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00151463,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00151489,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00151502,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00151528,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00151801,2002.0,OTHER,lead,S. Andrea Hospital,Phase 2
NCT00151879,2005.0,INDUSTRY,lead,UCB Pharma,Phase 2/Phase 3
NCT00152126,2003.0,OTHER,lead,St. Jude Children's Research Hospital,Not Applicable
NCT00152126,2003.0,OTHER,collaborator,University of Miami,Not Applicable
NCT00152373,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00152451,2005.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00152503,2005.0,INDUSTRY,lead,UCB Pharma SA,Phase 2
NCT00152516,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00152750,2006.0,OTHER,lead,"University Health Network, Toronto",Phase 4
NCT00152750,2006.0,OTHER,collaborator,The Hospital for Sick Children,Phase 4
NCT00152776,2005.0,OTHER,lead,Heidelberg University,Phase 4
NCT00152776,2005.0,INDUSTRY,collaborator,Wala GmbH,Phase 4
NCT00152958,2004.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00152997,2004.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00153010,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00153062,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00153062,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00153062,2003.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT00153660,2005.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT00153725,2003.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT00153946,2004.0,OTHER,lead,Combination Therapy for Acute Ischemic Stroke Study Group,Phase 4
NCT00153946,2004.0,OTHER,collaborator,Japan Cardiovascular Research Foundation,Phase 4
NCT00153972,2005.0,OTHER,lead,Technische Universität Dresden,Phase 4
NCT00153972,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00154076,2005.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT00154258,2001.0,INDUSTRY,lead,Novartis,Phase 2
NCT00154323,2003.0,INDUSTRY,lead,Novartis,Phase 4
NCT00154635,2005.0,OTHER,lead,National Taiwan University Hospital,Phase 2
NCT00154635,2005.0,OTHER_GOV,collaborator,"Development Center for Biotechnology, Taiwan",Phase 2
NCT00154635,2005.0,OTHER_GOV,collaborator,"Taipei Veterans General Hospital, Taiwan",Phase 2
NCT00154635,2005.0,UNKNOWN,collaborator,"Program Office, National Science & Technology, Biotechnology & Pharmaceuticals",Phase 2
NCT00156065,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00156091,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00156104,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00156117,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00156325,2004.0,OTHER,lead,The University of New South Wales,Phase 2
NCT00156637,2005.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00156715,2004.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00156715,2004.0,OTHER,collaborator,Augusta University,Phase 4
NCT00156715,2004.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00156910,2006.0,INDUSTRY,lead,Allergan,Phase 3
NCT00157248,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00158028,1995.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00158028,1995.0,INDUSTRY,collaborator,Janssen Pharmaceutica,Not Applicable
NCT00158054,2005.0,OTHER,lead,Columbia University,Not Applicable
NCT00158054,2005.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00158132,1999.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00158132,1999.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00158158,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00158171,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00158184,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00158184,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00158210,2006.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00158210,2006.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1
NCT00158223,2004.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00158223,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00158249,2009.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00158249,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00158262,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00158262,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00158275,2004.0,OTHER,lead,Kaiser Permanente,Not Applicable
NCT00158275,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00158288,1997.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00158288,1997.0,OTHER,collaborator,Yale University,Phase 2
NCT00158301,2004.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00158301,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00158600,2005.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00158990,2002.0,OTHER,lead,Hadassah Medical Organization,Phase 3
NCT00158990,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00159081,2000.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Phase 4
NCT00159081,2000.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00159081,2000.0,NETWORK,collaborator,German Research Network On Schizophrenia,Phase 4
NCT00159081,2000.0,INDUSTRY,collaborator,Janssen-Cilag Ltd.,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Bonn,Phase 4
NCT00159081,2000.0,OTHER,collaborator,Humboldt-Universität zu Berlin,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of München,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Göttingen,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Cologne,Phase 4
NCT00159081,2000.0,OTHER,collaborator,Mainz University,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University Hospital Tuebingen,Phase 4
NCT00159081,2000.0,OTHER,collaborator,Universität Duisburg-Essen,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Mannheim,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Jena,Phase 4
NCT00159081,2000.0,OTHER,collaborator,Martin-Luther-Universität Halle-Wittenberg,Phase 4
NCT00159081,2000.0,OTHER,collaborator,RWTH Aachen University,Phase 4
NCT00159081,2000.0,OTHER,collaborator,University of Wuerzburg,Phase 4
NCT00159133,2001.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Phase 4
NCT00159133,2001.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00159133,2001.0,NETWORK,collaborator,German Research Network On Schizophrenia,Phase 4
NCT00159133,2001.0,INDUSTRY,collaborator,Janssen-Cilag Ltd.,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Bonn,Phase 4
NCT00159133,2001.0,OTHER,collaborator,Humboldt-Universität zu Berlin,Phase 4
NCT00159133,2001.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Göttingen,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Cologne,Phase 4
NCT00159133,2001.0,OTHER,collaborator,Mainz University,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University Hospital Tuebingen,Phase 4
NCT00159133,2001.0,OTHER,collaborator,Universität Duisburg-Essen,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Mannheim,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Jena,Phase 4
NCT00159133,2001.0,OTHER,collaborator,Martin-Luther-Universität Halle-Wittenberg,Phase 4
NCT00159133,2001.0,OTHER,collaborator,RWTH Aachen University,Phase 4
NCT00159133,2001.0,OTHER,collaborator,University of Wuerzburg,Phase 4
NCT00159250,2007.0,OTHER,lead,Imperial College London,Phase 1/Phase 2
NCT00159250,2007.0,OTHER_GOV,collaborator,"Department of Health, United Kingdom",Phase 1/Phase 2
NCT00159250,2007.0,INDUSTRY,collaborator,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT00159705,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00159744,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00159744,2004.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00159757,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00159770,2001.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00159783,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00159783,2005.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00159796,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00159796,2004.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00159809,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00159809,2004.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00159848,2003.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00159900,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00159965,2003.0,OTHER,lead,Rhode Island Hospital,Phase 4
NCT00159965,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00160511,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00160576,2003.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00160615,2001.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT00160628,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00160654,2003.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00160667,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00161018,2003.0,OTHER,lead,"University of Maryland, Baltimore",Phase 3
NCT00161031,2004.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT00161070,1997.0,OTHER,lead,UMC Utrecht,Phase 4
NCT00161473,2001.0,OTHER,lead,University of Washington,Not Applicable
NCT00161473,2001.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT00161928,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00161967,2005.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00162916,2005.0,OTHER,lead,Ontario Neurotrauma Foundation,Phase 4
NCT00162968,2004.0,OTHER,lead,Odense University Hospital,Phase 4
NCT00162968,2004.0,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT00162968,2004.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00162981,2005.0,INDUSTRY,lead,Lundbeck LLC,Phase 2
NCT00163085,2005.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00163150,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00163553,2004.0,OTHER_GOV,lead,Austin Health,Phase 3
NCT00164242,2002.0,INDIV,lead,"Caroff, Stanley N., M.D.",Phase 4
NCT00164242,2002.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00164749,2004.0,OTHER,lead,Chinese University of Hong Kong,Phase 1/Phase 2
NCT00164749,2004.0,OTHER,collaborator,BUPA Foundation,Phase 1/Phase 2
NCT00164749,2004.0,OTHER,collaborator,Kwong Wah Hospital,Phase 1/Phase 2
NCT00164970,2004.0,OTHER,lead,Chinese University of Hong Kong,Phase 4
NCT00165659,2002.0,INDUSTRY,lead,Eisai Limited,Phase 2
NCT00165724,2004.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT00165737,2003.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00165750,2005.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT00165763,2005.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00165763,2005.0,INDUSTRY,collaborator,"Eisai Co., Ltd.",Phase 4
NCT00165789,2005.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00165828,2005.0,INDUSTRY,lead,Eisai GmbH,Phase 4
NCT00166322,2004.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Not Applicable
NCT00166595,2003.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT00166595,2003.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00167232,1998.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT00167232,1998.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00167245,2004.0,OTHER,lead,Kyle Kampman,Phase 2
NCT00167245,2004.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00167297,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00167297,2004.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00167310,2005.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00167310,2005.0,OTHER,collaborator,American Heart Association,Phase 2
NCT00167310,2005.0,FED,collaborator,VA Pittsburgh Healthcare System,Phase 2
NCT00167479,2003.0,OTHER,lead,University of South Florida,Phase 4
NCT00167479,2003.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00167544,2005.0,OTHER,lead,Nationwide Children's Hospital,Phase 2
NCT00167544,2005.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00167544,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00167609,2004.0,OTHER,lead,University of Versailles,Phase 2/Phase 3
NCT00167609,2004.0,OTHER,collaborator,"Association Française contre les Myopathies (AFM), Paris",Phase 2/Phase 3
NCT00167609,2004.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT00167765,2005.0,OTHER,lead,University of Zurich,Phase 3
NCT00167765,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00167817,2003.0,OTHER,lead,Veterans Medical Research Foundation,Phase 4
NCT00167856,2005.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00167934,2004.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00167934,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00168402,2002.0,INDUSTRY,lead,Allergan,Phase 3
NCT00168415,2005.0,INDUSTRY,lead,Allergan,Phase 4
NCT00168428,2006.0,INDUSTRY,lead,Allergan,Phase 3
NCT00168441,2004.0,INDUSTRY,lead,Allergan,Phase 2
NCT00168480,2003.0,INDUSTRY,lead,Allergan,Phase 4
NCT00168506,2002.0,OTHER,lead,Baker Heart Research Institute,Not Applicable
NCT00168506,2002.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Not Applicable
NCT00168701,2004.0,INDUSTRY,lead,Biogen,Phase 2
NCT00169026,1999.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00169026,1999.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00169026,1999.0,OTHER,collaborator,Harvard Medical School (HMS and HSDM),Phase 4
NCT00169026,1999.0,OTHER,collaborator,"Commonwealth Research Center, Massachusetts",Phase 4
NCT00169026,1999.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00169039,1994.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 4
NCT00169039,1994.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00169039,1994.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00169039,1994.0,OTHER,collaborator,"Commonwealth Research Center, Massachusetts",Phase 4
NCT00169039,1994.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00169065,1998.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 4
NCT00169065,1998.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00169065,1998.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00169065,1998.0,OTHER,collaborator,"Commonwealth Research Center, Massachusetts",Phase 4
NCT00169065,1998.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00169091,1996.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 4
NCT00169091,1996.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00169091,1996.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00169091,1996.0,OTHER,collaborator,"Commonwealth Research Center, Massachusetts",Phase 4
NCT00169091,1996.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00169611,2004.0,OTHER,lead,Hospices Civils de Lyon,Phase 4
NCT00169702,2003.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Not Applicable
NCT00169702,2003.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00169702,2003.0,UNKNOWN,collaborator,Else Kröner-Fresenius-Centre for Nutritional Medicine,Not Applicable
NCT00169702,2003.0,OTHER,collaborator,Technical University of Munich,Not Applicable
NCT00169988,2004.0,OTHER,lead,Northwell Health,Not Applicable
NCT00169988,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00169988,2004.0,INDUSTRY,collaborator,"Janssen Pharmaceutica N.V., Belgium",Not Applicable
NCT00169988,2004.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00170378,2002.0,OTHER,lead,Hennepin Healthcare Research Institute,Phase 4
NCT00170378,2002.0,INDUSTRY,collaborator,Aventis Pharmaceuticals,Phase 4
NCT00171730,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00171795,2002.0,INDUSTRY,lead,Novartis,Phase 3
NCT00171886,2002.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00171951,2004.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00172094,2003.0,INDUSTRY,lead,Shire,Phase 2
NCT00173706,2004.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT00173745,2003.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT00173745,2003.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Not Applicable
NCT00174174,2003.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT00174200,2004.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT00174239,2004.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00174265,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00174382,2005.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00174395,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00174447,2001.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00174486,2005.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00174525,2005.0,OTHER,lead,Pharmacology Research Institute,Phase 2
NCT00174551,2003.0,OTHER,lead,Rainier Associates,Not Applicable
NCT00174876,2004.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 2
NCT00174876,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT00174889,2005.0,OTHER,lead,Sha'ar Menashe Mental Health Center,Phase 1
NCT00174889,2005.0,OTHER_GOV,collaborator,Beersheva Mental Health Center,Phase 1
NCT00174902,2003.0,OTHER,lead,Swiss Federal Institute of Technology,Phase 1/Phase 2
NCT00174902,2003.0,OTHER,collaborator,Swiss National Science Foundation,Phase 1/Phase 2
NCT00174980,2005.0,INDUSTRY,lead,"Tenax Therapeutics, Inc.",Phase 2
NCT00174980,2005.0,OTHER,collaborator,Virginia Commonwealth University,Phase 2
NCT00175123,2005.0,OTHER,lead,University of Aarhus,Phase 4
NCT00175123,2005.0,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT00175305,2004.0,OTHER,lead,University of British Columbia,Phase 3
NCT00175513,2005.0,OTHER,lead,University of British Columbia,Phase 2
NCT00175513,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00175682,2004.0,OTHER,lead,University of British Columbia,Not Applicable
NCT00175825,2005.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00175851,2008.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00175864,2006.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00175890,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00175903,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00175916,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00175929,2005.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00176163,2005.0,OTHER,lead,Heidelberg University,Phase 2
NCT00176163,2005.0,OTHER,collaborator,"Central Institute of Mental Health, Mannheim",Phase 2
NCT00176163,2005.0,OTHER,collaborator,University of Mannheim,Phase 2
NCT00176163,2005.0,OTHER,collaborator,"Academic City Hospital, Germany",Phase 2
NCT00176163,2005.0,OTHER,collaborator,BG Trauma Center Ludwigshafen,Phase 2
NCT00176202,2003.0,OTHER,lead,University of Illinois at Chicago,Phase 3
NCT00176228,2004.0,OTHER,lead,University of Illinois at Chicago,Phase 2
NCT00176228,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00176423,2002.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00176423,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00176423,2002.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00176436,2004.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00176436,2004.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00176449,2001.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00176449,2001.0,FED,collaborator,US Department of Veterans Affairs,Phase 4
NCT00176553,2003.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Not Applicable
NCT00176592,2003.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 4
NCT00176904,1995.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2/Phase 3
NCT00177008,2004.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 4
NCT00177008,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00177177,2004.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00177177,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00177216,2002.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177216,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00177294,2004.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177294,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00177424,2004.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177424,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00177528,2000.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177567,2001.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177580,2003.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177580,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00177671,2003.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00177671,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00178035,1999.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00178048,1998.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00178048,1998.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00178100,1999.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00178451,,OTHER,lead,University of Rochester,Phase 1/Phase 2
NCT00178451,,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1/Phase 2
NCT00178646,2002.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 4
NCT00178646,2002.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT00178828,2002.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT00178919,2002.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT00178932,1998.0,OTHER,lead,Northwestern University,Not Applicable
NCT00178971,2003.0,OTHER,lead,Northwestern University,Phase 3
NCT00178971,2003.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00179062,2000.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT00179231,2000.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT00179244,2004.0,OTHER,lead,Vanderbilt University,Phase 3
NCT00179244,2004.0,INDUSTRY,collaborator,Janssen Pharmaceutica,Phase 3
NCT00179465,2003.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 3
NCT00179465,2003.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 3
NCT00179478,2001.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 4
NCT00179478,2001.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT00179517,2001.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT00179517,2001.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT00179881,1999.0,OTHER,lead,Ann & Robert H Lurie Children's Hospital of Chicago,Phase 2
NCT00180037,2003.0,OTHER,lead,Technische Universität Dresden,Phase 3
NCT00180037,2003.0,UNKNOWN,collaborator,Deutsche Parkinson-Vereinigung e.V.,Phase 3
NCT00180037,2003.0,UNKNOWN,collaborator,"MSE Pharmazeutika GmbH, Bad Homburg",Phase 3
NCT00180791,2002.0,OTHER,lead,"Gustave Roussy, Cancer Campus, Grand Paris",Phase 2
NCT00181116,2005.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT00181116,2005.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT00181246,2003.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00181246,2003.0,INDUSTRY,collaborator,"PriCara, Unit of Ortho-McNeil, Inc.",Not Applicable
NCT00181636,,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00181727,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181727,2004.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00181779,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181779,2003.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00181844,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181870,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181870,2005.0,INDUSTRY,collaborator,Shire,Phase 4
NCT00181883,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181896,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181922,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181922,2002.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00181935,2001.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181961,2007.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00181987,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00181987,2002.0,INDUSTRY,collaborator,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Phase 4
NCT00182000,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00182000,2003.0,OTHER,collaborator,Hartford Hospital,Phase 3
NCT00182078,2002.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00182091,2004.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00182442,2003.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 4
NCT00182442,2003.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00182507,2000.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 4
NCT00182507,2000.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00182520,2002.0,OTHER,lead,McMaster University,Phase 4
NCT00182520,2002.0,INDUSTRY,collaborator,"Janssen-Ortho Inc., Canada",Phase 4
NCT00182520,2002.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Phase 4
NCT00182533,2002.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 4
NCT00182533,2002.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00182845,2005.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00182884,2004.0,OTHER,lead,Indiana University Health,Phase 4
NCT00183040,2002.0,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT00183092,2005.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT00183092,2005.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00183170,2004.0,OTHER,lead,Boston University,Phase 2
NCT00183170,2004.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00183274,2004.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00183274,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00183430,2003.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00183430,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00183443,2005.0,OTHER,lead,Palo Alto Veterans Institute for Research,Phase 3
NCT00183443,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00183469,2004.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT00183469,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00183560,2004.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT00183560,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00183612,2000.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00183612,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00183625,2000.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00183625,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00183625,2000.0,FED,collaborator,US Department of Veterans Affairs,Phase 4
NCT00183677,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00183729,2005.0,OTHER,lead,Eric Lenze,Phase 4
NCT00183729,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00184106,2004.0,OTHER,lead,Norwegian University of Science and Technology,Phase 4
NCT00184106,2004.0,OTHER,collaborator,St. Olavs Hospital,Phase 4
NCT00184587,2005.0,OTHER,lead,Norwegian University of Science and Technology,Phase 2
NCT00184587,2005.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT00185211,2002.0,INDUSTRY,lead,Bayer,Phase 3
NCT00185575,2004.0,OTHER,lead,Stanford University,Not Applicable
NCT00185575,2004.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00185848,2005.0,OTHER,lead,Sanjiv Sam Gambhir,Phase 1
NCT00186017,2005.0,OTHER,lead,Stanford University,Phase 4
NCT00186017,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00186056,2003.0,OTHER,lead,Stanford University,Not Applicable
NCT00186186,2004.0,OTHER,lead,Stanford University,Phase 4
NCT00186186,2004.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00186186,2004.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00186446,2004.0,OTHER,lead,Stanford University,Phase 4
NCT00186446,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00186784,2000.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Early Phase 1
NCT00186784,2000.0,OTHER,collaborator,"Queen's University, Kingston, Ontario",Early Phase 1
NCT00187057,2002.0,OTHER,lead,St. Jude Children's Research Hospital,Not Applicable
NCT00187057,2002.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT00187057,2002.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00187174,2004.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 1
NCT00187174,2004.0,INDUSTRY,collaborator,Novartis,Phase 1
NCT00187525,2004.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT00187525,2004.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00187928,2003.0,OTHER,lead,University of Florida,Phase 3
NCT00187928,2003.0,INDUSTRY,collaborator,Ortho-McNeil Pharmaceutical,Phase 3
NCT00188383,2004.0,OTHER,lead,"University Health Network, Toronto",Phase 1/Phase 2
NCT00188383,2004.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 1/Phase 2
NCT00188396,2004.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT00188396,2004.0,OTHER_GOV,collaborator,Ontario Mental Health Foundation,Not Applicable
NCT00188643,2002.0,OTHER,lead,"University Health Network, Toronto",Phase 4
NCT00189995,,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00190008,2003.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00190008,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00190047,2005.0,INDUSTRY,lead,D-Pharm Ltd.,Phase 2
NCT00190060,2004.0,OTHER_GOV,lead,Manchester University NHS Foundation Trust,Phase 4
NCT00190060,2004.0,OTHER,collaborator,University of Manchester,Phase 4
NCT00190060,2004.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT00190268,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00190372,2004.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT00190450,2002.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00190749,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00190866,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00190866,2005.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00190892,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00190970,2004.0,INDUSTRY,lead,"Chromaderm, Inc.",Phase 2
NCT00191009,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2/Phase 3
NCT00191061,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00191399,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00191555,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00191906,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00191997,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00192725,2003.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT00192725,2003.0,OTHER_GOV,collaborator,Beersheva Mental Health Center,Not Applicable
NCT00192855,2003.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT00193687,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 3
NCT00193713,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 3
NCT00194012,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00194012,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT00194025,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT00194025,2004.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00194038,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT00194038,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00194064,2002.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00194064,2002.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00194077,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00194077,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT00194116,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00194116,2004.0,INDUSTRY,collaborator,Abbott,Phase 3
NCT00194129,1997.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00194129,1997.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00194129,1997.0,INDUSTRY,collaborator,Abbott,Phase 3
NCT00194480,2003.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00194480,2003.0,OTHER,collaborator,University of Washington,Phase 4
NCT00194909,2004.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00194909,2004.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00195013,2003.0,OTHER,lead,Weill Medical College of Cornell University,Phase 3
NCT00195143,2003.0,INDUSTRY,lead,"Neurologix, Inc.",Phase 1
NCT00195143,2003.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 1
NCT00195143,2003.0,OTHER,collaborator,North Shore University Hospital,Phase 1
NCT00195520,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00195598,2005.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00195741,2003.0,INDUSTRY,lead,Abbott,Phase 3
NCT00195754,2004.0,INDUSTRY,lead,Abbott,Phase 3
NCT00195806,2005.0,INDUSTRY,lead,Abbott,Phase 3
NCT00195845,2003.0,OTHER,lead,Cambridge Health Alliance,Phase 4
NCT00195845,2003.0,OTHER,collaborator,Northwestern University,Phase 4
NCT00196131,2005.0,OTHER,lead,Dalhousie University,Phase 1/Phase 2
NCT00196131,2005.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 1/Phase 2
NCT00196690,2003.0,OTHER,lead,Gabinete Berthier y Martínez,Phase 4
NCT00196690,2003.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00196703,2005.0,OTHER,lead,Gabinete Berthier y Martínez,Phase 4
NCT00196703,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00196716,2003.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00197080,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00197093,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00197834,2004.0,INDUSTRY,lead,Hearthstone Alzheimer Care,Phase 1
NCT00197834,2004.0,INDUSTRY,collaborator,Abbott,Phase 1
NCT00197951,2004.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 3
NCT00197951,2004.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00198094,2003.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00198094,2003.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00198094,2003.0,OTHER,collaborator,University of Pennsylvania,Phase 4
NCT00198094,2003.0,OTHER,collaborator,University of South Florida,Phase 4
NCT00198198,2005.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00199355,2005.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT00199368,2004.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 3
NCT00199368,2004.0,INDUSTRY,collaborator,"Kyowa Hakko Kirin UK, Ltd.",Phase 3
NCT00199381,2005.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 3
NCT00199394,2004.0,INDUSTRY,lead,"Kyowa Hakko Kirin UK, Ltd.",Phase 3
NCT00199407,2004.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 3
NCT00199420,2004.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 3
NCT00199433,2005.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 2
NCT00199446,2005.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 2
NCT00199511,2005.0,OTHER,lead,Lawson Health Research Institute,Not Applicable
NCT00199563,2004.0,OTHER,lead,Lawson Health Research Institute,Phase 4
NCT00199706,2002.0,OTHER,lead,Oslo University Hospital,Phase 2
NCT00199745,2005.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT00199745,2005.0,OTHER,collaborator,University of Oslo School of Pharmacy,Phase 4
NCT00199940,2003.0,OTHER,lead,Medical College of Wisconsin,Phase 4
NCT00199966,2003.0,OTHER,lead,Medical College of Wisconsin,Phase 4
NCT00200356,2004.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 4
NCT00200447,2004.0,OTHER,lead,Molecular NeuroImaging,Phase 2
NCT00200512,1999.0,INDUSTRY,lead,Mylan Bertek Pharmaceuticals,Phase 2/Phase 3
NCT00200525,2001.0,INDUSTRY,lead,Mylan Bertek Pharmaceuticals,Phase 3
NCT00200538,2005.0,OTHER,lead,Nantes University Hospital,Phase 2
NCT00200785,2006.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00200902,2005.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00200902,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 4
NCT00200902,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00200902,2005.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00200941,2001.0,OTHER,lead,Neurocare,Phase 4
NCT00200941,2001.0,INDUSTRY,collaborator,Ortho-McNeil Pharmaceutical,Phase 4
NCT00201461,2003.0,INDUSTRY,lead,NMT Medical,Phase 2/Phase 3
NCT00201994,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00201994,2003.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00202007,2005.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 2
NCT00202007,2005.0,INDUSTRY,collaborator,"Zhejiang Otsuka Pharmaceutical Co., Ltd.",Phase 2
NCT00202020,2004.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 3
NCT00202020,2004.0,INDUSTRY,collaborator,"Zhejiang Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00202124,2001.0,OTHER,lead,Queen's University,Phase 4
NCT00202163,2006.0,OTHER,lead,Queen's University,Phase 2
NCT00202293,2001.0,OTHER,lead,Melbourne Health,Phase 4
NCT00202306,2001.0,OTHER,lead,Melbourne Health,Phase 4
NCT00202306,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00202397,2005.0,OTHER,lead,S. Andrea Hospital,Phase 2
NCT00202410,2001.0,OTHER,lead,S. Andrea Hospital,Phase 2/Phase 3
NCT00202410,2001.0,OTHER,collaborator,Italian Multiple Sclerosis Foundation,Phase 2/Phase 3
NCT00202410,2001.0,OTHER,collaborator,Istituto Superiore di Sanità,Phase 2/Phase 3
NCT00202423,2005.0,OTHER,lead,S. Andrea Hospital,Phase 2
NCT00202423,2005.0,OTHER,collaborator,University of Roma La Sapienza,Phase 2
NCT00202449,2004.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00202449,2004.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT00202449,2004.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT00202462,2002.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00202462,2002.0,OTHER,collaborator,American Federation for Aging Research,Not Applicable
NCT00202462,2002.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT00202462,2002.0,OTHER,collaborator,Geriatric Research Education and Clinical Care,Not Applicable
NCT00202462,2002.0,OTHER,collaborator,University of Washington,Not Applicable
NCT00202462,2002.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Not Applicable
NCT00202514,2004.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 2/Phase 3
NCT00202514,2004.0,INDUSTRY,collaborator,Abbott,Phase 2/Phase 3
NCT00202930,2005.0,OTHER,lead,"Jean M. Tersak, M.D.",Phase 2
NCT00202930,2005.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00202995,2004.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT00203021,1994.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT00203034,2000.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00203047,2005.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT00203060,1997.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 3
NCT00203073,2003.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00203125,2000.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00203138,2004.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00203164,2002.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00203177,2001.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00203190,2004.0,OTHER,lead,Thomas Jefferson University,Phase 4
NCT00203190,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00203216,2002.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203216,2002.0,INDUSTRY,collaborator,UCB Pharma,Not Applicable
NCT00203229,2003.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203242,2003.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203242,2003.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT00203255,2003.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203255,2003.0,INDUSTRY,collaborator,Johnson & Johnson,Not Applicable
NCT00203268,2003.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203268,2003.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Not Applicable
NCT00203294,2005.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00203320,2005.0,OTHER,lead,"Tobinick, Edward Lewis, M.D.",Phase 1
NCT00203359,2004.0,OTHER,lead,"Tobinick, Edward Lewis, M.D.",Phase 1
NCT00203385,2003.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 4
NCT00203463,2001.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 4
NCT00203463,2001.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00203528,2004.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 4
NCT00203528,2004.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00203567,2005.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 4
NCT00203567,2005.0,INDUSTRY,collaborator,Shire,Phase 4
NCT00203775,2002.0,OTHER,lead,University of Connecticut,Not Applicable
NCT00203775,2002.0,INDUSTRY,collaborator,"Janssen Pharmaceutica N.V., Belgium",Not Applicable
NCT00203788,1999.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00203788,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00203957,2005.0,OTHER,lead,University of Chicago,Phase 3
NCT00203996,2003.0,OTHER,lead,University of Chicago,Phase 4
NCT00203996,2003.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT00203996,2003.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT00204061,2001.0,OTHER,lead,University of Cologne,Phase 4
NCT00204061,2001.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00204061,2001.0,NETWORK,collaborator,German Research Network On Schizophrenia,Phase 4
NCT00204061,2001.0,INDUSTRY,collaborator,Sanofi-Synthelabo,Phase 4
NCT00204061,2001.0,OTHER,collaborator,Department of Psychiatry University of Bonn,Phase 4
NCT00204061,2001.0,OTHER,collaborator,"Heinrich-Heine University, Duesseldorf",Phase 4
NCT00204061,2001.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 4
NCT00204074,2001.0,OTHER,lead,"University Hospital, Linkoeping",Phase 2/Phase 3
NCT00204295,2004.0,OTHER,lead,University Hospital Muenster,Phase 2
NCT00204347,2003.0,OTHER,lead,University of Alabama at Birmingham,Phase 4
NCT00204347,2003.0,INDUSTRY,collaborator,Janssen Pharmaceutica,Phase 4
NCT00204386,2002.0,OTHER,lead,University of Oklahoma,Phase 2/Phase 3
NCT00204386,2002.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 2/Phase 3
NCT00204971,2003.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT00205179,2005.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT00205179,2005.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00205179,2005.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00205491,2004.0,OTHER,lead,Virginia Commonwealth University,Phase 4
NCT00205491,2004.0,FED,collaborator,U.S. Department of Education,Phase 4
NCT00205582,2001.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 1
NCT00205660,2005.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00205660,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00205699,2006.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00205699,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00205712,2003.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00205712,2003.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00205725,2000.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00205725,2000.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00205738,2000.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00205738,2000.0,INDUSTRY,collaborator,"Janssen, LP",Not Applicable
NCT00206102,2003.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00206115,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00206128,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00206141,2005.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00206323,2004.0,OTHER,lead,Baylor College of Medicine,Phase 3
NCT00206323,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 3
NCT00206336,2004.0,OTHER,lead,Baylor College of Medicine,Phase 3
NCT00206336,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 3
NCT00206544,2004.0,OTHER,lead,The Alfred,Phase 2
NCT00206544,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00206544,2004.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 2
NCT00206557,2002.0,OTHER,lead,The Alfred,Phase 2
NCT00206557,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00206570,2001.0,OTHER_GOV,lead,Bayside Health,Phase 2
NCT00206570,2001.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 2
NCT00206570,2001.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00206570,2001.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 2
NCT00206648,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00206687,2003.0,INDUSTRY,lead,Bayer,Phase 2
NCT00206687,2003.0,INDUSTRY,collaborator,Titan Pharmaceuticals,Phase 2
NCT00206765,2003.0,OTHER,lead,Beth Israel Medical Center,Phase 2
NCT00206947,2002.0,OTHER,lead,Birte Glenthoj,Phase 2
NCT00206947,2002.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 2
NCT00206947,2002.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Phase 2
NCT00206947,2002.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00206960,1998.0,OTHER,lead,Birte Glenthoj,Not Applicable
NCT00206960,1998.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT00206960,1998.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT00206960,1998.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT00206960,1998.0,OTHER,collaborator,Hvidovre University Hospital,Not Applicable
NCT00206960,1998.0,OTHER,collaborator,The Danish Medical Research Council,Not Applicable
NCT00206960,1998.0,OTHER,collaborator,Copenhagen Hospital Corporation,Not Applicable
NCT00206960,1998.0,INDUSTRY,collaborator,Janssen-Cilag Ltd.,Not Applicable
NCT00206960,1998.0,OTHER,collaborator,The Novo Nordic Foundation,Not Applicable
NCT00206986,2005.0,OTHER,lead,Birte Glenthoj,Not Applicable
NCT00206986,2005.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT00206986,2005.0,OTHER,collaborator,Lundbeck Foundation,Not Applicable
NCT00206986,2005.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT00207064,2004.0,OTHER,lead,Birte Glenthoj,Not Applicable
NCT00207064,2004.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT00207064,2004.0,OTHER,collaborator,"Copenhagen University Hospital, Hvidovre",Not Applicable
NCT00207064,2004.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT00207064,2004.0,OTHER,collaborator,The Danish Medical Research Council,Not Applicable
NCT00207064,2004.0,OTHER,collaborator,Copenhagen Hospital Corporation,Not Applicable
NCT00207064,2004.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT00207064,2004.0,INDUSTRY,collaborator,AstraZeneca,Not Applicable
NCT00207727,2004.0,INDUSTRY,lead,"Centocor, Inc.",Phase 2
NCT00207727,2004.0,INDUSTRY,collaborator,Centocor BV,Phase 2
NCT00207935,2005.0,OTHER,lead,Children's National Research Institute,Phase 4
NCT00208065,2004.0,OTHER,lead,Clinvest,Phase 4
NCT00208065,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00208117,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT00208117,2005.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 1
NCT00208130,2001.0,OTHER,lead,Creighton University,Phase 4
NCT00208130,2001.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00208143,2003.0,OTHER,lead,Creighton University,Phase 4
NCT00208143,2003.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00208169,2005.0,OTHER,lead,Creighton University,Phase 4
NCT00208169,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00208182,2001.0,OTHER,lead,Creighton University,Phase 4
NCT00208182,2001.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00208195,2004.0,OTHER,lead,Creighton University,Phase 4
NCT00208195,2004.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00208208,2002.0,OTHER,lead,Creighton University,Phase 4
NCT00208208,2002.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00208572,2003.0,FED,lead,Walter Reed Army Medical Center,Not Applicable
NCT00208572,2003.0,FED,collaborator,The Defense and Veterans Brain Injury Center,Not Applicable
NCT00208572,2003.0,FED,collaborator,VA Palo Alto Health Care System,Not Applicable
NCT00208572,2003.0,FED,collaborator,Hunter Holmes McGuire VA Medical Center,Not Applicable
NCT00208572,2003.0,FED,collaborator,"United States Naval Medical Center, San Diego",Not Applicable
NCT00208572,2003.0,FED,collaborator,59th Medical Wing,Not Applicable
NCT00208572,2003.0,FED,collaborator,James A. Haley Veterans Administration Hospital,Not Applicable
NCT00208585,2000.0,FED,lead,Walter Reed Army Medical Center,Not Applicable
NCT00208585,2000.0,FED,collaborator,The Defense and Veterans Brain Injury Center,Not Applicable
NCT00208585,2000.0,FED,collaborator,Minneapolis Veterans Affairs Medical Center,Not Applicable
NCT00208585,2000.0,FED,collaborator,VA Palo Alto Health Care System,Not Applicable
NCT00208585,2000.0,FED,collaborator,Hunter Holmes McGuire VA Medical Center,Not Applicable
NCT00208585,2000.0,FED,collaborator,"United States Naval Medical Center, San Diego",Not Applicable
NCT00208585,2000.0,FED,collaborator,James A. Haley Veterans Administration Hospital,Not Applicable
NCT00208585,2000.0,FED,collaborator,59th Medical Wing,Not Applicable
NCT00208611,2006.0,OTHER,lead,Emory University,Phase 2/Phase 3
NCT00208611,2006.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2/Phase 3
NCT00208767,2005.0,OTHER,lead,Emory University,Phase 2
NCT00208819,2003.0,OTHER,lead,Emory University,Phase 4
NCT00208819,2003.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00208858,2004.0,OTHER,lead,Emory University,Phase 2
NCT00209027,2005.0,OTHER,lead,Emory University,Not Applicable
NCT00209027,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00209118,,OTHER,lead,Emory University,Not Applicable
NCT00209170,2004.0,OTHER,lead,Emory University,Phase 4
NCT00209170,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00209456,2003.0,INDUSTRY,lead,GE Healthcare,Phase 3
NCT00209508,2002.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00209508,2002.0,INDUSTRY,collaborator,Symphony Neuro Development Company,Phase 2
NCT00210301,2003.0,OTHER,lead,Institute for Clinical Research,Not Applicable
NCT00210457,2000.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00210483,2003.0,INDUSTRY,lead,Janssen-Ortho LLC,Phase 3
NCT00210483,2003.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00210496,2005.0,INDUSTRY,lead,Janssen-Ortho LLC,Phase 4
NCT00210496,2005.0,INDUSTRY,collaborator,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00210509,2004.0,INDUSTRY,lead,Janssen-Ortho LLC,Phase 4
NCT00210509,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00210522,2005.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00210548,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210574,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00210574,2005.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 2
NCT00210652,2004.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00210691,1999.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210704,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210717,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210769,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210782,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210782,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00210808,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2/Phase 3
NCT00210808,2003.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 2/Phase 3
NCT00210821,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210821,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00210847,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210847,2003.0,INDUSTRY,collaborator,"PriCara, Unit of Ortho-McNeil, Inc.",Phase 3
NCT00210860,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210860,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00210873,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210873,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00210912,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00210912,2003.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00211159,2000.0,OTHER,lead,Karolinska University Hospital,Not Applicable
NCT00211224,2000.0,OTHER,lead,King's College London,Phase 3
NCT00211224,2000.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00211224,2000.0,OTHER,collaborator,University of Ulm,Phase 3
NCT00211224,2000.0,INDUSTRY,collaborator,Aventis Pharmaceuticals,Phase 3
NCT00211250,2005.0,OTHER,lead,Joliet Center for Clinical Research,Phase 4
NCT00211250,2005.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00211263,2003.0,INDIV,lead,"Kupfer, David J., M.D.",Not Applicable
NCT00211263,2003.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00211263,2003.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT00211263,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00211263,2003.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00211263,2003.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00211302,2003.0,OTHER,lead,Louisiana State University Health Sciences Center Shreveport,Not Applicable
NCT00211302,2003.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00211367,2004.0,OTHER,lead,"Manhattan Eye, Ear & Throat Hospital",Phase 2
NCT00211367,2004.0,INDUSTRY,collaborator,Alcon Research,Phase 2
NCT00211380,2003.0,OTHER,lead,Louisiana State University Health Sciences Center Shreveport,Not Applicable
NCT00211380,2003.0,UNKNOWN,collaborator,SAM Technology & The San Francisco Brain Research Institute,Not Applicable
NCT00211562,2005.0,OTHER,lead,Augusta University,Phase 3
NCT00211562,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00211562,2005.0,UNKNOWN,collaborator,Medical Service Line ABRC,Phase 3
NCT00211562,2005.0,FED,collaborator,US Department of Veterans Affairs,Phase 3
NCT00211588,2004.0,OTHER,lead,Memorial Hospital of Rhode Island,Not Applicable
NCT00211588,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Not Applicable
NCT00211614,2006.0,OTHER,lead,MetroHealth Medical Center,Not Applicable
NCT00211809,2008.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00211887,2005.0,OTHER,lead,Fred Lublin,Phase 3
NCT00211887,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00212147,2003.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT00212316,2005.0,OTHER,lead,University of Rochester,Phase 2
NCT00212316,2005.0,OTHER,collaborator,HP Therapeutics Foundation,Phase 2
NCT00212316,2005.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00212316,2005.0,OTHER,collaborator,Columbia University,Phase 2
NCT00212316,2005.0,OTHER,collaborator,University of Iowa,Phase 2
NCT00212316,2005.0,OTHER,collaborator,"University of California, San Diego",Phase 2
NCT00212316,2005.0,OTHER,collaborator,University of Kansas,Phase 2
NCT00212316,2005.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 2
NCT00212316,2005.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00212355,2005.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT00212693,2004.0,INDUSTRY,lead,Ono Pharmaceutical Co. Ltd,Phase 2
NCT00212771,2004.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00212784,2003.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00212797,2004.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00212810,2005.0,INDUSTRY,lead,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00212823,2004.0,INDUSTRY,lead,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00212836,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00213135,2005.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00214071,2004.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT00214084,,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT00214500,2006.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00214578,2004.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00214682,2005.0,OTHER,lead,Australian National University,Phase 2
NCT00214682,2005.0,OTHER_GOV,collaborator,Australian Government Department of Health and Ageing,Phase 2
NCT00214682,2005.0,OTHER,collaborator,University of Sydney,Phase 2
NCT00214682,2005.0,OTHER_GOV,collaborator,"Commonwealth Scientific and Industrial Research Organisation, Australia",Phase 2
NCT00214877,2003.0,OTHER,lead,Nova Scotia Health Authority,Phase 3
NCT00214877,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00214968,2005.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00214994,2005.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00215163,2002.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00215163,2002.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00215163,2002.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT00215215,2005.0,INDUSTRY,lead,"Cyberonics, Inc.",Phase 4
NCT00215241,2004.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00215241,2004.0,INDUSTRY,collaborator,Janssen Pharmaceuticals,Phase 2/Phase 3
NCT00215527,2005.0,INDIV,lead,"Patricia I. Dickson, M.D.",Phase 1
NCT00215527,2005.0,OTHER,collaborator,The Ryan Foundation,Phase 1
NCT00215527,2005.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1
NCT00215527,2005.0,FED,collaborator,FDA Office of Orphan Products Development,Phase 1
NCT00215579,2004.0,OTHER,lead,Duke University,Phase 4
NCT00215579,2004.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00215592,2005.0,INDUSTRY,lead,Eisai Limited,Phase 4
NCT00215631,2005.0,OTHER,lead,Erasmus Medical Center,Phase 3
NCT00215800,1998.0,INDUSTRY,lead,AIM ImmunoTech Inc.,Phase 3
NCT00215878,2003.0,OTHER,lead,Herzog Hospital,Phase 2
NCT00215904,2003.0,OTHER,lead,Herzog Hospital,Phase 4
NCT00215917,,OTHER,lead,Herzog Hospital,Phase 1/Phase 2
NCT00216268,2005.0,OTHER_GOV,lead,Indian Council of Medical Research,Phase 2
NCT00216398,2004.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00216411,2004.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00216476,2004.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT00216502,2001.0,INDUSTRY,lead,Janssen-Cilag S.p.A.,Phase 3
NCT00216515,2004.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00216528,2005.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00216554,2004.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00216567,2002.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00216580,2004.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00216593,2003.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00216606,2003.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00216619,2003.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00216632,2005.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 4
NCT00216671,2005.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 4
NCT00216736,2005.0,OTHER,lead,The Joseph Epstein Centre for Emergency Medicine Research,Phase 4
NCT00217165,2005.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00217295,2004.0,OTHER,lead,Multiple Sclerosis Institute,Phase 2
NCT00217763,2005.0,INDUSTRY,lead,Bellus Health Inc. - a GSK company,Phase 3
NCT00217932,2000.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00217971,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00217971,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218023,2006.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218023,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218036,2006.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218036,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218036,2006.0,OTHER,collaborator,University of Texas,Phase 2
NCT00218049,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00218049,2004.0,OTHER,collaborator,University of Texas,Phase 1
NCT00218062,2006.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218062,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218075,2000.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218075,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218075,2000.0,OTHER,collaborator,University of Texas,Phase 2
NCT00218114,2000.0,OTHER,lead,New York State Psychiatric Institute,Phase 3
NCT00218114,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00218140,,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218153,2000.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00218166,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218218,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218231,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218244,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00218257,2002.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00218257,2002.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00218270,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218283,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218283,2005.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00218296,2006.0,OTHER,lead,University of Minnesota,Phase 2
NCT00218322,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00218322,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00218348,2003.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218348,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218374,2006.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00218387,2004.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00218387,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218439,2005.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00218439,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00218465,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00218465,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218465,2006.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT00218465,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00218491,2005.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00218491,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218517,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218543,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00218543,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218569,2003.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00218569,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00218608,2001.0,OTHER,lead,University of Arkansas,Phase 2
NCT00218608,2001.0,OTHER,collaborator,Yale University,Phase 2
NCT00218660,1998.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT00218660,1998.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00219232,2003.0,INDUSTRY,lead,Novartis,Phase 3
NCT00219401,2005.0,OTHER_GOV,lead,Papua New Guinea Institute of Medical Research,Phase 2
NCT00219401,2005.0,OTHER,collaborator,The University of Western Australia,Phase 2
NCT00219479,1997.0,OTHER,lead,Penn State University,Phase 4
NCT00219544,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00219869,2005.0,INDIV,lead,"Rapoport, Alan, M.D.",Phase 4
NCT00219869,2005.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00219908,1999.0,OTHER,lead,Rennes University Hospital,Phase 2
NCT00219908,1999.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT00219908,1999.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00219908,1999.0,UNKNOWN,collaborator,"Farmades, Italy",Phase 2
NCT00220272,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00220350,2001.0,INDIV,lead,"Schober, Justine, M.D.",Phase 2/Phase 3
NCT00220350,2001.0,INDUSTRY,collaborator,TAP Pharmaceutical Products Inc.,Phase 2/Phase 3
NCT00220428,1998.0,OTHER_GOV,lead,Sheba Medical Center,Phase 1/Phase 2
NCT00220493,2003.0,OTHER_GOV,lead,Sheba Medical Center,Phase 1
NCT00220584,2005.0,OTHER,lead,Stanford University,Phase 1
NCT00220675,2005.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2/Phase 3
NCT00220675,2005.0,INDUSTRY,collaborator,"Ortho Biotech, Inc.",Phase 2/Phase 3
NCT00220714,2004.0,OTHER,lead,State University of New York - Downstate Medical Center,Phase 4
NCT00220714,2004.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00220740,2004.0,INDUSTRY,lead,Grifols Therapeutics LLC,Phase 3
NCT00220779,2002.0,INDUSTRY,lead,Grifols Therapeutics LLC,Phase 2
NCT00220922,2004.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 4
NCT00221338,2006.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT00221390,2003.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT00221390,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00221403,2004.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT00221403,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00221416,2005.0,OTHER,lead,University of Cincinnati,Phase 3
NCT00221416,2005.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT00221416,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT00221429,2001.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT00221429,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00221468,2003.0,OTHER,lead,University of Cincinnati,Phase 3
NCT00221468,2003.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00221481,,OTHER,lead,Mayo Clinic,Phase 4
NCT00221481,,OTHER,collaborator,"University of California, Los Angeles",Phase 4
NCT00221611,2000.0,OTHER,lead,"University Hospital, Ghent",Phase 2
NCT00221637,2002.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2/Phase 3
NCT00221637,2002.0,INDUSTRY,collaborator,Sanofi-Synthelabo,Phase 2/Phase 3
NCT00221689,2003.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT00221689,2003.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 2
NCT00221975,2002.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00221988,2004.0,OTHER,lead,University Hospitals Cleveland Medical Center,Not Applicable
NCT00221988,2004.0,UNKNOWN,collaborator,"Michael Schoenberg, Ignacio Pita, Kyra Dawson",Not Applicable
NCT00222235,2000.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2/Phase 3
NCT00222235,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00222235,2000.0,OTHER,collaborator,The Zucker Hillside Hospital,Phase 2/Phase 3
NCT00222235,2000.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2/Phase 3
NCT00222235,2000.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2/Phase 3
NCT00222235,2000.0,UNKNOWN,collaborator,Sarah Herzog Hospital,Phase 2/Phase 3
NCT00222235,2000.0,OTHER,collaborator,"University of Maryland, College Park",Phase 2/Phase 3
NCT00222482,2003.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00222482,2003.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT00222482,2003.0,INDIV,collaborator,"Schulz, S. Charles, M.D.",Not Applicable
NCT00222495,2002.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00222495,2002.0,INDUSTRY,collaborator,AstraZeneca,Not Applicable
NCT00222495,2002.0,INDIV,collaborator,"Jensen, Jonathan B., M.D.",Not Applicable
NCT00222625,2005.0,OTHER,lead,University Of Perugia,Phase 2
NCT00222794,2003.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00222794,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00223197,2004.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00223197,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00223210,2005.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00223236,2010.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 3
NCT00223249,2002.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00223275,2005.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00223301,2004.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2/Phase 3
NCT00223301,2004.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 2/Phase 3
NCT00223301,2004.0,INDUSTRY,collaborator,Biogen,Phase 2/Phase 3
NCT00223418,2004.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Not Applicable
NCT00223418,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00223496,2004.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT00223496,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00223509,2005.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT00223509,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00223626,2007.0,OTHER,lead,Bankole Johnson,Phase 2
NCT00223626,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00223691,2002.0,OTHER,lead,Vanderbilt University,Phase 1
NCT00223743,2004.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 2
NCT00223743,2004.0,OTHER,collaborator,Ralph M. Parsons Foundation,Phase 2
NCT00223769,2004.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00223860,2001.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00224263,2005.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 2
NCT00224302,2005.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 4
NCT00224497,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00224510,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00224640,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 1/Phase 2
NCT00224757,2005.0,OTHER_GOV,lead,The Interuniversity Cardiology Institute of the Netherlands,Not Applicable
NCT00224770,2005.0,OTHER,lead,Daniel Hanley,Phase 2
NCT00224770,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00224770,2005.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00224770,2005.0,INDUSTRY,collaborator,Emissary International LLC,Phase 2
NCT00224822,2004.0,FED,lead,New Mexico VA Healthcare System,Phase 4
NCT00224822,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00225485,2003.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00225498,2002.0,OTHER,lead,Northwell Health,Not Applicable
NCT00225511,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00225524,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00225615,2005.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT00225862,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00225979,2002.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00226096,2005.0,OTHER,lead,The George Institute,Not Applicable
NCT00226096,2005.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Not Applicable
NCT00226122,2003.0,OTHER,lead,University of Aarhus,Phase 4
NCT00226135,2001.0,OTHER,lead,University of Aarhus,Phase 3
NCT00226135,2001.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00226135,2001.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00226278,2004.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT00226317,2004.0,OTHER,lead,Cambridge Health Alliance,Not Applicable
NCT00226317,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00226343,2003.0,OTHER,lead,Cambridge Health Alliance,Phase 4
NCT00226343,2003.0,OTHER,collaborator,Northwestern University,Phase 4
NCT00226356,2004.0,OTHER,lead,Cambridge Health Alliance,Phase 4
NCT00226356,2004.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00226460,1997.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00226460,1997.0,INDUSTRY,collaborator,Diacrin/Genzyme Corporation LLC,Phase 2
NCT00226642,,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00226655,2005.0,INDUSTRY,lead,Celtic Pharma Development Services,Phase 3
NCT00226655,2005.0,INDUSTRY,collaborator,Neurobiological Technologies,Phase 3
NCT00226668,2006.0,INDUSTRY,lead,Celtic Pharma Development Services,Phase 3
NCT00226668,2006.0,INDUSTRY,collaborator,Neurobiological Technologies,Phase 3
NCT00226824,2005.0,OTHER,lead,Parkinson's Disease and Movement Disorders Center,Phase 4
NCT00226824,2005.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00227123,2002.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00227123,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00227123,2002.0,OTHER,collaborator,University of North Texas Health Science Center,Not Applicable
NCT00227266,2005.0,OTHER,lead,University of Utah,Phase 2
NCT00227266,2005.0,OTHER,collaborator,Families of Spinal Muscular Atrophy,Phase 2
NCT00227266,2005.0,INDUSTRY,collaborator,"Leadiant Biosciences, Inc.",Phase 2
NCT00227266,2005.0,INDUSTRY,collaborator,Abbott,Phase 2
NCT00227292,2007.0,OTHER,lead,Martin-Luther-Universität Halle-Wittenberg,Phase 4
NCT00227305,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00227461,2005.0,OTHER,lead,Kessler Foundation,Phase 1
NCT00227461,2005.0,INDUSTRY,collaborator,UCB Pharma,Phase 1
NCT00227812,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00227942,2003.0,OTHER,lead,"Hadine Joffe, MD",Phase 4
NCT00227942,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00227955,1987.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00227981,1995.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00227994,2003.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00227994,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00228007,2000.0,OTHER,lead,Butler Hospital,Phase 3
NCT00228007,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00228033,2002.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT00228033,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00228150,2003.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00228163,2002.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00228228,2002.0,OTHER_GOV,lead,Sheba Medical Center,Phase 3
NCT00228397,2003.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00228462,2005.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00228553,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00228566,2005.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00228605,2005.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00228969,2005.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00229073,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00229177,2005.0,INDUSTRY,lead,Ono Pharmaceutical Co. Ltd,Phase 2/Phase 3
NCT00229307,2005.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT00229333,2004.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT00229333,2004.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00229385,2006.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT00229437,2005.0,INDUSTRY,lead,Takeda,Phase 2
NCT00229632,2005.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00229736,2004.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT00230074,2004.0,INDUSTRY,lead,Novartis,Phase 2
NCT00230568,2005.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00230568,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00230607,2006.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00230698,1995.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00230737,2004.0,OTHER,lead,Nalaka Gooneratne,Phase 2
NCT00230737,2004.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00230776,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00230828,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 3
NCT00230997,2002.0,INDUSTRY,lead,Neurological Research Center,Phase 3
NCT00230997,2002.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00231335,2006.0,OTHER,lead,Emory University,Phase 4
NCT00231335,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00231439,2003.0,OTHER,lead,Haukeland University Hospital,Phase 2/Phase 3
NCT00231556,1999.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00231595,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00231673,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00231894,2005.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00231946,2005.0,INDUSTRY,lead,Voyager Pharmaceutical Corporation,Phase 3
NCT00231959,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00231959,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00232141,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00232167,2005.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT00232284,2004.0,OTHER,lead,Dan Lubman,Phase 2
NCT00232336,2003.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 4
NCT00232336,2003.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00232349,2005.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 4
NCT00232570,2005.0,OTHER,lead,University of Vermont,Not Applicable
NCT00232570,2005.0,INDUSTRY,collaborator,AstraZeneca,Not Applicable
NCT00232570,2005.0,NIH,collaborator,National Center for Research Resources (NCRR),Not Applicable
NCT00232596,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00232596,2005.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 3
NCT00232687,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00232687,2005.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00233012,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00233025,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00233025,2005.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00233103,2003.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT00233103,2003.0,FED,collaborator,U.S. Department of Education,Phase 2
NCT00233155,2005.0,INDUSTRY,lead,NeurogesX,Phase 2
NCT00233519,2005.0,OTHER,lead,University of Rochester,Phase 1/Phase 2
NCT00233519,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00233519,2005.0,INDUSTRY,collaborator,Imsmed Incorporated,Phase 1/Phase 2
NCT00234065,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00234312,2005.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT00234312,2005.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00234377,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00234442,2004.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00234533,2004.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00234546,2003.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00234572,2000.0,INDUSTRY,lead,Ipsen,Phase 2/Phase 3
NCT00234637,2003.0,INDUSTRY,lead,Novartis,Phase 4
NCT00234676,2003.0,NETWORK,lead,The Parkinson Study Group,Phase 2
NCT00234676,2003.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00234676,2003.0,UNKNOWN,collaborator,Joseph and Rosalyn Newman Foundation,Phase 2
NCT00234689,2002.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT00235053,2005.0,OTHER,lead,Allergy & Asthma Medical Group & Research Center,Phase 4
NCT00235248,2002.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00235248,2002.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 3
NCT00235248,2002.0,INDUSTRY,collaborator,Sanofi,Phase 3
NCT00235248,2002.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT00235274,2005.0,OTHER,lead,Indiana University School of Medicine,Phase 2
NCT00235274,2005.0,INDIV,collaborator,"Shekhar, Anantha M.D., Ph.D.",Phase 2
NCT00235274,2005.0,INDUSTRY,collaborator,Repligen Corporation,Phase 2
NCT00235352,2002.0,OTHER,lead,North Suffolk Mental Health Association,Phase 2/Phase 3
NCT00235352,2002.0,INDUSTRY,collaborator,RespireRx,Phase 2/Phase 3
NCT00235443,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2/Phase 3
NCT00235469,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2/Phase 3
NCT00235716,2007.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00235716,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT00235716,2007.0,INDUSTRY,collaborator,"DSM Nutritional Products, Inc.",Phase 3
NCT00235755,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00235755,2005.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 3
NCT00235963,2002.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT00235989,2003.0,INDUSTRY,lead,Bayer,Phase 2
NCT00236015,2004.0,INDUSTRY,lead,Cephalon,Phase 3
NCT00236353,2002.0,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00236379,,INDUSTRY,lead,"Janssen, LP",Phase 4
NCT00236418,1994.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236431,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236444,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236457,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236470,2002.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236496,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236496,2001.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00236509,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236548,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236548,,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00236561,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236574,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236587,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236691,1988.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00236704,1994.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236717,1997.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236730,1988.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00236743,1994.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236756,1993.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236847,1989.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00236860,1989.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00236873,1989.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00236886,1998.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00236925,2003.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Early Phase 1
NCT00236925,2003.0,OTHER,collaborator,University of Zurich,Early Phase 1
NCT00237263,2003.0,INDUSTRY,lead,Novartis,Phase 2
NCT00237289,2001.0,INDUSTRY,lead,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00237302,2001.0,INDUSTRY,lead,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00237393,2003.0,FED,lead,Ralph H. Johnson VA Medical Center,Phase 4
NCT00237393,2003.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00237705,2004.0,OTHER,lead,Vancouver General Hospital,Not Applicable
NCT00237770,2003.0,FED,lead,US Department of Veterans Affairs,Phase 2/Phase 3
NCT00237809,2002.0,OTHER,lead,Yale University,Phase 3
NCT00237809,2002.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00237809,2002.0,OTHER,collaborator,Donaghue Medical Research Foundation,Phase 3
NCT00237848,2005.0,OTHER,lead,Yale University,Phase 3
NCT00237848,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00237848,2005.0,UNKNOWN,collaborator,Donaghue Foundation,Phase 3
NCT00237848,2005.0,FED,collaborator,US Department of Veterans Affairs,Phase 3
NCT00237848,2005.0,FED,collaborator,VA Office of Research and Development,Phase 3
NCT00237861,,OTHER,lead,Yale University,Phase 4
NCT00237861,,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00237874,2004.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT00237874,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2/Phase 3
NCT00237913,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00237913,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00237939,2002.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00237939,2002.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00238030,2004.0,OTHER,lead,Lawson Health Research Institute,Phase 1/Phase 2
NCT00238108,2005.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00238108,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00238108,2005.0,NIH,collaborator,Office of Dietary Supplements (ODS),Phase 2
NCT00238511,2002.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00238524,2003.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00238537,2001.0,OTHER,lead,Melbourne Health,Phase 2
NCT00238537,2001.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 2
NCT00238550,2003.0,OTHER,lead,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 2
NCT00238550,2003.0,OTHER,collaborator,Diabetes UK,Phase 2
NCT00238641,2002.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT00238641,2002.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 1/Phase 2
NCT00238667,2005.0,OTHER,lead,"St George's, University of London",Phase 3
NCT00238667,2005.0,OTHER,collaborator,"The Stroke Association, United Kingdom",Phase 3
NCT00239109,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00239356,2003.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00239356,2003.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00239486,2002.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00239525,2006.0,OTHER,lead,Duke University,Not Applicable
NCT00239564,2005.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 1/Phase 2
NCT00239655,2004.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00239746,2005.0,NIH,lead,National Institute on Aging (NIA),Phase 1
NCT00239993,2005.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 4
NCT00240032,2004.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT00240110,2006.0,OTHER,lead,University of Miami,Phase 1/Phase 2
NCT00240110,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00240227,2004.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00240409,2003.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00240617,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00240630,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00240695,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00240708,2004.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT00240721,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00240760,2005.0,OTHER,lead,King's College London,Not Applicable
NCT00240812,,INDUSTRY,lead,Johnson & Johnson Consumer and Personal Products Worldwide,Phase 2
NCT00240981,2005.0,OTHER,lead,Boston Medical Center,Phase 4
NCT00240981,2005.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT00241176,2005.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00241254,2005.0,OTHER,lead,"University Hospital, Bordeaux",Phase 3
NCT00241254,2005.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT00241579,2002.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00241670,1999.0,INDUSTRY,lead,medac GmbH,Phase 3
NCT00242008,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00242177,2003.0,OTHER,lead,University of Illinois at Chicago,Phase 1
NCT00242177,2003.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 1
NCT00242268,2005.0,OTHER,lead,"Alabama Neurology Associates, PC",Phase 3
NCT00242268,2005.0,INDUSTRY,collaborator,Biogen,Phase 3
NCT00242541,2003.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00242606,2005.0,OTHER,lead,Philipps University Marburg Medical Center,Phase 3
NCT00242606,2005.0,INDUSTRY,collaborator,UCB Pharma GmbH,Phase 3
NCT00242619,2007.0,OTHER,lead,Stanford University,Not Applicable
NCT00242632,2004.0,OTHER,lead,Stanford University,Not Applicable
NCT00242632,2004.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00242866,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00243152,2005.0,OTHER,lead,Pain and Analgesia Imaging and Neuroscience Group,Not Applicable
NCT00243152,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00243789,2005.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 1/Phase 2
NCT00243880,2005.0,OTHER,lead,Columbia University,Phase 1
NCT00243906,2003.0,OTHER,lead,University of Cincinnati,Phase 2
NCT00243906,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00243932,2005.0,OTHER,lead,Columbia University,Phase 2
NCT00243932,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00243971,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00244023,2005.0,OTHER,lead,SELARL du Dr Jacques BUVAT,Phase 3
NCT00244023,2005.0,INDUSTRY,collaborator,Bayer,Phase 3
NCT00244218,2005.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 1
NCT00244322,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00244361,2005.0,OTHER,lead,"National Pediatric Neuroinflammation Organization, Inc.",Phase 1/Phase 2
NCT00244361,2005.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1/Phase 2
NCT00244374,2004.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT00244374,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00244387,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00245206,2005.0,OTHER,lead,Veterans Medical Research Foundation,Phase 4
NCT00245206,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00245258,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00245479,2002.0,INDUSTRY,lead,Ferring Pharmaceuticals,Phase 4
NCT00245544,2005.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00245583,2005.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 3
NCT00245583,2005.0,INDUSTRY,collaborator,"Ortho-McNeil, Inc.",Phase 3
NCT00245596,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00245622,2006.0,INDUSTRY,lead,"Opexa Therapeutics, Inc.",Phase 2
NCT00245635,2004.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT00245635,2004.0,FED,collaborator,Food and Drug Administration (FDA),Phase 4
NCT00245674,2005.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00245713,2003.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00246246,2004.0,INDUSTRY,lead,"Janssen-Ortho Inc., Canada",Phase 3
NCT00246259,2004.0,INDUSTRY,lead,"Janssen-Ortho Inc., Canada",Phase 4
NCT00246272,2004.0,INDUSTRY,lead,"Janssen-Ortho Inc., Canada",Phase 3
NCT00246285,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00246324,2003.0,OTHER,lead,Louisiana State University Health Sciences Center Shreveport,Phase 4
NCT00246324,2003.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT00246337,2005.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00246389,,INDUSTRY,lead,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Phase 4
NCT00247247,2002.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 4
NCT00247364,2003.0,OTHER,lead,Sleep Health Centers,Phase 2
NCT00247364,2003.0,INDUSTRY,collaborator,UCB Pharma,Phase 2
NCT00247572,2005.0,INDUSTRY,lead,New River Pharmaceuticals,Phase 2
NCT00247585,2003.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00247624,2005.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT00247624,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00247624,2005.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00247624,2005.0,INDUSTRY,collaborator,Philips Healthcare,Phase 4
NCT00248092,2006.0,INDUSTRY,lead,New River Pharmaceuticals,Phase 1/Phase 2
NCT00248118,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00248183,2005.0,INDUSTRY,lead,"Epix Pharmaceuticals, Inc.",Phase 3
NCT00248209,2004.0,OTHER,lead,"Segraves, R., T., M.D., Ph.D.",Phase 2/Phase 3
NCT00248209,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00248378,2001.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00248612,2003.0,OTHER,lead,Boston Medical Center,Phase 2/Phase 3
NCT00248612,2003.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2/Phase 3
NCT00248625,2000.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00248625,2000.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 3
NCT00248807,2005.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00249119,,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00249132,,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00249145,1995.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00249158,1998.0,INDUSTRY,lead,Janssen-Cilag Pty Ltd,Phase 3
NCT00249171,2001.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 4
NCT00249223,2000.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00249236,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00249288,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00249288,2003.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00249431,2001.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00249431,2001.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00249444,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00249444,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00249483,1999.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00249483,1999.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00249509,2000.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00249691,2005.0,OTHER,lead,Bankole Johnson,Phase 3
NCT00249691,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00249730,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00249769,2005.0,OTHER,lead,PATH,Phase 3
NCT00249769,2005.0,UNKNOWN,collaborator,"Research Institute for Tropical Medicine, Manila, Philippines",Phase 3
NCT00249769,2005.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 3
NCT00249769,2005.0,OTHER,collaborator,Mahidol University,Phase 3
NCT00250081,2005.0,OTHER,lead,Shriners Hospitals for Children,Not Applicable
NCT00250237,2005.0,OTHER,lead,Bronovo Hospital,Phase 3
NCT00250354,1997.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00250367,1997.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00250393,2005.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT00250458,2006.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00250536,2000.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT00250575,2005.0,INDUSTRY,lead,Novartis,Phase 3
NCT00250601,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00250614,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00250627,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00250653,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00250939,2005.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00250991,2003.0,OTHER,lead,University of Cincinnati,Phase 1/Phase 2
NCT00250991,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00251303,2005.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00251784,2002.0,OTHER,lead,University of Cambridge,Phase 4
NCT00252044,2000.0,FED,lead,Bronx VA Medical Center,Not Applicable
NCT00252174,2007.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00252174,2007.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT00252226,2004.0,OTHER,lead,Mood Disorders Center of Ottawa,Phase 3
NCT00252226,2004.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00252239,2005.0,OTHER,lead,University of Virginia,Phase 2
NCT00252239,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00252343,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00252486,2001.0,OTHER,lead,University of Rochester,Not Applicable
NCT00252486,2001.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00252850,2005.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1
NCT00252850,2005.0,INDUSTRY,collaborator,Ceregene,Phase 1
NCT00252954,2005.0,OTHER,lead,Danish Pain Research Center,Phase 4
NCT00252954,2005.0,INDUSTRY,collaborator,UCB Nordic A/S,Phase 4
NCT00253084,2005.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT00253110,1996.0,INDUSTRY,lead,"Janssen, LP",Phase 4
NCT00253123,,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00253136,1999.0,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00253149,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253162,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253175,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253175,2000.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00253188,1997.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253201,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253214,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253227,1997.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00253266,2008.0,OTHER,lead,Max-Planck-Institute of Psychiatry,Phase 4
NCT00253903,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00253968,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00254007,2003.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00254007,2003.0,OTHER_GOV,collaborator,Ontario Mental Health Foundation,Phase 4
NCT00254020,2005.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00254033,2003.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00254033,2003.0,OTHER,collaborator,American Health Assistance Foundation,Phase 4
NCT00254202,2005.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 3
NCT00254241,2002.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00254488,2005.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00254488,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00254657,2004.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT00254657,2004.0,INDUSTRY,collaborator,UCB Pharma,Not Applicable
NCT00254722,2006.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT00254735,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00254748,2004.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00254761,2003.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00254774,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00254787,2005.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00254813,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00254917,2003.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00254930,2003.0,INDUSTRY,lead,Janssen-Cilag Ltd.,Phase 3
NCT00254969,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00255021,2005.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00255047,2005.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00255086,2005.0,OTHER,lead,Stanford University,Phase 3
NCT00255086,2005.0,OTHER,collaborator,Palo Alto Veterans Institute for Research,Phase 3
NCT00255086,2005.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT00255515,2005.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00255554,,FED,lead,Bronx VA Medical Center,Not Applicable
NCT00255580,2001.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00255879,1999.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT00255879,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00255918,2004.0,OTHER,lead,"University of Colorado, Denver",Phase 1
NCT00255918,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00256113,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00256204,2005.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00256256,2005.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00256399,2005.0,OTHER,lead,University Hospitals Cleveland Medical Center,Not Applicable
NCT00256399,2005.0,INDUSTRY,collaborator,Sanofi,Not Applicable
NCT00256685,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00256802,2004.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT00256854,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00256997,2006.0,INDUSTRY,lead,"Janssen-Ortho Inc., Canada",Phase 4
NCT00257010,2005.0,INDUSTRY,lead,Janssen-Ortho LLC,Phase 3
NCT00257010,2005.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 3
NCT00257023,2005.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT00257075,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00257166,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00257192,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00257270,2003.0,OTHER,lead,Tinnitus Research Consortium,Phase 2
NCT00257361,2005.0,OTHER,lead,University of Florida,Phase 2
NCT00257361,2005.0,OTHER,collaborator,Obsessive Compulsive Foundation,Phase 2
NCT00257673,2005.0,INDUSTRY,lead,Memory Pharmaceuticals,Phase 2
NCT00257868,2006.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 3
NCT00257868,2006.0,INDUSTRY,collaborator,Novartis,Phase 3
NCT00257894,2005.0,FED,lead,VA Office of Research and Development,Phase 2
NCT00257972,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00257972,2004.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00258089,1993.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00258089,1993.0,INDUSTRY,collaborator,"PriCara, Unit of Ortho-McNeil, Inc.",Phase 3
NCT00258479,2003.0,OTHER,lead,"Catherine Martin, MD",Phase 1
NCT00258479,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00258778,2005.0,INDUSTRY,lead,Protalix,Phase 1
NCT00258791,2012.0,OTHER,lead,Norwegian University of Science and Technology,Not Applicable
NCT00258843,2005.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00258856,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00259311,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00259337,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00259636,2004.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00259636,2004.0,INDUSTRY,collaborator,Eisai Inc.,Phase 4
NCT00259649,2004.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00259649,2004.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00259870,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00259883,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00259974,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00259974,2006.0,OTHER,collaborator,Groupe Hospitalier Pitie-Salpetriere,Phase 3
NCT00259974,2006.0,OTHER,collaborator,"University Hospital, Bordeaux",Phase 3
NCT00259974,2006.0,OTHER,collaborator,"University Hospital, Limoges",Phase 3
NCT00259974,2006.0,OTHER,collaborator,Henri Mondor University Hospital,Phase 3
NCT00259974,2006.0,OTHER,collaborator,"University Hospital, Marseille",Phase 3
NCT00259974,2006.0,OTHER,collaborator,Hospices Civils de Lyon,Phase 3
NCT00259974,2006.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Phase 3
NCT00260000,2005.0,OTHER_GOV,lead,The Kennedy Institute-National Eye Clinic,Phase 2
NCT00260000,2005.0,OTHER,collaborator,Sygekassernes Helsefond,Phase 2
NCT00260052,2003.0,OTHER,lead,Medical College of Wisconsin,Phase 2/Phase 3
NCT00260325,2004.0,OTHER,lead,Penn State University,Phase 4
NCT00260325,2004.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00260325,2004.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT00260442,2005.0,OTHER,lead,Texas A&M University,Phase 2
NCT00260481,2006.0,OTHER,lead,"University of California, Los Angeles",Phase 2/Phase 3
NCT00260624,2003.0,OTHER,lead,University of Rochester,Phase 4
NCT00260624,2003.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00260741,2003.0,OTHER,lead,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT00260793,2005.0,INDIV,lead,"Agarwal, Pinky, M.D.",Phase 3
NCT00260793,2005.0,OTHER,collaborator,Colorado Neurology,Phase 3
NCT00260793,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00260962,2000.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 2
NCT00260962,2000.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT00261326,2006.0,OTHER,lead,"Glostrup University Hospital, Copenhagen",Phase 3
NCT00261326,2006.0,INDUSTRY,collaborator,Alpharma ApS,Phase 3
NCT00261430,,INDUSTRY,lead,"Janssen, LP",Phase 4
NCT00261443,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00261508,1999.0,INDUSTRY,lead,"Janssen-Ortho Inc., Canada",Phase 3
NCT00261573,1998.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00261729,2004.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00262223,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00262223,2006.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00262600,2005.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00262600,2005.0,OTHER,collaborator,Population Health Research Institute,Phase 3
NCT00262600,2005.0,OTHER,collaborator,Uppsala University,Phase 3
NCT00263068,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00263133,2005.0,OTHER,lead,University Hospital Freiburg,Not Applicable
NCT00263393,2005.0,OTHER,lead,The George Institute,Phase 4
NCT00263393,2005.0,OTHER,collaborator,Byrraju Foundation,Phase 4
NCT00263393,2005.0,UNKNOWN,collaborator,"The Future Forum, UK",Phase 4
NCT00264173,2004.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00264238,2006.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT00264485,2004.0,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 3
NCT00264485,2004.0,INDUSTRY,collaborator,"PriCara, Unit of Ortho-McNeil, Inc.",Phase 3
NCT00264615,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00264797,2006.0,OTHER,lead,University of Cincinnati,Phase 3
NCT00264797,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00264797,2006.0,OTHER,collaborator,"University of Colorado, Denver",Phase 3
NCT00264875,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00264888,2005.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT00264888,2005.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 2
NCT00264914,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00264927,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00265109,2004.0,OTHER,lead,Butler Hospital,Phase 4
NCT00265109,2004.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT00265148,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00265265,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00265278,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00265291,1999.0,NIH,lead,National Institute of General Medical Sciences (NIGMS),Phase 2
NCT00265330,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00265343,2005.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00265382,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00265551,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00265616,2006.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT00266149,2003.0,OTHER,lead,University of Aarhus,Phase 3
NCT00266214,2005.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT00266409,2005.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00266552,,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00266591,1992.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00266604,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00266604,2005.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00266747,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00266864,2003.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT00266864,2003.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 2/Phase 3
NCT00267163,2000.0,NIH,lead,National Institute on Aging (NIA),Phase 4
NCT00267319,2003.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00267371,2005.0,INDUSTRY,lead,Abbott Medical Devices,Phase 3
NCT00267657,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00267813,2004.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00268749,2002.0,OTHER,lead,Yale University,Phase 2
NCT00268749,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00268944,2005.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00269035,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00269477,2005.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00269594,2006.0,OTHER,lead,University of Minnesota,Phase 2
NCT00269919,2005.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00270231,2004.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00270231,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00270803,2004.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00270803,2004.0,OTHER,collaborator,Hadassah Medical Organization,Not Applicable
NCT00270816,2005.0,OTHER,lead,S. Andrea Hospital,Phase 2/Phase 3
NCT00270816,2005.0,OTHER,collaborator,Italian Multiple Sclerosis Foundation,Phase 2/Phase 3
NCT00270959,2006.0,OTHER,lead,University of Washington,Phase 1
NCT00270959,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00271206,2004.0,OTHER,lead,Yale University,Phase 1
NCT00271206,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00271258,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00271479,2004.0,OTHER,lead,Epicentre,Phase 4
NCT00271479,2004.0,OTHER_GOV,collaborator,Norwegian Institute of Public Health,Phase 4
NCT00271479,2004.0,OTHER,collaborator,University of Oslo,Phase 4
NCT00271479,2004.0,OTHER,collaborator,"Medecins Sans Frontieres, Netherlands",Phase 4
NCT00271596,2005.0,OTHER,lead,University of Iowa,Phase 2
NCT00271596,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00271596,2005.0,UNKNOWN,collaborator,Cure Huntington's Disease Initiative (CHDI),Phase 2
NCT00271596,2005.0,OTHER,collaborator,University of Rochester,Phase 2
NCT00271596,2005.0,OTHER,collaborator,Mayo Clinic,Phase 2
NCT00271635,2006.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 2
NCT00271791,2005.0,OTHER,lead,Carmel Medical Center,Phase 2
NCT00271791,2005.0,OTHER,collaborator,"Clalit Health Services, Haifa and West Galilee",Phase 2
NCT00271791,2005.0,OTHER_GOV,collaborator,Hillel Yaffe Medical Center,Phase 2
NCT00271791,2005.0,OTHER,collaborator,Rambam Health Care Campus,Phase 2
NCT00271791,2005.0,OTHER,collaborator,"University Health Network, Toronto",Phase 2
NCT00272025,2006.0,OTHER,lead,Queen's University,Phase 1
NCT00272207,2006.0,OTHER,lead,Winnipeg Regional Health Authority,Phase 2
NCT00272207,2006.0,INDUSTRY,collaborator,Valeant Canada Limited,Phase 2
NCT00272454,2006.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00272454,2006.0,OTHER,collaborator,Seoul National University Boramae Hospital,Phase 4
NCT00272454,2006.0,UNKNOWN,collaborator,"Korea Otsuka International Asia Arab Co., Ltd.",Phase 4
NCT00272597,2005.0,OTHER,lead,University of British Columbia,Phase 4
NCT00272597,2005.0,UNKNOWN,collaborator,Riverview Hospital,Phase 4
NCT00272688,2006.0,OTHER,lead,"University Hospital, Akershus",Phase 4
NCT00272688,2006.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 4
NCT00272792,2006.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT00272896,2004.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT00272909,2004.0,INDUSTRY,lead,Daiichi Sankyo,Phase 2
NCT00273039,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00273351,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00273351,2006.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00273351,2006.0,OTHER,collaborator,Molecular NeuroImaging,Phase 2
NCT00273364,2005.0,OTHER,lead,Northwestern University,Phase 2
NCT00273364,2005.0,OTHER,collaborator,Uppsala University,Phase 2
NCT00273364,2005.0,OTHER,collaborator,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 2
NCT00273364,2005.0,OTHER,collaborator,University of Sao Paulo,Phase 2
NCT00273416,2006.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00273702,2006.0,OTHER,lead,University of Minnesota,Phase 1
NCT00273754,2003.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00274131,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00274170,2006.0,FED,lead,C.R.Darnall Army Medical Center,Phase 1/Phase 2
NCT00274586,2002.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00274677,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00275236,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00275275,2006.0,OTHER,lead,"Rajesh Pahwa, MD",Phase 3
NCT00275275,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00275301,2005.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00275301,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00275457,2002.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00276172,2003.0,INDUSTRY,lead,Biogen,Phase 3
NCT00276185,2005.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 3
NCT00276185,2005.0,UNKNOWN,collaborator,J. Rebeyrol Hospital in Limoges,Phase 3
NCT00276185,2005.0,OTHER,collaborator,Rennes University Hospital,Phase 3
NCT00276185,2005.0,UNKNOWN,collaborator,Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes),Phase 3
NCT00276185,2005.0,UNKNOWN,collaborator,Saint Jacques Hospital in Nantes,Phase 3
NCT00276185,2005.0,OTHER,collaborator,Centre Hospitalier Universitaire de Saint Etienne,Phase 3
NCT00276185,2005.0,UNKNOWN,collaborator,Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers,Phase 3
NCT00276185,2005.0,OTHER,collaborator,Centre Hospitalier Universitaire de Besancon,Phase 3
NCT00276263,2006.0,OTHER,lead,Herzog Hospital,Phase 2
NCT00276315,2005.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00276341,2003.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00276380,2003.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00276510,2002.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00276874,2006.0,OTHER,lead,Craig Rush,Phase 1
NCT00276874,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00276900,2003.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00276900,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00276952,2004.0,OTHER,lead,University of Chile,Phase 2
NCT00276965,2006.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00276965,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00276965,2006.0,OTHER,collaborator,"University of California, Los Angeles",Phase 3
NCT00276965,2006.0,OTHER,collaborator,Stanford University,Phase 3
NCT00277212,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00277212,2005.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00277355,2006.0,NETWORK,lead,Merit Cudkowicz,Phase 2/Phase 3
NCT00277355,2006.0,FED,collaborator,FDA Office of Orphan Products Development,Phase 2/Phase 3
NCT00277602,1999.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00277641,2006.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00277641,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00277641,2006.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00277654,2004.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00277654,2004.0,INDUSTRY,collaborator,Janssen Pharmaceuticals,Phase 3
NCT00277654,2004.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00277667,2004.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00277667,2004.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00277667,2004.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00277810,2006.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT00277914,2006.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00278655,2003.0,OTHER,lead,Northwestern University,Phase 1/Phase 2
NCT00279032,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00279149,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00279266,2006.0,OTHER,lead,Loma Linda University,Not Applicable
NCT00279617,2006.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00279617,2006.0,INDUSTRY,collaborator,UCB Pharma,Phase 3
NCT00279617,2006.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00279825,2006.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT00279942,2006.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT00279942,2006.0,INDUSTRY,collaborator,"Physicians Pharmaceuticals, Inc.",Not Applicable
NCT00280059,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00280267,2004.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT00280267,2004.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00280293,2006.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00280423,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00280436,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00280566,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00280592,2006.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT00280592,2006.0,INDUSTRY,collaborator,Pierre Fabre Laboratories,Phase 3
NCT00280592,2006.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT00280696,2005.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT00281320,2006.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00281502,2005.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT00281502,2005.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 2
NCT00282139,2004.0,OTHER,lead,University of Florida,Not Applicable
NCT00282139,2004.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00282152,2006.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT00282165,2006.0,OTHER,lead,UMC Utrecht,Phase 4
NCT00282165,2006.0,UNKNOWN,collaborator,"FPC De Kijvelanden, Poortugaal",Phase 4
NCT00282464,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00282607,2005.0,INDUSTRY,lead,"Dong-A PharmTech Co., Ltd.",Phase 2
NCT00282763,2005.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00282867,2006.0,OTHER,lead,University of Virginia,Phase 2
NCT00282867,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00282997,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00283088,2003.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT00283088,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00283179,2004.0,INDUSTRY,lead,"Taiwan Otsuka Pharm. Co., Ltd",Phase 3
NCT00283309,2005.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00283400,2006.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT00283400,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT00283595,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00283595,2006.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00283660,2006.0,OTHER,lead,Emory University,Not Applicable
NCT00283660,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00283660,2006.0,UNKNOWN,collaborator,Institute of Nutrition of Central America and Panama (INCAP),Not Applicable
NCT00283660,2006.0,OTHER_GOV,collaborator,Mexican National Institute of Public Health,Not Applicable
NCT00283699,2001.0,OTHER,lead,Columbia University,Phase 3
NCT00283699,2001.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00283842,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00283933,2006.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00283946,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT00283959,2006.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00284505,2005.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT00284505,2005.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT00284583,2005.0,OTHER,lead,Brown University,Not Applicable
NCT00285025,2005.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00285077,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00285350,2002.0,FED,lead,FDA Office of Orphan Products Development,Phase 3
NCT00285350,2002.0,OTHER,collaborator,Duke University,Phase 3
NCT00285402,2007.0,INDUSTRY,lead,"Ariston Pharmaceuticals, Inc.",Phase 2
NCT00285584,2002.0,OTHER,lead,NYU Langone Health,Phase 1
NCT00285584,2002.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00285584,2002.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 1
NCT00285818,2003.0,OTHER,lead,Stanford University,Not Applicable
NCT00286104,2004.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT00286377,2003.0,INDUSTRY,lead,Savient Pharmaceuticals,Phase 2
NCT00286377,2003.0,OTHER,collaborator,Neurologic AIDS Research Consortium (NARC),Phase 2
NCT00286689,2006.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00286897,2006.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT00286936,2004.0,OTHER,lead,Hvidovre University Hospital,Phase 4
NCT00286936,2004.0,OTHER,collaborator,IMK Fonden,Phase 4
NCT00286949,2005.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00286949,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00287092,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00287157,2006.0,INDUSTRY,lead,Teva GTC,Phase 1
NCT00287235,2000.0,INDUSTRY,lead,Baxter Healthcare Corporation,Not Applicable
NCT00287235,2000.0,INDUSTRY,collaborator,"Gambro Renal Products, Inc.",Not Applicable
NCT00287248,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00287248,2006.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT00287248,2006.0,OTHER,collaborator,Molecular NeuroImaging,Phase 1
NCT00287352,2005.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT00287352,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1
NCT00287742,2002.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT00287781,2002.0,OTHER,lead,Kern Medical Center,Not Applicable
NCT00287820,2004.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00287820,2004.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00288353,2006.0,OTHER,lead,Northwestern University,Phase 3
NCT00288353,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00288366,2006.0,OTHER,lead,Northwestern University,Not Applicable
NCT00288366,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT00288366,2006.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00288574,2000.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00288574,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00288626,2006.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00288626,2006.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 2
NCT00288639,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00288782,2006.0,OTHER,lead,University of Aarhus,Phase 4
NCT00288782,2006.0,OTHER,collaborator,The Danish Medical Research Council,Phase 4
NCT00288782,2006.0,UNKNOWN,collaborator,Fund for Advancement of Medical Science,Phase 4
NCT00288782,2006.0,UNKNOWN,collaborator,Max Woerzner's Research Award,Phase 4
NCT00289653,2005.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00289861,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00289861,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00290121,2006.0,OTHER,lead,Université de Montréal,Phase 4
NCT00290121,2006.0,OTHER,collaborator,Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal,Phase 4
NCT00290121,2006.0,OTHER,collaborator,Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal,Phase 4
NCT00290121,2006.0,OTHER,collaborator,Hopital du Sacre-Coeur de Montreal,Phase 4
NCT00290121,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00290186,2005.0,OTHER,lead,Dayton Children's Hospital,Not Applicable
NCT00290186,2005.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT00290186,2005.0,OTHER,collaborator,Kettering Health Network,Not Applicable
NCT00290823,2006.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT00291148,2006.0,OTHER,lead,University of Manitoba,Phase 3
NCT00291213,,OTHER,lead,Yale University,Phase 3
NCT00291213,,INDUSTRY,collaborator,UCB Pharma,Phase 3
NCT00291395,2005.0,OTHER,lead,Danish Headache Center,Phase 1
NCT00291655,2006.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00292110,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00292123,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00292188,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00292227,2006.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT00292266,1999.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00292266,1999.0,INDUSTRY,collaborator,Merck Serono International SA,Phase 3
NCT00292370,2006.0,FED,lead,VA Office of Research and Development,Phase 4
NCT00292370,2006.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00292461,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00292734,2005.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00292929,,FED,lead,U.S. Army Medical Research and Development Command,Phase 1
NCT00292942,2006.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 1
NCT00292942,2006.0,FED,collaborator,Walter Reed Army Institute of Research (WRAIR),Phase 1
NCT00293176,2003.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00293176,2003.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00294255,2003.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT00294255,2003.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00294554,2006.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00294554,2006.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00294593,2000.0,OTHER,lead,Institut Jerome Lejeune,Phase 2/Phase 3
NCT00294593,2000.0,OTHER,collaborator,Fondation Jérôme Lejeune,Phase 2/Phase 3
NCT00294619,2006.0,INDUSTRY,lead,LG Life Sciences,Phase 3
NCT00294619,2006.0,INDUSTRY,collaborator,BioPartners GmbH,Phase 3
NCT00294658,2006.0,OTHER,lead,University of Alabama at Birmingham,Phase 3
NCT00294658,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00294671,2006.0,OTHER,lead,Boston University,Phase 2/Phase 3
NCT00294671,2006.0,FED,collaborator,Food and Drug Administration (FDA),Phase 2/Phase 3
NCT00294671,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT00295412,,OTHER,lead,Université de Montréal,Phase 4
NCT00295412,,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00295776,2005.0,OTHER,lead,George Washington University,Phase 2/Phase 3
NCT00295776,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00296192,2006.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00296205,2003.0,OTHER,lead,Stony Brook University,Phase 2
NCT00296517,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00296621,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00296647,2004.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT00296647,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00296933,2005.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT00296933,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00296933,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT00296946,2004.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT00296946,2004.0,OTHER,collaborator,Parkinson's Disease Foundation,Phase 2
NCT00296959,2004.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT00297024,2005.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT00297024,2005.0,OTHER,collaborator,"Princess Margaret Hospital, Canada",Phase 2
NCT00297232,2006.0,INDUSTRY,lead,Biogen,Phase 3
NCT00297375,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00297375,2003.0,INDUSTRY,collaborator,"PriCara, Unit of Ortho-McNeil, Inc.",Phase 4
NCT00297388,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00297388,,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00297505,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00297544,2005.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT00297544,2005.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00297687,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00297739,2003.0,INDIV,lead,"Armenteros, Jorge L., M.D., P.A.",Phase 4
NCT00297739,2003.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00297778,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00297947,2004.0,OTHER,lead,Manhattan Psychiatric Center,Phase 2/Phase 3
NCT00297947,2004.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2/Phase 3
NCT00298038,2005.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 3
NCT00298597,2006.0,OTHER,lead,University Hospital Muenster,Phase 2
NCT00298623,2006.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT00298662,2003.0,OTHER,lead,Clinique de sclérose en plaques et neuromusculaire de l'Outaouais,Phase 2
NCT00299611,2005.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00299611,2005.0,INDUSTRY,collaborator,UCB Pharma,Phase 2/Phase 3
NCT00299702,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00299702,2006.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00299715,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00299988,2006.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT00299988,2006.0,INDUSTRY,collaborator,Baxter BioScience,Phase 2
NCT00299988,2006.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00300196,2006.0,INDUSTRY,lead,Neurobiological Technologies,Phase 3
NCT00300222,2006.0,INDUSTRY,lead,NeurogesX,Phase 3
NCT00300391,2006.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00300391,2006.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00300404,2002.0,OTHER,lead,Zentrum für Integrative Psychiatrie,Phase 3
NCT00300404,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00300417,2006.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00300716,2004.0,OTHER,lead,Oregon Health and Science University,Phase 2/Phase 3
NCT00300716,2004.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2/Phase 3
NCT00300716,2004.0,OTHER,collaborator,University of Southern California,Phase 2/Phase 3
NCT00300716,2004.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2/Phase 3
NCT00300716,2004.0,UNKNOWN,collaborator,MS-Hub Seattle,Phase 2/Phase 3
NCT00300846,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00300846,2005.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00300924,2006.0,OTHER,lead,Diamond Headache Clinic,Phase 3
NCT00300924,2006.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 3
NCT00300963,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00301223,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00301262,2005.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00301262,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00301431,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2/Phase 3
NCT00301574,2001.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT00301587,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00301665,2003.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00301873,2006.0,OTHER,lead,Duke University,Phase 2
NCT00301873,2006.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT00301873,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00302068,2006.0,OTHER,lead,Duke University,Phase 3
NCT00302068,2006.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00302107,2006.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00302133,2006.0,OTHER,lead,University of Miami,Phase 1/Phase 2
NCT00302159,2006.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00303082,2006.0,OTHER,lead,Oswaldo Cruz Foundation,Phase 3
NCT00303082,2006.0,OTHER_GOV,collaborator,"Ministry of Health, Brazil",Phase 3
NCT00303277,2002.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 4
NCT00303316,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00303433,2006.0,OTHER,lead,University of Rochester,Phase 4
NCT00303433,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00303446,2006.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00303602,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00304083,2005.0,OTHER,lead,Sarcoma Alliance for Research through Collaboration,Phase 2
NCT00304083,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00304161,2004.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00304161,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00304187,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00304187,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00304265,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT00304291,2001.0,OTHER,lead,State University of New York at Buffalo,Phase 4
NCT00304291,2001.0,INDUSTRY,collaborator,EMD Serono,Phase 4
NCT00304473,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00304512,2006.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00304616,2004.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00304629,2000.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00304655,2004.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00304707,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 3
NCT00305331,2006.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT00305370,2005.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 4
NCT00305422,2001.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00305474,2003.0,OTHER,lead,Central South University,Phase 4
NCT00305474,2003.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00305500,2006.0,OTHER_GOV,lead,Abarbanel Mental Health Center,Phase 3
NCT00305539,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00305539,2006.0,INDUSTRY,collaborator,Abbott,Phase 3
NCT00305578,2005.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00305591,2006.0,OTHER,lead,Imperial College London,Not Applicable
NCT00305591,2006.0,OTHER,collaborator,Royal College of Physicians,Not Applicable
NCT00305591,2006.0,OTHER,collaborator,Paddington Charitable Estates Educational Fund,Not Applicable
NCT00305591,2006.0,OTHER,collaborator,University of London,Not Applicable
NCT00305903,2006.0,INDUSTRY,lead,Novartis,Phase 4
NCT00306033,2004.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT00306124,2006.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT00306475,2006.0,OTHER,lead,Vanderbilt University,Phase 4
NCT00306475,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00306475,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00306540,2004.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00306592,2006.0,INDUSTRY,lead,Biogen,Phase 3
NCT00306592,2006.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 3
NCT00307203,1998.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00307450,2006.0,OTHER,lead,Technische Universität Dresden,Phase 4
NCT00307450,2006.0,INDUSTRY,collaborator,UCB Pharma GmbH,Phase 4
NCT00307567,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00307593,2004.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT00307671,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00307944,2004.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00307944,2004.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00308113,2007.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 3
NCT00308113,2007.0,FED,collaborator,United States Department of Defense,Phase 3
NCT00308360,1999.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00308360,1999.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00308360,1999.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 4
NCT00308503,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00308763,2004.0,OTHER,lead,University of Tennessee,Not Applicable
NCT00308763,2004.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00308776,2003.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00308776,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00308893,2006.0,OTHER,lead,"University Hospital, Tours",Phase 4
NCT00308893,2006.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00309088,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT00309101,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT00309686,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00309699,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00309725,,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00310323,2003.0,OTHER,lead,Virginia Commonwealth University,Not Applicable
NCT00310323,2003.0,OTHER,collaborator,University of Louisville,Not Applicable
NCT00310375,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00310388,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00310401,2007.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT00310401,2007.0,NETWORK,collaborator,California Transplant Donor Network,Phase 2
NCT00310401,2007.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT00310583,2006.0,OTHER,lead,Professional Associations Clinic Bergmannsheil,Phase 4
NCT00310583,2006.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00310791,2004.0,OTHER,lead,Boston Children's Hospital,Phase 2/Phase 3
NCT00310791,2004.0,FED,collaborator,United States Department of Defense,Phase 2/Phase 3
NCT00310791,2004.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT00310817,2005.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT00310817,2005.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT00310856,2005.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT00311363,2006.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT00311402,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00311441,2005.0,INDUSTRY,lead,Novartis,Phase 4
NCT00311441,2005.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT00311493,2006.0,INDUSTRY,lead,Novartis,Phase 4
NCT00311493,2006.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT00312494,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00312676,2006.0,FED,lead,"Veterans Affairs Medical Center, Miami",Phase 4
NCT00312676,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00312728,2006.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT00312767,2006.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00313105,2006.0,OTHER,lead,"University Hospital, Gentofte, Copenhagen",Phase 2/Phase 3
NCT00313105,2006.0,UNKNOWN,collaborator,"Danish Research Foundation, FSS, Copenhagen, Denmark",Phase 2/Phase 3
NCT00313391,2005.0,OTHER,lead,Emory University,Phase 4
NCT00313391,2005.0,UNKNOWN,collaborator,"Janssen, L.P. - Investigator Initiated Studies Program",Phase 4
NCT00313716,2006.0,OTHER,lead,Claudia Sue Robertson,Phase 2/Phase 3
NCT00313716,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT00313885,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00313898,2005.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT00313898,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00313976,,INDUSTRY,lead,Bayer,Phase 3
NCT00314041,1997.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00314132,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00314145,2005.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00314184,2005.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00314210,2006.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00314249,2006.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00314249,2006.0,INDUSTRY,collaborator,"Cypress Bioscience, Inc.",Phase 3
NCT00314288,2002.0,INDUSTRY,lead,EMD Serono,Phase 2
NCT00314314,2006.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT00314314,2006.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Phase 3
NCT00314327,2006.0,OTHER,lead,Northwell Health,Phase 4
NCT00314327,2006.0,OTHER,collaborator,The Zucker Hillside Hospital,Phase 4
NCT00314327,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00314613,2006.0,OTHER,lead,Duke University,Phase 4
NCT00314613,2006.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00314808,2006.0,OTHER,lead,Duke University,Phase 1
NCT00314808,2006.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 1
NCT00314821,2005.0,OTHER,lead,Cambridge Health Alliance,Phase 4
NCT00314821,2005.0,OTHER,collaborator,Emory University,Phase 4
NCT00314821,2005.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00314860,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00314912,2006.0,INDUSTRY,lead,Bellus Health Inc. - a GSK company,Phase 3
NCT00315055,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00315081,2006.0,OTHER,lead,"University Hospital, Bonn",Phase 3
NCT00315107,2006.0,OTHER,lead,Université de Montréal,Phase 2
NCT00315107,2006.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT00315250,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00315250,2006.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00315250,2006.0,OTHER,collaborator,Molecular NeuroImaging,Phase 2
NCT00315302,2005.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00315302,2005.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00315328,2005.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00315328,2005.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00315367,2004.0,INDUSTRY,lead,Neurognostics,Phase 4
NCT00315666,2006.0,OTHER,lead,Danish Headache Center,Phase 3
NCT00315900,2006.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 3
NCT00315900,2006.0,INDUSTRY,collaborator,Abbott,Phase 3
NCT00316004,2006.0,OTHER,lead,University of Washington,Phase 3
NCT00316004,2006.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00316004,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00316004,2006.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 3
NCT00316004,2006.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 3
NCT00316004,2006.0,OTHER_GOV,collaborator,Canadian Department of National Defense,Phase 3
NCT00316004,2006.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Phase 3
NCT00316147,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00316238,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00316303,2006.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 2
NCT00316303,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00316498,2002.0,NIH,lead,National Eye Institute (NEI),Phase 1
NCT00316563,2006.0,OTHER,lead,Alberta Health services,Phase 2
NCT00316563,2006.0,OTHER,collaborator,University of Alberta,Phase 2
NCT00316797,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00316797,2006.0,OTHER,collaborator,Molecular NeuroImaging,Phase 1
NCT00317447,2002.0,OTHER,lead,Kaiser Permanente,Phase 3
NCT00317460,2005.0,OTHER,lead,Yale University,Phase 4
NCT00317460,2005.0,OTHER,collaborator,The New York Academy of Medicine,Phase 4
NCT00317746,2006.0,OTHER,lead,Marina Klein,Phase 3
NCT00317746,2006.0,NETWORK,collaborator,Ontario HIV Treatment Network,Phase 3
NCT00317746,2006.0,INDUSTRY,collaborator,Schering-Plough,Phase 3
NCT00317746,2006.0,NETWORK,collaborator,CIHR Canadian HIV Trials Network,Phase 3
NCT00317850,2004.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT00317850,2004.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 2/Phase 3
NCT00318409,2006.0,OTHER_GOV,lead,San Francisco Department of Public Health,Phase 2
NCT00318409,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00318409,2006.0,OTHER,collaborator,"Public Health Foundation Enterprises, Inc.",Phase 2
NCT00318539,2003.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00318760,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00318929,2006.0,OTHER,lead,Virginia Commonwealth University,Not Applicable
NCT00318929,2006.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT00319137,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00319319,2003.0,OTHER,lead,Yale University,Phase 2
NCT00319319,2003.0,OTHER,collaborator,Donaghue Medical Research Foundation,Phase 2
NCT00319345,2003.0,OTHER,lead,Institut d'Anesthesiologie des Alpes Maritimes,Phase 2/Phase 3
NCT00319345,2003.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2/Phase 3
NCT00319345,2003.0,INDUSTRY,collaborator,PT Kalbe Farma Tbk,Phase 2/Phase 3
NCT00319501,2006.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00319592,2005.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00319592,2005.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 2
NCT00319709,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00319852,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00320047,2005.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00320047,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00320281,2006.0,OTHER,lead,Craig Hospital,Phase 4
NCT00320281,2006.0,OTHER,collaborator,The Craig H. Neilsen Foundation,Phase 4
NCT00320281,2006.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT00320463,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00320489,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00320632,1990.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 4
NCT00320632,1990.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00320671,2005.0,OTHER,lead,Northwell Health,Phase 4
NCT00320671,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00320697,2006.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00320723,2001.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00320736,2004.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00320736,2004.0,INDUSTRY,collaborator,Janssen Medical Affairs,Phase 4
NCT00321087,2006.0,INDUSTRY,lead,Taro Pharmaceuticals USA,Phase 2
NCT00321516,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT00321672,2006.0,INDUSTRY,lead,NeurogesX,Phase 3
NCT00321854,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00322023,2006.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00322023,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00322036,2006.0,INDUSTRY,lead,Myrexis Inc.,Phase 3
NCT00322309,2005.0,OTHER,lead,Boston University,Phase 2
NCT00322621,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00322621,2006.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 4
NCT00322764,2006.0,INDUSTRY,lead,Repligen Corporation,Phase 2
NCT00322803,2006.0,INDUSTRY,lead,elbion AG,Phase 2
NCT00323310,2006.0,INDUSTRY,lead,"Bracco Diagnostics, Inc",Phase 3
NCT00323947,2003.0,OTHER,lead,Boston Children's Hospital,Phase 4
NCT00323947,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00324025,2007.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00324051,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00324454,2006.0,OTHER,lead,Duke University,Phase 2
NCT00324454,2006.0,INDUSTRY,collaborator,UCB Pharma,Phase 2
NCT00324506,2006.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT00324506,2006.0,INDUSTRY,collaborator,Aspreva Pharmaceuticals,Phase 2
NCT00324896,2006.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 3
NCT00324896,2006.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 3
NCT00325130,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00325143,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00325156,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00325286,2006.0,OTHER,lead,Creighton University,Phase 4
NCT00325286,2006.0,INDUSTRY,collaborator,Shire,Phase 4
NCT00325637,2005.0,INDUSTRY,lead,"Boryung Pharmaceutical Co., Ltd",Phase 3
NCT00325689,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00325689,2006.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00326612,2006.0,OTHER,lead,University of Utah,Phase 2
NCT00326612,2006.0,OTHER,collaborator,Primary Children's Hospital,Phase 2
NCT00326625,2006.0,INDUSTRY,lead,"Teva Pharmaceutical Industries, Ltd.",Phase 2
NCT00326872,2006.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00327418,1997.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00327418,1997.0,OTHER,collaborator,Diabetes UK,Phase 4
NCT00327418,1997.0,OTHER_GOV,collaborator,"Department of Health, United Kingdom",Phase 4
NCT00327691,1998.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00327756,2006.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00328276,2004.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT00328276,2004.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 2
NCT00328276,2004.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT00328367,2005.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT00328367,2005.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00328458,2004.0,OTHER,lead,Sidney Kimmel Cancer Center at Thomas Jefferson University,Phase 1
NCT00328458,2004.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 1
NCT00328874,2006.0,OTHER,lead,German Parkinson Study Group (GPS),Phase 2
NCT00328874,2006.0,UNKNOWN,collaborator,"MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany",Phase 2
NCT00328874,2006.0,UNKNOWN,collaborator,Pitzer Stiftung,Phase 2
NCT00328874,2006.0,OTHER,collaborator,Philipps University Marburg Medical Center,Phase 2
NCT00328978,2003.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00329056,2006.0,INDUSTRY,lead,"Antipodean Pharmaceuticals, Inc.",Phase 2
NCT00329082,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00329147,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00329355,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00329459,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00329589,2005.0,OTHER,lead,Sidney Kimmel Cancer Center at Thomas Jefferson University,Phase 1
NCT00329589,2005.0,INDUSTRY,collaborator,"Millennium Pharmaceuticals, Inc.",Phase 1
NCT00329602,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00329732,2006.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00329758,2006.0,OTHER,lead,Universidad Autonoma de San Luis Potosí,Phase 2
NCT00329758,2006.0,OTHER,collaborator,"Hospital Central ""Dr. Ignacio Morones Prieto""",Phase 2
NCT00329758,2006.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT00329810,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT00329810,2005.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00329901,2006.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00330187,2004.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00330187,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00330239,2003.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT00330239,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00330291,2005.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 2
NCT00330434,2005.0,OTHER,lead,Tufts University,Not Applicable
NCT00330434,2005.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT00330486,2006.0,OTHER,lead,Medical University of South Carolina,Phase 1/Phase 2
NCT00330551,2006.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00330551,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00330551,2006.0,INDUSTRY,collaborator,"Janssen Scientific Affairs, LLC",Phase 4
NCT00330655,2006.0,OTHER,lead,Mclean Hospital,Phase 4
NCT00330655,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00330850,2006.0,INDUSTRY,lead,ProEthic Pharmaceuticals,Phase 3
NCT00330863,2006.0,OTHER,lead,Northwell Health,Phase 4
NCT00330863,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00331123,2002.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00331149,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00331214,2002.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00331305,1999.0,OTHER,lead,Duke University,Phase 3
NCT00331305,1999.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00331721,2006.0,INDUSTRY,lead,PAION Deutschland GmbH,Phase 2
NCT00331747,2006.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT00331825,2000.0,OTHER_GOV,lead,"Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan",Phase 4
NCT00331825,2000.0,AMBIG,collaborator,Department of Health,Phase 4
NCT00331890,2006.0,INDUSTRY,lead,Ferrer Internacional S.A.,Phase 3
NCT00331981,2004.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00332189,2006.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT00332579,2006.0,OTHER,lead,University of Minnesota,Phase 2
NCT00332644,2004.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT00332644,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00332787,2000.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00332787,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00332800,2003.0,OTHER,lead,Burke Rehabilitation Hospital,Not Applicable
NCT00332891,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00333138,2003.0,INDUSTRY,lead,Novartis,Phase 2
NCT00333164,2006.0,OTHER,lead,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Phase 3
NCT00333164,2006.0,OTHER,collaborator,Foundation for Biomedical Research and Innovation,Phase 3
NCT00333164,2006.0,OTHER,collaborator,"Neurology, Tokyo Women's Medical University, School of Medicine",Phase 3
NCT00333164,2006.0,OTHER,collaborator,Kobe City General Hospital,Phase 3
NCT00333164,2006.0,OTHER,collaborator,Tohoku University,Phase 3
NCT00333164,2006.0,OTHER,collaborator,Kyushu University,Phase 3
NCT00333164,2006.0,UNKNOWN,collaborator,"Department of Neurology, Saiseikai Central Hospital",Phase 3
NCT00333164,2006.0,OTHER_GOV,collaborator,China National Center for Cardiovascular Diseases,Phase 3
NCT00333177,2006.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00333177,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00333177,2006.0,INDUSTRY,collaborator,"Janssen Scientific Affairs, LLC",Phase 4
NCT00333281,2005.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00333281,2005.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00333359,2006.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT00333866,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00333931,2006.0,FED,lead,Michael E. DeBakey VA Medical Center,Not Applicable
NCT00333931,2006.0,UNKNOWN,collaborator,Dr. Thomas A. Kent,Not Applicable
NCT00333931,2006.0,UNKNOWN,collaborator,Dr. Stacey Holmes,Not Applicable
NCT00333931,2006.0,UNKNOWN,collaborator,Dr. Su Bailey,Not Applicable
NCT00333931,2006.0,UNKNOWN,collaborator,Dr. Mark Kunik,Not Applicable
NCT00333931,2006.0,UNKNOWN,collaborator,Dr. Melinda Stanley,Not Applicable
NCT00334035,2003.0,OTHER,lead,The University of Hong Kong,Phase 4
NCT00334347,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00334347,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00334477,,OTHER,lead,University of Pernambuco,Phase 2
NCT00334568,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00334906,2005.0,INDUSTRY,lead,Forest Laboratories,Phase 4
NCT00334958,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00335205,2003.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT00335205,2003.0,OTHER_GOV,collaborator,Jerusalem Mental Health Center,Phase 4
NCT00335777,2006.0,OTHER,lead,Thomas Jefferson University,Phase 4
NCT00335933,2006.0,INDUSTRY,lead,Depomed,Phase 3
NCT00335972,2006.0,OTHER,lead,The Cleveland Clinic,Phase 4
NCT00335985,2006.0,INDUSTRY,lead,Japan Blood Products Organization,Phase 3
NCT00336349,2006.0,OTHER,lead,Taipei Medical University Hospital,Not Applicable
NCT00336349,2006.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT00336466,2004.0,OTHER,lead,University of Calgary,Phase 2
NCT00336466,2004.0,OTHER,collaborator,Calgary Health Region,Phase 2
NCT00336466,2004.0,INDUSTRY,collaborator,"Ortho Biotech, Inc.",Phase 2
NCT00336531,2006.0,OTHER,lead,Samsung Medical Center,Phase 4
NCT00336596,2006.0,OTHER,lead,University of Zurich,Phase 3
NCT00336596,2006.0,OTHER,collaborator,Swiss National Science Foundation,Phase 3
NCT00336713,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00336882,2006.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT00336882,2006.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT00337350,2003.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00337350,2003.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00337350,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00337428,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00337597,2006.0,OTHER,lead,Nantes University Hospital,Phase 3
NCT00337636,2006.0,INDUSTRY,lead,"StemCells, Inc.",Phase 1
NCT00337662,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00337779,2006.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00338117,1995.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00338117,1995.0,INDUSTRY,collaborator,Shire,Phase 3
NCT00338273,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00338273,2006.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT00338312,2002.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00338598,2003.0,OTHER,lead,Yale University,Phase 2
NCT00338598,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00338767,2001.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00338767,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00338949,2006.0,OTHER,lead,Veterans Medical Research Foundation,Phase 4
NCT00338949,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00338949,2006.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00338962,2001.0,OTHER,lead,Yale University,Phase 3
NCT00339066,2001.0,OTHER,lead,Duke University,Not Applicable
NCT00339066,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00339079,2006.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT00339079,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT00340379,2003.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00340379,2003.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT00340379,2003.0,OTHER,collaborator,"National Institute of Mental Health and Neuro Sciences, India",Phase 2/Phase 3
NCT00340704,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00340834,2006.0,INDUSTRY,lead,Novartis,Phase 3
NCT00342134,2002.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00342381,2006.0,OTHER,lead,University of Aarhus,Phase 2
NCT00342381,2006.0,UNKNOWN,collaborator,The Danish Multiple Sclerosis Society,Phase 2
NCT00343096,2006.0,OTHER,lead,Kamuzu University of Health Sciences,Phase 3
NCT00343174,,OTHER,lead,Heidelberg University,Phase 3
NCT00343200,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00343421,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00344253,2006.0,OTHER,lead,Heidelberg University,Phase 3
NCT00344253,2006.0,UNKNOWN,collaborator,Serono GmbH,Phase 3
NCT00344565,2005.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT00344565,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00344682,2006.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT00344682,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00344695,,OTHER,lead,University of Arizona,Phase 3
NCT00344994,2006.0,OTHER,lead,Augusta University,Phase 4
NCT00344994,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00345033,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00345033,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00345098,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00345605,2008.0,OTHER,lead,Brendan Lee,Phase 2
NCT00345605,2008.0,NIH,collaborator,Office of Rare Diseases (ORD),Phase 2
NCT00345605,2008.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Phase 2
NCT00345605,2008.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00345982,2006.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00345982,2006.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT00346034,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00346827,2006.0,INDUSTRY,lead,Britannia Pharmaceuticals Ltd.,Phase 2/Phase 3
NCT00347152,2006.0,OTHER,lead,University of Kansas,Not Applicable
NCT00347152,2006.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT00347269,2006.0,OTHER,lead,University of Washington,Phase 4
NCT00347269,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00347295,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00348140,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00348192,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00348309,2006.0,INDUSTRY,lead,GlaxoSmithKline,Not Applicable
NCT00348387,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00348933,2006.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT00348933,2006.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT00348933,2006.0,OTHER,collaborator,"Rady Children's Hospital, San Diego",Not Applicable
NCT00348933,2006.0,OTHER,collaborator,Boston Children's Hospital,Not Applicable
NCT00348933,2006.0,OTHER,collaborator,Greenwood Genetic Center,Not Applicable
NCT00348933,2006.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Not Applicable
NCT00349193,2005.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00349531,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00349622,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00349622,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00349973,2001.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT00350311,2007.0,OTHER,lead,The University of New South Wales,Phase 2
NCT00350311,2007.0,OTHER_GOV,collaborator,Australian Government Department of Health and Ageing,Phase 2
NCT00350870,2005.0,OTHER,lead,Yale University,Phase 1
NCT00350870,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00351000,2005.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00351000,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00351299,2006.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00351611,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00351806,2005.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 4
NCT00351936,2005.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00351936,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00352339,2006.0,OTHER,lead,Inje University,Phase 4
NCT00352469,2006.0,OTHER,lead,Creighton University,Phase 4
NCT00352469,2006.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00352495,2006.0,NETWORK,lead,Children's Oncology Group,Phase 1
NCT00352495,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00352599,2009.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT00352651,2006.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT00352651,2006.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00352768,2006.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 4
NCT00352885,2006.0,OTHER,lead,Emory University,Phase 4
NCT00352885,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00352963,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00353379,1995.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00353379,1995.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00353665,2005.0,OTHER,lead,University of Lisbon,Phase 2/Phase 3
NCT00353665,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2/Phase 3
NCT00353938,2006.0,OTHER,lead,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT00353938,2006.0,UNKNOWN,collaborator,Swiss Medical Association for Psycholytic Therapy,Phase 2
NCT00354081,1999.0,OTHER,lead,Haukeland University Hospital,Phase 3
NCT00354081,1999.0,OTHER,collaborator,The Research Council of Norway,Phase 3
NCT00354081,1999.0,OTHER,collaborator,Norwegian Foundation for Health and Rehabilitation,Phase 3
NCT00354081,1999.0,UNKNOWN,collaborator,Norwegian Heart and Lung Patient Organisation,Phase 3
NCT00354081,1999.0,OTHER,collaborator,The Royal Norwegian Ministry of Health,Phase 3
NCT00354081,1999.0,OTHER,collaborator,"Locus for Homocysteine and Related Vitamins, University of Bergen, Norway",Phase 3
NCT00354081,1999.0,OTHER,collaborator,"Locus for Cardiac Research, University of Bergen, Norway",Phase 3
NCT00354081,1999.0,OTHER,collaborator,"Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway",Phase 3
NCT00354081,1999.0,INDUSTRY,collaborator,"Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",Phase 3
NCT00354133,2006.0,OTHER,lead,German Parkinson Study Group (GPS),Phase 4
NCT00354133,2006.0,OTHER,collaborator,University Hospital Schleswig-Holstein,Phase 4
NCT00354133,2006.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00354133,2006.0,NETWORK,collaborator,KKS Netzwerk,Phase 4
NCT00354770,2006.0,OTHER,lead,University of Chicago,Phase 2
NCT00354809,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00355082,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00355095,2006.0,OTHER,lead,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,Phase 2
NCT00355121,2006.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00355134,2006.0,INDUSTRY,lead,Novartis,Phase 3
NCT00355576,2006.0,OTHER,lead,Columbia University,Phase 2
NCT00355576,2006.0,OTHER,collaborator,ALS Association,Phase 2
NCT00355576,2006.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00355641,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00355927,2006.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT00356096,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00356278,2006.0,OTHER,lead,Emory University,Phase 2/Phase 3
NCT00356278,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00356603,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00357006,2006.0,OTHER,lead,The Alfred,Phase 2
NCT00357006,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00357097,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00357214,2006.0,OTHER,lead,Tufts University,Not Applicable
NCT00357214,2006.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Not Applicable
NCT00357357,2006.0,INDUSTRY,lead,Hunter-Fleming Ltd,Phase 2
NCT00357669,2006.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT00357786,2003.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00358150,2006.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00358293,2006.0,INDUSTRY,lead,Teva GTC,Phase 1/Phase 2
NCT00358631,2006.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00358969,2006.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00359125,2006.0,OTHER,lead,University of British Columbia,Phase 2
NCT00359125,2006.0,OTHER_GOV,collaborator,Western Economic Diversification Canada,Phase 2
NCT00359125,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00359216,2006.0,INDUSTRY,lead,Organon and Co,Phase 4
NCT00359424,2006.0,OTHER,lead,Joseph Broderick,Phase 3
NCT00359424,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00359424,2006.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT00359424,2006.0,OTHER,collaborator,University of Calgary,Phase 3
NCT00359632,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00359723,2004.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00359723,2004.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00359944,2006.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00360074,2004.0,OTHER,lead,University Hospital Freiburg,Phase 4
NCT00360126,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00360191,2004.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00360191,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00360243,2006.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00360269,2005.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00360269,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00360282,2006.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00360282,2006.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Not Applicable
NCT00360308,2006.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT00360399,2006.0,OTHER,lead,Emory University,Not Applicable
NCT00360399,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00360412,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00360529,2006.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00360555,2006.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00360568,2009.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 3
NCT00360568,2009.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 3
NCT00360906,2004.0,OTHER,lead,Haukeland University Hospital,Phase 2/Phase 3
NCT00360906,2004.0,UNKNOWN,collaborator,The Multiple Sclerosis National Competence Centre,Phase 2/Phase 3
NCT00360906,2004.0,UNKNOWN,collaborator,The Norwegian Multiple sclerosis Society,Phase 2/Phase 3
NCT00360906,2004.0,INDUSTRY,collaborator,Pronova BioPharma,Phase 2/Phase 3
NCT00360906,2004.0,UNKNOWN,collaborator,Serono Nordic,Phase 2/Phase 3
NCT00360906,2004.0,INDUSTRY,collaborator,Amersham Health,Phase 2/Phase 3
NCT00361010,2006.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT00361010,2006.0,INDUSTRY,collaborator,UCB Pharma,Not Applicable
NCT00361062,2006.0,OTHER,lead,"HaEmek Medical Center, Israel",Not Applicable
NCT00361166,2005.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2
NCT00361491,2006.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00361543,2006.0,OTHER,lead,The Alfred,Phase 4
NCT00361543,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00361543,2006.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 4
NCT00362024,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00362141,2006.0,OTHER,lead,Medical Center Haaglanden,Phase 2
NCT00362141,2006.0,INDUSTRY,collaborator,UCB Pharma,Phase 2
NCT00362336,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00362414,2006.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT00362414,2006.0,INDUSTRY,collaborator,Stem Cell Therapeutics Corp.,Phase 2
NCT00362414,2006.0,OTHER,collaborator,Hoag Memorial Hospital Presbyterian,Phase 2
NCT00362427,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00362427,2006.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00362661,2007.0,OTHER,lead,University of Zurich,Not Applicable
NCT00362804,2002.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00362804,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00362817,2004.0,OTHER,lead,Ohio State University Comprehensive Cancer Center,Phase 1/Phase 2
NCT00363298,2006.0,OTHER,lead,Stanford University,Not Applicable
NCT00363298,2006.0,OTHER,collaborator,Obsessive Compulsive Foundation,Not Applicable
NCT00363337,2006.0,OTHER,lead,Lindner Center of HOPE,Phase 4
NCT00363337,2006.0,OTHER,collaborator,University of Cincinnati,Phase 4
NCT00363571,2006.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT00363727,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00363753,2006.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT00363857,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00364429,2005.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00364481,2006.0,OTHER,lead,West Side ENT,Phase 1
NCT00364546,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00364546,2006.0,INDUSTRY,collaborator,Grünenthal GmbH,Phase 3
NCT00364559,2006.0,OTHER,lead,Universidad Autonoma de San Luis Potosí,Phase 2
NCT00364572,2006.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT00364572,2006.0,FED,collaborator,Walter Reed Army Medical Center,Phase 1/Phase 2
NCT00364689,2006.0,OTHER,lead,University of Miami,Phase 3
NCT00364689,2006.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 3
NCT00364806,2006.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT00364806,2006.0,OTHER,collaborator,Albert Einstein College of Medicine,Phase 4
NCT00364858,2001.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00365131,1997.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00365209,2006.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00365261,2006.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT00365352,2006.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT00365508,2006.0,OTHER,lead,Fox Chase Cancer Center,Phase 4
NCT00365508,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT00365768,2004.0,OTHER,lead,Columbia University,Phase 2
NCT00366080,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00366171,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00366327,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00366483,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00366535,2006.0,NIH,lead,National Institute of Nursing Research (NINR),Phase 2
NCT00366535,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00366535,2006.0,NIH,collaborator,National Institutes of Health Clinical Center (CC),Phase 2
NCT00366535,2006.0,OTHER,collaborator,University of Michigan,Phase 2
NCT00366535,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00366652,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00366704,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00366704,2006.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 3
NCT00367068,2002.0,OTHER,lead,Maastricht University,Phase 3
NCT00367068,2002.0,INDUSTRY,collaborator,Medtronic,Phase 3
NCT00367432,2006.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT00367484,2004.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT00367822,,INDUSTRY,lead,Axxonis Pharma AG,Phase 3
NCT00367874,2003.0,OTHER_GOV,lead,Sorlandet Hospital HF,Phase 4
NCT00368069,2006.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00368108,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00368251,2006.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00368290,2006.0,OTHER,lead,Kyle Kampman,Phase 2
NCT00368459,2006.0,OTHER,lead,Stanford University,Phase 2
NCT00368459,2006.0,OTHER,collaborator,Kaiser Permanente,Phase 2
NCT00368459,2006.0,OTHER,collaborator,Indiana University,Phase 2
NCT00368459,2006.0,OTHER,collaborator,Southern Illinois University,Phase 2
NCT00368472,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00368849,2005.0,OTHER,lead,University of Iowa,Phase 2
NCT00368849,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT00368862,2005.0,OTHER_GOV,lead,Finnish Institute for Health and Welfare,Phase 4
NCT00368862,2005.0,OTHER,collaborator,Finnish Foundation for Alcohol Studies,Phase 4
NCT00368927,2006.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT00369239,2006.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 4
NCT00369343,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00369564,2007.0,OTHER,lead,University of South Florida,Phase 3
NCT00369564,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00369564,2007.0,NETWORK,collaborator,Children's Oncology Group,Phase 3
NCT00369577,2006.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT00369603,2006.0,OTHER,lead,Duke University,Phase 4
NCT00369603,2006.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Phase 4
NCT00369785,2008.0,OTHER,lead,Wake Forest University Health Sciences,Phase 3
NCT00369785,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00369915,2006.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00370071,2006.0,INDUSTRY,lead,Bayer,Phase 3
NCT00370188,2006.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT00370500,2007.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Phase 4
NCT00370500,2007.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00370656,2007.0,OTHER,lead,University of Surrey,Phase 2/Phase 3
NCT00370838,2007.0,OTHER,lead,Harvey S. Singer,Phase 4
NCT00370838,2007.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT00370981,2006.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 2
NCT00371137,2006.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00371176,2006.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00371631,2006.0,FED,lead,US Department of Veterans Affairs,Phase 1
NCT00371878,2003.0,OTHER_GOV,lead,Royal Liverpool University Hospital,Phase 4
NCT00371878,2003.0,OTHER,collaborator,Kamuzu University of Health Sciences,Phase 4
NCT00371878,2003.0,OTHER,collaborator,Liverpool School of Tropical Medicine,Phase 4
NCT00371878,2003.0,OTHER,collaborator,Wellcome Trust,Phase 4
NCT00372125,2005.0,OTHER,lead,Karolinska University Hospital,Not Applicable
NCT00372125,2005.0,INDUSTRY,collaborator,Novo Nordisk A/S,Not Applicable
NCT00372151,2006.0,OTHER,lead,Sha'ar Menashe Mental Health Center,Phase 3
NCT00372151,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00372151,2006.0,OTHER_GOV,collaborator,Beersheva Mental Health Center,Phase 3
NCT00372528,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00372697,2005.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00372879,2006.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT00373087,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00373126,2005.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00373126,2005.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT00373295,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00373295,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00373503,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00373503,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00373542,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00373581,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00373581,2006.0,UNKNOWN,collaborator,Novel Cocaine Pharmacotherapies,Phase 2
NCT00373672,2006.0,OTHER,lead,Vanderbilt University,Phase 4
NCT00373672,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00373672,2006.0,INDUSTRY,collaborator,Cephalon,Phase 4
NCT00373880,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00373880,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00373893,2005.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT00374075,2003.0,OTHER,lead,University of Utah,Phase 1
NCT00374075,2003.0,OTHER,collaborator,Families of Spinal Muscular Atrophy,Phase 1
NCT00374075,2003.0,INDUSTRY,collaborator,"Leadiant Biosciences, Inc.",Phase 1
NCT00374075,2003.0,INDUSTRY,collaborator,Abbott,Phase 1
NCT00374127,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00374127,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00374166,2006.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00374244,2004.0,OTHER,lead,Yale University,Phase 2
NCT00374244,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00374348,2005.0,OTHER,lead,Jamaica Hospital Medical Center,Not Applicable
NCT00374348,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00374348,2005.0,UNKNOWN,collaborator,"Department of Psychiatry, Jamaica Hospital Medical Center",Not Applicable
NCT00374348,2005.0,AMBIG,collaborator,Research Division,Not Applicable
NCT00374530,2006.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT00374543,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00374543,2006.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00374777,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT00375050,2002.0,OTHER,lead,Yale University,Not Applicable
NCT00375050,2002.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00375284,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00375297,2001.0,OTHER,lead,University of New Mexico,Phase 4
NCT00375297,2001.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00375375,2004.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Phase 4
NCT00375557,2006.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00375557,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00375778,2005.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00375778,2005.0,OTHER,collaborator,Lundbeck Foundation,Not Applicable
NCT00375843,2005.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00375869,2006.0,OTHER,lead,Royal Alexandra Hospital,Phase 2
NCT00375869,2006.0,OTHER,collaborator,University of Alberta,Phase 2
NCT00375960,2006.0,INDUSTRY,lead,Vernalis (R&D) Ltd,Phase 2
NCT00375960,2006.0,INDUSTRY,collaborator,Cita NeuroPharmaceuticals,Phase 2
NCT00375973,2006.0,OTHER,lead,University of Cincinnati,Phase 2/Phase 3
NCT00375973,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2/Phase 3
NCT00376051,2006.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00376051,2006.0,OTHER,collaborator,Alzheimer Society of Canada,Phase 4
NCT00376064,2006.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00376168,2007.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00376194,2006.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00376220,2004.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00376220,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00376454,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00376766,2007.0,OTHER,lead,"University Hospital, Grenoble",Phase 3
NCT00376766,2007.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 3
NCT00376766,2007.0,INDUSTRY,collaborator,UCB Pharma,Phase 3
NCT00376779,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00376987,2003.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT00376987,2003.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00377039,2006.0,INDUSTRY,lead,Sosei,Phase 2
NCT00377299,2006.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00377299,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00377468,2006.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 2
NCT00377468,2006.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 2
NCT00377468,2006.0,NETWORK,collaborator,German Research Network on Neuropathic Pain,Phase 2
NCT00377598,2006.0,INDUSTRY,lead,Takeda,Phase 2/Phase 3
NCT00377715,2005.0,INDUSTRY,lead,"Medivation, Inc.",Phase 2
NCT00378092,2006.0,INDUSTRY,lead,Janssen Cilag N.V./S.A.,Phase 4
NCT00378183,2001.0,INDUSTRY,lead,"Janssen, LP",Phase 4
NCT00379496,2000.0,OTHER,lead,University of Sao Paulo,Early Phase 1
NCT00379626,2003.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1
NCT00379756,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00379886,2003.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT00380003,2006.0,INDUSTRY,lead,Evotec Neurosciences GmbH,Phase 2
NCT00380224,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00380276,2006.0,INDUSTRY,lead,Myrexis Inc.,Phase 3
NCT00380302,2006.0,INDUSTRY,lead,Sanofi,Phase 1/Phase 2
NCT00380913,2006.0,INDUSTRY,lead,"NEMA Research, Inc.",Phase 4
NCT00380965,2006.0,INDUSTRY,lead,"NEMA Research, Inc.",Phase 4
NCT00381199,2006.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Not Applicable
NCT00381238,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00381264,2006.0,INDUSTRY,lead,"NEMA Research, Inc.",Phase 4
NCT00381381,2006.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT00381433,2006.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT00381472,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00381537,,OTHER,lead,Institute of Child Health,Not Applicable
NCT00381732,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00381732,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00382135,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00382135,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00382161,2006.0,OTHER,lead,"University Hospital, Saarland",Phase 3
NCT00382161,2006.0,INDUSTRY,collaborator,Novartis,Phase 3
NCT00382291,2009.0,OTHER,lead,University of Florida,Phase 4
NCT00382291,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00382629,2006.0,INDUSTRY,lead,Bayhill Therapeutics,Phase 2
NCT00382824,2006.0,OTHER,lead,Lahey Clinic,Not Applicable
NCT00382993,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00383162,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00383448,2006.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2
NCT00383643,2006.0,OTHER,lead,Stanford University,Phase 2
NCT00383708,2006.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00383747,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00383747,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00383747,2004.0,OTHER,collaborator,North Suffolk Mental Health Association,Phase 4
NCT00383786,2006.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00383786,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00384046,2006.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00384332,2007.0,OTHER,lead,Vanderbilt University,Phase 4
NCT00384332,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00384397,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00384423,2006.0,INDUSTRY,lead,"Epix Pharmaceuticals, Inc.",Phase 2
NCT00384774,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00384774,2006.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 2
NCT00385008,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00385268,2006.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00385268,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00385385,2006.0,INDUSTRY,lead,ActivBiotics,Phase 2
NCT00385411,2006.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00385437,2003.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT00385437,2003.0,INDUSTRY,collaborator,Organon,Phase 2
NCT00385684,2007.0,FED,lead,VA Office of Research and Development,Phase 4
NCT00385710,2006.0,OTHER,lead,Nantes University Hospital,Phase 2
NCT00385801,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00385801,2005.0,INDUSTRY,collaborator,"Janssen, LP",Phase 2
NCT00386191,2006.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00386893,2006.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00386893,2006.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00387075,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00387075,2006.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00387075,2006.0,OTHER,collaborator,Molecular NeuroImaging,Phase 2
NCT00387179,2006.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00387270,2006.0,INDUSTRY,lead,"Medivation, Inc.",Phase 1/Phase 2
NCT00387270,2006.0,NETWORK,collaborator,Huntington Study Group,Phase 1/Phase 2
NCT00387348,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00387348,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00387413,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00389064,2006.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00389493,2006.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00389493,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00389831,2006.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00389883,2006.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00390221,2008.0,INDUSTRY,lead,Biogen,Phase 2
NCT00390221,2008.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT00390559,2005.0,OTHER,lead,Virginia Commonwealth University,Not Applicable
NCT00390559,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00390845,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00390923,2007.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00390923,2007.0,OTHER,collaborator,Canadian Tobacco Control Research Initiative,Not Applicable
NCT00391001,2006.0,OTHER,lead,Cambridge Health Alliance,Phase 1
NCT00391001,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1
NCT00391001,2006.0,OTHER,collaborator,Mclean Hospital,Phase 1
NCT00391079,2006.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00391222,2006.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 3
NCT00391261,2006.0,OTHER,lead,Cambridge Health Alliance,Phase 4
NCT00391261,2006.0,OTHER,collaborator,American Psychiatric Association,Phase 4
NCT00391430,2005.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00391430,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00391534,2006.0,INDUSTRY,lead,Desitin Arzneimittel GmbH,Phase 3
NCT00391534,2006.0,INDUSTRY,collaborator,FGK Clinical Research GmbH,Phase 3
NCT00391625,2004.0,INDUSTRY,lead,Shire,Phase 1/Phase 2
NCT00391755,2006.0,OTHER,lead,Charlottesville Neuroscience,Phase 4
NCT00391755,2006.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 4
NCT00391833,2004.0,OTHER,lead,Seoul National University Hospital,Phase 1/Phase 2
NCT00391898,2006.0,INDUSTRY,lead,Novartis,Phase 4
NCT00392041,2006.0,OTHER,lead,"Lesley A. Allen, Ph.D.",Phase 4
NCT00392041,2006.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00392197,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00392912,2007.0,FED,lead,Michael E. DeBakey VA Medical Center,Not Applicable
NCT00392912,2007.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Not Applicable
NCT00393562,2006.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00393874,2006.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00393874,2006.0,FED,collaborator,U.S. Army Medical Research and Development Command,Not Applicable
NCT00393965,2005.0,INDUSTRY,lead,Myrexis Inc.,Phase 1
NCT00393978,2006.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00393978,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00394056,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00394095,2006.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00394095,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00394862,2006.0,OTHER,lead,Emory University,Not Applicable
NCT00394862,2006.0,FED,collaborator,Centers for Disease Control and Prevention,Not Applicable
NCT00394901,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00395031,2003.0,OTHER,lead,Manhattan Psychiatric Center,Phase 2/Phase 3
NCT00395031,2003.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT00395044,2006.0,OTHER,lead,The Scripps Research Institute,Phase 2
NCT00395044,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00395317,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00395460,2006.0,INDUSTRY,lead,Bayer,Phase 3
NCT00395694,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00395850,2007.0,OTHER,lead,University of Arkansas,Phase 2
NCT00395850,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00395863,2006.0,INDUSTRY,lead,"Bracco Diagnostics, Inc",Phase 4
NCT00395915,2006.0,OTHER,lead,Universita di Verona,Phase 4
NCT00396019,2006.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT00396019,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00396058,2006.0,OTHER,lead,University of Aarhus,Phase 4
NCT00396214,2007.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 3
NCT00396214,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT00396214,2007.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00396565,2006.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT00396643,2004.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT00396643,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00396669,2007.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT00396734,2007.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT00397020,2006.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT00397020,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00397033,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00397033,2006.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00397098,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00397228,2006.0,OTHER,lead,Molecular NeuroImaging,Phase 2
NCT00397228,2006.0,OTHER,collaborator,Institute for Neurodegenerative Disorders,Phase 2
NCT00397254,2006.0,OTHER,lead,Clinvest,Phase 4
NCT00397254,2006.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT00397423,2006.0,OTHER,lead,Peking University,Phase 2
NCT00397696,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00397696,2006.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00397891,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00398632,2006.0,OTHER,lead,Stanford University,Phase 4
NCT00398632,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00398957,,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 1
NCT00399243,2006.0,OTHER,lead,Diamond Headache Clinic,Phase 4
NCT00399243,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00399295,,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 1
NCT00399477,2006.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 4
NCT00399633,2007.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT00399633,2007.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT00399633,2007.0,OTHER,collaborator,Bispebjerg Hospital,Not Applicable
NCT00399698,1999.0,OTHER,lead,Ohio State University,Phase 3
NCT00399763,2005.0,OTHER,lead,Denver Health and Hospital Authority,Not Applicable
NCT00399763,2005.0,OTHER,collaborator,American Academy of Child Adolescent Psychiatry.,Not Applicable
NCT00399893,2006.0,OTHER,lead,Duke University,Not Applicable
NCT00399893,2006.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00399893,2006.0,NIH,collaborator,National Center for Research Resources (NCRR),Not Applicable
NCT00399893,2006.0,INDUSTRY,collaborator,Novartis,Not Applicable
NCT00400075,1996.0,OTHER,lead,Hospices Civils de Lyon,Phase 4
NCT00400634,2006.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 2
NCT00400634,2006.0,INDUSTRY,collaborator,Ceregene,Phase 2
NCT00400790,2007.0,OTHER,lead,University of Melbourne,Not Applicable
NCT00400790,2007.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Not Applicable
NCT00400816,2005.0,OTHER,lead,The Cleveland Clinic,Phase 2
NCT00400816,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00401089,2002.0,OTHER,lead,Lawson Health Research Institute,Phase 1/Phase 2
NCT00401089,2002.0,OTHER,collaborator,Queen's University,Phase 1/Phase 2
NCT00401089,2002.0,OTHER,collaborator,Northern Ontario School of Medicine,Phase 1/Phase 2
NCT00401089,2002.0,OTHER,collaborator,Imperial College London,Phase 1/Phase 2
NCT00401167,2006.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00401167,2006.0,INDUSTRY,collaborator,Lundbeck Canada Inc.,Phase 4
NCT00401284,2006.0,INDUSTRY,lead,Evotec Neurosciences GmbH,Phase 2
NCT00401310,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00401531,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00401648,2002.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00401921,2006.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00401973,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00402233,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00402298,2007.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT00402389,2004.0,OTHER,lead,University of Arizona,Phase 2
NCT00402389,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00402480,2003.0,OTHER,lead,Duke University,Phase 2
NCT00402571,2002.0,OTHER,lead,Denver Health and Hospital Authority,Phase 4
NCT00402571,2002.0,INDUSTRY,collaborator,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Phase 4
NCT00402584,2000.0,INDUSTRY,lead,Abbott,Phase 3
NCT00403117,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00403117,2006.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT00403117,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00403247,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00403247,2004.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Not Applicable
NCT00403455,2006.0,FED,lead,VA Office of Research and Development,Phase 3
NCT00403520,2006.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00403546,2006.0,OTHER,lead,"Donald C. Goff, MD",Phase 3
NCT00403546,2006.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00403767,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00403767,2006.0,INDUSTRY,collaborator,Bayer,Phase 3
NCT00404170,2006.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00404170,2006.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00404352,2006.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT00404573,2006.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00404651,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00404729,2005.0,OTHER,lead,"Fondazione G.B. Bietti, IRCCS",Phase 4
NCT00405353,2002.0,OTHER,lead,"University of California, Los Angeles",Phase 1/Phase 2
NCT00405353,2002.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1/Phase 2
NCT00405535,2004.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Not Applicable
NCT00405535,2004.0,OTHER,collaborator,Obsessive Compulsive Foundation,Not Applicable
NCT00405860,2002.0,OTHER,lead,Mayo Clinic,Phase 1
NCT00405860,2002.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 1
NCT00405886,2005.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 2
NCT00405912,2005.0,OTHER,lead,Mayo Clinic,Phase 2
NCT00405912,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00406003,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00406029,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00406315,2006.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00406432,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00406640,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00407121,2006.0,OTHER,lead,Asociación para Evitar la Ceguera en México,Phase 3
NCT00407212,2002.0,INDUSTRY,lead,Novartis,Phase 1/Phase 2
NCT00407277,2007.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00407277,2007.0,OTHER,collaborator,Canadian Psychiatric Research Foundation,Not Applicable
NCT00407433,,OTHER,lead,"Gustave Roussy, Cancer Campus, Grand Paris",Phase 2
NCT00407576,2006.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00407732,2007.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT00407732,2007.0,INDUSTRY,collaborator,Roche Pharma AG,Not Applicable
NCT00407745,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00408525,2006.0,OTHER,lead,Vanderbilt University,Phase 1
NCT00408915,2006.0,INDUSTRY,lead,Axxonis Pharma AG,Phase 3
NCT00408993,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00408993,2006.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00409175,2007.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT00409201,2006.0,OTHER_GOV,lead,Abarbanel Mental Health Center,Phase 1
NCT00409435,2006.0,OTHER,lead,Mayo Clinic,Phase 2
NCT00409435,2006.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00409487,2006.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT00409721,2007.0,OTHER,lead,University of Alberta,Phase 2
NCT00409721,2007.0,OTHER,collaborator,ALS Association,Phase 2
NCT00410085,2005.0,OTHER,lead,Regional Hospital Holstebro,Phase 4
NCT00410371,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00410566,2006.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT00411203,2003.0,OTHER,lead,Stanley Medical Research Institute,Phase 3
NCT00411307,,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 2
NCT00411580,2005.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT00411619,2007.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT00411619,2007.0,INDUSTRY,collaborator,Novartis,Phase 1/Phase 2
NCT00411723,2006.0,INDUSTRY,lead,Artielle ImmunoTherapeutics,Phase 1
NCT00411866,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00412191,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00412373,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00412373,2006.0,INDUSTRY,collaborator,"Janssen, LP",Phase 3
NCT00412516,2006.0,OTHER,lead,PATH,Phase 3
NCT00412620,2006.0,INDUSTRY,lead,Abbott,Phase 2
NCT00412867,2006.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 4
NCT00412867,2006.0,INDUSTRY,collaborator,"Kyowa Kirin Co., Ltd.",Phase 4
NCT00413257,2006.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2/Phase 3
NCT00413296,2005.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT00413296,2005.0,INDUSTRY,collaborator,UCB Pharma,Phase 2/Phase 3
NCT00413946,2006.0,NETWORK,lead,Swiss Neonatal Network,Phase 2
NCT00413946,2006.0,OTHER,collaborator,Swiss National Science Foundation,Phase 2
NCT00414167,2005.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT00414167,2005.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT00414349,2006.0,INDUSTRY,lead,Grünenthal GmbH,Phase 3
NCT00414453,2007.0,OTHER,lead,University of Rochester,Phase 4
NCT00414453,2007.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Phase 4
NCT00414622,2006.0,INDUSTRY,lead,CoMentis,Phase 2
NCT00415142,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00415376,2007.0,OTHER,lead,Northwestern University,Not Applicable
NCT00415376,2007.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00415571,2006.0,INDUSTRY,lead,QuatRx Pharmaceuticals Company,Phase 2
NCT00415571,2006.0,INDUSTRY,collaborator,Hormos Medical,Phase 2
NCT00415610,2005.0,OTHER,lead,University of Minnesota,Phase 1
NCT00415610,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00416169,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00416195,2006.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 2
NCT00416195,2006.0,INDUSTRY,collaborator,Eisai Limited,Phase 2
NCT00416221,2006.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT00416221,2006.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00417482,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00417482,2004.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT00417482,2004.0,OTHER,collaborator,Columbia University,Phase 4
NCT00418145,2003.0,OTHER,lead,Fred Lublin,Phase 3
NCT00418145,2003.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 3
NCT00418145,2003.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00418171,2002.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00418275,2001.0,INDUSTRY,lead,Global Biotech,Phase 1/Phase 2
NCT00418288,2007.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00418691,2004.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 3
NCT00418847,2004.0,OTHER,lead,The Hospital for Sick Children,Phase 2
NCT00418847,2004.0,INDUSTRY,collaborator,Actelion,Phase 2
NCT00418873,2007.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT00418873,2007.0,INDUSTRY,collaborator,"Astellas Pharma Taiwan, Inc.",Phase 4
NCT00419094,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00419120,2006.0,INDUSTRY,lead,Tengion,Phase 2
NCT00419146,2001.0,OTHER,lead,"University Hospital, Aker",Phase 2/Phase 3
NCT00419146,2001.0,OTHER,collaborator,Diakonhjemmet Hospital,Phase 2/Phase 3
NCT00419146,2001.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Laxdale Ltd,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Scandinavian Society for Psychopharmacology,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Shipowner Emil Stray's legacy,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Johanne and Einar Eilertsen's research fund,Phase 2/Phase 3
NCT00419146,2001.0,INDUSTRY,collaborator,AstraZeneca,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Solveig and Johan P. Sommer's foundation,Phase 2/Phase 3
NCT00419146,2001.0,UNKNOWN,collaborator,Josef and Haldis Andresen's legacy,Phase 2/Phase 3
NCT00419146,2001.0,OTHER,collaborator,University of Oslo,Phase 2/Phase 3
NCT00419146,2001.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 2/Phase 3
NCT00419393,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00419471,2007.0,OTHER,lead,Chonnam National University Hospital,Phase 4
NCT00419471,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00419653,2003.0,OTHER,lead,University of Jena,Phase 4
NCT00419653,2003.0,INDUSTRY,collaborator,Sanofi,Phase 4
NCT00419692,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00419731,2006.0,OTHER,lead,University of Minnesota,Phase 2/Phase 3
NCT00419731,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00420212,2007.0,INDUSTRY,lead,Biogen,Phase 3
NCT00420420,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00420459,2007.0,OTHER,lead,Indiana University School of Medicine,Phase 2
NCT00420498,2005.0,OTHER,lead,Yale University,Phase 2
NCT00420498,2005.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 2
NCT00420641,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00420823,2007.0,OTHER,lead,Melbourne Health,Phase 2/Phase 3
NCT00420823,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT00420823,2007.0,OTHER,collaborator,Southern Health,Phase 2/Phase 3
NCT00421083,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00421083,2004.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00421460,2007.0,OTHER,lead,Chulalongkorn University,Phase 4
NCT00421460,2007.0,OTHER,collaborator,Ramathibodi Hospital,Phase 4
NCT00421460,2007.0,OTHER,collaborator,Siriraj Hospital,Phase 4
NCT00421603,2007.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00421603,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00421720,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00421954,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 3
NCT00421954,2006.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00422110,2008.0,INDUSTRY,lead,UCB Pharma,Phase 2/Phase 3
NCT00422123,2007.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00422214,2006.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00422292,2006.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00422331,2007.0,INDUSTRY,lead,JDS Pharmaceuticals,Phase 3
NCT00422422,2011.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00422578,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00422578,2004.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00422734,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00422734,2006.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00422812,2006.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT00422955,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00422994,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00423085,2007.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00423085,2007.0,INDUSTRY,collaborator,Ono Pharmaceutical Co. Ltd,Phase 3
NCT00423527,2007.0,OTHER,lead,Odense University Hospital,Phase 4
NCT00423605,2006.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00423813,2006.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00423878,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00423943,2005.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00423969,2003.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00424203,2006.0,OTHER,lead,UNICANCER,Phase 2
NCT00424372,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00424489,2002.0,OTHER,lead,Northwestern University,Phase 1
NCT00424892,,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2/Phase 3
NCT00424931,2007.0,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 2
NCT00425243,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00425256,2006.0,INDUSTRY,lead,"Palatin Technologies, Inc",Phase 2
NCT00425256,2006.0,INDUSTRY,collaborator,King Pharmaceuticals is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00425282,2006.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00425399,2007.0,OTHER,lead,Herzog Hospital,Not Applicable
NCT00425815,2009.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00425815,2009.0,OTHER,collaborator,University of Maryland,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Columbia University,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Duke University,Phase 2
NCT00425815,2009.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 2
NCT00426673,2005.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT00426816,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00426842,2007.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT00426946,2005.0,OTHER,lead,Geha Mental Health Center,Phase 4
NCT00427011,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00427076,2007.0,OTHER,lead,Rabin Medical Center,Phase 3
NCT00427206,2004.0,OTHER,lead,Denver Health and Hospital Authority,Phase 4
NCT00427206,2004.0,INDUSTRY,collaborator,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Phase 4
NCT00427674,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00427674,2007.0,OTHER,collaborator,Molecular NeuroImaging,Phase 1
NCT00428090,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00428298,2007.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00428298,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00428350,2006.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00428389,2007.0,INDUSTRY,lead,Novartis,Phase 3
NCT00428935,2006.0,OTHER,lead,Nationwide Children's Hospital,Phase 1
NCT00428935,2006.0,INDUSTRY,collaborator,"Asklepios Biopharmaceutical, Inc.",Phase 1
NCT00429169,2004.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00429169,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00429208,2007.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT00429260,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00429442,2008.0,OTHER,lead,Anna Tsakiri,Phase 3
NCT00429442,2008.0,INDUSTRY,collaborator,Sanofi,Phase 3
NCT00429676,2005.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT00429676,2005.0,OTHER,collaborator,Denver Health Medical Center,Phase 2
NCT00430105,1998.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 2/Phase 3
NCT00430573,2007.0,OTHER,lead,Boston University Charles River Campus,Phase 2
NCT00430573,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00430573,2007.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00431171,2007.0,OTHER,lead,The University of Hong Kong,Phase 1
NCT00431171,2007.0,NETWORK,collaborator,China Spinal Cord Injury Network,Phase 1
NCT00431184,2007.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00431184,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00431522,2004.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00431574,2002.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00431574,2002.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT00432042,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00432055,2007.0,OTHER,lead,Sunnaas Rehabilitation Hospital,Phase 4
NCT00432055,2007.0,OTHER,collaborator,The Royal Norwegian Ministry of Health,Phase 4
NCT00432081,2000.0,OTHER,lead,Radboud University Medical Center,Phase 3
NCT00432081,2000.0,OTHER,collaborator,American Health Assistance Foundation,Phase 3
NCT00432081,2000.0,OTHER,collaborator,Netherlands Brain Foundation,Phase 3
NCT00432081,2000.0,OTHER,collaborator,Netherlands Alzheimer Foundation,Phase 3
NCT00432237,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00432263,2007.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00432796,2006.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT00432796,2006.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 3
NCT00432796,2006.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00433121,2006.0,OTHER,lead,Sykehuset Innlandet HF,Phase 4
NCT00433121,2006.0,UNKNOWN,collaborator,"Demensforbundet, Norway",Phase 4
NCT00433147,2007.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00433368,2003.0,OTHER,lead,Aga Khan University,Phase 3
NCT00433667,2006.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00433719,2005.0,OTHER,lead,University of Oxford,Not Applicable
NCT00433719,2005.0,OTHER,collaborator,Wellcome Trust,Not Applicable
NCT00433732,2004.0,INDUSTRY,lead,POZEN,Phase 3
NCT00434083,2004.0,INDUSTRY,lead,POZEN,Phase 3
NCT00434148,2006.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00434304,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00434876,2007.0,FED,lead,Subhajit Chakravorty,Phase 3
NCT00435370,2006.0,OTHER,lead,Baylor College of Medicine,Phase 3
NCT00435370,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00436345,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00436371,2005.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00436826,2006.0,INDUSTRY,lead,"EMD Serono Research & Development Institute, Inc.",Phase 2
NCT00437125,2007.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00437281,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1/Phase 2
NCT00437372,2007.0,OTHER,lead,Sidney Kimmel Cancer Center at Thomas Jefferson University,Phase 1
NCT00437372,2007.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT00437385,2005.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 1
NCT00437385,2005.0,OTHER,collaborator,German Research Foundation,Phase 1
NCT00437632,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00437814,2005.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT00437840,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00438087,2007.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00438139,2007.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00438386,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00438386,2005.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00438451,2007.0,OTHER,lead,Johannes Gutenberg University Mainz,Phase 4
NCT00438451,2007.0,INDUSTRY,collaborator,UCB Pharma GmbH,Phase 4
NCT00438568,2006.0,OTHER,lead,University of Washington,Phase 2
NCT00438568,2006.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00438607,2007.0,INDUSTRY,lead,Biogen,Phase 2
NCT00438776,2007.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00438776,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00438776,2007.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00438971,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00438971,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00439166,2007.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 3
NCT00439166,2007.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 3
NCT00439413,2007.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00439413,2007.0,FED,collaborator,VA Office of Research and Development,Phase 2
NCT00439634,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00439699,2007.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 4
NCT00439699,2007.0,OTHER,collaborator,Ralph M. Parsons Foundation,Phase 4
NCT00439699,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00439868,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00440050,2007.0,OTHER,lead,Alzheimer's Disease Cooperative Study (ADCS),Phase 3
NCT00440050,2007.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00440050,2007.0,INDUSTRY,collaborator,"DSM Nutritional Products, Inc.",Phase 3
NCT00440232,2007.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00440323,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00440518,2007.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00440713,2004.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT00440843,2007.0,FED,lead,VA Connecticut Healthcare System,Phase 3
NCT00440843,2007.0,NETWORK,collaborator,"Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital",Phase 3
NCT00440843,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00441103,2006.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT00441259,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00441285,2010.0,OTHER,lead,Universidad Peruana Cayetano Heredia,Phase 2/Phase 3
NCT00441285,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT00441558,2007.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00441649,2000.0,OTHER,lead,Stony Brook University,Not Applicable
NCT00441649,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00441896,2007.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT00442104,2007.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT00442169,2005.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00442221,2004.0,INDUSTRY,lead,POZEN,Phase 3
NCT00442325,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00442780,2007.0,INDUSTRY,lead,Biogen,Phase 2
NCT00442845,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00442923,2007.0,OTHER,lead,Aaron J. Janowsky,Phase 2
NCT00442923,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00442936,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00443014,2003.0,OTHER,lead,University Hospital of North Norway,Phase 4
NCT00443014,2003.0,UNKNOWN,collaborator,"County Officer of Nordland, Moloveien 2, 8006 Bodø, Norway",Phase 4
NCT00443014,2003.0,OTHER,collaborator,Norwegian Foundation for Health and Rehabilitation,Phase 4
NCT00443014,2003.0,OTHER_GOV,collaborator,Norwegian Department of Health and Social Affairs,Phase 4
NCT00443209,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00443352,2007.0,OTHER,lead,Thomas Jefferson University,Phase 4
NCT00443404,2003.0,OTHER,lead,University of Patras,Phase 2/Phase 3
NCT00443417,2007.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 2
NCT00443625,2006.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 1
NCT00443846,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00443872,2007.0,OTHER,lead,Parkinson's Disease and Movement Disorder Center of Boca Raton,Phase 4
NCT00443872,2007.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 4
NCT00444028,2005.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 1
NCT00444873,2005.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00444886,2007.0,OTHER,lead,University of British Columbia,Phase 2
NCT00444886,2007.0,INDUSTRY,collaborator,Allergan,Phase 2
NCT00444964,2005.0,OTHER,lead,Children's Mercy Hospital Kansas City,Phase 3
NCT00445705,2007.0,INDUSTRY,lead,Allergan,Phase 2
NCT00446082,2006.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT00446550,2008.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00446641,2007.0,OTHER,lead,Asan Medical Center,Phase 4
NCT00446641,2007.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00446719,2007.0,OTHER,lead,"Mount Sinai Hospital, Canada",Phase 2/Phase 3
NCT00446992,2006.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1/Phase 2
NCT00447018,2002.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT00447044,2007.0,OTHER,lead,University of Arkansas,Not Applicable
NCT00447369,2007.0,OTHER,lead,Hospital Militar del General Luis Felipe Brieba Aran,Phase 3
NCT00447499,2007.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00447525,2007.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00447941,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00448058,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00448578,2005.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00448825,2007.0,OTHER,lead,Bankole Johnson,Phase 3
NCT00448825,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00448890,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00448916,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00449007,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00449007,2006.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00449397,2003.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00449683,2007.0,OTHER,lead,Thomas Jefferson University,Phase 4
NCT00449683,2007.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00449709,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00449774,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00449787,2007.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT00449865,2007.0,OTHER,lead,University of Rochester,Phase 3
NCT00449865,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00450437,2007.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00451074,2007.0,OTHER,lead,Nationwide Children's Hospital,Phase 1
NCT00451074,2007.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT00451074,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00451204,2007.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00451204,2007.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT00451204,2007.0,OTHER,collaborator,Ohio State University,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Medicine and Dentistry of New Jersey,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Chicago,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Utah,Phase 2
NCT00451204,2007.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Kansas Medical Center,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00451204,2007.0,OTHER,collaborator,Mayo Clinic,Phase 2
NCT00451204,2007.0,OTHER,collaborator,"University of Colorado, Denver",Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of New Mexico,Phase 2
NCT00451204,2007.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00451204,2007.0,OTHER,collaborator,Dartmouth-Hitchcock Medical Center,Phase 2
NCT00451204,2007.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT00451204,2007.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00451204,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00451230,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00451230,2005.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT00451451,2007.0,INDUSTRY,lead,Biogen,Phase 3
NCT00451516,2007.0,OTHER,lead,The University of Queensland,Phase 2
NCT00451633,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00451750,2007.0,OTHER,lead,University of Zurich,Not Applicable
NCT00451750,2007.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Not Applicable
NCT00451815,,INDUSTRY,lead,Biogen,Phase 2
NCT00452231,2007.0,OTHER,lead,Université de Montréal,Phase 2/Phase 3
NCT00452231,2007.0,OTHER,collaborator,Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal,Phase 2/Phase 3
NCT00452504,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00452621,2007.0,INDUSTRY,lead,Novartis,Phase 4
NCT00452621,2007.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT00453180,2007.0,OTHER,lead,Indiana University School of Medicine,Phase 2
NCT00453180,2007.0,OTHER,collaborator,National Alliance for Autism Research,Phase 2
NCT00453570,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00453609,2007.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 4
NCT00453804,2006.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 4
NCT00453804,2006.0,INDUSTRY,collaborator,Cephalon,Phase 4
NCT00453921,2007.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Not Applicable
NCT00453921,2007.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00454870,2007.0,INDUSTRY,lead,Memory Pharmaceuticals,Phase 2
NCT00455000,2007.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00455143,2006.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00455234,2005.0,OTHER,lead,"Christian Medical College, Vellore, India",Phase 3
NCT00455507,2007.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT00455520,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00455520,2007.0,INDUSTRY,collaborator,Grünenthal GmbH,Phase 3
NCT00455637,2007.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00455702,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00455715,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00456014,2006.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00456014,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00456339,2006.0,OTHER,lead,University of Chicago,Phase 4
NCT00456430,2003.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00456586,2002.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 2
NCT00456794,2002.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 2
NCT00456820,2004.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00456898,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00456937,2006.0,OTHER_GOV,lead,BeerYaakov Mental Health Center,Phase 4
NCT00456937,2006.0,INDUSTRY,collaborator,Lundbeck Israel,Phase 4
NCT00456976,2007.0,OTHER,lead,Tabriz University,Early Phase 1
NCT00457054,2003.0,OTHER,lead,Indiana University School of Medicine,Phase 4
NCT00457106,2002.0,OTHER,lead,Beth Israel Medical Center,Not Applicable
NCT00457197,2007.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00457730,2007.0,INDIV,lead,"Brown, Theodore R., M.D., MPH",Phase 2/Phase 3
NCT00457730,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2/Phase 3
NCT00457769,2007.0,OTHER,lead,Kessler Foundation,Phase 1
NCT00457769,2007.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT00457808,2002.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00457808,2002.0,OTHER,collaborator,The LAM Foundation,Phase 2
NCT00457808,2002.0,OTHER,collaborator,Tuberous Sclerosis Alliance,Phase 2
NCT00457899,2007.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00457964,2005.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT00457964,2005.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 1/Phase 2
NCT00458107,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00458211,2005.0,OTHER_GOV,lead,Bronx Psychiatric Center,Phase 4
NCT00458211,2005.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00458211,2005.0,OTHER,collaborator,Buffalo Psychiatric Center,Phase 4
NCT00458211,2005.0,OTHER,collaborator,Rochester Psychiatric Center,Phase 4
NCT00459264,2005.0,OTHER,lead,University of Oxford,Not Applicable
NCT00459264,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00459316,2007.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1/Phase 2
NCT00459316,2007.0,NETWORK,collaborator,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Phase 1/Phase 2
NCT00459420,2007.0,OTHER,lead,Ron Postuma,Phase 2/Phase 3
NCT00459420,2007.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2/Phase 3
NCT00459420,2007.0,OTHER,collaborator,University of Toronto,Phase 2/Phase 3
NCT00459550,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00459667,2007.0,INDUSTRY,lead,Bayer,Phase 3
NCT00459693,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Not Applicable
NCT00459953,2006.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT00459953,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00459953,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2/Phase 3
NCT00460148,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00460161,2009.0,OTHER,lead,Shaare Zedek Medical Center,Phase 3
NCT00460473,2007.0,INDUSTRY,lead,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 3
NCT00460486,2006.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00460512,2007.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT00460564,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00460655,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00461149,1995.0,OTHER,lead,Federico II University,Phase 4
NCT00461656,2009.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT00461656,2009.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 4
NCT00461656,2009.0,OTHER,collaborator,University Medicine Greifswald,Phase 4
NCT00461656,2009.0,OTHER,collaborator,Free University Medical Center,Phase 4
NCT00461656,2009.0,OTHER,collaborator,Leiden University Medical Center,Phase 4
NCT00461656,2009.0,OTHER,collaborator,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 4
NCT00461656,2009.0,UNKNOWN,collaborator,Rotterdam Eye Hospital,Phase 4
NCT00461656,2009.0,UNKNOWN,collaborator,Laurentius Hospital Roermond,Phase 4
NCT00461656,2009.0,OTHER,collaborator,Martin-Luther-Universität Halle-Wittenberg,Phase 4
NCT00461942,2006.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 2
NCT00461942,2006.0,OTHER_GOV,collaborator,"Ministry of Health, China",Phase 2
NCT00461942,2006.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT00462007,2006.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 4
NCT00462228,2007.0,OTHER,lead,University of Missouri-Columbia,Phase 4
NCT00462228,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00462254,2007.0,OTHER,lead,Southern California Institute for Research and Education,Phase 4
NCT00462449,2007.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00462449,2007.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT00463203,2007.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2
NCT00463346,2006.0,OTHER,lead,Yale University,Phase 3
NCT00463346,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT00463372,2006.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00463437,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00463476,2007.0,OTHER,lead,PATH,Phase 4
NCT00463580,2008.0,OTHER,lead,Emory University,Phase 4
NCT00463580,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00463684,2007.0,OTHER,lead,PATH,Phase 4
NCT00463684,2007.0,UNKNOWN,collaborator,Ministry of Health of Sri Lanka,Phase 4
NCT00463684,2007.0,OTHER,collaborator,Mahidol University,Phase 4
NCT00463684,2007.0,UNKNOWN,collaborator,Quintiles Singapore,Phase 4
NCT00463775,2007.0,OTHER,lead,Elizabeth Ralevski,Phase 3
NCT00463879,2005.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT00463879,2005.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 2/Phase 3
NCT00463957,2006.0,OTHER,lead,University of Cambridge,Not Applicable
NCT00464061,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00464191,2006.0,OTHER,lead,Nordfjord Psychiatric Centre,Phase 4
NCT00464191,2006.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00464243,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00464269,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00464334,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00464698,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00464698,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00464763,2007.0,INDUSTRY,lead,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 3
NCT00464958,2008.0,INDUSTRY,lead,Teva GTC,Phase 1/Phase 2
NCT00465153,2007.0,OTHER,lead,University of Saskatchewan,Phase 3
NCT00465153,2007.0,OTHER,collaborator,Gatorade Sports and Science Institute,Phase 3
NCT00465244,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT00465244,2008.0,INDUSTRY,collaborator,UCB Pharma,Phase 2/Phase 3
NCT00465283,2007.0,OTHER_GOV,lead,BeerYaakov Mental Health Center,Phase 4
NCT00465439,2007.0,OTHER,lead,Hamilton Health Sciences Corporation,Not Applicable
NCT00465452,2007.0,OTHER,lead,University of Toledo Health Science Campus,Phase 3
NCT00465517,2007.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT00465595,2007.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00465595,2007.0,OTHER,collaborator,Heffter Research Institute,Phase 2
NCT00465608,2007.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT00466167,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00466310,2007.0,OTHER,lead,Duke University,Phase 1
NCT00466310,2007.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 1
NCT00466609,2007.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT00466609,2007.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00466609,2007.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4
NCT00466609,2007.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00466661,2007.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT00466661,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00467207,2006.0,OTHER,lead,St. Olavs Hospital,Phase 2
NCT00467207,2006.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 2
NCT00467259,2007.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT00467454,2007.0,OTHER,lead,University of Minnesota,Phase 2
NCT00467584,2007.0,OTHER,lead,Mayo Clinic,Phase 3
NCT00467584,2007.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 3
NCT00467766,1999.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT00468052,2007.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 3
NCT00468078,2006.0,OTHER,lead,Asan Medical Center,Phase 3
NCT00468481,2007.0,INDUSTRY,lead,Bayer,Phase 3
NCT00468650,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00468897,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00468923,2007.0,OTHER,lead,Population Health Research Institute,Phase 4
NCT00469079,2007.0,OTHER,lead,University of Minnesota,Phase 2
NCT00469079,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00469079,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00469378,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00469456,2007.0,INDUSTRY,lead,Forest Laboratories,Phase 4
NCT00469664,2000.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 4
NCT00469664,2000.0,FED,collaborator,Bronx VA Medical Center,Phase 4
NCT00469664,2000.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00469885,2001.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00470418,2007.0,FED,lead,VA Office of Research and Development,Phase 2
NCT00470418,2007.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00470418,2007.0,INDUSTRY,collaborator,Humanetics Corporation,Phase 2
NCT00470509,2005.0,OTHER,lead,"University Hospital, Geneva",Phase 2
NCT00470925,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00470925,2007.0,OTHER,collaborator,Molecular NeuroImaging,Phase 1
NCT00471211,2006.0,INDUSTRY,lead,Prana Biotechnology Limited,Phase 2
NCT00471445,2007.0,OTHER,lead,Gary Morrow,Phase 3
NCT00471445,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00471588,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00471744,2006.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 3
NCT00472199,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00472355,2005.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00472355,2005.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00472381,2007.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT00472641,2007.0,OTHER,lead,Stanford University,Phase 4
NCT00472641,2007.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00473213,1999.0,OTHER,lead,"University of Turin, Italy",Phase 3
NCT00473213,1999.0,OTHER,collaborator,Dimensione Ricerca s.r.l.,Phase 3
NCT00473434,2007.0,INDUSTRY,lead,Janssen-Cilag Pty Ltd,Phase 3
NCT00473902,2003.0,OTHER,lead,Hamilton Health Sciences Corporation,Not Applicable
NCT00474058,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00474409,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00474487,2007.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00474513,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00474526,2007.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00474552,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00474916,2006.0,INDUSTRY,lead,DARA Therapeutics,Phase 2
NCT00475462,2001.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT00475501,2007.0,FED,lead,VA Office of Research and Development,Phase 2
NCT00475501,2007.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Phase 2
NCT00475501,2007.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00475514,2004.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT00475865,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00475878,2006.0,OTHER,lead,Butler Hospital,Phase 3
NCT00476008,2007.0,OTHER,lead,Florida Atlantic University,Phase 4
NCT00476008,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00476151,2007.0,INDUSTRY,lead,EpiCept Corporation,Phase 2
NCT00477295,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00477373,2006.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00477503,2007.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT00477659,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00477659,2007.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00477802,2007.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00477802,2007.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT00478179,2006.0,INDUSTRY,lead,Durect,Phase 2
NCT00478205,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00478205,2007.0,INDUSTRY,collaborator,Eisai Limited,Phase 3
NCT00478465,2007.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT00478647,2007.0,INDUSTRY,lead,Shire,Phase 2/Phase 3
NCT00478907,2004.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2
NCT00479154,2007.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00479219,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00479297,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00479349,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00479440,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00479557,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00479557,2007.0,UNKNOWN,collaborator,"Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC",Phase 2
NCT00479700,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00479765,2007.0,INDUSTRY,lead,Boston Scientific Corporation,Phase 1/Phase 2
NCT00480181,2007.0,OTHER,lead,University of Manitoba,Phase 4
NCT00480181,2007.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 4
NCT00480207,2007.0,OTHER_GOV,lead,Prof. RH Belmaker,Phase 2/Phase 3
NCT00480207,2007.0,OTHER,collaborator,The S. Daniel Abraham International Center for Health and Nutrition,Phase 2/Phase 3
NCT00480441,2006.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00480441,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00480467,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00480571,2007.0,INDUSTRY,lead,"BioLineRx, Ltd.",Phase 2
NCT00480701,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 2
NCT00480818,2006.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00480844,2008.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT00480870,1999.0,OTHER,lead,Associacao Fundo de Incentivo a Psicofarmcologia,Phase 4
NCT00480870,1999.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00481013,2007.0,OTHER,lead,University of Utah,Phase 2
NCT00481013,2007.0,OTHER,collaborator,Families of Spinal Muscular Atrophy,Phase 2
NCT00481013,2007.0,INDUSTRY,collaborator,Abbott,Phase 2
NCT00481520,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00481975,2004.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00482430,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00483028,2004.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT00483314,2007.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 2
NCT00483314,2007.0,OTHER,collaborator,March of Dimes,Phase 2
NCT00483379,2007.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00483535,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00483548,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00483574,2007.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00483652,2007.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00483704,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00483717,2007.0,INDUSTRY,lead,Egalet Ltd,Phase 2
NCT00483964,2005.0,OTHER,lead,Q.Mundewadi Ayurvedic Research & Charitable Trust,Phase 2
NCT00483964,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00484471,2007.0,INDUSTRY,lead,Korea Otsuka International Asia Arab,Phase 4
NCT00484536,2007.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00484536,2007.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT00484692,2005.0,OTHER,lead,Medical University Innsbruck,Phase 4
NCT00484757,2007.0,OTHER,lead,Zentrum für Integrative Psychiatrie,Not Applicable
NCT00485069,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00485498,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00485511,2007.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 2/Phase 3
NCT00485680,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00485771,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00485810,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1/Phase 2
NCT00485823,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00485862,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00485901,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00486005,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00486044,2005.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT00486044,2005.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00486044,2005.0,OTHER,collaborator,Paul Beeson Faculty Scholars Program,Phase 2
NCT00486044,2005.0,OTHER,collaborator,The John A. Hartford Foundation,Phase 2
NCT00486044,2005.0,OTHER,collaborator,The Atlantic Philanthropies,Phase 2
NCT00486044,2005.0,OTHER,collaborator,Starr Foundation,Phase 2
NCT00486044,2005.0,OTHER,collaborator,American Federation for Aging Research,Phase 2
NCT00486044,2005.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00486798,2007.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00486889,2008.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00487578,2006.0,INDIV,lead,"Cady, Roger, M.D.",Phase 4
NCT00487578,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00487578,2006.0,OTHER,collaborator,Clinvest,Phase 4
NCT00487630,2005.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00487942,2007.0,INDUSTRY,lead,Cephalon,Phase 2
NCT00488098,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00488163,2005.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 4
NCT00488163,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00488319,2007.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT00488514,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00488566,2007.0,INDUSTRY,lead,Biogen,Phase 1
NCT00488618,2007.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00488618,2007.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 2
NCT00488644,2006.0,OTHER,lead,M.D. Anderson Cancer Center,Not Applicable
NCT00488670,2010.0,OTHER,lead,University of British Columbia,Phase 3
NCT00488839,2007.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT00488969,2007.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT00488969,2007.0,FED,collaborator,U.S. Department of Education,Phase 2
NCT00489073,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00489255,2007.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00489255,2007.0,INDUSTRY,collaborator,INC Research Limited,Phase 4
NCT00489411,2008.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 3
NCT00489411,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00489450,2007.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 1
NCT00489476,2007.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT00489489,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00489606,2007.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 1
NCT00489866,2007.0,FED,lead,Durham VA Medical Center,Phase 2
NCT00489892,2003.0,OTHER,lead,Kessler Foundation,Not Applicable
NCT00489892,2003.0,OTHER,collaborator,University of Medicine and Dentistry of New Jersey,Not Applicable
NCT00489892,2003.0,INDUSTRY,collaborator,Cephalon,Not Applicable
NCT00490035,2007.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT00490191,1999.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00490269,2006.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00490516,2007.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2
NCT00490542,2006.0,OTHER,lead,Tufts Medical Center,Phase 2
NCT00490542,2006.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00490568,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00490789,2005.0,OTHER,lead,Cardiff University,Phase 2
NCT00490789,2005.0,OTHER,collaborator,University of Nottingham,Phase 2
NCT00490789,2005.0,UNKNOWN,collaborator,St Georges Hospital Medical School,Phase 2
NCT00490789,2005.0,OTHER,collaborator,Royal Sussex County Hospital,Phase 2
NCT00490789,2005.0,OTHER,collaborator,The Tuberous Sclerosis Association,Phase 2
NCT00490789,2005.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00490828,2007.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00490945,2004.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 2
NCT00490971,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00491192,2007.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Phase 4
NCT00491478,1992.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00491569,2005.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT00491569,2005.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT00491569,2005.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 2
NCT00491686,2007.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00491829,2007.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00491894,2007.0,INDUSTRY,lead,Shionogi,Phase 3
NCT00491998,2006.0,INDUSTRY,lead,Vernalis (R&D) Ltd,Phase 1/Phase 2
NCT00491998,2006.0,INDUSTRY,collaborator,Cita NeuroPharmaceuticals,Phase 1/Phase 2
NCT00491998,2006.0,OTHER,collaborator,Syneos Health,Phase 1/Phase 2
NCT00492323,2007.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00492336,2007.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00492336,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00492349,2007.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00492349,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00492414,,OTHER,lead,Inje University,Phase 4
NCT00492414,,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00492466,2003.0,INDUSTRY,lead,Biogen,Phase 4
NCT00492635,2004.0,INDUSTRY,lead,Bayer,Phase 3
NCT00492765,2006.0,INDUSTRY,lead,Biogen,Phase 4
NCT00493077,2004.0,INDUSTRY,lead,Biogen,Phase 4
NCT00493116,2003.0,INDUSTRY,lead,Biogen,Phase 4
NCT00493233,2006.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00493233,2006.0,OTHER,collaborator,Canadian Psychiatric Research Foundation,Not Applicable
NCT00494156,2003.0,OTHER,lead,"C. Clay Cothren, MD",Not Applicable
NCT00494195,2008.0,OTHER,lead,Nationwide Children's Hospital,Phase 1
NCT00494195,2008.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 1
NCT00494195,2008.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 1
NCT00494377,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00494468,2002.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00494468,2002.0,INDUSTRY,collaborator,Sanofi-Synthelabo,Phase 1/Phase 2
NCT00494507,2007.0,OTHER,lead,University of Rochester,Phase 3
NCT00494507,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00494728,2007.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1/Phase 2
NCT00494728,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT00494962,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00495092,2005.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 2/Phase 3
NCT00495118,2001.0,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00495183,2009.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT00495274,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00495352,2006.0,OTHER,lead,Yu-Li Hospital,Phase 4
NCT00495352,2006.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 4
NCT00495352,2006.0,OTHER_GOV,collaborator,"Department of Health, Executive Yuan, R.O.C. (Taiwan)",Phase 4
NCT00495417,2007.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT00495690,2004.0,OTHER,lead,Society for Applied Studies,Phase 3
NCT00495690,2004.0,OTHER_GOV,collaborator,Indian Council of Medical Research,Phase 3
NCT00495729,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00495768,2004.0,FED,lead,South Texas Veterans Health Care System,Not Applicable
NCT00495820,2007.0,FED,lead,VA Office of Research and Development,Phase 4
NCT00495885,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00496379,2007.0,OTHER,lead,"Nancy Lin, MD",Phase 2
NCT00496379,2007.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 2
NCT00496379,2007.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT00496379,2007.0,OTHER,collaborator,Breast Cancer Research Foundation,Phase 2
NCT00496457,2007.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT00496457,2007.0,INDUSTRY,collaborator,Ergomed GmbH,Phase 2
NCT00497055,2009.0,OTHER_GOV,lead,San Francisco Department of Public Health,Phase 2
NCT00497055,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00497081,2007.0,OTHER_GOV,lead,San Francisco Department of Public Health,Phase 2
NCT00497081,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00497081,2007.0,OTHER,collaborator,"Public Health Foundation Enterprises, Inc.",Phase 2
NCT00497120,,OTHER,lead,"University Hospital, Antwerp",Not Applicable
NCT00497159,2007.0,INDUSTRY,lead,"Medivation, Inc.",Phase 2
NCT00497159,2007.0,NETWORK,collaborator,Huntington Study Group,Phase 2
NCT00497562,2004.0,OTHER,lead,Centro Medico Teknon,Phase 2
NCT00497952,2007.0,INDUSTRY,lead,Talaris Therapeutics Inc.,Phase 1/Phase 2
NCT00498004,2007.0,OTHER,lead,Inje University,Phase 4
NCT00498186,2003.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00498485,2007.0,OTHER,lead,University of Medicine and Dentistry of New Jersey,Phase 4
NCT00498485,2007.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 4
NCT00498550,2000.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 4
NCT00498550,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00498550,2000.0,OTHER,collaborator,"University of Missouri, Kansas City",Phase 4
NCT00498550,2000.0,FED,collaborator,VA Medical Center-West Los Angeles,Phase 4
NCT00498550,2000.0,OTHER,collaborator,University of South Carolina,Phase 4
NCT00498602,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00498602,2007.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00498680,2007.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT00499200,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00499642,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00499993,2001.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00500201,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00500500,2005.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00500812,2005.0,INDUSTRY,lead,Vertex Pharmaceuticals Incorporated,Phase 1/Phase 2
NCT00500890,2005.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 3
NCT00501111,2007.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00501618,2006.0,OTHER,lead,Manhattan Psychiatric Center,Phase 4
NCT00501618,2006.0,INDUSTRY,collaborator,"Azur Pharma, Inc",Phase 4
NCT00501696,2007.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT00501748,2004.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT00501748,2004.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1
NCT00501865,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00501943,2006.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT00501943,2006.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT00501943,2006.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT00502216,2007.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT00502216,2007.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1/Phase 2
NCT00502216,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00502515,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00503204,2007.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00503230,2005.0,OTHER,lead,Butler Hospital,Phase 3
NCT00503230,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00503516,2007.0,INDUSTRY,lead,Rottapharm Spain,Phase 2/Phase 3
NCT00503529,2007.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00504348,2007.0,OTHER,lead,Tokyo Medical and Dental University,Phase 2/Phase 3
NCT00504348,2007.0,INDUSTRY,collaborator,Japan Medical Association,Phase 2/Phase 3
NCT00504348,2007.0,INDUSTRY,collaborator,Astellas Pharma Inc,Phase 2/Phase 3
NCT00504413,2007.0,OTHER,lead,University of Washington,Phase 1
NCT00504881,2007.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT00505076,2007.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00505076,2007.0,OTHER,collaborator,University of Maryland,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Columbia University,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Duke University,Phase 2
NCT00505076,2007.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 2
NCT00505167,2007.0,OTHER,lead,Hospital Miguel Servet,Phase 4
NCT00505167,2007.0,UNKNOWN,collaborator,Clinica Quiron de Zaragoza,Phase 4
NCT00505167,2007.0,OTHER,collaborator,Universidad de Zaragoza,Phase 4
NCT00505167,2007.0,UNKNOWN,collaborator,Hospital de Barbastro,Phase 4
NCT00505167,2007.0,UNKNOWN,collaborator,Hospital Royo Villanova,Phase 4
NCT00505284,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 2/Phase 3
NCT00505284,2007.0,INDUSTRY,collaborator,Eisai Limited,Phase 2/Phase 3
NCT00505505,2002.0,OTHER,lead,University of Roma La Sapienza,Phase 4
NCT00505622,2007.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT00505687,2005.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00505765,2007.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00505765,2007.0,OTHER,collaborator,University of Maryland,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Columbia University,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Duke University,Phase 2
NCT00505765,2007.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 2
NCT00505804,2005.0,OTHER_GOV,lead,Austin Health,Phase 2
NCT00505804,2005.0,OTHER,collaborator,The Alfred,Phase 2
NCT00505843,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00505934,2008.0,INDUSTRY,lead,UCB Pharma SA,Phase 2
NCT00505973,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00506012,2007.0,INDUSTRY,lead,Taro Pharmaceuticals USA,Phase 2
NCT00506259,2007.0,NIH,lead,National Human Genome Research Institute (NHGRI),Phase 1
NCT00506415,2007.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00506610,,INDUSTRY,lead,Pfizer,Phase 2
NCT00506675,2007.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00506675,2007.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00506909,2008.0,OTHER,lead,David Feifel,Not Applicable
NCT00506909,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00507117,2007.0,FED,lead,Walter Reed Army Medical Center,Phase 4
NCT00507117,2007.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00507286,2007.0,OTHER,lead,Keogh Institute for Medical Research,Not Applicable
NCT00507546,2007.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00507546,2007.0,OTHER,collaborator,Stanford University,Phase 4
NCT00507546,2007.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT00507715,2006.0,INDUSTRY,lead,Rottapharm Spain,Phase 1
NCT00507728,2005.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT00507728,2005.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2/Phase 3
NCT00507728,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00507936,2007.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT00508157,2007.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 4
NCT00508157,2007.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT00508430,2007.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 2
NCT00508859,1997.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT00508859,1997.0,OTHER_GOV,collaborator,Medical Research Council,Phase 4
NCT00509067,2007.0,OTHER,lead,Georgetown University,Phase 2
NCT00509067,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00509067,2007.0,FED,collaborator,Washington D.C. Veterans Affairs Medical Center,Phase 2
NCT00509145,2007.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00509886,2007.0,OTHER,lead,Northwestern University,Not Applicable
NCT00510016,2002.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00510016,2002.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00510146,2007.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00510172,2006.0,OTHER,lead,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT00510263,2001.0,OTHER,lead,Uppsala University Hospital,Phase 4
NCT00510263,2001.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00510263,2001.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00510419,2007.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00511134,2007.0,OTHER,lead,Yale University,Phase 4
NCT00511134,2007.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00511277,2007.0,OTHER,lead,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,Phase 4
NCT00511277,2007.0,OTHER,collaborator,University of Göttingen,Phase 4
NCT00511654,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00511940,2007.0,OTHER,lead,Lindner Center of HOPE,Phase 2/Phase 3
NCT00511940,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2/Phase 3
NCT00511940,2007.0,OTHER,collaborator,University of Cincinnati,Phase 2/Phase 3
NCT00512070,2007.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00512070,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00512317,2007.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT00512460,2006.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT00512460,2006.0,INDUSTRY,collaborator,"Reata Pharmaceuticals, Inc.",Phase 1
NCT00512616,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00512707,2006.0,OTHER,lead,Boston University,Phase 4
NCT00512707,2006.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT00513019,2007.0,OTHER,lead,University of Chicago,Phase 2
NCT00513279,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00514059,2007.0,OTHER_GOV,lead,Norwegian Institute of Public Health,Phase 4
NCT00514202,2007.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00514410,2007.0,OTHER,lead,Bangor University,Phase 4
NCT00514410,2007.0,OTHER,collaborator,NHS Health Technology Assessment Programme,Phase 4
NCT00514410,2007.0,OTHER,collaborator,Swansea University,Phase 4
NCT00514410,2007.0,OTHER,collaborator,Cardiff University,Phase 4
NCT00514410,2007.0,OTHER,collaborator,University of Liverpool,Phase 4
NCT00514410,2007.0,OTHER,collaborator,North West Wales NHS Trust,Phase 4
NCT00514410,2007.0,OTHER,collaborator,North East Wales NHS Trust,Phase 4
NCT00514410,2007.0,OTHER_GOV,collaborator,Swansea NHS Trust,Phase 4
NCT00514449,2007.0,OTHER,lead,Konasale Prasad,Phase 2
NCT00514449,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00514449,2007.0,OTHER,collaborator,Wayne State University,Phase 2
NCT00514774,2007.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT00514774,2007.0,NETWORK,collaborator,Huntington Study Group,Phase 1
NCT00514774,2007.0,OTHER,collaborator,Huntington Society of Canada,Phase 1
NCT00514995,2007.0,OTHER,lead,Lindner Center of HOPE,Phase 2/Phase 3
NCT00514995,2007.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2/Phase 3
NCT00514995,2007.0,OTHER,collaborator,University of Cincinnati,Phase 2/Phase 3
NCT00515255,2007.0,INDUSTRY,lead,Neuropharm,Phase 2
NCT00515281,2008.0,OTHER,lead,University of Chicago,Phase 2/Phase 3
NCT00515294,2006.0,OTHER,lead,Boston University,Phase 1/Phase 2
NCT00515294,2006.0,OTHER,collaborator,Brown University,Phase 1/Phase 2
NCT00515294,2006.0,OTHER,collaborator,University of Michigan,Phase 1/Phase 2
NCT00515294,2006.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 1/Phase 2
NCT00515333,2004.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 2
NCT00515619,2004.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00515723,2001.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00515723,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00515736,2003.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 3
NCT00515736,2003.0,INDUSTRY,collaborator,Fresenius Kabi,Phase 3
NCT00516139,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00516386,2007.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT00516386,2007.0,INDUSTRY,collaborator,Tercica,Phase 1/Phase 2
NCT00516516,2008.0,OTHER,lead,University of Southern California,Not Applicable
NCT00516516,2008.0,OTHER,collaborator,Health Research Association,Not Applicable
NCT00516737,2007.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00516893,2006.0,INDUSTRY,lead,Biogen,Phase 2
NCT00516893,2006.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT00517036,2006.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 3
NCT00517036,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00517036,2006.0,OTHER,collaborator,Massachusetts General Hospital,Phase 3
NCT00517153,2002.0,INDUSTRY,lead,Actelion,Phase 2
NCT00517179,2006.0,OTHER_GOV,lead,"Hospital Authority, Hong Kong",Not Applicable
NCT00517387,2007.0,OTHER,lead,University of British Columbia,Phase 3
NCT00517387,2007.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00517491,2008.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00517764,2006.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00517764,2006.0,OTHER,collaborator,Queen's University,Not Applicable
NCT00517842,2005.0,OTHER_GOV,lead,"Hospital Authority, Hong Kong",Not Applicable
NCT00517842,2005.0,INDUSTRY,collaborator,Vigconic (International) Ltd.,Not Applicable
NCT00517972,,OTHER,lead,University of Arizona,Phase 2
NCT00517972,,INDUSTRY,collaborator,Reliant Pharmaceuticals,Phase 2
NCT00518180,2007.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00518323,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00518713,2007.0,INDUSTRY,lead,Lundbeck LLC,Phase 3
NCT00518947,1994.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT00518947,1994.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00518973,2006.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT00518973,2006.0,OTHER,collaborator,University of South Florida,Not Applicable
NCT00518986,2007.0,INDUSTRY,lead,Cephalon,Phase 4
NCT00519012,2007.0,OTHER,lead,Oizumi Hospital,Phase 4
NCT00519181,2006.0,OTHER,lead,University Hospital Pierre Zobda-Quitman,Not Applicable
NCT00519532,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00520026,2001.0,OTHER,lead,University Hospital Schleswig-Holstein,Not Applicable
NCT00520026,2001.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Not Applicable
NCT00520026,2001.0,INDUSTRY,collaborator,Sanofi,Not Applicable
NCT00520026,2001.0,OTHER,collaborator,Technische Universität Dresden,Not Applicable
NCT00520026,2001.0,OTHER,collaborator,University of Bonn,Not Applicable
NCT00520026,2001.0,OTHER,collaborator,"Charite University, Berlin, Germany",Not Applicable
NCT00520026,2001.0,OTHER,collaborator,University of Erlangen-Nürnberg,Not Applicable
NCT00520507,2007.0,OTHER,lead,Queen's University,Phase 4
NCT00520507,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00520650,2006.0,INDUSTRY,lead,"Taiwan Otsuka Pharm. Co., Ltd",Phase 4
NCT00520663,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00520741,2007.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT00520923,2007.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00521248,2004.0,OTHER,lead,Thomas Jefferson University,Phase 1
NCT00521248,2004.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00521300,1999.0,OTHER,lead,St. Olavs Hospital,Phase 4
NCT00521300,1999.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00521365,2008.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00522015,2008.0,OTHER,lead,University Hospital Tuebingen,Phase 2
NCT00522275,2004.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT00522379,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00522418,2006.0,INDUSTRY,lead,"Cyberonics, Inc.",Phase 4
NCT00523445,2007.0,OTHER,lead,Inje University,Phase 3
NCT00523445,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00523666,2006.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00524030,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00524043,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00524134,2008.0,OTHER,lead,Columbia University,Phase 2/Phase 3
NCT00524134,2008.0,OTHER,collaborator,American Epilepsy Society,Phase 2/Phase 3
NCT00524134,2008.0,OTHER,collaborator,Milken Institute,Phase 2/Phase 3
NCT00524134,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00524914,2007.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT00525317,2002.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT00525317,2002.0,UNKNOWN,collaborator,Takeda Nycomed,Phase 4
NCT00525317,2002.0,OTHER,collaborator,Sykehuset Asker og Baerum,Phase 4
NCT00525837,2007.0,OTHER,lead,Butler Hospital,Not Applicable
NCT00525837,2007.0,OTHER,collaborator,Brown University,Not Applicable
NCT00525928,2007.0,OTHER,lead,Butler Hospital,Not Applicable
NCT00525928,2007.0,OTHER,collaborator,Brown University,Not Applicable
NCT00526071,2007.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00526214,2007.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT00526474,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00526474,2007.0,UNKNOWN,collaborator,The Thrombolysis in Myocardial Infarction Study (TIMI) Group,Phase 3
NCT00526630,2007.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00526630,2007.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 4
NCT00526877,2007.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT00526916,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00527020,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00527202,2004.0,OTHER,lead,Hospital Ambroise Paré Paris,Phase 4
NCT00527410,2006.0,INDUSTRY,lead,"Reata, a wholly owned subsidiary of Biogen",Phase 1
NCT00527579,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT00527657,2006.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT00527657,2006.0,INDUSTRY,collaborator,Celgene Corporation,Phase 1
NCT00527683,2007.0,OTHER,lead,NYU Langone Health,Phase 2
NCT00527683,2007.0,INDUSTRY,collaborator,"Catalyst Pharmaceuticals, Inc.",Phase 2
NCT00528151,2005.0,OTHER,lead,Mahidol University,Phase 3
NCT00528268,2007.0,OTHER,lead,University of Utah,Phase 1/Phase 2
NCT00528268,2007.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00528437,2005.0,OTHER,lead,NYU Langone Health,Phase 2
NCT00528437,2005.0,OTHER,collaborator,Children's Hospitals and Clinics of Minnesota,Phase 2
NCT00528437,2005.0,OTHER,collaborator,Schneider Children's Hospital,Phase 2
NCT00528905,2007.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00529581,2006.0,INDUSTRY,lead,"Cognition Pharmaceuticals, LLC",Phase 2
NCT00529659,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00530127,2008.0,INDUSTRY,lead,ApoPharma,Phase 1/Phase 2
NCT00530348,2007.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00530348,2007.0,INDUSTRY,collaborator,Bayer,Phase 3
NCT00530413,2007.0,OTHER,lead,University of Toledo Health Science Campus,Not Applicable
NCT00530478,,OTHER,lead,Samsung Medical Center,Not Applicable
NCT00530517,2007.0,INDUSTRY,lead,"Zogenix, Inc.",Phase 2
NCT00530530,2007.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 2
NCT00530556,2003.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00530790,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00530855,2008.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00531466,2007.0,INDUSTRY,lead,Avigen,Phase 2
NCT00531518,2007.0,OTHER,lead,MaineHealth,Not Applicable
NCT00531518,2007.0,OTHER,collaborator,Robert Wood Johnson Foundation,Not Applicable
NCT00531713,2003.0,OTHER,lead,Copenhagen University Hospital at Herlev,Phase 4
NCT00531804,2006.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT00531908,2007.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT00531908,2007.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT00532493,2010.0,FED,lead,VA Office of Research and Development,Phase 3
NCT00532532,2007.0,INDUSTRY,lead,Avigen,Phase 2
NCT00532571,2004.0,OTHER,lead,Lahey Clinic,Phase 2/Phase 3
NCT00532662,2007.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT00533117,2001.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00533117,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00533221,2007.0,OTHER,lead,University Hospital Freiburg,Phase 2
NCT00533221,2007.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 2
NCT00533286,2002.0,OTHER,lead,University Hospital Tuebingen,Phase 2
NCT00533351,2008.0,INDUSTRY,lead,Allergan,Phase 2
NCT00533546,2007.0,OTHER,lead,University of Rochester,Phase 2
NCT00533546,2007.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT00533910,2007.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Not Applicable
NCT00533910,2007.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Not Applicable
NCT00534001,2006.0,OTHER,lead,Roswell Park Cancer Institute,Phase 2
NCT00534261,1999.0,INDUSTRY,lead,Biogen,Phase 4
NCT00534378,2006.0,FED,lead,U.S. Army Office of the Surgeon General,Phase 1
NCT00534404,2011.0,OTHER,lead,University of Michigan,Not Applicable
NCT00534404,2011.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00534599,2007.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00534898,,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00535002,2007.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00535002,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00535002,2007.0,NIH,collaborator,Office of Research on Women's Health (ORWH),Phase 2
NCT00535132,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT00535145,2007.0,INDUSTRY,lead,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00535197,2007.0,OTHER,lead,Imperial College London,Phase 1/Phase 2
NCT00535262,2007.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00535340,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00535392,2007.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00535574,2008.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT00535587,2002.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00535587,2002.0,NIH,collaborator,National Institute of Nursing Research (NINR),Phase 2
NCT00535613,2007.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT00536120,2008.0,INDUSTRY,lead,Biogen,Phase 4
NCT00536172,2007.0,OTHER,lead,University of Nebraska,Phase 4
NCT00536172,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00537017,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00537082,2007.0,INDUSTRY,lead,Novartis,Phase 2
NCT00537082,2007.0,INDUSTRY,collaborator,Mitsubishi Tanabe Pharma Corporation,Phase 2
NCT00537147,2008.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT00537147,2008.0,OTHER,collaborator,Johns Hopkins Bloomberg School of Public Health,Phase 1
NCT00537459,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00537680,2007.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT00537940,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00538070,2007.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00538070,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00538616,2008.0,OTHER,lead,Carmelo Graffagnino,Phase 1/Phase 2
NCT00538616,2008.0,INDUSTRY,collaborator,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 1/Phase 2
NCT00538642,2007.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Not Applicable
NCT00539032,2007.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00539071,2008.0,OTHER,lead,Northwestern University,Phase 4
NCT00539071,2008.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00539188,2007.0,OTHER,lead,Yale University,Phase 2
NCT00539305,2009.0,OTHER,lead,University of Washington,Phase 3
NCT00539305,2009.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00539305,2009.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 3
NCT00539513,2006.0,OTHER,lead,Yale University,Phase 2
NCT00540098,2001.0,OTHER,lead,University of Göttingen,Phase 4
NCT00540098,2001.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00540527,2004.0,OTHER,lead,Niguarda Hospital,Phase 3
NCT00541164,2007.0,OTHER,lead,Memorial Medical Center,Phase 1/Phase 2
NCT00541164,2007.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT00541216,2007.0,OTHER,lead,Hadassah Medical Organization,Phase 1/Phase 2
NCT00541554,2007.0,INDUSTRY,lead,"Genovate Biotechnology Co., Ltd.,",Phase 4
NCT00541918,2007.0,OTHER,lead,Medical University of Gdansk,Phase 4
NCT00541996,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00542412,2001.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00542750,2008.0,OTHER,lead,Medical University of South Carolina,Phase 1/Phase 2
NCT00542750,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00542750,2008.0,OTHER,collaborator,American Academy of Child Adolescent Psychiatry.,Phase 1/Phase 2
NCT00542802,2007.0,OTHER,lead,Scienze Neurologiche Ospedaliere,Phase 3
NCT00543920,2002.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00544050,2002.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00544453,2007.0,OTHER,lead,Molecular NeuroImaging,Phase 1
NCT00544544,2007.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT00545142,2007.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00545467,2007.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT00545467,2007.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 4
NCT00545467,2007.0,OTHER_GOV,collaborator,"Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan",Phase 4
NCT00545493,2002.0,OTHER,lead,"University Hospital, Bonn",Phase 2/Phase 3
NCT00545493,2002.0,INDUSTRY,collaborator,Octapharma,Phase 2/Phase 3
NCT00545493,2002.0,INDUSTRY,collaborator,Astellas Pharma GmbH,Phase 2/Phase 3
NCT00545597,2005.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00545597,2005.0,FED,collaborator,Food and Drug Administration (FDA),Phase 3
NCT00545662,2007.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00545675,2007.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00545974,2007.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT00545974,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00546403,2003.0,OTHER,lead,Veterans Medical Research Foundation,Not Applicable
NCT00546403,2003.0,INDUSTRY,collaborator,Cephalon,Not Applicable
NCT00546494,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00546624,2002.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00546923,2004.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00547092,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00547092,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00547118,2007.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT00547118,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00547183,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547183,2004.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547287,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547287,2002.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547352,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00547352,2004.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00547417,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547417,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547495,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547495,2004.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547508,2002.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547508,2002.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547573,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00547573,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 3
NCT00547599,2003.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00547599,2003.0,INDUSTRY,collaborator,ICOS Corporation,Phase 4
NCT00547911,2007.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00548145,2007.0,OTHER,lead,Osaka University,Not Applicable
NCT00548145,2007.0,INDUSTRY,collaborator,"Kowa Company, Ltd.",Not Applicable
NCT00548223,2007.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT00548223,2007.0,OTHER,collaborator,Nanhai Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,People's hospital of Huizhou city,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Taishan city hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Ruijin Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,First Affiliated Hospital of Fujian Medical University,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Yangjiang City Hospital of TCM in Guangdong Province,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Xinxing county hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Southern branch of yuexiu district hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Xinhui hospital of TCM of Jiangmen,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Shanghai Pudong New Area People's Hospital,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,People's hospital of Jianyang city,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Luzhou Medical College,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Mianyang city hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Guangyuan city hospital of TCM of Sichuan Province,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The Third Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Shunde district hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Shenzhen People's Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Anyue County Hospital of Traditional Chinese,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Chengdu Integrated TCM&Western Medicine Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Guangzhou Red Cross Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Jiangsu Provincial People's Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Ankang Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Qishan county hospital of shaanxi province,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Zongrui Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,First Affiliated Hospital of Xinjiang Medical University,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Lianyungang Chinese Medicine Hospital,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Yufu City Hospital of TCM in Guangdong Province,Phase 4
NCT00548223,2007.0,OTHER,collaborator,169 Military Hospital of China,Phase 4
NCT00548223,2007.0,OTHER,collaborator,First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,The second affiliated hospital of shanxi college of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,URUMQI Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Hubei General Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The People's Hospital of Leshan,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Guagnzhou Liwan district Hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Longhua Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Shanghai Jiao Tong University School of Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Hangzhou City Hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Dongguan city hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Liuzhou City hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Maoming city hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Affiliated Hospital of Nantong University,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Xi'an city hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Jiangsu province hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The Third People's Hospital of Chengdu,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Zhejiang Provincial Hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The Second People's Hospital of Yibin,Phase 4
NCT00548223,2007.0,OTHER_GOV,collaborator,Shanxi Provincial People's Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The First Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Guangxi Ruikang Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT00548223,2007.0,OTHER,collaborator,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Afﬁliated Hospital of North Sichuan Medical College,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The Third Affiliated Hospital of Henan University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,ZhuHai Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,"Nanfang Hospital, Southern Medical University",Phase 4
NCT00548223,2007.0,OTHER,collaborator,West China Hospital,Phase 4
NCT00548223,2007.0,INDUSTRY,collaborator,Guangdong Second Provincial Traditional Chinese Medicine Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Handan First Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Conghua city hospital of TCM,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,The First Affiliated Hospital of Guangxi University of Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Hubei Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Jinan city hospital of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Shaanxi Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Suining People's Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Wuzhou Red Cross Hospital,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Wuhan Interated ＆Western Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Second Affiliated Hospital of Xi'an Jiaotong University,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Xi'an Central Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Zhengzhou City Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Xiangya Hospital of Central South University,Phase 4
NCT00548223,2007.0,OTHER,collaborator,"Second Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT00548223,2007.0,OTHER,collaborator,The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,ShuGuang Hospital,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Zhongshan Hospital Of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Foshan Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,UNKNOWN,collaborator,Teaching Hospital of Chengdu University of TCM,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Jiangmen Wuyi Hospital of Traditional Chinese Medicine,Phase 4
NCT00548223,2007.0,OTHER,collaborator,Guangdong Provincial Hospital of Traditional Chinese Medicine,Phase 4
NCT00548327,2007.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00548353,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00548405,2007.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00548405,2007.0,INDUSTRY,collaborator,Bayer,Phase 3
NCT00548470,2007.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00548470,2007.0,OTHER,collaborator,University of Illinois at Chicago,Phase 4
NCT00548769,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00549211,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00549471,2007.0,OTHER,lead,Shaare Zedek Medical Center,Phase 4
NCT00549601,2007.0,INDUSTRY,lead,Novartis,Phase 4
NCT00549718,2007.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00549783,2007.0,INDUSTRY,lead,Allergan,Phase 4
NCT00549939,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00550394,2008.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00550394,2008.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00550407,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00550420,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00550576,2007.0,OTHER,lead,Rambam Health Care Campus,Phase 2
NCT00551161,2007.0,OTHER,lead,Northwell Health,Phase 4
NCT00551161,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00551200,2007.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 2
NCT00551343,2007.0,OTHER,lead,Garvan Institute of Medical Research,Not Applicable
NCT00551772,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00552071,2007.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT00552071,2007.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 4
NCT00552175,2007.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00552175,2007.0,INDUSTRY,collaborator,Shionogi,Phase 3
NCT00552266,2007.0,OTHER,lead,Geha Mental Health Center,Phase 4
NCT00552266,2007.0,OTHER,collaborator,Clalit Health Services,Phase 4
NCT00552305,2001.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00552526,2007.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT00552604,2006.0,OTHER,lead,"Institut fur Klinische Forschung, Germany",Phase 3
NCT00552604,2006.0,INDUSTRY,collaborator,Weleda AG,Phase 3
NCT00552682,2007.0,OTHER,lead,Germans Trias i Pujol Hospital,Phase 3
NCT00552682,2007.0,OTHER,collaborator,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Phase 3
NCT00552760,2007.0,OTHER,lead,Lehigh Valley Hospital,Phase 4
NCT00552760,2007.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT00552786,2007.0,OTHER,lead,National Taiwan University Hospital,Phase 2
NCT00552786,2007.0,UNKNOWN,collaborator,"Institute of Occupational Safety and Health, Taiwan",Phase 2
NCT00552786,2007.0,UNKNOWN,collaborator,"Municipal Hospital of Tainan, Taiwan",Phase 2
NCT00552851,2006.0,OTHER,lead,University of Wuerzburg,Phase 4
NCT00552851,2006.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00553319,2007.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT00553319,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00553423,2007.0,OTHER,lead,Aga Khan University,Phase 3
NCT00554658,2008.0,OTHER,lead,University of Regensburg,Phase 4
NCT00554658,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00554723,2007.0,OTHER,lead,CHIMES Society,Phase 3
NCT00554723,2007.0,OTHER_GOV,collaborator,"National Medical Research Council (NMRC), Singapore",Phase 3
NCT00554840,2007.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT00554840,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00555009,2008.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00555087,2007.0,OTHER,lead,Hospital Santa Fe,Phase 4
NCT00555087,2007.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT00555204,2007.0,INDUSTRY,lead,Abbott,Phase 2
NCT00555880,2004.0,INDUSTRY,lead,Shire,Phase 4
NCT00555984,2007.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT00556387,2008.0,OTHER,lead,University of Arkansas,Phase 2
NCT00556439,2008.0,NIH,lead,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00556439,2008.0,OTHER,collaborator,The Cleveland Clinic,Phase 2
NCT00556439,2008.0,NIH,collaborator,Office of Rare Diseases (ORD),Phase 2
NCT00556439,2008.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Phase 2
NCT00556478,2007.0,INDUSTRY,lead,Plethora Solutions Ltd,Phase 2/Phase 3
NCT00556478,2007.0,INDUSTRY,collaborator,Shionogi Inc.,Phase 2/Phase 3
NCT00556660,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00556764,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Early Phase 1
NCT00556764,2007.0,FED,collaborator,United States Department of Defense,Early Phase 1
NCT00556764,2007.0,OTHER,collaborator,University of Oklahoma,Early Phase 1
NCT00557388,2007.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT00557388,2007.0,OTHER,collaborator,National Nutrition and Food Technology Institute,Not Applicable
NCT00557427,2009.0,INDUSTRY,lead,Rafa Laboratories,Phase 4
NCT00557544,2009.0,OTHER,lead,IRCCS Burlo Garofolo,Phase 3
NCT00557622,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00557973,2007.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT00558025,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00558038,2007.0,INDUSTRY,lead,Ocera Therapeutics,Phase 2
NCT00558298,2000.0,INDUSTRY,lead,"Janssen, LP",Phase 3
NCT00558337,2007.0,INDUSTRY,lead,Osmotica Pharmaceutical US LLC,Phase 2
NCT00558454,2004.0,OTHER,lead,Umeå University,Phase 4
NCT00558454,2004.0,OTHER_GOV,collaborator,"The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)",Phase 4
NCT00558454,2004.0,UNKNOWN,collaborator,"Jerring Foundation, Sweden",Phase 4
NCT00558454,2004.0,OTHER,collaborator,Oskar Foundation,Phase 4
NCT00558467,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00559494,2004.0,OTHER,lead,University of Calgary,Phase 1/Phase 2
NCT00559494,2004.0,OTHER,collaborator,Paralyzed Veterans of America,Phase 1/Phase 2
NCT00559494,2004.0,OTHER,collaborator,American Association of Neurological Surgeons,Phase 1/Phase 2
NCT00559494,2004.0,OTHER,collaborator,"Hotchkiss Brain Institute, University of Calgary",Phase 1/Phase 2
NCT00559702,2007.0,INDUSTRY,lead,Biogen,Phase 1
NCT00559702,2007.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 1
NCT00559871,2007.0,INDUSTRY,lead,Juvantia Pharma Ltd,Phase 2
NCT00559871,2007.0,INDUSTRY,collaborator,Santhera Pharmaceuticals,Phase 2
NCT00559988,2008.0,INDUSTRY,lead,"Biotronik, Inc.",Phase 4
NCT00560079,2003.0,OTHER,lead,Hospital Espirita de Porto Alegre,Phase 4
NCT00560079,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00560508,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2/Phase 3
NCT00560586,2004.0,OTHER,lead,University of Louisville,Phase 4
NCT00560612,2006.0,FED,lead,Durham VA Medical Center,Phase 4
NCT00560937,2005.0,FED,lead,Durham VA Medical Center,Not Applicable
NCT00561067,2008.0,OTHER,lead,Niguarda Hospital,Phase 3
NCT00561366,,INDUSTRY,lead,CytRx,Phase 2
NCT00561392,2007.0,INDUSTRY,lead,Novartis,Phase 4
NCT00561574,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00561678,2008.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00561678,2008.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT00561821,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00562289,2007.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00562588,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00562861,2007.0,OTHER,lead,Tufts Medical Center,Phase 2/Phase 3
NCT00562861,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00563017,2004.0,OTHER_GOV,lead,"Hospital Authority, Hong Kong",Not Applicable
NCT00563017,2004.0,INDUSTRY,collaborator,"Janssen Pharmaceutica N.V., Belgium",Not Applicable
NCT00563459,2007.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00563563,2007.0,INDUSTRY,lead,"Orexigen Therapeutics, Inc",Phase 2
NCT00563706,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00563732,2007.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00563797,2007.0,OTHER,lead,Yale University,Phase 3
NCT00563797,2007.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00563992,2001.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT00563992,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00564278,2008.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00564278,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00564564,2006.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT00564564,2006.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4
NCT00564902,2007.0,INDUSTRY,lead,"Chrysantis, Inc.",Not Applicable
NCT00564902,2007.0,INDUSTRY,collaborator,"Kowa Company, Ltd.",Not Applicable
NCT00564902,2007.0,INDUSTRY,collaborator,IMAGE TECHNOLOGIES INC.,Not Applicable
NCT00564915,2001.0,OTHER,lead,Institute of Child Health,Phase 4
NCT00565175,2008.0,OTHER,lead,Jesper Ekelund,Phase 4
NCT00565175,2008.0,UNKNOWN,collaborator,Finland: Lilly saatio foundation,Phase 4
NCT00565201,2007.0,OTHER,lead,Emory University,Early Phase 1
NCT00565201,2007.0,INDUSTRY,collaborator,Allergan,Early Phase 1
NCT00566020,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00566046,2007.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT00566046,2007.0,INDUSTRY,collaborator,UCB Pharma,Phase 3
NCT00566111,2007.0,OTHER,lead,Yale University,Not Applicable
NCT00566111,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00566150,2005.0,OTHER,lead,Yale University,Not Applicable
NCT00566150,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00566397,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00566397,2007.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT00566462,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00566501,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00566501,2007.0,INDUSTRY,collaborator,Eisai Limited,Phase 3
NCT00566514,2006.0,INDUSTRY,lead,"Bioenergy Life Science, Inc.",Not Applicable
NCT00566631,2007.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT00566735,2004.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00566735,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 3
NCT00566904,2006.0,INDUSTRY,lead,Biomedical Development Corporation,Phase 1
NCT00566904,2006.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 1
NCT00566904,2006.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1
NCT00566969,2007.0,OTHER,lead,Yale University,Not Applicable
NCT00566969,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00567008,2007.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00567008,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00567034,2006.0,OTHER,lead,Mclean Hospital,Phase 1
NCT00567060,2000.0,INDUSTRY,lead,UCB Pharma,Not Applicable
NCT00567086,2006.0,INDUSTRY,lead,TorreyPines Therapeutics,Phase 2
NCT00567099,2003.0,FED,lead,New Mexico VA Healthcare System,Not Applicable
NCT00567099,2003.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00567203,2007.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00567320,2007.0,OTHER,lead,Yale University,Not Applicable
NCT00567320,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00567320,2007.0,FED,collaborator,US Department of Veterans Affairs,Not Applicable
NCT00567424,2006.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00567710,2008.0,INDUSTRY,lead,"BioLineRx, Ltd.",Phase 2
NCT00567814,2007.0,INDUSTRY,lead,"Embera NeuroTherapeutics, Inc.",Not Applicable
NCT00568035,2006.0,INDUSTRY,lead,"Quigley Pharma, Inc.",Phase 2
NCT00568321,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00568555,2007.0,OTHER,lead,Stanford University,Not Applicable
NCT00568555,2007.0,OTHER,collaborator,American Fibromyalgia Syndrome Association,Not Applicable
NCT00568698,2004.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT00568776,2007.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 2
NCT00568802,2004.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT00569088,2007.0,OTHER,lead,Nanjing University of Traditional Chinese Medicine,Phase 2
NCT00570063,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00570128,2007.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00570128,2007.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00570219,2005.0,OTHER,lead,University of Helsinki,Not Applicable
NCT00570310,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00571103,2007.0,OTHER,lead,University of Iowa,Phase 4
NCT00571103,2007.0,OTHER,collaborator,University of Nebraska,Phase 4
NCT00571103,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00571155,2007.0,OTHER,lead,University Hospital Tuebingen,Phase 4
NCT00571246,2012.0,OTHER,lead,Yale University,Phase 3
NCT00571285,2007.0,OTHER,lead,Emory University,Phase 4
NCT00571688,2007.0,OTHER,lead,Vanderbilt University,Phase 4
NCT00571688,2007.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00571805,2007.0,OTHER,lead,NYU Langone Health,Phase 1/Phase 2
NCT00571805,2007.0,INDUSTRY,collaborator,Pfizer,Phase 1/Phase 2
NCT00572117,2007.0,OTHER,lead,Stanford University,Phase 4
NCT00572117,2007.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00572390,2001.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00572767,2001.0,OTHER,lead,Reha Rheinfelden,Phase 4
NCT00573170,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00573261,2006.0,OTHER,lead,Duke University,Phase 4
NCT00573261,2006.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00573287,2006.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Not Applicable
NCT00573287,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00573417,2003.0,OTHER,lead,North Suffolk Mental Health Association,Phase 4
NCT00573417,2003.0,INDUSTRY,collaborator,Cephalon,Phase 4
NCT00573547,2007.0,OTHER,lead,Creighton University,Phase 4
NCT00573885,2008.0,OTHER,lead,British Columbia Cancer Agency,Phase 2
NCT00573885,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00573885,2008.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT00574041,2007.0,INDUSTRY,lead,Biogen,Phase 4
NCT00574132,2007.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 3
NCT00574132,2007.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00575055,2007.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 3
NCT00575055,2007.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00575328,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00575328,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00575848,2007.0,OTHER,lead,North Suffolk Mental Health Association,Phase 1
NCT00575848,2007.0,OTHER,collaborator,Mclean Hospital,Phase 1
NCT00575848,2007.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 1
NCT00576108,2007.0,INDUSTRY,lead,"Kalypsys, Inc.",Phase 2
NCT00576277,2006.0,INDUSTRY,lead,Avigen,Phase 1/Phase 2
NCT00576472,2000.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 4
NCT00576472,2000.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT00576823,2007.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00576927,2007.0,OTHER,lead,Emory University,Phase 4
NCT00576927,2007.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT00577005,2007.0,OTHER,lead,Yale University,Phase 2
NCT00577005,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00577460,2007.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00578669,2008.0,OTHER,lead,Butler Hospital,Phase 3
NCT00578669,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT00578760,2008.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT00579085,2006.0,OTHER,lead,Drexel University College of Medicine,Phase 2
NCT00579280,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00579280,2007.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00579982,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00580125,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00580580,2012.0,OTHER,lead,University of Nebraska,Not Applicable
NCT00580619,2007.0,OTHER,lead,Vanderbilt University,Phase 1
NCT00580827,2003.0,OTHER,lead,Yale University,Not Applicable
NCT00580827,2003.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00580931,2008.0,OTHER,lead,"University of California, Irvine",Phase 1/Phase 2
NCT00580931,2008.0,OTHER,collaborator,Alzheimer's Association,Phase 1/Phase 2
NCT00581009,2001.0,OTHER,lead,"University of California, Irvine",Phase 1/Phase 2
NCT00581009,2001.0,OTHER,collaborator,"University of California, San Diego",Phase 1/Phase 2
NCT00581477,2004.0,OTHER,lead,Vanderbilt University,Phase 2/Phase 3
NCT00581477,2004.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2/Phase 3
NCT00581867,2007.0,OTHER,lead,"Jeff Burns, MD",Phase 1/Phase 2
NCT00582088,2008.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT00582491,2006.0,OTHER,lead,Yale University,Not Applicable
NCT00582491,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00582504,2007.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT00582673,2007.0,INDUSTRY,lead,Novartis,Phase 2
NCT00583193,2005.0,INDIV,lead,"Canive, Jose M., M.D.",Phase 3
NCT00583193,2005.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT00584025,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00584090,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00584155,2006.0,OTHER,lead,University of Oklahoma,Phase 1
NCT00584246,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00584376,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00584376,2007.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00584688,2007.0,OTHER,lead,University of South Florida,Phase 2
NCT00584688,2007.0,OTHER,collaborator,"University of California, San Diego",Phase 2
NCT00584805,2008.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT00584883,2003.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT00585169,2007.0,OTHER,lead,Yale University,Phase 2
NCT00585169,2007.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00585169,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2
NCT00585208,2007.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT00585208,2007.0,INDUSTRY,collaborator,Takeda,Phase 3
NCT00585208,2007.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT00585351,2007.0,OTHER,lead,University of Iowa,Not Applicable
NCT00585390,2008.0,OTHER,lead,University of Cincinnati,Phase 2/Phase 3
NCT00585520,2007.0,OTHER,lead,Yale University,Phase 1
NCT00585520,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00586066,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00586066,2005.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00586196,2007.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT00586196,2007.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00586430,2005.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT00586430,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00587691,2002.0,INDUSTRY,lead,"Opexa Therapeutics, Inc.",Phase 1/Phase 2
NCT00587717,2002.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT00587717,2002.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Not Applicable
NCT00587769,2007.0,OTHER,lead,Mayo Clinic,Phase 3
NCT00588393,2006.0,OTHER,lead,Mayo Clinic,Phase 2
NCT00588393,2006.0,INDUSTRY,collaborator,Endocyte,Phase 2
NCT00588731,2009.0,OTHER,lead,Yale University,Phase 2
NCT00588731,2009.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00588926,,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT00589498,2005.0,OTHER,lead,Mayo Clinic,Phase 3
NCT00589498,2005.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT00589784,2007.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 2
NCT00589784,2007.0,OTHER,collaborator,Dana-Farber Cancer Institute,Phase 2
NCT00589784,2007.0,OTHER,collaborator,University of Virginia,Phase 2
NCT00589784,2007.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT00589784,2007.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00589914,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00589953,2007.0,OTHER,lead,Atlantic Health System,Phase 2
NCT00590122,2006.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT00590122,2006.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT00590577,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00590707,2005.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00590707,2005.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT00591019,2006.0,OTHER,lead,University of Arkansas,Phase 1
NCT00591318,2007.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 1/Phase 2
NCT00591318,2007.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 1/Phase 2
NCT00591318,2007.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 1/Phase 2
NCT00591825,2006.0,OTHER,lead,University of Kansas Medical Center,Phase 2
NCT00591825,2006.0,OTHER,collaborator,American Psychological Foundation,Phase 2
NCT00591825,2006.0,UNKNOWN,collaborator,American Psychological Association,Phase 2
NCT00591994,2006.0,OTHER,lead,Faculdade de Medicina de Valenca,Not Applicable
NCT00592384,2007.0,OTHER,lead,University of Washington,Phase 4
NCT00592384,2007.0,OTHER,collaborator,University of Michigan,Phase 4
NCT00592384,2007.0,OTHER,collaborator,Shirley Ryan AbilityLab,Phase 4
NCT00592384,2007.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 4
NCT00592384,2007.0,OTHER,collaborator,Baylor Health Care System,Phase 4
NCT00592384,2007.0,OTHER,collaborator,University of Miami,Phase 4
NCT00592384,2007.0,OTHER,collaborator,New York University,Phase 4
NCT00592553,2008.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT00592618,,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Not Applicable
NCT00592774,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00592904,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 2/Phase 3
NCT00592930,2000.0,OTHER,lead,Northwell Health,Phase 4
NCT00592930,2000.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00592995,2007.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00593099,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00593125,2007.0,OTHER,lead,Yale University,Phase 2
NCT00593164,2017.0,OTHER,lead,Life Recovery Systems,Phase 2
NCT00593164,2017.0,OTHER,collaborator,Medical University of Vienna,Phase 2
NCT00593372,2003.0,OTHER,lead,University of Arkansas,Phase 1
NCT00593463,2006.0,OTHER,lead,University of Arkansas,Phase 1
NCT00593606,2007.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00593736,2007.0,INDUSTRY,lead,Takeda,Phase 2
NCT00593957,2004.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT00594087,2006.0,OTHER,lead,University of Vermont,Not Applicable
NCT00594256,2008.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00594256,2008.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT00594269,2008.0,OTHER,lead,Sykehuset Innlandet HF,Phase 4
NCT00594269,2008.0,OTHER,collaborator,Ullevaal University Hospital,Phase 4
NCT00594269,2008.0,OTHER,collaborator,Eikertun Nursing Home,Phase 4
NCT00594269,2008.0,OTHER,collaborator,University of Bergen,Phase 4
NCT00594269,2008.0,UNKNOWN,collaborator,"Innlandet Hospital Trust, Sanderud",Phase 4
NCT00594269,2008.0,UNKNOWN,collaborator,"Innlandet Hospital Trust, Reinsvoll",Phase 4
NCT00594269,2008.0,OTHER,collaborator,Diakonhjemmet Hospital,Phase 4
NCT00594269,2008.0,OTHER_GOV,collaborator,Sykehuset Telemark,Phase 4
NCT00594269,2008.0,UNKNOWN,collaborator,The Nordmøre and Romsdal Hospital Trust,Phase 4
NCT00594269,2008.0,OTHER,collaborator,Songdalstunet Nursing Home,Phase 4
NCT00594269,2008.0,OTHER,collaborator,Sykehuset Buskerud HF,Phase 4
NCT00594269,2008.0,OTHER,collaborator,"Kroken Nursing Home, Tromsø",Phase 4
NCT00594269,2008.0,UNKNOWN,collaborator,"Kløveråsen, Bodø",Phase 4
NCT00594269,2008.0,UNKNOWN,collaborator,"Bjørgene Omsorgssenter, Haugesund",Phase 4
NCT00594269,2008.0,OTHER,collaborator,Alesund Hospital,Phase 4
NCT00594386,2002.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00594464,2007.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00594568,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00594633,2004.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 1
NCT00594633,2004.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 1
NCT00594737,2007.0,OTHER,lead,"Tiffany Chow, MD",Phase 3
NCT00594737,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT00594945,2007.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT00594958,2006.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00595140,2008.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 4
NCT00595270,2005.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00595309,2007.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00595465,2007.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00595504,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00595504,2008.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT00595699,2006.0,OTHER,lead,"Conrad, Erich J., M.D.",Phase 4
NCT00595699,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00595790,2005.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00595868,2008.0,OTHER,lead,University of Vermont Medical Center,Phase 2
NCT00595868,2008.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00595920,2007.0,INDUSTRY,lead,"Opexa Therapeutics, Inc.",Phase 2
NCT00596024,2007.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00596024,2007.0,UNKNOWN,collaborator,Oregon Partnership for Alzheimer's Research,Phase 2
NCT00596037,2006.0,INDUSTRY,lead,LG Life Sciences,Phase 3
NCT00596037,2006.0,INDUSTRY,collaborator,BioPartners GmbH,Phase 3
NCT00596271,2005.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00596466,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00596531,2008.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT00596622,2007.0,OTHER,lead,Indiana University,Phase 4
NCT00596622,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00597389,2004.0,OTHER,lead,Kent State University,Not Applicable
NCT00597389,2004.0,OTHER,collaborator,Akron Children's Hospital,Not Applicable
NCT00597389,2004.0,UNKNOWN,collaborator,Ohio Board of Regents,Not Applicable
NCT00597402,2007.0,OTHER,lead,Duke University,Phase 2
NCT00597402,2007.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT00597402,2007.0,INDUSTRY,collaborator,Schering-Plough,Phase 2
NCT00597701,2003.0,OTHER,lead,Essentia Health,Not Applicable
NCT00597857,2005.0,OTHER,lead,Kent State University,Not Applicable
NCT00597857,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00597896,2005.0,OTHER,lead,Northwell Health,Phase 4
NCT00597896,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00597909,2007.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 2
NCT00598052,2007.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00598078,2007.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT00598572,2008.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 1
NCT00598572,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00598572,2008.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1
NCT00598572,2008.0,OTHER,collaborator,Medical College of Wisconsin,Phase 1
NCT00598572,2008.0,OTHER,collaborator,Medical University of South Carolina,Phase 1
NCT00598572,2008.0,OTHER,collaborator,Hartford Hospital,Phase 1
NCT00598585,2002.0,OTHER,lead,Charles Drew University of Medicine and Science,Phase 4
NCT00598585,2002.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00598923,2004.0,OTHER,lead,University of Pennsylvania,Early Phase 1
NCT00599287,2008.0,OTHER,lead,UMC Utrecht,Phase 3
NCT00599534,2007.0,OTHER,lead,University of Louisville,Phase 2
NCT00599534,2007.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT00599573,2007.0,OTHER,lead,University of Virginia,Not Applicable
NCT00599638,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00600093,2008.0,OTHER,lead,Rabin Medical Center,Phase 2
NCT00600145,2007.0,OTHER,lead,University of Virginia,Not Applicable
NCT00600145,2007.0,OTHER,collaborator,American Association of Chairs of Departments of Psychiatry,Not Applicable
NCT00600509,2001.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00600509,2001.0,INDUSTRY,collaborator,UCB Japan Co. Ltd.,Phase 2
NCT00600756,2008.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00600873,2007.0,INDIV,lead,"Bennett, James P., Jr., M.D., Ph.D.",Phase 1/Phase 2
NCT00600886,2008.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00601276,2007.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 3
NCT00601276,2007.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00601276,2007.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT00601276,2007.0,OTHER_GOV,collaborator,"Ministry of Higher Education and Research, France",Phase 3
NCT00601354,2007.0,OTHER,lead,Stanford University,Not Applicable
NCT00601354,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00601367,2008.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00601523,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00601536,2003.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00601575,2002.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00601588,2003.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00601978,2008.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00602186,2005.0,OTHER,lead,Tabriz University,Phase 1/Phase 2
NCT00602290,2008.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00602290,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00602381,2002.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00602394,2003.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00602537,2007.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00602537,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00602680,2008.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00602849,2003.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00602927,2007.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT00602927,2007.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00602927,2007.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00603018,2007.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00603018,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00603265,2007.0,INDUSTRY,lead,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Phase 2
NCT00603473,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00604058,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00604188,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 4
NCT00604279,2008.0,INDUSTRY,lead,Xian-Janssen Pharmaceutical Ltd.,Phase 3
NCT00604591,2011.0,OTHER,lead,Columbia University,Phase 2
NCT00604591,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00604630,2003.0,OTHER,lead,Max-Planck-Institute of Experimental Medicine,Phase 2/Phase 3
NCT00604630,2003.0,INDUSTRY,collaborator,Johnson & Johnson,Phase 2/Phase 3
NCT00604630,2003.0,INDUSTRY,collaborator,Parexel,Phase 2/Phase 3
NCT00604708,2005.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00604812,2007.0,INDUSTRY,lead,Organon and Co,Phase 1
NCT00605033,2008.0,INDUSTRY,lead,Indivior Inc.,Phase 4
NCT00605046,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00605059,2007.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00605085,2005.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00605215,2008.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00605241,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00605371,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00605553,2008.0,INDUSTRY,lead,Biotie Therapies Inc.,Phase 2
NCT00605683,2007.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT00605930,2004.0,OTHER,lead,University of Louisville,Not Applicable
NCT00605995,2008.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT00605995,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00605995,2008.0,OTHER_GOV,collaborator,Sheba Medical Center,Not Applicable
NCT00605995,2008.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Not Applicable
NCT00606164,2008.0,OTHER,lead,Blanchette Rockefeller Neurosciences Insitute,Phase 2
NCT00606203,2007.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT00606476,2006.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00606697,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00606775,2007.0,OTHER_GOV,lead,Suzuka Hospital,Phase 4
NCT00606775,2007.0,OTHER,collaborator,Nagoya University,Phase 4
NCT00606801,2007.0,OTHER,lead,Yale University,Not Applicable
NCT00606801,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00607256,2007.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00607282,2009.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT00607308,2008.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00607386,2007.0,INDUSTRY,lead,Shire,Phase 4
NCT00607386,2007.0,INDUSTRY,collaborator,Covance,Phase 4
NCT00607386,2007.0,INDUSTRY,collaborator,PharmaNet,Phase 4
NCT00607386,2007.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 4
NCT00607542,2008.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00607789,2006.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00607789,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00607919,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00607984,2006.0,OTHER,lead,Rabin Medical Center,Not Applicable
NCT00608231,2008.0,OTHER,lead,Vanderbilt University,Phase 2/Phase 3
NCT00608439,2007.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00608439,2007.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00608725,1996.0,OTHER,lead,Satish R. Raj,Not Applicable
NCT00608725,1996.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00608881,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00608881,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00608881,2008.0,OTHER,collaborator,University of Rochester,Phase 3
NCT00609063,2008.0,OTHER,lead,Hartford Hospital,Not Applicable
NCT00609063,2008.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00609323,2008.0,INDUSTRY,lead,ZARS Pharma Inc.,Phase 2
NCT00609531,2007.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT00609531,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00610103,2007.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT00610454,2004.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00610532,2006.0,OTHER,lead,Jim McAuley,Phase 4
NCT00610649,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00610727,2004.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 1
NCT00610727,2004.0,INDUSTRY,collaborator,PPD,Phase 1
NCT00611130,2008.0,INDUSTRY,lead,"Catalyst Pharmaceuticals, Inc.",Phase 2
NCT00611559,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00611650,2006.0,OTHER,lead,British Columbia Cancer Agency,Phase 2
NCT00611650,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00611650,2006.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT00611741,2007.0,OTHER,lead,Yale University,Phase 1
NCT00611806,2007.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00611806,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00611871,2007.0,OTHER,lead,Wayne State University,Phase 2
NCT00611871,2007.0,FED,collaborator,John D. Dingell VA Medical Center,Phase 2
NCT00611871,2007.0,OTHER,collaborator,New York University,Phase 2
NCT00612066,2007.0,OTHER,lead,Jonsson Comprehensive Cancer Center,Phase 2
NCT00612066,2007.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00612105,2007.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 2
NCT00612157,2008.0,FED,lead,Walter Reed Army Medical Center,Phase 4
NCT00612157,2008.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00612170,2007.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00612313,2008.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT00612313,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00612742,2008.0,INDUSTRY,lead,BioSante Pharmaceuticals,Phase 3
NCT00612859,2003.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00612872,2008.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00613002,2006.0,INDUSTRY,lead,BioSante Pharmaceuticals,Phase 3
NCT00613015,2008.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00613015,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00613470,2005.0,OTHER,lead,Mayo Clinic,Phase 1
NCT00613470,2005.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Phase 1
NCT00613470,2005.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 1
NCT00614250,2008.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00614705,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00615381,2009.0,OTHER,lead,Northwestern University,Not Applicable
NCT00615433,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00615472,2003.0,OTHER,lead,Columbia University,Not Applicable
NCT00615511,2007.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT00615511,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00615615,1999.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00616148,2007.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00616148,2007.0,OTHER,collaborator,The Epilepsy Study Consortium,Phase 2
NCT00616187,2003.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT00616187,2003.0,OTHER,collaborator,German Research Foundation,Phase 2
NCT00616187,2003.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 2
NCT00616187,2003.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00616343,2003.0,OTHER,lead,Loma Linda University,Not Applicable
NCT00616551,2007.0,INDUSTRY,lead,"Ambrilia Biopharma, Inc.",Phase 3
NCT00616681,2004.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00616733,2008.0,INDUSTRY,lead,Daiichi Sankyo,Phase 1
NCT00616798,2008.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT00616863,2004.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00616915,2007.0,OTHER,lead,Queen's University,Phase 1
NCT00617123,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00617123,2008.0,UNKNOWN,collaborator,The TIMI (Thrombolysis in Myocardial Infarction) Study Group,Phase 3
NCT00617123,2008.0,OTHER,collaborator,Duke Clinical Research Institute,Phase 3
NCT00617201,2007.0,OTHER,lead,Sharon Walsh,Phase 2
NCT00617201,2007.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT00617201,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00617461,2008.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT00617695,2003.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00617747,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00618046,2004.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00618280,2008.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Phase 1/Phase 2
NCT00618280,2008.0,OTHER,collaborator,German Research Foundation,Phase 1/Phase 2
NCT00618436,2007.0,OTHER,lead,University of Cincinnati,Phase 4
NCT00618436,2007.0,OTHER,collaborator,Mayfield Clinic & Spine Institute,Phase 4
NCT00618527,2006.0,OTHER,lead,Aaron Boster,Early Phase 1
NCT00618527,2006.0,INDUSTRY,collaborator,EMD Serono,Early Phase 1
NCT00618527,2006.0,INDUSTRY,collaborator,Pfizer,Early Phase 1
NCT00618865,2004.0,OTHER_GOV,lead,"National Science Council, Taiwan",Not Applicable
NCT00618956,2007.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00618956,2007.0,INDUSTRY,collaborator,"Cypress Bioscience, Inc.",Phase 3
NCT00619190,2006.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT00619190,2006.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT00619203,2008.0,OTHER,lead,Kamuzu University of Health Sciences,Phase 3
NCT00619333,2007.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT00619333,2007.0,OTHER,collaborator,The Dutch Galactosemia Society,Not Applicable
NCT00619476,2008.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT00619502,2007.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00619619,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00619723,2008.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00619723,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00619892,2008.0,OTHER,lead,Indiana University,Phase 4
NCT00619892,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00620165,2005.0,OTHER,lead,Southern California Institute for Research and Education,Phase 1/Phase 2
NCT00620555,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00620659,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00621010,2007.0,INDUSTRY,lead,CoMentis,Phase 1
NCT00621478,2008.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT00621517,2008.0,OTHER,lead,East Tennessee State University,Phase 2/Phase 3
NCT00621634,2008.0,OTHER,lead,Université de Montréal,Phase 2
NCT00621634,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 2
NCT00621647,2002.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00621751,2008.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT00621751,2008.0,FED,collaborator,U.S. Department of Education,Not Applicable
NCT00621764,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00621777,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00621777,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00621842,2008.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00621842,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00622011,2008.0,OTHER,lead,Changhua Christian Hospital,Phase 4
NCT00622570,2002.0,OTHER,lead,Hospital Universitari Son Dureta,Phase 3
NCT00622570,2002.0,OTHER,collaborator,Fondo de Investigacion Sanitaria,Phase 3
NCT00622609,2007.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00622700,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00622713,2008.0,INDUSTRY,lead,Novartis,Phase 4
NCT00622739,2007.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT00622739,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00622739,2007.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00622739,2007.0,OTHER,collaborator,Children's Medical Center Dallas,Phase 4
NCT00623363,2007.0,INDUSTRY,lead,Daiichi Sankyo,Phase 2
NCT00623415,2007.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT00623415,2007.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT00623467,2007.0,INDUSTRY,lead,Bayer,Phase 3
NCT00623506,2008.0,FED,lead,Durham VA Medical Center,Not Applicable
NCT00623636,2008.0,INDUSTRY,lead,Allergan,Phase 3
NCT00623636,2008.0,INDUSTRY,collaborator,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Phase 3
NCT00624013,2006.0,OTHER,lead,Charles Drew University of Medicine and Science,Phase 4
NCT00624026,2007.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT00624468,2008.0,INDUSTRY,lead,EMD Serono,Phase 2
NCT00624468,2008.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT00624858,2008.0,INDUSTRY,lead,"Orexigen Therapeutics, Inc",Phase 2
NCT00625131,2008.0,FED,lead,US Department of Veterans Affairs,Early Phase 1
NCT00625547,2003.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00625833,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00625950,2008.0,OTHER,lead,"Instituto Valenciano de Infertilidad, IVI VALENCIA",Phase 4
NCT00626210,2008.0,FED,lead,VA Palo Alto Health Care System,Phase 4
NCT00626340,1999.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00626418,2008.0,INDUSTRY,lead,Ligand Pharmaceuticals,Phase 2
NCT00626574,2007.0,OTHER,lead,University of South Florida,Phase 4
NCT00626574,2007.0,INDUSTRY,collaborator,"Ortho Biotech, Inc.",Phase 4
NCT00626613,,OTHER_GOV,lead,Jinan Mental Hospital,Phase 4
NCT00626613,,INDUSTRY,collaborator,Johnson & Johnson,Phase 4
NCT00626834,2008.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00627003,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00627250,2003.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT00627250,2003.0,FED,collaborator,U.S. Department of Education,Not Applicable
NCT00627458,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00627575,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00627588,2008.0,INDUSTRY,lead,Oxford BioMedica,Phase 1/Phase 2
NCT00627640,2009.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT00627796,2003.0,OTHER,lead,Federico II University,Phase 4
NCT00627796,2003.0,OTHER,collaborator,University of Genova,Phase 4
NCT00627991,2007.0,OTHER,lead,Stanford University,Not Applicable
NCT00627991,2007.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Not Applicable
NCT00628017,2003.0,OTHER,lead,"Taipei City Psychiatric Center, Taiwan",Not Applicable
NCT00628017,2003.0,OTHER_GOV,collaborator,"Department of Health, Executive Yuan, R.O.C. (Taiwan)",Not Applicable
NCT00628290,2002.0,OTHER,lead,University of Cologne,Phase 2
NCT00628316,2008.0,OTHER,lead,Faculdade de Medicina de Valenca,Not Applicable
NCT00628420,2005.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1
NCT00628420,2005.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1
NCT00628420,2005.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 1
NCT00629161,2008.0,OTHER,lead,Fudan University,Phase 2/Phase 3
NCT00629187,2004.0,OTHER,lead,Tufts Medical Center,Phase 1
NCT00629252,2008.0,OTHER,lead,University of Zurich,Not Applicable
NCT00629252,2008.0,OTHER,collaborator,"University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging",Not Applicable
NCT00629252,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT00629642,2008.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT00629889,2008.0,OTHER,lead,Dr Andrea Rossetti,Phase 2
NCT00630097,2009.0,OTHER,lead,California Pacific Medical Center Research Institute,Phase 2
NCT00630175,2003.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00630357,2003.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00630383,2008.0,OTHER,lead,University of Nottingham,Phase 2
NCT00630396,2008.0,OTHER,lead,"David Hess, MD",Phase 1/Phase 2
NCT00630396,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00630396,2008.0,OTHER,collaborator,University of Kentucky,Phase 1/Phase 2
NCT00630396,2008.0,OTHER,collaborator,Oregon Health and Science University,Phase 1/Phase 2
NCT00630474,2004.0,OTHER,lead,University of Zurich,Phase 4
NCT00630630,2002.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00630721,2007.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT00630747,2004.0,INDUSTRY,lead,Shire,Phase 2/Phase 3
NCT00630851,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00630968,2000.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00631150,2003.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00631202,2008.0,OTHER,lead,Federico II University,Phase 2
NCT00631657,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00631722,2007.0,OTHER,lead,Peking University,Not Applicable
NCT00631748,2008.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00631748,2008.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT00631748,2008.0,INDUSTRY,collaborator,AstraZeneca,Not Applicable
NCT00631943,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00631969,2008.0,INDUSTRY,lead,Bayer,Phase 3
NCT00631969,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00631969,2008.0,INDUSTRY,collaborator,Schering-Plough,Phase 3
NCT00631995,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 1
NCT00632099,2008.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT00632099,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00632229,2007.0,OTHER,lead,University of South Florida,Phase 2
NCT00632229,2007.0,OTHER,collaborator,Indiana University,Phase 2
NCT00632229,2007.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 2
NCT00632385,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00632528,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00632632,2005.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT00632645,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00632736,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00632762,2007.0,OTHER,lead,"University Hospital, Toulouse",Phase 4
NCT00633360,2008.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00633360,2008.0,INDUSTRY,collaborator,Bayer,Not Applicable
NCT00633841,2008.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT00634062,2004.0,OTHER,lead,Mclean Hospital,Phase 4
NCT00634062,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00634270,2008.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT00634270,2008.0,OTHER,collaborator,Boston Children's Hospital,Phase 2
NCT00634270,2008.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT00634270,2008.0,OTHER,collaborator,Children's National Research Institute,Phase 2
NCT00634270,2008.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00634270,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00634270,2008.0,OTHER,collaborator,University of Chicago,Phase 2
NCT00634270,2008.0,OTHER,collaborator,University of Utah,Phase 2
NCT00634270,2008.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00634283,2008.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00634348,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00634543,2006.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00634556,2006.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT00634556,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT00634660,2008.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1
NCT00634790,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00634972,2005.0,OTHER,lead,University of South Alabama,Phase 4
NCT00634985,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00634998,2007.0,OTHER,lead,Washington State University,Phase 1
NCT00635076,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00635128,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00635531,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00635765,2007.0,INDUSTRY,lead,"Ambrilia Biopharma, Inc.",Phase 3
NCT00635921,2004.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 2
NCT00635921,2004.0,OTHER_GOV,collaborator,"Ministry of Health, Spain",Phase 2
NCT00635921,2004.0,UNKNOWN,collaborator,REM-TAP Network,Phase 2
NCT00635921,2004.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00635960,2007.0,OTHER,lead,Federico II University,Phase 2
NCT00635960,2007.0,UNKNOWN,collaborator,"Istituto Biostrutture e Immagini, CNR Naples",Phase 2
NCT00635960,2007.0,OTHER_GOV,collaborator,Agenzia Italiana del Farmaco,Phase 2
NCT00636415,2004.0,OTHER,lead,Federal University of São Paulo,Not Applicable
NCT00636649,2008.0,OTHER,lead,Duke University,Not Applicable
NCT00636649,2008.0,OTHER,collaborator,St. Louis University,Not Applicable
NCT00636766,2005.0,OTHER,lead,Aristotle University Of Thessaloniki,Not Applicable
NCT00637221,2008.0,INDUSTRY,lead,Neuropharm,Phase 1/Phase 2
NCT00637234,2004.0,OTHER,lead,University of Cologne,Phase 2/Phase 3
NCT00637286,2004.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00637416,2008.0,OTHER,lead,University of Kansas Medical Center,Phase 4
NCT00637416,2008.0,INDUSTRY,collaborator,TAP Pharmaceutical Products Inc.,Phase 4
NCT00637442,2008.0,OTHER,lead,"University Hospital, Bonn",Not Applicable
NCT00637442,2008.0,OTHER_GOV,collaborator,"Federal Ministry of Health, Germany",Not Applicable
NCT00637468,2002.0,OTHER,lead,University Hospital Freiburg,Phase 3
NCT00637468,2002.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT00637494,2008.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT00638027,2006.0,OTHER,lead,University of Rochester,Phase 4
NCT00638027,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00638053,2002.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00638196,2008.0,OTHER,lead,University of Rochester,Phase 1
NCT00638248,2003.0,INDUSTRY,lead,PAION Deutschland GmbH,Phase 1/Phase 2
NCT00638781,2001.0,INDUSTRY,lead,PAION Deutschland GmbH,Phase 2
NCT00638833,2007.0,OTHER,lead,"Clinica Universidad de Navarra, Universidad de Navarra",Phase 2
NCT00638833,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT00638963,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00639119,2007.0,OTHER,lead,University of Turku,Phase 2
NCT00639483,2003.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00639730,2006.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT00639730,2006.0,OTHER,collaborator,Vascular Birthmarks Foundation,Phase 1
NCT00640003,2007.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT00640159,2007.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT00640198,2005.0,OTHER,lead,Gabinete Berthier y Martínez,Phase 4
NCT00640198,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00640328,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00640367,2008.0,OTHER,lead,Niguarda Hospital,Phase 3
NCT00640510,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00640562,2008.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00640601,2008.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00640952,2006.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT00640952,2006.0,OTHER,collaborator,National Parkinson Foundation,Not Applicable
NCT00640965,2008.0,INDUSTRY,lead,D-Pharm Ltd.,Phase 2
NCT00641108,2008.0,OTHER,lead,University of Pennsylvania,Phase 2/Phase 3
NCT00641108,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00641173,2008.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00641173,2008.0,OTHER,collaborator,Emory University,Not Applicable
NCT00641186,2004.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00641186,2004.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT00641303,2008.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT00641303,2008.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00641303,2008.0,OTHER,collaborator,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Not Applicable
NCT00641537,2008.0,INDUSTRY,lead,"EMD Serono Research & Development Institute, Inc.",Phase 3
NCT00641719,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00641719,2008.0,INDUSTRY,collaborator,Shionogi,Phase 3
NCT00641745,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00641797,2006.0,OTHER,lead,Lehigh Valley Hospital,Not Applicable
NCT00642356,2008.0,INDUSTRY,lead,Novartis,Phase 4
NCT00642369,2008.0,OTHER,lead,Guang Dong Provincial Mental Health Institute,Not Applicable
NCT00642421,2008.0,INDUSTRY,lead,"Ambrilia Biopharma, Inc.",Phase 3
NCT00642720,2006.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT00642889,2005.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT00642928,2007.0,OTHER,lead,Bioprojet,Phase 2
NCT00643045,2004.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT00643123,2007.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT00643123,2007.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00643136,2002.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00643162,2006.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT00643162,2006.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00643500,2002.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00643760,2008.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT00643890,2008.0,INDUSTRY,lead,"Neurologix, Inc.",Phase 2
NCT00643916,2004.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00644007,2007.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 3
NCT00644137,2007.0,OTHER,lead,Yale University,Early Phase 1
NCT00644137,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT00644137,2007.0,FED,collaborator,US Department of Veterans Affairs,Early Phase 1
NCT00644423,2008.0,FED,lead,Durham VA Medical Center,Not Applicable
NCT00644631,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00644748,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00644800,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00644904,2006.0,OTHER,lead,University of Toronto,Phase 1/Phase 2
NCT00644904,2006.0,UNKNOWN,collaborator,Direct MS-Proactive Charity,Phase 1/Phase 2
NCT00644904,2006.0,OTHER,collaborator,Multiple Sclerosis Society of Canada,Phase 1/Phase 2
NCT00644956,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00645099,2007.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT00645190,2004.0,INDUSTRY,lead,Xian-Janssen Pharmaceutical Ltd.,Phase 3
NCT00645229,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00645268,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00645307,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00645372,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00645398,2004.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00645450,2008.0,FED,lead,VA Office of Research and Development,Phase 4
NCT00645502,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00645515,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00645580,2008.0,OTHER,lead,Sha'ar Menashe Mental Health Center,Not Applicable
NCT00645749,2008.0,OTHER,lead,"University of Wisconsin, Madison",Phase 1
NCT00645749,2008.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1
NCT00645944,2008.0,OTHER,lead,Yale University,Not Applicable
NCT00645944,2008.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Not Applicable
NCT00646204,2006.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT00646204,2006.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00646451,2006.0,OTHER,lead,Baylor College of Medicine,Early Phase 1
NCT00646451,2006.0,INDUSTRY,collaborator,Pfizer,Early Phase 1
NCT00646581,2006.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT00647296,2008.0,INDUSTRY,lead,Knopp Biosciences,Phase 2
NCT00647998,2008.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00648375,2003.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00648375,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00648596,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00648908,2006.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00649064,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00649207,2008.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 1
NCT00649220,2008.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 4
NCT00649792,2007.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00649844,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00649961,2010.0,OTHER,lead,Imperial College London,Phase 2
NCT00649961,2010.0,OTHER_GOV,collaborator,British Medical Research Council,Phase 2
NCT00650104,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00650429,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00650611,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 2
NCT00650793,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00650871,2004.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00651040,2008.0,OTHER,lead,"Institute of Rheumatology, Prague",Phase 3
NCT00651040,2008.0,OTHER,collaborator,Karolinska Institutet,Phase 3
NCT00651690,2004.0,INDUSTRY,lead,Allergan,Phase 2
NCT00651729,2003.0,INDUSTRY,lead,Allergan,Phase 2
NCT00652171,2004.0,OTHER_GOV,lead,Institute of Social Security of the Civil Servants of Minas Gerais,Phase 3
NCT00652184,2008.0,INDUSTRY,lead,"aRigen Pharmaceuticals, Inc.",Phase 2
NCT00652262,2004.0,INDUSTRY,lead,Bayer,Phase 3
NCT00652379,2008.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00652379,2008.0,OTHER,collaborator,Aarhus University Hospital Skejby,Not Applicable
NCT00652379,2008.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT00652379,2008.0,OTHER,collaborator,"The Research Council for Health and Disease, Denmark",Not Applicable
NCT00652457,2004.0,OTHER,lead,"Jody Corey-Bloom, MD, PhD",Phase 4
NCT00652457,2004.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00653406,2002.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 1/Phase 2
NCT00653562,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT00654082,2002.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00654394,2000.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00654498,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00654576,2005.0,OTHER,lead,Central South University,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Shanghai Mental Health Center,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Sichuan University,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Capital Medical University,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Nanjing Medical University,Phase 4
NCT00654576,2005.0,UNKNOWN,collaborator,Jiangxi Mental Hospital,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Hunan Mental Hospital,Phase 4
NCT00654576,2005.0,OTHER,collaborator,Guangzhou Mental Hospital,Phase 4
NCT00654576,2005.0,UNKNOWN,collaborator,Chongqing Metal Institute,Phase 4
NCT00654576,2005.0,UNKNOWN,collaborator,Henan Mental Hospital,Phase 4
NCT00654680,2002.0,INDUSTRY,lead,Bayer,Phase 3
NCT00654680,2002.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00654706,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00654901,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00654914,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00654927,2003.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT00654953,2006.0,OTHER,lead,University of Arkansas,Phase 2
NCT00654953,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00655057,2005.0,OTHER,lead,University of Pennsylvania,Phase 2/Phase 3
NCT00655057,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT00655226,2008.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00655226,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00655278,2007.0,INDUSTRY,lead,Taro Pharmaceuticals USA,Phase 2
NCT00655486,2008.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT00655551,2008.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT00655590,2005.0,INDUSTRY,lead,Bayer,Phase 4
NCT00655629,2008.0,INDUSTRY,lead,Bayer,Phase 3
NCT00655629,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00655629,2008.0,INDUSTRY,collaborator,Schering-Plough,Phase 3
NCT00655681,2007.0,OTHER,lead,University of New Mexico,Not Applicable
NCT00655681,2007.0,OTHER,collaborator,Thrasher Research Fund,Not Applicable
NCT00656110,2008.0,OTHER,lead,Lowcountry Infectious Diseases,Not Applicable
NCT00656188,2002.0,INDUSTRY,lead,Bayer,Phase 2/Phase 3
NCT00656188,2002.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00656253,2008.0,OTHER,lead,Fudan University,Phase 2/Phase 3
NCT00656253,2008.0,OTHER_GOV,collaborator,State Administration of Traditional Chinese Medicine of the People's Republic of China,Phase 2/Phase 3
NCT00656357,2008.0,INDUSTRY,lead,Biotie Therapies Inc.,Phase 1/Phase 2
NCT00656357,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00656487,2008.0,OTHER,lead,The Scripps Research Institute,Phase 2
NCT00656487,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00656552,2008.0,OTHER,lead,Cairo University,Early Phase 1
NCT00657033,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00657033,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00657202,2008.0,OTHER,lead,Massachusetts General Hospital,Early Phase 1
NCT00657397,2009.0,OTHER_GOV,lead,French National Agency for Research on AIDS and Viral Hepatitis,Phase 3
NCT00657501,2008.0,INDUSTRY,lead,BioSante Pharmaceuticals,Phase 3
NCT00657644,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00657644,2003.0,INDUSTRY,collaborator,Amgen,Phase 3
NCT00657748,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00657748,2009.0,OTHER,collaborator,European Leukodystrophy Association,Phase 2
NCT00657813,2008.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00657813,2008.0,OTHER,collaborator,Molecular NeuroImaging,Phase 1
NCT00658177,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00658177,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00658476,2006.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 3
NCT00658476,2006.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00658645,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00658931,2008.0,OTHER,lead,"Jefferson Clinic, P.C.",Phase 4
NCT00658931,2008.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00659230,2009.0,OTHER,lead,Tuscaloosa Research & Education Advancement Corporation,Phase 2
NCT00659230,2009.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 2
NCT00659230,2009.0,FED,collaborator,Ralph H. Johnson VA Medical Center,Phase 2
NCT00659230,2009.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT00659230,2009.0,FED,collaborator,San Diego Veterans Healthcare System,Phase 2
NCT00659230,2009.0,FED,collaborator,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT00659334,2000.0,OTHER,lead,OHSU Knight Cancer Institute,Phase 2
NCT00659334,2000.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00659334,2000.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00659373,2007.0,NETWORK,lead,ETOP IBCSG Partners Foundation,Phase 3
NCT00659373,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00659373,2007.0,OTHER,collaborator,"Breast Cancer Trials, Australia and New Zealand",Phase 3
NCT00659373,2007.0,NETWORK,collaborator,Cancer and Leukemia Group B,Phase 3
NCT00659776,2004.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00659776,2004.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00659854,2008.0,OTHER,lead,Soroka University Medical Center,Not Applicable
NCT00659919,2000.0,OTHER_GOV,lead,BeerYaakov Mental Health Center,Phase 4
NCT00659958,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT00659958,2008.0,INDUSTRY,collaborator,Eisai Farmacêutica S.A.,Phase 4
NCT00660595,2008.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00660998,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00661063,2008.0,OTHER,lead,Irmandade da Santa Casa de Misericordia de Sao Paulo,Phase 3
NCT00661115,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00661219,2002.0,INDUSTRY,lead,Bayer,Phase 3
NCT00661297,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00661297,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00661596,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00661674,2008.0,OTHER,lead,Stanford University,Not Applicable
NCT00661700,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00662441,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00662441,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00662649,2008.0,INDUSTRY,lead,Novartis,Phase 3
NCT00662818,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00662870,2001.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00663026,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00663039,2009.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT00663039,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00663130,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00663130,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00663338,2010.0,OTHER,lead,"University College, London",Phase 2
NCT00663338,2010.0,OTHER_GOV,collaborator,Medical Research Council,Phase 2
NCT00663416,2008.0,INDUSTRY,lead,Stem Cell Therapeutics Corp.,Phase 2
NCT00663598,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00663728,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00663728,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00663845,2006.0,INDUSTRY,lead,Bayer,Phase 4
NCT00663845,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00663871,2008.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00663871,2008.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT00663871,2008.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00663871,2008.0,NIH,collaborator,Office of Dietary Supplements (ODS),Not Applicable
NCT00663936,2008.0,INDUSTRY,lead,"FUJIFILM Toyama Chemical Co., Ltd.",Phase 2
NCT00664157,2007.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT00664209,2008.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00664209,2008.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 3
NCT00664365,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00664755,2007.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00664833,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00664846,2008.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT00665054,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00665054,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00665223,2008.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00665340,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00665444,2008.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00665444,2008.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Not Applicable
NCT00665496,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00665977,2007.0,INDUSTRY,lead,Clayton Sleep Insititute,Phase 3
NCT00666068,2008.0,OTHER,lead,Max-Planck-Institute of Psychiatry,Not Applicable
NCT00666224,2004.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00666653,2003.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT00666653,2003.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 1
NCT00666757,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00666757,2008.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 4
NCT00666809,2006.0,INDUSTRY,lead,Bayer,Phase 2
NCT00666978,2007.0,OTHER,lead,"Lisa Sanderson Cox, PhD",Phase 4
NCT00666978,2007.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT00667602,2008.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00667745,2008.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00667810,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00667966,2005.0,INDUSTRY,lead,Bayer,Phase 4
NCT00667979,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00667979,2004.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00668005,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00668005,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00668018,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00668057,2002.0,INDUSTRY,lead,Bayer,Phase 3
NCT00668096,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT00668109,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00668135,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00668343,2005.0,OTHER,lead,Tehran University of Medical Sciences,Phase 3
NCT00668434,2008.0,OTHER,lead,Kaiser Permanente,Phase 2
NCT00668434,2008.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT00668564,2008.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2
NCT00668837,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00669461,2009.0,OTHER,lead,University of Arkansas,Not Applicable
NCT00669461,2009.0,INDUSTRY,collaborator,Takeda,Not Applicable
NCT00669695,2008.0,OTHER,lead,"University Hospital, Grenoble",Phase 2
NCT00669903,2008.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00670202,2008.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00670202,2008.0,OTHER,collaborator,Doris Duke Charitable Foundation,Phase 2
NCT00670449,2008.0,INDUSTRY,lead,Novartis,Phase 2
NCT00670449,2008.0,INDUSTRY,collaborator,Mitsubishi Tanabe Pharma Corporation,Phase 2
NCT00670813,2008.0,OTHER,lead,Technical University of Munich,Phase 2
NCT00670813,2008.0,INDUSTRY,collaborator,Cephalon,Phase 2
NCT00670904,2005.0,OTHER,lead,University of Montana,Not Applicable
NCT00670904,2005.0,OTHER,collaborator,Prevent Cancer Foundation,Not Applicable
NCT00671086,2003.0,INDUSTRY,lead,Takeda,Phase 3
NCT00671099,2008.0,OTHER,lead,Japan Science and Technology Agency,Phase 3
NCT00671099,2008.0,OTHER,collaborator,University of Toyama,Phase 3
NCT00671099,2008.0,OTHER,collaborator,Chiba University,Phase 3
NCT00671190,2005.0,INDUSTRY,lead,Takeda,Phase 2
NCT00671489,2008.0,OTHER,lead,Japan Science and Technology Agency,Phase 1/Phase 2
NCT00671489,2008.0,OTHER,collaborator,University of Toyama,Phase 1/Phase 2
NCT00671489,2008.0,OTHER,collaborator,Chiba University,Phase 1/Phase 2
NCT00671710,2008.0,OTHER,lead,Advocate Hospital System,Phase 1
NCT00671853,2008.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 3
NCT00671853,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00671853,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00672022,2004.0,OTHER,lead,Children's National Research Institute,Phase 3
NCT00672022,2004.0,INDUSTRY,collaborator,Actelion,Phase 3
NCT00672373,2006.0,OTHER,lead,Beijing HuiLongGuan Hospital,Phase 3
NCT00672373,2006.0,OTHER,collaborator,Peking University,Phase 3
NCT00672464,2008.0,OTHER,lead,Duke University,Phase 4
NCT00672659,2008.0,INDUSTRY,lead,PharmaNeuroBoost N.V.,Phase 2
NCT00672945,2008.0,INDUSTRY,lead,"Epix Pharmaceuticals, Inc.",Phase 2
NCT00673088,2004.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00673452,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00673452,2008.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 4
NCT00674219,2005.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT00674219,2005.0,OTHER,collaborator,Saban Family Foundation,Phase 3
NCT00674310,2004.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00674570,2009.0,FED,lead,VA Office of Research and Development,Phase 4
NCT00675025,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT00675025,2008.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00675090,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00675272,2008.0,OTHER,lead,Kuopio University Hospital,Not Applicable
NCT00675272,2008.0,OTHER,collaborator,Tampere University Hospital,Not Applicable
NCT00675532,2011.0,OTHER,lead,Yale University,Not Applicable
NCT00675623,2008.0,INDUSTRY,lead,"Medivation, Inc.",Phase 3
NCT00676143,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00676156,2005.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT00676156,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 1
NCT00676403,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 2
NCT00676676,2007.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00676676,2007.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00676715,2008.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT00676715,2008.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 2
NCT00677352,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00677898,2010.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00677963,2009.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT00678314,2004.0,OTHER,lead,Region Örebro County,Phase 4
NCT00678431,2008.0,FED,lead,US Department of Veterans Affairs,Phase 3
NCT00678431,2008.0,OTHER,collaborator,Alzheimer's Association,Phase 3
NCT00678431,2008.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 3
NCT00678704,2004.0,INDUSTRY,lead,Bayer,Phase 3
NCT00678795,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00679627,2008.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT00679900,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00680602,2006.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT00680602,2006.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00680823,2009.0,OTHER,lead,Robert Hickey,Not Applicable
NCT00681239,2008.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT00681239,2008.0,INDUSTRY,collaborator,"Nutricia, Inc.",Phase 3
NCT00681538,2008.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00681551,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00681629,2008.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00681772,2003.0,INDUSTRY,lead,Bayer,Phase 4
NCT00681772,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00681863,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT00682019,2003.0,INDUSTRY,lead,Bayer,Phase 3
NCT00682019,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00682734,2008.0,OTHER,lead,Montefiore Medical Center,Phase 3
NCT00682929,2004.0,OTHER,lead,"University of California, Davis",Phase 1/Phase 2
NCT00682929,2004.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1/Phase 2
NCT00683189,2007.0,OTHER,lead,The Cooper Health System,Not Applicable
NCT00683423,2008.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT00683566,2008.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT00683644,2008.0,OTHER,lead,University of Iowa,Phase 2
NCT00683644,2008.0,OTHER,collaborator,Tinnitus Research Initiative,Phase 2
NCT00684073,2007.0,INDUSTRY,lead,Indivior Inc.,Phase 4
NCT00684515,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00684710,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00684944,2007.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 2
NCT00685178,2007.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00685178,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00685269,2003.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT00685334,2003.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00685334,2003.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00685815,2006.0,INDUSTRY,lead,"American Regent, Inc.",Phase 2
NCT00685815,2006.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00685919,2008.0,OTHER,lead,Vanderbilt University,Phase 2/Phase 3
NCT00686127,2003.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT00686140,2006.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT00686140,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00686699,2006.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00686920,2007.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 3
NCT00686998,2008.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00687141,2007.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00687609,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00688207,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00688324,2008.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT00688324,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00688324,2008.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00688597,2008.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00688805,2007.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00688818,2008.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00688935,2005.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00688948,2007.0,OTHER,lead,Nova Scotia Health Authority,Phase 2/Phase 3
NCT00688948,2007.0,INDUSTRY,collaborator,Sanofi,Phase 2/Phase 3
NCT00689052,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00689559,2008.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00689572,2008.0,OTHER,lead,University of Virginia,Phase 2
NCT00689572,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00689585,2008.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 2
NCT00689585,2008.0,OTHER,collaborator,McGill University,Phase 2
NCT00689637,2007.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00690118,2008.0,OTHER,lead,University of Ulm,Phase 2
NCT00690235,2007.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT00690235,2007.0,INDUSTRY,collaborator,"Amylin Pharmaceuticals, LLC.",Phase 4
NCT00690274,2008.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT00690274,2008.0,OTHER,collaborator,Bioprojet,Phase 2
NCT00690274,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00690534,2005.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 1
NCT00690534,2005.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT00690716,2008.0,INDUSTRY,lead,"Capnia, Inc.",Phase 2
NCT00690898,2008.0,INDUSTRY,lead,Ipsen,Phase 3
NCT00690924,2008.0,OTHER,lead,Roswell Park Cancer Institute,Not Applicable
NCT00690924,2008.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00691132,2009.0,OTHER,lead,University of Minnesota,Phase 2
NCT00691132,2009.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00691314,2008.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT00691444,2002.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00691444,2002.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00691808,2008.0,INDUSTRY,lead,Lexicon Pharmaceuticals,Phase 2
NCT00692003,2008.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT00692094,2004.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00692094,2004.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT00692185,2005.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00692185,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00692328,2005.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00692328,2005.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT00692445,2008.0,INDUSTRY,lead,Targacept Inc.,Phase 2
NCT00692510,2007.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00693004,2008.0,INDUSTRY,lead,"Epix Pharmaceuticals, Inc.",Phase 2
NCT00693017,2008.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT00693121,2003.0,OTHER,lead,Methodist Rehabilitation Center,Phase 4
NCT00693121,2003.0,FED,collaborator,U.S. Department of Education,Phase 4
NCT00693472,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00694460,2002.0,INDUSTRY,lead,Novartis,Phase 2
NCT00694460,2002.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 2
NCT00694707,2008.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00694707,2008.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 2
NCT00694720,2008.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00695214,2004.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00695214,2004.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00695214,2004.0,OTHER,collaborator,American Academy of Otolaryngology-Head and Neck Surgery Foundation,Phase 2
NCT00696215,2007.0,OTHER,lead,Istanbul University,Phase 4
NCT00696787,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00697073,2008.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT00697138,2006.0,OTHER,lead,University of Kentucky,Phase 1
NCT00697138,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00697164,2007.0,OTHER,lead,Claude Bernard University,Phase 2/Phase 3
NCT00697762,2007.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00697814,2004.0,OTHER,lead,Federal University of São Paulo,Phase 2
NCT00697918,2008.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00698581,2008.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00698763,2008.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT00699283,2008.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00699465,2008.0,OTHER,lead,University of Oulu,Phase 4
NCT00699465,2008.0,OTHER,collaborator,University of Helsinki,Phase 4
NCT00699621,2009.0,OTHER,lead,University of Oulu,Not Applicable
NCT00699621,2009.0,OTHER,collaborator,University of Helsinki,Not Applicable
NCT00699634,2009.0,OTHER,lead,University of Manitoba,Phase 2
NCT00699634,2009.0,INDUSTRY,collaborator,Valeant Canada Limited,Phase 2
NCT00699946,2005.0,OTHER,lead,The New England Baptist Hospital,Not Applicable
NCT00700128,2008.0,OTHER,lead,Scott and White Hospital & Clinic,Not Applicable
NCT00700128,2008.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Not Applicable
NCT00700635,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00700713,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00701129,2009.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00701233,2012.0,OTHER,lead,University of Minnesota,Phase 2
NCT00701363,2008.0,INDUSTRY,lead,Ipsen,Phase 4
NCT00701389,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00701415,2008.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00701428,2008.0,OTHER_GOV,lead,Skaraborg Hospital,Phase 4
NCT00701428,2008.0,OTHER,collaborator,Göteborg University,Phase 4
NCT00701493,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00701532,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00701532,2009.0,OTHER,collaborator,Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie,Phase 3
NCT00701701,2008.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT00701909,2008.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT00702143,2008.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT00702468,2007.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00702780,2008.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT00702780,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT00702793,2008.0,OTHER,lead,University of British Columbia,Phase 4
NCT00702793,2008.0,OTHER,collaborator,Provincial Health Services Authority,Phase 4
NCT00703430,2008.0,OTHER,lead,Peking University,Not Applicable
NCT00703430,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT00703677,2008.0,OTHER,lead,Westat,Phase 1/Phase 2
NCT00703677,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00703742,2008.0,OTHER,lead,Kunming Medical University,Not Applicable
NCT00703742,2008.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Not Applicable
NCT00703885,2008.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT00703885,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00704301,2008.0,OTHER,lead,UMC Utrecht,Phase 4
NCT00704301,2008.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT00704301,2008.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00704301,2008.0,OTHER,collaborator,Netherlands Brain Foundation,Phase 4
NCT00704379,2008.0,OTHER,lead,Baylor College of Medicine,Phase 2/Phase 3
NCT00704379,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT00704509,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00704782,2008.0,INDUSTRY,lead,"Medivation, Inc.",Phase 2
NCT00704899,2006.0,OTHER,lead,Mahatma Gandhi Institute of Medical Sciences,Phase 3
NCT00705783,2008.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00705861,2007.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 3
NCT00705939,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00706147,2009.0,OTHER,lead,University of Miami,Phase 2/Phase 3
NCT00706147,2009.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT00706589,2008.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00706589,2008.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00706654,2008.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00706810,2007.0,OTHER,lead,University of Utah,Phase 2
NCT00706836,2008.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT00706836,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00707343,2007.0,OTHER,lead,University of Utah,Phase 1
NCT00707382,2008.0,OTHER,lead,Gesche Jurgens,Not Applicable
NCT00707382,2008.0,OTHER,collaborator,Bispebjerg Hospital,Not Applicable
NCT00707382,2008.0,UNKNOWN,collaborator,"Research Unit, Psyciatric Centre Bispebjerg",Not Applicable
NCT00707382,2008.0,UNKNOWN,collaborator,"Research Institute of Biological Psychiatry,Psychiatric Centre Sct. Hans",Not Applicable
NCT00707382,2008.0,OTHER,collaborator,Danish Centre for Health Technology Assessment,Not Applicable
NCT00707382,2008.0,OTHER_GOV,collaborator,"The Ministry of Health and Prevention, Denmark",Not Applicable
NCT00707382,2008.0,INDUSTRY,collaborator,"TrygFonden, Denmark",Not Applicable
NCT00707785,2006.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT00707785,2006.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT00707785,2006.0,FED,collaborator,United States Agency for International Development (USAID),Phase 3
NCT00707785,2006.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 3
NCT00708240,2007.0,OTHER,lead,University of Ottawa,Phase 4
NCT00708240,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00708396,2008.0,OTHER_GOV,lead,BeerYaakov Mental Health Center,Phase 4
NCT00708552,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00708994,2008.0,OTHER,lead,Yale University,Early Phase 1
NCT00708994,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT00709202,2008.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00709202,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00709696,2008.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00709696,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00709696,2008.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00709735,2007.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00709735,2007.0,FED,collaborator,VA Office of Research and Development,Phase 4
NCT00709852,2008.0,INDUSTRY,lead,Bayer,Phase 3
NCT00710034,2010.0,OTHER,lead,University of Minnesota,Phase 2
NCT00710034,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00710424,2005.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00710554,2005.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00710684,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00711087,2007.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00711087,2007.0,FED,collaborator,U.S. Department of Education,Phase 2
NCT00711269,2008.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT00711464,2008.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00711646,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00711880,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00711919,2007.0,OTHER,lead,Kyoto Prefectural University of Medicine,Not Applicable
NCT00711971,2008.0,OTHER,lead,University of Michigan,Phase 2/Phase 3
NCT00711971,2008.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2/Phase 3
NCT00712270,2005.0,OTHER,lead,Kettering Health Network,Phase 4
NCT00712348,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00712426,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT00712426,2009.0,OTHER,collaborator,University of Rochester,Phase 3
NCT00712426,2009.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00712660,2008.0,OTHER_GOV,lead,Prague Psychiatric Center,Not Applicable
NCT00712660,2008.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00712686,2000.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00712725,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00713323,2005.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00713583,2008.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00713583,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00713622,2008.0,INDUSTRY,lead,Eisai Limited,Phase 4
NCT00713726,2006.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT00713726,2006.0,OTHER,collaborator,Albert B. Sabin Vaccine Institute,Phase 3
NCT00713765,2008.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00713817,2007.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00713986,2006.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT00714090,2008.0,OTHER,lead,Club rTMS et Psychiatrie,Phase 3
NCT00714090,2008.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT00714090,2008.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3
NCT00714740,2008.0,OTHER,lead,University of Zurich,Phase 4
NCT00715039,2003.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT00715273,2001.0,OTHER,lead,University of Washington,Phase 4
NCT00715273,2001.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT00715273,2001.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00715273,2001.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT00715273,2001.0,INDUSTRY,collaborator,Daiichi Sankyo,Phase 4
NCT00715273,2001.0,INDUSTRY,collaborator,Upsher-Smith Laboratories,Phase 4
NCT00715364,2009.0,INDUSTRY,lead,Stem Cell Therapeutics Corp.,Phase 2
NCT00715377,2007.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00715520,2007.0,OTHER,lead,Emory University,Not Applicable
NCT00715520,2007.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00715520,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT00715858,2008.0,OTHER,lead,McMaster University,Phase 3
NCT00715858,2008.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 3
NCT00716066,2008.0,OTHER,lead,Fred Hutchinson Cancer Center,Phase 2
NCT00716274,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00716469,2008.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 1
NCT00716469,2008.0,FED,collaborator,United States Department of Defense,Phase 1
NCT00716755,2009.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00716976,2008.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT00716976,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00718328,2008.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00718328,2008.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2
NCT00718328,2008.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00718341,2008.0,INDUSTRY,lead,Novartis,Phase 2
NCT00718510,2009.0,OTHER,lead,University of Alberta,Not Applicable
NCT00718510,2009.0,OTHER,collaborator,Alberta Health services,Not Applicable
NCT00718627,2008.0,INDUSTRY,lead,Cytonet GmbH & Co. KG,Phase 2
NCT00718731,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00719394,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00719706,2008.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00719706,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00720018,2008.0,INDUSTRY,lead,NuPathe Inc.,Phase 1
NCT00720161,2006.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT00720369,2008.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT00720369,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT00720473,2006.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT00720759,2009.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00721526,2009.0,OTHER,lead,University of New Mexico,Phase 4
NCT00721526,2009.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT00721825,2008.0,INDUSTRY,lead,Moleac Pte Ltd.,Phase 2
NCT00722046,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00722124,2008.0,OTHER,lead,Mayo Clinic,Phase 2/Phase 3
NCT00722124,2008.0,INDUSTRY,collaborator,Pharmavite LLC,Phase 2/Phase 3
NCT00722176,2008.0,INDUSTRY,lead,"BioLineRx, Ltd.",Phase 2
NCT00723060,2008.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT00723450,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00723580,2008.0,OTHER,lead,Child Psychopharmacology Institute,Not Applicable
NCT00723606,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00723866,2005.0,OTHER,lead,Kaohsiung Veterans General Hospital.,Not Applicable
NCT00723918,2009.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT00723918,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00723983,2008.0,INDUSTRY,lead,NuPathe Inc.,Phase 1
NCT00724048,2008.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00724594,2008.0,OTHER,lead,Medical University of South Carolina,Phase 1/Phase 2
NCT00724594,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00724724,2008.0,OTHER,lead,Peking Union Medical College Hospital,Phase 4
NCT00724802,2008.0,OTHER,lead,Shaare Zedek Medical Center,Not Applicable
NCT00724815,2009.0,INDUSTRY,lead,NuPathe Inc.,Phase 3
NCT00724906,2010.0,INDUSTRY,lead,"Alseres Pharmaceuticals, Inc",Phase 3
NCT00725075,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00725270,1998.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT00725270,1998.0,OTHER,collaborator,Pritzker Family Foundation,Phase 2/Phase 3
NCT00725725,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00725790,2008.0,OTHER_GOV,lead,China Rehabilitation Research Center,Phase 4
NCT00725855,2008.0,INDUSTRY,lead,Memory Pharmaceuticals,Phase 2
NCT00725855,2008.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2
NCT00725920,2007.0,OTHER,lead,Federal University of São Paulo,Phase 4
NCT00725920,2007.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00725985,2008.0,INDUSTRY,lead,"EMD Serono Research & Development Institute, Inc.",Phase 3
NCT00726115,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00726726,2008.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00726960,2008.0,OTHER,lead,Karolinska University Hospital,Phase 1
NCT00726960,2008.0,OTHER_GOV,collaborator,"Ministry of Health and Social Affairs, Sweden",Phase 1
NCT00726960,2008.0,UNKNOWN,collaborator,County of Stockholm,Phase 1
NCT00727103,2008.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 4
NCT00727103,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00727194,2008.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2
NCT00727233,2008.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT00727246,2009.0,OTHER,lead,Patricia M. Arenth,Phase 2
NCT00727246,2009.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT00727922,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00728052,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00728091,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00728182,2008.0,INDUSTRY,lead,NoNO Inc.,Phase 2
NCT00728182,2008.0,INDUSTRY,collaborator,Arbor Vita Corporation,Phase 2
NCT00728195,2008.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00728208,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00728728,2009.0,FED,lead,VA Office of Research and Development,Phase 2
NCT00728897,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00728923,2008.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00729300,2006.0,OTHER,lead,Baylor College of Medicine,Phase 1/Phase 2
NCT00729963,2004.0,OTHER,lead,Laval University,Phase 4
NCT00730184,2007.0,OTHER,lead,Tufts University,Not Applicable
NCT00730184,2007.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT00730561,2006.0,OTHER,lead,Hospital Universitario Dr. Jose E. Gonzalez,Not Applicable
NCT00731055,2008.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00731055,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00731224,2008.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00731549,2008.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00731549,2008.0,INDUSTRY,collaborator,Covance,Phase 3
NCT00732108,2008.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT00732108,2008.0,OTHER,collaborator,American Academy of Otolaryngology-Head and Neck Surgery Foundation,Not Applicable
NCT00732238,2007.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00732251,2008.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT00732251,2008.0,UNKNOWN,collaborator,West Coast College of Biological Psychiatry Inc,Phase 4
NCT00732589,2008.0,OTHER,lead,Chulalongkorn University,Phase 2
NCT00732901,2008.0,OTHER,lead,Virginia Commonwealth University,Phase 2/Phase 3
NCT00732901,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00732901,2008.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2/Phase 3
NCT00733382,2008.0,OTHER,lead,Shiraz University of Medical Sciences,Phase 1
NCT00733525,2000.0,OTHER,lead,University of Minnesota,Not Applicable
NCT00733525,2000.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00733642,2008.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00733785,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00733863,2008.0,INDUSTRY,lead,Novartis,Phase 2
NCT00733967,2008.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT00733967,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00733993,2008.0,OTHER,lead,Virginia Commonwealth University,Phase 1/Phase 2
NCT00733993,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00733993,2008.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT00734422,2008.0,OTHER,lead,VU University of Amsterdam,Phase 2/Phase 3
NCT00734435,2008.0,INDUSTRY,lead,"Orexigen Therapeutics, Inc",Phase 2
NCT00734604,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00734656,2007.0,OTHER,lead,UConn Health,Not Applicable
NCT00734656,2007.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00734656,2007.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT00735007,2008.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00735085,2009.0,INDUSTRY,lead,Abbott Products,Phase 2
NCT00735085,2009.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 2
NCT00735124,2008.0,OTHER,lead,University of Oklahoma,Phase 2/Phase 3
NCT00735397,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00735527,2008.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 3
NCT00735644,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT00735670,2008.0,OTHER,lead,University of Michigan,Not Applicable
NCT00735670,2008.0,FED,collaborator,U.S. Department of Education,Not Applicable
NCT00736151,2004.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 2
NCT00736255,2007.0,OTHER,lead,Duke University,Not Applicable
NCT00736255,2007.0,INDUSTRY,collaborator,Shire,Not Applicable
NCT00736346,2005.0,OTHER,lead,Université du Québec a Montréal,Not Applicable
NCT00736346,2005.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT00736710,2008.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00736775,2008.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT00736931,2008.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT00737256,2008.0,OTHER,lead,Paul Saenger,Phase 2
NCT00737893,2017.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00738062,2008.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 3
NCT00738400,2008.0,INDUSTRY,lead,Bayer,Phase 4
NCT00738894,2008.0,INDUSTRY,lead,W.L.Gore & Associates,Not Applicable
NCT00739024,2008.0,OTHER,lead,Swedish Medical Center,Phase 2
NCT00739024,2008.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT00739037,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00740142,2008.0,OTHER,lead,Mahidol University,Phase 4
NCT00740259,2004.0,OTHER,lead,Ambulatório de Bipolaridade,Phase 4
NCT00740259,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT00740571,2008.0,OTHER,lead,Radboud University Medical Center,Phase 3
NCT00740571,2008.0,OTHER,collaborator,Erasmus Medical Center,Phase 3
NCT00740571,2008.0,OTHER,collaborator,University of Amsterdam,Phase 3
NCT00740623,2009.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00740714,2008.0,OTHER,lead,Weill Medical College of Cornell University,Phase 3
NCT00740714,2008.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00740714,2008.0,OTHER,collaborator,University of Rochester,Phase 3
NCT00741286,2006.0,OTHER,lead,Inje University,Phase 4
NCT00741286,2006.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00741585,2008.0,OTHER,lead,University of Vigo,Phase 4
NCT00741585,2008.0,OTHER_GOV,collaborator,Servicio Gallego de Salud,Phase 4
NCT00741598,2008.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00741598,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00741598,2008.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT00741767,2008.0,OTHER,lead,Northwestern University,Not Applicable
NCT00741767,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00742079,2006.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00742079,2006.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00742209,2008.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT00742209,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00742417,2007.0,INDUSTRY,lead,"Instituto Grifols, S.A.",Phase 2
NCT00742417,2007.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 2
NCT00742612,2009.0,INDUSTRY,lead,Archemix Corp.,Phase 2
NCT00742612,2009.0,OTHER,collaborator,"St George's, University of London",Phase 2
NCT00742638,2008.0,OTHER,lead,Shanghai Jiao Tong University School of Medicine,Not Applicable
NCT00743015,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 1
NCT00743743,2008.0,OTHER,lead,Medical College of Wisconsin,Phase 3
NCT00743834,2008.0,OTHER,lead,"Rogers Center for Research & Training, Inc.",Phase 4
NCT00743847,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00744055,2009.0,OTHER,lead,Yale University,Phase 3
NCT00744094,2007.0,OTHER,lead,Maastricht University Medical Center,Phase 1/Phase 2
NCT00744094,2007.0,OTHER,collaborator,The Anna Foundation,Phase 1/Phase 2
NCT00744094,2007.0,INDUSTRY,collaborator,DSM Food Specialties,Phase 1/Phase 2
NCT00744406,2003.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT00744406,2003.0,OTHER_GOV,collaborator,Ontario Mental Health Foundation,Phase 2
NCT00744679,2008.0,INDUSTRY,lead,Biogen,Phase 4
NCT00744679,2008.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 4
NCT00744731,2009.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00744978,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00745017,2001.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 1
NCT00745017,2001.0,OTHER_GOV,collaborator,Ontario Mental Health Foundation,Phase 1
NCT00745030,2008.0,OTHER,lead,Northwestern University,Not Applicable
NCT00745030,2008.0,INDUSTRY,collaborator,Takeda,Not Applicable
NCT00745095,2009.0,FED,lead,US Department of Veterans Affairs,Phase 4
NCT00745251,2008.0,INDUSTRY,lead,VIVUS LLC,Phase 1/Phase 2
NCT00745576,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00745615,2005.0,INDUSTRY,lead,"Teva Pharmaceutical Industries, Ltd.",Phase 2
NCT00745771,2007.0,INDUSTRY,lead,IDEA AG,Phase 2
NCT00746239,2008.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT00746239,2008.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Not Applicable
NCT00746252,2008.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT00746421,2010.0,OTHER,lead,Emory University,Phase 4
NCT00746421,2010.0,OTHER,collaborator,Duke University,Phase 4
NCT00746421,2010.0,OTHER,collaborator,University of Toronto,Phase 4
NCT00746603,2008.0,OTHER,lead,Columbia University,Not Applicable
NCT00746603,2008.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT00746798,2008.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00746941,2009.0,INDUSTRY,lead,Biogen,Phase 1/Phase 2
NCT00746941,2009.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 1/Phase 2
NCT00746954,2008.0,FED,lead,VA Office of Research and Development,Phase 3
NCT00746954,2008.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Phase 3
NCT00746967,2003.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 2
NCT00747487,2007.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 2
NCT00747643,2008.0,OTHER,lead,H. Lee Moffitt Cancer Center and Research Institute,Not Applicable
NCT00747643,2008.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00748007,2008.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT00748059,1996.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT00748098,2008.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT00748228,2004.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT00748501,2008.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 2
NCT00748644,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00748696,2006.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 3
NCT00748956,2010.0,OTHER,lead,Dennis Charney,Phase 2
NCT00748969,2008.0,OTHER,lead,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Phase 2/Phase 3
NCT00749125,2001.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00749125,2001.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00749203,2009.0,OTHER,lead,Dennis Charney,Phase 2
NCT00749203,2009.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00749216,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00749359,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00749463,2009.0,INDUSTRY,lead,McNeil AB,Phase 4
NCT00749658,2008.0,OTHER,lead,University of Minnesota,Phase 2/Phase 3
NCT00749658,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00749658,2008.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT00749814,2008.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 4
NCT00749983,2009.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT00750061,2008.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 2
NCT00750061,2008.0,OTHER_GOV,collaborator,China Rehabilitation Research Center,Phase 2
NCT00750061,2008.0,OTHER,collaborator,Buddhist Tzu Chi General Hospital,Phase 2
NCT00750230,2003.0,INDUSTRY,lead,"ESM Technologies, LLC",Not Applicable
NCT00750282,2008.0,INDUSTRY,lead,Life Molecular Imaging SA,Phase 2
NCT00750529,2008.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 1
NCT00750529,2008.0,INDUSTRY,collaborator,Janssen-Cilag Farmaceutica Ltda.,Phase 1
NCT00750854,2003.0,INDUSTRY,lead,"ESM Technologies, LLC",Not Applicable
NCT00750867,2008.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 2
NCT00750919,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00751257,2006.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00751257,2006.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00751517,,OTHER,lead,University of Parma,Phase 2
NCT00751803,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT00751855,2008.0,FED,lead,"VISN 3 Mental Illness Research, Education and Clinical Center",Not Applicable
NCT00751881,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00751907,2006.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT00751907,2006.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00752232,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00752232,2008.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00752427,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00752466,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00752466,2003.0,UNKNOWN,collaborator,Jan-Cil Italy,Phase 1
NCT00752466,2003.0,UNKNOWN,collaborator,Jan-Cil Spain,Phase 1
NCT00752466,2003.0,UNKNOWN,collaborator,Jan-Cil UK,Phase 1
NCT00752466,2003.0,UNKNOWN,collaborator,Jan-Cil Switzerland,Phase 1
NCT00752505,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00752778,2008.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 4
NCT00752778,2008.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT00753051,2008.0,OTHER,lead,Khon Kaen University,Not Applicable
NCT00753103,2003.0,OTHER,lead,University Hospital Birmingham NHS Foundation Trust,Phase 2
NCT00753493,2008.0,OTHER,lead,University of Minnesota,Phase 1
NCT00753506,2008.0,OTHER,lead,Sheppard Pratt Health System,Not Applicable
NCT00753506,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00753571,2008.0,OTHER,lead,Peking University,Phase 2
NCT00753623,2008.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00753623,2008.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Not Applicable
NCT00753636,2008.0,OTHER,lead,Northwestern University,Phase 2
NCT00753636,2008.0,OTHER,collaborator,Northwestern Memorial Hospital,Phase 2
NCT00753649,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00753792,2008.0,OTHER,lead,Germans Trias i Pujol Hospital,Phase 4
NCT00753948,2006.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT00754013,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00754013,2008.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00754052,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00754052,2008.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00754221,2008.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00754780,2000.0,OTHER,lead,Mayo Clinic,Phase 2
NCT00754793,2009.0,OTHER,lead,University of Washington,Phase 4
NCT00754793,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT00754793,2009.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00754832,2005.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00754832,2005.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT00754884,2008.0,OTHER,lead,Unidad de Investigacion en Enfermedades Cronico-Degenerativas,Phase 4
NCT00754936,2007.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT00754936,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00754936,2007.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00754962,2006.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00755027,2008.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 4
NCT00755079,2007.0,FED,lead,US Department of Veterans Affairs,Phase 2/Phase 3
NCT00755209,2008.0,OTHER,lead,Khon Kaen University,Phase 3
NCT00755209,2008.0,OTHER,collaborator,Thailand Research Fund,Phase 3
NCT00755209,2008.0,OTHER_GOV,collaborator,Khon Kaen Hospital,Phase 3
NCT00755495,2006.0,INDUSTRY,lead,Takeda,Phase 2
NCT00755508,2005.0,INDUSTRY,lead,Takeda,Phase 2
NCT00755521,2008.0,OTHER,lead,Meir Medical Center,Phase 4
NCT00755716,2006.0,OTHER,lead,UConn Health,Phase 3
NCT00755716,2006.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 3
NCT00755716,2006.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 3
NCT00755807,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00756002,2007.0,INDUSTRY,lead,Takeda,Phase 3
NCT00756041,2005.0,INDUSTRY,lead,Takeda,Phase 2
NCT00756275,2009.0,OTHER,lead,Brown University,Not Applicable
NCT00756275,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00757705,2008.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT00757913,2008.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 4
NCT00757978,2006.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 4
NCT00758030,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00758225,2008.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 2
NCT00758368,2009.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00758368,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00758836,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00758849,2008.0,INDUSTRY,lead,Juvantia Pharma Ltd,Phase 2
NCT00758849,2008.0,INDUSTRY,collaborator,Santhera Pharmaceuticals,Phase 2
NCT00758966,2008.0,INDUSTRY,lead,"Orexigen Therapeutics, Inc",Phase 2
NCT00759317,2001.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00759317,2001.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00759421,2006.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00759460,2007.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00759772,2008.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00759772,2008.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT00759876,2008.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT00759876,2008.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 2
NCT00760695,2008.0,OTHER,lead,Odense University Hospital,Phase 3
NCT00760734,2008.0,OTHER,lead,"Paul G. Harch, M.D.",Phase 1
NCT00760734,2008.0,UNKNOWN,collaborator,Semper Fi Fund,Phase 1
NCT00760734,2008.0,OTHER,collaborator,Marine Corps-Law Enforcement Foundation,Phase 1
NCT00760734,2008.0,UNKNOWN,collaborator,Coalition to Support America's Heroes,Phase 1
NCT00760734,2008.0,UNKNOWN,collaborator,Thirty-eight other contributors,Phase 1
NCT00760955,2006.0,INDUSTRY,lead,Takeda,Phase 2
NCT00761059,2008.0,OTHER,lead,University of Cologne,Not Applicable
NCT00761189,2008.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00761228,2010.0,INDUSTRY,lead,NeuroHealing Pharmaceuticals Inc.,Phase 2
NCT00761228,2010.0,FED,collaborator,FDA Office of Orphan Products Development,Phase 2
NCT00761579,2008.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00761605,2008.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00761670,2008.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00761774,2008.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT00762268,2008.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT00762268,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00762411,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00762554,2008.0,INDIV,lead,"Goodman, Evan, M.D.",Not Applicable
NCT00763178,2007.0,OTHER,lead,Yale University,Early Phase 1
NCT00763178,2007.0,FED,collaborator,VA Connecticut Healthcare System,Early Phase 1
NCT00763438,2007.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT00763750,2008.0,OTHER,lead,howard safran,Phase 2
NCT00763750,2008.0,OTHER,collaborator,Rhode Island Hospital,Phase 2
NCT00763750,2008.0,OTHER,collaborator,MaineHealth,Phase 2
NCT00763932,2003.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00764413,2009.0,OTHER,lead,Sykehuset Innlandet HF,Not Applicable
NCT00765115,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT00765323,2008.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT00765635,2008.0,OTHER,lead,Hospital Clinic of Barcelona,Phase 4
NCT00766038,2008.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00766038,2008.0,OTHER,collaborator,Baylor Health Care System,Phase 2
NCT00766064,2008.0,OTHER,lead,Yale University,Phase 4
NCT00766350,2008.0,OTHER,lead,Universidad de Granada,Phase 4
NCT00766350,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00766350,2008.0,OTHER,collaborator,Hospital Clinico Universitario San Cecilio,Phase 4
NCT00766363,2008.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 1
NCT00766363,2008.0,OTHER,collaborator,Syneos Health,Phase 1
NCT00766545,1992.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT00766675,2008.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT00766896,2009.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT00766896,2009.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00766896,2009.0,INDUSTRY,collaborator,"Accumetrics, Inc.",Phase 4
NCT00766896,2009.0,UNKNOWN,collaborator,Helena Laboratories Point of Care,Phase 4
NCT00766896,2009.0,UNKNOWN,collaborator,Chrono-Log Corporation,Phase 4
NCT00767091,2009.0,OTHER,lead,"University Hospital, Lille",Phase 3
NCT00767546,2009.0,OTHER,lead,Rabin Medical Center,Phase 1
NCT00767624,2008.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT00767624,2008.0,OTHER,collaborator,Duke University,Phase 2/Phase 3
NCT00767624,2008.0,OTHER,collaborator,University of Pittsburgh,Phase 2/Phase 3
NCT00767624,2008.0,OTHER,collaborator,University of Pennsylvania,Phase 2/Phase 3
NCT00767715,2004.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00767754,2007.0,OTHER,lead,Samsung Medical Center,Phase 4
NCT00767767,2008.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT00767767,2008.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00767767,2008.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Not Applicable
NCT00767871,2007.0,OTHER,lead,Samsung Medical Center,Phase 4
NCT00767871,2007.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00768248,2008.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT00768261,2004.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00768261,2004.0,OTHER,collaborator,Northwestern University,Phase 4
NCT00768326,2007.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT00768612,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT00768677,2003.0,OTHER,lead,The Zucker Hillside Hospital,Not Applicable
NCT00768820,2001.0,OTHER,lead,The Chaim Sheba Medical Center,Phase 4
NCT00769041,2008.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT00769041,2008.0,INDUSTRY,collaborator,Covance,Phase 1
NCT00769093,2008.0,OTHER,lead,OHSU Knight Cancer Institute,Phase 1
NCT00769093,2008.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00769093,2008.0,INDUSTRY,collaborator,"AMAG Pharmaceuticals, Inc.",Phase 1
NCT00769860,2008.0,OTHER,lead,"Richard Barohn, MD",Phase 2/Phase 3
NCT00770042,2008.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT00770718,2008.0,OTHER,lead,University of Utah,Phase 1
NCT00770718,2008.0,OTHER,collaborator,Sheila B. Terry Memorial Research Fund,Phase 1
NCT00770744,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT00771043,2008.0,INDUSTRY,lead,Biogen,Phase 4
NCT00771134,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT00771849,2003.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00771862,2008.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT00771862,2008.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Phase 4
NCT00772005,2008.0,INDUSTRY,lead,Cephalon,Phase 2
NCT00772070,2003.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00772187,2007.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT00772525,2008.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00772603,2008.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 3
NCT00772603,2008.0,INDUSTRY,collaborator,Parexel,Phase 3
NCT00772629,2004.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00772928,2003.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00773292,2006.0,OTHER,lead,Imperial College London,Phase 2/Phase 3
NCT00773292,2006.0,OTHER_GOV,collaborator,Medical Research Council,Phase 2/Phase 3
NCT00773292,2006.0,OTHER,collaborator,University Hospital Birmingham,Phase 2/Phase 3
NCT00773292,2006.0,OTHER,collaborator,Imperial College Healthcare NHS Trust,Phase 2/Phase 3
NCT00774306,2009.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT00774306,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT00774462,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00774462,2008.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT00774462,2008.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 2
NCT00774813,2007.0,INDUSTRY,lead,"Kalaco Scientific, Inc.",Phase 2
NCT00775229,2008.0,OTHER,lead,University of Chicago,Phase 2
NCT00776230,2008.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT00777062,2009.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00777062,2009.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 2
NCT00777062,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00777075,2003.0,OTHER,lead,Hannover Medical School,Phase 4
NCT00777075,2003.0,INDUSTRY,collaborator,Pharmacia,Phase 4
NCT00777218,2007.0,OTHER,lead,University of South Alabama,Not Applicable
NCT00777257,2005.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT00777361,2008.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00777569,2005.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT00777569,2005.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00777608,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00777790,2004.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00777985,2007.0,OTHER,lead,"University Hospital, Grenoble",Phase 2
NCT00777985,2007.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT00777985,2007.0,INDUSTRY,collaborator,Actelion,Phase 2
NCT00779324,2009.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,Indiana University,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,University of Washington,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,The Institute for Rehabilitaion and Research Foundation,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,Spaulding Rehabilitation Hospital,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,Ohio State University,Not Applicable
NCT00779324,2009.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00779506,2008.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00780455,2008.0,INDUSTRY,lead,Bayer,Phase 4
NCT00780702,2008.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT00780806,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1/Phase 2
NCT00781326,2008.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00781326,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00781391,2008.0,INDUSTRY,lead,Daiichi Sankyo,Phase 3
NCT00781391,2008.0,OTHER,collaborator,The TIMI Study Group,Phase 3
NCT00781456,2009.0,INDUSTRY,lead,Duramed Research,Phase 2
NCT00781755,,FED,lead,VA Boston Healthcare System,Phase 4
NCT00781794,2009.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00781872,2006.0,OTHER,lead,Hadassah Medical Organization,Phase 1/Phase 2
NCT00782951,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00783159,2008.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Not Applicable
NCT00783159,2008.0,OTHER,collaborator,Klinikum Nürnberg,Not Applicable
NCT00783159,2008.0,UNKNOWN,collaborator,Institute of Biomedicine of Aging,Not Applicable
NCT00783159,2008.0,OTHER,collaborator,University of Erlangen-Nürnberg,Not Applicable
NCT00783159,2008.0,UNKNOWN,collaborator,Institute of Sport Science and Sport,Not Applicable
NCT00783159,2008.0,OTHER,collaborator,Robert Bosch Medical Center,Not Applicable
NCT00783276,2008.0,OTHER,lead,Virginia Commonwealth University,Early Phase 1
NCT00783276,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT00783276,2008.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Early Phase 1
NCT00784238,2008.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00784836,2008.0,INDUSTRY,lead,Biogen,Phase 3
NCT00785603,2008.0,OTHER,lead,University of Southern Denmark,Phase 4
NCT00785759,2008.0,INDUSTRY,lead,GE Healthcare,Phase 2
NCT00785759,2008.0,INDUSTRY,collaborator,i3 Statprobe,Phase 2
NCT00785759,2008.0,INDUSTRY,collaborator,"Medpace, Inc.",Phase 2
NCT00785759,2008.0,OTHER,collaborator,Hvidovre University Hospital,Phase 2
NCT00786253,2005.0,INDUSTRY,lead,Bayer,Phase 2
NCT00786318,2008.0,OTHER,lead,George Washington University,Phase 4
NCT00786318,2008.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00786396,2004.0,OTHER,lead,Yale University,Not Applicable
NCT00786968,2008.0,INDIV,lead,"Patricia I. Dickson, M.D.",Phase 1
NCT00786968,2008.0,OTHER,collaborator,The Ryan Foundation,Phase 1
NCT00787722,2009.0,OTHER,lead,Northwestern University,Phase 1/Phase 2
NCT00788047,2008.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00788047,2008.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00788073,2008.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT00788515,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00788918,2008.0,OTHER,lead,Aarhus University Hospital,Not Applicable
NCT00788944,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 4
NCT00789061,2006.0,OTHER,lead,National Taiwan University Hospital,Phase 2/Phase 3
NCT00789074,2009.0,OTHER,lead,Queen Mary University of London,Phase 3
NCT00789113,2008.0,OTHER,lead,University of Minnesota,Phase 1/Phase 2
NCT00789113,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 1/Phase 2
NCT00789269,2009.0,OTHER,lead,Fudan University,Phase 2
NCT00789386,2008.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT00789568,2008.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1
NCT00789672,2009.0,OTHER,lead,Jaeb Center for Health Research,Phase 2
NCT00789672,2009.0,NIH,collaborator,National Eye Institute (NEI),Phase 2
NCT00789828,2009.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT00790192,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00790569,2008.0,OTHER,lead,Butler Hospital,Not Applicable
NCT00790569,2008.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00790582,2008.0,OTHER,lead,Forbes Norris MDA/ALS Research Center,Phase 2
NCT00790582,2008.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 2
NCT00790738,2008.0,OTHER,lead,Northwell Health,Phase 3
NCT00790738,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT00790751,2008.0,INDUSTRY,lead,VIVUS LLC,Phase 3
NCT00790777,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00790868,2008.0,OTHER,lead,Boston University Charles River Campus,Phase 2
NCT00790868,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00790868,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00790920,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00791024,2008.0,OTHER,lead,Ove Andersen,Phase 1/Phase 2
NCT00791024,2008.0,OTHER,collaborator,University of Copenhagen,Phase 1/Phase 2
NCT00791167,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791193,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791232,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791284,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791349,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791401,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791492,2008.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT00791622,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791648,2009.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT00791713,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00791739,2008.0,OTHER,lead,Universidad de Granada,Phase 4
NCT00791791,2008.0,OTHER,lead,University Hospital Schleswig-Holstein,Not Applicable
NCT00792103,2009.0,INDUSTRY,lead,NuPathe Inc.,Phase 3
NCT00792220,2008.0,OTHER,lead,"University Hospital, Saarland",Not Applicable
NCT00792220,2008.0,OTHER,collaborator,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,Not Applicable
NCT00792220,2008.0,UNKNOWN,collaborator,"Meytec Information Systems GmbH, Werneuchen",Not Applicable
NCT00792220,2008.0,OTHER,collaborator,Else Kröner Fresenius Foundation,Not Applicable
NCT00792220,2008.0,UNKNOWN,collaborator,"Mercedes-Benz AG, Niederlassung Saarbrücken",Not Applicable
NCT00792220,2008.0,UNKNOWN,collaborator,Stadt Homburg,Not Applicable
NCT00792220,2008.0,UNKNOWN,collaborator,Rettungsstiftung Saarland,Not Applicable
NCT00792220,2008.0,UNKNOWN,collaborator,"Rettungsdienst Logistik-Service GmbH, Saarland",Not Applicable
NCT00792584,2008.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT00792584,2008.0,OTHER,collaborator,University of Bern,Not Applicable
NCT00792584,2008.0,OTHER,collaborator,University of Lausanne Hospitals,Not Applicable
NCT00792584,2008.0,UNKNOWN,collaborator,Hospital Lugano,Not Applicable
NCT00792584,2008.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Not Applicable
NCT00792584,2008.0,UNKNOWN,collaborator,Hospital of Neuchâtel,Not Applicable
NCT00792636,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00792662,2008.0,OTHER,lead,University of Nebraska,Phase 4
NCT00792662,2008.0,OTHER,collaborator,Alzheimer's Association,Phase 4
NCT00792766,2008.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT00792766,2008.0,INDUSTRY,collaborator,Novartis,Phase 1/Phase 2
NCT00793052,2008.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00793468,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00793520,2008.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00793780,2008.0,OTHER,lead,Yale University,Not Applicable
NCT00793780,2008.0,UNKNOWN,collaborator,Ethel F. Donaghue Women's Health Investigator Program at Yale,Not Applicable
NCT00794040,2008.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00794196,2008.0,OTHER,lead,Fundació Sant Joan de Déu,Not Applicable
NCT00794196,2008.0,OTHER_GOV,collaborator,Carlos III Health Institute,Not Applicable
NCT00794196,2008.0,OTHER_GOV,collaborator,Catalan Institute of Health,Not Applicable
NCT00794196,2008.0,OTHER,collaborator,University of Barcelona,Not Applicable
NCT00794313,2009.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00794456,2009.0,INDUSTRY,lead,Marjan Industria e Comercio ltda,Phase 3
NCT00795236,2009.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00795236,2009.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00795288,2008.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT00795366,2008.0,OTHER,lead,University of Miami,Not Applicable
NCT00795418,2008.0,INDUSTRY,lead,Novartis,Phase 2
NCT00795587,2008.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT00795730,2009.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00795938,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT00796029,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796081,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796185,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796276,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796432,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796471,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796497,2008.0,OTHER,lead,"Institute of Neuroscience, Florence, Italy",Phase 4
NCT00796601,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00796614,2008.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2/Phase 3
NCT00796640,2003.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00796835,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00797277,2006.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT00797277,2006.0,OTHER,collaborator,Yu-Li Hospital,Phase 3
NCT00797407,2006.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT00797511,2008.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00797667,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00797797,2008.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT00797927,2007.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT00797927,2007.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 4
NCT00798304,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00798395,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00799045,2008.0,OTHER,lead,Laval University,Phase 4
NCT00799045,2008.0,INDUSTRY,collaborator,Sanofi,Phase 4
NCT00799045,2008.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00799201,2007.0,OTHER,lead,CAMC Health System,Phase 4
NCT00799890,2009.0,OTHER,lead,Friedemann Paul,Phase 2/Phase 3
NCT00799890,2009.0,UNKNOWN,collaborator,TAIYO EUROPE,Phase 2/Phase 3
NCT00799942,2009.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 2
NCT00800462,2008.0,OTHER,lead,Toronto Rehabilitation Institute,Phase 4
NCT00800462,2008.0,OTHER,collaborator,Ontario Neurotrauma Foundation,Phase 4
NCT00800501,2008.0,INDUSTRY,lead,Newron Sweden AB,Phase 1/Phase 2
NCT00800501,2008.0,INDUSTRY,collaborator,Medtronic,Phase 1/Phase 2
NCT00800501,2008.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 1/Phase 2
NCT00800514,2009.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT00800527,2007.0,OTHER,lead,Usak State Hospital,Phase 4
NCT00800553,2006.0,OTHER,lead,Duke-NUS Graduate Medical School,Phase 4
NCT00800553,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00800709,2008.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT00800709,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT00802048,2009.0,OTHER,lead,"University Hospital, Bordeaux",Phase 3
NCT00802100,2008.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00802321,2006.0,OTHER,lead,UConn Health,Not Applicable
NCT00802321,2006.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00802321,2006.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT00802412,2009.0,FED,lead,VA Office of Research and Development,Phase 2
NCT00802425,2008.0,INDUSTRY,lead,Auris Medical AG,Phase 2
NCT00802815,2005.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT00802815,2005.0,INDUSTRY,collaborator,Amgen,Early Phase 1
NCT00802867,2004.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT00802919,2008.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 4
NCT00803023,2010.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT00803049,2006.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00803400,2008.0,OTHER,lead,University of Buenos Aires,Phase 4
NCT00803868,2009.0,OTHER,lead,University of South Florida,Phase 2/Phase 3
NCT00803868,2009.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 2/Phase 3
NCT00803868,2009.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT00804271,2008.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT00804895,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT00804973,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00805207,2007.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00805311,2009.0,OTHER,lead,Russian Cardiology Research and Production Center,Phase 4
NCT00805376,2009.0,INDUSTRY,lead,"DNAtrix, Inc.",Phase 1
NCT00805454,2008.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT00805454,2008.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 1
NCT00805493,2008.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT00805818,2010.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT00806195,2008.0,INDUSTRY,lead,Novartis,Phase 3
NCT00806195,2008.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT00806234,2009.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT00806234,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00806234,2009.0,OTHER,collaborator,University of Maryland,Phase 4
NCT00806234,2009.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 4
NCT00806234,2009.0,OTHER,collaborator,The Zucker Hillside Hospital,Phase 4
NCT00806468,2009.0,OTHER,lead,Johannes Gutenberg University Mainz,Phase 4
NCT00806546,2009.0,INDUSTRY,lead,NuPathe Inc.,Phase 3
NCT00806624,2007.0,INDUSTRY,lead,"Daiichi Sankyo Co., Ltd.",Phase 2
NCT00806871,2008.0,OTHER,lead,Region Skane,Phase 2/Phase 3
NCT00807508,2007.0,OTHER,lead,Maastricht University Medical Center,Phase 1/Phase 2
NCT00807742,2008.0,OTHER,lead,Brown University,Not Applicable
NCT00807742,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00807768,2009.0,NETWORK,lead,Gynecologic Oncology Group,Phase 3
NCT00807768,2009.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT00807937,2008.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00807989,2008.0,OTHER,lead,Yonsei University,Phase 4
NCT00808028,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00808119,2008.0,OTHER,lead,RTI International,Phase 1
NCT00808119,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00808249,2008.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00808470,2008.0,OTHER,lead,University of Michigan,Phase 2
NCT00808470,2008.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 2
NCT00808470,2008.0,OTHER,collaborator,University of Florida,Phase 2
NCT00808470,2008.0,OTHER,collaborator,Southern Illinois University,Phase 2
NCT00808470,2008.0,UNKNOWN,collaborator,"Hearing Health Science, Inc.",Phase 2
NCT00809055,2008.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00809055,2008.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT00809146,2009.0,OTHER,lead,Robert Silbergleit,Phase 3
NCT00809146,2009.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT00809146,2009.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT00809146,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT00809289,2008.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00809471,2008.0,INDUSTRY,lead,VIVUS LLC,Phase 3
NCT00809510,2009.0,INDUSTRY,lead,Abbott,Phase 2
NCT00809562,2009.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT00809627,2007.0,FED,lead,"United States Naval Medical Center, Portsmouth",Not Applicable
NCT00809679,2008.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00809835,2007.0,OTHER,lead,Yale University,Phase 2
NCT00809835,2007.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00810147,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT00810667,2008.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT00810888,2010.0,OTHER,lead,University of Cincinnati,Phase 2
NCT00810888,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00811122,2009.0,OTHER,lead,University of Utah,Early Phase 1
NCT00811395,2007.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00811473,2009.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00811681,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT00811746,2008.0,OTHER,lead,Southern California Institute for Research and Education,Not Applicable
NCT00811785,2009.0,INDUSTRY,lead,"Cyprium Therapeutics, Inc.",Phase 3
NCT00811785,2009.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT00811785,2009.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT00811837,2009.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT00811902,2008.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00812006,2009.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00812214,2007.0,INDUSTRY,lead,MedVadis Research Corporation,Phase 4
NCT00812383,2003.0,OTHER,lead,Medstar Health Research Institute,Phase 2
NCT00812565,2009.0,INDUSTRY,lead,Octapharma,Phase 2
NCT00812812,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT00812851,2005.0,OTHER,lead,Cantonal Hospital of St. Gallen,Not Applicable
NCT00812851,2005.0,OTHER,collaborator,ALS Association,Not Applicable
NCT00812994,2003.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT00813436,2008.0,OTHER,lead,Shalvata Mental Health Center,Phase 2
NCT00813436,2008.0,OTHER,collaborator,University of Haifa,Phase 2
NCT00813566,2010.0,OTHER,lead,University of Utah,Phase 1
NCT00813709,2008.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT00813800,2009.0,OTHER,lead,Mark Frye,Not Applicable
NCT00813800,2009.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00813826,2009.0,INDUSTRY,lead,Solace Pharmaceuticals,Phase 2
NCT00813865,2009.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT00813917,2009.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT00813917,2009.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00813969,2011.0,OTHER,lead,The Cleveland Clinic,Phase 1
NCT00813969,2011.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Phase 1
NCT00814086,2009.0,NETWORK,lead,Gynecologic Oncology Group,Phase 1
NCT00814086,2009.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT00814138,2009.0,OTHER,lead,University of Kansas Medical Center,Phase 2
NCT00814268,2008.0,INDUSTRY,lead,Sanofi,Phase 4
NCT00814268,2008.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT00814346,2008.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00814502,2008.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00814502,2008.0,INDUSTRY,collaborator,Sanofi,Not Applicable
NCT00814658,2008.0,INDUSTRY,lead,Janssen-Cilag Farmaceutica Ltda.,Phase 4
NCT00814736,2008.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00814801,2007.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT00814957,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00815737,2009.0,OTHER,lead,Fudan University,Phase 2/Phase 3
NCT00815854,2008.0,OTHER,lead,University of Michigan,Not Applicable
NCT00815854,2008.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00816166,2008.0,INDUSTRY,lead,Codman & Shurtleff,Phase 2/Phase 3
NCT00816231,2006.0,OTHER,lead,H. Lee Moffitt Cancer Center and Research Institute,Not Applicable
NCT00816231,2006.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00816829,2005.0,INDUSTRY,lead,Solvay Pharmaceuticals,Phase 2
NCT00816894,2009.0,OTHER,lead,Herzog Hospital,Phase 2
NCT00816894,2009.0,OTHER,collaborator,Israel Science Foundation,Phase 2
NCT00816907,2009.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT00817011,2006.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT00817323,2009.0,OTHER,lead,University of British Columbia,Phase 3
NCT00817323,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00817336,2009.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT00817375,2003.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT00817609,,OTHER,lead,Fudan University,Phase 2/Phase 3
NCT00817648,2008.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT00817830,2008.0,INDUSTRY,lead,Cristália Produtos Químicos Farmacêuticos Ltda.,Phase 4
NCT00818103,2006.0,OTHER,lead,Sun Yat-sen University,Not Applicable
NCT00818103,2006.0,OTHER,collaborator,"Third Affiliated Hospital, Sun Yat-Sen University",Not Applicable
NCT00818298,2009.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00818298,2009.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00818389,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT00818389,2009.0,OTHER,collaborator,ALS Association,Phase 2/Phase 3
NCT00818389,2009.0,OTHER_GOV,collaborator,ALS Society of Canada,Phase 2/Phase 3
NCT00818389,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT00818389,2009.0,OTHER,collaborator,University of Toronto,Phase 2/Phase 3
NCT00818389,2009.0,OTHER,collaborator,State University of New York - Upstate Medical University,Phase 2/Phase 3
NCT00818389,2009.0,OTHER,collaborator,Columbia University,Phase 2/Phase 3
NCT00818389,2009.0,OTHER,collaborator,University of Kentucky,Phase 2/Phase 3
NCT00819845,2008.0,OTHER,lead,"Catholic University, Italy",Phase 4
NCT00819988,2009.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 3
NCT00819988,2009.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00820105,2008.0,INDUSTRY,lead,Addex Pharma S.A.,Phase 2
NCT00820326,2004.0,OTHER,lead,"University Hospital, Limoges",Phase 3
NCT00821483,2006.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 3
NCT00821600,2008.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00821691,2009.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 2/Phase 3
NCT00822029,2009.0,OTHER,lead,Department of Clinical Research and Innovation,Phase 3
NCT00822224,2009.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Not Applicable
NCT00822224,2009.0,OTHER,collaborator,Fondation de France,Not Applicable
NCT00822302,2006.0,OTHER,lead,"St George's, University of London",Not Applicable
NCT00822679,2007.0,OTHER,lead,University of Arizona,Phase 4
NCT00822679,2007.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00822679,2007.0,FED,collaborator,Southern Arizona VA Health Care System,Phase 4
NCT00822900,2010.0,OTHER,lead,David Wright,Phase 3
NCT00822900,2010.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT00822900,2010.0,NETWORK,collaborator,Neurological Emergencies Treatment Trials Network (NETT),Phase 3
NCT00822913,2008.0,OTHER,lead,University Of Perugia,Phase 4
NCT00822913,2008.0,OTHER,collaborator,University of Roma La Sapienza,Phase 4
NCT00823199,2005.0,OTHER_GOV,lead,Bronx Psychiatric Center,Not Applicable
NCT00823836,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00824512,2008.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00824590,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00824590,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00825045,2008.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00825084,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00825084,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00825097,2008.0,OTHER,lead,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 3
NCT00825097,2008.0,OTHER,collaborator,Fonds National de la Recherche Scientifique,Phase 3
NCT00825500,2009.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT00825539,2009.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1/Phase 2
NCT00825994,2008.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00825994,2008.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00826111,2007.0,OTHER,lead,"Steward St. Elizabeth's Medical Center of Boston, Inc.",Phase 4
NCT00826111,2007.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT00826228,2009.0,OTHER,lead,Thomas J. Schnitzer,Phase 4
NCT00826228,2009.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT00826228,2009.0,OTHER,collaborator,Shirley Ryan AbilityLab,Phase 4
NCT00826241,2009.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 2
NCT00826241,2009.0,NETWORK,collaborator,CERN Foundation - Collaborative Ependymoma Research Network,Phase 2
NCT00826553,2009.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT00826722,2007.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00826787,2005.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00826865,2005.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00827034,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00827034,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00827320,2007.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT00827840,2008.0,OTHER,lead,Chonnam National University Hospital,Phase 4
NCT00827840,2008.0,INDUSTRY,collaborator,"Janssen Korea, Ltd., Korea",Phase 4
NCT00827840,2008.0,OTHER_GOV,collaborator,"Ministry of Health, Republic of Korea",Phase 4
NCT00827892,2009.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT00827918,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00828204,2009.0,INDUSTRY,lead,Biogen,Phase 3
NCT00828659,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT00828958,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00829218,2009.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00829218,2009.0,OTHER,collaborator,University of Arizona,Not Applicable
NCT00829374,2009.0,INDUSTRY,lead,"Medivation, Inc.",Phase 3
NCT00829374,2009.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00829439,2009.0,OTHER,lead,Boston Children's Hospital,Phase 1
NCT00829816,2008.0,INDUSTRY,lead,"Medivation, Inc.",Phase 1
NCT00830128,2009.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00830154,2009.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 2/Phase 3
NCT00830154,2009.0,INDUSTRY,collaborator,Teva Pharmaceuticals USA,Phase 2/Phase 3
NCT00830167,2009.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00830245,2009.0,OTHER,lead,"Clinical Research Center for Solid Tumor, Korea",Phase 2
NCT00830245,2009.0,OTHER,collaborator,Seoul National University Hospital,Phase 2
NCT00830245,2009.0,OTHER,collaborator,Korean Cancer Study Group,Phase 2
NCT00830310,2009.0,OTHER,lead,University Hospitals Cleveland Medical Center,Not Applicable
NCT00830310,2009.0,OTHER,collaborator,Case Western Reserve University,Not Applicable
NCT00830362,2009.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00830362,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00830531,2010.0,INDIV,lead,"Soul, Janet , M.D.",Phase 1
NCT00830531,2010.0,OTHER,collaborator,Citizens United for Research in Epilepsy,Phase 1
NCT00830531,2010.0,UNKNOWN,collaborator,Harvard Catalyst- Harvard Clinical and Translational Science Center,Phase 1
NCT00830531,2010.0,UNKNOWN,collaborator,"Translational Research Program, Boston Children's Hospital",Phase 1
NCT00830531,2010.0,OTHER,collaborator,Charles H. Hood Foundation,Phase 1
NCT00830531,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00830531,2010.0,UNKNOWN,collaborator,"Mooney Family Initiative for Translational Studies in Rare Diseases, Boston Children's Hospital",Phase 1
NCT00830843,2009.0,OTHER,lead,Azienda Ospedaliera San Gerardo di Monza,Phase 4
NCT00830856,2006.0,OTHER,lead,University of Zimbabwe,Not Applicable
NCT00830856,2006.0,OTHER,collaborator,AIDS Care Research in Africa,Not Applicable
NCT00831155,2009.0,OTHER,lead,Duke University,Phase 1
NCT00831311,2004.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00831506,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00831506,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00832000,2008.0,OTHER,lead,"Richard Barohn, MD",Phase 2
NCT00832221,2009.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00832546,2008.0,INDUSTRY,lead,TorreyPines Therapeutics,Phase 1
NCT00832572,2009.0,INDUSTRY,lead,Gilead Sciences,Phase 4
NCT00832884,2010.0,OTHER,lead,Le Bonheur Children's Hospital,Phase 4
NCT00833300,2008.0,OTHER,lead,Richard Hall,Not Applicable
NCT00833300,2008.0,OTHER,collaborator,Dalhousie University,Not Applicable
NCT00833339,2008.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT00833443,2009.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT00833443,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00833547,2006.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00833547,2006.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Not Applicable
NCT00833547,2006.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Not Applicable
NCT00833638,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00833690,2009.0,NETWORK,lead,The Parkinson Study Group,Phase 2
NCT00833690,2009.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00833690,2009.0,OTHER,collaborator,Harvard School of Public Health (HSPH),Phase 2
NCT00833690,2009.0,OTHER,collaborator,University of Rochester,Phase 2
NCT00833690,2009.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT00833755,2008.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00833976,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00833976,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00834652,2007.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT00834652,2007.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00834834,2009.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT00834834,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00835107,2009.0,OTHER,lead,Queen's University,Phase 4
NCT00835107,2009.0,OTHER,collaborator,Providence Health & Services,Phase 4
NCT00835107,2009.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00835107,2009.0,INDUSTRY,collaborator,MDS Pharma Services,Phase 4
NCT00835120,2009.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT00835120,2009.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT00835120,2009.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 4
NCT00835159,2008.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00835159,2008.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT00835224,2010.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00835627,2008.0,OTHER,lead,Rhode Island Hospital,Phase 4
NCT00835627,2008.0,OTHER,collaborator,American Epilepsy Society,Phase 4
NCT00835627,2008.0,OTHER,collaborator,Epilepsy Foundation,Phase 4
NCT00835627,2008.0,OTHER,collaborator,University of Cincinnati,Phase 4
NCT00835627,2008.0,OTHER,collaborator,Stanford University,Phase 4
NCT00835770,2009.0,INDUSTRY,lead,Biogen,Phase 3
NCT00836069,2008.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 3
NCT00836069,2008.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00836693,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00836719,2009.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Phase 1
NCT00836719,2009.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 1
NCT00837044,2009.0,INDUSTRY,lead,Neurological Research Center,Not Applicable
NCT00837044,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00837343,2008.0,OTHER,lead,Guangzhou Mental Hospital,Phase 4
NCT00837343,2008.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Phase 4
NCT00837343,2008.0,OTHER,collaborator,Second Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT00837343,2008.0,UNKNOWN,collaborator,Guangzhou mental Hospital Attached to Guangzhou Civil Affairs Bureau,Phase 4
NCT00837707,2008.0,OTHER_GOV,lead,"Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan",Phase 4
NCT00837707,2008.0,AMBIG,collaborator,Department of Health,Phase 4
NCT00837785,2009.0,INDUSTRY,lead,Biogen,Phase 1
NCT00837824,2002.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT00837824,2002.0,UNKNOWN,collaborator,CRL/Medinet,Phase 2
NCT00838084,2008.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT00838110,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00838110,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 3
NCT00838227,2008.0,OTHER,lead,Manhattan Psychiatric Center,Phase 2
NCT00838435,2009.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT00838669,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00838877,2009.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00838981,2008.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT00838981,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00839358,2008.0,OTHER,lead,Hospital Clinic of Barcelona,Phase 4
NCT00839358,2008.0,OTHER,collaborator,Maternal-Infantil Vall d´Hebron Hospital,Phase 4
NCT00839358,2008.0,OTHER,collaborator,Hospital Universitari de Bellvitge,Phase 4
NCT00839397,2002.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00839449,2004.0,OTHER,lead,Yamaguchi University Hospital,Phase 4
NCT00839449,2004.0,OTHER,collaborator,Nakamura Memorial Hospital,Phase 4
NCT00839449,2004.0,OTHER,collaborator,Iwate Medical University,Phase 4
NCT00839449,2004.0,OTHER,collaborator,Tohoku University,Phase 4
NCT00839449,2004.0,UNKNOWN,collaborator,Ootemachi Hospital,Phase 4
NCT00839657,2009.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT00839657,2009.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT00839852,2009.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00839852,2009.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 2
NCT00840112,2010.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00840112,2010.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT00840112,2010.0,OTHER,collaborator,Oregon State University,Not Applicable
NCT00840671,2005.0,INDUSTRY,lead,Ever Neuro Pharma GmbH,Phase 3
NCT00840671,2005.0,UNKNOWN,collaborator,"JSW-Research Forschungslabor GmbH, Parkring 12, 8074 Grambach",Phase 3
NCT00840801,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00841100,2008.0,OTHER,lead,University of Miami,Phase 2
NCT00841230,2009.0,OTHER,lead,"University Hospital, Antwerp",Phase 4
NCT00841269,2009.0,OTHER,lead,University of Utah,Phase 2
NCT00841269,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00841321,2009.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00841633,2009.0,OTHER,lead,UMC Utrecht,Phase 3
NCT00841633,2009.0,OTHER_GOV,collaborator,Netherlands Organisation for Scientific Research,Phase 3
NCT00841971,2010.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00842309,2008.0,OTHER,lead,Massachusetts General Hospital,Early Phase 1
NCT00842439,2009.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT00842439,2009.0,OTHER_GOV,collaborator,Pennsylvania Department of Health,Not Applicable
NCT00842608,2009.0,OTHER,lead,Indiana University,Not Applicable
NCT00842608,2009.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT00842673,2009.0,INDUSTRY,lead,"Sonexa Therapeutics, Inc.",Phase 2
NCT00842816,2009.0,INDUSTRY,lead,"Sonexa Therapeutics, Inc.",Phase 2
NCT00842985,2008.0,OTHER,lead,Yale University,Early Phase 1
NCT00842985,2008.0,FED,collaborator,VA Office of Research and Development,Early Phase 1
NCT00842985,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT00843011,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00843024,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00843518,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00843687,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT00844194,2009.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT00844597,2009.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT00844597,2009.0,OTHER_GOV,collaborator,British Medical Research Council,Phase 1/Phase 2
NCT00844857,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00844922,2005.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00844974,2007.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00845000,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00845000,2009.0,OTHER,collaborator,Oregon Health and Science University,Phase 1
NCT00845026,2009.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 2
NCT00845338,2007.0,INDUSTRY,lead,Bayer,Phase 2
NCT00845351,2008.0,OTHER,lead,University of Virginia,Phase 1/Phase 2
NCT00845897,2005.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00845897,2005.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT00845923,2009.0,INDUSTRY,lead,Winston Laboratories,Phase 2
NCT00845988,2008.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT00845988,2008.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00846430,2008.0,OTHER,lead,Spectrum Health Hospitals,Phase 2
NCT00846456,2009.0,OTHER,lead,Oslo University Hospital,Phase 1/Phase 2
NCT00846495,2009.0,INDIV,lead,Clinvest,Phase 4
NCT00846495,2009.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Phase 4
NCT00846547,2009.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT00847379,2009.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT00847379,2009.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 2
NCT00847600,2009.0,OTHER,lead,Sha'ar Menashe Mental Health Center,Phase 4
NCT00847600,2009.0,OTHER_GOV,collaborator,Tirat Carmel Mental Health Center,Phase 4
NCT00847678,2006.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00847860,2008.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT00847860,2008.0,INDUSTRY,collaborator,"Zhejiang Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT00847977,2008.0,OTHER,lead,Nantes University Hospital,Phase 3
NCT00848172,2009.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00848432,2002.0,OTHER,lead,Capital Medical University,Phase 4
NCT00848484,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00848497,2007.0,OTHER,lead,Mohit Khera,Early Phase 1
NCT00848549,2008.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT00848692,2008.0,OTHER,lead,Haukeland University Hospital,Phase 2/Phase 3
NCT00848770,2008.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Not Applicable
NCT00849511,2009.0,OTHER,lead,Nordlandssykehuset HF,Phase 2
NCT00849511,2009.0,OTHER,collaborator,University of Tromso,Phase 2
NCT00850005,2009.0,OTHER,lead,University of Calgary,Phase 2
NCT00850278,2008.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT00850278,2008.0,OTHER_GOV,collaborator,"National Cancer Institute, France",Not Applicable
NCT00850421,2004.0,OTHER,lead,HealthPartners Institute,Not Applicable
NCT00850421,2004.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT00850603,2002.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT00851331,,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT00851461,2008.0,OTHER,lead,Ramathibodi Hospital,Phase 4
NCT00851461,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00851513,2008.0,OTHER,lead,Nantes University Hospital,Phase 4
NCT00851942,2008.0,OTHER,lead,Cardiff University,Phase 4
NCT00852046,2009.0,OTHER,lead,Avera McKennan Hospital & University Health Center,Phase 4
NCT00852202,2009.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT00852202,2009.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 2
NCT00852436,2009.0,OTHER,lead,University of Toronto,Phase 2
NCT00852436,2009.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00852631,2009.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00853580,2009.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT00853580,2009.0,OTHER,collaborator,Boston Children's Hospital,Phase 2
NCT00853580,2009.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT00853580,2009.0,OTHER,collaborator,Children's National Research Institute,Phase 2
NCT00853580,2009.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00853580,2009.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT00853580,2009.0,OTHER,collaborator,University of Chicago,Phase 2
NCT00853580,2009.0,OTHER,collaborator,University of Utah,Phase 2
NCT00853580,2009.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT00853580,2009.0,OTHER,collaborator,Sydney Children's Hospitals Network,Phase 2
NCT00853580,2009.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT00853606,2009.0,INDUSTRY,lead,VIVUS LLC,Phase 3
NCT00853866,2009.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 4
NCT00853866,2009.0,OTHER,collaborator,German Research Foundation,Phase 4
NCT00853866,2009.0,OTHER,collaborator,University Hospital Tuebingen,Phase 4
NCT00853879,2006.0,OTHER,lead,Northwell Health,Not Applicable
NCT00854737,2004.0,OTHER,lead,Mclean Hospital,Phase 2
NCT00854737,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT00854750,2009.0,OTHER,lead,Elliot Frohman,Phase 4
NCT00854750,2009.0,INDUSTRY,collaborator,Mallinckrodt,Phase 4
NCT00855270,2009.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT00855270,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00855270,2009.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00855582,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00855738,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT00855868,2009.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT00855868,2009.0,NETWORK,collaborator,American College of Radiology Imaging Network,Phase 2
NCT00855868,2009.0,INDUSTRY,collaborator,General Electric,Phase 2
NCT00855972,2010.0,OTHER,lead,Stanford University,Not Applicable
NCT00856297,2009.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT00856297,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT00856323,2009.0,OTHER,lead,"Friends Research Institute, Inc.",Phase 2
NCT00856323,2009.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT00856583,2002.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00856635,2009.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00856661,2009.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00857233,2004.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00857415,2008.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT00857506,2009.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT00857532,2009.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT00857532,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00857532,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00857584,2009.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00857623,2009.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00857649,2003.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00857818,2009.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT00857831,2008.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00857831,2008.0,OTHER,collaborator,Kessler Foundation,Not Applicable
NCT00858390,2009.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT00858390,2009.0,FED,collaborator,Health Resources and Services Administration (HRSA),Not Applicable
NCT00858390,2009.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT00858390,2009.0,UNKNOWN,collaborator,LifeGift,Not Applicable
NCT00858689,2007.0,OTHER,lead,FRAXA Research Foundation,Not Applicable
NCT00858689,2007.0,OTHER,collaborator,Fragile X Research Foundation of Canada,Not Applicable
NCT00859040,2009.0,OTHER,lead,"Patrick Y. Wen, MD",Phase 2
NCT00859040,2009.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Memorial Sloan Kettering Cancer Center,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Duke University,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Cedars-Sinai Medical Center,Phase 2
NCT00859040,2009.0,OTHER,collaborator,Northwestern University,Phase 2
NCT00859040,2009.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT00859872,2008.0,OTHER,lead,Central South University,Phase 4
NCT00859872,2008.0,UNKNOWN,collaborator,Wuhan Mental Health Institute,Phase 4
NCT00859872,2008.0,OTHER,collaborator,Capital Medical University,Phase 4
NCT00859872,2008.0,OTHER,collaborator,Shanghai Mental Health Center,Phase 4
NCT00859872,2008.0,OTHER,collaborator,Guangzhou Mental Hospital,Phase 4
NCT00859872,2008.0,UNKNOWN,collaborator,Chongqing Mental Hospital,Phase 4
NCT00860028,2008.0,OTHER,lead,Yale University,Phase 2
NCT00860028,2008.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00860275,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00860743,2009.0,FED,lead,VA Office of Research and Development,Early Phase 1
NCT00860808,2009.0,INDUSTRY,lead,Auris Medical AG,Phase 2
NCT00860899,2007.0,OTHER,lead,University Hospital Dubrava,Phase 4
NCT00861068,2002.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00861484,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00861497,2006.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00861497,2006.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 3
NCT00861796,2008.0,INDUSTRY,lead,Cyrenaic Pharmaceuticals,Phase 2
NCT00861939,2004.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00862459,2005.0,INDUSTRY,lead,Bayer,Phase 2
NCT00862888,2007.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00862940,2005.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT00862992,2008.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2
NCT00863057,2009.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00863122,2009.0,OTHER,lead,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,The Children's Tumor Foundation,Early Phase 1
NCT00863122,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,New York University,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,Ohio State University,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,House Research Institute,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,Washington University School of Medicine,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,Weill Medical College of Cornell University,Early Phase 1
NCT00863122,2009.0,OTHER,collaborator,Massachusetts General Hospital,Early Phase 1
NCT00863291,2007.0,OTHER_GOV,lead,Abarbanel Mental Health Center,Phase 3
NCT00863291,2007.0,OTHER_GOV,collaborator,"Ministry of Health, Israel",Phase 3
NCT00863538,,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 2
NCT00864006,2006.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00864045,2007.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT00864825,2009.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT00864851,2008.0,INDUSTRY,lead,Shire,Phase 3
NCT00864864,2007.0,OTHER,lead,Massachusetts General Hospital,Early Phase 1
NCT00864864,2007.0,OTHER,collaborator,Brigham and Women's Hospital,Early Phase 1
NCT00864864,2007.0,OTHER,collaborator,Dana-Farber Cancer Institute,Early Phase 1
NCT00864864,2007.0,INDUSTRY,collaborator,Pfizer,Early Phase 1
NCT00864981,2005.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00865579,2009.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT00865644,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT00865917,2008.0,OTHER,lead,Hannover Medical School,Phase 2
NCT00865917,2008.0,OTHER,collaborator,"Charite University, Berlin, Germany",Phase 2
NCT00866294,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00866463,2008.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT00866502,2009.0,INDUSTRY,lead,Newron Sweden AB,Phase 1/Phase 2
NCT00866502,2009.0,INDUSTRY,collaborator,Medtronic,Phase 1/Phase 2
NCT00866502,2009.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 1/Phase 2
NCT00866554,2009.0,OTHER,lead,CHU de Quebec-Universite Laval,Phase 2
NCT00866554,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00866593,2009.0,OTHER,lead,Shanghai Mental Health Center,Phase 2/Phase 3
NCT00866593,2009.0,INDUSTRY,collaborator,"Jiangsu Nhwa Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT00867360,2005.0,OTHER,lead,Stanford University,Phase 3
NCT00867399,2009.0,INDUSTRY,lead,Abbott,Phase 1
NCT00867828,2009.0,INDUSTRY,lead,NeuroBioPharm Inc.,Phase 4
NCT00867828,2009.0,INDUSTRY,collaborator,Neptune Technologies and Bioressources Inc.,Phase 4
NCT00868166,2009.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT00868166,2009.0,OTHER,collaborator,European Commission,Phase 3
NCT00868452,2009.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00868699,2009.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00868959,2009.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00869037,2009.0,OTHER,lead,University of Manitoba,Phase 4
NCT00869427,2009.0,OTHER,lead,Sunnaas Rehabilitation Hospital,Phase 4
NCT00869427,2009.0,INDUSTRY,collaborator,Dentsply Sirona Implants and Consumables,Phase 4
NCT00869622,2006.0,OTHER,lead,"Boston VA Research Institute, Inc.",Phase 4
NCT00869622,2006.0,INDUSTRY,collaborator,Procter and Gamble,Phase 4
NCT00869622,2006.0,OTHER,collaborator,Alliance for Better Bone Health,Phase 4
NCT00869622,2006.0,FED,collaborator,VA Boston Healthcare System,Phase 4
NCT00869765,2009.0,OTHER,lead,The University of New South Wales,Phase 2
NCT00869791,2008.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT00869804,2009.0,OTHER,lead,University of Nebraska,Not Applicable
NCT00869869,2009.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT00869869,2009.0,OTHER,collaborator,American Academy of Sleep Medicine,Phase 2
NCT00869986,2006.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2/Phase 3
NCT00869986,2006.0,INDUSTRY,collaborator,BioMS Technology Corp.,Phase 2/Phase 3
NCT00870311,1996.0,OTHER,lead,Wayne State University,Phase 4
NCT00870311,1996.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00870454,2009.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT00870519,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00870740,2009.0,INDUSTRY,lead,Biogen,Phase 2
NCT00870740,2009.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT00870779,2007.0,OTHER,lead,David W. Roberts,Phase 1
NCT00870779,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00870974,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00871000,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00871065,2008.0,OTHER,lead,University of Nebraska,Phase 2
NCT00871377,2008.0,NIH,lead,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00871455,2003.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00871455,2003.0,OTHER,collaborator,Kessler Foundation,Not Applicable
NCT00871741,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00872001,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT00872001,2009.0,OTHER,collaborator,Duke Clinical Research Institute,Phase 3
NCT00872027,2009.0,OTHER,lead,University of Minnesota,Phase 4
NCT00872027,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00872144,2010.0,OTHER,lead,Mary Lynch,Phase 3
NCT00872352,2009.0,OTHER_GOV,lead,Wolfson Medical Center,Phase 3
NCT00872911,2009.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 1
NCT00872911,2009.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT00873015,2010.0,INDUSTRY,lead,Hope Pharmaceuticals,Phase 2
NCT00873015,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00873379,2007.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT00873379,2007.0,OTHER,collaborator,"University of Western Ontario, Canada",Phase 3
NCT00873392,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00873535,2008.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT00873535,2008.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT00874549,2007.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 1/Phase 2
NCT00874575,2008.0,INDUSTRY,lead,Metabolic Technologies Inc.,Phase 1
NCT00874575,2008.0,OTHER,collaborator,Iowa State University,Phase 1
NCT00874575,2008.0,OTHER,collaborator,South Dakota State University,Phase 1
NCT00874939,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00875316,2009.0,INDUSTRY,lead,Phytopharm,Phase 1
NCT00875342,2008.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT00875446,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00875654,2010.0,OTHER,lead,"University Hospital, Grenoble",Phase 2
NCT00875654,2010.0,OTHER_GOV,collaborator,Commissariat A L'energie Atomique,Phase 2
NCT00875654,2010.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT00875784,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00875836,2009.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT00875836,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00876200,2009.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT00876304,2009.0,INDUSTRY,lead,"Taisho Pharmaceutical Co., Ltd.",Phase 1
NCT00876863,2008.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 2
NCT00876863,2008.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT00876993,2008.0,OTHER,lead,Johns Hopkins All Children's Hospital,Phase 1
NCT00876993,2008.0,OTHER,collaborator,The V Foundation,Phase 1
NCT00876993,2008.0,UNKNOWN,collaborator,Brain Tumor Alliance,Phase 1
NCT00877604,2008.0,OTHER,lead,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Phase 2
NCT00877604,2008.0,OTHER,collaborator,University of Palermo,Phase 2
NCT00877604,2008.0,OTHER,collaborator,Federico II University,Phase 2
NCT00878306,2008.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT00878306,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00878462,2005.0,INDUSTRY,lead,Organon and Co,Phase 2
NCT00878553,2010.0,INDUSTRY,lead,"Somnus Therapeutics, Inc.",Phase 2
NCT00878553,2010.0,INDUSTRY,collaborator,INC Research Limited,Phase 2
NCT00878631,2004.0,OTHER,lead,Unity Health Toronto,Phase 2/Phase 3
NCT00878631,2004.0,UNKNOWN,collaborator,"Sunnybrook Health Sciences Center, Toronto",Phase 2/Phase 3
NCT00878631,2004.0,INDUSTRY,collaborator,Defence Research and Development Canada,Phase 2/Phase 3
NCT00879021,2009.0,OTHER,lead,Nova Scotia Health Authority,Phase 3
NCT00879372,2009.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT00879372,2009.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 3
NCT00879372,2009.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT00879814,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00879827,2000.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00880048,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00880061,2009.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00880412,2008.0,INDUSTRY,lead,Exonhit,Phase 2
NCT00880620,2009.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT00880685,2009.0,OTHER,lead,University of Chicago,Phase 2
NCT00880919,2008.0,OTHER,lead,University of Minnesota,Phase 3
NCT00880919,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT00880919,2008.0,OTHER,collaborator,University of Iowa,Phase 3
NCT00880919,2008.0,OTHER,collaborator,Mclean Hospital,Phase 3
NCT00880997,2009.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT00880997,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00881205,2009.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT00882518,2009.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT00882934,2006.0,OTHER,lead,Rio de Janeiro State University,Not Applicable
NCT00882999,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00883051,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT00883051,2009.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 2
NCT00883337,2009.0,INDUSTRY,lead,Sanofi,Phase 3
NCT00883740,2009.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00884052,2007.0,OTHER,lead,Richard H. Haas,Phase 1/Phase 2
NCT00884052,2007.0,OTHER,collaborator,Thrasher Research Fund,Phase 1/Phase 2
NCT00884507,2009.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT00884533,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00884650,2005.0,OTHER,lead,"University of Colorado, Denver",Not Applicable
NCT00885157,2009.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT00885443,2009.0,OTHER,lead,University of British Columbia,Not Applicable
NCT00885586,2008.0,OTHER,lead,Dominik Irnich,Phase 4
NCT00885690,2009.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00885690,2009.0,OTHER,collaborator,Aalborg Psychiatric Hospital,Not Applicable
NCT00885690,2009.0,OTHER,collaborator,Malmö University,Not Applicable
NCT00885703,2010.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1/Phase 2
NCT00886106,2009.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT00886665,2008.0,OTHER,lead,Taichung Veterans General Hospital,Phase 3
NCT00886886,2009.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT00886925,2009.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT00886951,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00886977,2009.0,OTHER,lead,Yoshino Neurology Clinic,Phase 2
NCT00887328,2010.0,OTHER,lead,Neuroscience Trials Australia,Phase 3
NCT00887328,2010.0,OTHER_GOV,collaborator,"Commonwealth Scientific and Industrial Research Organisation, Australia",Phase 3
NCT00887328,2010.0,OTHER,collaborator,University of Melbourne,Phase 3
NCT00887328,2010.0,OTHER,collaborator,Melbourne Health,Phase 3
NCT00887328,2010.0,OTHER,collaborator,The Florey Institute of Neuroscience and Mental Health,Phase 3
NCT00887367,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00887562,2009.0,OTHER,lead,Michio Hirano,Phase 2
NCT00887562,2009.0,INDUSTRY,collaborator,Santhera Pharmaceuticals,Phase 2
NCT00887601,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00887679,2009.0,OTHER,lead,Duke University,Phase 3
NCT00887679,2009.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT00887861,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT00888004,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT00888186,2008.0,OTHER,lead,Uppsala University,Phase 4
NCT00888186,2008.0,UNKNOWN,collaborator,Swedish Parkinson's Disease Foundation,Phase 4
NCT00888186,2008.0,OTHER,collaborator,Swedish Society for Medical Research,Phase 4
NCT00888680,,INDUSTRY,lead,Boston Scientific Corporation,Phase 2
NCT00888693,2008.0,INDUSTRY,lead,AbbVie,Phase 1
NCT00888979,2009.0,OTHER,lead,Hartford Hospital,Not Applicable
NCT00888979,2009.0,OTHER,collaborator,UConn Health,Not Applicable
NCT00889512,2009.0,OTHER,lead,University Reproductive Associates,Phase 4
NCT00889512,2009.0,INDUSTRY,collaborator,EMD Serono,Phase 4
NCT00889525,2007.0,OTHER,lead,Seth Gordhandas Sunderdas Medical College,Phase 3
NCT00890422,2007.0,OTHER,lead,Elisabethinen Hospital,Phase 2
NCT00890422,2007.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 2
NCT00890422,2007.0,UNKNOWN,collaborator,ASOKLIF,Phase 2
NCT00890604,2009.0,OTHER,lead,University of Washington,Not Applicable
NCT00890604,2009.0,INDUSTRY,collaborator,"Gaymar Industries, Inc.",Not Applicable
NCT00890643,2009.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00890890,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT00891397,2007.0,OTHER,lead,McMaster University,Not Applicable
NCT00891397,2007.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00891397,2007.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Not Applicable
NCT00891696,2009.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 1
NCT00891696,2009.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 1
NCT00891826,2009.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Not Applicable
NCT00891917,2005.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00892021,2009.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00892047,2009.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT00892125,2006.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00892203,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT00892320,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00892450,2009.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00892489,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00892541,2004.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00892554,2007.0,OTHER,lead,Emory University,Not Applicable
NCT00892554,2007.0,OTHER,collaborator,Atlanta Clinical and Translational Science Institute,Not Applicable
NCT00892840,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00893074,2009.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT00893074,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT00893113,2009.0,OTHER,lead,Chesapeake Urology Research Associates,Phase 3
NCT00893113,2009.0,INDUSTRY,collaborator,Sanofi,Phase 3
NCT00893217,2002.0,INDUSTRY,lead,Bayer,Phase 2
NCT00893256,2004.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Phase 4
NCT00893269,2008.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT00893269,2008.0,FED,collaborator,Food and Drug Administration (FDA),Phase 1
NCT00893269,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00893581,2009.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT00893581,2009.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT00893737,2009.0,INDIV,lead,"Cady, Roger, M.D.",Phase 4
NCT00893737,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00893789,2009.0,INDUSTRY,lead,"Cephalon, Inc.",Phase 3
NCT00893841,2009.0,OTHER,lead,Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.,Phase 2
NCT00893841,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT00893945,2007.0,OTHER,lead,Rockefeller University,Phase 1
NCT00893945,2007.0,OTHER,collaborator,Memorial Sloan Kettering Cancer Center,Phase 1
NCT00894686,2009.0,INDUSTRY,lead,Pfizer,Phase 4
NCT00894803,2009.0,OTHER,lead,University of Cincinnati,Phase 2
NCT00894803,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00894842,2009.0,OTHER_GOV,lead,"National Research Foundation, Singapore",Phase 2/Phase 3
NCT00894842,2009.0,OTHER,collaborator,Duke University,Phase 2/Phase 3
NCT00894842,2009.0,OTHER,collaborator,National University of Singapore,Phase 2/Phase 3
NCT00894842,2009.0,OTHER,collaborator,Singapore Clinical Research Institute,Phase 2/Phase 3
NCT00895011,2009.0,INDUSTRY,lead,VIVUS LLC,Phase 3
NCT00895063,2007.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT00895063,2007.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT00895232,2003.0,INDUSTRY,lead,"American Regent, Inc.",Phase 2
NCT00895752,2009.0,OTHER,lead,Indiana University,Phase 4
NCT00895752,2009.0,OTHER,collaborator,Indiana Clinical and Translational Sciences Institute,Phase 4
NCT00895804,2001.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT00895804,2001.0,OTHER,collaborator,Heffter Research Institute,Phase 1
NCT00895895,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00895960,2009.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT00895960,2009.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 1
NCT00896038,2009.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT00896363,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00896441,2009.0,OTHER,lead,Stanford University,Not Applicable
NCT00896831,2008.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 4
NCT00896987,2006.0,OTHER,lead,Korean Epilepsy Society,Phase 4
NCT00896987,2006.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00897104,1995.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00897221,2009.0,INDUSTRY,lead,ApoPharma,Phase 2
NCT00897949,1995.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00898560,2008.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT00898677,1995.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00898807,2009.0,OTHER,lead,JHSPH Center for Clinical Trials,Phase 3
NCT00898807,2009.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT00898807,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT00899379,1995.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT00900237,2008.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT00900666,2009.0,OTHER,lead,Mary Free Bed Rehabilitation Hospital,Not Applicable
NCT00900666,2009.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT00900900,2009.0,OTHER,lead,Jed E. Rose,Phase 2
NCT00901407,2003.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Not Applicable
NCT00901407,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00901498,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00901940,2009.0,OTHER,lead,University of Oxford,Phase 3
NCT00901940,2009.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT00903877,2009.0,OTHER,lead,Stanford University,Not Applicable
NCT00903981,2009.0,INDUSTRY,lead,JW Pharmaceutical,Phase 3
NCT00904020,2002.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 4
NCT00904202,2003.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 4
NCT00904254,2015.0,OTHER,lead,Technische Universität Dresden,Phase 2
NCT00904254,2015.0,OTHER,collaborator,Klinikum Chemnitz gGmbH,Phase 2
NCT00904306,2008.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1/Phase 2
NCT00904306,2008.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 1/Phase 2
NCT00904436,1999.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT00904683,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00904748,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT00904826,2009.0,OTHER,lead,Mayo Clinic,Phase 1/Phase 2
NCT00904826,2009.0,INDUSTRY,collaborator,"Alexion Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT00905268,2006.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT00905307,2009.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT00905372,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00905931,2010.0,OTHER,lead,University of Cambridge,Phase 2
NCT00905931,2010.0,INDUSTRY,collaborator,Cambridge Theranostics Ltd,Phase 2
NCT00906191,2009.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00906269,2009.0,OTHER,lead,Hartford Hospital,Phase 4
NCT00906516,2009.0,INDUSTRY,lead,Bradmer Pharmaceuticals Inc.,Phase 2
NCT00906763,2009.0,OTHER,lead,Technische Universität Dresden,Not Applicable
NCT00906828,2008.0,OTHER,lead,Uppsala University,Phase 4
NCT00906828,2008.0,UNKNOWN,collaborator,Swedish Parkinson's Disease Foundation,Phase 4
NCT00906828,2008.0,OTHER,collaborator,Swedish Society for Medical Research,Phase 4
NCT00907283,2008.0,OTHER,lead,Ente Ospedaliero Ospedali Galliera,Phase 2
NCT00907595,2009.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00907829,2009.0,FED,lead,US Department of Veterans Affairs,Phase 2
NCT00907972,2009.0,OTHER,lead,Memorial Medical Center,Phase 2
NCT00907972,2009.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00907985,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00908063,2009.0,INDUSTRY,lead,"Tenax Therapeutics, Inc.",Phase 2
NCT00908076,2009.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT00908076,2009.0,OTHER,collaborator,University of South Florida,Phase 4
NCT00908154,2008.0,INDUSTRY,lead,Biogen,Phase 1
NCT00908206,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00908349,2009.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 3
NCT00908453,2009.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT00908700,2009.0,OTHER,lead,Population Health Research Institute,Phase 3
NCT00908700,2009.0,OTHER,collaborator,McMaster University,Phase 3
NCT00908700,2009.0,OTHER,collaborator,Sunnybrook Health Sciences Centre,Phase 3
NCT00908700,2009.0,OTHER,collaborator,London Health Sciences Centre,Phase 3
NCT00908700,2009.0,OTHER,collaborator,Université de Montréal,Phase 3
NCT00908856,2016.0,OTHER,lead,"University of California, Irvine",Phase 1
NCT00908856,2016.0,OTHER,collaborator,"University of California, San Diego",Phase 1
NCT00909012,2009.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Not Applicable
NCT00909012,2009.0,OTHER,collaborator,European Union,Not Applicable
NCT00909545,2009.0,OTHER,lead,Northwestern University,Phase 2
NCT00909545,2009.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT00909545,2009.0,UNKNOWN,collaborator,Northwestern University Dixon Fund,Phase 2
NCT00909545,2009.0,NETWORK,collaborator,The Parkinson Study Group,Phase 2
NCT00909883,2009.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 3
NCT00909883,2009.0,INDUSTRY,collaborator,Merz Pharmaceuticals,Phase 3
NCT00910234,2009.0,OTHER,lead,China Medical University Hospital,Phase 1/Phase 2
NCT00910247,2009.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT00910533,2009.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT00910598,2009.0,OTHER,lead,Amphia Hospital,Phase 4
NCT00910598,2009.0,INDUSTRY,collaborator,Sanofi,Phase 4
NCT00910598,2009.0,UNKNOWN,collaborator,TEVA Pharmachemie,Phase 4
NCT00910689,2001.0,OTHER,lead,Ohio University,Phase 4
NCT00910689,2001.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT00910689,2001.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT00910689,2001.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00911053,1997.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00911248,2009.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT00911248,2009.0,FED,collaborator,United States Department of Defense,Phase 2
NCT00911261,2003.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT00911365,2008.0,OTHER,lead,Yonsei University,Phase 2
NCT00911807,2004.0,INDUSTRY,lead,Ever Neuro Pharma GmbH,Phase 2
NCT00911807,2004.0,INDUSTRY,collaborator,acromion GmbH,Phase 2
NCT00912171,2009.0,OTHER,lead,University of Bologna,Phase 4
NCT00912288,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00912288,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 3
NCT00912457,2007.0,OTHER,lead,Associacao Fundo de Incentivo a Psicofarmcologia,Phase 4
NCT00912457,2007.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4
NCT00912808,2005.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT00912860,2003.0,INDUSTRY,lead,Biogen,Phase 2
NCT00913055,2007.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 2
NCT00913107,2007.0,OTHER,lead,University of Malaya,Phase 2/Phase 3
NCT00913237,1987.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913250,2003.0,INDUSTRY,lead,Biogen,Phase 1
NCT00913419,1988.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913484,2000.0,OTHER,lead,Yale University,Phase 2
NCT00913484,2000.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00913510,2009.0,INDUSTRY,lead,Wellspect HealthCare,Not Applicable
NCT00913588,1996.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913614,2009.0,INDUSTRY,lead,Sanofi,Phase 1
NCT00913666,2002.0,INDUSTRY,lead,Biogen,Phase 4
NCT00913718,1996.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913783,1992.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913809,1987.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913822,1987.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913848,2005.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913874,2005.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00913952,1994.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00914004,,INDUSTRY,lead,Sandoz,Phase 1
NCT00914056,2008.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Not Applicable
NCT00914095,2009.0,OTHER,lead,"University Hospital, Lille",Phase 4
NCT00914134,2009.0,OTHER,lead,University of Helsinki,Phase 4
NCT00914134,2009.0,INDUSTRY,collaborator,Solvay Pharmaceuticals,Phase 4
NCT00914277,2009.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00914290,2009.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT00914602,2009.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 1/Phase 2
NCT00914823,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT00915460,1999.0,INDUSTRY,lead,Biogen,Phase 4
NCT00915473,2009.0,OTHER,lead,Mayo Clinic,Phase 4
NCT00915473,2009.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 4
NCT00915512,2009.0,INDUSTRY,lead,Janssen-Cilag Turkey,Phase 4
NCT00915577,2005.0,INDUSTRY,lead,Biogen,Phase 3
NCT00915928,2009.0,OTHER,lead,Odense University Hospital,Not Applicable
NCT00915928,2009.0,UNKNOWN,collaborator,Alice Brenaa Foundation,Not Applicable
NCT00915928,2009.0,UNKNOWN,collaborator,Hede Nielsen Foundation,Not Applicable
NCT00915928,2009.0,UNKNOWN,collaborator,Overlægerådets legatudvalg,Not Applicable
NCT00915928,2009.0,OTHER,collaborator,University of Southern Denmark,Not Applicable
NCT00915954,2008.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT00916149,2007.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00916149,2007.0,UNKNOWN,collaborator,UCB Young Investigator Research Program,Not Applicable
NCT00916149,2007.0,UNKNOWN,collaborator,National EpiFellows Foundation,Not Applicable
NCT00916149,2007.0,INDUSTRY,collaborator,UCB Pharma,Not Applicable
NCT00916149,2007.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT00916201,2020.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 1
NCT00916201,2020.0,OTHER,collaborator,Max Planck Institute for Metabolism Research,Phase 1
NCT00916253,2010.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT00916396,2005.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00916552,2009.0,OTHER,lead,"Lars Vedel Kessing, professor, MD, DMSc.",Phase 2
NCT00916552,2009.0,OTHER_GOV,collaborator,"The Ministry of Science, Technology and Innovation, Denmark",Phase 2
NCT00916552,2009.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 2
NCT00916552,2009.0,OTHER,collaborator,University of Oxford,Phase 2
NCT00916552,2009.0,OTHER,collaborator,Max-Planck-Institute of Experimental Medicine,Phase 2
NCT00916617,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00916617,2009.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00916942,2009.0,INDUSTRY,lead,NeurogesX,Phase 2
NCT00917059,2009.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT00917059,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00917293,2009.0,INDUSTRY,lead,Medicure,Phase 2
NCT00917397,2009.0,OTHER,lead,Caecilie Buhmann,Phase 4
NCT00917501,2009.0,OTHER,lead,University of Cincinnati,Phase 2
NCT00917501,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT00917501,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT00917839,2009.0,OTHER,lead,Cantonal Hospital of St. Gallen,Phase 2
NCT00918021,2009.0,OTHER,lead,Niuvanniemi Hospital,Phase 4
NCT00918047,2009.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 1
NCT00918177,2009.0,INDUSTRY,lead,Intec Pharma Ltd.,Phase 2
NCT00918307,2009.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Phase 3
NCT00918307,2009.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00918320,2009.0,OTHER,lead,"Gustave Roussy, Cancer Campus, Grand Paris",Phase 2
NCT00918320,2009.0,OTHER,collaborator,St. Anna Kinderkrebsforschung,Phase 2
NCT00918320,2009.0,OTHER,collaborator,Catholic University of the Sacred Heart,Phase 2
NCT00918320,2009.0,OTHER,collaborator,Erasmus Medical Center,Phase 2
NCT00918684,2002.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT00918684,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00918684,2002.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00919555,2008.0,OTHER,lead,"Phoenix Neurological Associates, LTD",Phase 1/Phase 2
NCT00919607,2009.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00920439,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00920647,2009.0,INDUSTRY,lead,Shire,Phase 1/Phase 2
NCT00920699,2010.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00920699,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT00920946,2009.0,INDUSTRY,lead,"Medivation, Inc.",Phase 3
NCT00920946,2009.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00921128,2009.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT00921804,2009.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00923494,2009.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT00924703,2010.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT00925054,2009.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT00925301,2009.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT00925847,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT00926250,2009.0,OTHER,lead,University of Arkansas,Not Applicable
NCT00926393,2009.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00926965,2003.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Phase 4
NCT00926965,2003.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 4
NCT00927550,2009.0,OTHER,lead,Universita di Verona,Phase 4
NCT00927563,2009.0,OTHER,lead,University of Chicago,Phase 2
NCT00927953,2009.0,INDUSTRY,lead,MacroGenics,Phase 2
NCT00927953,2009.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT00928304,2009.0,INDUSTRY,lead,Life Molecular Imaging SA,Phase 2
NCT00928655,2009.0,OTHER,lead,University of Zurich,Phase 4
NCT00928915,2009.0,OTHER,lead,Heidelberg University,Phase 4
NCT00929045,2007.0,OTHER,lead,University of Virginia,Early Phase 1
NCT00929045,2007.0,OTHER,collaborator,Virginia Commonwealth University,Early Phase 1
NCT00929045,2007.0,NIH,collaborator,National Institutes of Health (NIH),Early Phase 1
NCT00929370,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00929955,2009.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 1
NCT00929955,2009.0,UNKNOWN,collaborator,Karwan e Hayat,Phase 1
NCT00929955,2009.0,OTHER,collaborator,Dow University of Health Sciences,Phase 1
NCT00930020,2009.0,OTHER_GOV,lead,Singhealth Foundation,Phase 4
NCT00930020,2009.0,OTHER,collaborator,National Neuroscience Institute,Phase 4
NCT00930020,2009.0,OTHER,collaborator,Changi General Hospital,Phase 4
NCT00930059,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00930293,2009.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT00930293,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00930332,2010.0,NETWORK,lead,NCIC Clinical Trials Group,Phase 1
NCT00930553,2009.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT00930553,2009.0,INDUSTRY,collaborator,Bayer,Phase 3
NCT00931060,2007.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00931073,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00931073,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00931788,2009.0,OTHER,lead,University of Alberta,Phase 4
NCT00931788,2009.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Phase 4
NCT00931788,2009.0,OTHER,collaborator,Alberta Heritage Foundation for Medical Research,Phase 4
NCT00931879,2009.0,OTHER,lead,Eastern Virginia Medical School,Phase 4
NCT00931879,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT00931944,2009.0,INDUSTRY,lead,Knopp Biosciences,Phase 2
NCT00931996,2009.0,OTHER,lead,University of Illinois at Chicago,Not Applicable
NCT00931996,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00932529,2003.0,OTHER,lead,University of Bergen,Phase 4
NCT00933608,2009.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00933608,2009.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT00933686,2007.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT00933686,2007.0,INDUSTRY,collaborator,"Merck, S.L., Spain",Phase 3
NCT00933868,2009.0,INDUSTRY,lead,"Relox Medical, LLC",Phase 2/Phase 3
NCT00934024,2009.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT00934050,2009.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 2
NCT00934466,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00934635,2009.0,INDUSTRY,lead,Janssen-Cilag G.m.b.H,Phase 4
NCT00934687,2009.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT00934687,2009.0,OTHER,collaborator,Hannover Medical School,Phase 2
NCT00934908,2009.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT00934908,2009.0,INDUSTRY,collaborator,Eli Lilly and Company,Not Applicable
NCT00935246,2008.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT00935246,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT00935545,2009.0,OTHER,lead,NYU Langone Health,Phase 1
NCT00935610,2009.0,INDUSTRY,lead,Immunotec Inc.,Phase 2
NCT00936182,2009.0,OTHER,lead,The Center for Autism and Related Disorders,Not Applicable
NCT00936182,2009.0,OTHER,collaborator,The International Child Development Resource Center,Not Applicable
NCT00936182,2009.0,OTHER,collaborator,Thoughtful House,Not Applicable
NCT00936299,2009.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT00936299,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT00937157,2007.0,OTHER,lead,University at Buffalo,Not Applicable
NCT00937157,2007.0,INDUSTRY,collaborator,"Teva Neuroscience, Inc.",Not Applicable
NCT00937235,2009.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00937235,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00937261,2009.0,OTHER,lead,"University of California, Irvine",Phase 4
NCT00937261,2009.0,INDUSTRY,collaborator,"Janssen, LP",Phase 4
NCT00937352,2009.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 3
NCT00937352,2009.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT00937404,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00937521,2009.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT00938184,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00938301,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00938314,2009.0,INDUSTRY,lead,Stem Cell Therapeutics Corp.,Phase 2
NCT00938366,2008.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 1
NCT00938366,2008.0,INDUSTRY,collaborator,"Merck Serono S.A., Geneva",Phase 1
NCT00938379,2009.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 3
NCT00938379,2009.0,OTHER,collaborator,Population Services International,Phase 3
NCT00938431,2009.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT00938912,2009.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT00939094,2009.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00939094,2009.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 2
NCT00939523,2009.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT00939549,2010.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT00939783,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00939783,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 3
NCT00939822,2009.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT00939822,2009.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT00939887,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00939991,2009.0,OTHER,lead,Katy Peters,Phase 1/Phase 2
NCT00939991,2009.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1/Phase 2
NCT00939991,2009.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1/Phase 2
NCT00940589,2009.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 2
NCT00940719,2009.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT00940719,2009.0,OTHER,collaborator,Orbis Medical Centre,Not Applicable
NCT00940914,2009.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT00941265,2007.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT00942097,2009.0,OTHER,lead,Edgard Costa de Vilhena,Phase 2/Phase 3
NCT00942097,2009.0,OTHER,collaborator,Amparo Maternal Maternidade Social,Phase 2/Phase 3
NCT00942214,2009.0,OTHER,lead,"University Hospital, Toulouse",Phase 4
NCT00942253,2006.0,OTHER,lead,University of Thessaly,Phase 2
NCT00942253,2006.0,UNKNOWN,collaborator,Center for Research and Technology Thessaly - CERETETH,Phase 2
NCT00942253,2006.0,OTHER,collaborator,European Social Fund,Phase 2
NCT00942591,2005.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 2
NCT00942591,2005.0,INDUSTRY,collaborator,PharmaPart,Phase 2
NCT00942591,2005.0,UNKNOWN,collaborator,Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel,Phase 2
NCT00943748,2009.0,OTHER,lead,"University Hospital, Lille",Phase 2/Phase 3
NCT00944034,2009.0,INDUSTRY,lead,Novartis Vaccines,Phase 2/Phase 3
NCT00944034,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT00944502,2009.0,INDUSTRY,lead,Bunker Industria Farmaceutica Ltda.,Phase 3
NCT00944554,2008.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT00944554,2008.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00944710,2009.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT00944710,2009.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT00944957,2009.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT00944957,2009.0,OTHER,collaborator,University of Bern,Not Applicable
NCT00944957,2009.0,OTHER,collaborator,University of Lausanne Hospitals,Not Applicable
NCT00944957,2009.0,UNKNOWN,collaborator,Hospital Lugano,Not Applicable
NCT00944957,2009.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Not Applicable
NCT00944957,2009.0,UNKNOWN,collaborator,Hospital of Neuchâtel,Not Applicable
NCT00944957,2009.0,OTHER,collaborator,"University Hospital, Zürich",Not Applicable
NCT00945503,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00945672,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00945919,2009.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT00945919,2009.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Not Applicable
NCT00946348,2009.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 1
NCT00946348,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00946348,2009.0,OTHER,collaborator,Indiana University,Phase 1
NCT00946348,2009.0,OTHER,collaborator,Columbia University,Phase 1
NCT00946348,2009.0,OTHER,collaborator,University of Vermont,Phase 1
NCT00946348,2009.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 1
NCT00946491,1987.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00946751,2004.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00946764,2005.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00946985,2009.0,INDUSTRY,lead,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00946998,2010.0,FED,lead,VA Office of Research and Development,Phase 3
NCT00946998,2010.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 3
NCT00946998,2010.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 3
NCT00947037,2012.0,INDUSTRY,lead,Intec Pharma Ltd.,Phase 2
NCT00947076,2001.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00947154,2009.0,OTHER,lead,Stanford University,Not Applicable
NCT00947297,2009.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT00947323,2006.0,OTHER,lead,Santa Casa de Porto Alegre,Phase 3
NCT00947375,2005.0,OTHER,lead,Central Mental Clinic for Outpatients of Baku City,Phase 4
NCT00947531,2006.0,INDUSTRY,lead,Ever Neuro Pharma GmbH,Phase 4
NCT00947531,2006.0,INDUSTRY,collaborator,acromion GmbH,Phase 4
NCT00947531,2006.0,UNKNOWN,collaborator,Geny Research Corp.,Phase 4
NCT00947544,2010.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 2
NCT00947752,2009.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT00947791,2009.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT00947895,2009.0,OTHER,lead,"Neurologique Foundation, Inc.",Phase 2/Phase 3
NCT00947895,2009.0,INDUSTRY,collaborator,Mallinckrodt,Phase 2/Phase 3
NCT00948155,2009.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00948155,2009.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00948649,2006.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00948649,2006.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00948766,2009.0,INDUSTRY,lead,Novartis,Phase 4
NCT00948909,2009.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT00949026,2009.0,OTHER,lead,Emory University,Phase 1
NCT00949026,2009.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT00949767,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00949806,2009.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT00949806,2009.0,UNKNOWN,collaborator,IPSEN PHARMA S.A.S,Phase 2
NCT00949845,2007.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT00950196,2008.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT00950391,2010.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT00950430,2008.0,OTHER,lead,Mayo Clinic,Phase 4
NCT00950430,2008.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT00950521,2009.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT00951132,2009.0,OTHER,lead,"University Hospital, Akershus",Phase 2
NCT00951132,2009.0,OTHER,collaborator,Oslo University Hospital,Phase 2
NCT00951132,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT00951483,2009.0,OTHER,lead,Loyola University,Phase 4
NCT00951834,2009.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2/Phase 3
NCT00952081,2009.0,OTHER,lead,NYU Langone Health,Phase 4
NCT00952081,2009.0,INDUSTRY,collaborator,The Medicines Company,Phase 4
NCT00952393,2010.0,FED,lead,VA Office of Research and Development,Phase 1
NCT00952432,2009.0,OTHER,lead,Taipei Medical University WanFang Hospital,Not Applicable
NCT00952601,2008.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT00952887,2009.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 1
NCT00954122,2009.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT00954252,2009.0,INDUSTRY,lead,CERESPIR,Phase 1
NCT00954369,2009.0,INDUSTRY,lead,Siemens Molecular Imaging,Early Phase 1
NCT00954538,2009.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00954603,2009.0,OTHER,lead,Chiang Mai University,Phase 3
NCT00954681,2009.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00954681,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00954902,2009.0,OTHER,lead,Penn State University,Not Applicable
NCT00954902,2009.0,OTHER,collaborator,McCormick Science Institute,Not Applicable
NCT00955045,2002.0,INDUSTRY,lead,"Kyowa Kirin, Inc.",Phase 2/Phase 3
NCT00955253,2010.0,OTHER,lead,Imperial College London,Phase 2
NCT00955253,2010.0,OTHER,collaborator,Wellcome Trust,Phase 2
NCT00955318,2009.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 3
NCT00955357,2009.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT00955409,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00955409,2009.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00955500,2003.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT00955526,2009.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 3
NCT00955877,2010.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT00955929,2009.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Not Applicable
NCT00955929,2009.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT00955955,2009.0,OTHER,lead,George I. Papakostas,Phase 4
NCT00955955,2009.0,INDUSTRY,collaborator,"Pamlab, L.L.C.",Phase 4
NCT00956085,2009.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00956319,2009.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT00956410,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT00956943,2009.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT00957047,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT00957203,2009.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 3
NCT00957372,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT00957424,2009.0,OTHER,lead,Roswell Park Cancer Institute,Not Applicable
NCT00957424,2009.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT00957671,2003.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 4
NCT00957671,2003.0,OTHER,collaborator,The Moody Foundation,Phase 4
NCT00957788,2009.0,INDUSTRY,lead,NeuroSystec Corporation,Phase 1
NCT00957801,2009.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 4
NCT00957918,2009.0,INDUSTRY,lead,"Neuraltus Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT00957983,2009.0,OTHER,lead,Danish Headache Center,Phase 1/Phase 2
NCT00957996,2009.0,INDUSTRY,lead,BioCryst Pharmaceuticals,Phase 3
NCT00957996,2009.0,FED,collaborator,Department of Health and Human Services,Phase 3
NCT00958009,2009.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT00958282,2009.0,OTHER,lead,University of Minnesota,Phase 2
NCT00958841,2009.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT00959192,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00959192,2009.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00960219,2009.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT00960245,1994.0,INDUSTRY,lead,Sandoz,Phase 1
NCT00960531,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00960531,2009.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT00960778,2009.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT00960830,2007.0,OTHER,lead,Universidad Nacional de Rosario,Not Applicable
NCT00961194,2009.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT00961441,2009.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT00961532,2010.0,OTHER,lead,Northwestern University,Phase 2
NCT00961532,2010.0,OTHER,collaborator,Northwestern Memorial Hospital,Phase 2
NCT00961766,2009.0,INDUSTRY,lead,Biogen,Phase 1
NCT00961779,2010.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 1
NCT00961922,2010.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Not Applicable
NCT00961922,2010.0,OTHER,collaborator,Dutch Cancer Society,Not Applicable
NCT00961961,2009.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT00961961,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00962429,2009.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00962429,2009.0,OTHER,collaborator,Collins Medical Trust,Phase 2
NCT00962988,2009.0,OTHER,lead,Ottawa Heart Institute Research Corporation,Phase 4
NCT00962988,2009.0,OTHER,collaborator,Heart and Stroke Foundation of Ontario,Phase 4
NCT00963638,2009.0,OTHER,lead,William Beaumont Hospitals,Not Applicable
NCT00963846,2010.0,INDUSTRY,lead,Biomedisyn Corporation,Phase 2
NCT00963846,2010.0,OTHER,collaborator,Yale University,Phase 2
NCT00963898,2007.0,OTHER,lead,Okayama University,Not Applicable
NCT00963924,2009.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT00963924,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT00963937,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00963976,2007.0,OTHER,lead,University of Alberta,Phase 2
NCT00963976,2007.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Phase 2
NCT00963976,2007.0,OTHER,collaborator,Alberta Heritage Foundation for Medical Research,Phase 2
NCT00964028,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT00964041,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT00964041,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT00964288,2009.0,INDUSTRY,lead,Biogen,Phase 1
NCT00964340,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00964639,2009.0,OTHER,lead,University of Aarhus,Phase 4
NCT00964912,2008.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00964990,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00965263,2003.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT00965432,2009.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 1
NCT00965432,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT00965497,2009.0,OTHER,lead,University of South Carolina,Phase 3
NCT00965575,2011.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT00965588,2009.0,INDUSTRY,lead,United Biomedical,Phase 1
NCT00965588,2009.0,OTHER_GOV,collaborator,"Taipei Veterans General Hospital, Taiwan",Phase 1
NCT00965588,2009.0,OTHER,collaborator,National Taiwan University Hospital,Phase 1
NCT00965809,2009.0,OTHER,lead,Hadassah Medical Organization,Phase 4
NCT00965887,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00966030,2008.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT00967005,2009.0,OTHER,lead,University of Chicago,Phase 2
NCT00967005,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00967005,2009.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT00967135,2010.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Not Applicable
NCT00967408,2009.0,OTHER,lead,Azienda Ospedaliero Universitaria Maggiore della Carita,Phase 4
NCT00968097,2008.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00968227,2007.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT00968227,2007.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT00968851,2009.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 2
NCT00968851,2009.0,OTHER,collaborator,Syneos Health,Phase 2
NCT00969059,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00969137,2009.0,OTHER,lead,Yale University,Phase 1
NCT00969137,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT00969878,2010.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT00969878,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00969878,2010.0,NETWORK,collaborator,US Department of Veterans Affairs Cooperative Studies Program,Phase 2
NCT00969878,2010.0,FED,collaborator,VA Maryland Health Care System,Phase 2
NCT00969878,2010.0,OTHER,collaborator,Columbia University,Phase 2
NCT00969878,2010.0,FED,collaborator,VA New York Harbor Healthcare System,Phase 2
NCT00969878,2010.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT00969878,2010.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT00969878,2010.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT00969878,2010.0,INDUSTRY,collaborator,Celtic Pharma Development Services,Phase 2
NCT00970229,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00970281,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT00970307,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00970333,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT00970450,2009.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT00970658,2009.0,INDUSTRY,lead,Hisamitsu Farmaceutica do Brasil Ltda,Phase 3
NCT00970944,2003.0,OTHER,lead,JFK Medical Center,Phase 2/Phase 3
NCT00970944,2003.0,FED,collaborator,U.S. Department of Education,Phase 2/Phase 3
NCT00971295,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT00971685,2009.0,OTHER,lead,Istituto Clinico Humanitas,Phase 2
NCT00971815,2009.0,OTHER,lead,University of Aarhus,Not Applicable
NCT00972062,2009.0,OTHER,lead,"University of North Carolina, Charlotte",Not Applicable
NCT00972062,2009.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Not Applicable
NCT00972075,2006.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 2
NCT00973674,2009.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT00973674,2009.0,OTHER,collaborator,University of Washington,Phase 2
NCT00973674,2009.0,NETWORK,collaborator,Resuscitation Outcomes Consortium,Phase 2
NCT00973739,2009.0,OTHER,lead,NYU Langone Health,Phase 2
NCT00973739,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT00973999,2009.0,OTHER,lead,HCA International Limited,Phase 2
NCT00974155,2009.0,OTHER,lead,K. Lieb,Phase 4
NCT00974155,2009.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT00974246,2009.0,OTHER,lead,Valley Medical Research,Phase 4
NCT00974376,2009.0,OTHER,lead,The Scripps Research Institute,Phase 2
NCT00974376,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00974974,2009.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT00975325,2009.0,INDUSTRY,lead,Walter Ritter GmbH & Co,Phase 4
NCT00975416,2008.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 4
NCT00975481,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00975481,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00975611,2009.0,OTHER,lead,"David C. Henderson, MD",Phase 4
NCT00975611,2009.0,INDUSTRY,collaborator,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT00975689,2009.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT00975689,2009.0,OTHER,collaborator,University of Oxford,Phase 1/Phase 2
NCT00975689,2009.0,OTHER,collaborator,Washington University School of Medicine,Phase 1/Phase 2
NCT00975689,2009.0,NIH,collaborator,National Human Genome Research Institute (NHGRI),Phase 1/Phase 2
NCT00975962,2009.0,OTHER,lead,Aarhus University Hospital,Phase 3
NCT00975962,2009.0,OTHER,collaborator,TRYG Foundation,Phase 3
NCT00975962,2009.0,OTHER,collaborator,Aase and Ejnar Danielsens Foundation,Phase 3
NCT00975962,2009.0,OTHER,collaborator,Danish National Research Foundation,Phase 3
NCT00976118,2006.0,INDUSTRY,lead,AB Science,Phase 2
NCT00976352,2010.0,OTHER,lead,University of Florida,Phase 1/Phase 2
NCT00976352,2010.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT00976534,2009.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00977171,2010.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 2
NCT00977249,2009.0,OTHER,lead,"University Hospital, Gentofte, Copenhagen",Phase 2/Phase 3
NCT00977249,2009.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT00977353,2009.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT00977353,2009.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT00977522,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00977665,2009.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00977665,2009.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT00977795,2009.0,OTHER,lead,NorthShore University HealthSystem,Phase 1/Phase 2
NCT00978341,2007.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Not Applicable
NCT00978822,2009.0,OTHER,lead,Henry Ford Health System,Phase 2
NCT00978822,2009.0,INDUSTRY,collaborator,The Medicines Company,Phase 2
NCT00979004,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT00979316,2009.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT00979589,2009.0,OTHER,lead,Beijing Tiantan Hospital,Phase 3
NCT00979589,2009.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT00980044,2009.0,OTHER,lead,Michelle Lofwall,Phase 2/Phase 3
NCT00980044,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT00980694,2009.0,OTHER,lead,University of Rochester,Phase 1
NCT00980694,2009.0,INDUSTRY,collaborator,Kaneka Corporation,Phase 1
NCT00980785,2009.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT00981084,2009.0,OTHER,lead,"University of Missouri, Kansas City",Phase 2/Phase 3
NCT00981084,2009.0,OTHER,collaborator,University of Kansas,Phase 2/Phase 3
NCT00981175,2003.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00981227,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT00981383,2010.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT00981383,2010.0,OTHER,collaborator,Toronto Rehabilitation Institute,Phase 3
NCT00981526,2009.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT00981526,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT00981630,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00982020,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT00982137,2004.0,INDUSTRY,lead,Sanofi,Phase 2
NCT00982150,2009.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT00982202,2002.0,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT00982202,2002.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 2
NCT00982787,2009.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT00982787,2009.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT00982787,2009.0,OTHER,collaborator,Oregon Clinical and Translational Research Institute,Phase 2
NCT00982787,2009.0,INDUSTRY,collaborator,Oregon's Wild Harvest,Phase 2
NCT00982982,2009.0,OTHER,lead,Yale University,Early Phase 1
NCT00983320,2008.0,OTHER,lead,Université de Sherbrooke,Phase 4
NCT00983320,2008.0,OTHER,collaborator,Université de Montréal,Phase 4
NCT00983437,2009.0,INDUSTRY,lead,"Cephalon, Inc.",Phase 3
NCT00983736,2009.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 3
NCT00983983,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT00983983,2009.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 2
NCT00984984,2008.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT00985517,2009.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1/Phase 2
NCT00986115,2010.0,OTHER,lead,"University of California, Davis",Not Applicable
NCT00986115,2010.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT00986128,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00986167,2009.0,OTHER_GOV,lead,Bayside Health,Phase 4
NCT00986167,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT00986245,2009.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT00986258,2009.0,INDUSTRY,lead,Grünenthal GmbH,Phase 3
NCT00986336,2001.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT00986414,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT00986505,2005.0,OTHER,lead,Federal University of São Paulo,Not Applicable
NCT00986531,2009.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT00986596,2006.0,OTHER,lead,Tufts University,Not Applicable
NCT00986596,2006.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT00986596,2006.0,OTHER,collaborator,Boston Medical Center,Not Applicable
NCT00986895,2006.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 1
NCT00986895,2006.0,OTHER,collaborator,"Ucyclyd Pharma, Inc.",Phase 1
NCT00986960,2009.0,OTHER,lead,University at Buffalo,Phase 2
NCT00986973,2010.0,OTHER,lead,Children's Hospital of Philadelphia,Not Applicable
NCT00987090,2009.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT00987116,2009.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT00987454,2010.0,OTHER,lead,Australian and New Zealand Intensive Care Research Centre,Phase 3
NCT00987454,2010.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 3
NCT00987454,2010.0,NETWORK,collaborator,Australian and New Zealand Intensive Care Society Clinical Trials Group,Phase 3
NCT00987454,2010.0,OTHER,collaborator,Monash University,Phase 3
NCT00987558,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT00988429,2008.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT00988429,2008.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 3
NCT00988481,2009.0,OTHER,lead,"Neuropsychiatric Research Institute, Fargo, North Dakota",Phase 4
NCT00988598,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00988624,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00988624,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00988728,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT00988949,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00988962,2009.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT00988962,2009.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT00988988,2010.0,OTHER,lead,University of Nebraska,Phase 4
NCT00988988,2010.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT00989053,2010.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT00989209,2005.0,OTHER,lead,University of Sao Paulo General Hospital,Not Applicable
NCT00989625,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT00989716,2001.0,OTHER,lead,University of Nottingham,Phase 3
NCT00989742,2009.0,OTHER,lead,University of Nottingham,Phase 4
NCT00989937,2009.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT00990028,2009.0,OTHER,lead,Universidad Autonoma de San Luis Potosí,Phase 1/Phase 2
NCT00990028,2009.0,OTHER,collaborator,"Hospital Central ""Dr. Ignacio Morones Prieto""",Phase 1/Phase 2
NCT00990028,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 1/Phase 2
NCT00990067,2009.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT00990106,2009.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT00990106,2009.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT00990106,2009.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT00990106,2009.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT00990509,2009.0,OTHER,lead,Georgetown University,Phase 2
NCT00990509,2009.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 2
NCT00990613,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT00990613,2009.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 1
NCT00990691,2009.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Phase 2
NCT00990834,2009.0,OTHER,lead,Scripps Health,Not Applicable
NCT00991029,2010.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT00991029,2010.0,NETWORK,collaborator,Neurological Emergencies Treatment Trials Network (NETT),Phase 3
NCT00991029,2010.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT00991029,2010.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 3
NCT00991068,2009.0,INDUSTRY,lead,ZARS Pharma Inc.,Phase 2
NCT00991172,2009.0,INDUSTRY,lead,Regeneron Pharmaceuticals,Phase 2
NCT00991172,2009.0,INDUSTRY,collaborator,Sanofi,Phase 2
NCT00991276,2009.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT00991419,2010.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT00991757,2007.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT00991809,2009.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT00991809,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00991848,2005.0,OTHER,lead,Federal University of São Paulo,Phase 1
NCT00992160,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00992407,2007.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT00992459,2009.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT00992771,2009.0,OTHER,lead,University of South Florida,Phase 2
NCT00992771,2009.0,OTHER,collaborator,National Ataxia Foundation,Phase 2
NCT00992771,2009.0,UNKNOWN,collaborator,Bob Allison Ataxia Research Center (BAARC),Phase 2
NCT00992771,2009.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT00993018,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT00993057,2009.0,OTHER,lead,Northwestern University,Early Phase 1
NCT00993265,2009.0,OTHER,lead,Yale University,Phase 2
NCT00993265,2009.0,OTHER,collaborator,Trichotillomania Learning Center,Phase 2
NCT00993356,2004.0,OTHER,lead,Shanghai Jiao Tong University School of Medicine,Phase 2
NCT00993356,2004.0,OTHER,collaborator,"First Affiliated Hospital, Sun Yat-Sen University",Phase 2
NCT00994214,2009.0,INDUSTRY,lead,Ipsen,Phase 2
NCT00994695,2005.0,OTHER,lead,"Armauer Hansen Research Institute, Ethiopia",Phase 2
NCT00994695,2005.0,OTHER,collaborator,World Health Organization,Phase 2
NCT00994695,2005.0,OTHER,collaborator,Addis Ababa University,Phase 2
NCT00994695,2005.0,UNKNOWN,collaborator,"LSHTM,UK",Phase 2
NCT00994786,2009.0,OTHER,lead,McMaster University,Phase 4
NCT00994786,2009.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT00994786,2009.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Phase 4
NCT00995683,2009.0,OTHER,lead,Institut d'Anesthesiologie des Alpes Maritimes,Phase 2/Phase 3
NCT00995683,2009.0,OTHER,collaborator,Université de Nice Sophia Antipolis,Phase 2/Phase 3
NCT00995683,2009.0,OTHER,collaborator,Medical University of Grenoble,Phase 2/Phase 3
NCT00996034,2009.0,OTHER,lead,Yale University,Phase 2
NCT00996034,2009.0,INDUSTRY,collaborator,Nabi Biopharmaceuticals,Phase 2
NCT00996034,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT00996164,2009.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00996242,2007.0,OTHER,lead,Göteborg University,Not Applicable
NCT00996242,2007.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT00996372,2009.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT00996918,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00996944,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT00996983,2009.0,OTHER,lead,"National Cancer Institute, Naples",Phase 2
NCT00997087,2009.0,OTHER,lead,Parkway Medical Center,Phase 2
NCT00997412,2009.0,INDUSTRY,lead,"Qualitix Clinical Research Co., Ltd.",Not Applicable
NCT00997438,2010.0,FED,lead,Portland VA Medical Center,Phase 1
NCT00997438,2010.0,OTHER,collaborator,Oregon Health and Science University,Phase 1
NCT00997490,2001.0,INDUSTRY,lead,Pascoe Pharmazeutische Praeparate GmbH,Phase 3
NCT00997672,2009.0,OTHER,lead,Federico II University,Phase 2
NCT00998608,2007.0,OTHER_GOV,lead,Kaohsiung Kai-Suan Psychiatric Hospital,Phase 4
NCT00998764,2009.0,INDUSTRY,lead,Pfizer,Phase 3
NCT00998972,2006.0,OTHER,lead,Institut d'Anesthesiologie des Alpes Maritimes,Phase 3
NCT00999167,2009.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 2
NCT00999180,2009.0,OTHER,lead,Federal University of Bahia,Phase 3
NCT00999219,2006.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT00999505,2010.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT00999544,2009.0,OTHER,lead,Sharon Walsh,Not Applicable
NCT00999544,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT00999544,2009.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Not Applicable
NCT01000064,2009.0,OTHER,lead,Vanderbilt University,Phase 3
NCT01000064,2009.0,INDUSTRY,collaborator,Shire,Phase 3
NCT01000350,2009.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT01000402,2008.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 4
NCT01000402,2008.0,OTHER,collaborator,Hospital de Clinicas de Porto Alegre,Phase 4
NCT01000493,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01000857,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01000870,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Early Phase 1
NCT01001520,2010.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01001520,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01001637,2009.0,OTHER,lead,Jaslok Hospital and Research Centre,Not Applicable
NCT01001637,2009.0,UNKNOWN,collaborator,Pharmanza Herbal Pvt Ltd,Not Applicable
NCT01001637,2009.0,INDUSTRY,collaborator,Verdure Sciences,Not Applicable
NCT01001637,2009.0,OTHER,collaborator,"University of California, Los Angeles",Not Applicable
NCT01001702,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01001988,2009.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01002079,2010.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01002079,2010.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT01002300,2009.0,OTHER,lead,Lawson Health Research Institute,Not Applicable
NCT01002300,2009.0,OTHER,collaborator,The Alzheimer Society London and Middlesex,Not Applicable
NCT01002820,2009.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT01003379,2009.0,INDUSTRY,lead,Targacept Inc.,Phase 2
NCT01003639,2010.0,OTHER,lead,St. Luke's-Roosevelt Hospital Center,Phase 2/Phase 3
NCT01003639,2010.0,NIH,collaborator,National Eye Institute (NEI),Phase 2/Phase 3
NCT01003639,2010.0,OTHER,collaborator,University of Rochester,Phase 2/Phase 3
NCT01003639,2010.0,OTHER,collaborator,University of Iowa,Phase 2/Phase 3
NCT01003639,2010.0,OTHER,collaborator,"University of California, Davis",Phase 2/Phase 3
NCT01004016,,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 2
NCT01004042,2009.0,OTHER,lead,Brazilan Center for Studies in Dermatology,Phase 4
NCT01004042,2009.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT01004354,2009.0,OTHER,lead,"University of Massachusetts, Worcester",Not Applicable
NCT01005004,2009.0,INDUSTRY,lead,"StemCells, Inc.",Phase 1
NCT01005810,2009.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01005810,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01005862,2010.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01006122,2009.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01006265,2009.0,INDUSTRY,lead,Actelion,Phase 2
NCT01006460,2009.0,OTHER,lead,Frederiksberg University Hospital,Not Applicable
NCT01006551,2002.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT01006551,2002.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01006551,2002.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01006694,2010.0,OTHER,lead,Vietnam Veterans of America Foundation,Not Applicable
NCT01006694,2010.0,OTHER,collaborator,RAND,Not Applicable
NCT01006694,2010.0,OTHER,collaborator,Vanderbilt University,Not Applicable
NCT01006707,2010.0,OTHER,lead,Stanford University,Not Applicable
NCT01006811,2009.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 2/Phase 3
NCT01007071,2009.0,OTHER,lead,Stanford University,Phase 3
NCT01007071,2009.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 3
NCT01007630,2009.0,OTHER,lead,The Parkinson's Institute,Phase 4
NCT01007630,2009.0,INDUSTRY,collaborator,"Teva Neuroscience, Inc.",Phase 4
NCT01007747,2008.0,OTHER,lead,Pennington Biomedical Research Center,Not Applicable
NCT01007773,2010.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT01007773,2010.0,INDUSTRY,collaborator,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 2
NCT01007864,2010.0,INDUSTRY,lead,Desitin Arzneimittel GmbH,Phase 3
NCT01007864,2010.0,INDUSTRY,collaborator,FGK Clinical Research GmbH,Phase 3
NCT01008098,2008.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT01008293,2009.0,INDUSTRY,lead,CD Pharma India Pvt. Ltd.,Phase 2/Phase 3
NCT01008293,2009.0,OTHER_GOV,collaborator,Indian Council of Medical Research,Phase 2/Phase 3
NCT01008293,2009.0,OTHER,collaborator,"All India Institute of Medical Sciences, New Delhi",Phase 2/Phase 3
NCT01008553,2008.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT01009047,2009.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT01009060,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01009255,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01009294,2010.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT01009294,2010.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 2
NCT01010204,2010.0,OTHER,lead,K.N. Roy Chengappa,Phase 4
NCT01010204,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01010204,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01010477,2009.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 4
NCT01010477,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01010711,2009.0,INDUSTRY,lead,Complen Health GmbH,Not Applicable
NCT01010776,2008.0,INDUSTRY,lead,Janssen-Cilag Farmaceutica Ltda.,Phase 4
NCT01010789,2009.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT01010789,2009.0,INDUSTRY,collaborator,Cephalon,Phase 3
NCT01010789,2009.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT01010802,2008.0,OTHER,lead,"International Center for Neurological Restoration, Cuba",Phase 1
NCT01010802,2008.0,INDUSTRY,collaborator,"Centro de Immunologia Molecular, Cuba",Phase 1
NCT01010932,2009.0,INDUSTRY,lead,Guerbet,Phase 3
NCT01011374,2009.0,OTHER,lead,"Retina Associates of Cleveland, Inc",Phase 1
NCT01011374,2009.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1
NCT01011829,2009.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01011829,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01011907,2010.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT01011907,2010.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT01012167,2010.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT01012167,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01012674,2009.0,INDUSTRY,lead,Guerbet,Phase 3
NCT01012830,2009.0,FED,lead,VA Nebraska Western Iowa Health Care System,Phase 4
NCT01012830,2009.0,OTHER,collaborator,American Legion of Iowa Foundation,Phase 4
NCT01013480,2009.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT01013532,2009.0,OTHER,lead,Asan Medical Center,Phase 4
NCT01013532,2009.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT01013870,2010.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT01013870,2010.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT01014221,2007.0,OTHER,lead,Kuang Tien General Hospital,Not Applicable
NCT01014403,2009.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1
NCT01014585,2009.0,INDUSTRY,lead,Forest Laboratories,Phase 4
NCT01014585,2009.0,INDUSTRY,collaborator,"Cypress Bioscience, Inc.",Phase 4
NCT01014767,2009.0,OTHER,lead,Tufts Medical Center,Phase 3
NCT01014858,2013.0,OTHER,lead,Newcastle-upon-Tyne Hospitals NHS Trust,Phase 3
NCT01014858,2013.0,OTHER,collaborator,University of Newcastle Upon-Tyne,Phase 3
NCT01014858,2013.0,OTHER,collaborator,University of Cambridge,Phase 3
NCT01014858,2013.0,OTHER,collaborator,University of Manchester,Phase 3
NCT01014858,2013.0,OTHER,collaborator,University of Birmingham,Phase 3
NCT01014858,2013.0,OTHER,collaborator,Bangor University,Phase 3
NCT01014858,2013.0,OTHER,collaborator,London School of Economics and Political Science,Phase 3
NCT01014858,2013.0,OTHER,collaborator,"University College, London",Phase 3
NCT01014858,2013.0,NETWORK,collaborator,Lancashire Care NHS Foundation Trust,Phase 3
NCT01014858,2013.0,OTHER,collaborator,Newcastle University,Phase 3
NCT01014858,2013.0,OTHER,collaborator,King's College London,Phase 3
NCT01015001,2008.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT01015170,2009.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT01015170,2009.0,OTHER_GOV,collaborator,Ontario Ministry of Health and Long Term Care,Phase 4
NCT01015430,2009.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01015482,2009.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT01015534,2006.0,OTHER,lead,Instituto Nacional de Cancerologia de Mexico,Phase 2
NCT01015586,2010.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT01015586,2010.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT01016119,2009.0,INDUSTRY,lead,Catalysis SL,Phase 3
NCT01016366,2009.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT01016470,2009.0,INDUSTRY,lead,Catalysis SL,Phase 3
NCT01016522,2009.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT01016522,2009.0,INDUSTRY,collaborator,Nutricia North America,Phase 3
NCT01016522,2009.0,OTHER,collaborator,Cornell University,Phase 3
NCT01016678,2010.0,OTHER,lead,Premiere Research Institute,Phase 2/Phase 3
NCT01016678,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT01016834,2009.0,INDUSTRY,lead,"Zogenix, Inc.",Phase 4
NCT01016834,2009.0,INDUSTRY,collaborator,"Synteract, Inc.",Phase 4
NCT01017159,2010.0,OTHER,lead,University of Aarhus,Phase 2
NCT01017159,2010.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 2
NCT01017159,2010.0,OTHER,collaborator,"GCP-unit at Aarhus University Hospital, Aarhus, Denmark",Phase 2
NCT01018056,2009.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT01018056,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01018394,2009.0,OTHER,lead,Mayo Clinic,Phase 2/Phase 3
NCT01018394,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2/Phase 3
NCT01018485,2008.0,OTHER,lead,Melbourne Health,Phase 3
NCT01018485,2008.0,OTHER,collaborator,Eastern Health,Phase 3
NCT01018732,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT01018732,2010.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT01018875,2009.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01018992,2009.0,OTHER,lead,Emory University,Phase 2
NCT01018992,2009.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01019421,2009.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT01019473,2009.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01020019,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT01020019,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01020331,2005.0,OTHER,lead,"Phoenix Neurological Associates, LTD",Phase 2
NCT01020331,2005.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2
NCT01020474,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT01020526,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT01020838,2009.0,INDUSTRY,lead,Life Molecular Imaging SA,Phase 3
NCT01021215,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT01021293,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01021553,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01021696,2009.0,OTHER,lead,University of Bergen,Phase 2/Phase 3
NCT01021696,2009.0,OTHER,collaborator,The Research Council of Norway,Phase 2/Phase 3
NCT01023282,2009.0,INDUSTRY,lead,NeuroSearch A/S,Phase 1
NCT01023425,2008.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01023425,2008.0,INDUSTRY,collaborator,Eisai Korea Inc.,Not Applicable
NCT01023659,2010.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT01023659,2010.0,OTHER_GOV,collaborator,Ontario Ministry of Health and Long Term Care,Phase 4
NCT01023685,2009.0,INDUSTRY,lead,Novartis,Phase 2
NCT01023867,2007.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01023867,2007.0,INDUSTRY,collaborator,Eisai Korea Inc.,Not Applicable
NCT01024192,2009.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01024491,2008.0,INDUSTRY,lead,MorePharma Corporation,Phase 3
NCT01024660,2009.0,INDUSTRY,lead,AstraZeneca,Early Phase 1
NCT01024777,2010.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT01024972,2009.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 1/Phase 2
NCT01024972,2009.0,OTHER,collaborator,American Heart Association,Phase 1/Phase 2
NCT01025219,2009.0,OTHER,lead,University Hospital Center of Martinique,Not Applicable
NCT01025245,2009.0,OTHER,lead,Yonsei University,Phase 4
NCT01025271,2010.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT01025271,2010.0,INDUSTRY,collaborator,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Not Applicable
NCT01025466,2008.0,OTHER,lead,Inha University Hospital,Phase 4
NCT01026311,2009.0,OTHER,lead,"Richard Deichmann, MD",Phase 4
NCT01026428,2009.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 1/Phase 2
NCT01026818,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT01027754,2009.0,OTHER,lead,Albert Einstein College of Medicine,Phase 4
NCT01027754,2009.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 4
NCT01027806,2010.0,OTHER,lead,University of Chicago,Phase 4
NCT01027806,2010.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT01027884,2009.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT01028053,2009.0,INDUSTRY,lead,GE Healthcare,Phase 3
NCT01028053,2009.0,INDUSTRY,collaborator,"Medpace, Inc.",Phase 3
NCT01028053,2009.0,INDUSTRY,collaborator,i3 Statprobe,Phase 3
NCT01028053,2009.0,INDUSTRY,collaborator,i3 Research,Phase 3
NCT01028053,2009.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 3
NCT01028209,2009.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT01028339,2008.0,OTHER,lead,Direction Centrale du Service de Santé des Armées,Phase 3
NCT01028508,2010.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01028508,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01028534,2010.0,OTHER,lead,"Kyoto University, Graduate School of Medicine",Not Applicable
NCT01028586,2009.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT01028677,2009.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT01028794,2008.0,OTHER,lead,"National Cerebral and Cardiovascular Center, Japan",Phase 1/Phase 2
NCT01028794,2008.0,OTHER,collaborator,"Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan",Phase 1/Phase 2
NCT01028820,2009.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT01028820,2009.0,OTHER,collaborator,Duke University,Phase 4
NCT01028820,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01028911,2009.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01029132,2007.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01029132,2007.0,INDUSTRY,collaborator,"Janssen Korea, Ltd., Korea",Not Applicable
NCT01029275,2005.0,OTHER,lead,"University Hospital, Rouen",Not Applicable
NCT01029769,2009.0,OTHER,lead,Technical University of Munich,Not Applicable
NCT01030692,2009.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01030692,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01030939,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01031199,2009.0,INDUSTRY,lead,Bayer,Phase 1
NCT01031303,2009.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01031537,2009.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT01031537,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01031901,2009.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT01031901,2009.0,OTHER,collaborator,Society for Pediatric Dermatology,Phase 1
NCT01031927,2007.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01031927,2007.0,OTHER_GOV,collaborator,Taipei City Hospital,Phase 2
NCT01031979,2010.0,FED,lead,VA Office of Research and Development,Phase 2
NCT01032018,2010.0,OTHER,lead,Columbia University,Phase 1/Phase 2
NCT01032018,2010.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT01032018,2010.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 1/Phase 2
NCT01032018,2010.0,OTHER,collaborator,Emory University,Phase 1/Phase 2
NCT01032018,2010.0,OTHER,collaborator,Yale University,Phase 1/Phase 2
NCT01032018,2010.0,OTHER,collaborator,Washington University School of Medicine,Phase 1/Phase 2
NCT01032018,2010.0,OTHER,collaborator,University of Pennsylvania,Phase 1/Phase 2
NCT01032083,2011.0,OTHER,lead,Imperial College London,Phase 4
NCT01032083,2011.0,OTHER,collaborator,University of Manchester,Phase 4
NCT01032083,2011.0,OTHER,collaborator,University of Southampton,Phase 4
NCT01032083,2011.0,OTHER,collaborator,King's College London,Phase 4
NCT01032083,2011.0,OTHER,collaborator,University of Oxford,Phase 4
NCT01032083,2011.0,OTHER,collaborator,"University College, London",Phase 4
NCT01032083,2011.0,OTHER,collaborator,University of Bristol,Phase 4
NCT01032135,2008.0,OTHER,lead,University of Pennsylvania,Phase 2/Phase 3
NCT01032200,2010.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT01032200,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01032434,2009.0,OTHER,lead,Guang Dong Provincial Mental Health Institute,Not Applicable
NCT01032993,2009.0,OTHER,lead,Catherine Buettner,Phase 2/Phase 3
NCT01032993,2009.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2/Phase 3
NCT01033149,2009.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT01033149,2009.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT01033565,2010.0,OTHER,lead,University of Nebraska,Phase 4
NCT01034020,2006.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01035138,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01035164,2007.0,INDUSTRY,lead,Bayer,Phase 1
NCT01035281,2008.0,OTHER,lead,University of Calgary,Phase 3
NCT01035671,2009.0,INDUSTRY,lead,Penwest Pharmaceuticals Co.,Phase 2
NCT01035983,2003.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT01035983,2003.0,INDUSTRY,collaborator,Vernalis (R&D) Ltd,Phase 3
NCT01036061,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01036139,2009.0,OTHER,lead,Bioprojet,Phase 3
NCT01036165,2010.0,INDUSTRY,lead,EMD Serono,Phase 3
NCT01036841,2009.0,OTHER,lead,"University Hospital, Ghent",Phase 4
NCT01037088,2009.0,OTHER,lead,"University of California, Davis",Phase 1/Phase 2
NCT01037088,2009.0,OTHER,collaborator,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT01037088,2009.0,FED,collaborator,VA Northern California Health Care System,Phase 1/Phase 2
NCT01037218,2009.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT01037244,2009.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT01037309,2009.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1/Phase 2
NCT01037608,2007.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01037907,2009.0,INDUSTRY,lead,Boston Scientific Corporation,Phase 2
NCT01038128,2009.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01038323,2009.0,OTHER,lead,Indiana University,Phase 4
NCT01038323,2009.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 4
NCT01038570,2009.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT01039194,2010.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01039454,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01039740,2003.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01039766,2010.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT01039909,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01040208,2010.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT01040429,2010.0,OTHER,lead,Oslo University Hospital,Phase 2
NCT01041092,2004.0,OTHER,lead,Fundació Sant Joan de Déu,Phase 4
NCT01041157,2008.0,OTHER,lead,Jyväskylä Central Hospital,Phase 1
NCT01041157,2008.0,OTHER,collaborator,Eurostars,Phase 1
NCT01041274,2010.0,OTHER,lead,NYU Langone Health,Phase 4
NCT01041274,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01041495,2009.0,OTHER,lead,State University of New York - Upstate Medical University,Phase 4
NCT01041495,2009.0,INDUSTRY,collaborator,Cephalon,Phase 4
NCT01041573,2010.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT01041755,2009.0,OTHER,lead,Centro Regional para el Estudio de las Enfermedades Digestivas,Phase 4
NCT01041755,2009.0,UNKNOWN,collaborator,MERZ PHARMA,Phase 4
NCT01041924,2010.0,OTHER,lead,Imperial College London,Phase 2
NCT01041924,2010.0,OTHER,collaborator,Imperial College Healthcare NHS Trust,Phase 2
NCT01042314,2010.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01042496,2009.0,OTHER,lead,Mayo Clinic,Phase 3
NCT01042496,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT01042574,2010.0,OTHER,lead,Methodist Healthcare,Phase 4
NCT01042574,2010.0,INDUSTRY,collaborator,The Medicines Company,Phase 4
NCT01042964,2006.0,INDUSTRY,lead,AdvanceCor GmbH,Phase 1
NCT01042964,2006.0,UNKNOWN,collaborator,Procorde GmbH,Phase 1
NCT01043198,2010.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT01043367,2010.0,INDUSTRY,lead,Catalysis SL,Phase 3
NCT01043458,2009.0,INDUSTRY,lead,Abbott,Phase 1
NCT01043640,2009.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2
NCT01044693,2010.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT01044693,2010.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT01044966,2009.0,OTHER,lead,Medical University of South Carolina,Phase 1/Phase 2
NCT01044992,2002.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT01045122,2006.0,OTHER,lead,University of Rochester,Not Applicable
NCT01045720,2010.0,OTHER,lead,Taichung Veterans General Hospital,Phase 2
NCT01046214,2010.0,INDUSTRY,lead,Teva Pharmaceuticals USA,Phase 1
NCT01046539,2010.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01046539,2010.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 1
NCT01046630,2009.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01046630,2009.0,OTHER,collaborator,University of Manchester,Phase 1
NCT01046630,2009.0,OTHER,collaborator,University of Oxford,Phase 1
NCT01046786,2010.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 1/Phase 2
NCT01046786,2010.0,OTHER,collaborator,Chinese University of Hong Kong,Phase 1/Phase 2
NCT01046786,2010.0,OTHER,collaborator,The University of Hong Kong,Phase 1/Phase 2
NCT01047215,2009.0,OTHER,lead,Taichung Veterans General Hospital,Phase 4
NCT01047488,2010.0,OTHER,lead,Odense University Hospital,Phase 4
NCT01047488,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01047488,2010.0,INDUSTRY,collaborator,Nycomed,Phase 4
NCT01047527,2009.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01047527,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01047579,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01047592,2009.0,OTHER_GOV,lead,Chang-Hua Hospital,Phase 2
NCT01047592,2009.0,OTHER,collaborator,China Medical University Hospital,Phase 2
NCT01047839,2010.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT01048138,2018.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01048138,2018.0,OTHER,collaborator,University of Sao Paulo,Phase 3
NCT01048190,2008.0,OTHER,lead,Chinese Academy of Medical Sciences,Phase 1
NCT01048190,2008.0,OTHER_GOV,collaborator,Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control,Phase 1
NCT01048190,2008.0,OTHER,collaborator,"National Institute for the Control of Pharmaceutical and Biological Products, China",Phase 1
NCT01048242,2006.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01048242,2006.0,INDUSTRY,collaborator,Takeda,Phase 3
NCT01048255,2010.0,INDUSTRY,lead,Vertex Pharmaceuticals Incorporated,Phase 2
NCT01048411,2006.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Not Applicable
NCT01048684,2010.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Not Applicable
NCT01048944,2005.0,OTHER,lead,Southern Illinois University Carbondale,Phase 4
NCT01048944,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01048957,2007.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01049035,2009.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT01049347,1997.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 3
NCT01049399,2009.0,INDUSTRY,lead,Noscira SA,Not Applicable
NCT01049399,2009.0,INDUSTRY,collaborator,i3 Research,Not Applicable
NCT01049451,2009.0,OTHER,lead,University of Southern California,Phase 1
NCT01049984,2009.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 4
NCT01049984,2009.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT01050244,2011.0,OTHER,lead,Dr. Yoram Shir,Phase 2
NCT01050244,2011.0,UNKNOWN,collaborator,Louise & Alan Edwards Foundation,Phase 2
NCT01050244,2011.0,OTHER,collaborator,McGill University,Phase 2
NCT01050478,2010.0,INDUSTRY,lead,Janssen Cilag N.V./S.A.,Phase 4
NCT01050569,2008.0,OTHER,lead,University of Minnesota,Phase 2
NCT01050569,2008.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01050582,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 4
NCT01051271,2009.0,OTHER,lead,Pamukkale University,Not Applicable
NCT01051349,2010.0,INDUSTRY,lead,Biogen,Phase 2
NCT01051349,2010.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT01051440,2010.0,OTHER,lead,"Steward St. Elizabeth's Medical Center of Boston, Inc.",Phase 4
NCT01051440,2010.0,INDUSTRY,collaborator,Shire,Phase 4
NCT01051531,2010.0,INDUSTRY,lead,Johnson & Johnson Pte Ltd,Phase 3
NCT01051882,2011.0,INDUSTRY,lead,Brainstorm-Cell Therapeutics,Phase 1/Phase 2
NCT01051882,2011.0,OTHER,collaborator,Hadassah Medical Organization,Phase 1/Phase 2
NCT01052103,2010.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 2
NCT01052337,2009.0,OTHER,lead,University of Roma La Sapienza,Phase 4
NCT01052363,2010.0,OTHER,lead,West Virginia University,Phase 1
NCT01052389,2007.0,OTHER,lead,Mario Negri Institute for Pharmacological Research,Phase 4
NCT01052389,2007.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT01052623,2010.0,OTHER,lead,Johann Wolfgang Goethe University Hospital,Phase 4
NCT01052831,2009.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01052831,2009.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 4
NCT01053156,2010.0,OTHER,lead,"University of California, Davis",Not Applicable
NCT01053156,2010.0,OTHER,collaborator,The National Fragile X Foundation,Not Applicable
NCT01053507,2010.0,INDIV,lead,"Cady, Roger, M.D.",Phase 4
NCT01053507,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT01054404,2010.0,OTHER,lead,Northwestern University,Not Applicable
NCT01054430,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01054599,2009.0,OTHER,lead,American Academy of Neurology,Not Applicable
NCT01054599,2009.0,INDUSTRY,collaborator,Forest Laboratories,Not Applicable
NCT01054859,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01054976,2006.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT01055171,2010.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01055171,2010.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01055379,2010.0,INDUSTRY,lead,Lundbeck Italia S.p.A.,Phase 4
NCT01055379,2010.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT01055392,2007.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT01056705,2009.0,OTHER,lead,Chinese Academy of Medical Sciences,Phase 2
NCT01056705,2009.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 2
NCT01056705,2009.0,OTHER,collaborator,"National Institute for the Control of Pharmaceutical and Biological Products, China",Phase 2
NCT01056965,2010.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT01057030,2010.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01057082,2010.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01057082,2010.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT01057160,2008.0,OTHER,lead,Universität Duisburg-Essen,Phase 4
NCT01057160,2008.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT01057680,2010.0,OTHER,lead,University of Saskatchewan,Phase 3
NCT01057849,2008.0,OTHER,lead,Peking University,Not Applicable
NCT01057849,2008.0,OTHER_GOV,collaborator,Ministry of Science and Technology of the People´s Republic of China,Not Applicable
NCT01057862,2009.0,OTHER,lead,Yale University,Phase 2
NCT01057862,2009.0,OTHER,collaborator,National Center for Responsible Gaming,Phase 2
NCT01057901,2010.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT01058005,2010.0,INDUSTRY,lead,Biogen,Phase 3
NCT01058005,2010.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 3
NCT01058096,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01058096,2010.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01058291,2010.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 3
NCT01058395,2010.0,OTHER,lead,Wayne State University,Phase 1/Phase 2
NCT01058642,2010.0,INDUSTRY,lead,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Phase 2
NCT01058642,2010.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01058668,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01058668,2010.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01058850,2011.0,OTHER,lead,Paul Graham Fisher,Phase 1
NCT01058850,2011.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT01058850,2011.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01058941,2010.0,OTHER,lead,Oregon Health and Science University,Phase 1/Phase 2
NCT01059396,2010.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 4
NCT01059890,2009.0,OTHER,lead,Poitiers University Hospital,Phase 1
NCT01060111,2006.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT01060228,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01060878,2010.0,INDUSTRY,lead,Phytopharm,Phase 2
NCT01061190,2010.0,OTHER,lead,Wilhelm Haverkamp,Phase 2/Phase 3
NCT01061190,2010.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 2/Phase 3
NCT01061372,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01061528,2009.0,OTHER,lead,Butler Hospital,Not Applicable
NCT01061528,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01061866,2006.0,OTHER,lead,"National Institute of Neurology and Neurosurgery, Mexico",Phase 1/Phase 2
NCT01061866,2006.0,OTHER,collaborator,"National Council of Science and Technology, Mexico",Phase 1/Phase 2
NCT01062451,2009.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01062451,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01062529,2009.0,OTHER,lead,University of Aarhus,Not Applicable
NCT01062529,2009.0,OTHER_GOV,collaborator,"The Ministry of Science, Technology and Innovation, Denmark",Not Applicable
NCT01062698,2010.0,OTHER,lead,"Central Hospital, Nancy, France",Not Applicable
NCT01062711,2008.0,OTHER,lead,McMaster University,Not Applicable
NCT01062711,2008.0,OTHER,collaborator,National Dairy Council,Not Applicable
NCT01062932,2009.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01062932,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01062945,2010.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01062945,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01063205,2010.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01063205,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01063348,2012.0,OTHER,lead,University of Chicago,Phase 2
NCT01063621,2010.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 3
NCT01063764,2010.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT01063855,2010.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3
NCT01064401,2010.0,INDUSTRY,lead,Biogen,Phase 3
NCT01064401,2010.0,INDUSTRY,collaborator,AbbVie,Phase 3
NCT01064505,2010.0,INDUSTRY,lead,Quark Pharmaceuticals,Phase 1
NCT01064973,2010.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT01065012,2010.0,INDUSTRY,lead,Warner Chilcott,Phase 3
NCT01065558,2010.0,INDUSTRY,lead,Psyadon Pharma,Phase 1
NCT01065727,2010.0,OTHER,lead,Rennes University Hospital,Not Applicable
NCT01066156,2010.0,OTHER,lead,Cambridge Health Alliance,Not Applicable
NCT01066299,2010.0,OTHER,lead,University of Zurich,Not Applicable
NCT01066299,2010.0,OTHER,collaborator,University of Basel,Not Applicable
NCT01066299,2010.0,OTHER,collaborator,University of Freiburg,Not Applicable
NCT01066403,2003.0,OTHER,lead,Heidelberg University,Not Applicable
NCT01066403,2003.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT01066442,2010.0,OTHER,lead,Bioprojet,Phase 3
NCT01066481,2010.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01066546,2010.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01066546,2010.0,INDUSTRY,collaborator,"Medivation, Inc.",Phase 3
NCT01066572,2010.0,OTHER,lead,Newcastle-upon-Tyne Hospitals NHS Trust,Phase 1
NCT01066572,2010.0,OTHER,collaborator,North East Ambulance Service NHS Foundation Trust,Phase 1
NCT01066572,2010.0,OTHER,collaborator,Northumbria Healthcare NHS Foundation Trust,Phase 1
NCT01066897,2010.0,OTHER,lead,Stanford University,Phase 4
NCT01066897,2010.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT01067222,2009.0,OTHER,lead,Bioprojet,Phase 3
NCT01067235,2009.0,OTHER,lead,Bioprojet,Phase 3
NCT01067391,2009.0,OTHER,lead,University of Manitoba,Phase 4
NCT01067391,2009.0,OTHER,collaborator,Manitoba Medical Service Foundation,Phase 4
NCT01067391,2009.0,OTHER,collaborator,Rick Hansen Foundation,Phase 4
NCT01067521,2010.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01067599,2012.0,OTHER,lead,University of Minnesota,Not Applicable
NCT01067599,2012.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT01067599,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01067846,2010.0,OTHER,lead,University of Arkansas,Not Applicable
NCT01067846,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01068353,2011.0,OTHER,lead,University of Southampton,Phase 2
NCT01068353,2011.0,OTHER,collaborator,Hampshire Hospitals NHS Foundation Trust,Phase 2
NCT01068353,2011.0,INDUSTRY,collaborator,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2
NCT01068847,2010.0,OTHER,lead,University of Arkansas,Phase 1
NCT01068847,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01069159,2010.0,INDIV,lead,"Mela, Mansfield, M.D.",Not Applicable
NCT01069536,2007.0,OTHER,lead,Pamukkale University,Not Applicable
NCT01070316,2010.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT01070316,2010.0,INDUSTRY,collaborator,Novartis,Phase 1/Phase 2
NCT01070628,2009.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 1
NCT01070732,2010.0,OTHER,lead,University of Athens,Phase 4
NCT01071044,2009.0,OTHER,lead,Rochester Center for Behavioral Medicine,Phase 4
NCT01071044,2009.0,INDUSTRY,collaborator,Shire,Phase 4
NCT01071083,2010.0,INDUSTRY,lead,Biogen,Phase 2
NCT01071083,2010.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT01071135,2009.0,OTHER,lead,Hannover Medical School,Phase 3
NCT01071135,2009.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT01071317,2010.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT01071395,2010.0,OTHER,lead,Rush University Medical Center,Phase 4
NCT01071395,2010.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 4
NCT01071512,2010.0,OTHER,lead,University of Chicago,Not Applicable
NCT01071512,2010.0,INDUSTRY,collaborator,Biogen,Not Applicable
NCT01071538,2010.0,OTHER,lead,University of Pittsburgh,Phase 2
NCT01071538,2010.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01071538,2010.0,INDUSTRY,collaborator,Reckitt Benckiser LLC,Phase 2
NCT01071538,2010.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2
NCT01071616,2010.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01071876,2011.0,OTHER,lead,Bioprojet,Phase 3
NCT01072370,2010.0,OTHER,lead,Augusta University,Phase 1/Phase 2
NCT01072630,2010.0,INDUSTRY,lead,Cephalon,Phase 3
NCT01072812,2010.0,INDUSTRY,lead,Annovis Bio Inc.,Phase 1
NCT01072929,2010.0,INDUSTRY,lead,Cephalon,Phase 3
NCT01072968,2011.0,OTHER,lead,Bioprojet,Phase 3
NCT01073007,2009.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT01073228,2010.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 2
NCT01073228,2010.0,INDUSTRY,collaborator,INC Research Limited,Phase 2
NCT01073319,2009.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01073319,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01073787,2010.0,OTHER,lead,University of Alberta,Phase 1/Phase 2
NCT01073800,2009.0,OTHER,lead,University of Alberta,Phase 2/Phase 3
NCT01073813,2010.0,OTHER,lead,University of Calgary,Phase 2
NCT01073813,2010.0,UNKNOWN,collaborator,Neuroscience Canada,Phase 2
NCT01073995,2010.0,OTHER,lead,Horizon Health Network,Phase 3
NCT01074073,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01074359,2010.0,INDUSTRY,lead,Penwest Pharmaceuticals Co.,Phase 2
NCT01074619,2005.0,OTHER,lead,"University Hospital, Caen",Phase 3
NCT01074619,2005.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT01074619,2005.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT01074944,2010.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT01075126,2006.0,INDIV,lead,"Lawson, William B., M.D., PhD, DFAPA",Phase 4
NCT01075126,2006.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT01075152,2010.0,OTHER,lead,University of Minnesota,Phase 4
NCT01075152,2010.0,OTHER,collaborator,Mbarara University of Science and Technology,Phase 4
NCT01075152,2010.0,OTHER,collaborator,Makerere University,Phase 4
NCT01075152,2010.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4
NCT01075152,2010.0,OTHER,collaborator,University of Cape Town,Phase 4
NCT01075763,2004.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01075763,2004.0,INDUSTRY,collaborator,"Merck Serono S.P.A., Italy",Phase 2
NCT01076478,2004.0,INDUSTRY,lead,"Otsuka Pharmaceutical, Inc., Philippines",Phase 4
NCT01077206,2010.0,OTHER,lead,Chinese University of Hong Kong,Phase 2/Phase 3
NCT01077206,2010.0,UNKNOWN,collaborator,Hong Kong Government,Phase 2/Phase 3
NCT01077375,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 4
NCT01077375,2010.0,INDUSTRY,collaborator,"Cypress Bioscience, Inc.",Phase 4
NCT01078168,2010.0,OTHER,lead,K. Lieb,Phase 2
NCT01078168,2010.0,UNKNOWN,collaborator,Alzheimer Forschungsinitiative e.V. (AFI),Phase 2
NCT01078298,2010.0,INDUSTRY,lead,Pfizer,Phase 4
NCT01078753,2010.0,INDUSTRY,lead,Ferring Pharmaceuticals,Phase 3
NCT01078870,2010.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT01079169,2010.0,OTHER,lead,Uppsala University,Not Applicable
NCT01079351,2007.0,INDUSTRY,lead,Lundbeck LLC,Phase 1
NCT01079819,2010.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01080677,2007.0,OTHER,lead,Stanford University,Phase 2
NCT01081418,2005.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 4
NCT01081769,2010.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT01081782,2010.0,INDUSTRY,lead,Ono Pharma USA Inc,Phase 2
NCT01081795,2007.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT01082250,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01082289,2008.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01082328,2010.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT01082328,2010.0,INDUSTRY,collaborator,Merck Serono Norway,Phase 4
NCT01082328,2010.0,OTHER,collaborator,Smerud Medical Research International AS,Phase 4
NCT01082588,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01082588,2010.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01082588,2010.0,OTHER,collaborator,North Suffolk Mental Health Association,Phase 4
NCT01082653,2010.0,INDUSTRY,lead,TCA Cellular Therapy,Phase 1
NCT01082848,2010.0,OTHER,lead,Juan A. Arnaiz,Phase 3
NCT01082926,2010.0,OTHER,lead,City of Hope Medical Center,Phase 1
NCT01082965,2010.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT01083381,2010.0,OTHER,lead,Farzan Institute,Phase 2
NCT01083901,2006.0,OTHER,lead,"University of Colorado, Denver",Not Applicable
NCT01083901,2006.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT01083966,2011.0,OTHER,lead,Northwell Health,Phase 1
NCT01083966,2011.0,OTHER,collaborator,Feinstein Institute for Medical Research,Phase 1
NCT01083966,2011.0,OTHER,collaborator,Hofstra North Shore,Phase 1
NCT01084135,2009.0,OTHER,lead,Duke University,Phase 1/Phase 2
NCT01084135,2009.0,UNKNOWN,collaborator,Taishoff Family Foundation,Phase 1/Phase 2
NCT01084135,2009.0,OTHER,collaborator,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 1/Phase 2
NCT01084187,2010.0,OTHER,lead,Hospital Universitario Pedro Ernesto,Phase 4
NCT01084603,2009.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01084707,2009.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01085123,2010.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01085266,2010.0,INDUSTRY,lead,"Medivation, Inc.",Phase 3
NCT01085266,2010.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT01085318,2010.0,INDUSTRY,lead,EMD Serono,Phase 4
NCT01085383,2010.0,OTHER,lead,University of Oxford,Phase 4
NCT01085383,2010.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 4
NCT01085812,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01086345,2010.0,OTHER,lead,Case Comprehensive Cancer Center,Early Phase 1
NCT01086423,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01086748,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01086969,2010.0,INDUSTRY,lead,Sanofi,Phase 3
NCT01086982,2010.0,INDUSTRY,lead,Azidus Brasil,Phase 1
NCT01087593,2001.0,OTHER,lead,"Ostergotland County Council, Sweden",Not Applicable
NCT01087736,2010.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT01087736,2010.0,FED,collaborator,United States Department of Defense,Phase 4
NCT01087736,2010.0,FED,collaborator,US Department of Veterans Affairs,Phase 4
NCT01088230,2009.0,OTHER,lead,New York Presbyterian Hospital,Phase 1/Phase 2
NCT01088256,2011.0,OTHER,lead,Ruhr University of Bochum,Phase 2
NCT01089010,2010.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT01089387,2010.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1/Phase 2
NCT01089621,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT01089647,2010.0,OTHER,lead,Romaker & Associates,Phase 3
NCT01089647,2010.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 3
NCT01089855,2009.0,INDUSTRY,lead,Novartis,Phase 4
NCT01090180,2010.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT01090440,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01090453,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01090518,2010.0,FED,lead,Bronx VA Medical Center,Not Applicable
NCT01090518,2010.0,UNKNOWN,collaborator,Lightfighter Trust,Not Applicable
NCT01090713,2010.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT01090713,2010.0,INDUSTRY,collaborator,Shire,Phase 3
NCT01090713,2010.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT01091142,2010.0,INDUSTRY,lead,"Neuraltus Pharmaceuticals, Inc.",Phase 1
NCT01091506,2010.0,INDUSTRY,lead,"Pamlab, Inc.",Not Applicable
NCT01091506,2010.0,OTHER,collaborator,Massachusetts General Hospital,Not Applicable
NCT01091662,2010.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01091701,2011.0,INDUSTRY,lead,Stempeutics Research Pvt Ltd,Phase 1/Phase 2
NCT01091701,2011.0,UNKNOWN,collaborator,Stempeutics Research Malaysia SDN BHD,Phase 1/Phase 2
NCT01091870,2010.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2
NCT01092065,2010.0,INDUSTRY,lead,Novartis,Phase 2
NCT01092221,2010.0,OTHER_GOV,lead,Sheba Medical Center,Phase 3
NCT01092507,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01092780,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01093261,2010.0,OTHER,lead,Nantes University Hospital,Phase 3
NCT01093261,2010.0,OTHER,collaborator,Société Française d'Anesthésie et de Réanimation,Phase 3
NCT01093326,2010.0,INDUSTRY,lead,Actelion,Phase 2
NCT01093365,2010.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01093365,2010.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01093664,2009.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT01093768,2010.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT01093937,2009.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT01093937,2009.0,OTHER,collaborator,Canadian Tobacco Control Research Initiative,Not Applicable
NCT01093937,2009.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT01093963,2010.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT01093963,2010.0,INDUSTRY,collaborator,Shire,Phase 3
NCT01093963,2010.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT01093976,2010.0,OTHER,lead,University of Chicago,Phase 2
NCT01094171,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01094249,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01094340,2010.0,OTHER,lead,Banner Health,Phase 2/Phase 3
NCT01095094,2009.0,OTHER,lead,Case Comprehensive Cancer Center,Phase 2
NCT01095588,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01096082,2011.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT01096095,2010.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2
NCT01096095,2010.0,OTHER,collaborator,"Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil",Phase 2
NCT01096186,2010.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT01096329,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01096550,2010.0,OTHER,lead,"Friends Research Institute, Inc.",Not Applicable
NCT01096550,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01096680,2010.0,INDUSTRY,lead,Shire,Phase 2
NCT01096797,2009.0,OTHER,lead,San Gerardo Hospital,Phase 4
NCT01096797,2009.0,OTHER,collaborator,University of Milano Bicocca,Phase 4
NCT01097096,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01097382,2010.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01097668,2010.0,INDUSTRY,lead,Apitope Technology (Bristol) Ltd.,Phase 1
NCT01097668,2010.0,INDUSTRY,collaborator,Aptiv Solutions,Phase 1
NCT01097668,2010.0,INDUSTRY,collaborator,"ClinStar, LLC",Phase 1
NCT01097798,2010.0,OTHER,lead,Laboratorio Brasileiro de Biologia,Phase 3
NCT01097811,2008.0,OTHER,lead,UPECLIN HC FM Botucatu Unesp,Not Applicable
NCT01097811,2008.0,UNKNOWN,collaborator,Biophisics Department of Biosciences Institute - Unesp,Not Applicable
NCT01097811,2008.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Not Applicable
NCT01098110,2010.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01098305,2011.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01098305,2011.0,OTHER,collaborator,"All India Institute of Medical Sciences, New Delhi",Phase 2
NCT01098318,2010.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01098318,2010.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT01098435,2010.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 2
NCT01099332,2009.0,INDUSTRY,lead,Adeona Pharmaceuticals,Phase 1/Phase 2
NCT01099501,2010.0,OTHER,lead,Rabin Medical Center,Phase 4
NCT01099501,2010.0,UNKNOWN,collaborator,Israeli Ministry of Security,Phase 4
NCT01099761,2010.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2
NCT01100021,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01100255,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT01100385,2010.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Not Applicable
NCT01100385,2010.0,INDUSTRY,collaborator,Cambridge Theranostics Ltd,Not Applicable
NCT01100554,2009.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT01100658,2010.0,OTHER,lead,University of Minnesota,Not Applicable
NCT01100658,2010.0,UNKNOWN,collaborator,Children's Cancer Research Fund United States,Not Applicable
NCT01100775,2010.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT01100775,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01101464,2002.0,INDUSTRY,lead,Organon and Co,Phase 2
NCT01101659,2010.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01101815,2010.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01101815,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01102101,2010.0,OTHER,lead,Medical University of Vienna,Phase 3
NCT01102101,2010.0,UNKNOWN,collaborator,"WWTF, Wiener Wissenschafts-, Forschungs- und Technologiefonds",Phase 3
NCT01102101,2010.0,OTHER,collaborator,Vienna General Hospital,Phase 3
NCT01102270,2009.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT01102270,2009.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Early Phase 1
NCT01102270,2009.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT01102686,2009.0,OTHER,lead,The Hospital for Sick Children,Phase 1/Phase 2
NCT01102803,2010.0,OTHER,lead,Southern Methodist University,Phase 3
NCT01103011,2010.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1
NCT01103180,2010.0,OTHER,lead,University of Chicago,Phase 2
NCT01103180,2010.0,OTHER,collaborator,Temple University,Phase 2
NCT01103180,2010.0,OTHER,collaborator,Northwestern University,Phase 2
NCT01103180,2010.0,OTHER,collaborator,University of Southern Mississippi,Phase 2
NCT01103362,2010.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 3
NCT01103583,2011.0,OTHER,lead,S. Andrea Hospital,Phase 2/Phase 3
NCT01104194,2008.0,OTHER,lead,Leiden University Medical Center,Not Applicable
NCT01104337,2007.0,OTHER,lead,Hopital Lariboisière,Phase 4
NCT01104649,2010.0,OTHER,lead,S. Andrea Hospital,Phase 2/Phase 3
NCT01104649,2010.0,OTHER_GOV,collaborator,Agenzia Italiana del Farmaco,Phase 2/Phase 3
NCT01104766,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01104766,2010.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01104779,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01104779,2010.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01104792,2010.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01104792,2010.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01106053,2010.0,OTHER,lead,"Neuropsychiatric Research Institute, Fargo, North Dakota",Phase 3
NCT01106716,2009.0,INDUSTRY,lead,KAI Pharmaceuticals,Phase 2
NCT01106716,2009.0,INDUSTRY,collaborator,Trident Clinical Research Pty Ltd,Phase 2
NCT01107353,2008.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT01107574,2004.0,OTHER,lead,"Good Samaritan Regional Medical Center, Oregon",Phase 3
NCT01107574,2004.0,UNKNOWN,collaborator,"Touro University,Vallejo,California",Phase 3
NCT01108029,2009.0,OTHER,lead,"University Hospital, Lille",Phase 4
NCT01108133,2010.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Not Applicable
NCT01108146,2008.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Not Applicable
NCT01108146,2008.0,OTHER,collaborator,German Research Foundation,Not Applicable
NCT01108393,2010.0,OTHER,lead,Institut de Recherches Internationales Servier,Phase 2
NCT01108549,2009.0,OTHER,lead,Kona Research Center,Not Applicable
NCT01108549,2009.0,INDUSTRY,collaborator,"Bioenergy Life Science, Inc.",Not Applicable
NCT01108549,2009.0,INDUSTRY,collaborator,"Integrative Therapeutics, Inc.",Not Applicable
NCT01108601,2008.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 1/Phase 2
NCT01108731,2010.0,OTHER,lead,Beth Israel Medical Center,Phase 2/Phase 3
NCT01108744,2012.0,OTHER,lead,Beth Israel Deaconess Medical Center,Not Applicable
NCT01109628,2009.0,OTHER,lead,Wageningen University,Not Applicable
NCT01109628,2009.0,OTHER,collaborator,Maastricht University Medical Center,Not Applicable
NCT01109628,2009.0,OTHER,collaborator,Top Institute Food and Nutrition,Not Applicable
NCT01110057,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01110187,2010.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01110187,2010.0,INDUSTRY,collaborator,UCB Pharma,Not Applicable
NCT01110317,2005.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01110369,2009.0,OTHER,lead,Wageningen University,Not Applicable
NCT01110369,2009.0,OTHER,collaborator,Top Institute Food and Nutrition,Not Applicable
NCT01110369,2009.0,OTHER,collaborator,Maastricht University Medical Center,Not Applicable
NCT01110434,2009.0,OTHER,lead,Brown University,Phase 2
NCT01110434,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01110447,2010.0,INDUSTRY,lead,CD Pharma India Pvt. Ltd.,Phase 2/Phase 3
NCT01110447,2010.0,UNKNOWN,collaborator,Postgraduate Institute of Medical Education and Research,Phase 2/Phase 3
NCT01110590,2010.0,INDUSTRY,lead,Bayer,Phase 1
NCT01110616,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01110720,2010.0,INDUSTRY,lead,Allon Therapeutics,Phase 2/Phase 3
NCT01111097,2010.0,OTHER,lead,University of Florida,Phase 1
NCT01111097,2010.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT01111149,2009.0,OTHER,lead,University of Minnesota,Phase 2
NCT01111149,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01111149,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01111682,2010.0,OTHER,lead,University of Cincinnati,Phase 3
NCT01111682,2010.0,FED,collaborator,United States Department of Defense,Phase 3
NCT01111734,2011.0,OTHER,lead,University of Minnesota,Phase 1
NCT01111734,2011.0,OTHER,collaborator,Minnesota Medical Foundation,Phase 1
NCT01112683,2008.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT01112683,2008.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01112748,2010.0,OTHER,lead,Danish Pain Research Center,Phase 4
NCT01112748,2010.0,UNKNOWN,collaborator,Grünenthal Denmark ApS,Phase 4
NCT01112813,2010.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT01113320,2010.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 2
NCT01113424,2008.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01113541,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01113567,2010.0,OTHER_GOV,lead,"Coordinación de Investigación en Salud, Mexico",Not Applicable
NCT01114100,2000.0,OTHER,lead,Maastricht University Medical Center,Phase 4
NCT01114100,2000.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01114698,2011.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT01114737,2010.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT01114854,2010.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 1
NCT01115530,2011.0,FED,lead,US Department of Veterans Affairs,Not Applicable
NCT01115686,2010.0,OTHER,lead,"University Hospital, Limoges",Phase 3
NCT01115699,2010.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT01115699,2010.0,OTHER,collaborator,Neuronetics,Not Applicable
NCT01116401,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01116401,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01116427,2010.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT01116427,2010.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 2
NCT01116531,2010.0,OTHER_GOV,lead,Turku University Hospital,Phase 4
NCT01116531,2010.0,OTHER,collaborator,University of Helsinki,Phase 4
NCT01116700,2010.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT01116830,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT01116986,2010.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01116986,2010.0,OTHER,collaborator,Dean Health System,Phase 4
NCT01116986,2010.0,NETWORK,collaborator,Mercy Health System,Phase 4
NCT01116986,2010.0,OTHER,collaborator,Aurora Health Care,Phase 4
NCT01116986,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT01117038,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01117181,2010.0,OTHER,lead,Johns Hopkins Bloomberg School of Public Health,Phase 2
NCT01117181,2010.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01117181,2010.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT01117181,2010.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT01117181,2010.0,OTHER,collaborator,University of Toronto,Phase 2
NCT01117220,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01117766,2006.0,INDUSTRY,lead,Pfizer,Not Applicable
NCT01117818,2010.0,INDUSTRY,lead,Affiris AG,Phase 2
NCT01117857,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01118455,2004.0,INDUSTRY,lead,"Cyberonics, Inc.",Phase 4
NCT01118949,2010.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT01118962,2010.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT01119014,2010.0,OTHER,lead,Anne Katrine Pagsberg,Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"The Psychiatric Centre for Children and Adolescents in Bispebjerg, Denmark",Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"Psychiatric Centre Copenhagen, Denmark",Phase 4
NCT01119014,2010.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4
NCT01119014,2010.0,OTHER,collaborator,Albert Einstein College of Medicine,Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"Research Institute for Biological Psychiatry, Sct. Hans Hospital, Denmark",Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"Capital Region Pharmacy, Denmark",Phase 4
NCT01119014,2010.0,OTHER,collaborator,"The Research Council for Health and Disease, Denmark",Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"Allocated inheritance from Elizabeth Stevn and Niels Rindom, Denmark",Phase 4
NCT01119014,2010.0,OTHER,collaborator,AP Moeller Foundation,Phase 4
NCT01119014,2010.0,UNKNOWN,collaborator,"Tryg Fonden, Denmark",Phase 4
NCT01119131,2011.0,FED,lead,VA Office of Research and Development,Phase 2
NCT01119131,2011.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT01119417,2010.0,OTHER,lead,Vanderbilt University,Phase 1
NCT01119482,2010.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 4
NCT01119482,2010.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT01119482,2010.0,OTHER,collaborator,Wellcome Trust,Phase 4
NCT01119599,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01119638,2008.0,OTHER_GOV,lead,Abarbanel Mental Health Center,Phase 4
NCT01119924,2009.0,INDUSTRY,lead,"Nang Kuang Pharmaceutical Co., Ltd.",Phase 4
NCT01119924,2009.0,OTHER,collaborator,Buddhist Tzu Chi General Hospital,Phase 4
NCT01120002,2010.0,OTHER,lead,Osaka City University,Phase 2
NCT01120626,2009.0,OTHER,lead,Stanford University,Phase 2
NCT01120626,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01120626,2009.0,OTHER,collaborator,Autism Speaks,Phase 2
NCT01120704,2010.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01120704,2010.0,OTHER,collaborator,Dean Health System,Phase 4
NCT01120704,2010.0,NETWORK,collaborator,Mercy Health System,Phase 4
NCT01120704,2010.0,OTHER,collaborator,Aurora Health Care,Phase 4
NCT01120704,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT01121042,2010.0,OTHER_GOV,lead,Bayside Health,Phase 3
NCT01121211,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01121211,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01121536,2010.0,INDUSTRY,lead,Cephalon,Phase 3
NCT01122056,2010.0,OTHER,lead,University of British Columbia,Not Applicable
NCT01122056,2010.0,INDUSTRY,collaborator,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Not Applicable
NCT01122238,2010.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01122238,2010.0,OTHER,collaborator,University of Illinois at Chicago,Phase 4
NCT01122238,2010.0,OTHER,collaborator,Dean Health System,Phase 4
NCT01122238,2010.0,NETWORK,collaborator,Mercy Health System,Phase 4
NCT01122238,2010.0,OTHER,collaborator,Aurora Health Care,Phase 4
NCT01122238,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT01122264,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT01122329,2010.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT01122329,2010.0,OTHER,collaborator,John Douglas French Foundation,Phase 4
NCT01122381,2011.0,FED,lead,US Department of Veterans Affairs,Phase 1/Phase 2
NCT01122381,2011.0,OTHER,collaborator,Thomas Jefferson University,Phase 1/Phase 2
NCT01122381,2011.0,OTHER,collaborator,University of Pittsburgh,Phase 1/Phase 2
NCT01123044,2011.0,OTHER_GOV,lead,"Ministry of Health, Malaysia",Phase 3
NCT01123161,2010.0,OTHER,lead,"University of California, San Diego",Phase 2/Phase 3
NCT01123161,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT01123161,2010.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2/Phase 3
NCT01123278,2004.0,OTHER,lead,University of Roma La Sapienza,Phase 4
NCT01123317,2010.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01123408,1999.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Not Applicable
NCT01124188,2010.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT01124617,2010.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT01124643,2010.0,INDUSTRY,lead,Shire,Phase 3
NCT01124851,2010.0,INDUSTRY,lead,Abbott,Phase 1
NCT01124877,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01125033,2008.0,OTHER,lead,Shiraz University of Medical Sciences,Phase 2/Phase 3
NCT01125046,2010.0,OTHER,lead,Northwestern University,Phase 2
NCT01125241,2010.0,OTHER,lead,Shanghai Zhongshan Hospital,Not Applicable
NCT01125241,2010.0,UNKNOWN,collaborator,Shanghai Wu Mengchao Medical Foundation,Not Applicable
NCT01125241,2010.0,UNKNOWN,collaborator,"Shanghai Ankang Pharmaceutical Co.,LTD",Not Applicable
NCT01125358,2010.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 2
NCT01125423,2010.0,OTHER,lead,Albany Medical College,Phase 4
NCT01125423,2010.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01125631,2010.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01125774,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2/Phase 3
NCT01126099,2010.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT01126099,2010.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT01126099,2010.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT01126307,2010.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT01126697,2010.0,NETWORK,lead,Cooperative International Neuromuscular Research Group,Phase 2/Phase 3
NCT01126697,2010.0,FED,collaborator,United States Department of Defense,Phase 2/Phase 3
NCT01127100,2010.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01127100,2010.0,OTHER,collaborator,Seoul National University Bundang Hospital,Phase 4
NCT01127100,2010.0,OTHER,collaborator,Asan Medical Center,Phase 4
NCT01127100,2010.0,OTHER,collaborator,Inje University,Phase 4
NCT01127100,2010.0,OTHER,collaborator,Chonnam National University Hospital,Phase 4
NCT01127100,2010.0,OTHER,collaborator,"Chung-Ang University Hosptial, Chung-Ang University College of Medicine",Phase 4
NCT01127100,2010.0,OTHER,collaborator,Dankook University,Phase 4
NCT01127165,2006.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT01127256,2006.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT01127490,2010.0,OTHER,lead,Albany Medical College,Not Applicable
NCT01127503,2010.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 2
NCT01127568,2010.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2/Phase 3
NCT01127568,2010.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT01127568,2010.0,OTHER,collaborator,Harvard University,Phase 2/Phase 3
NCT01127568,2010.0,OTHER,collaborator,McGill University,Phase 2/Phase 3
NCT01127568,2010.0,FED,collaborator,US Department of Veterans Affairs,Phase 2/Phase 3
NCT01127633,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01128218,2011.0,OTHER,lead,Southern Illinois University,Phase 1/Phase 2
NCT01128218,2011.0,INDUSTRY,collaborator,"DUSA Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT01128452,2010.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT01128452,2010.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2
NCT01128712,2010.0,OTHER,lead,Northeast Regional Epilepsy Group,Phase 4
NCT01128712,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01128738,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01128855,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01128959,2010.0,INDUSTRY,lead,Lundbeck LLC,Phase 3
NCT01128959,2010.0,INDUSTRY,collaborator,Ligand Pharmaceuticals,Phase 3
NCT01128959,2010.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 3
NCT01128959,2010.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 3
NCT01129479,2004.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT01129479,2004.0,INDUSTRY,collaborator,"Ortho-McNeil Neurologics, Inc.",Not Applicable
NCT01129531,2010.0,INDUSTRY,lead,Allergan,Phase 2
NCT01129674,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2/Phase 3
NCT01129882,2010.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01130103,2004.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 4
NCT01130103,2004.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01130493,2010.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT01130532,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT01130623,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01131559,2010.0,OTHER,lead,Lindner Center of HOPE,Phase 3
NCT01131559,2010.0,INDUSTRY,collaborator,Shire,Phase 3
NCT01131559,2010.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT01131884,2010.0,OTHER,lead,University of Rochester,Not Applicable
NCT01132690,2010.0,INDUSTRY,lead,Pfizer,Phase 4
NCT01132703,2010.0,INDUSTRY,lead,Biogen,Phase 1
NCT01133080,2010.0,OTHER,lead,Shalvata Mental Health Center,Phase 4
NCT01133223,2010.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2
NCT01133301,1998.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 2
NCT01133301,1998.0,OTHER,collaborator,University of Freiburg,Phase 2
NCT01133353,2011.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 2
NCT01133405,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01133574,2010.0,INDUSTRY,lead,Abbott,Phase 1
NCT01133574,2010.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 1
NCT01133821,2010.0,OTHER,lead,Holly Swartz,Phase 4
NCT01133821,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01134198,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT01134627,2006.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01135108,2009.0,INDUSTRY,lead,KAI Pharmaceuticals,Phase 2
NCT01135108,2009.0,INDUSTRY,collaborator,Trident Clinical Research Pty Ltd,Phase 2
NCT01135563,2010.0,OTHER,lead,The Hospital for Sick Children,Phase 1
NCT01135563,2010.0,OTHER,collaborator,Solving Kids' Cancer,Phase 1
NCT01136278,2010.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT01136642,2010.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01136772,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01136772,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01136772,2011.0,OTHER,collaborator,Duke University,Phase 4
NCT01136772,2011.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 4
NCT01137110,2010.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT01137396,2010.0,OTHER,lead,Yale University,Phase 2
NCT01137526,2010.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01137682,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01137773,2007.0,OTHER,lead,University of Louisville,Phase 4
NCT01137799,2009.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 1
NCT01137890,2010.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT01137890,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01138111,2008.0,INDUSTRY,lead,Life Molecular Imaging SA,Phase 1
NCT01138150,2009.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT01138150,2009.0,OTHER,collaborator,University of Toledo Health Science Campus,Phase 4
NCT01138150,2009.0,OTHER,collaborator,The Cleveland Clinic,Phase 4
NCT01139125,2009.0,OTHER,lead,Augusta University,Not Applicable
NCT01139281,2007.0,OTHER,lead,University of Brasilia,Phase 2
NCT01139996,2010.0,OTHER,lead,Memorial Health University Medical Center,Phase 4
NCT01140360,2012.0,OTHER,lead,Kent Robertson,Phase 1/Phase 2
NCT01140503,2010.0,OTHER,lead,Stanford University,Not Applicable
NCT01140529,2010.0,OTHER,lead,Thorax-Kärlkliniken,Phase 3
NCT01140620,2010.0,OTHER,lead,University of Manchester,Phase 4
NCT01140620,2010.0,OTHER,collaborator,Cardiff University,Phase 4
NCT01140620,2010.0,OTHER,collaborator,King's College London,Phase 4
NCT01140620,2010.0,INDUSTRY,collaborator,P1vital Limited,Phase 4
NCT01140867,2008.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT01141023,2010.0,OTHER,lead,"Ken Marek, MD",Phase 2
NCT01141023,2010.0,OTHER,collaborator,Institute for Neurodegenerative Disorders,Phase 2
NCT01141153,2010.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT01141595,2010.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT01141595,2010.0,INDUSTRY,collaborator,BioMarin Pharmaceutical,Not Applicable
NCT01141855,2008.0,OTHER,lead,The Queen Elizabeth Hospital,Phase 2/Phase 3
NCT01142154,2010.0,INDUSTRY,lead,DNage B.V.,Phase 1/Phase 2
NCT01142193,2010.0,INDUSTRY,lead,Upsher-Smith Laboratories,Phase 3
NCT01142258,2010.0,OTHER,lead,Brasilia University Hospital,Phase 3
NCT01142258,2010.0,OTHER,collaborator,Universidade Federal do Paraná,Phase 3
NCT01142336,2010.0,OTHER,lead,University of Washington,Phase 4
NCT01142336,2010.0,OTHER,collaborator,Seattle Institute for Biomedical and Clinical Research,Phase 4
NCT01142336,2010.0,FED,collaborator,VA Puget Sound Health Care System,Phase 4
NCT01142466,2005.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT01142466,2005.0,INDUSTRY,collaborator,Gesellschaft für Therapieforschung mbH,Phase 4
NCT01142596,2010.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01142596,2010.0,INDUSTRY,collaborator,"Meiji Seika Pharma Co., Ltd.",Phase 3
NCT01142856,2010.0,OTHER,lead,Mayo Clinic,Phase 1
NCT01143064,2010.0,INDUSTRY,lead,"BHR Pharma, LLC",Phase 3
NCT01143064,2010.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 3
NCT01143064,2010.0,OTHER,collaborator,Syneos Health,Phase 3
NCT01143077,2010.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01143090,2010.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01143441,2010.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01143857,2010.0,OTHER,lead,Jennifer Plebani,Phase 2
NCT01143857,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01144351,2010.0,INDUSTRY,lead,Elan Pharmaceuticals,Phase 1
NCT01144650,2009.0,INDUSTRY,lead,"Cidat, S.A. de C.V.",Phase 2/Phase 3
NCT01144650,2009.0,OTHER,collaborator,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Phase 2/Phase 3
NCT01145001,2009.0,OTHER,lead,Yale University,Not Applicable
NCT01145001,2009.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT01145001,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01145183,2010.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT01145183,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01145417,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01145482,2010.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT01146132,2009.0,OTHER,lead,Manon Gantenbein,Not Applicable
NCT01146132,2009.0,OTHER,collaborator,Centre Hospitalier du Luxembourg,Not Applicable
NCT01146301,2008.0,OTHER,lead,R&D Cardiologie,Phase 4
NCT01146509,2003.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT01146548,2008.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT01146548,2008.0,OTHER,collaborator,"Clinical Research Center, Toulouse",Phase 2
NCT01146951,2010.0,INDUSTRY,lead,Eisai Limited,Phase 3
NCT01147575,2005.0,OTHER,lead,Medical University of Vienna,Not Applicable
NCT01147653,2010.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 2
NCT01147653,2010.0,OTHER,collaborator,The Robertson Foundation,Phase 2
NCT01148017,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01148017,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT01148316,2010.0,OTHER,lead,Roseli Shavitt,Not Applicable
NCT01148316,2010.0,OTHER,collaborator,University of Pernambuco,Not Applicable
NCT01148342,2004.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01148498,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01148524,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 2/Phase 3
NCT01148810,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01148992,2010.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01149018,2010.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT01149018,2010.0,OTHER,collaborator,Hebrew University of Jerusalem,Not Applicable
NCT01149525,2010.0,OTHER,lead,"University Hospital, Bordeaux",Phase 3
NCT01149577,2007.0,OTHER,lead,"Central Institute of Psychiatry, Ranchi, India",Phase 4
NCT01149655,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01150448,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01150942,2010.0,INDUSTRY,lead,"Boryung Pharmaceutical Co., Ltd",Phase 3
NCT01150942,2010.0,OTHER,collaborator,Seoul National University Hospital,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Gachon University Gil Medical Center,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Inha University Hospital,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Inje University,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Korea Cancer Center Hospital,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Samsung Medical Center,Phase 3
NCT01150942,2010.0,OTHER,collaborator,The Catholic University of Korea,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Ewha Womans University,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Wonju Severance Christian Hospital,Phase 3
NCT01150942,2010.0,OTHER,collaborator,Kyunghee University Medical Center,Phase 3
NCT01151124,2010.0,INDUSTRY,lead,ReNeuron Limited,Phase 1
NCT01151540,2010.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 3
NCT01151813,2010.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01151813,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01151865,2011.0,OTHER_GOV,lead,Austin Health,Phase 2/Phase 3
NCT01151865,2011.0,INDUSTRY,collaborator,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 2/Phase 3
NCT01152216,2010.0,INDUSTRY,lead,"Medivation, Inc.",Phase 3
NCT01152216,2010.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT01152554,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01152554,2010.0,INDUSTRY,collaborator,Targacept Inc.,Phase 3
NCT01152723,2008.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01152736,2008.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01152749,2009.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01153204,,OTHER,lead,Federal University of São Paulo,Phase 4
NCT01153204,,OTHER,collaborator,University of Sao Paulo,Phase 4
NCT01153347,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01153347,2010.0,INDUSTRY,collaborator,Targacept Inc.,Phase 3
NCT01153490,2010.0,OTHER,lead,Northwell Health,Phase 4
NCT01153490,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01153581,2006.0,OTHER,lead,Yale University,Phase 2
NCT01153581,2006.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT01153802,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01153815,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01153932,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01154166,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01154647,2010.0,OTHER,lead,Vrije Universiteit Brussel,Not Applicable
NCT01154647,2010.0,OTHER,collaborator,Research Foundation Flanders,Not Applicable
NCT01154647,2010.0,OTHER,collaborator,Universiteit Antwerpen,Not Applicable
NCT01154647,2010.0,OTHER,collaborator,"University Hospital, Antwerp",Not Applicable
NCT01154647,2010.0,OTHER,collaborator,"Artesis University College, Antwerp",Not Applicable
NCT01154829,2008.0,OTHER,lead,University of Copenhagen,Not Applicable
NCT01154829,2008.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT01154829,2008.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT01154829,2008.0,OTHER,collaborator,"Institute of Psychiatry, London",Not Applicable
NCT01154829,2008.0,OTHER,collaborator,UMC Utrecht,Not Applicable
NCT01154829,2008.0,OTHER,collaborator,Copenhagen Hospital Corporation,Not Applicable
NCT01154894,2009.0,OTHER,lead,Ashiya University,Not Applicable
NCT01155167,2010.0,OTHER,lead,"University of California, San Francisco",Phase 2/Phase 3
NCT01155466,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT01155479,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT01155544,2011.0,OTHER,lead,Northwell Health,Phase 4
NCT01155544,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01155986,2010.0,INDUSTRY,lead,Grünenthal GmbH,Phase 2
NCT01156051,2010.0,OTHER,lead,Children's Specialized Hospital,Phase 4
NCT01156051,2010.0,INDUSTRY,collaborator,Shire,Phase 4
NCT01156311,2010.0,INDUSTRY,lead,Biogen,Phase 2
NCT01156909,2010.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT01156922,2010.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT01157078,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01157078,2010.0,INDUSTRY,collaborator,Targacept Inc.,Phase 3
NCT01157351,2010.0,INDUSTRY,lead,"Janssen Scientific Affairs, LLC",Phase 4
NCT01157416,2010.0,OTHER,lead,Tulane University School of Medicine,Phase 2
NCT01157416,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01157429,2010.0,OTHER,lead,Tulane University School of Medicine,Phase 2
NCT01157429,2010.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 2
NCT01158599,2010.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 4
NCT01158755,2010.0,OTHER,lead,Universitas Padjadjaran,Phase 2
NCT01158755,2010.0,OTHER,collaborator,Radboud University Medical Center,Phase 2
NCT01160263,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01160263,2012.0,OTHER,collaborator,"Association Française contre les Myopathies (AFM), Paris",Phase 3
NCT01160263,2012.0,UNKNOWN,collaborator,ARS (Association pour la Recherche sur la Sclérose Latérale Amyotrophique),Phase 3
NCT01160263,2012.0,OTHER,collaborator,Agence Générale des Equipements et Produits de Santé,Phase 3
NCT01160289,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01160692,2006.0,INDUSTRY,lead,Bayer,Phase 3
NCT01160770,2005.0,INDUSTRY,lead,Lundbeck LLC,Phase 3
NCT01160991,2004.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Not Applicable
NCT01160991,2004.0,INDUSTRY,collaborator,Sanofi,Not Applicable
NCT01161017,2008.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT01161108,2010.0,OTHER,lead,The Hospital for Sick Children,Phase 3
NCT01161277,2010.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT01161524,2010.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT01161654,2007.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT01161667,2007.0,INDUSTRY,lead,Roxane Laboratories,Not Applicable
NCT01161914,2011.0,INDUSTRY,lead,"ISU Abxis Co., Ltd.",Phase 3
NCT01162239,2010.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT01162239,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01162239,2010.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT01162460,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT01162915,2010.0,INDUSTRY,lead,TCA Cellular Therapy,Phase 1
NCT01163825,2008.0,INDUSTRY,lead,NsGene A/S,Phase 1
NCT01163825,2008.0,OTHER,collaborator,Karolinska Institutet,Phase 1
NCT01163825,2008.0,OTHER_GOV,collaborator,Region Stockholm,Phase 1
NCT01164059,2010.0,OTHER,lead,University of Bremen,Phase 4
NCT01164059,2010.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT01164189,2011.0,NETWORK,lead,European Organisation for Research and Treatment of Cancer - EORTC,Phase 2
NCT01164189,2011.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2
NCT01165008,2003.0,OTHER,lead,Karolinska Institutet,Phase 2/Phase 3
NCT01165060,2010.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Not Applicable
NCT01165060,2010.0,UNKNOWN,collaborator,The Stop ALD Foundation,Not Applicable
NCT01165294,2009.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 1
NCT01166152,2010.0,OTHER,lead,Tokyo University of Agriculture and Technology,Not Applicable
NCT01166152,2010.0,OTHER,collaborator,Ashiya University,Not Applicable
NCT01166152,2010.0,OTHER,collaborator,Saitama Medical University,Not Applicable
NCT01166178,2010.0,INDUSTRY,lead,Novartis,Phase 3
NCT01166425,2010.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT01166594,2010.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT01166594,2010.0,OTHER,collaborator,Glaucoma Research Society of Canada,Phase 4
NCT01167426,2010.0,INDUSTRY,lead,"Teva Neuroscience, Inc.",Phase 3
NCT01168596,2009.0,OTHER,lead,University of Florida,Phase 4
NCT01168674,2010.0,OTHER,lead,Tufts Medical Center,Phase 4
NCT01168674,2010.0,OTHER,collaborator,Duke University,Phase 4
NCT01168674,2010.0,OTHER,collaborator,University of South Carolina,Phase 4
NCT01168687,2008.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT01168687,2008.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT01168687,2008.0,OTHER,collaborator,University of California,Not Applicable
NCT01168817,2010.0,INDUSTRY,lead,Bayer,Phase 2
NCT01168908,2010.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT01168908,2010.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT01169142,2010.0,OTHER_GOV,lead,Bronx Psychiatric Center,Phase 4
NCT01169389,2009.0,OTHER,lead,"Orthopaedic Research and Innovation Foundation, Ireland",Not Applicable
NCT01169610,2011.0,OTHER,lead,Mayo Clinic,Phase 3
NCT01170117,2010.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT01170117,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01170117,2010.0,OTHER,collaborator,Weill Medical College of Cornell University,Not Applicable
NCT01170117,2010.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT01170117,2010.0,OTHER,collaborator,Johns Hopkins University,Not Applicable
NCT01170117,2010.0,OTHER,collaborator,University of Toronto,Not Applicable
NCT01170325,2010.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT01171183,2010.0,OTHER,lead,University of Arkansas,Phase 2
NCT01171183,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01171183,2010.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT01171209,2010.0,OTHER,lead,Melinda Magyari,Phase 2
NCT01171209,2010.0,OTHER,collaborator,University of Copenhagen,Phase 2
NCT01171313,2010.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT01171469,2010.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 1
NCT01171989,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01172145,2005.0,OTHER,lead,Brown University,Phase 3
NCT01172145,2005.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT01172145,2005.0,INDUSTRY,collaborator,Cephalon,Phase 3
NCT01172275,2012.0,OTHER,lead,Yale University,Phase 2
NCT01172288,2010.0,OTHER,lead,Yale University,Phase 2
NCT01172288,2010.0,OTHER,collaborator,American Academy of Child Adolescent Psychiatry.,Phase 2
NCT01172379,2004.0,INDUSTRY,lead,Eisai Limited,Phase 2
NCT01172652,2010.0,FED,lead,VA Palo Alto Health Care System,Phase 4
NCT01172652,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01172652,2010.0,OTHER,collaborator,University of South Florida,Phase 4
NCT01172652,2010.0,OTHER,collaborator,Lindner Center of HOPE,Phase 4
NCT01172873,2008.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT01172873,2008.0,OTHER,collaborator,Emory University,Not Applicable
NCT01173055,2010.0,OTHER,lead,University of Michigan,Phase 4
NCT01173055,2010.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01173432,2008.0,OTHER,lead,The University of Hong Kong,Not Applicable
NCT01173731,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01173874,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 3
NCT01174394,2010.0,OTHER,lead,The University of Hong Kong,Not Applicable
NCT01174394,2010.0,OTHER,collaborator,Tung Wah Hospital,Not Applicable
NCT01174394,2010.0,OTHER,collaborator,"Kowloon Hospital, Hong Kong",Not Applicable
NCT01174693,2010.0,OTHER,lead,Gangnam Severance Hospital,Phase 4
NCT01174693,2010.0,UNKNOWN,collaborator,Myung In Pharmaceutical Company,Phase 4
NCT01174693,2010.0,OTHER,collaborator,Yonsei University,Phase 4
NCT01174810,2010.0,OTHER,lead,"University College, London",Phase 2
NCT01174979,2011.0,INDUSTRY,lead,Phafag AG,Phase 3
NCT01175135,2010.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01175512,2010.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT01175525,,OTHER_GOV,lead,Wolfson Medical Center,Phase 3
NCT01175538,2008.0,OTHER_GOV,lead,Govind Ballabh Pant Hospital,Phase 4
NCT01175668,2010.0,OTHER,lead,Baystate Medical Center,Not Applicable
NCT01175954,2010.0,OTHER,lead,Evan Fertig,Phase 4
NCT01175954,2010.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT01176240,2010.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 3
NCT01176565,2011.0,OTHER,lead,University of Minnesota,Phase 3
NCT01176565,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01176565,2011.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT01176565,2011.0,OTHER,collaborator,Johns Hopkins University,Phase 3
NCT01176565,2011.0,OTHER,collaborator,University of Michigan,Phase 3
NCT01176565,2011.0,UNKNOWN,collaborator,Neurocritical Care Research Network,Phase 3
NCT01176565,2011.0,OTHER,collaborator,"National Cerebral and Cardiovascular Center, Japan",Phase 3
NCT01176565,2011.0,OTHER,collaborator,Japan Cardiovascular Research Foundation,Phase 3
NCT01176565,2011.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 3
NCT01176565,2011.0,OTHER,collaborator,China Medical University Hospital,Phase 3
NCT01176565,2011.0,OTHER,collaborator,University Hospital Heidelberg,Phase 3
NCT01176565,2011.0,OTHER,collaborator,Seoul National University Hospital,Phase 3
NCT01177319,2003.0,OTHER,lead,University of South Florida,Phase 2
NCT01177319,2003.0,INDUSTRY,collaborator,"Wellness Health & Pharmaceuticals, Inc.",Phase 2
NCT01177709,2008.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Not Applicable
NCT01177722,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01178047,2011.0,OTHER,lead,University of Zurich,Phase 4
NCT01178047,2011.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT01178164,2010.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT01178372,2008.0,OTHER_GOV,lead,Govind Ballabh Pant Hospital,Phase 4
NCT01178632,2010.0,INDUSTRY,lead,Millet Roux,Phase 3
NCT01178671,2010.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 4
NCT01178671,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01180283,2009.0,INDUSTRY,lead,Cristália Produtos Químicos Farmacêuticos Ltda.,Phase 4
NCT01180400,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01180400,2010.0,INDUSTRY,collaborator,Targacept Inc.,Phase 3
NCT01180608,2010.0,OTHER,lead,Universitair Ziekenhuis Brussel,Not Applicable
NCT01180608,2010.0,UNKNOWN,collaborator,Moens Maarten,Not Applicable
NCT01181115,2010.0,INDUSTRY,lead,Biogen,Phase 3
NCT01181232,2009.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT01181232,2009.0,INDUSTRY,collaborator,"Astellas Pharma Taiwan, Inc.",Phase 4
NCT01181310,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01181570,2010.0,OTHER,lead,Innovaderm Research Inc.,Phase 4
NCT01181570,2010.0,INDUSTRY,collaborator,Abbott,Phase 4
NCT01181921,2011.0,INDUSTRY,lead,"Janssen-Cilag, S.A.",Phase 4
NCT01181934,2010.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Early Phase 1
NCT01181934,2010.0,OTHER,collaborator,Agentschap voor Innovatie door Wetenschap en Technologie,Early Phase 1
NCT01182441,2010.0,INDUSTRY,lead,Boston Scientific Corporation,Phase 3
NCT01182727,2010.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01182727,2010.0,FED,collaborator,US Department of Veterans Affairs,Not Applicable
NCT01182766,2011.0,OTHER,lead,University of Virginia,Phase 2/Phase 3
NCT01182766,2011.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2/Phase 3
NCT01182766,2011.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT01182766,2011.0,OTHER,collaborator,"University of California, San Diego",Phase 2/Phase 3
NCT01182883,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01183208,2009.0,INDUSTRY,lead,Plethora Solutions Ltd,Phase 1
NCT01183208,2009.0,INDUSTRY,collaborator,"Bio-Kinetic Europe, Ltd.",Phase 1
NCT01183208,2009.0,INDUSTRY,collaborator,Omnicare Clinical Research,Phase 1
NCT01183312,2010.0,OTHER,lead,Lynn Marie Trotti,Phase 1/Phase 2
NCT01183312,2010.0,OTHER,collaborator,Georgia Research Alliance,Phase 1/Phase 2
NCT01183767,2010.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2/Phase 3
NCT01183806,2010.0,OTHER,lead,Federal University of Bahia,Phase 3
NCT01184105,2010.0,INDUSTRY,lead,Plethora Solutions Ltd,Phase 1
NCT01184443,2010.0,OTHER,lead,Children's Hospital of Eastern Ontario,Phase 3
NCT01184508,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01184664,2011.0,OTHER,lead,Queen Mary University of London,Phase 3
NCT01185574,2009.0,OTHER,lead,Loyola University,Not Applicable
NCT01185743,2010.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT01185821,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01186185,2012.0,OTHER,lead,Oregon Health and Science University,Early Phase 1
NCT01186471,2010.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Early Phase 1
NCT01186471,2010.0,OTHER,collaborator,Agentschap voor Innovatie door Wetenschap en Technologie,Early Phase 1
NCT01187550,2007.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT01187550,2007.0,INDUSTRY,collaborator,"Merck Serono Co., Ltd., China",Phase 4
NCT01187888,2010.0,OTHER,lead,Prof. Dr. Stefan Lorenzl,Phase 3
NCT01187888,2010.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01187888,2010.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 3
NCT01187966,2007.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT01188005,2010.0,OTHER,lead,University of Athens,Not Applicable
NCT01188096,2010.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT01188096,2010.0,OTHER,collaborator,Emory University,Phase 2
NCT01188148,2009.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 2/Phase 3
NCT01188148,2009.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2/Phase 3
NCT01188265,2007.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 3
NCT01188265,2007.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 3
NCT01188265,2007.0,INDUSTRY,collaborator,TTY Biopharm,Phase 3
NCT01188343,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01188603,2010.0,INDUSTRY,lead,"Sprout Pharmaceuticals, Inc",Phase 1
NCT01188759,2012.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01188811,2010.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT01188811,2010.0,OTHER,collaborator,Oregon Health and Science University,Phase 2/Phase 3
NCT01188967,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01188967,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01188967,2010.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT01188967,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT01189006,2005.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 2/Phase 3
NCT01189214,2009.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 3
NCT01189214,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT01189448,2010.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01189721,2010.0,OTHER,lead,Gangnam Severance Hospital,Phase 4
NCT01189812,2010.0,INDUSTRY,lead,Columbia Northwest Pharmaceuticals,Phase 2
NCT01190098,2010.0,OTHER,lead,The Cleveland Clinic,Phase 4
NCT01190098,2010.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT01190228,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01190553,2010.0,OTHER,lead,Rabin Medical Center,Not Applicable
NCT01190735,2010.0,OTHER,lead,Ron Postuma,Phase 2
NCT01190735,2010.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT01190813,2010.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT01190813,2010.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT01190930,2010.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT01190930,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT01191086,2010.0,INDUSTRY,lead,Upsher-Smith Laboratories,Phase 3
NCT01191125,2011.0,INDUSTRY,lead,Abbott Nutrition,Phase 3
NCT01191918,2005.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT01191918,2005.0,OTHER,collaborator,The Davis Foundations,Phase 4
NCT01191944,2010.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT01192113,2010.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 4
NCT01192503,2010.0,OTHER,lead,University of Virginia,Phase 2/Phase 3
NCT01192503,2010.0,INDUSTRY,collaborator,"Teva Neuroscience, Inc.",Phase 2/Phase 3
NCT01192529,2010.0,INDUSTRY,lead,"Vegenat, S.A.",Not Applicable
NCT01192568,2011.0,INDUSTRY,lead,AbbVie,Phase 4
NCT01192828,2010.0,OTHER,lead,"University of Colorado, Denver",Phase 1/Phase 2
NCT01192867,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01192880,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01192906,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01192997,2012.0,OTHER_GOV,lead,Public Health England,Phase 2/Phase 3
NCT01193153,2010.0,INDUSTRY,lead,"Janssen Scientific Affairs, LLC",Phase 3
NCT01193166,2010.0,INDUSTRY,lead,"Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 4
NCT01193270,2010.0,NETWORK,lead,NICHD Neonatal Research Network,Phase 1
NCT01193270,2010.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 1
NCT01193270,2010.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT01193608,2010.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01193608,2010.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 1
NCT01193660,2010.0,OTHER,lead,Sung Kwang Medical Foundation,Not Applicable
NCT01193816,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT01195363,2007.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT01195363,2007.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT01195636,2010.0,INDUSTRY,lead,Xenon Pharmaceuticals Inc.,Phase 2
NCT01195753,2010.0,INDUSTRY,lead,Cytonet GmbH & Co. KG,Phase 2
NCT01196676,2010.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01196871,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT01197846,2010.0,NETWORK,lead,Centro de Investigación Biomédica en Red de Salud Mental,Phase 3
NCT01198132,2009.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01198132,2009.0,INDUSTRY,collaborator,"Merck Serono S.A.S, France",Phase 2
NCT01198197,2010.0,NIH,lead,National Institute of Mental Health (NIMH),Early Phase 1
NCT01198353,2010.0,OTHER,lead,Soonchunhyang University Hospital,Phase 4
NCT01198353,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01198496,2010.0,OTHER,lead,Biomedis International Ltd.,Phase 4
NCT01199276,2010.0,INDUSTRY,lead,Air Liquide Santé International,Phase 2
NCT01199276,2010.0,UNKNOWN,collaborator,OptumInsight,Phase 2
NCT01199640,2005.0,INDUSTRY,lead,"Millennium Pharmaceuticals, Inc.",Phase 2
NCT01199978,2011.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01199978,2011.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01200615,2010.0,OTHER,lead,Shalvata Mental Health Center,Not Applicable
NCT01200901,2008.0,OTHER,lead,University of Cincinnati,Phase 4
NCT01201187,2010.0,INDUSTRY,lead,"Yuyu Pharma, Inc.",Phase 3
NCT01201317,2010.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT01201499,2010.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT01201642,2010.0,OTHER,lead,Xijing Hospital,Not Applicable
NCT01201863,2010.0,OTHER,lead,Craig Hospital,Phase 4
NCT01201863,2010.0,OTHER,collaborator,"University of Colorado, Denver",Phase 4
NCT01201967,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01201967,2010.0,OTHER,collaborator,American Heart Association,Phase 4
NCT01202110,2010.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT01202227,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01202500,2010.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 3
NCT01202955,2008.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01202994,2011.0,OTHER,lead,University of Utah,Phase 2
NCT01203202,2010.0,INDUSTRY,lead,Symyoo,Phase 2
NCT01203384,2010.0,INDUSTRY,lead,CERESPIR,Phase 1
NCT01203592,2010.0,OTHER,lead,Mayo Clinic,Phase 1
NCT01204268,2009.0,OTHER,lead,Xijing Hospital,Not Applicable
NCT01204333,2011.0,OTHER,lead,"Jan Stam, MD, PhD",Phase 2/Phase 3
NCT01204333,2011.0,OTHER,collaborator,Dutch Heart Foundation,Phase 2/Phase 3
NCT01204723,2009.0,OTHER,lead,University of Virginia,Phase 1
NCT01204723,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01204918,2011.0,OTHER,lead,Yale University,Phase 2
NCT01205282,2013.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01205282,2013.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT01205464,2005.0,OTHER_GOV,lead,Linkoeping University,Not Applicable
NCT01206010,2011.0,OTHER,lead,Queen Mary University of London,Phase 3
NCT01206517,2010.0,INDUSTRY,lead,Organon and Co,Phase 1
NCT01207050,2010.0,OTHER,lead,Kessler Foundation,Phase 4
NCT01207414,2010.0,INDUSTRY,lead,Novartis,Phase 4
NCT01207596,2010.0,OTHER,lead,International Clinical Research Institute,Phase 4
NCT01207622,,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01207622,,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT01207622,,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01207687,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01207908,2010.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT01207908,2010.0,INDUSTRY,collaborator,Ipsen,Phase 1/Phase 2
NCT01207908,2010.0,OTHER,collaborator,Charley's Fund,Phase 1/Phase 2
NCT01208038,2011.0,OTHER,lead,Imperial College Healthcare NHS Trust,Phase 4
NCT01208038,2011.0,OTHER,collaborator,Royal Brompton & Harefield NHS Foundation Trust,Phase 4
NCT01208038,2011.0,OTHER,collaborator,Chelsea and Westminster NHS Foundation Trust,Phase 4
NCT01208935,1999.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01209039,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01209156,2010.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT01209416,2012.0,OTHER,lead,University of Aarhus,Not Applicable
NCT01209741,2007.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01209845,2010.0,OTHER,lead,Yale University,Phase 1
NCT01210430,2010.0,OTHER,lead,New York Medical College,Early Phase 1
NCT01210885,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT01211145,2010.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT01211405,2010.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT01211522,2011.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT01211665,2010.0,INDUSTRY,lead,Biogen,Phase 4
NCT01211665,2010.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 4
NCT01211704,2010.0,OTHER,lead,University of Miami,Phase 4
NCT01211704,2010.0,INDUSTRY,collaborator,"Ortho-McNeil, Inc.",Phase 4
NCT01211782,,INDUSTRY,lead,Cerecin,Phase 2/Phase 3
NCT01211795,2009.0,INDIV,lead,"Behar, Caren, M.D.",Phase 3
NCT01211873,2010.0,INDUSTRY,lead,Guerbet,Phase 3
NCT01212094,2010.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT01212484,2009.0,OTHER,lead,NYU Langone Health,Phase 3
NCT01212588,2010.0,OTHER,lead,Indiana University,Phase 2
NCT01212679,2010.0,OTHER,lead,"Jinling Hospital, China",Phase 2
NCT01212744,2011.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT01213121,2010.0,OTHER,lead,Seoul National University Bundang Hospital,Phase 4
NCT01213524,2005.0,OTHER,lead,Brown University,Phase 2
NCT01213524,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01213836,2010.0,INDUSTRY,lead,AstraZeneca,Phase 4
NCT01214317,2010.0,OTHER,lead,Isfahan University of Medical Sciences,Not Applicable
NCT01214837,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01214889,2010.0,INDUSTRY,lead,Sanofi,Phase 3
NCT01215019,2010.0,OTHER,lead,Indiana University,Not Applicable
NCT01215227,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT01215357,2010.0,INDUSTRY,lead,Psyadon Pharma,Phase 2
NCT01216904,2010.0,OTHER,lead,University of Vermont,Phase 4
NCT01216904,2010.0,OTHER,collaborator,Parkinson's Disease Foundation,Phase 4
NCT01216904,2010.0,NETWORK,collaborator,The Parkinson Study Group,Phase 4
NCT01216982,2010.0,FED,lead,United States Department of Defense,Phase 2
NCT01216982,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT01217008,2010.0,INDUSTRY,lead,"Lineage Cell Therapeutics, Inc.",Phase 1
NCT01217021,2010.0,OTHER,lead,Institute for Neurodegenerative Disorders,Early Phase 1
NCT01217021,2010.0,OTHER,collaborator,Molecular NeuroImaging,Early Phase 1
NCT01217294,2011.0,OTHER,lead,Rachel Kearns,Not Applicable
NCT01217294,2011.0,OTHER,collaborator,NHS Greater Glasgow and Clyde,Not Applicable
NCT01217437,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01217970,2011.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT01217970,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01217970,2011.0,INDUSTRY,collaborator,MediciNova,Phase 1
NCT01218568,2010.0,OTHER,lead,"Institute of Liver and Biliary Sciences, India",Not Applicable
NCT01218659,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT01219049,2010.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT01219686,2010.0,OTHER,lead,Markus KOSEL,Phase 2/Phase 3
NCT01219686,2010.0,OTHER,collaborator,"University Hospital, Geneva",Phase 2/Phase 3
NCT01219686,2010.0,OTHER,collaborator,University of Lausanne Hospitals,Phase 2/Phase 3
NCT01219686,2010.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Phase 2/Phase 3
NCT01219686,2010.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2/Phase 3
NCT01220206,2011.0,INDUSTRY,lead,POM Wonderful LLC,Phase 2
NCT01220206,2011.0,INDUSTRY,collaborator,Target Health Inc.,Phase 2
NCT01220622,2010.0,OTHER_GOV,lead,Ministry of Science and Technology of the People´s Republic of China,Phase 4
NCT01221025,2010.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT01221025,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01221246,2011.0,INDUSTRY,lead,"Genervon Biopharmaceuticals, LLC",Phase 2
NCT01221246,2011.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT01221246,2011.0,OTHER_GOV,collaborator,Huntington Hospital,Phase 2
NCT01221246,2011.0,OTHER,collaborator,Hoag Memorial Hospital Presbyterian,Phase 2
NCT01221246,2011.0,OTHER,collaborator,Columbia University,Phase 2
NCT01221246,2011.0,OTHER,collaborator,California Pacific Medical Center Research Institute,Phase 2
NCT01221246,2011.0,OTHER,collaborator,University Hospital Erlangen,Phase 2
NCT01221246,2011.0,OTHER,collaborator,Sarasota Memorial Hospital,Phase 2
NCT01221246,2011.0,OTHER,collaborator,University of Louisville,Phase 2
NCT01221259,2010.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT01221792,2010.0,INDUSTRY,lead,Columbia Northwest Pharmaceuticals,Phase 2
NCT01221883,2013.0,OTHER,lead,Hadassah Medical Organization,Phase 4
NCT01222091,2009.0,OTHER,lead,Stanford University,Phase 2
NCT01222351,2010.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT01222351,2010.0,INDUSTRY,collaborator,Bayer,Not Applicable
NCT01222351,2010.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT01222780,2010.0,INDUSTRY,lead,Acrotech Biopharma Inc.,Phase 1
NCT01222780,2010.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01223001,1996.0,OTHER,lead,Rehabilitation Hospital of Indiana,Phase 2
NCT01223001,1996.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT01223742,2002.0,OTHER,lead,University of Catania,Not Applicable
NCT01224106,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01225055,2010.0,OTHER,lead,Thomas J. Schnitzer,Phase 2
NCT01225055,2010.0,FED,collaborator,Edward Hines Jr. VA Hospital,Phase 2
NCT01225055,2010.0,OTHER,collaborator,University of Illinois at Chicago,Phase 2
NCT01225263,2010.0,OTHER,lead,Rami Burstein,Phase 2
NCT01225276,2011.0,INDUSTRY,lead,Octapharma,Phase 2/Phase 3
NCT01225289,2009.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT01225562,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01226511,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01226667,2010.0,OTHER,lead,"Osteoporosis Medical Center, Beverly Hills, CA",Phase 4
NCT01226667,2010.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01226745,2010.0,INDUSTRY,lead,EMD Serono,Phase 2
NCT01226745,2010.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01226745,2010.0,INDUSTRY,collaborator,Ono Pharmaceutical Co. Ltd,Phase 2
NCT01227252,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01227265,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT01227512,2010.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01227564,2011.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01227564,2011.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT01227655,2011.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT01227681,2010.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Phase 2
NCT01227720,2009.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01227902,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01227980,2010.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01228266,2010.0,OTHER,lead,Albert Saiz,Phase 2
NCT01228266,2010.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 2
NCT01228357,2003.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01228370,2011.0,INDUSTRY,lead,JW Pharmaceutical,Phase 4
NCT01228552,2011.0,INDIV,lead,"Behar, Caren, M.D.",Phase 3
NCT01228617,2007.0,INDUSTRY,lead,Johnson & Johnson Consumer and Personal Products Worldwide,Not Applicable
NCT01228747,2010.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT01228838,2010.0,INDUSTRY,lead,NeurogesX,Phase 2
NCT01228994,2010.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01228994,2010.0,OTHER,collaborator,Canadian Tobacco Control Research Initiative,Phase 2
NCT01229332,2011.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1/Phase 2
NCT01229579,2010.0,OTHER,lead,Aga Khan University,Not Applicable
NCT01229579,2010.0,OTHER,collaborator,World Health Organization,Not Applicable
NCT01229735,2010.0,INDUSTRY,lead,"UCB Korea Co., Ltd.",Phase 4
NCT01230359,2010.0,INDUSTRY,lead,Hamad Medical Corporation,Not Applicable
NCT01230359,2010.0,OTHER,collaborator,Qatar University,Not Applicable
NCT01230359,2010.0,OTHER,collaborator,Heidelberg University,Not Applicable
NCT01230541,2010.0,INDUSTRY,lead,Warner Chilcott,Phase 1
NCT01230762,,INDUSTRY,lead,"Alza Corporation, DE, USA",Phase 3
NCT01230801,2011.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1/Phase 2
NCT01230853,2010.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT01231009,2010.0,OTHER,lead,Aristotle University Of Thessaloniki,Early Phase 1
NCT01231139,2010.0,OTHER,lead,Dr. M.K. Saxena,Phase 2
NCT01231139,2010.0,OTHER,collaborator,The George Institute,Phase 2
NCT01231139,2010.0,OTHER,collaborator,The University of New South Wales,Phase 2
NCT01231139,2010.0,OTHER_GOV,collaborator,Royal Brisbane and Women's Hospital,Phase 2
NCT01232400,2014.0,OTHER,lead,University of Michigan,Not Applicable
NCT01232790,2010.0,OTHER,lead,Yale University,Not Applicable
NCT01232790,2010.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT01234454,2002.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT01234506,2010.0,OTHER,lead,University of Saskatchewan,Phase 2
NCT01234506,2010.0,OTHER,collaborator,Saskatchewan Health Research Foundation,Phase 2
NCT01234675,2010.0,OTHER,lead,Mansoor Ahmed M.D.,Phase 4
NCT01234675,2010.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01234779,2011.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01234792,2008.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01234896,2010.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01235221,2010.0,INDUSTRY,lead,Biogen,Phase 3
NCT01235221,2010.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 3
NCT01235403,2010.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT01235520,2011.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01235559,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01235585,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01235754,2010.0,INDUSTRY,lead,BioSante Pharmaceuticals,Phase 3
NCT01236534,2010.0,OTHER,lead,University of Rochester,Phase 4
NCT01236534,2010.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT01236586,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01237275,1999.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01237587,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01238315,2010.0,INDUSTRY,lead,"StemCells, Inc.",Phase 1
NCT01238458,2009.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01238575,2011.0,OTHER,lead,Yale University,Phase 4
NCT01238575,2011.0,OTHER,collaborator,Emory University,Phase 4
NCT01238575,2011.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT01238575,2011.0,OTHER,collaborator,Seattle Children's Hospital,Phase 4
NCT01238575,2011.0,OTHER,collaborator,"University of California, Los Angeles",Phase 4
NCT01238575,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01238627,2007.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01238640,2008.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01238926,2008.0,OTHER,lead,New York Institute of Technology,Not Applicable
NCT01238926,2008.0,OTHER,collaborator,Stony Brook University,Not Applicable
NCT01238991,2010.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01238991,2010.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT01239043,2010.0,INDUSTRY,lead,Sanofi,Phase 2
NCT01239173,2010.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01239212,2010.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT01239706,2010.0,OTHER,lead,University of Calgary,Phase 2
NCT01239706,2010.0,INDUSTRY,collaborator,Stem Cell Therapeutics Corp.,Phase 2
NCT01239758,2010.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2
NCT01239888,2012.0,OTHER,lead,The Alfred,Phase 1
NCT01239888,2012.0,OTHER,collaborator,Monash University,Phase 1
NCT01240356,2008.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT01240356,2008.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 1/Phase 2
NCT01240876,2011.0,INDUSTRY,lead,Cephalon,Phase 1/Phase 2
NCT01241032,2006.0,OTHER,lead,Asan Medical Center,Phase 1
NCT01241032,2006.0,INDUSTRY,collaborator,"Dong-A Pharmaceutical Co., Ltd.",Phase 1
NCT01241474,2009.0,OTHER,lead,University of Aberdeen,Not Applicable
NCT01242371,2010.0,OTHER,lead,Sheppard Pratt Health System,Not Applicable
NCT01242371,2010.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT01243177,2011.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 3
NCT01243177,2011.0,INDUSTRY,collaborator,Eden Sarl,Phase 3
NCT01243541,2010.0,OTHER,lead,Northwestern University,Not Applicable
NCT01243541,2010.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT01243658,2011.0,OTHER,lead,Prof. Dr. Markus Heinrichs,Not Applicable
NCT01243697,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT01244113,2010.0,OTHER,lead,Yonsei University,Not Applicable
NCT01244139,2010.0,INDUSTRY,lead,Biogen,Phase 1
NCT01244269,2010.0,OTHER,lead,Laval University,Phase 4
NCT01244269,2010.0,OTHER_GOV,collaborator,Fonds de la Recherche en Santé du Québec,Phase 4
NCT01244269,2010.0,OTHER,collaborator,Quebec Memory and Motor Skills Disorders Research Center,Phase 4
NCT01244464,2010.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01244633,2010.0,INDUSTRY,lead,Psyadon Pharma,Phase 1/Phase 2
NCT01244724,2007.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT01244724,2007.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01244737,2010.0,OTHER,lead,Frederick Daniel Grant,Phase 2
NCT01244737,2010.0,OTHER,collaborator,Dana-Farber Cancer Institute,Phase 2
NCT01244828,2011.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01245049,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01245530,2008.0,INDUSTRY,lead,Whanin Pharmaceutical Company,Phase 3
NCT01245777,2009.0,OTHER,lead,University of Zurich,Phase 4
NCT01245777,2009.0,INDUSTRY,collaborator,Vifor Pharma,Phase 4
NCT01246232,2011.0,OTHER,lead,Imperial College London,Phase 4
NCT01246232,2011.0,OTHER,collaborator,University of Manchester,Phase 4
NCT01246232,2011.0,OTHER,collaborator,"University College, London",Phase 4
NCT01246310,2010.0,OTHER,lead,AGUNCO Obstetrics and Gynecology Centre,Not Applicable
NCT01246310,2010.0,UNKNOWN,collaborator,Centro Clinico Colle Cesarano Tivoli Rome Italy,Not Applicable
NCT01246401,2011.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT01246401,2011.0,OTHER,collaborator,Baystate Medical Center,Phase 1/Phase 2
NCT01246401,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01246479,2010.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT01246804,2010.0,OTHER,lead,Radboud University Medical Center,Phase 1
NCT01246804,2010.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT01247207,2010.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT01248052,2010.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01248195,2011.0,OTHER,lead,Rene Kahn,Phase 4
NCT01248195,2011.0,OTHER,collaborator,King's College London,Phase 4
NCT01248195,2011.0,OTHER,collaborator,Technical University of Munich,Phase 4
NCT01248195,2011.0,OTHER,collaborator,University of Manchester,Phase 4
NCT01248195,2011.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 4
NCT01248728,2010.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01248728,2010.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT01248728,2010.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2
NCT01248884,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01249183,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01249196,2010.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 3
NCT01249274,2011.0,OTHER,lead,Yale University,Not Applicable
NCT01249274,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01249417,2011.0,INDUSTRY,lead,Ipsen,Phase 3
NCT01250847,2010.0,OTHER,lead,Severance Hospital,Phase 4
NCT01251003,2011.0,OTHER,lead,Charles Cox,Phase 1/Phase 2
NCT01251055,2010.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01251211,2010.0,OTHER,lead,Hospital Ambroise Paré Paris,Phase 4
NCT01251380,2011.0,INDUSTRY,lead,Ipsen,Phase 3
NCT01251393,2011.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01251393,2011.0,OTHER,collaborator,Nacional Conseling of Scientific Development and Technology,Phase 3
NCT01251471,2011.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT01252160,2010.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 4
NCT01252875,2010.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT01252875,2010.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT01252875,2010.0,INDUSTRY,collaborator,AstraZeneca,Not Applicable
NCT01252875,2010.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Not Applicable
NCT01252979,2010.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Early Phase 1
NCT01253122,2010.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 1
NCT01253122,2010.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT01253317,2010.0,OTHER,lead,Boston Children's Hospital,Phase 1
NCT01253317,2010.0,OTHER,collaborator,International Rett Syndrome Foundation,Phase 1
NCT01253317,2010.0,OTHER,collaborator,Autism Speaks,Phase 1
NCT01253499,2010.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 1
NCT01253499,2010.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT01253629,2010.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01253915,2012.0,INDUSTRY,lead,"Capnia, Inc.",Phase 2
NCT01253915,2012.0,FED,collaborator,Walter Reed National Military Medical Center,Phase 2
NCT01253915,2012.0,FED,collaborator,"United States Naval Medical Center, San Diego",Phase 2
NCT01253915,2012.0,FED,collaborator,"United States Naval Medical Center, Portsmouth",Phase 2
NCT01253915,2012.0,FED,collaborator,Madigan Army Medical Center,Phase 2
NCT01254019,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01254045,2007.0,OTHER,lead,Stanford University,Phase 2
NCT01254383,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT01254396,2010.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT01254448,2010.0,INDUSTRY,lead,Targacept Inc.,Phase 1
NCT01254773,2010.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT01254773,2010.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01255046,2015.0,OTHER,lead,"Sinphar Pharmaceutical Co., Ltd",Phase 2
NCT01255163,2010.0,NIH,lead,National Institute on Aging (NIA),Phase 2
NCT01255358,2011.0,INDUSTRY,lead,Erydel,Phase 2
NCT01255878,2010.0,OTHER,lead,Mashhad University of Medical Sciences,Not Applicable
NCT01256021,2010.0,INDUSTRY,lead,Medy-Tox,Phase 4
NCT01256060,2010.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01256060,2010.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT01256060,2010.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2
NCT01256060,2010.0,OTHER,collaborator,University of Illinois at Chicago,Phase 2
NCT01256151,2011.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 1
NCT01256177,2010.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT01257581,2011.0,OTHER,lead,Nazem Atassi,Phase 2
NCT01257581,2011.0,OTHER,collaborator,ALS Therapy Alliance,Phase 2
NCT01257581,2011.0,OTHER,collaborator,State University of New York - Upstate Medical University,Phase 2
NCT01257737,2010.0,INDUSTRY,lead,"Horizon Therapeutics, LLC",Phase 4
NCT01257958,1998.0,OTHER,lead,"University of Wisconsin, Madison",Phase 1
NCT01258452,2011.0,INDUSTRY,lead,CERESPIR,Phase 1
NCT01258920,2010.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT01259050,2010.0,OTHER,lead,"Phoenix Neurological Associates, LTD",Phase 1/Phase 2
NCT01259388,2011.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT01259479,2010.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01259947,2006.0,OTHER,lead,Fabio Carmona,Phase 2
NCT01260103,2011.0,OTHER,lead,Burzynski Research Institute,Phase 3
NCT01261000,2010.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT01261143,2010.0,INDUSTRY,lead,Bukwang Pharmaceutical,Phase 3
NCT01261325,2010.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01261741,2010.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 2
NCT01261780,2011.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT01262170,2010.0,INDUSTRY,lead,"Rock Creek Pharmaceuticals, Inc.",Phase 1
NCT01262677,2011.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01263080,2010.0,OTHER,lead,Capital Medical University,Phase 4
NCT01263132,2008.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT01263132,2008.0,INDUSTRY,collaborator,"Merck S.A. de C.V., Mexico",Phase 3
NCT01263938,2011.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01263938,2011.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4
NCT01264237,2011.0,INDUSTRY,lead,Analgesic Solutions,Phase 4
NCT01264237,2011.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT01264861,2011.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 2
NCT01265043,2008.0,OTHER,lead,The University of Hong Kong,Phase 4
NCT01266174,2011.0,INDUSTRY,lead,"Amarantus BioScience Holdings, Inc.",Phase 2
NCT01267188,2011.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT01267292,2011.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01267422,2011.0,OTHER,lead,Bin Li,Not Applicable
NCT01267422,2011.0,OTHER,collaborator,Huazhong University of Science and Technology,Not Applicable
NCT01267994,2011.0,OTHER,lead,Andrea Vambutas,Phase 1/Phase 2
NCT01267994,2011.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 1/Phase 2
NCT01268020,2010.0,OTHER,lead,Institute for Neurodegenerative Disorders,Early Phase 1
NCT01268046,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT01268046,2009.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1/Phase 2
NCT01268124,2008.0,INDUSTRY,lead,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 1
NCT01268280,2010.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT01268280,2010.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01268631,2011.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT01268631,2011.0,OTHER,collaborator,"University of California, Davis",Not Applicable
NCT01268631,2011.0,OTHER,collaborator,Rambam Health Care Campus,Not Applicable
NCT01268891,2011.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01270282,2011.0,INDUSTRY,lead,"Auris Medical, Inc.",Phase 2
NCT01270503,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01270516,2014.0,OTHER,lead,Gerald Supinski,Not Applicable
NCT01270672,2011.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT01271244,2008.0,FED,lead,VA Nebraska Western Iowa Health Care System,Phase 4
NCT01271244,2008.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01271348,2011.0,INDUSTRY,lead,X-pert Med GmbH,Phase 1
NCT01271660,2011.0,OTHER,lead,Seoul National University Boramae Hospital,Phase 3
NCT01271660,2011.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT01271933,2011.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01272297,2010.0,OTHER,lead,Rambam Health Care Campus,Phase 3
NCT01272297,2010.0,INDUSTRY,collaborator,Medispec,Phase 3
NCT01272336,2010.0,OTHER,lead,Emory University,Phase 1
NCT01272336,2010.0,OTHER,collaborator,University of Saskatchewan,Phase 1
NCT01272336,2010.0,OTHER,collaborator,"University of Wisconsin, Madison",Phase 1
NCT01273337,2011.0,INDUSTRY,lead,Aldagen,Phase 2
NCT01273350,2004.0,OTHER,lead,SPSI d.b.a Capital Cardiovascular Associates,Not Applicable
NCT01273883,2011.0,OTHER,lead,Mayo Clinic,Phase 3
NCT01274897,2010.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01275586,2011.0,OTHER,lead,Indiana University,Early Phase 1
NCT01275586,2011.0,INDUSTRY,collaborator,Novartis,Early Phase 1
NCT01276977,2008.0,OTHER,lead,California Medical Clinic for Headache,Not Applicable
NCT01277887,2010.0,OTHER,lead,Yale University,Not Applicable
NCT01277887,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01278004,2010.0,OTHER,lead,Royal Marsden NHS Foundation Trust,Phase 2
NCT01278004,2010.0,OTHER,collaborator,Imperial College London,Phase 2
NCT01278342,2006.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01278433,2010.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01278498,2011.0,OTHER,lead,Asan Medical Center,Phase 4
NCT01278498,2011.0,INDUSTRY,collaborator,"Dong-A ST Co., Ltd.",Phase 4
NCT01278576,2011.0,OTHER,lead,The Catholic University of Korea,Phase 4
NCT01278576,2011.0,OTHER,collaborator,Bobath Memorial Hospital,Phase 4
NCT01279213,2009.0,OTHER,lead,Universidad Nacional de Rosario,Phase 4
NCT01279590,2011.0,INDUSTRY,lead,"Furiex Pharmaceuticals, Inc",Phase 2
NCT01279876,2010.0,OTHER,lead,Tehran University of Medical Sciences,Phase 2
NCT01280006,2011.0,OTHER,lead,University of Calgary,Phase 1/Phase 2
NCT01280123,2011.0,OTHER,lead,University of Rochester,Phase 2
NCT01280123,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01280123,2011.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01280305,2011.0,OTHER_GOV,lead,Sheba Medical Center,Phase 3
NCT01280968,2010.0,OTHER,lead,Alexey Mukhin,Phase 2
NCT01280968,2010.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 2
NCT01280968,2010.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01281189,2011.0,INDUSTRY,lead,Knopp Biosciences,Phase 3
NCT01281202,2011.0,INDUSTRY,lead,"Catalyst Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT01281202,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01281202,2011.0,FED,collaborator,VA Office of Research and Development,Phase 2/Phase 3
NCT01281475,2011.0,OTHER,lead,Wen-Hann Tan,Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,"Rady Children's Hospital, San Diego",Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,"University of California, San Francisco",Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,Baylor College of Medicine,Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,Greenwood Genetic Center,Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 2/Phase 3
NCT01281475,2011.0,OTHER,collaborator,"Angelman Syndrome Foundation, Inc.",Phase 2/Phase 3
NCT01281527,2010.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 3
NCT01281631,2011.0,INDUSTRY,lead,"Neuraltus Pharmaceuticals, Inc.",Phase 2
NCT01281956,2011.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01281969,2011.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 3
NCT01282242,2011.0,OTHER,lead,Lee Schwamm,Phase 2
NCT01282242,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01282242,2011.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT01282268,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 3
NCT01282619,2010.0,INDUSTRY,lead,"Shandong Luye Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT01283152,2011.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT01283347,2010.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01283412,2013.0,OTHER,lead,Huazhong University of Science and Technology,Phase 3
NCT01283594,2011.0,INDUSTRY,lead,Biotie Therapies Inc.,Phase 2/Phase 3
NCT01284387,2011.0,INDUSTRY,lead,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 2
NCT01284387,2011.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01284517,2010.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01284530,2011.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT01284556,2010.0,INDUSTRY,lead,West-Ward Pharmaceutical,Phase 3
NCT01284959,2010.0,OTHER,lead,Chonbuk National University Hospital,Phase 4
NCT01284959,2010.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT01284959,2010.0,INDUSTRY,collaborator,"Janssen Korea, Ltd., Korea",Phase 4
NCT01284959,2010.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT01284959,2010.0,INDUSTRY,collaborator,Sanofi-Synthelabo,Phase 4
NCT01285401,2011.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01285583,2010.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2/Phase 3
NCT01285856,2010.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT01286207,1995.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01286935,2007.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 3
NCT01287052,2011.0,OTHER,lead,Children's Hospitals and Clinics of Minnesota,Not Applicable
NCT01287221,2011.0,OTHER,lead,Phillip Low,Phase 3
NCT01287221,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01287221,2011.0,OTHER,collaborator,Vanderbilt University,Phase 3
NCT01287221,2011.0,UNKNOWN,collaborator,Rare Disease Research Network Autonomic Consortium,Phase 3
NCT01287494,2010.0,OTHER,lead,Zhejiang University,Phase 4
NCT01287949,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01288573,2014.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1/Phase 2
NCT01288573,2014.0,INDUSTRY,collaborator,Sanofi,Phase 1/Phase 2
NCT01288716,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT01288807,2011.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT01288807,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01288807,2011.0,FED,collaborator,US Department of Veterans Affairs,Phase 4
NCT01289080,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01289912,2011.0,OTHER,lead,Mustafa Sahin,Phase 2
NCT01289912,2011.0,OTHER,collaborator,Tuberous Sclerosis Alliance,Phase 2
NCT01289912,2011.0,OTHER,collaborator,Autism Speaks,Phase 2
NCT01289912,2011.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01289912,2011.0,UNKNOWN,collaborator,Seizure Tracker LLC,Phase 2
NCT01290939,2011.0,NETWORK,lead,European Organisation for Research and Treatment of Cancer - EORTC,Phase 3
NCT01290939,2011.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 3
NCT01291173,2011.0,INDUSTRY,lead,Shire,Phase 2
NCT01291316,2010.0,OTHER,lead,"University Hospital, Geneva",Phase 1/Phase 2
NCT01291511,2011.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 3
NCT01291537,2011.0,OTHER,lead,Poitiers University Hospital,Phase 2
NCT01292499,2009.0,OTHER,lead,Ospedale Amedeo di Savoia,Not Applicable
NCT01292642,2009.0,OTHER,lead,Mclean Hospital,Phase 2
NCT01292642,2009.0,OTHER,collaborator,Harvard Medical School (HMS and HSDM),Phase 2
NCT01292694,2011.0,OTHER,lead,Vanderbilt University,Phase 1
NCT01292837,2011.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT01293825,2011.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT01293825,2011.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01293838,2008.0,OTHER,lead,University of Ottawa,Phase 1
NCT01293838,2008.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT01294059,2009.0,OTHER,lead,University of Florida,Phase 1
NCT01294059,2009.0,INDUSTRY,collaborator,Forest Laboratories,Phase 1
NCT01294176,2011.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT01294540,2010.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT01294800,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT01295060,2011.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 3
NCT01295372,2011.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01295619,2011.0,INDUSTRY,lead,Kuros Biosurgery AG,Not Applicable
NCT01296360,2010.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 3
NCT01296464,2011.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT01296698,2011.0,INDUSTRY,lead,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Phase 3
NCT01296698,2011.0,INDUSTRY,collaborator,McNeil AB,Phase 3
NCT01296698,2011.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT01296802,2006.0,OTHER,lead,University of Zurich,Not Applicable
NCT01297036,2008.0,OTHER,lead,Korea University Anam Hospital,Phase 1
NCT01297036,2008.0,INDUSTRY,collaborator,Chong Kun Dang Pharmaceutical Corp.,Phase 1
NCT01298141,2011.0,INDUSTRY,lead,Shire,Phase 3
NCT01298180,2009.0,OTHER,lead,"University Hospital, Toulouse",Phase 4
NCT01298310,2011.0,INDUSTRY,lead,AstraZeneca,Early Phase 1
NCT01298466,2012.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 4
NCT01298765,2011.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 3
NCT01298921,2011.0,OTHER,lead,Geisinger Clinic,Phase 1
NCT01299389,2010.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT01299454,2010.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01299597,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01299870,2011.0,OTHER,lead,"Timothy Welty, PharmD",Phase 2
NCT01300364,2008.0,OTHER,lead,Fundació Sant Joan de Déu,Phase 4
NCT01300364,2008.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT01300455,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01300546,2010.0,INDIV,lead,"Cady, Roger, M.D.",Phase 4
NCT01300546,2010.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT01300637,2008.0,OTHER,lead,Taipei Medical University WanFang Hospital,Not Applicable
NCT01300637,2008.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Not Applicable
NCT01300819,2011.0,INDUSTRY,lead,UCB Pharma,Phase 4
NCT01300923,2010.0,OTHER,lead,Indiana University,Phase 2
NCT01301079,2010.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01301079,2010.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 3
NCT01301183,2011.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT01301898,2010.0,INDUSTRY,lead,Green Cross Corporation,Phase 1/Phase 2
NCT01302275,2011.0,OTHER,lead,Søren H. Sindrup,Phase 4
NCT01302275,2011.0,OTHER,collaborator,Danish Pain Research Center,Phase 4
NCT01302275,2011.0,OTHER,collaborator,Innovative Medicines Initiative,Phase 4
NCT01302327,2011.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT01302340,2011.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT01302340,2011.0,OTHER,collaborator,European Union,Phase 2
NCT01302964,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT01302964,2010.0,OTHER,collaborator,Autism Speaks,Phase 3
NCT01303146,2008.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01303146,2008.0,OTHER,collaborator,European Leukodystrophy Association,Phase 2
NCT01303146,2008.0,INDUSTRY,collaborator,Zymenex A/S,Phase 2
NCT01303146,2008.0,INDUSTRY,collaborator,Shire,Phase 2
NCT01303380,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01303406,2011.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT01303536,2009.0,OTHER,lead,"Institute of Neuroscience, Florence, Italy",Phase 4
NCT01303601,2009.0,OTHER,lead,"China Medical University, China",Phase 4
NCT01303744,2011.0,INDUSTRY,lead,CERESPIR,Phase 2
NCT01303861,2011.0,OTHER,lead,Duke University,Phase 3
NCT01303861,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01303861,2011.0,INDUSTRY,collaborator,"Philip Morris USA, Inc.",Phase 3
NCT01304277,2011.0,INDUSTRY,lead,Shire,Phase 2
NCT01305083,2010.0,INDUSTRY,lead,Abdi Ibrahim Ilac San. ve Tic A.S.,Phase 3
NCT01305408,2011.0,INDUSTRY,lead,Cephalon,Phase 3
NCT01305707,2009.0,OTHER,lead,Hospital Universitari de Bellvitge,Phase 4
NCT01306578,2007.0,OTHER,lead,Mansoura University Children Hospital,Not Applicable
NCT01306760,2011.0,OTHER,lead,University of Aberdeen,Phase 4
NCT01306760,2011.0,OTHER_GOV,collaborator,NHS Grampian,Phase 4
NCT01306760,2011.0,OTHER_GOV,collaborator,Chief Scientist Office of the Scottish Government,Phase 4
NCT01306929,2011.0,INDUSTRY,lead,Prilenia,Phase 2
NCT01306968,2011.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT01307332,2011.0,OTHER,lead,University of British Columbia,Phase 3
NCT01307332,2011.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 3
NCT01307800,2011.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 3
NCT01308736,2011.0,OTHER,lead,"Rutgers, The State University of New Jersey",Not Applicable
NCT01308736,2011.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT01308814,2010.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2/Phase 3
NCT01308814,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT01308957,2011.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT01308957,2011.0,INDUSTRY,collaborator,GlaxoSmithKline,Not Applicable
NCT01309074,2009.0,OTHER,lead,Rush University Medical Center,Phase 4
NCT01309581,2010.0,OTHER,lead,James Murrough,Not Applicable
NCT01309646,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01309685,2011.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01309763,2010.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT01309945,2011.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT01310114,2011.0,INDUSTRY,lead,Celularity Incorporated,Phase 2
NCT01310114,2011.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT01310712,2010.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT01310881,2011.0,INDUSTRY,lead,Neuralstem Inc.,Phase 1
NCT01311570,2012.0,OTHER,lead,Shalvata Mental Health Center,Phase 1
NCT01312272,2011.0,FED,lead,VA Greater Los Angeles Healthcare System,Not Applicable
NCT01312844,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01313117,2012.0,OTHER,lead,Northwestern University,Phase 1/Phase 2
NCT01313299,2011.0,INDUSTRY,lead,Ipsen,Phase 3
NCT01313312,2011.0,INDUSTRY,lead,Ipsen,Phase 3
NCT01313819,2011.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01313845,2011.0,OTHER,lead,Jee-Young Lee,Phase 4
NCT01313845,2011.0,OTHER,collaborator,Seoul National University Boramae Hospital,Phase 4
NCT01313845,2011.0,OTHER,collaborator,Samsung Medical Center,Phase 4
NCT01313845,2011.0,OTHER,collaborator,Seoul National University Bundang Hospital,Phase 4
NCT01313845,2011.0,OTHER,collaborator,Hanyang University,Phase 4
NCT01314001,2010.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01314001,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01314300,2011.0,OTHER,lead,Centre Leon Berard,Phase 2
NCT01315002,2008.0,OTHER,lead,"University Hospital, Bonn",Not Applicable
NCT01315002,2008.0,OTHER,collaborator,German Research Foundation,Not Applicable
NCT01315158,2011.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT01315210,2011.0,INDUSTRY,lead,"RiboCor, Inc.",Phase 2
NCT01315262,2011.0,OTHER,lead,Università Vita-Salute San Raffaele,Phase 3
NCT01315327,2003.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT01315327,2003.0,OTHER,collaborator,Tourette Association of America,Not Applicable
NCT01315639,2010.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT01315847,2010.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01315938,2011.0,OTHER,lead,Karolinska Institutet,Phase 2
NCT01315938,2011.0,OTHER,collaborator,"Institute of Rheumatology, Prague",Phase 2
NCT01315938,2011.0,OTHER,collaborator,King's College Hospital NHS Trust,Phase 2
NCT01316445,2011.0,OTHER,lead,Columbia University,Phase 1
NCT01316445,2011.0,INDUSTRY,collaborator,Upsher-Smith Laboratories,Phase 1
NCT01316926,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01317004,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01317849,2011.0,OTHER,lead,Xijing Hospital,Not Applicable
NCT01318226,2011.0,INDUSTRY,lead,Aestus Therapeutics,Phase 2
NCT01318226,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01318226,2011.0,UNKNOWN,collaborator,"Symbiance, Inc",Phase 2
NCT01318226,2011.0,OTHER,collaborator,"Parallax Clinical Research, LLC",Phase 2
NCT01318356,2011.0,OTHER,lead,Radboud University Medical Center,Phase 4
NCT01318356,2011.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT01318408,2006.0,OTHER,lead,Drexel University College of Medicine,Phase 4
NCT01318408,2006.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT01318421,2010.0,INDUSTRY,lead,Elan Pharmaceuticals,Phase 1
NCT01319188,2010.0,OTHER,lead,Ural State Medical University,Phase 4
NCT01319188,2010.0,OTHER,collaborator,Ural Institute of Cardiology,Phase 4
NCT01319188,2010.0,OTHER,collaborator,De Haar Research Foundation,Phase 4
NCT01319214,2011.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Not Applicable
NCT01319643,2009.0,OTHER,lead,University of Modena and Reggio Emilia,Phase 4
NCT01320527,2008.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 2
NCT01320527,2008.0,OTHER,collaborator,"University of Massachusetts, Lowell",Phase 2
NCT01320527,2008.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT01320982,2011.0,OTHER_GOV,lead,Sheba Medical Center,Phase 3
NCT01321333,2011.0,INDUSTRY,lead,"StemCells, Inc.",Phase 1/Phase 2
NCT01321489,2011.0,INDUSTRY,lead,Laboratório Teuto Brasileiro S/A,Phase 3
NCT01321931,2011.0,INDUSTRY,lead,McNeil AB,Phase 1
NCT01322048,2011.0,OTHER,lead,Vanderbilt University,Phase 2
NCT01322048,2011.0,UNKNOWN,collaborator,Vanderbilt Institute for Clinical and Translational Research (CTSA),Phase 2
NCT01322048,2011.0,UNKNOWN,collaborator,Eastern Association for the Surgery of Trauma (EAST),Phase 2
NCT01323205,2011.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT01323270,2011.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01323374,2009.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 2
NCT01323647,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01323855,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01323959,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01324232,2011.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 2
NCT01324518,2011.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT01324700,2010.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT01324700,2010.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT01325090,2011.0,OTHER,lead,"University Hospital, Limoges",Phase 3
NCT01325168,2011.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT01325220,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 3
NCT01325259,2009.0,OTHER,lead,"University Hospital, Tours",Phase 2
NCT01325571,2011.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT01325571,2011.0,INDUSTRY,collaborator,"Astellas Pharma China, Inc.",Phase 3
NCT01325740,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 2
NCT01326715,2013.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01327859,2003.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT01328015,2010.0,OTHER,lead,Federal University of São Paulo,Phase 2
NCT01328093,2011.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 3
NCT01328379,2011.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT01328860,2011.0,OTHER,lead,"James E.Baumgartner, MD",Phase 1
NCT01328860,2011.0,OTHER,collaborator,The Institute for Rehabilitaion and Research Foundation,Phase 1
NCT01328860,2011.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1
NCT01328860,2011.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 1
NCT01328860,2011.0,OTHER,collaborator,Baylor College of Medicine,Phase 1
NCT01328860,2011.0,OTHER,collaborator,Florida Hospital for Children,Phase 1
NCT01329614,2009.0,OTHER,lead,New York State Psychiatric Institute,Early Phase 1
NCT01329757,2011.0,OTHER,lead,Hospital Nacional de Parapléjicos de Toledo,Phase 3
NCT01329757,2011.0,UNKNOWN,collaborator,Ministerio de Salud y Politicas Sociales (Ministry of Health),Phase 3
NCT01329770,2010.0,OTHER,lead,Yolanda de Diego Otero,Phase 2
NCT01330030,2005.0,OTHER,lead,Stanford University,Phase 2
NCT01330030,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01331122,2012.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 1/Phase 2
NCT01331239,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01331304,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01331304,2010.0,FED,collaborator,Agency for Healthcare Research and Quality (AHRQ),Phase 4
NCT01331616,2011.0,OTHER,lead,West Penn Allegheny Health System,Early Phase 1
NCT01332305,2007.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT01332318,2007.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 2
NCT01332513,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01332695,2011.0,INDUSTRY,lead,"Sonexa Therapeutics, Inc.",Phase 2
NCT01333098,2012.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT01333358,2011.0,OTHER,lead,Central Texas Neurology Consultants,Phase 3
NCT01333358,2011.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 3
NCT01333488,2011.0,FED,lead,United States Department of Defense,Phase 2
NCT01333501,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01333865,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01335217,2011.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT01335295,2011.0,OTHER,lead,University of Messina,Phase 1
NCT01335789,2011.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT01335867,2011.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01335867,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01336088,2011.0,INDUSTRY,lead,Addex Pharma S.A.,Phase 2
NCT01336153,2009.0,OTHER,lead,Shahid Beheshti University,Phase 4
NCT01336153,2009.0,OTHER,collaborator,Shahid Beheshti University of Medical Sciences,Phase 4
NCT01336413,2013.0,FED,lead,VA Office of Research and Development,Phase 2
NCT01336439,2011.0,OTHER,lead,Yonsei University,Phase 4
NCT01336621,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01337427,2010.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT01337427,2010.0,INDUSTRY,collaborator,Biogen,Phase 3
NCT01337596,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01337687,2009.0,OTHER,lead,Montefiore Medical Center,Not Applicable
NCT01337687,2009.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT01337700,2011.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT01337700,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01338298,2011.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01338896,2011.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT01339247,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01339494,2009.0,OTHER,lead,Baylor College of Medicine,Early Phase 1
NCT01339559,2011.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT01339676,2008.0,OTHER,lead,University of Turku,Phase 4
NCT01339689,2011.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT01339689,2011.0,OTHER,collaborator,"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",Phase 2
NCT01339689,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT01339858,2011.0,OTHER,lead,Indiana University,Phase 4
NCT01339858,2011.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01339884,2011.0,OTHER,lead,Murdoch Childrens Research Institute,Phase 1/Phase 2
NCT01339884,2011.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 1/Phase 2
NCT01339923,2011.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01340885,2011.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT01340885,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT01340950,2010.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT01340950,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01340950,2010.0,OTHER_GOV,collaborator,"National Center for AIDS/STD Control and Prevention, China CDC",Phase 4
NCT01340950,2010.0,OTHER,collaborator,Beijing YouAn Hospital,Phase 4
NCT01340950,2010.0,OTHER,collaborator,Beijing Ditan Hospital,Phase 4
NCT01340950,2010.0,OTHER,collaborator,Peking University,Phase 4
NCT01341080,2010.0,OTHER,lead,Rush University Medical Center,Phase 2
NCT01341379,2010.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT01341379,2010.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT01341431,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01341925,2011.0,OTHER,lead,L. Eugene Arnold,Phase 1
NCT01341925,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01342237,2011.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT01342328,2012.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT01342328,2012.0,OTHER,collaborator,Masimo Labs,Not Applicable
NCT01342757,2010.0,NIH,lead,National Cancer Institute (NCI),Not Applicable
NCT01343329,2011.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT01343355,2011.0,OTHER,lead,St. Marianna University School of Medicine,Phase 2/Phase 3
NCT01343394,2011.0,OTHER,lead,"James E.Baumgartner, MD",Phase 1
NCT01343394,2011.0,INDUSTRY,collaborator,"Cord Blood Registry, Inc.",Phase 1
NCT01343394,2011.0,UNKNOWN,collaborator,Speech Therapists for Children,Phase 1
NCT01343394,2011.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1
NCT01343394,2011.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 1
NCT01343394,2011.0,OTHER,collaborator,Baylor College of Medicine,Phase 1
NCT01343394,2011.0,OTHER,collaborator,The Methodist Hospital Research Institute,Phase 1
NCT01343394,2011.0,OTHER,collaborator,Florida Hospital for Children,Phase 1
NCT01343563,2011.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01343862,2011.0,OTHER,lead,Hadassah Medical Organization,Phase 2
NCT01343966,2011.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT01344135,2011.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT01344135,2011.0,OTHER,collaborator,The Netherlands Asthma Foundation,Not Applicable
NCT01344135,2011.0,INDUSTRY,collaborator,Danone Research,Not Applicable
NCT01344447,2011.0,INDUSTRY,lead,Bayer,Phase 3
NCT01344759,2009.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT01345058,2011.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT01345136,2015.0,OTHER,lead,Jonsson Comprehensive Cancer Center,Phase 2
NCT01345136,2015.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01346163,2009.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT01346163,2009.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT01346293,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01347073,2011.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT01347112,2011.0,OTHER,lead,Mayo Clinic,Phase 2/Phase 3
NCT01347541,2011.0,OTHER,lead,University of Washington,Phase 1
NCT01347671,2011.0,INDUSTRY,lead,"Tris Pharma, Inc.",Phase 2
NCT01347671,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 2
NCT01347762,2010.0,OTHER,lead,Mclean Hospital,Phase 2/Phase 3
NCT01347762,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01348087,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01348100,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1/Phase 2
NCT01348100,2011.0,INDUSTRY,collaborator,Vanda Pharmaceuticals,Phase 1/Phase 2
NCT01348737,2011.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01348880,2011.0,INDUSTRY,lead,Bayer,Phase 1
NCT01348880,2011.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 1
NCT01348880,2011.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT01349205,2010.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT01349205,2010.0,OTHER,collaborator,Memorial Hermann Hospital,Not Applicable
NCT01349439,2011.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2
NCT01349439,2011.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT01349907,2011.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01350362,2011.0,INDUSTRY,lead,Noscira SA,Phase 2
NCT01350362,2011.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 2
NCT01350440,2011.0,OTHER,lead,University of South Florida,Phase 2
NCT01350440,2011.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 2
NCT01351168,,OTHER,lead,Rush University Medical Center,Phase 2
NCT01352013,2012.0,OTHER,lead,Dr. Yoram Shir,Phase 2
NCT01352013,2012.0,OTHER,collaborator,McGill University,Phase 2
NCT01352507,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT01352559,2001.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01352572,2002.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01352611,2014.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT01352637,2011.0,OTHER,lead,Weill Medical College of Cornell University,Phase 3
NCT01352637,2011.0,FED,collaborator,United States Department of Defense,Phase 3
NCT01352637,2011.0,OTHER,collaborator,Emory University,Phase 3
NCT01352637,2011.0,OTHER,collaborator,University of Southern California,Phase 3
NCT01352637,2011.0,FED,collaborator,VA Long Beach Healthcare System,Phase 3
NCT01352637,2011.0,FED,collaborator,National Intrepid Center of Excellence,Phase 3
NCT01352741,2011.0,INDUSTRY,lead,Grünenthal GmbH,Phase 4
NCT01352793,2012.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01353378,2011.0,OTHER,lead,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,Phase 4
NCT01353599,2011.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 1
NCT01353599,2011.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 1
NCT01353703,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01354158,2011.0,FED,lead,Bronx VA Medical Center,Phase 1
NCT01354158,2011.0,INDUSTRY,collaborator,Chelsea Therapeutics,Phase 1
NCT01354353,2011.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 1
NCT01354444,2011.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT01354444,2011.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01354483,2011.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 1/Phase 2
NCT01354483,2011.0,OTHER,collaborator,Chengdu PLA General Hospital,Phase 1/Phase 2
NCT01354691,2011.0,INDUSTRY,lead,Avraham Pharmaceuticals Ltd,Phase 2
NCT01355523,2011.0,OTHER,lead,Melissa Voigt Hansen,Phase 2/Phase 3
NCT01355523,2011.0,OTHER,collaborator,University of Copenhagen,Phase 2/Phase 3
NCT01355523,2011.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 2/Phase 3
NCT01355523,2011.0,INDUSTRY,collaborator,Pharma Nord,Phase 2/Phase 3
NCT01355549,2011.0,OTHER,lead,Kessler Foundation,Phase 1
NCT01355952,2011.0,OTHER,lead,Yale University,Not Applicable
NCT01355991,2011.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 1
NCT01355991,2011.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 1
NCT01356121,2010.0,OTHER_GOV,lead,Govind Ballabh Pant Hospital,Phase 4
NCT01356940,2010.0,INDIV,lead,"Brown, Theodore R., M.D., MPH",Phase 4
NCT01356940,2010.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 4
NCT01357031,2010.0,OTHER,lead,Hospital Israelita Albert Einstein,Phase 3
NCT01357031,2010.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 3
NCT01357213,2011.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT01357239,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01357421,2011.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 1
NCT01357681,2011.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT01357798,2010.0,OTHER,lead,Federal University of Bahia,Phase 3
NCT01357902,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01358825,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01359202,2011.0,OTHER,lead,Dr. David Gladstone,Phase 2
NCT01359202,2011.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT01359449,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01359566,2011.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 3
NCT01359670,2011.0,OTHER,lead,Cedars-Sinai Medical Center,Early Phase 1
NCT01359670,2011.0,OTHER,collaborator,Parent Project Muscular Dystrophy,Early Phase 1
NCT01359826,2011.0,OTHER,lead,Loma Linda University,Phase 4
NCT01359826,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01360450,2011.0,OTHER,lead,Johns Hopkins University,Phase 2/Phase 3
NCT01360450,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01360632,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01360645,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01360866,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01361555,2011.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT01361763,2011.0,OTHER,lead,S. Andrea Hospital,Phase 2
NCT01362205,2012.0,OTHER,lead,Denver Health and Hospital Authority,Phase 4
NCT01362439,2009.0,INDUSTRY,lead,Janssen-Cilag S.p.A.,Phase 4
NCT01362686,2011.0,OTHER,lead,Indiana University,Not Applicable
NCT01362686,2011.0,FED,collaborator,Agency for Healthcare Research and Quality (AHRQ),Not Applicable
NCT01362803,2011.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT01362959,2012.0,OTHER,lead,Gelderse Vallei Hospital,Phase 4
NCT01362959,2012.0,OTHER,collaborator,Deventer Ziekenhuis,Phase 4
NCT01362959,2012.0,OTHER,collaborator,Wageningen University,Phase 4
NCT01363349,2011.0,INDUSTRY,lead,"BioLineRx, Ltd.",Phase 2/Phase 3
NCT01363401,2011.0,INDUSTRY,lead,"Corestemchemon, Inc.",Phase 1/Phase 2
NCT01363492,2011.0,INDUSTRY,lead,Shire,Phase 2
NCT01363583,2002.0,OTHER,lead,Umeå University,Phase 1
NCT01363648,2010.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01364220,2010.0,OTHER,lead,Severance Hospital,Phase 3
NCT01364220,2010.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT01364259,2008.0,OTHER,lead,Stanford University,Phase 3
NCT01364545,2011.0,OTHER,lead,University of Oxford,Not Applicable
NCT01364558,2011.0,OTHER,lead,University of Minnesota,Phase 1
NCT01364558,2011.0,INDUSTRY,collaborator,"Neurelis, Inc.",Phase 1
NCT01364597,2011.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01364701,2011.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT01364792,2011.0,OTHER,lead,University Medical Center Groningen,Phase 2
NCT01364792,2011.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT01364857,2010.0,OTHER,lead,"University Hospital, Tours",Not Applicable
NCT01365104,2008.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT01365104,2008.0,NIH,collaborator,National Institute on Aging (NIA),Early Phase 1
NCT01365819,2012.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01366001,2011.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT01366001,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01366651,2012.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT01366820,2013.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT01366859,2011.0,OTHER,lead,Nova Southeastern University,Phase 2
NCT01366859,2011.0,INDUSTRY,collaborator,Immunotec Inc.,Phase 2
NCT01367080,2011.0,INDUSTRY,lead,Dong Wha Pharmaceutical Co. Ltd.,Phase 1
NCT01367080,2011.0,OTHER,collaborator,Chonbuk National University Hospital,Phase 1
NCT01367119,2011.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT01367158,2011.0,INDUSTRY,lead,Novartis Vaccines,Phase 2
NCT01367964,2011.0,OTHER,lead,Ann & Robert H Lurie Children's Hospital of Chicago,Not Applicable
NCT01367964,2011.0,OTHER,collaborator,Thrasher Research Fund,Not Applicable
NCT01368016,2011.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01368653,2012.0,OTHER,lead,Rutgers University,Not Applicable
NCT01368653,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01369095,2011.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT01369121,2010.0,INDUSTRY,lead,Celtic Pharma Development Services,Phase 1/Phase 2
NCT01369225,2011.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01369225,2011.0,INDUSTRY,collaborator,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Phase 1
NCT01369511,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01369576,2011.0,INDUSTRY,lead,OSR Medical Inc.,Phase 3
NCT01370044,2012.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2/Phase 3
NCT01370200,2011.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT01370304,2011.0,OTHER,lead,Xijing Hospital,Phase 3
NCT01370486,2011.0,OTHER,lead,Institution de Lavigny,Phase 4
NCT01370512,2011.0,OTHER,lead,Mayo Clinic,Phase 2
NCT01370512,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01371110,2012.0,OTHER,lead,Wayne Goodman MD,Phase 1/Phase 2
NCT01371110,2012.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 1/Phase 2
NCT01371383,2006.0,OTHER_GOV,lead,"National Science Council, Taiwan",Not Applicable
NCT01371565,2010.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT01371682,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01371799,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01372228,2011.0,INDUSTRY,lead,Talaris Therapeutics Inc.,Phase 1/Phase 2
NCT01372228,2011.0,OTHER,collaborator,Duke University,Phase 1/Phase 2
NCT01372449,2011.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01372449,2011.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01372449,2011.0,OTHER,collaborator,Rush University Medical Center,Phase 2
NCT01372449,2011.0,OTHER,collaborator,Nationwide Children's Hospital,Phase 2
NCT01372605,2010.0,OTHER,lead,Duke University,Not Applicable
NCT01372605,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01372605,2010.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Not Applicable
NCT01372605,2010.0,OTHER,collaborator,University of Alabama at Birmingham,Not Applicable
NCT01373697,2011.0,INDUSTRY,lead,Laboratório Teuto Brasileiro S/A,Phase 3
NCT01373710,2011.0,OTHER,lead,Institut Curie,Phase 1/Phase 2
NCT01373710,2011.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Centre Leon Berard,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Groupe Hospitalier Pitie-Salpetriere,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Centre Oscar Lambret,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Centre Francois Baclesse,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Institut Bergonié,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,"University Hospital, Toulouse",Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,Institut du Cancer de Montpellier - Val d'Aurelle,Phase 1/Phase 2
NCT01373710,2011.0,OTHER,collaborator,"University Hospital, Grenoble",Phase 1/Phase 2
NCT01373983,2011.0,OTHER,lead,"University Hospital, Linkoeping",Phase 4
NCT01374438,2011.0,INDUSTRY,lead,Metabolic Solutions Development Company,Phase 2
NCT01374633,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01374633,2011.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 2
NCT01374906,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01375374,2011.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01375920,2011.0,OTHER,lead,Jane Barnes,Phase 3
NCT01375920,2011.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 3
NCT01376076,2011.0,INDUSTRY,lead,Forest Laboratories,Phase 1
NCT01376908,2011.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT01377233,2011.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT01377662,2011.0,OTHER,lead,Tong Lee,Phase 2
NCT01377662,2011.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01377662,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01377870,2011.0,OTHER_GOV,lead,Royan Institute,Phase 1/Phase 2
NCT01377883,2010.0,OTHER,lead,Shaare Zedek Medical Center,Not Applicable
NCT01378182,2011.0,OTHER,lead,Murat Kantarcioglu,Not Applicable
NCT01378182,2011.0,OTHER,collaborator,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,Not Applicable
NCT01378650,2011.0,OTHER,lead,Jong Woo Chung,Not Applicable
NCT01378650,2011.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Not Applicable
NCT01378676,2011.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT01378741,2011.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT01378741,2011.0,INDUSTRY,collaborator,"Hospira, now a wholly owned subsidiary of Pfizer",Not Applicable
NCT01378858,2011.0,OTHER,lead,Albert Einstein College of Medicine,Not Applicable
NCT01378858,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01380288,2011.0,OTHER,lead,Dong-A University,Not Applicable
NCT01380288,2011.0,INDUSTRY,collaborator,Novartis Korea Ltd.,Not Applicable
NCT01380743,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 2
NCT01381354,2010.0,OTHER,lead,University of Iowa,Phase 1
NCT01381354,2010.0,UNKNOWN,collaborator,Direct MS Canada,Phase 1
NCT01381354,2010.0,INDUSTRY,collaborator,DJO Incorporated,Phase 1
NCT01381354,2010.0,INDUSTRY,collaborator,Pinnaclife Inc.,Phase 1
NCT01381354,2010.0,UNKNOWN,collaborator,"TZ Press, LLC",Phase 1
NCT01381419,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01382342,2011.0,OTHER,lead,Brown University,Phase 4
NCT01382342,2011.0,INDUSTRY,collaborator,Teva Pharmaceuticals USA,Phase 4
NCT01382719,2011.0,INDUSTRY,lead,"Palatin Technologies, Inc",Phase 2
NCT01383967,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01384162,2009.0,INDUSTRY,lead,Newron Sweden AB,Phase 1/Phase 2
NCT01384162,2009.0,INDUSTRY,collaborator,Medtronic,Phase 1/Phase 2
NCT01384162,2009.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 1/Phase 2
NCT01385033,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01385592,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01385735,2011.0,OTHER,lead,St. Josef Hospital Bochum,Phase 4
NCT01386177,2011.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT01386255,2009.0,OTHER,lead,Boston Children's Hospital,Phase 4
NCT01386255,2009.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 4
NCT01386333,2011.0,OTHER,lead,Lawson Health Research Institute,Phase 1
NCT01386333,2011.0,OTHER,collaborator,Consortium of Canadian Centres for Clinical Cognitive Research,Phase 1
NCT01386827,2008.0,OTHER,lead,Helsinki University Central Hospital,Phase 3
NCT01386827,2008.0,OTHER,collaborator,Karolinska Institutet,Phase 3
NCT01387217,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01387542,2009.0,INDUSTRY,lead,"Janssen-Cilag Ltd.,Thailand",Phase 4
NCT01387607,2012.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01388413,2011.0,OTHER,lead,"University Hospital, Tours",Phase 4
NCT01388478,2011.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT01388478,2011.0,OTHER,collaborator,University of Kansas,Phase 2
NCT01388478,2011.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT01388738,2011.0,OTHER,lead,"Clinical Institute of the Brain, Russia",Phase 3
NCT01388738,2011.0,INDUSTRY,collaborator,Nycomed,Phase 3
NCT01388738,2011.0,INDUSTRY,collaborator,Veropharm,Phase 3
NCT01388738,2011.0,INDUSTRY,collaborator,Ever Neuro Pharma GmbH,Phase 3
NCT01388764,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT01388842,2011.0,OTHER,lead,Epicentre,Phase 2
NCT01388842,2011.0,OTHER,collaborator,Mbarara University of Science and Technology,Phase 2
NCT01388842,2011.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT01388842,2011.0,OTHER,collaborator,Harvard Medical School (HMS and HSDM),Phase 2
NCT01388842,2011.0,OTHER,collaborator,"Medecins Sans Frontieres, Netherlands",Phase 2
NCT01389024,2012.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT01389024,2012.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2
NCT01389024,2012.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Vanderbilt University School of Medicine,Phase 2
NCT01389024,2012.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT01389024,2012.0,OTHER,collaborator,RTI International,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Columbia University,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Children's Mercy Hospital Kansas City,Phase 2
NCT01389024,2012.0,OTHER,collaborator,Sinai Hospital of Baltimore,Phase 2
NCT01389193,2013.0,OTHER,lead,Parisa Gazerani,Phase 1
NCT01389193,2013.0,OTHER_GOV,collaborator,"The Ministry of Science, Technology and Innovation, Denmark",Phase 1
NCT01389193,2013.0,OTHER,collaborator,Migraine Research Foundation,Phase 1
NCT01389687,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01389908,2011.0,OTHER,lead,Shalvata Mental Health Center,Not Applicable
NCT01390220,2011.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT01390246,2011.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 4
NCT01390246,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01390246,2011.0,OTHER,collaborator,UConn Health,Phase 4
NCT01390324,2011.0,INDUSTRY,lead,Ache Laboratorios Farmaceuticos S.A.,Phase 3
NCT01390376,2010.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01390376,2010.0,OTHER_GOV,collaborator,"Department of Health, Executive Yuan, R.O.C. (Taiwan)",Phase 2
NCT01390389,2011.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01390389,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01390662,2011.0,OTHER,lead,Region Syddanmark,Phase 4
NCT01391390,2008.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT01391390,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT01391403,2008.0,OTHER,lead,Beijing HuiLongGuan Hospital,Phase 3
NCT01391403,2008.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT01391598,2010.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01392768,2013.0,INDUSTRY,lead,Ache Laboratorios Farmaceuticos S.A.,Phase 3
NCT01392872,2009.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT01392872,2009.0,OTHER,collaborator,"University Hospital, Bordeaux",Not Applicable
NCT01392872,2009.0,OTHER,collaborator,"University Hospital, Caen",Not Applicable
NCT01392872,2009.0,OTHER,collaborator,"University Hospital, Marseille",Not Applicable
NCT01392872,2009.0,UNKNOWN,collaborator,Dr Remy MORELLO - CHU de Caen,Not Applicable
NCT01392963,2011.0,OTHER,lead,Seton Healthcare Family,Phase 2
NCT01392989,2011.0,OTHER,lead,Everett Meyer,Phase 2
NCT01393457,2011.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01393600,2011.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT01394471,2011.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT01394471,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01394796,2010.0,OTHER,lead,Parc de Salut Mar,Phase 2
NCT01394926,2011.0,INDUSTRY,lead,GE Healthcare,Phase 2
NCT01395316,2011.0,OTHER,lead,University of Chicago,Phase 4
NCT01395316,2011.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 4
NCT01395394,2011.0,OTHER,lead,Emory University,Phase 2
NCT01395563,2009.0,OTHER,lead,German Cancer Research Center,Not Applicable
NCT01395563,2009.0,OTHER,collaborator,Heidelberg University,Not Applicable
NCT01395563,2009.0,OTHER,collaborator,Technical University of Munich,Not Applicable
NCT01395797,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01395797,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01395797,2011.0,INDUSTRY,collaborator,Omeros Corporation,Phase 1/Phase 2
NCT01396239,2011.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 2
NCT01396252,2011.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01396447,2011.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT01396447,2011.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 2
NCT01396512,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01397006,2011.0,OTHER,lead,Newton-Wellesley Hospital,Phase 4
NCT01397006,2011.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01397422,2011.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT01397539,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01397578,2011.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT01397786,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01397968,2011.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT01398189,2011.0,OTHER,lead,Seoul National University Bundang Hospital,Not Applicable
NCT01398956,2011.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01399125,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01399450,2011.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01399450,2011.0,INDUSTRY,collaborator,Johnson & Johnson,Phase 4
NCT01399606,2011.0,OTHER,lead,Bioprojet,Phase 3
NCT01399905,2009.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT01400243,2011.0,OTHER,lead,Southern Illinois University Carbondale,Phase 4
NCT01400243,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01400256,2007.0,OTHER,lead,Stanford University,Phase 4
NCT01400464,2009.0,OTHER,lead,"University Hospital, Caen",Phase 4
NCT01400477,2011.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01400477,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01401244,2011.0,INDUSTRY,lead,Novo Nordisk A/S,Phase 1
NCT01401257,2010.0,OTHER,lead,Pharnext S.C.A.,Phase 2
NCT01401413,2008.0,OTHER,lead,Sleep Medicine Centers of WNY,Phase 4
NCT01401491,2008.0,OTHER,lead,Taipei Medical University Hospital,Phase 4
NCT01401491,2008.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 4
NCT01401543,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01401595,2009.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01401595,2009.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT01402492,2011.0,OTHER,lead,"University of California, Los Angeles",Phase 2/Phase 3
NCT01402492,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01402492,2011.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 2/Phase 3
NCT01402570,2011.0,OTHER,lead,University of Michigan,Not Applicable
NCT01402570,2011.0,OTHER,collaborator,Penn State University,Not Applicable
NCT01402596,2011.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT01402817,2012.0,OTHER,lead,Indiana University,Phase 2
NCT01402817,2012.0,FED,collaborator,United States Department of Defense,Phase 2
NCT01402817,2012.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01402882,2012.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 3
NCT01403376,2011.0,INDUSTRY,lead,Sanofi,Phase 2
NCT01403662,2011.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT01404091,2011.0,INDUSTRY,lead,"BlackThorn Therapeutics, Inc.",Phase 1
NCT01404195,2012.0,OTHER,lead,"Hospital Viamed Valvanera, Spain",Not Applicable
NCT01404195,2012.0,OTHER,collaborator,University of Navarra,Not Applicable
NCT01404208,2011.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01404208,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01404208,2011.0,OTHER,collaborator,University of South Florida,Not Applicable
NCT01404247,2011.0,OTHER,lead,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Phase 1
NCT01404663,2011.0,OTHER_GOV,lead,Royan Institute,Phase 1
NCT01404871,2009.0,OTHER,lead,Sunnybrook Health Sciences Centre,Not Applicable
NCT01404871,2009.0,OTHER,collaborator,Obsessive Compulsive Foundation,Not Applicable
NCT01404871,2009.0,OTHER,collaborator,Centre for Addiction and Mental Health,Not Applicable
NCT01405053,2011.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT01405482,2011.0,OTHER,lead,University of British Columbia,Phase 1
NCT01405482,2011.0,INDUSTRY,collaborator,Merz Pharmaceuticals,Phase 1
NCT01405508,2011.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01405807,2011.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 4
NCT01405820,2011.0,INDUSTRY,lead,Biogen,Phase 2
NCT01405833,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01406145,2011.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 1
NCT01406223,2011.0,OTHER,lead,Duke University,Phase 3
NCT01406223,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01406444,2011.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01406522,2012.0,OTHER,lead,Midwest Biomedical Research Foundation,Phase 2
NCT01406873,2011.0,OTHER,lead,University of Rochester,Phase 2
NCT01407094,2011.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT01407211,2011.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT01407523,2011.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 2
NCT01407575,2011.0,OTHER,lead,University of Pittsburgh,Phase 3
NCT01407575,2011.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 3
NCT01408537,2010.0,OTHER,lead,Mahidol University,Phase 3
NCT01408641,2012.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01408641,2012.0,FED,collaborator,US Department of Veterans Affairs,Not Applicable
NCT01408836,1995.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,University Hospital Birmingham,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,Imperial College London,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,London North West Healthcare NHS Trust,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,"University Hospitals, Leicester",Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,Lund University Hospital,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,University Medical Center Groningen,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,Fundacio Clinic Barcelona,Phase 2/Phase 3
NCT01408836,1995.0,OTHER,collaborator,University of Helsinki,Phase 2/Phase 3
NCT01409096,2010.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT01409096,2010.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01409694,2011.0,OTHER_GOV,lead,"University Hospital, Angers",Phase 3
NCT01409915,2011.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01409915,2011.0,OTHER,collaborator,The Dana Foundation,Phase 2
NCT01410474,2011.0,INDUSTRY,lead,Novartis,Phase 3
NCT01410474,2011.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT01410890,2014.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT01411085,2011.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 2
NCT01411085,2011.0,OTHER,collaborator,University of South Carolina,Phase 2
NCT01411085,2011.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 2
NCT01411085,2011.0,OTHER,collaborator,Michigan State University,Phase 2
NCT01411137,2011.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT01411137,2011.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 3
NCT01411150,2009.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01411150,2009.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01411163,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01411163,2010.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01411228,2011.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01411514,2011.0,OTHER_GOV,lead,Claudio Gobbi,Phase 4
NCT01411514,2011.0,OTHER,collaborator,"Ente Ospedaliero Cantonale, Ticino, Switzerland",Phase 4
NCT01412008,2010.0,OTHER,lead,New York Presbyterian Hospital,Not Applicable
NCT01412060,2011.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01412060,2011.0,INDUSTRY,collaborator,Gedeon Richter Ltd.,Phase 3
NCT01412424,2012.0,INDUSTRY,lead,"Chiasma, Inc.",Phase 3
NCT01412892,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01412892,2011.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT01413243,2012.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT01413438,2011.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01413529,2011.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT01413529,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01413711,2012.0,INDUSTRY,lead,Lundbeck LLC,Phase 4
NCT01414634,2010.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 1/Phase 2
NCT01415128,2010.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01416155,2010.0,INDUSTRY,lead,Biogen,Phase 2
NCT01416363,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01416441,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01416948,2011.0,OTHER,lead,"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",Phase 2
NCT01416948,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT01417026,2011.0,OTHER,lead,Robert Schultz,Phase 2
NCT01417078,2011.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT01417273,2010.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT01417312,2011.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT01417364,2016.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 4
NCT01418339,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01418352,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01418651,2011.0,OTHER,lead,Banner Health,Phase 3
NCT01418651,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT01419275,2009.0,OTHER,lead,Stanford University,Not Applicable
NCT01419470,2011.0,INDUSTRY,lead,Yuhan Corporation,Phase 1/Phase 2
NCT01419639,2011.0,OTHER,lead,NYU Langone Health,Phase 2
NCT01419639,2011.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01419639,2011.0,OTHER,collaborator,The Children's Tumor Foundation,Phase 2
NCT01420042,2012.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 1
NCT01420055,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01420575,2010.0,FED,lead,VA Nebraska Western Iowa Health Care System,Not Applicable
NCT01420575,2010.0,FED,collaborator,US Department of Veterans Affairs,Not Applicable
NCT01420575,2010.0,UNKNOWN,collaborator,Nebraska Educational Biomedical Research Association,Not Applicable
NCT01421056,2011.0,INDUSTRY,lead,Chiesi Farmaceutici S.p.A.,Phase 2
NCT01421719,2009.0,OTHER,lead,Stanford University,Phase 4
NCT01421719,2009.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT01421992,2008.0,OTHER,lead,Laval University,Phase 2/Phase 3
NCT01422187,2011.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01422200,2011.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT01422720,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT01423084,2011.0,INDUSTRY,lead,Novartis,Phase 3
NCT01423084,2011.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT01423370,2011.0,INDUSTRY,lead,Yuhan Corporation,Phase 2
NCT01423396,2010.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT01423396,2010.0,OTHER_GOV,collaborator,"Ministry of Health, France",Not Applicable
NCT01423916,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01424163,2011.0,INDUSTRY,lead,Knopp Biosciences,Phase 1
NCT01424163,2011.0,INDUSTRY,collaborator,Biogen,Phase 1
NCT01424176,2011.0,INDUSTRY,lead,Knopp Biosciences,Phase 1
NCT01424241,2006.0,OTHER,lead,Columbia University,Phase 4
NCT01424241,2006.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT01424423,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01424436,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01424449,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01424462,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01424475,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01424644,2011.0,INDUSTRY,lead,Novartis,Phase 4
NCT01424644,2011.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT01424735,2006.0,OTHER,lead,Sudhalkar Eye Hospital,Not Applicable
NCT01425125,2011.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT01425619,2011.0,OTHER,lead,Meir Medical Center,Not Applicable
NCT01425983,2011.0,INDUSTRY,lead,Kyberg Vital GmbH,Phase 3
NCT01426984,2012.0,OTHER,lead,Shalvata Mental Health Center,Not Applicable
NCT01427517,2011.0,OTHER,lead,University of Minnesota,Phase 1
NCT01427517,2011.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Phase 1
NCT01427517,2011.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 1
NCT01427517,2011.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01427517,2011.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1
NCT01428258,2011.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT01428258,2011.0,OTHER,collaborator,Boston Children's Hospital,Not Applicable
NCT01428310,2011.0,INDUSTRY,lead,"Rock Creek Pharmaceuticals, Inc.",Phase 1
NCT01428362,2011.0,INDUSTRY,lead,VIVUS LLC,Phase 2
NCT01428362,2011.0,INDUSTRY,collaborator,"Medpace, Inc.",Phase 2
NCT01428401,2008.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01428453,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01428726,2011.0,INDUSTRY,lead,Neurotec Pharma,Phase 2
NCT01428726,2011.0,INDUSTRY,collaborator,"Advancell - Advanced In Vitro Cell Technologies, S.A.",Phase 2
NCT01429077,2007.0,OTHER,lead,Shirley Ryan AbilityLab,Phase 2/Phase 3
NCT01429077,2007.0,FED,collaborator,U.S. Department of Education,Phase 2/Phase 3
NCT01429090,1999.0,OTHER,lead,University Medicine Greifswald,Phase 1
NCT01429090,1999.0,UNKNOWN,collaborator,RIEMSER Arzneimittel GmbH,Phase 1
NCT01429454,2011.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT01429454,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01429623,2012.0,INDUSTRY,lead,Avraham Pharmaceuticals Ltd,Phase 2
NCT01429740,2011.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01430325,2011.0,OTHER,lead,"Intermountain Health Care, Inc.",Not Applicable
NCT01430442,2011.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01430611,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01431092,2011.0,OTHER,lead,Lone Baandrup,Phase 4
NCT01431092,2011.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Phase 4
NCT01431092,2011.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4
NCT01431573,2011.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT01431586,,OTHER,lead,RTI International,Phase 1
NCT01431586,,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01431937,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01431963,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01431976,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01432236,2011.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01432444,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01432665,2011.0,INDUSTRY,lead,Emotional Brain NY Inc.,Phase 2
NCT01432704,2008.0,OTHER,lead,University of Turku,Phase 2/Phase 3
NCT01432704,2008.0,INDUSTRY,collaborator,Bayer,Phase 2/Phase 3
NCT01433055,2011.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01433055,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01433159,2011.0,INDUSTRY,lead,Healthpoint,Phase 2
NCT01433250,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01433354,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2/Phase 3
NCT01433666,2011.0,OTHER,lead,Maastricht University Medical Center,Phase 2
NCT01433666,2011.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 2
NCT01433757,2011.0,OTHER,lead,University of Florida,Phase 1
NCT01433757,2011.0,UNKNOWN,collaborator,"Tyler's Hope for a Dystonia Cure, Inc",Phase 1
NCT01434342,2011.0,OTHER,lead,Wake Forest University Health Sciences,Early Phase 1
NCT01434342,2011.0,NIH,collaborator,National Cancer Institute (NCI),Early Phase 1
NCT01434602,2012.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT01434680,2011.0,INDUSTRY,lead,Novartis,Phase 2
NCT01434680,2011.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 2
NCT01435772,2011.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT01435798,2003.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT01435798,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01435837,2010.0,OTHER,lead,Southern Illinois University Carbondale,Early Phase 1
NCT01435915,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01435928,2011.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01435993,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01436045,2011.0,OTHER,lead,HealthPartners Institute,Phase 2
NCT01436643,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01436955,2011.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT01437189,2011.0,OTHER,lead,Zhejiang University,Not Applicable
NCT01437293,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT01437293,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01437293,2010.0,OTHER,collaborator,Columbia University,Phase 1
NCT01437423,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01437644,2011.0,OTHER,lead,Guy's and St Thomas' NHS Foundation Trust,Phase 3
NCT01438060,2000.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01438060,2000.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT01438710,2011.0,INDUSTRY,lead,Veloxis Pharmaceuticals,Phase 3
NCT01439438,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01439555,2011.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 2
NCT01439555,2011.0,UNKNOWN,collaborator,The Glass Foundation,Phase 2
NCT01439828,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01439984,2011.0,INDUSTRY,lead,Symyoo,Phase 3
NCT01440062,2011.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT01440062,2011.0,OTHER,collaborator,"NeuroCure Clinical Research Center, Charite, Berlin",Phase 2
NCT01440101,2010.0,INDUSTRY,lead,Biogen,Phase 2/Phase 3
NCT01440985,2005.0,INDUSTRY,lead,McNeil AB,Not Applicable
NCT01441284,2017.0,OTHER,lead,University of Pecs,Phase 3
NCT01441557,2011.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Phase 2/Phase 3
NCT01442675,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT01442727,2006.0,OTHER,lead,Texas Tech University,Phase 3
NCT01442727,2006.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT01442727,2006.0,OTHER,collaborator,"American Cancer Society, Inc.",Phase 3
NCT01442766,2011.0,OTHER,lead,Imperial College London,Phase 1/Phase 2
NCT01442766,2011.0,OTHER,collaborator,International Stem Cell Forum,Phase 1/Phase 2
NCT01444131,2011.0,OTHER,lead,University of Stellenbosch,Phase 2
NCT01444131,2011.0,UNKNOWN,collaborator,QuitSupport,Phase 2
NCT01444300,2011.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT01444300,2011.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 2
NCT01444781,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01444898,2012.0,OTHER,lead,Children's Hospital Los Angeles,Not Applicable
NCT01445067,2011.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01445639,2011.0,OTHER,lead,Capital Medical University,Phase 4
NCT01445691,2015.0,OTHER,lead,Constantinos Hadjipanayis,Phase 2
NCT01445691,2015.0,UNKNOWN,collaborator,NX PharmaGen,Phase 2
NCT01445691,2015.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01446328,2011.0,OTHER,lead,Haukeland University Hospital,Phase 4
NCT01446328,2011.0,OTHER,collaborator,Helse Vest,Phase 4
NCT01446523,2011.0,OTHER_GOV,lead,Govind Ballabh Pant Hospital,Not Applicable
NCT01446614,2011.0,OTHER,lead,Guangzhou General Hospital of Guangzhou Military Command,Phase 1/Phase 2
NCT01446640,2011.0,OTHER,lead,Guangzhou General Hospital of Guangzhou Military Command,Phase 1/Phase 2
NCT01447095,2011.0,OTHER,lead,Rune Rasmussen,Phase 2
NCT01447719,2010.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT01448252,2002.0,OTHER,lead,Hadassah Medical Organization,Phase 1/Phase 2
NCT01448499,2011.0,OTHER,lead,Geha Mental Health Center,Not Applicable
NCT01448720,2011.0,INDUSTRY,lead,Janssen-Cilag Farmaceutica Ltda.,Phase 3
NCT01449565,2012.0,OTHER_GOV,lead,San Francisco Department of Public Health,Phase 2
NCT01449565,2012.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 2
NCT01449565,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01449578,2011.0,INDUSTRY,lead,Knopp Biosciences,Phase 1
NCT01449955,2008.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT01449955,2008.0,FED,collaborator,North Texas Veterans Healthcare System,Not Applicable
NCT01450111,2008.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT01450124,2011.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 2
NCT01450137,2011.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 2
NCT01450137,2011.0,OTHER,collaborator,University of Bern,Phase 2
NCT01450137,2011.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 2
NCT01450163,2011.0,OTHER,lead,University of Sao Paulo,Phase 3
NCT01450163,2011.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT01450228,2011.0,INDUSTRY,lead,"Kuhnil Pharmaceutical Co., Ltd.",Phase 3
NCT01450228,2011.0,INDUSTRY,collaborator,Neurim Pharmaceuticals Ltd.,Phase 3
NCT01450488,2005.0,INDUSTRY,lead,AB Science,Phase 2
NCT01450514,2012.0,INDUSTRY,lead,PharmaNeuroBoost N.V.,Phase 2
NCT01450995,2009.0,OTHER,lead,"Stephen H. Landy, M.D.",Phase 4
NCT01450995,2009.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT01451164,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT01451294,2011.0,OTHER,lead,G.J. de Borst,Not Applicable
NCT01451528,2014.0,OTHER,lead,Bundang CHA Hospital,Not Applicable
NCT01451593,2011.0,OTHER,lead,"University College, London",Phase 2
NCT01451593,2011.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT01451593,2011.0,UNKNOWN,collaborator,Multiple Sclerosis Society of Great Britain and Northern Ireland,Phase 2
NCT01451723,2011.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Phase 2
NCT01451723,2011.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT01451853,2018.0,INDUSTRY,lead,"Sound Pharmaceuticals, Incorporated",Phase 2
NCT01451853,2018.0,FED,collaborator,VA Puget Sound Health Care System,Phase 2
NCT01452607,2006.0,INDUSTRY,lead,"Sound Pharmaceuticals, Incorporated",Phase 1
NCT01452789,2011.0,OTHER,lead,Thomas Jefferson University,Phase 3
NCT01452789,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01452919,2011.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 3
NCT01453127,2011.0,OTHER,lead,Mayo Clinic,Phase 4
NCT01453348,2011.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01453348,2011.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT01453569,2011.0,INDUSTRY,lead,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Phase 2
NCT01453569,2011.0,OTHER,collaborator,Shanghai Mental Health Center,Phase 2
NCT01453998,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01454115,2007.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01454154,2011.0,INDUSTRY,lead,Biogen,Phase 2
NCT01454154,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT01454154,2011.0,OTHER,collaborator,"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",Phase 2
NCT01454453,2012.0,OTHER,lead,"Institute of Psychiatry, London",Phase 4
NCT01454791,2011.0,INDIV,lead,"Brown, Theodore R., M.D., MPH",Phase 4
NCT01454791,2011.0,INDUSTRY,collaborator,"Teva Neuroscience, Inc.",Phase 4
NCT01455012,2011.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 4
NCT01455207,2012.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT01455207,2012.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT01455207,2012.0,OTHER,collaborator,"National Research Agency, France",Not Applicable
NCT01455220,2011.0,OTHER,lead,University of South Florida,Not Applicable
NCT01455376,2010.0,OTHER,lead,Universitas Padjadjaran,Not Applicable
NCT01455935,2011.0,OTHER,lead,Jacobs Neurological Institute,Phase 2
NCT01455935,2011.0,OTHER,collaborator,University at Buffalo Neurosurgery,Phase 2
NCT01455935,2011.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT01456481,2011.0,OTHER,lead,Dr. Bob Sheldon,Phase 4
NCT01456481,2011.0,OTHER,collaborator,Vanderbilt University,Phase 4
NCT01456897,2011.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01457339,2011.0,INDUSTRY,lead,Shire,Phase 1
NCT01457469,2011.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT01457469,2011.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01457495,1998.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01457508,1999.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01457547,2003.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01457560,2000.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01457807,2011.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01457924,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01458015,2011.0,OTHER,lead,University Hospital Schleswig-Holstein,Phase 4
NCT01458119,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT01458327,2010.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT01458470,2011.0,OTHER,lead,University of British Columbia,Phase 2
NCT01458470,2011.0,OTHER,collaborator,Huntington Society of Canada,Phase 2
NCT01458470,2011.0,NETWORK,collaborator,Huntington Study Group,Phase 2
NCT01458964,2008.0,OTHER,lead,East Tennessee State University,Phase 4
NCT01458964,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT01459029,2011.0,OTHER,lead,Hadassah Medical Organization,Phase 2
NCT01459029,2011.0,OTHER,collaborator,Herzog Hospital,Phase 2
NCT01459237,2011.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT01460290,2011.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT01460290,2011.0,OTHER,collaborator,Case Western Reserve University,Phase 4
NCT01460355,2006.0,OTHER,lead,"University of Campinas, Brazil",Phase 4
NCT01461083,2011.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT01461109,2011.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT01461720,2012.0,OTHER,lead,National University of Malaysia,Phase 2
NCT01461720,2012.0,INDUSTRY,collaborator,Cytopeutics Sdn. Bhd.,Phase 2
NCT01462292,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01462318,2011.0,INDUSTRY,lead,Biogen,Phase 3
NCT01462669,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01462708,2011.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 1
NCT01462812,2011.0,INDUSTRY,lead,Optinose US Inc.,Phase 3
NCT01463033,2005.0,OTHER,lead,Pavel Klein,Phase 2
NCT01463033,2005.0,OTHER,collaborator,Medstar Health Research Institute,Phase 2
NCT01463111,2011.0,OTHER,lead,Emory University,Not Applicable
NCT01463384,2011.0,OTHER,lead,Huntington Medical Research Institutes,Phase 2
NCT01463397,2012.0,INDUSTRY,lead,Sanofi,Phase 2
NCT01463878,2011.0,OTHER,lead,Eastern Virginia Medical School,Phase 4
NCT01464905,2011.0,INDUSTRY,lead,Nuron Biotech Inc.,Phase 3
NCT01464983,2004.0,INDUSTRY,lead,Bayer,Phase 4
NCT01465074,2011.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT01465100,2011.0,OTHER,lead,Ira Fox,Phase 1/Phase 2
NCT01465893,2011.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2
NCT01465919,2011.0,OTHER,lead,Seoul National University Boramae Hospital,Phase 4
NCT01465997,2012.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 3
NCT01465997,2012.0,INDUSTRY,collaborator,Eden Sarl,Phase 3
NCT01466088,2011.0,INDUSTRY,lead,Targacept Inc.,Phase 2
NCT01466127,2011.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01466127,2011.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT01466205,2011.0,OTHER,lead,Larry J. Siever,Phase 2
NCT01466205,2011.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT01466270,2012.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT01466270,2012.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01466322,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01466387,2011.0,INDUSTRY,lead,Novartis,Phase 3
NCT01466387,2011.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT01466543,2011.0,OTHER,lead,Samsung Medical Center,Phase 2
NCT01466543,2011.0,INDUSTRY,collaborator,"Dong-A Pharmaceutical Co., Ltd.",Phase 2
NCT01467713,2011.0,INDUSTRY,lead,Takeda,Phase 3
NCT01467726,2011.0,INDUSTRY,lead,Theravance Biopharma,Phase 1
NCT01467999,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT01468012,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT01468038,2008.0,INDUSTRY,lead,Targeted Medical Pharma,Phase 3
NCT01468064,2011.0,OTHER,lead,"Southern Medical University, China",Phase 1/Phase 2
NCT01468064,2011.0,UNKNOWN,collaborator,The Second People's Hospital of Nanhai District of Foshan,Phase 1/Phase 2
NCT01468064,2011.0,OTHER,collaborator,The First People's Hospital of Haizhu District Guangzhou,Phase 1/Phase 2
NCT01468064,2011.0,INDUSTRY,collaborator,Cellonis Biotechnology Co. Ltd.,Phase 1/Phase 2
NCT01468519,2012.0,OTHER,lead,Jothydev's Diabetes and Research Centre,Phase 4
NCT01468948,2011.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01469039,2011.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT01469936,2011.0,INDUSTRY,lead,Lescuyer Laboratory,Not Applicable
NCT01469936,2011.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT01470027,2012.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1/Phase 2
NCT01470027,2012.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1/Phase 2
NCT01470040,2012.0,OTHER,lead,Hadassah Medical Organization,Phase 4
NCT01470352,2011.0,OTHER,lead,d_yarnitsky,Not Applicable
NCT01470469,2012.0,INDUSTRY,lead,Shire,Phase 2
NCT01470521,2011.0,OTHER,lead,University of Nottingham,Phase 2
NCT01470521,2011.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT01470859,2011.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT01470859,2011.0,INDUSTRY,collaborator,Boehringer Ingelheim,Not Applicable
NCT01471613,2011.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 1/Phase 2
NCT01471613,2011.0,OTHER,collaborator,Chengdu PLA General Hospital,Phase 1/Phase 2
NCT01471613,2011.0,INDUSTRY,collaborator,"StemCyte, Inc.",Phase 1/Phase 2
NCT01471652,2012.0,OTHER,lead,Columbia University,Phase 2
NCT01472263,2009.0,OTHER,lead,Hospital Universitário Professor Edgard Santos,Phase 3
NCT01472315,2000.0,OTHER_GOV,lead,Turku University Hospital,Phase 2/Phase 3
NCT01472874,2010.0,OTHER,lead,Yale University,Not Applicable
NCT01472874,2010.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Not Applicable
NCT01472926,2011.0,OTHER,lead,NHS Greater Glasgow and Clyde,Phase 2
NCT01472926,2011.0,OTHER,collaborator,University of Glasgow,Phase 2
NCT01473277,2012.0,OTHER,lead,The Foundation Institute San Raffaele G. Giglio of Cefalù,Phase 2
NCT01473277,2012.0,UNKNOWN,collaborator,Ospedale di Brunico,Phase 2
NCT01473277,2012.0,OTHER,collaborator,Fondazione Salvatore Maugeri,Phase 2
NCT01473277,2012.0,OTHER,collaborator,"IRCCS San Camillo, Venezia, Italy",Phase 2
NCT01473277,2012.0,OTHER,collaborator,"Azienda Ospedaliero, Universitaria Pisana",Phase 2
NCT01473277,2012.0,OTHER,collaborator,Università degli Studi di Ferrara,Phase 2
NCT01474395,2012.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT01474395,2012.0,OTHER,collaborator,Columbia University,Phase 2
NCT01474421,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01474473,2011.0,INDUSTRY,lead,"Organ, Tissue, Regeneration, Repair and Replacement",Not Applicable
NCT01474746,2012.0,OTHER,lead,"Randi J. Hagerman, MD",Phase 2
NCT01475383,2012.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01475539,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01475578,2002.0,OTHER,lead,"Sinphar Pharmaceutical Co., Ltd",Phase 2
NCT01476124,2011.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 1
NCT01476176,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01476930,2008.0,OTHER,lead,Birjand University of Medical Sciences,Phase 4
NCT01477203,2011.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT01477268,2007.0,OTHER,lead,Unity Health Toronto,Phase 4
NCT01477736,2009.0,OTHER,lead,Centro de Reabilitação e Readaptação Dr. Henrique Santillo,Not Applicable
NCT01477762,2011.0,OTHER,lead,Emory University,Not Applicable
NCT01477762,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01478035,2011.0,OTHER,lead,M. Carmen Cabellos Minguez,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Universitari de Bellvitge,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Vall d'Hebron,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Germans Trias i Pujol Hospital,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Clinic of Barcelona,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospitales Universitarios Virgen del Rocío,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Universitario La Paz,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Universitario Ramon y Cajal,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Juan Canalejo,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Mutua de Terrassa,Phase 4
NCT01478035,2011.0,OTHER,collaborator,Hospital Universitario Virgen Macarena,Phase 4
NCT01478230,2011.0,INDUSTRY,lead,McNeil AB,Early Phase 1
NCT01478347,2013.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01478347,2013.0,INDUSTRY,collaborator,Novartis,Phase 3
NCT01478633,2011.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 4
NCT01479530,2011.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01479556,2011.0,OTHER,lead,Julian Taylor Green,Phase 4
NCT01479829,2011.0,OTHER,lead,Loyola University,Phase 4
NCT01479829,2011.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01479920,2012.0,OTHER,lead,The University of Hong Kong,Not Applicable
NCT01479920,2012.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Not Applicable
NCT01479920,2012.0,OTHER,collaborator,"Kowloon Hospital, Hong Kong",Not Applicable
NCT01479920,2012.0,OTHER,collaborator,"Southern Medical University, China",Not Applicable
NCT01480076,2012.0,INDUSTRY,lead,Biogen,Phase 4
NCT01480232,2011.0,OTHER,lead,A. Eden Evins,Phase 2
NCT01480232,2011.0,INDUSTRY,collaborator,FORUM Pharmaceuticals Inc,Phase 2
NCT01480232,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01480245,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01480297,2011.0,OTHER,lead,University of Michigan,Phase 2
NCT01480609,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01480765,2011.0,OTHER,lead,Barts & The London NHS Trust,Phase 4
NCT01481103,2011.0,OTHER,lead,National University of Health Sciences,Not Applicable
NCT01481883,2012.0,OTHER,lead,The Alfred,Phase 4
NCT01482052,2011.0,INDUSTRY,lead,JN-International Medical Corporation,Phase 1
NCT01482143,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT01482845,2011.0,INDUSTRY,lead,Abbott,Phase 1
NCT01483846,2011.0,INDUSTRY,lead,"VistaGen Therapeutics, Inc.",Phase 1
NCT01483846,2011.0,INDUSTRY,collaborator,Cato Research,Phase 1
NCT01483846,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01484184,2013.0,OTHER,lead,Nordic Life Science Pipeline Inc.,Phase 1/Phase 2
NCT01484184,2013.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT01484977,2011.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01484990,2010.0,INDUSTRY,lead,AbbVie,Phase 1
NCT01484990,2010.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 1
NCT01485094,2012.0,INDUSTRY,lead,Grünenthal GmbH,Phase 2
NCT01485172,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01485185,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01485302,2012.0,INDUSTRY,lead,Sanofi,Phase 1
NCT01485640,2011.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01485692,2009.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT01485770,2011.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT01485952,2011.0,INDUSTRY,lead,Siena Biotech S.p.A.,Phase 1
NCT01485952,2011.0,OTHER,collaborator,Seventh Framework Programme,Phase 1
NCT01485952,2011.0,NETWORK,collaborator,European Huntington's Disease Network,Phase 1
NCT01485965,2011.0,INDUSTRY,lead,Siena Biotech S.p.A.,Phase 1
NCT01486628,2012.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1
NCT01486732,2013.0,OTHER,lead,Bundang CHA Hospital,Phase 2
NCT01486810,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01486810,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01486849,2011.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT01487083,2011.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01487096,2001.0,INDUSTRY,lead,Sanofi,Phase 2
NCT01487317,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01487317,2011.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 3
NCT01487395,2011.0,OTHER,lead,"University Hospital, Lille",Phase 1
NCT01487395,2011.0,OTHER,collaborator,Innovative Medicines Initiative,Phase 1
NCT01488929,2011.0,INDUSTRY,lead,Targacept Inc.,Phase 2
NCT01489137,2011.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT01489254,2011.0,INDUSTRY,lead,Synthon BV,Phase 3
NCT01489904,2011.0,OTHER,lead,Hospital Vall d'Hebron,Phase 2/Phase 3
NCT01489904,2011.0,INDUSTRY,collaborator,Allergan,Phase 2/Phase 3
NCT01489982,2011.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Early Phase 1
NCT01489995,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1
NCT01490086,2011.0,INDUSTRY,lead,Reviva Pharmaceuticals,Phase 2
NCT01490216,2011.0,OTHER,lead,University of Minnesota,Phase 1
NCT01490476,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT01490502,2012.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Oregon Health and Science University,Phase 3
NCT01490502,2012.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT01490502,2012.0,OTHER,collaborator,Washington University School of Medicine,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 3
NCT01490502,2012.0,OTHER,collaborator,University of Pennsylvania,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Yale University,Phase 3
NCT01490502,2012.0,OTHER,collaborator,The Cleveland Clinic,Phase 3
NCT01490502,2012.0,OTHER,collaborator,University of Rochester,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Stanford University,Phase 3
NCT01490502,2012.0,OTHER,collaborator,University of Virginia,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Swedish Medical Center,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Anne Arundel Health System Research Institute,Phase 3
NCT01490502,2012.0,OTHER,collaborator,Columbia University,Phase 3
NCT01490502,2012.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 3
NCT01490502,2012.0,OTHER,collaborator,Dignity Health,Phase 3
NCT01490567,2011.0,OTHER,lead,Central South University,Phase 4
NCT01491035,2012.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT01491087,2011.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01491490,2011.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT01491529,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01491932,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01492374,2012.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 1
NCT01492608,2011.0,OTHER,lead,Hvidovre University Hospital,Phase 3
NCT01492699,2012.0,INDUSTRY,lead,Ology Bioservices,Not Applicable
NCT01492920,2012.0,NETWORK,lead,Gynecologic Oncology Group,Phase 3
NCT01492920,2012.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT01493622,2010.0,OTHER,lead,Central South University,Phase 4
NCT01493674,2008.0,OTHER,lead,Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz,Phase 4
NCT01493726,2011.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT01493973,2013.0,OTHER,lead,Federico II University,Phase 2
NCT01493973,2013.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 2
NCT01493973,2013.0,UNKNOWN,collaborator,Associazione Italiana per la lotta alle Sindromi Atassiche (AISA),Phase 2
NCT01494532,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01494584,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01494584,2012.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 2
NCT01494701,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01495260,2011.0,INDIV,lead,"Onofre, Aurora Pujol, M.D.",Phase 2
NCT01495260,2011.0,OTHER_GOV,collaborator,"Ministerio de Sanidad, Servicios Sociales e Igualdad",Phase 2
NCT01495260,2011.0,OTHER,collaborator,Fundacion Hesperia,Phase 2
NCT01495403,2011.0,OTHER,lead,Mayo Clinic,Early Phase 1
NCT01495715,,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT01495793,2011.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT01495819,2017.0,OTHER,lead,Yale University,Early Phase 1
NCT01495819,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT01495845,2011.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT01495845,2011.0,UNKNOWN,collaborator,Kerr Drug,Phase 1
NCT01495845,2011.0,INDUSTRY,collaborator,Laboratory Corporation of America,Phase 1
NCT01495871,2011.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Not Applicable
NCT01495871,2011.0,OTHER,collaborator,The Moody Foundation,Not Applicable
NCT01495923,2011.0,OTHER,collaborator,Case Western Reserve University,Not Applicable
NCT01495923,2011.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01495923,2011.0,FED,collaborator,Walter Reed National Military Medical Center,Not Applicable
NCT01495923,2011.0,FED,collaborator,Brooke Army Medical Center,Not Applicable
NCT01495923,2011.0,FED,collaborator,Landstuhl Regional Medical Center,Not Applicable
NCT01495923,2011.0,FED,collaborator,Washington D.C. Veterans Affairs Medical Center,Not Applicable
NCT01495923,2011.0,FED,collaborator,"United States Naval Medical Center, San Diego",Not Applicable
NCT01495923,2011.0,OTHER,collaborator,Milton S. Hershey Medical Center,Not Applicable
NCT01496170,2011.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01496612,2011.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01496690,2012.0,OTHER,lead,University of Aarhus,Phase 4
NCT01496690,2012.0,OTHER,collaborator,Albert Einstein College of Medicine,Phase 4
NCT01496690,2012.0,OTHER,collaborator,"GCP-unit at Aarhus University Hospital, Aarhus, Denmark",Phase 4
NCT01496690,2012.0,UNKNOWN,collaborator,"The Hospital Pharmcacy North Denmark Region, Denmark",Phase 4
NCT01496690,2012.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01497262,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01497405,2012.0,OTHER,lead,RTI International,Phase 1
NCT01497405,2012.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 1
NCT01497548,2011.0,OTHER,lead,University of Malaya,Phase 3
NCT01497652,2012.0,OTHER,lead,Georgetown University,Phase 4
NCT01497652,2012.0,INDUSTRY,collaborator,"Teva Neuroscience, Inc.",Phase 4
NCT01498120,2011.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2
NCT01498822,2011.0,INDUSTRY,lead,"Korea UCB Co., Ltd.",Phase 4
NCT01498887,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01499485,2011.0,OTHER,lead,Hospital Son Llatzer,Phase 3
NCT01499563,2011.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 2
NCT01500018,2012.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT01500408,2012.0,INDUSTRY,lead,Biogen,Phase 1
NCT01500707,2013.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01501383,2011.0,INDUSTRY,lead,Vertex Pharmaceuticals Incorporated,Phase 2
NCT01501695,2008.0,INDUSTRY,lead,"Tasly Pharmaceuticals, Inc.",Phase 3
NCT01501773,2008.0,NETWORK,lead,Manipal Acunova Ltd.,Phase 2
NCT01501773,2008.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, India",Phase 2
NCT01502046,2011.0,OTHER,lead,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,Phase 2
NCT01502046,2011.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT01502644,2009.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT01502644,2009.0,OTHER,collaborator,Arthritis Foundation,Phase 4
NCT01502644,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01502748,2012.0,OTHER,lead,University of Southern California,Not Applicable
NCT01502748,2012.0,OTHER,collaborator,"University of California, Los Angeles",Not Applicable
NCT01502761,2012.0,OTHER,lead,University of Southern California,Phase 1/Phase 2
NCT01502761,2012.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1/Phase 2
NCT01503359,2012.0,OTHER,lead,Medical University of Lodz,Phase 2
NCT01503788,2012.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 2
NCT01503892,2011.0,OTHER,lead,"St. Luke's Hospital and Health Network, Pennsylvania",Not Applicable
NCT01503892,2011.0,UNKNOWN,collaborator,Goldfarb Foundation,Not Applicable
NCT01503892,2011.0,INDUSTRY,collaborator,"Pamlab, L.L.C.",Not Applicable
NCT01503944,2010.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1/Phase 2
NCT01504178,2011.0,OTHER,lead,"University Hospital, Toulouse",Phase 3
NCT01504178,2011.0,UNKNOWN,collaborator,French Parkinson Association,Phase 3
NCT01504659,2012.0,OTHER,lead,Juvenile Bipolar Research Foundation,Phase 2/Phase 3
NCT01504854,2012.0,OTHER,lead,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT01504854,2012.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01505062,2012.0,INDUSTRY,lead,Sanofi,Phase 1/Phase 2
NCT01505465,2012.0,OTHER,lead,"Hospital for Special Surgery, New York",Not Applicable
NCT01506141,2010.0,INDUSTRY,lead,Shire,Phase 1/Phase 2
NCT01506349,2015.0,OTHER,lead,Beth Israel Deaconess Medical Center,Not Applicable
NCT01506453,2012.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 2
NCT01506505,2012.0,OTHER,lead,UMC Utrecht,Not Applicable
NCT01506622,2011.0,OTHER,lead,Yonsei University,Not Applicable
NCT01506765,2003.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 1
NCT01506882,2011.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT01507610,2012.0,INDUSTRY,lead,Optinose US Inc.,Phase 1
NCT01507701,2010.0,OTHER,lead,Oslo University Hospital,Not Applicable
NCT01507753,2011.0,OTHER,lead,L. Eugene Arnold,Phase 1
NCT01507753,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01508494,2011.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT01508676,2011.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01509053,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01509079,2012.0,OTHER,lead,HealthPartners Institute,Phase 2
NCT01509079,2012.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT01509079,2012.0,OTHER,collaborator,University of Southern California,Phase 2
NCT01509456,2010.0,OTHER,lead,DLR German Aerospace Center,Not Applicable
NCT01509456,2010.0,OTHER,collaborator,University of Trieste,Not Applicable
NCT01509456,2010.0,OTHER,collaborator,University of Aarhus,Not Applicable
NCT01509456,2010.0,OTHER,collaborator,European Space Agency,Not Applicable
NCT01509547,2012.0,OTHER,lead,Medical University of South Carolina,Phase 3
NCT01510015,2012.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT01510366,2012.0,OTHER,lead,"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase 3
NCT01510366,2012.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 3
NCT01510366,2012.0,OTHER,collaborator,"National Institute for the Control of Pharmaceutical and Biological Products, China",Phase 3
NCT01511029,2012.0,INDUSTRY,lead,Knopp Biosciences,Phase 1
NCT01511497,2011.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01511510,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01511614,2013.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01512147,2011.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT01512355,2011.0,OTHER,lead,Yonsei University,Not Applicable
NCT01513291,2012.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT01514370,2012.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01514370,2012.0,INDUSTRY,collaborator,"Merck Serono S.P.A., Italy",Phase 2
NCT01514422,2011.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01514630,2013.0,OTHER,lead,Perry Renshaw,Phase 4
NCT01514682,2012.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01514903,2011.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 1
NCT01515410,2012.0,INDUSTRY,lead,Depomed,Phase 2
NCT01515423,2012.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT01515774,2011.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01515839,2009.0,INDUSTRY,lead,"Amen Clinics, Inc.",Not Applicable
NCT01515891,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01515917,2013.0,OTHER,lead,Deborah Yurgelun-Todd,Not Applicable
NCT01516372,2012.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 1
NCT01516424,2012.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 3
NCT01516554,2012.0,OTHER,lead,"Health Sciences Centre, Winnipeg, Manitoba",Phase 2
NCT01516554,2012.0,OTHER,collaborator,University of Manitoba,Phase 2
NCT01516554,2012.0,OTHER,collaborator,Consortium of Multiple Sclerosis Centers,Phase 2
NCT01516554,2012.0,OTHER,collaborator,Manitoba Medical Service Foundation,Phase 2
NCT01516892,2011.0,INDUSTRY,lead,Allergan,Phase 4
NCT01517282,2012.0,INDUSTRY,lead,MorphoSys AG,Phase 1/Phase 2
NCT01517360,2012.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 1
NCT01517360,2012.0,UNKNOWN,collaborator,National Alliance for Research in Schizophrenia and Affective Disorders,Phase 1
NCT01517698,2012.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01517711,2011.0,OTHER,lead,"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",Phase 4
NCT01517711,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 4
NCT01517932,2011.0,OTHER,lead,Fang Luo,Phase 4
NCT01518231,2012.0,OTHER,lead,Zhejiang Hospital,Phase 1
NCT01518231,2012.0,OTHER,collaborator,Zhejiang University,Phase 1
NCT01518374,2009.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT01518413,2011.0,OTHER,lead,HMeany,Phase 1
NCT01518634,2012.0,OTHER,lead,University of Aarhus,Phase 2
NCT01518894,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01518920,2011.0,INDUSTRY,lead,Biogen,Phase 1
NCT01518946,2012.0,INDUSTRY,lead,Shire,Phase 4
NCT01518972,2009.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 2
NCT01518972,2009.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01518972,2009.0,FED,collaborator,VA Puget Sound Health Care System,Phase 2
NCT01519271,2011.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01519284,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01519557,2011.0,OTHER,lead,New York State Psychiatric Institute,Early Phase 1
NCT01519713,2012.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01520350,2012.0,OTHER,lead,Serge Beaulieu,Phase 3
NCT01520350,2012.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT01520363,2012.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT01520363,2012.0,UNKNOWN,collaborator,The Johns Hopkins Institute for Clinical and Translational Research (ICTR),Phase 2
NCT01520467,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT01520649,2012.0,INDUSTRY,lead,Neuralstem Inc.,Phase 1
NCT01520727,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01520987,2011.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01521117,2011.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT01521546,2012.0,OTHER,lead,Subha Raman,Not Applicable
NCT01521546,2012.0,OTHER,collaborator,Ballou Skies,Not Applicable
NCT01521585,2011.0,INDUSTRY,lead,Siena Biotech S.p.A.,Phase 2
NCT01521663,2011.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT01521832,2009.0,INDUSTRY,lead,Siena Biotech S.p.A.,Phase 1
NCT01522066,2012.0,OTHER,lead,University of Alberta,Not Applicable
NCT01522105,2012.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 1
NCT01522963,2011.0,OTHER,lead,University of Minnesota,Not Applicable
NCT01522963,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01523301,2012.0,INDUSTRY,lead,"UCB Korea Co., Ltd.",Phase 4
NCT01523574,2009.0,OTHER,lead,Felipe Melo Cruz,Phase 2
NCT01524133,2011.0,FED,lead,VA Ann Arbor Healthcare System,Phase 4
NCT01524133,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 4
NCT01524250,2012.0,OTHER,lead,London Health Sciences Centre,Phase 2/Phase 3
NCT01524250,2012.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 2/Phase 3
NCT01524380,2011.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT01524406,2012.0,INDUSTRY,lead,"High Point Pharmaceuticals, LLC.",Phase 1
NCT01524497,2011.0,INDUSTRY,lead,Lee's Pharmaceutical Limited,Phase 2/Phase 3
NCT01524627,2011.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01524627,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01524627,2011.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01525290,2012.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 3
NCT01525680,2011.0,FED,lead,Bronx VA Medical Center,Not Applicable
NCT01525680,2011.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT01526148,2012.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT01526356,2012.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01526395,2011.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01526395,2011.0,OTHER,collaborator,Johns Hopkins Bloomberg School of Public Health,Not Applicable
NCT01526395,2011.0,OTHER,collaborator,Chhatrapati Shahuji Maharaj Medical University,Not Applicable
NCT01526785,2012.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT01526824,2011.0,OTHER,lead,Millard Fillmore Gates Hospital,Early Phase 1
NCT01526824,2011.0,OTHER,collaborator,Kaleida Health,Early Phase 1
NCT01527240,2009.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT01527305,2012.0,INDUSTRY,lead,Johnson & Johnson Pte Ltd,Phase 4
NCT01527513,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT01527695,2012.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT01527786,2010.0,OTHER,lead,BC Women's Hospital & Health Centre,Phase 3
NCT01527916,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01528007,2011.0,OTHER_GOV,lead,Finnish Institute for Health and Welfare,Phase 4
NCT01528241,2008.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT01528436,2012.0,OTHER,lead,"MinYoung Kim, M.D.",Phase 2
NCT01528592,2011.0,OTHER,lead,Northwestern University,Not Applicable
NCT01528839,2004.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2/Phase 3
NCT01528839,2004.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT01529034,2012.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT01529060,2013.0,OTHER,lead,Brendan Lee,Phase 2/Phase 3
NCT01529515,2012.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT01529619,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01529619,2012.0,INDUSTRY,collaborator,Ono Pharmaceutical Co. Ltd,Phase 4
NCT01530308,2012.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT01530542,2010.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01530620,2004.0,INDUSTRY,lead,APOGEPHA Arzneimittel GmbH,Phase 3
NCT01531582,2012.0,OTHER,lead,University of South Florida,Not Applicable
NCT01532115,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01532128,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01532141,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01533077,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01533116,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01533376,2012.0,OTHER,lead,Wills Eye,Phase 1
NCT01533376,2012.0,OTHER,collaborator,University of Medicine and Dentistry of New Jersey,Phase 1
NCT01533519,2012.0,OTHER,lead,James Murrough,Phase 1
NCT01534182,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01534806,2012.0,OTHER,lead,Akron Children's Hospital,Phase 4
NCT01535040,2012.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT01535040,2012.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01535183,2012.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT01535469,2012.0,OTHER,lead,University of Minnesota,Phase 4
NCT01535469,2012.0,OTHER,collaborator,"Infectious Diseases Institute, Uganda",Phase 4
NCT01535469,2012.0,OTHER,collaborator,Makerere University,Phase 4
NCT01535469,2012.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT01535573,2010.0,OTHER,lead,Joy Schmitz,Phase 2
NCT01535573,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01535937,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01535937,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01536210,2011.0,INDUSTRY,lead,"Yuyu Pharma, Inc.",Phase 3
NCT01536249,2012.0,INDUSTRY,lead,Knopp Biosciences,Phase 1
NCT01536314,2012.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 3
NCT01536366,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01536574,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01537042,2012.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 3
NCT01537549,2010.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1/Phase 2
NCT01537705,2012.0,INDUSTRY,lead,Targeted Medical Pharma,Phase 2
NCT01537757,2012.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT01538095,2012.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01538225,2012.0,INDUSTRY,lead,"Almirall, S.A.",Phase 3
NCT01538329,2012.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT01538693,2011.0,OTHER,lead,T. George Hornby,Not Applicable
NCT01538693,2011.0,OTHER,collaborator,University of Medicine and Dentistry of New Jersey,Not Applicable
NCT01538693,2011.0,OTHER,collaborator,Shirley Ryan AbilityLab,Not Applicable
NCT01538966,2012.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT01539733,2010.0,OTHER,lead,"Amsterdam UMC, location VUmc",Not Applicable
NCT01539733,2010.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Not Applicable
NCT01539837,2012.0,OTHER,lead,Imperial College London,Phase 2
NCT01540604,,INDUSTRY,lead,RSPR Pharma AB,Phase 2
NCT01540630,2012.0,INDUSTRY,lead,Biogen,Phase 2
NCT01540838,2012.0,OTHER,lead,University of Helsinki,Phase 4
NCT01540838,2012.0,OTHER,collaborator,"Foundation for Paediatric Research, Finland",Phase 4
NCT01541371,2008.0,INDUSTRY,lead,Xian-Janssen Pharmaceutical Ltd.,Phase 3
NCT01541397,2011.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT01541397,2011.0,INDUSTRY,collaborator,BioMarin Pharmaceutical,Not Applicable
NCT01541605,2012.0,OTHER,lead,Michael Kluge,Phase 3
NCT01541605,2012.0,NETWORK,collaborator,Spanish Clinical Research Network - SCReN,Phase 3
NCT01541644,2011.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01542242,2012.0,OTHER,lead,Vancouver General Hospital,Phase 4
NCT01542242,2012.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 4
NCT01542307,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01542892,2011.0,OTHER,lead,Tufts University,Not Applicable
NCT01542892,2011.0,OTHER,collaborator,Uppsala University,Not Applicable
NCT01542892,2011.0,OTHER,collaborator,Karolinska Institutet,Not Applicable
NCT01542892,2011.0,INDUSTRY,collaborator,Nestec Ltd.,Not Applicable
NCT01543139,2015.0,OTHER,lead,Ewha Womans University,Phase 2
NCT01543321,2012.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Phase 3
NCT01543724,2015.0,OTHER,lead,Ewha Womans University,Phase 4
NCT01543724,2015.0,OTHER,collaborator,Soon Chun Hyang University,Phase 4
NCT01544062,2012.0,OTHER,lead,University of Washington,Phase 4
NCT01544062,2012.0,INDUSTRY,collaborator,Mallinckrodt,Phase 4
NCT01544296,2012.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT01545076,2012.0,INDUSTRY,lead,CSL Behring,Phase 3
NCT01545076,2012.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 3
NCT01545297,2012.0,OTHER,lead,Nicolai Goettel,Not Applicable
NCT01545310,2011.0,INDUSTRY,lead,Abbott,Phase 1
NCT01545518,2011.0,OTHER,lead,Emory University,Phase 2
NCT01545518,2011.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 2
NCT01545843,2009.0,OTHER,lead,University of Michigan,Phase 2
NCT01546402,2011.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Phase 4
NCT01546688,2008.0,INDUSTRY,lead,Eisai Limited,Phase 4
NCT01546805,2012.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Not Applicable
NCT01546896,2012.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01546909,2012.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01547000,2012.0,OTHER,lead,Yale University,Phase 4
NCT01547000,2012.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01547000,2012.0,OTHER,collaborator,University of South Florida,Phase 4
NCT01547000,2012.0,INDUSTRY,collaborator,Shire,Phase 4
NCT01547000,2012.0,OTHER,collaborator,New York University,Phase 4
NCT01547169,2011.0,OTHER,lead,University of Washington,Phase 2
NCT01547169,2011.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01547494,2011.0,OTHER,lead,Physicians Committee for Responsible Medicine,Not Applicable
NCT01547689,2012.0,OTHER,lead,Affiliated Hospital to Academy of Military Medical Sciences,Phase 1/Phase 2
NCT01547689,2012.0,OTHER,collaborator,Peking University Third Hospital,Phase 1/Phase 2
NCT01547715,2012.0,INDUSTRY,lead,Novartis,Phase 3
NCT01547715,2012.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 3
NCT01548430,2011.0,INDUSTRY,lead,vTv Therapeutics,Phase 1
NCT01548521,2011.0,OTHER,lead,"University Hospital, Toulouse",Phase 1/Phase 2
NCT01548612,2006.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT01548638,2012.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01548937,2010.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01549041,2012.0,OTHER,lead,Duke University,Phase 4
NCT01549041,2012.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT01549288,2012.0,OTHER_GOV,lead,Lady Hardinge Medical College,Phase 2/Phase 3
NCT01549834,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01549847,,INDUSTRY,lead,Biolab Sanus Farmaceutica,Phase 3
NCT01550107,2015.0,OTHER,lead,University of Dundee,Phase 4
NCT01550341,2012.0,OTHER,lead,Yale University,Not Applicable
NCT01550341,2012.0,OTHER,collaborator,George Mason University,Not Applicable
NCT01550341,2012.0,OTHER,collaborator,Howard University,Not Applicable
NCT01550341,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01550484,2012.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT01550549,2011.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Not Applicable
NCT01550796,2012.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT01551225,2012.0,OTHER,lead,Maastricht University Medical Center,Phase 4
NCT01551329,2012.0,OTHER,lead,Yale University,Phase 1
NCT01551329,2012.0,FED,collaborator,VA Connecticut Healthcare System,Phase 1
NCT01551940,2012.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT01552057,2012.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01552057,2012.0,INDUSTRY,collaborator,Shionogi,Phase 3
NCT01552434,2012.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT01552434,2012.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01552772,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01552837,2007.0,OTHER,lead,RWTH Aachen University,Not Applicable
NCT01553084,2012.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01553084,2012.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT01553084,2012.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT01553149,2012.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01553318,2012.0,OTHER,lead,Indiana University,Phase 3
NCT01554124,2013.0,NETWORK,lead,PENTA Foundation,Phase 1/Phase 2
NCT01554124,2013.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 1/Phase 2
NCT01554202,2008.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT01554202,2008.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT01554488,2013.0,FED,lead,VA Office of Research and Development,Phase 4
NCT01554787,2012.0,OTHER,lead,China Medical University Hospital,Phase 4
NCT01555333,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 3
NCT01555580,2012.0,OTHER,lead,Muscular Dystrophy Association,Early Phase 1
NCT01555697,2014.0,OTHER,lead,"University of California, San Diego",Phase 1/Phase 2
NCT01555814,2011.0,OTHER,lead,Birte Glenthoj,Not Applicable
NCT01555814,2011.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT01555814,2011.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT01555814,2011.0,OTHER,collaborator,"Institute of Psychiatry, London",Not Applicable
NCT01555814,2011.0,OTHER,collaborator,UMC Utrecht,Not Applicable
NCT01555814,2011.0,OTHER,collaborator,Copenhagen Hospital Corporation,Not Applicable
NCT01555970,2012.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT01555970,2012.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 2
NCT01555983,2012.0,OTHER,lead,Barth Wilsey,Phase 2/Phase 3
NCT01555983,2012.0,FED,collaborator,VA Northern California Health Care System,Phase 2/Phase 3
NCT01555983,2012.0,OTHER,collaborator,"University of California, San Diego",Phase 2/Phase 3
NCT01555983,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01556100,2011.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01556165,2012.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01556646,2011.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Phase 3
NCT01556646,2011.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT01556685,2011.0,INDUSTRY,lead,Biogen,Phase 4
NCT01556763,2008.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 1
NCT01556802,2011.0,OTHER,lead,Hospital Universitario Hernando Moncaleano Perdomo,Phase 1
NCT01557010,2012.0,INDUSTRY,lead,Daewoong Pharmaceutical Co. LTD.,Phase 2
NCT01557153,2012.0,OTHER,lead,Gateshead Health NHS Foundation Trust,Phase 3
NCT01557153,2012.0,OTHER,collaborator,Newcastle-upon-Tyne Hospitals NHS Trust,Phase 3
NCT01557153,2012.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 3
NCT01557244,2012.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01557400,2012.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT01558154,2012.0,OTHER,lead,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Not Applicable
NCT01558154,2012.0,OTHER,collaborator,California Pacific Medical Center Research Institute,Not Applicable
NCT01558154,2012.0,OTHER,collaborator,Massachusetts General Hospital,Not Applicable
NCT01558193,2011.0,OTHER,lead,Swansea University,Not Applicable
NCT01558245,2011.0,OTHER,lead,"Jinling Hospital, China",Phase 2
NCT01559272,2008.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT01559298,2012.0,OTHER,lead,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,Phase 4
NCT01559298,2012.0,INDUSTRY,collaborator,Edwards Lifesciences,Phase 4
NCT01559519,2012.0,OTHER,lead,University of Roma La Sapienza,Phase 4
NCT01559636,2012.0,FED,lead,Centers for Disease Control and Prevention,Not Applicable
NCT01559636,2012.0,OTHER,collaborator,"Tribhuvan University, Nepal",Not Applicable
NCT01559675,2010.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT01559831,2012.0,INDUSTRY,lead,Valneva Austria GmbH,Phase 1
NCT01560182,2010.0,INDUSTRY,lead,Orchard Therapeutics,Phase 1/Phase 2
NCT01560182,2010.0,OTHER,collaborator,Ospedale San Raffaele,Phase 1/Phase 2
NCT01560286,2012.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT01560507,2012.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT01560507,2012.0,INDUSTRY,collaborator,"Philip Morris USA, Inc.",Phase 2/Phase 3
NCT01560585,2012.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 1/Phase 2
NCT01560754,2012.0,OTHER,lead,James BOYD MD,Phase 2
NCT01560754,2012.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01560754,2012.0,UNKNOWN,collaborator,Parkinson Study Group (PSG),Phase 2
NCT01560754,2012.0,INDUSTRY,collaborator,International Parkinson Fonds Germany GmbH,Phase 2
NCT01560754,2012.0,OTHER,collaborator,German Parkinson Study Group (GPS),Phase 2
NCT01560754,2012.0,OTHER,collaborator,German Parkinson Society (DPG),Phase 2
NCT01560754,2012.0,OTHER,collaborator,Philipps University Marburg Medical Center,Phase 2
NCT01561053,2012.0,INDUSTRY,lead,"Instituto Grifols, S.A.",Phase 2/Phase 3
NCT01561053,2012.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 2/Phase 3
NCT01561079,2012.0,OTHER,lead,Johns Hopkins University,Phase 2/Phase 3
NCT01561092,,OTHER,lead,University of Aarhus,Phase 4
NCT01561092,,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT01561430,2012.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1/Phase 2
NCT01561742,2012.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT01561742,2012.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT01561898,2006.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT01562444,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01562444,2012.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT01562496,2012.0,OTHER,lead,Radboud University Medical Center,Not Applicable
NCT01562496,2012.0,OTHER,collaborator,The Cleveland Clinic,Not Applicable
NCT01563016,2012.0,OTHER,lead,The University of Hong Kong,Not Applicable
NCT01563016,2012.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Not Applicable
NCT01563718,2012.0,OTHER,lead,Rhode Island Hospital,Phase 4
NCT01563718,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01563718,2012.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 4
NCT01563731,2013.0,OTHER,lead,Istituto Auxologico Italiano,Phase 4
NCT01563731,2013.0,OTHER,collaborator,European Society of Hypertension,Phase 4
NCT01563731,2013.0,UNKNOWN,collaborator,Chinese Hypertension League,Phase 4
NCT01563913,2012.0,FED,lead,VA Office of Research and Development,Phase 1
NCT01563913,2012.0,OTHER,collaborator,Oregon Health and Science University,Phase 1
NCT01564706,2007.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT01564979,2012.0,OTHER,lead,Khon Kaen University,Phase 2
NCT01565291,2007.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Early Phase 1
NCT01565330,2008.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT01565343,2008.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT01565356,2010.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Not Applicable
NCT01565369,2011.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Not Applicable
NCT01565382,2011.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT01565395,2012.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT01565395,2012.0,INDUSTRY,collaborator,Merz Pharmaceuticals,Phase 2
NCT01566162,2012.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01566370,2012.0,OTHER,lead,Yale University,Phase 2
NCT01566370,2012.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01566591,2012.0,INDUSTRY,lead,Brainsway,Not Applicable
NCT01567124,2012.0,OTHER,lead,Baker Heart and Diabetes Institute,Phase 4
NCT01567124,2012.0,OTHER,collaborator,The Alfred,Phase 4
NCT01567124,2012.0,OTHER,collaborator,Monash Medical Centre,Phase 4
NCT01567124,2012.0,OTHER,collaborator,Ballarat Health Services,Phase 4
NCT01567605,2012.0,OTHER,lead,Simon Fraser University,Phase 4
NCT01567605,2012.0,OTHER,collaborator,University of British Columbia,Phase 4
NCT01567670,2011.0,OTHER,lead,Lightlake Sinclair Ltd.,Phase 2/Phase 3
NCT01567865,2012.0,OTHER,lead,PATH,Phase 4
NCT01568034,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT01568047,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT01568073,2011.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT01568099,2012.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT01568203,2011.0,INDUSTRY,lead,Amgen,Phase 1
NCT01568216,2012.0,INDUSTRY,lead,Amgen,Phase 2
NCT01568229,2012.0,INDUSTRY,lead,Amgen,Phase 2
NCT01568528,2013.0,OTHER,lead,Emory University,Phase 2
NCT01568528,2013.0,FED,collaborator,Atlanta VA Medical Center,Phase 2
NCT01568684,2012.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT01568749,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01569451,2012.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01569451,2012.0,OTHER,collaborator,"Rocky Mountain MS Research Group, LLC",Phase 2
NCT01569464,2012.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01569516,2011.0,INDUSTRY,lead,"Changchun Huayang High-tech Co., Ltd",Phase 2
NCT01569516,2011.0,OTHER,collaborator,"Beijing Bionovo Medicine Development Co., Ltd.",Phase 2
NCT01569633,2011.0,OTHER,lead,East Tennessee State University,Not Applicable
NCT01569659,2011.0,OTHER,lead,Northwestern University,Phase 4
NCT01569659,2011.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT01569685,2012.0,OTHER,lead,Charlotte Sonne,Phase 4
NCT01569685,2012.0,OTHER,collaborator,Psychiatric Center Ballerup,Phase 4
NCT01569958,2012.0,OTHER,lead,Università degli Studi 'G. d'Annunzio' Chieti e Pescara,Phase 2
NCT01569958,2012.0,OTHER,collaborator,"Catholic University, Italy",Phase 2
NCT01569958,2012.0,OTHER,collaborator,Federico II University,Phase 2
NCT01569958,2012.0,OTHER,collaborator,"Ministero della Salute, Italy",Phase 2
NCT01571167,2011.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01571167,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01571362,2012.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01571505,2012.0,OTHER,lead,International Vaccine Institute,Phase 1
NCT01571505,2012.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 1
NCT01571505,2012.0,OTHER,collaborator,"National Institute of Cholera and Enteric Diseases, India",Phase 1
NCT01571505,2012.0,OTHER,collaborator,University of Virginia,Phase 1
NCT01571505,2012.0,OTHER,collaborator,University of Vermont,Phase 1
NCT01572623,2011.0,OTHER,lead,Campus Bio-Medico University,Phase 4
NCT01573273,2012.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT01573507,2012.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Not Applicable
NCT01573507,2012.0,OTHER,collaborator,Swiss National Science Foundation,Not Applicable
NCT01573507,2012.0,OTHER,collaborator,European Society of Intensive Care Medicine,Not Applicable
NCT01573819,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01574014,2009.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 2
NCT01574014,2009.0,OTHER,collaborator,University of Basel,Phase 2
NCT01574183,2012.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01574183,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01574313,2010.0,OTHER,lead,Chi Mei Medical Hospital,Phase 4
NCT01574742,2012.0,OTHER,lead,Shalvata Mental Health Center,Phase 1
NCT01574885,2012.0,INDUSTRY,lead,Tecno Sun SRL,Phase 2
NCT01574885,2012.0,OTHER,collaborator,Centro Studi Gised,Phase 2
NCT01575054,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01575158,1997.0,OTHER,lead,University of Aarhus,Not Applicable
NCT01575158,1997.0,UNKNOWN,collaborator,Danish University Antidepressant Group,Not Applicable
NCT01575470,2012.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT01575639,2012.0,OTHER_GOV,lead,Lady Hardinge Medical College,Phase 3
NCT01575678,2012.0,OTHER,lead,University of Aarhus,Phase 2
NCT01576354,2012.0,OTHER,lead,University of Zurich,Phase 2
NCT01576640,2005.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01576705,2012.0,OTHER,lead,Institut Jerome Lejeune,Phase 3
NCT01576705,2012.0,OTHER,collaborator,Hôpital Cochin,Phase 3
NCT01576705,2012.0,OTHER,collaborator,"Central Hospital, Nancy, France",Phase 3
NCT01576848,2011.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT01576874,2012.0,OTHER,lead,"Kevin Gray, MD",Not Applicable
NCT01576874,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01577160,2008.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT01577186,2008.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT01577732,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01577966,2012.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01577992,2011.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT01577992,2011.0,OTHER,collaborator,Fondation de France,Not Applicable
NCT01578161,2012.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01578330,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01578486,2011.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT01578486,2011.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT01578785,2012.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01579383,2012.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 1
NCT01579500,2012.0,OTHER,lead,Catholic University of Korea Saint Paul's Hospital,Phase 4
NCT01579500,2012.0,OTHER,collaborator,National Health Insurance Service Ilsan Hospital,Phase 4
NCT01579500,2012.0,INDUSTRY,collaborator,Medy-Tox,Phase 4
NCT01579825,2012.0,OTHER,lead,Johns Hopkins Bloomberg School of Public Health,Not Applicable
NCT01579825,2012.0,OTHER,collaborator,World Health Organization,Not Applicable
NCT01580033,2012.0,NETWORK,lead,Jiangsu Province Centers for Disease Control and Prevention,Phase 3
NCT01580033,2012.0,OTHER,collaborator,"Royal (Wuxi) Biological Co., LTD",Phase 3
NCT01580501,2012.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 1
NCT01580839,2012.0,OTHER,lead,Neuroscience Trials Australia,Phase 3
NCT01580839,2012.0,OTHER,collaborator,China Medical University Hospital,Phase 3
NCT01581281,2012.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 3
NCT01581281,2012.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01581450,2012.0,INDUSTRY,lead,Air Liquide Santé International,Phase 1
NCT01581450,2012.0,INDUSTRY,collaborator,ORION Clinical Services,Phase 1
NCT01582061,2011.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01582152,2012.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1/Phase 2
NCT01582152,2012.0,INDUSTRY,collaborator,"Cortice Biosciences, Inc.",Phase 1/Phase 2
NCT01582477,2012.0,INDUSTRY,lead,"Pacira Pharmaceuticals, Inc",Phase 4
NCT01582516,2010.0,OTHER,lead,Erasmus Medical Center,Phase 1/Phase 2
NCT01582516,2010.0,OTHER,collaborator,"Amsterdam UMC, location VUmc",Phase 1/Phase 2
NCT01582542,2012.0,OTHER,lead,Rabin Medical Center,Phase 4
NCT01583023,2014.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 4
NCT01583036,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01584076,2012.0,OTHER,lead,Boston Children's Hospital,Phase 1
NCT01584440,2012.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 2
NCT01584466,2014.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01584843,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01584934,2013.0,OTHER,lead,"University Hospital, Ghent",Phase 4
NCT01584934,2013.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT01585207,2012.0,OTHER,lead,Barbara J. Coffey,Phase 1/Phase 2
NCT01585298,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01585935,2012.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT01586052,2012.0,OTHER,lead,"MinYoung Kim, M.D.",Phase 1
NCT01586052,2012.0,INDUSTRY,collaborator,LG Life Sciences,Phase 1
NCT01586455,2013.0,OTHER,lead,New York Medical College,Phase 1
NCT01586572,2012.0,OTHER,lead,Aga Khan University,Not Applicable
NCT01586572,2012.0,OTHER,collaborator,World Health Organization,Not Applicable
NCT01586975,2007.0,OTHER,lead,Northwestern University,Phase 2/Phase 3
NCT01587066,2010.0,OTHER,lead,Bo-Hyun Yoon,Phase 4
NCT01587118,2012.0,OTHER,lead,"Lori Davis, MD",Phase 4
NCT01587118,2012.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT01587118,2012.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01587326,2012.0,OTHER_GOV,lead,"Beitou Armed Forces Hospital, Taipei, Taiwan",Not Applicable
NCT01588158,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01588314,2012.0,OTHER,lead,University of Minnesota,Phase 2
NCT01588314,2012.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 2
NCT01588561,2005.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01588561,2005.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01588717,2012.0,OTHER,lead,Thomas Jefferson University,Phase 1
NCT01588925,2011.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 2
NCT01589055,2005.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01589068,2007.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01589081,2008.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01589809,2012.0,OTHER,lead,Imperial College London,Phase 2
NCT01590888,2012.0,INDUSTRY,lead,Prana Biotechnology Limited,Phase 2
NCT01591096,2012.0,OTHER,lead,Seattle Children's Hospital,Phase 1
NCT01591096,2012.0,OTHER,collaborator,The Hospital for Sick Children,Phase 1
NCT01591096,2012.0,OTHER,collaborator,Medical College of Wisconsin,Phase 1
NCT01591096,2012.0,OTHER,collaborator,University of Texas at Austin,Phase 1
NCT01591096,2012.0,OTHER,collaborator,Alberta Children's Hospital,Phase 1
NCT01591096,2012.0,OTHER,collaborator,McMaster University,Phase 1
NCT01591551,2012.0,OTHER,lead,"Cornerstone Health Care, PA",Phase 4
NCT01591551,2012.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT01591759,2012.0,OTHER,lead,Mclean Hospital,Phase 2
NCT01592110,2012.0,INDUSTRY,lead,"Zogenix, Inc.",Phase 1
NCT01592201,2012.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT01592409,2012.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT01592409,2012.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT01592409,2012.0,OTHER_GOV,collaborator,Health Canada,Not Applicable
NCT01592747,2012.0,INDUSTRY,lead,Forest Laboratories,Phase 2
NCT01593514,2012.0,OTHER,lead,University of Oxford,Phase 4
NCT01593774,2012.0,OTHER,lead,Guilan University of Medical Sciences,Phase 2
NCT01594047,2009.0,OTHER,lead,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Not Applicable
NCT01594346,2000.0,OTHER_GOV,lead,New York State Institute for Basic Research,Phase 3
NCT01594346,2000.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT01594346,2000.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT01594346,2000.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 3
NCT01594346,2000.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 3
NCT01594346,2000.0,OTHER,collaborator,"University of California, San Diego",Phase 3
NCT01594346,2000.0,OTHER,collaborator,Columbia University,Phase 3
NCT01594346,2000.0,OTHER,collaborator,"Bronx Veterans Medical Research Foundation, Inc",Phase 3
NCT01595581,2012.0,OTHER,lead,University of Southern California,Phase 3
NCT01595581,2012.0,OTHER,collaborator,Boston University,Phase 3
NCT01595581,2012.0,OTHER,collaborator,University of Oregon,Phase 3
NCT01595646,2011.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT01595646,2011.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT01595867,2010.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01596634,2013.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT01596634,2013.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT01596673,2012.0,INDUSTRY,lead,Cephalon,Phase 1
NCT01596803,2010.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT01596803,2010.0,UNKNOWN,collaborator,Hospital Clinical Research Project 2010,Not Applicable
NCT01596803,2010.0,UNKNOWN,collaborator,Association Amis FSH France,Not Applicable
NCT01596803,2010.0,UNKNOWN,collaborator,FSH Dutch Fondation The Netherland,Not Applicable
NCT01597167,2011.0,OTHER,lead,University of Miami,Not Applicable
NCT01597167,2011.0,OTHER,collaborator,Life Extension Foundation Inc.,Not Applicable
NCT01597297,2012.0,INDUSTRY,lead,Biogen,Phase 2
NCT01597518,2013.0,NETWORK,lead,AOSpine North America Research Network,Phase 2/Phase 3
NCT01597518,2013.0,OTHER,collaborator,"AO Foundation, AO Spine",Phase 2/Phase 3
NCT01597518,2013.0,FED,collaborator,United States Department of Defense,Phase 2/Phase 3
NCT01597518,2013.0,OTHER,collaborator,Rick Hansen Institute,Phase 2/Phase 3
NCT01597518,2013.0,OTHER,collaborator,Christopher Reeve Paralysis Foundation,Phase 2/Phase 3
NCT01597596,2012.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT01598103,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01598753,2012.0,OTHER,lead,University of Washington,Phase 3
NCT01598857,2014.0,INDUSTRY,lead,Anthera Pharmaceuticals,Phase 2
NCT01598896,2012.0,OTHER,lead,Mclean Hospital,Phase 2/Phase 3
NCT01598896,2012.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 2/Phase 3
NCT01599234,2005.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01599286,2012.0,OTHER,lead,Mendel Tuchman,Phase 2
NCT01599286,2012.0,OTHER,collaborator,Children's National Research Institute,Phase 2
NCT01599286,2012.0,OTHER,collaborator,Boston Children's Hospital,Phase 2
NCT01599286,2012.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Phase 2
NCT01599286,2012.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT01599286,2012.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT01599286,2012.0,OTHER,collaborator,Stanford University,Phase 2
NCT01599286,2012.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01599286,2012.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT01599286,2012.0,OTHER,collaborator,Children's Hospital Colorado,Phase 2
NCT01599975,2012.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT01600170,2013.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01600235,2012.0,OTHER,lead,Samsung Medical Center,Phase 3
NCT01600235,2012.0,OTHER,collaborator,Inje University,Phase 3
NCT01600235,2012.0,OTHER,collaborator,Gyeongsang National University Hospital,Phase 3
NCT01600235,2012.0,OTHER,collaborator,Seoul National University Bundang Hospital,Phase 3
NCT01600235,2012.0,OTHER,collaborator,Keimyung University Dongsan Medical Center,Phase 3
NCT01600235,2012.0,OTHER,collaborator,Yeungnam University Hospital,Phase 3
NCT01600456,2011.0,OTHER,lead,Case Western Reserve University,Phase 3
NCT01600456,2011.0,OTHER,collaborator,University of Washington,Phase 3
NCT01600456,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT01600469,2012.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01600716,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01600859,2012.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT01601314,2012.0,OTHER,lead,Sara Varea,Phase 3
NCT01601509,2010.0,OTHER,lead,University of Athens,Not Applicable
NCT01601717,2010.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01601717,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01601730,2010.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01601730,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01602016,2012.0,OTHER,lead,University of Arkansas,Phase 2
NCT01602016,2012.0,OTHER,collaborator,Arkansas Children's Hospital Research Institute,Phase 2
NCT01602029,2010.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 2
NCT01602029,2010.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT01602029,2010.0,OTHER,collaborator,Dow University of Health Sciences,Phase 2
NCT01602029,2010.0,UNKNOWN,collaborator,Karwan e Hayat,Phase 2
NCT01602029,2010.0,OTHER,collaborator,Abbasi Shaheed Hospital,Phase 2
NCT01602185,2012.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Malou Navez, Pain Clinic, Saint-Etienne Hopital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Marc Sorel, Pain Clinic, Nemours Hospital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Anne-Margot Duclot, Pain Clinic, Paris Rotschild Hospital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Monique Belon, Pain Clinic, Aurillac Hospital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Marie-Christine Crosmary/Dr Renato Colamarino, Pain Clinic, Vichy Hospital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Mohamed El Ayadi, Pain Clinic, Issoire Hospital",Phase 2
NCT01602185,2012.0,UNKNOWN,collaborator,"Dr Géraldine Brumauld de Montgazon, Pain Clinic, La Rochelle Hospital",Phase 2
NCT01602393,2012.0,INDUSTRY,lead,Chiesi Farmaceutici S.p.A.,Phase 2
NCT01602471,2012.0,INDUSTRY,lead,Siemens Molecular Imaging,Phase 2
NCT01602510,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01602900,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01603069,2012.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT01603394,2012.0,INDUSTRY,lead,Pfizer,Phase 4
NCT01603407,2013.0,OTHER,lead,University of Rochester,Phase 3
NCT01603407,2013.0,OTHER,collaborator,Newcastle University,Phase 3
NCT01603407,2013.0,OTHER,collaborator,University Medical Center Freiburg,Phase 3
NCT01603407,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01603446,2012.0,OTHER,lead,The Hospital for Sick Children,Phase 2
NCT01603498,2011.0,OTHER,lead,Federal University of the Valleys of Jequitinhonha and Mucuri,Not Applicable
NCT01603602,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01603615,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01603628,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01603641,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01603667,2012.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,National Taiwan University Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Shin Kong Wu Ho-Su Memorial Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Tri-Service General Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Changhua Christian Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,National Cheng-Kung University Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Kaohsiung Medical University,Phase 2
NCT01603667,2012.0,OTHER,collaborator,En Chu Kong Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Kuang Tien General Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Chung Shan Medical University,Phase 2
NCT01603667,2012.0,OTHER_GOV,collaborator,"Taipei Veterans General Hospital, Taiwan",Phase 2
NCT01603667,2012.0,OTHER,collaborator,Kaohsiung Veterans General Hospital.,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Taipei Medical University Shuang Ho Hospital,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Cheng Hsin Rehabilitation Medical Center,Phase 2
NCT01603667,2012.0,OTHER,collaborator,Taipei Medical University WanFang Hospital,Phase 2
NCT01604265,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01604408,2012.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01604785,2012.0,OTHER,lead,Oregon Health and Science University,Phase 2/Phase 3
NCT01605253,2012.0,OTHER,lead,Rush University Medical Center,Phase 4
NCT01605253,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01605357,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT01606111,2013.0,INDUSTRY,lead,Ever Neuro Pharma GmbH,Phase 4
NCT01606137,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01606150,2012.0,OTHER,lead,Georgetown University,Not Applicable
NCT01606176,2002.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01606215,2013.0,OTHER,lead,Imperial College London,Phase 1/Phase 2
NCT01606228,2007.0,INDUSTRY,lead,Janssen Pharmaceutica,Phase 3
NCT01606254,2007.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT01606436,2012.0,INDUSTRY,lead,Denovo Biopharma LLC,Phase 1
NCT01607086,2008.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01607125,2012.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT01607346,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01607476,2012.0,OTHER,lead,Mayo Clinic,Phase 2
NCT01607671,2012.0,OTHER,lead,Fraser Health,Phase 1
NCT01608217,2012.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT01608217,2012.0,NETWORK,collaborator,"Health Valley, Netherlands",Phase 2
NCT01609153,2012.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Phase 4
NCT01609283,2012.0,OTHER,lead,Mayo Clinic,Phase 1
NCT01609335,2012.0,OTHER,lead,Mayo Clinic,Phase 1
NCT01609348,2012.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01610011,2010.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01610011,2010.0,OTHER,collaborator,Brain & Behavior Research Foundation,Not Applicable
NCT01610310,2012.0,INDUSTRY,lead,Biogen,Phase 1
NCT01610440,2011.0,INDUSTRY,lead,"Shenzhen Beike Bio-Technology Co., Ltd.",Phase 1/Phase 2
NCT01610440,2011.0,OTHER,collaborator,The Second Affiliated Hospital of Kunming Medical University,Phase 1/Phase 2
NCT01610687,2001.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01610700,2001.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01610713,2001.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01610739,2012.0,OTHER,lead,Henry Ford Health System,Not Applicable
NCT01611155,2012.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT01611194,2012.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT01611948,2011.0,OTHER,lead,The Scripps Research Institute,Phase 2
NCT01611948,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01612078,2012.0,INDUSTRY,lead,TSH Biopharm Corporation Limited,Phase 3
NCT01613248,2012.0,INDUSTRY,lead,Allergan,Phase 2
NCT01613417,2012.0,INDUSTRY,lead,"Bracco Diagnostics, Inc",Phase 4
NCT01614093,2012.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT01614249,2012.0,OTHER,lead,University of Nairobi,Not Applicable
NCT01614249,2012.0,UNKNOWN,collaborator,Consortium for Advanced Research Training in Africa (CARTA),Not Applicable
NCT01614249,2012.0,UNKNOWN,collaborator,Innovix Pharma Inc.,Not Applicable
NCT01614574,2012.0,INDUSTRY,lead,Shire,Phase 3
NCT01614886,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01614886,2012.0,INDUSTRY,collaborator,Ono Pharmaceutical Co. Ltd,Phase 3
NCT01614899,2012.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT01614912,2012.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT01615185,2008.0,OTHER_GOV,lead,Kaohsiung Kai-Suan Psychiatric Hospital,Phase 4
NCT01615367,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT01615510,2012.0,OTHER,lead,University Hospital Schleswig-Holstein,Phase 1
NCT01615887,2009.0,OTHER,lead,State University of New York at Buffalo,Phase 2
NCT01616108,2012.0,OTHER,lead,Smith-Kettlewell Eye Research Institute,Phase 2/Phase 3
NCT01616108,2012.0,OTHER,collaborator,Eidactics,Phase 2/Phase 3
NCT01616108,2012.0,OTHER,collaborator,Sutter Health,Phase 2/Phase 3
NCT01616108,2012.0,OTHER,collaborator,Strabismus Research Foundation,Phase 2/Phase 3
NCT01616485,2004.0,INDUSTRY,lead,VIVUS LLC,Phase 1
NCT01617044,2012.0,OTHER,lead,Children's Hospitals and Clinics of Minnesota,Phase 2
NCT01617135,2012.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT01617135,2012.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01617187,2012.0,INDUSTRY,lead,Organon and Co,Phase 3
NCT01617200,2012.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT01617577,2009.0,OTHER,lead,University of South Florida,Phase 1/Phase 2
NCT01617733,2011.0,OTHER,lead,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 2
NCT01617733,2011.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT01617733,2011.0,OTHER,collaborator,The Christie NHS Foundation Trust,Phase 2
NCT01617733,2011.0,OTHER,collaborator,Oxford University Hospitals NHS Trust,Phase 2
NCT01617733,2011.0,OTHER,collaborator,Barts & The London NHS Trust,Phase 2
NCT01618513,2012.0,OTHER,lead,University of Aarhus,Phase 4
NCT01618513,2012.0,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT01618513,2012.0,OTHER,collaborator,Odense University Hospital,Phase 4
NCT01618513,2012.0,OTHER,collaborator,Herlev Hospital,Phase 4
NCT01618513,2012.0,OTHER,collaborator,"Copenhagen University Hospital, Denmark",Phase 4
NCT01618513,2012.0,OTHER,collaborator,Aalborg University Hospital,Phase 4
NCT01618656,2012.0,OTHER,lead,Yale University,Phase 2
NCT01618656,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01619462,2011.0,OTHER_GOV,lead,Papua New Guinea Institute of Medical Research,Phase 3
NCT01619462,2011.0,OTHER,collaborator,The University of Western Australia,Phase 3
NCT01619566,2012.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT01619644,2012.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT01619644,2012.0,UNKNOWN,collaborator,Fondation Syndrome de Rubinstein-Taybi,Phase 2
NCT01620060,2012.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01620138,2010.0,OTHER,lead,Universidade Federal do Rio de Janeiro,Phase 2/Phase 3
NCT01621009,2001.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01621009,2001.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT01621009,2001.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01621022,2001.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01621022,2001.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT01621113,2012.0,OTHER,lead,Kessler Foundation,Phase 2
NCT01621113,2012.0,FED,collaborator,"National Institute on Disability, Independent Living, and Rehabilitation Research",Phase 2
NCT01621113,2012.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 2
NCT01621191,2012.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01621191,2012.0,INDUSTRY,collaborator,Shionogi,Phase 3
NCT01621256,2013.0,INDUSTRY,lead,Nordmark Arzneimittel GmbH & Co. KG,Phase 1/Phase 2
NCT01621256,2013.0,INDUSTRY,collaborator,ClinSupport GmbH,Phase 1/Phase 2
NCT01621256,2013.0,UNKNOWN,collaborator,MWI Medizinisches Wirtschaftsinstitut GmbH,Phase 1/Phase 2
NCT01621256,2013.0,UNKNOWN,collaborator,ProjectPharm s.r.o.,Phase 1/Phase 2
NCT01621256,2013.0,UNKNOWN,collaborator,LCR Leading Clinical Research s.r.o.,Phase 1/Phase 2
NCT01621256,2013.0,INDUSTRY,collaborator,X-act Cologne Clinical Research GmbH,Phase 1/Phase 2
NCT01621269,2013.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01621581,2013.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01621737,2011.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT01621737,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01622088,2012.0,INDUSTRY,lead,Knopp Biosciences,Phase 3
NCT01622088,2012.0,INDUSTRY,collaborator,Biogen,Phase 3
NCT01623284,2010.0,OTHER,lead,Mayo Clinic,Phase 1
NCT01623505,2010.0,OTHER,lead,Ottawa Heart Institute Research Corporation,Phase 4
NCT01623505,2010.0,OTHER,collaborator,Heart and Stroke Foundation of Ontario,Phase 4
NCT01623596,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01623713,2012.0,INDUSTRY,lead,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 2
NCT01624389,2012.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT01624428,2012.0,OTHER,lead,Yale University,Phase 1
NCT01624480,2012.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 1
NCT01624714,2012.0,OTHER,lead,"Samuel Forrester Hunter, MD, PhD",Phase 1
NCT01624779,2012.0,INDUSTRY,lead,Bukwang Pharmaceutical,Phase 1
NCT01625000,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT01625182,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01625182,2012.0,INDUSTRY,collaborator,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT01625845,2012.0,OTHER,lead,Indiana University,Phase 2
NCT01625845,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01625897,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT01625988,2012.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT01626391,2012.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 2
NCT01626456,2012.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT01626755,2013.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Not Applicable
NCT01626755,2013.0,OTHER,collaborator,European Society of Anaesthesiology,Not Applicable
NCT01626833,2013.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT01626833,2013.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 2/Phase 3
NCT01626859,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT01626872,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT01626885,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT01627860,2010.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT01627938,2012.0,OTHER,lead,PD Dr. Andrew Chan,Phase 2
NCT01628029,2014.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2
NCT01628029,2014.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01628783,2012.0,OTHER,lead,Jesper Ekelund,Phase 4
NCT01628783,2012.0,OTHER,collaborator,Academy of Finland,Phase 4
NCT01628848,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2
NCT01628926,2009.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01628965,2008.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT01629329,2010.0,OTHER,lead,Albert Einstein Healthcare Network,Phase 4
NCT01631630,2012.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01631682,2010.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01631812,2006.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2
NCT01631825,2009.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01632189,2012.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT01632189,2012.0,OTHER,collaborator,Ontario Lung Association,Not Applicable
NCT01632189,2012.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT01632215,2010.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01633086,2012.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT01633827,2012.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT01633827,2012.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01634243,2005.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2
NCT01634347,2012.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2
NCT01634360,2004.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT01634373,,INDUSTRY,lead,Torrent Pharmaceuticals Limited,Phase 1
NCT01634568,2011.0,INDUSTRY,lead,Vernalis (R&D) Ltd,Phase 1
NCT01635530,2012.0,OTHER_GOV,lead,Turku University Hospital,Phase 4
NCT01636037,2012.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01636310,2005.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01636323,2008.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01636336,2008.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT01636596,2013.0,OTHER,lead,Louisiana State University Health Sciences Center Shreveport,Not Applicable
NCT01636596,2013.0,UNKNOWN,collaborator,Acuity Center,Not Applicable
NCT01637077,2012.0,OTHER,lead,Academic and Community Cancer Research United,Phase 2
NCT01637168,,INDUSTRY,lead,EMS,Phase 3
NCT01637584,2010.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT01637662,2012.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT01638949,2012.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT01638949,2012.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT01639300,2012.0,INDUSTRY,lead,GeNeuro Innovation SAS,Phase 2
NCT01639872,2013.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 4
NCT01639872,2013.0,OTHER,collaborator,University of South Carolina,Phase 4
NCT01639872,2013.0,OTHER,collaborator,Michigan State University,Phase 4
NCT01639872,2013.0,OTHER,collaborator,University of Miami,Phase 4
NCT01639872,2013.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 4
NCT01639898,2012.0,OTHER,lead,"University Hospital, Limoges",Phase 2
NCT01639898,2012.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 2
NCT01639898,2012.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT01640067,2011.0,OTHER,lead,"Azienda Ospedaliera Santa Maria, Terni, Italy",Phase 1
NCT01640067,2011.0,OTHER,collaborator,Azienda Ospedaliero Universitaria Maggiore della Carita,Phase 1
NCT01640067,2011.0,UNKNOWN,collaborator,Università di Padova Italy,Phase 1
NCT01640145,2012.0,OTHER,lead,Bispebjerg Hospital,Not Applicable
NCT01641120,2012.0,OTHER,lead,Trinity Health Of New England,Not Applicable
NCT01641120,2012.0,INDUSTRY,collaborator,Biogen,Not Applicable
NCT01641159,2012.0,OTHER,lead,University of Cincinnati,Phase 2
NCT01641159,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01641900,2012.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01641900,2012.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Not Applicable
NCT01641900,2012.0,OTHER,collaborator,Mclean Hospital,Not Applicable
NCT01642056,2012.0,NIH,lead,National Human Genome Research Institute (NHGRI),Phase 1/Phase 2
NCT01642134,2013.0,OTHER_GOV,lead,"Andres Iñiguez Romo, MD, PhD",Phase 4
NCT01642433,2012.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01642433,2012.0,OTHER,collaborator,Ontario Lung Association,Phase 2
NCT01642524,2004.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT01642524,2004.0,INDUSTRY,collaborator,Defence Research and Development Canada,Phase 3
NCT01642550,2012.0,INDUSTRY,lead,"Motus Therapeutics, Inc.",Phase 2
NCT01642589,2012.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01642901,2012.0,OTHER,lead,Thomas Jefferson University,Phase 3
NCT01642901,2012.0,FED,collaborator,Department of Health and Human Services,Phase 3
NCT01643902,2013.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT01643902,2013.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT01645098,2011.0,OTHER,lead,Nationwide Children's Hospital,Not Applicable
NCT01645189,2012.0,INDUSTRY,lead,Green Cross Corporation,Phase 3
NCT01645306,2013.0,INDUSTRY,lead,AdvanceCor GmbH,Phase 2
NCT01645787,2012.0,OTHER,lead,Columbia University,Phase 2/Phase 3
NCT01646255,2012.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01646255,2012.0,UNKNOWN,collaborator,UCB Trading (Shanghai) Co. Ltd.,Phase 3
NCT01646827,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01647880,2013.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2/Phase 3
NCT01647880,2013.0,OTHER,collaborator,"NeuroCure Clinical Research Center, Charite, Berlin",Phase 2/Phase 3
NCT01648101,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01648634,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01648634,2012.0,OTHER,collaborator,"Association Française contre les Myopathies (AFM), Paris",Phase 3
NCT01648998,2012.0,OTHER,lead,Leiden University Medical Center,Phase 1
NCT01649557,2009.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT01649687,2012.0,OTHER,lead,National Yang Ming University,Phase 1/Phase 2
NCT01650415,2014.0,OTHER,lead,Bundang CHA Hospital,Phase 2
NCT01650415,2014.0,INDUSTRY,collaborator,LG Life Sciences,Phase 2
NCT01650779,2012.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT01651364,2011.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01651364,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01651377,2011.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01651377,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01651520,2013.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT01651754,2010.0,OTHER,lead,Radboud University Medical Center,Not Applicable
NCT01652001,2011.0,OTHER,lead,Universidad de Granada,Phase 2/Phase 3
NCT01652001,2011.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 2/Phase 3
NCT01652040,2012.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT01652040,2012.0,OTHER,collaborator,Virginia Commonwealth University,Phase 2/Phase 3
NCT01652313,2012.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT01652534,2011.0,OTHER,lead,Northwestern University,Phase 3
NCT01653262,2012.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01653444,2012.0,INDUSTRY,lead,Green Cross Corporation,Phase 1
NCT01653457,2012.0,OTHER,lead,Aragon Institute of Health Sciences,Phase 3
NCT01653522,2012.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT01654107,2012.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 1
NCT01654107,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01654601,2012.0,INDUSTRY,lead,Dong Wha Pharmaceutical Co. Ltd.,Phase 1
NCT01654601,2012.0,OTHER,collaborator,The Catholic University of Korea,Phase 1
NCT01654601,2012.0,OTHER,collaborator,Konkuk University Hospital,Phase 1
NCT01654601,2012.0,OTHER,collaborator,Naju National Hospital,Phase 1
NCT01654601,2012.0,OTHER_GOV,collaborator,Seoul National Hospital,Phase 1
NCT01654601,2012.0,OTHER,collaborator,Wonkwang University,Phase 1
NCT01654601,2012.0,OTHER,collaborator,DongGuk University,Phase 1
NCT01654640,2012.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01654640,2012.0,INDUSTRY,collaborator,Daewoong Pharmaceutical Co. LTD.,Phase 4
NCT01655212,2012.0,OTHER,lead,Dr. Ann C.T.M. Vossen,Phase 3
NCT01655212,2012.0,OTHER,collaborator,Stichting Nuts Ohra,Phase 3
NCT01655212,2012.0,OTHER,collaborator,Leiden University Medical Center,Phase 3
NCT01655680,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01655823,2012.0,INDUSTRY,lead,Wex Pharmaceuticals Inc.,Phase 2
NCT01655823,2012.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 2
NCT01655927,2012.0,OTHER,lead,Colombian Foundation for Epilepsy and Neurological Disease,Phase 3
NCT01656148,2012.0,OTHER,lead,University of Southern Denmark,Phase 4
NCT01656148,2012.0,OTHER,collaborator,Region of Southern Denmark,Phase 4
NCT01656148,2012.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT01656200,2012.0,OTHER_GOV,lead,Indian Institute of Science,Phase 4
NCT01656200,2012.0,OTHER,collaborator,"National Institute of Mental Health and Neuro Sciences, India",Phase 4
NCT01656200,2012.0,OTHER,collaborator,University of Liverpool,Phase 4
NCT01656200,2012.0,OTHER,collaborator,PATH,Phase 4
NCT01656200,2012.0,OTHER,collaborator,Wellcome Trust,Phase 4
NCT01656525,2012.0,INDUSTRY,lead,Chugai Pharmaceutical,Phase 1
NCT01656733,2012.0,OTHER,lead,UConn Health,Phase 4
NCT01656733,2012.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT01656785,2012.0,OTHER,lead,Peking Union Medical College Hospital,Early Phase 1
NCT01657019,2012.0,INDUSTRY,lead,Shire,Phase 3
NCT01657370,2012.0,INDUSTRY,lead,Allergan,Phase 2
NCT01658150,2012.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT01658150,2012.0,OTHER,collaborator,Brain & Behavior Research Foundation,Not Applicable
NCT01658228,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01658228,2011.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT01659320,2012.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT01659320,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01659996,2012.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01660672,2013.0,OTHER,lead,University of Rochester,Phase 1/Phase 2
NCT01660672,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT01660815,2012.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT01660815,2012.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1
NCT01661322,2009.0,OTHER,lead,University of Nottingham,Phase 3
NCT01661673,2012.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 2
NCT01661673,2012.0,INDUSTRY,collaborator,Parexel,Phase 2
NCT01661725,2006.0,INDUSTRY,lead,"Hualan Biological Engineering, Inc.",Phase 1
NCT01661738,2006.0,INDUSTRY,lead,"Hualan Biological Engineering, Inc.",Phase 2
NCT01661751,2006.0,INDUSTRY,lead,"Hualan Biological Engineering, Inc.",Phase 3
NCT01661855,2013.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01661855,2013.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT01661855,2013.0,OTHER,collaborator,McMaster University,Phase 2
NCT01661855,2013.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2
NCT01661855,2013.0,OTHER,collaborator,"University of Western Ontario, Canada",Phase 2
NCT01661855,2013.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT01661855,2013.0,OTHER,collaborator,University of Toronto,Phase 2
NCT01662297,2012.0,FED,lead,VA Connecticut Healthcare System,Phase 4
NCT01662310,2011.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT01662414,2011.0,OTHER,lead,Chulalongkorn University,Phase 4
NCT01662440,2012.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01662492,2012.0,INDUSTRY,lead,Allergan,Phase 3
NCT01662648,2007.0,INDUSTRY,lead,Janssen Pharmaceutica,Phase 3
NCT01662791,2012.0,OTHER,lead,Mayo Clinic,Phase 3
NCT01662882,2012.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT01662882,2012.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2/Phase 3
NCT01662895,2013.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT01662895,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01662895,2013.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Tufts Medical Center,Phase 2
NCT01662895,2013.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Maryland,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Virginia,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Duke University,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of North Carolina,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Florida,Phase 2
NCT01662895,2013.0,OTHER,collaborator,The Cleveland Clinic,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Henry Ford Hospital,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Ohio State University,Phase 2
NCT01662895,2013.0,OTHER,collaborator,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT01662895,2013.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT01662895,2013.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT01662895,2013.0,UNKNOWN,collaborator,Yale New Haven Hospital,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Iowa,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Hartford Hospital,Phase 2
NCT01662895,2013.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT01662895,2013.0,OTHER,collaborator,Rhode Island Hospital,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Stanford University,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Washington,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Calgary,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Hopital de l'Enfant-Jesus,Phase 2
NCT01662895,2013.0,OTHER,collaborator,University of Alberta,Phase 2
NCT01662895,2013.0,OTHER,collaborator,Dalhousie University,Phase 2
NCT01663077,2012.0,OTHER_GOV,lead,Tirat Carmel Mental Health Center,Phase 4
NCT01663077,2012.0,OTHER,collaborator,"Technion, Israel Institute of Technology",Phase 4
NCT01663077,2012.0,OTHER,collaborator,Ben-Gurion University of the Negev,Phase 4
NCT01663077,2012.0,OTHER_GOV,collaborator,Beersheva Mental Health Center,Phase 4
NCT01663077,2012.0,OTHER,collaborator,Sha'ar Menashe Mental Health Center,Phase 4
NCT01663077,2012.0,OTHER,collaborator,"HaEmek Medical Center, Israel",Phase 4
NCT01663077,2012.0,OTHER,collaborator,"The Nazareth Hospital, Israel",Phase 4
NCT01663467,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT01663467,2014.0,OTHER,collaborator,Soonchunhyang University Hospital,Not Applicable
NCT01663532,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01663532,2012.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT01663532,2012.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT01664260,2012.0,OTHER,lead,Ewha Womans University,Phase 2
NCT01664520,2013.0,OTHER_GOV,lead,Turku University Hospital,Phase 1/Phase 2
NCT01664520,2013.0,INDUSTRY,collaborator,"Orion Corporation, Orion Pharma",Phase 1/Phase 2
NCT01664741,2012.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT01664741,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01665846,2011.0,OTHER,lead,University of Hawaii,Phase 1
NCT01665846,2011.0,OTHER,collaborator,Oregon Health and Science University,Phase 1
NCT01665950,2012.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01666522,2011.0,OTHER,lead,University of Alexandria,Not Applicable
NCT01667484,2012.0,OTHER,lead,London Health Sciences Centre,Phase 2/Phase 3
NCT01668654,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01668654,2012.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 3
NCT01668667,2012.0,INDUSTRY,lead,"XenoPort, Inc.",Phase 4
NCT01669408,2012.0,OTHER,lead,University Hospital Heidelberg,Phase 2
NCT01669538,2012.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01669538,2012.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01669538,2012.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01669538,2012.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2
NCT01669538,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01669876,2012.0,INDUSTRY,lead,"Rock Creek Pharmaceuticals, Inc.",Phase 2
NCT01669876,2012.0,OTHER,collaborator,Roskamp Institute Inc.,Phase 2
NCT01669967,2011.0,OTHER,lead,Lawson Health Research Institute,Not Applicable
NCT01670071,2013.0,INDUSTRY,lead,Johnson & Johnson Taiwan Ltd,Phase 4
NCT01670526,2012.0,FED,lead,VA Office of Research and Development,Phase 3
NCT01671150,2011.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT01671150,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT01671384,2013.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 3
NCT01671410,2012.0,OTHER,lead,Thomas Jefferson University,Phase 1
NCT01671800,2008.0,OTHER,lead,Henry M. Jackson Foundation for the Advancement of Military Medicine,Phase 1
NCT01671800,2008.0,FED,collaborator,Walter Reed National Military Medical Center,Phase 1
NCT01672372,2011.0,OTHER,lead,University of Miami,Not Applicable
NCT01672372,2011.0,OTHER,collaborator,Premier Research Labs,Not Applicable
NCT01672554,2008.0,OTHER,lead,Corporation de Recherche en Neuropsycho Pharmacologie de Quebec,Phase 3
NCT01672827,2012.0,INDUSTRY,lead,GE Healthcare,Phase 3
NCT01673009,2006.0,OTHER,lead,Indiana University,Phase 2
NCT01673646,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01673724,2012.0,INDUSTRY,lead,Sandoz,Phase 4
NCT01673828,2013.0,OTHER,lead,"Michael A. Rogawski, MD, PhD",Phase 2
NCT01673828,2013.0,FED,collaborator,United States Department of Defense,Phase 2
NCT01673932,2012.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 1
NCT01673932,2012.0,OTHER,collaborator,Chinese University of Hong Kong,Phase 1
NCT01673932,2012.0,OTHER,collaborator,The University of Hong Kong,Phase 1
NCT01673932,2012.0,OTHER,collaborator,"Prince of Wales Hospital, Shatin, Hong Kong",Phase 1
NCT01673932,2012.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Phase 1
NCT01673932,2012.0,INDUSTRY,collaborator,"StemCyte, Inc.",Phase 1
NCT01674361,2012.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01674868,2013.0,OTHER,lead,Spaulding Rehabilitation Hospital,Not Applicable
NCT01675661,2014.0,OTHER,lead,Medical University of South Carolina,Phase 3
NCT01675661,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01676103,2012.0,OTHER,lead,New York Institute of Technology,Phase 1/Phase 2
NCT01676103,2012.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1/Phase 2
NCT01676311,2013.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 2
NCT01676441,2008.0,INDUSTRY,lead,"Pharmicell Co., Ltd.",Phase 2/Phase 3
NCT01676935,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01677182,2012.0,INDUSTRY,lead,Takeda,Phase 3
NCT01677208,2013.0,OTHER,lead,China Academy of Chinese Medical Sciences,Phase 4
NCT01677208,2013.0,OTHER_GOV,collaborator,China Food and Drug Administration,Phase 4
NCT01677377,2012.0,INDUSTRY,lead,Indivior Inc.,Phase 2
NCT01677572,2012.0,INDUSTRY,lead,Biogen,Phase 1
NCT01677741,2013.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1/Phase 2
NCT01677754,2012.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01678495,2012.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 2
NCT01678755,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01678898,2012.0,INDUSTRY,lead,Protalix,Phase 1/Phase 2
NCT01678898,2012.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 1/Phase 2
NCT01678924,2013.0,INDUSTRY,lead,Allergan,Phase 2
NCT01678976,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01679002,2003.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01679041,2012.0,INDUSTRY,lead,Seah Lim M.D.,Phase 2
NCT01680107,2012.0,OTHER,lead,University of Oxford,Phase 3
NCT01680107,2012.0,OTHER_GOV,collaborator,Medical Research Council,Phase 3
NCT01680146,2012.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT01680172,2012.0,OTHER,lead,Mayo Clinic,Phase 2
NCT01680588,2012.0,INDUSTRY,lead,Navidea Biopharmaceuticals,Phase 2
NCT01680887,2012.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01681121,2012.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT01681849,2009.0,OTHER,lead,Emory University,Phase 4
NCT01681849,2009.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01682161,2012.0,INDUSTRY,lead,"Janssen Korea, Ltd., Korea",Phase 4
NCT01682603,2012.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Phase 2
NCT01682811,2012.0,OTHER,lead,"Harry T Whelan, MD",Phase 1
NCT01683058,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01683058,2013.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT01683058,2013.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 3
NCT01683292,2006.0,OTHER,lead,South Glasgow University Hospitals NHS Trust,Phase 2
NCT01683292,2006.0,INDUSTRY,collaborator,Vectura Limited,Phase 2
NCT01683838,2002.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT01684085,2012.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT01684462,2012.0,OTHER,lead,Seoul St. Mary's Hospital,Phase 2
NCT01684462,2012.0,INDUSTRY,collaborator,Green Cross Corporation,Phase 2
NCT01684475,2012.0,OTHER,lead,Alexandra Marine and General Hospital,Phase 1/Phase 2
NCT01684657,2012.0,OTHER,lead,"University of California, Irvine",Phase 3
NCT01684657,2012.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 3
NCT01684761,2012.0,INDUSTRY,lead,"Opexa Therapeutics, Inc.",Phase 2
NCT01685073,2012.0,OTHER,lead,Johns Hopkins University,Phase 2/Phase 3
NCT01685073,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01685151,2012.0,INDUSTRY,lead,Takeda,Phase 3
NCT01685931,2012.0,INDUSTRY,lead,Xian-Janssen Pharmaceutical Ltd.,Phase 4
NCT01685996,2012.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT01685996,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01686087,2012.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT01686087,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01686464,1998.0,OTHER,lead,Wenzhou Medical University,Not Applicable
NCT01687101,2012.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT01687140,2012.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01687751,2012.0,OTHER,lead,Fraser Health,Phase 2
NCT01688037,2012.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT01688570,2011.0,OTHER,lead,Medical College of Wisconsin,Early Phase 1
NCT01688739,2012.0,INDUSTRY,lead,Amgen,Phase 1
NCT01688947,2012.0,INDUSTRY,lead,Purdue Pharma LP,Phase 2
NCT01689233,2012.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 3
NCT01689246,2013.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 3
NCT01689467,2013.0,OTHER,lead,Chonbuk National University Hospital,Not Applicable
NCT01689649,2008.0,INDUSTRY,lead,Johnson & Johnson Pte Ltd,Phase 4
NCT01689727,2002.0,INDUSTRY,lead,Endocyte,Phase 2
NCT01689909,2012.0,OTHER,lead,Augusta University,Phase 4
NCT01689909,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01689909,2012.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 4
NCT01689909,2012.0,OTHER,collaborator,"University of Wisconsin, Madison",Phase 4
NCT01689909,2012.0,OTHER,collaborator,Duke University,Phase 4
NCT01690195,2012.0,INDUSTRY,lead,"AbbVie (prior sponsor, Abbott)",Phase 2
NCT01690364,2012.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT01690962,2012.0,OTHER,lead,Physicians Committee for Responsible Medicine,Not Applicable
NCT01690988,2014.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT01690988,2014.0,OTHER,collaborator,Asan Medical Center,Phase 3
NCT01690988,2014.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 3
NCT01690988,2014.0,OTHER,collaborator,Harvard Medical School (HMS and HSDM),Phase 3
NCT01690988,2014.0,OTHER,collaborator,Medical College of Wisconsin,Phase 3
NCT01690988,2014.0,OTHER,collaborator,Memorial Sloan Kettering Cancer Center,Phase 3
NCT01690988,2014.0,OTHER_GOV,collaborator,Postgraduate Institute of Medical Education and Research,Phase 3
NCT01690988,2014.0,OTHER,collaborator,University of Bern,Phase 3
NCT01690988,2014.0,OTHER,collaborator,University of Michigan,Phase 3
NCT01690988,2014.0,OTHER,collaborator,University of Manitoba,Phase 3
NCT01690988,2014.0,OTHER,collaborator,"University Health Network, Toronto",Phase 3
NCT01690988,2014.0,OTHER,collaborator,Virginia Mason Hospital/Medical Center,Phase 3
NCT01691872,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01691924,2012.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1
NCT01691924,2012.0,INDUSTRY,collaborator,"Palo Biofarma, S.L",Phase 1
NCT01693081,2007.0,OTHER,lead,South Glasgow University Hospitals NHS Trust,Phase 2
NCT01693081,2007.0,INDUSTRY,collaborator,Vectura Limited,Phase 2
NCT01693692,2012.0,INDUSTRY,lead,Theravance Biopharma,Phase 2
NCT01694667,2012.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT01694667,2012.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT01695200,2011.0,OTHER_GOV,lead,"National Healthcare Group, Singapore",Phase 4
NCT01695291,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT01695291,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01695291,2012.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 2
NCT01695317,2013.0,OTHER,lead,Norwegian University of Science and Technology,Phase 4
NCT01696123,2011.0,OTHER,lead,Shahid Beheshti University of Medical Sciences,Phase 2
NCT01696435,2010.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT01696435,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01696929,2012.0,OTHER,lead,Brian Miller,Phase 1
NCT01697267,2013.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 3
NCT01697267,2013.0,OTHER,collaborator,Arthritis Research UK,Phase 3
NCT01697267,2013.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 3
NCT01697267,2013.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 3
NCT01697267,2013.0,OTHER,collaborator,University of Pennsylvania,Phase 3
NCT01697709,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT01697709,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01697878,2012.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01697878,2012.0,INDUSTRY,collaborator,ResMed,Not Applicable
NCT01698138,2012.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT01698138,2012.0,OTHER,collaborator,Sunnaas Rehabilitation Hospital,Phase 4
NCT01698684,2012.0,INDUSTRY,lead,VIVUS LLC,Phase 4
NCT01698749,2011.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Not Applicable
NCT01698788,2011.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Not Applicable
NCT01699126,2010.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 4
NCT01699308,2009.0,OTHER,lead,Joe Springer,Phase 1
NCT01699555,2011.0,INDUSTRY,lead,GeNeuro Innovation SAS,Phase 1
NCT01699607,2012.0,OTHER,lead,Yale University,Not Applicable
NCT01699607,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01699607,2012.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT01699997,2014.0,OTHER,lead,IRCCS Centro San Giovanni di Dio Fatebenefratelli,Phase 2
NCT01701362,2012.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT01701999,2013.0,OTHER,lead,California Department of Public Health,Phase 2
NCT01702389,2012.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT01702467,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01702480,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01702623,2009.0,INDUSTRY,lead,Roxane Laboratories,Phase 1
NCT01702636,2012.0,OTHER,lead,Neuroscience Trials Australia,Phase 2
NCT01702987,2012.0,OTHER,lead,Beth Israel Deaconess Medical Center,Not Applicable
NCT01703117,2013.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01703117,2013.0,OTHER,collaborator,Rockefeller University,Phase 2
NCT01703468,2009.0,INDUSTRY,lead,Roxane Laboratories,Phase 1
NCT01703533,2013.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT01703533,2013.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT01703533,2013.0,OTHER,collaborator,International Rett Syndrome Foundation,Phase 2
NCT01703702,2012.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 4
NCT01703702,2012.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT01703988,2012.0,INDUSTRY,lead,Biogen,Phase 1/Phase 2
NCT01704196,2013.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT01704339,2012.0,OTHER,lead,Emma Aitken,Phase 4
NCT01704638,2008.0,OTHER,lead,Karolinska Institutet,Phase 1
NCT01705197,2012.0,INDUSTRY,lead,JW Pharmaceutical,Phase 3
NCT01705457,2010.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT01706523,2011.0,INDUSTRY,lead,"Seaside Therapeutics, Inc.",Phase 3
NCT01706965,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01706965,2012.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1/Phase 2
NCT01707992,2013.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01708707,2012.0,OTHER,lead,Pediatrix,Phase 2
NCT01708720,2011.0,OTHER_GOV,lead,Pauline Verdijk,Phase 1
NCT01708720,2011.0,OTHER,collaborator,World Health Organization,Phase 1
NCT01708837,2012.0,OTHER,lead,Xiangya Hospital of Central South University,Phase 4
NCT01709071,2012.0,OTHER_GOV,lead,Pauline Verdijk,Phase 1/Phase 2
NCT01709071,2012.0,OTHER,collaborator,World Health Organization,Phase 1/Phase 2
NCT01709149,2012.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT01710137,2012.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01710137,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT01710189,2012.0,OTHER,lead,University of Surrey,Phase 4
NCT01710410,2016.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01710410,2016.0,INDUSTRY,collaborator,"Nuraleve, Inc.",Phase 2
NCT01710657,2012.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01710657,2012.0,INDUSTRY,collaborator,UCB Japan Co. Ltd.,Phase 3
NCT01712074,2012.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01712477,2011.0,OTHER,lead,Michigan State University,Phase 4
NCT01712646,2012.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT01712945,2012.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 1/Phase 2
NCT01713673,2011.0,INDUSTRY,lead,"Ulthera, Inc",Not Applicable
NCT01713777,2013.0,OTHER,lead,University of Cincinnati,Phase 4
NCT01713777,2013.0,OTHER,collaborator,Epilepsy Foundation,Phase 4
NCT01713777,2013.0,OTHER,collaborator,American Epilepsy Society,Phase 4
NCT01714011,2009.0,OTHER,lead,University of Malaya,Phase 4
NCT01714089,,INDUSTRY,lead,Revalesio Corporation,Phase 2
NCT01714167,2012.0,OTHER,lead,Wenzhou Medical University,Phase 1
NCT01714167,2012.0,OTHER,collaborator,University of North Texas Health Science Center,Phase 1
NCT01714323,2012.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01714323,2012.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT01714323,2012.0,OTHER,collaborator,North Shore Medical Center,Not Applicable
NCT01714661,2012.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT01714661,2012.0,OTHER,collaborator,Syneos Health,Phase 3
NCT01714661,2012.0,INDUSTRY,collaborator,"NeuroCog Trials, Inc.",Phase 3
NCT01714713,2013.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT01714713,2013.0,OTHER,collaborator,Syneos Health,Phase 3
NCT01715051,2014.0,OTHER,lead,Theresa Winhusen,Phase 2
NCT01715350,2012.0,INDUSTRY,lead,VTBIO Co. LTD,Phase 2
NCT01715350,2012.0,INDUSTRY,collaborator,ADM Korea Inc,Phase 2
NCT01715519,2012.0,OTHER,lead,Southern California Institute for Research and Education,Phase 4
NCT01715519,2012.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01715922,2012.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Phase 2/Phase 3
NCT01715922,2012.0,UNKNOWN,collaborator,"CHU Kamenge, BURUNDI",Phase 2/Phase 3
NCT01715922,2012.0,OTHER,collaborator,Hospital Avicenne,Phase 2/Phase 3
NCT01715922,2012.0,INDUSTRY,collaborator,Institut Pasteur,Phase 2/Phase 3
NCT01715922,2012.0,OTHER,collaborator,Hôpital Necker-Enfants Malades,Phase 2/Phase 3
NCT01715922,2012.0,UNKNOWN,collaborator,Institut de Médecine et Epidémiologie Appliquée (IMEA),Phase 2/Phase 3
NCT01715922,2012.0,UNKNOWN,collaborator,Hôpital de Treichville,Phase 2/Phase 3
NCT01715922,2012.0,UNKNOWN,collaborator,Hôpital Cocody,Phase 2/Phase 3
NCT01716221,2012.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT01716624,2011.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT01716637,2010.0,OTHER,lead,Life Extension Foundation Inc.,Phase 1
NCT01716676,,OTHER,lead,Hospital Clinic of Barcelona,Not Applicable
NCT01716767,2012.0,OTHER_GOV,lead,"National Research Centre for the Working Environment, Denmark",Not Applicable
NCT01716767,2012.0,OTHER,collaborator,Marquette University,Not Applicable
NCT01716858,2012.0,OTHER,lead,Chiba University,Phase 2
NCT01716897,2012.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT01716975,2012.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT01716975,2012.0,OTHER,collaborator,Syneos Health,Phase 3
NCT01716975,2012.0,INDUSTRY,collaborator,"NeuroCog Trials, Inc.",Phase 3
NCT01717040,2012.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT01717040,2012.0,OTHER,collaborator,The Depressive and Bipolar Disorder Alternative Treatment Foundation,Phase 4
NCT01717638,2012.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01717664,2013.0,INDUSTRY,lead,RedHill Biopharma Limited,Phase 2
NCT01718483,2012.0,INDUSTRY,lead,Shire,Phase 3
NCT01718509,2012.0,INDUSTRY,lead,Shire,Phase 3
NCT01719523,2012.0,OTHER,lead,Yale University,Phase 1
NCT01719523,2012.0,UNKNOWN,collaborator,Rembrandt Foundation,Phase 1
NCT01719523,2012.0,INDUSTRY,collaborator,Edison Pharmaceuticals Inc,Phase 1
NCT01720095,2009.0,OTHER,lead,Nova Scotia Health Authority,Phase 3
NCT01720316,2012.0,OTHER,lead,Mclean Hospital,Phase 2
NCT01720316,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01721317,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01721317,2012.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 4
NCT01721460,2012.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01721733,2012.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT01721733,2012.0,INDUSTRY,collaborator,Axio Research. LLC,Phase 2
NCT01722409,2012.0,OTHER,lead,"China Medical University, China",Phase 4
NCT01722578,2013.0,OTHER,lead,Dayanand Medical College and Hospital,Phase 4
NCT01723228,2012.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT01723514,2012.0,INDUSTRY,lead,Amgen,Phase 1
NCT01723527,2012.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT01723527,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01723670,2012.0,INDUSTRY,lead,CERESPIR,Phase 2
NCT01723722,2007.0,OTHER,lead,Eastern Maine Medical Center,Phase 4
NCT01723748,2012.0,OTHER,lead,University of Aarhus,Not Applicable
NCT01723826,2012.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT01723917,2012.0,OTHER,lead,University of Southern California,Not Applicable
NCT01723917,2012.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT01724359,2008.0,INDUSTRY,lead,"Janssen-Cilag, S.A.",Phase 4
NCT01724372,2012.0,OTHER,lead,St. Luke's-Roosevelt Hospital Center,Not Applicable
NCT01724372,2012.0,OTHER,collaborator,The Zucker Hillside Hospital,Not Applicable
NCT01724476,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01724476,2014.0,OTHER,collaborator,Addis Ababa University,Phase 4
NCT01724476,2014.0,UNKNOWN,collaborator,"Amanuel Mental Hospital, Addis Ababa, Ethiopia",Phase 4
NCT01724918,2013.0,OTHER,lead,Lawson Health Research Institute,Phase 2
NCT01724918,2013.0,INDUSTRY,collaborator,UCB Pharma GmbH,Phase 2
NCT01725308,2012.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 2/Phase 3
NCT01725802,2012.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1/Phase 2
NCT01726088,2012.0,OTHER,lead,Biomedical Research Foundation,Phase 2/Phase 3
NCT01726088,2012.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2/Phase 3
NCT01726088,2012.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Phase 2/Phase 3
NCT01726335,2006.0,INDUSTRY,lead,Janssen-Cilag Ltd.,Phase 4
NCT01726764,2013.0,OTHER,lead,University of Southern Denmark,Phase 1
NCT01726920,2014.0,INDUSTRY,lead,Ache Laboratorios Farmaceuticos S.A.,Phase 3
NCT01727193,2012.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Phase 3
NCT01727700,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01727713,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01727726,2012.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01728064,2012.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT01728077,2012.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01728194,2012.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT01728194,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01728909,2012.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT01728909,2012.0,FED,collaborator,San Francisco Veterans Affairs Medical Center,Early Phase 1
NCT01728922,2012.0,OTHER,lead,University College Dublin,Phase 1/Phase 2
NCT01728922,2012.0,OTHER,collaborator,"University of Dublin, Trinity College",Phase 1/Phase 2
NCT01728922,2012.0,OTHER,collaborator,"St Vincent's University Hospital, Ireland",Phase 1/Phase 2
NCT01729598,2012.0,OTHER,lead,"Gregory Jicha, 323-5550",Early Phase 1
NCT01729598,2012.0,OTHER,collaborator,University of Kentucky,Early Phase 1
NCT01729598,2012.0,UNKNOWN,collaborator,Kentucky Alzheimer's Center,Early Phase 1
NCT01730209,2012.0,OTHER,lead,Erasmus Medical Center,Phase 2/Phase 3
NCT01730209,2012.0,OTHER,collaborator,Utrecht University,Phase 2/Phase 3
NCT01730313,2016.0,FED,lead,Centers for Disease Control and Prevention,Phase 2
NCT01730313,2016.0,OTHER_GOV,collaborator,"Ministry of Health, Uganda",Phase 2
NCT01730469,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1
NCT01730482,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1
NCT01730495,2012.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT01730547,2013.0,OTHER,lead,Karolinska Institutet,Phase 1/Phase 2
NCT01730768,2012.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01731119,2012.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT01731119,2012.0,OTHER,collaborator,"Foundation of Hope, North Carolina",Phase 2
NCT01731171,2012.0,OTHER,lead,Sheppard Pratt Health System,Not Applicable
NCT01731171,2012.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT01731561,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01732289,2008.0,OTHER,lead,National Taiwan University Hospital,Early Phase 1
NCT01732289,2008.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Early Phase 1
NCT01732471,2012.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 3
NCT01732627,2012.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT01733043,2015.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT01733121,2012.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT01733199,2012.0,OTHER,lead,Nantes University Hospital,Phase 4
NCT01733394,2012.0,OTHER,lead,University of Cincinnati,Phase 4
NCT01733394,2012.0,OTHER,collaborator,American Epilepsy Society,Phase 4
NCT01733394,2012.0,OTHER,collaborator,Epilepsy Foundation,Phase 4
NCT01733654,2012.0,OTHER,lead,Stanford University,Phase 2
NCT01734551,2011.0,OTHER,lead,Henrietta Bada,Phase 4
NCT01734941,2014.0,OTHER,lead,Hadassah Medical Organization,Phase 2
NCT01735279,2013.0,OTHER,lead,Federal University of São Paulo,Phase 3
NCT01735630,2012.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 2
NCT01735630,2012.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT01735747,2008.0,OTHER,lead,Rongjie Tao,Phase 2
NCT01735747,2008.0,OTHER_GOV,collaborator,National Natural Science Foundation of China,Phase 2
NCT01737268,2012.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT01737398,2013.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT01737541,2012.0,OTHER,lead,Universidad Autónoma de Aguascalientes,Phase 3
NCT01737593,2012.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT01737671,2012.0,OTHER,lead,M.D. Anderson Cancer Center,Early Phase 1
NCT01738178,2014.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 3
NCT01738178,2014.0,OTHER,collaborator,Pontifícia Universidade Católica do Paraná,Phase 3
NCT01738178,2014.0,OTHER,collaborator,University of Calgary,Phase 3
NCT01738178,2014.0,UNKNOWN,collaborator,University of Newfoundland and Eastern Health,Phase 3
NCT01738178,2014.0,OTHER,collaborator,"University Health Network, Toronto",Phase 3
NCT01738178,2014.0,UNKNOWN,collaborator,UBC Hospital,Phase 3
NCT01738178,2014.0,UNKNOWN,collaborator,Movement Disorder Clinic - Deer Lodge Centre,Phase 3
NCT01738178,2014.0,OTHER,collaborator,The Ottawa Hospital,Phase 3
NCT01738191,2012.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01738191,2012.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01738698,2012.0,INDUSTRY,lead,Shire,Phase 3
NCT01738880,2012.0,OTHER,lead,Yonsei University,Not Applicable
NCT01738893,2011.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01739023,2012.0,OTHER,lead,W. Dalton Dietrich,Phase 1
NCT01739023,2012.0,OTHER,collaborator,The Miami Project to Cure Paralysis,Phase 1
NCT01739270,2012.0,OTHER,lead,University Hospital Dubrava,Not Applicable
NCT01739335,2012.0,FED,lead,VA Office of Research and Development,Phase 2
NCT01739348,2012.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2/Phase 3
NCT01739933,2013.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT01741194,2013.0,INDUSTRY,lead,Cerecin,Phase 2/Phase 3
NCT01741376,2012.0,OTHER,lead,University of Minnesota,Not Applicable
NCT01741532,2012.0,INDUSTRY,lead,ApoPharma,Phase 3
NCT01741532,2012.0,FED,collaborator,Food and Drug Administration (FDA),Phase 3
NCT01741701,2012.0,OTHER,lead,University of Kansas Medical Center,Phase 2/Phase 3
NCT01741701,2012.0,INDUSTRY,collaborator,Terra Biological LLC,Phase 2/Phase 3
NCT01742013,2013.0,OTHER,lead,"Ho Cheol Shin, M.D., Ph.D.",Phase 3
NCT01742013,2013.0,OTHER,collaborator,Ajou University School of Medicine,Phase 3
NCT01742013,2013.0,INDUSTRY,collaborator,Green Cross Corporation,Phase 3
NCT01742013,2013.0,INDUSTRY,collaborator,Symyoo,Phase 3
NCT01742390,2013.0,OTHER,lead,Si Tianmei,Phase 4
NCT01743144,2012.0,OTHER,lead,Cairo University,Phase 4
NCT01743144,2012.0,AMBIG,collaborator,anesthesia department,Phase 4
NCT01743144,2012.0,AMBIG,collaborator,faculty of medicine,Phase 4
NCT01743235,2012.0,INDUSTRY,lead,Emotional Brain NY Inc.,Phase 2
NCT01743651,2012.0,INDUSTRY,lead,"RVL Pharmaceuticals, Inc.",Phase 3
NCT01743651,2012.0,INDUSTRY,collaborator,Osmotica Pharmaceutical US LLC,Phase 3
NCT01743976,2012.0,OTHER,lead,Wake Forest University,Phase 4
NCT01743976,2012.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT01744275,2013.0,OTHER,lead,Hospital do Coracao,Phase 2/Phase 3
NCT01744548,2012.0,OTHER,lead,King's College London,Not Applicable
NCT01745497,2012.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01745497,2012.0,NETWORK,collaborator,Autism Treatment Network,Phase 2
NCT01745497,2012.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT01745497,2012.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 2
NCT01745497,2012.0,FED,collaborator,Health Resources and Services Administration (HRSA),Phase 2
NCT01745562,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01745575,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01745601,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01745679,2012.0,OTHER,lead,Nantes University Hospital,Phase 4
NCT01746303,2010.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT01747408,2006.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT01747746,2012.0,OTHER_GOV,lead,Cook County Health,Phase 4
NCT01747746,2012.0,OTHER,collaborator,Cook County Hospital,Phase 4
NCT01747850,2013.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01747850,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01747980,2013.0,INDUSTRY,lead,Protalix,Phase 1
NCT01748799,2013.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT01748799,2013.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT01748955,2010.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01748955,2010.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01749046,2012.0,INDUSTRY,lead,Valexfarm,Phase 3
NCT01749098,2012.0,INDUSTRY,lead,Biogen,Phase 1
NCT01750541,2012.0,OTHER,lead,Shahid Beheshti University of Medical Sciences,Phase 3
NCT01750723,2012.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT01750957,2013.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01751347,2013.0,OTHER,lead,University of British Columbia,Phase 4
NCT01751373,2011.0,OTHER,lead,Sunnybrook Health Sciences Centre,Not Applicable
NCT01751373,2011.0,INDUSTRY,collaborator,Allergan,Not Applicable
NCT01751386,2012.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT01751802,2012.0,INDUSTRY,lead,Psyadon Pharma,Phase 3
NCT01751828,2012.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT01751971,2012.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT01751971,2012.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01751971,2012.0,OTHER,collaborator,American Heart Association,Not Applicable
NCT01752322,2012.0,INDUSTRY,lead,Grünenthal GmbH,Phase 3
NCT01752712,2014.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01752712,2014.0,OTHER,collaborator,"University of California, San Diego",Not Applicable
NCT01753076,2012.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01753141,2008.0,OTHER,lead,Florida State University,Not Applicable
NCT01753375,2013.0,OTHER,lead,"AlJohara M AlQuaiz, M.D.",Phase 2
NCT01753882,2012.0,OTHER,lead,Shirley Ryan AbilityLab,Phase 1
NCT01755091,2013.0,OTHER,lead,University of Illinois at Chicago,Phase 2
NCT01755091,2013.0,OTHER,collaborator,Northwestern University,Phase 2
NCT01755091,2013.0,OTHER,collaborator,University of Chicago,Phase 2
NCT01755091,2013.0,OTHER,collaborator,Hektoen Institute for Medical Research,Phase 2
NCT01755091,2013.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT01755546,2012.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 3
NCT01755702,2009.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2/Phase 3
NCT01755871,2013.0,OTHER,lead,"Heinrich-Heine University, Duesseldorf",Phase 4
NCT01755871,2013.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 4
NCT01756053,2013.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01756209,2010.0,OTHER,lead,University of Catanzaro,Phase 4
NCT01756885,2013.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT01757340,2012.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT01757340,2012.0,INDUSTRY,collaborator,"Ajinomoto Co., Inc.",Not Applicable
NCT01757873,2012.0,INDUSTRY,lead,Zalicus,Phase 2
NCT01758497,2010.0,OTHER,lead,St. Luke's-Roosevelt Hospital Center,Not Applicable
NCT01758510,2012.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 1
NCT01758510,2012.0,INDUSTRY,collaborator,"Corestemchemon, Inc.",Phase 1
NCT01758614,2013.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 3
NCT01759602,2013.0,OTHER,lead,Michael Levy,Phase 1
NCT01759602,2013.0,INDUSTRY,collaborator,ViroPharma,Phase 1
NCT01759784,2014.0,OTHER_GOV,lead,Royan Institute,Phase 1
NCT01759797,2013.0,OTHER_GOV,lead,Royan Institute,Phase 1
NCT01759888,2011.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01759888,2011.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT01760005,2012.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT01760005,2012.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2/Phase 3
NCT01760005,2012.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2/Phase 3
NCT01760005,2012.0,OTHER,collaborator,Alzheimer's Association,Phase 2/Phase 3
NCT01760005,2012.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT01760005,2012.0,INDUSTRY,collaborator,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT01760005,2012.0,OTHER,collaborator,Accelerating Medicines Partnership (AMP),Phase 2/Phase 3
NCT01760005,2012.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2/Phase 3
NCT01760005,2012.0,INDUSTRY,collaborator,"Janssen, LP",Phase 2/Phase 3
NCT01760564,2008.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT01760889,2013.0,INDUSTRY,lead,Shire,Phase 3
NCT01760993,2013.0,INDUSTRY,lead,Shire,Phase 3
NCT01761227,2012.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 2
NCT01761227,2012.0,INDUSTRY,collaborator,Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited,Phase 2
NCT01761604,2011.0,OTHER,lead,Chicago Anesthesia Pain Specialists,Not Applicable
NCT01761825,2012.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 2
NCT01761942,2012.0,OTHER,lead,"Institute of Psychiatry and Neurology, Warsaw",Phase 2
NCT01762475,2013.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 2
NCT01762475,2013.0,FED,collaborator,Center for Neuroscience and Regenerative Medicine (CNRM),Phase 2
NCT01762475,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01762475,2013.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01763255,2012.0,OTHER_GOV,lead,Royan Institute,Phase 1/Phase 2
NCT01764243,2012.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2
NCT01764711,2013.0,OTHER,lead,Vanderbilt University,Not Applicable
NCT01764711,2013.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT01764711,2013.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01764737,2012.0,INDUSTRY,lead,Vaccinex Inc.,Phase 1
NCT01764737,2012.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT01765283,2012.0,INDUSTRY,lead,Cellaion SA,Phase 1/Phase 2
NCT01765608,2010.0,OTHER,lead,Göteborg University,Phase 2
NCT01765608,2010.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2
NCT01766128,2013.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 2/Phase 3
NCT01766258,2011.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT01766336,2013.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 2
NCT01766336,2013.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT01766791,2013.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Phase 3
NCT01766791,2013.0,OTHER,collaborator,Klinikum Nürnberg,Phase 3
NCT01767129,2013.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 2
NCT01767129,2013.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01767311,2012.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT01767311,2012.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT01767428,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01767493,2012.0,OTHER,lead,Institute for Neurodegenerative Disorders,Phase 4
NCT01767493,2012.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT01767701,2013.0,OTHER,lead,Queen Mary University of London,Phase 2
NCT01767701,2013.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT01767792,2013.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT01767792,2013.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT01767909,2014.0,OTHER,lead,University of Southern California,Phase 2/Phase 3
NCT01767909,2014.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT01767909,2014.0,OTHER,collaborator,Alzheimer's Therapeutic Research Institute,Phase 2/Phase 3
NCT01767909,2014.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 2/Phase 3
NCT01767922,2008.0,INDUSTRY,lead,Bionov,Phase 3
NCT01767922,2008.0,INDUSTRY,collaborator,Seppic,Phase 3
NCT01768039,2013.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 3
NCT01768676,2012.0,INDUSTRY,lead,VIVUS LLC,Phase 4
NCT01768767,2013.0,OTHER,lead,Yale University,Phase 2
NCT01768767,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01769703,2012.0,OTHER,lead,University of Alberta,Phase 2
NCT01770145,2012.0,INDUSTRY,lead,"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",Phase 4
NCT01770600,2010.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01771406,2013.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Phase 4
NCT01771627,2012.0,OTHER,lead,Roswell Park Cancer Institute,Not Applicable
NCT01771627,2012.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT01771640,2013.0,OTHER_GOV,lead,Royan Institute,Phase 1
NCT01772199,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01772524,2013.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 1
NCT01772641,2012.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01772641,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01773278,2008.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01773538,2013.0,OTHER,lead,Mette Munk Lauridsen,Not Applicable
NCT01773538,2013.0,OTHER,collaborator,Region of Southern Denmark,Not Applicable
NCT01773538,2013.0,OTHER,collaborator,Odense University Hospital,Not Applicable
NCT01773538,2013.0,OTHER,collaborator,Hospital of South West Jutland,Not Applicable
NCT01774435,2012.0,INDUSTRY,lead,Endo Pharmaceuticals,Phase 1
NCT01774864,2011.0,INDUSTRY,lead,"Dong-A Pharmaceutical Co., Ltd.",Phase 3
NCT01776320,2013.0,OTHER,lead,Lawson Health Research Institute,Phase 4
NCT01776970,2013.0,OTHER,lead,Ospedale San Raffaele,Phase 2/Phase 3
NCT01776970,2013.0,OTHER,collaborator,Fondazione Salvatore Maugeri,Phase 2/Phase 3
NCT01776970,2013.0,OTHER,collaborator,Niguarda Hospital,Phase 2/Phase 3
NCT01776970,2013.0,OTHER,collaborator,University of Padova,Phase 2/Phase 3
NCT01777139,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01777412,2013.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT01777412,2013.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1
NCT01777412,2013.0,OTHER,collaborator,Guthy Jackson Charitable Foundation,Phase 1
NCT01777542,2013.0,OTHER,lead,Boston Children's Hospital,Phase 2
NCT01777542,2013.0,OTHER,collaborator,International Rett Syndrome Foundation,Phase 2
NCT01777555,2013.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT01777646,2012.0,INDUSTRY,lead,Brainstorm-Cell Therapeutics,Phase 2
NCT01777646,2012.0,OTHER,collaborator,Hadassah Medical Organization,Phase 2
NCT01777672,2012.0,OTHER,lead,Hospital de Mataró,Phase 2
NCT01778010,2009.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT01778010,2009.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01778907,2013.0,OTHER,lead,University of Groningen,Phase 4
NCT01778907,2013.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT01778946,2013.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1/Phase 2
NCT01779700,2013.0,OTHER,lead,Indiana University,Phase 2
NCT01780246,2013.0,INDUSTRY,lead,Biogen,Phase 1
NCT01780467,2013.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 4
NCT01782027,2012.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT01782222,2013.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 4
NCT01782742,2013.0,OTHER,lead,The Cleveland Clinic,Phase 2
NCT01783041,2013.0,OTHER,lead,Montefiore Medical Center,Phase 2/Phase 3
NCT01783041,2013.0,OTHER,collaborator,The Gerber Foundation,Phase 2/Phase 3
NCT01783522,2013.0,OTHER,lead,Beth Faiman,Phase 2
NCT01783522,2013.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01783574,2013.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01783574,2013.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT01783574,2013.0,INDUSTRY,collaborator,Lawley Pharmaceuticals,Not Applicable
NCT01783847,2015.0,OTHER,lead,Tehran University of Medical Sciences,Phase 1/Phase 2
NCT01783847,2015.0,OTHER,collaborator,Iran University of Medical Sciences,Phase 1/Phase 2
NCT01783847,2015.0,OTHER,collaborator,Mashhad University of Medical Sciences,Phase 1/Phase 2
NCT01783847,2015.0,OTHER,collaborator,Shahid Beheshti University of Medical Sciences,Phase 1/Phase 2
NCT01783912,2012.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT01784614,2009.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01784666,2013.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01785290,2013.0,OTHER,lead,Radboud University Medical Center,Phase 4
NCT01785290,2013.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT01786174,2013.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01786174,2013.0,OTHER,collaborator,ALS Therapy Development Institute,Phase 2
NCT01786239,2013.0,OTHER,lead,Delbert Robinson,Not Applicable
NCT01786239,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01786239,2013.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Not Applicable
NCT01787123,2013.0,OTHER,lead,Kwong Wah Hospital,Phase 2/Phase 3
NCT01787578,2013.0,OTHER,lead,Thomas S. Scanlan,Phase 1
NCT01788072,2014.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01788072,2014.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT01788072,2014.0,OTHER,collaborator,McMaster University,Phase 2
NCT01788072,2014.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT01788176,2013.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 2
NCT01788176,2013.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT01788774,2013.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 1
NCT01788930,2013.0,OTHER,lead,"University Hospital, Grenoble",Not Applicable
NCT01788969,2005.0,OTHER,lead,Shirley Ryan AbilityLab,Phase 1
NCT01789047,2013.0,OTHER,lead,Rush University Medical Center,Phase 2
NCT01789047,2013.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01789125,2012.0,OTHER,lead,University of Houston,Phase 1
NCT01789125,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01789398,2012.0,OTHER,lead,Bioprojet,Phase 3
NCT01789606,2012.0,INDUSTRY,lead,Pfizer,Phase 3
NCT01790490,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT01790971,2020.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT01791153,2013.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT01791244,2013.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT01791296,2011.0,OTHER,lead,Maisonneuve-Rosemont Hospital,Phase 4
NCT01791296,2011.0,OTHER,collaborator,Tufts Medical Center,Phase 4
NCT01791296,2011.0,OTHER,collaborator,Northeastern University,Phase 4
NCT01791400,2009.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2
NCT01791725,2013.0,INDUSTRY,lead,"OPKO Health, Inc.",Phase 2
NCT01791725,2013.0,INDUSTRY,collaborator,Elan Pharmaceuticals,Phase 2
NCT01791816,2013.0,OTHER,lead,New York Medical College,Early Phase 1
NCT01792297,2012.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT01792297,2012.0,INDUSTRY,collaborator,Mitacs,Not Applicable
NCT01793415,2013.0,INDUSTRY,lead,PharmaLundensis AB,Phase 1/Phase 2
NCT01793441,2013.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT01793610,2013.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT01793935,2013.0,OTHER,lead,K.N. Roy Chengappa,Not Applicable
NCT01794429,2013.0,OTHER,lead,Bjorn H. Ebdrup,Phase 3
NCT01794455,2013.0,OTHER,lead,Vanderbilt University,Phase 4
NCT01794689,2013.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01794689,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01794793,2013.0,INDUSTRY,lead,RECORDATI GROUP,Phase 4
NCT01794897,2013.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT01794897,2013.0,OTHER_GOV,collaborator,Dr. Ram Manohar Lohia Hospital,Phase 4
NCT01794897,2013.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01795183,2012.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01795547,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01795547,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01795859,2013.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01795872,2013.0,INDUSTRY,lead,Bayer,Phase 4
NCT01796132,2012.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT01796132,2012.0,OTHER,collaborator,"University Hospital, Geneva",Phase 4
NCT01796132,2012.0,OTHER,collaborator,Hospices Civils de Lyon,Phase 4
NCT01796132,2012.0,OTHER,collaborator,"Central Hospital, Nancy, France",Phase 4
NCT01796574,2012.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Mayo Clinic,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Queen's Medical Center,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Rush University Medical Center,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Oregon Health and Science University,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Thomas Jefferson University,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,Intermountain Medical Center,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,NYU Langone Health,Not Applicable
NCT01796574,2012.0,OTHER,collaborator,University of Rochester,Not Applicable
NCT01796951,2013.0,OTHER,lead,Vanderbilt University,Early Phase 1
NCT01797380,2008.0,OTHER,lead,Duke University,Phase 4
NCT01797575,2013.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01797575,2013.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT01797965,2013.0,INDUSTRY,lead,Biogen,Phase 3
NCT01797965,2013.0,INDUSTRY,collaborator,AbbVie,Phase 3
NCT01798329,2013.0,OTHER,lead,A.O. Ospedale Papa Giovanni XXIII,Phase 3
NCT01798329,2013.0,OTHER,collaborator,University of Padova,Phase 3
NCT01798394,2014.0,OTHER,lead,University of Minnesota,Not Applicable
NCT01798394,2014.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT01798394,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01798667,2013.0,INDUSTRY,lead,"Dong-A Pharmaceutical Co., Ltd.",Phase 2
NCT01799590,2007.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT01799837,2012.0,OTHER,lead,Emory University,Phase 1
NCT01799941,2013.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 4
NCT01800097,2012.0,OTHER,lead,Herlev Hospital,Phase 3
NCT01801072,2013.0,OTHER,lead,University of Michigan,Phase 4
NCT01801423,2013.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT01801423,2013.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT01801423,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT01801423,2013.0,OTHER,collaborator,Aminu Kano Teaching Hospital,Not Applicable
NCT01801709,2014.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1/Phase 2
NCT01801709,2014.0,OTHER,collaborator,European Leukodystrophy Association,Phase 1/Phase 2
NCT01801709,2014.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 1/Phase 2
NCT01801917,2013.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01802385,2015.0,OTHER,lead,University of Minnesota,Phase 3
NCT01802385,2015.0,OTHER,collaborator,"Infectious Disease Institute, Kampala, Uganda",Phase 3
NCT01802385,2015.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01802385,2015.0,OTHER,collaborator,Mbarara University of Science and Technology,Phase 3
NCT01802385,2015.0,OTHER_GOV,collaborator,Medical Research Council,Phase 3
NCT01802385,2015.0,OTHER,collaborator,Wellcome Trust,Phase 3
NCT01802385,2015.0,OTHER,collaborator,Makerere University,Phase 3
NCT01802489,2013.0,OTHER,lead,University of Oxford,Phase 2
NCT01802489,2013.0,UNKNOWN,collaborator,Multiple Sclerosis Society of Great Britain and Northern Ireland,Phase 2
NCT01802502,2013.0,OTHER,lead,Universitas Padjadjaran,Phase 2
NCT01802502,2013.0,OTHER,collaborator,Radboud University Medical Center,Phase 2
NCT01802515,2012.0,OTHER,lead,Yale University,Not Applicable
NCT01802931,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01803412,2013.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT01803464,2012.0,OTHER,lead,University of Delaware,Not Applicable
NCT01803464,2012.0,OTHER,collaborator,Alfred I. duPont Hospital for Children,Not Applicable
NCT01803464,2012.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT01803646,2014.0,INDUSTRY,lead,"Auris Medical, Inc.",Phase 3
NCT01803867,2013.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT01803867,2013.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT01803945,2013.0,OTHER,lead,Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT01803945,2013.0,INDUSTRY,collaborator,Sanofi,Phase 1
NCT01804075,2011.0,OTHER,lead,Eastern Maine Medical Center,Phase 4
NCT01804920,2013.0,OTHER,lead,Herzog Hospital,Not Applicable
NCT01805440,2013.0,OTHER,lead,University of Utah,Not Applicable
NCT01805440,2013.0,OTHER,collaborator,The Depressive and Bipolar Disorder Alternative Treatment Foundation,Not Applicable
NCT01805895,2013.0,OTHER,lead,Augusta University,Phase 1/Phase 2
NCT01805895,2013.0,OTHER,collaborator,American Heart Association,Phase 1/Phase 2
NCT01806779,2013.0,OTHER,lead,Duke University,Phase 2
NCT01806779,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01806779,2013.0,INDUSTRY,collaborator,"Philip Morris USA, Inc.",Phase 2
NCT01806896,2013.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01807026,2013.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01807234,2013.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT01807234,2013.0,INDUSTRY,collaborator,"American Regent, Inc.",Phase 4
NCT01807741,2013.0,OTHER,lead,University of Cincinnati,Phase 2
NCT01807741,2013.0,OTHER,collaborator,University of Louisville,Phase 2
NCT01807741,2013.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT01807988,2013.0,OTHER_GOV,lead,Örebro County Council,Not Applicable
NCT01807988,2013.0,OTHER,collaborator,Uppsala University,Not Applicable
NCT01807988,2013.0,OTHER_GOV,collaborator,"Uppsala County Council, Sweden",Not Applicable
NCT01808261,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT01808482,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01808885,2013.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT01808885,2013.0,OTHER,collaborator,Hôpital de la Timone,Phase 1
NCT01808885,2013.0,INDUSTRY,collaborator,SGS S.A.,Phase 1
NCT01808885,2013.0,UNKNOWN,collaborator,STRAGEN Services,Phase 1
NCT01809158,2013.0,OTHER,lead,Addis Ababa University,Phase 4
NCT01809158,2013.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT01809340,2013.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT01809626,2010.0,OTHER,lead,Mclean Hospital,Early Phase 1
NCT01809626,2010.0,OTHER,collaborator,Brain & Behavior Research Foundation,Early Phase 1
NCT01809639,2013.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT01809639,2013.0,UNKNOWN,collaborator,American Medical Society for Sports Medicine (AMSSM) Foundation,Phase 4
NCT01810263,2012.0,OTHER,lead,Seoul National University Bundang Hospital,Phase 2/Phase 3
NCT01810263,2012.0,OTHER,collaborator,Myongji Hospital,Phase 2/Phase 3
NCT01810380,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01810380,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01810575,2013.0,INDUSTRY,lead,Warner Chilcott,Phase 2
NCT01810731,2014.0,FED,lead,Centers for Disease Control and Prevention,Phase 2/Phase 3
NCT01810783,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01810783,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01811004,2012.0,INDUSTRY,lead,"Cynosure, Inc.",Not Applicable
NCT01811147,2011.0,OTHER,lead,The Cleveland Clinic,Phase 4
NCT01811225,2012.0,OTHER,lead,University of Minnesota,Phase 2
NCT01811459,2013.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 3
NCT01811459,2013.0,OTHER,collaborator,Quebec Firefighters Foundation for Burns,Phase 3
NCT01811498,2013.0,OTHER,lead,Northwell Health,Phase 1/Phase 2
NCT01811498,2013.0,OTHER,collaborator,Feinstein Institute for Medical Research,Phase 1/Phase 2
NCT01811693,2013.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01811940,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT01811940,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT01812044,2013.0,OTHER,lead,Duke University,Not Applicable
NCT01812642,2008.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT01813604,2012.0,FED,lead,Centers for Disease Control and Prevention,Phase 3
NCT01813604,2012.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 3
NCT01813604,2012.0,UNKNOWN,collaborator,"Ministry of Health and Family Welfare, Bangladesh",Phase 3
NCT01813604,2012.0,INDUSTRY,collaborator,NanoPass Technologies Ltd,Phase 3
NCT01813799,2011.0,INDUSTRY,lead,"Dong-A ST Co., Ltd.",Phase 2
NCT01814527,2013.0,OTHER,lead,East Carolina University,Not Applicable
NCT01814618,2013.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT01814982,2007.0,INDUSTRY,lead,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT01815073,2013.0,OTHER,lead,"Changchun Keygen Biological Products Co., Ltd.",Phase 4
NCT01815073,2013.0,OTHER,collaborator,Guangdong Provincial Institute of Biological Products And Materia Medica,Phase 4
NCT01815125,2013.0,OTHER,lead,St. Justine's Hospital,Phase 1
NCT01816334,2013.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT01816620,2014.0,OTHER,lead,Peking Union Medical College Hospital,Phase 2
NCT01816620,2014.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT01817166,2013.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Phase 3
NCT01817816,2009.0,OTHER,lead,Changhua Christian Hospital,Not Applicable
NCT01817907,2013.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT01817907,2013.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01818661,2018.0,OTHER,lead,Mayo Clinic,Phase 4
NCT01818661,2018.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 4
NCT01818713,2013.0,OTHER,lead,The Netherlands Cancer Institute,Phase 2
NCT01818921,2013.0,INDUSTRY,lead,"Zafgen, Inc.",Phase 2
NCT01819441,2012.0,OTHER,lead,Yining Huang,Phase 4
NCT01819727,2013.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 3
NCT01820559,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT01820585,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT01820663,2012.0,OTHER,lead,Burke Rehabilitation Hospital,Phase 1/Phase 2
NCT01820715,2010.0,INDUSTRY,lead,"Dong-A Pharmaceutical Co., Ltd.",Phase 1
NCT01821118,2013.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01821378,2013.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01821560,2013.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01821560,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01821560,2013.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01821690,2013.0,OTHER,lead,Indiana University,Not Applicable
NCT01822249,2013.0,INDUSTRY,lead,Edison Pharmaceuticals Inc,Phase 2
NCT01822418,2013.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 4
NCT01822418,2013.0,INDUSTRY,collaborator,Servier,Phase 4
NCT01822535,2011.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT01822587,2013.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01822925,2013.0,INDUSTRY,lead,NeuroBo Pharmaceuticals Inc.,Phase 2
NCT01822925,2013.0,INDUSTRY,collaborator,"Dong-A ST Co., Ltd.",Phase 2
NCT01822951,,INDUSTRY,lead,Ever Neuro Pharma GmbH,Phase 4
NCT01823159,2013.0,OTHER,lead,University Hospital of Mont-Godinne,Phase 3
NCT01823159,2013.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT01823159,2013.0,OTHER,collaborator,Université Catholique de Louvain,Phase 3
NCT01823380,2012.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT01823822,2008.0,OTHER,lead,"University Hospital, Geneva",Phase 2/Phase 3
NCT01823822,2008.0,INDUSTRY,collaborator,Danone Research,Phase 2/Phase 3
NCT01824056,2010.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01824056,2010.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT01824082,2013.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT01824082,2013.0,FED,collaborator,United States Department of Defense,Phase 4
NCT01824121,2012.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Phase 1/Phase 2
NCT01825044,2013.0,INDUSTRY,lead,NeuroVive Pharmaceutical AB,Phase 2
NCT01825551,2012.0,OTHER,lead,Tehran University of Medical Sciences,Phase 2/Phase 3
NCT01825577,2012.0,OTHER,lead,St. Louis University,Phase 4
NCT01825616,2012.0,OTHER,lead,Appalachian State University,Not Applicable
NCT01825616,2012.0,INDUSTRY,collaborator,Dole Food Company,Not Applicable
NCT01825798,2013.0,INDIV,lead,Evdokia Anagnostou,Phase 3
NCT01825798,2013.0,OTHER,collaborator,Massachusetts General Hospital,Phase 3
NCT01825798,2013.0,OTHER,collaborator,Vanderbilt University,Phase 3
NCT01825798,2013.0,OTHER,collaborator,University of Pittsburgh,Phase 3
NCT01825798,2013.0,OTHER,collaborator,Nationwide Children's Hospital,Phase 3
NCT01825798,2013.0,OTHER,collaborator,Ohio State University,Phase 3
NCT01825941,2013.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT01826110,2013.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT01826110,2013.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT01826422,2013.0,OTHER_GOV,lead,"Coordinación de Investigación en Salud, Mexico",Not Applicable
NCT01826422,2013.0,OTHER_GOV,collaborator,Instituto Nacional de Rehabilitacion,Not Applicable
NCT01826474,2013.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1/Phase 2
NCT01826487,2013.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT01827046,2013.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT01827046,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT01827046,2013.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 3
NCT01827046,2013.0,INDUSTRY,collaborator,Emissary International LLC,Phase 3
NCT01827332,2013.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT01828203,2013.0,OTHER,lead,Rick Hansen Institute,Phase 3
NCT01828203,2013.0,OTHER,collaborator,University of Calgary,Phase 3
NCT01828203,2013.0,UNKNOWN,collaborator,Alberta Paraplegic foundation,Phase 3
NCT01828294,2011.0,OTHER,lead,St. Louis University,Phase 1
NCT01828294,2011.0,INDUSTRY,collaborator,CSL Behring,Phase 1
NCT01828437,2012.0,OTHER_GOV,lead,Lady Hardinge Medical College,Phase 3
NCT01828944,2012.0,INDUSTRY,lead,Lesieur,Not Applicable
NCT01828944,2012.0,OTHER,collaborator,"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement",Not Applicable
NCT01828944,2012.0,OTHER_GOV,collaborator,Centre de Recherche en Nutrition Humaine d'Auvergne,Not Applicable
NCT01829048,2013.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01829243,2011.0,OTHER,lead,Duke University,Phase 3
NCT01829243,2011.0,INDUSTRY,collaborator,Forest Laboratories,Phase 3
NCT01829867,2013.0,INDUSTRY,lead,Newron Sweden AB,Phase 1
NCT01830517,2007.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 4
NCT01830842,2014.0,OTHER,lead,Duke University,Not Applicable
NCT01831050,2013.0,OTHER,lead,Fidec Corporation,Phase 4
NCT01831050,2013.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT01831050,2013.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT01831440,2011.0,OTHER,lead,Nanjing Medical University,Not Applicable
NCT01831934,2010.0,OTHER,lead,Stanford University,Phase 4
NCT01831934,2010.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT01831986,2011.0,OTHER,lead,Sha'ar Menashe Mental Health Center,Not Applicable
NCT01831986,2011.0,OTHER_GOV,collaborator,Tirat Carmel Mental Health Center,Not Applicable
NCT01832038,2013.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01832038,2013.0,INDUSTRY,collaborator,UCB Japan Co. Ltd.,Phase 3
NCT01832350,2012.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 4
NCT01832350,2012.0,INDUSTRY,collaborator,Avanir Pharmaceuticals,Phase 4
NCT01832532,2013.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT01832532,2013.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 1/Phase 2
NCT01832753,2013.0,OTHER,lead,Children's Hospital of Philadelphia,Not Applicable
NCT01832753,2013.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT01832766,2005.0,OTHER,lead,"University of Colorado, Denver",Phase 1/Phase 2
NCT01832766,2005.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 1/Phase 2
NCT01833897,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01834053,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01834066,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01834079,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01834339,2013.0,OTHER,lead,Stephen E. Feinberg,Phase 2
NCT01834482,2013.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01834482,2013.0,INDUSTRY,collaborator,Nutricia Liverpool,Not Applicable
NCT01834586,2013.0,INDIV,lead,"Brown, Theodore R., M.D., MPH",Phase 4
NCT01834638,2013.0,INDUSTRY,lead,AbbVie,Phase 2
NCT01834794,2013.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Not Applicable
NCT01834794,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01834911,2013.0,OTHER,lead,New York Medical College,Phase 4
NCT01835847,2013.0,OTHER,lead,Chiba University,Phase 2
NCT01836549,2013.0,NETWORK,lead,Pediatric Brain Tumor Consortium,Phase 2
NCT01836549,2013.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT01837641,2013.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT01837862,2013.0,OTHER,lead,Julie Krystal,Phase 1/Phase 2
NCT01837862,2013.0,INDUSTRY,collaborator,Janssen Pharmaceuticals,Phase 1/Phase 2
NCT01838174,2013.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT01838174,2013.0,INDUSTRY,collaborator,Mallinckrodt,Phase 4
NCT01838174,2013.0,OTHER,collaborator,University of Pennsylvania,Phase 4
NCT01838616,2013.0,INDUSTRY,lead,Grünenthal GmbH,Phase 4
NCT01838668,2013.0,INDUSTRY,lead,Biogen,Phase 3
NCT01839526,2013.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT01839656,2013.0,INDUSTRY,lead,Biogen,Phase 2
NCT01840345,2014.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT01841125,2011.0,OTHER,lead,Konkuk University Medical Center,Phase 4
NCT01841502,2013.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT01841502,2013.0,INDUSTRY,collaborator,"Janssen, LP",Phase 2
NCT01841671,2013.0,OTHER,lead,University of Chile,Phase 4
NCT01841671,2013.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT01841827,2013.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT01842022,2011.0,OTHER,lead,Swansea University,Not Applicable
NCT01842113,2013.0,OTHER,lead,Tampa General Hospital,Phase 4
NCT01842334,2013.0,OTHER,lead,Mclean Hospital,Phase 1/Phase 2
NCT01842334,2013.0,OTHER,collaborator,American Lung Association,Phase 1/Phase 2
NCT01842581,2013.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 4
NCT01842841,2013.0,INDUSTRY,lead,Shire,Phase 3
NCT01842841,2013.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 3
NCT01843023,2013.0,OTHER,lead,"Friends Research Institute, Inc.",Phase 4
NCT01843023,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01843075,2014.0,OTHER,lead,Imperial College London,Phase 2
NCT01843075,2014.0,OTHER,collaborator,King's College Hospital NHS Trust,Phase 2
NCT01843075,2014.0,OTHER,collaborator,University of Oxford,Phase 2
NCT01843075,2014.0,OTHER,collaborator,University of Southampton,Phase 2
NCT01843075,2014.0,OTHER_GOV,collaborator,Avon and Wiltshire Mental Health Partnership NHS Trust,Phase 2
NCT01843699,2009.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT01844232,2013.0,INDUSTRY,lead,"RVL Pharmaceuticals, Inc.",Phase 3
NCT01844232,2013.0,INDUSTRY,collaborator,Osmotica Pharmaceutical US LLC,Phase 3
NCT01844414,2010.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT01844726,2013.0,OTHER,lead,Northwestern University,Phase 2
NCT01845441,2012.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 2
NCT01845441,2012.0,INDUSTRY,collaborator,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 2
NCT01845558,2013.0,INDUSTRY,lead,Mucos Pharma GmbH & Co. KG,Phase 4
NCT01845584,2013.0,INDUSTRY,lead,"Nihon Pharmaceutical Co., Ltd",Phase 2
NCT01845740,2007.0,INDUSTRY,lead,Gilead Sciences,Phase 1
NCT01845740,2007.0,FED,collaborator,United States Department of Defense,Phase 1
NCT01846481,2013.0,INDUSTRY,lead,Indivior Inc.,Phase 2
NCT01846663,2013.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 4
NCT01846806,2012.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT01846806,2012.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Not Applicable
NCT01847157,2013.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT01847157,2013.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Not Applicable
NCT01847521,2011.0,OTHER,lead,Attikon Hospital,Phase 2
NCT01847573,2013.0,INDUSTRY,lead,Processa Pharmaceuticals,Phase 1/Phase 2
NCT01847651,2013.0,OTHER,lead,Imperial College London,Phase 4
NCT01847755,2013.0,OTHER,lead,"Barry Miskin, MD",Phase 1/Phase 2
NCT01847755,2013.0,OTHER,collaborator,Jupiter Medical Center,Phase 1/Phase 2
NCT01847872,2013.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 4
NCT01849042,2013.0,OTHER,lead,Konkuk University Medical Center,Phase 4
NCT01849419,2010.0,OTHER,lead,University of Chicago,Not Applicable
NCT01849419,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01850238,2013.0,INDUSTRY,lead,Axon Neuroscience SE,Phase 1
NCT01850355,2013.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01850381,2013.0,INDUSTRY,lead,"Genervon Biopharmaceuticals, LLC",Phase 2
NCT01850381,2013.0,OTHER,collaborator,Columbia University,Phase 2
NCT01850420,2013.0,INDUSTRY,lead,"Innovative Med Concepts, LLC",Phase 2
NCT01850771,2013.0,INDUSTRY,lead,"Regenexx, LLC",Not Applicable
NCT01850784,2013.0,OTHER,lead,Dr. Sami Ulus Children's Hospital,Not Applicable
NCT01850953,2013.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT01850953,2013.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01851057,2013.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT01851057,2013.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT01851083,2013.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01851083,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01851148,2010.0,OTHER,lead,European Institute for Evidence Based Osteopathic Medicine,Not Applicable
NCT01851499,2013.0,OTHER,lead,Danish Pain Research Center,Not Applicable
NCT01851499,2013.0,OTHER,collaborator,Spinal Cord Injury Centre of Western Denmark,Not Applicable
NCT01851499,2013.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT01851499,2013.0,UNKNOWN,collaborator,"Epitech Group SRL, Italy",Not Applicable
NCT01851603,2013.0,OTHER,lead,"University of Colorado, Denver",Phase 1
NCT01851603,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01851850,2013.0,OTHER,lead,Rabin Medical Center,Phase 3
NCT01851863,2013.0,OTHER,lead,RenJi Hospital,Phase 4
NCT01852110,2013.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT01852331,2013.0,OTHER,lead,The University of Hong Kong,Phase 2
NCT01852331,2013.0,OTHER,collaborator,"Kowloon Hospital, Hong Kong",Phase 2
NCT01852331,2013.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Phase 2
NCT01852331,2013.0,OTHER,collaborator,Capital Medical University,Phase 2
NCT01852331,2013.0,OTHER,collaborator,Xijing Hospital,Phase 2
NCT01852383,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01852383,2006.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT01853020,2012.0,OTHER,lead,Yale University,Early Phase 1
NCT01853579,2013.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT01853579,2013.0,OTHER,collaborator,Leiden University Medical Center,Phase 4
NCT01853579,2013.0,OTHER,collaborator,University of Bern,Phase 4
NCT01853852,2011.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1
NCT01853956,2010.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01854294,2013.0,INDUSTRY,lead,"Genervon Biopharmaceuticals, LLC",Phase 2
NCT01854294,2013.0,OTHER,collaborator,Columbia University,Phase 2
NCT01854294,2013.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT01854359,2013.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1/Phase 2
NCT01854944,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01854957,2012.0,OTHER,lead,Antonio Uccelli,Phase 1/Phase 2
NCT01854957,2012.0,OTHER,collaborator,Azienda Ospedaliera Universitaria Integrata Verona,Phase 1/Phase 2
NCT01854957,2012.0,OTHER,collaborator,Ospedale San Raffaele,Phase 1/Phase 2
NCT01855074,2007.0,INDUSTRY,lead,Janssen-Cilag Ltd.,Phase 4
NCT01855256,2013.0,OTHER,lead,"University Hospital, Brest",Phase 3
NCT01855256,2013.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT01855594,2013.0,NETWORK,lead,China Spinal Cord Injury Network,Phase 2
NCT01855594,2013.0,OTHER_GOV,collaborator,China Rehabilitation Research Center,Phase 2
NCT01855594,2013.0,OTHER,collaborator,Second Affiliated Hospital of Xi'an Jiaotong University,Phase 2
NCT01855971,2013.0,OTHER,lead,Parc de Salut Mar,Phase 2
NCT01856205,2009.0,OTHER,lead,University of Liverpool,Phase 2
NCT01856205,2009.0,OTHER,collaborator,Kanti Children's Hospital,Phase 2
NCT01856205,2009.0,OTHER,collaborator,B.P. Koirala Institute of Health Sciences,Phase 2
NCT01856270,2013.0,OTHER,lead,University of Washington,Phase 2
NCT01856439,2011.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 1/Phase 2
NCT01856439,2011.0,INDUSTRY,collaborator,Oxford BioMedica,Phase 1/Phase 2
NCT01856738,2013.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT01856738,2013.0,OTHER,collaborator,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 4
NCT01856738,2013.0,OTHER,collaborator,Atrium Medical Center,Phase 4
NCT01856738,2013.0,OTHER,collaborator,University Medical Center Groningen,Phase 4
NCT01856738,2013.0,OTHER,collaborator,Leiden University Medical Center,Phase 4
NCT01856738,2013.0,OTHER,collaborator,University Medical Center Nijmegen,Phase 4
NCT01856738,2013.0,INDUSTRY,collaborator,International Parkinson Fonds Germany GmbH,Phase 4
NCT01856738,2013.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT01859624,2012.0,OTHER,lead,Duke University,Phase 1
NCT01859767,2013.0,OTHER,lead,Molecular NeuroImaging,Phase 1
NCT01860300,2013.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT01860404,2014.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT01860404,2014.0,OTHER,collaborator,The Dana Foundation,Phase 2
NCT01860404,2014.0,OTHER,collaborator,Main Line Health,Phase 2
NCT01860404,2014.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT01860404,2014.0,OTHER_GOV,collaborator,Pennsylvania Department of Health,Phase 2
NCT01860625,2013.0,INDUSTRY,lead,Icure Pharmaceutical Inc.,Phase 1
NCT01860781,2011.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT01860794,2013.0,OTHER,lead,Bundang CHA Hospital,Phase 1/Phase 2
NCT01861145,2013.0,OTHER,lead,University of Alberta,Phase 4
NCT01861717,2013.0,OTHER,lead,Saint John's Cancer Institute,Phase 4
NCT01861847,2013.0,INDUSTRY,lead,Humanetics Corporation,Phase 2
NCT01862640,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01862640,2013.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT01862952,2013.0,OTHER,lead,"University Hospital, Ghent",Not Applicable
NCT01863810,2013.0,INDUSTRY,lead,"KunWha Pharmaceutical Co., Ltd.",Phase 3
NCT01863888,2013.0,INDUSTRY,lead,Sanofi,Phase 3
NCT01864148,2013.0,INDUSTRY,lead,Biogen,Phase 2
NCT01864551,2008.0,OTHER,lead,Tri-Service General Hospital,Phase 4
NCT01864655,2013.0,OTHER,lead,Stephen M. Strittmatter,Phase 1
NCT01864655,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01865084,2013.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01865721,2013.0,OTHER,lead,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 4
NCT01866098,2013.0,OTHER,lead,Yale University,Not Applicable
NCT01866098,2013.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT01866111,2013.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 2
NCT01866995,2013.0,OTHER,lead,"The Clinic of Men's Health and Couple Longevity, Russia",Phase 3
NCT01867268,2012.0,OTHER,lead,Tehran University of Medical Sciences,Phase 2
NCT01867645,2004.0,OTHER,lead,Medical University of Vienna,Phase 1
NCT01867645,2004.0,UNKNOWN,collaborator,Biotest Pharma GmbH,Phase 1
NCT01867645,2004.0,OTHER_GOV,collaborator,National Bank of Austria,Phase 1
NCT01867775,2012.0,OTHER,lead,Brasilia University Hospital,Phase 3
NCT01868048,,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01868191,2013.0,OTHER,lead,Diabetes Schwerpunktpraxis,Phase 3
NCT01868191,2013.0,INDUSTRY,collaborator,Woerwag Pharma GmbH & Co. KG,Phase 3
NCT01868269,2013.0,OTHER,lead,Institut Curie,Phase 3
NCT01869374,2012.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01869478,2013.0,OTHER,lead,Mayo Clinic,Phase 2
NCT01869569,2013.0,OTHER,lead,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2
NCT01870024,2013.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT01870206,2013.0,OTHER,lead,"Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.",Phase 3
NCT01870999,2007.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01871610,2012.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT01872598,2012.0,INDUSTRY,lead,AB Science,Phase 3
NCT01873404,2013.0,INDUSTRY,lead,Biogen,Phase 2
NCT01873547,2012.0,OTHER,lead,General Hospital of Chinese Armed Police Forces,Phase 3
NCT01873716,2013.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT01874028,2013.0,INDUSTRY,lead,Univar BV,Phase 1
NCT01874028,2013.0,INDUSTRY,collaborator,Aptiv Solutions,Phase 1
NCT01874145,2013.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01874340,2013.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT01874756,2013.0,OTHER,lead,Indiana University,Phase 2
NCT01874756,2013.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT01874847,2013.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT01874847,2013.0,OTHER,collaborator,Children's Hospital of Eastern Ontario,Phase 2/Phase 3
NCT01874951,2013.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01874951,2013.0,UNKNOWN,collaborator,Boston Clinical Trials (BCT),Phase 2
NCT01875445,2013.0,OTHER,lead,University of Chicago,Phase 2
NCT01875601,2013.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT01875822,2009.0,INDIV,lead,"Woodbury, Michel, M.D.",Phase 1/Phase 2
NCT01875822,2009.0,OTHER,collaborator,Lawson Health Research Institute,Phase 1/Phase 2
NCT01876355,2024.0,OTHER,lead,Deventer Ziekenhuis,Phase 3
NCT01876810,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01876823,2006.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT01878136,2015.0,OTHER,lead,Rush University Medical Center,Phase 1/Phase 2
NCT01878513,2009.0,OTHER,lead,Northwell Health,Not Applicable
NCT01878578,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01878656,2013.0,OTHER,lead,"Chung-Ang University Hosptial, Chung-Ang University College of Medicine",Phase 4
NCT01879202,2012.0,OTHER,lead,Medical University of Vienna,Phase 2
NCT01879241,2013.0,OTHER,lead,University of Ulm,Phase 2
NCT01879332,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01879345,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT01879423,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01879722,2013.0,INDUSTRY,lead,Takeda,Phase 1
NCT01879748,2013.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 1
NCT01880099,2013.0,OTHER,lead,Yale University,Not Applicable
NCT01880099,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01880593,2013.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01880749,2013.0,OTHER,lead,NYU Langone Health,Early Phase 1
NCT01880957,2011.0,OTHER,lead,Stony Brook University,Not Applicable
NCT01880957,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT01880957,2011.0,OTHER,collaborator,The Dana Foundation,Not Applicable
NCT01881633,2010.0,INDUSTRY,lead,"ISU Abxis Co., Ltd.",Phase 1
NCT01881763,2010.0,OTHER,lead,Northwell Health,Phase 4
NCT01881763,2010.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT01882010,2013.0,OTHER,lead,University of Nebraska,Phase 1
NCT01882010,2013.0,INDUSTRY,collaborator,Sanofi,Phase 1
NCT01882010,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT01882010,2013.0,UNKNOWN,collaborator,Nebraska Neuroscience Alliance,Phase 1
NCT01882062,2013.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT01882400,2001.0,OTHER,lead,Gilles Boire,Phase 4
NCT01882400,2001.0,INDUSTRY,collaborator,Procter and Gamble,Phase 4
NCT01882556,2012.0,OTHER,lead,Sandwell & West Birmingham Hospitals NHS Trust,Phase 2
NCT01882556,2012.0,OTHER,collaborator,Keele University,Phase 2
NCT01882556,2012.0,UNKNOWN,collaborator,Stroke Research Network,Phase 2
NCT01883505,2014.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 2
NCT01883648,2013.0,OTHER,lead,University of South Florida,Phase 2/Phase 3
NCT01883661,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01883674,2012.0,OTHER,lead,Université de Sherbrooke,Not Applicable
NCT01883674,2012.0,OTHER,collaborator,Dairy Farmers of Canada,Not Applicable
NCT01884844,2013.0,OTHER,lead,"University of Massachusetts, Worcester",Not Applicable
NCT01884935,2013.0,INDUSTRY,lead,Biogen,Phase 1
NCT01885338,2013.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 1
NCT01885338,2013.0,FED,collaborator,"VISN 22 Mental Illness Research, Education, and Clinical Center",Phase 1
NCT01885338,2013.0,UNKNOWN,collaborator,American Psychiatric Foundation,Phase 1
NCT01885936,2013.0,OTHER,lead,Duke University,Phase 1/Phase 2
NCT01885988,2013.0,OTHER,lead,"Martin M. Miner, MD",Phase 4
NCT01885988,2013.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT01886196,2013.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT01886196,2013.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT01886313,2014.0,INDUSTRY,lead,Winston Laboratories,Phase 2
NCT01886560,2013.0,OTHER,lead,Sun Yat-sen University,Phase 2/Phase 3
NCT01886729,2012.0,OTHER,lead,"University Hospital, Antwerp",Not Applicable
NCT01886820,2013.0,INDUSTRY,lead,Navidea Biopharmaceuticals,Phase 3
NCT01887132,2013.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT01887366,2013.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT01887990,2012.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01888107,2005.0,INDUSTRY,lead,Janssen-Cilag S.p.A.,Phase 3
NCT01888835,2013.0,OTHER_GOV,lead,"Phillip Coffin, MD, MIA",Phase 2
NCT01888835,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01888848,2013.0,FED,lead,USDA Human Nutrition Research Center on Aging,Not Applicable
NCT01888848,2013.0,OTHER,collaborator,U.S. Highbush Blueberry Council,Not Applicable
NCT01888848,2013.0,OTHER,collaborator,Tufts University,Not Applicable
NCT01889004,2014.0,OTHER,lead,University of Turku,Phase 4
NCT01889004,2014.0,OTHER,collaborator,Academy of Finland,Phase 4
NCT01889004,2014.0,OTHER,collaborator,Hospital District of Southwestern Finland,Phase 4
NCT01889381,2012.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT01890343,2009.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT01890759,2013.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01890798,2014.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01891890,2013.0,OTHER,lead,Emory University,Phase 3
NCT01891890,2013.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 3
NCT01892176,2012.0,OTHER,lead,"National University Hospital, Singapore",Phase 2/Phase 3
NCT01892306,2013.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01892345,2014.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT01892384,2013.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 1
NCT01892722,2013.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT01892813,2013.0,OTHER,lead,Mark Vander Weg,Phase 3
NCT01892813,2013.0,FED,collaborator,VA Office of Research and Development,Phase 3
NCT01892995,2015.0,FED,lead,Brooke Army Medical Center,Not Applicable
NCT01893229,2013.0,OTHER_GOV,lead,Guiyun Xu,Phase 4
NCT01893229,2013.0,OTHER,collaborator,The University of Hong Kong,Phase 4
NCT01894919,2013.0,INDUSTRY,lead,Novartis Vaccines,Phase 3
NCT01894919,2013.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT01894958,2014.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT01895335,2013.0,INDUSTRY,lead,Sanofi,Phase 4
NCT01895348,2012.0,OTHER,lead,Yonsei University,Phase 4
NCT01895439,2012.0,OTHER,lead,University of Jordan,Phase 1/Phase 2
NCT01895452,2013.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT01895621,2013.0,OTHER,lead,Istituto Ortopedico Rizzoli,Phase 4
NCT01896037,2013.0,OTHER,lead,University of Manitoba,Phase 4
NCT01896037,2013.0,UNKNOWN,collaborator,The Association of Rehabilitation Medicine in Manitoba,Phase 4
NCT01896128,2008.0,OTHER,lead,Burke Rehabilitation Hospital,Phase 2
NCT01896128,2008.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT01896388,2014.0,OTHER,lead,Chiba University,Phase 1/Phase 2
NCT01896661,2014.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT01896700,2013.0,OTHER,lead,Oregon Health and Science University,Phase 2/Phase 3
NCT01896700,2013.0,FED,collaborator,Portland VA Medical Center,Phase 2/Phase 3
NCT01897402,2013.0,INDUSTRY,lead,JN-International Medical Corporation,Phase 2
NCT01897727,2009.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT01897727,2009.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01898364,2013.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT01898520,2013.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT01898676,2013.0,OTHER,lead,"Vince & Associates Clinical Research, Inc.",Phase 1
NCT01898676,2013.0,FED,collaborator,Food and Drug Administration (FDA),Phase 1
NCT01898884,2013.0,INDUSTRY,lead,Shire,Phase 1
NCT01899170,2014.0,OTHER,lead,University of Aarhus,Phase 2
NCT01899170,2014.0,OTHER,collaborator,Stanford University,Phase 2
NCT01899170,2014.0,OTHER,collaborator,California Pacific Medical Center Research Institute,Phase 2
NCT01899898,2012.0,OTHER_GOV,lead,Lady Hardinge Medical College,Phase 2/Phase 3
NCT01900093,2013.0,OTHER,lead,Aaron Miller,Not Applicable
NCT01900093,2013.0,INDUSTRY,collaborator,Mallinckrodt,Not Applicable
NCT01900444,2013.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01900522,2013.0,INDUSTRY,lead,Takeda,Phase 1
NCT01900522,2013.0,INDUSTRY,collaborator,"Intra-Cellular Therapies, Inc.",Phase 1
NCT01900665,2013.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01901588,2012.0,OTHER,lead,NYU Langone Health,Phase 4
NCT01901640,2011.0,INDUSTRY,lead,"Dong-A Pharmaceutical Co., Ltd.",Phase 3
NCT01901848,2013.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT01901887,2014.0,OTHER,lead,Medical University of South Carolina,Phase 1
NCT01901887,2014.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 1
NCT01902004,2013.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT01902004,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01902641,2011.0,INDUSTRY,lead,Dr. Horst Schmidt Klinik GmbH,Not Applicable
NCT01902771,2013.0,OTHER,lead,Edward Ziga,Phase 1
NCT01903096,2014.0,OTHER,lead,"Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo",Phase 4
NCT01903096,2014.0,OTHER_GOV,collaborator,"Ministry of Health, Spain",Phase 4
NCT01903421,2014.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT01903525,2013.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1
NCT01903525,2013.0,OTHER,collaborator,Children's Medical Center Dallas,Phase 1
NCT01903525,2013.0,OTHER,collaborator,Texas Scottish Rite Hospital for Children,Phase 1
NCT01903837,2013.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 2
NCT01904032,2013.0,OTHER,lead,Loyola University,Phase 2
NCT01904032,2013.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01904032,2013.0,NIH,collaborator,National Institute of Nursing Research (NINR),Phase 2
NCT01904097,2013.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2
NCT01904591,2013.0,OTHER,lead,McMaster University,Not Applicable
NCT01904760,2013.0,OTHER,lead,Peking University,Phase 4
NCT01905371,2001.0,OTHER,lead,Duke University,Phase 2
NCT01905605,2013.0,OTHER,lead,"University of Colorado, Denver",Phase 1/Phase 2
NCT01906346,2014.0,OTHER,lead,"Joshua A. Lile, Ph.D.",Early Phase 1
NCT01906372,2013.0,OTHER,lead,"Rohit Aggarwal, MD",Phase 2
NCT01906372,2013.0,INDUSTRY,collaborator,Mallinckrodt,Phase 2
NCT01906658,2013.0,INDUSTRY,lead,Mallinckrodt,Phase 2
NCT01906684,2013.0,OTHER,lead,Tanner Foundation for Multiple Sclerosis,Not Applicable
NCT01906684,2013.0,INDUSTRY,collaborator,Mallinckrodt,Not Applicable
NCT01906684,2013.0,UNKNOWN,collaborator,Auburn University MRI Research Center,Not Applicable
NCT01906684,2013.0,UNKNOWN,collaborator,iReportoire Inc,Not Applicable
NCT01906866,2013.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 3
NCT01907217,2008.0,OTHER,lead,"St Patrick's Hospital, Ireland",Phase 4
NCT01907217,2008.0,OTHER,collaborator,"Health Research Board, Ireland",Phase 4
NCT01908010,2013.0,INDUSTRY,lead,AbbVie,Phase 1
NCT01908114,2013.0,OTHER,lead,Aga Khan University,Phase 4
NCT01908114,2013.0,OTHER_GOV,collaborator,Pakistan Ministry of Health,Phase 4
NCT01908114,2013.0,OTHER,collaborator,"Trust for Vaccines and Immunization, Pakistan",Phase 4
NCT01908114,2013.0,OTHER,collaborator,"National Institutes of Health, Pakistan",Phase 4
NCT01908114,2013.0,OTHER,collaborator,Peshawar Medical College,Phase 4
NCT01908114,2013.0,OTHER,collaborator,World Health Organization,Phase 4
NCT01908114,2013.0,OTHER,collaborator,UNICEF,Phase 4
NCT01908114,2013.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT01908192,2014.0,INDUSTRY,lead,SyneuRx International (Taiwan) Corp,Phase 2/Phase 3
NCT01908205,2013.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT01908205,2013.0,FED,collaborator,United States Department of Defense,Phase 2
NCT01908400,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01908452,2011.0,OTHER_GOV,lead,Beersheva Mental Health Center,Phase 3
NCT01908452,2011.0,OTHER,collaborator,Sha'ar Menashe Mental Health Center,Phase 3
NCT01908452,2011.0,OTHER_GOV,collaborator,Tirat Carmel Mental Health Center,Phase 3
NCT01909154,2013.0,OTHER,lead,Puerta de Hierro University Hospital,Phase 1
NCT01909466,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT01909466,2013.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT01910038,2013.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 2
NCT01910649,2008.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT01911377,2013.0,OTHER,lead,University of Manitoba,Phase 2
NCT01911377,2013.0,INDUSTRY,collaborator,Allergan,Phase 2
NCT01911429,2013.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01911455,2013.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1
NCT01911455,2013.0,OTHER,collaborator,Rush University Medical Center,Phase 1
NCT01911975,2014.0,OTHER,lead,Academisch Ziekenhuis Maastricht,Phase 3
NCT01912391,2012.0,OTHER,lead,"Mood and Anxiety Research, Inc",Phase 3
NCT01912586,2013.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Phase 4
NCT01913327,2013.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT01913327,2013.0,OTHER,collaborator,The Dana Foundation,Phase 4
NCT01914042,2013.0,OTHER,lead,Rambam Health Care Campus,Phase 2
NCT01914133,2014.0,OTHER,lead,Kenneth Madden,Phase 2
NCT01914393,2013.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT01914939,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT01914939,2014.0,OTHER,collaborator,Massachusetts Institute of Technology,Phase 2
NCT01914965,2012.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT01914965,2012.0,OTHER,collaborator,University of Ulm,Phase 2
NCT01914965,2012.0,OTHER,collaborator,Ruhr University of Bochum,Phase 2
NCT01914965,2012.0,OTHER,collaborator,University Hospital Muenster,Phase 2
NCT01915459,2013.0,INDUSTRY,lead,Hugel,Phase 3
NCT01916200,2014.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT01917006,2013.0,INDUSTRY,lead,Allergan,Phase 2
NCT01917019,2013.0,INDUSTRY,lead,Biogen,Phase 3
NCT01917318,2013.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT01917318,2013.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01917825,2013.0,INDUSTRY,lead,Medtronic Spinal and Biologics,Phase 2
NCT01918384,2013.0,INDUSTRY,lead,Kobe University,Phase 2
NCT01918384,2013.0,INDUSTRY,collaborator,Japan Medical Association,Phase 2
NCT01918384,2013.0,INDUSTRY,collaborator,Nobelpharma,Phase 2
NCT01918475,2013.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT01918722,2013.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 4
NCT01918735,2013.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 1
NCT01919892,2010.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT01920334,2013.0,OTHER,lead,Associação Fundo de Incentivo à Pesquisa,Phase 4
NCT01920334,2013.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4
NCT01921205,2013.0,INDUSTRY,lead,UCB Pharma,Phase 3
NCT01921270,2013.0,OTHER,lead,Emory University,Phase 1/Phase 2
NCT01921270,2013.0,INDUSTRY,collaborator,Ipsen,Phase 1/Phase 2
NCT01921296,2013.0,OTHER,lead,Lynn Henry,Phase 2
NCT01921296,2013.0,OTHER,collaborator,Damon Runyon Cancer Research Foundation,Phase 2
NCT01921582,2013.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01921582,2013.0,OTHER_GOV,collaborator,Ontario Mental Health Foundation,Phase 2
NCT01921868,2013.0,OTHER,lead,University of South Florida,Not Applicable
NCT01921972,2004.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 4
NCT01921972,2004.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 4
NCT01922258,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT01922258,2013.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT01922999,2012.0,OTHER,lead,Southeast Renal Research Institute,Phase 2/Phase 3
NCT01923025,2013.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT01923376,2013.0,OTHER,lead,New York Presbyterian Brooklyn Methodist Hospital,Not Applicable
NCT01923584,2013.0,OTHER,lead,University of South Florida,Phase 2
NCT01923584,2013.0,INDUSTRY,collaborator,Edison Pharmaceuticals Inc,Phase 2
NCT01923896,2013.0,OTHER,lead,Emory University,Phase 1/Phase 2
NCT01923974,2013.0,OTHER,lead,Lars Peter Holst Andersen,Phase 2/Phase 3
NCT01923974,2013.0,OTHER,collaborator,University of Copenhagen,Phase 2/Phase 3
NCT01924065,2013.0,OTHER,lead,Suleyman Demirel University,Phase 3
NCT01924143,2013.0,INDUSTRY,lead,Theravance Biopharma,Phase 1
NCT01924468,2013.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT01924858,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01925092,2013.0,INDUSTRY,lead,Corcept Therapeutics,Phase 3
NCT01925092,2013.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT01925469,2011.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01925573,2014.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01925573,2014.0,INDUSTRY,collaborator,NovoCure Ltd.,Not Applicable
NCT01925781,2013.0,OTHER,lead,Creighton University,Phase 4
NCT01926626,2013.0,OTHER,lead,Jed E. Rose,Phase 2
NCT01926626,2013.0,INDUSTRY,collaborator,"Philip Morris USA, Inc.",Phase 2
NCT01926626,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01926834,2013.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 4
NCT01927055,2013.0,INDUSTRY,lead,Chelsea Therapeutics,Phase 3
NCT01928043,2013.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2
NCT01928043,2013.0,OTHER,collaborator,The Depressive and Bipolar Disorder Alternative Treatment Foundation,Phase 2
NCT01928420,2007.0,INDUSTRY,lead,Humanetics Corporation,Phase 2
NCT01928420,2007.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT01928420,2007.0,FED,collaborator,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT01928446,2015.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT01928719,2015.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT01928719,2015.0,OTHER,collaborator,George Washington University,Not Applicable
NCT01928719,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01928758,2015.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT01928758,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01928823,2011.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT01928823,2011.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 2
NCT01928849,2013.0,OTHER,lead,Duke University,Phase 2
NCT01928849,2013.0,FED,collaborator,United States Department of Defense,Phase 2
NCT01929317,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT01929343,2014.0,OTHER,lead,Bryon Adinoff,Phase 2
NCT01929343,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01929434,2013.0,OTHER,lead,General Hospital of Chinese Armed Police Forces,Phase 3
NCT01929642,2013.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2
NCT01929889,2012.0,OTHER,lead,Northwestern University,Phase 4
NCT01929889,2012.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 4
NCT01930604,2013.0,OTHER,lead,Carl Swartling,Phase 2
NCT01930708,2013.0,INDUSTRY,lead,Biogen,Phase 4
NCT01931033,2013.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT01931098,2015.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01931722,2016.0,OTHER,lead,"University of Western Ontario, Canada",Not Applicable
NCT01931878,2012.0,OTHER,lead,Yale University,Phase 2
NCT01931878,2012.0,INDUSTRY,collaborator,"Merz North America, Inc.",Phase 2
NCT01932203,2013.0,OTHER,lead,Inha University Hospital,Phase 4
NCT01932203,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT01932502,2013.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 4
NCT01932502,2013.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT01932541,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT01933217,2013.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT01933243,2013.0,OTHER,lead,Andrea Bonny,Phase 2
NCT01933321,2012.0,OTHER,lead,Hospital Universitario Dr. Jose E. Gonzalez,Phase 2/Phase 3
NCT01933802,2014.0,OTHER,lead,Tisch Multiple Sclerosis Research Center of New York,Phase 1
NCT01933919,2013.0,INDUSTRY,lead,AbbVie,Phase 3
NCT01933919,2013.0,INDUSTRY,collaborator,"Meiji Seika Pharma Co., Ltd.",Phase 3
NCT01934010,2014.0,INDUSTRY,lead,"Auris Medical, Inc.",Phase 3
NCT01934023,2013.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT01934023,2013.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT01934049,2013.0,OTHER,lead,Chinese PLA General Hospital,Phase 4
NCT01934153,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01934868,2013.0,OTHER,lead,Hadassah Medical Organization,Phase 4
NCT01934868,2013.0,OTHER,collaborator,Reuth Rehabilitation Hospital,Phase 4
NCT01934972,2013.0,OTHER,lead,University of Arizona,Phase 3
NCT01935206,2013.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 1
NCT01935271,2013.0,FED,lead,Central Arkansas Veterans Healthcare System,Not Applicable
NCT01935271,2013.0,OTHER,collaborator,University of Arkansas,Not Applicable
NCT01935518,2013.0,OTHER,lead,Peking University Third Hospital,Phase 2
NCT01935544,2013.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT01935908,2013.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT01937013,2013.0,OTHER,lead,Lawson Health Research Institute,Phase 2
NCT01937013,2013.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT01937078,2011.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT01937169,2014.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT01937871,2013.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT01938248,2015.0,OTHER,lead,Population Health Research Institute,Phase 4
NCT01938248,2015.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 4
NCT01938248,2015.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT01938248,2015.0,INDUSTRY,collaborator,Medtronic,Phase 4
NCT01938248,2015.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 4
NCT01938664,2013.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT01938664,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01938859,2012.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT01939314,2012.0,OTHER,lead,Indiana University,Phase 3
NCT01939366,2013.0,INDUSTRY,lead,"Tris Pharma, Inc.",Phase 2
NCT01939548,2013.0,INDUSTRY,lead,Pfizer,Phase 2
NCT01939561,2013.0,OTHER,lead,"Grete Andersen, MD",Phase 3
NCT01940159,2013.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01940315,2017.0,INDUSTRY,lead,"DynPort Vaccine Company LLC, A GDIT Company",Phase 3
NCT01940952,2013.0,OTHER,lead,Samsung Medical Center,Phase 3
NCT01940952,2013.0,INDUSTRY,collaborator,"Dong-A Pharmaceutical Co., Ltd.",Phase 3
NCT01940978,2014.0,INDIV,lead,Douglas Sears,Phase 4
NCT01941732,2003.0,OTHER,lead,Bispebjerg Hospital,Phase 4
NCT01941758,2013.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT01941758,2013.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01942148,2010.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01942161,2010.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT01942343,2013.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 3
NCT01942382,2009.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 1
NCT01942590,2013.0,OTHER,lead,"Dwight Koeberl, M.D., Ph.D.",Phase 1/Phase 2
NCT01943019,2013.0,OTHER,lead,Monash University,Phase 1
NCT01943019,2013.0,OTHER,collaborator,Universiti Kebangsaan Malaysia Medical Centre,Phase 1
NCT01943305,2013.0,OTHER,lead,Singapore General Hospital,Phase 2
NCT01943305,2013.0,OTHER,collaborator,Duke-NUS Graduate Medical School,Phase 2
NCT01943994,2008.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT01943994,2008.0,UNKNOWN,collaborator,Beckley Foundation,Not Applicable
NCT01943994,2008.0,OTHER,collaborator,Heffter Research Institute,Not Applicable
NCT01944046,2014.0,OTHER,lead,Linmarie Sikich,Phase 2
NCT01944046,2014.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT01944059,2013.0,INDUSTRY,lead,"Vincent Martin, MD",Phase 4
NCT01944059,2013.0,INDUSTRY,collaborator,Targeted Medical Pharma,Phase 4
NCT01944293,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01944293,2013.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 1/Phase 2
NCT01944423,2013.0,OTHER,lead,University of Texas at Austin,Early Phase 1
NCT01945684,2013.0,INDUSTRY,lead,Daewoong Pharmaceutical Co. LTD.,Phase 3
NCT01945801,2013.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 4
NCT01945957,2014.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT01945957,2014.0,OTHER,collaborator,Duke University,Phase 1
NCT01945957,2014.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT01946295,2014.0,OTHER,lead,Jesper Ekelund,Phase 2/Phase 3
NCT01946295,2014.0,OTHER,collaborator,Karolinska Institutet,Phase 2/Phase 3
NCT01946295,2014.0,OTHER_GOV,collaborator,Region Stockholm,Phase 2/Phase 3
NCT01946295,2014.0,OTHER,collaborator,City of Helsinki,Phase 2/Phase 3
NCT01946295,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT01946295,2014.0,UNKNOWN,collaborator,"Ahokas foundation, Finland",Phase 2/Phase 3
NCT01947205,2012.0,OTHER_GOV,lead,Gökhan Açmaz,Not Applicable
NCT01947803,2013.0,INDUSTRY,lead,Xian-Janssen Pharmaceutical Ltd.,Phase 4
NCT01948024,2013.0,INDUSTRY,lead,Sun Pharmaceutical Industries Limited,Phase 1
NCT01948024,2013.0,INDUSTRY,collaborator,"bioRASI, LLC",Phase 1
NCT01948193,2014.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01948596,2013.0,OTHER,lead,Tokyo Medical University,Phase 2
NCT01948596,2013.0,OTHER,collaborator,"China Medical University, Taiwan",Phase 2
NCT01948596,2013.0,UNKNOWN,collaborator,Japan Society for the Promotion of Science (JSPS),Phase 2
NCT01948596,2013.0,OTHER,collaborator,University of Toyama,Phase 2
NCT01948596,2013.0,OTHER,collaborator,Chiba University,Phase 2
NCT01948791,2014.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT01949571,2007.0,OTHER,lead,Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente,Phase 2
NCT01950338,2013.0,OTHER,lead,Universidad Rey Juan Carlos,Not Applicable
NCT01951118,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01951118,2013.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT01951118,2013.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT01951508,2013.0,OTHER,lead,"University Hospital, Basel, Switzerland",Early Phase 1
NCT01951924,2013.0,INDUSTRY,lead,Laboratoire français de Fractionnement et de Biotechnologies,Phase 3
NCT01951924,2013.0,INDUSTRY,collaborator,TFS Trial Form Support,Phase 3
NCT01951950,2013.0,OTHER,lead,Northwestern University,Phase 1
NCT01951989,2012.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT01952132,2013.0,INDUSTRY,lead,Omeros Corporation,Phase 2
NCT01952574,2013.0,INDUSTRY,lead,Amgen,Phase 2
NCT01952639,2014.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT01953341,2013.0,INDUSTRY,lead,Amgen,Phase 1
NCT01953432,2014.0,FED,lead,VA Office of Research and Development,Phase 2
NCT01953432,2014.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT01953601,2013.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT01953705,2014.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT01953705,2014.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01953757,2013.0,OTHER,lead,Physicians Committee for Responsible Medicine,Not Applicable
NCT01954121,2013.0,INDUSTRY,lead,UCB Pharma SA,Phase 3
NCT01954290,2015.0,OTHER,lead,University of Florida,Phase 2
NCT01954576,2013.0,OTHER,lead,University of Florida,Not Applicable
NCT01954576,2013.0,OTHER,collaborator,Washington University School of Medicine,Not Applicable
NCT01954576,2013.0,INDUSTRY,collaborator,NovoCure Ltd.,Not Applicable
NCT01954693,2012.0,OTHER,lead,Cardiff University,Phase 2
NCT01954693,2012.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT01954706,2013.0,FED,lead,Baltimore VA Medical Center,Not Applicable
NCT01954706,2013.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT01954810,2013.0,OTHER,lead,Khon Kaen University,Phase 4
NCT01954966,2010.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT01954966,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT01955161,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01955161,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01955564,2013.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 1
NCT01955616,2013.0,INDUSTRY,lead,"Motus Therapeutics, Inc.",Phase 2
NCT01955616,2013.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT01955967,2006.0,OTHER,lead,"Pain Relief & Palliative Care Center, Athens, Greece",Not Applicable
NCT01956604,2014.0,OTHER,lead,Oslo University Hospital,Phase 2
NCT01957059,2013.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1/Phase 2
NCT01957319,2010.0,OTHER,lead,University of Catania,Phase 3
NCT01957774,2013.0,INDUSTRY,lead,D-Pharm Ltd.,Phase 2
NCT01958177,2014.0,OTHER,lead,"Chaitanya Hospital, Pune",Phase 1/Phase 2
NCT01958476,2013.0,OTHER,lead,Tufts Medical Center,Phase 3
NCT01958593,2014.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT01959022,2013.0,FED,lead,San Francisco Veterans Affairs Medical Center,Phase 4
NCT01959022,2013.0,FED,collaborator,United States Department of Defense,Phase 4
NCT01959022,2013.0,OTHER,collaborator,Northern California Institute of Research and Education,Phase 4
NCT01959035,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01959035,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01960348,2013.0,INDUSTRY,lead,Alnylam Pharmaceuticals,Phase 3
NCT01961271,2013.0,INDUSTRY,lead,Mundipharma Pte Ltd.,Phase 4
NCT01961271,2013.0,INDUSTRY,collaborator,Mundipharma Korea Ltd,Phase 4
NCT01961271,2013.0,UNKNOWN,collaborator,Mundipharma (Hong Kong) Ltd,Phase 4
NCT01961271,2013.0,UNKNOWN,collaborator,Mundipharma Distribution GmBH (Philippine Branch),Phase 4
NCT01961804,2014.0,OTHER_GOV,lead,"University Hospital, Angers",Phase 3
NCT01962298,2013.0,OTHER,lead,"University Hospital, Antwerp",Phase 3
NCT01962363,2013.0,OTHER,lead,University of South Florida,Phase 2
NCT01962363,2013.0,INDUSTRY,collaborator,Edison Pharmaceuticals Inc,Phase 2
NCT01962363,2013.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 2
NCT01962571,2014.0,OTHER,lead,"University Eye Hospital, Freiburg",Phase 3
NCT01962571,2014.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 3
NCT01962870,2013.0,OTHER,lead,Stanford University,Phase 2
NCT01962870,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT01963078,2013.0,OTHER,lead,Megan Moran-Santa Maria,Phase 2
NCT01963091,2011.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT01963598,2013.0,INDUSTRY,lead,Regeneron Pharmaceuticals,Phase 2
NCT01963598,2013.0,INDUSTRY,collaborator,Sanofi,Phase 2
NCT01963611,2013.0,INDUSTRY,lead,EMD Serono,Phase 2
NCT01964404,2014.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Phase 1
NCT01964404,2014.0,OTHER,collaborator,Columbia University,Phase 1
NCT01964404,2014.0,OTHER,collaborator,Harvard Medical School (HMS and HSDM),Phase 1
NCT01964404,2014.0,OTHER,collaborator,Massachusetts Institute of Technology,Phase 1
NCT01964404,2014.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1
NCT01964404,2014.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 1
NCT01964404,2014.0,OTHER,collaborator,University of Vermont,Phase 1
NCT01964404,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT01964547,2012.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT01964560,2014.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT01964560,2014.0,INDUSTRY,collaborator,UCB Biopharma SRL,Phase 3
NCT01964573,2006.0,INDUSTRY,lead,UCB Pharma,Phase 1
NCT01965327,2013.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT01965327,2013.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 2
NCT01965327,2013.0,INDUSTRY,collaborator,Vidara Therapeutics Research Ltd,Phase 2
NCT01965366,2013.0,OTHER,lead,Emory University,Phase 4
NCT01965405,2013.0,OTHER,lead,Wayne State University,Not Applicable
NCT01965405,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT01965691,2013.0,OTHER,lead,University of British Columbia,Not Applicable
NCT01965691,2013.0,OTHER,collaborator,"Rare Disease Foundation, Vancouver, Canada",Not Applicable
NCT01965691,2013.0,UNKNOWN,collaborator,"Saudi Arabian Cultural Bureau, Ottawa",Not Applicable
NCT01965704,2014.0,OTHER,lead,Stanford University,Phase 2
NCT01965704,2014.0,OTHER,collaborator,Santa Clara Valley Medical Center,Phase 2
NCT01965704,2014.0,OTHER,collaborator,Thomas Jefferson University,Phase 2
NCT01965756,2013.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT01965912,2013.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 4
NCT01965925,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT01965925,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01966172,2007.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 4
NCT01966419,2014.0,INDUSTRY,lead,"Ocera Therapeutics, Inc.",Phase 2
NCT01966666,2013.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT01966679,2013.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT01967251,2015.0,INDUSTRY,lead,Takeda,Phase 2
NCT01967264,2013.0,INDUSTRY,lead,Takeda,Phase 1
NCT01967498,2013.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT01967537,2013.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01967667,2014.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT01967758,2014.0,OTHER,lead,Providence Health & Services,Phase 1
NCT01967758,2014.0,INDUSTRY,collaborator,"Aduro Biotech, Inc.",Phase 1
NCT01967823,2013.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT01968031,2013.0,INDUSTRY,lead,"Kyowa Hakko Kirin Pharma, Inc.",Phase 3
NCT01968031,2013.0,INDUSTRY,collaborator,"Kyowa Kirin Co., Ltd.",Phase 3
NCT01968226,2013.0,OTHER,lead,The Cleveland Clinic,Phase 2
NCT01968460,2013.0,INDUSTRY,lead,Pharma Two B Ltd.,Phase 2/Phase 3
NCT01968772,2013.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT01968772,2013.0,UNKNOWN,collaborator,Magnesium Direct,Not Applicable
NCT01968902,2013.0,OTHER,lead,Multiple Sclerosis Center of Northeastern New York,Phase 4
NCT01968902,2013.0,INDUSTRY,collaborator,"Merz North America, Inc.",Phase 4
NCT01969123,2013.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT01969136,2013.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT01969474,2013.0,OTHER_GOV,lead,Wolfson Medical Center,Phase 1
NCT01969851,2014.0,INDUSTRY,lead,UCB Pharma,Phase 2
NCT01970098,2013.0,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 3
NCT01970111,,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 3
NCT01970124,,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 3
NCT01970137,,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 3
NCT01970345,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT01970345,2014.0,OTHER,collaborator,Autism Science Foundation,Phase 2
NCT01970410,2013.0,OTHER,lead,Providence Health & Services,Phase 4
NCT01970410,2013.0,OTHER,collaborator,Multiple Sclerosis Center of Northeastern New York,Phase 4
NCT01970735,2013.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Not Applicable
NCT01971242,2014.0,OTHER,lead,"University College, London",Phase 2
NCT01972074,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT01972074,2015.0,OTHER,collaborator,Mclean Hospital,Phase 3
NCT01972464,2013.0,OTHER,lead,Yale University,Phase 2
NCT01972464,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01972711,2014.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01973400,2011.0,OTHER,lead,Universiti Sains Malaysia,Phase 3
NCT01973400,2011.0,OTHER,collaborator,"Clinical Research Centre, Malaysia",Phase 3
NCT01973400,2011.0,OTHER_GOV,collaborator,Malaysia Palm Oil Board,Phase 3
NCT01973491,2014.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT01973543,2013.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT01973543,2013.0,OTHER,collaborator,"University of California, San Francisco",Phase 1
NCT01973543,2013.0,OTHER,collaborator,"Veristat, Inc.",Phase 1
NCT01973543,2013.0,OTHER,collaborator,Feinstein Institute for Medical Research,Phase 1
NCT01973543,2013.0,OTHER,collaborator,Oregon Health and Science University,Phase 1
NCT01973543,2013.0,INDUSTRY,collaborator,Voyager Therapeutics,Phase 1
NCT01974700,2013.0,OTHER,lead,Indiana University,Phase 4
NCT01975116,2013.0,NETWORK,lead,Pediatric Brain Tumor Consortium,Phase 1
NCT01975116,2013.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT01975194,2012.0,OTHER,lead,Wayne State University,Phase 4
NCT01975298,2014.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT01975545,2012.0,OTHER,lead,Universidad Autonoma de San Luis Potosí,Phase 2
NCT01976871,2014.0,OTHER,lead,"John Winkelman, MD, PhD",Phase 4
NCT01976871,2014.0,INDUSTRY,collaborator,UCB Pharma,Phase 4
NCT01976936,2009.0,OTHER,lead,Mitchell S Elkind,Phase 2
NCT01976936,2009.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01977456,2013.0,OTHER,lead,Arthur Pancioli,Phase 2
NCT01977456,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01977820,2014.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT01977898,2011.0,OTHER,lead,Northwestern University,Not Applicable
NCT01977924,2013.0,OTHER_GOV,lead,"University Hospital, Angers",Not Applicable
NCT01978327,2013.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT01978366,2013.0,INDUSTRY,lead,Processa Pharmaceuticals,Phase 2
NCT01978431,2012.0,OTHER,lead,Yale University,Phase 1
NCT01978431,2012.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT01978535,2014.0,OTHER,lead,Mayo Clinic,Phase 1/Phase 2
NCT01978548,2013.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT01978730,2011.0,INDUSTRY,lead,"Shineway Pharmaceutical Co.,Ltd",Phase 2
NCT01978782,2014.0,OTHER,lead,Radboud University Medical Center,Phase 1
NCT01979133,2013.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 3
NCT01979679,2008.0,OTHER,lead,"University of California, Irvine",Phase 3
NCT01979679,2008.0,INDUSTRY,collaborator,Dainippon Sumitomo Pharma America,Phase 3
NCT01980550,2004.0,OTHER,lead,"National Institute on Drug Dependence, China",Phase 4
NCT01980550,2004.0,FED,collaborator,Bronx VA Medical Center,Phase 4
NCT01981395,2014.0,OTHER,lead,Laura Cavallone,Phase 1
NCT01981447,2010.0,OTHER,lead,Le Bonheur Children's Hospital,Phase 3
NCT01981486,2014.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01981499,2014.0,INDUSTRY,lead,Pfizer,Phase 1
NCT01981720,2014.0,INDUSTRY,lead,Protalix,Phase 1/Phase 2
NCT01981720,2014.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 1/Phase 2
NCT01981759,2014.0,OTHER,lead,NYU Langone Health,Phase 4
NCT01981759,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT01981811,2014.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT01981967,2013.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT01982578,2017.0,OTHER,lead,Fundación para la Investigación del Hospital Clínico de Valencia,Not Applicable
NCT01982578,2017.0,OTHER,collaborator,University of Valencia,Not Applicable
NCT01982812,2014.0,OTHER,lead,University of Rochester,Phase 2
NCT01982812,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT01983163,2013.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 2
NCT01983358,2013.0,INDUSTRY,lead,"Jeil Pharmaceutical Co., Ltd.",Phase 1
NCT01983475,2015.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT01983475,2015.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 4
NCT01983540,2013.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT01984814,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 2
NCT01985178,2013.0,OTHER,lead,McMaster University,Not Applicable
NCT01985451,2013.0,OTHER,lead,Rongjie Tao,Phase 2
NCT01985451,2013.0,OTHER_GOV,collaborator,National Natural Science Foundation of China,Phase 2
NCT01986075,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT01986075,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT01986101,2014.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT01986842,2014.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT01986998,2013.0,OTHER,lead,Germans Trias i Pujol Hospital,Phase 4
NCT01987167,2013.0,OTHER,lead,"Neuro-Ophthalmologic Associates, PC",Early Phase 1
NCT01987167,2013.0,INDUSTRY,collaborator,Mallinckrodt,Early Phase 1
NCT01987219,2013.0,OTHER,lead,NYU Langone Health,Phase 3
NCT01987960,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT01987960,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT01988584,2013.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT01988584,2013.0,UNKNOWN,collaborator,Cord Blood Registry (CBR),Phase 2
NCT01988584,2013.0,UNKNOWN,collaborator,Let's Cure CP Foundation,Phase 2
NCT01988584,2013.0,UNKNOWN,collaborator,"Mission Connect, a program of TIRR Foundation",Phase 2
NCT01988610,2013.0,OTHER,lead,Stanford University,Phase 1
NCT01988883,2014.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT01988883,2014.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Early Phase 1
NCT01989507,2014.0,OTHER,lead,Brown University,Phase 2
NCT01989793,2013.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT01989793,2013.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT01989793,2013.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01990079,2013.0,OTHER,lead,Duke University,Not Applicable
NCT01990755,2010.0,OTHER,lead,"University of Turin, Italy",Not Applicable
NCT01990755,2010.0,OTHER,collaborator,University of Milan,Not Applicable
NCT01990768,2015.0,OTHER,lead,University of Washington,Phase 2
NCT01990768,2015.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT01990768,2015.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT01990768,2015.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT01990768,2015.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Phase 2
NCT01990768,2015.0,OTHER,collaborator,American Heart Association,Phase 2
NCT01990768,2015.0,INDUSTRY,collaborator,Defence Research and Development Canada,Phase 2
NCT01991067,2014.0,OTHER,lead,Medical University of Vienna,Phase 2
NCT01991067,2014.0,OTHER,collaborator,Austrian Science Fund (FWF),Phase 2
NCT01991145,2013.0,OTHER,lead,"MinYoung Kim, MD, PhD",Not Applicable
NCT01991145,2013.0,OTHER_GOV,collaborator,"Ministry of Health & Welfare, Korea",Not Applicable
NCT01991145,2013.0,INDUSTRY,collaborator,LG Life Sciences,Not Applicable
NCT01991145,2013.0,INDUSTRY,collaborator,Chong Kun Dang Pharmaceutical,Not Applicable
NCT01991145,2013.0,OTHER,collaborator,CHA University,Not Applicable
NCT01992146,2015.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2
NCT01992146,2015.0,OTHER,collaborator,University of Kentucky,Phase 2
NCT01992146,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT01992380,2013.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT01993017,2013.0,OTHER,lead,Columbia University,Not Applicable
NCT01993017,2013.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT01993017,2013.0,OTHER,collaborator,Duke University,Not Applicable
NCT01993017,2013.0,OTHER,collaborator,HealthPartners Institute,Not Applicable
NCT01993017,2013.0,OTHER,collaborator,Kaiser Foundation Research Institute,Not Applicable
NCT01993251,2014.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT01993290,2013.0,OTHER,lead,Jens Borglum Neimann,Not Applicable
NCT01993459,2014.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT01993836,2013.0,OTHER,lead,Duke University,Phase 4
NCT01994473,2013.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT01995825,2012.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT01995825,2012.0,FED,collaborator,Food and Drug Administration (FDA),Phase 4
NCT01996852,2013.0,OTHER,lead,Case Comprehensive Cancer Center,Not Applicable
NCT01996852,2013.0,OTHER,collaborator,The Cleveland Clinic,Not Applicable
NCT01996852,2013.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Not Applicable
NCT01997255,2014.0,OTHER,lead,Baylor College of Medicine,Phase 2
NCT01997255,2014.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT01997489,2001.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 4
NCT01997632,2013.0,OTHER,lead,"University Hospital, Ghent",Phase 1
NCT01997749,2013.0,OTHER,lead,University of Copenhagen,Phase 1
NCT01997749,2013.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Phase 1
NCT01997749,2013.0,OTHER,collaborator,Bispebjerg Hospital,Phase 1
NCT01998841,2013.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT01998841,2013.0,OTHER,collaborator,Banner Alzheimer's Institute,Phase 2
NCT01998841,2013.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT01999309,2013.0,OTHER,lead,Iris Sommer,Phase 3
NCT01999309,2013.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT01999777,2013.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT01999803,2014.0,INDUSTRY,lead,Newron Sweden AB,Phase 1
NCT01999920,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT01999920,2013.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT02000674,2013.0,OTHER,lead,Centre Hospitalier Universitaire de la Réunion,Phase 3
NCT02000674,2013.0,UNKNOWN,collaborator,Unité de Soutien Méthodologique (CHU de La Réunion),Phase 3
NCT02000674,2013.0,UNKNOWN,collaborator,"SAMU de Paris, Hôpital Necker - Enfants Malades",Phase 3
NCT02000726,2013.0,OTHER,lead,University of Michigan,Phase 2
NCT02001103,2014.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT02001558,2013.0,OTHER,lead,University of Alabama at Birmingham,Phase 4
NCT02001558,2013.0,INDUSTRY,collaborator,"Oculus Innovative Sciences, Inc.",Phase 4
NCT02002325,2014.0,OTHER,lead,"National Cerebral and Cardiovascular Center, Japan",Phase 3
NCT02002325,2014.0,UNKNOWN,collaborator,Charitable Trust Mihara Cerebrovascular Disorder Research Promotion Fund,Phase 3
NCT02002325,2014.0,OTHER_GOV,collaborator,Japan Agency for Medical Research and Development,Phase 3
NCT02002390,2012.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2
NCT02002819,2014.0,OTHER,lead,University of Minnesota,Phase 2
NCT02002832,2013.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 3
NCT02002858,2014.0,OTHER,lead,University of Houston,Phase 1
NCT02002858,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02002884,2014.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT02003144,2015.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT02003313,2013.0,INDUSTRY,lead,"Beijing Minhai Biotechnology Co., Ltd",Phase 3
NCT02003495,2013.0,INDUSTRY,lead,"Beijing Minhai Biotechnology Co., Ltd",Phase 3
NCT02003638,2012.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT02003664,2013.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT02004171,2013.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT02004171,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02004288,2013.0,INDUSTRY,lead,BioGaia AB,Not Applicable
NCT02004392,2014.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 3
NCT02004691,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2/Phase 3
NCT02004704,2013.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT02005029,2013.0,OTHER,lead,Virginia Commonwealth University,Not Applicable
NCT02005536,2013.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02005822,2013.0,OTHER,lead,Dr. Ann C.T.M. Vossen,Phase 3
NCT02005822,2013.0,OTHER,collaborator,Stichting Nuts Ohra,Phase 3
NCT02005822,2013.0,OTHER,collaborator,Leiden University Medical Center,Phase 3
NCT02006121,2014.0,INDUSTRY,lead,Britannia Pharmaceuticals Ltd.,Phase 3
NCT02006160,2011.0,OTHER,lead,State University of New York at Buffalo,Phase 2/Phase 3
NCT02006290,2014.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02006472,2014.0,INDUSTRY,lead,Prilenia,Phase 2
NCT02006472,2014.0,NETWORK,collaborator,European Huntington's Disease Network,Phase 2
NCT02006472,2014.0,NETWORK,collaborator,Huntington Study Group,Phase 2
NCT02006628,2014.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02006641,2014.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02006641,2014.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT02006654,2014.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02006654,2014.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT02007447,2015.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 2/Phase 3
NCT02007694,2013.0,OTHER,lead,VU University of Amsterdam,Phase 2/Phase 3
NCT02007798,2014.0,OTHER,lead,"China Medical University, China",Not Applicable
NCT02007850,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02007928,2013.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Not Applicable
NCT02008292,2013.0,OTHER,lead,Yale University,Not Applicable
NCT02008292,2013.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02008292,2013.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02008357,2014.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02008357,2014.0,OTHER,collaborator,Alzheimer's Therapeutic Research Institute,Phase 3
NCT02008721,2014.0,OTHER,lead,Dr. Johannes Levin,Phase 3
NCT02008721,2014.0,OTHER,collaborator,German Center for Neurodegenerative Diseases (DZNE),Phase 3
NCT02008721,2014.0,UNKNOWN,collaborator,Deutsche Parkinson Vereinigung,Phase 3
NCT02008721,2014.0,OTHER,collaborator,German Foundation for Neurology,Phase 3
NCT02008721,2014.0,UNKNOWN,collaborator,ParkinsonFonds Deutschland gGmbH,Phase 3
NCT02008747,2011.0,INDUSTRY,lead,Dr. Horst Schmidt Klinik GmbH,Not Applicable
NCT02008773,2014.0,OTHER,lead,Indiana University,Phase 2
NCT02008773,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT02008773,2014.0,OTHER,collaborator,Sheppard Pratt Health System,Phase 2
NCT02008773,2014.0,OTHER,collaborator,University of Maryland,Phase 2
NCT02008773,2014.0,UNKNOWN,collaborator,"Centers for Behavioral Health, LLC",Phase 2
NCT02008773,2014.0,OTHER,collaborator,"Laureate Institute for Brain Research, Inc.",Phase 2
NCT02008773,2014.0,OTHER,collaborator,University of Kansas Medical Center,Phase 2
NCT02008773,2014.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT02008773,2014.0,OTHER,collaborator,Yale University,Phase 2
NCT02008773,2014.0,INDUSTRY,collaborator,"Innovative Clinical Research, Inc.",Phase 2
NCT02008773,2014.0,UNKNOWN,collaborator,"University of California Riverside at C.I. Trials, Inc.-Inland Empire",Phase 2
NCT02008773,2014.0,INDUSTRY,collaborator,Clinical Innovations,Phase 2
NCT02009124,2012.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 2
NCT02009163,2014.0,INDUSTRY,lead,Shire,Phase 3
NCT02010606,2014.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 1
NCT02011191,2006.0,OTHER,lead,"Heidi Moretti, MS, RD",Not Applicable
NCT02011191,2006.0,OTHER,collaborator,Saint Patrick Hospital,Not Applicable
NCT02011191,2006.0,OTHER,collaborator,University of Arkansas,Not Applicable
NCT02011321,2014.0,OTHER,lead,Henry Ford Health System,Phase 2
NCT02011451,2015.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Phase 2
NCT02011451,2015.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT02011516,2013.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT02011516,2013.0,OTHER_GOV,collaborator,Pennsylvania Department of Health,Phase 2
NCT02011750,2013.0,OTHER,lead,University of Pittsburgh,Phase 4
NCT02011750,2013.0,OTHER,collaborator,Mansoura University,Phase 4
NCT02011750,2013.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT02011971,2012.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT02012335,2014.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Not Applicable
NCT02012582,2009.0,INDUSTRY,lead,veriNOS operations GmbH,Phase 2
NCT02013232,2013.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT02013258,2015.0,OTHER,lead,University of Florida,Phase 1
NCT02013258,2015.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT02013466,2008.0,INDUSTRY,lead,Nutricia Research,Phase 1
NCT02013622,2013.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT02013622,2013.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT02015039,2013.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT02015481,2014.0,INDUSTRY,lead,Bioblast Pharma Ltd.,Phase 2
NCT02015949,2014.0,OTHER,lead,Imperial College London,Phase 4
NCT02016547,2013.0,OTHER,lead,SOS Attaque Cérébrale,Phase 4
NCT02016560,2013.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT02016885,2013.0,INDUSTRY,lead,Journey Medical Corporation,Phase 2
NCT02017119,2011.0,OTHER,lead,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Phase 2
NCT02017340,2013.0,OTHER,lead,Prof Brian Lawlor,Phase 3
NCT02017340,2013.0,OTHER,collaborator,"University of Dublin, Trinity College",Phase 3
NCT02017340,2013.0,UNKNOWN,collaborator,Molecular Medicine Ireland LBG,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Alzheimer Europe,Phase 3
NCT02017340,2013.0,INDUSTRY,collaborator,"Archer Pharmaceuticals, Inc.",Phase 3
NCT02017340,2013.0,UNKNOWN,collaborator,E-Search Limited,Phase 3
NCT02017340,2013.0,OTHER,collaborator,University College Dublin,Phase 3
NCT02017340,2013.0,OTHER,collaborator,King's College London,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Istituto Di Ricerche Farmacologiche Mario Negri,Phase 3
NCT02017340,2013.0,OTHER,collaborator,"University Hospital, Lille",Phase 3
NCT02017340,2013.0,OTHER,collaborator,University of Ulm,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Szeged University,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Göteborg University,Phase 3
NCT02017340,2013.0,OTHER,collaborator,University College Cork,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Aristotle University Of Thessaloniki,Phase 3
NCT02017340,2013.0,OTHER,collaborator,Stichting Katholieke Universiteit,Phase 3
NCT02017444,2014.0,OTHER,lead,University of Birmingham,Phase 2
NCT02018263,2013.0,OTHER,lead,Yale University,Phase 1
NCT02018406,2011.0,OTHER,lead,Yonsei University,Phase 1/Phase 2
NCT02019017,2013.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1/Phase 2
NCT02019017,2013.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT02019329,2014.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT02019550,2014.0,INDUSTRY,lead,EMD Serono,Phase 4
NCT02019667,2014.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02019940,2014.0,OTHER,lead,Yale University,Phase 1
NCT02019940,2014.0,FED,collaborator,National Center for PTSD,Phase 1
NCT02020408,2011.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT02020408,2011.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02021201,2008.0,OTHER,lead,Birte Glenthoj,Phase 4
NCT02021201,2008.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT02021214,2014.0,OTHER,lead,"University of California, San Diego",Early Phase 1
NCT02021461,2012.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT02021669,2014.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT02021669,2014.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT02021825,2009.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 4
NCT02022488,2012.0,OTHER,lead,Yeditepe University Hospital,Phase 4
NCT02022709,2014.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT02022709,2014.0,OTHER_GOV,collaborator,Shanghai Municipal Science and Technology Commission,Phase 4
NCT02022709,2014.0,OTHER,collaborator,Shanghai Jiao Tong University School of Medicine,Phase 4
NCT02023424,2014.0,OTHER_GOV,lead,Sheba Medical Center,Phase 1
NCT02024191,2013.0,OTHER_GOV,lead,Ankara Education and Research Hospital,Phase 3
NCT02024230,2014.0,OTHER,lead,Fujita Health University,Phase 4
NCT02024373,2013.0,OTHER,lead,Oriental Neurosurgery Evidence-Based-Study Team,Phase 2
NCT02024789,2014.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02024932,2014.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT02025179,2013.0,OTHER,lead,Northwestern University,Phase 2
NCT02025179,2013.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02025439,2014.0,FED,lead,Edward Hines Jr. VA Hospital,Not Applicable
NCT02025608,2013.0,OTHER,lead,Mauro Manconi,Phase 4
NCT02025608,2013.0,OTHER,collaborator,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT02025608,2013.0,OTHER,collaborator,Cardiocentro Ticino,Phase 4
NCT02025686,2012.0,OTHER,lead,Per Rotbøll Nielsen,Not Applicable
NCT02025855,2014.0,OTHER,lead,Henry Ford Health System,Phase 4
NCT02027246,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02027701,2014.0,INDUSTRY,lead,CSL Behring,Phase 3
NCT02027987,2013.0,OTHER,lead,Xijing Hospital,Phase 1
NCT02028104,2010.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02028260,2014.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT02029547,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Not Applicable
NCT02030015,2015.0,OTHER,lead,University of Minnesota,Phase 4
NCT02030015,2015.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Phase 4
NCT02030015,2015.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 4
NCT02030015,2015.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT02030015,2015.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 4
NCT02030015,2015.0,OTHER,collaborator,Lysosomal Disease Network,Phase 4
NCT02031198,2014.0,INDUSTRY,lead,Axon Neuroscience SE,Phase 1
NCT02031692,2013.0,OTHER,lead,Seoul National University Bundang Hospital,Phase 4
NCT02031692,2013.0,OTHER_GOV,collaborator,"Ministry of Food and Drug Safety, Korea",Phase 4
NCT02033941,2018.0,OTHER,lead,Hillel Grossman,Phase 2
NCT02033941,2018.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT02034071,2014.0,INDUSTRY,lead,"Essentialis, Inc.",Phase 1/Phase 2
NCT02034188,2014.0,INDUSTRY,lead,Translational Biosciences,Phase 1/Phase 2
NCT02034331,2012.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Not Applicable
NCT02034474,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT02034474,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT02034760,2014.0,OTHER,lead,Bispebjerg Hospital,Not Applicable
NCT02034760,2014.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02034760,2014.0,INDUSTRY,collaborator,Arla Foods,Not Applicable
NCT02035020,2013.0,OTHER,lead,Azienda Policlinico Umberto I,Phase 2
NCT02035111,2014.0,INDUSTRY,lead,"Jiangsu Kanion Pharmaceutical Co., Ltd",Phase 4
NCT02035111,2014.0,OTHER,collaborator,"Beijing Bionovo Medicine Development Co., Ltd.",Phase 4
NCT02035501,2014.0,OTHER,lead,Hadassah Medical Organization,Phase 2
NCT02035982,2010.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT02036125,2013.0,OTHER,lead,Université de Sherbrooke,Not Applicable
NCT02036450,2014.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT02036450,2014.0,OTHER,collaborator,Bispebjerg Hospital,Not Applicable
NCT02036450,2014.0,OTHER,collaborator,Zealand University Hospital,Not Applicable
NCT02036450,2014.0,OTHER,collaborator,Odense University Hospital,Not Applicable
NCT02036450,2014.0,OTHER,collaborator,University of Southern Denmark,Not Applicable
NCT02036450,2014.0,OTHER,collaborator,Aalborg University,Not Applicable
NCT02037035,2013.0,OTHER,lead,Yale University,Early Phase 1
NCT02037035,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT02037035,2013.0,OTHER,collaborator,American Psychiatric Association,Early Phase 1
NCT02037074,2014.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 1
NCT02037126,2015.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT02037815,2014.0,OTHER,lead,Capital Medical University,Phase 4
NCT02038712,2006.0,OTHER,lead,New York Obesity and Nutrition Research Center,Not Applicable
NCT02038712,2006.0,OTHER,collaborator,Columbia University,Not Applicable
NCT02038972,2013.0,OTHER,lead,"James Baumgartner, MD",Phase 1/Phase 2
NCT02038972,2013.0,OTHER,collaborator,"CBR Systems, Inc.",Phase 1/Phase 2
NCT02039024,2012.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT02039024,2012.0,OTHER_GOV,collaborator,"National Science Council, Taiwan",Phase 2
NCT02039349,2014.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1
NCT02039349,2014.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 1
NCT02039349,2014.0,OTHER,collaborator,University of Rhode Island,Phase 1
NCT02039375,2014.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT02039401,2014.0,INDUSTRY,lead,"Helixmith Co., Ltd.",Phase 1/Phase 2
NCT02039479,2014.0,OTHER,lead,Technische Universität Dresden,Not Applicable
NCT02039778,2013.0,OTHER,lead,Beth Israel Medical Center,Not Applicable
NCT02039778,2013.0,OTHER,collaborator,St. Luke's-Roosevelt Hospital Center,Not Applicable
NCT02040116,2013.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT02040194,2014.0,INDUSTRY,lead,Auris Medical AG,Phase 3
NCT02040207,2014.0,INDUSTRY,lead,Auris Medical AG,Phase 3
NCT02040298,2014.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT02040636,1999.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT02040883,2014.0,OTHER_GOV,lead,Qingyun Yin,Phase 4
NCT02040987,2014.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT02040987,2014.0,INDUSTRY,collaborator,Parexel,Phase 1
NCT02041455,2010.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT02042534,2014.0,OTHER,lead,Asan Medical Center,Phase 2
NCT02042534,2014.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT02042573,2013.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 4
NCT02043171,2014.0,INDUSTRY,lead,Metabolic Technologies Inc.,Phase 1
NCT02043171,2014.0,OTHER,collaborator,Iowa State University,Phase 1
NCT02043548,2014.0,OTHER,lead,Chester Oddis,Phase 2
NCT02043548,2014.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT02043977,2013.0,OTHER,lead,Life Extension Foundation Inc.,Phase 1
NCT02044510,2014.0,OTHER,lead,Lawson Health Research Institute,Phase 2/Phase 3
NCT02045212,2014.0,INDUSTRY,lead,Regenera Pharma Ltd,Phase 2
NCT02045732,2014.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02046434,2014.0,OTHER,lead,"University of Colorado, Denver",Phase 1
NCT02046551,2014.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT02046551,2014.0,FED,collaborator,VA Office of Research and Development,Phase 1/Phase 2
NCT02046629,2014.0,INDUSTRY,lead,Sanofi,Phase 1
NCT02047864,2014.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT02048072,2013.0,OTHER,lead,Jochen Vehoff,Phase 4
NCT02048241,2011.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT02048241,2011.0,INDUSTRY,collaborator,Shire,Phase 4
NCT02048358,2013.0,INDUSTRY,lead,BBB-Therapeutics B.V.,Phase 1
NCT02048969,2014.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT02048969,2014.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1/Phase 2
NCT02049385,2014.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT02050152,2013.0,OTHER,lead,State University of New York at Buffalo,Not Applicable
NCT02050776,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02050971,2010.0,OTHER,lead,Pomeranian Medical University Szczecin,Phase 1
NCT02051062,2014.0,INDUSTRY,lead,Emergent BioSolutions,Phase 4
NCT02051335,2014.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT02051387,2013.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 1
NCT02051387,2013.0,OTHER,collaborator,University of Cologne,Phase 1
NCT02051608,2014.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT02051764,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT02051790,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 4
NCT02052024,2014.0,OTHER,lead,Georgetown University,Phase 4
NCT02052024,2014.0,INDUSTRY,collaborator,Solstice Neurosciences,Phase 4
NCT02052414,2012.0,OTHER,lead,"The Center for Clinical Research, Winston-Salem, NC",Not Applicable
NCT02052414,2012.0,INDUSTRY,collaborator,Depomed,Not Applicable
NCT02052791,2014.0,INDUSTRY,lead,Biogen,Phase 1
NCT02053883,2015.0,INDUSTRY,lead,"BioAxone BioSciences, Inc.",Phase 2/Phase 3
NCT02054091,2014.0,OTHER,lead,Per Torp Sangild,Not Applicable
NCT02054208,2014.0,INDUSTRY,lead,Medipost Co Ltd.,Phase 1/Phase 2
NCT02054702,2014.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT02054702,2014.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT02054949,2013.0,OTHER,lead,Nationwide Children's Hospital,Not Applicable
NCT02055118,2014.0,INDUSTRY,lead,Shire,Phase 2/Phase 3
NCT02055274,2013.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT02055287,2013.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT02055638,2014.0,INDUSTRY,lead,Azevan Pharmaceuticals,Phase 1/Phase 2
NCT02055898,2014.0,OTHER,lead,Imperial College London,Phase 4
NCT02055898,2014.0,OTHER_GOV,collaborator,Medical Research Council,Phase 4
NCT02056106,2013.0,OTHER,lead,RAND,Phase 4
NCT02056171,2015.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1/Phase 2
NCT02056236,2014.0,OTHER,lead,University of Twente,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Rijnstate Hospital,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Medisch Spectrum Twente,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Radboud University Medical Center,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,University Medical Center Groningen,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,St. Antonius Hospital,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,VieCuri Medical Centre,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Université Libre de Bruxelles,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Maasstad Hospital,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Maastricht University Medical Center,Not Applicable
NCT02056236,2014.0,OTHER,collaborator,Canisius-Wilhelmina Hospital,Not Applicable
NCT02056574,2015.0,INDUSTRY,lead,NoNO Inc.,Phase 2
NCT02056665,2014.0,OTHER,lead,Puerta de Hierro University Hospital,Phase 2
NCT02056678,2014.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT02056808,2013.0,INDUSTRY,lead,Summit Therapeutics,Phase 1
NCT02057159,2020.0,INDUSTRY,lead,"Immune Response BioPharma, Inc.",Phase 2/Phase 3
NCT02057159,2020.0,AMBIG,collaborator,cro,Phase 2/Phase 3
NCT02057315,2014.0,INDUSTRY,lead,Achelios Therapeutics,Phase 1/Phase 2
NCT02057406,2014.0,OTHER,lead,Wei Jiang,Phase 3
NCT02057406,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT02058264,2014.0,INDUSTRY,lead,Botanix Pharmaceuticals,Phase 1
NCT02058823,2013.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT02058823,2013.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 4
NCT02058940,2015.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT02058940,2015.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT02058940,2015.0,INDUSTRY,collaborator,Medtronic,Phase 4
NCT02059070,2012.0,OTHER,lead,Anesthesiology WSU/DMC-NorthStar,Not Applicable
NCT02059070,2012.0,OTHER,collaborator,Wayne State University,Not Applicable
NCT02059733,2013.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT02059759,2015.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Phase 2
NCT02060084,2014.0,INDUSTRY,lead,Wang Hua,Phase 4
NCT02060383,2014.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT02061137,2013.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1/Phase 2
NCT02061137,2013.0,INDUSTRY,collaborator,Novartis,Phase 1/Phase 2
NCT02061397,2014.0,OTHER,lead,University of Pennsylvania,Phase 1/Phase 2
NCT02061397,2014.0,OTHER,collaborator,The LAM Foundation,Phase 1/Phase 2
NCT02061514,2014.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT02061514,2014.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Not Applicable
NCT02061878,2014.0,INDUSTRY,lead,"ReXceptor, Inc.",Phase 1
NCT02062086,2014.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT02062099,2014.0,OTHER,lead,"University Hospital, Tours",Phase 1
NCT02062190,2014.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 2
NCT02062190,2014.0,OTHER_GOV,collaborator,Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Phase 2
NCT02062333,2014.0,OTHER,lead,TC Erciyes University,Phase 4
NCT02062658,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT02062658,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT02063126,2013.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 2/Phase 3
NCT02063126,2013.0,UNKNOWN,collaborator,"VITAE NATURAL NUTRITION, S.L.",Phase 2/Phase 3
NCT02063269,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02063269,2014.0,INDUSTRY,collaborator,Novartis Korea Ltd.,Not Applicable
NCT02063308,2014.0,OTHER,lead,"Russell Swerdlow, MD",Not Applicable
NCT02063425,2014.0,OTHER,lead,Centre Hospitalier St Anne,Not Applicable
NCT02064075,2013.0,OTHER,lead,University of Debrecen,Phase 4
NCT02064166,2014.0,OTHER,lead,Peter Novak,Phase 2
NCT02064465,2014.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT02064569,2014.0,INDUSTRY,lead,GenSight Biologics,Phase 1/Phase 2
NCT02064816,2014.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT02064920,2014.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT02065011,2013.0,INDUSTRY,lead,Sanofi,Phase 2
NCT02065349,2014.0,INDUSTRY,lead,Astellas Pharma Europe B.V.,Phase 2
NCT02065388,2009.0,OTHER,lead,"Academia Sinica, Taiwan",Phase 3
NCT02065388,2009.0,OTHER,collaborator,Chang Gung Memorial Hospital,Phase 3
NCT02065388,2009.0,OTHER,collaborator,China Medical University Hospital,Phase 3
NCT02065388,2009.0,OTHER,collaborator,Kaohsiung Medical University,Phase 3
NCT02065778,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02066220,2014.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 2/Phase 3
NCT02066220,2014.0,OTHER,collaborator,Deutsche Kinderkrebsstiftung,Phase 2/Phase 3
NCT02066558,2014.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT02066571,2015.0,OTHER,lead,Henry Ford Health System,Phase 2
NCT02066948,2014.0,OTHER,lead,Purdue University,Not Applicable
NCT02066948,2014.0,OTHER,collaborator,National Pork Board,Not Applicable
NCT02066948,2014.0,OTHER,collaborator,American Egg Board,Not Applicable
NCT02066948,2014.0,OTHER,collaborator,Dairy Research Institute,Not Applicable
NCT02066948,2014.0,OTHER,collaborator,National Cattlemen's Beef Association,Not Applicable
NCT02067975,2014.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2/Phase 3
NCT02067975,2014.0,INDUSTRY,collaborator,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT02067975,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2/Phase 3
NCT02068027,2014.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 2
NCT02068547,2014.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT02068547,2014.0,INDUSTRY,collaborator,Harvest Technologies,Not Applicable
NCT02068560,2012.0,OTHER,lead,University of Aarhus,Not Applicable
NCT02068560,2012.0,INDUSTRY,collaborator,Ferring Pharmaceuticals,Not Applicable
NCT02069197,2014.0,OTHER,lead,"Mid-Atlantic Epilepsy and Sleep Center, LLC",Phase 2
NCT02069314,2012.0,OTHER,lead,Purdue University,Not Applicable
NCT02069366,2014.0,OTHER,lead,Wayne State University,Not Applicable
NCT02069379,2014.0,OTHER,lead,University of Michigan,Phase 4
NCT02069379,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02069392,2015.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT02069392,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02070302,2014.0,OTHER,lead,Benjamin Sucher,Phase 2
NCT02070302,2014.0,INDUSTRY,collaborator,Allergan,Phase 2
NCT02070380,2014.0,INDUSTRY,lead,"Bracco Diagnostics, Inc",Phase 4
NCT02070783,2012.0,OTHER,lead,Leiden University Medical Center,Phase 1/Phase 2
NCT02071407,2013.0,OTHER,lead,Subei People's Hospital of Jiangsu Province,Phase 4
NCT02071459,2014.0,OTHER,lead,"University Hospital, Toulouse",Phase 2/Phase 3
NCT02072187,2013.0,OTHER,lead,START Clinic for Mood and Anxiety Disorders,Phase 3
NCT02072187,2013.0,OTHER,collaborator,The Canadian College of Naturopathic Medicine,Phase 3
NCT02072226,2014.0,INDUSTRY,lead,"Genentech, Inc.",Phase 3
NCT02072642,2013.0,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT02072954,2013.0,INDUSTRY,lead,"Amneal Pharmaceuticals, LLC",Phase 2/Phase 3
NCT02072954,2013.0,INDUSTRY,collaborator,Accutest Research Laboratories (I) Pvt. Ltd.,Phase 2/Phase 3
NCT02074319,2013.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 1
NCT02074319,2013.0,OTHER,collaborator,Abbasi Shaheed Hospital,Phase 1
NCT02074319,2013.0,OTHER,collaborator,Dow University of Health Sciences,Phase 1
NCT02074319,2013.0,UNKNOWN,collaborator,"Karwan e Hayat, Karachi, Pakistan",Phase 1
NCT02074319,2013.0,UNKNOWN,collaborator,"Institute of Behavioural Sciences, Karachi, Pakistan",Phase 1
NCT02074410,2014.0,INDUSTRY,lead,Omeros Corporation,Phase 2
NCT02075047,2014.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT02075528,2009.0,OTHER_GOV,lead,Taipei City Hospital,Phase 4
NCT02075528,2009.0,INDUSTRY,collaborator,Johnson & Johnson Taiwan Ltd,Phase 4
NCT02075528,2009.0,OTHER_GOV,collaborator,Taipei Institute of Pathology,Phase 4
NCT02076698,2014.0,OTHER,lead,"University Hospital, Grenoble",Phase 3
NCT02076945,2014.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Not Applicable
NCT02078180,2014.0,OTHER,lead,University of Michigan,Phase 4
NCT02078310,2014.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 1/Phase 2
NCT02078583,2014.0,OTHER,lead,Peking University People's Hospital,Phase 4
NCT02078791,2012.0,OTHER,lead,University Rovira i Virgili,Phase 4
NCT02078791,2012.0,OTHER_GOV,collaborator,Catalan Institute of Health,Phase 4
NCT02078791,2012.0,OTHER,collaborator,Universidad Nacional de Educación a Distancia,Phase 4
NCT02079246,2014.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02079766,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT02079844,2014.0,INDUSTRY,lead,Takeda,Phase 1
NCT02079909,2014.0,INDUSTRY,lead,"FUJIFILM Toyama Chemical Co., Ltd.",Phase 2
NCT02079909,2014.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT02080169,2014.0,OTHER,lead,Qilu Hospital of Shandong University,Phase 4
NCT02080169,2014.0,NETWORK,collaborator,Chinese Medical Association,Phase 4
NCT02080364,2015.0,INDUSTRY,lead,vTv Therapeutics,Phase 3
NCT02080559,2014.0,OTHER,lead,University of Oxford,Phase 4
NCT02080559,2014.0,OTHER_GOV,collaborator,Public Health England,Phase 4
NCT02080559,2014.0,OTHER,collaborator,Imperial College London,Phase 4
NCT02080559,2014.0,INDUSTRY,collaborator,Novartis Vaccines,Phase 4
NCT02080559,2014.0,OTHER,collaborator,European Commission,Phase 4
NCT02080819,2014.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT02080819,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02080832,2010.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT02080832,2010.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT02080832,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02081027,2013.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Early Phase 1
NCT02081287,2014.0,FED,lead,San Diego Veterans Healthcare System,Phase 1
NCT02081287,2014.0,OTHER,collaborator,The Depressive and Bipolar Disorder Alternative Treatment Foundation,Phase 1
NCT02081625,2013.0,OTHER,lead,"National Center of Neurology and Psychiatry, Japan",Phase 1
NCT02081625,2013.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 1
NCT02081885,2014.0,OTHER_GOV,lead,Instituto Mexicano del Seguro Social,Phase 3
NCT02081885,2014.0,OTHER,collaborator,Hospital Civil de Guadalajara,Phase 3
NCT02082327,2014.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1
NCT02082678,2014.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT02082678,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT02082912,2010.0,OTHER,lead,Emory University,Phase 2
NCT02083328,2014.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Not Applicable
NCT02083328,2014.0,OTHER,collaborator,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT02084134,2012.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT02084303,2014.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Not Applicable
NCT02084303,2014.0,OTHER,collaborator,American Epilepsy Society,Not Applicable
NCT02084927,2014.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Phase 1
NCT02085265,2014.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2
NCT02085265,2014.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT02085265,2014.0,OTHER,collaborator,Weston Brain Institute,Phase 2
NCT02086188,2014.0,OTHER,lead,"Theodore R. Brown, MD MPH",Phase 4
NCT02086188,2014.0,INDUSTRY,collaborator,Astellas Pharma Inc,Phase 4
NCT02086240,2014.0,OTHER,lead,Imperial College London,Not Applicable
NCT02086786,2014.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 2
NCT02086825,2015.0,OTHER,lead,NYU Langone Health,Phase 3
NCT02087397,2014.0,INDUSTRY,lead,Ageless Regenerative Institute,Phase 1/Phase 2
NCT02087579,2014.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT02087631,2014.0,OTHER,lead,University of Calgary,Phase 1/Phase 2
NCT02087631,2014.0,OTHER,collaborator,Multiple Sclerosis Society of Canada,Phase 1/Phase 2
NCT02087722,2013.0,INDUSTRY,lead,"Kuhnil Pharmaceutical Co., Ltd.",Phase 3
NCT02087722,2013.0,INDUSTRY,collaborator,Neurim Pharmaceuticals Ltd.,Phase 3
NCT02087813,2014.0,OTHER,lead,Stanford University,Phase 1
NCT02088060,2015.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 2
NCT02088060,2015.0,OTHER,collaborator,Martin-Luther-Universität Halle-Wittenberg,Phase 2
NCT02088060,2015.0,OTHER,collaborator,Heidelberg University,Phase 2
NCT02088060,2015.0,OTHER,collaborator,Technical University of Munich,Phase 2
NCT02088060,2015.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Phase 2
NCT02088060,2015.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Phase 2
NCT02088177,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT02088632,2014.0,OTHER,lead,Thomas Jefferson University,Phase 2
NCT02088632,2014.0,INDUSTRY,collaborator,"Merz North America, Inc.",Phase 2
NCT02088866,2014.0,OTHER,lead,"University of California, Davis",Early Phase 1
NCT02089594,2014.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Phase 3
NCT02089594,2014.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 3
NCT02090348,2015.0,INDUSTRY,lead,Biogen,Phase 4
NCT02090413,2014.0,INDUSTRY,lead,Biogen,Phase 4
NCT02090608,2012.0,OTHER,lead,Federico II University,Not Applicable
NCT02090725,2004.0,OTHER,lead,"Jeffrey A. Cohen, MD",Phase 2
NCT02090725,2004.0,INDUSTRY,collaborator,Jacobus Pharmaceutical,Phase 2
NCT02090829,2014.0,OTHER,lead,University of Minnesota,Phase 2
NCT02090829,2014.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT02090959,2014.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT02091206,2014.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02091375,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02091388,2014.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT02091739,2014.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT02092168,2008.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02092883,2013.0,OTHER,lead,Wayne State University,Phase 4
NCT02094053,2013.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 2
NCT02094352,2014.0,OTHER,lead,"Hospital for Special Surgery, New York",Phase 2
NCT02094729,2013.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 1
NCT02094833,2014.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02094898,2014.0,OTHER,lead,Mayo Clinic,Phase 2
NCT02095171,2014.0,INDUSTRY,lead,Prothena Biosciences Limited,Phase 1
NCT02095171,2014.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 1
NCT02095899,2014.0,OTHER,lead,University of Zurich,Phase 2
NCT02095938,2014.0,OTHER,lead,CHA University,Phase 4
NCT02095938,2014.0,INDUSTRY,collaborator,Handok Inc.,Phase 4
NCT02096068,2014.0,OTHER,lead,Claudia Spies,Phase 4
NCT02096133,2014.0,OTHER,lead,Academic MS Center Limburg,Phase 2
NCT02096263,2014.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT02096601,2014.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1/Phase 2
NCT02096601,2014.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1/Phase 2
NCT02096913,2013.0,OTHER,lead,"Jan M. Schwab, MD, PhD",Phase 1
NCT02096913,2013.0,OTHER,collaborator,Else Kröner Fresenius Foundation,Phase 1
NCT02096952,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02097056,2014.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT02097706,2015.0,OTHER,lead,The Alfred,Phase 2
NCT02098148,2013.0,OTHER,lead,Mclean Hospital,Phase 2
NCT02098330,2014.0,OTHER,lead,Asan Medical Center,Phase 3
NCT02098434,2010.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT02098499,2013.0,FED,lead,"United States Naval Medical Center, Portsmouth",Phase 4
NCT02098824,2014.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 2/Phase 3
NCT02099357,2014.0,OTHER,lead,Universidade do Porto,Not Applicable
NCT02099695,2015.0,INDUSTRY,lead,Cristália Produtos Químicos Farmacêuticos Ltda.,Phase 3
NCT02099695,2015.0,OTHER,collaborator,Hospital Israelita Albert Einstein,Phase 3
NCT02099695,2015.0,OTHER,collaborator,University of Sao Paulo,Phase 3
NCT02099786,2015.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT02099825,2014.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT02099890,2014.0,OTHER,lead,Brock University,Phase 3
NCT02099890,2014.0,OTHER,collaborator,Ontario Neurotrauma Foundation,Phase 3
NCT02099955,2012.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 1/Phase 2
NCT02100150,2014.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT02100644,2014.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT02100956,2014.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT02100969,2015.0,OTHER,lead,"Mazen Dimachkie, MD",Phase 2
NCT02100969,2015.0,INDUSTRY,collaborator,CSL Behring,Phase 2
NCT02101190,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02101203,2013.0,INDUSTRY,lead,Emotional Brain NY Inc.,Phase 2
NCT02101606,2009.0,OTHER,lead,University of Alberta,Phase 2
NCT02101736,2014.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT02101840,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02101840,2014.0,OTHER,collaborator,University of Toronto,Phase 4
NCT02101892,2014.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT02101892,2014.0,OTHER,collaborator,Migraine Research Foundation,Not Applicable
NCT02101957,2010.0,OTHER_GOV,lead,"University Hospital, Angers",Phase 2/Phase 3
NCT02102100,2014.0,OTHER,lead,Yale University,Not Applicable
NCT02102100,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02102113,2014.0,OTHER,lead,Yale University,Early Phase 1
NCT02102594,2014.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT02102594,2014.0,UNKNOWN,collaborator,"Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)",Phase 2
NCT02102594,2014.0,OTHER,collaborator,"NeuroCure Clinical Research Center, Charite, Berlin",Phase 2
NCT02102698,2014.0,INDUSTRY,lead,Psyadon Pharma,Phase 2
NCT02103465,2013.0,OTHER,lead,Azienda Ospedaliera Cardinale G. Panico,Phase 2
NCT02103621,2014.0,OTHER,lead,Butler Hospital,Not Applicable
NCT02103621,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02103842,2014.0,OTHER,lead,Mayo Clinic,Phase 1
NCT02103894,2014.0,OTHER,lead,Molecular NeuroImaging,Phase 1
NCT02103894,2014.0,OTHER,collaborator,Institute for Neurodegenerative Disorders,Phase 1
NCT02104011,2015.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT02104128,2014.0,OTHER,lead,University of Oxford,Not Applicable
NCT02104128,2014.0,INDUSTRY,collaborator,"Janssen Research & Development, LLC",Not Applicable
NCT02104323,2014.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT02104323,2014.0,INDUSTRY,collaborator,"Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd",Phase 2
NCT02104661,2014.0,OTHER,lead,Queen Mary University of London,Phase 2
NCT02104661,2014.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT02104661,2014.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT02104661,2014.0,OTHER,collaborator,Barts & The London NHS Trust,Phase 2
NCT02104661,2014.0,OTHER,collaborator,"University College, London",Phase 2
NCT02104661,2014.0,OTHER,collaborator,Royal Free Hospital NHS Foundation Trust,Phase 2
NCT02104661,2014.0,OTHER,collaborator,Mid and South Essex NHS Foundation Trust,Phase 2
NCT02104661,2014.0,OTHER,collaborator,St George's Healthcare NHS Trust,Phase 2
NCT02104661,2014.0,OTHER,collaborator,Barnet and Chase Farm Hospitals NHS Trust,Phase 2
NCT02104752,2014.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 1/Phase 2
NCT02104752,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1/Phase 2
NCT02104752,2014.0,INDUSTRY,collaborator,"Theravalues, Inc.",Phase 1/Phase 2
NCT02104752,2014.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1/Phase 2
NCT02104765,2014.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02105233,2014.0,OTHER,lead,St. Olavs Hospital,Phase 1
NCT02105233,2014.0,UNKNOWN,collaborator,National Competence Services for Ultrasound and Image-guided Therapy,Phase 1
NCT02105233,2014.0,OTHER,collaborator,SINTEF Health Research,Phase 1
NCT02105922,2014.0,OTHER,lead,Bispebjerg Hospital,Not Applicable
NCT02105922,2014.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02105922,2014.0,INDUSTRY,collaborator,Arla Foods,Not Applicable
NCT02106325,2013.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02107014,2014.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT02107014,2014.0,OTHER,collaborator,Stanford University,Not Applicable
NCT02107118,2015.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT02107261,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT02107261,2014.0,INDUSTRY,collaborator,"Merz North America, Inc.",Phase 2
NCT02107469,2014.0,OTHER,lead,Rosenberg European Academy of Ayurveda,Not Applicable
NCT02107469,2014.0,UNKNOWN,collaborator,EUROPEAN PROFESSIONAL ASSOCIATION OF AYURVEDA PRACTITIONERS AND THERAPISTS,Not Applicable
NCT02107599,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 4
NCT02107846,2014.0,INDUSTRY,lead,Protalix,Phase 2
NCT02108210,2014.0,OTHER,lead,Radboud University Medical Center,Phase 2/Phase 3
NCT02108353,2015.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 3
NCT02108626,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02108704,2013.0,OTHER,lead,University of Malaya,Not Applicable
NCT02108795,2014.0,OTHER,lead,Yeungnam University College of Medicine,Not Applicable
NCT02108990,2013.0,OTHER,lead,Ohio State University,Phase 2
NCT02108990,2013.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 2
NCT02108990,2013.0,NIH,collaborator,National Center for Research Resources (NCRR),Phase 2
NCT02109081,2014.0,OTHER,lead,NorthShore University HealthSystem,Phase 4
NCT02109562,2014.0,INDUSTRY,lead,Indivior Inc.,Phase 3
NCT02110706,2014.0,OTHER,lead,Yale University,Phase 2
NCT02110706,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02111044,2014.0,INDUSTRY,lead,Italfarmaco,Phase 2
NCT02111135,2014.0,OTHER,lead,Vaxtrials S.A.,Phase 2
NCT02111135,2014.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT02111200,2014.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT02111330,2014.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1
NCT02111330,2014.0,INDUSTRY,collaborator,"Palo Biofarma, S.L",Phase 1
NCT02111369,2014.0,OTHER,lead,Emory University,Phase 4
NCT02111785,2014.0,OTHER,lead,University of Virginia,Phase 2/Phase 3
NCT02111798,2014.0,OTHER,lead,Johns Hopkins University,Phase 2/Phase 3
NCT02111798,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT02113358,2014.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT02113787,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02114736,2014.0,OTHER,lead,University Hospital of Mont-Godinne,Phase 4
NCT02114775,2014.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 1
NCT02115698,2014.0,OTHER,lead,Bispebjerg Hospital,Not Applicable
NCT02115698,2014.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02115698,2014.0,INDUSTRY,collaborator,Arla Foods,Not Applicable
NCT02116634,2015.0,OTHER,lead,"Alzahra Hospital, Iran",Phase 1/Phase 2
NCT02117050,2014.0,INDUSTRY,lead,EMD Serono,Phase 4
NCT02117076,2014.0,OTHER,lead,"Theresa Zesiewicz, MD",Phase 4
NCT02117635,2014.0,INDUSTRY,lead,ReNeuron Limited,Phase 2
NCT02117726,2014.0,OTHER_GOV,lead,Shandong Provincial Hospital,Phase 4
NCT02118610,2014.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT02118610,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT02118688,2011.0,OTHER,lead,Rochester General Hospital,Phase 4
NCT02118727,2018.0,OTHER,lead,University of Kansas Medical Center,Phase 2
NCT02118727,2018.0,OTHER,collaborator,University of Missouri-Columbia,Phase 2
NCT02119806,2017.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT02120664,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02120690,2014.0,OTHER,lead,Santa Casa Medical School,Phase 1/Phase 2
NCT02122393,2002.0,OTHER,lead,University of Melbourne,Phase 3
NCT02122393,2002.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT02123056,2014.0,OTHER,lead,University of Calgary,Phase 4
NCT02123056,2014.0,OTHER,collaborator,Vanderbilt University,Phase 4
NCT02123355,2014.0,OTHER,lead,Shaanxi Provincial People's Hospital,Phase 4
NCT02123355,2014.0,NETWORK,collaborator,Chinese Medical Association,Phase 4
NCT02123849,2014.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT02124070,2014.0,NIH,lead,National Human Genome Research Institute (NHGRI),Phase 1/Phase 2
NCT02124330,2013.0,OTHER,lead,Luca Ronfani,Not Applicable
NCT02124330,2013.0,OTHER,collaborator,University of Trieste,Not Applicable
NCT02124564,2014.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT02124811,2015.0,OTHER,lead,Emory University,Phase 4
NCT02124941,2014.0,OTHER,lead,Yale University,Phase 1
NCT02124941,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02125604,2014.0,INDUSTRY,lead,Biogen,Phase 4
NCT02126995,2014.0,INDUSTRY,lead,Alcobra Ltd.,Phase 2
NCT02127476,2014.0,INDUSTRY,lead,"Kyowa Hakko Kirin Pharma, Inc.",Phase 1
NCT02127853,2014.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02128828,2014.0,OTHER,lead,University of Hawaii,Phase 2
NCT02128828,2014.0,INDUSTRY,collaborator,"Tobira Therapeutics, Inc.",Phase 2
NCT02129348,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT02129348,2014.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02129647,2014.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02129660,2014.0,INDUSTRY,lead,Journey Medical Corporation,Phase 2
NCT02130258,2012.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT02130661,2017.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT02130674,2005.0,OTHER,lead,University of Zurich,Phase 4
NCT02130674,2005.0,OTHER,collaborator,Swiss National Science Foundation,Phase 4
NCT02130674,2005.0,INDUSTRY,collaborator,Fresenius Kabi,Phase 4
NCT02130674,2005.0,OTHER,collaborator,"University Hospital, Zürich",Phase 4
NCT02131545,2014.0,OTHER,lead,Mayo Clinic,Phase 1
NCT02132429,2014.0,INDUSTRY,lead,Amgen,Phase 1
NCT02133573,2014.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 2
NCT02133638,2014.0,OTHER_GOV,lead,Negovsky Reanimatology Research Institute,Phase 4
NCT02133664,2014.0,OTHER,lead,Oregon Health and Science University,Phase 1/Phase 2
NCT02133664,2014.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1/Phase 2
NCT02133898,2016.0,OTHER,lead,University of Florida,Not Applicable
NCT02133898,2016.0,INDUSTRY,collaborator,"Pamlab, Inc.",Not Applicable
NCT02133989,2014.0,OTHER,lead,Samsung Medical Center,Phase 3
NCT02133989,2014.0,INDUSTRY,collaborator,"Yuyu Pharma, Inc.",Phase 3
NCT02134002,2014.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT02134002,2014.0,OTHER,collaborator,"National Research Agency, France",Phase 4
NCT02134080,2014.0,OTHER,lead,Yale University,Phase 1
NCT02134080,2014.0,OTHER,collaborator,Tourette Association of America,Phase 1
NCT02134366,2014.0,OTHER,lead,The Cooper Health System,Phase 3
NCT02134366,2014.0,INDUSTRY,collaborator,Lundbeck LLC,Phase 3
NCT02135900,2009.0,OTHER,lead,Northwell Health,Phase 2
NCT02135900,2009.0,OTHER,collaborator,Staten Island University Hospital,Phase 2
NCT02136030,2011.0,INDUSTRY,lead,TTY Biopharm,Not Applicable
NCT02136914,2014.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT02137369,2014.0,OTHER,lead,Emory University,Phase 4
NCT02137369,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02137616,2012.0,OTHER,lead,Central South University,Not Applicable
NCT02137993,2012.0,INDUSTRY,lead,HK inno.N Corporation,Phase 4
NCT02138006,1982.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT02138357,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02139540,2012.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT02140632,2013.0,OTHER,lead,Kwong Wah Hospital,Phase 4
NCT02140788,2011.0,OTHER,lead,Duke University,Phase 4
NCT02140983,2013.0,OTHER,lead,Stanford University,Phase 1
NCT02140983,2013.0,OTHER,collaborator,American Diabetes Association,Phase 1
NCT02141022,2013.0,OTHER,lead,Stony Brook University,Not Applicable
NCT02141022,2013.0,INDUSTRY,collaborator,Novartis,Not Applicable
NCT02141035,2015.0,OTHER,lead,University of Alberta,Phase 2/Phase 3
NCT02141620,2014.0,OTHER,lead,University of Kentucky,Early Phase 1
NCT02141620,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT02142205,2012.0,INDUSTRY,lead,Biogen,Phase 4
NCT02142556,2008.0,OTHER,lead,Tri-Service General Hospital,Phase 3
NCT02142556,2008.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT02142712,2014.0,OTHER,lead,University of Florida,Phase 2
NCT02142764,2014.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT02142764,2014.0,INDUSTRY,collaborator,Merck Serono International SA,Not Applicable
NCT02142764,2014.0,UNKNOWN,collaborator,ADERA,Not Applicable
NCT02142777,2014.0,OTHER,lead,"Russell Swerdlow, MD",Phase 1
NCT02142777,2014.0,INDUSTRY,collaborator,"Ausio Pharmaceuticals, LLC",Phase 1
NCT02143167,2014.0,OTHER,lead,University of Southern Denmark,Phase 4
NCT02143167,2014.0,OTHER,collaborator,Region of Southern Denmark,Phase 4
NCT02143167,2014.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT02144155,2012.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02144688,2011.0,OTHER,lead,Marie-Josée Brouillette,Early Phase 1
NCT02144688,2011.0,OTHER_GOV,collaborator,Fonds de la Recherche en Santé du Québec,Early Phase 1
NCT02144688,2011.0,NETWORK,collaborator,CIHR Canadian HIV Trials Network,Early Phase 1
NCT02144792,2013.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT02144831,2014.0,OTHER,lead,University of Alberta,Phase 4
NCT02145676,2014.0,INDUSTRY,lead,Allergan,Phase 3
NCT02145689,2014.0,INDUSTRY,lead,Allergan,Phase 3
NCT02145949,2014.0,OTHER,lead,University of Oregon,Phase 2
NCT02145949,2014.0,UNKNOWN,collaborator,Slocum Center for Orthopedics and Sports Medicine,Phase 2
NCT02145949,2014.0,OTHER,collaborator,Slocum Research & Education Foundation,Phase 2
NCT02145949,2014.0,OTHER,collaborator,Oregon Research Institute,Phase 2
NCT02145949,2014.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT02145949,2014.0,OTHER,collaborator,University of Arkansas,Phase 2
NCT02145949,2014.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02146534,2013.0,OTHER,lead,Clinique Neuro-Outaouais,Phase 4
NCT02146534,2013.0,INDUSTRY,collaborator,CogState Ltd.,Phase 4
NCT02146547,2015.0,OTHER,lead,UMC Utrecht,Phase 4
NCT02146911,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT02146911,2014.0,UNKNOWN,collaborator,Global Research Awards for Nicotine Dependence (GRAND),Not Applicable
NCT02147561,2014.0,INDUSTRY,lead,Allergan,Phase 4
NCT02148367,2014.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 2
NCT02148367,2014.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT02148432,2014.0,OTHER,lead,Yonsei University,Not Applicable
NCT02148445,2014.0,OTHER,lead,University of Kansas Medical Center,Phase 3
NCT02148445,2014.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 3
NCT02148783,2014.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 2
NCT02148783,2014.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT02149017,2010.0,OTHER,lead,Seoul National University Hospital,Phase 1/Phase 2
NCT02149459,2014.0,OTHER_GOV,lead,Sheba Medical Center,Phase 1
NCT02149459,2014.0,OTHER,collaborator,European Union,Phase 1
NCT02149706,2020.0,INDUSTRY,lead,"Immune Response BioPharma, Inc.",Phase 2
NCT02149706,2020.0,AMBIG,collaborator,cro,Phase 2
NCT02149823,2013.0,OTHER,lead,Maria de las Mercedes Perez Rodriguez,Phase 1
NCT02149823,2013.0,FED,collaborator,James J. Peters Veterans Affairs Medical Center,Phase 1
NCT02149823,2013.0,FED,collaborator,"VISN 3 Mental Illness Research, Education and Clinical Center",Phase 1
NCT02149836,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT02149901,2014.0,OTHER,lead,Vanderbilt University,Early Phase 1
NCT02149901,2014.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT02149901,2014.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Early Phase 1
NCT02151162,2014.0,OTHER,lead,"National Center of Neurology and Psychiatry, Japan",Not Applicable
NCT02151591,2017.0,OTHER,lead,Yale University,Phase 1
NCT02151591,2017.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1
NCT02151656,2014.0,INDUSTRY,lead,Pierre Fabre Medicament,Phase 2
NCT02152280,2014.0,INDUSTRY,lead,"Beijing Bozhiyin T&S Co., Ltd.",Phase 4
NCT02152670,2014.0,OTHER,lead,Yale University,Not Applicable
NCT02152787,2014.0,OTHER,lead,Yonsei University,Not Applicable
NCT02153567,2013.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT02153632,2014.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT02153645,2014.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT02153723,2013.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT02153723,2013.0,OTHER,collaborator,Rett Syndrome Research Trust,Phase 2
NCT02153944,2014.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 4
NCT02154243,2014.0,OTHER,lead,"Hospital for Special Surgery, New York",Not Applicable
NCT02155361,2014.0,OTHER,lead,Shiraz University of Medical Sciences,Phase 1/Phase 2
NCT02155829,2013.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 1/Phase 2
NCT02155829,2013.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 1/Phase 2
NCT02155972,2013.0,OTHER,lead,Women's College Hospital,Phase 2
NCT02156908,2014.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT02157532,2013.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Not Applicable
NCT02157714,2014.0,INDUSTRY,lead,Prothena Biosciences Limited,Phase 1
NCT02157714,2014.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 1
NCT02158182,2014.0,OTHER_GOV,lead,Hospital General de Mexico,Phase 4
NCT02159027,2015.0,OTHER,lead,University of Hawaii,Phase 2/Phase 3
NCT02159027,2015.0,INDUSTRY,collaborator,ViiV Healthcare,Phase 2/Phase 3
NCT02159027,2015.0,OTHER,collaborator,University of Puerto Rico,Phase 2/Phase 3
NCT02159547,2014.0,OTHER,lead,Akdeniz University,Phase 4
NCT02160223,2012.0,OTHER,lead,Diskapi Teaching and Research Hospital,Phase 4
NCT02161055,2014.0,OTHER,lead,Lianyungang Oriental Hospital,Phase 4
NCT02161055,2014.0,OTHER,collaborator,The First People's Hospital of Lianyungang,Phase 4
NCT02161185,2014.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT02161380,2014.0,OTHER,lead,Byron Lam,Phase 1
NCT02161380,2014.0,NIH,collaborator,National Eye Institute (NEI),Phase 1
NCT02161718,2014.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 2
NCT02162433,2015.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Phase 4
NCT02162979,2002.0,OTHER,lead,Loma Linda University,Phase 2
NCT02163837,2014.0,OTHER,lead,Centre Hospitalier Universitaire Saint Pierre,Not Applicable
NCT02163993,2014.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT02164383,2014.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT02164383,2014.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT02164981,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02164981,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT02165306,2014.0,OTHER,lead,Qazvin University Of Medical Sciences,Not Applicable
NCT02165644,2015.0,OTHER,lead,University of Florida,Phase 2
NCT02165904,2014.0,OTHER,lead,Puerta de Hierro University Hospital,Phase 1
NCT02166346,2014.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT02166346,2014.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 2
NCT02166424,2014.0,OTHER,lead,Tokyo Medical University,Phase 3
NCT02166424,2014.0,OTHER,collaborator,"China Medical University, Taiwan",Phase 3
NCT02166424,2014.0,UNKNOWN,collaborator,Japan Society for the Promotion of Science (JSPS),Phase 3
NCT02166424,2014.0,OTHER,collaborator,University of Toyama,Phase 3
NCT02166424,2014.0,OTHER,collaborator,Chiba University,Phase 3
NCT02166424,2014.0,UNKNOWN,collaborator,National Center for Child Health and Development,Phase 3
NCT02166944,2014.0,OTHER,lead,Taipei Medical University Shuang Ho Hospital,Phase 1/Phase 2
NCT02167217,2014.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT02167217,2014.0,OTHER,collaborator,Nationwide Children's Hospital,Phase 2
NCT02167217,2014.0,OTHER,collaborator,Northwestern University Feinberg School of Medicine,Phase 2
NCT02167217,2014.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT02167217,2014.0,OTHER,collaborator,"University of California, Davis",Phase 2
NCT02167217,2014.0,UNKNOWN,collaborator,"Nemours Hospital, Orlando, FL",Phase 2
NCT02167256,2014.0,OTHER,lead,Yale University,Phase 2
NCT02167256,2014.0,OTHER,collaborator,Alzheimer's Therapeutic Research Institute,Phase 2
NCT02167594,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02167620,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02167633,2014.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT02167724,2014.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT02168075,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02168829,2016.0,OTHER,lead,Ottawa Heart Institute Research Corporation,Phase 4
NCT02168829,2016.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 4
NCT02168829,2016.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT02168829,2016.0,INDUSTRY,collaborator,Biotronik Canada Inc,Phase 4
NCT02168842,2014.0,OTHER,lead,University of Rochester,Phase 3
NCT02168842,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT02168842,2014.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 3
NCT02168842,2014.0,NETWORK,collaborator,The Parkinson Study Group,Phase 3
NCT02169167,2014.0,OTHER,lead,Janne J. Jokinen,Not Applicable
NCT02169167,2014.0,INDUSTRY,collaborator,Repolar Ltd.,Not Applicable
NCT02169219,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02169219,2014.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT02169271,2014.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT02169310,2014.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02169310,2014.0,FED,collaborator,Uniformed Services University of the Health Sciences,Phase 1
NCT02169830,2014.0,OTHER,lead,St. Louis University,Not Applicable
NCT02169843,2014.0,OTHER,lead,Tang-Du Hospital,Phase 4
NCT02169882,2014.0,OTHER,lead,Universitas Padjadjaran,Phase 2/Phase 3
NCT02169882,2014.0,FED,collaborator,United States Agency for International Development (USAID),Phase 2/Phase 3
NCT02169882,2014.0,OTHER,collaborator,Radboud University Medical Center,Phase 2/Phase 3
NCT02170064,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT02170077,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT02170415,2014.0,OTHER,lead,Royal Marsden NHS Foundation Trust,Not Applicable
NCT02170415,2014.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Not Applicable
NCT02170415,2014.0,OTHER,collaborator,"Institute of Cancer Research, United Kingdom",Not Applicable
NCT02170649,2001.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02171104,2014.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2
NCT02171195,2000.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02171234,2001.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02171988,2014.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02172573,1999.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02172742,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02172755,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02173132,2010.0,OTHER,lead,University of Catania,Phase 3
NCT02174250,2014.0,INDUSTRY,lead,"Kyowa Hakko Kirin Pharma, Inc.",Phase 1
NCT02174510,2014.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 1
NCT02174510,2014.0,OTHER,collaborator,"Xuhui Central Hospital, Shanghai",Phase 1
NCT02174523,2014.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 1
NCT02174523,2014.0,OTHER,collaborator,"Xuhui Central Hospital, Shanghai",Phase 1
NCT02174848,2014.0,INDUSTRY,lead,ApoPharma,Phase 3
NCT02175004,2014.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 3
NCT02175225,2014.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT02175225,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02175225,2014.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT02175225,2014.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Duke University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of North Carolina,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Florida,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Henry Ford Hospital,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Ohio State University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT02175225,2014.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT02175225,2014.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Yale New Haven Health System Center for Healthcare Solutions,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Iowa,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Hartford Hospital,Phase 2
NCT02175225,2014.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT02175225,2014.0,OTHER,collaborator,Rhode Island Hospital,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Stanford University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Washington,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Calgary,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Hopital de l'Enfant-Jesus,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University of Alberta,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Rush University Medical Center,Phase 2
NCT02175225,2014.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Columbia University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 2
NCT02175225,2014.0,OTHER,collaborator,NYU Langone Health,Phase 2
NCT02175225,2014.0,OTHER,collaborator,"Mount Sinai Hospital, New York",Phase 2
NCT02175225,2014.0,OTHER,collaborator,Loyola University,Phase 2
NCT02176044,2014.0,OTHER,lead,King's College London,Phase 1
NCT02176291,2014.0,OTHER,lead,Jordan F. Karp,Phase 2
NCT02176291,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT02176317,2014.0,OTHER,lead,Duke University,Phase 1
NCT02176317,2014.0,OTHER,collaborator,The Marcus Foundation,Phase 1
NCT02176317,2014.0,INDUSTRY,collaborator,"PerkinElmer, Inc.",Phase 1
NCT02176395,2014.0,OTHER,lead,China Academy of Chinese Medical Sciences,Phase 4
NCT02176395,2014.0,OTHER_GOV,collaborator,China Food and Drug Administration,Phase 4
NCT02176733,2011.0,OTHER_GOV,lead,"University Hospital, Angers",Phase 2
NCT02176837,2014.0,INDUSTRY,lead,Hope Pharmaceuticals,Phase 2
NCT02177357,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02177825,2014.0,OTHER,lead,St. Justine's Hospital,Phase 2
NCT02178124,2014.0,INDUSTRY,lead,Icure Pharmaceutical Inc.,Phase 1
NCT02178696,2011.0,OTHER,lead,University of Michigan,Phase 4
NCT02178813,2014.0,OTHER,lead,University of Pittsburgh,Phase 1
NCT02178826,2014.0,OTHER,lead,Uppsala University Hospital,Not Applicable
NCT02178826,2014.0,OTHER_GOV,collaborator,Örebro County Council,Not Applicable
NCT02178826,2014.0,OTHER_GOV,collaborator,"Uppsala County Council, Sweden",Not Applicable
NCT02178995,2014.0,OTHER,lead,Kimford Jay Meador,Phase 4
NCT02179151,2014.0,INDUSTRY,lead,"Zafgen, Inc.",Phase 3
NCT02179775,2014.0,OTHER,lead,Shiraz University of Medical Sciences,Not Applicable
NCT02179814,2012.0,OTHER,lead,University of Bern,Not Applicable
NCT02179814,2012.0,OTHER,collaborator,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT02179814,2012.0,OTHER,collaborator,University of Zurich,Not Applicable
NCT02180672,2014.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 3
NCT02180672,2014.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT02180867,2014.0,NIH,lead,National Cancer Institute (NCI),Phase 2/Phase 3
NCT02180880,2012.0,OTHER,lead,Ju Seok Ryu,Phase 4
NCT02181205,2014.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT02181231,2016.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT02181231,2016.0,INDUSTRY,collaborator,Reckitt Benckiser LLC,Phase 1/Phase 2
NCT02181491,2014.0,OTHER,lead,Yale University,Not Applicable
NCT02181803,2014.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT02183220,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02183233,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02183272,2016.0,OTHER,lead,University of Cincinnati,Phase 2/Phase 3
NCT02183519,2014.0,OTHER,lead,University of Florida,Phase 1/Phase 2
NCT02183688,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02183714,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02184260,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT02184494,2014.0,OTHER,lead,Florida State University,Not Applicable
NCT02185053,2014.0,INDUSTRY,lead,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Phase 2
NCT02185222,2014.0,OTHER,lead,"University Hospital, Tours",Phase 3
NCT02185651,2016.0,OTHER,lead,University of Florida,Phase 1
NCT02185651,2016.0,INDUSTRY,collaborator,Amicus Therapeutics,Phase 1
NCT02186366,2014.0,OTHER,lead,Sun Qing,Not Applicable
NCT02186769,2014.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT02187679,2014.0,OTHER,lead,Detroit Clinical Research Center,Not Applicable
NCT02187679,2014.0,INDUSTRY,collaborator,Ipsen,Not Applicable
NCT02188121,2015.0,OTHER,lead,Mclean Hospital,Phase 4
NCT02188121,2015.0,UNKNOWN,collaborator,Michael J. Gill Mental Health Clinic,Phase 4
NCT02188121,2015.0,UNKNOWN,collaborator,The Massachusetts Mental Health Center,Phase 4
NCT02188121,2015.0,UNKNOWN,collaborator,Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital,Phase 4
NCT02188121,2015.0,UNKNOWN,collaborator,"The Edinburg Center, Bedford MA",Phase 4
NCT02188277,2014.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 2
NCT02188277,2014.0,UNKNOWN,collaborator,"LLC Merz Pharma, Russia",Phase 2
NCT02188459,2014.0,OTHER,lead,Henry Kranzler,Phase 2
NCT02188849,2014.0,OTHER,lead,University of Chile,Phase 3
NCT02189213,2014.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT02189213,2014.0,OTHER,collaborator,Columbia University,Not Applicable
NCT02189811,2014.0,OTHER,lead,Aga Khan University,Phase 4
NCT02189811,2014.0,OTHER,collaborator,World Health Organization,Phase 4
NCT02189811,2014.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT02189811,2014.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT02189915,2012.0,OTHER,lead,Perry Renshaw,Not Applicable
NCT02189928,2015.0,OTHER,lead,Versailles Hospital,Not Applicable
NCT02189928,2015.0,UNKNOWN,collaborator,Unité de Recherche Clinique Paris IDF Ouest,Not Applicable
NCT02190760,2014.0,OTHER_GOV,lead,Hillel Yaffe Medical Center,Not Applicable
NCT02190994,2013.0,OTHER,lead,West China Hospital,Phase 4
NCT02191267,2015.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02191267,2015.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT02191267,2015.0,OTHER,collaborator,Boston University,Phase 2
NCT02191488,2014.0,OTHER,lead,David W. Roberts,Phase 1
NCT02191488,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02191579,2014.0,INDUSTRY,lead,Allergan,Phase 4
NCT02192320,2014.0,OTHER,lead,Oriental Neurosurgery Evidence-Based-Study Team,Phase 2
NCT02192684,2010.0,OTHER,lead,Stanford University,Not Applicable
NCT02192723,2012.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT02192814,2014.0,INDUSTRY,lead,UCB Japan Co. Ltd.,Phase 3
NCT02192814,2014.0,INDUSTRY,collaborator,Parexel,Phase 3
NCT02192931,2014.0,OTHER,lead,Perry Renshaw,Phase 4
NCT02193074,2014.0,INDUSTRY,lead,Biogen,Phase 3
NCT02193139,2013.0,INDUSTRY,lead,Watson Pharmaceuticals,Phase 2
NCT02193334,2014.0,INDUSTRY,lead,"Kringle Pharma, Inc.",Phase 1/Phase 2
NCT02193347,2016.0,OTHER,lead,"Katy Peters, MD, PhD",Phase 1
NCT02193698,2014.0,OTHER,lead,Chiba University,Phase 2
NCT02194075,2013.0,OTHER,lead,Guangdong Provincial People's Hospital,Phase 4
NCT02194985,2015.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT02195661,2014.0,OTHER,lead,University of Cape Town,Phase 3
NCT02195700,2014.0,INDUSTRY,lead,"Auspex Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT02195791,2014.0,OTHER,lead,Taipei Medical University Shuang Ho Hospital,Phase 2
NCT02195895,2014.0,OTHER,lead,Northwestern University,Phase 2
NCT02196142,2014.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 3
NCT02196467,2014.0,OTHER,lead,CHU de Quebec-Universite Laval,Phase 1/Phase 2
NCT02196506,2014.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT02196506,2014.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT02196883,2014.0,OTHER,lead,State University of New York - Upstate Medical University,Not Applicable
NCT02197130,2014.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02197286,2015.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02197286,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT02197286,2015.0,OTHER,collaborator,Columbia University,Phase 2
NCT02198248,2014.0,OTHER,lead,Chiba University,Phase 4
NCT02198339,1999.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02198794,2014.0,INDUSTRY,lead,"Auspex Pharmaceuticals, Inc.",Phase 3
NCT02199652,2014.0,OTHER,lead,Augusta University,Phase 4
NCT02199691,2014.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT02199743,2013.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT02199743,2013.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT02199847,2000.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02200185,2012.0,OTHER,lead,University of Monastir,Not Applicable
NCT02200406,2014.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 4
NCT02200406,2014.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT02200718,2020.0,INDUSTRY,lead,"Immune Response BioPharma, Inc.",Phase 1
NCT02201108,2014.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT02201212,2014.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 2
NCT02201212,2014.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT02201251,2014.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT02201849,2014.0,INDUSTRY,lead,Biogen,Phase 1
NCT02202213,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02202226,2013.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02202499,2014.0,OTHER,lead,H. Lee Moffitt Cancer Center and Research Institute,Early Phase 1
NCT02202499,2014.0,OTHER,collaborator,James and Esther King Biomedical Research Program,Early Phase 1
NCT02202499,2014.0,INDUSTRY,collaborator,Pfizer,Early Phase 1
NCT02202551,2014.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT02203552,2015.0,OTHER,lead,Ohio State University Comprehensive Cancer Center,Phase 2
NCT02203786,2009.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT02203786,2009.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT02203838,2014.0,INDUSTRY,lead,Indivior Inc.,Phase 3
NCT02204163,2014.0,INDUSTRY,lead,LG Life Sciences,Phase 3
NCT02204969,2015.0,OTHER,lead,American Society Of Thermalism And Climatology Inc,Phase 1/Phase 2
NCT02205034,2013.0,OTHER,lead,"University Hospital, Toulouse",Phase 1/Phase 2
NCT02205099,2014.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 1/Phase 2
NCT02205502,2013.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02205931,2015.0,OTHER,lead,"University College, London",Phase 4
NCT02205931,2015.0,OTHER,collaborator,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Cambridge University Hospitals NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Alder Hey Children's NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Bristol Royal Hospital for Children,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Birmingham Women's and Children's NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,The Leeds Teaching Hospitals NHS Trust,Phase 4
NCT02205931,2015.0,OTHER_GOV,collaborator,Manchester University NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Sheffield Children's NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 4
NCT02205931,2015.0,NETWORK,collaborator,Lancashire Care NHS Foundation Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,Newcastle-upon-Tyne Hospitals NHS Trust,Phase 4
NCT02205931,2015.0,OTHER,collaborator,St George's University Hospitals NHS Foundation Trust,Phase 4
NCT02206620,2014.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT02206620,2014.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT02206776,2014.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT02207387,2013.0,OTHER,lead,University of British Columbia,Not Applicable
NCT02207387,2013.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Not Applicable
NCT02208466,2014.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 2
NCT02208492,2011.0,OTHER,lead,Yonsei University,Phase 4
NCT02208934,2014.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1
NCT02208934,2014.0,INDUSTRY,collaborator,"Palo Biofarma, S.L",Phase 1
NCT02210195,2014.0,OTHER,lead,The Scripps Research Institute,Phase 2
NCT02210195,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02210286,2014.0,OTHER,lead,Stanford University,Not Applicable
NCT02210286,2014.0,INDUSTRY,collaborator,"Magceutics, Inc.",Not Applicable
NCT02210962,2011.0,OTHER,lead,Medical University of Lodz,Phase 4
NCT02211768,2014.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT02212119,2010.0,OTHER,lead,"Assistive Technology Clinic, Canada",Phase 2
NCT02212119,2010.0,INDUSTRY,collaborator,Merz Pharmaceuticals GmbH,Phase 2
NCT02212119,2010.0,OTHER,collaborator,Baycrest,Phase 2
NCT02212275,2015.0,OTHER,lead,Duke University,Phase 2/Phase 3
NCT02212275,2015.0,OTHER,collaborator,North Carolina Translational and Clinical Sciences Institute,Phase 2/Phase 3
NCT02212678,2014.0,OTHER,lead,University of Minnesota,Phase 2
NCT02212678,2014.0,UNKNOWN,collaborator,Parkinson's Disease Society of the United Kingdom,Phase 2
NCT02212886,2014.0,INDUSTRY,lead,Mapi Pharma Ltd.,Phase 1/Phase 2
NCT02213159,2014.0,OTHER,lead,American University of Beirut Medical Center,Phase 2/Phase 3
NCT02213679,2014.0,OTHER,lead,"Center for Health, Exercise and Sport Sciences, Serbia",Not Applicable
NCT02213887,2014.0,OTHER,lead,University of British Columbia,Phase 4
NCT02213900,2013.0,OTHER,lead,Indiana University,Phase 4
NCT02214550,2014.0,OTHER,lead,NorthShore University HealthSystem,Phase 4
NCT02214550,2014.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT02214550,2014.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 4
NCT02214862,2013.0,OTHER,lead,Fundacion Clinic per a la Recerca Biomédica,Early Phase 1
NCT02215083,2014.0,OTHER,lead,Eastern Regional Medical Center,Phase 1
NCT02215083,2014.0,INDUSTRY,collaborator,"TSPC America, Inc.",Phase 1
NCT02215616,2014.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT02216097,2014.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02216188,2014.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT02216500,2006.0,OTHER,lead,University of Florida,Not Applicable
NCT02216513,2014.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT02216513,2014.0,UNKNOWN,collaborator,Dr. Jeffrey Thomas Stroke Shield Foundation,Early Phase 1
NCT02216565,2014.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Not Applicable
NCT02216643,2017.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT02216643,2017.0,OTHER_GOV,collaborator,"Ministry of Health, Brazil",Phase 3
NCT02216643,2017.0,INDUSTRY,collaborator,Medtronic,Phase 3
NCT02216643,2017.0,INDUSTRY,collaborator,Penumbra Inc.,Phase 3
NCT02216643,2017.0,UNKNOWN,collaborator,"iSchemaView, Inc",Phase 3
NCT02216643,2017.0,INDUSTRY,collaborator,Brainomix Limited,Phase 3
NCT02217007,2015.0,INDUSTRY,lead,Synchroneuron Inc.,Phase 2
NCT02217267,2014.0,OTHER,lead,Mahidol University,Phase 3
NCT02217800,2013.0,INDUSTRY,lead,Aspireo Pharmaceuticals Limited,Phase 2
NCT02217982,2014.0,OTHER,lead,"Rocky Mountain MS Research Group, LLC",Phase 4
NCT02217982,2014.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT02218203,2003.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02218203,2003.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02218775,2014.0,OTHER,lead,Andrew Krystal,Phase 1
NCT02218775,2014.0,OTHER,collaborator,Yale University,Phase 1
NCT02219009,2014.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT02219646,2010.0,OTHER,lead,Azienda USL Modena,Phase 2
NCT02219932,2014.0,INDUSTRY,lead,Biogen,Phase 3
NCT02220114,2014.0,INDUSTRY,lead,Orphelia Pharma,Not Applicable
NCT02220114,2014.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT02220114,2014.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT02220114,2014.0,OTHER,collaborator,"National Research Agency, France",Not Applicable
NCT02220244,2013.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 3
NCT02220504,2004.0,OTHER,lead,Fundación Marques de Valdecilla,Not Applicable
NCT02220504,2004.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Not Applicable
NCT02220504,2004.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Not Applicable
NCT02220712,2014.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 1
NCT02220738,2014.0,INDUSTRY,lead,AbbVie,Phase 1
NCT02220803,2014.0,OTHER,lead,Göteborg University,Phase 2
NCT02220933,2013.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 3
NCT02220972,2015.0,INDUSTRY,lead,Eisai Inc.,Phase 4
NCT02221102,2013.0,OTHER,lead,Xijing Hospital,Phase 2/Phase 3
NCT02221219,2014.0,OTHER,lead,Hong Huang,Phase 1/Phase 2
NCT02221219,2014.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT02221271,2014.0,INDUSTRY,lead,"Nihon Pharmaceutical Co., Ltd",Phase 3
NCT02221570,2014.0,OTHER,lead,Tanta University,Not Applicable
NCT02221622,2014.0,OTHER,lead,University of Southern California,Phase 1
NCT02221622,2014.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT02221947,2014.0,INDUSTRY,lead,"Neurotrope Bioscience, Inc.",Phase 1/Phase 2
NCT02221947,2014.0,OTHER,collaborator,Blanchette Rockefeller Neurosciences Insitute,Phase 1/Phase 2
NCT02223299,2015.0,FED,lead,John D. Dingell VA Medical Center,Not Applicable
NCT02224560,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02224573,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02224664,2014.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02224690,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02224703,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02224846,2014.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT02225106,2014.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT02225106,2014.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02225548,2014.0,OTHER,lead,University of South Florida,Phase 4
NCT02225600,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT02226367,2015.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Not Applicable
NCT02226367,2015.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT02226367,2015.0,FED,collaborator,VA Puget Sound Health Care System,Not Applicable
NCT02226458,2014.0,INDUSTRY,lead,Edison Pharmaceuticals Inc,Phase 2
NCT02226848,2014.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02228005,2014.0,OTHER,lead,"University Health Network, Toronto",Phase 4
NCT02228460,2014.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT02228590,2014.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT02228863,2014.0,OTHER_GOV,lead,"National Rehabilitation Center, Seoul, Korea",Phase 4
NCT02228928,2009.0,INDUSTRY,lead,Samyang Biopharmaceuticals Corporation,Phase 1/Phase 2
NCT02229318,2014.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT02229318,2014.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT02229617,2015.0,OTHER,lead,University of British Columbia,Phase 1/Phase 2
NCT02229617,2015.0,OTHER,collaborator,Vancouver Coastal Health Research Institute,Phase 1/Phase 2
NCT02230904,2014.0,INDUSTRY,lead,UCB BIOSCIENCES GmbH,Phase 1
NCT02230904,2014.0,UNKNOWN,collaborator,Pharmaceutical Health Sciences,Phase 1
NCT02230904,2014.0,UNKNOWN,collaborator,Bracket Global,Phase 1
NCT02230930,2015.0,OTHER,lead,University Medical Center Groningen,Phase 2
NCT02231008,2015.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 2/Phase 3
NCT02231242,2013.0,OTHER,lead,Hospital Universitario Dr. Jose E. Gonzalez,Phase 2
NCT02231580,2014.0,INDUSTRY,lead,Ipsen,Phase 2
NCT02231632,2011.0,OTHER,lead,"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase 2/Phase 3
NCT02231632,2011.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 2/Phase 3
NCT02231905,2004.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT02231918,2006.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02232061,2014.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT02232347,2014.0,OTHER,lead,Pierre-Julien CUNGI,Phase 2
NCT02232425,2014.0,INDUSTRY,lead,Ixchelsis Limited,Phase 2
NCT02232425,2014.0,OTHER,collaborator,Carelon Research,Phase 2
NCT02232425,2014.0,INDUSTRY,collaborator,Novotech (Australia) Pty Limited,Phase 2
NCT02232425,2014.0,INDUSTRY,collaborator,ICON plc,Phase 2
NCT02232425,2014.0,INDUSTRY,collaborator,PHT Corporation,Phase 2
NCT02232529,2014.0,INDUSTRY,lead,Minerva Neurosciences,Phase 1
NCT02232789,2014.0,OTHER,lead,Parc de Salut Mar,Phase 1
NCT02232789,2014.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 1
NCT02233023,1998.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT02233452,2012.0,OTHER,lead,Universidade Federal de Santa Maria,Phase 4
NCT02233452,2012.0,OTHER,collaborator,Santa Casa de Misericórdia de Belo Horizonte,Phase 4
NCT02233452,2012.0,OTHER,collaborator,Hospital de Clinicas de Porto Alegre,Phase 4
NCT02233556,2014.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT02233829,2014.0,NIH,lead,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Early Phase 1
NCT02234011,2014.0,OTHER,lead,Mclean Hospital,Phase 2
NCT02234362,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02234362,2015.0,INDUSTRY,collaborator,"Takeda Pharmaceuticals North America, Inc.",Phase 4
NCT02234570,2014.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT02234713,2013.0,OTHER,lead,The Hospital for Sick Children,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,National Multiple Sclerosis Society,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Loma Linda University,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Boston Children's Hospital,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,University of Alabama at Birmingham,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Mayo Clinic,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,"University of Colorado, Denver",Not Applicable
NCT02234713,2013.0,OTHER,collaborator,"University of California, San Francisco",Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Washington University School of Medicine,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,Alberta Children's Hospital,Not Applicable
NCT02234713,2013.0,OTHER,collaborator,The Cleveland Clinic,Not Applicable
NCT02234713,2013.0,UNKNOWN,collaborator,DeltaQuest Foundation,Not Applicable
NCT02234752,2014.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT02235948,2014.0,OTHER,lead,Wenzhou Medical University,Phase 2
NCT02235987,2012.0,INDUSTRY,lead,Aspireo Pharmaceuticals Limited,Phase 2
NCT02236065,2014.0,OTHER,lead,"MinYoung Kim, M.D.",Not Applicable
NCT02236260,2014.0,OTHER,lead,Nantes University Hospital,Not Applicable
NCT02236624,2014.0,OTHER,lead,University of Aarhus,Not Applicable
NCT02236624,2014.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT02236624,2014.0,UNKNOWN,collaborator,MS-Clinic of Southern Jutland,Not Applicable
NCT02236624,2014.0,UNKNOWN,collaborator,MS-Clinic Viborg,Not Applicable
NCT02236624,2014.0,UNKNOWN,collaborator,MS-Clinic Odense,Not Applicable
NCT02236624,2014.0,INDUSTRY,collaborator,Biogen,Not Applicable
NCT02237235,2014.0,OTHER,lead,Northwestern University,Phase 2
NCT02237235,2014.0,INDUSTRY,collaborator,"Neurocentria, Inc.",Phase 2
NCT02237235,2014.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 2
NCT02237365,2014.0,OTHER,lead,"Oxford University Clinical Research Unit, Vietnam",Phase 2
NCT02237365,2014.0,OTHER,collaborator,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Phase 2
NCT02237417,2014.0,OTHER,lead,Deborah Yurgelun-Todd,Phase 4
NCT02237417,2014.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT02237547,2014.0,INDUSTRY,lead,Translational Biosciences,Phase 1/Phase 2
NCT02238626,2014.0,INDUSTRY,lead,MediciNova,Phase 2
NCT02238626,2014.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 2
NCT02239094,2015.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT02239094,2015.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Not Applicable
NCT02239120,2014.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02239380,2014.0,INDUSTRY,lead,Pfizer,Phase 3
NCT02239393,2015.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 2
NCT02239484,2014.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 1
NCT02240030,2014.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT02240329,2013.0,OTHER,lead,University of Florida,Early Phase 1
NCT02240329,2013.0,FED,collaborator,United States Department of Defense,Early Phase 1
NCT02240355,2014.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT02240407,2017.0,OTHER,lead,University of Florida,Phase 1
NCT02240407,2017.0,UNKNOWN,collaborator,Lacerta Therapeutics,Phase 1
NCT02240589,2014.0,OTHER,lead,Indiana University,Not Applicable
NCT02240693,2015.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02241395,2013.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02241434,2009.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02241460,2014.0,OTHER,lead,"Eugene Y Rhee, MD",Phase 3
NCT02241668,2015.0,OTHER,lead,M.D. Anderson Cancer Center,Not Applicable
NCT02241668,2015.0,INDUSTRY,collaborator,GE Healthcare,Not Applicable
NCT02241928,2009.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02242071,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02242487,2015.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT02243254,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02243644,2014.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 3
NCT02244541,2014.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2
NCT02244957,2014.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02245308,2014.0,FED,lead,VA Office of Research and Development,Phase 4
NCT02245568,2014.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 3
NCT02245698,2008.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02245711,2010.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02245724,2011.0,OTHER,lead,Neurogen Brain and Spine Institute,Phase 1
NCT02245841,2015.0,OTHER,lead,The Cleveland Clinic,Phase 4
NCT02245841,2015.0,INDUSTRY,collaborator,Mallinckrodt,Phase 4
NCT02246075,2015.0,INDUSTRY,lead,FORUM Pharmaceuticals Inc,Phase 2
NCT02246075,2015.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 2
NCT02246218,2014.0,INDUSTRY,lead,"Horizon Therapeutics, LLC",Phase 4
NCT02246478,2014.0,INDUSTRY,lead,"Taiho Pharmaceutical Co., Ltd.",Phase 1
NCT02246517,2014.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Early Phase 1
NCT02246712,2008.0,OTHER,lead,Universidade Estadual Paulista Júlio de Mesquita Filho,Phase 4
NCT02246712,2008.0,OTHER,collaborator,University of Sao Paulo,Phase 4
NCT02247128,2014.0,OTHER,lead,St. Antonius Hospital,Phase 4
NCT02247648,2013.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2
NCT02248116,1999.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2/Phase 3
NCT02248233,2014.0,OTHER,lead,Fengtian Hospital,Phase 4
NCT02248636,2015.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT02248701,2017.0,FED,lead,VA Office of Research and Development,Phase 2
NCT02248701,2017.0,OTHER,collaborator,University of Florida,Phase 2
NCT02249351,1999.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02249403,1999.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02249676,2013.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2
NCT02251197,2001.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02251457,2014.0,OTHER,lead,Ohio State University,Phase 1
NCT02251457,2014.0,INDUSTRY,collaborator,Gilead Sciences,Phase 1
NCT02251600,2014.0,INDUSTRY,lead,PTC Therapeutics,Phase 1
NCT02252341,2014.0,OTHER,lead,Universidade Estadual de Maringá,Phase 4
NCT02252770,2014.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT02253004,2014.0,OTHER,lead,Herlev Hospital,Early Phase 1
NCT02253212,2014.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 1/Phase 2
NCT02253524,2012.0,OTHER,lead,Pamukkale University,Phase 4
NCT02253784,2014.0,OTHER_GOV,lead,Hillel Yaffe Medical Center,Not Applicable
NCT02253966,2014.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2
NCT02253966,2014.0,OTHER,collaborator,Lundbeck Foundation,Phase 2
NCT02254863,2014.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1
NCT02254863,2014.0,OTHER,collaborator,The Marcus Foundation,Phase 1
NCT02255357,2015.0,OTHER,lead,New York State Psychiatric Institute,Phase 2/Phase 3
NCT02255435,2015.0,INDUSTRY,lead,"Reata, a wholly owned subsidiary of Biogen",Phase 2
NCT02255435,2015.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT02255435,2015.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 2
NCT02255617,2014.0,OTHER,lead,University of Alberta,Phase 1/Phase 2
NCT02255656,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT02255799,2013.0,OTHER,lead,Baylor College of Medicine,Phase 3
NCT02255799,2013.0,OTHER,collaborator,Spaulding Rehabilitation Hospital,Phase 3
NCT02255799,2013.0,OTHER,collaborator,Albert Einstein Healthcare Network,Phase 3
NCT02255799,2013.0,OTHER,collaborator,Indiana University,Phase 3
NCT02255799,2013.0,OTHER,collaborator,Craig Hospital,Phase 3
NCT02255799,2013.0,OTHER,collaborator,TIRR Memorial Hermann,Phase 3
NCT02256124,2014.0,OTHER,lead,Erasmus Medical Center,Phase 2/Phase 3
NCT02256124,2014.0,OTHER,collaborator,Universitaire Ziekenhuizen KU Leuven,Phase 2/Phase 3
NCT02256124,2014.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 2/Phase 3
NCT02256124,2014.0,OTHER,collaborator,Hospital Sant Joan de Deu,Phase 2/Phase 3
NCT02256215,2015.0,OTHER,lead,King Abdulaziz University,Phase 2/Phase 3
NCT02256215,2015.0,OTHER,collaborator,King AbdulAziz City for Science and Technology,Phase 2/Phase 3
NCT02256319,2014.0,OTHER,lead,"Clinica Universidad de Navarra, Universidad de Navarra",Phase 4
NCT02256358,2013.0,OTHER,lead,Inje University,Not Applicable
NCT02256475,2014.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT02258204,2015.0,OTHER,lead,"University Hospital, Caen",Phase 1/Phase 2
NCT02258204,2015.0,UNKNOWN,collaborator,Société Française d'Anesthésie Réanimation,Phase 1/Phase 2
NCT02258204,2015.0,UNKNOWN,collaborator,Fondation NRJ,Phase 1/Phase 2
NCT02258217,2014.0,OTHER,lead,OhioHealth,Not Applicable
NCT02258828,2005.0,FED,lead,Sriram Ramaswamy,Phase 4
NCT02258828,2005.0,INDUSTRY,collaborator,Forest Laboratories,Phase 4
NCT02258880,2014.0,INDUSTRY,lead,Daiichi Sankyo,Phase 2
NCT02258880,2014.0,OTHER,collaborator,Syneos Health,Phase 2
NCT02259075,2015.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1/Phase 2
NCT02259075,2015.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT02259361,2014.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT02259595,2014.0,INDUSTRY,lead,"Otologic Pharmaceutics, Inc.",Phase 1
NCT02259738,2013.0,OTHER,lead,XuanwuH 2,Phase 2
NCT02259751,2004.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 1
NCT02260141,2014.0,OTHER,lead,Practitioners Alliance Network,Not Applicable
NCT02260674,2014.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT02260830,2014.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02261519,2017.0,INDUSTRY,lead,SyneuRx International (Taiwan) Corp,Phase 2/Phase 3
NCT02261961,2014.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT02261961,2014.0,OTHER,collaborator,University of Arkansas,Not Applicable
NCT02262156,2014.0,OTHER,lead,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Not Applicable
NCT02262338,2015.0,INDUSTRY,lead,"ArmaGen, Inc",Phase 1
NCT02263235,2013.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT02263235,2013.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02263235,2013.0,OTHER,collaborator,"University Hospital, Clermont-Ferrand",Not Applicable
NCT02263235,2013.0,OTHER_GOV,collaborator,International Atomic Energy Agency,Not Applicable
NCT02263248,2014.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 1/Phase 2
NCT02263248,2014.0,INDUSTRY,collaborator,Reckitt Benckiser LLC,Phase 1/Phase 2
NCT02263872,2014.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 4
NCT02263872,2014.0,OTHER,collaborator,King's College London,Phase 4
NCT02264353,2014.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT02265367,2015.0,OTHER,lead,University of Minnesota,Not Applicable
NCT02266160,2014.0,OTHER,lead,"HaEmek Medical Center, Israel",Phase 4
NCT02266329,2016.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT02267057,2014.0,OTHER,lead,University of Bergen,Phase 4
NCT02267187,2014.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT02267187,2014.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT02267434,2014.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT02267434,2014.0,UNKNOWN,collaborator,PROSENEX AmbulatoriumbetriebsGMBH,Phase 1
NCT02267434,2014.0,OTHER,collaborator,Medical University Innsbruck,Phase 1
NCT02267434,2014.0,OTHER,collaborator,Forschungszentrum Juelich,Phase 1
NCT02267538,2014.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT02267538,2014.0,OTHER,collaborator,"Chinese Academy of Medical Sciences, Fuwai Hospital",Phase 4
NCT02267681,2014.0,OTHER,lead,Perihan Ekmekçi,Phase 4
NCT02267980,2014.0,OTHER,lead,Inonu University,Phase 4
NCT02268058,2013.0,OTHER,lead,McMaster Children's Hospital,Not Applicable
NCT02268552,2015.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1/Phase 2
NCT02269436,2015.0,INDUSTRY,lead,Newron Sweden AB,Phase 1
NCT02269930,2014.0,INDUSTRY,lead,Biogen,Phase 1
NCT02270489,2014.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT02270489,2014.0,OTHER,collaborator,"University Hospital, Bordeaux",Phase 1
NCT02270489,2014.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1
NCT02270489,2014.0,OTHER,collaborator,Forschungszentrum Juelich,Phase 1
NCT02270489,2014.0,OTHER,collaborator,"University Hospital, Toulouse",Phase 1
NCT02270619,2014.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT02270736,2015.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT02271165,2014.0,OTHER,lead,Thomas Jefferson University,Early Phase 1
NCT02271503,2015.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 2
NCT02271854,2014.0,INDUSTRY,lead,Novartis,Phase 3
NCT02271919,2015.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 4
NCT02271919,2015.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT02272387,2014.0,OTHER,lead,St. Luke's-Roosevelt Hospital Center,Not Applicable
NCT02273596,2014.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2
NCT02274051,2009.0,OTHER,lead,NYU Langone Health,Phase 1
NCT02274285,2014.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02274311,2011.0,OTHER,lead,Felipe Henning Gaia Duarte,Phase 2
NCT02274324,2014.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT02274324,2014.0,OTHER,collaborator,Tel Aviv University,Not Applicable
NCT02274558,2014.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT02274766,2014.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT02275117,2014.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 2
NCT02275182,2014.0,OTHER,lead,The First Affiliated Hospital of Anhui Medical University,Phase 4
NCT02275247,2014.0,OTHER,lead,General Hospital of Ningxia Medical University,Not Applicable
NCT02275884,2013.0,OTHER,lead,Technische Universität Dresden,Not Applicable
NCT02275884,2013.0,OTHER,collaborator,University of Wuerzburg,Not Applicable
NCT02276716,2011.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02276963,2016.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT02277106,2014.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT02277704,2014.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT02278354,2015.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02278354,2015.0,OTHER,collaborator,The Cleveland Clinic,Phase 1
NCT02278367,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT02279511,2014.0,OTHER,lead,Sara Varea,Phase 2
NCT02279667,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02279992,2012.0,OTHER,lead,Cedars-Sinai Medical Center,Early Phase 1
NCT02280083,2014.0,INDUSTRY,lead,"Lanzhou Institute of Biological Products Co., Ltd",Phase 3
NCT02280096,2014.0,OTHER_GOV,lead,"Coordinación de Investigación en Salud, Mexico",Phase 2
NCT02280876,2012.0,OTHER,lead,Universidad Austral de Chile,Phase 1/Phase 2
NCT02280876,2012.0,OTHER_GOV,collaborator,Comisión Nacional de Investigación Científica y Tecnológica,Phase 1/Phase 2
NCT02280876,2012.0,OTHER,collaborator,University of Chile,Phase 1/Phase 2
NCT02281175,2014.0,OTHER,lead,Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal,Not Applicable
NCT02281175,2014.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT02281175,2014.0,OTHER,collaborator,Universite du Quebec en Outaouais,Not Applicable
NCT02281175,2014.0,OTHER,collaborator,Université de Montréal,Not Applicable
NCT02281175,2014.0,OTHER,collaborator,Université de Sherbrooke,Not Applicable
NCT02281175,2014.0,OTHER,collaborator,Laval University,Not Applicable
NCT02281422,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02281448,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02281474,2014.0,OTHER,lead,Georgetown University,Phase 1
NCT02281526,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02281591,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02281773,2014.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02281838,2011.0,OTHER,lead,University of Alberta,Phase 2
NCT02282085,2014.0,OTHER,lead,Matt Byerly,Phase 4
NCT02282085,2014.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT02282098,2014.0,OTHER,lead,Population Health Research Institute,Phase 3
NCT02282241,2016.0,OTHER,lead,University of British Columbia,Phase 4
NCT02282514,2014.0,OTHER,lead,Northwestern University,Phase 1/Phase 2
NCT02282761,2014.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT02282878,2014.0,OTHER,lead,Yale University,Not Applicable
NCT02282917,2015.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Early Phase 1
NCT02282917,2015.0,OTHER,collaborator,Johns Hopkins University,Early Phase 1
NCT02282917,2015.0,OTHER,collaborator,Mayo Clinic,Early Phase 1
NCT02282917,2015.0,OTHER,collaborator,Stanford University,Early Phase 1
NCT02282917,2015.0,OTHER,collaborator,Ohio State University,Early Phase 1
NCT02282917,2015.0,OTHER,collaborator,Nationwide Children's Hospital,Early Phase 1
NCT02283294,2015.0,OTHER,lead,University of South Florida,Phase 3
NCT02283294,2015.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT02283671,2015.0,OTHER,lead,Sara Varea,Phase 1
NCT02283788,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02283801,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02283814,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02283827,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02283840,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02283853,2014.0,INDUSTRY,lead,Biogen,Phase 3
NCT02283879,2015.0,INDUSTRY,lead,"Shenzhen Hornetcorn Bio-technology Company, LTD",Phase 1
NCT02283879,2015.0,OTHER,collaborator,Fifth Affiliated Hospital of Guangzhou Medical University,Phase 1
NCT02284126,2014.0,OTHER,lead,Columbia University,Phase 3
NCT02284126,2014.0,FED,collaborator,Agency for Healthcare Research and Quality (AHRQ),Phase 3
NCT02284126,2014.0,OTHER,collaborator,Cornell University,Phase 3
NCT02284126,2014.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 3
NCT02284828,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02284854,2009.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02284880,2010.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02285673,2013.0,OTHER,lead,Acibadem University,Phase 1/Phase 2
NCT02285699,2014.0,OTHER,lead,McMaster University,Not Applicable
NCT02285699,2014.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Not Applicable
NCT02286206,2015.0,OTHER,lead,University of British Columbia,Phase 4
NCT02286947,2014.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 2
NCT02286960,2013.0,OTHER,lead,NYU Langone Health,Phase 4
NCT02286986,2014.0,OTHER,lead,University of Utah,Phase 1
NCT02287038,2014.0,FED,lead,VA Office of Research and Development,Phase 4
NCT02287064,2015.0,OTHER,lead,University of South Florida,Phase 1
NCT02287064,2015.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 1
NCT02287259,2014.0,OTHER,lead,Tadashi Hasegawa,Phase 4
NCT02287376,2015.0,INDUSTRY,lead,Depomed,Phase 4
NCT02287415,2002.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02287584,2014.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT02288000,2016.0,OTHER,lead,"University Hospital, Lille",Phase 1
NCT02288091,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT02288091,2015.0,UNKNOWN,collaborator,The Salah Foundation,Phase 1
NCT02288091,2015.0,UNKNOWN,collaborator,MGH cure ALS Fund,Phase 1
NCT02288312,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02288845,2014.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 2
NCT02288962,2014.0,OTHER,lead,St. Olavs Hospital,Phase 3
NCT02288962,2014.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 3
NCT02289248,2015.0,OTHER,lead,Yale University,Phase 1
NCT02290444,2013.0,OTHER,lead,State University of New York at Buffalo,Phase 3
NCT02290496,2015.0,OTHER,lead,Kaiser Permanente,Not Applicable
NCT02290496,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02290886,2014.0,OTHER,lead,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,Phase 1/Phase 2
NCT02290886,2014.0,OTHER,collaborator,Iniciativa Andaluza en Terapias Avanzadas,Phase 1/Phase 2
NCT02291263,2014.0,FED,lead,Centers for Disease Control and Prevention,Phase 3
NCT02291263,2014.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 3
NCT02291783,2013.0,INDUSTRY,lead,Heptares Therapeutics Limited,Phase 1
NCT02291861,2014.0,INDUSTRY,lead,"Auspex Pharmaceuticals, Inc.",Phase 3
NCT02292238,2015.0,OTHER,lead,Burke Medical Research Institute,Phase 2
NCT02292238,2015.0,OTHER,collaborator,Burke Rehabilitation Hospital,Phase 2
NCT02292238,2015.0,OTHER,collaborator,Columbia University,Phase 2
NCT02292238,2015.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02292238,2015.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT02292238,2015.0,OTHER,collaborator,Montefiore Medical Center,Phase 2
NCT02292537,2014.0,INDUSTRY,lead,Biogen,Phase 3
NCT02292654,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1/Phase 2
NCT02293031,2014.0,INDUSTRY,lead,NextGen Company Limited,Not Applicable
NCT02293031,2014.0,OTHER_GOV,collaborator,Burnasyan Federal Medical Biophysical Center,Not Applicable
NCT02293031,2014.0,OTHER,collaborator,Moscow State University of Medicine and Dentistry,Not Applicable
NCT02293187,2015.0,OTHER,lead,Tufts University,Not Applicable
NCT02293291,2014.0,OTHER,lead,American Society Of Thermalism And Climatology Inc,Phase 1/Phase 2
NCT02293460,2015.0,INDUSTRY,lead,Laboratoire français de Fractionnement et de Biotechnologies,Phase 3
NCT02294058,2014.0,INDUSTRY,lead,Celgene,Phase 3
NCT02294266,2014.0,OTHER,lead,Parc de Salut Mar,Phase 1
NCT02294266,2014.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 1
NCT02294591,2014.0,OTHER,lead,Region Syddanmark,Phase 2
NCT02294851,2014.0,INDUSTRY,lead,Biogen,Phase 1
NCT02295462,2014.0,OTHER,lead,Martin-Luther-Universität Halle-Wittenberg,Not Applicable
NCT02295462,2014.0,OTHER,collaborator,University of Luebeck,Not Applicable
NCT02295462,2014.0,OTHER,collaborator,University of Witten/Herdecke,Not Applicable
NCT02295748,2014.0,INDUSTRY,lead,PTC Therapeutics,Phase 1
NCT02295787,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02295826,2015.0,OTHER,lead,University of Alberta,Phase 2
NCT02296216,2015.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT02296840,2014.0,OTHER,lead,Emory University,Phase 4
NCT02297412,2014.0,OTHER,lead,Academic and Community Cancer Research United,Phase 2
NCT02297412,2014.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT02297763,2015.0,OTHER,lead,Seoul National University Hospital,Phase 3
NCT02297997,2014.0,OTHER,lead,Seoul National University Hospital,Early Phase 1
NCT02298660,2013.0,OTHER,lead,Rick Hansen Institute,Phase 4
NCT02298660,2013.0,OTHER,collaborator,University of British Columbia,Phase 4
NCT02298660,2013.0,OTHER,collaborator,International Collaboration on Repair Discoveries,Phase 4
NCT02298660,2013.0,OTHER_GOV,collaborator,Vancouver Coastal Health,Phase 4
NCT02298868,2012.0,OTHER,lead,University of Virginia,Phase 2
NCT02299089,2015.0,INDUSTRY,lead,Camurus AB,Phase 2
NCT02299089,2015.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT02299115,2017.0,OTHER,lead,The Hospital for Sick Children,Phase 3
NCT02299557,2014.0,INDUSTRY,lead,RDD Pharma Ltd,Phase 1/Phase 2
NCT02299804,2014.0,INDUSTRY,lead,Sihuan Pharmaceutical Holdings Group Ltd.,Phase 2
NCT02300038,2010.0,OTHER,lead,Uppsala University,Not Applicable
NCT02301169,2014.0,OTHER,lead,Tools4Patient,Not Applicable
NCT02302157,2015.0,INDUSTRY,lead,"Lineage Cell Therapeutics, Inc.",Phase 1/Phase 2
NCT02302209,2011.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT02302976,2014.0,OTHER,lead,Yale University,Phase 1
NCT02302976,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02303886,2009.0,OTHER,lead,Uppsala University,Not Applicable
NCT02304302,2014.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 2
NCT02304302,2014.0,UNKNOWN,collaborator,Alana USA Foundation,Phase 2
NCT02304432,2015.0,OTHER,lead,Mclean Hospital,Early Phase 1
NCT02304432,2015.0,OTHER,collaborator,University of Minnesota,Early Phase 1
NCT02304679,2015.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT02305017,2014.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02305030,2014.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02305069,2009.0,OTHER,lead,University of Nottingham,Not Applicable
NCT02305069,2009.0,OTHER,collaborator,Biotechnology and Biological Sciences Research Council,Not Applicable
NCT02305134,2015.0,OTHER,lead,Chiba University,Phase 1/Phase 2
NCT02305264,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02305316,2014.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02305329,2014.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02305394,2015.0,OTHER,lead,First Affiliated Hospital of Chongqing Medical University,Phase 4
NCT02305823,2005.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT02305823,2005.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT02305823,2005.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT02306590,2015.0,OTHER,lead,University of Ulm,Not Applicable
NCT02307305,2014.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 2
NCT02307396,2015.0,OTHER,lead,Technical University of Munich,Phase 4
NCT02307526,2011.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT02307565,2014.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 3
NCT02307565,2014.0,OTHER,collaborator,Kessler Foundation,Phase 3
NCT02308202,2012.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT02308592,2015.0,OTHER,lead,Women's College Hospital,Not Applicable
NCT02308592,2015.0,OTHER_GOV,collaborator,Ontario Ministry of Health and Long Term Care,Not Applicable
NCT02308592,2015.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT02308982,2016.0,OTHER,lead,University of Oxford,Phase 3
NCT02308982,2016.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 3
NCT02308982,2016.0,INDUSTRY,collaborator,CSL Behring,Phase 3
NCT02308982,2016.0,OTHER,collaborator,University of Liverpool,Phase 3
NCT02308982,2016.0,OTHER,collaborator,University College London Hospitals,Phase 3
NCT02308982,2016.0,OTHER,collaborator,Guy's and St Thomas' NHS Foundation Trust,Phase 3
NCT02308982,2016.0,OTHER_GOV,collaborator,Liverpool University Hospitals NHS Foundation Trust,Phase 3
NCT02308982,2016.0,OTHER,collaborator,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 3
NCT02310763,2014.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02310828,2013.0,INDUSTRY,lead,Biohit Oyj,Not Applicable
NCT02310828,2013.0,OTHER_GOV,collaborator,The Finnish Funding Agency for Technology and Innovation (TEKES),Not Applicable
NCT02310906,2015.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,"Institut de Myologie, France",Phase 1/Phase 2
NCT02310906,2015.0,UNKNOWN,collaborator,Consultants for Research in Imaging and Spectroscopy,Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,Catholic University of the Sacred Heart,Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,Royal Holloway University,Phase 1/Phase 2
NCT02310906,2015.0,INDUSTRY,collaborator,Sysnav,Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,"University College, London",Phase 1/Phase 2
NCT02310906,2015.0,OTHER,collaborator,University of Newcastle Upon-Tyne,Phase 1/Phase 2
NCT02311673,2015.0,INDUSTRY,lead,"Rhythm Pharmaceuticals, Inc.",Phase 2
NCT02311777,2015.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 3
NCT02311777,2015.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT02311907,2009.0,OTHER,lead,Alliance for Clinical Trials in Oncology,Phase 3
NCT02311907,2009.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT02312232,2014.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 1
NCT02312310,2015.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT02312310,2015.0,INDUSTRY,collaborator,"Mars, Inc.",Not Applicable
NCT02312635,2012.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT02312908,2015.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT02312908,2015.0,OTHER_GOV,collaborator,"Ministry of Food and Drug Safety, Korea",Phase 2
NCT02313194,2013.0,OTHER,lead,"University of California, Los Angeles",Phase 1/Phase 2
NCT02313909,2014.0,INDUSTRY,lead,Bayer,Phase 3
NCT02313909,2014.0,INDUSTRY,collaborator,"Janssen Research & Development, LLC",Phase 3
NCT02313909,2014.0,OTHER,collaborator,Population Health Research Institute,Phase 3
NCT02314195,2014.0,OTHER,lead,"Islamic Azad University, Marvdasht",Not Applicable
NCT02314208,2015.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT02314351,2014.0,OTHER,lead,Kocaeli University,Phase 4
NCT02314676,2014.0,INDUSTRY,lead,"Changchun GeneScience Pharmaceutical Co., Ltd.",Phase 4
NCT02315235,2014.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02315573,2014.0,OTHER,lead,"St. Mary's Research Center, Canada",Not Applicable
NCT02315833,2013.0,INDUSTRY,lead,Biohit Oyj,Not Applicable
NCT02315833,2013.0,OTHER_GOV,collaborator,The Finnish Funding Agency for Technology and Innovation (TEKES),Not Applicable
NCT02315872,2015.0,OTHER,lead,Providence Health & Services,Phase 3
NCT02315872,2015.0,INDUSTRY,collaborator,Mallinckrodt,Phase 3
NCT02316847,2014.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT02317263,,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT02317562,2015.0,INDUSTRY,lead,Laboratoire français de Fractionnement et de Biotechnologies,Phase 3
NCT02317640,2017.0,OTHER,lead,Kessler Foundation,Phase 1/Phase 2
NCT02317640,2017.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT02317744,2014.0,OTHER,lead,Yale University,Not Applicable
NCT02318446,2015.0,OTHER,lead,Maharashtra University of Health Sciences,Phase 3
NCT02318537,2017.0,INDUSTRY,lead,INSYS Therapeutics Inc,Phase 3
NCT02318602,2016.0,INDUSTRY,lead,INSYS Therapeutics Inc,Phase 3
NCT02319005,2014.0,INDUSTRY,lead,Alnylam Pharmaceuticals,Phase 3
NCT02320032,2014.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT02321436,2014.0,INDUSTRY,lead,Ipsen,Phase 4
NCT02321761,2014.0,OTHER,lead,Loewenstein Hospital,Phase 4
NCT02321917,2013.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT02322021,2014.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT02322021,2014.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT02322333,2015.0,INDUSTRY,lead,Pharmalyte Solutions LLC,Phase 2/Phase 3
NCT02322333,2015.0,OTHER,collaborator,Clinvest,Phase 2/Phase 3
NCT02322983,2011.0,OTHER,lead,Universidade Cruzeiro do Sul,Not Applicable
NCT02322983,2011.0,OTHER_GOV,collaborator,Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Not Applicable
NCT02323048,2014.0,OTHER,lead,University of Chicago,Not Applicable
NCT02323217,2015.0,OTHER,lead,Imperial College London,Early Phase 1
NCT02323217,2015.0,INDUSTRY,collaborator,GlaxoSmithKline,Early Phase 1
NCT02323334,2014.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02323698,2019.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 1/Phase 2
NCT02323698,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT02324153,2017.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT02324153,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02324426,2014.0,OTHER,lead,University of Washington,Phase 1
NCT02324426,2014.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT02324673,2015.0,INDUSTRY,lead,INSYS Therapeutics Inc,Phase 1/Phase 2
NCT02325414,2015.0,OTHER,lead,Northwestern University,Phase 2
NCT02325414,2015.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02325440,2014.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT02325440,2014.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT02325583,2014.0,OTHER,lead,Baskent University,Phase 3
NCT02326662,2014.0,OTHER_GOV,lead,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",Phase 1/Phase 2
NCT02326662,2014.0,UNKNOWN,collaborator,Novagenesis Foundation,Phase 1/Phase 2
NCT02326662,2014.0,UNKNOWN,collaborator,Ophiuchus Technologies AG,Phase 1/Phase 2
NCT02326935,2014.0,INDUSTRY,lead,American CryoStem Corporation,Phase 1
NCT02327091,2012.0,OTHER,lead,Indonesia University,Phase 3
NCT02327182,2014.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT02327793,2009.0,OTHER,lead,University of Alberta,Phase 2
NCT02328079,2013.0,OTHER,lead,Assiut University,Not Applicable
NCT02329288,2015.0,OTHER,lead,Second Military Medical University,Phase 3
NCT02329548,2014.0,OTHER,lead,Nationwide Children's Hospital,Not Applicable
NCT02329769,2014.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT02331433,2014.0,INDUSTRY,lead,CoMentis,Phase 1
NCT02331433,2014.0,INDUSTRY,collaborator,"Alpharmagen, Inc.",Phase 1
NCT02332174,2014.0,OTHER,lead,"Wuhan Union Hospital, China",Phase 1
NCT02332447,2015.0,OTHER,lead,Hospices Civils de Lyon,Phase 3
NCT02332655,2014.0,OTHER,lead,"Anne Comi, MD",Phase 1/Phase 2
NCT02332655,2014.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 1/Phase 2
NCT02332655,2014.0,OTHER,collaborator,Faneca 66 Foundation,Phase 1/Phase 2
NCT02332798,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02332902,2015.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02332902,2015.0,UNKNOWN,collaborator,Texas Neurofibromatosis Foundation,Phase 2
NCT02333071,2014.0,INDUSTRY,lead,"Palatin Technologies, Inc",Phase 3
NCT02333331,2014.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT02333487,2014.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02334098,2015.0,OTHER,lead,Dr. Annis Fung,Phase 2/Phase 3
NCT02334098,2015.0,OTHER,collaborator,University of Pennsylvania,Phase 2/Phase 3
NCT02334098,2015.0,OTHER,collaborator,The University of Hong Kong,Phase 2/Phase 3
NCT02334098,2015.0,OTHER,collaborator,Brooklyn College of the City University of New York,Phase 2/Phase 3
NCT02334163,2014.0,OTHER,lead,Ain Shams University,Phase 2
NCT02334163,2014.0,OTHER,collaborator,Al-Azhar University,Phase 2
NCT02334644,2018.0,OTHER,lead,McMaster University,Phase 4
NCT02334644,2018.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Phase 4
NCT02334644,2018.0,INDUSTRY,collaborator,Lallemand Health Solutions,Phase 4
NCT02334722,2015.0,OTHER,lead,University of Florida,Phase 4
NCT02335125,2015.0,OTHER,lead,University of Washington,Not Applicable
NCT02335125,2015.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02335125,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02335125,2015.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT02335658,2014.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT02335840,2011.0,OTHER,lead,Federal University of Paraíba,Not Applicable
NCT02336360,2015.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02336477,2011.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT02336503,2015.0,INDUSTRY,lead,Botanix Pharmaceuticals,Phase 2
NCT02336529,2016.0,OTHER,lead,Kenneth Geving Andersen,Phase 3
NCT02336555,2015.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT02336568,2015.0,OTHER,lead,Rambam Health Care Campus,Phase 4
NCT02336633,2015.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02336906,2020.0,OTHER,lead,Rabin Medical Center,Phase 4
NCT02336958,2013.0,OTHER,lead,Helios Research Center,Not Applicable
NCT02337413,2020.0,OTHER,lead,Rabin Medical Center,Phase 4
NCT02337634,2015.0,OTHER,lead,University of Chicago,Phase 2
NCT02337725,2015.0,INDUSTRY,lead,Takeda,Phase 3
NCT02337738,2015.0,INDUSTRY,lead,Takeda,Phase 2/Phase 3
NCT02337751,2015.0,INDUSTRY,lead,Takeda,Phase 3
NCT02337764,2015.0,INDUSTRY,lead,Takeda,Phase 3
NCT02337907,2015.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02338466,2016.0,OTHER,lead,University Hospital Center of Martinique,Phase 2
NCT02338960,2015.0,INDUSTRY,lead,"Palatin Technologies, Inc",Phase 3
NCT02338960,2015.0,INDUSTRY,collaborator,"AMAG Pharmaceuticals, Inc.",Phase 3
NCT02339064,2015.0,INDUSTRY,lead,"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",Phase 3
NCT02339493,2016.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT02339493,2016.0,INDUSTRY,collaborator,Daiichi Sankyo,Not Applicable
NCT02339844,2014.0,OTHER,lead,University of Copenhagen,Phase 4
NCT02340195,2015.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02341131,2012.0,OTHER,lead,Hospital Clinic of Barcelona,Not Applicable
NCT02341131,2012.0,OTHER,collaborator,University of Barcelona,Not Applicable
NCT02341794,2015.0,OTHER,lead,Tokyo Medical University,Not Applicable
NCT02342184,2014.0,INDUSTRY,lead,Japan Blood Products Organization,Phase 3
NCT02342262,2014.0,OTHER,lead,Wageningen University,Not Applicable
NCT02342366,2012.0,OTHER,lead,University of Zurich,Not Applicable
NCT02342366,2012.0,OTHER,collaborator,University of Regensburg,Not Applicable
NCT02342366,2012.0,OTHER,collaborator,University of Salerno,Not Applicable
NCT02342366,2012.0,OTHER,collaborator,University of Vienna,Not Applicable
NCT02342366,2012.0,OTHER,collaborator,University of Freiburg,Not Applicable
NCT02342548,2015.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02342704,2014.0,INDUSTRY,lead,Biogen,Phase 4
NCT02343159,2015.0,INDUSTRY,lead,Biogen,Phase 4
NCT02343991,2014.0,INDUSTRY,lead,InSightec,Not Applicable
NCT02344823,2012.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT02344849,2015.0,INDUSTRY,lead,"Pharmicell Co., Ltd.",Phase 1
NCT02345135,2012.0,OTHER,lead,Johann Wolfgang Goethe University Hospital,Not Applicable
NCT02345135,2012.0,INDUSTRY,collaborator,CSL Behring,Not Applicable
NCT02345213,2015.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 4
NCT02345668,2015.0,OTHER,lead,Universitat Jaume I,Not Applicable
NCT02345668,2015.0,UNKNOWN,collaborator,Consorcio Hospitalario Provincial de Castellón,Not Applicable
NCT02346201,2016.0,OTHER,lead,Johns Hopkins Bloomberg School of Public Health,Phase 3
NCT02346201,2016.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT02346539,2015.0,OTHER,lead,Mclean Hospital,Phase 1
NCT02346539,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02346630,2015.0,OTHER,lead,"Ross D. Zafonte, MD",Phase 4
NCT02347059,2015.0,OTHER,lead,University of Toronto,Phase 2
NCT02347059,2015.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT02347423,2015.0,OTHER,lead,Statens Serum Institut,Phase 2
NCT02347423,2015.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT02347423,2015.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 2
NCT02347423,2015.0,INDUSTRY,collaborator,Larix A/S,Phase 2
NCT02347605,2013.0,OTHER,lead,University of Minnesota,Not Applicable
NCT02347891,2015.0,OTHER,lead,Northwell Health,Phase 2/Phase 3
NCT02347891,2015.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2/Phase 3
NCT02348073,2015.0,OTHER,lead,Hospices Civils de Lyon,Phase 3
NCT02348125,2016.0,OTHER,lead,Drexel University,Phase 1
NCT02348203,2016.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT02348593,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02348606,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02348619,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02348632,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02348762,2014.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT02350634,2015.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02351115,2015.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT02351115,2015.0,OTHER,collaborator,The Epilepsy Study Consortium,Phase 2
NCT02351544,2015.0,OTHER,lead,Ohio State University,Not Applicable
NCT02351544,2015.0,OTHER,collaborator,"University of Wisconsin, Madison",Not Applicable
NCT02351544,2015.0,OTHER,collaborator,Massachusetts General Hospital,Not Applicable
NCT02351544,2015.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Not Applicable
NCT02351700,2015.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 4
NCT02351869,2015.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2
NCT02351882,2015.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2/Phase 3
NCT02352077,2015.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1
NCT02352077,2015.0,OTHER,collaborator,Affiliated Hospital of Logistics University of CAPF,Phase 1
NCT02352077,2015.0,OTHER,collaborator,The First Affiliated Hospital of Soochow University,Phase 1
NCT02352077,2015.0,OTHER_GOV,collaborator,First Hospitals affiliated to the China PLA General Hospital,Phase 1
NCT02352363,2015.0,INDUSTRY,lead,Acorda Therapeutics,Phase 3
NCT02352649,2015.0,OTHER,lead,"Human Stem Cell Institute, Russia",Phase 1/Phase 2
NCT02352649,2015.0,OTHER,collaborator,Kazan Federal University,Phase 1/Phase 2
NCT02352896,2014.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT02353598,2015.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT02353650,2014.0,OTHER,lead,"University Hospital, Antwerp",Not Applicable
NCT02353949,2015.0,OTHER,lead,University of Zurich,Phase 3
NCT02353949,2015.0,OTHER,collaborator,ETH Zurich,Phase 3
NCT02354001,2011.0,OTHER,lead,The Alfred,Phase 4
NCT02354001,2011.0,OTHER,collaborator,Monash University,Phase 4
NCT02354040,2015.0,OTHER,lead,Aga Khan University,Not Applicable
NCT02354040,2015.0,OTHER,collaborator,Baylor College of Medicine,Not Applicable
NCT02354352,2015.0,OTHER,lead,Ohio State University,Phase 3
NCT02354352,2015.0,OTHER,collaborator,"University of California, Los Angeles",Phase 3
NCT02354352,2015.0,OTHER,collaborator,University of Utah,Phase 3
NCT02354352,2015.0,OTHER,collaborator,"University of Colorado, Denver",Phase 3
NCT02354352,2015.0,OTHER,collaborator,University of Kansas Medical Center,Phase 3
NCT02354352,2015.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 3
NCT02354508,2015.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT02354625,2015.0,OTHER,lead,W. Dalton Dietrich,Phase 1
NCT02354625,2015.0,OTHER,collaborator,The Miami Project to Cure Paralysis,Phase 1
NCT02354781,2015.0,OTHER,lead,Jerry R. Mendell,Phase 1/Phase 2
NCT02354781,2015.0,UNKNOWN,collaborator,Duchenne Alliance,Phase 1/Phase 2
NCT02354781,2015.0,UNKNOWN,collaborator,Milo Therapeutics,Phase 1/Phase 2
NCT02355665,2015.0,INDUSTRY,lead,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Phase 3
NCT02355665,2015.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 3
NCT02355665,2015.0,INDUSTRY,collaborator,McNeil AB,Phase 3
NCT02355938,2014.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT02355938,2014.0,INDUSTRY,collaborator,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Phase 4
NCT02357225,2015.0,OTHER,lead,University of Florida,Early Phase 1
NCT02357290,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02357797,2016.0,OTHER,lead,Northwell Health,Phase 4
NCT02357797,2016.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT02358343,2015.0,OTHER,lead,University of Washington,Phase 3
NCT02358343,2015.0,OTHER,collaborator,University of Texas,Phase 3
NCT02358343,2015.0,OTHER,collaborator,University of New Mexico,Phase 3
NCT02358343,2015.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 3
NCT02358538,2015.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT02358681,2015.0,OTHER,lead,Columbia University,Phase 3
NCT02358681,2015.0,OTHER,collaborator,Migraine Research Foundation,Phase 3
NCT02359266,2011.0,OTHER,lead,Universität des Saarlandes,Not Applicable
NCT02359344,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02359448,2015.0,OTHER,lead,"University College, London",Phase 2
NCT02359513,2015.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Phase 4
NCT02359513,2015.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 4
NCT02359552,2015.0,OTHER,lead,The Cleveland Clinic,Phase 2
NCT02359825,2015.0,OTHER,lead,Vanderbilt University,Phase 1
NCT02360046,2015.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT02360319,2014.0,OTHER,lead,Vanguard Research Group,Phase 4
NCT02360319,2014.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT02360657,2015.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 1
NCT02361177,2016.0,OTHER,lead,University of Texas at Austin,Early Phase 1
NCT02361177,2016.0,OTHER,collaborator,Harvard University,Early Phase 1
NCT02361242,2013.0,OTHER,lead,Pharnext S.C.A.,Phase 2
NCT02361242,2013.0,OTHER,collaborator,Ascopharm Groupe Novasco,Phase 2
NCT02361424,2013.0,OTHER,lead,Pharnext S.C.A.,Phase 2
NCT02361424,2013.0,OTHER,collaborator,Ascopharm Groupe Novasco,Phase 2
NCT02361476,2015.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 4
NCT02362321,2007.0,OTHER,lead,CHU de Quebec-Universite Laval,Phase 4
NCT02362373,2011.0,OTHER,lead,Columbia University,Phase 4
NCT02362373,2011.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT02362412,2015.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT02362425,2015.0,NIH,lead,National Institute of Nursing Research (NINR),Phase 1/Phase 2
NCT02362438,2015.0,INDUSTRY,lead,"Taysha Gene Therapies, Inc.",Phase 1
NCT02362438,2015.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02363517,2015.0,OTHER,lead,Macfarlane Burnet Institute for Medical Research and Public Health Ltd,Phase 3
NCT02363517,2015.0,OTHER,collaborator,St Vincent's Hospital Melbourne,Phase 3
NCT02363738,2015.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT02363738,2015.0,NETWORK,collaborator,Clinical Investigation Centre for Innovative Technology Network,Phase 2
NCT02363738,2015.0,OTHER,collaborator,Stanford University,Phase 2
NCT02363803,2015.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT02364180,2013.0,OTHER,lead,University of Toledo Health Science Campus,Not Applicable
NCT02365012,2014.0,FED,lead,Corporal Michael J. Crescenz VA Medical Center,Not Applicable
NCT02365259,2015.0,OTHER,lead,University of Illinois at Urbana-Champaign,Phase 1
NCT02365610,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02365636,2015.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT02365870,2016.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT02365870,2016.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT02365909,2015.0,OTHER,lead,University of Arkansas,Early Phase 1
NCT02366299,2015.0,OTHER_GOV,lead,Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy,Phase 4
NCT02367014,2015.0,INDUSTRY,lead,Stealth BioTherapeutics Inc.,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,lead,Capital Medical University,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Peking University First Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,People's Hospital of Beijing Daxing District,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Haidian Hospital,Phase 1/Phase 2
NCT02367248,2015.0,UNKNOWN,collaborator,The 263 Hospital of PLA,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Aerospace General Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Peking University Third Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Pinggu District Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Shuyi Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,General Hospital of Beijing PLA Military Region,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Luhe Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Fangshan District Liangxiang Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Neurosurgical Institute,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Jishuitan Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Beijing Ditan Hospital,Phase 1/Phase 2
NCT02367248,2015.0,UNKNOWN,collaborator,Beijing Youyi Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Peking University People's Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,The Second Artillery General Hospital,Phase 1/Phase 2
NCT02367248,2015.0,OTHER,collaborator,Chinese PLA General Hospital,Phase 1/Phase 2
NCT02367664,2014.0,NETWORK,lead,Jiangsu Province Centers for Disease Control and Prevention,Phase 3
NCT02367664,2014.0,UNKNOWN,collaborator,"Shandong Hengye Biotech Co., Ltd.",Phase 3
NCT02368379,2014.0,OTHER,lead,Nationwide Children's Hospital,Not Applicable
NCT02369471,2015.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02369926,2014.0,INDUSTRY,lead,Transparency Life Sciences,Phase 2
NCT02370433,2012.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 1
NCT02370745,2014.0,OTHER,lead,University of Nottingham,Not Applicable
NCT02370862,2013.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Early Phase 1
NCT02371278,2015.0,OTHER,lead,McMaster University,Not Applicable
NCT02371278,2015.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT02372149,2015.0,OTHER,lead,University of Toronto,Phase 4
NCT02372149,2015.0,OTHER,collaborator,"University Health Network, Toronto",Phase 4
NCT02372409,2015.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT02373072,2015.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02373098,2015.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT02373449,2015.0,OTHER,lead,"University Health Network, Toronto",Not Applicable
NCT02374112,2016.0,OTHER,lead,"Center for Health, Exercise and Sport Sciences, Serbia",Not Applicable
NCT02374268,2015.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT02374567,2015.0,OTHER,lead,Hannover Medical School,Phase 3
NCT02376309,2015.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT02376374,2015.0,OTHER,lead,Stanford University,Not Applicable
NCT02376374,2015.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Not Applicable
NCT02376374,2015.0,OTHER,collaborator,"Instituto Nacional de Salud Publica, Mexico",Not Applicable
NCT02376816,2015.0,OTHER,lead,Jerry R. Mendell,Phase 1
NCT02376816,2015.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT02376881,2015.0,OTHER,lead,Tehran University of Medical Sciences,Phase 3
NCT02376881,2015.0,OTHER,collaborator,Iran University of Medical Sciences,Phase 3
NCT02377271,2015.0,OTHER,lead,"University Hospital, Grenoble",Phase 3
NCT02377713,2015.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT02377804,2014.0,OTHER,lead,Universidad Rey Juan Carlos,Not Applicable
NCT02378714,2015.0,OTHER,lead,Northwestern University,Phase 4
NCT02378714,2015.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT02378974,2015.0,INDUSTRY,lead,"CHABiotech CO., Ltd",Phase 1/Phase 2
NCT02379026,2014.0,OTHER,lead,Queen Margaret University,Not Applicable
NCT02379026,2014.0,OTHER,collaborator,University of Birmingham,Not Applicable
NCT02379156,2015.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT02379156,2015.0,OTHER,collaborator,The Craig H. Neilsen Foundation,Phase 4
NCT02379546,2013.0,OTHER,lead,Tokat Gaziosmanpasa University,Phase 4
NCT02379754,2015.0,OTHER,lead,Lund University,Phase 4
NCT02380573,2015.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2
NCT02380573,2015.0,UNKNOWN,collaborator,Texas Alzheimer's Research and Care Consortium (TARCC),Phase 2
NCT02381795,2015.0,INDIV,lead,"Cady, Roger, M.D.",Phase 2
NCT02381795,2015.0,INDUSTRY,collaborator,"Capnia, Inc.",Phase 2
NCT02382198,2016.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 2
NCT02382328,2016.0,OTHER,lead,Hospital Civil de Guadalajara,Phase 2
NCT02382445,2014.0,OTHER,lead,Heidelberg University,Not Applicable
NCT02382679,2015.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT02382679,2015.0,OTHER,collaborator,Rothman Institute Orthopaedics,Not Applicable
NCT02382848,2015.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT02383004,2015.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT02383511,2015.0,INDUSTRY,lead,Summit Therapeutics,Phase 1
NCT02383758,2015.0,OTHER,lead,Emory University,Not Applicable
NCT02383758,2015.0,OTHER,collaborator,Organization for Autism Research,Not Applicable
NCT02384343,2015.0,OTHER,lead,St. Justine's Hospital,Phase 3
NCT02384369,2016.0,INDUSTRY,lead,Synchroneuron Inc.,Phase 2
NCT02384928,2015.0,OTHER,lead,Jaseng Medical Foundation,Not Applicable
NCT02385500,2016.0,OTHER,lead,Sir Mortimer B. Davis - Jewish General Hospital,Phase 4
NCT02385799,2015.0,OTHER,lead,"Randi J. Hagerman, MD",Phase 2
NCT02385799,2015.0,FED,collaborator,Health Resources and Services Administration (HRSA),Phase 2
NCT02386293,2014.0,OTHER,lead,Augusta University,Phase 2
NCT02386306,2015.0,INDUSTRY,lead,"GliaCure, Inc.",Phase 1
NCT02386475,2015.0,OTHER,lead,Hospital de Granollers,Phase 4
NCT02386553,2015.0,INDUSTRY,lead,Biogen,Phase 2
NCT02387710,2015.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02388152,2015.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02389413,2015.0,INDUSTRY,lead,Vivoryon Therapeutics N.V.,Phase 2
NCT02389413,2015.0,INDUSTRY,collaborator,Julius Clinical,Phase 2
NCT02389413,2015.0,OTHER,collaborator,"Amsterdam UMC, location VUmc",Phase 2
NCT02389465,2014.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT02389712,2015.0,OTHER,lead,Mayo Clinic,Phase 4
NCT02389712,2015.0,UNKNOWN,collaborator,J Willard and Alice S. Marriott Foundation,Phase 4
NCT02389829,2015.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT02390089,2015.0,OTHER,lead,University of Florida,Phase 1
NCT02390089,2015.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 1
NCT02390752,2015.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT02390960,2015.0,INDUSTRY,lead,"Strategic Science & Technologies, LLC",Phase 2
NCT02391571,2015.0,INDUSTRY,lead,"Elite Laboratories, Inc",Phase 3
NCT02391961,2015.0,FED,lead,VA Office of Research and Development,Phase 2
NCT02392468,2015.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 1
NCT02393027,2015.0,OTHER,lead,"University Hospital, Tours",Early Phase 1
NCT02393339,2017.0,OTHER,lead,Hadassah Medical Organization,Early Phase 1
NCT02393547,2013.0,OTHER,lead,Mayo Clinic,Phase 1/Phase 2
NCT02393599,2015.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 1
NCT02394418,2017.0,OTHER_GOV,lead,Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy,Phase 4
NCT02394457,2010.0,FED,lead,"United States Naval Medical Center, San Diego",Phase 4
NCT02394457,2010.0,FED,collaborator,"United States Naval Medical Center, Portsmouth",Phase 4
NCT02395510,2015.0,OTHER,lead,Siyan Clinical Corporation,Phase 4
NCT02396069,2015.0,INDUSTRY,lead,"Jeil Pharmaceutical Co., Ltd.",Phase 1
NCT02396953,2015.0,INDUSTRY,lead,Ipsen,Phase 1/Phase 2
NCT02396979,2010.0,OTHER,lead,Yale University,Phase 4
NCT02396979,2010.0,OTHER,collaborator,University of Malaya,Phase 4
NCT02396979,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT02397018,2015.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1
NCT02397837,2014.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT02397837,2014.0,OTHER,collaborator,The Zucker Hillside Hospital,Phase 4
NCT02397837,2014.0,OTHER,collaborator,Northwell Health,Phase 4
NCT02397837,2014.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02397837,2014.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT02398136,2014.0,OTHER,lead,Adriana Feder,Phase 2/Phase 3
NCT02398279,2011.0,OTHER,lead,Hacettepe University,Not Applicable
NCT02398370,2013.0,OTHER,lead,Melissa Marchand,Phase 1
NCT02398656,2015.0,OTHER,lead,University of Calgary,Phase 3
NCT02398994,2015.0,OTHER,lead,Guy's and St Thomas' NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,King's College London,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Barts and the London School of Medicine and Dentistry,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Cardiff University,Phase 3
NCT02398994,2015.0,OTHER,collaborator,"University College, London",Phase 3
NCT02398994,2015.0,OTHER,collaborator,King's College Hospital NHS Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Barts & The London NHS Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Alder Hey Children's NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Walton Centre NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Oxford University Hospitals NHS Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Birmingham Women's and Children's NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,University Hospital Birmingham NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER_GOV,collaborator,Cardiff and Vale University Health Board,Phase 3
NCT02398994,2015.0,OTHER,collaborator,North Bristol NHS Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,University Hospitals Bristol and Weston NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER_GOV,collaborator,Manchester University NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Northern Care Alliance NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,University Hospital Southampton NHS Foundation Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Newcastle-upon-Tyne Hospitals NHS Trust,Phase 3
NCT02398994,2015.0,OTHER,collaborator,Nottingham University Hospitals NHS Trust,Phase 3
NCT02398994,2015.0,OTHER_GOV,collaborator,NHS Lothian,Phase 3
NCT02400619,2014.0,OTHER,lead,Xavi Vidal Novellas,Phase 1
NCT02400619,2014.0,OTHER,collaborator,Cerebral Palsy Association,Phase 1
NCT02401022,2015.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT02401113,2014.0,OTHER,lead,Pusan National University Hospital,Phase 2/Phase 3
NCT02401139,2015.0,OTHER,lead,The University of New South Wales,Phase 1
NCT02401139,2015.0,OTHER,collaborator,University of Sydney,Phase 1
NCT02401490,2015.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT02401490,2015.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 4
NCT02402114,2015.0,OTHER,lead,Albert Einstein Healthcare Network,Not Applicable
NCT02402530,2015.0,INDUSTRY,lead,Grünenthal GmbH,Phase 2/Phase 3
NCT02402608,2012.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT02402608,2012.0,OTHER,collaborator,University of Pavia,Not Applicable
NCT02403947,2015.0,OTHER,lead,"University Hospital, Toulouse",Phase 1/Phase 2
NCT02404155,2015.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT02404168,2015.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT02404298,2015.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02404337,2015.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT02404779,2015.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 4
NCT02405091,2015.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT02405403,2015.0,OTHER,lead,"University Hospital, Tours",Early Phase 1
NCT02405598,2013.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT02406027,2015.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT02406066,2015.0,INDUSTRY,lead,"Embera NeuroTherapeutics, Inc.",Phase 1
NCT02406066,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02406105,2015.0,OTHER,lead,Maria Sklodowska-Curie National Research Institute of Oncology,Phase 2
NCT02407028,2018.0,OTHER,lead,Hennepin Healthcare Research Institute,Phase 2
NCT02407028,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02407028,2018.0,UNKNOWN,collaborator,Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network,Phase 2
NCT02407340,2015.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT02407704,2015.0,OTHER,lead,"Kirk Erickson, PhD",Phase 4
NCT02407808,2015.0,OTHER,lead,Yale University,Phase 1
NCT02408172,2013.0,OTHER,lead,First Affiliated Hospital of Harbin Medical University,Phase 2/Phase 3
NCT02408523,2015.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT02408523,2015.0,OTHER,collaborator,Pharmaceutical Research Associates,Phase 3
NCT02408549,2015.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 3
NCT02408562,2015.0,INDUSTRY,lead,Newron Sweden AB,Phase 1/Phase 2
NCT02408562,2015.0,OTHER,collaborator,European Union,Phase 1/Phase 2
NCT02409433,2014.0,OTHER,lead,Lawson Health Research Institute,Phase 4
NCT02409433,2014.0,INDUSTRY,collaborator,UCB Pharma GmbH,Phase 4
NCT02409459,2015.0,INDUSTRY,lead,"American Regent, Inc.",Phase 2
NCT02410200,2015.0,INDUSTRY,lead,Biogen,Phase 2
NCT02410278,2015.0,INDUSTRY,lead,Biogen,Phase 4
NCT02411123,2015.0,INDUSTRY,lead,AltheaDx,Not Applicable
NCT02411123,2015.0,UNKNOWN,collaborator,Carolina Partners in Mental Healthcare,Not Applicable
NCT02411526,2015.0,INDUSTRY,lead,"Zogenix, Inc.",Phase 1
NCT02411695,2015.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT02411695,2015.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT02411903,2015.0,OTHER,lead,The Third Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT02412514,2015.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT02412514,2015.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT02412787,2015.0,INDUSTRY,lead,Shire,Phase 2/Phase 3
NCT02412917,2015.0,INDUSTRY,lead,"ContraVir Pharmaceuticals, Inc.",Phase 3
NCT02413099,2012.0,OTHER,lead,Hyun Jun Park,Phase 4
NCT02413554,2013.0,OTHER,lead,"Chung-Ang University Hosptial, Chung-Ang University College of Medicine",Phase 4
NCT02413918,2012.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT02413918,2012.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 4
NCT02413918,2012.0,INDUSTRY,collaborator,Vanda Pharmaceuticals,Phase 4
NCT02414152,2013.0,OTHER,lead,Andrea Vambutas,Phase 1/Phase 2
NCT02414308,2013.0,OTHER,lead,"Man Clinic for Andrology, Male Infertility and Sexual Dysfunction",Not Applicable
NCT02414503,2015.0,INDUSTRY,lead,OptiNose AS,Phase 1/Phase 2
NCT02414503,2015.0,OTHER,collaborator,Oslo University Hospital,Phase 1/Phase 2
NCT02414503,2015.0,OTHER,collaborator,University of Oslo,Phase 1/Phase 2
NCT02414932,2015.0,OTHER,lead,"St Patrick's Hospital, Ireland",Early Phase 1
NCT02414932,2015.0,OTHER,collaborator,"Health Research Board, Ireland",Early Phase 1
NCT02415062,2015.0,OTHER,lead,Inje University,Phase 2
NCT02415127,2015.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT02415127,2015.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 3
NCT02415153,2015.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT02415257,2015.0,OTHER,lead,Lund University,Phase 4
NCT02415387,2014.0,OTHER,lead,Ohio State University Comprehensive Cancer Center,Early Phase 1
NCT02416492,2016.0,INDUSTRY,lead,"SanBio, Inc.",Phase 2
NCT02417142,2014.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT02417142,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 4
NCT02417428,2015.0,OTHER,lead,Université du Québec a Montréal,Not Applicable
NCT02417428,2015.0,OTHER,collaborator,McGill University,Not Applicable
NCT02417428,2015.0,OTHER,collaborator,Université de Montréal,Not Applicable
NCT02417454,2015.0,OTHER,lead,McMaster University,Phase 3
NCT02417454,2015.0,INDUSTRY,collaborator,Lallemand Health Solutions,Phase 3
NCT02418273,2019.0,OTHER,lead,Indiana University,Phase 1/Phase 2
NCT02418325,2015.0,INDUSTRY,lead,Genesis Limited,Phase 1/Phase 2
NCT02418598,2015.0,OTHER,lead,Jichi Medical University,Phase 1/Phase 2
NCT02418598,2015.0,INDUSTRY,collaborator,Takara Bio Inc.,Phase 1/Phase 2
NCT02418598,2015.0,UNKNOWN,collaborator,"Gene Therapy Research Institution,Co.,Ltd.",Phase 1/Phase 2
NCT02418702,2016.0,FED,lead,"United States Naval Medical Center, San Diego",Phase 3
NCT02418819,2015.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02418949,2015.0,OTHER,lead,Shirley Ryan AbilityLab,Not Applicable
NCT02418949,2015.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02418949,2015.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT02419313,2012.0,OTHER,lead,Yale University,Phase 2
NCT02419378,2015.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT02419378,2015.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 4
NCT02420015,2017.0,OTHER,lead,Duke University,Phase 4
NCT02420418,2015.0,OTHER,lead,Universidade Estadual de Londrina,Not Applicable
NCT02421679,2015.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT02422264,2016.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT02422290,2015.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT02422290,2015.0,OTHER,collaborator,New York Presbyterian Hospital,Phase 1/Phase 2
NCT02422303,2015.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Not Applicable
NCT02422485,2015.0,OTHER,lead,Adam Boxer,Phase 1
NCT02422654,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT02422732,2009.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT02423018,2015.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02423083,2015.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02423122,2015.0,INDUSTRY,lead,EIP Pharma Inc,Phase 2
NCT02423200,2015.0,INDUSTRY,lead,EIP Pharma Inc,Phase 2
NCT02423395,2015.0,OTHER,lead,Sherief Abd-Elsalam,Phase 3
NCT02423395,2015.0,OTHER,collaborator,Tanta University,Phase 3
NCT02423408,2015.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT02423694,2013.0,OTHER,lead,Guangdong Provincial Hospital of Traditional Chinese Medicine,Not Applicable
NCT02423824,2015.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT02424318,2008.0,OTHER,lead,SMG-SNU Boramae Medical Center,Phase 4
NCT02424396,2016.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT02424396,2016.0,UNKNOWN,collaborator,Fondation ARSEP/AFM,Phase 2
NCT02424435,2015.0,OTHER,lead,Children's Hospital of Philadelphia,Early Phase 1
NCT02424435,2015.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Early Phase 1
NCT02424695,2015.0,OTHER,lead,Cleveland Sleep Research Center,Phase 4
NCT02424695,2015.0,INDUSTRY,collaborator,"XenoPort, Inc.",Phase 4
NCT02424695,2015.0,UNKNOWN,collaborator,YRT Limited,Phase 4
NCT02424708,2015.0,OTHER,lead,Bastyr University,Phase 2
NCT02424708,2015.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT02425202,2014.0,OTHER,lead,University of Manitoba,Phase 4
NCT02425644,2015.0,INDUSTRY,lead,Actelion,Phase 3
NCT02426047,2015.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT02426047,2015.0,INDUSTRY,collaborator,"Vitaflo International, Ltd",Not Applicable
NCT02426411,2015.0,INDUSTRY,lead,Spinifex Pharmaceuticals Pty Ltd,Phase 2
NCT02426411,2015.0,OTHER,collaborator,Syneos Health,Phase 2
NCT02426905,2016.0,INDUSTRY,lead,Univar BV,Phase 4
NCT02426983,2015.0,OTHER,lead,University of Ottawa,Phase 1/Phase 2
NCT02427230,2015.0,OTHER,lead,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT02427230,2015.0,OTHER,collaborator,Herlev Hospital,Not Applicable
NCT02427230,2015.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02427230,2015.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT02427295,2014.0,OTHER,lead,Asan Medical Center,Phase 4
NCT02427295,2014.0,INDUSTRY,collaborator,Novartis Korea Ltd.,Phase 4
NCT02427607,2015.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 3
NCT02427646,2011.0,OTHER,lead,"Western University, Canada",Phase 2
NCT02427776,2015.0,INDUSTRY,lead,Imcyse SA,Phase 1/Phase 2
NCT02428218,2016.0,INDUSTRY,lead,Biogen,Phase 3
NCT02428231,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02428478,2015.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02428491,2015.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02428972,2017.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Not Applicable
NCT02429453,2015.0,OTHER,lead,University of Utah,Not Applicable
NCT02429557,2015.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT02429557,2015.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1
NCT02429596,2012.0,OTHER,lead,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Phase 4
NCT02429921,2015.0,OTHER,lead,University of Calgary,Not Applicable
NCT02429921,2015.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Not Applicable
NCT02431468,2015.0,INDUSTRY,lead,"Neurotrope Bioscience, Inc.",Phase 2
NCT02431663,2015.0,OTHER,lead,Meyer Children's Hospital IRCCS,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Ospedali Riuniti Ancona,Phase 3
NCT02431663,2015.0,OTHER,collaborator,IRCCS Azienda Ospedaliero-Universitaria di Bologna,Phase 3
NCT02431663,2015.0,OTHER,collaborator,University of Padova,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Bambino Gesù Hospital and Research Institute,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Catholic University of the Sacred Heart,Phase 3
NCT02431663,2015.0,OTHER,collaborator,IRCCS Burlo Garofolo,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Azienda Ospedaliera Universitaria Integrata Verona,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Nuovo Regina Margherita Hospital,Phase 3
NCT02431663,2015.0,OTHER,collaborator,Vittore Buzzi Children's Hospital,Phase 3
NCT02431702,2015.0,INDUSTRY,lead,"Janssen Scientific Affairs, LLC",Phase 3
NCT02431728,2015.0,OTHER,lead,Duquesne University,Phase 1/Phase 2
NCT02431845,2013.0,OTHER,lead,Severance Hospital,Not Applicable
NCT02431936,2015.0,OTHER,lead,Augusta University,Phase 2
NCT02431936,2015.0,OTHER,collaborator,The University of Texas at Arlington,Phase 2
NCT02432066,2018.0,OTHER,lead,University of Florida,Phase 2
NCT02432066,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02432157,2015.0,OTHER,lead,Thomas Jefferson University,Phase 1/Phase 2
NCT02432339,2014.0,OTHER,lead,Augusta University,Phase 1/Phase 2
NCT02432703,2015.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT02432716,2015.0,OTHER,lead,HealthPartners Institute,Phase 1
NCT02432885,2009.0,OTHER,lead,InCor Heart Institute,Phase 3
NCT02432885,2009.0,OTHER,collaborator,Federal University of Minas Gerais,Phase 3
NCT02432885,2009.0,OTHER,collaborator,University of Sao Paulo,Phase 3
NCT02433041,2013.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 4
NCT02433041,2013.0,OTHER,collaborator,Kantonsspital Baden,Phase 4
NCT02433353,2016.0,FED,lead,Bayne-Jones Army Community Hospital,Phase 4
NCT02433717,2015.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT02434289,2015.0,OTHER,lead,Wageningen University,Not Applicable
NCT02434289,2015.0,OTHER,collaborator,Zorggroep Noordwest-Veluwe,Not Applicable
NCT02434289,2015.0,INDUSTRY,collaborator,FrieslandCampina,Not Applicable
NCT02434549,2015.0,OTHER,lead,Kristina Tedroff,Phase 2
NCT02434549,2015.0,OTHER,collaborator,Danderyd Hospital,Phase 2
NCT02434549,2015.0,OTHER,collaborator,Karolinska University Hospital,Phase 2
NCT02434718,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02434770,2015.0,OTHER,lead,PATH,Phase 3
NCT02434770,2015.0,UNKNOWN,collaborator,"Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio",Phase 3
NCT02435095,2015.0,OTHER,lead,RWTH Aachen University,Phase 4
NCT02435199,2015.0,INDUSTRY,lead,Spinifex Pharmaceuticals Pty Ltd,Phase 2
NCT02435199,2015.0,OTHER,collaborator,Syneos Health,Phase 2
NCT02435381,2013.0,OTHER,lead,Baylor College of Medicine,Phase 1/Phase 2
NCT02435836,1998.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT02436031,2015.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02436096,2015.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT02437110,2019.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02437253,2015.0,OTHER,lead,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Phase 1/Phase 2
NCT02438072,2014.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT02438137,2015.0,OTHER,lead,University of Michigan,Phase 2
NCT02438215,2014.0,INDUSTRY,lead,Io Therapeutics,Phase 1
NCT02438826,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02439125,2015.0,INDUSTRY,lead,"Amarantus BioScience Holdings, Inc.",Phase 2
NCT02439203,2015.0,INDUSTRY,lead,Bukwang Pharmaceutical,Phase 2
NCT02439203,2015.0,UNKNOWN,collaborator,Contera Pharma ApS,Phase 2
NCT02439216,2016.0,INDUSTRY,lead,Catabasis Pharmaceuticals,Phase 1/Phase 2
NCT02439255,2015.0,OTHER,lead,Ohio State University Comprehensive Cancer Center,Not Applicable
NCT02439255,2015.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT02439814,2015.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT02439879,2009.0,OTHER,lead,Universidad Popular Autónoma del Estado de Puebla,Phase 4
NCT02439944,2015.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2/Phase 3
NCT02441660,2016.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Not Applicable
NCT02442557,2009.0,INDUSTRY,lead,Delta Crystallon BV,Phase 1
NCT02442570,2012.0,INDUSTRY,lead,Delta Crystallon BV,Phase 2
NCT02442713,2014.0,OTHER,lead,Guang Dong Provincial Mental Health Institute,Not Applicable
NCT02442739,2016.0,OTHER,lead,Cedars-Sinai Medical Center,Early Phase 1
NCT02442739,2016.0,NIH,collaborator,National Cancer Institute (NCI),Early Phase 1
NCT02442791,2014.0,OTHER,lead,Jesper Kjaergaard,Not Applicable
NCT02442804,2015.0,OTHER,lead,Loma Linda University,Phase 2
NCT02442817,2015.0,OTHER,lead,"University of Nevada, Reno",Phase 4
NCT02442817,2015.0,OTHER,collaborator,Augusta University,Phase 4
NCT02443090,2015.0,INDUSTRY,lead,"NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)",Phase 2
NCT02443142,2015.0,OTHER,lead,Northwestern University,Phase 2
NCT02443142,2015.0,OTHER,collaborator,Northwestern Memorial Hospital,Phase 2
NCT02443194,2015.0,OTHER_GOV,lead,michal roll,Phase 3
NCT02444637,2015.0,OTHER,lead,National Neuroscience Institute,Phase 4
NCT02445651,2014.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT02445794,2015.0,INDUSTRY,lead,"Retrotope, Inc.",Phase 1/Phase 2
NCT02446730,2014.0,OTHER,lead,Chonnam National University Hospital,Phase 4
NCT02446886,2016.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT02446886,2016.0,INDUSTRY,collaborator,Mallinckrodt,Phase 4
NCT02448069,2015.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02448654,2015.0,OTHER,lead,Yale University,Not Applicable
NCT02448654,2015.0,FED,collaborator,US Department of Veterans Affairs,Not Applicable
NCT02448654,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02448914,2015.0,INDUSTRY,lead,LobSor Pharmaceuticals AB,Phase 1
NCT02448914,2015.0,INDUSTRY,collaborator,TFS Trial Form Support,Phase 1
NCT02449746,2015.0,OTHER,lead,University of Cambridge,Not Applicable
NCT02449746,2015.0,OTHER,collaborator,University of Oxford,Not Applicable
NCT02449746,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT02449746,2015.0,UNKNOWN,collaborator,McPin Foundation,Not Applicable
NCT02450188,2012.0,OTHER,lead,University of Florence,Phase 4
NCT02450253,2015.0,OTHER,lead,"St George's, University of London",Phase 2
NCT02450253,2015.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT02450253,2015.0,OTHER,collaborator,Alzheimer's Society,Phase 2
NCT02450253,2015.0,OTHER,collaborator,University of Copenhagen,Phase 2
NCT02450253,2015.0,OTHER,collaborator,University of Glasgow,Phase 2
NCT02450253,2015.0,OTHER,collaborator,St George's University Hospitals NHS Foundation Trust,Phase 2
NCT02450552,2015.0,OTHER,lead,Brian Wainger,Phase 2
NCT02450552,2015.0,OTHER,collaborator,ALS Association,Phase 2
NCT02450552,2015.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT02450552,2015.0,OTHER,collaborator,Harvard University,Phase 2
NCT02450552,2015.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT02450604,2015.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT02450786,2015.0,OTHER,lead,Yonsei University,Phase 2
NCT02451293,2016.0,OTHER,lead,Zealand University Hospital,Phase 2/Phase 3
NCT02451293,2016.0,OTHER,collaborator,"Psychiatric Research Unit, Region Zealand, Denmark",Phase 2/Phase 3
NCT02451293,2016.0,OTHER,collaborator,University of Copenhagen,Phase 2/Phase 3
NCT02451293,2016.0,INDUSTRY,collaborator,Pharma Nord,Phase 2/Phase 3
NCT02451306,2015.0,OTHER,lead,RWTH Aachen University,Not Applicable
NCT02451475,2013.0,OTHER,lead,Mansoura University,Phase 1/Phase 2
NCT02451696,2014.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02452216,2015.0,OTHER,lead,Michael Iv,Early Phase 1
NCT02452502,2015.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT02452502,2015.0,OTHER,collaborator,The First Hospital of Jilin University,Not Applicable
NCT02452606,2015.0,OTHER,lead,Asan Medical Center,Not Applicable
NCT02452723,2016.0,INDUSTRY,lead,Cyto Therapeutics Pty Limited,Phase 1
NCT02453061,2015.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT02453061,2015.0,INDUSTRY,collaborator,Ultragenyx Pharmaceutical Inc,Phase 2
NCT02453373,2017.0,OTHER,lead,Life Recovery Systems,Not Applicable
NCT02453373,2017.0,OTHER,collaborator,Tulane University School of Medicine,Not Applicable
NCT02453373,2017.0,OTHER,collaborator,Geisinger Clinic,Not Applicable
NCT02453386,2015.0,INDUSTRY,lead,Biotie Therapies Inc.,Phase 3
NCT02453893,2013.0,INDUSTRY,lead,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 3
NCT02455232,2015.0,OTHER,lead,Centre d'Investigation Clinique et Technologique 805,Not Applicable
NCT02455336,2015.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT02455401,2015.0,OTHER,lead,Inje University,Not Applicable
NCT02455440,2014.0,OTHER,lead,George Papanicolaou Hospital,Phase 3
NCT02455479,2012.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1
NCT02455479,2012.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02455622,2015.0,INDUSTRY,lead,Takeda,Phase 4
NCT02455622,2015.0,INDUSTRY,collaborator,"Takeda Development Center Americas, Inc.",Phase 4
NCT02456454,2006.0,OTHER,lead,Nationwide Children's Hospital,Phase 3
NCT02456454,2006.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT02456740,2015.0,INDUSTRY,lead,Amgen,Phase 3
NCT02456896,2015.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT02457546,2015.0,INDUSTRY,lead,"Ethicon, Inc.",Phase 3
NCT02458183,2015.0,INDUSTRY,lead,"Boryung Pharmaceutical Co., Ltd",Phase 3
NCT02458469,2015.0,FED,lead,VA Office of Research and Development,Phase 2
NCT02458690,2015.0,OTHER,lead,Indiana University,Phase 2
NCT02458690,2015.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT02458742,2015.0,OTHER,lead,Mahidol University,Not Applicable
NCT02458755,2012.0,OTHER,lead,Samsung Medical Center,Phase 4
NCT02458755,2012.0,UNKNOWN,collaborator,"Don-A Pharmaceutical, Seoul, South Korea",Phase 4
NCT02458924,2014.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2/Phase 3
NCT02459197,2015.0,OTHER,lead,Tools4Patient,Not Applicable
NCT02459197,2015.0,OTHER,collaborator,International Drug Development Institute,Not Applicable
NCT02459509,2015.0,OTHER,lead,The University of Hong Kong,Phase 4
NCT02459886,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02460094,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02460107,2015.0,OTHER,lead,Catholic University of Korea Saint Paul's Hospital,Early Phase 1
NCT02460107,2015.0,INDUSTRY,collaborator,Medy-Tox,Early Phase 1
NCT02460679,2016.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT02460692,2016.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT02460692,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02460731,2015.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT02461069,2015.0,OTHER,lead,University Hospital Muenster,Phase 4
NCT02461069,2015.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT02462109,2013.0,OTHER,lead,Makerere University,Phase 1
NCT02462109,2013.0,OTHER,collaborator,University of Mississippi Medical Center,Phase 1
NCT02462161,2015.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT02462161,2015.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT02462161,2015.0,INDUSTRY,collaborator,General Electric,Phase 1
NCT02462317,2015.0,OTHER,lead,"University Hospital, Toulouse",Phase 4
NCT02462317,2015.0,INDUSTRY,collaborator,Merz Pharmaceuticals GmbH,Phase 4
NCT02462473,2015.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT02462603,2016.0,INDUSTRY,lead,Edison Pharmaceuticals Inc,Phase 2
NCT02462629,2015.0,INDUSTRY,lead,Blaze Bioscience Inc.,Phase 1
NCT02462759,2015.0,INDUSTRY,lead,Biogen,Phase 2
NCT02463110,2015.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT02463110,2015.0,OTHER,collaborator,Action Research Group,Phase 4
NCT02463318,2012.0,OTHER,lead,Tehran University of Medical Sciences,Not Applicable
NCT02464124,2016.0,OTHER,lead,Sherief Abd-Elsalam,Phase 2/Phase 3
NCT02464124,2016.0,OTHER,collaborator,Tanta University,Phase 2/Phase 3
NCT02464514,2004.0,OTHER,lead,Duke University,Not Applicable
NCT02464514,2004.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02464514,2004.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT02464514,2004.0,OTHER,collaborator,Foundation for Prader-Willi Research,Not Applicable
NCT02464514,2004.0,OTHER,collaborator,Stollery Children's Hospital Foundation,Not Applicable
NCT02464514,2004.0,OTHER,collaborator,Alberta Diabetes Institute,Not Applicable
NCT02464514,2004.0,UNKNOWN,collaborator,Sarah W. Stedman Nutrition and Metabolism Center,Not Applicable
NCT02464514,2004.0,OTHER,collaborator,American Diabetes Association,Not Applicable
NCT02464514,2004.0,UNKNOWN,collaborator,Duke Children's Miracle Network,Not Applicable
NCT02464514,2004.0,NIH,collaborator,National Center for Research Resources (NCRR),Not Applicable
NCT02465853,2015.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT02466074,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02466087,2015.0,OTHER,lead,University of Vermont,Phase 2/Phase 3
NCT02466243,2015.0,INDUSTRY,lead,Corbus Pharmaceuticals Inc.,Phase 2
NCT02466243,2015.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT02466243,2015.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT02466334,2015.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT02466373,2016.0,OTHER,lead,Deventer Ziekenhuis,Phase 3
NCT02466477,2015.0,INDUSTRY,lead,Assurex Health Inc.,Phase 4
NCT02466477,2015.0,OTHER,collaborator,Programs for Assessment of Technology in Health Research Institute,Phase 4
NCT02466477,2015.0,OTHER,collaborator,Centre for Addiction and Mental Health,Phase 4
NCT02466477,2015.0,OTHER,collaborator,Genome Canada,Phase 4
NCT02466477,2015.0,UNKNOWN,collaborator,Assurex Health Ltd.,Phase 4
NCT02466477,2015.0,OTHER,collaborator,Mars Excellence in Clinical Innovation and Technology Evaluation,Phase 4
NCT02466685,2015.0,OTHER,lead,Herbert Meltzer,Phase 2
NCT02466685,2015.0,INDUSTRY,collaborator,"Janssen Research & Development, LLC",Phase 2
NCT02466750,2015.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT02467153,2017.0,OTHER,lead,University of Birmingham,Not Applicable
NCT02467153,2017.0,OTHER,collaborator,University Hospital Birmingham,Not Applicable
NCT02467153,2017.0,OTHER,collaborator,University of Surrey,Not Applicable
NCT02467413,2017.0,INDUSTRY,lead,Charsire Biotechnology Corp.,Phase 2
NCT02467413,2017.0,INDUSTRY,collaborator,A2 Healthcare Taiwan Corporation,Phase 2
NCT02467517,2015.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT02468674,2015.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT02469155,2015.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT02469259,2016.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT02469545,2014.0,OTHER,lead,Medical University of Bialystok,Phase 2
NCT02469896,2015.0,OTHER,lead,Barrow Neurological Institute,Phase 2
NCT02469896,2015.0,OTHER,collaborator,ALS Association,Phase 2
NCT02469896,2015.0,OTHER,collaborator,Barrow Neurological Foundation,Phase 2
NCT02469896,2015.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT02469896,2015.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT02469948,2015.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 3
NCT02470325,2015.0,OTHER_GOV,lead,Wolfson Medical Center,Phase 2
NCT02470546,2015.0,OTHER,lead,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Phase 4
NCT02470780,2015.0,OTHER,lead,University of Cincinnati,Phase 2/Phase 3
NCT02471196,2015.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT02471196,2015.0,INDUSTRY,collaborator,Janssen Pharmaceuticals,Phase 2
NCT02471222,2015.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 2
NCT02471560,2015.0,INDUSTRY,lead,Biogen,Phase 4
NCT02471833,2015.0,OTHER,lead,Emory University,Phase 1/Phase 2
NCT02471833,2015.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1/Phase 2
NCT02471898,2015.0,INDUSTRY,lead,Heron Therapeutics,Phase 2
NCT02472210,2014.0,OTHER,lead,"University Health Network, Toronto",Phase 4
NCT02472418,2015.0,INDUSTRY,lead,Dr. Reddy's Laboratories Limited,Phase 2
NCT02472938,2015.0,INDUSTRY,lead,Biogen,Phase 4
NCT02472938,2015.0,INDUSTRY,collaborator,GB Pharma Services & Consulting s.r.l.,Phase 4
NCT02473016,2015.0,INDUSTRY,lead,"Capnia, Inc.",Phase 2
NCT02473250,2015.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT02473276,2015.0,OTHER,lead,Columbia University,Phase 4
NCT02473458,2012.0,OTHER,lead,Shiraz University of Medical Sciences,Phase 1/Phase 2
NCT02473562,2013.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT02473562,2013.0,OTHER,collaborator,"Centre for Human Drug Research, Netherlands",Phase 4
NCT02473913,2015.0,OTHER,lead,University of Chicago,Phase 2
NCT02473965,2015.0,INDUSTRY,lead,Grifols Therapeutics LLC,Phase 2
NCT02474134,2015.0,INDUSTRY,lead,"Pfenex, Inc",Phase 1
NCT02474407,2015.0,INDUSTRY,lead,Acorda Therapeutics,Phase 2
NCT02475265,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02475265,2015.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT02475928,2015.0,OTHER,lead,Fundación Clínica Médica Sur,Not Applicable
NCT02476708,2016.0,OTHER,lead,Yale University,Not Applicable
NCT02477020,2015.0,INDUSTRY,lead,Takeda,Phase 2
NCT02477280,2016.0,OTHER,lead,Region Västmanland,Phase 4
NCT02477436,2008.0,OTHER,lead,Pusan National University Hospital,Phase 2
NCT02477527,2015.0,OTHER,lead,"Midtown Medical Center, Tampa, FL",Phase 4
NCT02477527,2015.0,INDUSTRY,collaborator,Gilead Sciences,Phase 4
NCT02477670,2015.0,INDUSTRY,lead,Avanir Pharmaceuticals,Phase 2
NCT02477800,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02478346,2015.0,OTHER,lead,AdventHealth,Phase 4
NCT02478450,2024.0,INDUSTRY,lead,"Q Therapeutics, Inc.",Phase 1/Phase 2
NCT02479139,2015.0,INDUSTRY,lead,Allergan,Phase 2
NCT02479698,2015.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2
NCT02479698,2015.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT02479802,2014.0,INDUSTRY,lead,"Instituto Grifols, S.A.",Phase 2
NCT02480803,2014.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 4
NCT02480803,2014.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT02480985,2015.0,OTHER,lead,CHU de Quebec-Universite Laval,Not Applicable
NCT02480985,2015.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT02480985,2015.0,OTHER,collaborator,Canadian Critical Care Trials Group,Not Applicable
NCT02480985,2015.0,OTHER_GOV,collaborator,Fonds de la Recherche en Santé du Québec,Not Applicable
NCT02481193,2013.0,OTHER,lead,Yangzhou No.1 People's Hospital,Phase 3
NCT02481232,2015.0,INDUSTRY,lead,"Lanzhou Institute of Biological Products Co., Ltd",Phase 1
NCT02481232,2015.0,OTHER,collaborator,"Air Force Military Medical University, China",Phase 1
NCT02481245,2015.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02481245,2015.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 2
NCT02481245,2015.0,UNKNOWN,collaborator,J Willard and Alice S. Marriott Foundation,Phase 2
NCT02481323,2016.0,OTHER,lead,University of Edinburgh,Phase 2
NCT02481323,2016.0,OTHER,collaborator,University of Nottingham,Phase 2
NCT02481440,2018.0,OTHER,lead,Limin Rong,Phase 1/Phase 2
NCT02481609,2014.0,OTHER,lead,University of Miami,Early Phase 1
NCT02481674,2015.0,INDUSTRY,lead,Vaccinex Inc.,Phase 2
NCT02481674,2015.0,NETWORK,collaborator,Huntington Study Group,Phase 2
NCT02481882,2017.0,OTHER,lead,University of Nottingham,Not Applicable
NCT02482194,2013.0,OTHER_GOV,lead,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",Phase 1
NCT02482194,2013.0,FED,collaborator,Armed Forces Institute of Regenerative Medicine,Phase 1
NCT02482233,2015.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT02483169,2009.0,OTHER,lead,Asan Medical Center,Phase 4
NCT02483169,2009.0,INDUSTRY,collaborator,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT02483585,2015.0,INDUSTRY,lead,Amgen,Phase 3
NCT02484001,2016.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 3
NCT02484027,2015.0,OTHER,lead,Second Affiliated Hospital of Soochow University,Phase 4
NCT02484027,2015.0,UNKNOWN,collaborator,Taicang No.1 People's hospital,Phase 4
NCT02484027,2015.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT02484027,2015.0,OTHER_GOV,collaborator,National Natural Science Foundation of China,Phase 4
NCT02484170,2015.0,OTHER,lead,University of British Columbia,Phase 1/Phase 2
NCT02484300,2015.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02484300,2015.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02484300,2015.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT02484547,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02484560,2015.0,OTHER,lead,University of Gaziantep,Phase 1
NCT02484560,2015.0,UNKNOWN,collaborator,"Istınye University, Cukurova University, Yıldırım Beyazıt University, Gaziantep Deva Hospital, Gaziantep Public Hospital",Phase 1
NCT02484703,2015.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02484755,2015.0,OTHER,lead,Huashan Hospital,Phase 2
NCT02484768,2015.0,INDUSTRY,lead,Pharmacosmos A/S,Phase 2
NCT02484768,2015.0,INDUSTRY,collaborator,BioStata,Phase 2
NCT02484768,2015.0,INDUSTRY,collaborator,Laboratory Corporation of America,Phase 2
NCT02485340,2015.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT02485418,2015.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT02485756,2013.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02485938,2016.0,INDUSTRY,lead,Capricor Inc.,Phase 1/Phase 2
NCT02486211,2015.0,OTHER,lead,"Jon Rittenberger, MD",Phase 2
NCT02486211,2015.0,OTHER,collaborator,American Heart Association,Phase 2
NCT02486276,2015.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT02486432,2015.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1
NCT02486432,2015.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT02487082,2015.0,OTHER,lead,Stony Brook University,Phase 2
NCT02487407,2015.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT02487485,2016.0,OTHER,lead,Yale University,Phase 2
NCT02487953,2018.0,OTHER,lead,Duke University,Phase 2
NCT02487953,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02488044,2016.0,INDUSTRY,lead,Aeglea Biotherapeutics,Phase 1/Phase 2
NCT02489097,2013.0,OTHER,lead,"University Hospital, Geneva",Phase 4
NCT02489097,2013.0,OTHER,collaborator,"Prince of Wales Hospital, Shatin, Hong Kong",Phase 4
NCT02489097,2013.0,OTHER,collaborator,Chinese University of Hong Kong,Phase 4
NCT02489292,2014.0,INDUSTRY,lead,Cellaion SA,Phase 2
NCT02489344,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT02490046,2015.0,OTHER,lead,"University College, London",Phase 1
NCT02490046,2015.0,UNKNOWN,collaborator,UCLH,Phase 1
NCT02490436,2015.0,OTHER_GOV,lead,Sorlandet Hospital HF,Phase 2
NCT02490436,2015.0,INDUSTRY,collaborator,"Frontier Science & Technology Research Foundation, Inc.",Phase 2
NCT02490436,2015.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT02490501,2015.0,INDUSTRY,lead,BioArctic AB,Phase 1/Phase 2
NCT02490501,2015.0,OTHER,collaborator,European Commission,Phase 1/Phase 2
NCT02492009,2015.0,OTHER,lead,King's College London,Not Applicable
NCT02492009,2015.0,OTHER,collaborator,University of Toronto,Not Applicable
NCT02492165,2015.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02492165,2015.0,OTHER,collaborator,"National Institute of Hygiene and Epidemiology, Vietnam",Phase 3
NCT02492295,2014.0,OTHER,lead,Albert Einstein Healthcare Network,Not Applicable
NCT02492516,2014.0,OTHER_GOV,lead,Royan Institute,Phase 1
NCT02493049,2015.0,OTHER,lead,University of Calgary,Phase 2
NCT02493049,2015.0,OTHER,collaborator,Alberta Innovates Health Solutions,Phase 2
NCT02493062,2013.0,OTHER,lead,St. Louis University,Not Applicable
NCT02493062,2013.0,OTHER,collaborator,SSM Health,Not Applicable
NCT02493179,2015.0,INDUSTRY,lead,Hayat Pharmaceutical Co. PLC,Phase 4
NCT02493426,2014.0,OTHER,lead,University of Minnesota,Phase 2
NCT02493517,2014.0,INDUSTRY,lead,Ipsen,Phase 3
NCT02494024,2015.0,INDUSTRY,lead,C2N Diagnostics,Phase 1
NCT02494102,2016.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 4
NCT02494778,2015.0,INDUSTRY,lead,Prilenia,Phase 2
NCT02495467,2015.0,INDUSTRY,lead,Futura Medical Developments Ltd.,Phase 2
NCT02495467,2015.0,INDUSTRY,collaborator,Richmond Pharmacology Limited,Phase 2
NCT02495766,2015.0,OTHER,lead,Banc de Sang i Teixits,Phase 1/Phase 2
NCT02495766,2015.0,UNKNOWN,collaborator,Vall d'Hebron Research Institute (VHIR),Phase 1/Phase 2
NCT02495883,2013.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT02495883,2013.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT02496520,2014.0,OTHER,lead,"Clinica Universidad de Navarra, Universidad de Navarra",Phase 1/Phase 2
NCT02496767,2015.0,INDUSTRY,lead,Cytokinetics,Phase 3
NCT02496845,2015.0,OTHER,lead,VasoLead (2012) Ltd.,Phase 1/Phase 2
NCT02496884,2015.0,INDUSTRY,lead,Daiichi Sankyo,Phase 3
NCT02496884,2015.0,OTHER,collaborator,Syneos Health,Phase 3
NCT02496962,2015.0,OTHER,lead,Shi Yang,Not Applicable
NCT02496975,2017.0,OTHER,lead,"Edward Hall,PhD",Phase 1/Phase 2
NCT02497443,2011.0,OTHER_GOV,lead,"Ministry of Public Health, Republic of Belarus",Phase 1/Phase 2
NCT02498392,2015.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT02499029,2013.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT02499354,2014.0,OTHER,lead,Auerbach Hematology Oncology Associates P C,Phase 2
NCT02499354,2014.0,INDUSTRY,collaborator,"AMAG Pharmaceuticals, Inc.",Phase 2
NCT02499900,2015.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT02500342,2014.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT02500342,2014.0,OTHER,collaborator,University College Cork,Phase 4
NCT02500342,2014.0,OTHER,collaborator,University of Lausanne Hospitals,Phase 4
NCT02500381,2016.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT02500459,2015.0,OTHER,lead,"Michael Vogelbaum, MD, PhD",Early Phase 1
NCT02500459,2015.0,INDUSTRY,collaborator,"Infuseon Therapeutics, Inc.",Early Phase 1
NCT02500602,2016.0,FED,lead,VA Office of Research and Development,Phase 2
NCT02500602,2016.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT02500628,2015.0,OTHER,lead,Woodinville Psychiatric Associates,Phase 2
NCT02500732,2015.0,OTHER,lead,University of Calgary,Phase 2
NCT02500732,2015.0,OTHER,collaborator,Cardiac Arrhythmia Network of Canada,Phase 2
NCT02500784,2023.0,OTHER,lead,Palo Alto Veterans Institute for Research,Phase 2
NCT02500784,2023.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT02500784,2023.0,INDUSTRY,collaborator,Mylan Inc.,Phase 2
NCT02501109,2015.0,INDUSTRY,lead,CMG Pharmaceutical Co. Ltd,Phase 1
NCT02501265,2017.0,OTHER,lead,Duke University,Phase 2
NCT02501265,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02501265,2017.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT02501434,2016.0,OTHER,lead,Robert F. James,Phase 2
NCT02501434,2016.0,OTHER,collaborator,Indiana University School of Medicine,Phase 2
NCT02501928,2015.0,INDUSTRY,lead,Pfizer,Phase 3
NCT02501941,2015.0,OTHER,lead,University of New Mexico,Phase 1
NCT02502032,2015.0,OTHER,lead,Zhuan Zhang,Phase 3
NCT02502162,2015.0,OTHER,lead,Stanford University,Not Applicable
NCT02502253,2015.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT02502253,2015.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 1
NCT02503124,2015.0,OTHER,lead,"Sahlgrenska University Hospital, Sweden",Not Applicable
NCT02504008,2015.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT02504151,2016.0,OTHER,lead,Yale University,Phase 2
NCT02504554,2014.0,OTHER,lead,Arizona State University,Phase 1/Phase 2
NCT02504554,2014.0,OTHER,collaborator,Northern Arizona University,Phase 1/Phase 2
NCT02504554,2014.0,OTHER,collaborator,University of Arizona,Phase 1/Phase 2
NCT02504554,2014.0,OTHER,collaborator,University of Minnesota,Phase 1/Phase 2
NCT02504931,2011.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 4
NCT02504931,2011.0,UNKNOWN,collaborator,STRONG STAR Multidisciplinary PTSD Research Consortium,Phase 4
NCT02504931,2011.0,FED,collaborator,South Texas Veterans Health Care System,Phase 4
NCT02504931,2011.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 4
NCT02504931,2011.0,FED,collaborator,United States Department of Defense,Phase 4
NCT02504996,2015.0,OTHER,lead,Akdeniz University,Phase 4
NCT02504996,2015.0,OTHER,collaborator,Pamukkale University,Phase 4
NCT02504996,2015.0,OTHER_GOV,collaborator,Antalya Training and Research Hospital,Phase 4
NCT02504996,2015.0,OTHER,collaborator,University of Gaziantep,Phase 4
NCT02504996,2015.0,OTHER,collaborator,Ataturk University,Phase 4
NCT02505477,2017.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT02505802,2014.0,OTHER,lead,Sir Run Run Shaw Hospital,Phase 4
NCT02506140,2015.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2/Phase 3
NCT02506140,2015.0,OTHER,collaborator,Beijing Municipal Science & Technology Commission,Phase 2/Phase 3
NCT02506673,2016.0,OTHER,lead,"Hospital for Special Surgery, New York",Not Applicable
NCT02506686,2008.0,OTHER,lead,Huashan Hospital,Phase 4
NCT02506751,2015.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT02507206,2013.0,OTHER,lead,Antonia New,Phase 2
NCT02507206,2013.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT02507206,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT02507284,2016.0,INDUSTRY,lead,Azevan Pharmaceuticals,Phase 2
NCT02507284,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02507284,2016.0,UNKNOWN,collaborator,NeuroNEXT Network,Phase 2
NCT02507700,2015.0,OTHER,lead,Diskapi Teaching and Research Hospital,Not Applicable
NCT02508259,2015.0,OTHER,lead,"University of California, San Diego",Phase 1/Phase 2
NCT02508311,2016.0,FED,lead,VA Office of Research and Development,Phase 4
NCT02509520,2015.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT02509793,2018.0,OTHER,lead,"William Ondo, MD",Phase 4
NCT02509793,2018.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT02509936,2015.0,OTHER,lead,"Wuqu' Kawoq, Maya Health Alliance",Not Applicable
NCT02509936,2015.0,OTHER,collaborator,"Universidad del Valle, Guatemala",Not Applicable
NCT02509936,2015.0,OTHER,collaborator,Grand Challenges Canada,Not Applicable
NCT02510222,2015.0,OTHER,lead,Ain Shams University,Not Applicable
NCT02510586,2015.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02511028,2015.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02511028,2015.0,NIH,collaborator,National Institutes of Health Clinical Center (CC),Phase 1
NCT02511704,2014.0,OTHER,lead,Parc de Salut Mar,Phase 1
NCT02511704,2014.0,OTHER,collaborator,Istituto Superiore di Sanità,Phase 1
NCT02511873,2016.0,OTHER,lead,PNA Center for Neurological Research,Phase 2
NCT02511873,2016.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2
NCT02512029,2015.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT02512588,2015.0,INDUSTRY,lead,Balance Therapeutics,Phase 2
NCT02512809,2015.0,OTHER,lead,Nationwide Children's Hospital,Phase 3
NCT02512809,2015.0,OTHER,collaborator,Ohio State University,Phase 3
NCT02513433,2012.0,OTHER,lead,"Government Medical College, Haldwani",Not Applicable
NCT02513485,2015.0,OTHER,lead,Emory University,Phase 4
NCT02513485,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02513589,2017.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT02513654,2015.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT02513992,2016.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT02514044,2015.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02514746,2015.0,OTHER,lead,PATH,Phase 4
NCT02514746,2015.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT02515695,2005.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 1
NCT02515695,2005.0,INDUSTRY,collaborator,BioPartners GmbH,Phase 1
NCT02515773,2015.0,OTHER,lead,Melissa Delbello,Phase 4
NCT02515773,2015.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT02515890,2015.0,OTHER,lead,University of Pittsburgh,Phase 1
NCT02515890,2015.0,OTHER,collaborator,Foundation for Anesthesia Education and Research,Phase 1
NCT02516046,2015.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT02516085,2012.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 1
NCT02517424,2017.0,INDUSTRY,lead,Tilray,Phase 2
NCT02517424,2017.0,OTHER,collaborator,University of British Columbia,Phase 2
NCT02517788,2006.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 1
NCT02517788,2006.0,INDUSTRY,collaborator,BioPartners GmbH,Phase 1
NCT02517931,2019.0,OTHER,lead,University of Arkansas,Not Applicable
NCT02518464,2015.0,OTHER,lead,Columbia University,Phase 4
NCT02518464,2015.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT02518789,2015.0,OTHER,lead,Tang-Du Hospital,Phase 4
NCT02519036,2015.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT02519387,2013.0,INDUSTRY,lead,Mundipharma Pharmaceuticals Sdn. Bhd.,Phase 4
NCT02519400,2015.0,OTHER,lead,Asan Medical Center,Phase 1
NCT02519543,2015.0,OTHER,lead,Cynthia Calkin,Phase 3
NCT02519543,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT02520934,2015.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT02520934,2015.0,INDUSTRY,collaborator,Actelion,Not Applicable
NCT02520947,2014.0,OTHER,lead,Baskent University Ankara Hospital,Not Applicable
NCT02521012,2015.0,OTHER,lead,Kuopio University Hospital,Not Applicable
NCT02521311,2017.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT02521311,2017.0,OTHER,collaborator,Moorfields Eye Hospital NHS Foundation Trust,Phase 2
NCT02521493,2015.0,NETWORK,lead,Children's Oncology Group,Phase 3
NCT02521493,2015.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT02521545,2015.0,INDUSTRY,lead,Biogen,Phase 1
NCT02523664,2014.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT02523690,2015.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT02523703,2007.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT02524301,2009.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Not Applicable
NCT02524301,2009.0,OTHER_GOV,collaborator,"Ministry of Health, France",Not Applicable
NCT02524899,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT02524899,2014.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 2
NCT02525172,2015.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT02525302,2015.0,INDUSTRY,lead,Akashi Therapeutics,Phase 2
NCT02525432,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02525432,2016.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02525432,2016.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT02525874,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02526030,2008.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT02526030,2008.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT02526030,2008.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT02526394,2013.0,OTHER_GOV,lead,Public Health England,Phase 4
NCT02526550,2014.0,OTHER,lead,Siriraj Hospital,Phase 4
NCT02526550,2014.0,INDUSTRY,collaborator,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02527460,2015.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02527460,2015.0,OTHER,collaborator,Johns Hopkins University,Phase 1
NCT02527564,2015.0,OTHER,lead,Stanford University,Phase 4
NCT02527564,2015.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT02528409,2016.0,OTHER,lead,University of Chicago,Phase 2
NCT02528409,2016.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT02528513,2015.0,OTHER,lead,West China Hospital,Phase 4
NCT02529124,2012.0,OTHER,lead,Phil Jakeman,Not Applicable
NCT02529423,2015.0,OTHER,lead,University of the Balearic Islands,Not Applicable
NCT02529423,2015.0,OTHER,collaborator,VU University of Amsterdam,Not Applicable
NCT02529423,2015.0,OTHER,collaborator,University of Exeter,Not Applicable
NCT02529423,2015.0,OTHER,collaborator,University of Leipzig,Not Applicable
NCT02529670,2014.0,OTHER,lead,University of Nove de Julho,Not Applicable
NCT02529670,2014.0,OTHER_GOV,collaborator,Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Not Applicable
NCT02529839,2015.0,OTHER,lead,Hadassah Medical Organization,Not Applicable
NCT02529917,2015.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT02530164,2015.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Not Applicable
NCT02530255,2016.0,OTHER,lead,Chippewa Valley Eye Clinic,Not Applicable
NCT02530255,2016.0,UNKNOWN,collaborator,TA-Sciences,Not Applicable
NCT02530281,2015.0,INDUSTRY,lead,Journey Medical Corporation,Phase 3
NCT02530294,2015.0,INDUSTRY,lead,Journey Medical Corporation,Phase 3
NCT02530905,2015.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT02531217,2015.0,INDUSTRY,lead,"aTyr Pharma, Inc.",Phase 1/Phase 2
NCT02531633,2015.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT02531880,2024.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02532023,2015.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT02532153,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT02532322,2015.0,OTHER,lead,Children's National Research Institute,Phase 2
NCT02532491,2014.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT02532491,2014.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT02532491,2014.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT02532569,2015.0,INDUSTRY,lead,"Boryung Pharmaceutical Co., Ltd",Phase 4
NCT02532660,2018.0,INDUSTRY,lead,Laboratório Catarinense SA,Phase 3
NCT02532660,2018.0,OTHER,collaborator,Universidade Federal do Ceara,Phase 3
NCT02532660,2018.0,OTHER,collaborator,Financiadora de Estudos e Projetos,Phase 3
NCT02532686,2014.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT02532686,2014.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Phase 2
NCT02533128,2015.0,OTHER,lead,"Miodrag Filipovic, Prof. Dr. med.",Not Applicable
NCT02533232,2022.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 1
NCT02534363,2005.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT02534363,2005.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT02534363,2005.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT02534454,2015.0,OTHER,lead,The Mind Research Network,Not Applicable
NCT02534454,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02534480,2015.0,INDUSTRY,lead,NeuroGenetic Pharmaceuticals Inc,Phase 1
NCT02534844,2015.0,INDUSTRY,lead,Mandos LLC,Phase 2/Phase 3
NCT02535039,2015.0,OTHER,lead,Shengjing Hospital,Phase 1/Phase 2
NCT02535091,2016.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT02535156,2003.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1/Phase 2
NCT02536417,2016.0,OTHER,lead,Fraser Health,Phase 3
NCT02536755,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT02536911,2015.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 1
NCT02536937,2015.0,INDUSTRY,lead,Sanofi,Phase 1
NCT02536976,2015.0,OTHER,lead,HealthPartners Institute,Phase 4
NCT02537106,2015.0,OTHER,lead,University Hospital Hradec Kralove,Not Applicable
NCT02537197,2016.0,OTHER,lead,University of Calgary,Phase 1
NCT02537197,2016.0,OTHER,collaborator,Alberta Health services,Phase 1
NCT02537899,2015.0,INDUSTRY,lead,Moleac Pte Ltd.,Phase 4
NCT02537938,2016.0,INDUSTRY,lead,NeuroGenetic Pharmaceuticals Inc,Phase 1
NCT02537938,2016.0,INDUSTRY,collaborator,WCCT Global,Phase 1
NCT02537951,2015.0,OTHER,lead,Erasmus Medical Center,Not Applicable
NCT02538081,2015.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT02538081,2015.0,OTHER,collaborator,"University of Colorado, Denver",Phase 1/Phase 2
NCT02538302,2013.0,OTHER,lead,Hormozgan University of Medical Sciences,Phase 3
NCT02538744,2015.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT02539134,2015.0,INDUSTRY,lead,Takeda,Phase 1
NCT02539186,2015.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT02540655,2015.0,INDUSTRY,lead,Steminent Biotherapeutics Inc.,Phase 2
NCT02541032,2015.0,OTHER,lead,University of South Carolina,Phase 3
NCT02541032,2015.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 3
NCT02541370,2015.0,OTHER,lead,Chinese PLA General Hospital,Phase 1/Phase 2
NCT02541500,2013.0,OTHER,lead,Universiti Sains Malaysia,Phase 3
NCT02541500,2013.0,OTHER,collaborator,Yale University,Phase 3
NCT02541513,2013.0,OTHER,lead,Universiti Sains Malaysia,Phase 3
NCT02541513,2013.0,OTHER,collaborator,Yale University,Phase 3
NCT02541526,2013.0,OTHER,lead,Universiti Sains Malaysia,Phase 3
NCT02541526,2013.0,OTHER,collaborator,Yale University,Phase 3
NCT02542605,2015.0,INDUSTRY,lead,Amgen,Phase 1
NCT02542696,2015.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT02542839,2015.0,OTHER,lead,University of Florida,Not Applicable
NCT02542839,2015.0,OTHER,collaborator,American Brain Foundation,Not Applicable
NCT02542839,2015.0,OTHER,collaborator,Neuronetics,Not Applicable
NCT02543203,2015.0,OTHER,lead,Jill Hollway,Phase 2
NCT02543203,2015.0,UNKNOWN,collaborator,Young Living Essential Oils,Phase 2
NCT02543944,2016.0,OTHER,lead,University of Arkansas,Phase 2/Phase 3
NCT02543944,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT02543983,2015.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT02544217,2015.0,INDUSTRY,lead,Khondrion BV,Phase 1
NCT02544217,2015.0,UNKNOWN,collaborator,"Drug Research Unit Ghent, Belgium",Phase 1
NCT02544607,2016.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02544607,2016.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 4
NCT02544607,2016.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT02544750,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02544750,2016.0,UNKNOWN,collaborator,GW Pharmaceuticals,Phase 3
NCT02544763,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02545114,2015.0,INDIV,lead,"Polderman, Kees, H., MD, PhD",Not Applicable
NCT02545114,2015.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT02545868,2015.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT02545959,2015.0,OTHER,lead,Centre Hospitalier de PAU,Phase 2
NCT02545959,2015.0,OTHER,collaborator,"University Hospital, Bordeaux",Phase 2
NCT02546310,2015.0,INDUSTRY,lead,Heptares Therapeutics Limited,Phase 1
NCT02546310,2015.0,INDUSTRY,collaborator,P1vital Limited,Phase 1
NCT02546765,2015.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 4
NCT02546999,2015.0,OTHER,lead,St. Olavs Hospital,Phase 4
NCT02546999,2015.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 4
NCT02546999,2015.0,OTHER,collaborator,The Hospital of Vestfold,Phase 4
NCT02546999,2015.0,OTHER,collaborator,University Hospital of North Norway,Phase 4
NCT02546999,2015.0,OTHER,collaborator,Oslo University Hospital,Phase 4
NCT02546999,2015.0,OTHER,collaborator,Haukeland University Hospital,Phase 4
NCT02546999,2015.0,OTHER,collaborator,Fondation Lenval,Phase 4
NCT02546999,2015.0,UNKNOWN,collaborator,"Mazowieckie Centrum Neuropsychiatrii, Warszawa",Phase 4
NCT02547818,2015.0,INDUSTRY,lead,"AZTherapies, Inc.",Phase 3
NCT02547818,2015.0,UNKNOWN,collaborator,PharmaConsulting Group,Phase 3
NCT02547818,2015.0,UNKNOWN,collaborator,KCAS Bio,Phase 3
NCT02547818,2015.0,UNKNOWN,collaborator,APCER Life Sciences,Phase 3
NCT02548923,2014.0,OTHER,lead,University of Tennessee Graduate School of Medicine,Phase 4
NCT02549118,2015.0,OTHER,lead,Ain Shams Maternity Hospital,Phase 2
NCT02549170,2015.0,INDUSTRY,lead,Baxalta now part of Shire,Phase 3
NCT02549170,2015.0,INDUSTRY,collaborator,"Takeda Development Center Americas, Inc.",Phase 3
NCT02549573,2016.0,INDUSTRY,lead,"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",Phase 4
NCT02549716,2017.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 4
NCT02549768,2015.0,OTHER,lead,Pontificia Universidad Catolica de Chile,Phase 4
NCT02549898,2015.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT02549963,2015.0,OTHER,lead,Shulin Wu,Phase 4
NCT02549963,2015.0,OTHER,collaborator,Wuhan Asia Heart Hospital,Phase 4
NCT02549963,2015.0,OTHER,collaborator,Beijing Anzhen Hospital,Phase 4
NCT02549963,2015.0,OTHER,collaborator,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT02549963,2015.0,OTHER,collaborator,Second Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT02549963,2015.0,OTHER,collaborator,The First Affiliated Hospital of Guangzhou Medical University,Phase 4
NCT02549963,2015.0,OTHER,collaborator,Guangdong Medical College,Phase 4
NCT02549963,2015.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Phase 4
NCT02549963,2015.0,OTHER,collaborator,"Nanfang Hospital, Southern Medical University",Phase 4
NCT02550509,2013.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Not Applicable
NCT02550665,2014.0,OTHER,lead,Asan Medical Center,Phase 3
NCT02550665,2014.0,OTHER,collaborator,Dong-A University,Phase 3
NCT02550665,2014.0,OTHER,collaborator,Myongji Hospital,Phase 3
NCT02550665,2014.0,OTHER,collaborator,Seoul National University Bundang Hospital,Phase 3
NCT02550665,2014.0,OTHER,collaborator,Seoul St. Mary's Hospital,Phase 3
NCT02550665,2014.0,OTHER,collaborator,Chung-Ang University,Phase 3
NCT02550665,2014.0,INDUSTRY,collaborator,Eisai Inc.,Phase 3
NCT02550756,2014.0,INDUSTRY,lead,Centrexion Therapeutics,Phase 1
NCT02551003,2015.0,OTHER,lead,Children's Hospital of Fudan University,Phase 1/Phase 2
NCT02551003,2015.0,OTHER,collaborator,Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region,Phase 1/Phase 2
NCT02551003,2015.0,OTHER,collaborator,Guangzhou Women and Children's Medical Center,Phase 1/Phase 2
NCT02551380,2015.0,OTHER,lead,"Central Hospital, Nancy, France",Phase 2
NCT02551731,2016.0,INDUSTRY,lead,INSYS Therapeutics Inc,Phase 2
NCT02551809,2015.0,INDUSTRY,lead,United Neuroscience Ltd.,Phase 2
NCT02551848,2014.0,OTHER,lead,"Western University, Canada",Phase 2
NCT02552147,2015.0,OTHER,lead,Yale University,Phase 1
NCT02552147,2015.0,OTHER,collaborator,Autism Speaks,Phase 1
NCT02552277,2015.0,INDUSTRY,lead,Celularity Incorporated,Phase 2
NCT02552303,2014.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT02552303,2014.0,INDUSTRY,collaborator,"Teva Pharmaceutical Industries, Ltd.",Not Applicable
NCT02552758,2015.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT02553161,2015.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT02553161,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02553265,2015.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02553798,2015.0,INDUSTRY,lead,Journey Medical Corporation,Phase 3
NCT02553824,2015.0,OTHER,lead,Stanford University,Phase 1
NCT02554253,2015.0,OTHER,lead,Mayo Clinic,Phase 2
NCT02554487,2015.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT02554487,2015.0,OTHER,collaborator,Swiss National Science Foundation,Not Applicable
NCT02554487,2015.0,UNKNOWN,collaborator,TROPOS Stiftung für Humane Verhaltensforschung,Not Applicable
NCT02554734,2015.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 1
NCT02555215,2016.0,INDUSTRY,lead,Biogen,Phase 3
NCT02556320,2013.0,OTHER,lead,"University Hospital, Rouen",Not Applicable
NCT02557737,2012.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 3
NCT02558569,2015.0,OTHER,lead,Mahidol University,Phase 4
NCT02558972,2015.0,OTHER,lead,New York Medical College,Phase 2
NCT02558972,2015.0,INDUSTRY,collaborator,Lundbeck LLC,Phase 2
NCT02559102,2015.0,OTHER_GOV,lead,KK Women's and Children's Hospital,Phase 3
NCT02559102,2015.0,OTHER_GOV,collaborator,Singhealth Foundation,Phase 3
NCT02559102,2015.0,OTHER,collaborator,Singapore Institute for Clinical Sciences,Phase 3
NCT02559102,2015.0,OTHER,collaborator,Duke-NUS Graduate Medical School,Phase 3
NCT02559167,2016.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2
NCT02559830,2015.0,OTHER,lead,Shenzhen Second People's Hospital,Phase 1/Phase 2
NCT02559830,2015.0,OTHER,collaborator,Shenzhen University,Phase 1/Phase 2
NCT02559830,2015.0,OTHER,collaborator,Guangzhou Women and Children's Medical Center,Phase 1/Phase 2
NCT02559895,2015.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 3
NCT02560324,2015.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT02560324,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02560324,2015.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT02560389,2016.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT02560545,2015.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT02560753,2015.0,INDUSTRY,lead,"T3D Therapeutics, Inc.",Phase 1/Phase 2
NCT02560805,2015.0,OTHER,lead,Emory University,Phase 2
NCT02560805,2015.0,OTHER,collaborator,American Heart Association,Phase 2
NCT02560935,2016.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT02560935,2016.0,OTHER,collaborator,Aminu Kano Teaching Hospital,Phase 3
NCT02560935,2016.0,OTHER,collaborator,Murtala Muhammed Specialist Hospital,Phase 3
NCT02560935,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT02560935,2016.0,UNKNOWN,collaborator,Barau Dikko Teaching Hospital/Kaduna State University,Phase 3
NCT02561091,2015.0,INDUSTRY,lead,Auris Medical AG,Phase 3
NCT02561156,2015.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT02561156,2015.0,INDUSTRY,collaborator,Takeda,Phase 1
NCT02561481,2015.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 1/Phase 2
NCT02561481,2015.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 1/Phase 2
NCT02561481,2015.0,OTHER,collaborator,Johns Hopkins University,Phase 1/Phase 2
NCT02561702,2015.0,OTHER,lead,University of Rochester,Phase 2
NCT02561754,2015.0,OTHER,lead,University of Kansas Medical Center,Not Applicable
NCT02561754,2015.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT02562066,2016.0,INDUSTRY,lead,"Catalyst Pharmaceuticals, Inc.",Phase 3
NCT02562183,2015.0,INDUSTRY,lead,"Techpool Bio-Pharma Co., Ltd.",Phase 4
NCT02562287,2015.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 4
NCT02562287,2015.0,OTHER_GOV,collaborator,Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Phase 4
NCT02562287,2015.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4
NCT02562430,2016.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02562768,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02562820,2015.0,OTHER,lead,The Cleveland Clinic,Phase 1
NCT02562989,2015.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT02563288,2016.0,OTHER,lead,George Papanicolaou Hospital,Phase 3
NCT02563769,2016.0,OTHER,lead,Temple University,Phase 1
NCT02563769,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02563769,2016.0,OTHER,collaborator,University of Pennsylvania,Phase 1
NCT02563860,2015.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT02563860,2015.0,OTHER,collaborator,Rett Syndrome Research Trust,Phase 2
NCT02563899,2015.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT02564068,2015.0,OTHER,lead,George Washington University,Early Phase 1
NCT02564328,2014.0,OTHER,lead,"Southern Medical University, China",Phase 1
NCT02564328,2014.0,OTHER,collaborator,Second Affiliated Hospital of Guangzhou Medical University,Phase 1
NCT02564341,2015.0,OTHER,lead,Boston Medical Center,Not Applicable
NCT02564341,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02564341,2015.0,OTHER,collaborator,Emory University,Not Applicable
NCT02564341,2015.0,OTHER,collaborator,Grady Health System,Not Applicable
NCT02564588,2015.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2/Phase 3
NCT02564939,2017.0,OTHER,lead,Hartford Hospital,Phase 4
NCT02564952,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02565108,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02565121,2013.0,OTHER,lead,St. Olavs Hospital,Not Applicable
NCT02565121,2013.0,OTHER,collaborator,Norwegian University of Science and Technology,Not Applicable
NCT02565186,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02565186,2015.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 3
NCT02565316,2014.0,OTHER,lead,Shiraz University of Medical Sciences,Phase 2/Phase 3
NCT02565628,2015.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02565693,2014.0,OTHER,lead,UMC Utrecht,Phase 2
NCT02565693,2014.0,OTHER,collaborator,Dutch Heart Foundation,Phase 2
NCT02565693,2014.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 2
NCT02565732,2015.0,INDUSTRY,lead,"Revance Therapeutics, Inc.",Phase 2
NCT02566057,2014.0,OTHER,lead,Northwell Health,Not Applicable
NCT02566057,2014.0,INDUSTRY,collaborator,"Genomind, LLC",Not Applicable
NCT02566226,2015.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT02566356,2012.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT02566356,2012.0,FED,collaborator,San Francisco Veterans Affairs Medical Center,Early Phase 1
NCT02566590,2015.0,OTHER,lead,University of Utah,Not Applicable
NCT02566720,2016.0,OTHER,lead,Hamilton Health Sciences Corporation,Not Applicable
NCT02567032,2010.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT02567032,2010.0,FED,collaborator,San Francisco Veterans Affairs Medical Center,Early Phase 1
NCT02567279,2016.0,OTHER,lead,"University Hospital, Montpellier",Phase 3
NCT02567279,2016.0,OTHER,collaborator,"University Hospital, Lille",Phase 3
NCT02567279,2016.0,OTHER,collaborator,Nantes University Hospital,Phase 3
NCT02567279,2016.0,OTHER,collaborator,"University Hospital, Paris",Phase 3
NCT02567279,2016.0,OTHER,collaborator,"University Hospital, Rouen",Phase 3
NCT02568020,2016.0,OTHER,lead,YUAN Wei-jie,Phase 4
NCT02568124,2015.0,OTHER,lead,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Phase 2/Phase 3
NCT02568124,2015.0,OTHER,collaborator,Université de Sherbrooke,Phase 2/Phase 3
NCT02568644,2014.0,OTHER,lead,Federal University of Minas Gerais,Not Applicable
NCT02568709,2012.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT02568878,2015.0,OTHER,lead,Montana State University,Phase 3
NCT02569307,2015.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 2
NCT02569775,2014.0,OTHER,lead,Vinmec Healthcare System,Phase 2
NCT02569970,2010.0,OTHER,lead,Hospices Civils de Lyon,Phase 3
NCT02570282,2015.0,INDUSTRY,lead,"Strategic Science & Technologies, LLC",Phase 2
NCT02570724,2013.0,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT02570932,2015.0,OTHER,lead,Puerta de Hierro University Hospital,Phase 2
NCT02571101,2015.0,INDUSTRY,lead,"CTC Bio, Inc.",Phase 2
NCT02571101,2015.0,INDUSTRY,collaborator,Symyoo,Phase 2
NCT02572674,2010.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02573168,2016.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Not Applicable
NCT02573168,2016.0,OTHER,collaborator,Programs for Assessment of Technology in Health Research Institute,Not Applicable
NCT02573168,2016.0,OTHER,collaborator,Centre for Addiction and Mental Health,Not Applicable
NCT02573168,2016.0,OTHER,collaborator,Genome Canada,Not Applicable
NCT02573168,2016.0,OTHER,collaborator,AssureRx Canada Ltd,Not Applicable
NCT02573168,2016.0,INDUSTRY,collaborator,Assurex Health Inc.,Not Applicable
NCT02573168,2016.0,OTHER,collaborator,Mars Excellence in Clinical Innovation and Technology Evaluation,Not Applicable
NCT02573701,2011.0,OTHER_GOV,lead,"Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico",Not Applicable
NCT02573740,2015.0,INDUSTRY,lead,AbbVie,Phase 1
NCT02574286,2016.0,INDUSTRY,lead,Shire,Phase 4
NCT02574572,2017.0,OTHER,lead,Hospital Sao Rafael,Phase 1
NCT02574585,2019.0,OTHER,lead,Hospital Sao Rafael,Phase 2
NCT02574741,2012.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT02574923,2015.0,OTHER,lead,Vinmec Healthcare System,Phase 2
NCT02575183,2016.0,OTHER,lead,American University of Beirut Medical Center,Phase 4
NCT02575183,2016.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT02575235,2015.0,OTHER,lead,Seoul National University Hospital,Early Phase 1
NCT02575521,2015.0,OTHER,lead,Mansoura University,Not Applicable
NCT02576639,2015.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT02576717,2015.0,INDUSTRY,lead,Celgene,Phase 3
NCT02577250,2015.0,FED,lead,Minneapolis Veterans Affairs Medical Center,Phase 1
NCT02577523,2015.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 2
NCT02577575,2010.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT02577575,2010.0,FED,collaborator,San Francisco Veterans Affairs Medical Center,Early Phase 1
NCT02578719,2016.0,OTHER,lead,Bozok University,Phase 4
NCT02579148,2015.0,OTHER,lead,Leilei Zhu,Phase 1
NCT02579148,2015.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Phase 1
NCT02579239,2015.0,INDUSTRY,lead,"aTyr Pharma, Inc.",Phase 1/Phase 2
NCT02579252,2016.0,INDUSTRY,lead,Axon Neuroscience SE,Phase 2
NCT02579421,2015.0,OTHER,lead,University of Minnesota,Not Applicable
NCT02579473,2016.0,INDUSTRY,lead,Serina Therapeutics,Phase 1
NCT02579642,2015.0,OTHER,lead,University of Alberta,Phase 4
NCT02579642,2015.0,OTHER,collaborator,Alberta Health services,Phase 4
NCT02579681,2014.0,INDUSTRY,lead,Biogen,Phase 3
NCT02579928,2015.0,OTHER,lead,Yale University,Phase 4
NCT02579928,2015.0,OTHER,collaborator,American Academy of Child Adolescent Psychiatry.,Phase 4
NCT02580019,2016.0,OTHER,lead,Affiliated Hospital to Academy of Military Medical Sciences,Phase 2
NCT02580201,2015.0,OTHER,lead,Fidec Corporation,Phase 4
NCT02580201,2015.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT02580305,2015.0,INDUSTRY,lead,Suven Life Sciences Limited,Phase 2
NCT02580838,2015.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 3
NCT02580968,2015.0,OTHER,lead,Shanghai University of Traditional Chinese Medicine,Not Applicable
NCT02581111,2015.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT02581826,2013.0,OTHER,lead,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",Phase 2
NCT02581865,2015.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT02582151,2016.0,OTHER,lead,Lawson Health Research Institute,Not Applicable
NCT02582255,2015.0,OTHER,lead,Fidec Corporation,Phase 4
NCT02582255,2015.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT02582476,2015.0,OTHER,lead,"University College, London",Phase 2
NCT02582515,2015.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT02582866,2016.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT02582866,2016.0,INDUSTRY,collaborator,Parexel,Phase 3
NCT02582905,2016.0,OTHER,lead,"Sherwood Brown, MD, PhD",Phase 4
NCT02582905,2016.0,OTHER,collaborator,University of Miami,Phase 4
NCT02582905,2016.0,OTHER,collaborator,University of Texas Rio Grande Valley,Phase 4
NCT02582996,2020.0,INDUSTRY,lead,Ache Laboratorios Farmaceuticos S.A.,Phase 3
NCT02584413,2013.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT02584413,2013.0,OTHER,collaborator,St. Louis Children's Hospital,Not Applicable
NCT02584426,2017.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Not Applicable
NCT02584712,2014.0,OTHER,lead,Federal University of Maranhao,Not Applicable
NCT02585765,2017.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT02585934,2015.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 3
NCT02586142,2010.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 3
NCT02586649,2014.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT02586909,2016.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 3
NCT02586935,2016.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT02586935,2016.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT02586935,2016.0,OTHER,collaborator,McMaster University,Phase 2
NCT02586935,2016.0,OTHER,collaborator,"University of Western Ontario, Canada",Phase 2
NCT02586935,2016.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT02586935,2016.0,OTHER,collaborator,University of Toronto,Phase 2
NCT02587195,2015.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 3
NCT02587715,2015.0,INDUSTRY,lead,Novo Cellular Medicine Institute LLP,Phase 1/Phase 2
NCT02587806,2015.0,INDUSTRY,lead,Novo Cellular Medicine Institute LLP,Phase 1/Phase 2
NCT02587988,2014.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 3
NCT02588196,2015.0,OTHER,lead,Hui Bu,Phase 4
NCT02588742,2015.0,OTHER,lead,Yonsei University,Not Applicable
NCT02588807,2021.0,INDUSTRY,lead,Herb Spirit,Phase 1
NCT02588807,2021.0,OTHER,collaborator,Carmel Medical Center,Phase 1
NCT02589262,2015.0,INDUSTRY,lead,Autifony Therapeutics Limited,Phase 1
NCT02589340,2016.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT02589340,2016.0,FED,collaborator,Portland VA Medical Center,Phase 1
NCT02590367,2015.0,OTHER,lead,Jiangsu Province Hospital of Traditional Chinese Medicine,Phase 2/Phase 3
NCT02590393,2021.0,OTHER,lead,Duke University,Phase 1/Phase 2
NCT02590393,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT02590510,2015.0,OTHER,lead,Hui Bu,Phase 4
NCT02590848,2016.0,OTHER,lead,Barcelona Institute for Global Health,Not Applicable
NCT02590848,2016.0,OTHER_GOV,collaborator,Carlos III Health Institute,Not Applicable
NCT02590874,2016.0,OTHER,lead,University of North Texas Health Science Center,Phase 4
NCT02591004,2015.0,OTHER,lead,Kasr El Aini Hospital,Phase 2/Phase 3
NCT02591173,2016.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT02591290,2015.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02591901,2018.0,OTHER,lead,Buckinghamshire Healthcare NHS Trust,Phase 2
NCT02591901,2018.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 2
NCT02591901,2018.0,UNKNOWN,collaborator,Oxford Clinical Trials Research Unit,Phase 2
NCT02592863,2015.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT02593097,2016.0,OTHER,lead,Mayo Clinic,Phase 3
NCT02593396,2015.0,OTHER,lead,University of Malaya,Phase 2
NCT02593643,2016.0,OTHER,lead,Sunnybrook Health Sciences Centre,Early Phase 1
NCT02593682,2016.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT02593734,2013.0,OTHER,lead,University of Ghana Medical School,Phase 4
NCT02593773,2015.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT02593773,2015.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 3
NCT02593942,2015.0,OTHER,lead,Yeditepe University Hospital,Phase 4
NCT02594124,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02594358,2014.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT02594579,2015.0,OTHER,lead,Mahidol University,Phase 3
NCT02594735,2015.0,OTHER,lead,George Washington University,Phase 4
NCT02595749,2016.0,OTHER,lead,University of Southern California,Phase 4
NCT02595983,2015.0,INDUSTRY,lead,Alnylam Pharmaceuticals,Phase 2
NCT02596022,2013.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT02596360,2015.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 1
NCT02596412,2015.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT02596412,2015.0,OTHER,collaborator,Fondation Apicil,Not Applicable
NCT02596412,2015.0,OTHER,collaborator,Fondation Motrice,Not Applicable
NCT02597231,2015.0,OTHER,lead,Scripps Health,Phase 1/Phase 2
NCT02597231,2015.0,OTHER,collaborator,Scripps Clinic,Phase 1/Phase 2
NCT02597257,2015.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT02597257,2015.0,OTHER_GOV,collaborator,"Ministry of Food and Drug Safety, Korea",Phase 2
NCT02599207,2015.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1
NCT02599571,2016.0,OTHER,lead,Duke University,Not Applicable
NCT02599571,2016.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT02599571,2016.0,FED,collaborator,Food and Drug Administration (FDA),Not Applicable
NCT02599571,2016.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT02599753,2015.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT02600130,2016.0,INDUSTRY,lead,Longeveron Inc.,Phase 1
NCT02600494,2015.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT02600507,2016.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT02600715,2015.0,OTHER,lead,"Edgar LeClaire, MD",Phase 4
NCT02601586,2016.0,OTHER,lead,"University Hospital, Toulouse",Phase 2/Phase 3
NCT02601677,2015.0,OTHER,lead,Tang-Du Hospital,Not Applicable
NCT02601885,2016.0,INDUSTRY,lead,AbbVie,Phase 1
NCT02602288,2016.0,OTHER,lead,Temple University,Not Applicable
NCT02602288,2016.0,INDUSTRY,collaborator,"N.O.R.T.H., Inc.",Not Applicable
NCT02602652,2013.0,OTHER,lead,Chulalongkorn University,Not Applicable
NCT02602652,2013.0,INDUSTRY,collaborator,"Sanofi Pasteur, a Sanofi Company",Not Applicable
NCT02603198,2014.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT02603458,,OTHER,lead,NYU Langone Health,Phase 2
NCT02603458,,INDUSTRY,collaborator,"Naurex, Inc, an affiliate of Allergan plc",Phase 2
NCT02604186,2016.0,OTHER,lead,"University of Campinas, Brazil",Phase 2/Phase 3
NCT02604186,2016.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 2/Phase 3
NCT02604186,2016.0,INDUSTRY,collaborator,Cristália Produtos Químicos Farmacêuticos Ltda.,Phase 2/Phase 3
NCT02604459,2015.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT02604654,2015.0,OTHER,lead,Yi Yang,Phase 4
NCT02604654,2015.0,INDUSTRY,collaborator,"Shineway Pharmaceutical Co.,Ltd",Phase 4
NCT02604914,2015.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 1
NCT02604914,2015.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT02604927,2016.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT02605434,2016.0,INDUSTRY,lead,Intec Pharma Ltd.,Phase 3
NCT02605707,2014.0,OTHER,lead,"Southern Medical University, China",Phase 1/Phase 2
NCT02605707,2014.0,OTHER,collaborator,Second Affiliated Hospital of Guangzhou Medical University,Phase 1/Phase 2
NCT02605785,2015.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT02606136,2016.0,INDUSTRY,lead,FibroGen,Phase 2
NCT02606279,2014.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT02606279,2014.0,OTHER,collaborator,Johns Hopkins University,Not Applicable
NCT02606630,2015.0,INDUSTRY,lead,AbbVie,Phase 1
NCT02607891,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02607904,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02607917,2015.0,OTHER,lead,University of Minnesota,Not Applicable
NCT02607943,2015.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT02607943,2015.0,OTHER,collaborator,Chang Gung Memorial Hospital,Phase 3
NCT02607943,2015.0,OTHER,collaborator,Taipei Medical University Shuang Ho Hospital,Phase 3
NCT02608931,2015.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02609022,2016.0,INDUSTRY,lead,CuraVac,Phase 1/Phase 2
NCT02609022,2016.0,INDUSTRY,collaborator,Aepodia,Phase 1/Phase 2
NCT02609022,2016.0,OTHER,collaborator,"University Hospital, Antwerp",Phase 1/Phase 2
NCT02609022,2016.0,OTHER,collaborator,Leiden University Medical Center,Phase 1/Phase 2
NCT02609087,2015.0,OTHER,lead,Chonnam National University Hospital,Phase 4
NCT02609477,2016.0,INDUSTRY,lead,"Kyowa Hakko Kirin Pharma, Inc.",Phase 1
NCT02609477,2016.0,INDUSTRY,collaborator,"Kyowa Kirin Co., Ltd.",Phase 1
NCT02609607,2016.0,OTHER,lead,David Levinthal,Phase 2
NCT02609607,2016.0,OTHER,collaborator,Consortium of Multiple Sclerosis Centers,Phase 2
NCT02609945,2015.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT02610231,2015.0,INDUSTRY,lead,"Kyowa Hakko Kirin Pharma, Inc.",Phase 3
NCT02610231,2015.0,INDUSTRY,collaborator,"Kyowa Kirin Co., Ltd.",Phase 3
NCT02611167,2017.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT02611921,2015.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1
NCT02611921,2015.0,INDUSTRY,collaborator,"Roivant Sciences, Inc.",Phase 1
NCT02611921,2015.0,OTHER,collaborator,Cures Within Reach,Phase 1
NCT02612129,2016.0,INDUSTRY,lead,ZevraDenmark,Phase 2/Phase 3
NCT02612441,2015.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT02612857,2015.0,INDUSTRY,lead,"Idera Pharmaceuticals, Inc.",Phase 2
NCT02612948,2013.0,OTHER,lead,University of Tennessee Graduate School of Medicine,Phase 4
NCT02614131,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02614183,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02614196,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02614287,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02614586,2015.0,INDUSTRY,lead,Takeda,Phase 1
NCT02615002,2015.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 2
NCT02615119,2015.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Not Applicable
NCT02615119,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02615340,2017.0,OTHER,lead,"Mount Sinai Hospital, Canada",Phase 2
NCT02615340,2017.0,OTHER,collaborator,Sunnybrook Health Sciences Centre,Phase 2
NCT02615340,2017.0,OTHER,collaborator,Hopital du Sacre-Coeur de Montreal,Phase 2
NCT02615873,2016.0,INDUSTRY,lead,Intec Pharma Ltd.,Phase 3
NCT02616120,2015.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 2
NCT02616172,2015.0,OTHER,lead,"James Baumgartner, MD",Phase 1/Phase 2
NCT02616484,2020.0,OTHER,lead,University of Florida,Phase 3
NCT02616484,2020.0,INDUSTRY,collaborator,Medosome Biotec LLC,Phase 3
NCT02616484,2020.0,INDUSTRY,collaborator,Saol Therapeutics Inc,Phase 3
NCT02616484,2020.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT02616523,2014.0,OTHER,lead,University Medical Centre Ljubljana,Phase 4
NCT02617511,2015.0,OTHER,lead,University of Manitoba,Not Applicable
NCT02617511,2015.0,OTHER,collaborator,Manitoba Medical Service Foundation,Not Applicable
NCT02618382,2015.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 4
NCT02618382,2015.0,OTHER,collaborator,Barrow Neurological Foundation,Phase 4
NCT02618603,2016.0,OTHER,lead,Sir Run Run Shaw Hospital,Phase 4
NCT02618902,2017.0,OTHER,lead,"University Hospital, Antwerp",Phase 1
NCT02618941,2016.0,INDUSTRY,lead,Affiris AG,Phase 1
NCT02620150,2017.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT02620995,2014.0,OTHER_GOV,lead,"National Institute of Cardiology, Laranjeiras, Brazil",Phase 4
NCT02621320,2015.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Not Applicable
NCT02621606,2016.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT02621931,2016.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT02623205,2015.0,OTHER,lead,Stony Brook University,Phase 4
NCT02623231,2015.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 2/Phase 3
NCT02623504,2016.0,INDUSTRY,lead,Validus Pharmaceuticals,Phase 4
NCT02623699,2016.0,INDUSTRY,lead,Biogen,Phase 3
NCT02623699,2016.0,INDUSTRY,collaborator,"Ionis Pharmaceuticals, Inc.",Phase 3
NCT02624388,2016.0,OTHER,lead,University of Virginia,Phase 2
NCT02624401,2016.0,OTHER,lead,University of Turku,Phase 4
NCT02624401,2016.0,OTHER,collaborator,"University of California, Irvine",Phase 4
NCT02624401,2016.0,OTHER,collaborator,University of Michigan,Phase 4
NCT02624401,2016.0,OTHER,collaborator,Yale University,Phase 4
NCT02624401,2016.0,OTHER,collaborator,University of Helsinki,Phase 4
NCT02624453,2015.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Not Applicable
NCT02624453,2015.0,OTHER_GOV,collaborator,Yaounde Central Hospital,Not Applicable
NCT02624453,2015.0,OTHER,collaborator,"St George's, University of London",Not Applicable
NCT02624596,2016.0,OTHER,lead,Stanford University,Phase 2
NCT02624596,2016.0,OTHER,collaborator,University of Connecticut,Phase 2
NCT02624661,2016.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1/Phase 2
NCT02624661,2016.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT02624778,2015.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02625103,2015.0,OTHER,lead,"Anders Fink-Jensen, MD, DMSci",Phase 4
NCT02625103,2015.0,OTHER,collaborator,University of Copenhagen,Phase 4
NCT02625103,2015.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 4
NCT02625779,2016.0,OTHER,lead,Ewha Womans University Mokdong Hospital,Phase 2
NCT02625948,2015.0,OTHER_GOV,lead,Ministry of Science and Technology of the People´s Republic of China,Phase 2
NCT02625948,2015.0,OTHER,collaborator,Beijing Municipal Science & Technology Commission,Phase 2
NCT02626494,2015.0,OTHER,lead,"Psychiatric University Hospital, Zurich",Phase 4
NCT02626494,2015.0,OTHER,collaborator,Zurich Center for Integrative Human Physiology,Phase 4
NCT02626494,2015.0,OTHER,collaborator,Swiss Federal Institute of Technology,Phase 4
NCT02626494,2015.0,UNKNOWN,collaborator,Max-Planck-Institut Tübingen,Phase 4
NCT02626572,2015.0,OTHER,lead,Institut de Recherches Internationales Servier,Phase 2
NCT02627404,2013.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02627508,2016.0,OTHER,lead,Stanford University,Phase 2
NCT02627508,2016.0,OTHER,collaborator,Simons Foundation,Phase 2
NCT02628743,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02628847,2012.0,OTHER,lead,University of Utah,Phase 1
NCT02628964,2015.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT02629549,2015.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT02629861,2016.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT02629991,2015.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT02629991,2015.0,OTHER,collaborator,Foundation for Prader-Willi Research,Phase 2
NCT02630069,2015.0,OTHER,lead,Ewha Womans University Mokdong Hospital,Phase 2
NCT02630121,2023.0,OTHER,lead,University of South Florida,Phase 4
NCT02630459,2016.0,INDUSTRY,lead,Amgen,Phase 2
NCT02630719,2016.0,OTHER,lead,"University of Missouri, Kansas City",Not Applicable
NCT02630719,2016.0,OTHER,collaborator,Truman Medical Center,Not Applicable
NCT02630862,2010.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT02630862,2010.0,OTHER,collaborator,"Civic Hospital, Italy",Not Applicable
NCT02630888,2014.0,OTHER,lead,University of Sao Paulo,Phase 2
NCT02631694,2016.0,OTHER,lead,VU University of Amsterdam,Phase 2
NCT02632279,2015.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT02632279,2015.0,OTHER,collaborator,Netherlands Brain Foundation,Not Applicable
NCT02633241,2017.0,OTHER,lead,Joseph Cravero,Phase 4
NCT02633371,2016.0,OTHER,lead,"University of Colorado, Denver",Not Applicable
NCT02633371,2016.0,OTHER,collaborator,Society for Pediatric Dermatology,Not Applicable
NCT02633618,2005.0,INDUSTRY,lead,VanWorld Pharmaceutical (Rugao) Company Limited,Phase 3
NCT02633709,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT02633787,2015.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02634307,2015.0,INDUSTRY,lead,Biogen,Phase 3
NCT02634307,2015.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 3
NCT02634320,2015.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 4
NCT02634346,2015.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT02634684,2014.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT02634931,2015.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT02635789,2015.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT02635893,2019.0,OTHER,lead,Shirley Ryan AbilityLab,Phase 4
NCT02635893,2019.0,OTHER,collaborator,The Craig H. Neilsen Foundation,Phase 4
NCT02635919,2016.0,OTHER,lead,Duke University,Not Applicable
NCT02635919,2016.0,INDUSTRY,collaborator,"Intelligent Automation, Inc.",Not Applicable
NCT02635919,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02636218,2016.0,OTHER,lead,Dr. Andrew Baker,Phase 2/Phase 3
NCT02636218,2016.0,INDUSTRY,collaborator,Defence Research and Development Canada,Phase 2/Phase 3
NCT02636647,2015.0,FED,lead,Jasmohan Bajaj,Phase 1
NCT02636647,2015.0,INDUSTRY,collaborator,OpenBiome,Phase 1
NCT02636829,2016.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT02636842,2015.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT02637648,2015.0,OTHER,lead,Ramin Khatami,Phase 3
NCT02637700,2016.0,OTHER,lead,Academisch Ziekenhuis Maastricht,Phase 2
NCT02637856,2016.0,INDUSTRY,lead,"Genentech, Inc.",Phase 3
NCT02637895,2016.0,OTHER,lead,University of Miami,Phase 4
NCT02637895,2016.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT02637895,2016.0,OTHER,collaborator,Emory University,Phase 4
NCT02638038,2015.0,INDUSTRY,lead,"InteKrin Therapeutics, Inc.",Phase 2
NCT02638103,2016.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT02638519,2016.0,OTHER,lead,Thunder Bay Regional Health Research Institute,Early Phase 1
NCT02638519,2016.0,OTHER,collaborator,Lakehead University,Early Phase 1
NCT02638519,2016.0,OTHER,collaborator,Thunder Bay Regional Health Sciences Centre,Early Phase 1
NCT02638701,2018.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT02638714,2013.0,OTHER,lead,Stem Cells Arabia,Phase 1/Phase 2
NCT02639221,2016.0,INDUSTRY,lead,Prexton Therapeutics,Phase 1
NCT02639533,2014.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT02639533,2014.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 2/Phase 3
NCT02639533,2014.0,OTHER_GOV,collaborator,Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Phase 2/Phase 3
NCT02639533,2014.0,OTHER,collaborator,"Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil",Phase 2/Phase 3
NCT02639702,2016.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02639819,2016.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 1
NCT02640092,2015.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT02640300,1999.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT02640300,1999.0,UNKNOWN,collaborator,The Ian Douglas Bebensee Foundation,Phase 4
NCT02640404,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT02640729,2015.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 2
NCT02640794,2015.0,OTHER,lead,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,Phase 4
NCT02641041,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02641054,2016.0,INDUSTRY,lead,CleveXel Pharma,Phase 2
NCT02642289,2015.0,OTHER,lead,Pablo Román López,Not Applicable
NCT02642315,2016.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT02642393,2016.0,OTHER,lead,Michael Alan Schwarzschild,Phase 3
NCT02642393,2016.0,NETWORK,collaborator,The Parkinson Study Group,Phase 3
NCT02642393,2016.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 3
NCT02642393,2016.0,OTHER,collaborator,University of Rochester,Phase 3
NCT02642393,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT02642653,2016.0,OTHER,lead,"University of California, Davis",Phase 4
NCT02643251,2015.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 2
NCT02643355,2015.0,OTHER,lead,Hennepin Healthcare Research Institute,Not Applicable
NCT02643368,2015.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT02643368,2015.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT02643433,2015.0,OTHER_GOV,lead,"Centers for Disease Control and Prevention, China",Phase 4
NCT02643433,2015.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT02643433,2015.0,OTHER_GOV,collaborator,Zhejiang Provincial Center for Disease Control and Prevention,Phase 4
NCT02643433,2015.0,OTHER,collaborator,Hubei Provincial Center for Disease Control and Prevention,Phase 4
NCT02643615,2014.0,OTHER,lead,Ohio State University,Not Applicable
NCT02643719,2015.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT02643914,2015.0,OTHER,lead,Stony Brook University,Not Applicable
NCT02643979,2016.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 4
NCT02644161,2015.0,OTHER,lead,The University of Hong Kong,Not Applicable
NCT02644161,2015.0,OTHER,collaborator,Tung Wah Hospital,Not Applicable
NCT02644161,2015.0,OTHER,collaborator,"Kowloon Hospital, Hong Kong",Not Applicable
NCT02644239,2012.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT02644421,2015.0,OTHER,lead,Brigham and Women's Hospital,Phase 1
NCT02644473,2016.0,OTHER,lead,Albert Einstein College of Medicine,Phase 4
NCT02644577,2012.0,OTHER,lead,"China Medical University, China",Phase 4
NCT02644668,2016.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT02644668,2016.0,INDUSTRY,collaborator,"Astellas Pharma Global Development, Inc.",Phase 2
NCT02644980,2015.0,OTHER,lead,Xijing Hospital,Phase 4
NCT02645279,2015.0,OTHER,lead,Baskent University,Phase 4
NCT02645370,2016.0,OTHER,lead,Xijing Hospital,Phase 1
NCT02645370,2016.0,UNKNOWN,collaborator,Ecion Pharmaceutical CO..LTD,Phase 1
NCT02645461,2014.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT02645552,2016.0,OTHER,lead,RenJi Hospital,Phase 3
NCT02645552,2016.0,UNKNOWN,collaborator,Shanghai Pudong Emergency Center,Phase 3
NCT02645942,2020.0,OTHER,lead,Poznan University of Medical Sciences,Not Applicable
NCT02647437,2013.0,OTHER,lead,"University of Colorado, Denver",Not Applicable
NCT02648022,2012.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT02648386,2016.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1/Phase 2
NCT02648386,2016.0,OTHER,collaborator,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Phase 1/Phase 2
NCT02648672,2015.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 1
NCT02648906,2015.0,INDUSTRY,lead,Daewoong Pharmaceutical Co. LTD.,Phase 4
NCT02648997,2016.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 2
NCT02648997,2016.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT02649608,2016.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02649985,2016.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT02650102,2013.0,OTHER,lead,Shanxi Medical University,Phase 1/Phase 2
NCT02650544,2015.0,OTHER,lead,Sun Yat-sen University,Phase 2
NCT02650609,2016.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT02651519,2016.0,OTHER,lead,"China Medical University, China",Phase 4
NCT02652390,2016.0,OTHER,lead,Region Skane,Phase 4
NCT02652598,2015.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT02652598,2015.0,UNKNOWN,collaborator,Lieber Institute for Brain Development (LIBD),Phase 2
NCT02653703,2014.0,OTHER,lead,Aalborg University,Not Applicable
NCT02653729,2015.0,OTHER,lead,Aisha Andleeb,Phase 2
NCT02653833,2017.0,OTHER,lead,Cedars-Sinai Medical Center,Early Phase 1
NCT02654314,2016.0,OTHER,lead,Yale University,Phase 3
NCT02654405,2016.0,OTHER,lead,Nathan Kline Institute for Psychiatric Research,Phase 2/Phase 3
NCT02654405,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT02654509,2008.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT02655198,2016.0,OTHER,lead,KU Leuven,Phase 2
NCT02655198,2016.0,INDUSTRY,collaborator,"Zogenix, Inc.",Phase 2
NCT02655276,2016.0,OTHER,lead,Eberhard Schulz,Not Applicable
NCT02655276,2016.0,UNKNOWN,collaborator,Biotiki,Not Applicable
NCT02655315,2016.0,OTHER,lead,"University Hospital, Lille",Phase 2
NCT02655315,2016.0,OTHER,collaborator,European Commission,Phase 2
NCT02655315,2016.0,INDUSTRY,collaborator,ApoPharma,Phase 2
NCT02655354,2015.0,OTHER,lead,University of Washington,Not Applicable
NCT02655354,2015.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT02655354,2015.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02655354,2015.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT02655471,2017.0,OTHER,lead,Universidad Peruana Cayetano Heredia,Early Phase 1
NCT02655471,2017.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Early Phase 1
NCT02655536,2017.0,OTHER,lead,National Taiwan University Hospital,Phase 2
NCT02655614,2016.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT02655692,2016.0,FED,lead,VA Office of Research and Development,Phase 2
NCT02655692,2016.0,OTHER,collaborator,The University of Texas Health Science Center at San Antonio,Phase 2
NCT02655692,2016.0,FED,collaborator,Brooke Army Medical Center,Phase 2
NCT02655692,2016.0,FED,collaborator,Minneapolis Veterans Affairs Medical Center,Phase 2
NCT02656160,2016.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT02656342,2015.0,OTHER,lead,Haukeland University Hospital,Phase 4
NCT02656342,2015.0,OTHER,collaborator,The Research Council of Norway,Phase 4
NCT02656342,2015.0,OTHER,collaborator,Helse Vest,Phase 4
NCT02656498,2016.0,OTHER,lead,Jae Seung Kim,Phase 2
NCT02656498,2016.0,OTHER_GOV,collaborator,Korea Health Industry Development Institute,Phase 2
NCT02656498,2016.0,OTHER,collaborator,Samsung Medical Center,Phase 2
NCT02658188,2007.0,INDUSTRY,lead,Astellas Pharma Inc,Phase 3
NCT02658357,2015.0,INDUSTRY,lead,Braeburn Pharmaceuticals,Phase 2
NCT02658916,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02659228,2016.0,OTHER,lead,University of Michigan,Not Applicable
NCT02659228,2016.0,OTHER,collaborator,McGill University,Not Applicable
NCT02659228,2016.0,OTHER,collaborator,McMaster University,Not Applicable
NCT02659475,2015.0,OTHER,lead,Lindner Center of HOPE,Phase 2
NCT02659475,2015.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT02659488,2015.0,OTHER,lead,Lindner Center of HOPE,Phase 2
NCT02659488,2015.0,OTHER,collaborator,University of Cincinnati,Phase 2
NCT02659787,2016.0,OTHER,lead,University of Chicago,Not Applicable
NCT02660112,2016.0,OTHER,lead,Ralitza Gavrilova,Phase 2
NCT02660112,2016.0,INDUSTRY,collaborator,"Cardero Therapeutics, Inc.",Phase 2
NCT02661061,2015.0,OTHER,lead,"St Patrick's Hospital, Ireland",Phase 1
NCT02661347,2016.0,OTHER,lead,Northwell Health,Not Applicable
NCT02661789,2011.0,OTHER,lead,Gitte Moos Knudsen,Not Applicable
NCT02661789,2011.0,OTHER,collaborator,"Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak",Not Applicable
NCT02661789,2011.0,UNKNOWN,collaborator,Fertility Clinic Rigshospitalet,Not Applicable
NCT02661789,2011.0,UNKNOWN,collaborator,"CNSR, Glostrup Psychiatric Center",Not Applicable
NCT02661789,2011.0,UNKNOWN,collaborator,Danish Multiple Sclerosis Center Rigshospitalet,Not Applicable
NCT02661789,2011.0,UNKNOWN,collaborator,"Dept. of Clinical Immunology, Rigshospitalet",Not Applicable
NCT02661828,2016.0,OTHER,lead,Emory University,Not Applicable
NCT02662257,2015.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Hebei Medical University Fourth Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,The People's Hospital of Ningxia,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,"Beijing Shijitan Hospital, Capital Medical University",Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Guizhou Provincial People's Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Affiliated Hospital of Qinghai University,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,The Third Xiangya Hospital of Central South University,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Cancer Hospital of Guangxi Medical University,Not Applicable
NCT02662257,2015.0,OTHER_GOV,collaborator,Shanxi Provincial People's Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Zhongda Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,The First Affiliated Hospital of Zhengzhou University,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Tang-Du Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Tianjin Nankai Hospital,Not Applicable
NCT02662257,2015.0,OTHER,collaborator,Shenzhen Second People's Hospital,Not Applicable
NCT02662972,2016.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1/Phase 2
NCT02662972,2016.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT02663024,2016.0,INDUSTRY,lead,Green Cross Corporation,Phase 2
NCT02663284,2012.0,OTHER,lead,Hopital Foch,Not Applicable
NCT02664571,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT02664623,2016.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT02665221,2015.0,OTHER,lead,NYU Langone Health,Phase 4
NCT02665273,2015.0,OTHER,lead,Montefiore Medical Center,Phase 3
NCT02665533,2016.0,OTHER,lead,Federal University of the Valleys of Jequitinhonha and Mucuri,Not Applicable
NCT02666742,2017.0,OTHER,lead,Kansas City Heart Rhythm Institute,Phase 4
NCT02666742,2017.0,OTHER,collaborator,Kansas City Heart Rhythm Research Foundation,Phase 4
NCT02667353,2011.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT02667353,2011.0,OTHER,collaborator,VU University of Amsterdam,Not Applicable
NCT02667483,2015.0,INDUSTRY,lead,"Daiichi Sankyo Co., Ltd.",Phase 1/Phase 2
NCT02667483,2015.0,UNKNOWN,collaborator,"Orphan Disease Treatment Institute Co., Ltd.",Phase 1/Phase 2
NCT02667587,2016.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 3
NCT02667587,2016.0,INDUSTRY,collaborator,Ono Pharmaceutical Co. Ltd,Phase 3
NCT02668146,2015.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 2
NCT02668172,2015.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT02668172,2015.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT02668497,2016.0,OTHER,lead,"Western University, Canada",Phase 2
NCT02668848,2016.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2/Phase 3
NCT02669030,2017.0,OTHER,lead,"Institute for Advanced Medical Research, Alpharetta, GA",Phase 4
NCT02669030,2017.0,UNKNOWN,collaborator,"Augusta University, Dept. of Psychiatry",Phase 4
NCT02669043,2016.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT02669043,2016.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02669758,2016.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT02670083,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT02670096,2016.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT02670161,2016.0,OTHER,lead,NorthShore University HealthSystem,Phase 4
NCT02670538,2016.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT02670551,2016.0,INDUSTRY,lead,Forest Laboratories,Phase 3
NCT02671266,2014.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02672306,2017.0,OTHER,lead,South China Research Center for Stem Cell and Regenerative Medicine,Phase 1/Phase 2
NCT02672306,2017.0,UNKNOWN,collaborator,Guangzhou General Hospital of Guangzhou Military Command of PLA,Phase 1/Phase 2
NCT02672306,2017.0,OTHER,collaborator,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 1/Phase 2
NCT02672995,2018.0,OTHER,lead,National Taiwan University Hospital,Phase 1
NCT02673619,2016.0,INDUSTRY,lead,"Stiefel, a GSK Company",Phase 2
NCT02673619,2016.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT02673866,2016.0,INDUSTRY,lead,Daiichi Sankyo,Phase 2
NCT02673931,2016.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT02675413,2016.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT02675413,2016.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT02675465,2016.0,INDUSTRY,lead,Amicus Therapeutics,Phase 1/Phase 2
NCT02675530,2007.0,OTHER,lead,Yale University,Phase 1
NCT02675530,2007.0,INDUSTRY,collaborator,AstraZeneca,Phase 1
NCT02675790,2017.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT02675790,2017.0,OTHER,collaborator,Aminu Kano Teaching Hospital,Phase 3
NCT02675790,2017.0,OTHER,collaborator,Murtala Muhammed Specialist Hospital,Phase 3
NCT02676154,2016.0,OTHER,lead,University of British Columbia,Phase 2
NCT02676154,2016.0,INDUSTRY,collaborator,Pfizer,Phase 2
NCT02676154,2016.0,OTHER,collaborator,International Collaboration on Repair Discoveries,Phase 2
NCT02676154,2016.0,OTHER_GOV,collaborator,Vancouver Coastal Health,Phase 2
NCT02676375,2014.0,OTHER,lead,Brentwood Biomedical Research Institute,Phase 4
NCT02676739,2016.0,OTHER,lead,Sarah Morrow,Phase 2/Phase 3
NCT02676843,2016.0,OTHER,lead,Columbia University,Phase 2
NCT02676843,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02676882,2017.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT02676882,2017.0,UNKNOWN,collaborator,"JayMac Pharmaceuticals, LLC",Not Applicable
NCT02677051,2016.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 2
NCT02677051,2016.0,OTHER,collaborator,Rowan University,Phase 2
NCT02677207,2016.0,OTHER,lead,Tangent Data,Phase 2
NCT02677207,2016.0,INDUSTRY,collaborator,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 2
NCT02677545,2016.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT02677870,2018.0,OTHER,lead,University Hospitals Cleveland Medical Center,Phase 4
NCT02677870,2018.0,INDUSTRY,collaborator,BioMarin Pharmaceutical,Phase 4
NCT02678767,2015.0,OTHER,lead,Beau Nakamoto,Phase 2
NCT02678767,2015.0,OTHER,collaborator,Hawaii Pacific Health,Phase 2
NCT02678767,2015.0,OTHER,collaborator,University of Hawaii,Phase 2
NCT02678767,2015.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02678793,2015.0,INDUSTRY,lead,Centrexion Therapeutics,Phase 2
NCT02679079,2016.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT02679742,2017.0,OTHER,lead,Parc de Salut Mar,Not Applicable
NCT02679846,2016.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT02680379,2016.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT02680379,2016.0,OTHER,collaborator,FRAXA Research Foundation,Phase 2
NCT02680977,2016.0,OTHER,lead,ASST Gaetano Pini-CTO,Phase 2
NCT02680977,2016.0,OTHER,collaborator,Grisons Foundation for Parkinson's Disease,Phase 2
NCT02681211,2016.0,OTHER,lead,University of Louisville,Not Applicable
NCT02682225,2016.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT02682238,2016.0,INDUSTRY,lead,Botanix Pharmaceuticals,Phase 2
NCT02682927,2016.0,INDUSTRY,lead,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",Phase 3
NCT02683174,2015.0,OTHER_GOV,lead,NHS Lothian,Not Applicable
NCT02683213,2014.0,OTHER,lead,Karolinska Institutet,Phase 3
NCT02683213,2014.0,OTHER_GOV,collaborator,The Swedish Research Council,Phase 3
NCT02683213,2014.0,OTHER,collaborator,Swedish Heart Lung Foundation,Phase 3
NCT02683213,2014.0,UNKNOWN,collaborator,Stroke-Riksförbundet,Phase 3
NCT02683213,2014.0,UNKNOWN,collaborator,Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse,Phase 3
NCT02683213,2014.0,UNKNOWN,collaborator,Hjärnfonden (The Swedish Brain foundation),Phase 3
NCT02683213,2014.0,OTHER,collaborator,The Swedish Medical Association,Phase 3
NCT02683629,2016.0,INDUSTRY,lead,Living Cell Technologies,Phase 2
NCT02683629,2016.0,UNKNOWN,collaborator,Statistecol Consultants Limited,Phase 2
NCT02683863,2015.0,OTHER,lead,Multiple Sclerosis Center of Northeastern New York,Phase 4
NCT02683863,2015.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT02684136,2016.0,OTHER,lead,Henry Ford Health System,Phase 4
NCT02684279,2016.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT02684812,2012.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 2/Phase 3
NCT02684812,2012.0,OTHER,collaborator,Stichting Nuts Ohra,Phase 2/Phase 3
NCT02685709,2016.0,INDUSTRY,lead,"Chiasma, Inc.",Phase 3
NCT02685748,2017.0,OTHER,lead,"Clinic for Psychiatric Disorders, Dr Laza Lazarevic",Phase 2/Phase 3
NCT02685748,2017.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT02686216,2015.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 1
NCT02686697,2015.0,OTHER,lead,Abraham Reichenberg,Phase 2/Phase 3
NCT02686697,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT02686788,2015.0,OTHER,lead,Dr. Frank Behrens,Phase 2
NCT02686788,2015.0,INDUSTRY,collaborator,SocraMetrics GmbH,Phase 2
NCT02686853,2016.0,OTHER,lead,Hui Bu,Phase 4
NCT02687191,2016.0,INDUSTRY,lead,Pfizer,Phase 1
NCT02687542,2016.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02687672,2016.0,OTHER,lead,Stem Cells Arabia,Phase 2
NCT02687984,2016.0,INDUSTRY,lead,Indivior Inc.,Phase 1
NCT02688049,2016.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1/Phase 2
NCT02688049,2016.0,OTHER,collaborator,Affiliated Hospital of Logistics University of CAPF,Phase 1/Phase 2
NCT02688062,2016.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1/Phase 2
NCT02688062,2016.0,OTHER_GOV,collaborator,First Hospitals affiliated to the China PLA General Hospital,Phase 1/Phase 2
NCT02688374,2016.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT02688465,2016.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 4
NCT02689713,2018.0,OTHER,lead,Kenneth Hargreaves,Phase 2
NCT02689713,2018.0,FED,collaborator,San Antonio Military Medical Center,Phase 2
NCT02689713,2018.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT02690675,2006.0,OTHER,lead,University Rovira i Virgili,Not Applicable
NCT02691013,2016.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02692235,2016.0,OTHER,lead,Gdansk University of Physical Education and Sport,Phase 3
NCT02692235,2016.0,OTHER_GOV,collaborator,"National Science Centre, Poland",Phase 3
NCT02693119,2016.0,INDUSTRY,lead,Stealth BioTherapeutics Inc.,Phase 2
NCT02694328,2016.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT02694783,2016.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT02695004,2016.0,INDUSTRY,lead,"Dongkook Pharmaceutical Co., Ltd.",Phase 1
NCT02695537,2015.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT02696044,2016.0,OTHER,lead,"Center for Rare Neurological Diseases, Norcross, GA",Phase 2
NCT02696044,2016.0,INDUSTRY,collaborator,Ultragenyx Pharmaceutical Inc,Phase 2
NCT02696044,2016.0,OTHER,collaborator,Rett Syndrome Research Trust,Phase 2
NCT02696512,2016.0,OTHER,lead,International Brain Research Foundation,Phase 1/Phase 2
NCT02696590,2015.0,OTHER,lead,Isfahan University of Medical Sciences,Not Applicable
NCT02697045,2017.0,INDUSTRY,lead,Abdi İbrahim Otsuka,Phase 4
NCT02697162,2016.0,OTHER,lead,Children's Hospital Zagreb,Phase 2/Phase 3
NCT02697162,2016.0,UNKNOWN,collaborator,GuardianMed j.d.o.o. Research and development in medicine,Phase 2/Phase 3
NCT02697227,2016.0,OTHER,lead,M.D. Anderson Cancer Center,Not Applicable
NCT02697227,2016.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT02697734,2016.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT02698215,2016.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT02698215,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02698267,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02699125,2015.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT02699801,2016.0,OTHER,lead,University of British Columbia,Not Applicable
NCT02700230,2017.0,OTHER,lead,Mayo Clinic,Phase 1
NCT02700230,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT02700412,2015.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT02701582,2014.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT02702076,2017.0,OTHER,lead,University Medical Center Groningen,Phase 2
NCT02702102,2015.0,OTHER,lead,William Charles Kreisl,Phase 2
NCT02702102,2015.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02702765,2016.0,OTHER,lead,University of Aarhus,Not Applicable
NCT02702765,2016.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT02702817,2012.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2
NCT02702817,2012.0,OTHER,collaborator,McGill University,Phase 2
NCT02702817,2012.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT02703220,2015.0,FED,lead,VA Office of Research and Development,Phase 4
NCT02703363,2016.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 3
NCT02703363,2016.0,OTHER,collaborator,Dow University of Health Sciences,Phase 3
NCT02703363,2016.0,OTHER,collaborator,Abbasi Shaheed Hospital,Phase 3
NCT02703363,2016.0,OTHER,collaborator,"Rawalpindi Medical College, Pakistan",Phase 3
NCT02703363,2016.0,OTHER,collaborator,University of Manchester,Phase 3
NCT02703363,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT02704325,2016.0,OTHER,lead,Kevin Flanigan,Phase 1/Phase 2
NCT02704624,2016.0,OTHER,lead,Federal University of Juiz de Fora,Phase 4
NCT02704624,2016.0,OTHER,collaborator,Fundação de Amparo à Pesquisa do estado de Minas Gerais,Phase 4
NCT02704754,2016.0,OTHER,lead,Howard University,Phase 4
NCT02704754,2016.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT02704962,2012.0,OTHER_GOV,lead,Kaohsiung Kai-Suan Psychiatric Hospital,Phase 4
NCT02704962,2012.0,OTHER_GOV,collaborator,"Department of Health, Executive Yuan, R.O.C. (Taiwan)",Phase 4
NCT02705547,2016.0,OTHER,lead,Children's Hospital of Philadelphia,Early Phase 1
NCT02705547,2016.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Early Phase 1
NCT02705755,2017.0,INDUSTRY,lead,Theravance Biopharma,Phase 2
NCT02705950,2014.0,OTHER,lead,Institut Guttmann,Not Applicable
NCT02705950,2014.0,INDUSTRY,collaborator,Medtronic,Not Applicable
NCT02706522,2016.0,OTHER,lead,Gangnam Severance Hospital,Not Applicable
NCT02707016,2015.0,OTHER,lead,Pontificia Universidad Catolica de Chile,Not Applicable
NCT02707549,2015.0,OTHER,lead,Federal University of São Paulo,Phase 2
NCT02707965,2017.0,FED,lead,Food and Drug Administration (FDA),Phase 1
NCT02707965,2017.0,OTHER,collaborator,"University of Maryland, Baltimore",Phase 1
NCT02707978,2017.0,OTHER,lead,"Tammie L. S. Benzinger, MD, PhD",Phase 2
NCT02708186,2016.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 2
NCT02708693,2013.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT02708849,2015.0,OTHER,lead,Yale University,Phase 1
NCT02708901,2015.0,OTHER,lead,IRCCS Fondazione Stella Maris,Not Applicable
NCT02708901,2015.0,OTHER_GOV,collaborator,"Ministry of Health, Italy",Not Applicable
NCT02708901,2015.0,OTHER,collaborator,Istituto di Fisiologia Clinica CNR,Not Applicable
NCT02709018,2016.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT02709018,2016.0,OTHER,collaborator,Mclean Hospital,Not Applicable
NCT02709018,2016.0,OTHER,collaborator,Massachusetts General Hospital,Not Applicable
NCT02709018,2016.0,UNKNOWN,collaborator,"Henry M. Jackson Foundation, Walter Reed National Military Medical Center",Not Applicable
NCT02709018,2016.0,OTHER,collaborator,"Foundation for Atlanta Veterans Education and Research, Inc.",Not Applicable
NCT02709018,2016.0,OTHER,collaborator,NYU Langone Health,Not Applicable
NCT02709018,2016.0,OTHER,collaborator,George Washington University,Not Applicable
NCT02709356,2015.0,OTHER,lead,Université de Sherbrooke,Not Applicable
NCT02709356,2015.0,OTHER,collaborator,Fondation Vitae,Not Applicable
NCT02709668,2013.0,OTHER,lead,High Point Regional Health Systems,Phase 4
NCT02710110,2016.0,OTHER,lead,University of Florida,Early Phase 1
NCT02710110,2016.0,OTHER,collaborator,ALS Association,Early Phase 1
NCT02710162,2016.0,OTHER,lead,University of Florida,Early Phase 1
NCT02710188,2016.0,INDUSTRY,lead,Heptares Therapeutics Limited,Phase 1
NCT02710188,2016.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT02710214,2016.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT02710214,2016.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT02710578,2016.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT02710578,2016.0,UNKNOWN,collaborator,Ontario Ministry of Transportation,Not Applicable
NCT02710591,2016.0,OTHER,lead,EspeRare Foundation,Phase 1
NCT02710890,2017.0,INDUSTRY,lead,"UCB BIOSCIENCES, Inc.",Phase 2/Phase 3
NCT02711982,2010.0,OTHER,lead,Shanghai Changzheng Hospital,Not Applicable
NCT02711982,2010.0,OTHER,collaborator,RenJi Hospital,Not Applicable
NCT02711995,2015.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT02712411,2015.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 1
NCT02712476,2013.0,OTHER,lead,Istanbul University,Not Applicable
NCT02712996,2017.0,OTHER,lead,Vanderbilt University,Phase 4
NCT02712996,2017.0,INDUSTRY,collaborator,Shire,Phase 4
NCT02713087,2015.0,OTHER,lead,University of Aarhus,Phase 4
NCT02713282,2016.0,INDUSTRY,lead,Janssen-Cilag Ltd.,Phase 3
NCT02713412,2013.0,OTHER,lead,Royal Adelaide Hospital,Not Applicable
NCT02713789,2015.0,INDUSTRY,lead,Urovant Sciences GmbH,Phase 2
NCT02713789,2015.0,OTHER,collaborator,Dasman Diabetes Institute,Phase 2
NCT02713789,2015.0,INDUSTRY,collaborator,Ion Channel Innovations,Phase 2
NCT02714036,2016.0,INDUSTRY,lead,MediciNova,Phase 1/Phase 2
NCT02714036,2016.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1/Phase 2
NCT02714036,2016.0,INDUSTRY,collaborator,South Shore Neurologic Associates,Phase 1/Phase 2
NCT02714049,2017.0,OTHER,lead,San Diego Sexual Medicine,Phase 4
NCT02714400,2016.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT02714959,2016.0,OTHER,lead,Seoul National University Hospital,Phase 1/Phase 2
NCT02715115,2016.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT02715115,2016.0,UNKNOWN,collaborator,rettsyndrome.org,Phase 2
NCT02715232,2017.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT02715401,2015.0,INDUSTRY,lead,Hanmi Pharmaceutical Company Limited,Phase 1
NCT02715440,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02717052,2016.0,OTHER,lead,Medical University of Vienna,Phase 2
NCT02717130,2016.0,OTHER,lead,Florida Atlantic University,Not Applicable
NCT02717130,2016.0,OTHER,collaborator,Washington University School of Medicine,Not Applicable
NCT02717130,2016.0,OTHER,collaborator,University of Missouri-Columbia,Not Applicable
NCT02717130,2016.0,OTHER,collaborator,"University of Missouri, Kansas City",Not Applicable
NCT02717130,2016.0,UNKNOWN,collaborator,Burrell Behavioral Health,Not Applicable
NCT02717195,2016.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02717780,2016.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT02717819,2016.0,OTHER,lead,Forskningsenheden,Not Applicable
NCT02717819,2016.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02717819,2016.0,OTHER,collaborator,"The Danish Dairy Research Foundation, Denmark",Not Applicable
NCT02717819,2016.0,INDUSTRY,collaborator,Arla Foods,Not Applicable
NCT02717819,2016.0,OTHER,collaborator,"Glostrup University Hospital, Copenhagen",Not Applicable
NCT02717819,2016.0,OTHER,collaborator,"University Hospital, Gentofte, Copenhagen",Not Applicable
NCT02719327,2017.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT02719327,2017.0,OTHER,collaborator,"University of Wisconsin, Madison",Phase 2/Phase 3
NCT02719392,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02719925,2016.0,INDUSTRY,lead,My Goodlife SAS,Not Applicable
NCT02719925,2016.0,INDUSTRY,collaborator,Neptune,Not Applicable
NCT02720263,2016.0,INDUSTRY,lead,"Astellas Pharma Global Development, Inc.",Phase 1
NCT02720744,2016.0,INDUSTRY,lead,Avadel,Phase 3
NCT02722967,2016.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT02723344,2016.0,FED,lead,VA Office of Research and Development,Phase 1
NCT02724046,2017.0,OTHER,lead,Epicentre,Phase 4
NCT02724046,2017.0,OTHER,collaborator,"Medecins Sans Frontieres, Netherlands",Phase 4
NCT02724241,2015.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT02724761,2016.0,OTHER,lead,Andrew Chung,Not Applicable
NCT02724761,2016.0,OTHER,collaborator,More Foundation,Not Applicable
NCT02724761,2016.0,OTHER,collaborator,Banner Health,Not Applicable
NCT02724917,2016.0,INDUSTRY,lead,CoMentis,Phase 1/Phase 2
NCT02724917,2016.0,INDUSTRY,collaborator,"Alpharmagen, Inc.",Phase 1/Phase 2
NCT02725060,2016.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT02725060,2016.0,OTHER,collaborator,University of Oklahoma,Not Applicable
NCT02726035,2014.0,OTHER,lead,Western Michigan University School of Medicine,Phase 4
NCT02726035,2014.0,OTHER,collaborator,Kalamazoo Community Foundation,Phase 4
NCT02726074,2016.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT02726386,2016.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 2
NCT02726659,2016.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT02726711,2016.0,OTHER,lead,Vanderbilt University,Phase 1
NCT02726867,2014.0,OTHER,lead,"Mid-Atlantic Epilepsy and Sleep Center, LLC",Phase 3
NCT02726919,2015.0,OTHER,lead,Pavel Klein,Phase 4
NCT02726919,2015.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT02727101,2015.0,OTHER,lead,"Mid-Atlantic Epilepsy and Sleep Center, LLC",Phase 4
NCT02727101,2015.0,INDUSTRY,collaborator,Eisai Inc.,Phase 4
NCT02727699,2017.0,INDUSTRY,lead,Actinogen Medical,Phase 2
NCT02727699,2017.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 2
NCT02727907,2015.0,INDUSTRY,lead,Biocad,Phase 2/Phase 3
NCT02727998,2015.0,OTHER,lead,Yale University,Phase 2
NCT02728115,2017.0,INDUSTRY,lead,Azidus Brasil,Phase 1
NCT02728115,2017.0,OTHER,collaborator,Cellavita Pesquisa Científica Ltda,Phase 1
NCT02728115,2017.0,OTHER,collaborator,Azidus Brasil Scientific Research and Development Ltda,Phase 1
NCT02728752,2017.0,INDUSTRY,lead,Octapharma,Phase 3
NCT02728778,2016.0,OTHER,lead,Hannover Medical School,Phase 2
NCT02728843,2016.0,INDUSTRY,lead,ApoPharma,Phase 2
NCT02728947,2016.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT02729766,2016.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2/Phase 3
NCT02731235,2016.0,OTHER,lead,Herlev Hospital,Not Applicable
NCT02731235,2016.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT02731235,2016.0,OTHER,collaborator,Association of Danish Physiotherapists,Not Applicable
NCT02731495,2015.0,OTHER,lead,National Nutrition and Food Technology Institute,Phase 2/Phase 3
NCT02731495,2015.0,OTHER,collaborator,Tehran University of Medical Sciences,Phase 2/Phase 3
NCT02731612,2017.0,OTHER,lead,Nazlin Walji,Phase 3
NCT02732288,2016.0,OTHER,lead,Rockefeller University,Not Applicable
NCT02732288,2016.0,OTHER,collaborator,Weill Medical College of Cornell University,Not Applicable
NCT02733614,2016.0,INDUSTRY,lead,Azevan Pharmaceuticals,Phase 2
NCT02733614,2016.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 2
NCT02733614,2016.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02733614,2016.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 2
NCT02733679,2016.0,OTHER_GOV,lead,NHS Tayside,Phase 4
NCT02733679,2016.0,OTHER,collaborator,University of Dundee,Phase 4
NCT02734602,2016.0,OTHER,lead,Yale University,Not Applicable
NCT02734602,2016.0,FED,collaborator,VA Office of Research and Development,Not Applicable
NCT02735694,2015.0,OTHER,lead,University of Manitoba,Phase 1
NCT02735694,2015.0,OTHER,collaborator,University of Calgary,Phase 1
NCT02736474,2016.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT02736474,2016.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 4
NCT02736695,2016.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT02736890,2016.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT02736955,2016.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT02737189,2016.0,OTHER,lead,"Xuanwu Hospital, Beijing",Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Zhangzhou Municipal Hospital of Fujian Province,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The First People's Hospital of Changzhou,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Xinqiao Hospital of Chongqing,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Changhai Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Baotou Central Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,The 904 Hospital of PLA,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Linyi People's Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,"The 985 Hospital of PLA, Taiyuan, Shanxi",Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The First Affiliated Hospital with Nanjing Medical University,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,Tianjin TEDA Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Liaocheng People's Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Luoyang Central Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Subei People's Hospital of Jiangsu Province,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,"PLA 148 Hospital, Zibo, Shandong",Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Hebei General Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Shengli Oilfield Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,Shenzhen Bao'an District People's Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The First Hospital of Jilin University,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Henan Provincial People's Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,Peking University Binhai Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Beijing Tiantan Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,"The Military General Hospital of Beijing, PLA",Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The First Affiliated Hospital of Shanxi Medical University,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Beijing Luhe Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Affiliated Hospital of Nantong University,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The Affiliated Hospital Of Guizhou Medical University,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Nanning Second People's Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Chongqing Three Gorges Central Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,The First Affiliated Hospital of Dalian Medical University,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,The Fifth Central Hospital of Tianjin，TianJin,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,Yantaishan Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Nanyang Central Hospital,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Second Affiliated Hospital of Soochow University,Not Applicable
NCT02737189,2016.0,OTHER,collaborator,Tianjin Huanhu Hospital,Not Applicable
NCT02737189,2016.0,UNKNOWN,collaborator,"The Affiliated Hospital of Northwest University, Xi'an NO.3 Hospital",Not Applicable
NCT02737358,2016.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT02737358,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02737423,2012.0,OTHER,lead,Baqai Institute of Diabetology and Endocrinology,Not Applicable
NCT02737527,2016.0,OTHER,lead,Seoul National University,Not Applicable
NCT02737930,2016.0,OTHER,lead,Bogachan Sahin,Phase 2
NCT02738450,2016.0,INDUSTRY,lead,AC Immune SA,Phase 1
NCT02738450,2016.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT02738450,2016.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 1
NCT02738450,2016.0,OTHER,collaborator,LuMind IDSC Foundation,Phase 1
NCT02738775,2016.0,INDUSTRY,lead,"TG Therapeutics, Inc.",Phase 2
NCT02739061,2014.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT02739282,2016.0,OTHER,lead,Dr Jan Novy,Not Applicable
NCT02739568,2016.0,OTHER,lead,Bioprojet,Phase 3
NCT02740595,2015.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT02740634,2016.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT02740634,2016.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT02740933,2016.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT02740972,2016.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 2
NCT02740972,2016.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 2
NCT02740972,2016.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT02740972,2016.0,UNKNOWN,collaborator,Therapeutic Research in Neuromuscular Disorders Solutions,Phase 2
NCT02741076,2016.0,INDUSTRY,lead,Member Companies of the Opioid PMR Consortium,Phase 4
NCT02741947,2014.0,OTHER,lead,IRCCS San Raffaele,Phase 4
NCT02741947,2014.0,OTHER_GOV,collaborator,Agenzia Italiana del Farmaco,Phase 4
NCT02742532,2017.0,OTHER,lead,Jennifer Mitchell,Phase 2
NCT02742532,2017.0,FED,collaborator,"United States Naval Medical Center, San Diego",Phase 2
NCT02742532,2017.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02742532,2017.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 2
NCT02742532,2017.0,FED,collaborator,Eisenhower Army Medical Center,Phase 2
NCT02742857,2016.0,INDUSTRY,lead,Bioquark Inc.,Phase 1
NCT02742857,2016.0,UNKNOWN,collaborator,Revita Life Sciences,Phase 1
NCT02742857,2016.0,OTHER,collaborator,Anupam Hospital,Phase 1
NCT02743377,2018.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT02744222,2017.0,INDUSTRY,lead,Biocad,Phase 2/Phase 3
NCT02745808,2015.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1
NCT02745808,2015.0,OTHER,collaborator,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Phase 1
NCT02745990,2016.0,OTHER,lead,Huiqing Sun,Not Applicable
NCT02745990,2016.0,OTHER,collaborator,Zhengzhou University,Not Applicable
NCT02745990,2016.0,OTHER,collaborator,Göteborg University,Not Applicable
NCT02746107,2016.0,OTHER,lead,Cristian Baicus,Not Applicable
NCT02746510,2016.0,OTHER,lead,Hôpital le Vinatier,Not Applicable
NCT02746510,2016.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT02746744,2016.0,OTHER,lead,Anders Svenningsson,Phase 3
NCT02746848,2014.0,OTHER_GOV,lead,Royan Institute,Phase 1/Phase 2
NCT02747511,2015.0,OTHER,lead,Western Michigan University School of Medicine,Phase 4
NCT02747940,2015.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Phase 4
NCT02747940,2015.0,UNKNOWN,collaborator,"Ministry of Science and Technology, R.O.C.",Phase 4
NCT02748694,2016.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT02748694,2016.0,INDUSTRY,collaborator,Takeda,Phase 1
NCT02748798,2020.0,OTHER,lead,Thunder Bay Regional Health Research Institute,Early Phase 1
NCT02748798,2020.0,OTHER,collaborator,Thunder Bay Regional Health Sciences Centre,Early Phase 1
NCT02748798,2020.0,OTHER,collaborator,St. Joseph's Care Group,Early Phase 1
NCT02748798,2020.0,OTHER,collaborator,Lakehead University,Early Phase 1
NCT02749227,2017.0,OTHER,lead,Columbia University,Phase 2
NCT02749591,2016.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 3
NCT02750306,2016.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT02750969,2016.0,OTHER,lead,"HaEmek Medical Center, Israel",Phase 4
NCT02751268,2016.0,OTHER,lead,Armed Forces Hampyeong Hospital,Phase 4
NCT02751632,2016.0,OTHER,lead,Orygen,Phase 3
NCT02751632,2016.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT02751632,2016.0,OTHER,collaborator,"University of California, Davis",Phase 3
NCT02751632,2016.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT02751905,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02752048,2016.0,INDUSTRY,lead,"Taiho Pharmaceutical Co., Ltd.",Phase 2
NCT02752503,2015.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Not Applicable
NCT02752503,2015.0,OTHER,collaborator,Hospital Universitari General de Catalunya,Not Applicable
NCT02752906,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02753101,2016.0,OTHER,lead,Stanford University,Early Phase 1
NCT02753101,2016.0,OTHER,collaborator,University of Mississippi Medical Center,Early Phase 1
NCT02753205,2016.0,OTHER,lead,Gachon University Gil Medical Center,Not Applicable
NCT02753530,2017.0,INDUSTRY,lead,ZevraDenmark,Phase 2
NCT02753530,2017.0,OTHER,collaborator,University of Kansas Medical Center,Phase 2
NCT02753530,2017.0,OTHER,collaborator,"University College, London",Phase 2
NCT02753725,2016.0,OTHER,lead,University of Nairobi,Not Applicable
NCT02754830,2016.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT02755142,2000.0,INDUSTRY,lead,medac GmbH,Phase 1/Phase 2
NCT02755142,2000.0,UNKNOWN,collaborator,IKP,Phase 1/Phase 2
NCT02755922,2010.0,OTHER_GOV,lead,Instituto Mexicano del Seguro Social,Phase 3
NCT02756858,2016.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2
NCT02757066,2016.0,INDUSTRY,lead,Nobelpharma,Phase 2/Phase 3
NCT02757079,2016.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT02757404,2016.0,INDUSTRY,lead,Medy-Tox,Phase 4
NCT02757521,2016.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT02757521,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Early Phase 1
NCT02757521,2016.0,INDUSTRY,collaborator,PPD,Early Phase 1
NCT02757807,2016.0,INDUSTRY,lead,Eco Fusion,Not Applicable
NCT02758067,2016.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02758067,2016.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT02758626,2016.0,OTHER,lead,NYU Langone Health,Phase 2
NCT02758626,2016.0,INDUSTRY,collaborator,PTC Therapeutics,Phase 2
NCT02758730,,INDUSTRY,lead,Affiris AG,Phase 1
NCT02758730,,OTHER,collaborator,University Hospital Tuebingen,Phase 1
NCT02758990,2016.0,INDUSTRY,lead,Verifomics LLC,Not Applicable
NCT02759185,2017.0,OTHER,lead,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT02760056,2016.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT02760264,2016.0,INDUSTRY,lead,"ReveraGen BioPharma, Inc.",Phase 2
NCT02760264,2016.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT02760264,2016.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT02760264,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02760264,2016.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT02760277,2016.0,INDUSTRY,lead,"ReveraGen BioPharma, Inc.",Phase 2
NCT02760277,2016.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT02760277,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02760277,2016.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT02760277,2016.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT02760602,2016.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02761161,2016.0,OTHER,lead,"Mental Health Services in the Capital Region, Denmark",Phase 4
NCT02761161,2016.0,OTHER,collaborator,Danish Center for Sleep Medicine,Phase 4
NCT02761330,2016.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT02761330,2016.0,OTHER,collaborator,James S McDonnell Foundation,Not Applicable
NCT02762539,2016.0,OTHER,lead,Mansoura University,Not Applicable
NCT02763137,2014.0,OTHER,lead,IRCCS San Raffaele Roma,Phase 2
NCT02763137,2014.0,INDUSTRY,collaborator,SynAgile Corporation,Phase 2
NCT02763787,2000.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02763800,2000.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02763839,2001.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02763852,2001.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02764125,2016.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 2
NCT02764892,2012.0,INDUSTRY,lead,Vernalis (R&D) Ltd,Phase 1
NCT02765100,2014.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT02765100,2014.0,OTHER,collaborator,Weill Cornell Medical College in Qatar,Not Applicable
NCT02765555,2010.0,INDUSTRY,lead,Indivior Inc.,Phase 1
NCT02766192,2013.0,OTHER,lead,The Cooper Health System,Not Applicable
NCT02766517,2016.0,INDUSTRY,lead,Eli Lilly and Company,Early Phase 1
NCT02767037,2016.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Not Applicable
NCT02767817,2016.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1
NCT02767817,2016.0,OTHER,collaborator,Affiliated Hospital of Logistics University of CAPF,Phase 1
NCT02767999,2017.0,OTHER,lead,"University Hospital, Toulouse",Phase 4
NCT02768077,2016.0,INDUSTRY,lead,"Kuhnil Pharmaceutical Co., Ltd.",Phase 4
NCT02768389,2016.0,OTHER,lead,Case Comprehensive Cancer Center,Early Phase 1
NCT02768389,2016.0,OTHER,collaborator,University of Cincinnati,Early Phase 1
NCT02768389,2016.0,UNKNOWN,collaborator,OhioHealth Research Institute,Early Phase 1
NCT02768441,2016.0,OTHER,lead,The Netherlands Cancer Institute,Early Phase 1
NCT02768571,2016.0,OTHER,lead,Samsung Medical Center,Phase 4
NCT02768571,2016.0,INDUSTRY,collaborator,Ever Neuro Pharma GmbH,Phase 4
NCT02768649,2011.0,INDUSTRY,lead,Indivior Inc.,Phase 1
NCT02769065,2016.0,INDUSTRY,lead,Takeda,Phase 1
NCT02769689,2019.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 4
NCT02769793,2015.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02769793,2015.0,OTHER,collaborator,SMG-SNU Boramae Medical Center,Phase 4
NCT02769793,2015.0,OTHER,collaborator,Samsung Medical Center,Phase 4
NCT02769936,2013.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT02770482,2014.0,OTHER,lead,CHU de Reims,Not Applicable
NCT02770768,2016.0,OTHER,lead,University of Chicago,Not Applicable
NCT02770807,2017.0,INDUSTRY,lead,Erydel,Phase 3
NCT02770885,2016.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT02771587,2016.0,OTHER,lead,Parc de Salut Mar,Phase 1
NCT02772614,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02772627,2001.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02772978,2014.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT02772978,2014.0,OTHER,collaborator,National Center for Responsible Gaming,Not Applicable
NCT02773212,2017.0,OTHER,lead,University of Illinois at Chicago,Phase 2
NCT02773212,2017.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT02773576,2016.0,INDUSTRY,lead,Braeburn Pharmaceuticals,Phase 3
NCT02773771,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT02774239,2014.0,OTHER,lead,University of Alberta,Phase 3
NCT02774239,2014.0,INDUSTRY,collaborator,CSL Behring,Phase 3
NCT02774564,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02775110,2012.0,OTHER,lead,University at Buffalo,Phase 4
NCT02775591,2016.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02775591,2016.0,OTHER,collaborator,Samsung Medical Center,Phase 4
NCT02775591,2016.0,OTHER,collaborator,Korea University Guro Hospital,Phase 4
NCT02775591,2016.0,OTHER,collaborator,Hanyang University,Phase 4
NCT02775591,2016.0,OTHER,collaborator,Seoul Veterans Hospital,Phase 4
NCT02775591,2016.0,OTHER,collaborator,SMG-SNU Boramae Medical Center,Phase 4
NCT02775942,2015.0,OTHER,lead,"National Institute of Hygiene and Epidemiology, Vietnam",Phase 2
NCT02775942,2015.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Vietnam",Phase 2
NCT02776189,2012.0,OTHER,lead,Maharashtra University of Health Sciences,Phase 4
NCT02776215,2016.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 1
NCT02776488,2020.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT02777320,2016.0,OTHER,lead,Pamukkale University,Phase 4
NCT02777424,2016.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 4
NCT02777671,2007.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT02778581,2016.0,INDUSTRY,lead,Team Foods Colombia S.A.,Not Applicable
NCT02778581,2016.0,INDUSTRY,collaborator,Biopolis S.L.,Not Applicable
NCT02778945,2016.0,OTHER,lead,The Catholic University of Korea,Phase 4
NCT02779140,2016.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT02779868,2016.0,OTHER_GOV,lead,Brazilian National Cancer Institute,Not Applicable
NCT02779959,2016.0,OTHER,lead,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Phase 3
NCT02780570,2016.0,OTHER,lead,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2
NCT02780570,2016.0,UNKNOWN,collaborator,GBS-CIDP Foundation International,Phase 2
NCT02780570,2016.0,OTHER_GOV,collaborator,"National Institute of Neurosciences and Hospital, Dhaka",Phase 2
NCT02780570,2016.0,OTHER,collaborator,Erasmus Medical Center,Phase 2
NCT02780804,2017.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT02780895,2014.0,INDUSTRY,lead,"Celavie Bioscences, LLC",Phase 1
NCT02780895,2014.0,OTHER,collaborator,Hospital Angeles del Pedregal,Phase 1
NCT02781090,2016.0,OTHER,lead,Montefiore Medical Center,Not Applicable
NCT02781090,2016.0,OTHER,collaborator,Westat,Not Applicable
NCT02781090,2016.0,OTHER,collaborator,Johns Hopkins University,Not Applicable
NCT02781727,2016.0,INDUSTRY,lead,Ascendis Pharma Endocrinology Division A/S,Phase 3
NCT02782208,2016.0,OTHER,lead,University of Aarhus,Not Applicable
NCT02782429,2016.0,OTHER,lead,Flavia orange,Phase 4
NCT02782429,2016.0,UNKNOWN,collaborator,Rebeca Gonelli Albanez da Cunha Andrade,Phase 4
NCT02782481,2016.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 3
NCT02782858,2016.0,INDUSTRY,lead,GeNeuro SA,Phase 2
NCT02782858,2016.0,UNKNOWN,collaborator,Les Laboratoires Servier (LLS),Phase 2
NCT02782858,2016.0,OTHER,collaborator,Institut de Recherches Internationales Servier,Phase 2
NCT02782858,2016.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT02782897,2016.0,OTHER,lead,Wei Wang,Phase 2
NCT02782975,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02783092,2019.0,OTHER,lead,Antonio Waldo Zuardi,Phase 3
NCT02783092,2019.0,INDUSTRY,collaborator,Prati Donaduzzi & Cia Ltda,Phase 3
NCT02783430,2016.0,OTHER,lead,"University Hospital, Lille",Phase 2/Phase 3
NCT02783573,2016.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT02783573,2016.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT02783846,2016.0,OTHER,lead,General Hospital of Ningxia Medical University,Not Applicable
NCT02784145,2016.0,OTHER,lead,Universität des Saarlandes,Not Applicable
NCT02784210,2016.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02784821,2017.0,OTHER,lead,University of Florida,Phase 2
NCT02784821,2017.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT02784821,2017.0,OTHER,collaborator,Society for Pediatric Dermatology,Phase 2
NCT02784847,2016.0,OTHER,lead,University of Liege,Early Phase 1
NCT02785393,2011.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT02785393,2011.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02785601,2017.0,INDUSTRY,lead,Lee's Pharmaceutical Limited,Phase 1
NCT02785614,2017.0,INDUSTRY,lead,Lee's Pharmaceutical Limited,Phase 1
NCT02785705,2015.0,OTHER_GOV,lead,Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control,Phase 3
NCT02785705,2015.0,OTHER,collaborator,"Air Force Military Medical University, China",Phase 3
NCT02785705,2015.0,INDUSTRY,collaborator,"Beijing Tiantan Biological Products Co., Ltd.",Phase 3
NCT02785978,2016.0,OTHER,lead,"Institut de Myologie, France",Not Applicable
NCT02786667,2012.0,OTHER,lead,"University Hospital, Grenoble",Phase 3
NCT02787590,2016.0,OTHER,lead,University Hospital Plymouth NHS Trust,Phase 2
NCT02787590,2016.0,OTHER,collaborator,University of Plymouth,Phase 2
NCT02787746,2016.0,OTHER,lead,Beijing Friendship Hospital,Phase 4
NCT02787746,2016.0,INDUSTRY,collaborator,Eisai China Inc.,Phase 4
NCT02787746,2016.0,OTHER,collaborator,"Xuanwu Hospital, Beijing",Phase 4
NCT02788513,2016.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02788552,2014.0,OTHER,lead,Menzies School of Health Research,Phase 4
NCT02789020,2016.0,OTHER,lead,University of Florida,Phase 2
NCT02789020,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02789592,2016.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT02789592,2016.0,INDUSTRY,collaborator,"Kuhnil Pharmaceutical Co., Ltd.",Phase 2
NCT02790034,2016.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 2/Phase 3
NCT02790970,2016.0,INDUSTRY,lead,P1vital Products Limited,Not Applicable
NCT02791191,2016.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT02792153,2016.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT02792179,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT02792257,2017.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT02792257,2017.0,OTHER,collaborator,Mclean Hospital,Phase 2
NCT02792257,2017.0,UNKNOWN,collaborator,Miami Jewish Health,Phase 2
NCT02792257,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02792257,2017.0,OTHER,collaborator,Tufts Medical Center,Phase 2
NCT02792517,2016.0,INDUSTRY,lead,Amgen,Phase 1
NCT02793466,2016.0,OTHER,lead,Leo Mascarenhas,Phase 1
NCT02793648,2014.0,OTHER,lead,Yolanda de Diego Otero,Phase 2
NCT02794168,2016.0,INDUSTRY,lead,veriNOS operations GmbH,Phase 3
NCT02794168,2016.0,INDUSTRY,collaborator,ICON plc,Phase 3
NCT02794389,2016.0,OTHER,lead,University of Oxford,Not Applicable
NCT02794441,2016.0,OTHER,lead,Children's Hospital of Eastern Ontario,Phase 3
NCT02794441,2016.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 3
NCT02794857,2016.0,INDUSTRY,lead,"Neuraltus Pharmaceuticals, Inc.",Phase 2
NCT02795455,2016.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT02795455,2016.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT02795676,2016.0,INDUSTRY,lead,Protalix,Phase 3
NCT02795676,2016.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 3
NCT02795780,2016.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT02796144,2016.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT02796144,2016.0,OTHER,collaborator,Columbia University,Phase 4
NCT02796144,2016.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 4
NCT02796859,2016.0,OTHER,lead,Brian Miller,Phase 1/Phase 2
NCT02796859,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1/Phase 2
NCT02797015,2016.0,INDUSTRY,lead,Celgene,Phase 1
NCT02797080,2016.0,INDUSTRY,lead,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3
NCT02797080,2016.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 3
NCT02797197,2016.0,OTHER,lead,CHU de Reims,Not Applicable
NCT02797951,2016.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02798159,2016.0,INDUSTRY,lead,Vietstar Biomedical Research,Phase 2/Phase 3
NCT02798406,2016.0,INDUSTRY,lead,"DNAtrix, Inc.",Phase 2
NCT02798406,2016.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT02798601,2017.0,OTHER,lead,Hospital Pablo Tobón Uribe,Not Applicable
NCT02798601,2017.0,OTHER,collaborator,CES University,Not Applicable
NCT02799511,2015.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT02799797,2016.0,OTHER,lead,Cui Xulei,Not Applicable
NCT02799797,2016.0,NETWORK,collaborator,Medical Consulting Center,Not Applicable
NCT02800070,2016.0,OTHER,lead,"University Health Network, Toronto",Phase 1
NCT02800070,2016.0,INDUSTRY,collaborator,Ozmosis Research Inc.,Phase 1
NCT02800083,2016.0,OTHER,lead,Bioprojet,Phase 2
NCT02800161,2016.0,OTHER_GOV,lead,Consorcio Centro de Investigación Biomédica en Red (CIBER),Phase 3
NCT02800161,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT02800174,2006.0,OTHER,lead,Beijing Jishuitan Hospital,Not Applicable
NCT02800486,2016.0,OTHER,lead,Northwell Health,Phase 2
NCT02800577,2014.0,INDUSTRY,lead,P1vital Products Limited,Phase 1
NCT02801032,2016.0,OTHER,lead,Christina Kruuse,Phase 2
NCT02801071,2016.0,OTHER,lead,Dirk Fischer,Phase 3
NCT02801357,2016.0,INDUSTRY,lead,"USWM, LLC (dba US WorldMeds)",Phase 1
NCT02802072,2013.0,OTHER,lead,Beijing Chao Yang Hospital,Not Applicable
NCT02803749,2016.0,OTHER,lead,University of Rochester,Phase 2
NCT02803749,2016.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT02804126,2017.0,OTHER,lead,Michał Borys,Phase 4
NCT02804373,2014.0,OTHER,lead,"University Hospital, Toulouse",Phase 2/Phase 3
NCT02804568,2016.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT02806128,2016.0,OTHER,lead,Huisheng Chen,Not Applicable
NCT02806284,2001.0,OTHER,lead,Uppsala University,Phase 2
NCT02806440,2016.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 4
NCT02806882,2015.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 1
NCT02806895,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02806908,2016.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT02807467,2019.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 4
NCT02807649,2015.0,INDUSTRY,lead,Access Business Group,Not Applicable
NCT02807649,2015.0,OTHER,collaborator,"Sinphar Pharmaceutical Co., Ltd",Not Applicable
NCT02807649,2015.0,OTHER,collaborator,Sprim Advanced Life Sciences,Not Applicable
NCT02807649,2015.0,OTHER,collaborator,Fudan University,Not Applicable
NCT02807675,2016.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT02808624,2015.0,OTHER,lead,Cairo University,Phase 1/Phase 2
NCT02808624,2015.0,OTHER,collaborator,Misr International University,Phase 1/Phase 2
NCT02808624,2015.0,OTHER,collaborator,Ain Shams University,Phase 1/Phase 2
NCT02809079,2016.0,OTHER,lead,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT02809079,2016.0,OTHER,collaborator,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Phase 4
NCT02809079,2016.0,OTHER,collaborator,"Southern Medical University, China",Phase 4
NCT02809131,2016.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT02809131,2016.0,OTHER,collaborator,Thomas Jefferson University,Phase 3
NCT02809131,2016.0,OTHER,collaborator,The Cooper Health System,Phase 3
NCT02809131,2016.0,OTHER,collaborator,Valley Health System,Phase 3
NCT02809131,2016.0,INDUSTRY,collaborator,Medtronic,Phase 3
NCT02809261,2016.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT02809937,2011.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT02809937,2011.0,OTHER,collaborator,Peking University Third Hospital,Phase 4
NCT02810392,2016.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT02810483,2012.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT02810782,2001.0,OTHER,lead,University of Zurich,Phase 3
NCT02810899,2015.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT02810899,2015.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 4
NCT02810964,2017.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT02811133,2023.0,OTHER,lead,"Ronald M. Glick, MD",Phase 1/Phase 2
NCT02811133,2023.0,UNKNOWN,collaborator,The Fine Foundation,Phase 1/Phase 2
NCT02811133,2023.0,INDUSTRY,collaborator,Jarrow Formulas Inc,Phase 1/Phase 2
NCT02811627,2016.0,OTHER,lead,University of Missouri-Columbia,Early Phase 1
NCT02811653,2015.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Not Applicable
NCT02812147,2016.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT02812147,2016.0,OTHER,collaborator,Arizona State University,Phase 2
NCT02812368,2016.0,OTHER,lead,Ohio State University,Phase 2
NCT02812368,2016.0,NETWORK,collaborator,Autism Treatment Network,Phase 2
NCT02812368,2016.0,UNKNOWN,collaborator,Autism Intervention Research Network on Physical Health,Phase 2
NCT02812394,2016.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT02813044,2016.0,OTHER,lead,Yonsei University,Not Applicable
NCT02813070,2012.0,INDUSTRY,lead,GE Healthcare,Phase 2
NCT02813434,2014.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Phase 3
NCT02813447,2016.0,OTHER,lead,Duke University,Not Applicable
NCT02813512,2017.0,INDUSTRY,lead,"Gwo Xi Stem Cell Applied Technology Co., Ltd.",Phase 1
NCT02814565,2016.0,INDUSTRY,lead,Takeda,Phase 3
NCT02815540,2017.0,OTHER,lead,Gillette Children's Specialty Healthcare,Phase 1/Phase 2
NCT02815800,2016.0,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT02815800,2016.0,UNKNOWN,collaborator,ETHNODYNE,Not Applicable
NCT02816554,2015.0,OTHER,lead,"National Institute of Hygiene and Epidemiology, Vietnam",Phase 2
NCT02816554,2015.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Vietnam",Phase 2
NCT02816554,2015.0,OTHER_GOV,collaborator,"Ministry of Health, Vietnam",Phase 2
NCT02816762,2016.0,OTHER,lead,Hospital Universitario La Paz,Phase 4
NCT02816827,2016.0,INDUSTRY,lead,Vedic Lifesciences Pvt. Ltd.,Not Applicable
NCT02816827,2016.0,INDUSTRY,collaborator,Enovate Biolife Pvt Ltd,Not Applicable
NCT02817321,2016.0,OTHER,lead,Cui Xulei,Not Applicable
NCT02817451,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02818777,2016.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT02818777,2016.0,OTHER_GOV,collaborator,Colorado Department of Public Health and Environment,Phase 2
NCT02818777,2016.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT02819557,2016.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT02819778,2016.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT02820441,2016.0,OTHER,lead,"University Hospital, Grenoble",Phase 4
NCT02820519,2016.0,OTHER,lead,University of Witten/Herdecke,Phase 2
NCT02820610,2016.0,OTHER,lead,Assiut University,Phase 2
NCT02820896,2016.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT02821689,2016.0,OTHER,lead,RenJi Hospital,Phase 4
NCT02821715,2016.0,INDUSTRY,lead,Theranexus,Phase 2
NCT02822144,2016.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT02824055,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT02824107,2016.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT02824627,2017.0,OTHER,lead,University of Nebraska,Phase 2
NCT02824666,2016.0,INDUSTRY,lead,Braeburn Pharmaceuticals,Phase 1
NCT02824770,2017.0,OTHER,lead,Eskisehir Osmangazi University,Not Applicable
NCT02825199,2016.0,OTHER,lead,Instituto Brasiliense de Otorrinolaringologia,Phase 4
NCT02825745,2016.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT02826200,2016.0,OTHER,lead,Semmelweis University Heart and Vascular Center,Phase 4
NCT02826694,2016.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT02826694,2016.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT02826694,2016.0,NIH,collaborator,National Human Genome Research Institute (NHGRI),Not Applicable
NCT02826694,2016.0,OTHER,collaborator,RTI International,Not Applicable
NCT02828072,2011.0,OTHER,lead,University of Milan,Not Applicable
NCT02829268,2017.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT02829268,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1/Phase 2
NCT02829268,2017.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1/Phase 2
NCT02829814,2016.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT02830152,2017.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT02830152,2017.0,INDUSTRY,collaborator,Abbott Medical Devices,Not Applicable
NCT02831101,2012.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT02831231,2016.0,INDUSTRY,lead,Karuna Therapeutics,Phase 1
NCT02831257,2016.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02831257,2016.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT02831257,2016.0,FED,collaborator,United States Department of Defense,Phase 2
NCT02831283,2016.0,OTHER,lead,"James M Noble, MD, MS, CPH, FAAN",Phase 2
NCT02831283,2016.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02831517,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02831608,2016.0,OTHER,lead,"Ole Frobert, MD, PhD",Phase 4
NCT02831608,2016.0,OTHER,collaborator,Swedish Heart Lung Foundation,Phase 4
NCT02831608,2016.0,INDUSTRY,collaborator,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02831608,2016.0,OTHER,collaborator,Uppsala University,Phase 4
NCT02831608,2016.0,UNKNOWN,collaborator,Lytics,Phase 4
NCT02832037,2016.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT02832128,2016.0,INDUSTRY,lead,Autifony Therapeutics Limited,Phase 2
NCT02832336,2016.0,OTHER,lead,King Saud University,Phase 1/Phase 2
NCT02832336,2016.0,OTHER_GOV,collaborator,King Saud Medical City,Phase 1/Phase 2
NCT02832401,2016.0,OTHER,lead,Nova Scotia Health Authority,Not Applicable
NCT02832401,2016.0,OTHER,collaborator,Dalhousie University,Not Applicable
NCT02832401,2016.0,OTHER,collaborator,Mount Saint Vincent University,Not Applicable
NCT02833142,2016.0,INDUSTRY,lead,Biogen,Phase 1
NCT02833792,2016.0,INDUSTRY,lead,"Stemedica Cell Technologies, Inc.",Phase 2
NCT02833792,2016.0,UNKNOWN,collaborator,Stemedica International SA,Phase 2
NCT02834208,2015.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT02835079,2016.0,OTHER,lead,Hadassah Medical Organization,Phase 1
NCT02836288,2016.0,OTHER,lead,"Scott A. Irwin, MD, PhD",Early Phase 1
NCT02836288,2016.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Early Phase 1
NCT02836418,2016.0,INDUSTRY,lead,"aTyr Pharma, Inc.",Phase 1/Phase 2
NCT02836743,2016.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT02837432,2016.0,OTHER,lead,Stanford University,Early Phase 1
NCT02838043,2016.0,OTHER,lead,Queen's University,Phase 3
NCT02838043,2016.0,INDUSTRY,collaborator,Lallemand Health Solutions,Phase 3
NCT02838043,2016.0,OTHER,collaborator,McMaster University,Phase 3
NCT02838589,2016.0,OTHER,lead,Christina Kruuse,Phase 2
NCT02838758,2016.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 1
NCT02838797,2016.0,OTHER,lead,Virginia Commonwealth University,Phase 1
NCT02838797,2016.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT02838797,2016.0,INDUSTRY,collaborator,RaQualia Pharma Inc.,Phase 1
NCT02838901,2012.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT02838979,2016.0,OTHER,lead,University of Washington,Phase 2
NCT02838979,2016.0,OTHER,collaborator,New York Medical College,Phase 2
NCT02838979,2016.0,OTHER,collaborator,Emory University,Phase 2
NCT02838979,2016.0,OTHER,collaborator,Vanderbilt University,Phase 2
NCT02838979,2016.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT02839720,2017.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT02839785,2017.0,OTHER,lead,"University Hospital, Brest",Phase 3
NCT02839915,2020.0,OTHER,lead,Southwest Autism Research & Resource Center,Phase 2
NCT02839915,2020.0,OTHER,collaborator,Emory University,Phase 2
NCT02839915,2020.0,OTHER,collaborator,Harvard University,Phase 2
NCT02839915,2020.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT02839915,2020.0,OTHER,collaborator,State University of New York - Downstate Medical Center,Phase 2
NCT02840097,2019.0,OTHER,lead,"Daniel Nishijima, MD, MAS",Phase 2
NCT02840097,2019.0,NETWORK,collaborator,Pediatric Emergency Care Applied Research Network,Phase 2
NCT02840279,2016.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 1
NCT02840591,2016.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT02842853,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02842866,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02843451,2016.0,OTHER,lead,University of Chicago,Phase 2
NCT02843906,2015.0,OTHER,lead,"University Hospital, Grenoble",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,"University Hospital, Tours",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02843906,2015.0,OTHER,collaborator,"University Hospital, Marseille",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT02843906,2015.0,OTHER,collaborator,"Central Hospital, Nancy, France",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,"University Hospital, Clermont-Ferrand",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Versailles Hospital,Not Applicable
NCT02843906,2015.0,OTHER,collaborator,"University Hospital, Montpellier",Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Reims University Hospital,Not Applicable
NCT02843906,2015.0,OTHER,collaborator,Centre Hospitalier Princesse Grace,Not Applicable
NCT02844439,2016.0,INDUSTRY,lead,"Kadmon Corporation, LLC",Phase 2
NCT02844933,2018.0,INDUSTRY,lead,"Radius Pharmaceuticals, Inc.",Phase 2
NCT02844998,2015.0,OTHER,lead,Ankara Training and Research Hospital,Not Applicable
NCT02845453,2017.0,OTHER,lead,Boston Medical Center,Phase 4
NCT02845453,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT02846207,2016.0,OTHER,lead,Dongfang Hospital Beijing University of Chinese Medicine,Not Applicable
NCT02846207,2016.0,OTHER,collaborator,Xingtai People's Hospital,Not Applicable
NCT02846558,2016.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT02846701,2016.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 4
NCT02847026,2016.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT02847026,2016.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT02847182,2016.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 2
NCT02847494,2016.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT02847650,2016.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02847845,2016.0,OTHER,lead,Eun Jung Kim,Not Applicable
NCT02848469,2013.0,OTHER,lead,University College Cork,Phase 2
NCT02849457,2016.0,OTHER,lead,Martina Bebin,Phase 2
NCT02849457,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02849548,2017.0,OTHER,lead,Howard University,Phase 4
NCT02849548,2017.0,OTHER,collaborator,Georgetown-Howard Universities Center for Clinical and Translational Science,Phase 4
NCT02849548,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT02849639,2017.0,OTHER,lead,Daniela Moga,Early Phase 1
NCT02849639,2017.0,NIH,collaborator,National Institute on Aging (NIA),Early Phase 1
NCT02849782,2014.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Phase 4
NCT02850081,2017.0,OTHER,lead,Columbia University,Phase 3
NCT02850146,2016.0,OTHER,lead,University of Southern California,Phase 1
NCT02850146,2016.0,OTHER,collaborator,Alzheimer's Therapeutic Research Institute,Phase 1
NCT02850146,2016.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT02850146,2016.0,INDUSTRY,collaborator,Avid Radiopharmaceuticals,Phase 1
NCT02850445,2012.0,OTHER_GOV,lead,Guangzhou Psychiatric Hospital,Not Applicable
NCT02850718,2016.0,OTHER,lead,iX Biopharma Ltd.,Phase 3
NCT02850718,2016.0,INDUSTRY,collaborator,Linear Clinical Research,Phase 3
NCT02850913,2016.0,OTHER,lead,Makerere University,Phase 2
NCT02850913,2016.0,OTHER,collaborator,University of Oxford,Phase 2
NCT02851303,2016.0,OTHER,lead,University of New Mexico,Phase 4
NCT02851797,2017.0,INDUSTRY,lead,Italfarmaco,Phase 3
NCT02851797,2017.0,OTHER,collaborator,Syneos Health,Phase 3
NCT02851914,2015.0,OTHER,lead,St. Louis University,Early Phase 1
NCT02852382,2014.0,OTHER,lead,Istanbul University,Phase 2
NCT02852577,2000.0,OTHER,lead,Universidade Federal do Rio de Janeiro,Phase 4
NCT02852577,2000.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4
NCT02853240,2016.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT02853929,2016.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT02854683,2016.0,OTHER,lead,New York Medical College,Phase 1
NCT02854683,2016.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT02854683,2016.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT02855034,2016.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT02855086,2016.0,OTHER,lead,Eben Rosenthal,Phase 1/Phase 2
NCT02855086,2016.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1/Phase 2
NCT02856477,2007.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT02856594,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT02856594,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT02856802,2016.0,INDUSTRY,lead,Upsher-Smith Laboratories,Phase 2
NCT02857036,2013.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT02857036,2013.0,OTHER,collaborator,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT02857036,2013.0,OTHER,collaborator,"University Hospital, Strasbourg, France",Not Applicable
NCT02857153,2016.0,OTHER,lead,Hu Anmin,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,West China Hospital,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,The Affiliated Hospital Of Guizhou Medical University,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,Taihe Hospital,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,The Third Affiliated Hospital of Kunming Medical College.,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,Sichuan Provincial People's Hospital,Not Applicable
NCT02857153,2016.0,OTHER,collaborator,Henan Provincial People's Hospital,Not Applicable
NCT02857192,2015.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT02857244,2016.0,OTHER,lead,University of Chicago,Phase 2
NCT02858362,2016.0,INDUSTRY,lead,Summit Therapeutics,Phase 2
NCT02858908,2016.0,INDUSTRY,lead,AMO Pharma Limited,Phase 2
NCT02859103,2017.0,OTHER,lead,Unity Health Toronto,Phase 4
NCT02859285,2016.0,OTHER,lead,"ProHealth Care, Inc",Not Applicable
NCT02859792,2019.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Phase 2
NCT02860065,2016.0,INDUSTRY,lead,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Phase 2
NCT02861014,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT02861846,2017.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT02861898,2016.0,OTHER,lead,Northwell Health,Phase 1/Phase 2
NCT02862301,2016.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT02862483,2016.0,INDUSTRY,lead,IlDong Pharmaceutical Co Ltd,Phase 3
NCT02862769,2017.0,OTHER,lead,Lawson Health Research Institute,Phase 4
NCT02864004,2017.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT02864927,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 4
NCT02864953,2018.0,INDUSTRY,lead,Biogen,Phase 3
NCT02865018,2014.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 1/Phase 2
NCT02865018,2014.0,OTHER,collaborator,Guthy Jackson Charitable Foundation,Phase 1/Phase 2
NCT02865629,2016.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT02865642,2016.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 2
NCT02865642,2016.0,OTHER,collaborator,Cantonal Hospital of St. Gallen,Phase 2
NCT02866331,2016.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 2
NCT02866331,2016.0,OTHER_GOV,collaborator,"Ministry of Health & Welfare, Korea",Phase 2
NCT02866604,2016.0,OTHER,lead,University of Malaya,Not Applicable
NCT02866838,2016.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2/Phase 3
NCT02866838,2016.0,OTHER,collaborator,Swiss National Science Foundation,Phase 2/Phase 3
NCT02867592,2017.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT02868580,2016.0,OTHER,lead,Neuroscience Trials Australia,Phase 2
NCT02868580,2016.0,OTHER,collaborator,"Macquarie University, Australia",Phase 2
NCT02868580,2016.0,UNKNOWN,collaborator,Westmead Hosptial,Phase 2
NCT02868580,2016.0,UNKNOWN,collaborator,Calvary Health Care Bethlehem,Phase 2
NCT02868580,2016.0,UNKNOWN,collaborator,The University of Sydney - Brain and Mind Centre,Phase 2
NCT02868801,2015.0,INDUSTRY,lead,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3
NCT02868814,2016.0,INDUSTRY,lead,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3
NCT02868996,2016.0,INDUSTRY,lead,DiaMedica Therapeutics Inc,Phase 1
NCT02868996,2016.0,INDUSTRY,collaborator,Novotech (Australia) Pty Limited,Phase 1
NCT02869425,2016.0,INDUSTRY,lead,"RVL Pharmaceuticals, Inc.",Phase 3
NCT02869425,2016.0,INDUSTRY,collaborator,Osmotica Pharmaceutical US LLC,Phase 3
NCT02869451,2016.0,OTHER,lead,Duke University,Not Applicable
NCT02869945,2016.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02870218,2019.0,INDUSTRY,lead,"Rose Research Center, LLC",Phase 2
NCT02870218,2019.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT02870218,2019.0,FED,collaborator,Food and Drug Administration (FDA),Phase 2
NCT02870218,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02870283,2010.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 4
NCT02870543,2014.0,OTHER,lead,Universidade Federal do Rio de Janeiro,Phase 3
NCT02870634,2016.0,INDUSTRY,lead,Collaborative Medicinal Development Pty Limited,Phase 1
NCT02870673,2016.0,OTHER,lead,Taipei Medical University Hospital,Phase 2/Phase 3
NCT02871349,2016.0,OTHER,lead,University of Missouri-Columbia,Early Phase 1
NCT02871349,2016.0,FED,collaborator,United States Department of Defense,Early Phase 1
NCT02871427,2016.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 2
NCT02872142,2016.0,INDUSTRY,lead,Grifols Therapeutics LLC,Phase 2
NCT02872142,2016.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 2
NCT02872857,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT02873208,2016.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT02873559,2016.0,OTHER,lead,"University Hospital, Gentofte, Copenhagen",Phase 2/Phase 3
NCT02874313,2016.0,OTHER,lead,Hospital Universitario La Paz,Phase 4
NCT02874573,2016.0,OTHER,lead,Brian Miller,Phase 1
NCT02874573,2016.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 1
NCT02874690,2016.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Early Phase 1
NCT02874807,2016.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2/Phase 3
NCT02874820,2016.0,OTHER,lead,Imperial College London,Early Phase 1
NCT02874820,2016.0,INDUSTRY,collaborator,GlaxoSmithKline,Early Phase 1
NCT02875262,2022.0,OTHER,lead,Radboud University Medical Center,Phase 1/Phase 2
NCT02875262,2022.0,OTHER,collaborator,University Medical Center Groningen,Phase 1/Phase 2
NCT02876172,2016.0,INDUSTRY,lead,Lykos Therapeutics,Phase 1/Phase 2
NCT02876900,2016.0,INDUSTRY,lead,"Noven Pharmaceuticals, Inc.",Phase 3
NCT02877641,2014.0,OTHER,lead,Roswell Park Cancer Institute,Phase 2
NCT02877641,2014.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT02878291,2016.0,INDUSTRY,lead,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 1
NCT02878291,2016.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 1
NCT02878291,2016.0,UNKNOWN,collaborator,Sanjiang Center for Disease Control and Prevention,Phase 1
NCT02878291,2016.0,OTHER,collaborator,"National Institutes for Food and Drug Control, China",Phase 1
NCT02878291,2016.0,OTHER,collaborator,"Air Force Military Medical University, China",Phase 1
NCT02878291,2016.0,INDUSTRY,collaborator,"Simoon Record Pharma Information Consulting Co., Ltd.",Phase 1
NCT02878408,2014.0,OTHER,lead,Pr. Marion Leboyer,Not Applicable
NCT02878408,2014.0,OTHER,collaborator,"National Research Agency, France",Not Applicable
NCT02878408,2014.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02878694,2019.0,OTHER,lead,"University Hospital, Caen",Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,"University Hospital, Rouen",Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,Rennes University Hospital,Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,"Centre Hospitalier Universitaire, Amiens",Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,"University Hospital, Lille",Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,"University Hospital, Brest",Phase 2/Phase 3
NCT02878694,2019.0,OTHER,collaborator,Groupe Hospitalier Pitie-Salpetriere,Phase 2/Phase 3
NCT02878707,2017.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT02878772,2014.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2/Phase 3
NCT02878928,2016.0,INDUSTRY,lead,AltheaDx,Not Applicable
NCT02878928,2016.0,INDUSTRY,collaborator,Innovis LLC,Not Applicable
NCT02879110,2016.0,OTHER,lead,Central South University,Not Applicable
NCT02879110,2016.0,UNKNOWN,collaborator,Davis family funding,Not Applicable
NCT02879110,2016.0,OTHER,collaborator,University of California,Not Applicable
NCT02879110,2016.0,OTHER,collaborator,University of Illinois at Chicago,Not Applicable
NCT02879136,2016.0,OTHER,lead,Hubert Fernandez,Early Phase 1
NCT02879578,2016.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT02880033,2011.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT02880462,2016.0,OTHER,lead,Central South University,Phase 2
NCT02880462,2016.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT02880865,2016.0,OTHER,lead,PATH,Phase 4
NCT02880865,2016.0,OTHER_GOV,collaborator,Research Institute for Tropical Medicine,Phase 4
NCT02880865,2016.0,OTHER,collaborator,Syneos Health,Phase 4
NCT02880865,2016.0,UNKNOWN,collaborator,"DF/Net Research, Inc.",Phase 4
NCT02880956,2017.0,INDUSTRY,lead,AbbVie,Phase 2
NCT02880995,2017.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT02881957,2016.0,OTHER,lead,University of Utah,Phase 2/Phase 3
NCT02882477,2016.0,OTHER,lead,Hadassah Medical Organization,Phase 2/Phase 3
NCT02882711,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02884492,2016.0,OTHER,lead,William Charles Kreisl,Phase 2
NCT02884492,2016.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT02884908,2016.0,OTHER,lead,"University of Maryland, Baltimore",Phase 3
NCT02884908,2016.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 3
NCT02885207,2015.0,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT02885311,2017.0,OTHER,lead,Northwell Health,Phase 1/Phase 2
NCT02885311,2017.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1/Phase 2
NCT02885545,2016.0,OTHER,lead,Population Health Research Institute,Phase 4
NCT02886156,2017.0,OTHER,lead,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Not Applicable
NCT02886390,2018.0,OTHER,lead,Capital Medical University,Not Applicable
NCT02889302,2016.0,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 3
NCT02889562,2016.0,OTHER,lead,Sanford Health,Phase 2/Phase 3
NCT02889562,2016.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2/Phase 3
NCT02889627,2016.0,OTHER,lead,The Second Hospital of Nanjing Medical University,Phase 2/Phase 3
NCT02890290,2016.0,OTHER,lead,Molde University College,Not Applicable
NCT02890823,2015.0,OTHER,lead,Chulalongkorn University,Phase 4
NCT02891070,2016.0,INDUSTRY,lead,Baxter Healthcare Corporation,Phase 3
NCT02891512,2015.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT02892110,2017.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT02892110,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02892422,2016.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT02892890,2016.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT02893111,2015.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2
NCT02893553,2016.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT02893553,2016.0,OTHER,collaborator,Kessler Foundation,Phase 2
NCT02893618,2017.0,INDUSTRY,lead,"Essentialis, Inc.",Phase 2
NCT02896400,2017.0,OTHER,lead,Yale University,Phase 3
NCT02896400,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT02896400,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT02896621,2014.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT02896712,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02897063,2016.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT02897336,2016.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT02897570,2013.0,OTHER,lead,Ospedale San Donato,Not Applicable
NCT02897570,2013.0,UNKNOWN,collaborator,Soremartec Italia S.r.l.,Not Applicable
NCT02897856,2016.0,INDUSTRY,lead,Hamad Medical Corporation,Phase 4
NCT02898610,2016.0,OTHER,lead,University College Dublin,Phase 3
NCT02898610,2016.0,OTHER,collaborator,"Health Research Board, Ireland",Phase 3
NCT02898610,2016.0,OTHER,collaborator,Irish Heart Foundation,Phase 3
NCT02898610,2016.0,OTHER,collaborator,University of Limerick,Phase 3
NCT02898610,2016.0,OTHER,collaborator,University of Edinburgh,Phase 3
NCT02898610,2016.0,OTHER,collaborator,"National University of Ireland, Galway, Ireland",Phase 3
NCT02898610,2016.0,OTHER,collaborator,Universitat de Lleida,Phase 3
NCT02898610,2016.0,OTHER,collaborator,Universitaire Ziekenhuizen KU Leuven,Phase 3
NCT02898610,2016.0,OTHER,collaborator,University of Athens,Phase 3
NCT02898753,2017.0,INDUSTRY,lead,"Valerion Therapeutics, LLC",Phase 1/Phase 2
NCT02898792,2016.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT02899091,2016.0,INDUSTRY,lead,"CHABiotech CO., Ltd",Phase 1/Phase 2
NCT02899611,2016.0,INDUSTRY,lead,Cerebral Therapeutics LLC,Phase 1/Phase 2
NCT02899611,2016.0,OTHER,collaborator,Neuroscience Trials Australia,Phase 1/Phase 2
NCT02899741,2016.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT02901106,2017.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 4
NCT02901249,2010.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 4
NCT02901431,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02901587,2016.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT02902081,2013.0,OTHER,lead,University of Chicago,Not Applicable
NCT02902081,2013.0,INDUSTRY,collaborator,INSYS Therapeutics Inc,Not Applicable
NCT02902133,2016.0,OTHER,lead,University of Miami,Phase 2
NCT02902731,2017.0,OTHER,lead,"University Hospital, Caen",Phase 3
NCT02902731,2017.0,OTHER,collaborator,Hôpital Claude-Huriez,Phase 3
NCT02902731,2017.0,OTHER,collaborator,Amiens University Hospital,Phase 3
NCT02902731,2017.0,OTHER,collaborator,"University Hospital, Rouen",Phase 3
NCT02902731,2017.0,OTHER,collaborator,"University Hospital, Limoges",Phase 3
NCT02902731,2017.0,OTHER_GOV,collaborator,Central Hospital Saint Quentin,Phase 3
NCT02902731,2017.0,UNKNOWN,collaborator,"Valenciennes Hospital, Valenciennes, FRANCE",Phase 3
NCT02903030,2016.0,OTHER,lead,Ohio State University,Early Phase 1
NCT02903030,2016.0,NETWORK,collaborator,Autism Treatment Network,Early Phase 1
NCT02903030,2016.0,OTHER,collaborator,Autism Speaks,Early Phase 1
NCT02903251,2016.0,OTHER,lead,Norwegian University of Science and Technology,Phase 3
NCT02903251,2016.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT02903251,2016.0,UNKNOWN,collaborator,Lade Addiction Treatment Center,Phase 3
NCT02903537,2017.0,OTHER,lead,Fundació Institut Germans Trias i Pujol,Phase 1
NCT02903537,2017.0,OTHER,collaborator,"Clinica Universidad de Navarra, Universidad de Navarra",Phase 1
NCT02903680,2014.0,OTHER,lead,St. Justine's Hospital,Phase 1
NCT02903823,2016.0,OTHER,lead,Vanderbilt University,Phase 4
NCT02903823,2016.0,INDUSTRY,collaborator,Medtronic,Phase 4
NCT02903901,2015.0,OTHER,lead,Loyola University,Phase 4
NCT02904265,2016.0,OTHER,lead,Mayo Clinic,Phase 2/Phase 3
NCT02904876,2015.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 4
NCT02904915,2017.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 4
NCT02905227,2016.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT02905305,2013.0,OTHER,lead,The Hearing Cooperative Research Centre,Not Applicable
NCT02905305,2013.0,INDUSTRY,collaborator,Cochlear,Not Applicable
NCT02905305,2013.0,OTHER_GOV,collaborator,Royal Victoria Eye and Ear Hospital,Not Applicable
NCT02905305,2013.0,OTHER,collaborator,"Royal Prince Alfred Hospital, Sydney, Australia",Not Applicable
NCT02905305,2013.0,OTHER,collaborator,St Vincent's Hospital Melbourne,Not Applicable
NCT02905305,2013.0,UNKNOWN,collaborator,"Westmead Hospital, New South Wales",Not Applicable
NCT02905734,2017.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT02906020,2016.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 2
NCT02906553,2016.0,OTHER,lead,King's College London,Not Applicable
NCT02906553,2016.0,OTHER,collaborator,South London and Maudsley NHS Foundation Trust,Not Applicable
NCT02906644,2016.0,OTHER,lead,Duke University,Phase 2
NCT02906644,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT02906995,2017.0,OTHER,lead,"Friends Research Institute, Inc.",Phase 1
NCT02906995,2017.0,INDUSTRY,collaborator,"Rose Research Center, LLC",Phase 1
NCT02907177,2017.0,INDUSTRY,lead,Actelion,Phase 3
NCT02907294,2016.0,INDUSTRY,lead,Palobiofarma SL,Phase 1
NCT02907294,2016.0,OTHER,collaborator,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1
NCT02907437,2015.0,OTHER_GOV,lead,Beer Yaakov - Ness Ziona Mental Health Center,Phase 3
NCT02907437,2015.0,OTHER,collaborator,"Bar-Ilan University, Israel",Phase 3
NCT02907554,2017.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 4
NCT02907554,2017.0,OTHER,collaborator,"University Hospital, Estaing",Phase 4
NCT02907554,2017.0,OTHER,collaborator,Centre Hospitalier Universitaire de Nice,Phase 4
NCT02907554,2017.0,OTHER,collaborator,Groupe Hospitalier Pitie-Salpetriere,Phase 4
NCT02907554,2017.0,OTHER,collaborator,Centre Hospitalier Universitaire de Nīmes,Phase 4
NCT02907554,2017.0,OTHER,collaborator,"University Hospital, Montpellier",Phase 4
NCT02907554,2017.0,UNKNOWN,collaborator,Hôtel Dieu (Nantes),Phase 4
NCT02907554,2017.0,OTHER,collaborator,Poitiers University Hospital,Phase 4
NCT02907554,2017.0,OTHER,collaborator,"University Hospital, Toulouse",Phase 4
NCT02907554,2017.0,OTHER,collaborator,Hôpital de la Timone,Phase 4
NCT02907567,2016.0,INDUSTRY,lead,Cognition Therapeutics,Phase 1/Phase 2
NCT02907619,2016.0,INDUSTRY,lead,Pfizer,Phase 2
NCT02908685,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02909088,2016.0,OTHER,lead,"Gerald Maguire, MD",Phase 2/Phase 3
NCT02909088,2016.0,UNKNOWN,collaborator,University of California Riverisde School of Medicine,Phase 2/Phase 3
NCT02909309,2017.0,OTHER,lead,Erasme University Hospital,Not Applicable
NCT02909400,2016.0,INDUSTRY,lead,Khondrion BV,Phase 2
NCT02909400,2016.0,OTHER,collaborator,Radboud University Medical Center,Phase 2
NCT02909504,2016.0,OTHER,lead,Keming Gao,Phase 4
NCT02909504,2016.0,OTHER,collaborator,CellPrint Biotechnology,Phase 4
NCT02909504,2016.0,OTHER,collaborator,National Alliance for Research on Schizophrenia and Depression,Phase 4
NCT02909777,2016.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 1
NCT02909777,2016.0,INDUSTRY,collaborator,"Curis, Inc.",Phase 1
NCT02909907,2016.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT02909959,2017.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT02909959,2017.0,OTHER,collaborator,North Carolina Translational and Clinical Sciences Institute,Phase 2
NCT02910102,2016.0,INDUSTRY,lead,Axovant Sciences Ltd.,Phase 2
NCT02910427,2009.0,OTHER,lead,"Academia Sinica, Taiwan",Not Applicable
NCT02910739,2016.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT02911194,2016.0,OTHER,lead,Northumbria University,Not Applicable
NCT02911194,2016.0,UNKNOWN,collaborator,ESPA Research,Not Applicable
NCT02911194,2016.0,INDUSTRY,collaborator,a2 Milk Company Ltd.,Not Applicable
NCT02911324,2016.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT02911597,2016.0,OTHER,lead,Stanford University,Phase 1
NCT02911597,2016.0,INDIV,collaborator,"Schatzberg, Alan, M.D.",Phase 1
NCT02912130,2016.0,OTHER,lead,Liverpool Hope University,Not Applicable
NCT02912169,2015.0,INDUSTRY,lead,Ageless Regenerative Institute,Phase 1/Phase 2
NCT02912182,2015.0,OTHER,lead,Lund University,Phase 4
NCT02912364,2016.0,OTHER,lead,Stanford University,Phase 4
NCT02912364,2016.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT02912897,2021.0,OTHER,lead,Nantes University Hospital,Phase 1
NCT02912936,2016.0,OTHER,lead,University of British Columbia,Not Applicable
NCT02912936,2016.0,OTHER,collaborator,Université de Sherbrooke,Not Applicable
NCT02913183,2016.0,OTHER,lead,Xinqiao Hospital of Chongqing,Phase 2
NCT02913482,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02914015,2018.0,OTHER,lead,Cui Xulei,Not Applicable
NCT02914314,2017.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT02915211,2016.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT02915263,2017.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT02915263,2017.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 2
NCT02915510,2016.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT02916056,2016.0,INDUSTRY,lead,vTv Therapeutics,Phase 3
NCT02916121,2016.0,OTHER,lead,Taipei Medical University WanFang Hospital,Not Applicable
NCT02916160,2016.0,OTHER,lead,"University Hospital, Montpellier",Phase 4
NCT02916693,2017.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT02916693,2017.0,INDUSTRY,collaborator,"Astellas Pharma US, Inc.",Phase 1/Phase 2
NCT02917122,2015.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 1/Phase 2
NCT02917967,2016.0,OTHER,lead,Yonsei University,Not Applicable
NCT02918097,2010.0,OTHER,lead,Federal University of Rio Grande do Sul,Phase 4
NCT02918318,2016.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 2
NCT02918370,2016.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 3
NCT02918825,2016.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT02918864,2016.0,OTHER,lead,Rush University Medical Center,Phase 2
NCT02918864,2016.0,OTHER,collaborator,University of Illinois at Chicago,Phase 2
NCT02918864,2016.0,OTHER,collaborator,University of Chicago,Phase 2
NCT02918864,2016.0,OTHER,collaborator,Northwestern University,Phase 2
NCT02918864,2016.0,OTHER,collaborator,Eotvos Lorand University,Phase 2
NCT02919293,2016.0,INDUSTRY,lead,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 1/Phase 2
NCT02919293,2016.0,OTHER_GOV,collaborator,Guangdong Center for Disease Prevention and Control,Phase 1/Phase 2
NCT02919293,2016.0,OTHER,collaborator,Guizhou Center for Disease Control and Prevention,Phase 1/Phase 2
NCT02919293,2016.0,OTHER,collaborator,"National Institutes for Food and Drug Control, China",Phase 1/Phase 2
NCT02919293,2016.0,OTHER,collaborator,"Air Force Military Medical University, China",Phase 1/Phase 2
NCT02919293,2016.0,INDUSTRY,collaborator,"Simoon Record Pharma Information Consulting Co., Ltd.",Phase 1/Phase 2
NCT02919345,2017.0,OTHER,lead,"University of Campinas, Brazil",Phase 4
NCT02919345,2017.0,INDUSTRY,collaborator,AstraZeneca,Phase 4
NCT02919917,2017.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 2/Phase 3
NCT02919917,2017.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 2/Phase 3
NCT02920892,2017.0,OTHER,lead,Elizabeth Berry-Kravis,Phase 2
NCT02920892,2017.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT02920892,2017.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 2
NCT02921360,2016.0,OTHER_GOV,lead,"City Clinical Hospital No. 67, Moscow, Russia",Not Applicable
NCT02921477,2016.0,OTHER,lead,Neurological Associates of West Los Angeles,Phase 1
NCT02921477,2016.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT02921620,2017.0,INDUSTRY,lead,Protalix,Phase 3
NCT02921893,2016.0,OTHER,lead,Mayo Clinic,Early Phase 1
NCT02922803,2010.0,OTHER,lead,Uppsala University,Not Applicable
NCT02922894,2017.0,FED,lead,John D. Dingell VA Medical Center,Phase 4
NCT02922894,2017.0,FED,collaborator,United States Department of Defense,Phase 4
NCT02922959,2017.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT02922959,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT02923102,2016.0,INDUSTRY,lead,Vital Solutions GmbH,Not Applicable
NCT02923128,2016.0,OTHER,lead,Zhejiang Cancer Hospital,Phase 4
NCT02923297,2015.0,OTHER,lead,Centre Hospitalier Régional d'Orléans,Not Applicable
NCT02923297,2015.0,UNKNOWN,collaborator,National Scientific Research Centre,Not Applicable
NCT02923817,2016.0,OTHER,lead,Da Nang Hospital,Phase 2
NCT02923817,2016.0,UNKNOWN,collaborator,Kitano Hospital,Phase 2
NCT02923817,2016.0,OTHER,collaborator,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Phase 2
NCT02924090,2016.0,OTHER,lead,University of Manitoba,Phase 4
NCT02925611,2016.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Phase 4
NCT02925650,2017.0,INDUSTRY,lead,Annovis Bio Inc.,Phase 1/Phase 2
NCT02925650,2017.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 1/Phase 2
NCT02926859,2017.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Phase 2
NCT02926976,2016.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT02927080,2016.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2
NCT02928211,2016.0,INDUSTRY,lead,"Cognoptix, Inc.",Phase 1
NCT02928393,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02928497,2017.0,INDUSTRY,lead,Boston Scientific Corporation,Not Applicable
NCT02929147,2016.0,OTHER,lead,Istanbul University,Phase 4
NCT02929667,2017.0,OTHER,lead,Rup Kamal Sainju,Phase 2
NCT02930005,2015.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT02930018,2017.0,INDUSTRY,lead,NoNO Inc.,Phase 3
NCT02930018,2017.0,OTHER,collaborator,University of Calgary,Phase 3
NCT02930551,2016.0,OTHER,lead,Danish Pain Research Center,Not Applicable
NCT02930551,2016.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT02930655,2015.0,INDUSTRY,lead,Idorsia Pharmaceuticals Ltd.,Phase 1
NCT02930837,2016.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT02931474,2016.0,NIH,lead,National Institute of Nursing Research (NINR),Phase 2
NCT02932280,2016.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,Milton S. Hershey Medical Center,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,Stanford University,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,Arkansas Children's Hospital Research Institute,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,Alberta Children's Hospital,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,Phoenix Children's Hospital,Phase 1/Phase 2
NCT02932280,2016.0,OTHER,collaborator,University of Texas,Phase 1/Phase 2
NCT02932605,2017.0,OTHER,lead,UMC Utrecht,Not Applicable
NCT02933372,2015.0,OTHER,lead,University of Michigan,Phase 2
NCT02933606,2016.0,INDUSTRY,lead,Bionomics Limited,Phase 2
NCT02933736,2016.0,OTHER,lead,Nader Sanai,Early Phase 1
NCT02933736,2016.0,INDUSTRY,collaborator,Novartis,Early Phase 1
NCT02933736,2016.0,OTHER,collaborator,Ivy Brain Tumor Center,Early Phase 1
NCT02933736,2016.0,OTHER,collaborator,Barrow Neurological Institute,Early Phase 1
NCT02934256,2016.0,OTHER,lead,Li Peng,Phase 2
NCT02934256,2016.0,INDUSTRY,collaborator,"Betta Pharmaceuticals Co., Ltd.",Phase 2
NCT02934763,2016.0,OTHER,lead,Pontificia Universidad Catolica de Chile,Phase 4
NCT02934919,2016.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT02934932,2017.0,OTHER,lead,Duke University,Phase 2
NCT02934932,2017.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 2
NCT02935101,2016.0,OTHER,lead,"Prof. Dominique de Quervain, MD",Phase 2
NCT02935101,2016.0,OTHER,collaborator,Psychiatric Hospital of the University of Basel,Phase 2
NCT02935725,2016.0,INDUSTRY,lead,Autifony Therapeutics Limited,Phase 1
NCT02935725,2016.0,OTHER,collaborator,University of Manchester,Phase 1
NCT02935998,2016.0,OTHER,lead,Yang Fude,Phase 4
NCT02935998,2016.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT02936037,2016.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 3
NCT02936414,2014.0,OTHER,lead,Tianjin Anding Hospital,Not Applicable
NCT02936843,2016.0,OTHER,lead,University of Michigan,Phase 2/Phase 3
NCT02937285,2010.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT02938182,2016.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Phase 4
NCT02938468,2016.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT02938923,2017.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT02938923,2017.0,OTHER,collaborator,"University of Maryland, Baltimore",Phase 3
NCT02938923,2017.0,OTHER,collaborator,"University of Colorado, Denver",Phase 3
NCT02938923,2017.0,OTHER,collaborator,"The University of Texas Medical Branch, Galveston",Phase 3
NCT02938923,2017.0,OTHER,collaborator,Johns Hopkins University,Phase 3
NCT02938923,2017.0,OTHER,collaborator,Harvard University,Phase 3
NCT02938923,2017.0,OTHER,collaborator,University of Connecticut,Phase 3
NCT02938923,2017.0,OTHER,collaborator,University of Utah,Phase 3
NCT02938923,2017.0,OTHER,collaborator,University of Pittsburgh Medical Center,Phase 3
NCT02939079,2015.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2/Phase 3
NCT02939079,2015.0,OTHER,collaborator,Shiraz University of Medical Sciences,Phase 2/Phase 3
NCT02939300,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02939300,2018.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT02939391,2016.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT02939482,2016.0,OTHER,lead,Navamindradhiraj University,Not Applicable
NCT02939495,2016.0,INDUSTRY,lead,Neutec Ar-Ge San ve Tic A.Ş,Phase 4
NCT02939833,2017.0,OTHER,lead,RenJi Hospital,Not Applicable
NCT02939937,2017.0,OTHER,lead,Tehran University of Medical Sciences,Phase 2
NCT02940574,2015.0,OTHER,lead,KU Leuven,Phase 4
NCT02940574,2015.0,OTHER,collaborator,The Branco Weiss Fellowship,Phase 4
NCT02940574,2015.0,OTHER,collaborator,Research Foundation Flanders,Phase 4
NCT02940912,2018.0,OTHER,lead,Clinique Beau Soleil,Phase 4
NCT02941328,2015.0,OTHER,lead,UMC Utrecht,Phase 2
NCT02941822,2016.0,OTHER,lead,"University College, London",Phase 2
NCT02941822,2016.0,UNKNOWN,collaborator,The Cure Parkinson's Trust,Phase 2
NCT02942264,2016.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT02943096,2016.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT02943096,2016.0,OTHER,collaborator,Columbia University,Not Applicable
NCT02943356,2016.0,OTHER,lead,The Catholic University of Korea,Phase 4
NCT02943356,2016.0,INDUSTRY,collaborator,Hanmi Pharmaceutical Company Limited,Phase 4
NCT02943850,2017.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 1
NCT02943850,2017.0,OTHER,collaborator,California Institute for Regenerative Medicine (CIRM),Phase 1
NCT02943902,2017.0,OTHER,lead,"University of Witwatersrand, South Africa",Phase 3
NCT02943902,2017.0,OTHER,collaborator,"University College, London",Phase 3
NCT02944032,2016.0,OTHER,lead,Kristina Hardy,Not Applicable
NCT02944032,2016.0,OTHER,collaborator,Children's National Health System,Not Applicable
NCT02944032,2016.0,OTHER,collaborator,Royal Children's Hospital,Not Applicable
NCT02944032,2016.0,OTHER,collaborator,Children's Hospital Los Angeles,Not Applicable
NCT02944032,2016.0,OTHER,collaborator,Sydney Children's Hospitals Network,Not Applicable
NCT02945462,2013.0,OTHER,lead,University of Jordan,Phase 1
NCT02945527,2015.0,OTHER,lead,Universidad Peruana Cayetano Heredia,Phase 2/Phase 3
NCT02945644,2017.0,FED,lead,Louis Stokes VA Medical Center,Phase 1
NCT02945839,2016.0,OTHER,lead,NYU Langone Health,Phase 4
NCT02946424,2017.0,OTHER,lead,Craig Hospital,Phase 2
NCT02946489,2016.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT02946489,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT02947581,2016.0,OTHER,lead,Universidad Peruana Cayetano Heredia,Phase 3
NCT02947893,2017.0,OTHER,lead,Georgetown University,Phase 2
NCT02948023,2016.0,OTHER,lead,L.V. Prasad Eye Institute,Phase 1
NCT02948244,2017.0,OTHER,lead,Murdoch Childrens Research Institute,Not Applicable
NCT02948322,2014.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT02948322,2014.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT02948660,2017.0,OTHER,lead,Xijing Hospital,Phase 2
NCT02948660,2017.0,OTHER,collaborator,Guangzhou University of Chinese Medicine,Phase 2
NCT02948660,2017.0,OTHER,collaborator,University of Melbourne,Phase 2
NCT02948660,2017.0,OTHER,collaborator,Tianjin University,Phase 2
NCT02949232,2014.0,OTHER,lead,UMC Utrecht,Phase 4
NCT02950467,2018.0,OTHER,lead,Joshua Woolley,Phase 1
NCT02950467,2018.0,OTHER,collaborator,Heffter Research Institute,Phase 1
NCT02950467,2018.0,UNKNOWN,collaborator,River Styx Foundation,Phase 1
NCT02950467,2018.0,OTHER,collaborator,Usona Institute,Phase 1
NCT02950467,2018.0,UNKNOWN,collaborator,Stupski Foundation,Phase 1
NCT02951143,2017.0,OTHER,lead,Virginia Polytechnic Institute and State University,Not Applicable
NCT02951143,2017.0,OTHER,collaborator,University of Kentucky,Not Applicable
NCT02951377,2017.0,OTHER,lead,University of Alberta,Phase 1
NCT02951377,2017.0,OTHER,collaborator,University of Calgary,Phase 1
NCT02951377,2017.0,UNKNOWN,collaborator,Alberta College and Association of Phyiotherapists,Phase 1
NCT02951715,2013.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT02951715,2013.0,OTHER,collaborator,Chang Gung University,Not Applicable
NCT02952196,2016.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2
NCT02952885,2017.0,OTHER,lead,Unity Health Toronto,Phase 3
NCT02953548,2017.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02953639,2016.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT02953665,2017.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT02953665,2017.0,UNKNOWN,collaborator,The Cure Parkinson's Trust,Phase 2
NCT02953665,2017.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 2
NCT02954276,2016.0,INDUSTRY,lead,Targia Pharmaceuticals Ltd.,Phase 1
NCT02954276,2016.0,INDUSTRY,collaborator,SoluBest Ltd.,Phase 1
NCT02954887,2017.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT02954978,2017.0,OTHER,lead,Georgetown University,Phase 2
NCT02955147,2016.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT02955329,2019.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT02955329,2019.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT02955329,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT02955355,2016.0,INDUSTRY,lead,Baxalta now part of Shire,Phase 3
NCT02955355,2016.0,INDUSTRY,collaborator,"Takeda Development Center Americas, Inc.",Phase 3
NCT02955654,2017.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT02955706,2016.0,INDUSTRY,lead,"Dong-A ST Co., Ltd.",Phase 4
NCT02955719,2016.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT02955719,2016.0,OTHER,collaborator,McMaster University,Not Applicable
NCT02955797,2017.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT02956200,2016.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 2
NCT02956200,2016.0,OTHER,collaborator,Shaoxing People's Hospital,Phase 2
NCT02956200,2016.0,OTHER,collaborator,Affiliated Hospital of Jiaxing University,Phase 2
NCT02956200,2016.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 2
NCT02956200,2016.0,OTHER,collaborator,The Second Affiliated Hospital of Jiaxing University,Phase 2
NCT02956200,2016.0,UNKNOWN,collaborator,Jinhua Center Hospital,Phase 2
NCT02956200,2016.0,OTHER,collaborator,Taizhou Hospital,Phase 2
NCT02956447,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT02956486,2016.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 3
NCT02956486,2016.0,INDUSTRY,collaborator,Biogen,Phase 3
NCT02956954,2017.0,OTHER,lead,"University Hospital, Rouen",Not Applicable
NCT02957123,2016.0,OTHER,lead,Russian Academy of Medical Sciences,Phase 1/Phase 2
NCT02957331,2016.0,OTHER,lead,University of Tennessee,Phase 4
NCT02957851,2016.0,INDUSTRY,lead,Air Liquide Santé International,Phase 2
NCT02957851,2016.0,INDUSTRY,collaborator,AMS Advanced Medical Services GmbH,Phase 2
NCT02958202,2016.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 2
NCT02958709,2017.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT02958709,2017.0,UNKNOWN,collaborator,"National Institute for Research in Tuberculosis, Chennai, India",Phase 1/Phase 2
NCT02958709,2017.0,OTHER,collaborator,University of North Carolina,Phase 1/Phase 2
NCT02958709,2017.0,OTHER,collaborator,"B. J. Medical College, Pune",Phase 1/Phase 2
NCT02958709,2017.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT02958800,2016.0,OTHER,lead,McMaster University,Not Applicable
NCT02958800,2016.0,OTHER,collaborator,College of Family Physicians of Canada,Not Applicable
NCT02958800,2016.0,UNKNOWN,collaborator,MediSystem Pharmacy,Not Applicable
NCT02959177,2016.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT02959190,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT02960425,2016.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT02960893,2016.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT02961504,2017.0,INDUSTRY,lead,Healios K.K.,Phase 2/Phase 3
NCT02961803,2014.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 2/Phase 3
NCT02962414,2017.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT02963181,2018.0,OTHER,lead,Lawson Health Research Institute,Early Phase 1
NCT02963545,2012.0,OTHER,lead,Versailles Hospital,Not Applicable
NCT02963896,2014.0,OTHER,lead,"University Hospital, Motol",Not Applicable
NCT02964338,2017.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT02964377,2016.0,OTHER,lead,"Craig McDonald, MD",Phase 1/Phase 2
NCT02964377,2016.0,INDUSTRY,collaborator,"Cardero Therapeutics, Inc.",Phase 1/Phase 2
NCT02964416,2016.0,OTHER,lead,Aga Khan University,Phase 4
NCT02964884,2016.0,OTHER,lead,Vanderbilt University,Phase 2
NCT02964884,2016.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT02965027,2016.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 4
NCT02965027,2016.0,FED,collaborator,VA Puget Sound Health Care System,Phase 4
NCT02965027,2016.0,FED,collaborator,Madigan Army Medical Center,Phase 4
NCT02965573,2016.0,INDUSTRY,lead,argenx,Phase 2
NCT02965573,2016.0,INDUSTRY,collaborator,"Quintiles, Inc.",Phase 2
NCT02965768,2016.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT02966119,2016.0,OTHER,lead,"University Hospital, Lille",Phase 3
NCT02966119,2016.0,UNKNOWN,collaborator,"Région Hauts de France, France",Phase 3
NCT02966119,2016.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT02967250,2020.0,OTHER,lead,University of Minnesota,Phase 1
NCT02967380,2011.0,OTHER,lead,University of Southern California,Not Applicable
NCT02967380,2011.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT02967484,2016.0,OTHER,lead,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Not Applicable
NCT02967484,2016.0,OTHER_GOV,collaborator,State Administration of Traditional Chinese Medicine of the People's Republic of China,Not Applicable
NCT02967679,2016.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 2
NCT02967783,2017.0,OTHER,lead,"Medical Research Council Unit, The Gambia",Not Applicable
NCT02967783,2017.0,OTHER,collaborator,World Health Organization,Not Applicable
NCT02967783,2017.0,FED,collaborator,Centers for Disease Control and Prevention,Not Applicable
NCT02968121,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT02968121,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT02968342,2016.0,OTHER,lead,Bezmialem Vakif University,Phase 4
NCT02968602,2017.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT02968602,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT02968719,2016.0,INDUSTRY,lead,"Corium, Inc.",Phase 1
NCT02969382,2016.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT02969876,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT02969876,2017.0,INDUSTRY,collaborator,Takeda,Phase 4
NCT02970019,2017.0,INDUSTRY,lead,Sun Pharma Advanced Research Company Limited,Phase 1
NCT02970292,2016.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT02970305,2016.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2
NCT02970773,2017.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Phase 4
NCT02970929,2017.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT02971254,2016.0,OTHER_GOV,lead,Asklepieion Voulas General Hospital,Phase 2
NCT02971683,2017.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 3
NCT02972281,2015.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT02972281,2015.0,OTHER,collaborator,Imagine Institute,Not Applicable
NCT02972281,2015.0,INDUSTRY,collaborator,Octapharma,Not Applicable
NCT02972281,2015.0,INDUSTRY,collaborator,CSL Behring,Not Applicable
NCT02972281,2015.0,INDUSTRY,collaborator,Laboratoire français de Fractionnement et de Biotechnologies,Not Applicable
NCT02972281,2015.0,INDUSTRY,collaborator,Air Liquide SA,Not Applicable
NCT02972281,2015.0,UNKNOWN,collaborator,The Binding Site Ltd,Not Applicable
NCT02972359,2016.0,INDUSTRY,lead,Grünenthal GmbH,Phase 3
NCT02972502,2014.0,OTHER,lead,OhioHealth,Phase 4
NCT02972554,2016.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT02972658,2017.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT02972658,2017.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT02973659,2015.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT02974010,2018.0,INDUSTRY,lead,"NeuroRx, Inc.",Phase 2
NCT02974010,2018.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT02974010,2018.0,INDUSTRY,collaborator,Target Health Inc.,Phase 2
NCT02974153,2016.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 3
NCT02974283,2016.0,OTHER,lead,Capital Medical University,Not Applicable
NCT02975076,2016.0,OTHER,lead,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Not Applicable
NCT02976337,2017.0,OTHER,lead,mads u werner,Phase 2
NCT02976337,2017.0,OTHER,collaborator,University of Kentucky,Phase 2
NCT02976441,2017.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT02976766,2017.0,OTHER,lead,First Affiliated Hospital of Guangxi Medical University,Phase 2
NCT02977208,2016.0,OTHER,lead,São Paulo State University,Phase 4
NCT02977208,2016.0,OTHER,collaborator,University of Sao Paulo,Phase 4
NCT02978599,2016.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT02978599,2016.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT02978651,,OTHER,lead,Bioprojet,Phase 3
NCT02978781,2017.0,INDUSTRY,lead,Biogen,Phase 2
NCT02980042,2017.0,OTHER,lead,"University of Colorado, Denver",Phase 3
NCT02980198,2017.0,INDUSTRY,lead,Neovacs,Phase 2
NCT02981095,2010.0,OTHER,lead,Istanbul University,Not Applicable
NCT02981173,2016.0,OTHER,lead,Yale University,Phase 1
NCT02981173,2016.0,OTHER,collaborator,Heffter Research Institute,Phase 1
NCT02981173,2016.0,UNKNOWN,collaborator,Ceruvia Lifesciences,Phase 1
NCT02981173,2016.0,UNKNOWN,collaborator,CH TAC LLC,Phase 1
NCT02981576,2016.0,OTHER,lead,University of Jordan,Phase 1/Phase 2
NCT02982512,2017.0,OTHER,lead,"Clinica Universidad de Navarra, Universidad de Navarra",Phase 4
NCT02982668,2017.0,OTHER,lead,Xijing Hospital,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,Tang-Du Hospital,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,Xi'an Central Hospital,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,Xi'an Gaoxin Hospital,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,Yan'an University Affiliated Hospital,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,The PLA 940 hospital,Not Applicable
NCT02982668,2017.0,OTHER_GOV,collaborator,Xi'an No.3 Hospital,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,The First Affiliated Hospital of Xi'an Medical University,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,Yulin No.1 Hospital,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,The First People's Hospital of Xianyang,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,Tongchuan Mining Hospital,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,The PLA General Hospital of Xinjiang,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,Tongchuan People's Hospital,Not Applicable
NCT02982668,2017.0,UNKNOWN,collaborator,Yulin No.2 Hospital,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT02982668,2017.0,OTHER,collaborator,Ankang Central Hospital,Not Applicable
NCT02982824,2016.0,OTHER,lead,Ain Shams University,Not Applicable
NCT02983188,2018.0,OTHER,lead,The University of Hong Kong,Phase 2/Phase 3
NCT02983188,2018.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Phase 2/Phase 3
NCT02983188,2018.0,OTHER,collaborator,"Kowloon Hospital, Hong Kong",Phase 2/Phase 3
NCT02983188,2018.0,OTHER_GOV,collaborator,Castle Peak Hospital,Phase 2/Phase 3
NCT02983188,2018.0,OTHER,collaborator,Zhejiang Provincial Tongde Hospital,Phase 2/Phase 3
NCT02983695,2017.0,OTHER,lead,The Hospital for Sick Children,Phase 1
NCT02983695,2017.0,INDUSTRY,collaborator,Tilray,Phase 1
NCT02983708,2011.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 1/Phase 2
NCT02983708,2011.0,OTHER_GOV,collaborator,"Ministry of Health & Welfare, Korea",Phase 1/Phase 2
NCT02985320,2016.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 1/Phase 2
NCT02985398,2016.0,INDUSTRY,lead,"Alder Biopharmaceuticals, Inc.",Phase 3
NCT02985749,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT02985879,2016.0,INDUSTRY,lead,AbbVie,Phase 2
NCT02986347,2017.0,OTHER,lead,Hospital Alvorada,Not Applicable
NCT02986347,2017.0,OTHER,collaborator,Federal University of São Paulo,Not Applicable
NCT02986490,2014.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT02986828,2016.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT02986919,2017.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT02987413,2015.0,OTHER,lead,Hospital e Maternidade Dr. Christóvão da Gama,Phase 1
NCT02987413,2015.0,OTHER,collaborator,IEP São Lucas - Instituto de Ensino e Pesquisa,Phase 1
NCT02987413,2015.0,UNKNOWN,collaborator,Clinica Jordy Sinapse,Phase 1
NCT02987413,2015.0,UNKNOWN,collaborator,TECHLIFE - Centro de Tecnologia Celular,Phase 1
NCT02988050,2013.0,OTHER,lead,Menoufia University,Not Applicable
NCT02988297,2024.0,INDUSTRY,lead,Revalesio Corporation,Phase 2
NCT02988401,2017.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT02988401,2017.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT02989402,2018.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT02989727,2003.0,OTHER,lead,University of Saskatchewan,Phase 4
NCT02989727,2003.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 4
NCT02989779,2017.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Phase 1/Phase 2
NCT02989779,2017.0,OTHER,collaborator,"University Health Network, Toronto",Phase 1/Phase 2
NCT02989792,2017.0,OTHER,lead,Tools4Patient,Not Applicable
NCT02990364,2015.0,OTHER,lead,American University of Beirut Medical Center,Phase 3
NCT02990910,2016.0,OTHER,lead,Children's Hospital of Fudan University,Not Applicable
NCT02990962,2016.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT02991001,2017.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT02991235,2016.0,INDUSTRY,lead,Bioiberica,Not Applicable
NCT02992938,2016.0,OTHER,lead,University of Chile,Phase 4
NCT02994082,2016.0,FED,lead,Mark Vander Weg,Not Applicable
NCT02994082,2016.0,FED,collaborator,Iowa City VA Health Care System,Not Applicable
NCT02994875,2016.0,OTHER,lead,Yale University,Early Phase 1
NCT02994875,2016.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT02995993,2016.0,INDUSTRY,lead,Greenovation Biotech GmbH,Phase 1
NCT02995993,2016.0,INDUSTRY,collaborator,FGK Clinical Research GmbH,Phase 1
NCT02996305,2016.0,INDUSTRY,lead,Ovid Therapeutics Inc.,Phase 2
NCT02997982,2016.0,OTHER,lead,Hugo Lovheim,Phase 2
NCT02998151,2016.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Early Phase 1
NCT02998151,2016.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Early Phase 1
NCT02998905,2017.0,OTHER,lead,Population Health Research Institute,Phase 2
NCT02999945,2019.0,OTHER,lead,Medical University of Vienna,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,Medical University of Graz,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,Ludwig-Maximilians - University of Munich,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,University Hospital Tuebingen,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,University of Erlangen-Nürnberg Medical School,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,University of Milan,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,Poznan University of Medical Sciences,Not Applicable
NCT02999945,2019.0,OTHER,collaborator,Lund University,Not Applicable
NCT03000127,2018.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT03000127,2018.0,OTHER,collaborator,Washington University School of Medicine,Phase 2
NCT03000283,2017.0,OTHER,lead,Jesse Corry,Phase 1
NCT03000387,2018.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT03000387,2018.0,OTHER,collaborator,Canadian Cancer Society (CCS),Phase 4
NCT03000387,2018.0,OTHER,collaborator,Ottawa Heart Institute Research Corporation,Phase 4
NCT03000569,2016.0,INDUSTRY,lead,Biogen,Phase 2
NCT03000777,2016.0,INDUSTRY,lead,"Laboratorios Viñas, S.A.",Not Applicable
NCT03000777,2016.0,OTHER,collaborator,Hospital Vall d'Hebron,Not Applicable
NCT03000777,2016.0,UNKNOWN,collaborator,Laboratorio Echevarne,Not Applicable
NCT03001349,2017.0,OTHER,lead,M.D. Anderson Cancer Center,Early Phase 1
NCT03001349,2017.0,NIH,collaborator,National Cancer Institute (NCI),Early Phase 1
NCT03001960,2017.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 3
NCT03001960,2017.0,UNKNOWN,collaborator,"Prof. Dr. Jochen Fiebach, Center for Stroke Research Berlin (CSB), Charité - Universitaetsmedizin Berlin",Phase 3
NCT03002038,2015.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2/Phase 3
NCT03002649,2017.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT03002649,2017.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT03003949,2017.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT03003949,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03004430,2017.0,OTHER,lead,Diakonie Kliniken Zschadraß,Not Applicable
NCT03004430,2017.0,OTHER,collaborator,University Hospital Dresden,Not Applicable
NCT03004443,2017.0,OTHER,lead,Emory University,Phase 4
NCT03004443,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03004573,2017.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT03004976,2017.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 2
NCT03004976,2017.0,OTHER,collaborator,The Marcus Foundation,Phase 2
NCT03004976,2017.0,OTHER,collaborator,Emory University,Phase 2
NCT03004976,2017.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 2
NCT03005119,2018.0,INDUSTRY,lead,"PhytoTech Therapeutics, Ltd.",Phase 2
NCT03005665,2016.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Not Applicable
NCT03006003,2017.0,OTHER,lead,Taichung Veterans General Hospital,Phase 4
NCT03006276,2016.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 3
NCT03006393,2016.0,OTHER,lead,Emory University,Phase 4
NCT03006393,2016.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03006861,2016.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT03006861,2016.0,OTHER,collaborator,University of Guelph,Not Applicable
NCT03006861,2016.0,OTHER,collaborator,University of Prince Edward Island,Not Applicable
NCT03007394,2017.0,NIH,lead,National Institute on Drug Abuse (NIDA),Phase 2
NCT03007420,2018.0,OTHER,lead,Boston Children's Hospital,Phase 3
NCT03007420,2018.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 3
NCT03007420,2018.0,OTHER,collaborator,Harvard University,Phase 3
NCT03008161,2016.0,INDUSTRY,lead,"Proclara Biosciences, Inc.",Phase 1
NCT03008161,2016.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT03008889,2018.0,OTHER,lead,Emory University,Phase 2
NCT03009019,2016.0,INDUSTRY,lead,BioDelivery Sciences International,Phase 3
NCT03009019,2016.0,INDUSTRY,collaborator,Dr. Reddy's Laboratories Limited,Phase 3
NCT03009162,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03009162,2017.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 1
NCT03009500,2017.0,OTHER,lead,"University Health Network, Toronto",Phase 3
NCT03010228,2017.0,INDUSTRY,lead,Pfizer,Phase 1
NCT03010228,2017.0,INDUSTRY,collaborator,Valneva Austria GmbH,Phase 1
NCT03010540,2015.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Not Applicable
NCT03010865,2017.0,OTHER,lead,Shanghai Mental Health Center,Phase 2/Phase 3
NCT03010865,2017.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT03011476,2017.0,OTHER,lead,Kyung Hee University Hospital,Phase 4
NCT03012334,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03012334,2017.0,INDUSTRY,collaborator,Algorithme Pharma Inc,Phase 1
NCT03012334,2017.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 1
NCT03012334,2017.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 1
NCT03012620,2017.0,OTHER,lead,UNICANCER,Phase 2
NCT03012620,2017.0,OTHER_GOV,collaborator,"National Cancer Institute, France",Phase 2
NCT03012620,2017.0,OTHER,collaborator,"Ligue contre le cancer, France",Phase 2
NCT03012620,2017.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT03012971,2017.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Affiliated Hospital of Hebei University,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Qingdao Municipal Hospital,Not Applicable
NCT03012971,2017.0,UNKNOWN,collaborator,The Second Affiliated Hospital of Air Force Medical University,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Beijing Chao Yang Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,"Beijing Shijitan Hospital, Capital Medical University",Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Beijing Tsinghua Chang Gung Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Peking University International Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Beijing Ditan Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Guizhou Provincial People's Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,The Third Xiangya Hospital of Central South University,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Shanxi Provincial Cancer Hospital,Not Applicable
NCT03012971,2017.0,UNKNOWN,collaborator,Tianjin Hospital of ITCWM-Nankai Hospital,Not Applicable
NCT03012971,2017.0,OTHER,collaborator,Zhongda Hospital,Not Applicable
NCT03012984,2017.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Affiliated Hospital of Hebei University,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Qingdao Municipal Hospital,Not Applicable
NCT03012984,2017.0,UNKNOWN,collaborator,The Second Affiliated Hospital of Air Force Medical University,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Peking University International Hospital,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Guizhou Provincial People's Hospital,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,The Third Xiangya Hospital of Central South University,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Shanxi Provincial Cancer Hospital,Not Applicable
NCT03012984,2017.0,UNKNOWN,collaborator,Tianjin Hospital of ITCWM-Nankai Hospital,Not Applicable
NCT03012984,2017.0,OTHER,collaborator,Zhongda Hospital,Not Applicable
NCT03012984,2017.0,UNKNOWN,collaborator,Chongqing University Fuling Hospital,Not Applicable
NCT03013387,2017.0,OTHER,lead,Sue O'Dorisio,Phase 2
NCT03013387,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03013387,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT03013400,2017.0,OTHER,lead,University of Oxford,Phase 2
NCT03013400,2017.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT03013400,2017.0,INDUSTRY,collaborator,"Sound Pharmaceuticals, Incorporated",Phase 2
NCT03013790,2016.0,OTHER,lead,MICE Trial Group,Phase 4
NCT03015701,1992.0,NETWORK,lead,SWOG Cancer Research Network,Phase 3
NCT03015701,1992.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT03016650,2017.0,OTHER,lead,Muharrem Ucar,Phase 4
NCT03016949,2017.0,OTHER,lead,Fidec Corporation,Phase 3
NCT03016949,2017.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT03018132,2017.0,OTHER,lead,Cedars-Sinai Medical Center,Not Applicable
NCT03018132,2017.0,UNKNOWN,collaborator,Maternal Mental Health NOW,Not Applicable
NCT03018236,2017.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 4
NCT03018236,2017.0,UNKNOWN,collaborator,Secretaria Nacional de Políticas sobre Drogas (SENAD),Phase 4
NCT03018730,2017.0,INDUSTRY,lead,Protalix,Phase 3
NCT03018730,2017.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 3
NCT03019081,2017.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Not Applicable
NCT03019081,2017.0,OTHER,collaborator,Brain & Behavior Research Foundation,Not Applicable
NCT03019523,2016.0,OTHER,lead,University of Mary Hardin-Baylor,Not Applicable
NCT03019523,2016.0,INDUSTRY,collaborator,"NBTY, Inc.",Not Applicable
NCT03019536,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03020797,2017.0,OTHER,lead,Stony Brook University,Not Applicable
NCT03020797,2017.0,INDUSTRY,collaborator,Eisai Inc.,Not Applicable
NCT03021018,2017.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 2
NCT03021317,2017.0,OTHER,lead,University of Chicago,Phase 4
NCT03021486,2017.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT03021486,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2/Phase 3
NCT03021486,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2/Phase 3
NCT03021486,2017.0,NIH,collaborator,National Institute of Nursing Research (NINR),Phase 2/Phase 3
NCT03021928,2017.0,OTHER,lead,University of Texas at Austin,Phase 3
NCT03021928,2017.0,UNKNOWN,collaborator,Lone Star Stroke Research Consortium,Phase 3
NCT03021928,2017.0,OTHER,collaborator,Texas Department of State Health Services,Phase 3
NCT03022799,2016.0,INDUSTRY,lead,Kainos Medicine Inc.,Phase 1
NCT03022838,2017.0,OTHER,lead,Nordlandssykehuset HF,Phase 2/Phase 3
NCT03022838,2017.0,OTHER,collaborator,King's College London,Phase 2/Phase 3
NCT03022838,2017.0,OTHER,collaborator,University Hospital of North Norway,Phase 2/Phase 3
NCT03022968,2017.0,OTHER,lead,"University Hospital, Tours",Phase 2
NCT03023449,2017.0,OTHER,lead,Steven Messe,Phase 2
NCT03023449,2017.0,INDUSTRY,collaborator,Mallinckrodt,Phase 2
NCT03024151,2016.0,OTHER,lead,Inje University,Not Applicable
NCT03024151,2016.0,OTHER,collaborator,Dongnam Institute of Radiological & Medical Sciences,Not Applicable
NCT03024255,2016.0,INDUSTRY,lead,Botanix Pharmaceuticals,Phase 2
NCT03024944,2017.0,OTHER,lead,Columbia University,Phase 2
NCT03024944,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03025750,2017.0,OTHER,lead,Statens Serum Institut,Phase 3
NCT03025750,2017.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT03025750,2017.0,INDUSTRY,collaborator,Larix A/S,Phase 3
NCT03025750,2017.0,OTHER,collaborator,Vaxtrials S.A.,Phase 3
NCT03025750,2017.0,INDUSTRY,collaborator,AJ Vaccines A/S,Phase 3
NCT03026101,2017.0,OTHER,lead,Montefiore Medical Center,Not Applicable
NCT03026231,2017.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT03026231,2017.0,OTHER,collaborator,Kelsey Research Foundation,Phase 1/Phase 2
NCT03026504,2017.0,OTHER,lead,Matthew J Koster,Phase 2
NCT03026504,2017.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT03027674,2016.0,OTHER,lead,Pontificia Universidad Catolica de Chile,Early Phase 1
NCT03028298,2016.0,OTHER,lead,University of Mississippi Medical Center,Phase 1
NCT03028454,2017.0,OTHER,lead,Old Dominion University,Not Applicable
NCT03029442,2017.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT03029442,2017.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 4
NCT03029897,2017.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT03030105,2017.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 1
NCT03031054,2017.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT03031184,2017.0,OTHER,lead,University of Sussex,Phase 3
NCT03031184,2017.0,UNKNOWN,collaborator,Norwich Clinical Trials Unit,Phase 3
NCT03031184,2017.0,OTHER,collaborator,University of East Anglia,Phase 3
NCT03031184,2017.0,OTHER,collaborator,University of Cambridge,Phase 3
NCT03031184,2017.0,OTHER,collaborator,"University College, London",Phase 3
NCT03031184,2017.0,OTHER,collaborator,London School of Economics and Political Science,Phase 3
NCT03031184,2017.0,OTHER,collaborator,University of Manchester,Phase 3
NCT03031184,2017.0,OTHER,collaborator,University of Newcastle Upon-Tyne,Phase 3
NCT03031184,2017.0,OTHER,collaborator,Birmingham and Solihull Mental Health NHS Foundation Trust,Phase 3
NCT03031184,2017.0,OTHER,collaborator,Alzheimer's Society,Phase 3
NCT03031184,2017.0,UNKNOWN,collaborator,"The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT",Phase 3
NCT03031626,2016.0,OTHER,lead,The Hospital for Sick Children,Phase 4
NCT03032172,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT03032302,2017.0,OTHER,lead,Sheffield Hallam University,Not Applicable
NCT03032302,2017.0,OTHER,collaborator,Sheffield Teaching Hospitals NHS Foundation Trust,Not Applicable
NCT03032302,2017.0,UNKNOWN,collaborator,Rotherham Doncaster and South Humber NHS Foundation Trust,Not Applicable
NCT03032328,2016.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT03032419,2017.0,OTHER,lead,Statens Serum Institut,Phase 3
NCT03032419,2017.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT03032419,2017.0,INDUSTRY,collaborator,Larix A/S,Phase 3
NCT03032419,2017.0,OTHER,collaborator,Syneos Health,Phase 3
NCT03032419,2017.0,INDUSTRY,collaborator,AJ Vaccines A/S,Phase 3
NCT03032458,2017.0,OTHER,lead,Mansoura University,Phase 4
NCT03032601,2017.0,OTHER,lead,Thomas Jefferson University,Not Applicable
NCT03032757,2017.0,OTHER,lead,University of Birmingham,Not Applicable
NCT03033069,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT03033069,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT03033784,2017.0,OTHER,lead,Emory University,Phase 2
NCT03033784,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT03034356,2018.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT03034538,2016.0,OTHER,lead,The Cooper Health System,Phase 4
NCT03034564,2017.0,OTHER,lead,The Cooper Health System,Phase 4
NCT03035838,2021.0,OTHER,lead,Arun Gupta,Early Phase 1
NCT03035838,2021.0,OTHER,collaborator,Cambridge University Hospitals NHS Foundation Trust,Early Phase 1
NCT03037203,2017.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03037879,2017.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Not Applicable
NCT03037879,2017.0,OTHER,collaborator,Kessler Foundation,Not Applicable
NCT03038035,2016.0,OTHER,lead,"National University Hospital, Singapore",Phase 2
NCT03038282,2017.0,OTHER,lead,Metabolic Therapy Inc.,Not Applicable
NCT03038308,2016.0,OTHER,lead,Columbia University,Phase 1/Phase 2
NCT03038308,2016.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1/Phase 2
NCT03038334,2017.0,OTHER,lead,Metabolic Therapy Inc.,Not Applicable
NCT03038399,2017.0,INDUSTRY,lead,"ReveraGen BioPharma, Inc.",Phase 2
NCT03038399,2017.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT03038399,2017.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT03038867,2016.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT03039504,2017.0,INDUSTRY,lead,"Research Center, LLC",Not Applicable
NCT03039673,2017.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Phase 2
NCT03039686,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2/Phase 3
NCT03040128,2013.0,OTHER,lead,University of Tennessee,Phase 1/Phase 2
NCT03040128,2013.0,OTHER,collaborator,University of Southern California,Phase 1/Phase 2
NCT03040479,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03040479,2017.0,INDUSTRY,collaborator,Algorithme Pharma Inc,Phase 1
NCT03040479,2017.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 1
NCT03040713,2017.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT03041116,2017.0,INDUSTRY,lead,"Travere Therapeutics, Inc.",Phase 3
NCT03041324,2017.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1/Phase 2
NCT03041363,2017.0,OTHER,lead,Juan Pascual,Phase 1
NCT03041363,2017.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT03042416,2017.0,OTHER,lead,University of Alberta,Phase 3
NCT03042416,2017.0,OTHER,collaborator,Alberta Health services,Phase 3
NCT03043443,2017.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT03043560,2017.0,OTHER,lead,James Murrough,Phase 2
NCT03043560,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT03043560,2017.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT03043820,2016.0,OTHER,lead,Iris Sommer,Phase 3
NCT03043820,2016.0,OTHER,collaborator,Julius Center,Phase 3
NCT03043820,2016.0,OTHER,collaborator,Rudolf Magnus Institute - University of Utrecht,Phase 3
NCT03043820,2016.0,OTHER,collaborator,GGZ Eindhoven,Phase 3
NCT03043820,2016.0,OTHER,collaborator,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 3
NCT03043820,2016.0,OTHER,collaborator,GGZ Centraal,Phase 3
NCT03043820,2016.0,UNKNOWN,collaborator,Altrecht GGZ,Phase 3
NCT03043820,2016.0,UNKNOWN,collaborator,Reinier van Arkel Group,Phase 3
NCT03043820,2016.0,OTHER,collaborator,Ziekenhuis Netwerk Antwerpen (ZNA),Phase 3
NCT03044249,2017.0,OTHER,lead,Mediti Pharma Inc.,Phase 2
NCT03044665,2017.0,OTHER,lead,Yonsei University,Not Applicable
NCT03045302,2017.0,INDUSTRY,lead,Ipsen,Phase 2
NCT03046108,2016.0,OTHER,lead,Complejo Hospitalario Universitario de Granada,Phase 4
NCT03046251,2015.0,OTHER,lead,State University of New York at Buffalo,Phase 4
NCT03047005,2017.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT03047005,2017.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT03047278,2015.0,OTHER,lead,Natalia Valadares de Moraes,Phase 4
NCT03047278,2015.0,OTHER,collaborator,University of Sao Paulo,Phase 4
NCT03047629,2017.0,INDUSTRY,lead,Enterin Inc.,Phase 1/Phase 2
NCT03047980,2017.0,OTHER,lead,"Anne Comi, MD",Phase 2/Phase 3
NCT03047980,2017.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 2/Phase 3
NCT03047980,2017.0,INDUSTRY,collaborator,Pfizer,Phase 2/Phase 3
NCT03047980,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2/Phase 3
NCT03047980,2017.0,OTHER,collaborator,Faneca 66 Foundation,Phase 2/Phase 3
NCT03047980,2017.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2/Phase 3
NCT03048383,2012.0,OTHER,lead,University of Utah,Phase 4
NCT03048929,2019.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT03048929,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT03049046,2017.0,INDUSTRY,lead,"Chemigen, LLC",Phase 1
NCT03049306,2017.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT03049306,2017.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT03050450,2016.0,OTHER,lead,Johns Hopkins All Children's Hospital,Phase 1
NCT03051607,2017.0,INDUSTRY,lead,Biotie Therapies Inc.,Phase 3
NCT03051607,2017.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 3
NCT03052751,2017.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 2
NCT03052998,2017.0,OTHER,lead,Robert Colebunders,Phase 4
NCT03053908,2018.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT03053908,2018.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT03054168,2016.0,OTHER,lead,University of Nottingham,Phase 3
NCT03054285,2017.0,OTHER,lead,Loyola University,Phase 4
NCT03054857,2015.0,OTHER,lead,Chulalongkorn University,Phase 4
NCT03055767,2017.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT03055767,2017.0,OTHER,collaborator,American Society of Regional Anesthesia,Phase 2
NCT03055806,2017.0,INDUSTRY,lead,Ixchelsis Limited,Phase 2
NCT03056209,2017.0,INDUSTRY,lead,"Yungjin Pharm. Co., Ltd.",Phase 1
NCT03056352,2017.0,OTHER,lead,Montefiore Medical Center,Phase 1/Phase 2
NCT03056495,2017.0,OTHER,lead,German Center for Neurodegenerative Diseases (DZNE),Phase 1
NCT03056495,2017.0,OTHER,collaborator,"University Hospital, Bonn",Phase 1
NCT03056495,2017.0,OTHER,collaborator,University of Göttingen,Phase 1
NCT03056690,2017.0,INDUSTRY,lead,"Astellas Pharma Global Development, Inc.",Phase 2
NCT03056729,2017.0,INDUSTRY,lead,Biogen,Phase 1
NCT03058224,2017.0,INDUSTRY,lead,IgNova GmbH,Not Applicable
NCT03058224,2017.0,INDUSTRY,collaborator,Scope International AG,Not Applicable
NCT03058224,2017.0,OTHER,collaborator,Klinar CRO,Not Applicable
NCT03058224,2017.0,INDUSTRY,collaborator,CenTrial GmbH,Not Applicable
NCT03058224,2017.0,UNKNOWN,collaborator,Pharmasolutions4U,Not Applicable
NCT03058224,2017.0,UNKNOWN,collaborator,idv Data Analysis and Study Planning,Not Applicable
NCT03058562,2017.0,INDUSTRY,lead,Abide Therapeutics,Phase 1
NCT03058848,2017.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT03058965,2016.0,OTHER,lead,Molecular NeuroImaging,Early Phase 1
NCT03059160,2017.0,OTHER_GOV,lead,Sheba Medical Center,Phase 2
NCT03059160,2017.0,INDUSTRY,collaborator,Ultragenyx Pharmaceutical Inc,Phase 2
NCT03059836,2017.0,OTHER,lead,McMaster University,Not Applicable
NCT03059836,2017.0,OTHER,collaborator,University of Guelph,Not Applicable
NCT03059888,2017.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT03059888,2017.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Early Phase 1
NCT03060174,2014.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT03060265,2017.0,OTHER_GOV,lead,Bnai Zion Medical Center,Not Applicable
NCT03061006,2017.0,OTHER,lead,"Intermountain Health Care, Inc.",Phase 4
NCT03061006,2017.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 4
NCT03061136,2016.0,OTHER,lead,Palo Alto Veterans Institute for Research,Phase 4
NCT03061136,2016.0,OTHER,collaborator,Stanford University,Phase 4
NCT03061136,2016.0,OTHER,collaborator,"University of California, Los Angeles",Phase 4
NCT03061474,2017.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT03061513,2012.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT03062449,2017.0,OTHER,lead,Aleksandra Stark,Phase 2
NCT03062449,2017.0,UNKNOWN,collaborator,"Brain Chemistry Labs, Institute for Ethnomedicine",Phase 2
NCT03062488,2017.0,OTHER,lead,Nemours Children's Clinic,Early Phase 1
NCT03062488,2017.0,OTHER,collaborator,University of Central Florida,Early Phase 1
NCT03062540,2017.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT03062540,2017.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 3
NCT03062579,2017.0,OTHER,lead,Fu-Dong Shi,Phase 1/Phase 2
NCT03063606,2017.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT03063606,2017.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT03063736,2017.0,OTHER,lead,Baylor College of Medicine,Early Phase 1
NCT03064048,2017.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT03064048,2017.0,NETWORK,collaborator,Rare Diseases Clinical Research Network,Not Applicable
NCT03064048,2017.0,OTHER,collaborator,Neogenis Laboratories,Not Applicable
NCT03065192,2017.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT03065192,2017.0,INDUSTRY,collaborator,Voyager Therapeutics,Phase 1
NCT03065335,2017.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT03065348,2017.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT03065998,2017.0,OTHER_GOV,lead,"Ministry of Health, Israel",Early Phase 1
NCT03066193,2017.0,OTHER,lead,Yale University,Phase 2
NCT03066193,2017.0,INDUSTRY,collaborator,SciSparc,Phase 2
NCT03066518,2016.0,OTHER,lead,Hospital Universitario Dr. Jose E. Gonzalez,Phase 4
NCT03066544,2016.0,OTHER,lead,Hartford HealthCare,Phase 1/Phase 2
NCT03066635,2017.0,OTHER,lead,Norwegian University of Science and Technology,Phase 1/Phase 2
NCT03066635,2017.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT03066739,2023.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT03067831,2015.0,OTHER,lead,Stem Cells Arabia,Phase 1/Phase 2
NCT03067857,2016.0,OTHER,lead,Stem Cells Arabia,Phase 1/Phase 2
NCT03068429,2016.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT03068468,2017.0,INDUSTRY,lead,Biogen,Phase 2
NCT03068481,2017.0,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 1
NCT03068754,2017.0,INDUSTRY,lead,Mallinckrodt,Phase 2/Phase 3
NCT03069170,2016.0,OTHER,lead,Stem Cells Arabia,Phase 1
NCT03069482,2017.0,OTHER,lead,Duke University,Phase 1
NCT03069482,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03069768,2018.0,OTHER,lead,Duke University,Phase 1
NCT03069768,2018.0,INDUSTRY,collaborator,"Intelligent Automation, Inc.",Phase 1
NCT03069768,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03069781,2017.0,OTHER,lead,McMaster University,Early Phase 1
NCT03069911,2018.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT03070132,2023.0,INDUSTRY,lead,Biogen,Phase 3
NCT03070730,2011.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 1/Phase 2
NCT03070730,2011.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT03071224,2016.0,OTHER,lead,Invicro,Early Phase 1
NCT03071354,2017.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT03071874,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03071874,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT03071874,2017.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT03072173,2017.0,OTHER,lead,Lovisenberg Diakonale Hospital,Not Applicable
NCT03072290,2017.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT03072628,2017.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT03073603,2017.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT03073603,2017.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT03073603,2017.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 4
NCT03073603,2017.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 4
NCT03073876,2005.0,OTHER,lead,NYU Langone Health,Phase 4
NCT03073876,2005.0,OTHER,collaborator,"Queens College, The City University of New York",Phase 4
NCT03075020,2016.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03075241,2016.0,OTHER,lead,Brasilia University Hospital,Phase 3
NCT03075501,2015.0,OTHER,lead,University of Illinois at Chicago,Phase 4
NCT03075501,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT03075657,2017.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT03076970,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03076970,2017.0,INDUSTRY,collaborator,"SNBL Clinical Pharmacology Center, Inc.",Phase 1
NCT03076970,2017.0,INDUSTRY,collaborator,CoLucid Pharmaceuticals,Phase 1
NCT03077438,2017.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT03078621,2016.0,OTHER,lead,Stem Cells Arabia,Phase 1/Phase 2
NCT03078946,2013.0,OTHER,lead,Ain Shams University,Phase 4
NCT03079115,2017.0,OTHER_GOV,lead,Beijing Hospital,Phase 4
NCT03079999,2018.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Phase 2
NCT03079999,2018.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03079999,2018.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT03080051,2016.0,OTHER,lead,Molecular NeuroImaging,Early Phase 1
NCT03080129,2017.0,OTHER,lead,Medical University of Graz,Not Applicable
NCT03080181,2013.0,OTHER,lead,University of Palermo,Phase 4
NCT03080194,2017.0,OTHER,lead,Maosheng Fang,Phase 4
NCT03080571,2015.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Phase 1
NCT03081065,2017.0,OTHER,lead,University of Las Palmas de Gran Canaria,Not Applicable
NCT03081065,2017.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Not Applicable
NCT03081117,2017.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT03081169,2017.0,OTHER,lead,Loyola University,Phase 4
NCT03081832,2017.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT03082014,2018.0,OTHER,lead,Ludwig-Maximilians - University of Munich,Phase 3
NCT03082014,2018.0,OTHER,collaborator,University of Edinburgh,Phase 3
NCT03082014,2018.0,OTHER,collaborator,Maastricht University Medical Center,Phase 3
NCT03082014,2018.0,OTHER,collaborator,UMC Utrecht,Phase 3
NCT03082014,2018.0,OTHER,collaborator,University of Oxford,Phase 3
NCT03082755,2017.0,OTHER,lead,University of Texas at Austin,Phase 4
NCT03082755,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT03083132,2017.0,OTHER,lead,University of Arkansas,Phase 2
NCT03083353,2020.0,OTHER,lead,University of Texas at Austin,Early Phase 1
NCT03083353,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03083665,2017.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT03084523,2017.0,OTHER,lead,Yale University,Phase 1
NCT03085706,2010.0,OTHER,lead,The First Affiliated Hospital of Dalian Medical University,Not Applicable
NCT03085810,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03087110,2016.0,OTHER,lead,Murdoch Childrens Research Institute,Phase 1
NCT03087110,2016.0,UNKNOWN,collaborator,The Royal Children's Hospital,Phase 1
NCT03087110,2016.0,UNKNOWN,collaborator,Children's Health Queensland,Phase 1
NCT03087110,2016.0,OTHER,collaborator,Monash Health,Phase 1
NCT03087110,2016.0,OTHER,collaborator,Sydney Children's Hospitals Network,Phase 1
NCT03087110,2016.0,OTHER,collaborator,Cerebral Palsy Alliance,Phase 1
NCT03087201,2018.0,OTHER,lead,Hannover Medical School,Phase 3
NCT03087201,2018.0,OTHER,collaborator,German Research Foundation,Phase 3
NCT03089918,2017.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT03090269,2018.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Phase 2
NCT03090269,2018.0,OTHER,collaborator,Hopital Paul Brousse,Phase 2
NCT03090490,2014.0,OTHER,lead,Fundación Marques de Valdecilla,Not Applicable
NCT03090490,2014.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Not Applicable
NCT03090490,2014.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Not Applicable
NCT03090503,2014.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT03090503,2014.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT03090503,2014.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT03090971,2017.0,OTHER,lead,Fundação Educacional Serra dos Órgãos,Phase 2
NCT03091400,2017.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT03091543,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03091569,2017.0,INDUSTRY,lead,Biogen,Phase 4
NCT03091868,2004.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03092011,2018.0,OTHER,lead,The Cooper Health System,Phase 4
NCT03092544,2015.0,OTHER,lead,Multiple Sclerosis Center of Northeastern New York,Phase 4
NCT03092544,2015.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 4
NCT03092544,2015.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT03092726,2017.0,INDUSTRY,lead,"Astellas Pharma Global Development, Inc.",Phase 2
NCT03092791,2017.0,INDUSTRY,lead,Takeda,Phase 1/Phase 2
NCT03092817,2017.0,OTHER,lead,"Oxford University Clinical Research Unit, Vietnam",Phase 3
NCT03092817,2017.0,OTHER,collaborator,"Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",Phase 3
NCT03092817,2017.0,OTHER,collaborator,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Phase 3
NCT03092817,2017.0,UNKNOWN,collaborator,"Cipto Mangunkusumo Hospital, Jakarta, Indonesia",Phase 3
NCT03092817,2017.0,UNKNOWN,collaborator,"RSUP Persahabatan Hospital, Jakarta, Indonesia",Phase 3
NCT03092817,2017.0,OTHER,collaborator,"Eijkman Oxford Clinical Research Unit, Indonesia",Phase 3
NCT03093064,2017.0,OTHER,lead,King's College London,Phase 1
NCT03093064,2017.0,OTHER,collaborator,South London and Maudsley NHS Foundation Trust,Phase 1
NCT03093324,2017.0,INDUSTRY,lead,Biogen,Phase 3
NCT03093324,2017.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 3
NCT03093389,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03093415,2017.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT03093467,2017.0,OTHER,lead,Instituto Milenio para Investigación en Depresión y Personalidad,Not Applicable
NCT03093467,2017.0,UNKNOWN,collaborator,"Psicomedica Clinical & Research Group, Chile",Not Applicable
NCT03093467,2017.0,OTHER,collaborator,University Hospital Heidelberg,Not Applicable
NCT03093467,2017.0,OTHER,collaborator,"National Fund for Research and Development in Health, Chile",Not Applicable
NCT03093519,2017.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT03094156,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03095092,2005.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03095105,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03095248,2017.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT03095248,2017.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT03097211,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03097484,2015.0,OTHER,lead,John M. Daniel,Phase 3
NCT03098732,2017.0,INDUSTRY,lead,Pulse Therapeutics,Not Applicable
NCT03098810,2017.0,OTHER,lead,Ain Shams University,Phase 4
NCT03099239,2017.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1
NCT03099239,2017.0,OTHER,collaborator,The Marcus Foundation,Phase 1
NCT03100019,2014.0,OTHER,lead,Northumbria University,Not Applicable
NCT03100149,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT03100149,2017.0,INDUSTRY,collaborator,Prothena Biosciences Limited,Phase 2
NCT03100513,2017.0,OTHER,lead,Sherief Abd-Elsalam,Phase 4
NCT03100786,2018.0,OTHER,lead,"Oxford University Clinical Research Unit, Vietnam",Phase 3
NCT03100786,2018.0,OTHER,collaborator,"Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",Phase 3
NCT03100786,2018.0,OTHER,collaborator,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Phase 3
NCT03101085,2017.0,OTHER,lead,Russell Swerdlow,Phase 1/Phase 2
NCT03101085,2017.0,INDUSTRY,collaborator,"Ausio Pharmaceuticals, LLC",Phase 1/Phase 2
NCT03101241,2017.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03101319,2019.0,OTHER,lead,"Central Institute of Psychiatry, Ranchi, India",Not Applicable
NCT03101319,2019.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT03101319,2019.0,OTHER_GOV,collaborator,Dr. Ram Manohar Lohia Hospital,Not Applicable
NCT03101722,2017.0,OTHER,lead,Zhijun Bao,Not Applicable
NCT03102398,2017.0,INDUSTRY,lead,"Tritech Biopharmaceuticals Co., Ltd.",Phase 1/Phase 2
NCT03102398,2017.0,INDUSTRY,collaborator,A2 Healthcare Taiwan Corporation,Phase 1/Phase 2
NCT03102736,2017.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT03102762,2017.0,OTHER,lead,Cairo University,Phase 2/Phase 3
NCT03103399,2006.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 2
NCT03103815,2017.0,OTHER,lead,Wujin People's Hospital,Not Applicable
NCT03103815,2017.0,OTHER,collaborator,Nanjing 1718,Not Applicable
NCT03104725,2017.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT03105765,2011.0,INDUSTRY,lead,Dr. Horst Schmidt Klinik GmbH,Not Applicable
NCT03106363,2017.0,OTHER,lead,Centre for Addiction and Mental Health,Early Phase 1
NCT03106363,2017.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Early Phase 1
NCT03106363,2017.0,OTHER_GOV,collaborator,Health Canada,Early Phase 1
NCT03107026,2017.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT03107052,2017.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03107871,2018.0,OTHER,lead,Albert Park,Phase 2
NCT03107871,2018.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 2
NCT03107871,2018.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT03107884,2019.0,OTHER,lead,University of Utah,Early Phase 1
NCT03107975,2017.0,OTHER,lead,The Second Affiliated Hospital of Fujian Medical University,Phase 1
NCT03107975,2017.0,INDUSTRY,collaborator,"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China",Phase 1
NCT03108066,2017.0,INDUSTRY,lead,"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Phase 2
NCT03108066,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03108729,2017.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT03108781,2017.0,OTHER,lead,Soroka University Medical Center,Not Applicable
NCT03108846,2018.0,OTHER,lead,JHSPH Center for Clinical Trials,Phase 3
NCT03108846,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT03109288,2017.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1/Phase 2
NCT03109301,2017.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT03109314,2012.0,OTHER,lead,Dennis Levi,Phase 4
NCT03109418,2016.0,OTHER,lead,University of Alabama at Birmingham,Phase 2/Phase 3
NCT03109756,2017.0,INDUSTRY,lead,Ovid Therapeutics Inc.,Phase 1
NCT03110120,2015.0,OTHER,lead,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Not Applicable
NCT03110315,2017.0,OTHER,lead,"Theodore R. Brown, MD MPH",Phase 4
NCT03110315,2017.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT03110341,2017.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Phase 3
NCT03110341,2017.0,OTHER_GOV,collaborator,Xian Children's Hospital,Phase 3
NCT03110341,2017.0,OTHER,collaborator,Shaanxi Provincial People's Hospital,Phase 3
NCT03110341,2017.0,OTHER,collaborator,Second Affiliated Hospital of Xi'an Jiaotong University,Phase 3
NCT03110341,2017.0,OTHER,collaborator,Tang-Du Hospital,Phase 3
NCT03110341,2017.0,OTHER,collaborator,Xijing Hospital,Phase 3
NCT03110341,2017.0,UNKNOWN,collaborator,Xi'an No.4 Hospital,Phase 3
NCT03110341,2017.0,OTHER,collaborator,"Northwest Women's and Children's Hospital, Xi'an, Shaanxi",Phase 3
NCT03110575,2017.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT03110575,2017.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 3
NCT03111186,2017.0,OTHER,lead,University of Southern California,Phase 2
NCT03111485,2017.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 4
NCT03111485,2017.0,OTHER,collaborator,Weston Brain Institute,Phase 4
NCT03112031,2017.0,OTHER,lead,"Oxford University Clinical Research Unit, Vietnam",Phase 2
NCT03112031,2017.0,OTHER,collaborator,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Phase 2
NCT03112031,2017.0,OTHER,collaborator,Cho Ray Hospital,Phase 2
NCT03112031,2017.0,OTHER,collaborator,University of Liverpool,Phase 2
NCT03112031,2017.0,OTHER,collaborator,University of Rochester,Phase 2
NCT03112031,2017.0,OTHER,collaborator,Liverpool School of Tropical Medicine,Phase 2
NCT03112096,2017.0,OTHER,lead,Asan Foundation,Phase 1
NCT03112720,2016.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 3
NCT03112720,2016.0,OTHER,collaborator,New Jersey Medical School,Phase 3
NCT03113162,2015.0,OTHER,lead,Makati Medical Center,Phase 1
NCT03113370,2016.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT03113812,2014.0,INDUSTRY,lead,Araclon Biotech S.L.,Phase 1
NCT03113890,2017.0,OTHER,lead,Mclean Hospital,Not Applicable
NCT03113890,2017.0,INDUSTRY,collaborator,"Genomind, LLC",Not Applicable
NCT03113968,2017.0,OTHER,lead,Bo Hu,Phase 2/Phase 3
NCT03113968,2017.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 2/Phase 3
NCT03113994,2018.0,OTHER,lead,Dr. B. Catharine. Craven,Phase 2
NCT03113994,2018.0,OTHER,collaborator,The Craig H. Neilsen Foundation,Phase 2
NCT03113994,2018.0,OTHER,collaborator,Toronto Rehabilitation Institute,Phase 2
NCT03113994,2018.0,OTHER,collaborator,"University Health Network, Toronto",Phase 2
NCT03113994,2018.0,OTHER,collaborator,University of Miami,Phase 2
NCT03113994,2018.0,OTHER,collaborator,Rick Hansen Institute,Phase 2
NCT03114215,2016.0,INDUSTRY,lead,MedDay Pharmaceuticals SA,Phase 2
NCT03114371,2016.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT03114657,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03115034,2016.0,OTHER,lead,Peking Union Medical College Hospital,Phase 4
NCT03115489,2017.0,OTHER,lead,University of Alabama at Birmingham,Phase 2/Phase 3
NCT03115671,2016.0,OTHER,lead,"Institute of Mental Health, Singapore",Not Applicable
NCT03115827,2017.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT03115827,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 4
NCT03115827,2017.0,OTHER,collaborator,American Academy of Neurology,Phase 4
NCT03116126,2019.0,OTHER,lead,Imperial College London,Phase 3
NCT03116295,2017.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03116308,2014.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03116321,2016.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03117322,2017.0,OTHER,lead,Andrea Garcia Contreras,Phase 4
NCT03117530,2017.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT03117738,2017.0,INDUSTRY,lead,Nature Cell Co. Ltd.,Phase 1/Phase 2
NCT03117790,2017.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03118193,2017.0,OTHER,lead,"University Hospital, Tours",Not Applicable
NCT03119194,2017.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03119597,2017.0,OTHER,lead,University of Reading,Not Applicable
NCT03119597,2017.0,UNKNOWN,collaborator,Wild Blueberry Association of North America (WBANA),Not Applicable
NCT03119610,2017.0,OTHER,lead,Sara Espinoza,Phase 1/Phase 2
NCT03119610,2017.0,OTHER,collaborator,The University of Texas Health Science Center at San Antonio,Phase 1/Phase 2
NCT03119610,2017.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT03119610,2017.0,OTHER,collaborator,"The University of Texas Medical Branch, Galveston",Phase 1/Phase 2
NCT03119636,2017.0,OTHER_GOV,lead,Chinese Academy of Sciences,Phase 1/Phase 2
NCT03119636,2017.0,OTHER,collaborator,The First Affiliated Hospital of Zhengzhou University,Phase 1/Phase 2
NCT03119948,2014.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT03119948,2014.0,INDUSTRY,collaborator,Merz Pharmaceuticals GmbH,Phase 2
NCT03119961,2017.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 1/Phase 2
NCT03119961,2017.0,INDUSTRY,collaborator,CarThera,Phase 1/Phase 2
NCT03119961,2017.0,OTHER,collaborator,BPIfrance,Phase 1/Phase 2
NCT03120026,2017.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT03120182,2018.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT03120442,2017.0,OTHER,lead,Mahidol University,Not Applicable
NCT03121586,2017.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT03122158,2017.0,OTHER_GOV,lead,Erzurum Regional Training & Research Hospital,Phase 4
NCT03122197,2017.0,OTHER,lead,University of Cincinnati,Early Phase 1
NCT03122652,2017.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 3
NCT03122652,2017.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 3
NCT03123913,2017.0,OTHER,lead,University of Rochester,Phase 1
NCT03124355,2017.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT03124459,2017.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2
NCT03125083,2017.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT03125083,2017.0,OTHER,collaborator,Société Française de Cardiologie,Not Applicable
NCT03126214,2018.0,OTHER,lead,University of Alberta,Phase 4
NCT03126214,2018.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Phase 4
NCT03126214,2018.0,OTHER,collaborator,Canadian Stroke Prevention Intervention Network,Phase 4
NCT03126760,2017.0,INDUSTRY,lead,Mallinckrodt ARD LLC,Phase 4
NCT03127267,2021.0,INDUSTRY,lead,AB Science,Phase 3
NCT03127514,2017.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 2
NCT03127514,2017.0,OTHER,collaborator,ALS Finding a Cure,Phase 2
NCT03127514,2017.0,OTHER,collaborator,ALS Association,Phase 2
NCT03127514,2017.0,OTHER,collaborator,Northeast ALS Consortium,Phase 2
NCT03127514,2017.0,OTHER,collaborator,Neurological Clinical Research Institute at Massachusetts General Hospital,Phase 2
NCT03127514,2017.0,OTHER,collaborator,Leandro P. Rizzuto Foundation,Phase 2
NCT03128177,2016.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT03128177,2016.0,OTHER,collaborator,American Heart Association,Not Applicable
NCT03128450,2017.0,OTHER,lead,Second Affiliated Hospital of Soochow University,Phase 2/Phase 3
NCT03128489,2017.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT03128593,2017.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 1/Phase 2
NCT03128749,2018.0,OTHER,lead,Corporacion Parc Tauli,Not Applicable
NCT03128749,2018.0,OTHER,collaborator,Hospital Universitari de Bellvitge,Not Applicable
NCT03128749,2018.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT03128749,2018.0,OTHER,collaborator,University of Arizona,Not Applicable
NCT03128957,2017.0,OTHER,lead,University of Michigan,Not Applicable
NCT03129009,2017.0,OTHER,lead,Xuzhou Medical University,Not Applicable
NCT03129360,2017.0,OTHER,lead,NYU Langone Health,Phase 2
NCT03129360,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03129906,2015.0,OTHER,lead,Federal University of Minas Gerais,Not Applicable
NCT03130179,2017.0,INDUSTRY,lead,McNeil AB,Phase 1
NCT03130816,2015.0,OTHER,lead,Bundang CHA Hospital,Phase 1/Phase 2
NCT03131375,2017.0,OTHER,lead,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""",Phase 2/Phase 3
NCT03131466,2017.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT03131466,2017.0,OTHER,collaborator,Beijing Friendship Hospital,Not Applicable
NCT03131466,2017.0,OTHER,collaborator,Beijing Ditan Hospital,Not Applicable
NCT03132051,2013.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT03132142,2017.0,OTHER,lead,Aalborg University,Not Applicable
NCT03132233,2017.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT03132259,2016.0,OTHER,lead,Mahidol University,Phase 4
NCT03132571,2017.0,OTHER,lead,Yale University,Phase 2
NCT03132701,2017.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT03134547,2016.0,OTHER,lead,Yeungnam University College of Medicine,Not Applicable
NCT03134703,2017.0,OTHER,lead,Johns Hopkins All Children's Hospital,Phase 2
NCT03134703,2017.0,OTHER_GOV,collaborator,Florida Department of Health,Phase 2
NCT03135327,2007.0,OTHER,lead,University of Miami,Not Applicable
NCT03136809,2018.0,INDUSTRY,lead,Collaborative Medicinal Development Pty Limited,Phase 1/Phase 2
NCT03138421,2017.0,INDUSTRY,lead,Abide Therapeutics,Phase 1
NCT03139435,2017.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT03139435,2017.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT03140813,2018.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1
NCT03140956,2017.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 1
NCT03142399,2018.0,OTHER_GOV,lead,"National Institute of Cardiology, Laranjeiras, Brazil",Not Applicable
NCT03143374,2016.0,OTHER,lead,University of Pennsylvania,Phase 2/Phase 3
NCT03143374,2016.0,INDUSTRY,collaborator,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT03143543,2015.0,OTHER,lead,Virginia Commonwealth University,Phase 1
NCT03143543,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03146104,2017.0,OTHER_GOV,lead,Jawaharlal Institute of Postgraduate Medical Education & Research,Phase 4
NCT03147560,2017.0,OTHER_GOV,lead,Zhejiang Provincial Center for Disease Control and Prevention,Phase 4
NCT03147560,2017.0,INDUSTRY,collaborator,China National Biotec Group Company Limited,Phase 4
NCT03147599,2017.0,OTHER,lead,Mansoura University,Phase 4
NCT03148899,2016.0,OTHER,lead,George Washington University,Phase 2
NCT03149783,2018.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT03149809,2018.0,FED,lead,VA Office of Research and Development,Phase 3
NCT03149991,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03150225,2019.0,OTHER,lead,Laboratório de Pesquisa em Lazer e Atividade Física,Not Applicable
NCT03150511,2018.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT03150511,2018.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03150771,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT03150771,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT03150797,2017.0,OTHER,lead,Amy Gelfand,Phase 2
NCT03150797,2017.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT03150966,2016.0,OTHER,lead,Tabriz University of Medical Sciences,Phase 2
NCT03151291,2016.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Not Applicable
NCT03151382,2017.0,OTHER,lead,Zhejiang Provincial People's Hospital,Phase 4
NCT03151460,2014.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 4
NCT03151681,2015.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2/Phase 3
NCT03151863,2018.0,OTHER,lead,Walid HABRE,Phase 3
NCT03152123,2017.0,OTHER,lead,Bioprojet,Phase 1
NCT03152175,2017.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2
NCT03152175,2017.0,OTHER,collaborator,Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail,Phase 2
NCT03152188,2017.0,OTHER,lead,Virginia Commonwealth University,Phase 1
NCT03152188,2017.0,INDUSTRY,collaborator,OpenBiome,Phase 1
NCT03152188,2017.0,OTHER,collaborator,Medical College of Wisconsin,Phase 1
NCT03152188,2017.0,FED,collaborator,Hunter Holmes McGuire VA Medical Center,Phase 1
NCT03152188,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT03152318,2017.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 1
NCT03152318,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT03152318,2017.0,INDUSTRY,collaborator,"Candel Therapeutics, Inc.",Phase 1
NCT03152409,2018.0,OTHER,lead,Jessica Harder,Phase 2
NCT03152409,2018.0,OTHER,collaborator,Columbia University,Phase 2
NCT03152955,2017.0,OTHER,lead,Xiangya Hospital of Central South University,Phase 4
NCT03153046,2017.0,OTHER,lead,University of Oxford,Not Applicable
NCT03153046,2017.0,INDUSTRY,collaborator,Clasado Biosciences Ltd,Not Applicable
NCT03153150,2018.0,OTHER,lead,University of Edinburgh,Phase 3
NCT03153150,2018.0,OTHER_GOV,collaborator,NHS Lothian,Phase 3
NCT03153293,2017.0,OTHER,lead,Huazhong University of Science and Technology,Phase 2/Phase 3
NCT03153293,2017.0,OTHER,collaborator,Taihe Hospital,Phase 2/Phase 3
NCT03153319,2017.0,OTHER,lead,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Phase 1/Phase 2
NCT03153579,2017.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT03154567,2017.0,OTHER,lead,Wayne State University,Phase 1
NCT03154580,2017.0,OTHER,lead,Wayne State University,Phase 1
NCT03156153,2017.0,OTHER,lead,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2
NCT03156153,2017.0,OTHER,collaborator,Shanghai Jiao Tong University School of Medicine,Phase 2
NCT03156439,2017.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 1
NCT03156439,2017.0,OTHER,collaborator,Melbourne Health,Phase 1
NCT03156504,2017.0,OTHER,lead,Mayo Clinic,Phase 4
NCT03156504,2017.0,UNKNOWN,collaborator,National Network of Depression Centers,Phase 4
NCT03156920,2017.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03158259,2017.0,OTHER,lead,Norwegian Air Ambulance Foundation,Not Applicable
NCT03158259,2017.0,OTHER,collaborator,Ostfold Hospital Trust,Not Applicable
NCT03158259,2017.0,OTHER,collaborator,University of Oslo,Not Applicable
NCT03158259,2017.0,OTHER,collaborator,Oslo University Hospital,Not Applicable
NCT03158805,2017.0,OTHER,lead,Lindner Center of HOPE,Phase 2
NCT03159000,2017.0,OTHER,lead,Thomas Jefferson University,Phase 4
NCT03159338,2017.0,OTHER,lead,Shiraz University of Medical Sciences,Not Applicable
NCT03159338,2017.0,OTHER,collaborator,Shahid Beheshti University of Medical Sciences,Not Applicable
NCT03160898,2017.0,INDUSTRY,lead,Cytokinetics,Phase 2
NCT03160898,2017.0,INDUSTRY,collaborator,Astellas Pharma Inc,Phase 2
NCT03161028,2018.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03162588,2010.0,OTHER,lead,Ajou University School of Medicine,Phase 1/Phase 2
NCT03162874,2017.0,INDUSTRY,lead,Prexton Therapeutics,Phase 2
NCT03163459,2018.0,OTHER,lead,Capital Medical University,Phase 2/Phase 3
NCT03163615,2017.0,OTHER,lead,Shao-Ping Nie,Not Applicable
NCT03164876,2017.0,INDUSTRY,lead,Autifony Therapeutics Limited,Phase 1
NCT03164876,2017.0,OTHER,collaborator,King's College London,Phase 1
NCT03165981,2017.0,OTHER,lead,Duke University,Phase 4
NCT03165981,2017.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT03165981,2017.0,OTHER,collaborator,Kaiser Permanente,Phase 4
NCT03166449,2014.0,OTHER,lead,University of Malaya,Not Applicable
NCT03166501,2018.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT03166501,2018.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT03166800,2018.0,OTHER,lead,Oregon Health and Science University,Phase 1/Phase 2
NCT03166800,2018.0,UNKNOWN,collaborator,MitoQ Limited,Phase 1/Phase 2
NCT03166800,2018.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1/Phase 2
NCT03167138,2017.0,OTHER,lead,Kessler Foundation,Early Phase 1
NCT03167255,2017.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 2
NCT03167255,2017.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 2
NCT03167255,2017.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT03167255,2017.0,UNKNOWN,collaborator,Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS),Phase 2
NCT03167307,2017.0,OTHER,lead,Gregor Berger,Phase 3
NCT03167307,2017.0,OTHER,collaborator,Swiss National Science Foundation,Phase 3
NCT03167697,2017.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT03168191,2017.0,OTHER,lead,Yale University,Phase 1
NCT03168399,2017.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT03168399,2017.0,OTHER,collaborator,Birmingham Women's and Children's NHS Foundation Trust,Not Applicable
NCT03168581,2017.0,INDUSTRY,lead,AegisCN LLC,Phase 2
NCT03168581,2017.0,OTHER,collaborator,Duke Clinical Research Institute,Phase 2
NCT03168581,2017.0,INDUSTRY,collaborator,"PharPoint Research, Inc.",Phase 2
NCT03168711,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03168711,2017.0,UNKNOWN,collaborator,The Salah Foundation,Phase 2
NCT03168711,2017.0,UNKNOWN,collaborator,MGH cure ALS Fund,Phase 2
NCT03168997,2017.0,OTHER,lead,Wei Cuibai,Phase 4
NCT03169582,2016.0,OTHER,lead,Eduardo Vargas-Baquero,Phase 4
NCT03169725,2017.0,INDUSTRY,lead,LG Chem,Phase 2/Phase 3
NCT03170713,2017.0,OTHER,lead,Erzincan University,Not Applicable
NCT03171740,2017.0,OTHER,lead,Brasilia University Hospital,Phase 3
NCT03172026,2019.0,OTHER,lead,"University of California, Los Angeles",Phase 2/Phase 3
NCT03172117,2017.0,INDUSTRY,lead,Medipost Co Ltd.,Phase 1/Phase 2
NCT03172533,2016.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Phase 2
NCT03172741,2017.0,OTHER,lead,Colorado State University,Phase 2/Phase 3
NCT03172871,2017.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 3
NCT03172897,2017.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03172897,2017.0,OTHER,collaborator,Peking University Third Hospital,Phase 4
NCT03173781,2016.0,OTHER,lead,Colorado Springs Neurological Associates,Not Applicable
NCT03173781,2016.0,INDUSTRY,collaborator,H. Lundbeck A/S,Not Applicable
NCT03173950,2017.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT03174886,2017.0,INDUSTRY,lead,Axon Neuroscience SE,Phase 1
NCT03175224,2017.0,INDUSTRY,lead,Apollomics Inc.,Phase 2
NCT03175900,2017.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 4
NCT03175900,2017.0,OTHER,collaborator,"Zhejiang Liaoyuan Pharmaceutical Co., Ltd.",Phase 4
NCT03176498,2023.0,INDUSTRY,lead,"Sclnow Biotechnology Co., Ltd.",Phase 1/Phase 2
NCT03176771,2017.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 2/Phase 3
NCT03176784,2017.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT03176784,2017.0,OTHER,collaborator,Washington University School of Medicine,Phase 4
NCT03176784,2017.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT03176966,2016.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT03177083,2017.0,INDUSTRY,lead,Biogen,Phase 4
NCT03177252,2020.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT03177746,2022.0,INDUSTRY,lead,Neutec Ar-Ge San ve Tic A.Ş,Phase 4
NCT03177915,2016.0,OTHER,lead,Assiut University,Not Applicable
NCT03179293,2017.0,OTHER,lead,Assiut University,Phase 4
NCT03179501,2017.0,OTHER,lead,Beau Nakamoto,Phase 1
NCT03179501,2017.0,INDUSTRY,collaborator,"Neuraltus Pharmaceuticals, Inc.",Phase 1
NCT03179631,2017.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT03179839,2017.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT03179878,2017.0,INDUSTRY,lead,Synlogic,Phase 1
NCT03179891,2017.0,INDUSTRY,lead,Aquestive Therapeutics,Phase 2
NCT03179891,2017.0,OTHER,collaborator,inVentiv Health Clinical,Phase 2
NCT03179891,2017.0,INDUSTRY,collaborator,Covance,Phase 2
NCT03180125,2017.0,OTHER,lead,Assiut University,Phase 1
NCT03180840,2017.0,INDUSTRY,lead,Protalix,Phase 3
NCT03180840,2017.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 3
NCT03181360,2017.0,OTHER,lead,University Hospital of North Norway,Phase 3
NCT03181360,2017.0,OTHER,collaborator,UiT The Arctic University of Norway,Phase 3
NCT03181360,2017.0,OTHER,collaborator,The Royal Norwegian Ministry of Health,Phase 3
NCT03181360,2017.0,OTHER,collaborator,Norwegian Health Association,Phase 3
NCT03181399,2018.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT03181399,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT03181464,2018.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT03181581,2017.0,OTHER,lead,St. Olavs Hospital,Phase 2
NCT03181581,2017.0,UNKNOWN,collaborator,Norwegian National Advisory Unit for Ultrasound and Image-guided Therapy,Phase 2
NCT03181581,2017.0,OTHER,collaborator,SINTEF Health Research,Phase 2
NCT03181828,2017.0,OTHER,lead,Nicholas Ah Mew,Phase 1/Phase 2
NCT03181893,2018.0,INDUSTRY,lead,Pfizer,Phase 2
NCT03181945,2016.0,UNKNOWN,lead,Postgraduate Institute of Medical Education and Research,Not Applicable
NCT03182413,2015.0,INDUSTRY,lead,Theranexus,Phase 1
NCT03182413,2015.0,UNKNOWN,collaborator,"Institut de recherche biomédicale des armées (IRBA), Bretigny sur Orge, France",Phase 1
NCT03182725,2018.0,OTHER,lead,"University of California, San Diego",Phase 3
NCT03182725,2018.0,INDUSTRY,collaborator,Amgen,Phase 3
NCT03183076,2015.0,OTHER_GOV,lead,Instituto Mexicano del Seguro Social,Not Applicable
NCT03184467,2017.0,INDUSTRY,lead,GemVax & Kael,Phase 2
NCT03184584,2017.0,INDUSTRY,lead,Liminal BioSciences Ltd.,Phase 2/Phase 3
NCT03184597,2017.0,OTHER,lead,Second Affiliated Hospital of Guangzhou Medical University,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,Guangzhou First People's Hospital,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,West China Hospital,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,Guangdong Provincial People's Hospital,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,Guangdong 999 Brain Hospital,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,"First Affiliated Hospital, Sun Yat-Sen University",Not Applicable
NCT03184597,2017.0,OTHER,collaborator,Wuhan Women and Children's Medical Center,Not Applicable
NCT03184597,2017.0,OTHER,collaborator,"First People's Hospital, Shunde China",Not Applicable
NCT03184688,2017.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT03186027,2017.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Not Applicable
NCT03186027,2017.0,INDUSTRY,collaborator,Vitae Health Innovation,Not Applicable
NCT03186040,2017.0,OTHER,lead,Chiba University,Phase 1/Phase 2
NCT03186456,2023.0,INDUSTRY,lead,"Sclnow Biotechnology Co., Ltd.",Phase 1
NCT03186729,2018.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT03186742,2014.0,OTHER,lead,Poznan University of Medical Sciences,Phase 4
NCT03187301,2017.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT03187405,2018.0,OTHER,lead,"University Hospital, Caen",Phase 3
NCT03187769,2017.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT03187795,2019.0,OTHER,lead,Kessler Foundation,Phase 2
NCT03187795,2019.0,FED,collaborator,"National Institute on Disability, Independent Living, and Rehabilitation Research",Phase 2
NCT03189173,2017.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT03189173,2017.0,OTHER,collaborator,Monash University,Phase 2
NCT03189173,2017.0,OTHER,collaborator,American Heart Association,Phase 2
NCT03189173,2017.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT03189173,2017.0,UNKNOWN,collaborator,Heart Foundation of Australia,Phase 2
NCT03189563,2018.0,INDUSTRY,lead,"Dong-A ST Co., Ltd.",Phase 2
NCT03190044,2017.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT03190044,2017.0,UNKNOWN,collaborator,Gianluca Coppola,Not Applicable
NCT03190044,2017.0,UNKNOWN,collaborator,Francesco Pierelli,Not Applicable
NCT03190577,2017.0,OTHER,lead,Nantes University Hospital,Not Applicable
NCT03190577,2017.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT03190915,2018.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT03190915,2018.0,NETWORK,collaborator,Children's Oncology Group,Phase 2
NCT03192215,2018.0,OTHER,lead,Columbia University,Phase 3
NCT03192215,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT03192215,2018.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT03192215,2018.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT03192215,2018.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 3
NCT03192215,2018.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT03192215,2018.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 3
NCT03192215,2018.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 3
NCT03192215,2018.0,OTHER,collaborator,University of Washington,Phase 3
NCT03192631,2017.0,OTHER,lead,Focus Community Mental Health Team,Not Applicable
NCT03192657,2017.0,OTHER,lead,RenJi Hospital,Phase 2
NCT03192969,2017.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 3
NCT03193346,2017.0,INDUSTRY,lead,Allergan,Phase 3
NCT03193359,2018.0,INDUSTRY,lead,Allergan,Phase 3
NCT03194217,2017.0,INDUSTRY,lead,BenevolentAI Bio,Phase 2
NCT03194594,2017.0,OTHER,lead,Wonkwang University Hospital,Phase 4
NCT03194815,2017.0,OTHER,lead,University of Cambridge,Phase 2
NCT03194815,2017.0,OTHER,collaborator,University of Oxford,Phase 2
NCT03195348,2017.0,OTHER,lead,King's College London,Not Applicable
NCT03195348,2017.0,OTHER,collaborator,Guy's and St Thomas' NHS Foundation Trust,Not Applicable
NCT03195465,2017.0,OTHER,lead,Loma Linda University,Not Applicable
NCT03195673,2018.0,OTHER,lead,Capital Medical University,Phase 2
NCT03195673,2018.0,OTHER,collaborator,The Luhe Teaching Hospital of the Capital Medical University,Phase 2
NCT03195673,2018.0,OTHER,collaborator,Beijing Anzhen Hospital,Phase 2
NCT03195933,2013.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT03195933,2013.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT03195933,2013.0,OTHER,collaborator,Brain & Behavior Research Foundation,Not Applicable
NCT03196271,2017.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT03196375,2017.0,INDUSTRY,lead,"Flex Pharma, Inc.",Phase 2
NCT03196765,2018.0,INDUSTRY,lead,"NeuroVia, Inc.",Phase 1/Phase 2
NCT03196817,2016.0,OTHER,lead,Hospital Alvorada,Phase 4
NCT03197662,2018.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT03197740,2017.0,INDUSTRY,lead,Icure Pharmaceutical Inc.,Phase 3
NCT03197922,2017.0,OTHER,lead,Emory University,Phase 3
NCT03197922,2017.0,FED,collaborator,United States Department of Defense,Phase 3
NCT03198078,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03198078,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03198702,2018.0,OTHER,lead,"University Hospital, Brest",Phase 3
NCT03198936,2017.0,INDUSTRY,lead,Vedic Lifesciences Pvt. Ltd.,Not Applicable
NCT03198936,2017.0,UNKNOWN,collaborator,Leading Edge Marketing LTD.,Not Applicable
NCT03199170,2017.0,OTHER,lead,Mahidol University,Not Applicable
NCT03199625,2016.0,OTHER,lead,Nanjing Medical University,Phase 2
NCT03199950,2017.0,OTHER,lead,Zuyderland Medisch Centrum,Phase 4
NCT03200600,2017.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03200600,2017.0,OTHER,collaborator,Peking University Cancer Hospital & Institute,Phase 4
NCT03200613,2017.0,OTHER,lead,McMaster University,Phase 2
NCT03200951,2017.0,OTHER,lead,Yonsei University,Not Applicable
NCT03201094,2017.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT03201757,2017.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT03202108,2018.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT03202303,2019.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT03202303,2019.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03202303,2019.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT03202368,2017.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03202719,2017.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT03202719,2017.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT03203174,2015.0,OTHER,lead,"University of California, Davis",Phase 1
NCT03204227,2017.0,OTHER,lead,"National Institute of Hygiene and Epidemiology, Vietnam",Phase 2
NCT03204227,2017.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Vietnam",Phase 2
NCT03204227,2017.0,OTHER_GOV,collaborator,"Ministry of Health, Vietnam",Phase 2
NCT03204500,2016.0,OTHER,lead,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Phase 2
NCT03204604,2016.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT03204786,2018.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT03204786,2018.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT03204929,2017.0,INDUSTRY,lead,Collaborative Medicinal Development Pty Limited,Phase 1
NCT03204955,2017.0,OTHER,lead,Emory University,Phase 1
NCT03205033,2016.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2
NCT03205358,2015.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 2
NCT03205371,2016.0,INDUSTRY,lead,"Sanofi Pasteur, a Sanofi Company",Phase 3
NCT03205488,2017.0,OTHER,lead,Northwestern University,Phase 2
NCT03205488,2017.0,OTHER,collaborator,University of Rochester,Phase 2
NCT03205488,2017.0,OTHER,collaborator,University of Iowa,Phase 2
NCT03205488,2017.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT03205956,2017.0,OTHER,lead,"Kevin J. Black, MD",Phase 1
NCT03205956,2017.0,UNKNOWN,collaborator,The Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT03206463,2017.0,OTHER,lead,Yale University,Phase 1
NCT03206554,2015.0,OTHER_GOV,lead,Asklepieion Voulas General Hospital,Phase 2
NCT03206957,2017.0,OTHER,lead,Queen Fabiola Children's University Hospital,Not Applicable
NCT03207464,2017.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT03208101,2017.0,INDUSTRY,lead,LG Chem,Phase 1
NCT03209102,2017.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 2
NCT03209323,2007.0,OTHER,lead,Medical University of Silesia,Not Applicable
NCT03209323,2007.0,OTHER,collaborator,Silesian University of Medicine,Not Applicable
NCT03210051,2017.0,OTHER,lead,Capital Medical University,Phase 1
NCT03210480,2017.0,INDUSTRY,lead,Aziende Chimiche Riunite Angelini Francesco S.p.A,Phase 4
NCT03210480,2017.0,OTHER,collaborator,Mediolanum Cardio Research,Phase 4
NCT03211013,2017.0,OTHER,lead,Palo Alto Veterans Institute for Research,Early Phase 1
NCT03212092,2018.0,OTHER,lead,Leiden University Medical Center,Not Applicable
NCT03213002,2017.0,OTHER,lead,Northwell Health,Phase 1/Phase 2
NCT03213379,2017.0,INDUSTRY,lead,Orkyn',Not Applicable
NCT03213418,2018.0,OTHER,lead,New York State Psychiatric Institute,Not Applicable
NCT03214146,2017.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 1
NCT03214146,2017.0,INDUSTRY,collaborator,"Corestemchemon, Inc.",Phase 1
NCT03214588,2017.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03214588,2017.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT03215927,2017.0,OTHER,lead,"Rohit Aggarwal, MD",Phase 2
NCT03215927,2017.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 2
NCT03216356,2016.0,OTHER,lead,Boston University Charles River Campus,Phase 2/Phase 3
NCT03216356,2016.0,OTHER,collaborator,James S McDonnell Foundation,Phase 2/Phase 3
NCT03216941,2015.0,OTHER,lead,Universidad Nacional de Rosario,Phase 4
NCT03217942,2017.0,OTHER,lead,Aalborg University,Early Phase 1
NCT03218969,2017.0,OTHER,lead,"William Ondo, MD",Phase 1/Phase 2
NCT03218969,2017.0,UNKNOWN,collaborator,Restless Legs Syndrome Foundation,Phase 1/Phase 2
NCT03218995,2017.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 2
NCT03219008,2017.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Shanghai Jiao Tong University School of Medicine,Phase 4
NCT03219008,2017.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Shanxi Medical University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Central South University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Second Military Medical University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Peking University Sixth Hospital,Phase 4
NCT03219008,2017.0,OTHER,collaborator,First Affiliated Hospital Xi'an Jiaotong University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,First Affiliated Hospital of Kunming Medical University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,"Air Force Military Medical University, China",Phase 4
NCT03219008,2017.0,OTHER,collaborator,Zhejiang University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Wuhan Mental Health Centre,Phase 4
NCT03219008,2017.0,UNKNOWN,collaborator,"Corning Hospital, Shenzhen City",Phase 4
NCT03219008,2017.0,UNKNOWN,collaborator,the First Specialized Subject Hospital of Harbin,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Renmin Hospital of Wuhan University,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Seventh People's Hospital of Hangzhou,Phase 4
NCT03219008,2017.0,OTHER,collaborator,Shandong Mental Health Center,Phase 4
NCT03220113,2017.0,OTHER,lead,"Corona Doctors Medical Clinics, Inc.",Phase 1/Phase 2
NCT03220646,2017.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 2
NCT03220646,2017.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT03220776,2017.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT03220776,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03220776,2017.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT03220958,2017.0,OTHER,lead,Montefiore Medical Center,Phase 3
NCT03221231,2016.0,OTHER,lead,Universitair Ziekenhuis Brussel,Phase 4
NCT03221569,2016.0,OTHER,lead,The Brooklyn Hospital Center,Phase 4
NCT03221751,2016.0,FED,lead,VA Office of Research and Development,Phase 4
NCT03222349,2017.0,INDUSTRY,lead,Aquestive Therapeutics,Phase 2
NCT03222349,2017.0,OTHER,collaborator,Syneos Health,Phase 2
NCT03222349,2017.0,INDUSTRY,collaborator,Covance,Phase 2
NCT03222570,2018.0,OTHER,lead,University of Minnesota,Phase 2
NCT03222570,2018.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT03222973,2017.0,INDUSTRY,lead,Biogen,Phase 2
NCT03223844,2018.0,OTHER,lead,Medical University of Vienna,Not Applicable
NCT03223896,2017.0,OTHER_GOV,lead,Finnish Institute for Health and Welfare,Phase 2
NCT03224468,2017.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT03225690,2017.0,OTHER,lead,Cukurova University,Phase 4
NCT03225833,2017.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT03225846,2017.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT03226223,2016.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT03226522,2017.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 2/Phase 3
NCT03228355,2017.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03228394,2017.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT03228524,2017.0,OTHER,lead,Neuromed IRCCS,Early Phase 1
NCT03228940,2022.0,INDUSTRY,lead,Resverlogix Corp,Phase 1/Phase 2
NCT03228992,2017.0,OTHER,lead,Jean Brown Research,Phase 4
NCT03229031,2018.0,INDUSTRY,lead,"Eusol Biotech Co., Ltd.",Phase 3
NCT03229174,2018.0,OTHER,lead,"William Ondo, MD",Phase 4
NCT03229174,2018.0,INDUSTRY,collaborator,Lundbeck LLC,Phase 4
NCT03229486,2017.0,OTHER,lead,Pusan National University Yangsan Hospital,Phase 4
NCT03229798,2018.0,INDUSTRY,lead,"Sorrento Therapeutics, Inc.",Phase 1
NCT03229798,2018.0,INDUSTRY,collaborator,Kimberly-Clark Corporation,Phase 1
NCT03230071,2017.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 2
NCT03230071,2017.0,UNKNOWN,collaborator,Beijing Union pharmaceutical factory II,Phase 2
NCT03230071,2017.0,UNKNOWN,collaborator,Beijing Compete Medical Technology Development Co. Ltd.,Phase 2
NCT03230097,2017.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT03230526,2018.0,OTHER,lead,Nantes University Hospital,Phase 2
NCT03231306,2017.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT03231306,2017.0,INDUSTRY,collaborator,Array BioPharma,Phase 2
NCT03231306,2017.0,OTHER,collaborator,Pacific Pediatric Neuro-Oncology Consortium,Phase 2
NCT03231878,2017.0,INDUSTRY,lead,"Minoryx Therapeutics, S.L.",Phase 2/Phase 3
NCT03232073,2017.0,INDUSTRY,lead,Actelion,Phase 3
NCT03232320,2017.0,INDUSTRY,lead,Medy-Tox,Phase 3
NCT03232502,2017.0,OTHER,lead,University of Arizona,Phase 3
NCT03234309,2017.0,OTHER,lead,OHSU Knight Cancer Institute,Phase 2
NCT03234309,2017.0,INDUSTRY,collaborator,"AMAG Pharmaceuticals, Inc.",Phase 2
NCT03234309,2017.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT03234920,2015.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT03235037,2013.0,OTHER,lead,Bennett Lavenstein,Not Applicable
NCT03236012,2019.0,OTHER,lead,University of Utah,Phase 1
NCT03236012,2019.0,FED,collaborator,US Department of Veterans Affairs,Phase 1
NCT03236012,2019.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 1
NCT03237052,2018.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT03237286,2017.0,OTHER,lead,Rebecca Price,Phase 1/Phase 2
NCT03237286,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT03237741,2017.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT03237741,2017.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT03237832,2016.0,INDUSTRY,lead,Arrien Pharmaceuticals,Phase 1
NCT03237832,2016.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 1
NCT03238326,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03238326,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03238924,2015.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT03239210,2017.0,OTHER,lead,NYU Langone Health,Phase 4
NCT03239210,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT03239496,2017.0,OTHER,lead,Fidec Corporation,Phase 3
NCT03239496,2017.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT03239561,2017.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Early Phase 1
NCT03239860,2017.0,INDUSTRY,lead,GeNeuro SA,Phase 2
NCT03239860,2017.0,UNKNOWN,collaborator,Les Laboratoires Servier,Phase 2
NCT03239860,2017.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT03239860,2017.0,OTHER,collaborator,Institut de Recherches Internationales Servier,Phase 2
NCT03242499,2017.0,OTHER,lead,National Taiwan University Hospital,Phase 2
NCT03242772,2018.0,OTHER,lead,Duke University,Phase 2
NCT03242772,2018.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT03243175,2019.0,OTHER,lead,"University Hospital, Lille",Phase 3
NCT03243175,2019.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 3
NCT03243175,2019.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 3
NCT03243630,2018.0,OTHER,lead,Yale University,Early Phase 1
NCT03243630,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03244527,2017.0,OTHER,lead,Taipei Medical University WanFang Hospital,Not Applicable
NCT03244540,2017.0,OTHER,lead,Medical University of Lublin,Phase 4
NCT03244709,2015.0,OTHER,lead,Hospital of Prato,Phase 4
NCT03245437,2018.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT03245437,2018.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03245762,2017.0,OTHER,lead,University of Florida,Phase 1/Phase 2
NCT03245762,2017.0,UNKNOWN,collaborator,Prader-Willi Syndrome Association,Phase 1/Phase 2
NCT03247244,2018.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT03247413,2019.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT03247790,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03247998,2017.0,OTHER,lead,Lawson Health Research Institute,Not Applicable
NCT03248167,2019.0,OTHER,lead,NYU Langone Health,Phase 1/Phase 2
NCT03248167,2019.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1/Phase 2
NCT03248167,2019.0,INDUSTRY,collaborator,Tilray,Phase 1/Phase 2
NCT03248544,2017.0,OTHER,lead,Shahid Beheshti University,Not Applicable
NCT03248713,2017.0,OTHER,lead,Yale University,Early Phase 1
NCT03249103,2017.0,INDUSTRY,lead,Aptinyx,Phase 2
NCT03249103,2017.0,OTHER,collaborator,inVentiv Health Clinical,Phase 2
NCT03249207,2018.0,OTHER,lead,University of Manchester,Phase 3
NCT03249207,2018.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 3
NCT03249207,2018.0,OTHER,collaborator,"Clinical Trials Unit, Manchester",Phase 3
NCT03249207,2018.0,OTHER,collaborator,Northern Care Alliance NHS Foundation Trust,Phase 3
NCT03249376,2017.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT03250117,2017.0,INDUSTRY,lead,Titan Pharmaceuticals,Phase 1/Phase 2
NCT03250377,2017.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT03250741,2016.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 2
NCT03251326,2015.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT03251326,2015.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT03251651,2017.0,OTHER,lead,Seoul National University Bundang Hospital,Not Applicable
NCT03251716,2015.0,OTHER,lead,Tianjin Anding Hospital,Not Applicable
NCT03252353,2017.0,INDUSTRY,lead,"Chiasma, Inc.",Phase 3
NCT03252535,2018.0,INDUSTRY,lead,Azidus Brasil,Phase 2
NCT03252535,2018.0,OTHER,collaborator,Cellavita Pesquisa Científica Ltda,Phase 2
NCT03252626,2022.0,OTHER,lead,The First Hospital of Jilin University,Phase 4
NCT03254186,2017.0,OTHER,lead,Emory University,Phase 2/Phase 3
NCT03254186,2017.0,OTHER,collaborator,Atlanta Clinical and Translational Science Institute,Phase 2/Phase 3
NCT03254199,2017.0,INDUSTRY,lead,"Flex Pharma, Inc.",Phase 2
NCT03254680,2018.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT03255330,2017.0,OTHER,lead,Masaryk University,Phase 3
NCT03255408,2023.0,OTHER,lead,University of Calgary,Phase 1/Phase 2
NCT03255642,2017.0,OTHER,lead,Kyung Hee University Hospital at Gangdong,Not Applicable
NCT03256162,2017.0,OTHER,lead,"St Patrick's Hospital, Ireland",Phase 1
NCT03257046,2017.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 1/Phase 2
NCT03257592,2010.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT03257631,2017.0,INDUSTRY,lead,Celgene,Phase 2
NCT03257865,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03257865,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03258294,2016.0,OTHER,lead,KIMJisun,Phase 4
NCT03258294,2016.0,INDUSTRY,collaborator,"Kuhnil Pharmaceutical Co., Ltd.",Phase 4
NCT03258346,2017.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT03258346,2017.0,INDUSTRY,collaborator,POM Wonderful LLC,Not Applicable
NCT03259373,2017.0,OTHER,lead,Harvard Pilgrim Health Care,Not Applicable
NCT03259373,2017.0,OTHER,collaborator,Duke Clinical Research Institute,Not Applicable
NCT03259373,2017.0,OTHER,collaborator,Clinical Trials Transformation Initiative,Not Applicable
NCT03259373,2017.0,INDUSTRY,collaborator,Humana Inc.,Not Applicable
NCT03259373,2017.0,INDUSTRY,collaborator,"Aetna, Inc.",Not Applicable
NCT03259373,2017.0,UNKNOWN,collaborator,"OptumInsight Life Sciences, Inc.",Not Applicable
NCT03259373,2017.0,FED,collaborator,Food and Drug Administration (FDA),Not Applicable
NCT03259555,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03259555,2017.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03259607,2017.0,INDUSTRY,lead,McNeil AB,Phase 1
NCT03259607,2017.0,UNKNOWN,collaborator,Janssen (China) Research & Development Center,Phase 1
NCT03259958,2017.0,INDUSTRY,lead,"Corium, Inc.",Phase 1
NCT03259971,2017.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT03260153,2017.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT03260153,2017.0,UNKNOWN,collaborator,Beijing Stroke Association,Not Applicable
NCT03260569,2018.0,OTHER,lead,University of Cincinnati,Phase 3
NCT03260920,2018.0,OTHER,lead,Lawson Health Research Institute,Phase 2
NCT03260920,2018.0,OTHER,collaborator,Weston Brain Institute,Phase 2
NCT03260920,2018.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT03260920,2018.0,OTHER,collaborator,Berry Consultants,Phase 2
NCT03261570,2017.0,OTHER,lead,New York Medical College,Early Phase 1
NCT03261570,2017.0,NIH,collaborator,National Institutes of Health (NIH),Early Phase 1
NCT03263117,2018.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 4
NCT03263117,2018.0,INDUSTRY,collaborator,Stryker Neurovascular,Phase 4
NCT03263442,2017.0,OTHER,lead,UNC Lineberger Comprehensive Cancer Center,Phase 2
NCT03263442,2017.0,OTHER,collaborator,Rising Tide Foundation,Phase 2
NCT03263533,2017.0,OTHER,lead,Virginia Commonwealth University,Early Phase 1
NCT03265197,2015.0,OTHER,lead,saad elzayat,Phase 1
NCT03265444,2018.0,INDUSTRY,lead,"Corestemchemon, Inc.",Phase 1
NCT03266731,2018.0,OTHER,lead,Assiut University,Not Applicable
NCT03266939,2018.0,OTHER,lead,Mclean Hospital,Phase 1
NCT03266965,2018.0,OTHER,lead,University of Miami,Phase 1
NCT03266965,2018.0,FED,collaborator,United States Department of Defense,Phase 1
NCT03267277,2017.0,NIH,lead,National Institute of Environmental Health Sciences (NIEHS),Phase 2/Phase 3
NCT03267303,2017.0,INDUSTRY,lead,"Taisho Pharmaceutical Co., Ltd.",Phase 2
NCT03267745,2017.0,OTHER,lead,McMaster University,Not Applicable
NCT03267745,2017.0,INDUSTRY,collaborator,"Axcella Health, Inc",Not Applicable
NCT03267836,2018.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT03267836,2018.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT03268187,2017.0,OTHER,lead,Rehazentrum Wilhelmshaven,Not Applicable
NCT03268590,2017.0,OTHER,lead,Case Western Reserve University,Phase 4
NCT03268603,2017.0,OTHER,lead,Mayo Clinic,Phase 2
NCT03268603,2017.0,UNKNOWN,collaborator,State of Minnesota Regenerative Medicine Minnesota,Phase 2
NCT03269435,2017.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT03270059,2017.0,OTHER,lead,OHSU Knight Cancer Institute,Phase 2
NCT03270059,2017.0,INDUSTRY,collaborator,Celgene Corporation,Phase 2
NCT03270059,2017.0,OTHER,collaborator,Oregon Health and Science University,Phase 2
NCT03271814,2025.0,OTHER,lead,"University of Maryland, Baltimore",Phase 1
NCT03271866,2017.0,OTHER,lead,Central South University,Not Applicable
NCT03272165,2017.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT03272165,2017.0,INDUSTRY,collaborator,Covance,Phase 1
NCT03272165,2017.0,UNKNOWN,collaborator,"MMS Holdings, Inc",Phase 1
NCT03272165,2017.0,INDUSTRY,collaborator,Catalent,Phase 1
NCT03272165,2017.0,INDUSTRY,collaborator,Takeda,Phase 1
NCT03272230,2017.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT03272503,2017.0,OTHER,lead,University of Calgary,Phase 2
NCT03272503,2017.0,UNKNOWN,collaborator,ALS Canada,Phase 2
NCT03272503,2017.0,OTHER,collaborator,Brain Canada,Phase 2
NCT03272685,2018.0,OTHER,lead,University of Minnesota,Phase 3
NCT03272685,2018.0,OTHER,collaborator,Duke University,Phase 3
NCT03272685,2018.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT03272685,2018.0,OTHER,collaborator,Wake Forest University,Phase 3
NCT03272685,2018.0,OTHER,collaborator,University of Pennsylvania,Phase 3
NCT03272685,2018.0,OTHER,collaborator,Brown University,Phase 3
NCT03272802,2017.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 2/Phase 3
NCT03273062,2017.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT03273062,2017.0,UNKNOWN,collaborator,Lieber Institute for Brain Development,Phase 2
NCT03273712,2017.0,OTHER,lead,University of Iowa,Phase 2
NCT03273712,2017.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03273712,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT03274375,2021.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT03274440,2017.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT03274817,2009.0,OTHER,lead,NYU Langone Health,Phase 1
NCT03274856,2018.0,OTHER,lead,GLWL Research Inc.,Phase 2
NCT03275740,2017.0,INDUSTRY,lead,Pfizer,Phase 1
NCT03275922,2017.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT03275922,2017.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT03276494,2017.0,OTHER,lead,Ohio State University,Phase 2
NCT03276676,2018.0,OTHER,lead,University of Utah,Phase 2
NCT03276676,2018.0,INDUSTRY,collaborator,Blue Earth Diagnostics,Phase 2
NCT03276689,2017.0,OTHER,lead,Rambam Health Care Campus,Not Applicable
NCT03276689,2017.0,OTHER,collaborator,Israel Science Foundation,Not Applicable
NCT03276975,2017.0,OTHER,lead,Duke University,Phase 2
NCT03277573,2017.0,OTHER,lead,Adam Boxer,Phase 1
NCT03277586,2018.0,OTHER,lead,Queen's University,Phase 3
NCT03277846,2017.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT03277846,2017.0,OTHER,collaborator,Carrier Clinic,Not Applicable
NCT03279224,2018.0,OTHER,lead,Valerie Taylor,Phase 2/Phase 3
NCT03279224,2018.0,OTHER,collaborator,"University Health Network, Toronto",Phase 2/Phase 3
NCT03279393,2017.0,OTHER,lead,Zahi Fayad,Early Phase 1
NCT03279393,2017.0,OTHER,collaborator,Massachusetts General Hospital,Early Phase 1
NCT03279393,2017.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT03279393,2017.0,NIH,collaborator,National Institutes of Health (NIH),Early Phase 1
NCT03279471,2017.0,OTHER,lead,"University of California, Davis",Phase 2
NCT03279731,2017.0,OTHER,lead,Kelly Allison,Phase 3
NCT03279731,2017.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 3
NCT03280017,2017.0,OTHER,lead,Mahidol University,Phase 4
NCT03280212,2017.0,OTHER,lead,Unity Health Toronto,Phase 3
NCT03280342,2017.0,OTHER,lead,University of Minnesota,Phase 2
NCT03280342,2017.0,INDUSTRY,collaborator,"Supernus Pharmaceuticals, Inc.",Phase 2
NCT03282123,2017.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT03282227,2017.0,INDUSTRY,lead,Zosano Pharma Corporation,Phase 3
NCT03282370,2017.0,OTHER,lead,"National Institute of Hygiene and Epidemiology, Vietnam",Phase 3
NCT03282370,2017.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Vietnam",Phase 3
NCT03282370,2017.0,OTHER_GOV,collaborator,"Ministry of Health, Vietnam",Phase 3
NCT03282838,2017.0,INDUSTRY,lead,Dr. Reddy's Laboratories Limited,Phase 1
NCT03282916,2018.0,OTHER,lead,Columbia University,Phase 2
NCT03282916,2018.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT03282916,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03283059,2017.0,OTHER,lead,Shanghai Mental Health Center,Phase 3
NCT03283059,2017.0,INDUSTRY,collaborator,"Changchun Huayang High-tech Co., Ltd",Phase 3
NCT03283059,2017.0,UNKNOWN,collaborator,"Jiangsu Sheneryang High-tech Co., Ltd",Phase 3
NCT03283397,2019.0,INDUSTRY,lead,Bosnalijek D.D,Phase 3
NCT03283397,2019.0,INDUSTRY,collaborator,MonitorCRO,Phase 3
NCT03283930,2001.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 2
NCT03284294,2020.0,OTHER,lead,Universitas Padjadjaran,Phase 3
NCT03284307,2017.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT03284463,2018.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Phase 2/Phase 3
NCT03285217,2017.0,OTHER_GOV,lead,Instituto Aragones de Ciencias de la Salud,Not Applicable
NCT03285217,2017.0,UNKNOWN,collaborator,Refbio2: Trans-Pyrenean cooperation network for biomedical research,Not Applicable
NCT03285503,2018.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 1
NCT03286634,2017.0,OTHER,lead,National Hospital Organization Nagoya Medical Center,Phase 2
NCT03286803,2017.0,OTHER,lead,Aga Khan University,Phase 4
NCT03286803,2017.0,OTHER,collaborator,World Health Organization,Phase 4
NCT03287232,2017.0,INDUSTRY,lead,EndoCeutics Inc.,Phase 3
NCT03287505,2017.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 1
NCT03287778,2017.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT03287778,2017.0,OTHER,collaborator,"Foundation of Hope, North Carolina",Not Applicable
NCT03288155,2017.0,OTHER,lead,Oxford Brookes University,Not Applicable
NCT03288155,2017.0,UNKNOWN,collaborator,European Parkinson Therapy Centre,Not Applicable
NCT03288389,2017.0,OTHER,lead,Institute for Molecular Medicine,Not Applicable
NCT03288675,2017.0,OTHER,lead,University Ghent,Not Applicable
NCT03288675,2017.0,OTHER,collaborator,"University Hospital, Ghent",Not Applicable
NCT03289143,2017.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT03289702,2017.0,INDUSTRY,lead,Medy-Tox,Phase 3
NCT03290131,2018.0,INDUSTRY,lead,"RVL Pharmaceuticals, Inc.",Phase 3
NCT03290131,2018.0,INDUSTRY,collaborator,Osmotica Pharmaceutical US LLC,Phase 3
NCT03291197,2017.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 4
NCT03292016,2017.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 2
NCT03292146,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT03292146,2017.0,INDUSTRY,collaborator,Amgen,Phase 3
NCT03292315,2018.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT03292315,2018.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 4
NCT03293069,2019.0,OTHER,lead,"University Hospital, Lille",Phase 2/Phase 3
NCT03293069,2019.0,OTHER_GOV,collaborator,"Ministry of Health, France",Phase 2/Phase 3
NCT03293524,2018.0,INDUSTRY,lead,GenSight Biologics,Phase 3
NCT03293927,2018.0,OTHER,lead,Duke University,Phase 2
NCT03295019,2017.0,INDUSTRY,lead,You First Services,Not Applicable
NCT03295318,2017.0,INDUSTRY,lead,Serum Institute of India Pvt. Ltd.,Phase 2
NCT03295318,2017.0,OTHER,collaborator,PATH,Phase 2
NCT03295786,2017.0,INDUSTRY,lead,Herantis Pharma Plc.,Phase 1/Phase 2
NCT03295786,2017.0,UNKNOWN,collaborator,Renishaw plc.,Phase 1/Phase 2
NCT03296176,2017.0,OTHER_GOV,lead,"University Hospital, Angers",Not Applicable
NCT03296501,2015.0,OTHER,lead,Mossakowski Medical Research Centre Polish Academy of Sciences,Phase 1
NCT03296501,2015.0,OTHER,collaborator,Medical University of Warsaw,Phase 1
NCT03296852,2018.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT03296852,2018.0,INDUSTRY,collaborator,"Burl Concepts, Inc.",Early Phase 1
NCT03297944,2017.0,OTHER,lead,Marion Coe,Phase 4
NCT03297944,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT03298672,2017.0,INDUSTRY,lead,Athira Pharma,Phase 1
NCT03298672,2017.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 1
NCT03298672,2017.0,UNKNOWN,collaborator,Biotrial Inc.,Phase 1
NCT03299166,2017.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT03299972,2017.0,OTHER,lead,Coventry University,Not Applicable
NCT03299972,2017.0,OTHER,collaborator,University Hospitals Coventry and Warwickshire NHS Trust,Not Applicable
NCT03300440,2017.0,OTHER,lead,Medical University of Graz,Not Applicable
NCT03300648,2018.0,OTHER,lead,Michigan State University,Phase 3
NCT03300648,2018.0,OTHER,collaborator,Children's National Research Institute,Phase 3
NCT03300648,2018.0,OTHER,collaborator,Nationwide Children's Hospital,Phase 3
NCT03300648,2018.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT03300648,2018.0,OTHER,collaborator,"University of Maryland, Baltimore",Phase 3
NCT03300648,2018.0,OTHER,collaborator,Kamuzu University of Health Sciences,Phase 3
NCT03300687,2017.0,INDUSTRY,lead,Frequency Therapeutics,Early Phase 1
NCT03301272,2018.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT03302585,2017.0,OTHER,lead,University of Calgary,Phase 2
NCT03302871,2016.0,OTHER,lead,Kocaeli University,Phase 3
NCT03303079,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT03303092,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 2/Phase 3
NCT03303105,2017.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT03303534,2017.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT03303651,2017.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT03304457,2017.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT03304522,2017.0,INDUSTRY,lead,Vertex Pharmaceuticals Incorporated,Phase 2
NCT03304899,2018.0,OTHER,lead,Leila Dehghani,Phase 1/Phase 2
NCT03305016,2017.0,INDUSTRY,lead,Ascendis Pharma Endocrinology Division A/S,Phase 3
NCT03305055,2017.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT03305055,2017.0,FED,collaborator,United States Department of Defense,Phase 4
NCT03305055,2017.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 4
NCT03305809,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT03306212,2014.0,OTHER,lead,Kocaeli University,Phase 3
NCT03306329,2017.0,INDUSTRY,lead,"Dart NeuroScience, LLC",Phase 2
NCT03306615,2021.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT03306940,2017.0,OTHER,lead,Tongji University,Not Applicable
NCT03307993,2017.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT03308084,2015.0,OTHER,lead,Rush University Medical Center,Phase 3
NCT03308448,2018.0,OTHER,lead,Iran University of Medical Sciences,Phase 3
NCT03308448,2018.0,OTHER,collaborator,Mashhad University of Medical Sciences,Phase 3
NCT03308448,2018.0,OTHER,collaborator,Tehran University of Medical Sciences,Phase 3
NCT03308565,2017.0,OTHER,lead,Mohamad Bydon,Phase 1
NCT03308578,2018.0,OTHER,lead,Mayo Clinic,Phase 1/Phase 2
NCT03308578,2018.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT03308747,2017.0,OTHER,lead,University of Thessaly,Not Applicable
NCT03309319,2016.0,OTHER,lead,Zhaoyun Zhang,Not Applicable
NCT03309514,2022.0,INDUSTRY,lead,NeuroGeneration,Phase 1/Phase 2
NCT03310593,2017.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT03310593,2017.0,OTHER,collaborator,Federal University of Rio Grande do Sul,Phase 2/Phase 3
NCT03310593,2017.0,OTHER,collaborator,University of Sao Paulo,Phase 2/Phase 3
NCT03312361,2016.0,OTHER,lead,The Hospital for Sick Children,Not Applicable
NCT03313102,2017.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT03315793,2017.0,INDUSTRY,lead,Shionogi,Phase 3
NCT03315793,2017.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT03315897,2017.0,OTHER,lead,Lars Vedel Kessing,Phase 2
NCT03315897,2017.0,OTHER,collaborator,"Mental Health Services in the Capital Region, Denmark",Phase 2
NCT03315897,2017.0,OTHER,collaborator,Lundbeck Foundation,Phase 2
NCT03316066,2018.0,OTHER,lead,Maisonneuve-Rosemont Hospital,Not Applicable
NCT03316898,2018.0,INDUSTRY,lead,Allergan,Phase 1
NCT03317067,2017.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 3
NCT03317171,2016.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Not Applicable
NCT03317613,2017.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Phase 2
NCT03317613,2017.0,OTHER,collaborator,Institut de Cancérologie de la Loire,Phase 2
NCT03317678,2017.0,OTHER,lead,Rush University Medical Center,Not Applicable
NCT03318523,2018.0,INDUSTRY,lead,Biogen,Phase 2
NCT03318744,2018.0,OTHER,lead,First People's Hospital of Shenyang,Not Applicable
NCT03319732,2018.0,INDUSTRY,lead,"RVL Pharmaceuticals, Inc.",Phase 3
NCT03319732,2018.0,INDUSTRY,collaborator,Osmotica Pharmaceutical US LLC,Phase 3
NCT03321006,2018.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT03321006,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT03321955,2016.0,OTHER,lead,Albany Medical College,Phase 4
NCT03322462,2017.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT03323437,2017.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT03323437,2017.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 4
NCT03323437,2017.0,OTHER,collaborator,Columbia University,Phase 4
NCT03323437,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03324035,2017.0,OTHER,lead,University of Sao Paulo,Phase 3
NCT03324035,2017.0,INDUSTRY,collaborator,Cristália Produtos Químicos Farmacêuticos Ltda.,Phase 3
NCT03324399,2017.0,OTHER,lead,Avera McKennan Hospital & University Health Center,Not Applicable
NCT03324867,2022.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Not Applicable
NCT03325010,2017.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03325959,2017.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Not Applicable
NCT03326388,2019.0,OTHER,lead,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 1/Phase 2
NCT03326388,2019.0,INDUSTRY,collaborator,AstraZeneca,Phase 1/Phase 2
NCT03326505,2017.0,OTHER,lead,University of Jordan,Phase 1/Phase 2
NCT03326648,2016.0,OTHER,lead,Truls Raastad,Not Applicable
NCT03326648,2016.0,OTHER,collaborator,University of Padova,Not Applicable
NCT03326648,2016.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT03326648,2016.0,INDUSTRY,collaborator,Tine,Not Applicable
NCT03327272,2018.0,OTHER,lead,Rush University Medical Center,Phase 3
NCT03329508,2018.0,INDUSTRY,lead,Pharma Two B Ltd.,Phase 3
NCT03329573,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT03330418,2018.0,INDUSTRY,lead,"RemeGen Co., Ltd.",Phase 3
NCT03330470,2017.0,OTHER_GOV,lead,Slovak Academy of Sciences,Not Applicable
NCT03330470,2017.0,OTHER,collaborator,Comenius University,Not Applicable
NCT03330470,2017.0,OTHER,collaborator,University Hospital Bratislava,Not Applicable
NCT03330470,2017.0,OTHER,collaborator,National Cheng Kung University,Not Applicable
NCT03330613,2017.0,OTHER,lead,Aydin Adnan Menderes University,Not Applicable
NCT03330639,2017.0,OTHER,lead,University of Nebraska,Not Applicable
NCT03331848,2018.0,INDUSTRY,lead,Prexton Therapeutics,Phase 2
NCT03331913,2017.0,OTHER,lead,The First Affiliated Hospital of Zhengzhou University,Phase 3
NCT03333590,2017.0,OTHER,lead,Kevin Flanigan,Phase 1/Phase 2
NCT03333603,2016.0,OTHER,lead,National Taiwan University Hospital,Phase 4
NCT03333603,2016.0,OTHER,collaborator,National Taiwan University,Phase 4
NCT03333720,2019.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT03334721,2017.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT03334721,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT03334786,2018.0,INDUSTRY,lead,"Flex Pharma, Inc.",Phase 1/Phase 2
NCT03335163,2018.0,OTHER,lead,"University of Colorado, Denver",Phase 1
NCT03335163,2018.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT03335488,2018.0,INDUSTRY,lead,"Horizon Therapeutics, LLC",Phase 4
NCT03335527,2017.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03336398,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT03336450,2018.0,INDUSTRY,lead,Shire,Phase 3
NCT03336450,2018.0,INDUSTRY,collaborator,"Takeda Development Center Americas, Inc.",Phase 3
NCT03336645,2017.0,INDUSTRY,lead,Shire,Phase 3
NCT03337035,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT03337373,2017.0,OTHER,lead,Mahidol University,Phase 4
NCT03337529,2017.0,OTHER,lead,Makassed General Hospital,Not Applicable
NCT03337620,2017.0,INDUSTRY,lead,Tian Medical Inc.,Phase 3
NCT03337620,2017.0,UNKNOWN,collaborator,"TAMM Net, Inc.",Phase 3
NCT03337620,2017.0,INDUSTRY,collaborator,"Clinvest Research, LLC",Phase 3
NCT03337620,2017.0,INDUSTRY,collaborator,Ki Health Partners. LLC,Phase 3
NCT03337646,2018.0,OTHER,lead,JPM van Stralen Medicine Professional,Phase 4
NCT03337646,2018.0,INDUSTRY,collaborator,Shire,Phase 4
NCT03338114,2017.0,INDUSTRY,lead,"Flex Pharma, Inc.",Phase 1/Phase 2
NCT03338387,2003.0,OTHER,lead,"Charles University, Czech Republic",Phase 2
NCT03338478,2017.0,OTHER,lead,Erik J. Kobylarz,Not Applicable
NCT03338478,2017.0,OTHER,collaborator,American Epilepsy Society,Not Applicable
NCT03338907,2018.0,OTHER,lead,University of Zurich,Phase 2
NCT03339024,2017.0,OTHER,lead,Norwegian University of Science and Technology,Phase 3
NCT03339024,2017.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT03339024,2017.0,UNKNOWN,collaborator,Lade Addiction Treatment Center,Phase 3
NCT03339258,2018.0,FED,lead,San Francisco Veterans Affairs Medical Center,Phase 2
NCT03339258,2018.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03339258,2018.0,OTHER,collaborator,Northern California Institute of Research and Education,Phase 2
NCT03339336,2018.0,INDUSTRY,lead,Biogen,Phase 2
NCT03339505,2017.0,OTHER,lead,Peter Siesjö,Phase 3
NCT03339505,2017.0,OTHER,collaborator,University of Stellenbosch,Phase 3
NCT03339596,2017.0,OTHER,lead,Martin Balslev Jørgensen,Phase 2
NCT03339596,2017.0,OTHER,collaborator,"The Augustinus Foundation, Denmark.",Phase 2
NCT03339596,2017.0,OTHER,collaborator,"Mental Health Services in the Capital Region, Denmark",Phase 2
NCT03340350,2017.0,FED,lead,Sriram Ramaswamy,Phase 4
NCT03340350,2017.0,OTHER,collaborator,Creighton University,Phase 4
NCT03340909,2018.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT03340909,2018.0,OTHER_GOV,collaborator,Helse Stavanger HF,Phase 2
NCT03340909,2018.0,OTHER,collaborator,St. Olavs Hospital,Phase 2
NCT03341689,2017.0,OTHER,lead,Yale University,Phase 1
NCT03341689,2017.0,UNKNOWN,collaborator,Ceruvia Lifesciences,Phase 1
NCT03342053,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT03342638,2017.0,OTHER,lead,Northwestern University,Phase 3
NCT03344458,2017.0,INDUSTRY,lead,Ascendis Pharma A/S,Phase 3
NCT03345342,2017.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT03345576,2018.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03345576,2018.0,FED,collaborator,Hunter Holmes McGuire VA Medical Center,Phase 2
NCT03345940,2017.0,OTHER,lead,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Phase 4
NCT03345940,2017.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT03345940,2017.0,OTHER,collaborator,Universita degli Studi di Genova,Phase 4
NCT03345953,2018.0,OTHER,lead,Bioprojet,Phase 2
NCT03345979,2017.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT03346252,2017.0,OTHER,lead,State University of New York at Buffalo,Early Phase 1
NCT03347188,2017.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT03347526,2018.0,OTHER,lead,"University of Colorado, Denver",Phase 3
NCT03347526,2018.0,UNKNOWN,collaborator,Pediatric Epilepsy Research Foundation,Phase 3
NCT03347526,2018.0,UNKNOWN,collaborator,"West Therapuetics, Inc",Phase 3
NCT03347929,2017.0,OTHER,lead,Ostfold Hospital Trust,Phase 4
NCT03347929,2017.0,OTHER,collaborator,Vestre Viken Hospital Trust,Phase 4
NCT03347929,2017.0,OTHER_GOV,collaborator,Sykehuset Telemark,Phase 4
NCT03347929,2017.0,OTHER_GOV,collaborator,Helse Stavanger HF,Phase 4
NCT03347929,2017.0,OTHER,collaborator,Oslo University Hospital,Phase 4
NCT03348735,2018.0,OTHER,lead,"University Hospital, Antwerp",Phase 4
NCT03348930,2018.0,OTHER,lead,University of Chicago,Phase 2/Phase 3
NCT03349515,2017.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT03349528,2018.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT03349606,2010.0,OTHER,lead,University of Pittsburgh,Early Phase 1
NCT03349606,2010.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03350035,2018.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT03350633,2017.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2/Phase 3
NCT03351244,2017.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT03351517,2017.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Not Applicable
NCT03351569,2015.0,OTHER,lead,Azienda Socio Sanitaria Territoriale di Mantova,Phase 3
NCT03352024,2018.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT03352557,2018.0,INDUSTRY,lead,Biogen,Phase 2
NCT03353025,2016.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Not Applicable
NCT03353103,2018.0,OTHER,lead,"University Hospital, Caen",Phase 2
NCT03353259,2017.0,OTHER,lead,Oslo University Hospital,Phase 2/Phase 3
NCT03353441,2017.0,NETWORK,lead,Daacro,Not Applicable
NCT03353441,2017.0,UNKNOWN,collaborator,OOO MNPK BIOTIKI,Not Applicable
NCT03354039,2018.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 3
NCT03354455,2017.0,OTHER,lead,Danish Research Centre for Magnetic Resonance,Not Applicable
NCT03354455,2017.0,OTHER,collaborator,University Hospital Bispebjerg and Frederiksberg,Not Applicable
NCT03354455,2017.0,UNKNOWN,collaborator,Danish Movement Disorder Society (DANMODIS),Not Applicable
NCT03354455,2017.0,OTHER,collaborator,Danish Parkinson Association,Not Applicable
NCT03354507,2018.0,OTHER,lead,McMaster Children's Hospital,Not Applicable
NCT03354624,2017.0,OTHER,lead,Aalborg University,Not Applicable
NCT03355053,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03355053,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT03355209,2017.0,INDUSTRY,lead,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",Phase 3
NCT03355365,2018.0,OTHER,lead,Tisch Multiple Sclerosis Research Center of New York,Phase 2
NCT03355963,2016.0,OTHER,lead,Benha University,Phase 2
NCT03355963,2016.0,OTHER,collaborator,Cairo University,Phase 2
NCT03356483,2018.0,OTHER,lead,Yale University,Phase 1
NCT03356483,2018.0,OTHER,collaborator,Heffter Research Institute,Phase 1
NCT03356483,2018.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT03356639,2018.0,INDUSTRY,lead,"Astellas Pharma Global Development, Inc.",Phase 1
NCT03356769,2017.0,OTHER,lead,Peking Union Medical College Hospital,Phase 2
NCT03356769,2017.0,INDUSTRY,collaborator,Shijiazhuang Yiling Pharmaceutical Co. Ltd,Phase 2
NCT03357978,2016.0,OTHER,lead,Johann Wolfgang Goethe University Hospital,Not Applicable
NCT03358433,2016.0,OTHER,lead,"Gerencia de Atención Primaria, Albacete",Not Applicable
NCT03359213,2018.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 2
NCT03359265,2015.0,OTHER,lead,"National Defense Medical Center, Taiwan",Not Applicable
NCT03359538,2017.0,OTHER,lead,Azienda Ospedaliero-Universitaria di Modena,Phase 2
NCT03359538,2017.0,OTHER,collaborator,University of Modena and Reggio Emilia,Phase 2
NCT03359538,2017.0,OTHER,collaborator,Azienda Ospedaliero Universitaria Maggiore della Carita,Phase 2
NCT03359538,2017.0,OTHER,collaborator,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",Phase 2
NCT03359538,2017.0,OTHER,collaborator,"University of Turin, Italy",Phase 2
NCT03359538,2017.0,OTHER,collaborator,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Phase 2
NCT03359538,2017.0,OTHER,collaborator,Azienda Ospedaliera Niguarda Cà Granda,Phase 2
NCT03359538,2017.0,OTHER,collaborator,Fondazione Salvatore Maugeri,Phase 2
NCT03359538,2017.0,OTHER,collaborator,University of Padova,Phase 2
NCT03359785,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03359785,2018.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT03361631,2018.0,OTHER,lead,"Central Hospital, Nancy, France",Phase 1
NCT03362502,2018.0,INDUSTRY,lead,Pfizer,Phase 1
NCT03363217,2018.0,OTHER,lead,St. Justine's Hospital,Phase 2
NCT03363217,2018.0,OTHER,collaborator,Montreal Children's Hospital of the MUHC,Phase 2
NCT03363217,2018.0,OTHER,collaborator,CHU de Quebec-Universite Laval,Phase 2
NCT03363269,2016.0,INDUSTRY,lead,IlDong Pharmaceutical Co Ltd,Phase 2
NCT03363763,2017.0,INDUSTRY,lead,"Aucta Pharmaceuticals, Inc",Phase 2
NCT03364036,2018.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT03364660,2017.0,OTHER,lead,University of Louisville,Not Applicable
NCT03364660,2017.0,OTHER,collaborator,Christopher Reeve Paralysis Foundation,Not Applicable
NCT03365011,2016.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT03365362,2018.0,OTHER,lead,Albert Einstein College of Medicine,Phase 4
NCT03365362,2018.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT03365362,2018.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT03365362,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT03365414,2022.0,OTHER,lead,University of Alberta,Phase 3
NCT03367403,2017.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT03367429,2018.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT03367429,2018.0,INDUSTRY,collaborator,Allergan,Phase 4
NCT03367533,2018.0,OTHER,lead,Yale University,Phase 1
NCT03367650,2014.0,OTHER,lead,Centre Hospitalier Universitaire de Pointe-a-Pitre,Not Applicable
NCT03368170,2018.0,INDUSTRY,lead,Integrative Research Laboratories AB,Phase 2
NCT03368170,2018.0,INDUSTRY,collaborator,The Clinical Trial Company,Phase 2
NCT03368664,2017.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT03368742,2017.0,INDUSTRY,lead,Solid Biosciences Inc.,Phase 1/Phase 2
NCT03368794,2017.0,OTHER,lead,Anders C Håkansson,Not Applicable
NCT03368872,2015.0,INDUSTRY,lead,"Astavita, Inc.",Not Applicable
NCT03369015,2018.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT03369015,2018.0,OTHER,collaborator,Emory University,Phase 1
NCT03369093,2018.0,OTHER,lead,"International Centre for Diarrhoeal Disease Research, Bangladesh",Not Applicable
NCT03369379,2017.0,OTHER,lead,Universidad Autonoma de Nuevo Leon,Phase 4
NCT03369431,2018.0,OTHER,lead,"University College, London",Not Applicable
NCT03369665,2018.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 4
NCT03369795,2017.0,OTHER_GOV,lead,Sheba Medical Center,Phase 2
NCT03370510,2018.0,OTHER,lead,Yale University,Phase 2
NCT03370640,2017.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 1
NCT03371329,2017.0,OTHER,lead,Mayo Clinic,Phase 1
NCT03371420,2016.0,INDUSTRY,lead,"Samus Therapeutics, Inc.",Early Phase 1
NCT03371420,2016.0,OTHER,collaborator,Memorial Sloan Kettering Cancer Center,Early Phase 1
NCT03371420,2016.0,OTHER,collaborator,Weill Medical College of Cornell University,Early Phase 1
NCT03371420,2016.0,OTHER,collaborator,Rockefeller University,Early Phase 1
NCT03371589,2018.0,OTHER_GOV,lead,Hillel Yaffe Medical Center,Not Applicable
NCT03371836,2017.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 4
NCT03371888,2017.0,OTHER,lead,Medical University of Silesia,Phase 2/Phase 3
NCT03372499,2017.0,OTHER,lead,Li Yang,Not Applicable
NCT03372499,2017.0,OTHER,collaborator,West China Hospital,Not Applicable
NCT03372876,2017.0,OTHER,lead,Federal University of Uberlandia,Not Applicable
NCT03373604,2017.0,OTHER,lead,"James M Noble, MD, MS, CPH, FAAN",Phase 2
NCT03373604,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03373968,2017.0,INDUSTRY,lead,Italfarmaco,Phase 2/Phase 3
NCT03373968,2017.0,INDUSTRY,collaborator,Cromsource,Phase 2/Phase 3
NCT03374514,2017.0,OTHER,lead,Hospital Italiano de Buenos Aires,Phase 3
NCT03374709,2018.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT03375034,2017.0,OTHER,lead,Jules Desmeules,Phase 1
NCT03375164,2018.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT03375255,2018.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT03375294,2018.0,OTHER,lead,Stanford University,Phase 2
NCT03375541,2018.0,OTHER,lead,Duke University,Not Applicable
NCT03375697,2017.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT03376139,2019.0,OTHER,lead,Pharmacotherapies for Alcohol and Substance Use Disorders Alliance,Phase 2
NCT03376139,2019.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 2
NCT03376139,2019.0,FED,collaborator,Michael E. DeBakey VA Medical Center,Phase 2
NCT03376139,2019.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT03376269,2014.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Not Applicable
NCT03376763,2017.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT03377257,2018.0,OTHER,lead,Xijing Hospital,Phase 4
NCT03377309,2019.0,OTHER,lead,American University of Beirut Medical Center,Phase 2
NCT03377322,2017.0,OTHER,lead,University of Malaya,Not Applicable
NCT03378414,2023.0,INDUSTRY,lead,"Sclnow Biotechnology Co., Ltd.",Phase 2
NCT03378531,2017.0,INDUSTRY,lead,Aeglea Biotherapeutics,Phase 2
NCT03379597,2017.0,OTHER,lead,Central South University,Not Applicable
NCT03380091,2017.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT03380949,2017.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT03381170,2017.0,INDUSTRY,lead,"TG Therapeutics, Inc.",Phase 2
NCT03381261,2017.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03381261,2017.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 4
NCT03381521,2018.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT03381729,2017.0,INDUSTRY,lead,Novartis Gene Therapies,Phase 1
NCT03382639,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03382639,2018.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT03384329,2018.0,OTHER,lead,Russian Academy of Medical Sciences,Phase 4
NCT03384329,2018.0,OTHER,collaborator,Russian Science Foundation,Phase 4
NCT03384433,2019.0,OTHER,lead,Isfahan University of Medical Sciences,Phase 1/Phase 2
NCT03384433,2019.0,OTHER,collaborator,Tarbiat Modarres University,Phase 1/Phase 2
NCT03384784,2017.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT03384784,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT03385174,2017.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03385356,2017.0,OTHER,lead,University Medical Centre Maribor,Phase 4
NCT03385356,2017.0,UNKNOWN,collaborator,Medical Faculty Maribor,Phase 4
NCT03385499,2018.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT03385967,2019.0,OTHER,lead,University of Florida,Phase 4
NCT03386448,2018.0,INDUSTRY,lead,The Taub Group,Phase 4
NCT03386669,2017.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT03387046,2018.0,INDUSTRY,lead,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT03388164,2018.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Phase 2
NCT03388671,2017.0,OTHER,lead,Assiut University,Phase 2/Phase 3
NCT03389412,2017.0,OTHER,lead,University of Aarhus,Phase 4
NCT03389412,2017.0,OTHER,collaborator,University Ghent,Phase 4
NCT03389412,2017.0,UNKNOWN,collaborator,"First Affiliated Hospital of Zhengzhou University, China",Phase 4
NCT03389412,2017.0,UNKNOWN,collaborator,"University Clinical Centre in Gdansk, Poland",Phase 4
NCT03389789,2016.0,OTHER,lead,IRCCS Burlo Garofolo,Not Applicable
NCT03390933,2018.0,OTHER,lead,MetroHealth Medical Center,Phase 4
NCT03392376,2018.0,OTHER,lead,Zealand University Hospital,Phase 4
NCT03392376,2018.0,OTHER,collaborator,Centre for Research in Intensive Care (CRIC),Phase 4
NCT03392376,2018.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4
NCT03392376,2018.0,OTHER,collaborator,Scandinavian Critical Care Trials Group,Phase 4
NCT03392376,2018.0,UNKNOWN,collaborator,The Danish Centre of Applied Social Science (VIVE),Phase 4
NCT03392987,2018.0,INDUSTRY,lead,Orchard Therapeutics,Phase 2
NCT03392987,2018.0,OTHER,collaborator,Ospedale San Raffaele,Phase 2
NCT03393026,2018.0,INDUSTRY,lead,"Standard Chem. & Pharm. Co., Ltd.",Phase 4
NCT03393689,2018.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2
NCT03395314,2018.0,OTHER,lead,Yale University,Phase 2
NCT03395314,2018.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 2
NCT03395314,2018.0,OTHER,collaborator,American Foundation for Suicide Prevention,Phase 2
NCT03395353,2018.0,INDUSTRY,lead,Shionogi,Phase 3
NCT03395353,2018.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 3
NCT03395392,2022.0,INDUSTRY,lead,"NeuroRx, Inc.",Phase 2/Phase 3
NCT03395392,2022.0,UNKNOWN,collaborator,"Prevail Infoworks, Inc",Phase 2/Phase 3
NCT03396068,2019.0,INDUSTRY,lead,"NeuroRx, Inc.",Phase 3
NCT03396068,2019.0,INDUSTRY,collaborator,Target Health Inc.,Phase 3
NCT03396588,2017.0,OTHER,lead,Henrietta Bada,Phase 3
NCT03396588,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT03396601,2019.0,INDUSTRY,lead,"NeuroRx, Inc.",Phase 3
NCT03396601,2019.0,INDUSTRY,collaborator,Target Health Inc.,Phase 3
NCT03397446,2018.0,OTHER,lead,Aaron Keshen,Phase 2
NCT03397446,2018.0,OTHER,collaborator,Nova Scotia Health Authority,Phase 2
NCT03397576,2017.0,OTHER,lead,University of Illinois at Chicago,Not Applicable
NCT03397576,2017.0,OTHER,collaborator,Indonesia University,Not Applicable
NCT03398044,2017.0,OTHER,lead,University Hospital Ostrava,Not Applicable
NCT03399175,2015.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT03399175,2015.0,OTHER_GOV,collaborator,Fundação de Amparo à Pesquisa do Estado de São Paulo,Not Applicable
NCT03399318,2019.0,OTHER,lead,University of Rochester,Phase 2
NCT03399318,2019.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT03399435,2018.0,INDUSTRY,lead,Grünenthal GmbH,Phase 1
NCT03399877,2017.0,OTHER,lead,Yonsei University,Not Applicable
NCT03400189,2018.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 1
NCT03400189,2018.0,INDUSTRY,collaborator,Advicenne Pharma,Phase 1
NCT03400852,2018.0,INDUSTRY,lead,Mallinckrodt ARD LLC,Phase 2
NCT03400865,2018.0,OTHER,lead,Zhebao Wu,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,Xinqiao Hospital of Chongqing,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,First Hospital of China Medical University,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,Beijing Tiantan Hospital,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,First Affiliated Hospital of Wenzhou Medical University,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,First Affiliated Hospital of Fujian Medical University,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,Peking Union Medical College Hospital,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,Huashan Hospital,Not Applicable
NCT03400865,2018.0,OTHER,collaborator,Chinese PLA General Hospital,Not Applicable
NCT03401073,2018.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT03401073,2018.0,OTHER,collaborator,"Phoenix Neurological Associates, LTD",Phase 2
NCT03401346,2017.0,INDUSTRY,lead,Impel Pharmaceuticals,Phase 1
NCT03401515,2016.0,OTHER,lead,Ain Shams University,Phase 4
NCT03401788,2018.0,INDUSTRY,lead,"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Phase 2
NCT03401801,2017.0,OTHER,lead,Seoul National University,Not Applicable
NCT03402152,2018.0,INDUSTRY,lead,"NeuroRx, Inc.",Phase 2/Phase 3
NCT03402152,2018.0,INDUSTRY,collaborator,Target Health Inc.,Phase 2/Phase 3
NCT03402503,2018.0,INDUSTRY,lead,IntelGenx Corp.,Phase 2
NCT03402659,2017.0,INDUSTRY,lead,EIP Pharma Inc,Phase 2
NCT03402659,2017.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT03402659,2017.0,OTHER,collaborator,"Amsterdam UMC, location VUmc",Phase 2
NCT03402789,2024.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT03403205,2018.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT03403309,2018.0,OTHER,lead,Yonsei University,Phase 2
NCT03403842,2018.0,OTHER,lead,IRCCS San Raffaele,Not Applicable
NCT03405714,2018.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 2
NCT03405727,2018.0,OTHER,lead,Brugmann University Hospital,Not Applicable
NCT03406104,2018.0,INDUSTRY,lead,GenSight Biologics,Phase 3
NCT03406169,2017.0,FED,lead,Brooke Army Medical Center,Phase 3
NCT03406169,2017.0,FED,collaborator,Walter Reed National Military Medical Center,Phase 3
NCT03406611,2019.0,INDUSTRY,lead,"Travere Therapeutics, Inc.",Phase 1/Phase 2
NCT03406702,2018.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03406780,2018.0,INDUSTRY,lead,Capricor Inc.,Phase 2
NCT03407378,2018.0,OTHER,lead,Tools4Patient,Phase 1/Phase 2
NCT03408080,2017.0,OTHER,lead,"University of California, Los Angeles",Phase 3
NCT03408873,2018.0,OTHER,lead,Martha Sajatovic,Phase 4
NCT03408873,2018.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT03408886,2018.0,OTHER,lead,Arizona State University,Phase 2
NCT03410446,2018.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT03412513,2017.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT03414112,2018.0,OTHER,lead,University of Minnesota,Early Phase 1
NCT03414112,2018.0,UNKNOWN,collaborator,Klarman Foundation,Early Phase 1
NCT03415061,2021.0,OTHER,lead,"Hiroaki Sato, MD., PhD.",Not Applicable
NCT03415360,2018.0,OTHER,lead,Military Institute od Medicine National Research Institute,Not Applicable
NCT03416348,2018.0,OTHER,lead,University of Utah,Phase 1
NCT03416348,2018.0,FED,collaborator,US Department of Veterans Affairs,Phase 1
NCT03416348,2018.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 1
NCT03417492,2018.0,OTHER,lead,University of Pennsylvania,Phase 1
NCT03417492,2018.0,OTHER,collaborator,Boston University,Phase 1
NCT03417531,2018.0,OTHER,lead,University of Zurich,Not Applicable
NCT03417531,2018.0,OTHER,collaborator,Swiss National Science Foundation,Not Applicable
NCT03417531,2018.0,OTHER,collaborator,"University Hospital, Zürich",Not Applicable
NCT03417531,2018.0,UNKNOWN,collaborator,"University Geriatric Medicine Felix Platter, Basel, Switzerland",Not Applicable
NCT03417531,2018.0,UNKNOWN,collaborator,"Omanda AG, Baar, Switzerland",Not Applicable
NCT03417531,2018.0,OTHER,collaborator,Ferrari Data Solution,Not Applicable
NCT03417531,2018.0,UNKNOWN,collaborator,"City Hospital Waid and Triemli, Zurich, Switzerland",Not Applicable
NCT03417531,2018.0,UNKNOWN,collaborator,"Cantonal Hospital St. Gallen, Switzerland",Not Applicable
NCT03417531,2018.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Not Applicable
NCT03417986,2017.0,INDUSTRY,lead,Immungenetics AG,Phase 2
NCT03418376,2017.0,OTHER,lead,Hasselt University,Not Applicable
NCT03418675,2018.0,OTHER,lead,University of Chicago,Phase 2
NCT03418675,2018.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 2
NCT03418688,2018.0,INDUSTRY,lead,Cortexyme Inc.,Phase 1
NCT03418831,2018.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03419000,2018.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT03419039,2018.0,OTHER_GOV,lead,Helse Stavanger HF,Not Applicable
NCT03419325,2020.0,OTHER,lead,University of Puerto Rico,Early Phase 1
NCT03419325,2020.0,NIH,collaborator,National Institute on Minority Health and Health Disparities (NIMHD),Early Phase 1
NCT03419325,2020.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Early Phase 1
NCT03419715,2018.0,INDUSTRY,lead,Manistee Partners,Phase 2
NCT03419767,2017.0,OTHER,lead,Peking Union Medical College Hospital,Phase 4
NCT03419806,2018.0,OTHER_GOV,lead,Vastra Gotaland Region,Phase 1
NCT03419806,2018.0,OTHER_GOV,collaborator,The Swedish Research Council,Phase 1
NCT03419806,2018.0,UNKNOWN,collaborator,Dizlin Medical Design AB,Phase 1
NCT03419806,2018.0,OTHER,collaborator,Göteborg University,Phase 1
NCT03419819,2018.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT03419819,2018.0,OTHER,collaborator,Oregon Health and Science University,Not Applicable
NCT03420105,2018.0,OTHER,lead,Centre Francois Baclesse,Not Applicable
NCT03420105,2018.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT03420222,2018.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT03420339,2018.0,OTHER,lead,"Matthew J O'Brien, PhD, BCBA-D",Phase 4
NCT03420482,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03420482,2018.0,UNKNOWN,collaborator,Center for Microbiome Informatics and Therapeutics,Phase 2
NCT03420794,2018.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT03421496,2018.0,INDUSTRY,lead,"Radius Pharmaceuticals, Inc.",Phase 3
NCT03422796,2017.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03422900,2017.0,OTHER,lead,"Endocrinology and Clinical Nutrition Research Center, Spain",Not Applicable
NCT03423667,2019.0,OTHER,lead,Salvatore Campanella,Phase 2
NCT03423680,2018.0,INDUSTRY,lead,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT03424460,2018.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT03424460,2018.0,UNKNOWN,collaborator,AFM-Téléthon (Funding),Not Applicable
NCT03424460,2018.0,OTHER,collaborator,Recherche Clinique Paris Descartes Necker Cochin Sainte Anne,Not Applicable
NCT03424733,2017.0,OTHER,lead,"Holy Name Medical Center, Inc.",Phase 4
NCT03424733,2017.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT03425539,2018.0,INDUSTRY,lead,Idorsia Pharmaceuticals Ltd.,Phase 3
NCT03425552,2018.0,INDUSTRY,lead,Pharmathen S.A.,Phase 1/Phase 2
NCT03426085,2016.0,OTHER,lead,Eastern Virginia Medical School,Phase 2
NCT03426891,2018.0,OTHER,lead,H. Lee Moffitt Cancer Center and Research Institute,Phase 1
NCT03426891,2018.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT03426982,2018.0,OTHER,lead,Wuhan Asia Heart Hospital,Phase 4
NCT03427086,2018.0,OTHER,lead,American University of Beirut Medical Center,Phase 2
NCT03427892,2017.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT03427892,2017.0,INDUSTRY,collaborator,Otsuka America Pharmaceutical,Phase 4
NCT03427983,2018.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT03428360,2018.0,INDUSTRY,lead,Aquestive Therapeutics,Phase 3
NCT03428360,2018.0,OTHER,collaborator,Syneos Health,Phase 3
NCT03428360,2018.0,INDUSTRY,collaborator,Covance,Phase 3
NCT03428633,2018.0,OTHER_GOV,lead,Asklepieion Voulas General Hospital,Phase 2
NCT03428633,2018.0,UNKNOWN,collaborator,Michail Tsagkaris,Phase 2
NCT03428633,2018.0,UNKNOWN,collaborator,Chryssoula Staikou,Phase 2
NCT03428633,2018.0,UNKNOWN,collaborator,Ioannis Karavokyros,Phase 2
NCT03429491,2017.0,OTHER,lead,University College Dublin,Not Applicable
NCT03430180,2018.0,OTHER_GOV,lead,Finnish Institute for Health and Welfare,Phase 2
NCT03430349,2017.0,OTHER,lead,Pierre Van Damme,Phase 1
NCT03430349,2017.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 1
NCT03430349,2017.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 1
NCT03430349,2017.0,OTHER,collaborator,PATH,Phase 1
NCT03430349,2017.0,INDUSTRY,collaborator,Celerion,Phase 1
NCT03430388,2018.0,OTHER,lead,University of Sao Paulo General Hospital,Not Applicable
NCT03430531,2019.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 2
NCT03431402,2018.0,OTHER,lead,Kasr El Aini Hospital,Not Applicable
NCT03431675,2019.0,OTHER,lead,Epicentre,Phase 4
NCT03431675,2019.0,OTHER,collaborator,"Medecins Sans Frontieres, Netherlands",Phase 4
NCT03432065,2023.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03432195,2018.0,INDUSTRY,lead,"Corium, Inc.",Phase 1
NCT03432858,2018.0,OTHER,lead,WellSpan Health,Phase 4
NCT03432871,2017.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Not Applicable
NCT03432871,2017.0,OTHER,collaborator,University of Cambridge,Not Applicable
NCT03432871,2017.0,UNKNOWN,collaborator,Medical Research Council Mitochondrial Biology Unit,Not Applicable
NCT03433183,2019.0,OTHER,lead,Sarcoma Alliance for Research through Collaboration,Phase 2
NCT03433183,2019.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03433183,2019.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT03433482,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT03433651,2019.0,FED,lead,Mike O'Callaghan Military Hospital,Phase 4
NCT03433859,2016.0,OTHER,lead,Direction Centrale du Service de Santé des Armées,Phase 3
NCT03434210,2018.0,OTHER,lead,"Yi Li MD, PhD",Not Applicable
NCT03434262,2018.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 1
NCT03434262,2018.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 1
NCT03434366,2018.0,OTHER,lead,Guangzhou Women and Children's Medical Center,Phase 2
NCT03435185,2014.0,OTHER_GOV,lead,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Not Applicable
NCT03435861,2018.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT03435861,2018.0,OTHER,collaborator,Fondation Plan Alzheimer,Phase 2
NCT03436121,2019.0,OTHER,lead,Maria Pacella,Phase 2/Phase 3
NCT03436121,2019.0,OTHER,collaborator,University of Pittsburgh Physicians,Phase 2/Phase 3
NCT03436173,2012.0,OTHER,lead,University of Oxford,Not Applicable
NCT03436199,2018.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT03436433,2019.0,OTHER,lead,Duke University,Phase 2
NCT03436472,2017.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT03436472,2017.0,OTHER,collaborator,Peking University Third Hospital,Not Applicable
NCT03436953,2019.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03437668,2018.0,OTHER,lead,"Chengappa, K.N. Roy, MD",Phase 2/Phase 3
NCT03437668,2018.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2/Phase 3
NCT03437668,2018.0,UNKNOWN,collaborator,Maryland Psychiatric Research Center,Phase 2/Phase 3
NCT03438604,2018.0,INDUSTRY,lead,"Corium, Inc.",Phase 1
NCT03439670,2018.0,INDUSTRY,lead,"ReveraGen BioPharma, Inc.",Phase 2
NCT03439670,2018.0,OTHER,collaborator,European Union,Phase 2
NCT03439670,2018.0,NETWORK,collaborator,Cooperative International Neuromuscular Research Group,Phase 2
NCT03439670,2018.0,OTHER,collaborator,Newcastle University,Phase 2
NCT03439670,2018.0,OTHER,collaborator,University of Pittsburgh,Phase 2
NCT03439943,2018.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT03439943,2018.0,UNKNOWN,collaborator,Cure Parkinson,Phase 2
NCT03439943,2018.0,UNKNOWN,collaborator,Réseau NS-Park,Phase 2
NCT03439943,2018.0,OTHER,collaborator,EUCLID Clinical Trial Platform,Phase 2
NCT03439943,2018.0,INDUSTRY,collaborator,Sanofi,Phase 2
NCT03439982,2016.0,OTHER,lead,University of Alberta,Phase 1/Phase 2
NCT03439982,2016.0,INDUSTRY,collaborator,Rebiotix Inc.,Phase 1/Phase 2
NCT03440034,2018.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT03440112,2018.0,OTHER,lead,"Nicolaas Bohnen, MD, PhD",Phase 1/Phase 2
NCT03440112,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT03440814,2018.0,INDUSTRY,lead,"Soleno Therapeutics, Inc.",Phase 3
NCT03441399,2018.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT03441399,2018.0,OTHER,collaborator,Columbia University,Not Applicable
NCT03441516,2018.0,INDUSTRY,lead,Yuhan Corporation,Phase 4
NCT03442166,2018.0,OTHER,lead,University of Nove de Julho,Phase 2
NCT03443596,2014.0,OTHER,lead,National University of Singapore,Phase 2/Phase 3
NCT03443973,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03444038,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03444519,2018.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT03444870,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03445416,2018.0,OTHER,lead,Ann & Robert H Lurie Children's Hospital of Chicago,Not Applicable
NCT03445416,2018.0,OTHER,collaborator,Northwestern University,Not Applicable
NCT03445416,2018.0,OTHER,collaborator,Florida State University,Not Applicable
NCT03446001,2018.0,INDUSTRY,lead,TauRx Therapeutics Ltd,Phase 3
NCT03446807,2021.0,OTHER,lead,Loma Linda University,Phase 2
NCT03446807,2021.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT03446924,2015.0,OTHER,lead,University of Birmingham,Not Applicable
NCT03446924,2015.0,OTHER,collaborator,University of Nottingham,Not Applicable
NCT03447756,2017.0,INDUSTRY,lead,Abide Therapeutics,Phase 1
NCT03448159,2019.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT03448159,2019.0,OTHER,collaborator,University of British Columbia,Phase 2
NCT03448159,2019.0,OTHER,collaborator,Sunnybrook Health Sciences Centre,Phase 2
NCT03448159,2019.0,OTHER,collaborator,University of Calgary,Phase 2
NCT03448159,2019.0,OTHER,collaborator,Dalhousie University,Phase 2
NCT03448159,2019.0,OTHER,collaborator,"Parkwood Hospital, London, Ontario",Phase 2
NCT03448159,2019.0,OTHER,collaborator,Riverview Health Centre Foundation,Phase 2
NCT03448159,2019.0,OTHER,collaborator,Memorial University of Newfoundland,Phase 2
NCT03448159,2019.0,OTHER,collaborator,Applied Health Research Centre,Phase 2
NCT03448159,2019.0,OTHER,collaborator,Brain Canada,Phase 2
NCT03448159,2019.0,UNKNOWN,collaborator,Heart and Stroke Foundation Canadian Partnership for Stroke Recovery,Phase 2
NCT03448575,2018.0,OTHER,lead,Kaiser Permanente,Not Applicable
NCT03448575,2018.0,OTHER,collaborator,Nationwide Children's Hospital,Not Applicable
NCT03448575,2018.0,OTHER,collaborator,Seattle Children's Hospital,Not Applicable
NCT03448575,2018.0,OTHER,collaborator,University of Washington,Not Applicable
NCT03449771,2018.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT03449940,2015.0,OTHER,lead,"Ministry of Health, Jamaica",Not Applicable
NCT03449940,2015.0,OTHER,collaborator,University Hospital of the West Indies,Not Applicable
NCT03450161,2018.0,OTHER,lead,"University Hospital, Ghent",Phase 4
NCT03450161,2018.0,OTHER,collaborator,"University Hospital, Basel, Switzerland",Phase 4
NCT03451591,2018.0,OTHER,lead,University of Edinburgh,Phase 2/Phase 3
NCT03451591,2018.0,OTHER,collaborator,British Heart Foundation,Phase 2/Phase 3
NCT03451591,2018.0,OTHER,collaborator,University of Nottingham,Phase 2/Phase 3
NCT03452488,2018.0,INDUSTRY,lead,Biophytis,Phase 2
NCT03452943,2018.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2/Phase 3
NCT03452943,2018.0,INDUSTRY,collaborator,"Nuvelution TS Pharma, Inc.",Phase 2/Phase 3
NCT03453463,2018.0,OTHER,lead,University of Erlangen-Nürnberg Medical School,Not Applicable
NCT03453749,2018.0,OTHER,lead,Peter Siesjö,Phase 2
NCT03454217,2018.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT03454646,2024.0,OTHER,lead,"University Hospital, Bordeaux",Phase 4
NCT03454893,2018.0,INDUSTRY,lead,AVROBIO,Phase 1/Phase 2
NCT03455088,2018.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT03455088,2018.0,OTHER,collaborator,Peking University Sixth Hospital,Not Applicable
NCT03455088,2018.0,OTHER,collaborator,"Shanghai Tongji Hospital, Tongji University School of Medicine",Not Applicable
NCT03456349,2017.0,INDUSTRY,lead,Heptares Therapeutics Limited,Phase 1
NCT03456349,2017.0,INDUSTRY,collaborator,Allergan,Phase 1
NCT03456388,2017.0,INDUSTRY,lead,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1
NCT03456687,2018.0,OTHER,lead,University of Florida,Phase 1
NCT03456687,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT03456882,2017.0,OTHER,lead,Mario Negri Institute for Pharmacological Research,Phase 2
NCT03456882,2017.0,OTHER,collaborator,ALS Association,Phase 2
NCT03456882,2017.0,UNKNOWN,collaborator,Get out ONLUS,Phase 2
NCT03457025,2019.0,OTHER,lead,NYU Langone Health,Early Phase 1
NCT03457129,2018.0,OTHER,lead,University of Arizona,Phase 4
NCT03457129,2018.0,INDUSTRY,collaborator,Eisai Inc.,Phase 4
NCT03457389,2018.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT03457493,2018.0,OTHER,lead,University of Alabama at Birmingham,Phase 1/Phase 2
NCT03457740,2018.0,OTHER,lead,Appalachian State University,Not Applicable
NCT03457740,2018.0,UNKNOWN,collaborator,Purity Products,Not Applicable
NCT03458416,2018.0,INDUSTRY,lead,"Radius Pharmaceuticals, Inc.",Phase 2
NCT03458416,2018.0,INDUSTRY,collaborator,Benuvia Therapeutics Inc.,Phase 2
NCT03459833,2016.0,OTHER,lead,Cairo University,Phase 3
NCT03460756,2017.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT03461276,2017.0,INDUSTRY,lead,Araclon Biotech S.L.,Phase 2
NCT03462641,2018.0,OTHER,lead,University of Michigan,Phase 1/Phase 2
NCT03462641,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT03462680,2016.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT03462771,2018.0,OTHER,lead,Eduardo Ferriolli,Not Applicable
NCT03463707,2018.0,INDUSTRY,lead,Ivix LLX,Phase 3
NCT03464383,2018.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT03464487,2018.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Not Applicable
NCT03465787,2018.0,INDUSTRY,lead,Bukwang Pharmaceutical,Phase 3
NCT03466346,2020.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT03466346,2020.0,OTHER,collaborator,University of Nairobi,Not Applicable
NCT03466346,2020.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT03466346,2020.0,OTHER,collaborator,Kenya Medical Research Institute,Not Applicable
NCT03466346,2020.0,OTHER,collaborator,"University of California, San Diego",Not Applicable
NCT03466346,2020.0,OTHER,collaborator,Makerere University,Not Applicable
NCT03466528,2016.0,OTHER,lead,Glasgow Royal Infirmary,Phase 2/Phase 3
NCT03466671,2018.0,OTHER,lead,Hamamatsu University,Phase 2
NCT03466671,2018.0,OTHER_GOV,collaborator,Japan Agency for Medical Research and Development,Phase 2
NCT03467113,2018.0,INDUSTRY,lead,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",Phase 1
NCT03467477,2018.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 2
NCT03467750,2018.0,OTHER,lead,Emory University,Phase 4
NCT03468049,2018.0,OTHER,lead,"Bayero University Kano, Nigeria",Early Phase 1
NCT03468049,2018.0,OTHER,collaborator,Physiotherapy Associates,Early Phase 1
NCT03468439,2014.0,OTHER,lead,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital,Not Applicable
NCT03469089,2018.0,OTHER,lead,University of Eastern Finland,Phase 1
NCT03469999,2018.0,OTHER,lead,Columbia University,Phase 3
NCT03470038,2018.0,OTHER,lead,Aalborg University,Early Phase 1
NCT03471143,2019.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT03471143,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT03471169,2017.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 1
NCT03471169,2017.0,OTHER,collaborator,Chinese PLA General Hospital,Phase 1
NCT03471169,2017.0,OTHER,collaborator,Peking University People's Hospital,Phase 1
NCT03471182,2018.0,OTHER,lead,Yale University,Phase 1
NCT03471182,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03471767,2018.0,OTHER,lead,James Davis,Phase 2
NCT03471767,2018.0,INDUSTRY,collaborator,"Axsome Therapeutics, Inc.",Phase 2
NCT03471871,2018.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT03471871,2018.0,INDUSTRY,collaborator,Purdue Pharma LP,Phase 1
NCT03472092,2018.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT03472092,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT03472092,2018.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT03472261,2018.0,OTHER,lead,Kocaeli University,Phase 3
NCT03472378,2018.0,OTHER,lead,Hartford Hospital,Phase 2
NCT03472378,2018.0,UNKNOWN,collaborator,"Rami Burstein, PhD, Beth Israel Deaconess Medical Center",Phase 2
NCT03472378,2018.0,INDUSTRY,collaborator,Dr. Reddy's Laboratories Limited,Phase 2
NCT03473301,2018.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1/Phase 2
NCT03473301,2018.0,OTHER,collaborator,The Marcus Foundation,Phase 1/Phase 2
NCT03474263,2019.0,INDUSTRY,lead,Implicit Bioscience,Phase 2
NCT03475225,2018.0,OTHER,lead,Centre Hospitalier St Anne,Phase 3
NCT03475225,2018.0,OTHER,collaborator,APHP,Phase 3
NCT03475225,2018.0,UNKNOWN,collaborator,FFRE,Phase 3
NCT03475225,2018.0,UNKNOWN,collaborator,LFCE,Phase 3
NCT03475784,2018.0,OTHER,lead,Cairo University,Phase 3
NCT03477500,2018.0,OTHER,lead,Haukeland University Hospital,Phase 3
NCT03478527,2018.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT03478982,2018.0,INDUSTRY,lead,"Engage Therapeutics, Inc.",Phase 2
NCT03479476,2018.0,OTHER,lead,"University of California, Davis",Phase 2/Phase 3
NCT03479476,2018.0,OTHER,collaborator,University of Alberta,Phase 2/Phase 3
NCT03479476,2018.0,OTHER,collaborator,St. Justine's Hospital,Phase 2/Phase 3
NCT03480061,2018.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT03480191,2018.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 2
NCT03480555,2018.0,OTHER,lead,King Abdullah International Medical Research Center,Not Applicable
NCT03480880,2016.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Phase 4
NCT03481400,2016.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03482115,2018.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT03482297,2018.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1/Phase 2
NCT03482297,2018.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT03482479,2019.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT03485274,2018.0,OTHER,lead,The University of Hong Kong,Phase 2/Phase 3
NCT03485274,2018.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Phase 2/Phase 3
NCT03485287,2018.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT03487211,2018.0,OTHER,lead,Shaheed Zulfiqar Ali Bhutto Medical University,Phase 2/Phase 3
NCT03487237,2018.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT03487263,2017.0,INDUSTRY,lead,Implicit Bioscience,Phase 1
NCT03487263,2017.0,OTHER_GOV,collaborator,Royal Brisbane and Women's Hospital,Phase 1
NCT03487783,2018.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 3
NCT03488524,2018.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 2
NCT03488524,2018.0,UNKNOWN,collaborator,Massachusetts General Hospital Neurology Clinical Research Institute,Phase 2
NCT03488563,2018.0,INDUSTRY,lead,AOBiome LLC,Phase 2
NCT03488563,2018.0,OTHER,collaborator,"Veristat, Inc.",Phase 2
NCT03488888,2017.0,OTHER,lead,Federal University of São Paulo,Not Applicable
NCT03489044,2018.0,OTHER,lead,University of Oxford,Phase 2
NCT03489044,2018.0,OTHER,collaborator,Oxford University Hospitals NHS Trust,Phase 2
NCT03489044,2018.0,OTHER_GOV,collaborator,Oxford Health NHS Foundation Trust,Phase 2
NCT03489044,2018.0,OTHER,collaborator,"Northumberland, Tyne and Wear NHS Foundation Trust",Phase 2
NCT03489044,2018.0,INDUSTRY,collaborator,UCB Pharma,Phase 2
NCT03489200,2017.0,INDUSTRY,lead,Elysium Health,Not Applicable
NCT03489200,2017.0,OTHER,collaborator,Fundación Universidad Católica de Valencia San Vicente Mártir,Not Applicable
NCT03489200,2017.0,OTHER,collaborator,University of Valencia,Not Applicable
NCT03489551,2011.0,OTHER,lead,Michelle Weckmann,Phase 4
NCT03489551,2011.0,OTHER,collaborator,"American Cancer Society, Inc.",Phase 4
NCT03490019,2018.0,OTHER,lead,University Hospital Tuebingen,Phase 2
NCT03490786,2017.0,INDUSTRY,lead,"Gila Therapeutics, Inc.",Phase 1
NCT03491007,2019.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03491150,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03491462,2018.0,INDUSTRY,lead,ZevraDenmark,Phase 3
NCT03491696,2018.0,OTHER,lead,Centre Hospitalier Rouffach,Phase 4
NCT03491696,2018.0,OTHER,collaborator,"University Hospital, Strasbourg, France",Phase 4
NCT03492736,2018.0,OTHER,lead,Naomi Deacon,Early Phase 1
NCT03492970,2018.0,OTHER,lead,Hôpital le Vinatier,Not Applicable
NCT03492970,2018.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT03493282,2018.0,INDUSTRY,lead,Cognition Therapeutics,Phase 1/Phase 2
NCT03493282,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1/Phase 2
NCT03493321,2019.0,OTHER,lead,Cairo University,Not Applicable
NCT03493607,2018.0,OTHER,lead,Alexander Kolevzon,Phase 2
NCT03493841,2018.0,OTHER,lead,Rebecca Spain,Phase 1
NCT03493919,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT03494725,2018.0,NETWORK,lead,Daacro,Not Applicable
NCT03494725,2018.0,INDUSTRY,collaborator,DuPont Nutrition and Health,Not Applicable
NCT03495024,2019.0,FED,lead,Corporal Michael J. Crescenz VA Medical Center,Phase 4
NCT03495206,2018.0,INDUSTRY,lead,"Yantai YenePharma Co., Ltd.",Phase 1
NCT03495375,2019.0,OTHER,lead,Hospital Vall d'Hebron,Not Applicable
NCT03495375,2019.0,OTHER,collaborator,Goethe University,Not Applicable
NCT03495375,2019.0,OTHER,collaborator,Semmelweis University,Not Applicable
NCT03495375,2019.0,OTHER,collaborator,University Medical Center Nijmegen,Not Applicable
NCT03496116,2018.0,OTHER,lead,Virginia Commonwealth University,Not Applicable
NCT03496389,2018.0,OTHER_GOV,lead,"Hospital Authority, Hong Kong",Phase 2/Phase 3
NCT03496545,2018.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT03496870,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT03496883,2021.0,OTHER,lead,"Joseph Broderick, MD",Phase 3
NCT03496883,2021.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 3
NCT03496883,2021.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT03497299,2018.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT03497299,2018.0,OTHER,collaborator,Yale University,Phase 2
NCT03497299,2018.0,OTHER,collaborator,Oregon State University,Phase 2
NCT03497442,2018.0,OTHER,lead,"University of California, San Francisco",Early Phase 1
NCT03498131,2018.0,OTHER,lead,Providence Health & Services,Early Phase 1
NCT03499119,2018.0,INDUSTRY,lead,Amgen,Phase 1
NCT03500029,2018.0,OTHER,lead,Health Science Center of Xi'an Jiaotong University,Phase 1
NCT03500094,2018.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT03500289,2018.0,OTHER,lead,Johns Hopkins University,Phase 1/Phase 2
NCT03500289,2018.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 1/Phase 2
NCT03501966,2019.0,OTHER,lead,Jaeb Center for Health Research,Phase 3
NCT03501966,2019.0,NIH,collaborator,National Eye Institute (NEI),Phase 3
NCT03501966,2019.0,OTHER,collaborator,University of Iowa,Phase 3
NCT03501966,2019.0,OTHER,collaborator,Icahn School of Medicine at Mount Sinai,Phase 3
NCT03502551,2019.0,OTHER,lead,"University of California, Davis",Phase 2
NCT03502941,2018.0,OTHER,lead,University of Arkansas,Not Applicable
NCT03502967,2018.0,OTHER,lead,University of Texas Southwestern Medical Center,Early Phase 1
NCT03503318,2018.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03503331,2018.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT03503513,2018.0,OTHER,lead,University of Michigan,Phase 2/Phase 3
NCT03503513,2018.0,FED,collaborator,Department of Health and Human Services,Phase 2/Phase 3
NCT03504475,2018.0,OTHER,lead,Beijing Tongren Hospital,Phase 1
NCT03504475,2018.0,UNKNOWN,collaborator,"Beijing Winsunny Pharmceutical Co.,Ltd.",Phase 1
NCT03504917,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03505021,2018.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 3
NCT03505034,2019.0,OTHER,lead,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 2
NCT03505034,2019.0,OTHER,collaborator,West China Hospital,Phase 2
NCT03505034,2019.0,OTHER,collaborator,Shanghai East Hospital,Phase 2
NCT03505099,2018.0,INDUSTRY,lead,Novartis Gene Therapies,Phase 3
NCT03505099,2018.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 3
NCT03506178,2017.0,OTHER,lead,Beijing Tongren Hospital,Not Applicable
NCT03506516,2016.0,OTHER,lead,Zealand University Hospital,Not Applicable
NCT03506841,2016.0,OTHER,lead,Mansoura University Children Hospital,Phase 1
NCT03507127,2018.0,OTHER,lead,Brown University,Phase 2
NCT03507374,2018.0,OTHER,lead,University of Utah,Early Phase 1
NCT03507374,2018.0,INDUSTRY,collaborator,Regeneron Pharmaceuticals,Early Phase 1
NCT03507569,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT03508440,2018.0,OTHER,lead,University of Missouri-Columbia,Phase 2/Phase 3
NCT03508453,2019.0,INDUSTRY,lead,Implicit Bioscience,Phase 2
NCT03508700,2018.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT03508882,2015.0,OTHER,lead,The University of Hong Kong,Phase 4
NCT03508882,2015.0,OTHER_GOV,collaborator,"Food and Health Bureau, Hong Kong",Phase 4
NCT03508947,2018.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1
NCT03510325,2018.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03510338,2018.0,INDUSTRY,lead,N4 Pharma UK Ltd.,Phase 1
NCT03510338,2018.0,INDUSTRY,collaborator,BDD Pharma Ltd,Phase 1
NCT03510546,2018.0,OTHER,lead,University of Aarhus,Phase 4
NCT03510546,2018.0,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT03510572,2018.0,OTHER,lead,Asan Medical Center,Early Phase 1
NCT03510572,2018.0,OTHER_GOV,collaborator,Korea Health Industry Development Institute,Early Phase 1
NCT03510741,2019.0,OTHER,lead,Pakistan Institute of Living and Learning,Phase 2
NCT03510975,2015.0,OTHER,lead,Ankara Training and Research Hospital,Phase 4
NCT03511677,2015.0,OTHER,lead,Federal University of São Paulo,Not Applicable
NCT03511677,2015.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Not Applicable
NCT03511846,2018.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT03511846,2018.0,OTHER,collaborator,"University of California, San Francisco",Phase 1
NCT03512418,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT03512418,2019.0,INDUSTRY,collaborator,Gilead Sciences,Phase 3
NCT03512418,2019.0,OTHER,collaborator,The Fenway Institute,Phase 3
NCT03512977,2017.0,OTHER,lead,Derince Training and Research Hospital,Not Applicable
NCT03513302,2019.0,OTHER,lead,Indiana University,Not Applicable
NCT03513328,2018.0,OTHER,lead,University of Florida,Phase 1/Phase 2
NCT03513328,2018.0,UNKNOWN,collaborator,Live Like Bella Pediatric Cancer Research,Phase 1/Phase 2
NCT03513757,2018.0,OTHER,lead,Medical College of Wisconsin,Phase 4
NCT03513822,2018.0,OTHER,lead,Redar,Phase 3
NCT03513822,2018.0,OTHER,collaborator,Hôpital Raymond Poincaré,Phase 3
NCT03513822,2018.0,OTHER,collaborator,Hopital Lariboisière,Phase 3
NCT03513822,2018.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 3
NCT03513822,2018.0,OTHER,collaborator,Fondation Apicil,Phase 3
NCT03513822,2018.0,OTHER,collaborator,Hospital Ambroise Paré Paris,Phase 3
NCT03513822,2018.0,OTHER,collaborator,Recherche Clinique Paris Descartes Necker Cochin Sainte Anne,Phase 3
NCT03514784,2016.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT03514784,2016.0,UNKNOWN,collaborator,Texas Higher Education Coordinating Board,Phase 1/Phase 2
NCT03514784,2016.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1/Phase 2
NCT03514875,2019.0,OTHER,lead,University of Nebraska,Not Applicable
NCT03515213,2017.0,OTHER,lead,"University of California, Irvine",Phase 2
NCT03515733,2018.0,OTHER,lead,University of Oxford,Phase 1
NCT03516487,2018.0,INDUSTRY,lead,Synlogic,Phase 1/Phase 2
NCT03516526,2016.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT03516526,2016.0,INDUSTRY,collaborator,Prothya Biosolutions,Phase 4
NCT03516526,2016.0,OTHER,collaborator,Erasmus Medical Center,Phase 4
NCT03516526,2016.0,OTHER,collaborator,St. Antonius Hospital,Phase 4
NCT03516526,2016.0,NETWORK,collaborator,OLVG,Phase 4
NCT03516526,2016.0,OTHER,collaborator,Rijnstate Hospital,Phase 4
NCT03516604,2018.0,OTHER,lead,University of Oxford,Phase 1
NCT03516604,2018.0,OTHER_GOV,collaborator,Medical Research Council,Phase 1
NCT03516604,2018.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT03518021,2018.0,OTHER,lead,Norwegian University of Science and Technology,Phase 3
NCT03518021,2018.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT03518021,2018.0,OTHER,collaborator,Oslo University Hospital,Phase 3
NCT03518801,2019.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03518801,2019.0,OTHER,collaborator,"University of California, San Diego",Phase 2
NCT03520517,2018.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 1
NCT03520517,2018.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 1
NCT03520998,2018.0,INDUSTRY,lead,"Alkahest, Inc.",Phase 2
NCT03521323,2019.0,OTHER,lead,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 2
NCT03521323,2019.0,OTHER,collaborator,West China Hospital,Phase 2
NCT03521323,2019.0,OTHER,collaborator,Shanghai East Hospital,Phase 2
NCT03521336,2019.0,OTHER,lead,"Third Affiliated Hospital, Sun Yat-Sen University",Phase 2
NCT03521336,2019.0,OTHER,collaborator,West China Hospital,Phase 2
NCT03521336,2019.0,OTHER,collaborator,Shanghai East Hospital,Phase 2
NCT03521635,2018.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 4
NCT03522129,2018.0,INDUSTRY,lead,Cognition Therapeutics,Phase 1
NCT03522207,2018.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 4
NCT03522844,2018.0,OTHER,lead,Georgetown University,Phase 4
NCT03522844,2018.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT03522987,2018.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT03526354,2018.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 4
NCT03526354,2018.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT03526354,2018.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 4
NCT03526354,2018.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT03526354,2018.0,OTHER,collaborator,Augusta University,Phase 4
NCT03526822,2018.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT03526978,2017.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT03527186,2018.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 1
NCT03529344,2016.0,OTHER,lead,University of Bergen,Not Applicable
NCT03530033,2018.0,OTHER,lead,"Bo Wang,MD",Not Applicable
NCT03530202,2018.0,OTHER,lead,University of Regina,Phase 2
NCT03530293,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03530774,2017.0,OTHER,lead,The University of Texas at San Antonio,Not Applicable
NCT03530774,2017.0,OTHER,collaborator,Texas State University,Not Applicable
NCT03530774,2017.0,OTHER,collaborator,American Egg Board,Not Applicable
NCT03530800,2018.0,OTHER,lead,University of Chicago,Phase 2/Phase 3
NCT03531060,2016.0,INDUSTRY,lead,Integrative Research Laboratories AB,Phase 1/Phase 2
NCT03531242,2021.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT03531684,2018.0,INDUSTRY,lead,"Neurocentria, Inc.",Phase 2
NCT03531684,2018.0,OTHER,collaborator,Ohio State University,Phase 2
NCT03531710,2018.0,INDUSTRY,lead,United Neuroscience Ltd.,Phase 2
NCT03532542,2018.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT03533114,2018.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT03533257,2018.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 2
NCT03533257,2018.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT03533257,2018.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT03533673,2018.0,INDUSTRY,lead,"Asklepios Biopharmaceutical, Inc.",Phase 1/Phase 2
NCT03535298,2019.0,OTHER,lead,The Cleveland Clinic,Phase 4
NCT03535298,2019.0,OTHER,collaborator,University of Nottingham,Phase 4
NCT03536559,2018.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT03536559,2018.0,UNKNOWN,collaborator,Clene Australia Pty Ltd,Phase 2
NCT03536845,2018.0,OTHER,lead,King Saud University,Phase 3
NCT03536845,2018.0,UNKNOWN,collaborator,Dallah hospital,Phase 3
NCT03536871,2018.0,OTHER,lead,McMaster University,Not Applicable
NCT03537014,2018.0,INDUSTRY,lead,Lykos Therapeutics,Phase 3
NCT03537495,2021.0,OTHER,lead,Universitas Padjadjaran,Phase 2
NCT03537495,2021.0,OTHER,collaborator,Radboud University Medical Center,Phase 2
NCT03537495,2021.0,OTHER,collaborator,Global Alliance for TB Drug Development,Phase 2
NCT03537547,2018.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT03537547,2018.0,INDUSTRY,collaborator,"AssureRx Health, Inc.",Phase 4
NCT03537950,2016.0,OTHER,lead,King's College London,Not Applicable
NCT03538054,2018.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT03538431,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03538431,2018.0,OTHER,collaborator,Massachusetts Institute of Technology,Phase 4
NCT03538522,2018.0,INDUSTRY,lead,"NeuroActiva, Inc.",Phase 2
NCT03539575,2018.0,OTHER,lead,Yale University,Not Applicable
NCT03539575,2018.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT03539575,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT03539614,2018.0,FED,lead,VA Office of Research and Development,Phase 3
NCT03539887,2018.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 3
NCT03539900,2018.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT03539900,2018.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT03539952,2018.0,INDUSTRY,lead,Orphalan,Phase 3
NCT03540095,2018.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT03540485,2019.0,OTHER,lead,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Phase 1/Phase 2
NCT03540602,2018.0,OTHER,lead,Jacksonville University,Phase 1
NCT03540602,2018.0,UNKNOWN,collaborator,"Specnova, inc",Phase 1
NCT03540745,2018.0,OTHER,lead,University of Arizona,Not Applicable
NCT03540745,2018.0,OTHER,collaborator,Carrier Clinic,Not Applicable
NCT03541031,2018.0,OTHER,lead,Eastern Maine Medical Center,Not Applicable
NCT03541044,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT03541356,2018.0,INDUSTRY,lead,Impel Pharmaceuticals,Phase 2
NCT03542357,2018.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03542656,2014.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT03542851,2018.0,INDUSTRY,lead,Balance Therapeutics,Phase 2
NCT03542864,2017.0,OTHER,lead,BiomediKcal,Not Applicable
NCT03542864,2017.0,OTHER,collaborator,University of Alicante,Not Applicable
NCT03542864,2017.0,OTHER,collaborator,Universidad Miguel Hernandez de Elche,Not Applicable
NCT03542903,2018.0,OTHER_GOV,lead,Centre Hospitalier du Rouvray,Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Rouen",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Bordeaux",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,Nantes University Hospital,Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Toulouse",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Caen",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,Centre Hospitalier Henri Laborit,Not Applicable
NCT03542903,2018.0,OTHER,collaborator,Centre Hospitalier St Anne,Not Applicable
NCT03542903,2018.0,UNKNOWN,collaborator,Centre Hospitalier de Cadillac,Not Applicable
NCT03542903,2018.0,OTHER,collaborator,Hôpital Louis Mourier,Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Montpellier",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"University Hospital, Clermont-Ferrand",Not Applicable
NCT03542903,2018.0,OTHER,collaborator,"Centre hospitalier de Ville-Evrard, France",Not Applicable
NCT03543137,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT03543254,2018.0,OTHER,lead,Norwegian University of Science and Technology,Phase 2
NCT03543254,2018.0,OTHER,collaborator,St. Olavs Hospital,Phase 2
NCT03543254,2018.0,OTHER,collaborator,Mayo Clinic,Phase 2
NCT03543826,2018.0,OTHER,lead,University of Washington,Phase 4
NCT03545789,2018.0,OTHER,lead,Invicro,Phase 1
NCT03545997,2019.0,OTHER,lead,"University Hospital, Grenoble",Phase 3
NCT03545997,2019.0,OTHER,collaborator,Act For Chronic Diseases,Phase 3
NCT03545997,2019.0,OTHER_GOV,collaborator,Direction Générale de l'Offre de Soins,Phase 3
NCT03546283,2018.0,OTHER,lead,"Rong Hu, MD",Phase 3
NCT03546634,2018.0,OTHER_GOV,lead,"Centers for Disease Control and Prevention, China",Phase 4
NCT03546634,2018.0,OTHER,collaborator,Shandong Province Centers for Disease Control and Prevention,Phase 4
NCT03546959,2018.0,OTHER,lead,Marmara University,Not Applicable
NCT03547219,2015.0,OTHER,lead,Seoul National University,Not Applicable
NCT03547219,2015.0,OTHER,collaborator,National Research Foundation of Korea,Not Applicable
NCT03548155,2014.0,OTHER,lead,Tianjin Anding Hospital,Not Applicable
NCT03548311,2017.0,OTHER,lead,University of Tokushima,Phase 3
NCT03548311,2017.0,INDUSTRY,collaborator,"Eisai Co., Ltd.",Phase 3
NCT03548415,2018.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 2
NCT03548480,2018.0,OTHER,lead,Fundació Sant Joan de Déu,Not Applicable
NCT03548584,2018.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03548584,2018.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03549325,2017.0,OTHER,lead,University Hospital Southampton NHS Foundation Trust,Not Applicable
NCT03549325,2017.0,OTHER,collaborator,University of Southampton,Not Applicable
NCT03549520,2020.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 3
NCT03549520,2020.0,INDUSTRY,collaborator,"Bracco Diagnostics, Inc",Phase 3
NCT03549819,2021.0,OTHER,lead,McMaster University,Phase 3
NCT03549819,2021.0,INDUSTRY,collaborator,Tilray,Phase 3
NCT03549936,2014.0,OTHER,lead,MetroHealth Medical Center,Not Applicable
NCT03549975,2016.0,OTHER_GOV,lead,"National Rehabilitation Center, Seoul, Korea",Phase 4
NCT03550183,2018.0,INDUSTRY,lead,"Hebei Newtherapy BIo-Pharma technology Co., Ltd.",Phase 1
NCT03550209,2018.0,OTHER,lead,Sarah Keim,Phase 2
NCT03550209,2018.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT03551275,2018.0,INDUSTRY,lead,Biocad,Phase 1
NCT03551769,2018.0,INDUSTRY,lead,Cerecin,Phase 1
NCT03552068,2019.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT03552237,2018.0,OTHER,lead,"TsaoTun Psychiatric Center, Department of Health, Taiwan",Not Applicable
NCT03553095,2018.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT03553875,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT03554031,2018.0,INDUSTRY,lead,"Changchun GeneScience Pharmaceutical Co., Ltd.",Phase 3
NCT03554031,2018.0,OTHER,collaborator,Children's Hospital of Fudan University,Phase 3
NCT03554031,2018.0,UNKNOWN,collaborator,Tongji medical college huazhong university of science & technology,Phase 3
NCT03554031,2018.0,OTHER,collaborator,Beijing Children's Hospital,Phase 3
NCT03554031,2018.0,OTHER,collaborator,Peking University First Hospital,Phase 3
NCT03554031,2018.0,OTHER,collaborator,Peking Union Medical College Hospital,Phase 3
NCT03554031,2018.0,OTHER,collaborator,The Children's Hospital of Zhejiang University School of Medicine,Phase 3
NCT03554265,2018.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 3
NCT03554798,2018.0,OTHER,lead,Fidec Corporation,Phase 2
NCT03554798,2018.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT03555292,2017.0,OTHER,lead,Oriental Neurosurgery Evidence-Based-Study Team,Phase 2
NCT03555916,2019.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT03555916,2019.0,OTHER,collaborator,Karolinska Institutet,Phase 3
NCT03555916,2019.0,OTHER,collaborator,University of Aarhus,Phase 3
NCT03556137,2018.0,OTHER,lead,Stanford University,Phase 1
NCT03556137,2018.0,INDUSTRY,collaborator,GE Healthcare,Phase 1
NCT03556371,2018.0,OTHER,lead,"University of Concepcion, Chile",Phase 2
NCT03556371,2018.0,OTHER_GOV,collaborator,Comisión Nacional de Investigación Científica y Tecnológica,Phase 2
NCT03557294,2018.0,OTHER,lead,Arizona State University,Phase 4
NCT03557294,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT03557294,2018.0,UNKNOWN,collaborator,Los Angeles Clinical Trials,Phase 4
NCT03557294,2018.0,OTHER,collaborator,"University of Nevada, Reno",Phase 4
NCT03557294,2018.0,INDUSTRY,collaborator,Pfizer,Phase 4
NCT03557333,2018.0,INDUSTRY,lead,Impel Pharmaceuticals,Phase 3
NCT03557684,2018.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT03557684,2018.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT03557931,2018.0,INDUSTRY,lead,"Astellas Pharma Global Development, Inc.",Phase 2
NCT03558269,2019.0,OTHER_GOV,lead,Sheba Medical Center,Phase 1/Phase 2
NCT03558516,2018.0,OTHER,lead,Mahidol University,Phase 3
NCT03558958,2018.0,INDUSTRY,lead,"Phrixus Pharmaceuticals, Inc.",Phase 2
NCT03558958,2018.0,OTHER,collaborator,Charley's Fund,Phase 2
NCT03559114,2018.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT03559114,2018.0,OTHER,collaborator,Sunnybrook Research Institute,Phase 3
NCT03559114,2018.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 3
NCT03559257,2018.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT03559426,2016.0,OTHER,lead,"University College, London",Phase 4
NCT03559985,2018.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT03560024,2018.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03560245,2018.0,INDUSTRY,lead,"Neurotrope Bioscience, Inc.",Phase 2
NCT03560245,2018.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT03560349,2018.0,OTHER,lead,University of Utah,Phase 2
NCT03560349,2018.0,OTHER,collaborator,"University of Colorado, Denver",Phase 2
NCT03560349,2018.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT03560349,2018.0,OTHER,collaborator,Duke University,Phase 2
NCT03560349,2018.0,OTHER,collaborator,Mayo Clinic,Phase 2
NCT03560349,2018.0,OTHER,collaborator,Harvard University,Phase 2
NCT03560375,2018.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 4
NCT03560739,2018.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT03560960,2020.0,OTHER,lead,Boston University,Early Phase 1
NCT03560960,2020.0,NIH,collaborator,National Institute on Aging (NIA),Early Phase 1
NCT03562351,2018.0,OTHER,lead,Boston Children's Hospital,Not Applicable
NCT03562494,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 1
NCT03562494,2018.0,INDUSTRY,collaborator,Voyager Therapeutics,Phase 1
NCT03563053,2018.0,INDUSTRY,lead,Erydel,Phase 3
NCT03564132,2018.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT03565068,2018.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT03566017,2018.0,INDUSTRY,lead,Chiesi Farmaceutici S.p.A.,Phase 3
NCT03566303,2018.0,OTHER,lead,Hospital Geral Roberto Santos,Phase 2/Phase 3
NCT03566394,2018.0,OTHER,lead,British Columbia Cancer Agency,Phase 2/Phase 3
NCT03566589,2018.0,OTHER,lead,Professor Lu Neurological Clinic,Not Applicable
NCT03567057,2018.0,INDUSTRY,lead,"Adamas Pharmaceuticals, Inc.",Phase 3
NCT03567291,2018.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03567291,2018.0,INDUSTRY,collaborator,"Nuvelution TS Pharma, Inc.",Phase 3
NCT03567447,2018.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT03567447,2018.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 2
NCT03567447,2018.0,OTHER,collaborator,Arizona State University,Phase 2
NCT03567681,2018.0,OTHER,lead,"Collaborative Care Initiative, LLC",Phase 4
NCT03567681,2018.0,UNKNOWN,collaborator,"Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital",Phase 4
NCT03568175,2018.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 2/Phase 3
NCT03568500,2018.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT03568890,2018.0,OTHER,lead,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,Phase 4
NCT03568968,2020.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT03569579,2018.0,INDUSTRY,lead,Chong Kun Dang Pharmaceutical,Phase 1
NCT03569631,2018.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 2
NCT03570450,2018.0,OTHER,lead,"University Hospital, Grenoble",Phase 1
NCT03570450,2018.0,OTHER,collaborator,Horizon 2020 - European Commission,Phase 1
NCT03570450,2018.0,OTHER,collaborator,University Grenoble Alps,Phase 1
NCT03570450,2018.0,OTHER,collaborator,"Servicio Madrileño de Salud, Madrid, Spain",Phase 1
NCT03570450,2018.0,OTHER,collaborator,"St. Anne's University Hospital Brno, Czech Republic",Phase 1
NCT03570450,2018.0,OTHER_GOV,collaborator,Andaluz Health Service,Phase 1
NCT03570450,2018.0,OTHER,collaborator,University of Glasgow,Phase 1
NCT03570450,2018.0,OTHER,collaborator,University of Eastern Finland,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Etablissement Français du Sang,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Tampere University,Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"Histocell SL, Spain",Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"Medfiles CRO, Finland",Phase 1
NCT03570450,2018.0,OTHER_GOV,collaborator,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1
NCT03570450,2018.0,OTHER,collaborator,Hospices Civils de Lyon,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Association Groupe ESSEC,Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"NOVADISCOVERY SAS, France",Phase 1
NCT03570450,2018.0,OTHER,collaborator,Finovatis,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Centre Hospitalier Universitaire de Besancon,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 1
NCT03570450,2018.0,OTHER,collaborator,"University Hospital, Toulouse",Phase 1
NCT03570450,2018.0,OTHER,collaborator,"University Hospital, Bordeaux",Phase 1
NCT03570450,2018.0,OTHER,collaborator,"University Hospital, Caen",Phase 1
NCT03570450,2018.0,OTHER,collaborator,Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"Servicio de Salud de Castilla La Mancha, Albacete, Spain",Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"Servizo Galego de Saude, Santiago de Compostela, Spain",Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"Pirkanmaa Hospital District, Tampere, Finland",Phase 1
NCT03570450,2018.0,OTHER,collaborator,Hospital Vall d'Hebron,Phase 1
NCT03570450,2018.0,OTHER,collaborator,Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta,Phase 1
NCT03570450,2018.0,UNKNOWN,collaborator,"CH Sainte-Anne, Paris, France",Phase 1
NCT03570489,2018.0,OTHER_GOV,lead,Vastra Gotaland Region,Not Applicable
NCT03571256,2018.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03571256,2018.0,INDUSTRY,collaborator,"Nuvelution TS Pharma, Inc.",Phase 3
NCT03571594,2018.0,INDUSTRY,lead,Ono Pharmaceutical Co. Ltd,Phase 1
NCT03572257,2019.0,OTHER,lead,Medical College of Wisconsin,Phase 2/Phase 3
NCT03572517,2017.0,OTHER,lead,AC Camargo Cancer Center,Not Applicable
NCT03572686,2018.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Not Applicable
NCT03572790,2018.0,OTHER,lead,University of Oxford,Not Applicable
NCT03573297,2018.0,INDUSTRY,lead,AbbVie,Phase 3
NCT03573349,2019.0,OTHER,lead,Mayo Clinic,Early Phase 1
NCT03573583,2019.0,OTHER,lead,University of Florida,Not Applicable
NCT03573583,2019.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT03573999,2018.0,OTHER,lead,Aristotle University Of Thessaloniki,Phase 4
NCT03574428,2018.0,INDUSTRY,lead,GeNeuro Australia PTY Ltd,Phase 1
NCT03575000,2023.0,FED,lead,VA Pittsburgh Healthcare System,Phase 4
NCT03575195,2019.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT03575195,2019.0,OTHER,collaborator,Nova Southeastern University,Phase 1/Phase 2
NCT03575195,2019.0,INDUSTRY,collaborator,Gateway Institute for Brain Research,Phase 1/Phase 2
NCT03575390,2018.0,OTHER,lead,Dalin Tzu Chi General Hospital,Not Applicable
NCT03575676,2018.0,INDUSTRY,lead,SOM Innovation Biotech SA,Phase 2
NCT03576001,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT03576001,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT03576001,2019.0,OTHER,collaborator,Spaulding Rehabilitation Hospital,Phase 2
NCT03576638,2018.0,INDUSTRY,lead,Intec Pharma Ltd.,Phase 2
NCT03576664,2018.0,OTHER,lead,Gitte Moos Knudsen,Early Phase 1
NCT03576664,2018.0,UNKNOWN,collaborator,"Center for translational Neuromedicine, University of Copenhagen, Denmark",Early Phase 1
NCT03576664,2018.0,OTHER,collaborator,Danish Center for Sleep Medicine,Early Phase 1
NCT03576820,2018.0,OTHER,lead,New York City Health and Hospitals Corporation,Phase 3
NCT03576911,2016.0,OTHER,lead,"University of Dublin, Trinity College",Not Applicable
NCT03576911,2016.0,OTHER,collaborator,Liverpool John Moores University,Not Applicable
NCT03576911,2016.0,OTHER_GOV,collaborator,Royal Liverpool University Hospital,Not Applicable
NCT03577262,2018.0,INDUSTRY,lead,"Alkermes, Inc.",Early Phase 1
NCT03577262,2018.0,INDUSTRY,collaborator,QPS Netherlands B.V.,Early Phase 1
NCT03577262,2018.0,OTHER,collaborator,University Medical Center Groningen,Early Phase 1
NCT03577262,2018.0,OTHER,collaborator,"Amsterdam UMC, location VUmc",Early Phase 1
NCT03578354,2019.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Phase 2
NCT03578783,2018.0,INDUSTRY,lead,Plethora Solutions Ltd,Phase 2
NCT03579693,2018.0,OTHER,lead,University of Washington,Phase 2
NCT03579693,2018.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT03580174,2019.0,OTHER,lead,Hacettepe University,Not Applicable
NCT03580525,2019.0,OTHER,lead,Yale University,Early Phase 1
NCT03580525,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03581305,2018.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 1
NCT03582085,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03582137,2018.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT03582137,2018.0,OTHER_GOV,collaborator,Colorado Department of Public Health and Environment,Phase 2
NCT03582267,2017.0,OTHER,lead,Texas Christian University,Not Applicable
NCT03582293,2018.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 3
NCT03582293,2018.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 3
NCT03582488,2018.0,OTHER,lead,Kejal Kantarci,Phase 4
NCT03582488,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT03582800,2020.0,OTHER,lead,"University Hospital, Limoges",Phase 2
NCT03583112,2018.0,OTHER,lead,Xidian University,Not Applicable
NCT03585257,2018.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Phase 2
NCT03585257,2018.0,OTHER,collaborator,McGuire Research Institute,Phase 2
NCT03585257,2018.0,INDUSTRY,collaborator,"Instituto Grifols, S.A.",Phase 2
NCT03585569,2018.0,OTHER,lead,Neurology Center of New England P.C.,Phase 3
NCT03585569,2018.0,INDUSTRY,collaborator,Ipsen,Phase 3
NCT03585868,2017.0,OTHER,lead,"National Polytechnic Institute, Mexico",Not Applicable
NCT03585907,2019.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT03586089,2021.0,OTHER,lead,Unity Health Toronto,Not Applicable
NCT03586557,2018.0,OTHER,lead,Chinese PLA General Hospital,Not Applicable
NCT03587207,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT03587220,2018.0,OTHER,lead,Aalborg University,Not Applicable
NCT03587350,2017.0,OTHER,lead,The Leeds Teaching Hospitals NHS Trust,Not Applicable
NCT03587376,2018.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Early Phase 1
NCT03587441,2018.0,OTHER,lead,Fayoum University Hospital,Phase 4
NCT03587649,2018.0,OTHER,lead,Invicro,Phase 1
NCT03588689,2018.0,OTHER,lead,University of Saskatchewan,Phase 4
NCT03589066,2018.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT03589105,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT03589898,2017.0,OTHER,lead,"University of Massachusetts, Worcester",Early Phase 1
NCT03589898,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT03589898,2017.0,OTHER,collaborator,Johns Hopkins University,Early Phase 1
NCT03589976,2018.0,OTHER,lead,NYU Langone Health,Phase 2
NCT03589976,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT03590197,2018.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT03590314,2017.0,OTHER,lead,Universita di Verona,Not Applicable
NCT03592121,2018.0,INDUSTRY,lead,"Applied Biology, Inc.",Early Phase 1
NCT03593213,2018.0,INDUSTRY,lead,AbbVie,Phase 3
NCT03593239,2018.0,INDUSTRY,lead,"Juul Labs, Inc.",Not Applicable
NCT03593473,2019.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT03593473,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT03594123,2018.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT03594123,2018.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 3
NCT03594487,2018.0,OTHER,lead,Jeffrey Gelfand,Phase 1
NCT03594552,2018.0,OTHER,lead,King's College London,Not Applicable
NCT03594656,2018.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 3
NCT03595774,2018.0,OTHER,lead,Indiana University,Phase 1
NCT03595826,2018.0,OTHER,lead,University of KwaZulu,Not Applicable
NCT03596047,2018.0,INDUSTRY,lead,Boston Medical Group,Not Applicable
NCT03596775,2018.0,OTHER,lead,Xuzhou Medical University,Early Phase 1
NCT03597529,2017.0,OTHER,lead,Amy Gelfand,Phase 2
NCT03597555,2018.0,OTHER,lead,"University Hospital, Montpellier",Phase 2/Phase 3
NCT03597919,2018.0,OTHER_GOV,lead,"Centers for Disease Control and Prevention, China",Phase 4
NCT03597919,2018.0,OTHER,collaborator,Shandong Province Centers for Disease Control and Prevention,Phase 4
NCT03597919,2018.0,OTHER,collaborator,World Health Organization,Phase 4
NCT03598140,2018.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 2
NCT03598413,2018.0,OTHER,lead,Royal Surrey County Hospital NHS Foundation Trust,Not Applicable
NCT03599245,2018.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03599609,2018.0,OTHER,lead,"University of Campinas, Brazil",Phase 1/Phase 2
NCT03599726,2018.0,OTHER,lead,Oregon Health and Science University,Early Phase 1
NCT03599726,2018.0,OTHER,collaborator,"Medical Research Foundation, Oregon",Early Phase 1
NCT03600454,2018.0,OTHER,lead,Ziekenhuis Oost-Limburg,Not Applicable
NCT03600727,2018.0,OTHER,lead,The First Affiliated Hospital of Anhui Medical University,Not Applicable
NCT03600766,2018.0,OTHER,lead,Mansoura University,Phase 2
NCT03600805,2018.0,INDUSTRY,lead,Sanofi,Phase 3
NCT03600805,2018.0,INDUSTRY,collaborator,Regeneron Pharmaceuticals,Phase 3
NCT03601169,2018.0,INDUSTRY,lead,"Neurocentria, Inc.",Phase 2
NCT03601494,2017.0,OTHER,lead,Assiut University,Not Applicable
NCT03602014,2018.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT03602014,2018.0,OTHER_GOV,collaborator,New York State Department of Health,Phase 4
NCT03603288,2018.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 3
NCT03603665,2018.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT03603678,2018.0,INDUSTRY,lead,Bayer,Phase 2
NCT03605147,2018.0,OTHER,lead,Shanghai Zhongshan Hospital,Not Applicable
NCT03605238,2018.0,OTHER,lead,Chinese PLA General Hospital,Phase 1
NCT03605342,2018.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03605667,2018.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 2
NCT03605667,2018.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT03606356,2015.0,OTHER,lead,Corfu Headache Clinic,Phase 4
NCT03606460,2018.0,INDUSTRY,lead,"Genentech, Inc.",Phase 3
NCT03606473,2018.0,OTHER,lead,Gale Richardson,Early Phase 1
NCT03606473,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03607331,2018.0,OTHER,lead,China Academy of Chinese Medical Sciences,Early Phase 1
NCT03607851,2018.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT03607851,2018.0,OTHER,collaborator,Dongsan Medical Center,Phase 4
NCT03607851,2018.0,OTHER,collaborator,Konkuk University,Phase 4
NCT03608137,2018.0,OTHER,lead,Hôpital le Vinatier,Not Applicable
NCT03608371,2018.0,INDUSTRY,lead,"BlackThorn Therapeutics, Inc.",Phase 2
NCT03608696,2018.0,OTHER,lead,Thomas Jefferson University,Phase 1/Phase 2
NCT03608696,2018.0,INDUSTRY,collaborator,Chiesi Farmaceutici S.p.A.,Phase 1/Phase 2
NCT03610139,2018.0,OTHER,lead,American University of Beirut Medical Center,Not Applicable
NCT03611439,2013.0,INDUSTRY,lead,Genescient Corporation,Not Applicable
NCT03611478,2018.0,OTHER,lead,Swinburne University of Technology,Phase 2
NCT03611478,2018.0,INDUSTRY,collaborator,DuPont Nutrition and Health,Phase 2
NCT03611569,2018.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT03612401,2018.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Early Phase 1
NCT03612960,2020.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT03612960,2020.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT03613129,2018.0,OTHER,lead,"LUCINDA BATEMAN, MD",Phase 1/Phase 2
NCT03613181,2023.0,INDUSTRY,lead,Angiochem Inc,Phase 3
NCT03613558,2014.0,OTHER,lead,Montefiore Medical Center,Phase 1/Phase 2
NCT03613571,2018.0,INDUSTRY,lead,TikoMed AB,Phase 2
NCT03614234,2018.0,INDUSTRY,lead,Chiesi Farmaceutici S.p.A.,Phase 3
NCT03614403,2017.0,OTHER,lead,Shahid Beheshti University,Not Applicable
NCT03614663,2018.0,INDUSTRY,lead,"Zynerba Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT03614702,2015.0,OTHER,lead,"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase 3
NCT03614702,2015.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 3
NCT03615508,2018.0,OTHER,lead,Denver Health and Hospital Authority,Phase 4
NCT03615508,2018.0,OTHER,collaborator,"University of Colorado, Denver",Phase 4
NCT03615651,2018.0,OTHER,lead,"Örebro University, Sweden",Not Applicable
NCT03615651,2018.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT03616067,2022.0,OTHER,lead,Hospices Civils de Lyon,Phase 3
NCT03616223,2018.0,INDUSTRY,lead,Frequency Therapeutics,Phase 1/Phase 2
NCT03616262,2016.0,FED,lead,VA Connecticut Healthcare System,Early Phase 1
NCT03616262,2016.0,INDUSTRY,collaborator,Allergan,Early Phase 1
NCT03616353,2018.0,OTHER,lead,Leslie Witton,Early Phase 1
NCT03616509,2017.0,OTHER,lead,Corporacion Parc Tauli,Phase 4
NCT03616509,2017.0,OTHER,collaborator,Parc de Salut Mar,Phase 4
NCT03617783,2019.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT03618589,2016.0,OTHER,lead,Seoul National University Hospital,Phase 1
NCT03620370,2018.0,OTHER,lead,Capital Medical University,Not Applicable
NCT03621046,2018.0,OTHER,lead,Aston University,Phase 2
NCT03621046,2018.0,OTHER,collaborator,University Hospital Birmingham NHS Foundation Trust,Phase 2
NCT03621280,2019.0,INDUSTRY,lead,Cortendo AB,Phase 3
NCT03621761,2018.0,OTHER,lead,University of Michigan,Phase 4
NCT03621761,2018.0,OTHER,collaborator,University of Washington,Phase 4
NCT03621761,2018.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT03621761,2018.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 4
NCT03623243,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT03623711,2018.0,OTHER,lead,Yuqi Cheng,Early Phase 1
NCT03623828,2018.0,OTHER,lead,University of Liege,Phase 2
NCT03623828,2018.0,OTHER,collaborator,Université Catholique de Louvain,Phase 2
NCT03624556,2018.0,OTHER,lead,Parc de Salut Mar,Not Applicable
NCT03624556,2018.0,OTHER,collaborator,"Hospital Infantil Universitario Niño Jesús, Madrid, Spain",Not Applicable
NCT03624556,2018.0,UNKNOWN,collaborator,"Instituto Hispalense de Pediatría, Sevilla, Spain",Not Applicable
NCT03624556,2018.0,OTHER,collaborator,Hospital Universitario Marqués de Valdecilla,Not Applicable
NCT03624556,2018.0,OTHER,collaborator,Institut Jerome Lejeune,Not Applicable
NCT03624595,2019.0,OTHER,lead,Dong-Xin Wang,Not Applicable
NCT03624595,2019.0,OTHER,collaborator,"Fu Wai Hospital, Beijing, China",Not Applicable
NCT03624920,2018.0,INDUSTRY,lead,Theranexus,Phase 2
NCT03625128,2018.0,OTHER,lead,Chang Gung Memorial Hospital,Early Phase 1
NCT03625401,2018.0,INDUSTRY,lead,Zhejiang Hisun Pharmaceutical Co. Ltd.,Phase 2
NCT03625401,2018.0,INDUSTRY,collaborator,"Medpace, Inc.",Phase 2
NCT03625453,2018.0,INDUSTRY,lead,Abide Therapeutics,Phase 2
NCT03625453,2018.0,INDUSTRY,collaborator,FGK Clinical Research GmbH,Phase 2
NCT03625453,2018.0,INDUSTRY,collaborator,"BASi (Bioanalytical Systems, Inc.)",Phase 2
NCT03625453,2018.0,INDUSTRY,collaborator,CogState Ltd.,Phase 2
NCT03625804,2014.0,OTHER,lead,The Hong Kong Polytechnic University,Not Applicable
NCT03625986,2022.0,OTHER,lead,Milton S. Hershey Medical Center,Not Applicable
NCT03625986,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT03626012,2018.0,INDUSTRY,lead,Biogen,Phase 1
NCT03626064,2014.0,OTHER,lead,Ottawa Hospital Research Institute,Not Applicable
NCT03626727,2020.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT03627195,2018.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT03627312,2011.0,OTHER_GOV,lead,Singapore Prison Service,Phase 2/Phase 3
NCT03627312,2011.0,OTHER,collaborator,University of Pennsylvania,Phase 2/Phase 3
NCT03627494,2018.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT03628040,2019.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT03628365,2018.0,OTHER,lead,Mette M Berger,Not Applicable
NCT03628365,2018.0,OTHER,collaborator,Texas A&M University,Not Applicable
NCT03628391,2018.0,OTHER,lead,Erasmus Medical Center,Phase 3
NCT03628391,2018.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 3
NCT03629262,2018.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03629262,2018.0,OTHER,collaborator,Beijing Jishuitan Hospital,Phase 4
NCT03629483,2018.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT03629483,2018.0,OTHER,collaborator,Beijing Jishuitan Hospital,Phase 4
NCT03629769,2017.0,OTHER,lead,University of Pisa,Phase 3
NCT03630250,2018.0,OTHER,lead,University of Southampton,Early Phase 1
NCT03630250,2018.0,OTHER,collaborator,University Hospital Southampton NHS Foundation Trust,Early Phase 1
NCT03630419,2018.0,OTHER,lead,"Perseverance Research Center, LLC",Phase 1/Phase 2
NCT03630419,2018.0,UNKNOWN,collaborator,Cerulean Advanced Fitness and Wellness,Phase 1/Phase 2
NCT03631901,2017.0,OTHER,lead,Tanta University,Phase 4
NCT03631953,2019.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Phase 1
NCT03632512,2018.0,OTHER,lead,"Providence University, Taiwan",Not Applicable
NCT03632863,2018.0,OTHER,lead,Women's College Hospital,Not Applicable
NCT03632863,2018.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT03633058,2019.0,OTHER,lead,Rett Syndrome Research Trust,Phase 2
NCT03633058,2019.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 2
NCT03633357,2018.0,OTHER,lead,King's College London,Not Applicable
NCT03633474,2018.0,OTHER,lead,University of Southampton,Early Phase 1
NCT03633474,2018.0,OTHER,collaborator,University Hospital Southampton NHS Foundation Trust,Early Phase 1
NCT03633565,2018.0,OTHER,lead,Assiut University,Phase 4
NCT03634007,2019.0,INDUSTRY,lead,Lexeo Therapeutics,Phase 1/Phase 2
NCT03634007,2019.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 1/Phase 2
NCT03634007,2019.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 1/Phase 2
NCT03634839,2022.0,OTHER,lead,Yale University,Phase 1
NCT03634839,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03634956,2018.0,OTHER_GOV,lead,Lütfiye Nuri Burat Government Hospital,Not Applicable
NCT03635047,2018.0,INDUSTRY,lead,Alector Inc.,Phase 1
NCT03635073,2018.0,INDUSTRY,lead,Takeda,Phase 2
NCT03635333,2019.0,OTHER,lead,Yale University,Phase 1
NCT03635333,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03635749,2018.0,OTHER,lead,Beijing Tiantan Hospital,Phase 3
NCT03635749,2018.0,UNKNOWN,collaborator,Ministry of Science and Technology of the People's Republic of China,Phase 3
NCT03635827,2021.0,INDUSTRY,lead,Nobilis Therapeutics Inc.,Phase 2/Phase 3
NCT03635879,2019.0,INDUSTRY,lead,Cerecin,Phase 1
NCT03636204,2018.0,INDUSTRY,lead,Alector Inc.,Phase 1
NCT03636958,2021.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT03637361,2014.0,INDUSTRY,lead,"Relmada Therapeutics, Inc.",Phase 1
NCT03637387,2023.0,INDUSTRY,lead,Biogen,Phase 3
NCT03638869,2015.0,INDUSTRY,lead,"Relmada Therapeutics, Inc.",Phase 1
NCT03639064,2020.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT03639064,2020.0,OTHER,collaborator,Parkinson Society Canada,Phase 2
NCT03639558,2018.0,OTHER_GOV,lead,Joseph Dib,Phase 4
NCT03639558,2018.0,OTHER,collaborator,University of Nottingham,Phase 4
NCT03639558,2018.0,OTHER_GOV,collaborator,Hopital Psychiatrique De La Croix,Phase 4
NCT03639831,2017.0,INDUSTRY,lead,Activ'inside,Not Applicable
NCT03639831,2017.0,OTHER,collaborator,Northumbria University,Not Applicable
NCT03639987,2018.0,INDUSTRY,lead,Biogen,Phase 2
NCT03640052,2018.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT03640156,2018.0,OTHER,lead,KU Leuven,Phase 3
NCT03641846,2018.0,OTHER,lead,"Institute for the Study of Urological Diseases, Greece",Not Applicable
NCT03642028,2019.0,FED,lead,VA Office of Research and Development,Phase 4
NCT03642145,2018.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT03642366,2018.0,OTHER,lead,"Institute for the Study of Urological Diseases, Greece",Not Applicable
NCT03642509,2019.0,OTHER,lead,University of Aarhus,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Aalborg University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Odense University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,"Sahlgrenska University Hospital, Sweden",Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Karolinska University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Haukeland University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Helsinki University Central Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Gødstrup Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Lund University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Oslo University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Trondheim University Hospital,Not Applicable
NCT03642509,2019.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT03642509,2019.0,OTHER,collaborator,Jena University Hospital,Not Applicable
NCT03642860,2018.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2
NCT03642860,2018.0,INDUSTRY,collaborator,Ultragenyx Pharmaceutical Inc,Phase 2
NCT03643159,2018.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4
NCT03643562,2018.0,INDUSTRY,lead,Mandos LLC,Phase 3
NCT03644693,2018.0,OTHER,lead,"University of Colorado, Denver",Not Applicable
NCT03645447,2020.0,INDUSTRY,lead,Ranvier Health Ltd,Not Applicable
NCT03646487,2018.0,OTHER,lead,University of Illinois at Chicago,Not Applicable
NCT03646487,2018.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT03646526,2018.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Phase 1
NCT03646526,2018.0,UNKNOWN,collaborator,Hunan DongtingPharm.Co.Ltd,Phase 1
NCT03646552,2018.0,INDUSTRY,lead,SciSparc,Phase 2
NCT03647982,2018.0,INDUSTRY,lead,Medy-Tox,Phase 1
NCT03648021,2018.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 4
NCT03648034,2018.0,OTHER,lead,RenJi Hospital,Not Applicable
NCT03648658,2019.0,OTHER,lead,Mette Cathrine Oerngreen,Phase 4
NCT03648658,2019.0,OTHER,collaborator,Elsass Foundation,Phase 4
NCT03648827,2018.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT03649477,2018.0,INDUSTRY,lead,"Levo Therapeutics, Inc.",Phase 3
NCT03649698,2018.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT03649698,2018.0,OTHER,collaborator,KU Leuven,Not Applicable
NCT03649698,2018.0,UNKNOWN,collaborator,VISTA-Life,Not Applicable
NCT03649698,2018.0,UNKNOWN,collaborator,Nestlé Health Science Belgium,Not Applicable
NCT03649724,2020.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT03649724,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03649724,2020.0,UNKNOWN,collaborator,Tolmar Pharmaceuticals,Phase 2
NCT03649763,2018.0,OTHER,lead,New York School of Regional Anesthesia,Phase 4
NCT03650452,2018.0,INDUSTRY,lead,Takeda,Phase 2
NCT03650452,2018.0,INDUSTRY,collaborator,Ovid Therapeutics Inc.,Phase 2
NCT03651349,2021.0,INDUSTRY,lead,"Everfront Biotech Co., Ltd.",Phase 1
NCT03651427,2017.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Not Applicable
NCT03651726,2018.0,INDUSTRY,lead,SciSparc,Phase 2
NCT03651726,2018.0,INDUSTRY,collaborator,FGK Clinical Research GmbH,Phase 2
NCT03651856,2013.0,OTHER,lead,Medical University of South Carolina,Phase 3
NCT03652363,2012.0,OTHER,lead,North Bristol NHS Trust,Phase 2
NCT03652545,2018.0,OTHER,lead,Catherine Bollard,Phase 1
NCT03652545,2018.0,OTHER,collaborator,Children's National Research Institute,Phase 1
NCT03652805,2018.0,INDUSTRY,lead,Immunity Pharma Ltd.,Phase 1/Phase 2
NCT03652870,2021.0,OTHER,lead,"University College, London",Phase 3
NCT03652870,2021.0,OTHER,collaborator,London North West Healthcare NHS Trust,Phase 3
NCT03652870,2021.0,OTHER,collaborator,King's College London,Phase 3
NCT03652870,2021.0,OTHER,collaborator,University Hospital Plymouth NHS Trust,Phase 3
NCT03652870,2021.0,OTHER_GOV,collaborator,NHS Lothian,Phase 3
NCT03652922,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03652974,2018.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03652974,2018.0,UNKNOWN,collaborator,Shanghai Pudong New Area Mental Health Center,Phase 4
NCT03652974,2018.0,UNKNOWN,collaborator,The Affiliated Brain Hospital of Guangzhou Medical University,Phase 4
NCT03653273,2019.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT03654716,2018.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 1
NCT03654716,2018.0,UNKNOWN,collaborator,TeamConnor Childhood Cancer Foundation,Phase 1
NCT03654716,2018.0,OTHER,collaborator,Cookies for Kids' Cancer,Phase 1
NCT03654716,2018.0,INDUSTRY,collaborator,"Aileron Therapeutics, Inc.",Phase 1
NCT03655847,2018.0,OTHER,lead,Second Affiliated Hospital of Wenzhou Medical University,Phase 4
NCT03656042,2009.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT03656627,2019.0,OTHER,lead,"Alliance Foundation Trials, LLC.",Phase 1
NCT03656627,2019.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 1
NCT03658135,2018.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT03659266,2019.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT03659331,2018.0,OTHER_GOV,lead,Prof. Elon Pras,Not Applicable
NCT03659682,2019.0,OTHER,lead,Oslo University Hospital,Phase 2
NCT03659760,2018.0,OTHER_GOV,lead,Diskapi Yildirim Beyazit Education and Research Hospital,Not Applicable
NCT03660280,2018.0,OTHER,lead,Region Skane,Not Applicable
NCT03660280,2018.0,INDUSTRY,collaborator,BioGaia AB,Not Applicable
NCT03661411,2018.0,OTHER,lead,General Hospital of Shenyang Military Region,Phase 4
NCT03661463,2019.0,OTHER,lead,University Hospital Southampton NHS Foundation Trust,Phase 2
NCT03662425,2018.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT03662425,2018.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Not Applicable
NCT03663465,2013.0,OTHER,lead,Calo Psychiatric Center,Not Applicable
NCT03664141,2018.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Phase 3
NCT03664141,2018.0,UNKNOWN,collaborator,Tikun Olam,Phase 3
NCT03664232,2018.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT03664921,2018.0,INDUSTRY,lead,"Syntrix Biosystems, Inc.",Phase 2
NCT03664921,2018.0,UNKNOWN,collaborator,DF/Net Research,Phase 2
NCT03664921,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT03665454,2018.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 1
NCT03665454,2018.0,INDUSTRY,collaborator,Pfizer,Phase 1
NCT03665493,2020.0,OTHER,lead,Giovanni Mirabella,Not Applicable
NCT03666494,2018.0,OTHER,lead,University of Saskatchewan,Phase 4
NCT03666663,2019.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT03666949,2018.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT03667404,2018.0,OTHER,lead,Northwestern University,Phase 2
NCT03667404,2018.0,OTHER,collaborator,University of Illinois at Chicago,Phase 2
NCT03667846,2019.0,OTHER,lead,NYU Langone Health,Phase 2
NCT03667846,2019.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT03668405,2018.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT03668548,2018.0,UNKNOWN,lead,St Mary's University College,Not Applicable
NCT03668548,2018.0,OTHER,collaborator,University of Gloucestershire,Not Applicable
NCT03669250,2018.0,INDUSTRY,lead,"Cerevance Alpha, Inc.",Phase 1
NCT03670160,2018.0,OTHER,lead,University of Tennessee Medical Center,Phase 2
NCT03670810,2019.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT03671525,2018.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT03671616,2018.0,OTHER,lead,Statens Serum Institut,Phase 3
NCT03671616,2018.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT03671616,2018.0,INDUSTRY,collaborator,Larix A/S,Phase 3
NCT03671616,2018.0,OTHER,collaborator,Vaxtrials S.A.,Phase 3
NCT03671616,2018.0,INDUSTRY,collaborator,AJ Vaccines A/S,Phase 3
NCT03671785,2019.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT03671785,2019.0,OTHER,collaborator,Kelsey Research Foundation,Phase 1
NCT03672669,2017.0,OTHER,lead,"Near East University, Turkey",Not Applicable
NCT03672812,2018.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 3
NCT03674099,2018.0,OTHER,lead,Tomas Olsson,Phase 2
NCT03674099,2018.0,OTHER_GOV,collaborator,The Swedish Research Council,Phase 2
NCT03674138,2018.0,OTHER,lead,H. Lee Moffitt Cancer Center and Research Institute,Not Applicable
NCT03674541,2020.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT03674671,2018.0,OTHER,lead,University of Ottawa,Phase 3
NCT03674671,2018.0,OTHER,collaborator,McGill University,Phase 3
NCT03674671,2018.0,OTHER,collaborator,Queen's University,Phase 3
NCT03674671,2018.0,OTHER,collaborator,"University Health Network, Toronto",Phase 3
NCT03674671,2018.0,OTHER,collaborator,Ontario Shores Centre for Mental Health Sciences,Phase 3
NCT03675022,2018.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT03675126,2018.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT03675282,2018.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1/Phase 2
NCT03675282,2018.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT03675295,2017.0,OTHER,lead,Assiut University,Not Applicable
NCT03676569,2015.0,OTHER,lead,Mossakowski Medical Research Centre Polish Academy of Sciences,Phase 1
NCT03676569,2015.0,OTHER,collaborator,"Institute of Mother and Child, Warsaw, Poland",Phase 1
NCT03676634,2019.0,OTHER,lead,California Department of Public Health,Phase 2
NCT03678129,2018.0,OTHER,lead,King's College London,Not Applicable
NCT03679390,2017.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT03679611,2019.0,OTHER,lead,"University Health Network, Toronto",Phase 4
NCT03679611,2019.0,INDUSTRY,collaborator,Merck Canada Inc.,Phase 4
NCT03679949,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 1
NCT03679975,2018.0,INDUSTRY,lead,Aquestive Therapeutics,Phase 2
NCT03679975,2018.0,OTHER,collaborator,inVentiv Health Clinical,Phase 2
NCT03679975,2018.0,INDUSTRY,collaborator,Covance,Phase 2
NCT03680196,2018.0,OTHER,lead,Ju Seok Ryu,Not Applicable
NCT03680911,2018.0,OTHER,lead,University of Miami,Phase 3
NCT03681080,2017.0,OTHER,lead,RWTH Aachen University,Not Applicable
NCT03681158,2018.0,INDUSTRY,lead,Sanofi,Phase 1
NCT03681392,2021.0,INDUSTRY,lead,Robert E. Pyke,Not Applicable
NCT03681691,2019.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT03681691,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT03682601,2018.0,OTHER,lead,"GTO Pharmaceutical, LLC",Phase 2
NCT03682939,2019.0,OTHER,lead,"St George's, University of London",Phase 4
NCT03682978,2019.0,OTHER,lead,"Celso Arango, MD, PhD",Phase 2
NCT03682978,2019.0,OTHER,collaborator,UMC Utrecht,Phase 2
NCT03683225,2019.0,INDUSTRY,lead,Chase Therapeutics Corporation,Phase 2
NCT03684122,2018.0,OTHER,lead,University of Jordan,Phase 1/Phase 2
NCT03684564,2021.0,OTHER,lead,"University College, London",Phase 2
NCT03684564,2021.0,OTHER,collaborator,University College London Hospitals,Phase 2
NCT03684564,2021.0,OTHER,collaborator,"Barking, Havering and Redbridge University Hospitals NHS Trust",Phase 2
NCT03684564,2021.0,OTHER,collaborator,Hammersmith Hospitals NHS Trust,Phase 2
NCT03684564,2021.0,OTHER,collaborator,Epsom and St Helier University Hospitals NHS Trust,Phase 2
NCT03684564,2021.0,OTHER,collaborator,Barts & The London NHS Trust,Phase 2
NCT03684564,2021.0,OTHER,collaborator,King's College Hospital NHS Trust,Phase 2
NCT03684564,2021.0,UNKNOWN,collaborator,Versus Arthritis (Funder),Phase 2
NCT03685630,2019.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 3
NCT03686774,2019.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Phase 2
NCT03686969,2018.0,INDUSTRY,lead,Octapharma,Phase 3
NCT03687190,2013.0,OTHER,lead,Changhua Christian Hospital,Not Applicable
NCT03687333,2018.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT03687476,2020.0,INDUSTRY,lead,"Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company",Phase 2
NCT03688100,2018.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT03688100,2018.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT03688568,2018.0,OTHER,lead,Indiana University,Phase 2
NCT03688633,2019.0,OTHER,lead,"University Hospital, Limoges",Phase 2
NCT03688685,2019.0,INDUSTRY,lead,Cadent Therapeutics,Phase 2
NCT03689114,2020.0,OTHER,lead,Mario Negri Institute for Pharmacological Research,Phase 4
NCT03689114,2020.0,OTHER,collaborator,Azienda Ospedaliera San Gerardo di Monza,Phase 4
NCT03689114,2020.0,OTHER_GOV,collaborator,"Ministry of Health, Italy",Phase 4
NCT03689348,2018.0,OTHER,lead,Northumbria University,Not Applicable
NCT03689348,2018.0,INDUSTRY,collaborator,Anklam Extrakt,Not Applicable
NCT03689972,2018.0,INDUSTRY,lead,Biogen,Phase 3
NCT03690791,2019.0,OTHER_GOV,lead,Gold Coast Hospital and Health Service,Phase 3
NCT03690791,2019.0,INDUSTRY,collaborator,Bod Australia,Phase 3
NCT03691038,2018.0,OTHER,lead,Kangbuk Samsung Hospital,Not Applicable
NCT03691077,2018.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT03691077,2018.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 3
NCT03691077,2018.0,UNKNOWN,collaborator,Institut du Cerveau et de la Moelle épinière,Phase 3
NCT03691519,2018.0,OTHER,lead,"University Hospital, Toulouse",Phase 3
NCT03691987,2019.0,OTHER,lead,University Hospital of North Norway,Phase 2
NCT03691987,2019.0,OTHER,collaborator,The Research Council of Norway,Phase 2
NCT03691987,2019.0,OTHER,collaborator,Quadram Institute Bioscience,Phase 2
NCT03691987,2019.0,OTHER,collaborator,Umeå University,Phase 2
NCT03691987,2019.0,OTHER,collaborator,Cornell University,Phase 2
NCT03693781,2019.0,OTHER,lead,Azienda Ospedaliero-Universitaria di Modena,Phase 2
NCT03693781,2019.0,OTHER,collaborator,University of Modena and Reggio Emilia,Phase 2
NCT03693781,2019.0,OTHER,collaborator,"University of Turin, Italy",Phase 2
NCT03693781,2019.0,OTHER,collaborator,Istituto Auxologico Italiano,Phase 2
NCT03693781,2019.0,OTHER,collaborator,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Phase 2
NCT03693781,2019.0,OTHER,collaborator,University of Bari,Phase 2
NCT03693781,2019.0,OTHER,collaborator,IRCCS San Raffaele,Phase 2
NCT03693781,2019.0,OTHER,collaborator,University of Padova,Phase 2
NCT03693781,2019.0,OTHER,collaborator,University of Milan,Phase 2
NCT03693781,2019.0,OTHER,collaborator,Istituto Di Ricerche Farmacologiche Mario Negri,Phase 2
NCT03693781,2019.0,OTHER,collaborator,"University of Campania ""Luigi Vanvitelli""",Phase 2
NCT03693781,2019.0,OTHER,collaborator,Catholic University of the Sacred Heart,Phase 2
NCT03693872,2019.0,OTHER,lead,Rennes University Hospital,Not Applicable
NCT03694639,2018.0,OTHER,lead,Mansoura University,Phase 4
NCT03695094,2018.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 1
NCT03696121,2019.0,OTHER,lead,University of Nottingham,Phase 2
NCT03696121,2019.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Phase 2
NCT03697252,2018.0,INDUSTRY,lead,Karuna Therapeutics,Phase 2
NCT03698032,2019.0,OTHER,lead,San Diego State University,Not Applicable
NCT03698162,2021.0,OTHER,lead,University of Southern California,Not Applicable
NCT03698162,2021.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT03698695,2018.0,INDUSTRY,lead,Theranexus,Phase 1
NCT03700580,2012.0,OTHER,lead,Carlos E Salas,Phase 2
NCT03701399,2019.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT03702582,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT03702816,2018.0,OTHER,lead,"Aaron Ritter, MD",Phase 2
NCT03703570,2018.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 2
NCT03703856,2019.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT03703882,2018.0,INDUSTRY,lead,Catabasis Pharmaceuticals,Phase 3
NCT03704155,2017.0,OTHER,lead,University of Nove de Julho,Not Applicable
NCT03704155,2017.0,UNKNOWN,collaborator,Claudia Santos Oliveira,Not Applicable
NCT03704155,2017.0,UNKNOWN,collaborator,Daniela Aparecida Biasotto-Gonzalez,Not Applicable
NCT03705065,2018.0,INDUSTRY,lead,Heron Therapeutics,Phase 4
NCT03705351,2019.0,OTHER,lead,Providence Health & Services,Phase 1
NCT03705351,2019.0,OTHER,collaborator,"University of California, San Francisco",Phase 1
NCT03705351,2019.0,INDUSTRY,collaborator,NovoCure Ltd.,Phase 1
NCT03705390,2019.0,OTHER,lead,University of Birmingham,Phase 2
NCT03705390,2019.0,INDUSTRY,collaborator,TikoMed AB,Phase 2
NCT03705390,2019.0,OTHER,collaborator,University Hospital Birmingham,Phase 2
NCT03705390,2019.0,UNKNOWN,collaborator,Neuregenix,Phase 2
NCT03705728,2018.0,OTHER,lead,"Centre Clinical, France",Not Applicable
NCT03705780,2018.0,OTHER,lead,Children's Hospital of Fudan University,Not Applicable
NCT03706261,2019.0,OTHER,lead,Adam Brickman,Phase 1
NCT03706261,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT03706885,2018.0,OTHER,lead,Case Western Reserve University,Phase 1
NCT03706885,2018.0,OTHER,collaborator,University Hospitals Cleveland Medical Center,Phase 1
NCT03706885,2018.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1
NCT03706989,2019.0,OTHER,lead,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Not Applicable
NCT03708237,2019.0,OTHER,lead,University of Alberta,Phase 2
NCT03708315,2020.0,OTHER,lead,Yale University,Phase 2
NCT03708341,2018.0,OTHER,lead,Saint-Joseph University,Phase 3
NCT03708549,2021.0,OTHER,lead,Tianjin Anding Hospital,Phase 4
NCT03708744,2018.0,INDUSTRY,lead,Zosano Pharma Corporation,Phase 1
NCT03708900,2021.0,INDUSTRY,lead,RECORDATI GROUP,Phase 2
NCT03708965,2019.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 2
NCT03710343,2023.0,OTHER,lead,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT03710343,2023.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2
NCT03710642,2018.0,OTHER,lead,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT03710642,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03710642,2018.0,FED,collaborator,VA Puget Sound Health Care System,Phase 2
NCT03710642,2018.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT03710655,2019.0,INDUSTRY,lead,"Apimeds, Inc.",Phase 3
NCT03710707,2018.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 1
NCT03711500,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT03711500,2019.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 1/Phase 2
NCT03711825,2018.0,INDUSTRY,lead,Lyndra Inc.,Early Phase 1
NCT03711903,2019.0,OTHER,lead,National Neuroscience Institute,Phase 2
NCT03711903,2019.0,INDUSTRY,collaborator,AegisCN LLC,Phase 2
NCT03711903,2019.0,OTHER,collaborator,Singapore Clinical Research Institute,Phase 2
NCT03712475,2018.0,INDUSTRY,lead,"Yung Shin Pharm. Ind. Co., Ltd.",Phase 4
NCT03712475,2018.0,OTHER,collaborator,Taichung Veterans General Hospital,Phase 4
NCT03712787,2019.0,INDUSTRY,lead,AbbVie,Phase 2
NCT03712917,2019.0,OTHER,lead,Ataturk University,Not Applicable
NCT03713424,2019.0,OTHER,lead,University of Missouri-Columbia,Phase 2
NCT03713658,2018.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 4
NCT03713892,2018.0,INDUSTRY,lead,Chong Kun Dang Pharmaceutical,Phase 1
NCT03713957,2018.0,INDUSTRY,lead,"Alkahest, Inc.",Phase 2
NCT03713957,2018.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT03714373,2018.0,INDUSTRY,lead,"Soleno Therapeutics, Inc.",Phase 3
NCT03716570,2019.0,INDUSTRY,lead,Biogen,Phase 1
NCT03717272,2018.0,INDUSTRY,lead,Aelis Farma,Phase 2
NCT03717272,2018.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT03717272,2018.0,OTHER,collaborator,Columbia University,Phase 2
NCT03717272,2018.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT03717272,2018.0,INDUSTRY,collaborator,"ClinStar, LLC",Phase 2
NCT03717454,2018.0,OTHER,lead,Zhebao Wu,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,Xinqiao Hospital of Chongqing,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,First Hospital of China Medical University,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,Beijing Tiantan Hospital,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,First Affiliated Hospital of Wenzhou Medical University,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,First Affiliated Hospital of Fujian Medical University,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,Peking Union Medical College Hospital,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,Huashan Hospital,Not Applicable
NCT03717454,2018.0,OTHER,collaborator,Chinese PLA General Hospital,Not Applicable
NCT03717909,2018.0,OTHER,lead,University of Birmingham,Phase 2
NCT03718208,2018.0,INDUSTRY,lead,Société des Produits Nestlé (SPN),Not Applicable
NCT03719391,2018.0,INDUSTRY,lead,"Juul Labs, Inc.",Not Applicable
NCT03720275,2018.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT03720275,2018.0,OTHER,collaborator,University of Bordeaux,Not Applicable
NCT03720418,2018.0,INDUSTRY,lead,Sio Gene Therapies,Phase 1/Phase 2
NCT03720548,2018.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03720899,2019.0,OTHER,lead,University of Alabama at Birmingham,Phase 2/Phase 3
NCT03721627,2018.0,OTHER,lead,Mansoura University Children Hospital,Phase 4
NCT03722004,2018.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT03722004,2018.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT03722290,2018.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT03722290,2018.0,OTHER,collaborator,FRAXA Research Foundation,Phase 2
NCT03722303,2016.0,OTHER,lead,Columbia University,Early Phase 1
NCT03722303,2016.0,UNKNOWN,collaborator,Orthopaedic Scientific Research Foundation,Early Phase 1
NCT03723447,2018.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT03723694,2019.0,OTHER,lead,Columbia University,Not Applicable
NCT03723694,2019.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT03723837,2018.0,OTHER,lead,"Tribhuvan University Teaching Hospital, Institute Of Medicine.",Phase 4
NCT03723837,2018.0,OTHER,collaborator,World Health Organization,Phase 4
NCT03723837,2018.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT03724448,2018.0,OTHER,lead,Hôpital Universitaire Sahloul,Phase 1
NCT03726749,2018.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03726749,2018.0,INDUSTRY,collaborator,Roche-Genentech,Phase 4
NCT03728153,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03728153,2019.0,OTHER,collaborator,Muhimbili University of Health and Allied Sciences,Phase 2
NCT03728777,2018.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT03728933,2018.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT03729011,2019.0,NETWORK,lead,Meshalkin Research Institute of Pathology of Circulation,Phase 4
NCT03729375,2018.0,OTHER,lead,University of South Florida,Phase 1
NCT03730064,2018.0,OTHER,lead,Martin Lan,Early Phase 1
NCT03730194,2019.0,OTHER,lead,University of Nebraska,Not Applicable
NCT03730194,2019.0,NIH,collaborator,National Institute of Nursing Research (NINR),Not Applicable
NCT03730857,2008.0,OTHER,lead,Calo Psychiatric Center,Phase 1
NCT03731715,2019.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 1
NCT03732534,2018.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT03732638,2018.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT03733561,2018.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT03734263,2018.0,OTHER,lead,Fondazione Telethon,Phase 2
NCT03735901,2019.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 3
NCT03735901,2019.0,OTHER,collaborator,Swiss National Science Foundation,Phase 3
NCT03736538,2018.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT03736538,2018.0,OTHER,collaborator,American Foundation for Suicide Prevention,Phase 1
NCT03737214,2018.0,INDUSTRY,lead,Idorsia Pharmaceuticals Ltd.,Phase 3
NCT03737916,2018.0,OTHER_GOV,lead,Ankara Education and Research Hospital,Not Applicable
NCT03739476,2019.0,OTHER,lead,Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León,Phase 3
NCT03739476,2019.0,OTHER,collaborator,Instituto de Investigación Biomédica de Salamanca,Phase 3
NCT03739476,2019.0,OTHER,collaborator,Grupo Español de Rehabilitación Multimodal,Phase 3
NCT03740009,2019.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT03740009,2019.0,OTHER,collaborator,"Foundation of Hope, North Carolina",Phase 4
NCT03740178,2019.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT03740204,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT03740295,2018.0,OTHER,lead,Fundación Universidad Católica de Valencia San Vicente Mártir,Phase 2
NCT03740295,2018.0,UNKNOWN,collaborator,Valencian Institute of Neurorehabilitation Foundation,Phase 2
NCT03740958,2018.0,OTHER,lead,General Hospital of Shenyang Military Region,Phase 4
NCT03740971,2018.0,OTHER,lead,General Hospital of Shenyang Military Region,Not Applicable
NCT03741101,2019.0,OTHER,lead,Region Skane,Phase 2
NCT03741101,2019.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT03741530,2018.0,OTHER,lead,Xijing Hospital,Not Applicable
NCT03742466,2018.0,OTHER,lead,Assiut University,Not Applicable
NCT03743649,2019.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT03743649,2019.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2/Phase 3
NCT03743805,2019.0,OTHER,lead,Prisma Health-Midlands,Early Phase 1
NCT03744312,2018.0,OTHER,lead,Columbia University,Phase 1/Phase 2
NCT03745586,2018.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 1/Phase 2
NCT03745898,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT03745898,2019.0,OTHER,collaborator,Ohio State University,Phase 3
NCT03746665,2018.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 3
NCT03746665,2018.0,OTHER_GOV,collaborator,Public Health England,Phase 3
NCT03746665,2018.0,OTHER_GOV,collaborator,"Department of State for Health and Social Welfare, The Gambia",Phase 3
NCT03746665,2018.0,OTHER,collaborator,World Health Organization,Phase 3
NCT03746665,2018.0,OTHER,collaborator,University of Cambridge,Phase 3
NCT03746665,2018.0,OTHER,collaborator,Stanford University,Phase 3
NCT03747328,2022.0,INDUSTRY,lead,"Aadi Bioscience, Inc.",Phase 2
NCT03747562,2019.0,OTHER,lead,"University Hospital, Ghent",Phase 3
NCT03747562,2019.0,OTHER,collaborator,General Hospital Groeninge,Phase 3
NCT03747562,2019.0,UNKNOWN,collaborator,KU Leuven Campus Kulak Kortrijk,Phase 3
NCT03747562,2019.0,OTHER,collaborator,Anglia Ruskin University,Phase 3
NCT03747900,2017.0,OTHER,lead,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",Not Applicable
NCT03748290,2018.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT03748290,2018.0,OTHER,collaborator,Tel Aviv University,Phase 4
NCT03748303,2019.0,OTHER,lead,University of Arizona,Phase 1
NCT03748303,2019.0,OTHER,collaborator,University of Southern California,Phase 1
NCT03748303,2019.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT03748355,2018.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT03748446,2019.0,OTHER,lead,Massachusetts General Hospital,Early Phase 1
NCT03748706,2019.0,INDUSTRY,lead,Pain Therapeutics,Phase 2
NCT03748706,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03748979,2018.0,INDUSTRY,lead,Takeda,Phase 1
NCT03749057,2018.0,OTHER,lead,General Hospital of Shenyang Military Region,Phase 4
NCT03749096,2018.0,OTHER,lead,Mayo Clinic,Phase 3
NCT03749096,2018.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 3
NCT03749915,2018.0,OTHER,lead,University of British Columbia,Not Applicable
NCT03751280,2018.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT03751488,2018.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT03752307,2019.0,OTHER,lead,University of New Mexico,Phase 1/Phase 2
NCT03752463,2015.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT03752463,2015.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Phase 2
NCT03752749,2014.0,OTHER,lead,Shirley Ryan AbilityLab,Not Applicable
NCT03752918,2024.0,OTHER,lead,Yale University,Phase 1
NCT03753750,2020.0,OTHER,lead,University of Southern California,Not Applicable
NCT03753750,2020.0,OTHER,collaborator,"University of California, Los Angeles",Not Applicable
NCT03753763,2019.0,INDUSTRY,lead,Zambon SpA,Phase 2
NCT03754582,2018.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 2
NCT03754725,2020.0,OTHER,lead,Duke University,Phase 1/Phase 2
NCT03755310,2019.0,OTHER,lead,"Diego García-Borreguero, MD, PhD",Phase 2
NCT03755310,2019.0,UNKNOWN,collaborator,"Sleep Research Institute (Paseo de la Habana 151, Madrid 28036, SPAIN)",Phase 2
NCT03755960,2019.0,OTHER,lead,Benno Brinkhaus,Not Applicable
NCT03755960,2019.0,OTHER,collaborator,Karl and Veronica Carstens Foundation,Not Applicable
NCT03756246,2019.0,OTHER,lead,University of Texas at Austin,Phase 4
NCT03757325,2019.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 1
NCT03757351,2018.0,INDUSTRY,lead,Sanofi,Phase 1
NCT03757351,2018.0,INDUSTRY,collaborator,Denali Therapeutics Inc.,Phase 1
NCT03757507,2019.0,OTHER,lead,G.M. van Dam,Not Applicable
NCT03757559,2013.0,INDUSTRY,lead,"Tris Pharma, Inc.",Phase 1
NCT03757585,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03757585,2019.0,UNKNOWN,collaborator,Demarest Lloyd Jr. Foundation,Phase 4
NCT03757910,2019.0,OTHER,lead,José A. Luchsinger,Early Phase 1
NCT03757910,2019.0,OTHER,collaborator,Albert Einstein College of Medicine,Early Phase 1
NCT03757910,2019.0,OTHER,collaborator,George Washington University,Early Phase 1
NCT03757910,2019.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Early Phase 1
NCT03758924,2019.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2
NCT03758924,2019.0,UNKNOWN,collaborator,International Rett Syndrome Foundation Rettsyndrome.org,Phase 2
NCT03759366,2018.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT03759522,2019.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT03759639,2019.0,INDUSTRY,lead,IntraBio Inc,Phase 2
NCT03759665,2019.0,INDUSTRY,lead,IntraBio Inc,Phase 2
NCT03759678,2020.0,INDUSTRY,lead,IntraBio Inc,Phase 2
NCT03759938,2019.0,OTHER,lead,"University College, London",Not Applicable
NCT03761030,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT03761030,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03761511,2023.0,OTHER,lead,RWTH Aachen University,Phase 2
NCT03761511,2023.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT03762317,2018.0,OTHER,lead,"Hennepin County Medical Center, Minneapolis",Phase 4
NCT03762343,2019.0,OTHER,lead,Kasr El Aini Hospital,Phase 3
NCT03762746,2018.0,OTHER,lead,Dr Cipto Mangunkusumo General Hospital,Phase 3
NCT03762798,2018.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT03763929,2019.0,INDUSTRY,lead,Diffusion Pharmaceuticals Inc,Phase 2
NCT03763929,2019.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT03763929,2019.0,OTHER,collaborator,University of Virginia,Phase 2
NCT03764215,2018.0,OTHER,lead,Georgetown University,Phase 1
NCT03764683,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03764748,2017.0,OTHER,lead,Faming Zhang,Phase 1/Phase 2
NCT03765138,2019.0,OTHER,lead,"Research Foundation for Mental Hygiene, Inc.",Phase 3
NCT03765294,2019.0,INDUSTRY,lead,Idorsia Pharmaceuticals Ltd.,Phase 1
NCT03765346,2018.0,INDUSTRY,lead,Grünenthal GmbH,Phase 1
NCT03765788,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT03765801,2003.0,INDUSTRY,lead,Grünenthal GmbH,Phase 1
NCT03766074,2018.0,OTHER,lead,"Tirang R. Neyestani, Ph.D.",Not Applicable
NCT03766321,2020.0,OTHER,lead,Azienda Ospedaliero-Universitaria di Modena,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,University of Modena and Reggio Emilia,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,Catholic University of the Sacred Heart,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,Campus Bio-Medico University,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,Azienda Ospedaliero-Universitaria Careggi,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,Azienda Ospedaliera di Perugia,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,University of Chieti,Not Applicable
NCT03766321,2020.0,OTHER,collaborator,University of Florence,Not Applicable
NCT03767270,2019.0,INDUSTRY,lead,"Translate Bio, Inc.",Phase 1/Phase 2
NCT03768648,2019.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT03768648,2019.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Not Applicable
NCT03768726,2018.0,INDUSTRY,lead,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Phase 3
NCT03769116,2018.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1/Phase 2
NCT03769896,2017.0,OTHER,lead,Medical University Innsbruck,Phase 2
NCT03771391,2018.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT03771391,2018.0,UNKNOWN,collaborator,Kreiskliniken Reutlingen,Not Applicable
NCT03771391,2018.0,OTHER,collaborator,Johannes Gutenberg University Mainz,Not Applicable
NCT03771560,2018.0,OTHER,lead,"University of California, San Francisco",Phase 2/Phase 3
NCT03772314,2019.0,OTHER,lead,Emory University,Phase 2
NCT03772314,2019.0,OTHER,collaborator,American Academy of Sleep Medicine,Phase 2
NCT03772951,2019.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03773003,2021.0,OTHER,lead,"University Hospital, Saarland",Not Applicable
NCT03773328,2022.0,INDUSTRY,lead,"Cellenkos, Inc.",Phase 1
NCT03773562,2019.0,OTHER,lead,Mayo Clinic,Phase 4
NCT03773796,2018.0,OTHER,lead,Medical University Innsbruck,Phase 3
NCT03774407,2019.0,OTHER,lead,Texas Tech University Health Sciences Center,Phase 2/Phase 3
NCT03774446,2018.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT03775096,2019.0,OTHER,lead,"Michele Tagliati, MD",Phase 2
NCT03775252,2017.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT03775538,2018.0,INDUSTRY,lead,Herantis Pharma Plc.,Phase 1/Phase 2
NCT03775538,2018.0,UNKNOWN,collaborator,Renishaw plc.,Phase 1/Phase 2
NCT03776994,2018.0,INDUSTRY,lead,SRI International,Phase 1
NCT03776994,2018.0,FED,collaborator,US Army Medical Research Institute of Infectious Diseases,Phase 1
NCT03777319,2018.0,OTHER,lead,Kevin Flanigan,Phase 1
NCT03777319,2018.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 1
NCT03777683,2019.0,OTHER,lead,Mashhad University of Medical Sciences,Phase 1/Phase 2
NCT03777826,2019.0,INDUSTRY,lead,Nutricia Research,Not Applicable
NCT03777956,2019.0,OTHER,lead,Danish Pain Research Center,Phase 2
NCT03777956,2019.0,OTHER,collaborator,Odense University Hospital,Phase 2
NCT03778333,2012.0,OTHER,lead,Karolinska Institutet,Phase 1
NCT03779334,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT03779646,2019.0,OTHER,lead,Peking Union Medical College Hospital,Phase 2/Phase 3
NCT03779646,2019.0,OTHER_GOV,collaborator,National Natural Science Foundation of China,Phase 2/Phase 3
NCT03779646,2019.0,OTHER,collaborator,Chinese Academy of Medical Sciences,Phase 2/Phase 3
NCT03780257,2019.0,INDUSTRY,lead,ProQR Therapeutics,Phase 1/Phase 2
NCT03780907,2003.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 2
NCT03781115,2017.0,OTHER,lead,University of Arizona,Phase 1
NCT03781115,2017.0,OTHER,collaborator,"Sidney R. Baer, Jr. Foundation",Phase 1
NCT03781128,2019.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT03781479,2019.0,INDUSTRY,lead,"Catalyst Pharmaceuticals, Inc.",Phase 2
NCT03781700,2019.0,OTHER,lead,"Dalarna County Council, Sweden",Phase 4
NCT03781700,2019.0,OTHER,collaborator,Karolinska Institutet,Phase 4
NCT03781791,2018.0,INDUSTRY,lead,Enterin Inc.,Phase 2
NCT03783312,2018.0,OTHER,lead,Inonu University,Not Applicable
NCT03783572,2020.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT03783754,2018.0,OTHER,lead,The George Institute,Not Applicable
NCT03783754,2018.0,OTHER,collaborator,University of Sydney,Not Applicable
NCT03783923,2019.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT03784300,2017.0,INDUSTRY,lead,Pain Therapeutics,Phase 1
NCT03784300,2017.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT03784456,2019.0,OTHER,lead,National Yang Ming University,Not Applicable
NCT03784456,2019.0,UNKNOWN,collaborator,"Laurel Corporation, Taiwan",Not Applicable
NCT03784495,2014.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT03785067,2020.0,OTHER,lead,The George Institute,Phase 3
NCT03785067,2020.0,OTHER,collaborator,University of Sydney,Phase 3
NCT03785223,2019.0,OTHER,lead,McMaster University,Phase 4
NCT03785223,2019.0,INDUSTRY,collaborator,"Purdue Pharma, Canada",Phase 4
NCT03786744,2018.0,OTHER,lead,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Phase 1/Phase 2
NCT03787758,2019.0,INDUSTRY,lead,Sage Therapeutics,Phase 1
NCT03787849,2018.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT03787940,2019.0,OTHER,lead,Beijing Chest Hospital,Not Applicable
NCT03788343,2019.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT03788343,2019.0,OTHER,collaborator,University of Zurich,Phase 4
NCT03788577,2018.0,OTHER,lead,National Yang Ming University,Not Applicable
NCT03788733,2018.0,OTHER,lead,Universidad de Murcia,Not Applicable
NCT03788759,2019.0,OTHER,lead,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,Phase 2/Phase 3
NCT03788759,2019.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 2/Phase 3
NCT03789175,2019.0,NIH,lead,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT03789656,2019.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 2
NCT03789734,2019.0,INDUSTRY,lead,BioLeaders Corporation,Phase 1
NCT03789760,2019.0,INDUSTRY,lead,"Shineway Pharmaceutical Co.,Ltd",Phase 3
NCT03790085,2018.0,OTHER,lead,Tianjin Medical University General Hospital,Early Phase 1
NCT03790085,2018.0,OTHER,collaborator,Shanghai Mental Health Center,Early Phase 1
NCT03790085,2018.0,OTHER,collaborator,Nanjing Medical University,Early Phase 1
NCT03790085,2018.0,OTHER,collaborator,Tianjin Anding Hospital,Early Phase 1
NCT03790085,2018.0,UNKNOWN,collaborator,Harbin First Specialist Hospital,Early Phase 1
NCT03790085,2018.0,OTHER,collaborator,First Affiliated Hospital of Chongqing Medical University,Early Phase 1
NCT03790085,2018.0,UNKNOWN,collaborator,Anhui Mental Health Center,Early Phase 1
NCT03790085,2018.0,UNKNOWN,collaborator,Wuhan Psychiatric Hospital,Early Phase 1
NCT03790085,2018.0,UNKNOWN,collaborator,Wenzhou Seventh People's Hospital,Early Phase 1
NCT03790085,2018.0,OTHER,collaborator,First Affiliated Hospital of Harbin Medical University,Early Phase 1
NCT03790345,2019.0,OTHER,lead,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,Phase 2/Phase 3
NCT03790436,2018.0,OTHER,lead,University of Southern California,Not Applicable
NCT03790436,2018.0,INDUSTRY,collaborator,"Vitaflo International, Ltd",Not Applicable
NCT03790670,2019.0,OTHER,lead,University of Nebraska,Phase 1
NCT03790709,2018.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2/Phase 3
NCT03790709,2018.0,INDUSTRY,collaborator,Anavex Australia Pty Ltd.,Phase 2/Phase 3
NCT03790709,2018.0,INDUSTRY,collaborator,Anavex Germany GmbH,Phase 2/Phase 3
NCT03790709,2018.0,UNKNOWN,collaborator,Anavex Canada Ltd.,Phase 2/Phase 3
NCT03790800,2020.0,OTHER,lead,"The George Institute for Global Health, China",Phase 3
NCT03790800,2020.0,UNKNOWN,collaborator,"Shanghai East Hospital, China",Phase 3
NCT03790800,2020.0,UNKNOWN,collaborator,"First Affiliated Hospital of Chengdu Medical College, China",Phase 3
NCT03790800,2020.0,UNKNOWN,collaborator,"Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China",Phase 3
NCT03790865,2019.0,INDUSTRY,lead,Millendo Therapeutics SAS,Phase 2/Phase 3
NCT03790982,2018.0,INDUSTRY,lead,Zhejiang Hisun Pharmaceutical Co. Ltd.,Phase 2
NCT03791515,2018.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03792490,2019.0,OTHER,lead,University Medical Center Goettingen,Phase 2
NCT03792555,2018.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 2
NCT03792945,2019.0,OTHER,lead,Ahi Evran University Education and Research Hospital,Phase 4
NCT03793712,2018.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT03793868,2018.0,OTHER,lead,Mayo Clinic,Early Phase 1
NCT03794076,2019.0,OTHER,lead,"Vishwajit Nimgaonkar, MD PhD",Phase 1/Phase 2
NCT03794076,2019.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1/Phase 2
NCT03795974,2017.0,OTHER,lead,Tehran University of Medical Sciences,Phase 2
NCT03795974,2017.0,OTHER,collaborator,Hormozgan University of Medical Sciences,Phase 2
NCT03796026,2019.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT03796598,2019.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT03796637,2019.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT03796962,2019.0,INDUSTRY,lead,Xenon Pharmaceuticals Inc.,Phase 2
NCT03796962,2019.0,UNKNOWN,collaborator,Novotech Health Holdings Pte. Ltd.,Phase 2
NCT03797131,2019.0,INDUSTRY,lead,Kaleido Biosciences,Not Applicable
NCT03797521,2018.0,INDUSTRY,lead,"Promentis Pharmaceuticals, Inc.",Phase 2
NCT03797560,2019.0,OTHER,lead,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Not Applicable
NCT03798418,2019.0,OTHER,lead,Changhua Christian Hospital,Not Applicable
NCT03799562,2019.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03799718,2019.0,INDUSTRY,lead,Brainstorm-Cell Therapeutics,Phase 2
NCT03799783,2018.0,OTHER,lead,Azienda Ospedaliera di Padova,Phase 2
NCT03800641,2019.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Phase 4
NCT03801135,2018.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT03801642,2019.0,OTHER,lead,"Jeff Burns, MD",Phase 1/Phase 2
NCT03802396,2018.0,OTHER,lead,"Miles Berger, MD PhD",Phase 2
NCT03802422,2019.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT03802435,2019.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT03802552,2019.0,OTHER,lead,"University of Colorado, Denver",Phase 1
NCT03802565,2019.0,INDUSTRY,lead,"Neurana Pharmaceuticals, Inc.",Phase 2
NCT03802799,2018.0,INDUSTRY,lead,"Zynerba Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT03802838,2017.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT03803800,2019.0,OTHER,lead,Hasselt University,Not Applicable
NCT03804229,2019.0,OTHER,lead,Capital Medical University,Phase 3
NCT03804229,2019.0,INDUSTRY,collaborator,"CSPC-NBP Pharmaceutical Co., Ltd.",Phase 3
NCT03804476,2018.0,INDUSTRY,lead,"Aeromics, Inc.",Phase 1
NCT03804476,2018.0,INDUSTRY,collaborator,Covance,Phase 1
NCT03805750,2019.0,OTHER,lead,"University of California, San Diego",Phase 1/Phase 2
NCT03805750,2019.0,OTHER,collaborator,International Essential Tremor Foundation,Phase 1/Phase 2
NCT03805750,2019.0,INDUSTRY,collaborator,Tilray,Phase 1/Phase 2
NCT03805750,2019.0,OTHER,collaborator,Center for Medicinal Cannabis Research,Phase 1/Phase 2
NCT03806478,2023.0,INDUSTRY,lead,Aphios,Phase 2
NCT03806530,2019.0,OTHER,lead,Population Health Research Institute,Phase 3
NCT03806985,2019.0,OTHER,lead,Yale University,Phase 1
NCT03807011,2017.0,OTHER,lead,Yeungnam University College of Medicine,Not Applicable
NCT03807973,2021.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT03808519,2019.0,OTHER,lead,McMaster University,Not Applicable
NCT03808740,2018.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT03808935,2019.0,OTHER,lead,The Epilepsy Research Program of the Ontario Brain Institute,Phase 3
NCT03808935,2019.0,OTHER,collaborator,Ontario Brain Institute,Phase 3
NCT03808935,2019.0,OTHER,collaborator,University of Toronto,Phase 3
NCT03808935,2019.0,OTHER,collaborator,"University Health Network, Toronto",Phase 3
NCT03808935,2019.0,OTHER,collaborator,London Health Sciences Centre,Phase 3
NCT03808935,2019.0,INDUSTRY,collaborator,MedReleaf,Phase 3
NCT03808961,2020.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT03809234,2019.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT03809351,2020.0,OTHER,lead,University of Alabama at Birmingham,Phase 1
NCT03809897,2019.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Phase 4
NCT03809897,2019.0,UNKNOWN,collaborator,Clínica Galatea,Phase 4
NCT03809897,2019.0,UNKNOWN,collaborator,Hospital Sant Rafael,Phase 4
NCT03809897,2019.0,OTHER,collaborator,Hospital de Sant Pau,Phase 4
NCT03810794,2019.0,OTHER,lead,Shanghai University of Traditional Chinese Medicine,Not Applicable
NCT03810794,2019.0,OTHER,collaborator,Shanghai Mental Health Center,Not Applicable
NCT03810794,2019.0,OTHER,collaborator,Huashan Hospital,Not Applicable
NCT03810898,2021.0,OTHER,lead,"CHDI Foundation, Inc.",Early Phase 1
NCT03810898,2021.0,OTHER,collaborator,Universitaire Ziekenhuizen KU Leuven,Early Phase 1
NCT03811366,2011.0,OTHER,lead,University of Sao Paulo,Not Applicable
NCT03811847,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03811860,2019.0,OTHER,lead,"Mount Sinai Hospital, Canada",Not Applicable
NCT03812094,2019.0,OTHER,lead,"Dalarna County Council, Sweden",Not Applicable
NCT03812094,2019.0,OTHER,collaborator,Uppsala University,Not Applicable
NCT03812224,2019.0,INDUSTRY,lead,Amgen,Phase 3
NCT03812302,2019.0,OTHER,lead,University of Alberta,Phase 2
NCT03812744,2016.0,OTHER,lead,Auburn University,Not Applicable
NCT03813121,2019.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1/Phase 2
NCT03813160,2018.0,INDUSTRY,lead,Corbus Pharmaceuticals Inc.,Phase 3
NCT03813238,2019.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03813992,2018.0,INDUSTRY,lead,Futura Medical Developments Ltd.,Phase 3
NCT03814226,2018.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03814356,2020.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT03815071,2019.0,INDUSTRY,lead,"Allife Medical Science and Technology Co., Ltd.",Early Phase 1
NCT03815071,2019.0,UNKNOWN,collaborator,The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital,Early Phase 1
NCT03815071,2019.0,OTHER,collaborator,Henan Provincial People's Hospital,Early Phase 1
NCT03815071,2019.0,OTHER_GOV,collaborator,Beijing Hospital,Early Phase 1
NCT03815201,2017.0,OTHER_GOV,lead,Basque Health Service,Not Applicable
NCT03815201,2017.0,OTHER,collaborator,University of the Basque Country (UPV/EHU),Not Applicable
NCT03815201,2017.0,OTHER,collaborator,Hospital Universitario de Álava,Not Applicable
NCT03815916,2019.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT03815916,2019.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT03816020,2019.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT03816046,2018.0,OTHER,lead,"St Joseph University, Beirut, Lebanon",Phase 4
NCT03816345,2019.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT03817229,2019.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT03817229,2019.0,NIH,collaborator,National Institute of Nursing Research (NINR),Not Applicable
NCT03817229,2019.0,OTHER,collaborator,Medical University of South Carolina,Not Applicable
NCT03817229,2019.0,OTHER,collaborator,Children's Hospital of Orange County,Not Applicable
NCT03817229,2019.0,OTHER,collaborator,University of Cincinnati,Not Applicable
NCT03817229,2019.0,OTHER,collaborator,Nationwide Children's Hospital,Not Applicable
NCT03817229,2019.0,OTHER,collaborator,North Carolina State University,Not Applicable
NCT03817424,2018.0,INDUSTRY,lead,Viela Bio,Phase 1
NCT03817502,2019.0,INDUSTRY,lead,Gedeon Richter Plc.,Phase 3
NCT03817528,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT03817528,2019.0,INDUSTRY,collaborator,"Intra-Cellular Therapies, Inc.",Phase 2
NCT03817554,2019.0,OTHER,lead,Dong Jie,Phase 4
NCT03817684,2019.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 2
NCT03817931,2019.0,OTHER,lead,Baylor Research Institute,Phase 4
NCT03817931,2019.0,OTHER,collaborator,The Methodist Hospital Research Institute,Phase 4
NCT03817931,2019.0,UNKNOWN,collaborator,International Urogynecological Association,Phase 4
NCT03818204,2019.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Not Applicable
NCT03818451,2016.0,OTHER,lead,University of Messina,Not Applicable
NCT03818581,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03819699,2018.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT03820037,2019.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT03821129,2019.0,INDUSTRY,lead,W.L.Gore & Associates,Not Applicable
NCT03821155,2019.0,OTHER,lead,Aalborg University Hospital,Not Applicable
NCT03821350,2013.0,OTHER,lead,Hitit University,Not Applicable
NCT03821441,2018.0,OTHER,lead,Chinese Academy of Medical Sciences,Phase 3
NCT03821441,2018.0,OTHER_GOV,collaborator,Guangxi Center for Disease Control and Prevention,Phase 3
NCT03821857,2019.0,OTHER,lead,Mayo Clinic,Phase 4
NCT03821857,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT03821883,2020.0,OTHER,lead,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Not Applicable
NCT03822013,2019.0,OTHER,lead,Tehran University of Medical Sciences,Phase 3
NCT03822013,2019.0,OTHER,collaborator,Mashhad University of Medical Sciences,Phase 3
NCT03822013,2019.0,OTHER,collaborator,Kashan University of Medical Sciences,Phase 3
NCT03822208,2019.0,INDUSTRY,lead,Alector Inc.,Phase 1
NCT03822364,2018.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 1
NCT03822416,2019.0,OTHER,lead,University of Minnesota,Phase 2
NCT03822416,2019.0,OTHER,collaborator,"Hennepin County Medical Center, Minneapolis",Phase 2
NCT03822416,2019.0,OTHER,collaborator,Brown University,Phase 2
NCT03822754,2018.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT03822767,2018.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT03823404,2019.0,INDUSTRY,lead,Cortexyme Inc.,Phase 2/Phase 3
NCT03824938,2019.0,OTHER,lead,Columbia University,Phase 3
NCT03824938,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT03826134,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Early Phase 1
NCT03826498,2018.0,OTHER,lead,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Phase 2
NCT03826563,2019.0,OTHER,lead,Children's Hospital of Philadelphia,Not Applicable
NCT03826563,2019.0,OTHER,collaborator,University of Pennsylvania,Not Applicable
NCT03826563,2019.0,UNKNOWN,collaborator,"Brain and Behavior Research Foundation (NARSAD Young Investigator Award, Grant Number 26742)",Not Applicable
NCT03826615,2019.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT03826628,2019.0,INDUSTRY,lead,Dermatology Specialties Limited Partnership,Phase 2/Phase 3
NCT03826693,2021.0,OTHER,lead,Stanford University,Phase 2
NCT03826693,2021.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 2
NCT03826875,2019.0,OTHER,lead,University of Washington,Phase 2
NCT03826914,2018.0,OTHER,lead,University of Manitoba,Not Applicable
NCT03826940,2019.0,OTHER,lead,University of Coimbra,Not Applicable
NCT03827018,2018.0,INDUSTRY,lead,"Kiniksa Pharmaceuticals, Ltd.",Phase 2
NCT03827122,2018.0,OTHER,lead,Riyadh Colleges of Dentistry and Pharmacy,Phase 2
NCT03828032,2019.0,UNKNOWN,lead,Ting Li,Not Applicable
NCT03828032,2019.0,UNKNOWN,collaborator,Affiliated Hospital of Armed Police Logistics College,Not Applicable
NCT03828123,2012.0,INDUSTRY,lead,"Bioinova, s.r.o.",Phase 1/Phase 2
NCT03828123,2012.0,UNKNOWN,collaborator,"Department of Neurology, University Hospital Motol, Prague, Czech Republic",Phase 1/Phase 2
NCT03828539,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT03828747,2019.0,INDUSTRY,lead,"Genentech, Inc.",Phase 2
NCT03829124,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 4
NCT03829566,2019.0,OTHER,lead,Northwestern University,Phase 2/Phase 3
NCT03829878,2020.0,INDUSTRY,lead,Finch Research and Development LLC.,Phase 2
NCT03830164,2019.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2
NCT03830164,2019.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT03830398,2018.0,OTHER,lead,Mustafa Kemal University,Phase 4
NCT03830528,2019.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT03830762,2019.0,INDUSTRY,lead,Actinogen Medical,Phase 1
NCT03830762,2019.0,INDUSTRY,collaborator,ICON plc,Phase 1
NCT03830827,2020.0,OTHER,lead,Sir Run Run Shaw Hospital,Phase 4
NCT03830827,2020.0,OTHER,collaborator,Shenzhen Mental Health Center,Phase 4
NCT03830827,2020.0,OTHER,collaborator,Huazhong University of Science and Technology,Phase 4
NCT03831399,2019.0,OTHER,lead,University of Valencia,Phase 1
NCT03831399,2019.0,UNKNOWN,collaborator,Armonea Group - La Saleta,Phase 1
NCT03831399,2019.0,UNKNOWN,collaborator,Bonusan BV,Phase 1
NCT03831425,2023.0,OTHER,lead,The Hospital for Sick Children,Phase 2
NCT03831425,2023.0,OTHER,collaborator,Foundation for Prader-Willi Research,Phase 2
NCT03831841,2018.0,OTHER,lead,Universidad de Zaragoza,Not Applicable
NCT03832309,2017.0,OTHER,lead,CHRISTUS Health,Not Applicable
NCT03832712,2018.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT03832712,2018.0,OTHER,collaborator,Umeå University,Not Applicable
NCT03832712,2018.0,OTHER,collaborator,Uppsala University,Not Applicable
NCT03832712,2018.0,OTHER,collaborator,Lund University,Not Applicable
NCT03832712,2018.0,OTHER,collaborator,"University Hospital, Linkoeping",Not Applicable
NCT03832712,2018.0,OTHER,collaborator,Göteborg University,Not Applicable
NCT03832998,2019.0,INDUSTRY,lead,Amgen,Phase 3
NCT03832998,2019.0,INDUSTRY,collaborator,Novartis,Phase 3
NCT03834610,2017.0,OTHER,lead,Aswan University Hospital,Not Applicable
NCT03834961,2019.0,NETWORK,lead,Children's Oncology Group,Phase 2
NCT03834961,2019.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT03835117,2020.0,OTHER,lead,Rossignol Medical Center,Phase 2
NCT03835117,2020.0,OTHER,collaborator,Southwest Autism Research & Resource Center,Phase 2
NCT03835325,2019.0,INDUSTRY,lead,Eurofarma Laboratorios S.A.,Not Applicable
NCT03835507,2016.0,OTHER,lead,Hanyang University Seoul Hospital,Phase 1/Phase 2
NCT03836040,2019.0,INDUSTRY,lead,Amgen,Phase 3
NCT03836040,2019.0,INDUSTRY,collaborator,Novartis,Phase 3
NCT03836664,2017.0,OTHER,lead,University of Kansas Medical Center,Phase 2
NCT03836716,2019.0,INDUSTRY,lead,ZevraDenmark,Phase 3
NCT03838185,2019.0,INDUSTRY,lead,"Abrexa Pharmaceuticals, Inc.",Phase 1
NCT03838185,2019.0,INDUSTRY,collaborator,Iqvia Pty Ltd,Phase 1
NCT03838484,2019.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT03838484,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT03838484,2019.0,OTHER,collaborator,University of Florida,Not Applicable
NCT03838952,2019.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT03839251,2018.0,OTHER,lead,Chonbuk National University Hospital,Phase 4
NCT03839251,2018.0,INDUSTRY,collaborator,"Otsuka Pharmaceutical Co., Ltd.",Phase 4
NCT03840005,2018.0,OTHER,lead,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 2
NCT03840005,2018.0,OTHER,collaborator,JP Moulton Charitable Foundation,Phase 2
NCT03840005,2018.0,UNKNOWN,collaborator,PRO.MED.CS Praha a.s.,Phase 2
NCT03840005,2018.0,UNKNOWN,collaborator,"Clinical Trials Research Unit, University of Sheffield",Phase 2
NCT03840837,2019.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT03840837,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT03841292,2018.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT03841474,2021.0,OTHER,lead,Klinički Bolnički Centar Zagreb,Not Applicable
NCT03841539,2019.0,OTHER,lead,University of Kansas Medical Center,Not Applicable
NCT03841539,2019.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT03841604,2019.0,INDUSTRY,lead,Zambon SpA,Phase 4
NCT03841734,2019.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 3
NCT03841773,2019.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT03842436,2018.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT03842436,2018.0,INDUSTRY,collaborator,Gilead Sciences,Phase 4
NCT03842969,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT03843008,2022.0,OTHER,lead,University of Florida,Not Applicable
NCT03843281,2019.0,OTHER,lead,Bruno Minotti,Phase 4
NCT03843463,2021.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT03843463,2021.0,OTHER,collaborator,University of South Carolina,Phase 2
NCT03843463,2021.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT03843463,2021.0,OTHER,collaborator,"University of California, Irvine",Phase 2
NCT03843463,2021.0,NIH,collaborator,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 2
NCT03843710,2020.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT03843710,2020.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT03843944,2018.0,OTHER,lead,IRCCS San Raffaele Roma,Phase 4
NCT03844243,2019.0,OTHER,lead,Aalborg University,Early Phase 1
NCT03844412,2019.0,OTHER,lead,Duke University,Phase 2
NCT03844412,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT03845023,2019.0,INDUSTRY,lead,Apnimed,Phase 2
NCT03845322,2018.0,OTHER,lead,University of New Mexico,Early Phase 1
NCT03845387,2019.0,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 2
NCT03846102,2019.0,OTHER,lead,Zuyderland Medisch Centrum,Phase 4
NCT03846102,2019.0,INDUSTRY,collaborator,Fresenius Kabi,Phase 4
NCT03846271,2018.0,OTHER,lead,University of Electronic Science and Technology of China,Not Applicable
NCT03846284,2017.0,OTHER,lead,Mansoura University,Not Applicable
NCT03847155,2015.0,OTHER,lead,University Hospital Ostrava,Not Applicable
NCT03847545,2018.0,OTHER,lead,University of Southern Denmark,Not Applicable
NCT03847545,2018.0,OTHER,collaborator,Odense University Hospital,Not Applicable
NCT03847545,2018.0,OTHER,collaborator,Sygehus Lillebaelt,Not Applicable
NCT03847545,2018.0,OTHER,collaborator,Region of Southern Denmark,Not Applicable
NCT03847545,2018.0,OTHER,collaborator,"The Augustinus Foundation, Denmark.",Not Applicable
NCT03847545,2018.0,UNKNOWN,collaborator,Lounkær Fonden,Not Applicable
NCT03847545,2018.0,UNKNOWN,collaborator,Fonden for scleroseramte på Fyn,Not Applicable
NCT03847545,2018.0,UNKNOWN,collaborator,The Danish Multiple Sclerosis Society,Not Applicable
NCT03847545,2018.0,UNKNOWN,collaborator,TH MAIGAARDS EFTF. FRU LILY BENTHINE LUNDS FOND AF 1. JUNI 1978,Not Applicable
NCT03847545,2018.0,OTHER,collaborator,Fonden til Lægevidenskabens Fremme,Not Applicable
NCT03847545,2018.0,UNKNOWN,collaborator,Overlægeråds forskningsfond,Not Applicable
NCT03847883,2011.0,OTHER_GOV,lead,Rajavithi Hospital,Phase 4
NCT03847883,2011.0,UNKNOWN,collaborator,Lumpang Hospital,Phase 4
NCT03848143,2019.0,OTHER,lead,Isabel Moreno Hay,Phase 2
NCT03848143,2019.0,INDUSTRY,collaborator,"Allergan Sales, LLC",Phase 2
NCT03848234,2015.0,OTHER,lead,Tangent Data,Phase 3
NCT03848234,2015.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT03848481,2020.0,OTHER,lead,Montefiore Medical Center,Phase 2
NCT03848481,2020.0,OTHER,collaborator,Foundation for Prader-Willi Research,Phase 2
NCT03848481,2020.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT03848715,2019.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT03848832,2019.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT03849326,2023.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Not Applicable
NCT03849326,2023.0,UNKNOWN,collaborator,University of Saint-Etienne,Not Applicable
NCT03849456,2020.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03849534,2023.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT03849534,2023.0,OTHER_GOV,collaborator,Folktandvården Stockholms län AB,Not Applicable
NCT03849872,2019.0,INDUSTRY,lead,Ono Pharmaceutical Co. Ltd,Phase 1
NCT03850106,2018.0,INDUSTRY,lead,"The Center for Applied Health Sciences, LLC",Not Applicable
NCT03850106,2018.0,UNKNOWN,collaborator,Indus Biotech,Not Applicable
NCT03850301,2018.0,OTHER,lead,Imperial College London,Not Applicable
NCT03850834,2019.0,INDUSTRY,lead,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1
NCT03851172,2019.0,OTHER,lead,Assiut University,Phase 2
NCT03851562,2018.0,OTHER,lead,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,Phase 2
NCT03852303,2017.0,OTHER,lead,Universiteit Antwerpen,Phase 4
NCT03852303,2017.0,OTHER,collaborator,European Research Council,Phase 4
NCT03852628,2019.0,OTHER,lead,Pharmacotherapies for Alcohol and Substance Use Disorders Alliance,Phase 2
NCT03852628,2019.0,FED,collaborator,United States Department of Defense,Phase 2
NCT03852628,2019.0,OTHER,collaborator,RTI International,Phase 2
NCT03853746,2019.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT03853746,2019.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 4
NCT03854019,2019.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 3
NCT03854019,2019.0,OTHER,collaborator,Cures Within Reach,Phase 3
NCT03854409,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT03854409,2019.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT03854409,2019.0,INDUSTRY,collaborator,H. Lundbeck A/S,Phase 1
NCT03854500,2019.0,OTHER,lead,Haukeland University Hospital,Phase 3
NCT03855774,2018.0,OTHER_GOV,lead,Institut de Recherche Biomedicale des Armees,Not Applicable
NCT03856359,2019.0,OTHER,lead,Duke University,Phase 2
NCT03856359,2019.0,INDUSTRY,collaborator,"Bausch Health Americas, Inc.",Phase 2
NCT03856502,2012.0,OTHER,lead,General Hospital Sveti Duh,Not Applicable
NCT03856866,2019.0,OTHER,lead,The Hospital for Sick Children,Phase 2
NCT03857243,2014.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT03857243,2014.0,OTHER,collaborator,American Heart Association,Not Applicable
NCT03857581,2020.0,OTHER,lead,Augusta University,Phase 4
NCT03858192,2019.0,OTHER,lead,University of Birmingham,Not Applicable
NCT03858192,2019.0,UNKNOWN,collaborator,Dowager Countess Eleanor Peel Trust,Not Applicable
NCT03858192,2019.0,OTHER,collaborator,University Hospital Birmingham NHS Foundation Trust,Not Applicable
NCT03858192,2019.0,UNKNOWN,collaborator,MRC-Arthritis Research UK Centre for Musculoskeletal Ageing Research,Not Applicable
NCT03858270,2019.0,OTHER,lead,Wayne State University,Phase 3
NCT03858621,2019.0,OTHER,lead,"Victor Contreras, MSN",Not Applicable
NCT03858751,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT03859973,2019.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT03860194,2017.0,OTHER,lead,Far Eastern Memorial Hospital,Not Applicable
NCT03860233,2019.0,OTHER,lead,Vivek Jain,Phase 1
NCT03860233,2019.0,OTHER,collaborator,George Washington University,Phase 1
NCT03860597,2018.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT03860857,2018.0,OTHER,lead,"University of California, Irvine",Phase 3
NCT03860857,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT03861000,2019.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT03861299,2019.0,OTHER,lead,Jasper Gerritsen,Not Applicable
NCT03861299,2019.0,OTHER,collaborator,Elisabeth-TweeSteden Ziekenhuis,Not Applicable
NCT03861299,2019.0,OTHER,collaborator,University Medical Center Groningen,Not Applicable
NCT03861299,2019.0,OTHER,collaborator,Medical Center Haaglanden,Not Applicable
NCT03861299,2019.0,OTHER,collaborator,"University Hospital, Ghent",Not Applicable
NCT03861832,2018.0,OTHER,lead,Howard University,Not Applicable
NCT03861832,2018.0,UNKNOWN,collaborator,Medical Home Development Group,Not Applicable
NCT03861832,2018.0,UNKNOWN,collaborator,Geneus Health,Not Applicable
NCT03862547,2019.0,OTHER,lead,University Of Perugia,Not Applicable
NCT03862547,2019.0,UNKNOWN,collaborator,"Ester Illiano, MD",Not Applicable
NCT03862547,2019.0,UNKNOWN,collaborator,"Mario Rende,Full Professor",Not Applicable
NCT03862547,2019.0,UNKNOWN,collaborator,"Alessandra Psitilli, Researcher",Not Applicable
NCT03862547,2019.0,UNKNOWN,collaborator,"Anna Stabile, Researcher",Not Applicable
NCT03862859,2019.0,OTHER,lead,Nicholas Carlson,Phase 4
NCT03862859,2019.0,OTHER,collaborator,Danish Heart Foundation,Phase 4
NCT03862937,2019.0,OTHER,lead,Federal University of Health Science of Porto Alegre,Not Applicable
NCT03862950,2019.0,OTHER,lead,University of Alberta,Phase 2
NCT03862950,2019.0,OTHER,collaborator,St. Justine's Hospital,Phase 2
NCT03863080,2019.0,INDUSTRY,lead,Immunovant Sciences GmbH,Phase 2
NCT03863236,2019.0,OTHER,lead,University of Oulu,Not Applicable
NCT03863366,2017.0,OTHER,lead,University of Oxford,Not Applicable
NCT03863873,2017.0,OTHER,lead,Mansoura University,Not Applicable
NCT03863925,2017.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 4
NCT03864523,2016.0,INDIV,lead,"Onofre, Aurora Pujol, M.D.",Phase 2
NCT03864523,2016.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 2
NCT03864523,2016.0,OTHER,collaborator,Fundacion Hesperia,Phase 2
NCT03864523,2016.0,UNKNOWN,collaborator,ELA España Association,Phase 2
NCT03865017,2019.0,INDUSTRY,lead,VTBIO Co. LTD,Phase 1/Phase 2
NCT03865017,2019.0,UNKNOWN,collaborator,BHT Lifescience Austrailia Pty Ltd.,Phase 1/Phase 2
NCT03865121,2019.0,OTHER,lead,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Phase 2
NCT03865121,2019.0,OTHER,collaborator,Howard University,Phase 2
NCT03865719,2019.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT03865719,2019.0,OTHER,collaborator,Massachusetts General Hospital,Not Applicable
NCT03865940,2019.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT03865953,2019.0,INDUSTRY,lead,Lateral Pharma Pty Ltd,Phase 2
NCT03866668,2019.0,OTHER,lead,Stanford University,Phase 2
NCT03866668,2019.0,UNKNOWN,collaborator,SPARK (Stanford University),Phase 2
NCT03867201,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT03867539,2019.0,OTHER,lead,Kettering Health Network,Phase 4
NCT03867539,2019.0,OTHER,collaborator,American Society for Surgery of the Hand,Phase 4
NCT03868839,2019.0,OTHER,lead,Xiaoduo Fan,Phase 2
NCT03869736,2019.0,OTHER_GOV,lead,Bayside Health,Phase 2
NCT03870763,2019.0,INDUSTRY,lead,Biogen,Phase 3
NCT03870776,2019.0,INDUSTRY,lead,Mapreg,Phase 2
NCT03870776,2019.0,INDUSTRY,collaborator,Eurofins Optimed,Phase 2
NCT03870880,2017.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 3
NCT03871257,2020.0,NIH,lead,National Cancer Institute (NCI),Phase 3
NCT03872453,2019.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT03872479,2019.0,INDUSTRY,lead,"Editas Medicine, Inc.",Phase 1/Phase 2
NCT03872596,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT03872596,2019.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT03873129,2019.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT03873129,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT03873337,2019.0,OTHER,lead,"Rutgers, The State University of New Jersey",Not Applicable
NCT03873337,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT03874494,2019.0,INDUSTRY,lead,Otsuka Beijing Research Institute,Phase 3
NCT03874832,2018.0,INDUSTRY,lead,"Satsuma Pharmaceuticals, Inc.",Phase 1
NCT03875378,2020.0,OTHER,lead,"Pouneh K. Fazeli, MD",Phase 2
NCT03875378,2020.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT03875391,2019.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT03875638,2019.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT03876002,2016.0,OTHER,lead,Molecular NeuroImaging,Phase 1
NCT03876119,2018.0,OTHER,lead,Hospital Clinic of Barcelona,Phase 2/Phase 3
NCT03876119,2018.0,OTHER,collaborator,Fundació La Marató de TV3,Phase 2/Phase 3
NCT03876119,2018.0,OTHER,collaborator,Fundacion Clinic per a la Recerca Biomédica,Phase 2/Phase 3
NCT03876444,2019.0,OTHER_GOV,lead,Suvasini Sharma,Phase 2/Phase 3
NCT03877120,2017.0,OTHER,lead,"Centro Medico Nacional La Raza, IMSS",Phase 4
NCT03877120,2017.0,OTHER,collaborator,Universidad de La Frontera,Phase 4
NCT03877510,2019.0,INDUSTRY,lead,"Impax Laboratories, LLC",Phase 3
NCT03877718,2019.0,INDUSTRY,lead,"Charleston Laboratories, Inc",Phase 2
NCT03879538,2019.0,OTHER,lead,The Cleveland Clinic,Phase 3
NCT03879603,2019.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1
NCT03879655,2019.0,INDUSTRY,lead,Mandos LLC,Phase 2/Phase 3
NCT03879746,2019.0,OTHER,lead,Assiut University,Phase 3
NCT03880487,2019.0,INDUSTRY,lead,"Kalyra Pharmaceuticals, Inc.",Phase 1
NCT03880487,2019.0,FED,collaborator,United States Department of Defense,Phase 1
NCT03880487,2019.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT03881371,2019.0,INDUSTRY,lead,Zambon SpA,Phase 3
NCT03881449,2019.0,FED,lead,Durham VA Medical Center,Phase 4
NCT03881449,2019.0,UNKNOWN,collaborator,"Otsuka Pharmaceutical Development and Commercialization, Inc.",Phase 4
NCT03881852,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 2
NCT03882034,2019.0,NIH,lead,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3
NCT03882060,2019.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT03882320,2019.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Not Applicable
NCT03882320,2019.0,OTHER,collaborator,Pitié-Salpêtrière Hospital,Not Applicable
NCT03882437,2019.0,INDUSTRY,lead,Rocket Pharmaceuticals Inc.,Phase 1
NCT03882788,2013.0,OTHER,lead,Stanford University,Not Applicable
NCT03882788,2013.0,OTHER,collaborator,The Gerber Foundation,Not Applicable
NCT03882918,2019.0,INDUSTRY,lead,Ovid Therapeutics Inc.,Phase 3
NCT03883204,2015.0,OTHER,lead,Fundación Marques de Valdecilla,Phase 4
NCT03883204,2015.0,NETWORK,collaborator,Centro de Investigación Biomédica en Red de Salud Mental,Phase 4
NCT03883204,2015.0,OTHER,collaborator,Instituto de Investigación Marqués de Valdecilla,Phase 4
NCT03883581,2019.0,OTHER,lead,University of Florida,Phase 1/Phase 2
NCT03883581,2019.0,OTHER,collaborator,"Holy Cross Hospital, Florida",Phase 1/Phase 2
NCT03883581,2019.0,OTHER,collaborator,ALS Association,Phase 1/Phase 2
NCT03884530,2019.0,OTHER,lead,Kafrelsheikh University,Phase 3
NCT03884530,2019.0,OTHER,collaborator,Ain Shams University,Phase 3
NCT03884959,2018.0,INDUSTRY,lead,"HLB Cell Co., Ltd.",Phase 2
NCT03885258,2017.0,OTHER,lead,University of Sao Paulo,Early Phase 1
NCT03886675,2022.0,OTHER,lead,Imperial College London,Not Applicable
NCT03886675,2022.0,OTHER,collaborator,Imperial College Healthcare NHS Trust,Not Applicable
NCT03886675,2022.0,OTHER,collaborator,Guy's and St Thomas' NHS Foundation Trust,Not Applicable
NCT03886675,2022.0,OTHER,collaborator,St George's University Hospitals NHS Foundation Trust,Not Applicable
NCT03886675,2022.0,OTHER,collaborator,University Hospitals Coventry and Warwickshire NHS Trust,Not Applicable
NCT03886675,2022.0,UNKNOWN,collaborator,"South Canterbury DHB, New Zealand",Not Applicable
NCT03886675,2022.0,OTHER,collaborator,Baylor Scott and White Health,Not Applicable
NCT03886675,2022.0,OTHER,collaborator,University Hospital Southampton NHS Foundation Trust,Not Applicable
NCT03886675,2022.0,UNKNOWN,collaborator,Health New Zealand,Not Applicable
NCT03887000,2019.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT03887000,2019.0,UNKNOWN,collaborator,"CIC Inserm 1405, University Hospital Clermont-Ferrand, France",Not Applicable
NCT03887065,2019.0,OTHER,lead,"Cook, Stuart, MD",Early Phase 1
NCT03887182,2020.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT03887273,2022.0,INDUSTRY,lead,"Q Therapeutics, Inc.",Phase 1/Phase 2
NCT03887325,2019.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03887429,2019.0,INDUSTRY,lead,"Promentis Pharmaceuticals, Inc.",Phase 2
NCT03887429,2019.0,INDUSTRY,collaborator,Celerion,Phase 2
NCT03887429,2019.0,OTHER,collaborator,Baylor College of Medicine,Phase 2
NCT03887676,2019.0,INDIV,lead,Evdokia Anagnostou,Phase 2
NCT03887676,2019.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT03887676,2019.0,OTHER,collaborator,McMaster University,Phase 2
NCT03887676,2019.0,OTHER,collaborator,"University of Western Ontario, Canada",Phase 2
NCT03887676,2019.0,OTHER,collaborator,Queen's University,Phase 2
NCT03887676,2019.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT03887676,2019.0,OTHER,collaborator,University of Toronto,Phase 2
NCT03887754,2016.0,OTHER,lead,Minia University,Phase 2
NCT03887884,2019.0,INDUSTRY,lead,Acorda Therapeutics,Phase 1
NCT03888664,2016.0,OTHER,lead,IRCCS Eugenio Medea,Phase 2
NCT03888716,2019.0,INDUSTRY,lead,Abliva AB,Phase 1
NCT03888924,2019.0,OTHER,lead,S. Andrea Hospital,Phase 2
NCT03889249,2019.0,OTHER,lead,University of Calgary,Phase 3
NCT03890133,2019.0,OTHER,lead,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Not Applicable
NCT03890497,2018.0,OTHER,lead,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT03890497,2018.0,OTHER,collaborator,World Health Organization,Phase 4
NCT03891134,2016.0,OTHER,lead,Chimei Medical Center,Not Applicable
NCT03891134,2016.0,UNKNOWN,collaborator,The Taiwanese Osteoporosis Association.,Not Applicable
NCT03891277,2019.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT03891758,2019.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma Corporation,Phase 3
NCT03891758,2019.0,OTHER,collaborator,The Research Foundation for Microbial Diseases of Osaka University,Phase 3
NCT03892070,2019.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT03892122,2019.0,OTHER,lead,"Ospedale Monsignor R. Dimiccoli, Barletta",Phase 4
NCT03892772,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT03892772,2019.0,INDUSTRY,collaborator,Apnimed,Phase 1/Phase 2
NCT03892785,2020.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 3
NCT03893240,2019.0,INDUSTRY,lead,Spark Therapeutics,Not Applicable
NCT03893617,2017.0,OTHER,lead,Dana Bovbjerg,Phase 1
NCT03893617,2017.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT03893825,2019.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT03894085,2019.0,OTHER,lead,Central South University,Not Applicable
NCT03894345,2019.0,OTHER,lead,University of Manitoba,Phase 1
NCT03894826,2018.0,OTHER,lead,University of Calgary,Phase 2
NCT03896009,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT03896659,2019.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT03896659,2019.0,OTHER,collaborator,"University of California, Irvine",Phase 4
NCT03896659,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT03896945,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2/Phase 3
NCT03898843,2020.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT03899168,2014.0,OTHER,lead,Leibniz-Institut für Wissensmedien,Not Applicable
NCT03899246,2019.0,OTHER,lead,Children's Hospital of Michigan,Phase 1
NCT03899298,2019.0,INDUSTRY,lead,R3 Stem Cell,Phase 1
NCT03899324,2019.0,INDUSTRY,lead,B&A Therapeutics,Phase 2
NCT03899584,2019.0,OTHER_GOV,lead,"Coordinación de Investigación en Salud, Mexico",Phase 3
NCT03900754,2020.0,FED,lead,VA Office of Research and Development,Phase 2
NCT03900754,2020.0,OTHER,collaborator,"University of California, San Francisco",Phase 2
NCT03900754,2020.0,FED,collaborator,VA Greater Los Angeles Healthcare System,Phase 2
NCT03900923,2019.0,OTHER,lead,NYU Langone Health,Phase 2
NCT03901092,2019.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT03901105,2019.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 3
NCT03901482,2019.0,INDUSTRY,lead,"Satsuma Pharmaceuticals, Inc.",Phase 3
NCT03901638,2019.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT03902548,2018.0,INDUSTRY,lead,"Five Eleven Pharma, Inc.",Phase 1
NCT03902613,2019.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT03902613,2019.0,OTHER,collaborator,Columbia University,Phase 4
NCT03903211,2019.0,OTHER,lead,Jae Seung Kim,Phase 2
NCT03903549,2022.0,INDUSTRY,lead,"Five Eleven Pharma, Inc.",Phase 1
NCT03904511,2019.0,OTHER,lead,University of Ottawa,Phase 1
NCT03904511,2019.0,UNKNOWN,collaborator,Souroubea Botanicals Inc.,Phase 1
NCT03905811,2019.0,OTHER,lead,Jordan Schultz,Phase 1/Phase 2
NCT03905811,2019.0,OTHER,collaborator,University of Iowa,Phase 1/Phase 2
NCT03906123,2017.0,OTHER,lead,Tianjin Medical University General Hospital,Not Applicable
NCT03906721,2019.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 2
NCT03907046,2020.0,OTHER,lead,Yale University,Phase 3
NCT03907046,2020.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT03907072,2019.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 2/Phase 3
NCT03907124,2019.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT03907176,2019.0,INDUSTRY,lead,Heron Therapeutics,Phase 3
NCT03907592,2017.0,OTHER,lead,Gdansk University of Physical Education and Sport,Not Applicable
NCT03907592,2017.0,OTHER,collaborator,Medical University of Gdansk,Not Applicable
NCT03907592,2017.0,OTHER_GOV,collaborator,"National Science Centre, Poland",Not Applicable
NCT03908580,2013.0,INDUSTRY,lead,Medy-Tox,Phase 4
NCT03910088,2019.0,OTHER,lead,Cairo University,Phase 4
NCT03910101,2019.0,OTHER_GOV,lead,Vastra Gotaland Region,Not Applicable
NCT03910621,2020.0,INDUSTRY,lead,Actelion,Phase 4
NCT03910738,2019.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 2
NCT03910738,2019.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT03910738,2019.0,UNKNOWN,collaborator,Fédération Hospitalo-Universitaire NEUROGENYCS,Phase 2
NCT03910738,2019.0,INDUSTRY,collaborator,Grünenthal GmbH,Phase 2
NCT03911388,2019.0,OTHER,lead,"Gregory K. Friedman, MD",Phase 1
NCT03911388,2019.0,OTHER,collaborator,Cannonball Kids' Cancer Foundation,Phase 1
NCT03911388,2019.0,UNKNOWN,collaborator,"Treovir, Inc",Phase 1
NCT03911414,2019.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT03911466,2020.0,OTHER,lead,"T. John Winhusen, PhD",Phase 3
NCT03911466,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT03911466,2020.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 3
NCT03911726,2020.0,OTHER,lead,"Central Institute of Mental Health, Mannheim",Not Applicable
NCT03911739,2021.0,OTHER,lead,"T. John Winhusen, PhD",Phase 3
NCT03911739,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT03911739,2021.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 3
NCT03911960,2019.0,OTHER,lead,The Miriam Hospital,Not Applicable
NCT03912220,2020.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT03912220,2020.0,UNKNOWN,collaborator,Adelson Medical Research Foundation,Phase 2
NCT03912337,2019.0,INDUSTRY,lead,Amgen,Phase 4
NCT03912337,2019.0,INDUSTRY,collaborator,Novartis,Phase 4
NCT03912350,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT03912428,2019.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT03913130,2019.0,INDUSTRY,lead,ProQR Therapeutics,Phase 1/Phase 2
NCT03913143,2019.0,INDUSTRY,lead,ProQR Therapeutics,Phase 2/Phase 3
NCT03914625,2019.0,NIH,lead,National Cancer Institute (NCI),Phase 3
NCT03914638,2019.0,OTHER,lead,University of Aarhus,Phase 2/Phase 3
NCT03914677,2019.0,OTHER,lead,Wayne State University,Phase 4
NCT03915613,2021.0,OTHER,lead,"University Health Network, Toronto",Phase 1/Phase 2
NCT03915938,2017.0,OTHER,lead,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT03917225,2019.0,INDUSTRY,lead,"Minoryx Therapeutics, S.L.",Phase 2
NCT03917459,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT03917719,2019.0,INDUSTRY,lead,Catabasis Pharmaceuticals,Phase 3
NCT03918850,2020.0,OTHER,lead,"T. John Winhusen, PhD",Phase 3
NCT03918850,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT03918850,2020.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 3
NCT03919162,2021.0,INDUSTRY,lead,Vivoryon Therapeutics N.V.,Phase 2
NCT03919162,2021.0,OTHER,collaborator,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT03919162,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03919669,2019.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT03919669,2019.0,UNKNOWN,collaborator,"Cerveau Technologies, Inc.",Phase 2
NCT03919773,2018.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1/Phase 2
NCT03919773,2018.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 1/Phase 2
NCT03919773,2018.0,OTHER,collaborator,Dysautonomia International,Phase 1/Phase 2
NCT03919955,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT03920111,2021.0,OTHER,lead,University of Liverpool,Not Applicable
NCT03920540,2017.0,INDUSTRY,lead,Green Cross Corporation,Phase 3
NCT03920865,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT03921151,2014.0,OTHER,lead,Virginia Commonwealth University,Phase 1/Phase 2
NCT03921151,2014.0,OTHER,collaborator,"The University of Texas Medical Branch, Galveston",Phase 1/Phase 2
NCT03921151,2014.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT03921528,2019.0,INDUSTRY,lead,"Scholar Rock, Inc.",Phase 2
NCT03921541,2019.0,INDUSTRY,lead,Aeglea Biotherapeutics,Phase 3
NCT03922048,2023.0,INDUSTRY,lead,Heron Therapeutics,Phase 2
NCT03922061,2019.0,OTHER,lead,University of Vermont,Phase 1
NCT03922711,2019.0,INDUSTRY,lead,Prilenia,Phase 2
NCT03923738,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT03924193,2019.0,OTHER,lead,Yale University,Phase 3
NCT03924193,2019.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 3
NCT03924414,2019.0,OTHER,lead,California Pacific Medical Center Research Institute,Phase 4
NCT03924414,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT03924414,2019.0,OTHER,collaborator,"University of California, San Francisco",Phase 4
NCT03924414,2019.0,OTHER,collaborator,Duke University,Phase 4
NCT03924414,2019.0,OTHER,collaborator,University of Pittsburgh,Phase 4
NCT03924414,2019.0,OTHER,collaborator,Parkinson's Foundation,Phase 4
NCT03924791,2019.0,OTHER,lead,C.L.A.Vleggeert-Lankamp,Not Applicable
NCT03924791,2019.0,OTHER,collaborator,Spaarne Gasthuis,Not Applicable
NCT03924791,2019.0,OTHER,collaborator,Stichting Achmea Gezondheidszor,Not Applicable
NCT03924791,2019.0,UNKNOWN,collaborator,Posthumus Meyjes Fonds,Not Applicable
NCT03926052,2019.0,OTHER,lead,Yale University,Phase 3
NCT03926052,2019.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 3
NCT03926351,2018.0,OTHER,lead,"University Hospital, Akershus",Phase 2
NCT03926351,2018.0,INDUSTRY,collaborator,BASF AS,Phase 2
NCT03926351,2018.0,UNKNOWN,collaborator,Pre Diagnostics AS,Phase 2
NCT03926702,2019.0,OTHER,lead,"University of California, Berkeley",Early Phase 1
NCT03926702,2019.0,OTHER,collaborator,"University of California, San Francisco",Early Phase 1
NCT03927313,2019.0,OTHER,lead,University of Cape Town,Phase 2
NCT03928093,2019.0,OTHER,lead,The Hospital for Sick Children,Phase 3
NCT03928093,2019.0,UNKNOWN,collaborator,Epidemolysis Bullosa Research Partnership,Phase 3
NCT03928236,2019.0,OTHER,lead,Population Health Research Institute,Not Applicable
NCT03928496,2013.0,FED,lead,VA Greater Los Angeles Healthcare System,Phase 4
NCT03928496,2013.0,INDUSTRY,collaborator,Ipsen,Phase 4
NCT03928808,2023.0,OTHER,lead,"University of North Carolina, Chapel Hill",Early Phase 1
NCT03928808,2023.0,INDUSTRY,collaborator,OpenBiome,Early Phase 1
NCT03928808,2023.0,OTHER,collaborator,"Foundation of Hope, North Carolina",Early Phase 1
NCT03929068,2019.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT03929497,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT03930446,2016.0,OTHER,lead,University of Chicago,Early Phase 1
NCT03930563,2019.0,OTHER,lead,University of Iowa,Not Applicable
NCT03931018,2017.0,OTHER,lead,Fundació Institut Germans Trias i Pujol,Not Applicable
NCT03931018,2017.0,OTHER,collaborator,Germans Trias i Pujol Hospital,Not Applicable
NCT03931070,2019.0,OTHER,lead,Rhode Island Hospital,Phase 4
NCT03931161,2019.0,OTHER,lead,Imperial College Healthcare NHS Trust,Phase 4
NCT03931161,2019.0,OTHER,collaborator,Imperial College London,Phase 4
NCT03931408,2019.0,OTHER,lead,University of Louisville,Phase 2
NCT03932669,2018.0,OTHER,lead,Seoul National University Hospital,Phase 2
NCT03932825,2019.0,OTHER,lead,Lingjiang Li,Phase 2
NCT03933072,2016.0,OTHER,lead,Nicholls Spinal Injury Foundation,Phase 1/Phase 2
NCT03933072,2016.0,OTHER,collaborator,Wroclaw Medical University,Phase 1/Phase 2
NCT03933072,2016.0,UNKNOWN,collaborator,"Akson, Neuro-Rehabilitation Center for the Treatment of Spinal Cord Injuries",Phase 1/Phase 2
NCT03933072,2016.0,OTHER,collaborator,"University College, London",Phase 1/Phase 2
NCT03933072,2016.0,OTHER,collaborator,Poznan University of Medical Sciences,Phase 1/Phase 2
NCT03933163,2019.0,OTHER,lead,Murdoch Childrens Research Institute,Phase 2
NCT03933410,2019.0,INDUSTRY,lead,Kaleido Biosciences,Phase 2
NCT03935568,2019.0,INDUSTRY,lead,"Samus Therapeutics, Inc.",Phase 1
NCT03935724,2022.0,INDUSTRY,lead,Neuroplast,Phase 2/Phase 3
NCT03936361,2020.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,NINDS Stroke Trials Network (StrokeNet),Phase 3
NCT03936361,2020.0,OTHER,collaborator,Canadian Stroke Consortium (CSC),Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Yale University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,MetroHealth Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,"UH, Cleveland Medical Center",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Spectrum Health Hospitals,Phase 3
NCT03936361,2020.0,OTHER,collaborator,West Virginia University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Columbia University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,New York Presbyterian Brooklyn Methodist Hospital,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Buffalo General Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,State University of New York - Upstate Medical University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"St. Joseph's Regional Medical Center, New Jersey",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Tufts Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Massachusetts General Hospital,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,UMASS Memorial Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Baystate Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Vermont Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Lahey Hospital & Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Augusta University Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Prisma Health-Upstate,Phase 3
NCT03936361,2020.0,OTHER,collaborator,The Moses H. Cone Memorial Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Virginia,Phase 3
NCT03936361,2020.0,OTHER,collaborator,George Washington University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of Maryland, Baltimore",Phase 3
NCT03936361,2020.0,OTHER,collaborator,"Mount Sinai Hospital, New York",Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,NYU Langone Medical Center - Tisch Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Montefiore Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,NYU Langone Hospital - Brooklyn,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Froedtert Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Central DuPage Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Rush University Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Loyola University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Stanford University,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Mercy San Juan Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Oregon Health and Science University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Kaiser Permanente,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Southern California,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Cedars-Sinai Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of New Mexico,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Long Beach Memorial Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Kaiser Permanente Fontana,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of California, Irvine",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Arrowhead Regional Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Huntington Memorial Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Scripps Health,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of California, San Diego",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Ochsner Health System,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Desert Care Network,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Eden Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,San Francisco General Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of California, San Francisco",Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Louisville,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Ohio State University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Iowa,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Sanford Medical Center Fargo,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Nebraska,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Tampa General Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Florida,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Jackson Health System,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Mayo Clinic,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Baptist Medical Center Jacksonville,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Wayne State University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Michigan,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Mercy Health Saint Mary Grand Rapids,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"Metro Health, Michigan",Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Kentucky,Phase 3
NCT03936361,2020.0,OTHER,collaborator,McLaren Health Care,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Regions Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Allina Health System,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Kansas,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Minnesota,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,St. Cloud Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Milton S. Hershey Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Abington Memorial Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Temple University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Pennsylvania,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Lehigh Valley Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"York Hospital, York, PA",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Thomas Jefferson University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Pittsburgh,Phase 3
NCT03936361,2020.0,OTHER,collaborator,St. David's HealthCare,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Baylor College of Medicine,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Tulane Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,The University of Texas Health Science Center at San Antonio,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,OU Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Utah,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Swedish Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,St. Mary's Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Banner University Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Intermountain Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Legacy Emanuel Medical Center,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Sacred Heart Medical Center Springfield,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Harborview Injury Prevention and Research Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of Wisconsin, Madison",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Aurora BayCare Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Aurora Health Care,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of South Alabama,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Carolinas Medical Center,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Barnes-Jewish Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"St. Luke's Hospital, Kansas City, Missouri",Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Arkansas,Phase 3
NCT03936361,2020.0,OTHER,collaborator,OSF Healthcare System,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Cox Medical Center South,Phase 3
NCT03936361,2020.0,OTHER,collaborator,North Shore University Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Rhode Island Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Hartford Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Staten Island University Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Johns Hopkins University,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Phase 3
NCT03936361,2020.0,OTHER,collaborator,University of Alberta,Phase 3
NCT03936361,2020.0,OTHER,collaborator,The Ottawa Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,London Health Sciences Centre,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Hamilton General Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Hopital de l'Enfant-Jesus,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Montreal Neurological Institute and Hospital,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Foothills Medical Centre,Phase 3
NCT03936361,2020.0,OTHER,collaborator,"University Health Network, Toronto",Phase 3
NCT03936361,2020.0,OTHER,collaborator,"Health Sciences Centre, Winnipeg, Manitoba",Phase 3
NCT03936361,2020.0,OTHER,collaborator,Thunder Bay Regional Health Sciences Centre,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Fraser Health,Phase 3
NCT03936361,2020.0,UNKNOWN,collaborator,Hopital de Chicoutimi,Phase 3
NCT03936361,2020.0,OTHER,collaborator,Université de Sherbrooke,Phase 3
NCT03936426,2018.0,INDUSTRY,lead,Clarity Pharmaceuticals Ltd,Phase 1/Phase 2
NCT03936777,2019.0,INDUSTRY,lead,"Zogenix, Inc.",Phase 3
NCT03936777,2019.0,INDUSTRY,collaborator,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",Phase 3
NCT03936894,2019.0,OTHER,lead,Children's National Research Institute,Phase 1/Phase 2
NCT03936894,2019.0,UNKNOWN,collaborator,Foundation to Eradicate Duchenne,Phase 1/Phase 2
NCT03938584,2017.0,OTHER,lead,Hennepin Healthcare Research Institute,Not Applicable
NCT03938584,2017.0,UNKNOWN,collaborator,Regions Hospital,Not Applicable
NCT03938584,2017.0,OTHER,collaborator,University of Minnesota,Not Applicable
NCT03938922,2024.0,INDUSTRY,lead,Enterin Inc.,Phase 1
NCT03939052,2019.0,OTHER,lead,University of British Columbia,Not Applicable
NCT03939052,2019.0,INDUSTRY,collaborator,"Vitaflo International, Ltd",Not Applicable
NCT03939507,2006.0,OTHER,lead,University of Pavia,Not Applicable
NCT03939507,2006.0,OTHER,collaborator,University of Catanzaro,Not Applicable
NCT03939507,2006.0,OTHER,collaborator,University of Bologna,Not Applicable
NCT03939780,2020.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT03939780,2020.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT03941301,2019.0,OTHER,lead,Mackay Memorial Hospital,Not Applicable
NCT03941301,2019.0,UNKNOWN,collaborator,"National Tsing Hua University,Taiwan",Not Applicable
NCT03941301,2019.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Not Applicable
NCT03941444,2019.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 3
NCT03941678,2019.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT03941678,2019.0,OTHER,collaborator,University of Regina,Not Applicable
NCT03941834,2019.0,INDUSTRY,lead,Pfizer,Phase 2
NCT03943264,2019.0,INDUSTRY,lead,"Inmune Bio, Inc.",Phase 1
NCT03943264,2019.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT03943290,2019.0,INDUSTRY,lead,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2
NCT03943498,2019.0,OTHER,lead,Mayo Clinic,Early Phase 1
NCT03943498,2019.0,NIH,collaborator,National Cancer Institute (NCI),Early Phase 1
NCT03943537,2019.0,OTHER,lead,Mclean Hospital,Phase 2
NCT03944447,2018.0,NETWORK,lead,"OMNI Medical Services, LLC",Phase 2
NCT03944447,2018.0,UNKNOWN,collaborator,OMNI Medical Services Inc,Phase 2
NCT03944460,2018.0,OTHER,lead,Prof. Dr. Dieter Willbold,Phase 1
NCT03944460,2018.0,UNKNOWN,collaborator,"Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany",Phase 1
NCT03944460,2018.0,OTHER,collaborator,Medical University of Vienna,Phase 1
NCT03944460,2018.0,UNKNOWN,collaborator,"NeuroScios, Austria",Phase 1
NCT03944460,2018.0,UNKNOWN,collaborator,"Triskelion, The Netherlands",Phase 1
NCT03944460,2018.0,OTHER,collaborator,"Fundación Teófilo Hernando, Spain",Phase 1
NCT03944876,2019.0,OTHER,lead,Norwegian University of Science and Technology,Phase 3
NCT03944876,2019.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT03944876,2019.0,OTHER,collaborator,"University College, London",Phase 3
NCT03944876,2019.0,OTHER,collaborator,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Phase 3
NCT03944876,2019.0,OTHER,collaborator,Catholic University of Valencia,Phase 3
NCT03944876,2019.0,OTHER,collaborator,Universitätsklinikum Hamburg-Eppendorf,Phase 3
NCT03944954,2017.0,OTHER,lead,"Michael J. Wesley, PhD",Early Phase 1
NCT03944954,2017.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03945110,2019.0,OTHER,lead,The University of Western Australia,Phase 1/Phase 2
NCT03945110,2019.0,OTHER,collaborator,Royal Perth Hospital,Phase 1/Phase 2
NCT03945110,2019.0,OTHER,collaborator,Fiona Stanley Hospital,Phase 1/Phase 2
NCT03945110,2019.0,UNKNOWN,collaborator,Perth Urology Clinic,Phase 1/Phase 2
NCT03945279,2019.0,INDUSTRY,lead,Biogen,Phase 1
NCT03945448,2019.0,OTHER,lead,Makerere University,Phase 2/Phase 3
NCT03945448,2019.0,OTHER,collaborator,University of Minnesota,Phase 2/Phase 3
NCT03945448,2019.0,INDUSTRY,collaborator,Gilead Sciences,Phase 2/Phase 3
NCT03945526,2010.0,OTHER,lead,Indonesia University,Phase 1
NCT03946111,2019.0,OTHER,lead,Yale University,Phase 2/Phase 3
NCT03946111,2019.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2/Phase 3
NCT03947216,2020.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 2
NCT03947216,2020.0,UNKNOWN,collaborator,NS-PARK,Phase 2
NCT03947216,2020.0,OTHER,collaborator,EUCLID Clinical Trial Platform,Phase 2
NCT03947216,2020.0,UNKNOWN,collaborator,F-CRIN,Phase 2
NCT03947554,2019.0,INDUSTRY,lead,"EuroPharma, Inc.",Phase 1/Phase 2
NCT03947554,2019.0,UNKNOWN,collaborator,Botalys SA,Phase 1/Phase 2
NCT03948178,2019.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 3
NCT03948347,2019.0,OTHER,lead,First Affiliated Hospital of Jinan University,Not Applicable
NCT03949478,2021.0,OTHER,lead,University of Calgary,Phase 2
NCT03950076,2019.0,OTHER,lead,Population Health Research Institute,Phase 4
NCT03950427,2019.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT03950427,2019.0,OTHER,collaborator,Tobacco Related Disease Research Program,Phase 4
NCT03952156,2019.0,INDUSTRY,lead,"Homology Medicines, Inc",Phase 1/Phase 2
NCT03952234,2021.0,OTHER,lead,Baylor College of Medicine,Phase 1
NCT03952234,2021.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT03952234,2021.0,OTHER,collaborator,University of South Florida,Phase 1
NCT03952234,2021.0,OTHER,collaborator,Columbia University,Phase 1
NCT03952299,2021.0,OTHER,lead,"University of California, Davis",Phase 3
NCT03952494,2022.0,OTHER,lead,Weill Medical College of Cornell University,Not Applicable
NCT03952494,2022.0,OTHER,collaborator,Leon Lowenstein Foundation Inc.,Not Applicable
NCT03952637,2019.0,NIH,lead,National Human Genome Research Institute (NHGRI),Phase 1/Phase 2
NCT03952637,2019.0,INDUSTRY,collaborator,Sio Gene Therapies,Phase 1/Phase 2
NCT03952806,2019.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT03953612,2019.0,OTHER,lead,Yale University,Early Phase 1
NCT03953612,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT03953820,2019.0,INDUSTRY,lead,Aquestive Therapeutics,Phase 1/Phase 2
NCT03954041,2019.0,INDUSTRY,lead,Biogen,Phase 2
NCT03954106,2019.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT03954314,2019.0,OTHER,lead,Population Health Research Institute,Phase 3
NCT03954613,2020.0,INDUSTRY,lead,Neutec Ar-Ge San ve Tic A.Ş,Phase 4
NCT03955211,2019.0,INDUSTRY,lead,Heron Therapeutics,Phase 2
NCT03955380,2018.0,OTHER,lead,Prof. Dr. Dieter Willbold,Phase 1
NCT03955380,2018.0,UNKNOWN,collaborator,"Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany",Phase 1
NCT03955380,2018.0,OTHER,collaborator,Medical University of Vienna,Phase 1
NCT03955380,2018.0,UNKNOWN,collaborator,"NeuroScios, Austria",Phase 1
NCT03955380,2018.0,UNKNOWN,collaborator,"Nuvisan, Germany",Phase 1
NCT03955380,2018.0,OTHER,collaborator,"Fundación Teófilo Hernando, Spain",Phase 1
NCT03955380,2018.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT03955523,2019.0,OTHER,lead,University of British Columbia,Not Applicable
NCT03955549,2019.0,OTHER,lead,Agiad Psychiatry Hospital,Phase 3
NCT03955549,2019.0,OTHER,collaborator,University of Pittsburgh,Phase 3
NCT03956368,2020.0,OTHER,lead,Chinese University of Hong Kong,Phase 3
NCT03956446,2014.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT03956446,2014.0,OTHER,collaborator,"University of Ljubljana School of Medicine, Slovenia",Not Applicable
NCT03956979,2019.0,INDUSTRY,lead,Contera Pharma,Phase 2
NCT03956979,2019.0,INDUSTRY,collaborator,Bukwang Pharmaceutical,Phase 2
NCT03957499,2019.0,OTHER,lead,Samaa Rashwan,Phase 1
NCT03957720,2019.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Early Phase 1
NCT03958331,2019.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT03958331,2019.0,NIH,collaborator,National Institute of Nursing Research (NINR),Not Applicable
NCT03958331,2019.0,OTHER,collaborator,Nationwide Children's Hospital,Not Applicable
NCT03958396,2015.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT03958630,2019.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT03958708,2019.0,OTHER,lead,Taipei Medical University Shuang Ho Hospital,Phase 1/Phase 2
NCT03958877,2019.0,INDUSTRY,lead,Biogen,Phase 3
NCT03959124,2020.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Not Applicable
NCT03959124,2020.0,OTHER,collaborator,Beijing Tiantan Hospital,Not Applicable
NCT03959189,2019.0,INDUSTRY,lead,"Expansion Therapeutics, Inc.",Phase 1
NCT03961087,2019.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT03962114,2019.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT03962114,2019.0,OTHER,collaborator,A-T Children's Project,Phase 2
NCT03962114,2019.0,UNKNOWN,collaborator,Twan foundation (https://twanfoundation.nl),Phase 2
NCT03962543,2019.0,INDUSTRY,lead,"SpringWorks Therapeutics, Inc.",Phase 2
NCT03962738,2019.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT03963336,2017.0,OTHER,lead,Fayoum University,Early Phase 1
NCT03963362,2019.0,INDUSTRY,lead,GL Pharm Tech Corporation,Phase 1
NCT03963375,2019.0,OTHER,lead,Washington University School of Medicine,Phase 4
NCT03963375,2019.0,INDUSTRY,collaborator,EMD Serono,Phase 4
NCT03963479,2019.0,OTHER,lead,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2
NCT03964012,2019.0,INDUSTRY,lead,Serum Institute of India Pvt. Ltd.,Phase 3
NCT03964012,2019.0,OTHER,collaborator,PATH,Phase 3
NCT03965091,2019.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2
NCT03965871,2019.0,INDUSTRY,lead,Celon Pharma SA,Phase 2
NCT03965871,2019.0,OTHER,collaborator,"National Center for Research and Development, Poland",Phase 2
NCT03967249,2019.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 2
NCT03968133,2020.0,OTHER,lead,University of British Columbia,Phase 2
NCT03968133,2020.0,UNKNOWN,collaborator,The W. Garfield Weston Foundation,Phase 2
NCT03968393,2019.0,OTHER,lead,Population Health Research Institute,Phase 4
NCT03968393,2019.0,OTHER,collaborator,Hamilton Health Sciences Corporation,Phase 4
NCT03969732,2018.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT03970239,2019.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT03970798,2019.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT03971071,2019.0,INDUSTRY,lead,Amgen,Phase 4
NCT03971123,2019.0,INDUSTRY,lead,Cerecin,Phase 1
NCT03971461,2019.0,OTHER,lead,NYU Langone Health,Phase 2
NCT03971487,2019.0,OTHER,lead,The Methodist Hospital Research Institute,Phase 1/Phase 2
NCT03971487,2019.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 1/Phase 2
NCT03971617,2019.0,OTHER,lead,Stony Brook University,Phase 2/Phase 3
NCT03973203,2014.0,OTHER,lead,University of Helsinki,Not Applicable
NCT03973203,2014.0,OTHER,collaborator,Helsinki University Central Hospital,Not Applicable
NCT03973203,2014.0,OTHER,collaborator,Institute for Molecular Medicine,Not Applicable
NCT03973203,2014.0,OTHER,collaborator,University of Iowa,Not Applicable
NCT03973229,2019.0,OTHER,lead,Emory University,Early Phase 1
NCT03973229,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT03973268,2020.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT03973502,2017.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT03974269,2018.0,OTHER,lead,Centre Chirurgical Marie Lannelongue,Not Applicable
NCT03974360,2019.0,OTHER,lead,Danish Headache Center,Phase 2
NCT03974360,2019.0,INDUSTRY,collaborator,Novartis,Phase 2
NCT03974360,2019.0,INDUSTRY,collaborator,Amgen,Phase 2
NCT03974867,2019.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Not Applicable
NCT03974932,2019.0,INDUSTRY,lead,Heron Therapeutics,Phase 3
NCT03975829,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT03976349,2019.0,INDUSTRY,lead,Biogen,Phase 1
NCT03976349,2019.0,INDUSTRY,collaborator,"Ionis Pharmaceuticals, Inc.",Phase 1
NCT03977441,2019.0,OTHER,lead,Second Affiliated Hospital of Soochow University,Phase 4
NCT03977584,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT03977584,2019.0,OTHER,collaborator,Banner Alzheimer's Institute,Phase 2
NCT03977584,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT03977649,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT03978052,2019.0,OTHER,lead,Parc de Salut Mar,Not Applicable
NCT03978052,2019.0,OTHER,collaborator,Fundacion IMIM,Not Applicable
NCT03978052,2019.0,OTHER,collaborator,"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",Not Applicable
NCT03978286,2016.0,OTHER,lead,Universidad Juárez Autónoma de Tabasco,Phase 4
NCT03978338,2019.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT03978338,2019.0,UNKNOWN,collaborator,"Zhitong Biopharma CO.,LTD",Not Applicable
NCT03978403,2019.0,INDUSTRY,lead,Zosano Pharma Corporation,Phase 1
NCT03978442,2019.0,FED,lead,VA Office of Research and Development,Phase 4
NCT03978832,2019.0,INDUSTRY,lead,Indivior Inc.,Phase 4
NCT03978988,2020.0,OTHER,lead,"Central Hospital, Nancy, France",Not Applicable
NCT03979456,2018.0,OTHER,lead,Karolinska Institutet,Phase 3
NCT03979742,2022.0,INDUSTRY,lead,"StemCyte, Inc.",Phase 2
NCT03979898,2017.0,INDUSTRY,lead,R-Bio,Early Phase 1
NCT03979898,2017.0,OTHER,collaborator,Kyung Hee University Hospital at Gangdong,Early Phase 1
NCT03980184,2019.0,OTHER,lead,Yale University,Phase 2
NCT03980184,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT03980431,2018.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT03980431,2018.0,OTHER,collaborator,Peking University,Not Applicable
NCT03980431,2018.0,OTHER,collaborator,Peking University Cancer Hospital & Institute,Not Applicable
NCT03980730,2019.0,INDUSTRY,lead,vTv Therapeutics,Phase 2
NCT03980938,2019.0,INDUSTRY,lead,EIP Pharma Inc,Phase 2
NCT03980938,2019.0,INDUSTRY,collaborator,"Voisin Consulting, Inc.",Phase 2
NCT03981341,2019.0,OTHER,lead,Laval University,Phase 3
NCT03981341,2019.0,UNKNOWN,collaborator,V Joseph,Phase 3
NCT03981341,2019.0,UNKNOWN,collaborator,C Minville,Phase 3
NCT03981341,2019.0,UNKNOWN,collaborator,C Rheaume,Phase 3
NCT03981510,2019.0,OTHER,lead,University of Aarhus,Not Applicable
NCT03981536,2019.0,INDUSTRY,lead,AL-S Pharma,Phase 1
NCT03981744,2019.0,INDUSTRY,lead,Janssen Pharmaceutical K.K.,Phase 3
NCT03983018,2019.0,OTHER,lead,Region Örebro County,Phase 1
NCT03983018,2019.0,OTHER,collaborator,"Örebro University, Sweden",Phase 1
NCT03983031,2019.0,OTHER,lead,Region Örebro County,Phase 1
NCT03983031,2019.0,OTHER,collaborator,"Örebro University, Sweden",Phase 1
NCT03983252,2019.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT03983252,2019.0,INDUSTRY,collaborator,"Genzyme, a Sanofi Company",Phase 1/Phase 2
NCT03983720,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Phase 2
NCT03984656,2019.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Phase 3
NCT03985228,2015.0,OTHER,lead,University of Bologna,Not Applicable
NCT03985878,2019.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 2
NCT03985995,2019.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT03986424,2018.0,INDUSTRY,lead,Merz Pharmaceuticals GmbH,Phase 3
NCT03986424,2018.0,UNKNOWN,collaborator,"LLC Merz Pharma, Russia",Phase 3
NCT03986762,2019.0,OTHER,lead,Temple University,Phase 1
NCT03986762,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT03987126,2021.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT03987126,2021.0,UNKNOWN,collaborator,The W. Garfield Weston Foundation,Phase 3
NCT03987126,2021.0,OTHER,collaborator,St. Joseph's Health Care London,Phase 3
NCT03987126,2021.0,OTHER,collaborator,"Parkwood Hospital, London, Ontario",Phase 3
NCT03987295,2019.0,INDUSTRY,lead,Alector Inc.,Phase 2
NCT03987750,2019.0,INDUSTRY,lead,Zambon SpA,Phase 3
NCT03987893,2018.0,UNKNOWN,lead,Postgraduate Institute of Medical Education and Research,Phase 4
NCT03988088,2019.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT03988907,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT03989817,2019.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT03990649,2019.0,INDUSTRY,lead,"Millennium Pharmaceuticals, Inc.",Phase 2
NCT03990766,2019.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT03990909,2019.0,FED,lead,Portland VA Medical Center,Not Applicable
NCT03991052,2019.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT03991052,2019.0,OTHER,collaborator,"University of California, Los Angeles",Not Applicable
NCT03991052,2019.0,OTHER,collaborator,"University of California, Irvine",Not Applicable
NCT03991195,2019.0,OTHER,lead,XuanwuH 2,Not Applicable
NCT03991195,2019.0,OTHER,collaborator,First Hospital of Tsinghua University,Not Applicable
NCT03991195,2019.0,OTHER,collaborator,Beijing Normal University,Not Applicable
NCT03991988,2019.0,OTHER,lead,Emory University,Phase 2
NCT03992196,2019.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT03992430,2020.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT03993171,2019.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT03993171,2019.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Phase 2
NCT03993457,2019.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT03993535,2018.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT03993535,2018.0,OTHER,collaborator,University of Stellenbosch,Phase 4
NCT03993535,2018.0,OTHER,collaborator,Columbia University,Phase 4
NCT03993535,2018.0,OTHER,collaborator,"National Institute of Mental Health and Neuro Sciences, India",Phase 4
NCT03993535,2018.0,OTHER,collaborator,"Amsterdam UMC, location VUmc",Phase 4
NCT03994965,2020.0,OTHER,lead,Bjorn H. Ebdrup,Phase 2
NCT03994965,2020.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 2
NCT03994965,2020.0,UNKNOWN,collaborator,"GCP unit, Copenhagen University Hospital",Phase 2
NCT03994965,2020.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 2
NCT03995810,2019.0,OTHER,lead,"University of Novi Sad, Faculty of Sport and Physical Education",Not Applicable
NCT03995810,2019.0,UNKNOWN,collaborator,CarnoMed,Not Applicable
NCT03996148,2017.0,OTHER,lead,The Cooper Health System,Phase 4
NCT03996772,2019.0,OTHER,lead,Imperial College London,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Wuerzburg University Hospital,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Julius-Maximilians University,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Medical University of Graz,Phase 3
NCT03996772,2019.0,OTHER,collaborator,University of Liverpool,Phase 3
NCT03996772,2019.0,OTHER,collaborator,King's College London,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Hospital Universitari Vall d'Hebron Research Institute,Phase 3
NCT03996772,2019.0,OTHER,collaborator,University of Bordeaux,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Azienda Ospedaliera di Perugia,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Aalborg University,Phase 3
NCT03996772,2019.0,UNKNOWN,collaborator,STROKE ALLIANCE FOR EUROPE,Phase 3
NCT03996772,2019.0,OTHER,collaborator,University Hospital Heidelberg,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Imperial College Healthcare NHS Trust,Phase 3
NCT03996772,2019.0,OTHER,collaborator,Alfried Krupp Krankenhaus,Phase 3
NCT03996772,2019.0,OTHER,collaborator,"University Hospital, Bordeaux",Phase 3
NCT03997006,2019.0,OTHER_GOV,lead,Damanhour Teaching Hospital,Phase 4
NCT03997058,2019.0,OTHER,lead,"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine",Phase 4
NCT03997864,2020.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT03998020,2020.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT03998020,2020.0,UNKNOWN,collaborator,INSERM U1061 Montpellier,Not Applicable
NCT03998423,2019.0,OTHER,lead,"University of Wisconsin, Madison",Phase 1
NCT03998423,2019.0,OTHER,collaborator,Wisconsin Partnership Program,Phase 1
NCT03999099,2019.0,OTHER,lead,Mclean Hospital,Phase 1
NCT03999164,2020.0,OTHER,lead,"University of California, Davis",Phase 1
NCT03999424,2019.0,OTHER,lead,W. Dalton Dietrich,Phase 1
NCT03999424,2019.0,OTHER,collaborator,The Miami Project to Cure Paralysis,Phase 1
NCT04000308,2019.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT04000919,2019.0,OTHER,lead,Jessica M D'Amico,Phase 2/Phase 3
NCT04000932,2018.0,OTHER,lead,Baskent University,Phase 3
NCT04002219,2019.0,OTHER_GOV,lead,"National Science Council, Taiwan",Not Applicable
NCT04002219,2019.0,OTHER,collaborator,National Taiwan University,Not Applicable
NCT04002934,2019.0,OTHER,lead,"Riley Bove, MD",Phase 2
NCT04003090,2018.0,NETWORK,lead,Istituto di Ricerca Neuroftalmologia S.r.l.,Not Applicable
NCT04003090,2018.0,OTHER,collaborator,"Fondazione G.B. Bietti, IRCCS",Not Applicable
NCT04003948,2020.0,OTHER,lead,"International Center for Ethnobotanical Education, Research, and Service",Phase 2
NCT04003948,2020.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT04003948,2020.0,OTHER,collaborator,University Rovira i Virgili,Phase 2
NCT04003948,2020.0,OTHER,collaborator,Universidad Autonoma de Madrid,Phase 2
NCT04003948,2020.0,OTHER,collaborator,Hospital Universitari Sant Joan de Reus,Phase 2
NCT04003948,2020.0,OTHER,collaborator,University of Sao Paulo,Phase 2
NCT04004065,2019.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 2
NCT04004416,2020.0,OTHER,lead,University of Michigan,Phase 4
NCT04004416,2020.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04004702,2020.0,FED,lead,Walter Reed National Military Medical Center,Phase 2
NCT04005053,2019.0,OTHER,lead,University of Minnesota,Phase 2
NCT04005287,2019.0,INDUSTRY,lead,"WinSanTor, Inc",Phase 2
NCT04006054,2019.0,OTHER,lead,Xiangya Hospital of Central South University,Phase 4
NCT04006210,2019.0,INDUSTRY,lead,NeuroDerm Ltd.,Phase 3
NCT04006925,2019.0,OTHER,lead,Stanford University,Phase 4
NCT04006925,2019.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 4
NCT04007224,2019.0,OTHER,lead,Fundatia Bio-Forum,Phase 1
NCT04007224,2019.0,UNKNOWN,collaborator,Spitalul Angiomedica,Phase 1
NCT04007263,2019.0,INDUSTRY,lead,Neurop Inc.,Phase 1
NCT04007263,2019.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT04007263,2019.0,UNKNOWN,collaborator,Pharmaron,Phase 1
NCT04007874,2019.0,OTHER,lead,Leiden University Medical Center,Phase 3
NCT04007874,2019.0,OTHER,collaborator,Erasmus Medical Center,Phase 3
NCT04007874,2019.0,OTHER,collaborator,Netherlands Brain Foundation,Phase 3
NCT04007874,2019.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 3
NCT04007991,2019.0,INDUSTRY,lead,Emalex Biosciences Inc.,Phase 2
NCT04008355,2020.0,INDUSTRY,lead,AlzProtect SAS,Phase 2
NCT04008732,2017.0,INDUSTRY,lead,Futura Medical Developments Ltd.,Phase 1
NCT04010305,2019.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 1
NCT04010305,2019.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 1
NCT04010578,2024.0,OTHER,lead,Academisch Ziekenhuis Maastricht,Not Applicable
NCT04010578,2024.0,OTHER,collaborator,Horizon 2020 - European Commission,Not Applicable
NCT04011280,2019.0,OTHER,lead,"University of California, San Diego",Phase 4
NCT04011280,2019.0,OTHER,collaborator,Veterans Medical Research Foundation,Phase 4
NCT04011280,2019.0,OTHER,collaborator,University of California,Phase 4
NCT04011449,2019.0,OTHER,lead,University of Minnesota,Not Applicable
NCT04011787,2022.0,OTHER,lead,University Hospitals of North Midlands NHS Trust,Not Applicable
NCT04012047,2019.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04012268,2019.0,OTHER,lead,Capital Medical University,Not Applicable
NCT04012333,2020.0,OTHER,lead,RWTH Aachen University,Phase 3
NCT04012333,2020.0,OTHER,collaborator,Clinical Evaluation Research Unit at Kingston General Hospital,Phase 3
NCT04012411,2020.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT04012905,2020.0,OTHER,lead,"University Hospital, Caen",Phase 3
NCT04012905,2020.0,OTHER,collaborator,"University Hospital, Lille",Phase 3
NCT04012905,2020.0,OTHER,collaborator,Amiens University Hospital,Phase 3
NCT04012905,2020.0,OTHER,collaborator,"University Hospital, Rouen",Phase 3
NCT04012905,2020.0,OTHER,collaborator,"University Hospital, Limoges",Phase 3
NCT04012905,2020.0,OTHER_GOV,collaborator,Central Hospital Saint Quentin,Phase 3
NCT04012905,2020.0,UNKNOWN,collaborator,"Central Hospital, Valenciennes",Phase 3
NCT04012905,2020.0,UNKNOWN,collaborator,"Central Hospital, Lisieux",Phase 3
NCT04013555,2020.0,OTHER,lead,"University of Maryland, Baltimore",Phase 1/Phase 2
NCT04013646,2019.0,OTHER,lead,Bundang CHA Hospital,Phase 1/Phase 2
NCT04013646,2019.0,OTHER,collaborator,Korea Evaluation Institute of Industrial Technology,Phase 1/Phase 2
NCT04014244,2021.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT04015479,2019.0,OTHER,lead,Auburn University,Not Applicable
NCT04015479,2019.0,OTHER,collaborator,Edward Via Virginia College of Osteopathic Medicine,Not Applicable
NCT04015479,2019.0,OTHER,collaborator,The Peanut Institute,Not Applicable
NCT04015596,2020.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04016740,2019.0,OTHER,lead,Beth Israel Deaconess Medical Center,Early Phase 1
NCT04017052,2015.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT04017390,2022.0,OTHER,lead,John Fowler,Phase 4
NCT04017390,2022.0,INDUSTRY,collaborator,"Avadim Technologies, Inc.",Phase 4
NCT04017741,2018.0,OTHER,lead,Barts & The London NHS Trust,Phase 4
NCT04018157,2019.0,OTHER_GOV,lead,Zagazig University,Early Phase 1
NCT04018911,2019.0,INDUSTRY,lead,Sonova AG,Not Applicable
NCT04019704,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04020055,2022.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT04020588,2019.0,OTHER_GOV,lead,"Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico",Phase 4
NCT04021017,2020.0,OTHER,lead,University of Saskatchewan,Phase 1
NCT04021017,2020.0,UNKNOWN,collaborator,Jim Pattison Children's Hospital Foundation,Phase 1
NCT04021121,2021.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT04021121,2021.0,OTHER,collaborator,MRC/UVRI and LSHTM Uganda Research Unit,Phase 2
NCT04021121,2021.0,OTHER,collaborator,London School of Hygiene and Tropical Medicine,Phase 2
NCT04021121,2021.0,NIH,collaborator,Fogarty International Center of the National Institute of Health,Phase 2
NCT04021550,2023.0,OTHER,lead,University of British Columbia,Early Phase 1
NCT04021550,2023.0,OTHER,collaborator,Heart and Stroke Foundation of Canada,Early Phase 1
NCT04021550,2023.0,OTHER,collaborator,Michael Smith Foundation for Health Research,Early Phase 1
NCT04021706,2019.0,OTHER,lead,Tufts University,Phase 1
NCT04021706,2019.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 1
NCT04022473,2019.0,INDUSTRY,lead,Banner Life Sciences LLC,Phase 1
NCT04023669,2019.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 1
NCT04023669,2019.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1
NCT04025203,2019.0,OTHER,lead,Francisco Unda Solano,Phase 4
NCT04025554,2019.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1/Phase 2
NCT04026607,2019.0,OTHER,lead,McMaster University,Not Applicable
NCT04026958,2019.0,OTHER,lead,Emory University,Phase 2
NCT04026958,2019.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT04027036,2020.0,OTHER_GOV,lead,"Instituto Nacional de Saúde, Mozambique",Phase 2
NCT04027036,2020.0,OTHER,collaborator,World Health Organization,Phase 2
NCT04027751,2019.0,OTHER,lead,Beijing Chao Yang Hospital,Phase 4
NCT04027972,2020.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Early Phase 1
NCT04028206,2019.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT04028596,2019.0,OTHER,lead,Rijnstate Hospital,Phase 2
NCT04028596,2019.0,OTHER,collaborator,University of Twente,Phase 2
NCT04028596,2019.0,OTHER,collaborator,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 2
NCT04029831,2017.0,OTHER,lead,Indonesia University,Not Applicable
NCT04030143,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1/Phase 2
NCT04030169,2020.0,INDUSTRY,lead,MAPS Europe B.V.,Phase 2
NCT04030169,2020.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT04031755,2019.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1
NCT04031833,2019.0,INDUSTRY,lead,"Matinas BioPharma Nanotechnologies, Inc.",Phase 1/Phase 2
NCT04031833,2019.0,OTHER,collaborator,University of Minnesota,Phase 1/Phase 2
NCT04032301,2019.0,OTHER,lead,University of Minnesota,Phase 1
NCT04032301,2019.0,FED,collaborator,Minneapolis Veterans Affairs Medical Center,Phase 1
NCT04032626,2020.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT04032626,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04032626,2020.0,OTHER,collaborator,The Cleveland Clinic,Phase 2
NCT04032795,2019.0,OTHER_GOV,lead,Guangzhou Psychiatric Hospital,Not Applicable
NCT04032795,2019.0,OTHER,collaborator,Fifth Affiliated Hospital of Guangzhou Medical University,Not Applicable
NCT04033237,2019.0,OTHER,lead,University of Vermont,Phase 1/Phase 2
NCT04033237,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT04033237,2019.0,FED,collaborator,Food and Drug Administration (FDA),Phase 1/Phase 2
NCT04033237,2019.0,OTHER,collaborator,University of Kentucky,Phase 1/Phase 2
NCT04033926,2020.0,INDUSTRY,lead,"Kezar Life Sciences, Inc.",Phase 2
NCT04034771,2018.0,OTHER,lead,Cairo University,Phase 3
NCT04035135,2020.0,INDUSTRY,lead,"Annexon, Inc.",Phase 1
NCT04035135,2020.0,OTHER,collaborator,ResearchPoint Global,Phase 1
NCT04035135,2020.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 1
NCT04035889,2019.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT04038541,2020.0,OTHER,lead,Columbia University,Not Applicable
NCT04038541,2020.0,OTHER,collaborator,National Multiple Sclerosis Society,Not Applicable
NCT04038541,2020.0,UNKNOWN,collaborator,Exegi Pharma,Not Applicable
NCT04038840,2019.0,OTHER,lead,"Davidzon, Guido, M.D.",Phase 1
NCT04038840,2019.0,UNKNOWN,collaborator,Weston Havens Foundation,Phase 1
NCT04038957,2019.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT04039022,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04040049,2019.0,INDUSTRY,lead,Freeline Therapeutics,Phase 1/Phase 2
NCT04040348,2019.0,OTHER,lead,Bernard (Barry) Baumel,Phase 1
NCT04040790,2019.0,OTHER,lead,University Ghent,Not Applicable
NCT04041284,2019.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 4
NCT04041349,2019.0,OTHER,lead,Zhujiang Hospital,Phase 4
NCT04041349,2019.0,OTHER,collaborator,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT04041349,2019.0,OTHER,collaborator,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 4
NCT04041349,2019.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Phase 4
NCT04041349,2019.0,OTHER,collaborator,Guangdong 999 Brain Hospital,Phase 4
NCT04041349,2019.0,OTHER_GOV,collaborator,Dongguan People's Hospital,Phase 4
NCT04041349,2019.0,UNKNOWN,collaborator,Houjie Hospital of Dongguan City,Phase 4
NCT04041349,2019.0,OTHER,collaborator,First Affiliated Hospital of Shantou University Medical College,Phase 4
NCT04041349,2019.0,OTHER,collaborator,Wuhan University,Phase 4
NCT04041349,2019.0,OTHER,collaborator,The First Affiliated Hospital of Guangdong Pharmaceutical University,Phase 4
NCT04041713,2019.0,INDIV,lead,"Anagnostou, Evdokia, M.D.",Phase 2
NCT04041713,2019.0,OTHER,collaborator,Ontario Brain Institute,Phase 2
NCT04041713,2019.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT04041713,2019.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT04042753,2019.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 2
NCT04043052,2020.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT04043338,2019.0,INDUSTRY,lead,Xoc Pharmaceuticals,Phase 1
NCT04043338,2019.0,INDUSTRY,collaborator,Celerion,Phase 1
NCT04043598,2022.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT04044131,2019.0,OTHER,lead,Istanbul Medipol University Hospital,Phase 2
NCT04044131,2019.0,INDUSTRY,collaborator,ScandiBio Therapeutics AB,Phase 2
NCT04044131,2019.0,OTHER,collaborator,Alanya Alaaddin Keykubat University,Phase 2
NCT04044131,2019.0,OTHER,collaborator,"Sahlgrenska University Hospital, Sweden",Phase 2
NCT04044131,2019.0,OTHER,collaborator,KTH Royal Institute of Technology,Phase 2
NCT04044534,2023.0,FED,lead,VA Connecticut Healthcare System,Phase 2
NCT04044547,2013.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04044547,2013.0,INDUSTRY,collaborator,"Beijing Bozhiyin T&S Co., Ltd.",Phase 1
NCT04044664,2019.0,INDUSTRY,lead,Aptinyx,Phase 2
NCT04044664,2019.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 2
NCT04044664,2019.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT04044690,2019.0,INDUSTRY,lead,CSL Behring,Phase 3
NCT04045665,2019.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 3
NCT04045665,2019.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT04045665,2019.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 3
NCT04045678,2017.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04045678,2017.0,INDUSTRY,collaborator,"Beijing Bozhiyin T&S Co., Ltd.",Phase 1
NCT04046224,2019.0,INDUSTRY,lead,Sangamo Therapeutics,Phase 1/Phase 2
NCT04046484,2018.0,INDUSTRY,lead,"Pharmazz, Inc.",Phase 2
NCT04047355,2021.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 2
NCT04047355,2021.0,UNKNOWN,collaborator,New Jersey Governor's Council for Medical Research and Treatment of Autism,Phase 2
NCT04047355,2021.0,OTHER_GOV,collaborator,New York State Institute for Basic Research,Phase 2
NCT04047563,2019.0,INDUSTRY,lead,"Pharmazz, Inc.",Phase 3
NCT04047602,2019.0,OTHER,lead,Indiana University,Not Applicable
NCT04047628,2019.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT04047628,2019.0,NETWORK,collaborator,Immune Tolerance Network (ITN),Phase 3
NCT04047628,2019.0,NETWORK,collaborator,Blood and Marrow Transplant Clinical Trials Network,Phase 3
NCT04047628,2019.0,INDUSTRY,collaborator,PPD,Phase 3
NCT04047628,2019.0,INDUSTRY,collaborator,"Rho Federal Systems Division, Inc.",Phase 3
NCT04048096,2018.0,OTHER,lead,University of Glasgow,Not Applicable
NCT04048577,2019.0,OTHER,lead,"Berkovich, Regina MD, PhD Inc.",Phase 4
NCT04048577,2019.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT04048577,2019.0,OTHER,collaborator,Cedars-Sinai Medical Center,Phase 4
NCT04049097,2019.0,INDUSTRY,lead,ZevraDenmark,Phase 3
NCT04049097,2019.0,OTHER,collaborator,University of Kansas Medical Center,Phase 3
NCT04049097,2019.0,OTHER,collaborator,"University College, London",Phase 3
NCT04049331,2021.0,OTHER,lead,Seattle Institute for Biomedical and Clinical Research,Phase 2
NCT04049578,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04049656,2020.0,OTHER,lead,University of Florida,Not Applicable
NCT04049656,2020.0,UNKNOWN,collaborator,Mdoloris Medical Systems,Not Applicable
NCT04049760,2019.0,INDUSTRY,lead,Amicus Therapeutics,Phase 3
NCT04049994,2020.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Phase 4
NCT04049994,2020.0,UNKNOWN,collaborator,Swiss Spinal Cord Injury Cohort Study (SwiSCI),Phase 4
NCT04050293,2020.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 4
NCT04050410,2019.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT04050410,2019.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT04050475,2018.0,OTHER,lead,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Not Applicable
NCT04050475,2018.0,OTHER,collaborator,University of Palermo,Not Applicable
NCT04050475,2018.0,UNKNOWN,collaborator,Centro Studi Psicoterapia Neo-Funzionale,Not Applicable
NCT04050839,2019.0,OTHER,lead,Kutahya Health Sciences University,Not Applicable
NCT04050852,2019.0,OTHER,lead,NYU Langone Health,Early Phase 1
NCT04050852,2019.0,OTHER,collaborator,Winthrop University Hospital,Early Phase 1
NCT04051086,2019.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT04051320,2020.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT04051320,2020.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT04052178,2016.0,OTHER,lead,Hospital de Mataró,Not Applicable
NCT04052568,2019.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT04052737,2018.0,INDUSTRY,lead,"Pharmazz, Inc.",Phase 2
NCT04052776,2020.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 1
NCT04052776,2020.0,OTHER,collaborator,Ecole Polytechnique Fédérale de Lausanne,Phase 1
NCT04053036,2019.0,OTHER,lead,University of Chicago,Early Phase 1
NCT04053218,2018.0,OTHER,lead,The University of The West Indies,Phase 3
NCT04054024,2019.0,OTHER,lead,Danish Headache Center,Phase 2
NCT04054960,2019.0,OTHER,lead,"Western University, Canada",Not Applicable
NCT04054973,2019.0,OTHER,lead,"University of Massachusetts, Worcester",Phase 2
NCT04055467,2019.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT04055467,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT04056689,2019.0,INDUSTRY,lead,Biogen,Phase 1
NCT04056897,2019.0,INDUSTRY,lead,Biocad,Phase 2
NCT04057456,2023.0,OTHER,lead,"Eldon Loh, MD",Phase 3
NCT04057456,2023.0,OTHER,collaborator,Ontario Neurotrauma Foundation,Phase 3
NCT04057807,2018.0,OTHER,lead,Yale University,Early Phase 1
NCT04057807,2018.0,NIH,collaborator,National Institute on Aging (NIA),Early Phase 1
NCT04057898,2020.0,INDUSTRY,lead,MediciNova,Phase 2/Phase 3
NCT04058132,2019.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 2
NCT04058132,2019.0,FED,collaborator,Walter Reed National Military Medical Center,Phase 2
NCT04058899,2019.0,OTHER,lead,Ain Shams University,Phase 1/Phase 2
NCT04059978,2020.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT04060017,2020.0,OTHER,lead,Southwest Autism Research & Resource Center,Phase 2
NCT04060017,2020.0,OTHER,collaborator,State University of New York - Downstate Medical Center,Phase 2
NCT04060017,2020.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04060030,2020.0,OTHER,lead,Southwest Autism Research & Resource Center,Phase 2
NCT04060030,2020.0,OTHER,collaborator,Autism Speaks,Phase 2
NCT04060030,2020.0,OTHER,collaborator,State University of New York - Downstate Medical Center,Phase 2
NCT04060199,2020.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 3
NCT04060199,2020.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 3
NCT04060771,2018.0,OTHER,lead,Universidade Federal Fluminense,Phase 3
NCT04061668,2019.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04062019,2019.0,OTHER,lead,Peking University People's Hospital,Phase 2
NCT04062331,2019.0,OTHER,lead,Maimónides Biomedical Research Institute of Córdoba,Phase 1/Phase 2
NCT04062331,2019.0,UNKNOWN,collaborator,Isaac Tunez-Fiñana,Phase 1/Phase 2
NCT04062331,2019.0,UNKNOWN,collaborator,Eduardo Agüera-Morales,Phase 1/Phase 2
NCT04062526,2019.0,OTHER,lead,University of Pennsylvania,Early Phase 1
NCT04062981,2019.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 1
NCT04063124,2020.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 1/Phase 2
NCT04063124,2020.0,OTHER,collaborator,Mayo Clinic,Phase 1/Phase 2
NCT04063150,2019.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT04063150,2019.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT04063215,2020.0,INDUSTRY,lead,Hope Biosciences,Phase 1/Phase 2
NCT04063215,2020.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 1/Phase 2
NCT04063384,2019.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT04066023,2019.0,INDUSTRY,lead,Zosano Pharma Corporation,Phase 2/Phase 3
NCT04066088,2019.0,OTHER,lead,NYU Langone Health,Phase 4
NCT04066088,2019.0,OTHER,collaborator,Winthrop University Hospital,Phase 4
NCT04066244,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT04068051,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04068727,2019.0,OTHER,lead,"University of Massachusetts, Worcester",Not Applicable
NCT04068727,2019.0,FED,collaborator,Agency for Healthcare Research and Quality (AHRQ),Not Applicable
NCT04069897,2019.0,OTHER,lead,St. Olavs Hospital,Phase 3
NCT04069897,2019.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 3
NCT04069897,2019.0,OTHER,collaborator,Oslo University Hospital,Phase 3
NCT04069897,2019.0,OTHER,collaborator,Haukeland University Hospital,Phase 3
NCT04069897,2019.0,OTHER,collaborator,Nordlandssykehuset HF,Phase 3
NCT04070378,2019.0,OTHER,lead,"Marc L Gordon, MD",Phase 2
NCT04070378,2019.0,INDUSTRY,collaborator,"Janssen Scientific Affairs, LLC",Phase 2
NCT04070391,2019.0,OTHER,lead,Arizona State University,Not Applicable
NCT04070495,2019.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT04070833,2016.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT04070833,2016.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT04071600,2019.0,OTHER,lead,New York Medical College,Phase 1/Phase 2
NCT04071600,2019.0,OTHER,collaborator,Westchester Medical Center,Phase 1/Phase 2
NCT04071600,2019.0,FED,collaborator,U.S. Army Medical Research and Development Command,Phase 1/Phase 2
NCT04071639,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 1
NCT04072354,2019.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT04072380,2019.0,INDUSTRY,lead,Suven Life Sciences Limited,Phase 2
NCT04072575,2019.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT04072640,2021.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Early Phase 1
NCT04072640,2021.0,OTHER,collaborator,Wenzhou Central Hospital,Early Phase 1
NCT04073290,2020.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 4
NCT04073290,2020.0,OTHER,collaborator,Erasmus Medical Center,Phase 4
NCT04073290,2020.0,OTHER,collaborator,Leiden University Medical Center,Phase 4
NCT04073290,2020.0,OTHER,collaborator,Maastricht University Medical Center,Phase 4
NCT04073290,2020.0,OTHER,collaborator,Radboud University Medical Center,Phase 4
NCT04073290,2020.0,OTHER,collaborator,University Medical Center Groningen,Phase 4
NCT04073290,2020.0,OTHER,collaborator,Universitaire Ziekenhuizen KU Leuven,Phase 4
NCT04073290,2020.0,INDUSTRY,collaborator,Norgine,Phase 4
NCT04073459,2019.0,INDUSTRY,lead,LG Chem,Phase 2
NCT04073693,2017.0,OTHER,lead,Puerta de Hierro University Hospital,Not Applicable
NCT04074265,2019.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT04074265,2019.0,OTHER,collaborator,Northwestern University,Phase 4
NCT04074785,2019.0,OTHER,lead,University of Texas Southwestern Medical Center,Early Phase 1
NCT04074837,2019.0,INDUSTRY,lead,"Neuronascent, Inc.",Phase 1
NCT04074837,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT04075266,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT04075318,2019.0,INDUSTRY,lead,United Neuroscience Ltd.,Phase 1
NCT04075318,2019.0,OTHER,collaborator,"Centre for Human Drug Research, Netherlands",Phase 1
NCT04075318,2019.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 1
NCT04075318,2019.0,INDUSTRY,collaborator,"Vaxxinity, Inc.",Phase 1
NCT04075435,2021.0,OTHER,lead,Mclean Hospital,Early Phase 1
NCT04075435,2021.0,UNKNOWN,collaborator,Spier Family Foundation,Early Phase 1
NCT04076176,2019.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT04076176,2019.0,INDUSTRY,collaborator,Arla Foods,Not Applicable
NCT04076371,2012.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT04076462,2019.0,INDUSTRY,lead,Camurus AB,Phase 3
NCT04076826,2019.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT04076982,2018.0,OTHER,lead,Arizona State University,Not Applicable
NCT04076982,2018.0,UNKNOWN,collaborator,Christopher Wharton,Not Applicable
NCT04076982,2018.0,UNKNOWN,collaborator,Eric Bartholomae,Not Applicable
NCT04076982,2018.0,UNKNOWN,collaborator,April Incollingo,Not Applicable
NCT04076982,2018.0,UNKNOWN,collaborator,Maricarmen Vizcaino,Not Applicable
NCT04077333,2017.0,OTHER,lead,Peking University Third Hospital,Not Applicable
NCT04077398,2020.0,OTHER,lead,Bruce Ben-David,Phase 4
NCT04077437,2020.0,INDUSTRY,lead,Lykos Therapeutics,Phase 3
NCT04078048,2017.0,OTHER,lead,University of Health Sciences Lahore,Not Applicable
NCT04078204,2018.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT04078438,2014.0,OTHER,lead,Yeungnam University Hospital,Not Applicable
NCT04078737,2019.0,OTHER,lead,Beijing Tiantan Hospital,Phase 3
NCT04078737,2019.0,OTHER_GOV,collaborator,Ministry of Science and Technology of the People´s Republic of China,Phase 3
NCT04079803,2019.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 2
NCT04079803,2019.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04079907,2020.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT04080427,2021.0,OTHER,lead,Wayne State University,Phase 1
NCT04080427,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT04080544,2019.0,OTHER,lead,"Neil M Rofsky, MD, MHA",Phase 2
NCT04082000,2019.0,INDUSTRY,lead,Breath of Life International Pharma Ltd,Phase 1/Phase 2
NCT04082728,2019.0,OTHER,lead,Jessa Hospital,Not Applicable
NCT04082780,2019.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Phase 2
NCT04082832,2019.0,INDUSTRY,lead,Collaborative Medicinal Development Pty Limited,Phase 2/Phase 3
NCT04082858,2020.0,OTHER,lead,"St Patrick's Hospital, Ireland",Phase 1
NCT04083144,2019.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT04083144,2019.0,INDUSTRY,collaborator,Pfizer,Not Applicable
NCT04083144,2019.0,INDUSTRY,collaborator,Brainsway,Not Applicable
NCT04083352,2016.0,OTHER,lead,Augusta University,Not Applicable
NCT04084210,2020.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT04084210,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT04084314,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT04085354,2019.0,OTHER,lead,Sohag University,Phase 3
NCT04085666,2019.0,INDUSTRY,lead,Société des Produits Nestlé (SPN),Phase 1
NCT04085887,2024.0,OTHER,lead,Stanford University,Phase 1/Phase 2
NCT04086147,2019.0,OTHER,lead,Huashan Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,The First Affiliated Hospital of Shanxi Medical University,Phase 2
NCT04086147,2019.0,OTHER,collaborator,Ningbo No. 1 Hospital,Phase 2
NCT04086147,2019.0,UNKNOWN,collaborator,Zhejiang Province People's Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,Shanghai 5th People's Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,Shanghai 10th People's Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,Shanghai 6th People's Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,The Second Affiliated Hospital of Chongqing Medical University,Phase 2
NCT04086147,2019.0,OTHER,collaborator,The Second People's Hospital of Huai'an,Phase 2
NCT04086147,2019.0,UNKNOWN,collaborator,Pu'er City People's Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,ShuGuang Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,Shanghai East Hospital,Phase 2
NCT04086147,2019.0,OTHER,collaborator,First People's Hospital of Shenyang,Phase 2
NCT04086810,2019.0,INDUSTRY,lead,"Soleno Therapeutics, Inc.",Phase 3
NCT04088513,2020.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT04088630,2020.0,OTHER,lead,Wake Forest University Health Sciences,Early Phase 1
NCT04088929,2019.0,INDUSTRY,lead,Pure Green,Phase 2
NCT04089566,2020.0,INDUSTRY,lead,Biogen,Phase 3
NCT04089579,2020.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 2
NCT04089579,2020.0,OTHER,collaborator,The Marcus Foundation,Phase 2
NCT04089579,2020.0,UNKNOWN,collaborator,Cryo-Cell International,Phase 2
NCT04089852,2021.0,OTHER,lead,Boston Children's Hospital,Phase 2/Phase 3
NCT04089852,2021.0,UNKNOWN,collaborator,"Praxair Distribution, Inc.",Phase 2/Phase 3
NCT04091074,2022.0,OTHER,lead,Assiut University,Phase 1
NCT04091412,2019.0,OTHER,lead,The Second Hospital of Hebei Medical University,Phase 4
NCT04091425,2019.0,INDUSTRY,lead,"Millennium Pharmaceuticals, Inc.",Phase 1
NCT04091438,2020.0,INDUSTRY,lead,"Millennium Pharmaceuticals, Inc.",Phase 1
NCT04091789,2019.0,INDUSTRY,lead,Pure Green,Phase 2
NCT04091932,2019.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Phase 2
NCT04092686,2019.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT04092894,2020.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 4
NCT04092894,2020.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT04093219,2020.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 3
NCT04093219,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 3
NCT04093336,2019.0,OTHER,lead,Shanghai East Hospital,Phase 1/Phase 2
NCT04093349,2020.0,INDUSTRY,lead,Spark Therapeutics,Phase 1/Phase 2
NCT04093518,2019.0,OTHER,lead,Tangent Data,Phase 3
NCT04093518,2019.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 3
NCT04093518,2019.0,UNKNOWN,collaborator,MediStat Ltd.,Phase 3
NCT04093518,2019.0,UNKNOWN,collaborator,PCI pharma services (formerly BIOTEC SERVICES INTERNATIONAL LIMITED),Phase 3
NCT04093518,2019.0,UNKNOWN,collaborator,S.C. IMUNOTEHNOMED S.R.L.,Phase 3
NCT04093518,2019.0,UNKNOWN,collaborator,Tangent Data Srl,Phase 3
NCT04094038,2019.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT04094038,2019.0,INDUSTRY,collaborator,Baxter Healthcare Corporation,Phase 4
NCT04094129,2020.0,INDUSTRY,lead,GenMont Biotech Incorporation,Not Applicable
NCT04094129,2020.0,OTHER,collaborator,Chang Gung Memorial Hospital,Not Applicable
NCT04094207,2019.0,OTHER,lead,Sadat City University,Phase 1/Phase 2
NCT04094584,2020.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT04094584,2020.0,UNKNOWN,collaborator,The CARESTAR Foundation,Phase 4
NCT04096014,2019.0,OTHER,lead,The Cleveland Clinic,Not Applicable
NCT04096443,2019.0,OTHER,lead,Griffin Hospital,Early Phase 1
NCT04096443,2019.0,OTHER,collaborator,Yale-Griffin Prevention Research Center,Early Phase 1
NCT04096443,2019.0,OTHER,collaborator,"Multiple Sclerosis Treatment Center, Derby, Connecticut",Early Phase 1
NCT04096716,2019.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT04096716,2019.0,UNKNOWN,collaborator,Lloyd J. Old STAR Program,Phase 1
NCT04096950,2020.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma America Inc.,Phase 1
NCT04097080,2019.0,INDUSTRY,lead,Nobilis Therapeutics Inc.,Phase 1
NCT04098029,2019.0,OTHER,lead,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Phase 2
NCT04098029,2019.0,UNKNOWN,collaborator,"INBIO, LLC",Phase 2
NCT04098250,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04098250,2021.0,OTHER,collaborator,University of Arizona,Phase 2
NCT04098250,2021.0,OTHER,collaborator,Translational Genomics Research Institute,Phase 2
NCT04098250,2021.0,OTHER,collaborator,Arizona State University,Phase 2
NCT04098250,2021.0,FED,collaborator,Phoenix VA Health Care System,Phase 2
NCT04098250,2021.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04098250,2021.0,INDUSTRY,collaborator,Amgen,Phase 2
NCT04098406,2019.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT04098406,2019.0,UNKNOWN,collaborator,Clene Australia Pty Ltd,Phase 2
NCT04099381,2019.0,OTHER,lead,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Phase 1/Phase 2
NCT04099381,2019.0,UNKNOWN,collaborator,"INBIO, LLC",Phase 1/Phase 2
NCT04100096,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT04100135,2021.0,INDUSTRY,lead,W.L.Gore & Associates,Not Applicable
NCT04100759,2019.0,OTHER,lead,Ain Shams University,Phase 1/Phase 2
NCT04100759,2019.0,OTHER,collaborator,"Drug Research Centre, Cairo, Egypt",Phase 1/Phase 2
NCT04100824,2020.0,OTHER,lead,Assiut University,Phase 2
NCT04102267,2018.0,INDUSTRY,lead,Heron Therapeutics,Phase 4
NCT04102501,2019.0,INDUSTRY,lead,"Retrotope, Inc.",Phase 3
NCT04102579,2019.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT04102579,2019.0,NETWORK,collaborator,Huntington Study Group,Phase 3
NCT04102956,2017.0,OTHER,lead,The Second Hospital of Hebei Medical University,Phase 4
NCT04103034,2019.0,INDUSTRY,lead,Band Therapeutics,Phase 1
NCT04103333,2019.0,INDUSTRY,lead,Biogen,Early Phase 1
NCT04103684,2020.0,OTHER,lead,Assiut University,Phase 4
NCT04104022,2021.0,OTHER,lead,University of Vermont,Not Applicable
NCT04104399,2019.0,INDUSTRY,lead,Xoc Pharmaceuticals,Phase 1
NCT04104594,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Not Applicable
NCT04105114,2019.0,OTHER,lead,University of Louisville,Early Phase 1
NCT04105114,2019.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT04105426,2019.0,OTHER,lead,National and Kapodistrian University of Athens,Phase 2
NCT04106050,2020.0,INDUSTRY,lead,Biogen,Phase 1
NCT04107480,2019.0,OTHER,lead,Leiden University Medical Center,Phase 4
NCT04107740,2019.0,INDUSTRY,lead,"HLB Pharmaceutical Co., Ltd.",Phase 4
NCT04108234,2019.0,INDUSTRY,lead,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1
NCT04108819,2019.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT04109118,2021.0,OTHER,lead,Boston Medical Center,Phase 2
NCT04109118,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT04109885,2020.0,OTHER,lead,"Christian Fromm, MD",Phase 2
NCT04109950,2019.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT04110496,2020.0,INDUSTRY,lead,Rubius Therapeutics,Phase 1
NCT04110535,2015.0,INDUSTRY,lead,Paion UK Ltd.,Phase 1
NCT04110535,2015.0,INDUSTRY,collaborator,PRA Health Sciences,Phase 1
NCT04110678,2015.0,OTHER,lead,"International Center for Neurological Restoration, Cuba",Phase 1/Phase 2
NCT04110678,2015.0,OTHER,collaborator,"Center of Molecular Immunology, Cuba",Phase 1/Phase 2
NCT04110678,2015.0,OTHER,collaborator,University of Electronic Science and Technology of China,Phase 1/Phase 2
NCT04111484,2019.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04111627,2021.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT04111627,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04112823,2019.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT04112862,2022.0,OTHER,lead,Radboud University Medical Center,Early Phase 1
NCT04112875,2016.0,OTHER,lead,Rio de Janeiro State University,Not Applicable
NCT04112875,2016.0,UNKNOWN,collaborator,Laboratory for Clinical and Experimental Research on Vascular Biology,Not Applicable
NCT04113993,2019.0,OTHER,lead,The Alfred,Phase 4
NCT04113993,2019.0,OTHER,collaborator,Monash University,Phase 4
NCT04113993,2019.0,OTHER,collaborator,Monash Health,Phase 4
NCT04114630,2019.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT04115319,2019.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT04115878,2020.0,OTHER,lead,University of Arizona,Phase 2
NCT04115878,2020.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT04116060,2020.0,OTHER,lead,"University Hospital, Essen",Not Applicable
NCT04116112,2020.0,OTHER,lead,University of Cincinnati,Phase 2
NCT04116112,2020.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT04116112,2020.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 2
NCT04116554,2019.0,OTHER,lead,Fayoum University,Phase 4
NCT04117074,2021.0,OTHER,lead,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 3
NCT04117074,2021.0,INDUSTRY,collaborator,"Pacira Pharmaceuticals, Inc",Phase 3
NCT04117178,2020.0,OTHER,lead,Zealand University Hospital,Phase 4
NCT04117178,2020.0,OTHER,collaborator,Filadelfia Epilepsy Hospital,Phase 4
NCT04117672,2020.0,OTHER,lead,Peter Siesjö,Phase 2
NCT04117672,2020.0,OTHER,collaborator,Skane University Hospital,Phase 2
NCT04117672,2020.0,OTHER,collaborator,Lantmannen Medical AB,Phase 2
NCT04118127,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 1
NCT04118764,2020.0,OTHER,lead,Elisa Konofagou,Not Applicable
NCT04118764,2020.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04118829,2019.0,OTHER,lead,Carilion Clinic,Phase 4
NCT04119297,2009.0,OTHER,lead,Necmettin Erbakan University,Not Applicable
NCT04119297,2009.0,OTHER,collaborator,Istanbul University,Not Applicable
NCT04119739,2020.0,OTHER,lead,Francisco Unda Solano,Phase 4
NCT04120116,2019.0,INDUSTRY,lead,Frequency Therapeutics,Phase 2
NCT04120493,2019.0,INDUSTRY,lead,UniQure Biopharma B.V.,Phase 1/Phase 2
NCT04120766,2021.0,OTHER,lead,"Gregory Jicha, MD, PhD",Phase 2
NCT04120766,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04121013,2021.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT04121091,2019.0,OTHER,lead,Region Skane,Phase 2
NCT04121091,2019.0,OTHER,collaborator,Lund University,Phase 2
NCT04121208,2020.0,OTHER,lead,University of Oxford,Phase 1
NCT04121208,2020.0,INDUSTRY,collaborator,Janssen Pharmaceutica,Phase 1
NCT04121221,2019.0,INDUSTRY,lead,Mapi Pharma Ltd.,Phase 3
NCT04121338,2019.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT04121403,2019.0,OTHER,lead,Oslo University Hospital,Phase 3
NCT04121403,2019.0,OTHER,collaborator,University of Oslo,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Göteborg University,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Sykehuset Ostfold,Phase 3
NCT04121403,2019.0,OTHER_GOV,collaborator,Sykehuset Telemark,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Vestre Viken Hospital Trust,Phase 3
NCT04121403,2019.0,OTHER_GOV,collaborator,Sorlandet Hospital HF,Phase 3
NCT04121403,2019.0,OTHER_GOV,collaborator,Helse Stavanger HF,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Sykehuset Innlandet HF,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Sykehuset i Vestfold HF,Phase 3
NCT04121403,2019.0,OTHER,collaborator,Helse Forde,Phase 3
NCT04121403,2019.0,OTHER,collaborator,University Hospital of North Norway,Phase 3
NCT04121403,2019.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT04121637,2019.0,OTHER,lead,Firat University,Not Applicable
NCT04121637,2019.0,OTHER,collaborator,Pamukkale University,Not Applicable
NCT04121780,2019.0,OTHER,lead,Center for Neurological Studies,Phase 2
NCT04121780,2019.0,INDUSTRY,collaborator,Novo Nordisk A/S,Phase 2
NCT04123067,2020.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 1/Phase 2
NCT04123314,2021.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT04123626,2019.0,INDUSTRY,lead,ProQR Therapeutics,Phase 1/Phase 2
NCT04123873,2020.0,OTHER,lead,Naestved Hospital,Phase 4
NCT04124276,2019.0,OTHER_GOV,lead,Guangzhou Psychiatric Hospital,Not Applicable
NCT04124276,2019.0,OTHER,collaborator,Fifth Affiliated Hospital of Guangzhou Medical University,Not Applicable
NCT04124614,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT04125810,2019.0,INDUSTRY,lead,Danisco,Phase 2
NCT04125810,2019.0,INDUSTRY,collaborator,ICON plc,Phase 2
NCT04125810,2019.0,NETWORK,collaborator,Daacro,Phase 2
NCT04125810,2019.0,INDUSTRY,collaborator,4Pharma Ltd.,Phase 2
NCT04125836,2019.0,INDUSTRY,lead,Camurus AB,Phase 3
NCT04126135,2022.0,OTHER,lead,Loma Linda University,Phase 3
NCT04126135,2022.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT04126135,2022.0,OTHER,collaborator,Mongolian National University of Medical Sciences,Phase 3
NCT04126252,2018.0,OTHER,lead,"International Islamic University, Islamabad",Not Applicable
NCT04127058,2019.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 1
NCT04127279,2018.0,OTHER,lead,University of Parma,Phase 4
NCT04127500,2019.0,OTHER,lead,"Nanjing First Hospital, Nanjing Medical University",Not Applicable
NCT04127578,2020.0,INDUSTRY,lead,Prevail Therapeutics,Phase 1/Phase 2
NCT04127578,2020.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1/Phase 2
NCT04127695,2020.0,INDUSTRY,lead,AbbVie,Phase 1
NCT04128462,2021.0,INDUSTRY,lead,Mallinckrodt,Phase 3
NCT04128683,2020.0,OTHER,lead,"University of California, San Diego",Early Phase 1
NCT04129060,2020.0,OTHER,lead,University of Vermont,Early Phase 1
NCT04129060,2020.0,OTHER,collaborator,Vanderbilt University Medical Center,Early Phase 1
NCT04129294,2019.0,OTHER,lead,"National Center of Neurology and Psychiatry, Japan",Phase 1/Phase 2
NCT04129294,2019.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 1/Phase 2
NCT04129775,2019.0,INDUSTRY,lead,"Otonomy, Inc.",Phase 1/Phase 2
NCT04129983,2020.0,OTHER,lead,Dan Su,Not Applicable
NCT04131595,2019.0,INDUSTRY,lead,Bavarian Nordic,Phase 1
NCT04131595,2019.0,UNKNOWN,collaborator,JPM CBRN Medical,Phase 1
NCT04131829,2019.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT04131829,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT04132843,2020.0,OTHER,lead,M.D. Anderson Cancer Center,Not Applicable
NCT04132843,2020.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT04133233,2020.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT04133233,2020.0,INDUSTRY,collaborator,Iltoo Pharma,Phase 2
NCT04133454,2019.0,INDUSTRY,lead,Libella Gene Therapeutics,Phase 1
NCT04133480,2020.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT04134416,2019.0,OTHER,lead,University of Malaga,Phase 3
NCT04135053,2019.0,OTHER,lead,University of Southampton,Not Applicable
NCT04135053,2019.0,OTHER,collaborator,University Hospital Southampton NHS Foundation Trust,Not Applicable
NCT04135378,2018.0,OTHER,lead,Kufa University,Phase 4
NCT04135677,2022.0,OTHER,lead,Shanghai Zhongshan Hospital,Phase 4
NCT04136743,2019.0,OTHER,lead,Kessler Foundation,Phase 2
NCT04136873,2019.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT04137198,2020.0,OTHER,lead,Centre Hospitalier Universitaire Saint Pierre,Phase 4
NCT04137458,2019.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT04140136,2019.0,OTHER,lead,University of Malaya,Phase 2
NCT04140305,2020.0,INDUSTRY,lead,Celgene,Phase 3
NCT04140461,2020.0,OTHER_GOV,lead,Shanghai Public Health Clinical Center,Phase 3
NCT04140721,2021.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT04140721,2021.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT04140773,2021.0,OTHER,lead,Dragos Inta,Not Applicable
NCT04140903,2020.0,OTHER,lead,Henrik Nielsen,Phase 4
NCT04141150,2022.0,INDUSTRY,lead,"APRINOIA Therapeutics, LLC",Phase 2
NCT04141163,2019.0,OTHER,lead,Rowan University,Phase 1/Phase 2
NCT04141163,2019.0,OTHER,collaborator,FRAXA Research Foundation,Phase 1/Phase 2
NCT04141163,2019.0,OTHER,collaborator,University of Pennsylvania,Phase 1/Phase 2
NCT04141787,2019.0,OTHER,lead,Vancouver Island Health Authority,Phase 4
NCT04141904,2020.0,OTHER,lead,University of Oxford,Phase 1/Phase 2
NCT04141904,2020.0,OTHER,collaborator,Wellcome Trust,Phase 1/Phase 2
NCT04141904,2020.0,OTHER_GOV,collaborator,Medical Research Council,Phase 1/Phase 2
NCT04142411,2019.0,OTHER,lead,Assiut University,Early Phase 1
NCT04142840,2019.0,OTHER,lead,RenJi Hospital,Early Phase 1
NCT04143880,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT04143880,2020.0,OTHER,collaborator,Korea University Anam Hospital,Phase 4
NCT04143880,2020.0,OTHER,collaborator,Seoul National University Hospital,Phase 4
NCT04143880,2020.0,OTHER,collaborator,Lishui Country People's Hospital,Phase 4
NCT04143880,2020.0,OTHER,collaborator,Jinhua Central Hospital,Phase 4
NCT04143880,2020.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 4
NCT04143880,2020.0,OTHER,collaborator,The Affiliated Hospital of Hangzhou Normal University,Phase 4
NCT04143958,2020.0,INDUSTRY,lead,Sanofi,Phase 4
NCT04144218,2019.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT04144218,2019.0,OTHER,collaborator,Tongji Hospital,Phase 4
NCT04144218,2019.0,OTHER,collaborator,Michigan State University,Phase 4
NCT04144218,2019.0,OTHER,collaborator,Juntendo University,Phase 4
NCT04144218,2019.0,OTHER,collaborator,Technical University of Munich,Phase 4
NCT04144218,2019.0,OTHER,collaborator,RIKEN,Phase 4
NCT04144218,2019.0,OTHER,collaborator,"University of California, Los Angeles",Phase 4
NCT04144257,2020.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT04144257,2020.0,FED,collaborator,U.S. Army Medical Research Acquisition Activity,Phase 1/Phase 2
NCT04144439,2018.0,OTHER,lead,Sherief Abd-Elsalam,Phase 4
NCT04144933,2021.0,OTHER,lead,University of Saskatchewan,Phase 3
NCT04145037,2019.0,INDUSTRY,lead,AVROBIO,Phase 1/Phase 2
NCT04145076,2014.0,OTHER,lead,King's College London,Not Applicable
NCT04145258,2021.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Phase 3
NCT04145258,2021.0,OTHER,collaborator,European Union,Phase 3
NCT04145258,2021.0,OTHER_GOV,collaborator,European and Developing Countries Clinical Trials Partnership (EDCTP),Phase 3
NCT04145310,2018.0,INDUSTRY,lead,Breath of Life International Pharma Ltd,Phase 1/Phase 2
NCT04145674,2022.0,OTHER,lead,Mauro Manconi,Phase 2
NCT04145674,2022.0,OTHER,collaborator,Clinical Trial Unit Ente Ospedaliero Cantonale,Phase 2
NCT04146285,2020.0,INDUSTRY,lead,Bio-Thera Solutions,Phase 1
NCT04147741,2019.0,OTHER,lead,University of Greenwich,Not Applicable
NCT04147741,2019.0,UNKNOWN,collaborator,Crown Sport Nutrition,Not Applicable
NCT04147741,2019.0,UNKNOWN,collaborator,Go Fit Spain,Not Applicable
NCT04147858,2019.0,INDUSTRY,lead,Aptinyx,Phase 2
NCT04147858,2019.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT04147949,2022.0,INDUSTRY,lead,"VistaGen Therapeutics, Inc.",Phase 2
NCT04148261,2020.0,OTHER,lead,Stanford University,Early Phase 1
NCT04148391,2019.0,INDUSTRY,lead,Aptinyx,Phase 2
NCT04148391,2019.0,INDUSTRY,collaborator,CogState Ltd.,Phase 2
NCT04148391,2019.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2
NCT04148573,2019.0,INDUSTRY,lead,Neurofix S.L.,Phase 2
NCT04148781,2022.0,OTHER,lead,Courtney Casserly,Early Phase 1
NCT04148846,2019.0,OTHER,lead,University of Sao Paulo General Hospital,Not Applicable
NCT04148872,2019.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT04148963,2019.0,INDUSTRY,lead,Lee's Pharmaceutical Limited,Phase 3
NCT04149379,2020.0,INDUSTRY,lead,Norwegian Underwater Intervention (NUI),Phase 2
NCT04149379,2020.0,OTHER,collaborator,Western Norway University of Applied Sciences,Phase 2
NCT04149379,2020.0,OTHER,collaborator,Helse-Bergen HF,Phase 2
NCT04149483,2019.0,OTHER,lead,Beijing Neurosurgical Institute,Phase 2
NCT04149860,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04150380,2020.0,FED,lead,VA Eastern Colorado Health Care System,Phase 2
NCT04150380,2020.0,OTHER,collaborator,"University of Colorado, Denver",Phase 2
NCT04150380,2020.0,OTHER,collaborator,"University of Colorado, Boulder",Phase 2
NCT04150549,2023.0,OTHER,lead,Lawson Health Research Institute,Phase 2
NCT04150757,2020.0,OTHER,lead,Abigail Nixon,Phase 3
NCT04150835,2020.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 4
NCT04150835,2020.0,OTHER,collaborator,Peking University Third Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Beijing Shuyi Hospital,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Airport Hospital of Shunyi District Beijing,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The NO.4 People's Hospital of Hengshui,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The Second Hospital of Hebei Medical University,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Affiliated Hospital of Shaanxi University of Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,Tianshui Hospital of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Affiliated Hospital of Changzhi Academy of TCM,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Zibo Hospital of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Yantai Yuhuangding Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Shandong University of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Zhejiang Provincial Hospital of TCM,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Zhejiang Provincial Tongde Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Second Affiliated Hospital of Wenzhou Medical University,Phase 4
NCT04150835,2020.0,OTHER,collaborator,People's Hospital of Quzhou,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Longhua Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Taizhou Traditional Chinese Medicine Hospital,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The First Affiliated Hospital of Guizhou University of TCM,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,Guangzhou Hospital of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The First Affiliated Hospital of Guangxi University of Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,Liling Hospital of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,Hunan Academy of Traditional Chinese Medicine Affiliated Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Hubei Hospital of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The First Hospital of Jilin University,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Anshan Central Hospital,Phase 4
NCT04150835,2020.0,OTHER,collaborator,First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The First Hospital of Qiqihar City,Phase 4
NCT04150835,2020.0,OTHER,collaborator,Haikou People's Hospital,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Second People's Hospital of Anhui Province,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Third Affiliated Hospital of Shenzhen University,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The Third People's Hospital of Hubei Province,Phase 4
NCT04150835,2020.0,OTHER,collaborator,The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Phase 4
NCT04150835,2020.0,UNKNOWN,collaborator,The Third Hospital of Xi'an City,Phase 4
NCT04150913,2020.0,OTHER,lead,"Marcela V. Maus, M.D.,Ph.D.",Phase 2
NCT04150913,2020.0,INDUSTRY,collaborator,"Kite, A Gilead Company",Phase 2
NCT04151082,2019.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1/Phase 2
NCT04151082,2019.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1/Phase 2
NCT04151472,2021.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 3
NCT04152083,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT04152083,2019.0,INDUSTRY,collaborator,"Alder Biopharmaceuticals, Inc.",Phase 3
NCT04152655,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Peking Union Medical College Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER_GOV,collaborator,Beijing Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Jiangsu Province Nanjing Brain Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,The First Affiliated Hospital of Anhui Medical University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Huashan Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Tongji Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Second Affiliated Hospital of Soochow University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Guizhou Medical University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,The First Affiliated Hospital of Guangzhou Medical University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Peking University Shenzhen Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,West China Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,"Wuhan Union Hospital, China",Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Sir Run Run Shaw Hospital,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,The Affiliated Hospital of Hangzhou Normal University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,The First Affiliated Hospital of Dalian Medical University,Phase 2/Phase 3
NCT04152655,2020.0,OTHER,collaborator,Qilu Hospital of Shandong University,Phase 2/Phase 3
NCT04153175,2020.0,INDUSTRY,lead,Cerebral Therapeutics LLC,Phase 2
NCT04153422,2023.0,OTHER,lead,Henry Ford Health System,Phase 2
NCT04153422,2023.0,UNKNOWN,collaborator,"Octapharma USA, Inc.",Phase 2
NCT04153942,2023.0,OTHER,lead,Brian Silver,Phase 3
NCT04154072,2020.0,INDUSTRY,lead,"Neuraly, Inc.",Phase 2
NCT04154891,2020.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT04154891,2020.0,OTHER_GOV,collaborator,Commissariat A L'energie Atomique,Not Applicable
NCT04154891,2020.0,OTHER,collaborator,Hospices Civils de Lyon,Not Applicable
NCT04154891,2020.0,OTHER,collaborator,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT04154891,2020.0,OTHER,collaborator,"University Hospital, Rouen",Not Applicable
NCT04154891,2020.0,OTHER,collaborator,"University Hospital, Strasbourg",Not Applicable
NCT04154891,2020.0,OTHER,collaborator,APHP,Not Applicable
NCT04155099,2021.0,OTHER,lead,Ochsner Health System,Phase 2
NCT04155099,2021.0,INDUSTRY,collaborator,Rebiotix Inc.,Phase 2
NCT04155424,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT04155632,2020.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT04155632,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT04156464,2020.0,OTHER,lead,OSF Healthcare System,Phase 4
NCT04156646,2019.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04157933,2019.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 1
NCT04158167,2013.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Not Applicable
NCT04158388,2019.0,OTHER,lead,University of Alicante,Not Applicable
NCT04158687,2019.0,INDUSTRY,lead,Concert Pharmaceuticals,Phase 2
NCT04158687,2019.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 2
NCT04158752,2020.0,OTHER,lead,Duke University,Phase 4
NCT04158752,2020.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 4
NCT04159805,2020.0,INDUSTRY,lead,Takeda,Phase 2
NCT04159987,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Not Applicable
NCT04160377,2019.0,OTHER,lead,Lingjiang Li,Phase 2
NCT04160611,2019.0,OTHER,lead,"University Hospital ""Sestre Milosrdnice""",Phase 3
NCT04161027,2020.0,OTHER,lead,Seoul National University Hospital,Phase 3
NCT04161053,2018.0,OTHER,lead,Tanta University,Phase 3
NCT04161144,2018.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT04161209,2019.0,OTHER,lead,University of Oxford,Not Applicable
NCT04161209,2019.0,OTHER,collaborator,University of Bath,Not Applicable
NCT04161339,2019.0,OTHER,lead,Instituto de Cardiologia do Rio Grande do Sul,Phase 4
NCT04161339,2019.0,OTHER,collaborator,Hospital de Clinicas de Porto Alegre,Phase 4
NCT04161690,2019.0,OTHER,lead,KAT General Hospital,Phase 2
NCT04161729,2020.0,OTHER,lead,Aristotle University Of Thessaloniki,Phase 4
NCT04162275,2017.0,INDUSTRY,lead,Yiling Pharmaceutical Inc.,Phase 1
NCT04162743,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 4
NCT04163185,2019.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04164121,2019.0,INDUSTRY,lead,Yiling Pharmaceutical Inc.,Phase 1
NCT04164758,2019.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2
NCT04165239,2019.0,INDUSTRY,lead,Khondrion BV,Phase 2
NCT04165239,2019.0,INDUSTRY,collaborator,Julius Clinical,Phase 2
NCT04165486,2022.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 1
NCT04165837,2019.0,INDUSTRY,lead,"1ST Biotherapeutics, Inc.",Phase 1
NCT04165850,2019.0,INDUSTRY,lead,NeuroSense Therapeutics Ltd.,Phase 2
NCT04167371,2019.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Not Applicable
NCT04167540,2020.0,INDUSTRY,lead,"Brain Neurotherapy Bio, Inc.",Phase 1
NCT04167540,2020.0,INDUSTRY,collaborator,"Asklepios Biopharmaceutical, Inc.",Phase 1
NCT04167540,2020.0,OTHER,collaborator,California Institute for Regenerative Medicine (CIRM),Phase 1
NCT04168879,2021.0,OTHER,lead,Assiut University,Not Applicable
NCT04168879,2021.0,UNKNOWN,collaborator,saeid metwaly abouelyazid elsawy,Not Applicable
NCT04169126,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04169230,2019.0,OTHER,lead,University of Oxford,Not Applicable
NCT04169230,2019.0,OTHER,collaborator,University of Bath,Not Applicable
NCT04170738,2019.0,OTHER,lead,Jeffrey Newcorn,Phase 4
NCT04170738,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT04170907,2022.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT04170907,2022.0,OTHER,collaborator,University of Bern,Not Applicable
NCT04171310,2019.0,INDUSTRY,lead,Sanofi,Phase 1
NCT04172285,2019.0,OTHER,lead,I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio,Not Applicable
NCT04172376,2021.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04172376,2021.0,OTHER,collaborator,Huashan Hospital,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,First Affiliated Hospital of Guangxi Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,"Southern Medical University, China",Not Applicable
NCT04172376,2021.0,OTHER,collaborator,China-Japan Friendship Hospital,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,The First Affiliated Hospital of Anhui Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,Second Affiliated Hospital of Xi'an Jiaotong University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,The Affiliated Hospital Of Southwest Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,Tibet Autonomous Region People's Hospital,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,The Second Affiliated Hospital of Harbin Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,First Affiliated Hospital of Xinjiang Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,The Affiliated Hospital of Inner Mongolia Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,General Hospital of Ningxia Medical University,Not Applicable
NCT04172376,2021.0,OTHER,collaborator,Central South University,Not Applicable
NCT04172558,2019.0,OTHER,lead,Benha University,Phase 2/Phase 3
NCT04172792,2019.0,OTHER,lead,"Albert Christian Ludolph, Prof.",Phase 1
NCT04172792,2019.0,UNKNOWN,collaborator,"Nutritia GmbH, 91052 Erlangen, Germany",Phase 1
NCT04172831,2019.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT04173364,2019.0,OTHER,lead,"University Hospital, Lille",Phase 3
NCT04174170,2019.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3
NCT04174287,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04175132,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04175223,2019.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Not Applicable
NCT04175834,2020.0,OTHER,lead,Providence Health & Services,Phase 3
NCT04175834,2020.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 3
NCT04176172,2020.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT04176172,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT04176172,2020.0,OTHER,collaborator,Northwestern University,Phase 3
NCT04176302,2019.0,OTHER,lead,Consorci Sanitari de l'Alt Penedès i Garraf,Not Applicable
NCT04176302,2019.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Not Applicable
NCT04176302,2019.0,OTHER,collaborator,European Regional Development Fund,Not Applicable
NCT04176835,2016.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Not Applicable
NCT04176991,2019.0,INDUSTRY,lead,"Larimar Therapeutics, Inc.",Phase 1
NCT04176991,2019.0,OTHER,collaborator,"Veristat, Inc.",Phase 1
NCT04176991,2019.0,UNKNOWN,collaborator,"Metrum Research Group, LLC",Phase 1
NCT04177615,2019.0,OTHER,lead,University of Medicine and Pharmacy at Ho Chi Minh City,Not Applicable
NCT04177706,2020.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT04177706,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT04177719,2019.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Not Applicable
NCT04178005,2020.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT04178005,2020.0,INDUSTRY,collaborator,EMD Serono,Phase 4
NCT04178057,2018.0,INDUSTRY,lead,"Genor Biopharma Co., Ltd.",Phase 1
NCT04179266,2019.0,INDUSTRY,lead,CCH Pharmaceuticals,Phase 1/Phase 2
NCT04179266,2019.0,OTHER,collaborator,Danish Headache Center,Phase 1/Phase 2
NCT04179409,2020.0,OTHER,lead,Kevin Flanigan,Phase 2
NCT04179409,2020.0,INDUSTRY,collaborator,"Sarepta Therapeutics, Inc.",Phase 2
NCT04179474,2019.0,INDUSTRY,lead,Allergan,Phase 1
NCT04179734,2019.0,OTHER,lead,Imperial College Healthcare NHS Trust,Phase 4
NCT04179734,2019.0,INDUSTRY,collaborator,"AMAG Pharmaceuticals, Inc.",Phase 4
NCT04179747,2018.0,OTHER,lead,"International Islamic University, Islamabad",Not Applicable
NCT04181723,2019.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT04182399,2020.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04182633,2019.0,OTHER,lead,Arizona State University,Phase 2
NCT04182633,2019.0,OTHER,collaborator,University of Minnesota,Phase 2
NCT04182633,2019.0,UNKNOWN,collaborator,Finch Therapeutics,Phase 2
NCT04182763,2019.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT04182763,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Not Applicable
NCT04182763,2019.0,OTHER,collaborator,Washington State University,Not Applicable
NCT04182763,2019.0,OTHER,collaborator,Oregon State University,Not Applicable
NCT04182763,2019.0,UNKNOWN,collaborator,Spoonbill Foundation,Not Applicable
NCT04183205,2019.0,FED,lead,VA Office of Research and Development,Phase 4
NCT04183205,2019.0,UNKNOWN,collaborator,Middlebury College,Phase 4
NCT04183205,2019.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT04183205,2019.0,FED,collaborator,Ralph H. Johnson VA Medical Center,Phase 4
NCT04183634,2019.0,INDUSTRY,lead,Sandoz,Phase 1
NCT04184063,2019.0,INDUSTRY,lead,EmeraMed,Phase 2
NCT04185038,2019.0,OTHER,lead,Seattle Children's Hospital,Phase 1
NCT04185415,2019.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04185441,2021.0,INDUSTRY,lead,EMS,Phase 3
NCT04186286,2021.0,OTHER,lead,University of Calgary,Phase 2
NCT04186286,2021.0,OTHER,collaborator,Dysautonomia International,Phase 2
NCT04186403,2020.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2/Phase 3
NCT04186494,2019.0,OTHER,lead,"St Vincent's University Hospital, Ireland",Not Applicable
NCT04186494,2019.0,OTHER,collaborator,University College Dublin,Not Applicable
NCT04186494,2019.0,OTHER,collaborator,"Health Research Board, Ireland",Not Applicable
NCT04187547,2022.0,INDUSTRY,lead,Cerecin,Phase 3
NCT04187560,2020.0,INDUSTRY,lead,LB Pharmaceuticals Inc.,Phase 1
NCT04188873,2020.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT04188873,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT04189107,2020.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 3
NCT04189107,2020.0,UNKNOWN,collaborator,Candys Foundation,Phase 3
NCT04189107,2020.0,OTHER,collaborator,Region Capital Denmark,Phase 3
NCT04189107,2020.0,OTHER,collaborator,Odense University Hospital,Phase 3
NCT04189107,2020.0,OTHER,collaborator,Aarhus University Hospital,Phase 3
NCT04189666,2019.0,OTHER,lead,Ain Shams University,Phase 1/Phase 2
NCT04190004,2018.0,OTHER,lead,"National Institute of Mental Health and Neuro Sciences, India",Not Applicable
NCT04191577,2019.0,INDUSTRY,lead,"Cerevance Beta, Inc.",Phase 2
NCT04192266,2020.0,OTHER,lead,NYU Langone Health,Phase 3
NCT04192656,2019.0,OTHER,lead,Beijing Tsinghua Chang Gung Hospital,Phase 4
NCT04192773,2021.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Early Phase 1
NCT04193527,2020.0,INDUSTRY,lead,GE Healthcare,Phase 3
NCT04193527,2020.0,INDUSTRY,collaborator,PPD,Phase 3
NCT04195204,2020.0,OTHER,lead,Beijing Chao Yang Hospital,Phase 4
NCT04196946,2013.0,OTHER,lead,Nigde Omer Halisdemir University,Not Applicable
NCT04196959,2019.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT04197102,2020.0,OTHER,lead,University of Texas at Austin,Phase 2
NCT04197349,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04197349,2019.0,INDUSTRY,collaborator,"Alder Biopharmaceuticals, Inc.",Phase 1
NCT04198129,2020.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 1
NCT04200066,2022.0,OTHER,lead,University of Rochester,Phase 1
NCT04200352,2020.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT04200911,2020.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Early Phase 1
NCT04200911,2020.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Early Phase 1
NCT04201080,2019.0,INDUSTRY,lead,Trevena Inc.,Phase 1
NCT04201093,2019.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 3
NCT04201262,2019.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT04201652,2019.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT04201678,2019.0,OTHER,lead,Gulhane School of Medicine,Not Applicable
NCT04201834,2020.0,OTHER,lead,University of Rochester,Phase 2
NCT04202757,2018.0,OTHER,lead,The Neurology Center,Early Phase 1
NCT04202757,2018.0,UNKNOWN,collaborator,Carolina Longevity Institute,Early Phase 1
NCT04203017,2019.0,OTHER,lead,St. Petersburg State Pavlov Medical University,Phase 1
NCT04203056,2019.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT04203056,2019.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 4
NCT04205019,2020.0,INDUSTRY,lead,Neuroplast,Phase 1
NCT04205136,2022.0,OTHER,lead,University of Michigan,Phase 4
NCT04205539,2021.0,OTHER,lead,Neurological Associates of West Los Angeles,Phase 1
NCT04205565,2019.0,INDUSTRY,lead,"Nanjing Yoko Biomedical Co., Ltd.",Phase 3
NCT04205578,2020.0,OTHER,lead,yuanli Zhao,Phase 3
NCT04205578,2020.0,OTHER,collaborator,Peking University International Hospital,Phase 3
NCT04205890,2020.0,OTHER,lead,Neurological Associates of West Los Angeles,Phase 1
NCT04207359,2020.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Not Applicable
NCT04207359,2020.0,UNKNOWN,collaborator,ThriveWell Cancer Foundation,Not Applicable
NCT04207385,2019.0,OTHER,lead,Xijing Hospital,Phase 4
NCT04207723,2020.0,INDUSTRY,lead,Boston Medical Group,Not Applicable
NCT04209322,2017.0,OTHER,lead,University of Roma La Sapienza,Not Applicable
NCT04210310,2020.0,OTHER,lead,NYU Langone Health,Phase 3
NCT04210713,2020.0,OTHER,lead,"University of Maryland, Baltimore",Phase 1
NCT04210713,2020.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1
NCT04210804,2014.0,OTHER,lead,"National University of Ireland, Galway, Ireland",Phase 2
NCT04210804,2014.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 2
NCT04211233,2019.0,OTHER,lead,University Clinic Frankfurt,Not Applicable
NCT04211740,2019.0,OTHER,lead,"National Center of Neurology and Psychiatry, Japan",Phase 2
NCT04212793,2020.0,OTHER,lead,University Medical Center Groningen,Phase 1
NCT04213391,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04217577,2019.0,FED,lead,VA Palo Alto Health Care System,Not Applicable
NCT04218539,2021.0,OTHER,lead,Yale University,Phase 1
NCT04218539,2021.0,UNKNOWN,collaborator,Wallace Research Foundation,Phase 1
NCT04218968,2019.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT04219241,2020.0,INDUSTRY,lead,Azidus Brasil,Phase 2/Phase 3
NCT04219241,2020.0,OTHER,collaborator,Cellavita Pesquisa Científica Ltda,Phase 2/Phase 3
NCT04219280,2020.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT04219280,2020.0,OTHER,collaborator,"University of California, Davis",Phase 4
NCT04219735,2020.0,OTHER,lead,Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude,Phase 2
NCT04219774,2020.0,OTHER,lead,Duke University,Phase 2
NCT04219969,2018.0,OTHER,lead,M.D. Anderson Cancer Center,Not Applicable
NCT04219969,2018.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT04219995,2020.0,OTHER,lead,Louisiana State University Health Sciences Center in New Orleans,Phase 1/Phase 2
NCT04220021,2020.0,OTHER,lead,University of Florida,Phase 2
NCT04220021,2020.0,OTHER,collaborator,ALS Association,Phase 2
NCT04220125,2022.0,OTHER,lead,Northwestern University,Phase 4
NCT04220190,2020.0,INDUSTRY,lead,Rapa Therapeutics LLC,Phase 2/Phase 3
NCT04220190,2020.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT04220190,2020.0,OTHER,collaborator,Hackensack Meridian Health,Phase 2/Phase 3
NCT04220515,2018.0,OTHER,lead,"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase 4
NCT04220515,2018.0,OTHER,collaborator,Shanghai Center for Disease Control and Prevention,Phase 4
NCT04220606,2015.0,OTHER,lead,Leiden University Medical Center,Not Applicable
NCT04220606,2015.0,OTHER_GOV,collaborator,Netherlands Organisation for Scientific Research,Not Applicable
NCT04220606,2015.0,OTHER,collaborator,European Commission,Not Applicable
NCT04220762,2020.0,OTHER,lead,Medi Help Line,Phase 2
NCT04220996,2019.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT04221451,2020.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 3
NCT04221997,2019.0,OTHER,lead,University of Cincinnati,Phase 4
NCT04221997,2019.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4
NCT04223193,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 3
NCT04223206,2020.0,OTHER,lead,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,Not Applicable
NCT04223206,2020.0,OTHER,collaborator,University of Bari Aldo Moro,Not Applicable
NCT04224519,2018.0,OTHER,lead,"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase 4
NCT04224519,2018.0,OTHER,collaborator,Yunnan Center for Disease Control and Prevention,Phase 4
NCT04225221,2020.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT04225221,2020.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT04225312,2020.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT04225312,2020.0,UNKNOWN,collaborator,Stichting MS Research,Phase 4
NCT04225312,2020.0,OTHER,collaborator,Innovatiefonds Zorgverzekeraars,Phase 4
NCT04225312,2020.0,UNKNOWN,collaborator,Stichting Treatmeds,Phase 4
NCT04226170,2021.0,INDUSTRY,lead,"DAS-MG, Inc",Phase 2
NCT04226248,2020.0,OTHER,lead,University of Bristol,Phase 3
NCT04226248,2020.0,OTHER,collaborator,Royal United Hospitals Bath NHS Foundation Trust,Phase 3
NCT04226456,2021.0,OTHER,lead,Centre Hospitalier Universitaire Saint Pierre,Phase 4
NCT04226547,2020.0,INDUSTRY,lead,Abbott Medical Devices,Not Applicable
NCT04226898,2022.0,OTHER,lead,Sheppard Pratt Health System,Phase 2
NCT04226924,2017.0,INDUSTRY,lead,Bioblast Pharma Ltd.,Phase 2
NCT04227093,2020.0,OTHER,lead,"University Hospital, Antwerp",Phase 4
NCT04227470,2020.0,INDUSTRY,lead,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 1
NCT04228289,2020.0,FED,lead,VA Office of Research and Development,Phase 2
NCT04228289,2020.0,FED,collaborator,San Francisco VA Health Care System,Phase 2
NCT04228666,2020.0,OTHER,lead,Hope Biosciences Stem Cell Research Foundation,Phase 1/Phase 2
NCT04228666,2020.0,INDUSTRY,collaborator,Hope Biosciences,Phase 1/Phase 2
NCT04228965,2020.0,OTHER,lead,Medical University of South Carolina,Phase 4
NCT04228965,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 4
NCT04228965,2020.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT04229186,2020.0,OTHER,lead,University of Bari Aldo Moro,Not Applicable
NCT04229186,2020.0,UNKNOWN,collaborator,Med & Food and Schena Foundation,Not Applicable
NCT04229758,2021.0,OTHER,lead,University of Texas at Austin,Phase 3
NCT04230174,2020.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04230174,2020.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT04230226,2020.0,INDUSTRY,lead,Pharmanex,Not Applicable
NCT04230226,2020.0,OTHER,collaborator,"University of North Carolina, Chapel Hill",Not Applicable
NCT04230681,2020.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT04231539,2020.0,OTHER,lead,Roswell Park Cancer Institute,Not Applicable
NCT04231539,2020.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT04231643,2021.0,OTHER,lead,"University of California, San Diego",Early Phase 1
NCT04231643,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT04232046,2016.0,OTHER,lead,Mazandaran University of Medical Sciences,Not Applicable
NCT04232605,2020.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04232644,2019.0,INDUSTRY,lead,"Vallon Pharmaceuticals, Inc.",Phase 1
NCT04232943,2020.0,OTHER,lead,PATH,Phase 1
NCT04232969,2020.0,OTHER,lead,"University College, London",Phase 3
NCT04233437,2020.0,INDUSTRY,lead,Moleac Pte Ltd.,Phase 1
NCT04233437,2020.0,UNKNOWN,collaborator,Moleac Australia Pty Ltd,Phase 1
NCT04233502,2020.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 3
NCT04234776,2018.0,OTHER,lead,University of Sao Paulo,Phase 4
NCT04235478,2017.0,OTHER,lead,Marmara University,Not Applicable
NCT04235686,2020.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04235686,2020.0,OTHER,collaborator,Lindner Center of HOPE,Phase 2
NCT04236440,2020.0,INDUSTRY,lead,Bayer,Phase 2
NCT04236986,2017.0,OTHER,lead,Yale University,Phase 1
NCT04236986,2017.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT04237987,2020.0,OTHER,lead,Peking University People's Hospital,Phase 2
NCT04238208,2019.0,OTHER,lead,Corporacion Parc Tauli,Phase 4
NCT04238416,2019.0,UNKNOWN,lead,Postgraduate Institute of Medical Education and Research,Phase 1
NCT04238572,2020.0,OTHER,lead,"University Hospital, Caen",Not Applicable
NCT04239196,2020.0,OTHER,lead,Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,Phase 2
NCT04239196,2020.0,INDUSTRY,collaborator,Roche Chugai,Phase 2
NCT04239469,2020.0,INDUSTRY,lead,Knop Laboratorios,Phase 2
NCT04239755,2020.0,OTHER,lead,Damanhour University,Phase 4
NCT04239755,2020.0,OTHER,collaborator,Tanta University,Phase 4
NCT04240314,2020.0,OTHER,lead,Megan Waldrop,Phase 1/Phase 2
NCT04240314,2020.0,INDUSTRY,collaborator,Audentes Therapeutics,Phase 1/Phase 2
NCT04240496,2019.0,OTHER,lead,University of Monastir,Not Applicable
NCT04241068,2020.0,INDUSTRY,lead,Biogen,Phase 3
NCT04241965,2020.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1
NCT04242056,2020.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 1/Phase 2
NCT04242914,2019.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Phase 1/Phase 2
NCT04243382,2020.0,OTHER_GOV,lead,Sheba Medical Center,Phase 2
NCT04244058,2020.0,OTHER,lead,Weill Medical College of Cornell University,Early Phase 1
NCT04244175,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT04245319,2020.0,OTHER,lead,Cairo University,Not Applicable
NCT04245371,2020.0,OTHER,lead,"John Papakonstantinou, MD",Phase 4
NCT04245371,2020.0,INDUSTRY,collaborator,Scilex Ltd.,Phase 4
NCT04245436,2020.0,OTHER,lead,University of Cincinnati,Phase 4
NCT04245592,2020.0,OTHER,lead,University of Jaén,Not Applicable
NCT04245592,2020.0,UNKNOWN,collaborator,Junta de Andalucía,Not Applicable
NCT04245709,2020.0,OTHER,lead,"Dwight Koeberl, M.D., Ph.D.",Phase 2
NCT04245748,2020.0,OTHER,lead,University of Cincinnati,Phase 4
NCT04245761,2018.0,INDUSTRY,lead,Italfarmaco,Not Applicable
NCT04245761,2018.0,OTHER,collaborator,"Opera CRO, a TIGERMED Group Company",Not Applicable
NCT04246372,2020.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT04246372,2020.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT04246437,2020.0,OTHER,lead,Daniel Claassen,Phase 1
NCT04246697,2019.0,OTHER,lead,University of Kansas Medical Center,Phase 4
NCT04246905,2020.0,OTHER,lead,Central South University,Phase 2
NCT04247646,2020.0,OTHER,lead,Scripps Health,Not Applicable
NCT04247659,2020.0,OTHER,lead,The Second Hospital of Hebei Medical University,Phase 4
NCT04248270,2020.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 1/Phase 2
NCT04248465,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT04248608,2020.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT04249544,2019.0,OTHER,lead,Vanderbilt University Medical Center,Phase 1
NCT04249544,2019.0,FED,collaborator,United States Department of Defense,Phase 1
NCT04249869,2020.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Phase 1/Phase 2
NCT04250493,2020.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT04250493,2020.0,OTHER,collaborator,University of Bordeaux,Not Applicable
NCT04250493,2020.0,OTHER,collaborator,Labex Brain,Not Applicable
NCT04250493,2020.0,OTHER,collaborator,"Centre National de la Recherche Scientifique, France",Not Applicable
NCT04250727,2021.0,OTHER,lead,Yale University,Not Applicable
NCT04250805,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Phase 2
NCT04250805,2020.0,OTHER,collaborator,Institut de Cancérologie de la Loire,Phase 2
NCT04251026,2020.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 1/Phase 2
NCT04251182,2021.0,INDUSTRY,lead,"T3D Therapeutics, Inc.",Phase 2
NCT04251182,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04251182,2021.0,OTHER,collaborator,"Clinilabs, Inc.",Phase 2
NCT04251182,2021.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT04251585,2020.0,OTHER,lead,HealthPartners Institute,Phase 2
NCT04251819,2021.0,OTHER,lead,University of Alabama at Birmingham,Phase 2/Phase 3
NCT04251910,2019.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 1/Phase 2
NCT04251910,2019.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 1/Phase 2
NCT04252131,2018.0,OTHER,lead,Calo Psychiatric Center,Phase 1
NCT04252313,2019.0,OTHER,lead,American University of Beirut Medical Center,Not Applicable
NCT04252521,2019.0,OTHER,lead,Adiyaman University Research Hospital,Not Applicable
NCT04252586,2020.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 3
NCT04252586,2020.0,UNKNOWN,collaborator,GW Pharmaceuticals,Phase 3
NCT04252742,2020.0,INDUSTRY,lead,Amgen,Phase 4
NCT04253132,2021.0,OTHER,lead,"NeuroTau, Inc.",Phase 1/Phase 2
NCT04253132,2021.0,OTHER,collaborator,The Cleveland Clinic,Phase 1/Phase 2
NCT04253457,2020.0,OTHER,lead,University Hospital Plymouth NHS Trust,Phase 3
NCT04256252,2014.0,OTHER,lead,Tang-Du Hospital,Phase 4
NCT04256603,2019.0,OTHER,lead,MetroHealth Medical Center,Phase 4
NCT04256655,2020.0,INDUSTRY,lead,Société des Produits Nestlé (SPN),Phase 1
NCT04256785,2018.0,OTHER,lead,Elena Pita Calandre,Not Applicable
NCT04256785,2018.0,INDUSTRY,collaborator,Actial Farmaceutica S.r.l.,Not Applicable
NCT04256785,2018.0,INDUSTRY,collaborator,Ferring Pharmaceuticals,Not Applicable
NCT04257695,2021.0,OTHER,lead,Albert Einstein College of Medicine,Not Applicable
NCT04257695,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT04257851,2020.0,OTHER_GOV,lead,Damanhour Teaching Hospital,Phase 4
NCT04257929,2020.0,INDUSTRY,lead,"Harmony Biosciences, LLC",Phase 2
NCT04258774,2020.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT04259281,2020.0,INDUSTRY,lead,Ultragenyx Pharmaceutical Inc,Phase 1/Phase 2
NCT04259307,2020.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT04259307,2020.0,OTHER_GOV,collaborator,Korean Center for Disease Control and Prevention,Not Applicable
NCT04260035,2020.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04260581,2020.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT04260607,2020.0,FED,lead,Naval Medical Center Camp Lejeune,Phase 3
NCT04260711,2020.0,OTHER,lead,"Amsterdam UMC, location VUmc",Not Applicable
NCT04261335,2020.0,OTHER,lead,Nagoya University,Phase 1
NCT04261335,2020.0,UNKNOWN,collaborator,"Life Science Institute, Inc.",Phase 1
NCT04261478,2020.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Not Applicable
NCT04261478,2020.0,OTHER,collaborator,McGill University,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,Laval University,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,Queen's University,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,University of Ottawa,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,McMaster University,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,University of Calgary,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,University of British Columbia,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,Dalhousie University,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,Health Sciences North Research Institute,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,University of Toronto,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,University of Alberta,Not Applicable
NCT04261478,2020.0,OTHER,collaborator,Canadian Stroke Consortium (CSC),Not Applicable
NCT04261712,2019.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 2
NCT04261790,2020.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT04261790,2020.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT04262206,2020.0,OTHER,lead,Duke University,Phase 4
NCT04262206,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT04262206,2020.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT04262206,2020.0,OTHER,collaborator,Wake Forest University Health Sciences,Phase 4
NCT04262817,2020.0,OTHER,lead,Yale University,Phase 1
NCT04262817,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT04262895,2021.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT04263337,2020.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 1
NCT04263337,2020.0,OTHER,collaborator,Boston Children's Hospital,Phase 1
NCT04263337,2020.0,OTHER,collaborator,Medical College of Wisconsin,Phase 1
NCT04263337,2020.0,OTHER,collaborator,National Football League,Phase 1
NCT04263363,2022.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT04263363,2022.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT04263454,2020.0,OTHER,lead,University of Alabama at Birmingham,Phase 2/Phase 3
NCT04263454,2020.0,OTHER,collaborator,American Fibromyalgia Syndrome Association,Phase 2/Phase 3
NCT04263519,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT04263623,2020.0,INDUSTRY,lead,Atacama Therapeutics,Phase 2
NCT04263844,2019.0,OTHER,lead,Indonesia University,Phase 4
NCT04264026,2021.0,FED,lead,VA Loma Linda Health Care System,Phase 2
NCT04264026,2021.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT04264546,2017.0,NETWORK,lead,Jiangsu Province Centers for Disease Control and Prevention,Phase 1/Phase 2
NCT04264598,2017.0,NETWORK,lead,Jiangsu Province Centers for Disease Control and Prevention,Phase 1
NCT04264598,2017.0,INDUSTRY,collaborator,"Beijing Minhai Biotechnology Co., Ltd",Phase 1
NCT04265027,2018.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 1
NCT04265053,2021.0,OTHER,lead,"University of Wisconsin, Madison",Early Phase 1
NCT04265053,2021.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT04265209,2021.0,INDUSTRY,lead,Zionexa,Phase 3
NCT04265755,2020.0,INDUSTRY,lead,Amgen,Phase 4
NCT04266288,2019.0,OTHER,lead,MercyOne Des Moines Medical Center,Phase 4
NCT04266665,2020.0,OTHER,lead,Georgia Tsaousi,Phase 4
NCT04267926,2020.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT04268303,2020.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 3
NCT04268303,2020.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 3
NCT04268953,2020.0,INDUSTRY,lead,Cerecin,Phase 1
NCT04270019,2020.0,OTHER,lead,Nova Scotia Health Authority,Phase 1/Phase 2
NCT04270877,2021.0,OTHER,lead,Odense University Hospital,Phase 2
NCT04270877,2021.0,OTHER,collaborator,University of Southern Denmark,Phase 2
NCT04270877,2021.0,OTHER,collaborator,University Hospital Bispebjerg and Frederiksberg,Phase 2
NCT04271878,2022.0,OTHER,lead,University of Calgary,Not Applicable
NCT04271943,2019.0,OTHER,lead,Istanbul Medipol University Hospital,Not Applicable
NCT04272736,2023.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT04273165,2020.0,OTHER,lead,IRCCS Eugenio Medea,Phase 2
NCT04273165,2020.0,OTHER,collaborator,University of Rome Tor Vergata,Phase 2
NCT04273269,2021.0,INDUSTRY,lead,LYSOGENE,Phase 1/Phase 2
NCT04273516,2020.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 2/Phase 3
NCT04273737,2020.0,OTHER,lead,Columbia University,Phase 4
NCT04273841,2017.0,FED,lead,Walter Reed Army Institute of Research (WRAIR),Not Applicable
NCT04273932,2019.0,OTHER,lead,State University of New York at Buffalo,Phase 1
NCT04274179,2020.0,OTHER,lead,Johns Hopkins University,Phase 3
NCT04274998,2020.0,OTHER,lead,University of Pennsylvania,Early Phase 1
NCT04275219,2019.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 4
NCT04275219,2019.0,UNKNOWN,collaborator,People's Hospital of Ganzhou City,Phase 4
NCT04275219,2019.0,UNKNOWN,collaborator,People's Hospital of Lianjiang City,Phase 4
NCT04275219,2019.0,UNKNOWN,collaborator,Yangjiang Hospital of Traditional Chinese Medicine,Phase 4
NCT04275219,2019.0,UNKNOWN,collaborator,Shenyang No. 2 Hospital of Traditional Chinese Medicine,Phase 4
NCT04275219,2019.0,OTHER,collaborator,Guangdong Provincial Hospital of Traditional Chinese Medicine,Phase 4
NCT04275492,2020.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT04275492,2020.0,UNKNOWN,collaborator,Hongguan biological pharmaceutical co.,Not Applicable
NCT04275661,2020.0,OTHER,lead,Assiut University,Phase 2
NCT04276259,2020.0,OTHER,lead,"Marta Peciña, MD PhD",Phase 4
NCT04276883,2020.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 3
NCT04276883,2020.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 3
NCT04277247,2021.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT04277247,2021.0,INDUSTRY,collaborator,Allergan,Phase 2/Phase 3
NCT04278755,2020.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT04278755,2020.0,OTHER,collaborator,"Foundation of Hope, North Carolina",Phase 2
NCT04278898,2021.0,OTHER,lead,Stanford University,Phase 2
NCT04278898,2021.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT04279314,2020.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT04279418,2019.0,OTHER,lead,XuanwuH 2,Not Applicable
NCT04280055,2020.0,OTHER,lead,Gitte Moos Knudsen,Phase 1/Phase 2
NCT04280289,2020.0,OTHER,lead,"University of Mississippi, Oxford",Early Phase 1
NCT04280601,2020.0,OTHER,lead,Christian Pagnoux,Not Applicable
NCT04280965,2019.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Early Phase 1
NCT04280965,2019.0,UNKNOWN,collaborator,South Central MIRECC,Early Phase 1
NCT04281485,2020.0,INDUSTRY,lead,Pfizer,Phase 3
NCT04283136,2020.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04283227,2022.0,INDUSTRY,lead,Orchard Therapeutics,Phase 3
NCT04283227,2022.0,OTHER,collaborator,Ospedale San Raffaele,Phase 3
NCT04283578,2020.0,OTHER,lead,"University Hospital, Toulouse",Phase 3
NCT04283578,2020.0,OTHER,collaborator,International Clinical Trials Association,Phase 3
NCT04283578,2020.0,OTHER,collaborator,Epidemiological and Clinical Research Information Network,Phase 3
NCT04283656,2022.0,OTHER,lead,Thomas Jefferson University,Phase 1
NCT04283669,2020.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT04283669,2020.0,OTHER,collaborator,Memorial Sloan Kettering Cancer Center,Phase 2
NCT04285255,2020.0,OTHER,lead,Al Mashfa Medical Center,Not Applicable
NCT04285281,2020.0,OTHER,lead,Universidad Europea de Madrid,Phase 4
NCT04285333,2020.0,OTHER,lead,University Tunis El Manar,Not Applicable
NCT04285333,2020.0,OTHER,collaborator,Institut Kassab d'Orthopédie,Not Applicable
NCT04285346,2020.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT04285515,2020.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT04287140,2020.0,OTHER,lead,Marmara University,Not Applicable
NCT04287543,2021.0,OTHER_GOV,lead,Instituto Mexicano del Seguro Social,Phase 2/Phase 3
NCT04287881,2019.0,OTHER,lead,Istanbul Medeniyet University,Not Applicable
NCT04288856,2020.0,INDUSTRY,lead,Biogen,Phase 1
NCT04288934,2017.0,OTHER,lead,University of Jordan,Phase 1
NCT04289142,2019.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 4
NCT04289142,2019.0,OTHER,collaborator,London Health Sciences Centre,Phase 4
NCT04289142,2019.0,OTHER,collaborator,"University Health Network, Toronto",Phase 4
NCT04289142,2019.0,OTHER,collaborator,McMaster University,Phase 4
NCT04289467,2023.0,OTHER,lead,Children's Hospital of Orange County,Phase 2
NCT04290169,2020.0,OTHER,lead,Sunnaas Rehabilitation Hospital,Not Applicable
NCT04290169,2020.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT04290169,2020.0,OTHER,collaborator,Göteborg University,Not Applicable
NCT04290169,2020.0,UNKNOWN,collaborator,CP-foreningen,Not Applicable
NCT04290182,2020.0,OTHER,lead,Karolinska University Hospital,Phase 1/Phase 2
NCT04290182,2020.0,OTHER,collaborator,Swedish Foundation for Strategic Research,Phase 1/Phase 2
NCT04291066,2019.0,OTHER,lead,HonorHealth Research Institute,Phase 2
NCT04291456,2020.0,OTHER,lead,University of Calgary,Phase 3
NCT04291456,2020.0,OTHER,collaborator,"Hotchkiss Brain Institute, University of Calgary",Phase 3
NCT04291456,2020.0,OTHER,collaborator,Multiple Sclerosis Society of Canada,Phase 3
NCT04291469,2022.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT04291469,2022.0,UNKNOWN,collaborator,BaoJi Rehabilitation Hospital,Not Applicable
NCT04291469,2022.0,OTHER,collaborator,Xiangyang Central Hospital,Not Applicable
NCT04291469,2022.0,UNKNOWN,collaborator,WeiNan Psychiatry Hospital,Not Applicable
NCT04291469,2022.0,UNKNOWN,collaborator,HanZhong Psychiatric Hospital,Not Applicable
NCT04291859,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04292457,2020.0,OTHER,lead,Helse Nord-Trøndelag HF,Not Applicable
NCT04292457,2020.0,UNKNOWN,collaborator,ØNH Legen Trondheim,Not Applicable
NCT04292457,2020.0,OTHER,collaborator,St. Olavs Hospital,Not Applicable
NCT04292561,2020.0,OTHER,lead,The First Affiliated Hospital of Anhui Medical University,Not Applicable
NCT04293159,2019.0,OTHER,lead,University of Salerno,Not Applicable
NCT04293159,2019.0,UNKNOWN,collaborator,Roberto Erro,Not Applicable
NCT04293159,2019.0,UNKNOWN,collaborator,Maria Teresa Pellecchia,Not Applicable
NCT04293159,2019.0,UNKNOWN,collaborator,Antonella Santonicola,Not Applicable
NCT04293159,2019.0,UNKNOWN,collaborator,Carolina Ciacci,Not Applicable
NCT04293380,2012.0,OTHER,lead,Karadeniz Technical University,Not Applicable
NCT04293783,2020.0,OTHER,lead,University of Rome Tor Vergata,Not Applicable
NCT04293783,2020.0,OTHER,collaborator,University of Bari,Not Applicable
NCT04293874,2018.0,OTHER,lead,University of Connecticut,Not Applicable
NCT04293874,2018.0,OTHER,collaborator,Hartford HealthCare,Not Applicable
NCT04293874,2018.0,UNKNOWN,collaborator,Seafood Industry Research Fund,Not Applicable
NCT04293874,2018.0,UNKNOWN,collaborator,Alaskan Seafood Marketing Institute,Not Applicable
NCT04293874,2018.0,OTHER,collaborator,Academy of Nutrition and Dietetics,Not Applicable
NCT04294147,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT04294290,2021.0,OTHER,lead,Duke University,Phase 1
NCT04294290,2021.0,OTHER,collaborator,The Marcus Foundation,Phase 1
NCT04294654,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT04294654,2020.0,INDUSTRY,collaborator,ICON plc,Phase 4
NCT04295642,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT04297111,2019.0,OTHER,lead,University College Dublin,Not Applicable
NCT04297111,2019.0,UNKNOWN,collaborator,Kerry Group,Not Applicable
NCT04297358,2017.0,OTHER,lead,Hyperbaric Center Basel,Phase 4
NCT04297683,2020.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT04297683,2020.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT04298541,2021.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT04298541,2021.0,OTHER,collaborator,Cornell University,Phase 2
NCT04298853,2020.0,OTHER,lead,Indiana University,Phase 4
NCT04299893,2020.0,OTHER,lead,"Bernardino Clavo, MD, PhD",Phase 2/Phase 3
NCT04299893,2020.0,OTHER,collaborator,Servicio Canario de Salud,Phase 2/Phase 3
NCT04299893,2020.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 2/Phase 3
NCT04299893,2020.0,OTHER,collaborator,Red de Investigación en Servicios de Salud en Enfermedades Crónicas,Phase 2/Phase 3
NCT04299893,2020.0,UNKNOWN,collaborator,"Fundación DISA, Spain",Phase 2/Phase 3
NCT04299893,2020.0,UNKNOWN,collaborator,Fundación Española del Dolor (FED),Phase 2/Phase 3
NCT04301284,2021.0,INDUSTRY,lead,Cadent Therapeutics,Phase 2
NCT04301492,2019.0,OTHER,lead,IRCCS San Raffaele Roma,Phase 4
NCT04301609,2021.0,INDUSTRY,lead,Vitae Health Innovation,Not Applicable
NCT04301609,2021.0,OTHER,collaborator,Hospital Vall d'Hebron,Not Applicable
NCT04301726,2020.0,OTHER,lead,Fundacion Huntington Puerto Rico,Phase 1
NCT04302116,2020.0,OTHER_GOV,lead,Kullasate Sakpichaisakul,Not Applicable
NCT04302181,2020.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Early Phase 1
NCT04302181,2020.0,FED,collaborator,United States Department of Defense,Early Phase 1
NCT04302870,2020.0,OTHER,lead,University of Edinburgh,Phase 2/Phase 3
NCT04302870,2020.0,OTHER,collaborator,"University College, London",Phase 2/Phase 3
NCT04302870,2020.0,OTHER,collaborator,University of Warwick,Phase 2/Phase 3
NCT04302870,2020.0,OTHER_GOV,collaborator,NHS Lothian,Phase 2/Phase 3
NCT04303065,2020.0,OTHER,lead,Hospital Son Espases,Phase 3
NCT04303325,2021.0,OTHER,lead,"China Medical University, China",Phase 4
NCT04303416,2020.0,INDIV,lead,"Onofre, Aurora Pujol, M.D.",Phase 2/Phase 3
NCT04304274,2020.0,OTHER,lead,Cui Xulei,Not Applicable
NCT04304482,2020.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2/Phase 3
NCT04304482,2020.0,INDUSTRY,collaborator,Anavex Australia Pty Ltd.,Phase 2/Phase 3
NCT04304482,2020.0,INDUSTRY,collaborator,Anavex Germany GmbH,Phase 2/Phase 3
NCT04305002,2020.0,OTHER,lead,"Center for Neurology, Stockholm",Phase 2
NCT04305002,2020.0,OTHER,collaborator,Karolinska Institutet,Phase 2
NCT04305210,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04305275,2020.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT04305470,2020.0,INDUSTRY,lead,NX Development Corp,Phase 3
NCT04305522,2020.0,INDUSTRY,lead,Biopolis S.L.,Not Applicable
NCT04306146,2020.0,INDUSTRY,lead,Cadent Therapeutics,Phase 1
NCT04306354,2018.0,OTHER,lead,Pontificia Universidade Católica do Rio Grande do Sul,Phase 1/Phase 2
NCT04306354,2018.0,UNKNOWN,collaborator,Secretaria Nacional de Políticas sobre Drogas (SENAD),Phase 1/Phase 2
NCT04306354,2018.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 1/Phase 2
NCT04306562,2019.0,OTHER,lead,Siriraj Hospital,Not Applicable
NCT04308304,2021.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT04308577,2020.0,OTHER,collaborator,"Rigshospitalet, Denmark",Not Applicable
NCT04308577,2020.0,OTHER,lead,Jens Rikardt Andersen,Not Applicable
NCT04309149,2018.0,INDUSTRY,lead,Dr. Schär AG / SPA,Not Applicable
NCT04309214,2018.0,INDUSTRY,lead,Dr. Schär AG / SPA,Not Applicable
NCT04309292,2021.0,OTHER,lead,King's College London,Not Applicable
NCT04309292,2021.0,UNKNOWN,collaborator,Co-sponsor: Guy's and St Thomas' NHS Foundation Trust,Not Applicable
NCT04309331,2018.0,INDUSTRY,lead,Dr. Schär AG / SPA,Not Applicable
NCT04309708,2018.0,INDUSTRY,lead,B. Braun Medical International Trading Company Ltd.,Not Applicable
NCT04309877,2023.0,OTHER,lead,"University of California, Los Angeles",Early Phase 1
NCT04311099,2021.0,OTHER,lead,"Claus Anders Bertelsen, PhD, MD",Phase 4
NCT04311463,2020.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT04311515,2020.0,INDUSTRY,lead,"Samus Therapeutics, Inc.",Phase 2
NCT04312152,2019.0,OTHER,lead,Antonio Persico,Not Applicable
NCT04312152,2019.0,UNKNOWN,collaborator,Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM),Not Applicable
NCT04312152,2019.0,OTHER,collaborator,University of Bari,Not Applicable
NCT04312399,2018.0,OTHER,lead,"University Hospital, Ghent",Not Applicable
NCT04312932,2021.0,OTHER,lead,Sarah Keim,Phase 2
NCT04312932,2021.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT04313166,2020.0,INDUSTRY,lead,Collaborative Medicinal Development Pty Limited,Phase 2
NCT04313335,2021.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,China-Japan Friendship Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Tianjin Medical University Second Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Taiyuan Central Hospital of Shanxi Medical University,Not Applicable
NCT04313335,2021.0,UNKNOWN,collaborator,Linfen Fourth People's Hospital,Not Applicable
NCT04313335,2021.0,OTHER_GOV,collaborator,Shandong Provincial Hospital,Not Applicable
NCT04313335,2021.0,UNKNOWN,collaborator,Qingdao Municipal Hospital (Group),Not Applicable
NCT04313335,2021.0,OTHER,collaborator,The Second People's Hospital of Huai'an,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,First Hospital of China Medical University,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Second Affiliated Hospital of Zhengzhou University,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Fujian Provincial Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Cangzhou Central Hospital,Not Applicable
NCT04313335,2021.0,UNKNOWN,collaborator,The People's Hospital of Fujian Province,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Beijing Tsinghua Chang Gung Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Peking University International Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Tianjin First Central Hospital,Not Applicable
NCT04313335,2021.0,OTHER,collaborator,Tianjin Huanhu Hospital,Not Applicable
NCT04313335,2021.0,UNKNOWN,collaborator,Baoding First Central Hospital,Not Applicable
NCT04313374,2016.0,OTHER,lead,Istanbul University,Phase 4
NCT04314687,2021.0,INDUSTRY,lead,PT. Prodia Stem Cell Indonesia,Phase 1/Phase 2
NCT04314934,2019.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2/Phase 3
NCT04314934,2019.0,INDUSTRY,collaborator,Anavex Australia Pty Ltd.,Phase 2/Phase 3
NCT04314934,2019.0,INDUSTRY,collaborator,Anavex Germany GmbH,Phase 2/Phase 3
NCT04315415,2020.0,INDUSTRY,lead,"Sofregen Medical, Inc.",Not Applicable
NCT04315935,2019.0,INDUSTRY,lead,"Jiangsu Hengrui Pharmaceutical Co., Ltd.",Phase 4
NCT04316494,2020.0,OTHER,lead,Guy's and St Thomas' NHS Foundation Trust,Phase 4
NCT04316494,2020.0,OTHER_GOV,collaborator,Medical Research Council,Phase 4
NCT04316650,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT04316702,2020.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Not Applicable
NCT04316702,2020.0,UNKNOWN,collaborator,The Emili Sagol Creative Arts Therapies Research Center,Not Applicable
NCT04317235,2016.0,OTHER,lead,Saint George Hospital,Not Applicable
NCT04318067,2020.0,OTHER,lead,Allan Hvolby,Phase 4
NCT04318067,2020.0,OTHER,collaborator,Sygehus Lillebaelt,Phase 4
NCT04318509,2019.0,INDUSTRY,lead,Dr. Schär AG / SPA,Not Applicable
NCT04319588,2020.0,OTHER,lead,Campus Bio-Medico University,Not Applicable
NCT04320940,2021.0,INDUSTRY,lead,"NEMA Research, Inc.",Phase 3
NCT04321889,2020.0,OTHER,lead,S.Anna Rehabilitation Institute,Not Applicable
NCT04322149,2020.0,INDUSTRY,lead,"Anelixis Therapeutics, LLC",Phase 2
NCT04322227,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04322461,2022.0,OTHER,lead,Université de Sherbrooke,Not Applicable
NCT04322461,2022.0,INDUSTRY,collaborator,Société des Produits Nestlé (SPN),Not Applicable
NCT04322526,2017.0,OTHER,lead,"Marta Peciña, MD PhD",Phase 4
NCT04322526,2017.0,OTHER,collaborator,Brain & Behavior Research Foundation,Phase 4
NCT04323566,2022.0,OTHER,lead,Uppsala University Hospital,Phase 2
NCT04323566,2022.0,OTHER,collaborator,Uppsala University,Phase 2
NCT04323735,2020.0,OTHER,lead,Medstar Health Research Institute,Phase 2
NCT04323735,2020.0,OTHER,collaborator,Children's National Research Institute,Phase 2
NCT04325113,2019.0,OTHER,lead,University of Liege,Not Applicable
NCT04325685,2020.0,OTHER,lead,Northern State Medical University,Not Applicable
NCT04325737,2020.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 1
NCT04325932,2016.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT04326283,2020.0,INDUSTRY,lead,Genuv Inc.,Phase 1/Phase 2
NCT04326374,2019.0,INDUSTRY,lead,"Visen Pharmaceuticals (Shanghai) Co., Ltd.",Phase 3
NCT04326374,2019.0,INDUSTRY,collaborator,Ascendis Pharma A/S,Phase 3
NCT04327726,2020.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT04327843,2019.0,OTHER,lead,Case Western Reserve University,Phase 3
NCT04327843,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT04328805,2020.0,OTHER,lead,Universidad Europea de Madrid,Phase 4
NCT04330547,2018.0,OTHER,lead,University of Liege,Phase 1
NCT04331405,2013.0,OTHER_GOV,lead,Sklifosovsky Institute of Emergency Care,Phase 1/Phase 2
NCT04331405,2013.0,OTHER_GOV,collaborator,"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation",Phase 1/Phase 2
NCT04331704,2021.0,OTHER,lead,University of Florida,Phase 4
NCT04331704,2021.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4
NCT04331938,2020.0,OTHER,lead,Mayo Clinic,Phase 1
NCT04332276,2020.0,OTHER,lead,"University Hospital, Lille",Phase 1/Phase 2
NCT04332276,2020.0,UNKNOWN,collaborator,InBrain Pharma,Phase 1/Phase 2
NCT04333277,2020.0,OTHER,lead,Federal University of Minas Gerais,Not Applicable
NCT04334031,2020.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT04334031,2020.0,UNKNOWN,collaborator,FHU IMMINeNT,Not Applicable
NCT04334031,2020.0,UNKNOWN,collaborator,FHU PRECISE: Projet Fédératif Hospitalo-Universitaire PREcision health in Complex Immune-mediated inflammatory diseaSEs,Not Applicable
NCT04334031,2020.0,UNKNOWN,collaborator,Fond de dotation de la Société Française de Dermatologie (SFD),Not Applicable
NCT04334317,2020.0,INDUSTRY,lead,Takeda,Phase 2
NCT04334317,2020.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT04334408,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04334863,2020.0,OTHER,lead,Emory University,Phase 1
NCT04334863,2020.0,OTHER,collaborator,"CURE Childhood Cancer, Inc.",Phase 1
NCT04334863,2020.0,UNKNOWN,collaborator,Peach Bowl LegACy Fund,Phase 1
NCT04335461,2021.0,OTHER,lead,Montefiore Medical Center,Early Phase 1
NCT04335461,2021.0,OTHER,collaborator,Jacobi Medical Center,Early Phase 1
NCT04336046,2023.0,OTHER,lead,Tanta University,Not Applicable
NCT04338997,2020.0,INDUSTRY,lead,Inflazome UK Ltd,Phase 1
NCT04339413,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT04339751,2024.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT04341155,2021.0,OTHER,lead,Universitas Padjadjaran,Phase 2
NCT04341844,2019.0,OTHER,lead,Fudan University,Not Applicable
NCT04342273,2020.0,INDUSTRY,lead,"Kyowa Kirin Co., Ltd.",Phase 1
NCT04345432,2014.0,OTHER,lead,Medstar Health Research Institute,Not Applicable
NCT04345718,2021.0,OTHER,lead,Hennepin Healthcare Research Institute,Phase 2/Phase 3
NCT04345718,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2/Phase 3
NCT04345718,2021.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 2/Phase 3
NCT04346030,2020.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT04346394,2021.0,OTHER,lead,Nathaniel M. Robbins,Early Phase 1
NCT04346888,2020.0,INDUSTRY,lead,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 2
NCT04348136,2019.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 2/Phase 3
NCT04350125,2022.0,OTHER,lead,Mayo Clinic,Phase 1
NCT04350177,2021.0,INDUSTRY,lead,"Inhibikase Therapeutics, Inc.",Phase 1
NCT04350762,2019.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT04351061,2020.0,OTHER,lead,University of Miami,Phase 2
NCT04351373,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04353505,2020.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1
NCT04354103,2022.0,OTHER,lead,Poitiers University Hospital,Phase 2
NCT04354896,2014.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT04354896,2014.0,OTHER,collaborator,University of Lausanne Hospitals,Phase 4
NCT04354896,2014.0,OTHER,collaborator,Leiden University Medical Center,Phase 4
NCT04355117,2020.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT04355689,2020.0,INDUSTRY,lead,"Nacuity Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT04355689,2020.0,OTHER,collaborator,Foundation Fighting Blindness,Phase 1/Phase 2
NCT04357353,2021.0,OTHER,lead,University of Nebraska,Phase 3
NCT04357951,2023.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT04360044,2020.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT04360044,2020.0,OTHER,collaborator,Migraine Research Foundation,Phase 2
NCT04360070,2022.0,OTHER,lead,Fraser Health,Not Applicable
NCT04360148,2020.0,INDUSTRY,lead,New Penta SRL,Not Applicable
NCT04360148,2020.0,OTHER,collaborator,IRCCS San Raffaele,Not Applicable
NCT04360681,2021.0,OTHER,lead,Pharmacotherapies for Alcohol and Substance Use Disorders Alliance,Phase 2
NCT04360681,2021.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04360681,2021.0,OTHER,collaborator,RTI International,Phase 2
NCT04360681,2021.0,FED,collaborator,Michael E. DeBakey VA Medical Center,Phase 2
NCT04360681,2021.0,INDUSTRY,collaborator,"USWM, LLC (dba US WorldMeds)",Phase 2
NCT04361305,2020.0,OTHER,lead,Yan-Ping Huang,Phase 3
NCT04361344,2020.0,OTHER,lead,Centre Hospitalier de PAU,Not Applicable
NCT04361357,2020.0,OTHER,lead,"Xuanwu Hospital, Beijing",Not Applicable
NCT04361474,2020.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 3
NCT04361474,2020.0,OTHER,collaborator,Hopital Lariboisière,Phase 3
NCT04361552,2020.0,OTHER,lead,Emory University,Phase 3
NCT04361552,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT04363606,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Saint Etienne,Not Applicable
NCT04363606,2020.0,UNKNOWN,collaborator,University of Saint-Etienne,Not Applicable
NCT04363606,2020.0,OTHER,collaborator,Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques,Not Applicable
NCT04364074,2020.0,OTHER,lead,Medical College of Wisconsin,Not Applicable
NCT04366518,2021.0,OTHER,lead,Yale University,Early Phase 1
NCT04366518,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Early Phase 1
NCT04369391,2020.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT04369430,2020.0,INDUSTRY,lead,"Alkahest, Inc.",Phase 2
NCT04370665,2020.0,INDUSTRY,lead,InSightec,Not Applicable
NCT04371666,2020.0,INDUSTRY,lead,FibroGen,Phase 3
NCT04372264,2018.0,OTHER,lead,Pamukkale University,Phase 4
NCT04372316,2017.0,OTHER,lead,Peking University Third Hospital,Phase 2
NCT04372615,2022.0,OTHER,lead,University of Utah,Phase 2
NCT04373512,2020.0,OTHER,lead,Medstar Health Research Institute,Phase 2
NCT04373512,2020.0,OTHER,collaborator,Children's National Research Institute,Phase 2
NCT04373616,2021.0,INDUSTRY,lead,AC Immune SA,Phase 2
NCT04374136,2020.0,INDUSTRY,lead,Alector Inc.,Phase 3
NCT04374253,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT04374305,2020.0,OTHER,lead,"Scott R. Plotkin, MD, PhD",Phase 2
NCT04374305,2020.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT04374305,2020.0,OTHER,collaborator,The Children's Tumor Foundation,Phase 2
NCT04374305,2020.0,NETWORK,collaborator,National Comprehensive Cancer Network,Phase 2
NCT04374994,2018.0,OTHER,lead,University of Alexandria,Phase 4
NCT04375436,2019.0,INDUSTRY,lead,"NeuroTherapia, Inc.",Phase 1
NCT04375436,2019.0,INDUSTRY,collaborator,Integrium,Phase 1
NCT04375436,2019.0,OTHER,collaborator,Orange County Research Center,Phase 1
NCT04377399,2018.0,OTHER,lead,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Phase 4
NCT04377399,2018.0,OTHER,collaborator,Tameside Hospital NHS Foundation Trust,Phase 4
NCT04377945,2021.0,INDUSTRY,lead,Bukwang Pharmaceutical,Phase 2
NCT04378075,2020.0,INDUSTRY,lead,PTC Therapeutics,Phase 2/Phase 3
NCT04378426,2021.0,FED,lead,VA Office of Research and Development,Phase 2
NCT04378621,2020.0,OTHER_GOV,lead,Vastra Gotaland Region,Not Applicable
NCT04379011,2021.0,OTHER,lead,University of Minnesota,Phase 1/Phase 2
NCT04381468,2021.0,INDUSTRY,lead,Vaccinex Inc.,Phase 1/Phase 2
NCT04381468,2021.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 1/Phase 2
NCT04381468,2021.0,OTHER,collaborator,Alzheimer's Association,Phase 1/Phase 2
NCT04381780,2020.0,OTHER,lead,Practitioners Alliance Network,Not Applicable
NCT04381793,2019.0,OTHER,lead,Practitioners Alliance Network,Not Applicable
NCT04382170,2020.0,OTHER,lead,"Jeff C. Huffman, MD",Phase 2
NCT04382170,2020.0,INDUSTRY,collaborator,BioXcel Therapeutics Inc,Phase 2
NCT04382885,2020.0,INDUSTRY,lead,AbbVie,Phase 1
NCT04384224,2020.0,OTHER,lead,China Medical University Hospital,Not Applicable
NCT04384367,2022.0,INDUSTRY,lead,Eurofarma Laboratorios S.A.,Phase 3
NCT04384666,2020.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04385082,2021.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT04385082,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT04385966,2020.0,OTHER,lead,Instituto de Investigación Sanitaria Aragón,Phase 3
NCT04385966,2020.0,OTHER,collaborator,Hospital Miguel Servet,Phase 3
NCT04386317,2020.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT04386525,2020.0,OTHER_GOV,lead,King Fahad Medical City,Phase 4
NCT04386642,2021.0,OTHER,lead,Chiang Mai University,Phase 4
NCT04386707,2020.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT04387305,2024.0,OTHER,lead,"Daniel Nishijima, MD, MAS",Phase 3
NCT04387305,2024.0,NETWORK,collaborator,Pediatric Emergency Care Applied Research Network,Phase 3
NCT04387773,2020.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT04387773,2020.0,INDUSTRY,collaborator,"Adamas Pharmaceuticals, Inc.",Phase 4
NCT04388254,2020.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 2
NCT04388254,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04388982,2020.0,OTHER,lead,Ruijin Hospital,Phase 1/Phase 2
NCT04388982,2020.0,INDUSTRY,collaborator,Cellular Biomedicine Group Ltd.,Phase 1/Phase 2
NCT04389762,2019.0,OTHER,lead,Professor Lu Neurological Clinic,Not Applicable
NCT04390009,2023.0,OTHER,lead,Brain Health Alliance,Early Phase 1
NCT04390646,2020.0,OTHER,lead,Nelly Pitteloud,Phase 2/Phase 3
NCT04391361,2020.0,OTHER,lead,Ruijin Hospital,Phase 2
NCT04391452,2020.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT04391569,2020.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 3
NCT04391855,2020.0,OTHER,lead,Aristotle University Of Thessaloniki,Phase 4
NCT04392063,2016.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04393610,2020.0,OTHER,lead,Assiut University,Phase 2/Phase 3
NCT04394130,2020.0,OTHER,lead,Eric Albrecht,Not Applicable
NCT04394143,2020.0,OTHER,lead,Raphael Heinzer,Phase 2/Phase 3
NCT04394143,2020.0,INDUSTRY,collaborator,Apnimed,Phase 2/Phase 3
NCT04394481,2020.0,OTHER,lead,GCS Ramsay Santé pour l'Enseignement et la Recherche,Phase 4
NCT04394481,2020.0,INDUSTRY,collaborator,Euraxi Pharma,Phase 4
NCT04394546,2020.0,INDUSTRY,lead,Boston Scientific Corporation,Not Applicable
NCT04394845,2020.0,INDUSTRY,lead,"Genentech, Inc.",Phase 1
NCT04394845,2020.0,OTHER,collaborator,Invicro,Phase 1
NCT04395339,2020.0,OTHER,lead,Sun Yat-sen University,Phase 3
NCT04396236,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT04396496,2020.0,OTHER,lead,University of Arkansas,Phase 2
NCT04396496,2020.0,INDUSTRY,collaborator,"Janssen Scientific Affairs, LLC",Phase 2
NCT04396574,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT04396795,2020.0,OTHER,lead,University of Miami,Phase 2
NCT04396834,2019.0,OTHER,lead,The Mind Research Network,Phase 2
NCT04396873,2021.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT04397354,2020.0,OTHER,lead,Pamukkale University,Not Applicable
NCT04398784,2019.0,OTHER,lead,"Louisiana State University, Baton Rouge",Not Applicable
NCT04398784,2019.0,OTHER,collaborator,U.S. Highbush Blueberry Council,Not Applicable
NCT04398784,2019.0,UNKNOWN,collaborator,"Louisiana Health Care Practitioners, LLC",Not Applicable
NCT04398784,2019.0,UNKNOWN,collaborator,"Collective Healthcare Solutions, LLC",Not Applicable
NCT04398784,2019.0,UNKNOWN,collaborator,"uBiome, Inc.",Not Applicable
NCT04399070,2020.0,OTHER,lead,Yan Qiu,Not Applicable
NCT04399083,2021.0,OTHER,lead,University of Arizona,Not Applicable
NCT04399083,2021.0,FED,collaborator,Walter Reed Army Institute of Research (WRAIR),Not Applicable
NCT04399265,2020.0,OTHER,lead,National University of Malaysia,Not Applicable
NCT04399265,2020.0,OTHER,collaborator,Radboud University Medical Center,Not Applicable
NCT04399343,2021.0,OTHER,lead,Capital Medical University,Phase 4
NCT04400266,2020.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04400331,2020.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT04400331,2020.0,NETWORK,collaborator,Huntington Study Group,Phase 3
NCT04400747,2020.0,OTHER_GOV,lead,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,Not Applicable
NCT04401137,2020.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 1
NCT04401878,2020.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT04403399,2017.0,OTHER,lead,University of Michigan,Phase 2
NCT04403711,2018.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT04404439,2019.0,OTHER,lead,"University of California, Irvine",Phase 4
NCT04404712,2020.0,OTHER,lead,Yale University,Early Phase 1
NCT04405336,2020.0,OTHER,lead,Aljazeera Hospital,Not Applicable
NCT04405596,2025.0,OTHER,lead,Lawson Health Research Institute,Phase 1/Phase 2
NCT04406259,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 4
NCT04406376,2020.0,OTHER,lead,Carmel Medical Center,Phase 4
NCT04406649,2020.0,INDUSTRY,lead,"Satsuma Pharmaceuticals, Inc.",Phase 3
NCT04406818,2021.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT04406818,2021.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT04406948,2023.0,INDUSTRY,lead,MGC Pharmaceuticals d.o.o,Phase 2
NCT04408625,2020.0,INDUSTRY,lead,Prevail Therapeutics,Phase 1/Phase 2
NCT04408625,2020.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1/Phase 2
NCT04409210,2020.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Not Applicable
NCT04409210,2020.0,OTHER,collaborator,"The Seventh Affiliated Hospital, Southern Medical University",Not Applicable
NCT04410965,2020.0,INDUSTRY,lead,Sanofi,Phase 4
NCT04411914,2020.0,OTHER,lead,Temple University,Phase 1
NCT04411914,2020.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 1
NCT04411914,2020.0,OTHER,collaborator,University of Pennsylvania,Phase 1
NCT04411914,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT04412694,2020.0,OTHER,lead,Medical University of Lodz,Phase 4
NCT04412850,2020.0,OTHER,lead,Dow University of Health Sciences,Early Phase 1
NCT04413344,2020.0,OTHER,lead,Kyoto University,Phase 1/Phase 2
NCT04413344,2020.0,OTHER,collaborator,Mie University,Phase 1/Phase 2
NCT04413344,2020.0,OTHER,collaborator,Osaka University,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,Tokushima University,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,Tokyo Metropolitan Geriatric Medical Center,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,Asakayama Hospital,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,Kawasaki Medical School Hospital,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,Nagoya City University Hospital,Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,"Time Therapeutics, Inc.",Phase 1/Phase 2
NCT04413344,2020.0,UNKNOWN,collaborator,"Towa Pharmaceutical Co.,Ltd.",Phase 1/Phase 2
NCT04414345,2020.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT04414345,2020.0,INDUSTRY,collaborator,Clene Nanomedicine,Phase 2/Phase 3
NCT04414813,2020.0,OTHER,lead,Shanghai East Hospital,Early Phase 1
NCT04414813,2020.0,INDUSTRY,collaborator,"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China",Early Phase 1
NCT04414930,2020.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT04414995,2020.0,OTHER,lead,Indonesia University,Phase 2/Phase 3
NCT04415658,2020.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT04415658,2020.0,OTHER,collaborator,Mid-America Transplant,Phase 3
NCT04416126,2020.0,INDUSTRY,lead,"Arcturus Therapeutics, Inc.",Phase 1
NCT04417049,2021.0,OTHER,lead,"University Health Network, Toronto",Early Phase 1
NCT04417543,2018.0,OTHER,lead,Assiut University,Phase 1
NCT04417595,2020.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT04417595,2020.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT04417907,2021.0,OTHER,lead,Kimford Jay Meador,Phase 4
NCT04417907,2021.0,INDUSTRY,collaborator,Eisai Inc.,Phase 4
NCT04418440,2021.0,OTHER,lead,Queen Mary University of London,Not Applicable
NCT04418466,2021.0,INDUSTRY,lead,"Delpor, Inc.",Phase 1/Phase 2
NCT04418466,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT04418765,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT04419272,2023.0,FED,lead,VA Office of Research and Development,Phase 4
NCT04419272,2023.0,FED,collaborator,VA New York Harbor Healthcare System,Phase 4
NCT04419272,2023.0,FED,collaborator,Portland VA Medical Center,Phase 4
NCT04419272,2023.0,FED,collaborator,Miami VA Healthcare System,Phase 4
NCT04419272,2023.0,FED,collaborator,VA Boston Healthcare System,Phase 4
NCT04419337,2019.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04419337,2019.0,OTHER,collaborator,National Taiwan University Hospital,Phase 2
NCT04419337,2019.0,OTHER,collaborator,Chiayi Christian Hospital,Phase 2
NCT04419337,2019.0,UNKNOWN,collaborator,Tainan Sin-lau Hospital,Phase 2
NCT04419857,2020.0,OTHER,lead,Yale University,Not Applicable
NCT04419857,2020.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Not Applicable
NCT04420377,2020.0,INDUSTRY,lead,Applied Science & Performance Institute,Not Applicable
NCT04420377,2020.0,INDUSTRY,collaborator,Lonza Ltd.,Not Applicable
NCT04420585,2020.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT04421339,2021.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Not Applicable
NCT04421339,2021.0,UNKNOWN,collaborator,Huntington's Disease Society of America,Not Applicable
NCT04421456,2020.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT04421521,2020.0,OTHER,lead,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Applicable
NCT04421573,2023.0,OTHER,lead,Dr. Dean Reeves Clinic,Not Applicable
NCT04421573,2023.0,UNKNOWN,collaborator,"Francois Louw, M.D",Not Applicable
NCT04421573,2023.0,UNKNOWN,collaborator,"Jannice Bowler, M.D.",Not Applicable
NCT04421573,2023.0,UNKNOWN,collaborator,"Stanley Lam, M.D.",Not Applicable
NCT04421573,2023.0,UNKNOWN,collaborator,"Paul Johnson, D.O. Asserted to be a recognized organization",Not Applicable
NCT04421677,2020.0,OTHER,lead,University of Kansas Medical Center,Phase 1
NCT04422275,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04422431,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2
NCT04424251,2020.0,INDUSTRY,lead,"Haisco Pharmaceutical Group Co., Ltd.",Phase 2
NCT04424394,2023.0,INDUSTRY,lead,BioIntegrate,Phase 1/Phase 2
NCT04425473,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2/Phase 3
NCT04426123,2020.0,OTHER,lead,Region Örebro County,Phase 2
NCT04426123,2020.0,OTHER,collaborator,Region Västmanland,Phase 2
NCT04426123,2020.0,OTHER,collaborator,Landstinget i Värmland,Phase 2
NCT04426149,2018.0,OTHER,lead,National University of Malaysia,Not Applicable
NCT04426487,2020.0,OTHER,lead,Minia University,Early Phase 1
NCT04427241,2023.0,OTHER,lead,Konkuk University Medical Center,Phase 4
NCT04427241,2023.0,INDUSTRY,collaborator,Ever Neuro Pharma GmbH,Phase 4
NCT04428281,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04428476,2020.0,INDUSTRY,lead,Capricor Inc.,Phase 2
NCT04428775,2020.0,INDUSTRY,lead,"AZTherapies, Inc.",Phase 2
NCT04428983,2020.0,OTHER,lead,National Cheng-Kung University Hospital,Not Applicable
NCT04429568,2020.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT04429568,2020.0,OTHER,collaborator,Tobacco Related Disease Research Program,Not Applicable
NCT04430556,2018.0,OTHER,lead,Hospital Universitario Dr. Jose E. Gonzalez,Not Applicable
NCT04430556,2018.0,UNKNOWN,collaborator,Instituto de Información e Investigación en Salud Mental A. C.,Not Applicable
NCT04431713,2020.0,OTHER,lead,"University College, London",Phase 2
NCT04432155,2021.0,INDUSTRY,lead,Nobilis Therapeutics Inc.,Phase 2/Phase 3
NCT04432935,2020.0,OTHER,lead,Aga Khan University,Not Applicable
NCT04432935,2020.0,FED,collaborator,Centers for Disease Control and Prevention,Not Applicable
NCT04433234,2020.0,INDUSTRY,lead,"Daiichi Sankyo Co., Ltd.",Phase 2
NCT04433559,2020.0,INDUSTRY,lead,Lidia Larrañaga,Phase 3
NCT04433767,2020.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT04434105,2020.0,OTHER,lead,Tanta University,Phase 2/Phase 3
NCT04434768,2020.0,INDUSTRY,lead,"Ever Supreme Bio Technology Co., Ltd.",Phase 1
NCT04435431,2020.0,INDUSTRY,lead,Integrative Research Laboratories AB,Phase 2
NCT04435665,2020.0,INDUSTRY,lead,"NFlection Therapeutics, Inc.",Phase 2
NCT04435821,2020.0,OTHER,lead,Stanford University,Phase 1
NCT04435821,2020.0,INDUSTRY,collaborator,GE Healthcare,Phase 1
NCT04435886,2020.0,INDUSTRY,lead,Biopolis S.L.,Not Applicable
NCT04436081,2021.0,OTHER,lead,Eastern Virginia Medical School,Phase 2
NCT04436081,2021.0,OTHER,collaborator,Old Dominion University,Phase 2
NCT04436081,2021.0,UNKNOWN,collaborator,"Ananda Hemp, Inc.",Phase 2
NCT04436224,2020.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Phase 4
NCT04436250,2020.0,OTHER,lead,Grand Hôpital de Charleroi,Not Applicable
NCT04436497,2020.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT04436497,2020.0,INDUSTRY,collaborator,Ra Pharmaceuticals,Phase 2/Phase 3
NCT04436510,2020.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT04436510,2020.0,INDUSTRY,collaborator,"Biohaven Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT04436601,2020.0,OTHER,lead,Aga Khan University,Phase 4
NCT04436978,2023.0,OTHER,lead,St. Antonius Hospital,Phase 4
NCT04436978,2023.0,INDUSTRY,collaborator,Daiichi Sankyo,Phase 4
NCT04437199,2020.0,INDUSTRY,lead,Cerecin,Phase 2
NCT04437303,2020.0,OTHER,lead,St. Antonius Hospital,Phase 4
NCT04437485,2020.0,OTHER,lead,Indiana University,Phase 2
NCT04437485,2020.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT04437511,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT04440085,2020.0,OTHER,lead,Bürgerspital Solothurn,Phase 4
NCT04442061,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT04442061,2022.0,OTHER,collaborator,Fondation de France,Phase 2
NCT04442061,2022.0,UNKNOWN,collaborator,Fondation Malakoff Médéric,Phase 2
NCT04442347,2020.0,INDUSTRY,lead,"Arcturus Therapeutics, Inc.",Phase 1
NCT04442906,2020.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT04445571,2021.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT04445688,2020.0,INDUSTRY,lead,Apnimed,Phase 2
NCT04445831,2019.0,INDUSTRY,lead,AC Immune SA,Phase 1/Phase 2
NCT04445831,2019.0,INDUSTRY,collaborator,"Janssen Research & Development, LLC",Phase 1/Phase 2
NCT04445857,2020.0,OTHER,lead,Ain Shams University,Phase 4
NCT04446234,2021.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT04446234,2021.0,OTHER,collaborator,Shanghai Jiao Tong University School of Medicine,Phase 4
NCT04446416,2020.0,INDUSTRY,lead,NaviFUS Corporation,Not Applicable
NCT04446416,2020.0,OTHER,collaborator,Chang Gung Memorial Hospital,Not Applicable
NCT04446715,2020.0,OTHER,lead,Makassed General Hospital,Not Applicable
NCT04446819,2020.0,OTHER,lead,Fudan University,Not Applicable
NCT04447846,2019.0,OTHER,lead,"Anne Comi, MD",Phase 2
NCT04447846,2019.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT04447846,2019.0,OTHER,collaborator,Faneca 66 Foundation,Phase 2
NCT04447911,2021.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 4
NCT04447911,2021.0,OTHER,collaborator,Luzerner Kantonsspital,Phase 4
NCT04447911,2021.0,OTHER,collaborator,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT04448132,2020.0,INDUSTRY,lead,AJ Vaccines A/S,Phase 4
NCT04448808,2020.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT04448808,2020.0,INDUSTRY,collaborator,Bionorica SE,Phase 2
NCT04449133,2020.0,OTHER,lead,Istituto Auxologico Italiano,Phase 2
NCT04449133,2020.0,UNKNOWN,collaborator,"YGHEA, CRO Division of Ecol Studio spa",Phase 2
NCT04449133,2020.0,UNKNOWN,collaborator,STM Pharma PRO srl,Phase 2
NCT04449133,2020.0,UNKNOWN,collaborator,Apnimed Inc.,Phase 2
NCT04449484,2020.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT04449484,2020.0,INDUSTRY,collaborator,Takeda,Phase 1
NCT04449510,2021.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT04449510,2021.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT04449510,2021.0,FED,collaborator,Food and Drug Administration (FDA),Not Applicable
NCT04449510,2021.0,NIH,collaborator,National Cancer Institute (NCI),Not Applicable
NCT04449510,2021.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT04449848,2020.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT04449926,2020.0,INDUSTRY,lead,"Mindful Diagnostics and Therapeutics, LLC",Phase 2
NCT04450290,2020.0,INDUSTRY,lead,MED-EL Elektromedizinische Geräte GesmbH,Not Applicable
NCT04451096,2018.0,OTHER,lead,National University of Malaysia,Phase 3
NCT04451408,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 1
NCT04451668,2020.0,INDUSTRY,lead,Avadel,Phase 3
NCT04451863,2021.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT04451863,2021.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 1
NCT04452383,2020.0,OTHER_GOV,lead,Zagazig University,Phase 4
NCT04452500,2022.0,FED,lead,VA Office of Research and Development,Phase 2
NCT04452656,2020.0,OTHER,lead,Cairo University,Not Applicable
NCT04452929,2020.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04452929,2020.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Not Applicable
NCT04453917,2021.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT04454281,2020.0,OTHER,lead,Seema Capoor,Phase 1
NCT04454684,2024.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT04454840,2016.0,OTHER,lead,Peking University Third Hospital,Early Phase 1
NCT04455230,2020.0,INDUSTRY,lead,Freeline Therapeutics,Phase 1/Phase 2
NCT04455555,2018.0,OTHER,lead,Peking University Third Hospital,Phase 3
NCT04456530,2020.0,OTHER,lead,The Stone Research Foundation for Sports Medicine and Arthritis,Phase 2/Phase 3
NCT04456985,2020.0,OTHER,lead,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,Not Applicable
NCT04458324,2020.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 2
NCT04458857,2020.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT04459052,2020.0,OTHER,lead,Thomas Jefferson University,Phase 2
NCT04460521,2021.0,OTHER,lead,David Tang,Phase 4
NCT04460872,2021.0,OTHER,lead,North Florida Foundation for Research and Education,Phase 2
NCT04460872,2021.0,OTHER,collaborator,North Florida/South Georgia Veterans Health System,Phase 2
NCT04460872,2021.0,OTHER,collaborator,Brooks Rehabilitation,Phase 2
NCT04460872,2021.0,OTHER,collaborator,University of Florida,Phase 2
NCT04461119,2020.0,INDUSTRY,lead,Newron Pharmaceuticals SPA,Phase 2
NCT04461444,2020.0,OTHER,lead,"University Hospital, Strasbourg, France",Not Applicable
NCT04461561,2020.0,OTHER,lead,Altoosi University College,Not Applicable
NCT04461561,2020.0,OTHER,collaborator,Babylon University,Not Applicable
NCT04461795,2020.0,INDUSTRY,lead,David True,Phase 4
NCT04461886,2020.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT04462198,2020.0,INDUSTRY,lead,Contineum Therapeutics,Phase 1/Phase 2
NCT04462536,2020.0,INDUSTRY,lead,NoNO Inc.,Phase 3
NCT04462536,2020.0,OTHER,collaborator,University of Calgary,Phase 3
NCT04462796,2020.0,OTHER,lead,OSF Healthcare System,Not Applicable
NCT04464148,2021.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1
NCT04464707,2020.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT04465357,2020.0,OTHER,lead,Merle Diamond,Phase 4
NCT04465357,2020.0,INDUSTRY,collaborator,"Clinvest Research, LLC",Phase 4
NCT04465357,2020.0,INDIV,collaborator,"Smith, Timothy R., M.D.",Phase 4
NCT04465643,2021.0,OTHER,lead,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 1
NCT04465643,2021.0,INDUSTRY,collaborator,Bristol-Myers Squibb,Phase 1
NCT04466410,2021.0,INDUSTRY,lead,"Xalud Therapeutics, Inc.",Phase 1
NCT04466826,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04468230,2020.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT04468347,2014.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Phase 1
NCT04468360,2022.0,OTHER,lead,Boston University,Phase 2
NCT04468360,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT04469504,2022.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT04469504,2022.0,OTHER,collaborator,Groupement Interrégional de Recherche Clinique et d'Innovation,Not Applicable
NCT04469504,2022.0,OTHER,collaborator,Santelys Association,Not Applicable
NCT04469777,2019.0,OTHER,lead,Alexandria University,Phase 1/Phase 2
NCT04470128,2020.0,INDUSTRY,lead,"Haisco Pharmaceutical Group Co., Ltd.",Phase 2
NCT04471545,2020.0,OTHER,lead,Catharina Ziekenhuis Eindhoven,Not Applicable
NCT04471714,2020.0,OTHER,lead,University of Alberta,Phase 2
NCT04474366,2020.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT04474405,2013.0,INDUSTRY,lead,Avid Radiopharmaceuticals,Early Phase 1
NCT04474847,2021.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT04475029,2020.0,OTHER,lead,University of Aarhus,Not Applicable
NCT04475549,2020.0,INDUSTRY,lead,Tisento Therapeutics,Phase 2
NCT04475848,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04476017,2020.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT04476303,2020.0,INDUSTRY,lead,BeyondBio Inc.,Phase 1
NCT04476446,2020.0,INDUSTRY,lead,"Janssen-Cilag, S.A.",Phase 3
NCT04476615,2017.0,OTHER,lead,Universita di Verona,Not Applicable
NCT04476615,2017.0,OTHER,collaborator,University of Southern California,Not Applicable
NCT04477161,2019.0,OTHER,lead,University of Florida,Not Applicable
NCT04478734,2023.0,OTHER,lead,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Phase 2
NCT04478734,2023.0,UNKNOWN,collaborator,Ciberned (Centro de Investigación Biomédica en Red),Phase 2
NCT04479241,2020.0,INDUSTRY,lead,"Istari Oncology, Inc.",Phase 2
NCT04479566,2020.0,OTHER,lead,"China Medical University, China",Phase 4
NCT04479917,2020.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 2
NCT04479917,2020.0,OTHER,collaborator,"Shanghai Institute of Materia Medica, Chinese Academy of Sciences",Phase 2
NCT04480164,2020.0,OTHER,lead,Besson Marie,Phase 2
NCT04480307,2020.0,INDUSTRY,lead,GeNeuro Innovation SAS,Phase 2
NCT04480658,2018.0,OTHER,lead,University of Zurich,Not Applicable
NCT04480853,2020.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT04481035,2019.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT04481048,2020.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT04481048,2020.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04482413,2023.0,INDUSTRY,lead,Nature Cell Co. Ltd.,Phase 2
NCT04482842,2020.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT04483427,2020.0,OTHER,lead,Bahaa Mohammed Refaie,Not Applicable
NCT04483479,2020.0,INDUSTRY,lead,Enterin Inc.,Phase 2
NCT04484077,2022.0,OTHER,lead,"Joanne Kurtzberg, MD",Phase 1
NCT04484077,2022.0,OTHER,collaborator,The Marcus Foundation,Phase 1
NCT04484350,2020.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 2
NCT04484493,2020.0,OTHER,lead,Benha University,Phase 3
NCT04485117,2020.0,OTHER,lead,Sameh Fathy,Not Applicable
NCT04485273,2019.0,OTHER,lead,Sameh Fathy,Not Applicable
NCT04486092,2015.0,OTHER,lead,National Cheng-Kung University Hospital,Not Applicable
NCT04486430,2017.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT04486430,2017.0,UNKNOWN,collaborator,Zhejiang Apeloa Jiayuan Pharmaceutical Co. Ltd.,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Subei People's Hospital of Jiangsu Province,Phase 2
NCT04486430,2017.0,OTHER,collaborator,The First Hospital of Jilin University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,First Hospital of China Medical University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,General Hospital of Shenyang Military Region,Phase 2
NCT04486430,2017.0,OTHER,collaborator,The First Affiliated Hospital of BaoTou Medical College,Phase 2
NCT04486430,2017.0,OTHER,collaborator,"Xuanwu Hospital, Beijing",Phase 2
NCT04486430,2017.0,OTHER,collaborator,Peking University First Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Peking University Third Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Tianjin First Central Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Tianjin Huanhu Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Hebei Medical University Third Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,The Second Hospital of Hebei Medical University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Hebei General Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Second Hospital of Shanxi Medical University,Phase 2
NCT04486430,2017.0,OTHER_GOV,collaborator,Shandong Provincial Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Qilu Hospital of Shandong University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,The First Affiliated Hospital of Soochow University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Nanjing PLA General Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2
NCT04486430,2017.0,OTHER,collaborator,Shanghai Minhang Central Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,First Affiliated Hospital of Zhejiang University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 2
NCT04486430,2017.0,OTHER,collaborator,First Affiliated Hospital of Wenzhou Medical University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Xiangya Hospital of Central South University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Guangzhou First People's Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Second Affiliated Hospital of Guangzhou Medical University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,"Nanfang Hospital, Southern Medical University",Phase 2
NCT04486430,2017.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Tongji Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,The Central Hospital of Lishui City,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Shanghai Pudong New Area People's Hospital,Phase 2
NCT04486430,2017.0,UNKNOWN,collaborator,Inner Mongolia Baogang Hospital,Phase 2
NCT04486430,2017.0,OTHER,collaborator,Daqing Oil Field Hospital,Phase 2
NCT04486859,2020.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT04486859,2020.0,OTHER,collaborator,Peking Union Medical College Hospital,Not Applicable
NCT04486859,2020.0,OTHER,collaborator,West China Hospital,Not Applicable
NCT04487470,2020.0,OTHER,lead,UConn Health,Not Applicable
NCT04487470,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT04488133,2021.0,INDUSTRY,lead,Biogen,Phase 4
NCT04488172,2015.0,OTHER,lead,National Cheng-Kung University Hospital,Not Applicable
NCT04488419,2020.0,INDUSTRY,lead,Athira Pharma,Phase 2/Phase 3
NCT04488874,2020.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Phase 3
NCT04488926,2020.0,INDUSTRY,lead,Epitech Group SpA,Phase 4
NCT04488926,2020.0,OTHER,collaborator,Azienda Ospedaliera Universitaria Integrata Verona,Phase 4
NCT04489017,2019.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 2
NCT04489160,2021.0,OTHER,lead,Leiden University Medical Center,Phase 2
NCT04489160,2021.0,OTHER,collaborator,Netherlands Brain Foundation,Phase 2
NCT04489160,2021.0,INDUSTRY,collaborator,Takeda,Phase 2
NCT04489641,2020.0,OTHER,lead,Universidad de Córdoba,Not Applicable
NCT04490954,2019.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04490980,2020.0,OTHER,lead,Tongji Hospital,Not Applicable
NCT04491006,2020.0,INDUSTRY,lead,Athira Pharma,Phase 2
NCT04491006,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04491383,2021.0,OTHER,lead,National Neuroscience Institute,Phase 2
NCT04491383,2021.0,INDUSTRY,collaborator,Hovid Berhad,Phase 2
NCT04491474,2020.0,OTHER_GOV,lead,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Phase 4
NCT04491695,2020.0,OTHER,lead,Capital Medical University,Phase 2/Phase 3
NCT04492020,2020.0,INDUSTRY,lead,AbbVie,Phase 3
NCT04493320,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT04493320,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04493320,2021.0,OTHER,collaborator,Vanderbilt University Medical Center,Phase 4
NCT04493320,2021.0,OTHER,collaborator,Columbia University,Phase 4
NCT04493320,2021.0,OTHER,collaborator,Emory University,Phase 4
NCT04494256,2020.0,INDUSTRY,lead,Biogen,Phase 1/Phase 2
NCT04494828,2020.0,OTHER,lead,Capital Medical University,Phase 4
NCT04495127,2020.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT04495374,2019.0,OTHER,lead,Universidade Federal de Alfenas,Phase 4
NCT04495816,2020.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT04496193,2020.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 4
NCT04496310,2020.0,OTHER_GOV,lead,Azienda Usl di Bologna,Not Applicable
NCT04496856,2020.0,OTHER,lead,University of Copenhagen,Not Applicable
NCT04496856,2020.0,OTHER,collaborator,Herlev and Gentofte Hospital,Not Applicable
NCT04497142,2020.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 1/Phase 2
NCT04497142,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1/Phase 2
NCT04497142,2020.0,INDUSTRY,collaborator,Eisai Inc.,Phase 1/Phase 2
NCT04497168,2021.0,OTHER,lead,University of Michigan,Phase 2
NCT04497168,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04498078,2022.0,OTHER,lead,"University of Novi Sad, Faculty of Sport and Physical Education",Not Applicable
NCT04498910,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT04498962,2020.0,OTHER,lead,Jingqing Hu,Not Applicable
NCT04499560,2020.0,OTHER,lead,Franklin Health Research,Not Applicable
NCT04499560,2020.0,UNKNOWN,collaborator,Young Living Essential Oils,Not Applicable
NCT04499755,2020.0,OTHER,lead,Sherief Abd-Elsalam,Phase 3
NCT04499963,2020.0,OTHER,lead,"Richard Bedlack, M.D., Ph.D.",Phase 2
NCT04500249,2015.0,OTHER,lead,Medical University of Silesia,Not Applicable
NCT04500249,2015.0,OTHER,collaborator,Silesian University of Medicine,Not Applicable
NCT04500847,2021.0,OTHER,lead,Butler Hospital,Phase 1
NCT04500847,2021.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT04500847,2021.0,OTHER,collaborator,Brown University,Phase 1
NCT04500847,2021.0,OTHER,collaborator,The Miriam Hospital,Phase 1
NCT04502251,2018.0,OTHER,lead,Centro Universitario La Salle,Phase 2/Phase 3
NCT04502251,2018.0,OTHER,collaborator,Hospital de Clinicas de Porto Alegre,Phase 2/Phase 3
NCT04502875,2020.0,OTHER,lead,Puerta de Hierro University Hospital,Phase 2
NCT04504877,2020.0,OTHER,lead,University of Sao Paulo,Phase 2/Phase 3
NCT04505189,2021.0,OTHER,lead,Imperial College London,Phase 1/Phase 2
NCT04505280,2020.0,OTHER_GOV,lead,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Not Applicable
NCT04505540,2019.0,OTHER,lead,University of Vermont,Not Applicable
NCT04505540,2019.0,FED,collaborator,Substance Abuse and Mental Health Services Administration (SAMHSA),Not Applicable
NCT04505540,2019.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT04505800,2019.0,OTHER,lead,National Yang Ming University,Not Applicable
NCT04505904,2015.0,OTHER,lead,University of Arizona,Not Applicable
NCT04506073,2020.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT04506073,2020.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT04506905,2020.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT04507373,2018.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT04507555,2020.0,OTHER,lead,PD Dr. med. Thorsten Mikoteit,Not Applicable
NCT04507555,2020.0,UNKNOWN,collaborator,Psychiatrische Dienste Solothurn,Not Applicable
NCT04507555,2020.0,UNKNOWN,collaborator,Privatklinik Wyss,Not Applicable
NCT04508244,2020.0,INDUSTRY,lead,Hamad Medical Corporation,Phase 4
NCT04508621,2020.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT04509518,2018.0,OTHER,lead,Cairo University,Not Applicable
NCT04510181,2020.0,OTHER,lead,"Pekarovics, Susan, MD",Not Applicable
NCT04510298,2020.0,INDUSTRY,lead,"Sirtsei Pharmaceuticals, Inc.",Phase 1
NCT04510389,2019.0,OTHER,lead,Federal University of Minas Gerais,Not Applicable
NCT04510922,2019.0,OTHER,lead,"Alberto Espay, MD, MSc",Phase 4
NCT04510922,2019.0,INDUSTRY,collaborator,Lundbeck LLC,Phase 4
NCT04512261,2022.0,OTHER,lead,Reva Basho,Phase 1/Phase 2
NCT04512261,2022.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1/Phase 2
NCT04512261,2022.0,INDUSTRY,collaborator,Seagen Inc.,Phase 1/Phase 2
NCT04512599,2020.0,OTHER,lead,Rush University Medical Center,Not Applicable
NCT04513002,2022.0,OTHER,lead,The University of Queensland,Phase 2
NCT04513002,2022.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 2
NCT04513340,2020.0,INDUSTRY,lead,"Hong Kong WD Pharmaceutical Co., Limited",Phase 1
NCT04514367,2020.0,INDUSTRY,lead,"Annexon, Inc.",Phase 2
NCT04515901,2021.0,OTHER,lead,McMaster University,Not Applicable
NCT04515966,2020.0,OTHER,lead,Mercy Health Ohio,Phase 4
NCT04516057,2021.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 3
NCT04516057,2021.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 3
NCT04516057,2021.0,OTHER,collaborator,Weston Brain Institute,Phase 3
NCT04516096,2020.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 2/Phase 3
NCT04516421,2020.0,OTHER,lead,Asia University,Not Applicable
NCT04516993,2021.0,OTHER,lead,Huashan Hospital,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Puer People's Hospital,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Shanghai 6th People's Hospital,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Hexigten Traditional Chinese and Mongolian Medicine Hospital,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,"Yangpu Hospital, School of Medicine, Tongji University",Phase 2
NCT04516993,2021.0,OTHER,collaborator,The First Affiliated Hospital of Shanxi Medical University,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Linyi People's Hospital,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Shanghai 10th People's Hospital,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Nanshi Hospital of Nanyang,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,"Shanghai Fifth People's Hospital,Fudan University",Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Xuzhou Medical University Affiliated Hospital of Huaian,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,The First Affiliated Hospital of Soochow Medical University,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Affiliated Haian People's Hospital of Nantong University,Phase 2
NCT04516993,2021.0,OTHER,collaborator,First Affiliated Hospital of Harbin Medical University,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,the Third Hospital of Mianyang,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,Zhejiang Province People's Hospital,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Shanghai East Hospital,Phase 2
NCT04516993,2021.0,UNKNOWN,collaborator,The Central Hospital of Jiaozuo Coal Group,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Zhejiang University,Phase 2
NCT04516993,2021.0,OTHER,collaborator,The Second Affiliated Hospital of Chongqing Medical University,Phase 2
NCT04516993,2021.0,OTHER,collaborator,Ningbo No. 1 Hospital,Phase 2
NCT04517799,2020.0,OTHER,lead,"University of California, San Diego",Phase 2/Phase 3
NCT04517799,2020.0,UNKNOWN,collaborator,Wholistic Research and Education Foundation,Phase 2/Phase 3
NCT04518254,2021.0,OTHER,lead,Direction Centrale du Service de Santé des Armées,Not Applicable
NCT04518319,2020.0,OTHER,lead,Shanghai Mental Health Center,Phase 2
NCT04518540,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04519346,2019.0,OTHER,lead,Ataturk University,Not Applicable
NCT04519463,2020.0,OTHER,lead,Muhamed Masalha,Early Phase 1
NCT04519567,2020.0,INDUSTRY,lead,"Larimar Therapeutics, Inc.",Phase 1
NCT04519567,2020.0,OTHER,collaborator,"Veristat, Inc.",Phase 1
NCT04519567,2020.0,UNKNOWN,collaborator,"Metrum Research Group, LLC",Phase 1
NCT04519645,2021.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 2
NCT04519749,2020.0,INDUSTRY,lead,4D Molecular Therapeutics,Phase 1/Phase 2
NCT04520178,2020.0,OTHER,lead,University of Alberta,Phase 2/Phase 3
NCT04520178,2020.0,OTHER,collaborator,Wings for Life,Phase 2/Phase 3
NCT04520373,2020.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04520412,2020.0,INDUSTRY,lead,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",Phase 3
NCT04520646,2020.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT04520685,2021.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT04521556,2019.0,OTHER,lead,University Hospital of Split,Phase 4
NCT04521647,2022.0,OTHER,lead,Yale University,Phase 1
NCT04521647,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT04521868,2020.0,OTHER,lead,Central South University,Phase 2
NCT04521881,2021.0,OTHER,lead,London School of Hygiene and Tropical Medicine,Phase 3
NCT04522102,2021.0,OTHER,lead,"The George Institute for Global Health, China",Phase 3
NCT04522102,2021.0,OTHER,collaborator,University of Edinburgh,Phase 3
NCT04522102,2021.0,OTHER,collaborator,Huashan Hospital,Phase 3
NCT04522102,2021.0,OTHER,collaborator,The University of Western Australia,Phase 3
NCT04522180,2021.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 2
NCT04522739,2022.0,OTHER,lead,Emory University,Phase 4
NCT04522739,2022.0,OTHER,collaborator,Alzheimer's Association,Phase 4
NCT04522960,2020.0,OTHER,lead,Universitair Ziekenhuis Brussel,Not Applicable
NCT04523922,2021.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT04523922,2021.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT04523935,2005.0,OTHER,lead,Sathbhavana Brain Clinic,Phase 4
NCT04524273,2020.0,INDUSTRY,lead,Viela Bio (acquired by Horizon Therapeutics),Phase 3
NCT04524351,2020.0,INDUSTRY,lead,Annovis Bio Inc.,Phase 1/Phase 2
NCT04524351,2020.0,INDUSTRY,collaborator,Parexel,Phase 1/Phase 2
NCT04525014,2023.0,INDUSTRY,lead,"EpicentRx, Inc.",Phase 1
NCT04525014,2023.0,OTHER,collaborator,Texas Children's Cancer Center,Phase 1
NCT04525066,2013.0,OTHER,lead,Ayhman Al Afif,Phase 2
NCT04525066,2013.0,OTHER,collaborator,Nova Scotia Health Authority,Phase 2
NCT04525144,2020.0,OTHER,lead,National Neuroscience Institute,Phase 2
NCT04525144,2020.0,INDUSTRY,collaborator,Dr. Willmar Schwabe GmbH & Co. KG,Phase 2
NCT04526197,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 1
NCT04526210,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 1
NCT04527289,2020.0,OTHER,lead,Damanhour University,Phase 4
NCT04527393,2022.0,OTHER,lead,Children's Hospital of Fudan University,Phase 4
NCT04528173,2020.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 4
NCT04528173,2020.0,OTHER,collaborator,University of Pennsylvania,Phase 4
NCT04528173,2020.0,OTHER,collaborator,University of Tennessee,Phase 4
NCT04528329,2021.0,OTHER,lead,ClinAmygate,Phase 4
NCT04528550,2020.0,OTHER,lead,Shanghai Changzheng Hospital,Phase 2
NCT04528563,2021.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 3
NCT04528797,2010.0,OTHER,lead,Medical University of South Carolina,Not Applicable
NCT04528797,2010.0,UNKNOWN,collaborator,We Are Sharing Hope SC,Not Applicable
NCT04529161,2020.0,OTHER,lead,Uniter Onlus,Not Applicable
NCT04529161,2020.0,OTHER,collaborator,University of Rome Tor Vergata,Not Applicable
NCT04529226,2020.0,OTHER,lead,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Phase 2
NCT04529265,2021.0,OTHER,lead,Fudan University,Not Applicable
NCT04529291,2022.0,OTHER,lead,Fondation Hôpital Saint-Joseph,Not Applicable
NCT04529356,2020.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT04529538,2021.0,OTHER,lead,PATH,Phase 1
NCT04529538,2021.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 1
NCT04529538,2021.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 1
NCT04529538,2021.0,UNKNOWN,collaborator,Viroclinics Biosciences B.V.,Phase 1
NCT04529538,2021.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 1
NCT04529954,2021.0,INDUSTRY,lead,Cerebral Therapeutics LLC,Phase 1/Phase 2
NCT04530110,2020.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT04530318,2020.0,OTHER,lead,Judit Pich,Phase 2
NCT04530747,2021.0,OTHER,lead,Pennington Biomedical Research Center,Phase 1/Phase 2
NCT04530747,2021.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1/Phase 2
NCT04530955,2020.0,OTHER,lead,Culicchia Neurological Clinic,Not Applicable
NCT04530955,2020.0,INDUSTRY,collaborator,Flowonix Medical,Not Applicable
NCT04531215,2021.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT04531982,2020.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT04532606,2021.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT04532606,2021.0,OTHER,collaborator,Beijing Tsinghua Chang Gung Hospital,Phase 4
NCT04532606,2021.0,OTHER,collaborator,"Navy General Hospital, Beijing",Phase 4
NCT04532606,2021.0,OTHER,collaborator,Guizhou Provincial People's Hospital,Phase 4
NCT04532606,2021.0,OTHER,collaborator,Jiangsu Provincial People's Hospital,Phase 4
NCT04532606,2021.0,OTHER,collaborator,Shanghai 10th People's Hospital,Phase 4
NCT04533230,2020.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT04533724,2020.0,OTHER,lead,Shanghai Mental Health Center,Early Phase 1
NCT04534023,2020.0,OTHER,lead,Ruijin Hospital,Phase 2
NCT04534023,2020.0,OTHER,collaborator,Second Affiliated Hospital of Soochow University,Phase 2
NCT04534023,2020.0,OTHER,collaborator,"Wuhan Union Hospital, China",Phase 2
NCT04534842,2020.0,INDUSTRY,lead,Synlogic,Phase 2
NCT04535089,2020.0,OTHER_GOV,lead,Zagazig University,Phase 1/Phase 2
NCT04535362,2021.0,OTHER,lead,Yale University,Early Phase 1
NCT04535362,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT04535817,2021.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 1
NCT04535817,2021.0,INDUSTRY,collaborator,Novartis,Phase 1
NCT04537377,2021.0,INDUSTRY,lead,Vivet Therapeutics SAS,Phase 1/Phase 2
NCT04537429,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04538066,2020.0,INDUSTRY,lead,"Neurotrope Bioscience, Inc.",Phase 2
NCT04538066,2020.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT04538066,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04538274,2021.0,OTHER,lead,AGIR à Dom,Not Applicable
NCT04538521,2019.0,OTHER,lead,University of Helsinki,Not Applicable
NCT04538521,2019.0,OTHER,collaborator,Helsinki University Central Hospital,Not Applicable
NCT04538521,2019.0,OTHER,collaborator,Institute for Molecular Medicine,Not Applicable
NCT04539223,2020.0,OTHER,lead,Canadian Medical and Surgical Knowledge Translation Research Group,Phase 4
NCT04539223,2020.0,INDUSTRY,collaborator,Amgen,Phase 4
NCT04539340,2020.0,INDUSTRY,lead,AO GENERIUM,Phase 1
NCT04539951,2020.0,OTHER,lead,Shanghai Mental Health Center,Phase 2
NCT04539951,2020.0,UNKNOWN,collaborator,The first specialized hospital of harbin,Phase 2
NCT04539951,2020.0,OTHER,collaborator,Guizhou Provincial People's Hospital,Phase 2
NCT04539951,2020.0,OTHER,collaborator,First Affiliated Hospital of Jinan University,Phase 2
NCT04539951,2020.0,OTHER,collaborator,West China Hospital,Phase 2
NCT04539951,2020.0,OTHER,collaborator,Suzhou Psychiatric Hospital,Phase 2
NCT04539951,2020.0,OTHER,collaborator,Nanjing Medical University,Phase 2
NCT04539951,2020.0,OTHER,collaborator,Wuhan Mental Health Centre,Phase 2
NCT04539951,2020.0,OTHER,collaborator,Seventh People's Hospital of Hangzhou,Phase 2
NCT04539951,2020.0,OTHER,collaborator,First Affiliated Hospital of Kunming Medical University,Phase 2
NCT04539951,2020.0,OTHER,collaborator,General Hospital of Ningxia Medical University,Phase 2
NCT04539951,2020.0,OTHER,collaborator,The First Affiliated Hospital of Nanchang University,Phase 2
NCT04539951,2020.0,UNKNOWN,collaborator,The Second Affiliated Hospital of Xinxiang Medical University,Phase 2
NCT04541082,2020.0,INDUSTRY,lead,Chimerix,Phase 1
NCT04541082,2020.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1
NCT04541823,2021.0,OTHER,lead,Beijing Chao Yang Hospital,Phase 4
NCT04542161,2020.0,OTHER,lead,Weill Medical College of Cornell University,Phase 2
NCT04542161,2020.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT04542499,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 3
NCT04542629,2020.0,OTHER,lead,Assiut University,Phase 4
NCT04543188,2021.0,INDUSTRY,lead,Pfizer,Phase 1
NCT04544280,2018.0,OTHER,lead,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Not Applicable
NCT04544436,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT04544787,2018.0,OTHER,lead,Pierre Van Damme,Phase 2
NCT04544787,2018.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT04544787,2018.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 2
NCT04544787,2018.0,OTHER,collaborator,PATH,Phase 2
NCT04544787,2018.0,INDUSTRY,collaborator,Celerion,Phase 2
NCT04545892,2019.0,OTHER,lead,Juan Manuel Marquez Romero,Phase 1
NCT04545892,2019.0,OTHER,collaborator,Centenario Hospital Miguel Hidalgo,Phase 1
NCT04545892,2019.0,OTHER,collaborator,Universidad de Guanajuato,Phase 1
NCT04546035,2020.0,OTHER,lead,Rizky Kusuma Wardhani,Not Applicable
NCT04546334,2020.0,OTHER,lead,Tanta University,Not Applicable
NCT04546399,2020.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT04547179,2021.0,OTHER,lead,Manhattan Beach Orthodontics,Not Applicable
NCT04547985,2021.0,OTHER,lead,Weill Medical College of Cornell University,Phase 4
NCT04548999,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT04549168,2020.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 3
NCT04549194,2020.0,OTHER,lead,Direction Centrale du Service de Santé des Armées,Not Applicable
NCT04549844,2019.0,OTHER,lead,Fayoum University Hospital,Phase 4
NCT04550377,2021.0,OTHER,lead,NYU Langone Health,Phase 2
NCT04550377,2021.0,UNKNOWN,collaborator,Brockman Foundation,Phase 2
NCT04550455,2020.0,OTHER,lead,"Keith Edwards, M.D.",Phase 4
NCT04550455,2020.0,INDUSTRY,collaborator,EMD Serono,Phase 4
NCT04550611,2021.0,OTHER,lead,Assiut University,Not Applicable
NCT04552041,2020.0,INDUSTRY,lead,Materia Medica Holding,Phase 3
NCT04552574,2020.0,OTHER,lead,Chungbuk National University Hospital,Not Applicable
NCT04552795,2021.0,OTHER,lead,"Bess Frost, PhD",Phase 1/Phase 2
NCT04552795,2021.0,UNKNOWN,collaborator,Owens Medical Research Foundation,Phase 1/Phase 2
NCT04552873,2020.0,OTHER,lead,"University Hospital, Grenoble",Not Applicable
NCT04553510,2016.0,OTHER,lead,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2
NCT04553978,2020.0,INDUSTRY,lead,"Hong Kong WD Pharmaceutical Co., Limited",Phase 1
NCT04556552,2020.0,OTHER,lead,Emory University,Phase 3
NCT04556552,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT04556552,2020.0,UNKNOWN,collaborator,CUNY,Phase 3
NCT04556552,2020.0,OTHER,collaborator,Georgia Institute of Technology,Phase 3
NCT04556656,2020.0,INDUSTRY,lead,Prilenia,Phase 3
NCT04557410,2020.0,OTHER,lead,University of Missouri-Columbia,Phase 1
NCT04557410,2020.0,UNKNOWN,collaborator,Band of Hope Foundation,Phase 1
NCT04558034,2020.0,OTHER,lead,Parkview Health,Not Applicable
NCT04558112,2021.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT04558112,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT04558346,2020.0,OTHER,lead,"Michael Rippee, MD",Phase 2
NCT04558346,2020.0,UNKNOWN,collaborator,University of Kansas Health System,Phase 2
NCT04558346,2020.0,OTHER,collaborator,University of Kansas Medical Center,Phase 2
NCT04559295,2018.0,OTHER,lead,Stem Cures,Phase 2/Phase 3
NCT04560660,2021.0,FED,lead,VA Office of Research and Development,Phase 2
NCT04560868,2020.0,OTHER,lead,Kaiser Permanente,Phase 1
NCT04560868,2020.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT04561557,2020.0,OTHER,lead,Tongji Hospital,Early Phase 1
NCT04561557,2020.0,INDUSTRY,collaborator,"Nanjing IASO Biotechnology Co., Ltd.",Early Phase 1
NCT04562324,2019.0,OTHER,lead,Tianjin Anding Hospital,Not Applicable
NCT04562831,2020.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT04562831,2020.0,INDUSTRY,collaborator,Elysium Health,Not Applicable
NCT04565925,2021.0,OTHER,lead,"The University of Texas Medical Branch, Galveston",Phase 2
NCT04566601,2020.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT04567147,2018.0,OTHER,lead,China Agricultural University,Phase 1
NCT04567784,2020.0,INDIV,lead,"Hurd,Yasmin, Ph.D.",Phase 2
NCT04567784,2020.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT04569435,2021.0,INDUSTRY,lead,"Annexon, Inc.",Phase 2
NCT04569448,2021.0,OTHER,lead,Douglas Mental Health University Institute,Phase 3
NCT04569448,2021.0,OTHER,collaborator,McMaster University,Phase 3
NCT04569448,2021.0,OTHER,collaborator,Jewish General Hospital,Phase 3
NCT04569591,2024.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT04569656,2016.0,OTHER,lead,IRCCS San Raffaele Roma,Phase 2
NCT04569760,2021.0,OTHER,lead,McMaster University,Phase 3
NCT04569760,2021.0,UNKNOWN,collaborator,MediPharm Labs Corp,Phase 3
NCT04570085,2021.0,OTHER,lead,"University Hospital, Lille",Phase 3
NCT04570085,2021.0,OTHER,collaborator,Groupement Interrégional de Recherche Clinique et d'Innovation,Phase 3
NCT04570085,2021.0,UNKNOWN,collaborator,Laboratory of excellence DISTALZ,Phase 3
NCT04570085,2021.0,OTHER,collaborator,"Région Nord-Pas de Calais, France",Phase 3
NCT04570085,2021.0,UNKNOWN,collaborator,Meo coffee,Phase 3
NCT04570293,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT04570475,2021.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 3
NCT04570644,2020.0,INDUSTRY,lead,"AZTherapies, Inc.",Phase 1
NCT04570670,2017.0,INDUSTRY,lead,Banner Life Sciences LLC,Phase 1
NCT04571060,2020.0,INDUSTRY,lead,Pfizer,Phase 3
NCT04571164,2020.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 3
NCT04571164,2020.0,INDUSTRY,collaborator,Parexel,Phase 3
NCT04571216,2021.0,INDUSTRY,lead,NFL Biosciences SAS,Phase 2
NCT04571944,2020.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 3
NCT04571996,2020.0,INDUSTRY,lead,"Orion Corporation, Orion Pharma",Phase 1
NCT04572243,2020.0,INDUSTRY,lead,Eisai Inc.,Phase 3
NCT04572789,2020.0,OTHER,lead,Kuang Tien General Hospital,Not Applicable
NCT04572906,2020.0,INDUSTRY,lead,Neuraptive Therapeutics Inc.,Phase 2
NCT04573023,2022.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 3
NCT04573309,2020.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2
NCT04573803,2021.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 3
NCT04573803,2021.0,OTHER,collaborator,University of Cambridge,Phase 3
NCT04574024,2022.0,OTHER,lead,"Suhayl Dhib-Jalbut, MD",Phase 1/Phase 2
NCT04574713,2020.0,OTHER,lead,St. Olavs Hospital,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Nordlandssykehuset HF,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Molde Hospital,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Haukeland University Hospital,Phase 2
NCT04574713,2020.0,OTHER_GOV,collaborator,Sorlandet Hospital HF,Phase 2
NCT04574713,2020.0,OTHER,collaborator,"University Hospital, Akershus",Phase 2
NCT04574713,2020.0,OTHER,collaborator,Ullevaal University Hospital,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Rikshospitalet University Hospital,Phase 2
NCT04574713,2020.0,OTHER,collaborator,University Hospital of North Norway,Phase 2
NCT04574713,2020.0,OTHER,collaborator,Tartu University Hospital,Phase 2
NCT04575090,2016.0,OTHER,lead,University of Texas Southwestern Medical Center,Not Applicable
NCT04575090,2016.0,UNKNOWN,collaborator,Abhimanyu Garg,Not Applicable
NCT04575090,2016.0,UNKNOWN,collaborator,Prishant Mishra,Not Applicable
NCT04575090,2016.0,UNKNOWN,collaborator,Jimin Ren,Not Applicable
NCT04575727,2021.0,OTHER,lead,Columbia University,Early Phase 1
NCT04576026,2020.0,OTHER,lead,"Western University, Canada",Not Applicable
NCT04576494,2022.0,OTHER,lead,CHU de Reims,Not Applicable
NCT04576507,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT04576507,2021.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 2
NCT04576793,2020.0,OTHER,lead,"James M Noble, MD, MS, CPH, FAAN",Phase 2
NCT04576793,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04576910,2020.0,OTHER_GOV,lead,Zhejiang Provincial Center for Disease Control and Prevention,Phase 4
NCT04576910,2020.0,UNKNOWN,collaborator,China National Biotec Group Company ltd,Phase 4
NCT04577352,2020.0,INDUSTRY,lead,PTC Therapeutics,Phase 2/Phase 3
NCT04577443,2020.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04578028,2020.0,INDUSTRY,lead,Ono Pharmaceutical Co. Ltd,Phase 1
NCT04578028,2020.0,INDUSTRY,collaborator,Parexel,Phase 1
NCT04578470,2020.0,OTHER,lead,Changi General Hospital,Phase 2
NCT04578639,2020.0,OTHER,lead,Haukeland University Hospital,Phase 3
NCT04578639,2020.0,OTHER,collaborator,"University Hospital, Akershus",Phase 3
NCT04578639,2020.0,OTHER,collaborator,Oslo University Hospital,Phase 3
NCT04578639,2020.0,OTHER_GOV,collaborator,Helse Stavanger HF,Phase 3
NCT04578639,2020.0,OTHER,collaborator,St. Olavs Hospital,Phase 3
NCT04578639,2020.0,OTHER,collaborator,University Hospital of North Norway,Phase 3
NCT04578756,2021.0,INDUSTRY,lead,AbbVie,Phase 3
NCT04578782,2018.0,OTHER,lead,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Phase 2
NCT04578886,2020.0,OTHER,lead,University of Alabama at Birmingham,Phase 3
NCT04579510,2021.0,FED,lead,Centers for Disease Control and Prevention,Phase 2
NCT04579510,2021.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2
NCT04579666,2020.0,INDUSTRY,lead,"Apellis Pharmaceuticals, Inc.",Phase 2
NCT04579783,2020.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT04580134,2022.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 4
NCT04580134,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04580134,2022.0,OTHER,collaborator,Beth Israel Deaconess Medical Center,Phase 4
NCT04580134,2022.0,OTHER,collaborator,Hartford Hospital,Phase 4
NCT04580134,2022.0,OTHER,collaborator,University of Georgia,Phase 4
NCT04580134,2022.0,OTHER,collaborator,University of Chicago,Phase 4
NCT04580238,2023.0,OTHER,lead,University of Alberta,Phase 1
NCT04580394,2020.0,INDUSTRY,lead,Apnimed,Phase 2
NCT04581395,2020.0,OTHER,lead,Indiana University,Phase 3
NCT04582916,2021.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT04584346,2021.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT04584983,2021.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT04584983,2021.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 2
NCT04585347,2015.0,INDUSTRY,lead,Alzheon Inc.,Phase 1
NCT04585347,2015.0,OTHER,collaborator,Quotient Clinical,Phase 1
NCT04585620,2022.0,OTHER,lead,"Allan Vestergaard Danielsen, MD",Phase 1/Phase 2
NCT04586348,2021.0,OTHER,lead,South Australian Health and Medical Research Institute,Phase 4
NCT04586348,2021.0,OTHER_GOV,collaborator,"Women's and Children's Hospital, Australia",Phase 4
NCT04586348,2021.0,OTHER_GOV,collaborator,Flinders Medical Centre,Phase 4
NCT04586348,2021.0,OTHER,collaborator,Mater Mothers' Hospital,Phase 4
NCT04586348,2021.0,UNKNOWN,collaborator,The Royal Women's Hospital,Phase 4
NCT04586348,2021.0,OTHER,collaborator,Royal North Shore Hospital,Phase 4
NCT04587505,2019.0,OTHER,lead,University Hospital of Split,Phase 4
NCT04587908,2020.0,INDUSTRY,lead,"Taiho Pharmaceutical Co., Ltd.",Phase 3
NCT04588129,2021.0,INDUSTRY,lead,LB Pharmaceuticals Inc.,Phase 1
NCT04588129,2021.0,OTHER,collaborator,Washington University School of Medicine,Phase 1
NCT04588207,2021.0,OTHER,lead,"Helbert Rondon Berrios, MD, MS",Phase 2
NCT04588207,2021.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT04588311,2020.0,OTHER,lead,Australian and New Zealand Intensive Care Research Centre,Phase 3
NCT04588311,2020.0,OTHER,collaborator,University College Dublin,Phase 3
NCT04588311,2020.0,OTHER,collaborator,Medical Research Institute of New Zealand,Phase 3
NCT04588311,2020.0,OTHER,collaborator,Medical Research Future Fund,Phase 3
NCT04588311,2020.0,OTHER,collaborator,"Health Research Board, Ireland",Phase 3
NCT04588311,2020.0,OTHER,collaborator,"Health Research Council, New Zealand",Phase 3
NCT04588311,2020.0,UNKNOWN,collaborator,Irish Critical Care Clinical Trials Network,Phase 3
NCT04588311,2020.0,NETWORK,collaborator,ANZICS Clinical Trials Group,Phase 3
NCT04588311,2020.0,OTHER,collaborator,Monash University,Phase 3
NCT04588519,2020.0,INDUSTRY,lead,"Spark Biomedical, Inc.",Not Applicable
NCT04588519,2020.0,OTHER,collaborator,Medical University of South Carolina,Not Applicable
NCT04589364,2023.0,OTHER_GOV,lead,Rajavithi Hospital,Phase 3
NCT04590235,2020.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT04590235,2020.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT04590612,2021.0,OTHER,lead,"Western University, Canada",Not Applicable
NCT04591535,2020.0,INDUSTRY,lead,"Hong Kong WD Pharmaceutical Co., Limited",Phase 1
NCT04592159,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2/Phase 3
NCT04592341,2020.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT04592536,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT04592874,2021.0,INDUSTRY,lead,Alector Inc.,Phase 2
NCT04592874,2021.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT04592952,2020.0,OTHER,lead,Danish Headache Center,Phase 4
NCT04593511,2021.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04594226,2020.0,OTHER,lead,The Third Affiliated hospital of Zhejiang Chinese Medical University,Not Applicable
NCT04594226,2020.0,UNKNOWN,collaborator,Lishui Hospital of Traditional Chinese Medicine,Not Applicable
NCT04594226,2020.0,OTHER,collaborator,Zhejiang Provincial Tongde Hospital,Not Applicable
NCT04594850,2020.0,INDUSTRY,lead,"Pharmicell Co., Ltd.",Phase 2
NCT04595045,2019.0,OTHER,lead,Aránzazu Vázquez Doce,Phase 3
NCT04595318,2015.0,OTHER,lead,Albert Einstein College of Medicine,Phase 4
NCT04595513,2020.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT04595786,2020.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT04595942,2020.0,OTHER,lead,Tehran Heart Center,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Mahidol University,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Rajaie Cardiovascular Medical and Research Center,Phase 3
NCT04595942,2020.0,UNKNOWN,collaborator,Tehran Arrhythmia Center,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Imam Khomeini Hospital,Phase 3
NCT04595942,2020.0,OTHER,collaborator,AJA University of Medical Sciences,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Urmia University of Medical Sciences,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Isfahan University of Medical Sciences,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Shahid Beheshti University of Medical Sciences,Phase 3
NCT04595942,2020.0,OTHER,collaborator,Ahvaz Jundishapur University of Medical Sciences,Phase 3
NCT04596644,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT04596644,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT04597190,2021.0,OTHER,lead,University of Washington,Phase 4
NCT04597190,2021.0,OTHER,collaborator,Stanford University,Phase 4
NCT04597190,2021.0,OTHER,collaborator,Boston University,Phase 4
NCT04597190,2021.0,OTHER,collaborator,Washington State University,Phase 4
NCT04597190,2021.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT04597450,2020.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04597931,2020.0,OTHER_GOV,lead,Sheba Medical Center,Phase 4
NCT04598230,2021.0,OTHER,lead,Ann & Robert H Lurie Children's Hospital of Chicago,Phase 3
NCT04598230,2021.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT04598230,2021.0,OTHER,collaborator,"University of California, Los Angeles",Phase 3
NCT04598243,2020.0,OTHER,lead,Practitioners Alliance Network,Early Phase 1
NCT04599348,2020.0,OTHER,lead,Practitioners Alliance Network,Early Phase 1
NCT04601038,2021.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT04601233,2024.0,OTHER,lead,Tulane University,Phase 4
NCT04601233,2024.0,OTHER,collaborator,Louisiana State University Health Sciences Center in New Orleans,Phase 4
NCT04601233,2024.0,INDUSTRY,collaborator,Antares Pharma Inc.,Phase 4
NCT04601909,2020.0,INDUSTRY,lead,Frequency Therapeutics,Phase 1
NCT04601974,2024.0,OTHER,lead,"University College, London",Phase 1/Phase 2
NCT04601974,2024.0,OTHER_GOV,collaborator,Medical Research Council,Phase 1/Phase 2
NCT04602390,2020.0,INDUSTRY,lead,Anokion SA,Phase 1
NCT04602494,2020.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04602494,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT04602624,2021.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT04602936,2021.0,OTHER,lead,Lindner Center of HOPE,Phase 4
NCT04602936,2021.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 4
NCT04603066,2021.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT04603443,2021.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT04603443,2021.0,OTHER,collaborator,Children's Hospital of Philadelphia,Not Applicable
NCT04603443,2021.0,OTHER,collaborator,Oregon Health and Science University,Not Applicable
NCT04603638,2020.0,OTHER,lead,Istanbul University,Not Applicable
NCT04603781,2020.0,OTHER,lead,University of Texas at Austin,Phase 2/Phase 3
NCT04603781,2020.0,UNKNOWN,collaborator,Way West Wellness,Phase 2/Phase 3
NCT04603781,2020.0,UNKNOWN,collaborator,SunFlora.Inc,Phase 2/Phase 3
NCT04603976,2020.0,OTHER,lead,Danish Headache Center,Phase 4
NCT04604587,2020.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT04604600,2020.0,OTHER,lead,National Taiwan University Hospital,Phase 3
NCT04605393,2021.0,OTHER,lead,King's College London,Not Applicable
NCT04607278,2019.0,OTHER,lead,Ankara University,Not Applicable
NCT04607447,2020.0,OTHER,lead,Huashan Hospital,Not Applicable
NCT04607525,2020.0,OTHER,lead,Ain Shams University,Phase 4
NCT04608331,2021.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT04609514,2021.0,OTHER,lead,Duke University,Not Applicable
NCT04609514,2021.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT04610827,2020.0,OTHER,lead,Mayo Clinic,Phase 4
NCT04610879,2019.0,OTHER,lead,King's College London,Phase 4
NCT04610879,2019.0,OTHER,collaborator,King's College Hospital NHS Trust,Phase 4
NCT04610879,2019.0,OTHER,collaborator,University of Liverpool,Phase 4
NCT04610879,2019.0,OTHER,collaborator,Bangor University,Phase 4
NCT04610879,2019.0,OTHER,collaborator,Edge Hill University,Phase 4
NCT04610879,2019.0,OTHER,collaborator,Oxford Brookes University,Phase 4
NCT04611425,2020.0,OTHER,lead,Nantes University Hospital,Phase 2
NCT04611425,2020.0,INDUSTRY,collaborator,Paion UK Ltd.,Phase 2
NCT04611438,2020.0,OTHER,lead,Yonsei University,Phase 3
NCT04612127,2020.0,OTHER,lead,Universidad Católica San Antonio de Murcia,Not Applicable
NCT04615923,2020.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT04615923,2020.0,UNKNOWN,collaborator,Prilenia Therapeutics,Phase 2/Phase 3
NCT04616456,2020.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT04616456,2020.0,INDUSTRY,collaborator,"Biohaven Pharmaceuticals, Inc.",Early Phase 1
NCT04617015,2016.0,OTHER,lead,State University of New York at Buffalo,Early Phase 1
NCT04617015,2016.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Early Phase 1
NCT04617847,2020.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT04617860,2019.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT04617951,2020.0,OTHER,lead,Pusan National University Yangsan Hospital,Not Applicable
NCT04618640,2019.0,INDUSTRY,lead,"Boryung Biopharma Co., Ltd.",Phase 3
NCT04618783,2019.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Not Applicable
NCT04619420,2021.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT04619862,2021.0,OTHER,lead,University of British Columbia,Phase 2
NCT04619862,2021.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT04619862,2021.0,OTHER,collaborator,Child-Bright Network,Phase 2
NCT04619862,2021.0,OTHER,collaborator,BC Children's Hospital Research Institute,Phase 2
NCT04620382,2020.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT04620382,2020.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT04620486,2020.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT04620772,2021.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 2/Phase 3
NCT04621110,2021.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 3
NCT04621305,2020.0,OTHER,lead,Second Affiliated Hospital of Wenzhou Medical University,Phase 4
NCT04621357,2020.0,OTHER,lead,"University Hospital, Lille",Not Applicable
NCT04621357,2020.0,UNKNOWN,collaborator,"Conseil Régional Hauts-de-France, France",Not Applicable
NCT04621357,2020.0,UNKNOWN,collaborator,Fondation pour la recherche sur les AVC,Not Applicable
NCT04621383,2019.0,OTHER,lead,Universidade Estadual de Londrina,Not Applicable
NCT04621383,2019.0,OTHER_GOV,collaborator,Conselho Nacional de Desenvolvimento Científico e Tecnológico,Not Applicable
NCT04621383,2019.0,OTHER,collaborator,Coordination for the Improvement of Higher Education Personnel,Not Applicable
NCT04621383,2019.0,INDUSTRY,collaborator,Rousselot BVBA,Not Applicable
NCT04621799,2018.0,OTHER,lead,"Pauza, Kevin, MD",Phase 2/Phase 3
NCT04622293,2021.0,OTHER,lead,Rochester Center for Behavioral Medicine,Phase 4
NCT04622553,2021.0,INDUSTRY,lead,Lupin Ltd.,Not Applicable
NCT04622904,2020.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT04623242,2012.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT04623242,2012.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2/Phase 3
NCT04623242,2012.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2/Phase 3
NCT04623242,2012.0,OTHER,collaborator,Alzheimer's Association,Phase 2/Phase 3
NCT04623242,2012.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT04623242,2012.0,INDUSTRY,collaborator,Avid Radiopharmaceuticals,Phase 2/Phase 3
NCT04623242,2012.0,OTHER,collaborator,Accelerating Medicines Partnership (AMP),Phase 2/Phase 3
NCT04623398,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT04623840,2020.0,OTHER,lead,Cairo University,Not Applicable
NCT04624243,2020.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT04624750,2021.0,INDUSTRY,lead,Lupin Ltd.,Phase 3
NCT04625153,2021.0,INDUSTRY,lead,"RemeGen Co., Ltd.",Phase 2
NCT04625361,2021.0,INDUSTRY,lead,"Sunshine Lake Pharma Co., Ltd.",Phase 1
NCT04626674,2020.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT04626674,2020.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 1
NCT04627155,2013.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04627285,2020.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT04627922,2021.0,OTHER,lead,Ellen Herbst,Phase 4
NCT04627922,2021.0,OTHER,collaborator,Tobacco Related Disease Research Program,Phase 4
NCT04628936,2020.0,INDUSTRY,lead,"Kezar Life Sciences, Inc.",Phase 2
NCT04629404,2018.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04629495,2021.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2
NCT04629547,2022.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04629547,2022.0,UNKNOWN,collaborator,Good Ventures Foundation,Phase 2
NCT04629547,2022.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 2
NCT04629560,2008.0,OTHER,lead,"Mt. Sinai Medical Center, Miami",Early Phase 1
NCT04629664,2020.0,INDUSTRY,lead,Frequency Therapeutics,Phase 1
NCT04630444,2017.0,OTHER,lead,Mclean Hospital,Early Phase 1
NCT04630444,2017.0,OTHER,collaborator,Brain & Behavior Research Foundation,Early Phase 1
NCT04630847,2022.0,OTHER,lead,ProgenaBiome,Phase 1
NCT04630847,2022.0,UNKNOWN,collaborator,Ventura Clinical Trials,Phase 1
NCT04630860,2020.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04630964,2021.0,OTHER,lead,Section for Affective Disorders; Northern Stockholm Psychiatry,Phase 2
NCT04630964,2021.0,OTHER,collaborator,Karolinska Institutet,Phase 2
NCT04630977,2023.0,OTHER,lead,University of Greenwich,Not Applicable
NCT04630977,2023.0,UNKNOWN,collaborator,Ingesport Health Spa Consulting,Not Applicable
NCT04631107,2020.0,INDUSTRY,lead,Apnimed,Phase 2
NCT04631471,2021.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 3
NCT04632069,2021.0,OTHER,lead,Medical University of South Carolina,Early Phase 1
NCT04632069,2021.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Early Phase 1
NCT04632225,2021.0,INDUSTRY,lead,"Helixmith Co., Ltd.",Phase 2
NCT04632940,2020.0,INDUSTRY,lead,FibroGen,Phase 3
NCT04633447,2020.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT04633577,2020.0,OTHER,lead,General Hospital of Ningxia Medical University,Not Applicable
NCT04633694,2020.0,OTHER,lead,University of Aarhus,Not Applicable
NCT04633694,2020.0,OTHER,collaborator,AP Moeller Foundation,Not Applicable
NCT04633694,2020.0,OTHER,collaborator,Beckett Foundation,Not Applicable
NCT04634136,2020.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT04634136,2020.0,UNKNOWN,collaborator,PharmaHemp,Not Applicable
NCT04634136,2020.0,OTHER,collaborator,"University of Ljubljana, Faculty of Medicine",Not Applicable
NCT04634682,2020.0,INDUSTRY,lead,"Myogem Health Company, S.L.",Not Applicable
NCT04634994,2021.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT04634994,2021.0,OTHER,collaborator,Massachusetts General Hospital,Early Phase 1
NCT04635176,2022.0,OTHER,lead,University of Calgary,Phase 4
NCT04635176,2022.0,OTHER,collaborator,Alberta Health services,Phase 4
NCT04635176,2022.0,OTHER,collaborator,Alberta Hip and Knee Clinic,Phase 4
NCT04635774,2021.0,OTHER,lead,University of Kansas Medical Center,Phase 1/Phase 2
NCT04638387,2020.0,OTHER,lead,Colorado State University,Not Applicable
NCT04639193,2020.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT04639310,2021.0,INDUSTRY,lead,Xenon Pharmaceuticals Inc.,Phase 3
NCT04640077,2020.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT04640636,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT04640636,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04641143,2020.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT04641819,2021.0,OTHER,lead,ShuGuang Hospital,Phase 4
NCT04641819,2021.0,INDUSTRY,collaborator,LinkDoc Technology (Beijing) Co. Ltd.,Phase 4
NCT04641819,2021.0,INDUSTRY,collaborator,"Shaanxi Buchang Pharmaceutical Co., Ltd",Phase 4
NCT04641949,2020.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT04643327,2021.0,OTHER,lead,The University of Queensland,Phase 2
NCT04643327,2021.0,OTHER,collaborator,Queensland University of Technology,Phase 2
NCT04643327,2021.0,OTHER,collaborator,Johns Hopkins University,Phase 2
NCT04643327,2021.0,UNKNOWN,collaborator,Cleveland Clinic Lou Ruvo Center for Brain Health,Phase 2
NCT04643327,2021.0,OTHER_GOV,collaborator,Royal Brisbane and Women's Hospital,Phase 2
NCT04644003,2020.0,INDUSTRY,lead,Stalicla SA,Phase 1
NCT04644315,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT04645524,2020.0,INDUSTRY,lead,Apnimed,Phase 2
NCT04645719,2022.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 3
NCT04646135,2020.0,OTHER,lead,Bambino Gesù Hospital and Research Institute,Phase 2
NCT04646135,2020.0,OTHER,collaborator,"Ministero della Salute, Italy",Phase 2
NCT04646135,2020.0,OTHER,collaborator,"University College, London",Phase 2
NCT04646876,2019.0,OTHER,lead,Osama Mohamed Abdelwahab,Phase 3
NCT04647019,2021.0,OTHER,lead,University of Reading,Not Applicable
NCT04647019,2021.0,UNKNOWN,collaborator,Wild Blueberry Association of North America (WBANA),Not Applicable
NCT04647292,2021.0,OTHER,lead,University College Dublin,Phase 2
NCT04647292,2021.0,OTHER,collaborator,"St Vincent's University Hospital, Ireland",Phase 2
NCT04647292,2021.0,OTHER,collaborator,Cork University Hospital,Phase 2
NCT04647292,2021.0,OTHER,collaborator,Tallaght University Hospital,Phase 2
NCT04647292,2021.0,OTHER,collaborator,University of Limerick,Phase 2
NCT04647292,2021.0,OTHER,collaborator,University of Calgary,Phase 2
NCT04647292,2021.0,OTHER,collaborator,Universitaire Ziekenhuizen KU Leuven,Phase 2
NCT04647292,2021.0,OTHER,collaborator,Attikon Hospital,Phase 2
NCT04647292,2021.0,OTHER,collaborator,Hospital Universitario La Paz,Phase 2
NCT04647292,2021.0,UNKNOWN,collaborator,HRB Stroke Trials Network Ireland,Phase 2
NCT04647292,2021.0,OTHER,collaborator,"National University of Ireland, Galway, Ireland",Phase 2
NCT04647292,2021.0,OTHER,collaborator,Mater Misericordiae University Hospital,Phase 2
NCT04647292,2021.0,OTHER,collaborator,University of Oslo,Phase 2
NCT04647292,2021.0,OTHER,collaborator,Newcastle University,Phase 2
NCT04647292,2021.0,OTHER,collaborator,University Hospital Waterford,Phase 2
NCT04647383,2021.0,INDUSTRY,lead,Eisai Inc.,Phase 1
NCT04647903,2020.0,INDUSTRY,lead,"Vallon Pharmaceuticals, Inc.",Phase 1
NCT04648150,2021.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Not Applicable
NCT04648150,2021.0,INDUSTRY,collaborator,Remedee SA,Not Applicable
NCT04648241,2021.0,INDUSTRY,lead,Pfizer,Phase 3
NCT04649203,2020.0,INDUSTRY,lead,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 3
NCT04649281,2020.0,OTHER,lead,Göteborg University,Not Applicable
NCT04649281,2020.0,OTHER_GOV,collaborator,Vastra Gotaland Region,Not Applicable
NCT04649866,2021.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT04649866,2021.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Not Applicable
NCT04650074,2021.0,OTHER,lead,Hospices Civils de Lyon,Phase 2/Phase 3
NCT04650204,2020.0,OTHER,lead,Mayo Clinic,Phase 4
NCT04650217,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT04650217,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04650217,2021.0,OTHER,collaborator,Columbia University,Phase 4
NCT04650282,2021.0,OTHER,lead,University of Michigan,Phase 2
NCT04650321,2021.0,OTHER,lead,"University of Colorado, Denver",Phase 4
NCT04650321,2021.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT04650893,2021.0,OTHER,lead,University of Nebraska,Phase 3
NCT04651153,2020.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04651855,2020.0,INDUSTRY,lead,Polski Bank Komorek Macierzystych JSC (PBKM),Phase 1/Phase 2
NCT04651855,2020.0,OTHER,collaborator,"National Center for Research and Development, Poland",Phase 1/Phase 2
NCT04652089,2020.0,OTHER,lead,University of Oxford,Phase 1/Phase 2
NCT04652128,2019.0,OTHER,lead,Yonsei University,Not Applicable
NCT04652544,2021.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Phase 3
NCT04652882,2020.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 3
NCT04652908,2021.0,OTHER,lead,Diana Lee Farmer,Phase 1/Phase 2
NCT04652908,2021.0,OTHER,collaborator,California Institute for Regenerative Medicine (CIRM),Phase 1/Phase 2
NCT04652921,2020.0,OTHER,lead,"University of Novi Sad, Faculty of Sport and Physical Education",Not Applicable
NCT04654429,2020.0,OTHER,lead,Dr Lim Siu Min,Phase 4
NCT04654689,2021.0,OTHER,lead,Fundación Universidad Católica de Valencia San Vicente Mártir,Phase 2
NCT04655326,2020.0,OTHER,lead,Arizona State University,Early Phase 1
NCT04655326,2020.0,UNKNOWN,collaborator,Sun Genomics,Early Phase 1
NCT04656301,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT04656301,2021.0,INDUSTRY,collaborator,COMPASS Pathways,Phase 2
NCT04656301,2021.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT04656470,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT04656600,2021.0,INDUSTRY,lead,Sanofi,Phase 4
NCT04656860,2020.0,OTHER,lead,"University of Alabama, Tuscaloosa",Not Applicable
NCT04656860,2020.0,OTHER,collaborator,University of North Texas Health Science Center,Not Applicable
NCT04657107,2020.0,OTHER,lead,Beijing Obstetrics and Gynecology Hospital,Not Applicable
NCT04657107,2020.0,UNKNOWN,collaborator,China Health Promotion Foundation,Not Applicable
NCT04657107,2020.0,OTHER,collaborator,Beijing Haidian Maternal and Child Health Hospital,Not Applicable
NCT04657107,2020.0,OTHER,collaborator,Obstetrics & Gynecology Hospital of Fudan University,Not Applicable
NCT04657107,2020.0,OTHER,collaborator,Fourth Hospital of Shijiazhuang City,Not Applicable
NCT04657107,2020.0,UNKNOWN,collaborator,Changzhi Maternal and Child Health Hospital,Not Applicable
NCT04657107,2020.0,UNKNOWN,collaborator,Linfen Maternity&Child Healthcare Hospital,Not Applicable
NCT04657107,2020.0,OTHER,collaborator,"Maternal and Child Health Hospital, Jiading District",Not Applicable
NCT04657107,2020.0,UNKNOWN,collaborator,Tongzhou Maternal and Child Healthcare Hospital of Beijing,Not Applicable
NCT04657107,2020.0,UNKNOWN,collaborator,Beijing Chaoyang District Maternal and Child Health Care Hospital,Not Applicable
NCT04657133,2021.0,OTHER,lead,Capital Medical University,Phase 3
NCT04657315,2020.0,OTHER,lead,CHA University,Phase 1/Phase 2
NCT04657315,2020.0,OTHER,collaborator,Ajou University School of Medicine,Phase 1/Phase 2
NCT04657809,2020.0,OTHER,lead,Soad Ali,Phase 2
NCT04657809,2020.0,OTHER,collaborator,Minia University,Phase 2
NCT04657952,2020.0,OTHER,lead,Tanta University,Phase 4
NCT04658199,2020.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04658472,2021.0,INDUSTRY,lead,"Bioverativ, a Sanofi company",Phase 2
NCT04658836,2020.0,OTHER,lead,Medical University of Vienna,Phase 1
NCT04659031,2021.0,INDUSTRY,lead,"Abcuro, Inc.",Phase 1
NCT04659161,2020.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT04659174,2021.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT04659226,2021.0,OTHER,lead,University of L'Aquila,Not Applicable
NCT04659226,2021.0,INDUSTRY,collaborator,Novartis,Not Applicable
NCT04659278,2021.0,INDUSTRY,lead,"Endourage, LLC",Not Applicable
NCT04659408,2021.0,NETWORK,lead,"Swiss Paraplegic Research, Nottwil",Not Applicable
NCT04660539,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT04661280,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT04661280,2022.0,OTHER,collaborator,France Alzheimer,Phase 3
NCT04661514,2021.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT04661514,2021.0,INDUSTRY,collaborator,COMPASS Pathways,Phase 2
NCT04662125,2020.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT04662177,2018.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT04662281,2020.0,INDUSTRY,lead,Lexicon Pharmaceuticals,Phase 2
NCT04663854,2020.0,OTHER,lead,Mashhad University of Medical Sciences,Phase 1
NCT04664530,2020.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT04665453,2020.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT04665791,2021.0,OTHER,lead,Center for Vaccine Development - Mali,Not Applicable
NCT04665791,2021.0,OTHER,collaborator,University of Southampton,Not Applicable
NCT04665791,2021.0,OTHER,collaborator,"University of Maryland, College Park",Not Applicable
NCT04665791,2021.0,OTHER,collaborator,"University College, London",Not Applicable
NCT04665791,2021.0,OTHER,collaborator,University of Oxford,Not Applicable
NCT04665791,2021.0,OTHER_GOV,collaborator,Public Health England,Not Applicable
NCT04666714,2023.0,INDUSTRY,lead,EMS,Phase 3
NCT04667637,2021.0,OTHER,lead,Hui-Sheng Chen,Phase 2
NCT04669028,2021.0,INDUSTRY,lead,BioVie Inc.,Phase 3
NCT04669535,2021.0,OTHER,lead,Terence Flotte,Phase 1
NCT04669535,2021.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 1
NCT04669535,2021.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1
NCT04670770,2021.0,INDUSTRY,lead,Reistone Biopharma Company Limited,Phase 2
NCT04671030,2018.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 1
NCT04671082,2020.0,INDUSTRY,lead,"Neurana Pharmaceuticals, Inc.",Phase 3
NCT04672135,2020.0,INDUSTRY,lead,reMYND,Phase 1
NCT04672135,2020.0,UNKNOWN,collaborator,NeuroScios GmbH,Phase 1
NCT04673578,2021.0,OTHER,lead,University of British Columbia,Phase 2
NCT04673578,2021.0,OTHER,collaborator,BC Children's Hospital Research Institute,Phase 2
NCT04673578,2021.0,OTHER,collaborator,Obsessive Compulsive Foundation,Phase 2
NCT04674020,2020.0,OTHER,lead,Danish Headache Center,Phase 4
NCT04674163,2023.0,OTHER,lead,Centre Hospitalier Régional d'Orléans,Not Applicable
NCT04674163,2023.0,UNKNOWN,collaborator,Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM),Not Applicable
NCT04674241,2021.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT04674618,2020.0,OTHER,lead,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Applicable
NCT04674670,2021.0,OTHER,lead,susanne becker,Not Applicable
NCT04674670,2021.0,UNKNOWN,collaborator,SNSF,Not Applicable
NCT04674735,2023.0,INDUSTRY,lead,Apsen Farmaceutica S.A.,Phase 1
NCT04675450,2023.0,INDUSTRY,lead,"Conjupro Biotherapeutics, Inc.",Phase 2
NCT04675450,2023.0,INDUSTRY,collaborator,"CSPC-NBP Pharmaceutical Co., Ltd.",Phase 2
NCT04675762,2021.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 2
NCT04675762,2021.0,OTHER,collaborator,Shaoxing People's Hospital,Phase 2
NCT04675762,2021.0,OTHER,collaborator,Affiliated Hospital of Jiaxing University,Phase 2
NCT04675762,2021.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 2
NCT04675762,2021.0,OTHER,collaborator,The Second Affiliated Hospital of Jiaxing University,Phase 2
NCT04675762,2021.0,UNKNOWN,collaborator,Jinhua Center Hospital,Phase 2
NCT04675762,2021.0,OTHER,collaborator,Taizhou Hospital,Phase 2
NCT04675775,2021.0,OTHER,lead,University of Michigan,Not Applicable
NCT04675775,2021.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04676139,2020.0,OTHER,lead,Mansoura University,Phase 3
NCT04676373,2021.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT04677829,2021.0,INDUSTRY,lead,"Pinteon Therapeutics, Inc",Phase 1
NCT04677829,2021.0,FED,collaborator,United States Department of Defense,Phase 1
NCT04677985,2019.0,OTHER,lead,Memorial University of Newfoundland,Not Applicable
NCT04678453,2021.0,INDUSTRY,lead,"NKGen Biotech, Inc.",Phase 1
NCT04679467,2020.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT04679623,2021.0,INDUSTRY,lead,Rafa Laboratories,Phase 1
NCT04679623,2021.0,INDUSTRY,collaborator,Ology Bioservices,Phase 1
NCT04679623,2021.0,UNKNOWN,collaborator,"Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical",Phase 1
NCT04680065,2023.0,INDUSTRY,lead,"Brain Neurotherapy Bio, Inc.",Phase 1
NCT04680143,2020.0,OTHER,lead,Alexandria University,Phase 1/Phase 2
NCT04681651,2021.0,OTHER,lead,Capital Medical University,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Tianjin Huanhu Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Shengli Oilfield Hospital,Phase 2
NCT04681651,2021.0,UNKNOWN,collaborator,Beijing Fengtai You'anmen Hospital,Phase 2
NCT04681651,2021.0,OTHER_GOV,collaborator,Jiujiang University Affiliated Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Zhangzhou Municipal Hospital of Fujian Province,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Baotou Central Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Luoyang Central Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Nanyang Central Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Qingdao Central Hospital,Phase 2
NCT04681651,2021.0,UNKNOWN,collaborator,The Third People's Hospital of Jinan,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Rizhao People's Hospital,Phase 2
NCT04681651,2021.0,UNKNOWN,collaborator,Anyang People's Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Shanghai 10th People's Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Dalian Municipal Central Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Zhoukou Central Hospital,Phase 2
NCT04681651,2021.0,UNKNOWN,collaborator,Nanshi Hospital of Nanyang,Phase 2
NCT04681651,2021.0,UNKNOWN,collaborator,The second Nanning People's Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Zhumadian Central Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Taizhou Hospital,Phase 2
NCT04681651,2021.0,OTHER,collaborator,Second Affiliated Hospital of Nanchang University,Phase 2
NCT04683848,2021.0,INDUSTRY,lead,Mitsubishi Tanabe Pharma America Inc.,Phase 2
NCT04684277,2021.0,OTHER,lead,Peking University,Not Applicable
NCT04684602,2020.0,INDUSTRY,lead,Thomas Advanced Medical LLC,Phase 1/Phase 2
NCT04684602,2020.0,UNKNOWN,collaborator,HeartStem Institute,Phase 1/Phase 2
NCT04684602,2020.0,UNKNOWN,collaborator,NuStem,Phase 1/Phase 2
NCT04685057,2021.0,OTHER,lead,Fundació Sant Joan de Déu,Not Applicable
NCT04685265,2020.0,INDUSTRY,lead,MODAG GmbH,Phase 1
NCT04685265,2020.0,INDUSTRY,collaborator,Aptuit,Phase 1
NCT04685265,2020.0,INDUSTRY,collaborator,Quotient Sciences,Phase 1
NCT04685265,2020.0,OTHER,collaborator,Nottingham University Hospitals NHS Trust,Phase 1
NCT04685590,2021.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT04685590,2021.0,OTHER,collaborator,The University of Texas Health Science Center at San Antonio,Phase 2
NCT04685642,2020.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Phase 4
NCT04686110,2021.0,OTHER_GOV,lead,"University Hospital, Angers",Not Applicable
NCT04686786,2020.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT04686916,2020.0,INDUSTRY,lead,Initiator Pharma,Phase 2
NCT04687020,2021.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 4
NCT04687111,2015.0,OTHER,lead,Mark Ledwidge,Phase 2
NCT04687111,2015.0,OTHER,collaborator,The Heartbeat Trust,Phase 2
NCT04687566,2020.0,OTHER,lead,National Cheng-Kung University Hospital,Phase 2/Phase 3
NCT04687566,2020.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Phase 2/Phase 3
NCT04687878,2020.0,OTHER,lead,dr.dargahi,Phase 2
NCT04688788,2021.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 3
NCT04688788,2021.0,OTHER,collaborator,Odense University Hospital,Phase 3
NCT04688788,2021.0,OTHER,collaborator,Aarhus University Hospital,Phase 3
NCT04688788,2021.0,OTHER,collaborator,Aalborg University Hospital,Phase 3
NCT04688788,2021.0,OTHER,collaborator,Herlev Hospital,Phase 3
NCT04688788,2021.0,OTHER,collaborator,"Hillerod Hospital, Denmark",Phase 3
NCT04688788,2021.0,OTHER,collaborator,Kolding Sygehus,Phase 3
NCT04688788,2021.0,OTHER,collaborator,Gødstrup Hospital,Phase 3
NCT04688788,2021.0,OTHER,collaborator,Hvidovre University Hospital,Phase 3
NCT04688788,2021.0,UNKNOWN,collaborator,"Hospital of South West Jutland, Esbjerg, Denmark",Phase 3
NCT04688788,2021.0,UNKNOWN,collaborator,"GCP unit, Copenhagen University Hospital",Phase 3
NCT04688788,2021.0,OTHER,collaborator,"GCP-unit at Aarhus University Hospital, Aarhus, Denmark",Phase 3
NCT04688788,2021.0,UNKNOWN,collaborator,"Hospital of Southern Jutland, Sønderborg, Denmark",Phase 3
NCT04688788,2021.0,UNKNOWN,collaborator,"Hospital of Central Denmark Region, Viborg, Denmark",Phase 3
NCT04688788,2021.0,OTHER,collaborator,Danske Regioner,Phase 3
NCT04688788,2021.0,UNKNOWN,collaborator,"Hospital of Southern Jutland, Aabenraa, Denmark",Phase 3
NCT04689165,2020.0,UNKNOWN,lead,Wei Cun,Phase 3
NCT04689165,2020.0,OTHER,collaborator,Yunnan Center for Disease Control and Prevention,Phase 3
NCT04689191,2020.0,UNKNOWN,lead,Wei Cun,Phase 3
NCT04689191,2020.0,OTHER,collaborator,Yunnan Center for Disease Control and Prevention,Phase 3
NCT04689282,2020.0,OTHER,lead,Russian Academy of Medical Sciences,Phase 1/Phase 2
NCT04690647,2018.0,OTHER,lead,"Saint Lucas Hospital, Poland",Not Applicable
NCT04691128,2021.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT04691661,2021.0,INDUSTRY,lead,"Il-Yang Pharm. Co., Ltd.",Phase 2
NCT04691986,2023.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT04691986,2023.0,OTHER,collaborator,University at Buffalo,Not Applicable
NCT04692441,2021.0,OTHER,lead,University of Washington,Not Applicable
NCT04692441,2021.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04693039,2021.0,INDUSTRY,lead,Shijiazhuang Yiling Pharmaceutical Co. Ltd,Phase 1
NCT04693039,2021.0,OTHER,collaborator,"Xuanwu Hospital, Beijing",Phase 1
NCT04693286,2020.0,OTHER,lead,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2
NCT04693286,2020.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT04693286,2020.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 2
NCT04693286,2020.0,OTHER,collaborator,PATH,Phase 2
NCT04693286,2020.0,OTHER,collaborator,World Health Organization,Phase 2
NCT04693286,2020.0,INDUSTRY,collaborator,PT Bio Farma,Phase 2
NCT04693351,2021.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT04693533,2021.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 4
NCT04693533,2021.0,INDUSTRY,collaborator,Teva Pharmaceuticals USA,Phase 4
NCT04693598,2021.0,INDUSTRY,lead,"Forge Biologics, Inc",Phase 1/Phase 2
NCT04694417,2021.0,OTHER,lead,Tampere University Hospital,Not Applicable
NCT04694417,2021.0,OTHER,collaborator,Tampere University,Not Applicable
NCT04696120,2021.0,OTHER,lead,Korea University Guro Hospital,Phase 2
NCT04696120,2021.0,INDUSTRY,collaborator,Dt&Sanomedics,Phase 2
NCT04696380,2021.0,OTHER,lead,University of Vermont,Phase 2
NCT04696458,2021.0,OTHER,lead,Scripps Health,Not Applicable
NCT04696458,2021.0,INDUSTRY,collaborator,Kaneka Corporation,Not Applicable
NCT04696523,2023.0,OTHER_GOV,lead,Turku University Hospital,Phase 2
NCT04696523,2023.0,OTHER,collaborator,Academy of Finland,Phase 2
NCT04697381,2021.0,INDUSTRY,lead,Pfizer,Phase 3
NCT04697407,2021.0,OTHER,lead,Rennes University Hospital,Not Applicable
NCT04697693,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT04698343,2021.0,INDUSTRY,lead,"Noctrix Health, Inc.",Not Applicable
NCT04698343,2021.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT04698525,2019.0,OTHER,lead,Universidad Autonoma de San Luis Potosí,Phase 3
NCT04698603,2019.0,INDUSTRY,lead,GH Research Ireland Limited,Phase 1/Phase 2
NCT04699422,2020.0,OTHER,lead,Jessa Hospital,Not Applicable
NCT04699747,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT04700566,2022.0,OTHER,lead,University of Southern California,Phase 3
NCT04701164,2020.0,INDUSTRY,lead,"Annexon, Inc.",Phase 3
NCT04701866,2021.0,OTHER,lead,Douglas Mental Health University Institute,Not Applicable
NCT04701866,2021.0,UNKNOWN,collaborator,"Réseau québécois sur le suicide, les troubles de l'humeur et les troubles associés",Not Applicable
NCT04701957,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT04701957,2023.0,OTHER,collaborator,France Alzheimer,Not Applicable
NCT04702087,2021.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT04702087,2021.0,INDUSTRY,collaborator,Abiogen Pharma,Not Applicable
NCT04702971,2021.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Phase 4
NCT04703127,2020.0,OTHER,lead,Sohag University,Phase 3
NCT04703257,2021.0,OTHER,lead,Jessa Hospital,Not Applicable
NCT04705298,2021.0,OTHER,lead,British Columbia Children's Hospital,Phase 4
NCT04706091,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04706091,2021.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT04706377,2018.0,OTHER,lead,Aristotle University Of Thessaloniki,Not Applicable
NCT04706377,2018.0,OTHER,collaborator,University of Sheffield,Not Applicable
NCT04706377,2018.0,OTHER,collaborator,University Hospital Tuebingen,Not Applicable
NCT04706806,2020.0,OTHER,lead,Arizona State University,Not Applicable
NCT04706910,2021.0,OTHER,lead,University of Alberta,Phase 3
NCT04707391,2021.0,INDUSTRY,lead,GlaxoSmithKline,Phase 3
NCT04707963,2021.0,OTHER,lead,Auburn University,Not Applicable
NCT04707963,2021.0,UNKNOWN,collaborator,Edward Via College of Osteopathic Medicine-Auburn,Not Applicable
NCT04707963,2021.0,OTHER,collaborator,The Peanut Institute,Not Applicable
NCT04708314,2020.0,OTHER,lead,"Rare Disease Research, LLC",Phase 4
NCT04708314,2020.0,INDUSTRY,collaborator,"Sarepta Therapeutics, Inc.",Phase 4
NCT04708834,2021.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT04708886,2021.0,OTHER,lead,Northwestern University,Phase 2
NCT04708886,2021.0,INDUSTRY,collaborator,Amgen,Phase 2
NCT04709029,2021.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04709224,2020.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 1
NCT04709471,2021.0,OTHER,lead,University of Vermont,Phase 2
NCT04710069,2020.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT04710550,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT04711148,2021.0,INDUSTRY,lead,"Beijing InnoCare Pharma Tech Co., Ltd.",Phase 2
NCT04711915,2021.0,OTHER,lead,Yale University,Phase 1
NCT04712721,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Early Phase 1
NCT04712734,2021.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 1
NCT04712968,2021.0,OTHER,lead,University of Aarhus,Not Applicable
NCT04713475,2021.0,INDUSTRY,lead,"Passage Bio, Inc.",Phase 1/Phase 2
NCT04713826,2021.0,INDUSTRY,lead,Bayer,Phase 2
NCT04713982,2021.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2/Phase 3
NCT04713982,2021.0,INDUSTRY,collaborator,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2/Phase 3
NCT04714112,2021.0,OTHER,lead,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Phase 4
NCT04714177,2021.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Phase 2
NCT04714177,2021.0,INDUSTRY,collaborator,"Jiangsu Simcere Pharmaceutical Co., Ltd.",Phase 2
NCT04714359,2021.0,INDUSTRY,lead,Lykos Therapeutics,Phase 3
NCT04714541,2021.0,INDUSTRY,lead,"Homeostasis Therapeutics, LLC",Phase 1
NCT04714996,2020.0,INDUSTRY,lead,ES Therapeutics Australia Pty Ltd,Phase 2
NCT04715646,2021.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 3
NCT04715750,2020.0,INDUSTRY,lead,Life Molecular Imaging GmbH,Phase 1
NCT04715750,2020.0,INDUSTRY,collaborator,Life Molecular Imaging SA,Phase 1
NCT04715932,2021.0,OTHER,lead,Montreal Heart Institute,Phase 2
NCT04715932,2021.0,UNKNOWN,collaborator,Ingenew Pharmaceuticals Inc.,Phase 2
NCT04716036,2021.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT04717141,2021.0,OTHER,lead,Nantes University Hospital,Not Applicable
NCT04718064,2021.0,OTHER,lead,The Affiliated Hospital of Xuzhou Medical University,Not Applicable
NCT04718116,2022.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT04718155,2021.0,OTHER,lead,Assiut University,Not Applicable
NCT04718181,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04718259,2020.0,OTHER,lead,Tanta University,Early Phase 1
NCT04718779,2021.0,INDUSTRY,lead,Takeda,Phase 4
NCT04720040,2019.0,INDUSTRY,lead,Ybrain Inc.,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,The Catholic University of Korea,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,Inje University,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,Korea University,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,Seoul National University Bundang Hospital,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,Hallym University Medical Center,Not Applicable
NCT04720040,2019.0,OTHER,collaborator,Soonchunhyang University Hospital,Not Applicable
NCT04721353,2020.0,FED,lead,VA Puget Sound Health Care System,Phase 4
NCT04721353,2020.0,OTHER,collaborator,University of Washington,Phase 4
NCT04721353,2020.0,FED,collaborator,"VA Mental Illness Research, Education and Clinical Centers",Phase 4
NCT04722211,2020.0,OTHER,lead,Professor Lu Neurological Clinic,Not Applicable
NCT04723147,2021.0,OTHER,lead,Emory University,Phase 4
NCT04723147,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04723303,2021.0,OTHER,lead,University of Florida,Early Phase 1
NCT04723303,2021.0,INDUSTRY,collaborator,"Restem, LLC.",Early Phase 1
NCT04724668,2021.0,OTHER,lead,University of Cincinnati,Phase 1/Phase 2
NCT04724668,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT04724668,2021.0,OTHER,collaborator,Lindner Center of HOPE,Phase 1/Phase 2
NCT04724954,2019.0,INDUSTRY,lead,Bright Cloud International Corp,Not Applicable
NCT04724954,2019.0,OTHER,collaborator,Kessler Foundation,Not Applicable
NCT04724954,2019.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04725175,2021.0,INDUSTRY,lead,Contineum Therapeutics,Phase 1
NCT04725383,2023.0,OTHER,lead,"University of Missouri, Kansas City",Phase 3
NCT04726410,2022.0,OTHER,lead,Jason Sperry,Phase 2
NCT04726410,2022.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04726592,2021.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT04726982,2021.0,OTHER,lead,"University Hospital, Antwerp",Phase 4
NCT04727970,2021.0,INDUSTRY,lead,Cerecin,Phase 1
NCT04728308,2021.0,OTHER,lead,"Armed Forces Hospital, Pakistan",Early Phase 1
NCT04728425,2020.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT04729179,2021.0,OTHER,lead,Marius Henriksen,Phase 3
NCT04729907,2021.0,INDUSTRY,lead,Biogen,Phase 3
NCT04730635,2021.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT04730973,2021.0,OTHER,lead,Azienda Ospedaliera Ordine Mauriziano di Torino,Phase 4
NCT04731974,2023.0,OTHER,lead,Children's National Research Institute,Phase 2
NCT04732065,2021.0,OTHER,lead,"Sabine Mueller, MD, PhD",Phase 1
NCT04732065,2021.0,INDUSTRY,collaborator,Chimerix,Phase 1
NCT04732065,2021.0,UNKNOWN,collaborator,Mithil Prasad Foundation,Phase 1
NCT04732065,2021.0,UNKNOWN,collaborator,Storm the Heavens Fund,Phase 1
NCT04732065,2021.0,UNKNOWN,collaborator,The ChadTough Defeat DIPG Foundation,Phase 1
NCT04732065,2021.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT04732182,2022.0,INDUSTRY,lead,Bright Cloud International Corp,Not Applicable
NCT04732182,2022.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04732182,2022.0,OTHER,collaborator,"Rutgers, The State University of New Jersey",Not Applicable
NCT04732455,2021.0,OTHER,lead,Gamal Mohamed Taha Abouelmagd,Not Applicable
NCT04733742,2022.0,OTHER,lead,Xinqiao Hospital of Chongqing,Phase 2/Phase 3
NCT04733742,2022.0,UNKNOWN,collaborator,"CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD",Phase 2/Phase 3
NCT04734379,2021.0,INDUSTRY,lead,Woolsey Pharmaceuticals,Phase 2
NCT04734548,2020.0,INDUSTRY,lead,aptaTargets S.L.,Phase 1/Phase 2
NCT04734548,2020.0,UNKNOWN,collaborator,Science and Innovation Spanish Ministry,Phase 1/Phase 2
NCT04734548,2020.0,UNKNOWN,collaborator,Anagram,Phase 1/Phase 2
NCT04735172,2022.0,OTHER,lead,"University Hospital, Clermont-Ferrand",Not Applicable
NCT04735536,2020.0,INDUSTRY,lead,Cognition Therapeutics,Phase 2
NCT04735536,2020.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04735627,2021.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT04736836,2015.0,OTHER_GOV,lead,National Hepatology & Tropical Medicine Research Institute,Phase 4
NCT04737096,2020.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04737278,2014.0,INDUSTRY,lead,Mitosynergy LLC,Phase 1/Phase 2
NCT04738097,2021.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 3
NCT04738123,2021.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT04740580,2022.0,OTHER,lead,Baylor College of Medicine,Early Phase 1
NCT04740580,2022.0,OTHER,collaborator,The Methodist Hospital Research Institute,Early Phase 1
NCT04741841,2020.0,INDUSTRY,lead,ImmuneBiotech Medical Sweden AB,Not Applicable
NCT04741841,2020.0,OTHER,collaborator,Karolinska Institutet,Not Applicable
NCT04742010,2021.0,OTHER,lead,Stinus Gadegaard Hansen,Phase 2
NCT04742010,2021.0,UNKNOWN,collaborator,"Research Unit of Health Sciences, Hospital of South West Jutland",Phase 2
NCT04742010,2021.0,UNKNOWN,collaborator,"Department of Regional Health Research, University of Southern Denmark",Phase 2
NCT04742010,2021.0,UNKNOWN,collaborator,"OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark",Phase 2
NCT04742010,2021.0,UNKNOWN,collaborator,"Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark",Phase 2
NCT04742010,2021.0,OTHER,collaborator,Odense University Hospital,Phase 2
NCT04742062,2019.0,INDUSTRY,lead,aptaTargets S.L.,Phase 1
NCT04742062,2019.0,UNKNOWN,collaborator,Science and Innovation Spanish Ministry,Phase 1
NCT04742062,2019.0,UNKNOWN,collaborator,Anagram,Phase 1
NCT04742205,2021.0,OTHER,lead,Kathmandu Medical College and Teaching Hospital,Phase 2/Phase 3
NCT04742244,2020.0,OTHER,lead,National Taiwan Sport University,Not Applicable
NCT04742374,2021.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Early Phase 1
NCT04742400,2021.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 2
NCT04742673,2021.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT04742673,2021.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT04742673,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04743310,2021.0,OTHER,lead,John Yu,Phase 2
NCT04743310,2021.0,INDUSTRY,collaborator,Blaze Bioscience Inc.,Phase 2
NCT04744051,2021.0,INDUSTRY,lead,American CryoStem Corporation,Phase 1
NCT04744129,2022.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04744532,2019.0,OTHER,lead,Kyoto University,Phase 1/Phase 2
NCT04744532,2019.0,UNKNOWN,collaborator,Tokushima University,Phase 1/Phase 2
NCT04744532,2019.0,OTHER,collaborator,Kitasato University,Phase 1/Phase 2
NCT04744532,2019.0,UNKNOWN,collaborator,Tottori University,Phase 1/Phase 2
NCT04744532,2019.0,OTHER,collaborator,Nara Medical University,Phase 1/Phase 2
NCT04744532,2019.0,UNKNOWN,collaborator,Toho University,Phase 1/Phase 2
NCT04744532,2019.0,OTHER,collaborator,Hiroshima University,Phase 1/Phase 2
NCT04744532,2019.0,INDUSTRY,collaborator,Pfizer,Phase 1/Phase 2
NCT04744545,2021.0,INDUSTRY,lead,"Meru Health, Inc.",Not Applicable
NCT04744675,2021.0,OTHER,lead,Ottawa Hospital Research Institute,Phase 4
NCT04745026,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT04745104,2021.0,INDUSTRY,lead,Atridia Pty Ltd.,Phase 1
NCT04745143,2018.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT04745143,2018.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 2
NCT04745299,2021.0,INDUSTRY,lead,"Corestemchemon, Inc.",Phase 3
NCT04746079,2021.0,OTHER,lead,Mercy Health Ohio,Not Applicable
NCT04746079,2021.0,OTHER,collaborator,Lake Erie College of Osteopathic Medicine,Not Applicable
NCT04747275,2021.0,OTHER,lead,Children's Mercy Hospital Kansas City,Phase 4
NCT04747431,2021.0,INDUSTRY,lead,"Passage Bio, Inc.",Phase 1/Phase 2
NCT04748601,2021.0,INDUSTRY,lead,Upsher-Smith Laboratories,Phase 4
NCT04748705,2021.0,INDUSTRY,lead,"Virios Therapeutics, Inc.",Phase 2
NCT04749069,2012.0,OTHER_GOV,lead,Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital,Not Applicable
NCT04749069,2012.0,UNKNOWN,collaborator,Trakya University Faculty of Medicine,Not Applicable
NCT04749433,2021.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT04749433,2021.0,UNKNOWN,collaborator,Precision Molecular,Phase 1
NCT04749667,2021.0,OTHER,lead,Haukeland University Hospital,Phase 1/Phase 2
NCT04749667,2021.0,OTHER,collaborator,University of Bergen,Phase 1/Phase 2
NCT04749667,2021.0,OTHER,collaborator,University Hospital Ulm,Phase 1/Phase 2
NCT04749667,2021.0,OTHER,collaborator,"University Hospital, Akershus",Phase 1/Phase 2
NCT04749667,2021.0,OTHER,collaborator,St. Olavs Hospital,Phase 1/Phase 2
NCT04749667,2021.0,OTHER,collaborator,University Hospital of North Norway,Phase 1/Phase 2
NCT04749745,2020.0,OTHER,lead,Butler Hospital,Early Phase 1
NCT04750395,2021.0,OTHER,lead,HCA Hospice Care,Phase 2
NCT04750642,2021.0,INDUSTRY,lead,Cochlear,Not Applicable
NCT04750642,2021.0,OTHER,collaborator,NAMSA,Not Applicable
NCT04750642,2021.0,INDUSTRY,collaborator,Avania,Not Applicable
NCT04750642,2021.0,OTHER,collaborator,Vanderbilt University,Not Applicable
NCT04750928,2021.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT04750967,2021.0,OTHER_GOV,lead,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Not Applicable
NCT04751136,2016.0,OTHER,lead,Mansoura University Children Hospital,Phase 2
NCT04752566,2021.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT04752631,2021.0,OTHER,lead,General Hospital of Shenyang Military Region,Phase 4
NCT04753164,2021.0,INDUSTRY,lead,Idorsia Pharmaceuticals Ltd.,Phase 2
NCT04753944,2018.0,OTHER,lead,Pomeranian Medical University Szczecin,Not Applicable
NCT04753970,2021.0,OTHER,lead,Mayo Clinic,Phase 1/Phase 2
NCT04755283,2021.0,INDUSTRY,lead,"Anthos Therapeutics, Inc.",Phase 2
NCT04755283,2021.0,OTHER,collaborator,The TIMI Study Group,Phase 2
NCT04755283,2021.0,INDUSTRY,collaborator,Laboratory Corporation of America,Phase 2
NCT04755712,2021.0,OTHER,lead,GCS Ramsay Santé pour l'Enseignement et la Recherche,Phase 4
NCT04755920,2022.0,OTHER,lead,Leiden University Medical Center,Phase 2
NCT04755920,2022.0,OTHER,collaborator,Medical Center Haaglanden,Phase 2
NCT04755920,2022.0,INDUSTRY,collaborator,Surgimab,Phase 2
NCT04756544,2020.0,OTHER,lead,Medical University of Lodz,Phase 3
NCT04756856,2021.0,OTHER,lead,IRCCS Policlinico S. Matteo,Not Applicable
NCT04757675,2021.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Early Phase 1
NCT04758650,2021.0,OTHER,lead,Universitair Ziekenhuis Brussel,Phase 2
NCT04758936,2021.0,OTHER,lead,Erasme University Hospital,Phase 4
NCT04759040,2020.0,INDUSTRY,lead,Herbacure Natural,Not Applicable
NCT04759196,2021.0,OTHER,lead,Université de Sherbrooke,Phase 4
NCT04759365,2021.0,INDUSTRY,lead,Asceneuron Pty Ltd.,Phase 1
NCT04759365,2021.0,INDUSTRY,collaborator,Asceneuron S.A.,Phase 1
NCT04759365,2021.0,OTHER,collaborator,Neuroscience Trials Australia,Phase 1
NCT04759703,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 2/Phase 3
NCT04760275,2021.0,OTHER,lead,Children's Hospital Los Angeles,Phase 3
NCT04760275,2021.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 3
NCT04760613,2022.0,OTHER,lead,NYU Langone Health,Phase 1/Phase 2
NCT04760613,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT04760717,2021.0,OTHER,lead,Yale University,Phase 2
NCT04760717,2021.0,OTHER,collaborator,American Heart Association,Phase 2
NCT04760769,2021.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 3
NCT04760912,2020.0,OTHER,lead,Clinical Hospital Centre Zagreb,Not Applicable
NCT04761588,2021.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT04761861,2021.0,OTHER,lead,Sadat City University,Phase 2
NCT04762017,2021.0,INDUSTRY,lead,Oculis,Phase 2
NCT04762017,2021.0,UNKNOWN,collaborator,Neurotrials,Phase 2
NCT04762082,2023.0,INDUSTRY,lead,Seattle Gummy Company,Phase 1
NCT04762147,2016.0,OTHER,lead,Aga Khan University,Phase 3
NCT04762589,2021.0,INDUSTRY,lead,"Retrotope, Inc.",Phase 2
NCT04762758,2021.0,OTHER,lead,Pharnext S.C.A.,Phase 3
NCT04762758,2021.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 3
NCT04763876,2020.0,FED,lead,William Beaumont Army Medical Center,Phase 4
NCT04764045,2019.0,OTHER,lead,Bispebjerg Hospital,Not Applicable
NCT04764383,2022.0,OTHER,lead,University of Miami,Phase 2
NCT04764669,2021.0,INDUSTRY,lead,Eisai Inc.,Phase 2
NCT04765085,2021.0,OTHER,lead,Children's Hospital of Fudan University,Not Applicable
NCT04765488,2021.0,OTHER,lead,I.M. Sechenov First Moscow State Medical University,Not Applicable
NCT04766450,2021.0,OTHER,lead,Ain Shams University,Phase 4
NCT04766853,2021.0,OTHER,lead,Seoul National University Hospital,Phase 1/Phase 2
NCT04766918,2021.0,OTHER,lead,Tri-Service General Hospital,Not Applicable
NCT04767698,2021.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT04767698,2021.0,INDUSTRY,collaborator,GlaxoSmithKline,Phase 2
NCT04768023,2019.0,OTHER,lead,Medical University of Gdansk,Not Applicable
NCT04768062,2021.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 3
NCT04768062,2021.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 3
NCT04768101,2020.0,OTHER,lead,Vanderbilt University Medical Center,Early Phase 1
NCT04768400,2021.0,OTHER,lead,Gangnam Severance Hospital,Not Applicable
NCT04768569,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04768569,2021.0,OTHER,collaborator,University of Texas,Phase 2
NCT04768569,2021.0,INDUSTRY,collaborator,"Gateway Biotechnology, Inc.",Phase 2
NCT04768569,2021.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04768972,2021.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 3
NCT04770194,2019.0,INDUSTRY,lead,Shin Poong Pharmaceutical Co. Ltd.,Phase 1
NCT04771026,2020.0,OTHER,lead,Universiti Sains Malaysia,Not Applicable
NCT04771104,2017.0,OTHER,lead,"Rigshospitalet, Denmark",Not Applicable
NCT04771416,2022.0,INDUSTRY,lead,"Passage Bio, Inc.",Phase 1/Phase 2
NCT04771767,2021.0,OTHER,lead,Queen's University,Phase 2
NCT04772040,2021.0,OTHER,lead,University of Stirling,Not Applicable
NCT04772040,2021.0,INDUSTRY,collaborator,Danone Nutricia Research,Not Applicable
NCT04772547,2021.0,OTHER,lead,University of Florida,Phase 2
NCT04772547,2021.0,OTHER,collaborator,Yale University,Phase 2
NCT04772547,2021.0,OTHER,collaborator,Thomas Jefferson University,Phase 2
NCT04772547,2021.0,OTHER,collaborator,American Heart Association,Phase 2
NCT04772742,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT04773470,2022.0,OTHER,lead,University of Giessen,Not Applicable
NCT04774250,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04774250,2021.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04774250,2021.0,OTHER,collaborator,University of Texas,Phase 2
NCT04774250,2021.0,INDUSTRY,collaborator,"Gateway Biotechnology, Inc.",Phase 2
NCT04776213,2021.0,INDUSTRY,lead,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 4
NCT04776226,2017.0,OTHER,lead,Ege University,Not Applicable
NCT04776746,2020.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 3
NCT04777006,2021.0,OTHER,lead,RAND,Phase 4
NCT04777006,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT04777006,2021.0,OTHER,collaborator,Partners in Health,Phase 4
NCT04777006,2021.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 4
NCT04777006,2021.0,UNKNOWN,collaborator,Malawi Ministry of Health,Phase 4
NCT04777006,2021.0,UNKNOWN,collaborator,Blantyre College of Medicine,Phase 4
NCT04777006,2021.0,OTHER,collaborator,University of Birmingham,Phase 4
NCT04777110,2021.0,OTHER,lead,First Affiliated Hospital of Chongqing Medical University,Early Phase 1
NCT04777279,2020.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT04777357,2021.0,INDUSTRY,lead,AbbVie,Phase 3
NCT04778176,2021.0,INDUSTRY,lead,SynAgile Corporation,Phase 2
NCT04778176,2021.0,UNKNOWN,collaborator,Clintrex Research Corporation,Phase 2
NCT04778176,2021.0,INDUSTRY,collaborator,TFS Trial Form Support,Phase 2
NCT04778176,2021.0,UNKNOWN,collaborator,Clinical Data Science GmbH,Phase 2
NCT04779177,2021.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 1
NCT04779216,2021.0,OTHER,lead,"Karen Klahr Miller, MD",Phase 3
NCT04779216,2021.0,INDUSTRY,collaborator,Amgen,Phase 3
NCT04779255,2021.0,OTHER,lead,Poitiers University Hospital,Not Applicable
NCT04779632,2019.0,OTHER,lead,University of Copenhagen,Not Applicable
NCT04780399,2021.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 2
NCT04781309,2021.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT04781309,2021.0,INDUSTRY,collaborator,NeoImmuneTech,Early Phase 1
NCT04781751,2021.0,OTHER,lead,Minia University,Not Applicable
NCT04781998,2021.0,OTHER,lead,"Anders Fink-Jensen, MD, DMSci",Phase 4
NCT04782180,2022.0,OTHER,lead,University of Miami,Phase 4
NCT04782830,2021.0,OTHER,lead,Vanderbilt University Medical Center,Not Applicable
NCT04783493,2021.0,OTHER,lead,University of Sao Paulo General Hospital,Not Applicable
NCT04783935,2021.0,INDUSTRY,lead,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 4
NCT04784143,2021.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT04784416,2021.0,OTHER,lead,NYU Langone Health,Phase 2
NCT04784416,2021.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT04784416,2021.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT04784416,2021.0,INDUSTRY,collaborator,LiteCure LLC,Phase 2
NCT04785300,2022.0,OTHER,lead,"James L. Kirkland, MD, PhD",Phase 1/Phase 2
NCT04786223,2021.0,OTHER,lead,Val Lowe,Phase 2
NCT04786548,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT04787276,2017.0,OTHER,lead,Bogomolets National Medical University,Not Applicable
NCT04787302,2021.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT04787497,2022.0,OTHER,lead,University of Cyprus,Not Applicable
NCT04787497,2022.0,UNKNOWN,collaborator,World Olive Center for Health,Not Applicable
NCT04787497,2022.0,UNKNOWN,collaborator,"Ellis-Farm, Eliama Daily Value",Not Applicable
NCT04787887,2020.0,INDUSTRY,lead,"ISU Abxis Co., Ltd.",Phase 1
NCT04788615,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT04788745,2021.0,OTHER,lead,The University of Queensland,Phase 2
NCT04788745,2021.0,UNKNOWN,collaborator,FightMND,Phase 2
NCT04788745,2021.0,OTHER,collaborator,UMC Utrecht,Phase 2
NCT04788745,2021.0,OTHER,collaborator,King's College London,Phase 2
NCT04788745,2021.0,INDUSTRY,collaborator,Julius Clinical,Phase 2
NCT04789044,2023.0,OTHER,lead,Major Extremity Trauma Research Consortium,Phase 2
NCT04789044,2023.0,FED,collaborator,United States Department of Defense,Phase 2
NCT04789070,2022.0,OTHER,lead,University of Kansas Medical Center,Phase 3
NCT04789070,2022.0,UNKNOWN,collaborator,The Perron Institute,Phase 3
NCT04789174,2021.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 4
NCT04789499,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT04789616,2022.0,OTHER,lead,University of Calgary,Phase 2
NCT04789616,2022.0,OTHER,collaborator,"University Health Network, Toronto",Phase 2
NCT04789616,2022.0,OTHER,collaborator,"University of California, Los Angeles",Phase 2
NCT04789616,2022.0,OTHER,collaborator,Sunnybrook Health Sciences Centre,Phase 2
NCT04789616,2022.0,OTHER,collaborator,University of British Columbia,Phase 2
NCT04789616,2022.0,OTHER,collaborator,Memorial University of Newfoundland,Phase 2
NCT04789616,2022.0,OTHER,collaborator,Dalhousie University,Phase 2
NCT04789616,2022.0,OTHER,collaborator,"Parkwood Hospital, London, Ontario",Phase 2
NCT04789616,2022.0,OTHER,collaborator,Riverview Health Centre Foundation,Phase 2
NCT04789616,2022.0,UNKNOWN,collaborator,The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation,Phase 2
NCT04789915,2021.0,OTHER,lead,Bjorn H. Ebdrup,Phase 1
NCT04789915,2021.0,OTHER,collaborator,Lundbeck Foundation,Phase 1
NCT04789915,2021.0,OTHER,collaborator,Danish Research Centre for Magnetic Resonance,Phase 1
NCT04789915,2021.0,OTHER,collaborator,University of Copenhagen,Phase 1
NCT04791579,2024.0,OTHER,lead,University of Alberta,Phase 2
NCT04792307,2021.0,OTHER,lead,Nottingham University Hospitals NHS Trust,Not Applicable
NCT04792645,2021.0,OTHER,lead,University of Chicago,Phase 2
NCT04793490,2021.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04793659,2020.0,INDUSTRY,lead,Woolsey Pharmaceuticals,Phase 2
NCT04794413,2018.0,OTHER,lead,Joseph Jankovic,Early Phase 1
NCT04794413,2018.0,UNKNOWN,collaborator,"Andrew Billnitzer, MD",Early Phase 1
NCT04794491,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT04795466,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 2
NCT04796714,2022.0,OTHER,lead,"University Hospital, Bordeaux",Phase 4
NCT04797715,2020.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04797936,2020.0,OTHER,lead,Ivano-Frankivsk National Medical University,Phase 4
NCT04798053,2021.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT04798053,2021.0,OTHER,collaborator,Societe Francaise de Rhumatologie,Not Applicable
NCT04798391,2021.0,OTHER,lead,"Combined Military Hospital, Pakistan",Phase 4
NCT04798651,2021.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT04798651,2021.0,OTHER,collaborator,University of Bordeaux,Not Applicable
NCT04799015,2021.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT04799782,2017.0,OTHER,lead,Wayne State University,Phase 2
NCT04801303,2021.0,OTHER,lead,Berta Alemany,Phase 4
NCT04801303,2021.0,OTHER,collaborator,Institut de Recerca Biomèdica de Lleida,Phase 4
NCT04801303,2021.0,OTHER,collaborator,Universitat de Lleida,Phase 4
NCT04801303,2021.0,OTHER,collaborator,Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta,Phase 4
NCT04801368,2021.0,OTHER,lead,Mayo Clinic,Phase 4
NCT04801589,2021.0,OTHER,lead,Vanderbilt University Medical Center,Phase 3
NCT04801589,2021.0,INDUSTRY,collaborator,Pfizer,Phase 3
NCT04801589,2021.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 3
NCT04801953,2021.0,OTHER,lead,Medical University of Vienna,Phase 2
NCT04802707,2021.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 2
NCT04803071,2020.0,OTHER_GOV,lead,Guangzhou Psychiatric Hospital,Not Applicable
NCT04804033,2021.0,INDUSTRY,lead,Pfizer,Phase 2/Phase 3
NCT04804241,2022.0,OTHER,lead,"University of California, Davis",Phase 2
NCT04805385,2021.0,OTHER,lead,China Medical University Hospital,Not Applicable
NCT04805385,2021.0,INDUSTRY,collaborator,"Bened Biomedical Co., Ltd.",Not Applicable
NCT04805879,2021.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT04805879,2021.0,UNKNOWN,collaborator,Cumming school of medicine,Phase 2/Phase 3
NCT04805879,2021.0,UNKNOWN,collaborator,The W. Garfield Westin Foundation,Phase 2/Phase 3
NCT04805957,2022.0,OTHER,lead,"Rutgers, The State University of New Jersey",Not Applicable
NCT04805983,2021.0,OTHER,lead,Yale University,Phase 1
NCT04805983,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT04807517,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04807634,2021.0,OTHER,lead,Ain Shams University,Not Applicable
NCT04809116,2022.0,OTHER,lead,Baylor College of Medicine,Phase 4
NCT04809116,2022.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 4
NCT04809532,2021.0,OTHER,lead,"Armed Forces Hospital, Pakistan",Not Applicable
NCT04809974,2021.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT04810104,2022.0,OTHER,lead,King's College London,Phase 2
NCT04810104,2022.0,OTHER_GOV,collaborator,Helse Stavanger HF,Phase 2
NCT04810104,2022.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT04810104,2022.0,UNKNOWN,collaborator,Parkinsons Org UK,Phase 2
NCT04810104,2022.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT04810104,2022.0,OTHER,collaborator,Masaryk University,Phase 2
NCT04810104,2022.0,UNKNOWN,collaborator,"Norges Parkinsonforbund, Norway",Phase 2
NCT04810104,2022.0,OTHER,collaborator,University of Exeter,Phase 2
NCT04810104,2022.0,UNKNOWN,collaborator,Stichting Lygature,Phase 2
NCT04810104,2022.0,OTHER,collaborator,Innovative Medicines Initiative,Phase 2
NCT04811014,2021.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 4
NCT04811404,2021.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT04813016,2021.0,OTHER,lead,"National Cancer Institute, Egypt",Phase 2/Phase 3
NCT04813445,2021.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Not Applicable
NCT04813445,2021.0,OTHER,collaborator,Affiliated Hospital of Nantong University,Not Applicable
NCT04813445,2021.0,OTHER,collaborator,Nanjing Brian Hospital,Not Applicable
NCT04813445,2021.0,OTHER,collaborator,Affiliated Hospital of Chengde Medical University,Not Applicable
NCT04814537,2021.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT04815187,2021.0,OTHER,lead,House Ear Institute,Phase 4
NCT04815187,2021.0,OTHER,collaborator,Cures Within Reach,Phase 4
NCT04815967,2021.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT04815967,2021.0,INDUSTRY,collaborator,Solstice Neurosciences,Phase 2/Phase 3
NCT04816500,2019.0,OTHER,lead,Capital Medical University,Not Applicable
NCT04816916,2021.0,INDUSTRY,lead,"Axcella Health, Inc",Phase 2
NCT04817072,2021.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT04817111,2021.0,INDUSTRY,lead,"Metro International Biotech, LLC",Phase 2
NCT04817111,2021.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT04817917,2021.0,OTHER_GOV,lead,Zhejiang Provincial Center for Disease Control and Prevention,Phase 4
NCT04817917,2021.0,INDUSTRY,collaborator,"Liaoning Chengda Biotechnology CO., LTD",Phase 4
NCT04818450,2021.0,OTHER,lead,Mahidol University,Not Applicable
NCT04818515,2021.0,INDUSTRY,lead,AbbVie,Phase 1
NCT04819360,2021.0,OTHER,lead,Brigitte Schürch,Phase 4
NCT04819360,2021.0,OTHER,collaborator,Centre Hospitalier Universitaire Vaudois,Phase 4
NCT04819503,2021.0,OTHER,lead,Oslo University Hospital,Not Applicable
NCT04820309,2021.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT04820361,2022.0,OTHER,lead,"Albina Nowak, MD",Not Applicable
NCT04820361,2022.0,OTHER,collaborator,Swiss National Science Foundation,Not Applicable
NCT04820478,2022.0,OTHER,lead,University of Ulm,Not Applicable
NCT04821271,2021.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT04821271,2021.0,INDUSTRY,collaborator,"Taisho Pharmaceutical Co., Ltd.",Phase 2
NCT04821479,2016.0,OTHER,lead,Hadassah Medical Organization,Phase 1/Phase 2
NCT04821596,2020.0,OTHER,lead,"University Hospital, Rouen",Not Applicable
NCT04821687,2021.0,INDUSTRY,lead,"SK Chemicals Co., Ltd.",Phase 4
NCT04821817,2021.0,OTHER,lead,Tanta University,Not Applicable
NCT04821856,2021.0,OTHER,lead,Murdoch Childrens Research Institute,Phase 2
NCT04821856,2021.0,OTHER,collaborator,Monash University,Phase 2
NCT04821856,2021.0,OTHER,collaborator,University of Sydney,Phase 2
NCT04821856,2021.0,OTHER,collaborator,Deakin University,Phase 2
NCT04822883,2021.0,INDUSTRY,lead,Recognify Life Sciences,Phase 2
NCT04823000,2013.0,OTHER,lead,Hadassah Medical Organization,Phase 1/Phase 2
NCT04823052,2022.0,INDUSTRY,lead,Healx Limited,Phase 2
NCT04824144,2023.0,OTHER,lead,Bruyere Research Institute,Phase 1/Phase 2
NCT04824144,2023.0,OTHER,collaborator,The Ottawa Hospital,Phase 1/Phase 2
NCT04824144,2023.0,UNKNOWN,collaborator,Bruyère Continuing Care,Phase 1/Phase 2
NCT04824144,2023.0,OTHER,collaborator,Foothills Medical Centre,Phase 1/Phase 2
NCT04824911,2021.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT04825678,2021.0,INDUSTRY,lead,Amgen,Phase 4
NCT04825847,2021.0,OTHER,lead,Ciusss de L'Est de l'Île de Montréal,Not Applicable
NCT04825847,2021.0,INDUSTRY,collaborator,Medtronic,Not Applicable
NCT04825860,2021.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 2/Phase 3
NCT04826510,2020.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT04826692,2021.0,OTHER,lead,Instituto de Investigacion Sanitaria La Fe,Phase 3
NCT04827992,2021.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT04827992,2021.0,OTHER,collaborator,Cambridge Health Alliance,Not Applicable
NCT04827992,2021.0,OTHER,collaborator,MaineHealth,Not Applicable
NCT04828226,2021.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Phase 4
NCT04828226,2021.0,OTHER,collaborator,University of Bern,Phase 4
NCT04829760,2021.0,OTHER,lead,University of Florida,Not Applicable
NCT04829838,2019.0,OTHER,lead,ayesha tariq,Phase 4
NCT04829838,2019.0,OTHER,collaborator,King Edward Medical University,Phase 4
NCT04833218,2020.0,OTHER,lead,Minia University,Early Phase 1
NCT04833322,2021.0,OTHER,lead,Hospital Ruber Internacional,Not Applicable
NCT04833777,2021.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT04833777,2021.0,OTHER,collaborator,Saskatoon City Hospital,Not Applicable
NCT04833907,2021.0,INDUSTRY,lead,Myrtelle Inc.,Phase 1/Phase 2
NCT04834362,2021.0,OTHER_GOV,lead,"National Institute of Neurosciences and Hospital, Dhaka",Phase 4
NCT04834388,2022.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT04834388,2022.0,OTHER,collaborator,Dutch Heart Foundation,Phase 2
NCT04834427,2021.0,OTHER,lead,Chinese PLA General Hospital,Phase 4
NCT04834427,2021.0,OTHER,collaborator,"Southern Medical University, China",Phase 4
NCT04834427,2021.0,OTHER,collaborator,Beijing Children's Hospital,Phase 4
NCT04834427,2021.0,OTHER,collaborator,Shanghai Children's Medical Center,Phase 4
NCT04834427,2021.0,OTHER_GOV,collaborator,Hunan Children's Hospital,Phase 4
NCT04836533,2023.0,OTHER,lead,"Queens College, The City University of New York",Phase 1
NCT04836533,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT04836533,2023.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 1
NCT04837040,2021.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 3
NCT04838301,2023.0,OTHER,lead,University of Arizona,Phase 2
NCT04838301,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04838301,2023.0,OTHER,collaborator,Syneos Health,Phase 2
NCT04838301,2023.0,UNKNOWN,collaborator,"ADM Diagnostics, Inc.",Phase 2
NCT04838301,2023.0,OTHER,collaborator,University of Southern California,Phase 2
NCT04839926,2021.0,INDUSTRY,lead,"Jiangsu Nhwa Pharmaceutical Co., Ltd.",Phase 1
NCT04840667,2021.0,INDUSTRY,lead,Shire,Phase 3
NCT04840823,2021.0,OTHER,lead,McGill University,Phase 1/Phase 2
NCT04840823,2021.0,OTHER,collaborator,Weizmann Institute of Science,Phase 1/Phase 2
NCT04840823,2021.0,INDUSTRY,collaborator,Apotex Inc.,Phase 1/Phase 2
NCT04840979,2021.0,OTHER,lead,Columbia University,Phase 2
NCT04840979,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04841564,2021.0,OTHER,lead,Mansoura University,Not Applicable
NCT04841720,2021.0,INDUSTRY,lead,"Haisco Pharmaceutical Group Co., Ltd.",Phase 1
NCT04841720,2021.0,UNKNOWN,collaborator,The Fourth Hospital of Hebei Medical University,Phase 1
NCT04842045,2021.0,OTHER,lead,"University of Wisconsin, Madison",Phase 1
NCT04842552,2021.0,OTHER,lead,Shahid Sadoughi University of Medical Sciences and Health Services,Phase 3
NCT04842552,2021.0,UNKNOWN,collaborator,National Institute for Medical Research Development (NIMAD),Phase 3
NCT04842552,2021.0,OTHER,collaborator,McMaster University,Phase 3
NCT04842812,2021.0,OTHER,lead,Second Affiliated Hospital of Guangzhou Medical University,Phase 1
NCT04842812,2021.0,OTHER,collaborator,Guangdong Zhaotai InVivo Biomedicine Co. Ltd.,Phase 1
NCT04843813,2021.0,OTHER,lead,University of Illinois at Urbana-Champaign,Not Applicable
NCT04843813,2021.0,UNKNOWN,collaborator,"Division of Nutritional Sciences, University of Illinois at Urbana-Champaign",Not Applicable
NCT04843813,2021.0,UNKNOWN,collaborator,National Institutes of Health Rehabilitation Research Resource to Enhance Clinical Trials (REACT),Not Applicable
NCT04844034,2022.0,OTHER,lead,University of Roehampton,Not Applicable
NCT04844164,2019.0,OTHER_GOV,lead,"Endocrinology Research Centre, Moscow",Phase 1
NCT04844164,2019.0,OTHER,collaborator,Russian Science Foundation,Phase 1
NCT04844489,2021.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT04845178,2021.0,INDUSTRY,lead,"AEON Biopharma, Inc.",Phase 2
NCT04845178,2021.0,INDUSTRY,collaborator,PPD,Phase 2
NCT04845282,2021.0,OTHER,lead,Wake Forest University,Not Applicable
NCT04845737,2021.0,OTHER,lead,Abant Izzet Baysal University,Not Applicable
NCT04845776,2021.0,OTHER,lead,Arizona State University,Not Applicable
NCT04845776,2021.0,OTHER,collaborator,Southwest College of Naturopathic Medicine,Not Applicable
NCT04846036,2021.0,INDUSTRY,lead,Khondrion BV,Phase 2
NCT04846036,2021.0,INDUSTRY,collaborator,Julius Clinical,Phase 2
NCT04846036,2021.0,UNKNOWN,collaborator,ProPharma Group,Phase 2
NCT04846036,2021.0,UNKNOWN,collaborator,Europees Fonds voor Regionale Ontwikkeling (EFRO),Phase 2
NCT04846036,2021.0,UNKNOWN,collaborator,Ardena,Phase 2
NCT04846036,2021.0,INDUSTRY,collaborator,Certara,Phase 2
NCT04846335,2011.0,OTHER,lead,Mario Negri Institute for Pharmacological Research,Phase 2
NCT04846335,2011.0,OTHER,collaborator,Fondazione Telethon,Phase 2
NCT04846868,2021.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT04846881,2021.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT04847921,2021.0,OTHER,lead,"University of Colorado, Denver",Phase 2/Phase 3
NCT04848324,2018.0,OTHER,lead,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital,Not Applicable
NCT04849026,2021.0,INDUSTRY,lead,Whanin Pharmaceutical Company,Phase 1
NCT04849741,2021.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 3
NCT04850664,2021.0,INDUSTRY,lead,Evon Medics LLC,Phase 2
NCT04850664,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT04850664,2021.0,OTHER,collaborator,Howard University,Phase 2
NCT04850664,2021.0,UNKNOWN,collaborator,"Family and Medical Counseling Service, Inc",Phase 2
NCT04850664,2021.0,UNKNOWN,collaborator,Maryland Treatment Centers @ ARTC,Phase 2
NCT04850664,2021.0,UNKNOWN,collaborator,"Clinics of Dr. Edwin Chapman, MD, PC @ MHDG",Phase 2
NCT04850703,2021.0,OTHER,lead,Moises Domingo,Phase 1/Phase 2
NCT04850703,2021.0,UNKNOWN,collaborator,Dr. Alejandro Molina Cabeza,Phase 1/Phase 2
NCT04850703,2021.0,UNKNOWN,collaborator,Susana Ferrandis Martinez,Phase 1/Phase 2
NCT04850911,2021.0,OTHER,lead,University of Oxford,Not Applicable
NCT04850911,2021.0,OTHER_GOV,collaborator,Medical Research Council,Not Applicable
NCT04850911,2021.0,INDUSTRY,collaborator,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Not Applicable
NCT04850937,2021.0,OTHER,lead,Yangzhou University,Not Applicable
NCT04851392,2019.0,OTHER,lead,"University College, London",Not Applicable
NCT04851392,2019.0,OTHER_GOV,collaborator,Medical Research Council,Not Applicable
NCT04851392,2019.0,OTHER,collaborator,Invicro,Not Applicable
NCT04851691,2021.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT04851691,2021.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT04851873,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT04852484,2021.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT04852484,2021.0,OTHER,collaborator,KAT General Hospital,Not Applicable
NCT04853797,2021.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04853836,2020.0,OTHER,lead,University Of Perugia,Phase 4
NCT04853836,2020.0,UNKNOWN,collaborator,"Azienda Ospedaliera Ospedali Riuniti Marche Nord, Italy",Phase 4
NCT04853836,2020.0,OTHER,collaborator,Federico II University,Phase 4
NCT04853836,2020.0,OTHER,collaborator,"Humanitas Hospital, Italy",Phase 4
NCT04853836,2020.0,OTHER,collaborator,San Giovanni Addolorata Hospital,Phase 4
NCT04853836,2020.0,OTHER,collaborator,"Policlinico Universitario, Catania",Phase 4
NCT04853836,2020.0,OTHER,collaborator,Azienda Ospedaliero-Universitaria Careggi,Phase 4
NCT04853836,2020.0,OTHER,collaborator,Azienda Ospedaliero Universitaria di Sassari,Phase 4
NCT04853836,2020.0,OTHER,collaborator,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Phase 4
NCT04853836,2020.0,UNKNOWN,collaborator,"Ospedale Universitario di Genova, Italy",Phase 4
NCT04853836,2020.0,UNKNOWN,collaborator,Istituto per la Sicurezza Sociale (ISS) della Repubblica di San Marino,Phase 4
NCT04853836,2020.0,UNKNOWN,collaborator,"Ospedale Bufalini di Cesena, Italy",Phase 4
NCT04854395,2021.0,OTHER,lead,Regionshospitalet Silkeborg,Phase 4
NCT04854811,2021.0,OTHER,lead,Maastricht University,Phase 2
NCT04854811,2021.0,OTHER,collaborator,Netherlands Brain Foundation,Phase 2
NCT04855045,2021.0,INDUSTRY,lead,ProQR Therapeutics,Phase 2/Phase 3
NCT04855266,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT04855526,2022.0,OTHER,lead,Hartford Hospital,Early Phase 1
NCT04855526,2022.0,OTHER,collaborator,Yale University,Early Phase 1
NCT04855747,2021.0,INDUSTRY,lead,"Relmada Therapeutics, Inc.",Phase 3
NCT04857307,2021.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04857359,2021.0,INDUSTRY,lead,Addex Pharma S.A.,Phase 2/Phase 3
NCT04857632,2021.0,OTHER,lead,Capital Medical University,Phase 2/Phase 3
NCT04857671,2022.0,OTHER,lead,Helse Nord-Trøndelag HF,Phase 3
NCT04857671,2022.0,OTHER,collaborator,Norwegian University of Science and Technology,Phase 3
NCT04857671,2022.0,UNKNOWN,collaborator,Sandvika Nevrosenter,Phase 3
NCT04857983,2021.0,OTHER,lead,"University of California, San Diego",Phase 2/Phase 3
NCT04858074,2022.0,OTHER,lead,University of Ibadan,Phase 1/Phase 2
NCT04858139,2021.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 2
NCT04858711,2021.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT04858841,2020.0,OTHER,lead,National Cheng Kung University,Not Applicable
NCT04858841,2020.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Not Applicable
NCT04858841,2020.0,OTHER,collaborator,National Cheng-Kung University Hospital,Not Applicable
NCT04859062,2021.0,OTHER,lead,"Research Institute of Ophthalmology, Egypt",Not Applicable
NCT04859296,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT04859296,2023.0,OTHER,collaborator,Center for Medicinal Cannabis Research,Phase 1
NCT04859374,2021.0,OTHER,lead,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Not Applicable
NCT04860635,2024.0,INDUSTRY,lead,Arthritis Innovation Corporation,Phase 2/Phase 3
NCT04860830,2021.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT04861051,2021.0,OTHER,lead,Stanford University,Phase 1
NCT04861857,2021.0,OTHER,lead,University of Padova,Not Applicable
NCT04862221,2022.0,NIH,lead,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2
NCT04862221,2022.0,OTHER,collaborator,Ann & Robert H Lurie Children's Hospital of Chicago,Phase 2
NCT04863339,2022.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT04863794,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT04865562,2015.0,OTHER,lead,University of Texas at Austin,Phase 4
NCT04865835,2021.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT04866407,2021.0,OTHER,lead,"Rutgers, The State University of New Jersey",Not Applicable
NCT04867551,2021.0,INDUSTRY,lead,"Kissei Pharmaceutical Co., Ltd.",Phase 2
NCT04867616,2021.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 2
NCT04867642,2021.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 1
NCT04868253,2021.0,INDUSTRY,lead,"Rose Research Center, LLC",Phase 2/Phase 3
NCT04868253,2021.0,OTHER,collaborator,Foundation for a Smoke Free World INC,Phase 2/Phase 3
NCT04868253,2021.0,INDUSTRY,collaborator,"Embera NeuroTherapeutics, Inc.",Phase 2/Phase 3
NCT04869358,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT04870372,2020.0,OTHER,lead,Second Affiliated Hospital of Soochow University,Phase 4
NCT04870866,2019.0,OTHER,lead,"University Hospital, Akershus",Phase 2
NCT04870866,2019.0,OTHER,collaborator,The Bergesen Foundation,Phase 2
NCT04870866,2019.0,OTHER,collaborator,South-Eastern Norway Regional Health Authority,Phase 2
NCT04870866,2019.0,OTHER,collaborator,Sykehuset Innlandet HF,Phase 2
NCT04870866,2019.0,OTHER,collaborator,Oslo University Hospital,Phase 2
NCT04870866,2019.0,OTHER,collaborator,St. Olavs Hospital,Phase 2
NCT04870866,2019.0,OTHER,collaborator,Haukeland University Hospital,Phase 2
NCT04870866,2019.0,OTHER,collaborator,University Hospital of North Norway,Phase 2
NCT04870866,2019.0,OTHER,collaborator,University of Bergen,Phase 2
NCT04871074,2018.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT04871074,2018.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04871464,2021.0,OTHER,lead,Beijing Friendship Hospital,Phase 4
NCT04872374,2021.0,OTHER,lead,University of Padova,Not Applicable
NCT04872387,2021.0,INDUSTRY,lead,Bayer,Phase 1
NCT04873115,2021.0,INDUSTRY,lead,Proveca Pharma Limited,Phase 4
NCT04873297,2021.0,OTHER,lead,Shaheed Zulfiqar Ali Bhutto Medical University,Phase 4
NCT04873752,2021.0,INDUSTRY,lead,"Rohto Pharmaceutical Co., Ltd.",Phase 1/Phase 2
NCT04874350,2021.0,INDUSTRY,lead,Lipocine Inc.,Phase 2
NCT04874545,2021.0,OTHER,lead,Beni-Suef University,Phase 4
NCT04875039,2021.0,OTHER,lead,University of Chile,Phase 4
NCT04875364,2020.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT04875949,2016.0,OTHER,lead,Istituto Clinico Humanitas,Not Applicable
NCT04875949,2016.0,OTHER,collaborator,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Not Applicable
NCT04875949,2016.0,OTHER,collaborator,Fondazione Salvatore Maugeri,Not Applicable
NCT04875962,2019.0,INDUSTRY,lead,UCB Biopharma S.P.R.L.,Phase 1
NCT04876326,2020.0,OTHER,lead,Indonesia University,Not Applicable
NCT04876638,2019.0,OTHER,lead,University of Southern California,Phase 2
NCT04876937,2021.0,OTHER,lead,Peking University First Hospital,Not Applicable
NCT04876937,2021.0,OTHER,collaborator,China-Japan Friendship Hospital,Not Applicable
NCT04876937,2021.0,OTHER_GOV,collaborator,Beijing Hospital,Not Applicable
NCT04876937,2021.0,OTHER,collaborator,Beijing Friendship Hospital,Not Applicable
NCT04876937,2021.0,OTHER,collaborator,"Beijing Shijitan Hospital, Capital Medical University",Not Applicable
NCT04876937,2021.0,OTHER,collaborator,Beijing Tongren Hospital,Not Applicable
NCT04877093,2023.0,OTHER,lead,Aurora Health Care,Phase 3
NCT04877457,2022.0,OTHER,lead,Yale University,Phase 4
NCT04877457,2022.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT04878198,2022.0,OTHER,lead,Education University of Hong Kong,Not Applicable
NCT04878198,2022.0,OTHER,collaborator,Chinese University of Hong Kong,Not Applicable
NCT04878198,2022.0,OTHER_GOV,collaborator,Castle Peak Hospital,Not Applicable
NCT04878198,2022.0,OTHER,collaborator,University of Leicester,Not Applicable
NCT04878198,2022.0,OTHER,collaborator,United Christian Hospital,Not Applicable
NCT04878627,2022.0,OTHER,lead,"University of California, San Diego",Early Phase 1
NCT04879004,2021.0,OTHER,lead,Democritus University of Thrace,Not Applicable
NCT04879004,2021.0,OTHER,collaborator,Aristotle University Of Thessaloniki,Not Applicable
NCT04879134,2022.0,OTHER,lead,University of Calgary,Phase 2/Phase 3
NCT04879134,2022.0,OTHER,collaborator,Paladin Labs Inc.,Phase 2/Phase 3
NCT04879277,2021.0,OTHER,lead,"University Hospital, Tours",Not Applicable
NCT04879615,2021.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 3
NCT04879615,2021.0,OTHER,collaborator,Shaoxing People's Hospital,Phase 3
NCT04879615,2021.0,OTHER,collaborator,Affiliated Hospital of Jiaxing University,Phase 3
NCT04879615,2021.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Phase 3
NCT04879615,2021.0,OTHER,collaborator,The Second Affiliated Hospital of Jiaxing University,Phase 3
NCT04879615,2021.0,UNKNOWN,collaborator,Zhoushan People's Hospital,Phase 3
NCT04879615,2021.0,UNKNOWN,collaborator,"Fourth Affiliated Hospital of Zhejiang University, School of Medicine",Phase 3
NCT04879615,2021.0,OTHER,collaborator,Lishui Country People's Hospital,Phase 3
NCT04879628,2021.0,INDUSTRY,lead,Sanofi,Phase 2
NCT04879823,2021.0,OTHER,lead,"David Chi, MD",Phase 3
NCT04880278,2022.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT04880278,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT04880577,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT04880577,2022.0,INDUSTRY,collaborator,Gilead Sciences,Phase 2
NCT04880616,2021.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT04881318,2021.0,OTHER,lead,University of Calgary,Not Applicable
NCT04881435,2020.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT04881682,2023.0,OTHER,lead,University of Ulm,Phase 2
NCT04881682,2023.0,INDUSTRY,collaborator,Miltenyi Biomedicine GmbH,Phase 2
NCT04884503,2019.0,OTHER,lead,Wroclaw Medical University,Phase 2
NCT04884815,2021.0,INDUSTRY,lead,Ultragenyx Pharmaceutical Inc,Phase 1/Phase 2
NCT04885075,2021.0,OTHER,lead,Shaheed Zulfiqar Ali Bhutto Medical University,Phase 4
NCT04885101,2021.0,OTHER,lead,Centro de Atenção ao Assoalho Pélvico,Not Applicable
NCT04885101,2021.0,INDUSTRY,collaborator,Indústria Brasileira Equipamentos Médicos - IBRAMED,Not Applicable
NCT04885114,2021.0,INDUSTRY,lead,Voyager Therapeutics,Phase 1
NCT04885257,2022.0,FED,lead,VA Office of Research and Development,Phase 2
NCT04885829,2021.0,OTHER,lead,Syneos Health,Phase 1
NCT04885829,2021.0,INDUSTRY,collaborator,Dr. Reddy's Laboratories Limited,Phase 1
NCT04886063,2021.0,INDUSTRY,lead,Athira Pharma,Phase 2/Phase 3
NCT04886518,2021.0,INDUSTRY,lead,"Harmony Biosciences, LLC",Phase 2
NCT04887311,2021.0,INDUSTRY,lead,"Matrix Biomed, Inc.",Phase 2
NCT04887311,2021.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT04887467,2021.0,OTHER,lead,Rennes University Hospital,Phase 4
NCT04887792,2022.0,OTHER,lead,"Vishwajit Nimgaonkar, MD PhD",Phase 1/Phase 2
NCT04887792,2022.0,OTHER,collaborator,Stanley Medical Research Institute,Phase 1/Phase 2
NCT04888221,2021.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT04888221,2021.0,INDUSTRY,collaborator,Roche Chugai,Phase 3
NCT04888221,2021.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 3
NCT04888858,2020.0,OTHER,lead,Henry Ford Health System,Phase 4
NCT04889664,2021.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT04890379,2021.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 2
NCT04891211,2021.0,OTHER,lead,Adiyaman University,Not Applicable
NCT04892199,2021.0,OTHER,lead,"Anders Fink-Jensen, MD, DMSci",Phase 4
NCT04893746,2020.0,OTHER,lead,National Taiwan Sport University,Not Applicable
NCT04893746,2020.0,INDUSTRY,collaborator,Synbio Tech Inc.,Not Applicable
NCT04894240,2022.0,INDUSTRY,lead,PharmAust Ltd,Phase 1
NCT04894240,2022.0,UNKNOWN,collaborator,FightMND,Phase 1
NCT04894240,2022.0,UNKNOWN,collaborator,Calvary Health Care Bethlehem,Phase 1
NCT04894240,2022.0,OTHER,collaborator,"Macquarie University, Australia",Phase 1
NCT04897750,2021.0,INDUSTRY,lead,Cessatech A/S,Phase 2
NCT04897802,2021.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 4
NCT04897802,2021.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 4
NCT04898270,2019.0,OTHER,lead,Taichung Veterans General Hospital,Phase 4
NCT04898712,2021.0,OTHER,lead,Unity Health Toronto,Phase 2
NCT04898712,2021.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 2
NCT04898829,2022.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT04899115,2021.0,OTHER,lead,Patricia Bloom,Phase 2
NCT04899115,2021.0,INDUSTRY,collaborator,"Vedanta Biosciences, Inc.",Phase 2
NCT04899115,2021.0,OTHER,collaborator,American College of Gastroenterology,Phase 2
NCT04899115,2021.0,OTHER,collaborator,American Association for the Study of Liver Diseases,Phase 2
NCT04899687,2022.0,OTHER,lead,Stanford University,Phase 2
NCT04899687,2022.0,UNKNOWN,collaborator,Avy L. & Roberta L. Miller Foundation,Phase 2
NCT04899908,2021.0,OTHER,lead,Dana-Farber Cancer Institute,Phase 2
NCT04899908,2021.0,OTHER,collaborator,NH TherAguix SAS,Phase 2
NCT04901208,2020.0,OTHER,lead,Yale University,Not Applicable
NCT04901208,2020.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Not Applicable
NCT04901208,2020.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT04901871,2021.0,OTHER,lead,Gangnam Severance Hospital,Phase 3
NCT04902235,2021.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 4
NCT04902235,2021.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 4
NCT04902703,2022.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT04902703,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT04902703,2022.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT04902703,2022.0,INDUSTRY,collaborator,"Partner Therapeutics, Inc.",Phase 2
NCT04903314,2021.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 1
NCT04903353,2022.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT04904341,2021.0,OTHER,lead,Military Institute od Medicine National Research Institute,Phase 3
NCT04904341,2021.0,INDUSTRY,collaborator,Brainomix Limited,Phase 3
NCT04905654,2021.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04905979,2021.0,INDUSTRY,lead,Apnimed,Phase 2
NCT04906460,2021.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT04906590,2021.0,OTHER,lead,Michael J. Fox Foundation for Parkinson's Research,Phase 2
NCT04906590,2021.0,OTHER,collaborator,Institute for Neurodegenerative Disorders,Phase 2
NCT04906655,2020.0,OTHER,lead,"Pariser, Robert J., M.D.",Phase 2
NCT04906655,2020.0,OTHER,collaborator,"Virginia Clinical Research, Inc.",Phase 2
NCT04907825,2023.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 4
NCT04907825,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT04908423,2021.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT04908423,2021.0,INDUSTRY,collaborator,Merz Pharmaceuticals GmbH,Phase 4
NCT04910477,2021.0,OTHER,lead,Assiut University,Phase 3
NCT04910776,2021.0,INDUSTRY,lead,Sanofi,Phase 3
NCT04912115,2021.0,INDUSTRY,lead,PharmaTher Inc.,Phase 2
NCT04912752,2020.0,OTHER,lead,University of Gaziantep,Not Applicable
NCT04912856,2021.0,INDUSTRY,lead,Xenon Pharmaceuticals Inc.,Phase 3
NCT04913831,2021.0,OTHER,lead,Yonsei University,Phase 4
NCT04915183,2024.0,NIH,lead,National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 3
NCT04915729,2021.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT04916548,2021.0,OTHER,lead,Rebecca Price,Phase 1/Phase 2
NCT04917185,2021.0,OTHER,lead,Chengdu University of Traditional Chinese Medicine,Not Applicable
NCT04917211,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT04917302,2020.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT04917302,2020.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Phase 2
NCT04917458,2021.0,OTHER,lead,Indonesia University,Phase 2
NCT04920682,2021.0,OTHER,lead,Pontificia Universidade Catolica de Sao Paulo,Phase 4
NCT04920786,2021.0,INDUSTRY,lead,"TrueBinding, Inc.",Phase 1
NCT04921007,2021.0,OTHER,lead,Sameh Fathy,Not Applicable
NCT04921046,2015.0,OTHER,lead,Rawalpindi Medical College,Phase 4
NCT04921384,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT04921930,2022.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1/Phase 2
NCT04921930,2022.0,OTHER,collaborator,Imagine Institute,Phase 1/Phase 2
NCT04921982,2023.0,OTHER,lead,Rennes University Hospital,Phase 2
NCT04922593,2021.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT04923594,2021.0,INDUSTRY,lead,NLS Pharmaceutics,Phase 2
NCT04924036,2021.0,OTHER,lead,University of Utah,Phase 2
NCT04924166,2021.0,OTHER,lead,Rachel Yehuda,Phase 2
NCT04924166,2021.0,FED,collaborator,James J. Peters Veterans Affairs Medical Center,Phase 2
NCT04924166,2021.0,OTHER,collaborator,The Chaim Sheba Medical Center,Phase 2
NCT04924608,2021.0,INDUSTRY,lead,AstraZeneca,Phase 3
NCT04924608,2021.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 3
NCT04925414,2023.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 4
NCT04925440,2021.0,INDUSTRY,lead,PrecisionBiotics Group Ltd.,Not Applicable
NCT04925440,2021.0,INDUSTRY,collaborator,Atlantia Food Clinical Trials,Not Applicable
NCT04925882,2022.0,OTHER,lead,"Clinique Saint Jean, France",Not Applicable
NCT04926259,2021.0,OTHER,lead,First Affiliated Hospital of Fujian Medical University,Early Phase 1
NCT04926272,2021.0,OTHER,lead,First Affiliated Hospital of Fujian Medical University,Phase 2
NCT04926844,2021.0,OTHER,lead,Sohag University,Phase 2
NCT04927208,2021.0,OTHER,lead,Chungnam National University Hospital,Not Applicable
NCT04927741,2021.0,OTHER,lead,Aurora Health Care,Not Applicable
NCT04928287,2021.0,OTHER,lead,Hope Biosciences Stem Cell Research Foundation,Phase 2
NCT04928287,2021.0,INDUSTRY,collaborator,Hope Biosciences,Phase 2
NCT04930887,2023.0,OTHER,lead,Stanford University,Phase 2
NCT04931433,2020.0,OTHER,lead,University of Malaya,Phase 4
NCT04931459,2021.0,INDUSTRY,lead,Acumen Pharmaceuticals,Phase 1
NCT04931459,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT04931628,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04931628,2023.0,OTHER,collaborator,First Affiliated Hospital of Wenzhou Medical University,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Second Affiliated Hospital of Wenzhou Medical University,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Zhejiang University,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Ningbo No. 1 Hospital,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Zhejiang Hospital,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Zhejiang Provincial Tongde Hospital,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,The First Affiliated Hospital of Zhejiang Chinese Medical University,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,Xiaoshan People's Hospital,Not Applicable
NCT04931628,2023.0,OTHER,collaborator,"Red Cross Hospital, Hangzhou, China",Not Applicable
NCT04932096,2023.0,OTHER,lead,Oregon Health and Science University,Phase 2
NCT04932096,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT04932291,2021.0,INDUSTRY,lead,Oryzon Genomics S.A.,Phase 2
NCT04932434,2021.0,OTHER,lead,"Joshua Woolley, MD/PhD",Phase 2
NCT04933916,2021.0,INDUSTRY,lead,"Embera NeuroTherapeutics, Inc.",Phase 1/Phase 2
NCT04933916,2021.0,OTHER,collaborator,Foundation for a Smoke Free World INC,Phase 1/Phase 2
NCT04933916,2021.0,INDUSTRY,collaborator,"Rose Research Center, LLC",Phase 1/Phase 2
NCT04933916,2021.0,UNKNOWN,collaborator,Segal Trials,Phase 1/Phase 2
NCT04935671,2020.0,OTHER,lead,Dr Saara (Ahmad) Muddasir Khan,Not Applicable
NCT04935671,2020.0,OTHER,collaborator,University of Karachi,Not Applicable
NCT04935788,2021.0,OTHER,lead,Wageningen University,Not Applicable
NCT04935788,2021.0,OTHER,collaborator,NIZO Food Research,Not Applicable
NCT04935788,2021.0,INDUSTRY,collaborator,Ingredia S.A.,Not Applicable
NCT04935931,2021.0,OTHER,lead,Children's Mercy Hospital Kansas City,Early Phase 1
NCT04935931,2021.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Early Phase 1
NCT04935931,2021.0,OTHER,collaborator,University of Kansas Medical Center,Early Phase 1
NCT04937452,2021.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 2
NCT04937452,2021.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT04937530,2021.0,INDUSTRY,lead,"Retrotope, Inc.",Phase 2
NCT04938713,2021.0,OTHER,lead,Centre Hospitalier Universitaire de Charleroi,Not Applicable
NCT04938713,2021.0,OTHER,collaborator,Centre Hospitalier Universitaire de Liege,Not Applicable
NCT04939623,2023.0,OTHER,lead,University of Calgary,Phase 2
NCT04939649,2021.0,OTHER,lead,"University of Dublin, Trinity College",Phase 3
NCT04939675,2021.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT04939974,2021.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Not Applicable
NCT04940039,2021.0,INDUSTRY,lead,Janssen-Cilag International NV,Phase 4
NCT04940143,2020.0,OTHER,lead,Marmara University,Not Applicable
NCT04940390,2021.0,INDUSTRY,lead,"Satsuma Pharmaceuticals, Inc.",Phase 3
NCT04940572,2021.0,OTHER,lead,Centre d'Etude des Cellules Souches,Phase 2
NCT04940572,2021.0,OTHER,collaborator,Genethon,Phase 2
NCT04941040,2021.0,OTHER,lead,Kasr El Aini Hospital,Phase 1
NCT04941508,2021.0,OTHER,lead,Assiut University,Phase 3
NCT04941781,2021.0,INDUSTRY,lead,Contineum Therapeutics,Phase 1
NCT04942002,2021.0,OTHER,lead,Asociación para Evitar la Ceguera en México,Phase 2/Phase 3
NCT04942522,2021.0,OTHER,lead,Yan Hao,Phase 1
NCT04943068,2021.0,INDUSTRY,lead,"Kwang Dong Pharmaceutical co., ltd.",Phase 3
NCT04944017,2021.0,OTHER,lead,Yale University,Phase 2
NCT04944017,2021.0,UNKNOWN,collaborator,Fox (Michael J.) Foundation for Parkinson's Research,Phase 2
NCT04944641,2013.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04944641,2013.0,OTHER_GOV,collaborator,Hangzhou Center of Disease Control and Prevention,Not Applicable
NCT04944641,2013.0,OTHER,collaborator,The Central Hospital of Lishui City,Not Applicable
NCT04944641,2013.0,OTHER,collaborator,The Second Affiliated Hospital of Jiaxing University,Not Applicable
NCT04944641,2013.0,UNKNOWN,collaborator,Shengzhou People's Hospital,Not Applicable
NCT04944641,2013.0,UNKNOWN,collaborator,Children's Hospital Affiliated to Zhejiang University School of Medicine,Not Applicable
NCT04944784,2021.0,INDUSTRY,lead,Cytokinetics,Phase 3
NCT04946669,2021.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Early Phase 1
NCT04946669,2021.0,OTHER_GOV,collaborator,National Natural Science Foundation of China,Early Phase 1
NCT04946734,2021.0,OTHER,lead,Guangdong Provincial People's Hospital,Phase 3
NCT04946825,2021.0,OTHER,lead,University of Vermont,Phase 2
NCT04946981,2021.0,INDUSTRY,lead,Givaudan France Naturals,Not Applicable
NCT04946981,2021.0,INDUSTRY,collaborator,Atlantia Food Clinical Trials,Not Applicable
NCT04947345,2021.0,OTHER,lead,Peking Union Medical College Hospital,Phase 3
NCT04947345,2021.0,INDUSTRY,collaborator,"Yichang Humanwell Pharmaceutical Co., Ltd., China",Phase 3
NCT04947488,2021.0,OTHER,lead,University of Milan,Not Applicable
NCT04947553,2021.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT04947761,2021.0,OTHER,lead,Chinese PLA General Hospital,Phase 4
NCT04948138,2021.0,OTHER,lead,Jesús González de la Aleja Tejera,Not Applicable
NCT04948645,2021.0,INDUSTRY,lead,Calico Life Sciences LLC,Phase 1
NCT04948645,2021.0,INDUSTRY,collaborator,AbbVie,Phase 1
NCT04948749,2021.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT04948814,2022.0,OTHER,lead,Tongji Hospital,Phase 1
NCT04949607,2021.0,INDUSTRY,lead,Centre for Neuro Skills,Not Applicable
NCT04949607,2021.0,OTHER,collaborator,University of Texas,Not Applicable
NCT04950413,2021.0,OTHER,lead,Nada Gamal Saad,Not Applicable
NCT04950426,2021.0,OTHER,lead,Centre Hospitalier Henri Laborit,Phase 2
NCT04950621,2021.0,OTHER,lead,"Air Force Military Medical University, China",Not Applicable
NCT04950647,2020.0,OTHER,lead,Peking University Third Hospital,Phase 2
NCT04950647,2020.0,OTHER,collaborator,West China Hospital,Phase 2
NCT04950920,2021.0,OTHER,lead,Peking University Third Hospital,Phase 3
NCT04950933,2020.0,OTHER,lead,Peking University Third Hospital,Phase 2/Phase 3
NCT04950933,2020.0,OTHER,collaborator,The Second Hospital of Hebei Medical University,Phase 2/Phase 3
NCT04951076,2021.0,INDUSTRY,lead,Bionomics Limited,Phase 2
NCT04951362,2021.0,OTHER,lead,South Valley University,Phase 2/Phase 3
NCT04951622,2021.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT04951843,2018.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT04951843,2018.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Not Applicable
NCT04951843,2018.0,OTHER,collaborator,Taipei Medical University,Not Applicable
NCT04952155,2020.0,OTHER,lead,Peking University Third Hospital,Phase 2
NCT04952194,2022.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 4
NCT04952766,2021.0,OTHER,lead,Centre Hospitalier Régional d'Orléans,Phase 4
NCT04953663,2021.0,OTHER,lead,Peking University Third Hospital,Phase 1/Phase 2
NCT04954001,2021.0,INDUSTRY,lead,Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,Phase 1/Phase 2
NCT04954534,2021.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT04954534,2021.0,INDUSTRY,collaborator,Medipost Co Ltd.,Not Applicable
NCT04955236,2021.0,OTHER,lead,Kasr El Aini Hospital,Phase 1
NCT04955249,2021.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT04956289,2021.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 2
NCT04956289,2021.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 2
NCT04956705,2021.0,OTHER,lead,University College Copenhagen,Not Applicable
NCT04956705,2021.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT04956744,2021.0,INDUSTRY,lead,ImStem Biotechnology,Phase 1
NCT04956744,2021.0,INDUSTRY,collaborator,"Rho, Inc.",Phase 1
NCT04958512,2017.0,OTHER,lead,Peking University Third Hospital,Not Applicable
NCT04958512,2017.0,OTHER_GOV,collaborator,Beijing Hospital,Not Applicable
NCT04958642,2015.0,INDUSTRY,lead,Mandos LLC,Phase 2/Phase 3
NCT04959032,2021.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT04959201,2020.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT04959201,2020.0,OTHER_GOV,collaborator,"Ministry of Science and Technology, Taiwan",Phase 2
NCT04960657,2020.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT04961190,2022.0,OTHER,lead,University of Pennsylvania,Phase 4
NCT04961190,2022.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT04961190,2022.0,FED,collaborator,Corporal Michael J. Crescenz VA Medical Center,Phase 4
NCT04961190,2022.0,UNKNOWN,collaborator,Coatesville VA Medical Center,Phase 4
NCT04961190,2022.0,FED,collaborator,Milwaukee VA Medical Center,Phase 4
NCT04961190,2022.0,FED,collaborator,North Texas Veterans Healthcare System,Phase 4
NCT04961190,2022.0,FED,collaborator,San Diego Veterans Healthcare System,Phase 4
NCT04961190,2022.0,FED,collaborator,VA Palo Alto Health Care System,Phase 4
NCT04961281,2021.0,OTHER,lead,Assiut University,Not Applicable
NCT04962451,2017.0,OTHER,lead,Peking University Third Hospital,Phase 4
NCT04962451,2017.0,UNKNOWN,collaborator,"AstraZeneca Investment (China) Co., Ltd",Phase 4
NCT04963855,2021.0,INDUSTRY,lead,"Generian Pharmaceuticals, Inc.",Phase 1
NCT04964414,2021.0,OTHER,lead,Amanda Stapleton,Phase 1/Phase 2
NCT04965987,2021.0,OTHER,lead,University of Kansas Medical Center,Phase 1
NCT04965987,2021.0,INDUSTRY,collaborator,Terra Biological LLC,Phase 1
NCT04966338,2019.0,INDUSTRY,lead,Cinnagen,Phase 3
NCT04966546,2022.0,OTHER,lead,University of New Mexico,Early Phase 1
NCT04966741,2022.0,INDUSTRY,lead,"Rhythm Pharmaceuticals, Inc.",Phase 3
NCT04967326,2016.0,OTHER,lead,Gia Dinh People Hospital,Phase 4
NCT04968613,2018.0,OTHER,lead,Peking University Third Hospital,Phase 4
NCT04968613,2018.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Phase 4
NCT04968938,2022.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT04969133,2021.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Not Applicable
NCT04969198,2021.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT04969198,2021.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT04969497,2021.0,INDUSTRY,lead,Zosano Pharma Corporation,Phase 1
NCT04969523,2021.0,OTHER,lead,Zhongnan Hospital,Not Applicable
NCT04969666,2021.0,INDUSTRY,lead,Initiator Pharma,Phase 2
NCT04969809,2021.0,OTHER,lead,University Medical Centre Ljubljana,Not Applicable
NCT04970355,2021.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT04970667,2018.0,OTHER,lead,Peking University Third Hospital,Phase 4
NCT04971005,2021.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Phase 2
NCT04971005,2021.0,INDUSTRY,collaborator,Neovii Biotech,Phase 2
NCT04971005,2021.0,OTHER,collaborator,Clinical Trial Center North (CTC North GmbH & Co. KG),Phase 2
NCT04971733,2021.0,INDUSTRY,lead,Eisai Inc.,Phase 1/Phase 2
NCT04972123,2021.0,OTHER,lead,"University of Wisconsin, Madison",Phase 2
NCT04972227,2021.0,INDUSTRY,lead,Tisento Therapeutics,Phase 1
NCT04972643,2012.0,OTHER,lead,Taichung Veterans General Hospital,Not Applicable
NCT04972760,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT04973189,2021.0,INDUSTRY,lead,"Shanghai Hengrui Pharmaceutical Co., Ltd.",Phase 1
NCT04973800,2021.0,OTHER,lead,University of Oxford,Not Applicable
NCT04973800,2021.0,OTHER,collaborator,Wellcome Trust,Not Applicable
NCT04974060,2021.0,OTHER,lead,Capital Medical University,Not Applicable
NCT04974359,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04974385,2021.0,OTHER,lead,University of Virginia,Phase 3
NCT04974580,2021.0,OTHER,lead,Ohio State University,Phase 4
NCT04974580,2021.0,OTHER,collaborator,American Heart Association,Phase 4
NCT04974580,2021.0,INDUSTRY,collaborator,"Optum, Inc.",Phase 4
NCT04974606,2016.0,INDUSTRY,lead,PepsiCo Global R&D,Not Applicable
NCT04974749,2022.0,INDUSTRY,lead,Takeda,Phase 3
NCT04975035,2012.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 1/Phase 2
NCT04975802,2021.0,INDUSTRY,lead,PepsiCo Global R&D,Not Applicable
NCT04976127,2021.0,INDUSTRY,lead,InnoMedica Schweiz AG,Phase 1
NCT04976140,2021.0,INDUSTRY,lead,Paean Biotechnology Inc.,Phase 1/Phase 2
NCT04976374,2021.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT04976387,2021.0,OTHER,lead,Loma Linda University,Phase 3
NCT04976959,2021.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 1
NCT04977232,2021.0,OTHER,lead,Central South University,Not Applicable
NCT04977271,2024.0,OTHER,lead,University of Alabama at Birmingham,Phase 4
NCT04977388,2021.0,OTHER,lead,"Stephen G. Kaler, MD",Phase 1/Phase 2
NCT04977544,2019.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT04977986,2021.0,INDUSTRY,lead,"Zynerba Pharmaceuticals, Inc.",Phase 3
NCT04978415,2021.0,OTHER,lead,Abeer Samir Salem,Not Applicable
NCT04978415,2021.0,OTHER,collaborator,"Research Institute of Ophthalmology, Egypt",Not Applicable
NCT04978428,2022.0,OTHER,lead,University of Chicago,Phase 2
NCT04979338,2021.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 3
NCT04979650,2021.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 2
NCT04981067,2021.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT04982211,2021.0,OTHER,lead,Douglas Mental Health University Institute,Phase 2
NCT04982211,2021.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT04982796,2022.0,OTHER,lead,"Portland VA Research Foundation, Inc",Phase 1/Phase 2
NCT04982796,2022.0,OTHER,collaborator,Steven & Alexandra Cohen Foundation,Phase 1/Phase 2
NCT04983290,2021.0,OTHER,lead,Milko Zanini,Not Applicable
NCT04983290,2021.0,OTHER,collaborator,Azienda Sanitaria Locale 3 Genovese,Not Applicable
NCT04983355,2021.0,INDUSTRY,lead,Abyss Ingredients,Not Applicable
NCT04983355,2021.0,NETWORK,collaborator,Daacro,Not Applicable
NCT04983368,2021.0,INDUSTRY,lead,Actinogen Medical,Phase 1/Phase 2
NCT04983368,2021.0,INDUSTRY,collaborator,Avance Clinical Pty Ltd.,Phase 1/Phase 2
NCT04983667,2021.0,OTHER,lead,Instituto Tecnologico y de Estudios Superiores de Monterey,Not Applicable
NCT04984720,2021.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Not Applicable
NCT04984993,2021.0,INDUSTRY,lead,Futura Medical Developments Ltd.,Phase 3
NCT04985305,2021.0,OTHER,lead,University of Copenhagen,Not Applicable
NCT04985305,2021.0,OTHER,collaborator,Velux Fonden,Not Applicable
NCT04985305,2021.0,OTHER,collaborator,Danish College of General Practitioners,Not Applicable
NCT04985305,2021.0,OTHER,collaborator,Region Capital Denmark,Not Applicable
NCT04985344,2023.0,OTHER,lead,"University Hospital, Toulouse",Phase 3
NCT04985877,2021.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT04985877,2021.0,INDUSTRY,collaborator,"Yakult Honsha Co., LTD",Not Applicable
NCT04986072,2022.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 2
NCT04986982,2021.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 4
NCT04986995,2021.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 4
NCT04987229,2021.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT04987372,2019.0,OTHER,lead,"University Hospital, Ghent",Phase 4
NCT04987463,2021.0,OTHER,lead,Katarzyna Kotulska,Phase 2/Phase 3
NCT04988425,2022.0,OTHER,lead,Shanghai Changzheng Hospital,Phase 1/Phase 2
NCT04988425,2022.0,OTHER,collaborator,The First People's Hospital of Kunshan,Phase 1/Phase 2
NCT04988425,2022.0,UNKNOWN,collaborator,"Traditional Chinese Medicine Hospital of Kunshan, China",Phase 1/Phase 2
NCT04988425,2022.0,UNKNOWN,collaborator,"Wuxi 904 Hospital, China",Phase 1/Phase 2
NCT04988425,2022.0,UNKNOWN,collaborator,"The Sixth People's Hospital of Nantong, China",Phase 1/Phase 2
NCT04988425,2022.0,OTHER,collaborator,Zhejiang Provincial Hospital of TCM,Phase 1/Phase 2
NCT04988867,2021.0,INDUSTRY,lead,ACADIA Pharmaceuticals Inc.,Phase 2/Phase 3
NCT04990219,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT04990284,2021.0,INDUSTRY,lead,Bial - Portela C S.A.,Phase 4
NCT04991389,2019.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT04991389,2019.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT04993755,2021.0,INDUSTRY,lead,"Transposon Therapeutics, Inc.",Phase 2
NCT04993768,2021.0,INDUSTRY,lead,"Transposon Therapeutics, Inc.",Phase 2
NCT04994054,2021.0,OTHER,lead,Pusan National University Yangsan Hospital,Not Applicable
NCT04994483,2021.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 3
NCT04994483,2021.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 3
NCT04995081,2021.0,OTHER,lead,Hope Biosciences Stem Cell Research Foundation,Phase 2
NCT04995081,2021.0,INDUSTRY,collaborator,Hope Biosciences,Phase 2
NCT04996199,2021.0,OTHER,lead,Postgraduate Institute of Dental Sciences Rohtak,Phase 4
NCT04997317,2021.0,OTHER,lead,"University Hospital, Basel, Switzerland",Early Phase 1
NCT04997317,2021.0,OTHER,collaborator,Swiss Cancer League,Early Phase 1
NCT04997954,2021.0,OTHER_GOV,lead,Gold Coast Hospital and Health Service,Phase 4
NCT04997954,2021.0,INDUSTRY,collaborator,Bod Australia,Phase 4
NCT04998305,2022.0,OTHER,lead,Hiroshi Mitsumoto,Phase 1/Phase 2
NCT04998305,2022.0,UNKNOWN,collaborator,"Tsumura & Co., Tokyo, Japan",Phase 1/Phase 2
NCT04998396,2021.0,INDUSTRY,lead,Aspa Therapeutics,Phase 1/Phase 2
NCT04998812,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT04998812,2022.0,INDUSTRY,collaborator,PPD,Phase 4
NCT04998812,2022.0,INDUSTRY,collaborator,Laboratory Corporation of America,Phase 4
NCT04998812,2022.0,UNKNOWN,collaborator,Illingworth Research Group,Phase 4
NCT04998851,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT04998851,2021.0,INDUSTRY,collaborator,PPD,Phase 4
NCT04998851,2021.0,INDUSTRY,collaborator,Laboratory Corporation of America,Phase 4
NCT04998851,2021.0,UNKNOWN,collaborator,Illingworth Research Group,Phase 4
NCT04999020,2021.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT04999488,2023.0,OTHER,lead,AdventHealth Translational Research Institute,Early Phase 1
NCT04999618,2020.0,OTHER,lead,"Center for Vascular Pathology, Moscow",Phase 4
NCT04999644,2022.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT04999644,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT05000060,2022.0,OTHER,lead,University of Texas at Austin,Phase 3
NCT05000658,2021.0,OTHER,lead,Nantes University Hospital,Phase 3
NCT05001217,2022.0,OTHER,lead,Hong Kong Baptist University,Phase 2/Phase 3
NCT05001217,2022.0,OTHER,collaborator,Chinese University of Hong Kong,Phase 2/Phase 3
NCT05001750,2021.0,OTHER,lead,Montefiore Medical Center,Phase 1
NCT05002309,2021.0,OTHER,lead,Rudolf Uher,Phase 2
NCT05003102,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT05003388,2021.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05003570,2021.0,OTHER,lead,"Southeast University, China",Phase 3
NCT05003648,2023.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT05003648,2023.0,OTHER,collaborator,European Leukodystrophy Association,Phase 4
NCT05003921,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05004688,2022.0,OTHER,lead,"Steven E Arnold, MD",Phase 2
NCT05004896,2022.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT05004987,2022.0,OTHER,lead,NYU Langone Health,Phase 4
NCT05004987,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT05005819,2021.0,OTHER,lead,Invicro,Phase 1
NCT05005845,2021.0,INDUSTRY,lead,"NFlection Therapeutics, Inc.",Phase 2
NCT05006352,2021.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 1
NCT05006599,2025.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT05006781,2025.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT05007483,2022.0,OTHER,lead,Terry L. Wahls,Not Applicable
NCT05007730,2022.0,OTHER,lead,University of Oregon,Not Applicable
NCT05007730,2022.0,OTHER,collaborator,Oregon Health and Science University,Not Applicable
NCT05007730,2022.0,UNKNOWN,collaborator,Oregon Partnership for Alzheimer's Research,Not Applicable
NCT05008042,2019.0,OTHER,lead,Linnaeus University,Phase 1/Phase 2
NCT05008042,2019.0,OTHER,collaborator,Landstinget i Kalmar Län,Phase 1/Phase 2
NCT05008042,2019.0,OTHER,collaborator,Region Östergötland,Phase 1/Phase 2
NCT05008042,2019.0,OTHER,collaborator,Karolinska Institutet,Phase 1/Phase 2
NCT05008042,2019.0,OTHER_GOV,collaborator,Kronoberg County Council,Phase 1/Phase 2
NCT05008341,2021.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 1
NCT05008354,2020.0,OTHER,lead,Nasim Tabrizi,Phase 4
NCT05008354,2020.0,OTHER,collaborator,Mazandaran University of Medical Sciences,Phase 4
NCT05008484,2021.0,FED,lead,VA Office of Research and Development,Phase 2/Phase 3
NCT05008484,2021.0,OTHER,collaborator,Virginia Commonwealth University,Phase 2/Phase 3
NCT05008484,2021.0,OTHER,collaborator,NYU Langone Health,Phase 2/Phase 3
NCT05008705,2021.0,OTHER,lead,University of Sao Paulo General Hospital,Not Applicable
NCT05008926,2022.0,OTHER,lead,"University Hospital, Brest",Phase 3
NCT05010148,2021.0,OTHER,lead,"University of California, San Francisco",Phase 3
NCT05011669,2021.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 4
NCT05011851,2022.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT05012098,2022.0,NIH,lead,National Cancer Institute (NCI),Phase 2
NCT05013164,2020.0,OTHER,lead,Nishtar Medical University,Phase 2
NCT05013606,2019.0,OTHER,lead,Stony Brook University,Not Applicable
NCT05014919,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT05015192,2021.0,INDUSTRY,lead,"Jiangsu Nhwa Pharmaceutical Co., Ltd.",Phase 1
NCT05015439,2023.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT05015439,2023.0,INDUSTRY,collaborator,Canopy Growth Corporation,Phase 1
NCT05015595,2021.0,OTHER,lead,University of Roma La Sapienza,Phase 3
NCT05015673,2014.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT05016427,2020.0,INDUSTRY,lead,VTBIO Co. LTD,Phase 1
NCT05016661,2021.0,INDUSTRY,lead,"AEON Biopharma, Inc.",Phase 2
NCT05016661,2021.0,INDUSTRY,collaborator,PPD,Phase 2
NCT05018793,2021.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05018819,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05018832,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05018871,2021.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05019105,2021.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 1
NCT05019183,2021.0,OTHER,lead,Direction Centrale du Service de Santé des Armées,Not Applicable
NCT05019885,2022.0,OTHER,lead,Madeline Fields,Phase 2
NCT05020535,2022.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT05020535,2022.0,OTHER,collaborator,University of Kentucky,Phase 2
NCT05020535,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05021536,2021.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 3
NCT05021978,2020.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 2
NCT05021991,2021.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 2
NCT05022121,2022.0,OTHER,lead,University of Minnesota,Not Applicable
NCT05022121,2022.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT05022121,2022.0,OTHER,collaborator,Duke University,Not Applicable
NCT05022121,2022.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT05022147,2021.0,OTHER,lead,James Liao,Phase 1
NCT05023278,2021.0,OTHER,lead,"University of California, San Francisco",Phase 4
NCT05023278,2021.0,OTHER,collaborator,Orthopedic Research and Education Foundation,Phase 4
NCT05023473,2022.0,OTHER,lead,Suez Canal University,Not Applicable
NCT05023889,2022.0,OTHER,lead,Austin Neuromuscular Center,Early Phase 1
NCT05023889,2022.0,INDUSTRY,collaborator,Alnylam Pharmaceuticals,Early Phase 1
NCT05024110,2021.0,OTHER,lead,Taif University,Not Applicable
NCT05024747,2021.0,INDUSTRY,lead,HALEON,Phase 1
NCT05025553,2018.0,OTHER,lead,University of Messina,Not Applicable
NCT05025605,2021.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 1
NCT05025605,2021.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 1
NCT05025917,2019.0,OTHER,lead,University of Exeter,Not Applicable
NCT05026177,2021.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 3
NCT05026177,2021.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 3
NCT05026203,2021.0,OTHER,lead,Mahidol University,Phase 4
NCT05026866,2021.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05027269,2021.0,INDUSTRY,lead,"Avidity Biosciences, Inc.",Phase 1/Phase 2
NCT05027997,2021.0,INDUSTRY,lead,Addex Pharma S.A.,Phase 2
NCT05028023,2020.0,OTHER,lead,Aristotle University Of Thessaloniki,Not Applicable
NCT05028114,2021.0,INDUSTRY,lead,Cerecin,Phase 1
NCT05028634,2021.0,INDUSTRY,lead,Celgene,Phase 3
NCT05029050,2022.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT05029050,2022.0,OTHER,collaborator,Haukeland University Hospital,Phase 4
NCT05029050,2022.0,OTHER,collaborator,University Hospital of North Norway,Phase 4
NCT05029050,2022.0,OTHER,collaborator,UMC Utrecht,Phase 4
NCT05029050,2022.0,OTHER,collaborator,"Sahlgrenska University Hospital, Sweden",Phase 4
NCT05029050,2022.0,OTHER,collaborator,St. Olavs Hospital,Phase 4
NCT05029232,2021.0,OTHER,lead,Sohag University,Not Applicable
NCT05029609,2021.0,INDUSTRY,lead,Tiziana Life Sciences LTD,Phase 1
NCT05029960,2022.0,OTHER,lead,University of Rochester,Early Phase 1
NCT05030129,2021.0,OTHER,lead,Elizabeth Berry-Kravis,Phase 2
NCT05030272,2021.0,OTHER,lead,Duke University,Not Applicable
NCT05030272,2021.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT05030272,2021.0,OTHER,collaborator,University at Buffalo,Not Applicable
NCT05030272,2021.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05031143,2020.0,OTHER,lead,Benha University,Phase 2/Phase 3
NCT05032131,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 1
NCT05032196,2021.0,INDUSTRY,lead,Wave Life Sciences Ltd.,Phase 1/Phase 2
NCT05032326,2021.0,OTHER,lead,"University Hospital, Toulouse",Phase 3
NCT05032573,2021.0,OTHER,lead,University of Florida,Not Applicable
NCT05033561,2021.0,OTHER,lead,Fidec Corporation,Phase 3
NCT05033561,2021.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT05035121,2017.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT05035316,2022.0,OTHER,lead,Lars Vedel Kessing,Phase 2
NCT05035550,2021.0,OTHER,lead,Michigan State University,Not Applicable
NCT05035927,2022.0,INDUSTRY,lead,TRYP Therapeutics,Phase 2
NCT05036473,2021.0,INDUSTRY,lead,"Shanghai WD Pharmaceutical Co., Ltd.",Phase 2
NCT05037032,2021.0,FED,lead,VA Loma Linda Health Care System,Phase 4
NCT05037487,2022.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT05038306,2021.0,OTHER,lead,Changhua Christian Hospital,Phase 2
NCT05039099,2021.0,INDUSTRY,lead,AL-S Pharma,Phase 2
NCT05039190,2021.0,INDUSTRY,lead,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 3
NCT05039268,2021.0,OTHER,lead,"Macquarie University, Australia",Phase 2
NCT05039268,2021.0,INDUSTRY,collaborator,"ZZ Biotech, LLC",Phase 2
NCT05039489,2021.0,OTHER,lead,Central South University,Not Applicable
NCT05040217,2022.0,OTHER,lead,Mark Tuszynski,Phase 1
NCT05040217,2022.0,OTHER,collaborator,Ohio State University,Phase 1
NCT05040321,2021.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05041322,2020.0,OTHER,lead,Spaulding Rehabilitation Hospital,Phase 2
NCT05041582,2021.0,OTHER,lead,Chih-Wei Tang,Phase 3
NCT05041582,2021.0,OTHER_GOV,collaborator,"Taipei Veterans General Hospital, Taiwan",Phase 3
NCT05041582,2021.0,OTHER,collaborator,University of Oxford,Phase 3
NCT05041647,2023.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Phase 2
NCT05041647,2023.0,OTHER,collaborator,McMaster University,Phase 2
NCT05042037,2022.0,OTHER,lead,Universiti Putra Malaysia,Not Applicable
NCT05042466,2023.0,NETWORK,lead,NWTraumatherapies,Phase 1
NCT05042466,2023.0,OTHER,collaborator,World Health Organization,Phase 1
NCT05042817,2021.0,OTHER,lead,University of Liege,Not Applicable
NCT05043519,2022.0,OTHER,lead,Peking University Third Hospital,Phase 1/Phase 2
NCT05043519,2022.0,OTHER_GOV,collaborator,Chinese Academy of Sciences,Phase 1/Phase 2
NCT05043675,2021.0,OTHER,lead,"Nanjing First Hospital, Nanjing Medical University",Early Phase 1
NCT05043896,2019.0,OTHER_GOV,lead,Dr. Soetomo General Hospital,Not Applicable
NCT05044611,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 4
NCT05044819,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT05045170,2021.0,OTHER,lead,I.M. Sechenov First Moscow State Medical University,Not Applicable
NCT05045248,2020.0,OTHER,lead,American University of Beirut Medical Center,Phase 2
NCT05046106,2025.0,INDUSTRY,lead,Moleac Pte Ltd.,Phase 2/Phase 3
NCT05046353,2022.0,OTHER,lead,New York State Psychiatric Institute,Phase 1/Phase 2
NCT05046353,2022.0,OTHER,collaborator,Nathan Kline Institute for Psychiatric Research,Phase 1/Phase 2
NCT05046353,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT05046522,2021.0,INDUSTRY,lead,RDC Clinical Pty Ltd,Phase 3
NCT05047172,2022.0,OTHER,lead,University of Florida,Phase 3
NCT05047172,2022.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT05047172,2022.0,OTHER,collaborator,University of Cincinnati,Phase 3
NCT05047172,2022.0,OTHER,collaborator,Medical University of South Carolina,Phase 3
NCT05047172,2022.0,INDUSTRY,collaborator,"Janssen Scientific Affairs, LLC",Phase 3
NCT05047172,2022.0,INDUSTRY,collaborator,AstraZeneca,Phase 3
NCT05047523,2021.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 3
NCT05047913,2021.0,OTHER,lead,M.D. Anderson Cancer Center,Early Phase 1
NCT05048667,2022.0,OTHER,lead,University of Miami,Phase 1
NCT05048667,2022.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1
NCT05049161,2021.0,INDUSTRY,lead,GeNeuro Innovation SAS,Phase 2
NCT05049707,2024.0,OTHER,lead,Thomas Jefferson University,Phase 3
NCT05050864,2022.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Not Applicable
NCT05051449,2022.0,OTHER,lead,"University of Maryland, Baltimore",Phase 1
NCT05051501,2021.0,OTHER,lead,"National Institute of Mental Health, Czech Republic",Phase 2
NCT05051501,2021.0,UNKNOWN,collaborator,C2P s.r.o.,Phase 2
NCT05051501,2021.0,UNKNOWN,collaborator,University Hospital Vinohrady,Phase 2
NCT05051501,2021.0,UNKNOWN,collaborator,"Ministry of Industry and Trade, Czech Republic",Phase 2
NCT05051657,2021.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT05052879,2024.0,INDUSTRY,lead,EMS,Phase 3
NCT05053035,2021.0,INDUSTRY,lead,Alector Inc.,Phase 2
NCT05053217,2021.0,OTHER,lead,Marmara University,Not Applicable
NCT05053321,2024.0,OTHER,lead,Yale University,Phase 1
NCT05053321,2024.0,INDUSTRY,collaborator,Neurocrine Biosciences,Phase 1
NCT05053477,2018.0,OTHER,lead,Alexandria University,Phase 1
NCT05054140,2021.0,INDUSTRY,lead,Immunic AG,Phase 2
NCT05054387,2021.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT05055024,2021.0,INDUSTRY,lead,NLS Pharmaceutics,Phase 2
NCT05056194,2021.0,INDUSTRY,lead,XWPharma,Phase 2
NCT05058040,2021.0,INDUSTRY,lead,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",Phase 4
NCT05058391,2022.0,INDUSTRY,lead,Takeda,Phase 4
NCT05058677,2021.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 4
NCT05059223,2021.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT05060549,2024.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT05061758,2022.0,INDUSTRY,lead,Audion Therapeutics BV,Phase 2
NCT05062083,2022.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 2
NCT05062083,2022.0,OTHER,collaborator,University of Maryland,Phase 2
NCT05062226,2020.0,INDUSTRY,lead,Nutricia UK Ltd,Not Applicable
NCT05063539,2021.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT05063630,2019.0,OTHER,lead,Can Tho Stroke International Services Hospital,Not Applicable
NCT05063656,2022.0,OTHER,lead,David Cochran,Phase 4
NCT05063656,2022.0,UNKNOWN,collaborator,Eagles Autism Foundation,Phase 4
NCT05063721,2020.0,OTHER,lead,Maastricht University,Phase 1
NCT05063851,2021.0,OTHER,lead,University of Virginia,Phase 2
NCT05063877,2021.0,INDUSTRY,lead,Equilibre Biopharmaceuticals B.V.,Phase 2
NCT05064319,2022.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT05064319,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT05064371,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT05064397,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT05065216,2021.0,INDUSTRY,lead,DiaMedica Therapeutics Inc,Phase 2/Phase 3
NCT05066217,2024.0,INDUSTRY,lead,Epygenix,Phase 2
NCT05066308,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT05066360,2021.0,OTHER,lead,"Near East University, Turkey",Not Applicable
NCT05066503,2020.0,OTHER,lead,University of Arkansas,Not Applicable
NCT05066620,2021.0,OTHER,lead,Guangzhou University of Traditional Chinese Medicine,Phase 3
NCT05066620,2021.0,OTHER,collaborator,The George Institute,Phase 3
NCT05066633,2021.0,OTHER,lead,Medical University of Gdansk,Phase 3
NCT05067244,2021.0,INDUSTRY,lead,Remedy,Phase 2
NCT05067244,2021.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT05067387,2024.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT05067582,2022.0,INDUSTRY,lead,Yamo Pharmaceuticals LLC,Phase 2
NCT05067634,2022.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT05067790,2022.0,INDUSTRY,lead,Biogen,Phase 3
NCT05067868,2022.0,INDUSTRY,lead,Shire,Phase 4
NCT05068349,2022.0,OTHER,lead,Qianfoshan Hospital,Phase 4
NCT05068830,2021.0,OTHER,lead,Norwegian University of Science and Technology,Phase 2
NCT05068830,2021.0,OTHER,collaborator,St. Olavs Hospital,Phase 2
NCT05069428,2023.0,OTHER,lead,Centennial Medical Center,Phase 4
NCT05070351,2022.0,OTHER,lead,Duke University,Phase 1/Phase 2
NCT05071352,2021.0,OTHER,lead,Cairo University,Phase 3
NCT05071430,2022.0,INDUSTRY,lead,Honeybrains Biotech LLC,Phase 2
NCT05071430,2022.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 2
NCT05071716,2022.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 3
NCT05073133,2021.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT05073640,2019.0,OTHER,lead,Mazra Mental Health Center,Phase 1/Phase 2
NCT05073640,2019.0,OTHER,collaborator,Ben-Gurion University of the Negev,Phase 1/Phase 2
NCT05073679,2022.0,OTHER,lead,Rosemary Claire Roden,Phase 2/Phase 3
NCT05073679,2022.0,OTHER,collaborator,Children's Miracle Network,Phase 2/Phase 3
NCT05074056,2022.0,OTHER,lead,St. Louis University,Phase 4
NCT05074498,2021.0,INDUSTRY,lead,"TrueBinding, Inc.",Phase 1/Phase 2
NCT05075499,2021.0,OTHER_GOV,lead,Sheba Medical Center,Not Applicable
NCT05075499,2021.0,INDUSTRY,collaborator,Sanofi,Not Applicable
NCT05076838,2021.0,INDUSTRY,lead,"Neurelis, Inc.",Phase 1/Phase 2
NCT05077501,2021.0,INDUSTRY,lead,AlzeCure Pharma,Phase 1
NCT05077631,2021.0,INDUSTRY,lead,AlzeCure Pharma,Phase 1
NCT05078177,2020.0,OTHER,lead,St. Petersburg State Pavlov Medical University,Phase 1
NCT05079854,2021.0,OTHER,lead,Federal University of São Paulo,Phase 4
NCT05080270,2020.0,OTHER,lead,FibroBiologics,Early Phase 1
NCT05081180,2021.0,INDUSTRY,lead,"EMD Serono Research & Development Institute, Inc.",Phase 1
NCT05081180,2021.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 1
NCT05081219,2021.0,OTHER,lead,Wake Forest University Health Sciences,Phase 2
NCT05081245,2022.0,INDUSTRY,lead,MapLight Therapeutics,Phase 2
NCT05081271,2021.0,OTHER,lead,Griffin Hospital,Early Phase 1
NCT05081271,2021.0,OTHER,collaborator,Yale-Griffin Prevention Research Center,Early Phase 1
NCT05081271,2021.0,UNKNOWN,collaborator,Multiple Sclerosis Treatment Center,Early Phase 1
NCT05081518,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT05083260,2022.0,INDUSTRY,lead,BioVie Inc.,Phase 1/Phase 2
NCT05084365,2021.0,OTHER,lead,Central South University,Phase 2
NCT05085483,2021.0,INDUSTRY,lead,Société des Produits Nestlé (SPN),Not Applicable
NCT05085483,2021.0,UNKNOWN,collaborator,Healint Pte Ltd,Not Applicable
NCT05085483,2021.0,UNKNOWN,collaborator,Diex Research Sherbrooke Inc.,Not Applicable
NCT05085782,2022.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT05085808,2024.0,OTHER,lead,University of Southern California,Phase 4
NCT05086276,2021.0,INDUSTRY,lead,Frequency Therapeutics,Phase 2
NCT05087056,2021.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT05088252,2021.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05089526,2021.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT05089604,2023.0,OTHER,lead,University of British Columbia,Phase 4
NCT05089604,2023.0,OTHER,collaborator,Paladin Labs Inc.,Phase 4
NCT05090371,2022.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 4
NCT05091242,2021.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 2/Phase 3
NCT05092685,2023.0,OTHER,lead,"University College, London",Phase 1/Phase 2
NCT05093218,2021.0,OTHER,lead,"Institute of Liver and Biliary Sciences, India",Not Applicable
NCT05093582,2021.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05093829,2022.0,OTHER,lead,Emory University,Phase 3
NCT05093829,2022.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3
NCT05094011,2024.0,INDUSTRY,lead,"Taiwan Mitochondrion Applied Technology Co., Ltd.",Phase 1
NCT05094050,2022.0,INDUSTRY,lead,AbbVie,Phase 1
NCT05095571,2021.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT05095571,2021.0,INDUSTRY,collaborator,Elysium Health,Not Applicable
NCT05095857,2023.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 4
NCT05095857,2023.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4
NCT05096221,2021.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT05096221,2021.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 3
NCT05096468,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2/Phase 3
NCT05096988,2021.0,INDUSTRY,lead,"Vitaflo International, Ltd",Not Applicable
NCT05097261,2021.0,OTHER,lead,"Geert Meyfroidt, MD, PhD",Phase 4
NCT05097261,2021.0,OTHER,collaborator,University of Liege,Phase 4
NCT05097261,2021.0,OTHER,collaborator,Centre Hospitalier Régional de la Citadelle,Phase 4
NCT05097261,2021.0,OTHER,collaborator,AZ Delta,Phase 4
NCT05097261,2021.0,OTHER,collaborator,AZ Sint-Jan AV,Phase 4
NCT05097261,2021.0,OTHER,collaborator,AZ Turnhout,Phase 4
NCT05097261,2021.0,OTHER,collaborator,"Imelda Hospital, Bonheiden",Phase 4
NCT05098509,2022.0,INDUSTRY,lead,"Radius Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT05098574,2022.0,OTHER,lead,St. Joseph's Healthcare Hamilton,Phase 2
NCT05098574,2022.0,OTHER,collaborator,Hamilton Academic Health Sciences Organization,Phase 2
NCT05098574,2022.0,OTHER,collaborator,McMaster University,Phase 2
NCT05099055,2022.0,OTHER,lead,St. Justine's Hospital,Phase 3
NCT05099107,2021.0,OTHER_GOV,lead,Vastra Gotaland Region,Not Applicable
NCT05099341,2021.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Not Applicable
NCT05099640,2021.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT05099796,2016.0,OTHER,lead,Marmara University,Not Applicable
NCT05100459,2021.0,OTHER,lead,Indiana University,Not Applicable
NCT05100654,2022.0,OTHER,lead,University of Chicago,Early Phase 1
NCT05100654,2022.0,OTHER,collaborator,Loyola University,Early Phase 1
NCT05101018,2021.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT05101018,2021.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 4
NCT05101122,2021.0,INDUSTRY,lead,Apnimed,Phase 1/Phase 2
NCT05101148,2021.0,INDUSTRY,lead,AstraZeneca,Phase 1
NCT05101148,2021.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1
NCT05102045,2016.0,OTHER,lead,Istanbul Medipol University Hospital,Not Applicable
NCT05102396,2021.0,OTHER,lead,Samantha Rodrigues Camargo Neves de Moura,Phase 2
NCT05102396,2021.0,OTHER,collaborator,Science Valley Research Institute,Phase 2
NCT05102591,2022.0,OTHER,lead,University of Calgary,Phase 3
NCT05103410,2021.0,OTHER,lead,Ain Shams University,Phase 4
NCT05103618,2023.0,OTHER,lead,Andrew Newberg,Phase 2
NCT05103657,2021.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 2
NCT05104424,2021.0,OTHER_GOV,lead,"Ministry of Health, Saudi Arabia",Phase 1
NCT05104476,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT05104762,2021.0,OTHER,lead,Assiut University,Phase 2/Phase 3
NCT05104983,2021.0,OTHER,lead,Darcy Krueger,Phase 2
NCT05105542,2021.0,OTHER,lead,Yale University,Phase 2
NCT05105542,2021.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05105958,2025.0,OTHER,lead,"University Hospital, Geneva",Phase 2
NCT05105958,2025.0,OTHER,collaborator,University of Lausanne Hospitals,Phase 2
NCT05105958,2025.0,OTHER,collaborator,University of Zurich,Phase 2
NCT05105958,2025.0,OTHER,collaborator,University of Bern,Phase 2
NCT05105958,2025.0,OTHER,collaborator,Cantonal Hospital of St. Gallen,Phase 2
NCT05106309,2021.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT05106686,2021.0,OTHER,lead,Pusan National University Yangsan Hospital,Not Applicable
NCT05107128,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05107752,2022.0,OTHER,lead,Ohio State University,Phase 2
NCT05107752,2022.0,UNKNOWN,collaborator,The Stellate Institute,Phase 2
NCT05107752,2022.0,UNKNOWN,collaborator,Navy SEAL Foundation,Phase 2
NCT05108922,2021.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05109091,2022.0,INDUSTRY,lead,Alterity Therapeutics,Phase 2
NCT05109169,2023.0,OTHER,lead,Imperial College London,Phase 2
NCT05109169,2023.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT05109169,2023.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT05109169,2023.0,UNKNOWN,collaborator,Alzheimerfonden,Phase 2
NCT05109169,2023.0,OTHER_GOV,collaborator,Region Stockholm,Phase 2
NCT05109169,2023.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT05109169,2023.0,OTHER_GOV,collaborator,Finnish Institute for Health and Welfare,Phase 2
NCT05109169,2023.0,OTHER,collaborator,Fingers Brain Health Institute,Phase 2
NCT05109169,2023.0,OTHER,collaborator,Karolinska University Hospital,Phase 2
NCT05109169,2023.0,OTHER,collaborator,Karolinska Institutet,Phase 2
NCT05109312,2021.0,INDUSTRY,lead,Heron Therapeutics,Phase 4
NCT05109364,2022.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT05109377,2021.0,OTHER,lead,Ankara Training and Research Hospital,Not Applicable
NCT05110157,2021.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT05110417,2021.0,OTHER,lead,Eastern Virginia Medical School,Phase 4
NCT05111821,2022.0,OTHER,lead,"University Hospital, Bordeaux",Phase 2
NCT05113628,2020.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT05113745,2021.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT05113953,2021.0,INDUSTRY,lead,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2
NCT05114941,2024.0,OTHER,lead,The First Affiliated Hospital of Zhengzhou University,Not Applicable
NCT05116540,2021.0,OTHER,lead,Hope Biosciences Stem Cell Research Foundation,Phase 2
NCT05116813,2021.0,INDUSTRY,lead,Addex Pharma S.A.,Phase 2/Phase 3
NCT05116878,2021.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT05116930,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05117034,2022.0,OTHER_GOV,lead,Tel-Aviv Sourasky Medical Center,Not Applicable
NCT05117112,2022.0,OTHER,lead,University of Arkansas,Not Applicable
NCT05117281,2021.0,OTHER,lead,Assiut University,Not Applicable
NCT05117632,2021.0,INDUSTRY,lead,Alto Neuroscience,Phase 2
NCT05118204,2022.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT05118906,2022.0,OTHER,lead,Bioprojet,Phase 2
NCT05118997,2021.0,INDUSTRY,lead,IRRAS,Not Applicable
NCT05118997,2021.0,OTHER,collaborator,University of Helsinki,Not Applicable
NCT05118997,2021.0,OTHER,collaborator,Northwestern University,Not Applicable
NCT05118997,2021.0,OTHER,collaborator,West Virginia University,Not Applicable
NCT05118997,2021.0,UNKNOWN,collaborator,Klinikum Bergmannstrost,Not Applicable
NCT05118997,2021.0,OTHER,collaborator,Brigham and Women's Hospital,Not Applicable
NCT05119075,2021.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT05119075,2021.0,OTHER,collaborator,"University Hospital, Geneva",Not Applicable
NCT05119075,2021.0,OTHER,collaborator,Ecole Polytechnique Fédérale de Lausanne,Not Applicable
NCT05119894,2021.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 1
NCT05120505,2021.0,OTHER,lead,Children's Hospital of Fudan University,Phase 4
NCT05120960,2023.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 1
NCT05121324,2022.0,OTHER,lead,Baylor College of Medicine,Phase 3
NCT05121324,2022.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT05121324,2022.0,OTHER,collaborator,University of Utah,Phase 3
NCT05121831,2022.0,INDUSTRY,lead,Digestome Therapeutics,Phase 1
NCT05122559,2022.0,OTHER,lead,"Emmanuelle Waubant, MD PhD",Phase 2
NCT05122559,2022.0,FED,collaborator,United States Department of Defense,Phase 2
NCT05122650,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT05122949,2017.0,OTHER,lead,Tan Tock Seng Hospital,Not Applicable
NCT05123092,2021.0,OTHER,lead,Fayoum University Hospital,Not Applicable
NCT05123703,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT05123703,2022.0,INDUSTRY,collaborator,PPD,Phase 3
NCT05124067,2021.0,OTHER,lead,Tanta University,Phase 1
NCT05125081,2022.0,OTHER,lead,Shanghai Jiao Tong University School of Medicine,Phase 2
NCT05125081,2022.0,OTHER,collaborator,Shanghai University of Traditional Chinese Medicine,Phase 2
NCT05125302,2022.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05126238,2021.0,OTHER_GOV,lead,Negovsky Reanimatology Research Institute,Phase 3
NCT05126238,2021.0,OTHER_GOV,collaborator,Demikhov Municipal Clinical Hospital 68,Phase 3
NCT05126264,2021.0,OTHER,lead,Universidad Complutense de Madrid,Not Applicable
NCT05126264,2021.0,OTHER,collaborator,McGill University,Not Applicable
NCT05126693,2020.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT05126693,2020.0,OTHER,collaborator,KU Leuven,Not Applicable
NCT05126758,2022.0,INDUSTRY,lead,Capricor Inc.,Phase 3
NCT05126888,2024.0,INDUSTRY,lead,SciSparc,Phase 2
NCT05127226,2021.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT05127226,2021.0,INDUSTRY,collaborator,Biogen,Phase 1/Phase 2
NCT05127369,2022.0,INDUSTRY,lead,"CAR-T (Shanghai) Biotechnology Co., Ltd.",Not Applicable
NCT05127486,2021.0,INDUSTRY,lead,Eli Lilly and Company,Phase 4
NCT05127694,2019.0,OTHER,lead,Istanbul Medipol University Hospital,Not Applicable
NCT05127954,2022.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05128162,2023.0,OTHER,lead,Kevin Boehnke,Phase 2
NCT05128175,2021.0,INDUSTRY,lead,"Shanghai WD Pharmaceutical Co., Ltd.",Phase 1
NCT05128292,2018.0,OTHER,lead,Hospital Universitari Vall d'Hebron Research Institute,Not Applicable
NCT05128292,2018.0,INDUSTRY,collaborator,Pharma Nord,Not Applicable
NCT05128305,2021.0,OTHER,lead,Qianfoshan Hospital,Phase 3
NCT05128344,2023.0,INDUSTRY,lead,Amzell,Phase 3
NCT05128812,2021.0,OTHER,lead,University of Alicante,Not Applicable
NCT05128903,2022.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 2
NCT05129020,2022.0,INDUSTRY,lead,"Spark Biomedical, Inc.",Not Applicable
NCT05129020,2022.0,OTHER,collaborator,Medical University of South Carolina,Not Applicable
NCT05129020,2022.0,OTHER,collaborator,University of Texas Southwestern Medical Center,Not Applicable
NCT05130866,2022.0,INDUSTRY,lead,Recursion Pharmaceuticals Inc.,Phase 2/Phase 3
NCT05131295,2007.0,OTHER,lead,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Phase 3
NCT05131828,2022.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 2
NCT05131828,2022.0,OTHER,collaborator,University of Cambridge,Phase 2
NCT05131971,2021.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT05132569,2021.0,INDUSTRY,lead,Sanofi,Phase 3
NCT05132699,2022.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 1/Phase 2
NCT05132699,2022.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 1/Phase 2
NCT05133323,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 2
NCT05133804,2022.0,OTHER,lead,University of Haifa,Phase 2
NCT05134441,2021.0,INDUSTRY,lead,Immunic AG,Phase 3
NCT05136885,2022.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT05136885,2022.0,INDUSTRY,collaborator,"Seelos Therapeutics, Inc.",Phase 2/Phase 3
NCT05137678,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05137678,2021.0,OTHER,collaborator,Beijing Tongren Hospital,Phase 4
NCT05137938,2021.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT05140863,2021.0,INDUSTRY,lead,"Haisco Pharmaceutical Group Co., Ltd.",Phase 3
NCT05141877,2022.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 4
NCT05141877,2022.0,OTHER,collaborator,Tri-Service General Hospital,Phase 4
NCT05142085,2021.0,INDUSTRY,lead,Distribuidora Biolife SA de CV,Not Applicable
NCT05142228,2022.0,OTHER,lead,"University of Maryland, Baltimore",Phase 2
NCT05142228,2022.0,INDUSTRY,collaborator,Amgen,Phase 2
NCT05143463,2021.0,INDUSTRY,lead,"Neuracle Science Co., LTD.",Phase 1
NCT05143528,2022.0,INDUSTRY,lead,"KeifeRx, LLC",Phase 3
NCT05143528,2022.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 3
NCT05143528,2022.0,INDUSTRY,collaborator,Life Molecular Imaging GmbH,Phase 3
NCT05143528,2022.0,UNKNOWN,collaborator,Sun Pharmaceuticals Industries Limited,Phase 3
NCT05143762,2021.0,OTHER,lead,Benha University,Phase 2
NCT05145361,2022.0,INDUSTRY,lead,"Shanghai Pharmaceuticals Holding Co., Ltd",Early Phase 1
NCT05145413,2021.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT05145452,2021.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT05145881,2020.0,INDUSTRY,lead,Hsieh-Hsun Ho,Not Applicable
NCT05146089,2016.0,OTHER,lead,University of Missouri-Columbia,Early Phase 1
NCT05146089,2016.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Early Phase 1
NCT05146089,2016.0,OTHER,collaborator,Mayo Clinic,Early Phase 1
NCT05146245,2021.0,OTHER,lead,Erasmus Medical Center,Phase 4
NCT05146245,2021.0,UNKNOWN,collaborator,Stichting de Merel,Phase 4
NCT05146245,2021.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT05146284,2023.0,INDUSTRY,lead,Poxel SA,Phase 2
NCT05146570,2021.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT05146739,2023.0,NIH,lead,National Cancer Institute (NCI),Phase 1
NCT05146739,2023.0,UNKNOWN,collaborator,Childrens Oncology Group (COG),Phase 1
NCT05146739,2023.0,UNKNOWN,collaborator,LLS PedAL LLC,Phase 1
NCT05146921,2019.0,OTHER,lead,King's College Hospital NHS Trust,Not Applicable
NCT05146921,2019.0,OTHER,collaborator,King's College London,Not Applicable
NCT05147701,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05147779,2021.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05148403,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 1/Phase 2
NCT05148403,2021.0,OTHER,collaborator,Beijing Tongren Hospital,Phase 1/Phase 2
NCT05148715,2022.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT05148715,2022.0,OTHER,collaborator,McMaster University,Phase 2
NCT05151601,2022.0,OTHER,lead,The University of Queensland,Not Applicable
NCT05152290,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05152368,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05152394,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05153434,2022.0,INDUSTRY,lead,"Aardvark Therapeutics, Inc.",Phase 2
NCT05153434,2022.0,OTHER,collaborator,Children's Hospital Colorado,Phase 2
NCT05153434,2022.0,OTHER,collaborator,Stanford University,Phase 2
NCT05154734,2021.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 1/Phase 2
NCT05155137,2021.0,OTHER,lead,Hospital Moinhos de Vento,Phase 3
NCT05155137,2021.0,OTHER_GOV,collaborator,"Ministry of Health, Brazil",Phase 3
NCT05155137,2021.0,UNKNOWN,collaborator,World Stroke Organization,Phase 3
NCT05156047,2022.0,INDUSTRY,lead,"Harmony Biosciences, LLC",Phase 3
NCT05156320,2022.0,INDUSTRY,lead,"Scholar Rock, Inc.",Phase 3
NCT05156398,2022.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05158101,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05158166,2023.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT05158296,2021.0,INDUSTRY,lead,ProQR Therapeutics,Phase 2/Phase 3
NCT05158439,2022.0,OTHER,lead,The Foundation for Orthopaedics and Regenerative Medicine,Phase 1
NCT05159219,2022.0,OTHER,lead,Population Health Research Institute,Phase 2
NCT05159687,2022.0,OTHER,lead,University of Calgary,Phase 3
NCT05159934,2022.0,OTHER,lead,Yale University,Phase 1
NCT05159947,2022.0,OTHER,lead,"Wuhan Union Hospital, China",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,"Suzhou Huyun New Drug Research and Development Co., Ltd",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,"Shanghai Canming Pharmaceutical Technology Co., Ltd",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,"Beijing Haijinge Pharmaceutical Technology Co., Ltd",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,"The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Xiang Yang NO.1 People's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Xiangyang Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Wuhan NO. 4 hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The Affiliated Hospital of Xuzhou Medical University,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Xuzhou Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,"Yan'an University Xianyang hospital Co., Ltd",Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Hengshui People's Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Inner Mongolia Baogang Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Daqing oilfield general hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The Fourth Affiliated Hospital of Harbin Medical University,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The First Hospital of Jilin University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Meihekou Central Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Jiangsu Taizhou People's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Tianjin People's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Taizhou Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Zhejiang Taizhou hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,The First Affiliated Hospital of Nanhua University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Affiliated hospital of jining medical college,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Zhongshan Hospital Xiamen University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Neijiang Second People's Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Tancheng first people's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The Affiliated Hospital of Qingdao University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Taian Central Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Weihai Municipal Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Nanyang nanshai hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Dezhou People's Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,The First Affiliated Hospital of Nanyang Medical College,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Deyang People's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Yantai Yuhuangding Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Qingdao Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Fukuang General Hospital of Liaoning health industry group,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Xi'an Gaoxin Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Affiliated Hospital of Jiaxing University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Fujian Zhangzhou hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The Affiliated Hospital of Inner Mongolia Medical University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Daqing people's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Hainan People's Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Qujing first people's Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,The Third Affiliated Hospital of Qiqihar Medical College,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The First Affiliated Hospital of Hebei North University,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Linfen Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Xuancheng people's hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,The First Affiliated Hospital of Shihezi University Medical College,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Guangzhou Red Cross Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,People's Hospital of Wuhan University,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Wuhan Central Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Jingzhou Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Huanggang Central Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Sinopharm Dongfeng General Hospital,Phase 3
NCT05159947,2022.0,UNKNOWN,collaborator,Changjiang Shipping General Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Yichang Central People's Hospital,Phase 3
NCT05159947,2022.0,OTHER,collaborator,The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture,Phase 3
NCT05159947,2022.0,OTHER,collaborator,Xiangtan Central Hospital,Phase 3
NCT05160350,2021.0,OTHER,lead,Mazandaran University of Medical Sciences,Phase 4
NCT05160558,2022.0,INDUSTRY,lead,Biogen,Phase 1
NCT05161871,2022.0,OTHER,lead,University of L'Aquila,Not Applicable
NCT05161975,2021.0,OTHER,lead,Lithuanian Sports University,Not Applicable
NCT05161975,2021.0,UNKNOWN,collaborator,Kappa Bioscience AS,Not Applicable
NCT05161975,2021.0,UNKNOWN,collaborator,LSMU Kauno ligonine,Not Applicable
NCT05162638,2022.0,OTHER,lead,University of Pennsylvania,Not Applicable
NCT05162638,2022.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Not Applicable
NCT05162638,2022.0,OTHER,collaborator,Novartis Institutes for BioMedical Research,Not Applicable
NCT05162768,2022.0,INDUSTRY,lead,Stealth BioTherapeutics Inc.,Phase 3
NCT05163288,2022.0,INDUSTRY,lead,IntraBio Inc,Phase 3
NCT05163496,2022.0,OTHER,lead,University of Washington,Phase 3
NCT05163561,2022.0,INDUSTRY,lead,Serum Institute of India Pvt. Ltd.,Phase 3
NCT05163808,2022.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 2/Phase 3
NCT05163886,2021.0,INDUSTRY,lead,OrphAI Therapeutics,Phase 2
NCT05164003,2017.0,INDUSTRY,lead,Medy-Tox,Phase 1
NCT05164055,2022.0,INDUSTRY,lead,"Genzyme, a Sanofi Company",Phase 4
NCT05164172,2021.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 3
NCT05164367,2022.0,OTHER,lead,University of Utah,Early Phase 1
NCT05164536,2021.0,OTHER,lead,Invicro,Phase 1
NCT05165394,2021.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT05165836,2021.0,OTHER,lead,Kafrelsheikh University,Not Applicable
NCT05166031,2020.0,OTHER,lead,Fidec Corporation,Phase 3
NCT05166031,2020.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 3
NCT05166161,2022.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT05167370,2010.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT05167721,2021.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05167760,2023.0,OTHER,lead,University of Alabama at Birmingham,Phase 4
NCT05168007,2021.0,INDUSTRY,lead,Whanin Pharmaceutical Company,Phase 3
NCT05168280,2022.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05168475,2021.0,OTHER,lead,Cambridge University Hospitals NHS Foundation Trust,Phase 2
NCT05168735,2022.0,OTHER,lead,Rebecca Price,Phase 1/Phase 2
NCT05168774,2022.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 1/Phase 2
NCT05168774,2022.0,OTHER,collaborator,Friedreich's Ataxia Research Alliance,Phase 1/Phase 2
NCT05168774,2022.0,INDUSTRY,collaborator,Stealth BioTherapeutics Inc.,Phase 1/Phase 2
NCT05169021,2021.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05169060,2023.0,OTHER,lead,University of Iowa,Phase 1/Phase 2
NCT05169060,2023.0,OTHER,collaborator,University of Michigan,Phase 1/Phase 2
NCT05169450,2013.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Not Applicable
NCT05170464,2022.0,OTHER,lead,"Western University, Canada",Phase 2/Phase 3
NCT05172128,2022.0,OTHER,lead,Duke University,Not Applicable
NCT05172128,2022.0,OTHER,collaborator,U.S. Highbush Blueberry Council,Not Applicable
NCT05172947,2021.0,OTHER,lead,University of Sulaimani,Not Applicable
NCT05173012,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05173012,2022.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT05173701,2021.0,OTHER,lead,Franca Marino,Not Applicable
NCT05173701,2021.0,OTHER,collaborator,"Università degli Studi del Piemonte Orientale ""Amedeo Avogadro""",Not Applicable
NCT05173701,2021.0,OTHER,collaborator,Università degli Studi dell'Insubria,Not Applicable
NCT05173831,2023.0,INDUSTRY,lead,Lykos Therapeutics,Phase 2
NCT05173896,2022.0,OTHER,lead,Christina Kruuse,Phase 2
NCT05173896,2022.0,OTHER,collaborator,Danish Research Centre for Magnetic Resonance,Phase 2
NCT05173896,2022.0,OTHER,collaborator,Bispebjerg Hospital,Phase 2
NCT05173896,2022.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 2
NCT05173896,2022.0,OTHER,collaborator,"Hillerod Hospital, Denmark",Phase 2
NCT05173896,2022.0,OTHER,collaborator,University of Copenhagen,Phase 2
NCT05173896,2022.0,OTHER,collaborator,The Novo Nordic Foundation,Phase 2
NCT05174559,2023.0,OTHER,lead,University of Southern California,Not Applicable
NCT05174559,2023.0,UNKNOWN,collaborator,National PKU Alliance,Not Applicable
NCT05175521,2021.0,OTHER,lead,HonorHealth Research Institute,Not Applicable
NCT05175547,2021.0,OTHER,lead,ProMedica Health System,Phase 3
NCT05176093,2021.0,INDUSTRY,lead,"Helixmith Co., Ltd.",Phase 2
NCT05176158,2023.0,OTHER,lead,Universidad Complutense de Madrid,Not Applicable
NCT05176158,2023.0,OTHER,collaborator,McGill University,Not Applicable
NCT05176418,2022.0,OTHER,lead,Yale University,Early Phase 1
NCT05176717,2021.0,INDUSTRY,lead,ProQR Therapeutics,Phase 2/Phase 3
NCT05177055,2022.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT05177055,2022.0,OTHER,collaborator,University of Bergen,Not Applicable
NCT05177445,2022.0,OTHER,lead,Respiralab,Not Applicable
NCT05177601,2021.0,OTHER,lead,University of Calgary,Phase 2
NCT05177718,2022.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT05177718,2022.0,INDUSTRY,collaborator,Biogen,Phase 4
NCT05178316,2021.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT05178810,2021.0,INDUSTRY,lead,Ferrer Internacional S.A.,Phase 3
NCT05178810,2021.0,INDUSTRY,collaborator,Julius Clinical,Phase 3
NCT05178810,2021.0,OTHER,collaborator,Stichting TRICALS Foundation,Phase 3
NCT05179252,2022.0,OTHER,lead,Shandong University of Traditional Chinese Medicine,Not Applicable
NCT05179252,2022.0,OTHER,collaborator,Shandong Institute of Science and Technology Information,Not Applicable
NCT05179525,2021.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 1
NCT05180032,2021.0,FED,lead,James J. Peters Veterans Affairs Medical Center,Phase 4
NCT05180032,2021.0,INDUSTRY,collaborator,Kessler Institute for Rehabilitation,Phase 4
NCT05180136,2022.0,OTHER,lead,Pusan National University Yangsan Hospital,Not Applicable
NCT05180890,2022.0,INDUSTRY,lead,Takeda,Phase 1
NCT05180916,2021.0,OTHER,lead,Eindhoven University of Technology,Not Applicable
NCT05180916,2021.0,OTHER,collaborator,Clinical Trial Center Maastricht B.V.,Not Applicable
NCT05181150,2021.0,OTHER,lead,University of Copenhagen,Not Applicable
NCT05181150,2021.0,OTHER,collaborator,Hvidovre University Hospital,Not Applicable
NCT05181189,2024.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT05181215,2021.0,INDUSTRY,lead,Banner Life Sciences LLC,Phase 1
NCT05181475,2021.0,INDUSTRY,lead,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",Phase 4
NCT05181891,2022.0,OTHER,lead,Washington State University,Phase 2
NCT05181995,2021.0,INDUSTRY,lead,Aptinyx,Phase 2/Phase 3
NCT05181995,2021.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 2/Phase 3
NCT05182476,2021.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT05182619,2022.0,OTHER,lead,Sohag University,Early Phase 1
NCT05183165,2022.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Not Applicable
NCT05183334,2021.0,OTHER,lead,Assiut University,Phase 4
NCT05183516,2023.0,INDUSTRY,lead,"Mindful Diagnostics and Therapeutics, LLC",Phase 1/Phase 2
NCT05183516,2023.0,UNKNOWN,collaborator,Infectious Disease Society of America,Phase 1/Phase 2
NCT05183594,2022.0,INDUSTRY,lead,"Tasly Pharmaceuticals, Inc.",Not Applicable
NCT05184192,2022.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT05184335,2022.0,INDUSTRY,lead,Reviva Pharmaceuticals,Phase 3
NCT05185011,2021.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT05185011,2021.0,OTHER,collaborator,"Shanghai Institute of Materia Medica, Chinese Academy of Sciences",Phase 1
NCT05185622,2022.0,INDUSTRY,lead,Santhera Pharmaceuticals,Phase 2
NCT05187546,2022.0,INDUSTRY,lead,Life Molecular Imaging GmbH,Phase 1
NCT05188131,2021.0,OTHER,lead,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Phase 4
NCT05188833,2020.0,OTHER,lead,Istanbul Medipol University Hospital,Not Applicable
NCT05188989,2021.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 3
NCT05189106,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT05189535,2021.0,OTHER,lead,Ain Shams University,Phase 2/Phase 3
NCT05191277,2022.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT05191277,2022.0,OTHER,collaborator,Philipps University Marburg Medical Center,Not Applicable
NCT05191277,2022.0,OTHER,collaborator,Helmut Schmidt University,Not Applicable
NCT05191277,2022.0,OTHER,collaborator,"University Hospital, Essen",Not Applicable
NCT05191719,2022.0,OTHER,lead,Rebecka Ohm,Not Applicable
NCT05192200,2021.0,INDUSTRY,lead,Pfizer,Phase 2
NCT05192304,2022.0,INDUSTRY,lead,"Jiangsu Kanion Pharmaceutical Co., Ltd",Phase 1
NCT05192304,2022.0,OTHER,collaborator,Shanghai Mental Health Center,Phase 1
NCT05192382,2021.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 3
NCT05193578,2022.0,OTHER,lead,Jan Frystyk,Phase 2
NCT05193578,2022.0,OTHER,collaborator,Region Zealand,Phase 2
NCT05193578,2022.0,OTHER,collaborator,Region of Southern Denmark,Phase 2
NCT05193578,2022.0,OTHER_GOV,collaborator,Steno Diabetes Center Sjaelland,Phase 2
NCT05193578,2022.0,OTHER,collaborator,Steno Diabetes Center Odense,Phase 2
NCT05193851,2022.0,INDUSTRY,lead,"Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.",Phase 1
NCT05193994,2022.0,OTHER,lead,"Macquarie University, Australia",Phase 3
NCT05193994,2022.0,OTHER,collaborator,King's College London,Phase 3
NCT05193994,2022.0,OTHER,collaborator,Stichting TRICALS Foundation,Phase 3
NCT05194124,2021.0,INDUSTRY,lead,"Rhythm Pharmaceuticals, Inc.",Phase 3
NCT05194163,2022.0,INDUSTRY,lead,Neurokine Therapeutics,Phase 2
NCT05194163,2022.0,OTHER,collaborator,Columbia University,Phase 2
NCT05194163,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05195034,2022.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05195775,2021.0,OTHER,lead,University of Florida,Phase 2/Phase 3
NCT05195996,2021.0,OTHER,lead,Menoufia University,Phase 4
NCT05196191,2022.0,INDUSTRY,lead,"VIVEX Biologics, Inc.",Not Applicable
NCT05196256,2022.0,OTHER,lead,Brugmann University Hospital,Phase 3
NCT05196308,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT05196425,2021.0,OTHER,lead,Sohag University,Not Applicable
NCT05196503,2022.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 3
NCT05197309,2022.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Not Applicable
NCT05197439,2023.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05198362,2021.0,INDUSTRY,lead,Saniona,Phase 2
NCT05199194,2022.0,OTHER,lead,Hospital Moinhos de Vento,Phase 3
NCT05199194,2022.0,OTHER_GOV,collaborator,"Ministry of Health, Brazil",Phase 3
NCT05199194,2022.0,INDUSTRY,collaborator,Boehringer Ingelheim,Phase 3
NCT05199194,2022.0,INDUSTRY,collaborator,Medtronic,Phase 3
NCT05199688,2024.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT05199727,2021.0,OTHER,lead,Menoufia University,Not Applicable
NCT05200104,2023.0,INDUSTRY,lead,Poxel SA,Phase 2
NCT05200208,2022.0,OTHER,lead,Emory University,Not Applicable
NCT05200208,2022.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT05200208,2022.0,UNKNOWN,collaborator,Goizueta Alzheimer's Disease Research Center (ADRC),Not Applicable
NCT05201313,2022.0,OTHER,lead,Azienda Sanitaria-Universitaria Integrata di Udine,Phase 3
NCT05201560,2022.0,OTHER,lead,Shanghai Zhongshan Hospital,Not Applicable
NCT05201638,2022.0,INDUSTRY,lead,Immunic AG,Phase 3
NCT05202574,2021.0,OTHER,lead,Minia University,Phase 2
NCT05202899,2020.0,OTHER,lead,Guangzhou General Hospital of Guangzhou Military Command,Phase 4
NCT05204069,2021.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT05204407,2022.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT05204407,2022.0,OTHER,collaborator,"University of California, Los Angeles",Not Applicable
NCT05204407,2022.0,OTHER,collaborator,Stanley Medical Research Institute,Not Applicable
NCT05204641,2021.0,OTHER,lead,Medical University of Warsaw,Phase 1/Phase 2
NCT05204641,2021.0,INDUSTRY,collaborator,Human Biome Institute S.A.,Phase 1/Phase 2
NCT05206149,2021.0,OTHER,lead,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Phase 4
NCT05206227,2021.0,OTHER,lead,University of Oregon,Early Phase 1
NCT05206253,2022.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT05206253,2022.0,UNKNOWN,collaborator,Egg Farmers of Canada,Not Applicable
NCT05206435,2022.0,OTHER,lead,Butler Hospital,Phase 4
NCT05206435,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT05206487,2022.0,OTHER,lead,"University Hospital, Toulouse",Not Applicable
NCT05206487,2022.0,UNKNOWN,collaborator,Société nationale française de gastro-entérologie,Not Applicable
NCT05206513,2022.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT05206773,2022.0,INDUSTRY,lead,Sanofi,Phase 3
NCT05207436,2022.0,FED,lead,San Diego Veterans Healthcare System,Phase 2
NCT05207865,2022.0,INDUSTRY,lead,Pfizer,Phase 4
NCT05208190,2022.0,OTHER,lead,New York State Psychiatric Institute,Phase 4
NCT05208190,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT05208281,2021.0,INDUSTRY,lead,AO GENERIUM,Phase 2/Phase 3
NCT05208814,2022.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT05208814,2022.0,OTHER,collaborator,"Shanghai Institute of Materia Medica, Chinese Academy of Sciences",Phase 1
NCT05208840,2023.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT05208918,2022.0,OTHER,lead,Mansoura University,Not Applicable
NCT05208918,2022.0,OTHER_GOV,collaborator,Zagazig University,Not Applicable
NCT05209035,2022.0,OTHER,lead,Chinese University of Hong Kong,Phase 4
NCT05209035,2022.0,OTHER,collaborator,Hong Kong University of Science and Technology,Phase 4
NCT05210621,2022.0,OTHER,lead,Centre Hospitalier Universitaire de Nice,Phase 3
NCT05211063,2022.0,OTHER,lead,University of Alicante,Not Applicable
NCT05211063,2022.0,INDUSTRY,collaborator,Pharmactive Biotech Products S.L.U,Not Applicable
NCT05211635,2022.0,OTHER,lead,"University Hospital, Akershus",Not Applicable
NCT05211635,2022.0,OTHER,collaborator,University of Oslo,Not Applicable
NCT05211635,2022.0,OTHER,collaborator,Oslo University Hospital,Not Applicable
NCT05211947,2022.0,INDUSTRY,lead,Boehringer Ingelheim,Phase 3
NCT05211986,2022.0,INDUSTRY,lead,"Immunis, Inc.",Phase 1/Phase 2
NCT05212298,2021.0,OTHER,lead,Dalin Tzu Chi General Hospital,Not Applicable
NCT05212493,2019.0,OTHER_GOV,lead,Assaf-Harofeh Medical Center,Phase 3
NCT05212493,2019.0,UNKNOWN,collaborator,Seach Sarid Ltd,Phase 3
NCT05212493,2019.0,UNKNOWN,collaborator,Canndoc Ltd,Phase 3
NCT05212571,2022.0,OTHER,lead,Erasmus Medical Center,Not Applicable
NCT05213143,2021.0,INDUSTRY,lead,"Sumitomo Pharma (Suzhou) Co., Ltd.",Phase 4
NCT05213169,2021.0,OTHER,lead,University of Liege,Phase 2/Phase 3
NCT05213169,2021.0,UNKNOWN,collaborator,Centre Hospitalier Neurologique William Lennox (Belgium),Phase 2/Phase 3
NCT05213169,2021.0,UNKNOWN,collaborator,Hôpital Valdor - ISoSL (Belgium),Phase 2/Phase 3
NCT05213169,2021.0,UNKNOWN,collaborator,VITHAS hospitales (Spain),Phase 2/Phase 3
NCT05213832,2020.0,OTHER,lead,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Phase 2
NCT05214222,2022.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Phase 2
NCT05214287,2022.0,OTHER,lead,Radboud University Medical Center,Phase 1/Phase 2
NCT05214287,2022.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1/Phase 2
NCT05215158,2022.0,OTHER,lead,Aswan University Hospital,Not Applicable
NCT05215197,2022.0,OTHER,lead,Pamukkale University,Not Applicable
NCT05216211,2021.0,OTHER,lead,Ataturk University,Not Applicable
NCT05216614,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT05216770,2022.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Early Phase 1
NCT05216770,2022.0,OTHER,collaborator,"University of California, San Francisco",Early Phase 1
NCT05217498,2024.0,OTHER,lead,"Randy Trumbower, PT, PhD",Phase 1/Phase 2
NCT05217628,2022.0,INDUSTRY,lead,Noema Pharma AG,Phase 2/Phase 3
NCT05217706,2022.0,OTHER,lead,"Rady Children's Hospital, San Diego",Early Phase 1
NCT05217706,2022.0,OTHER,collaborator,"University of California, San Diego",Early Phase 1
NCT05217927,2022.0,INDUSTRY,lead,Pfizer,Phase 4
NCT05218018,2020.0,OTHER,lead,University of Washington,Not Applicable
NCT05218018,2020.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT05218096,2021.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2
NCT05218577,2021.0,OTHER,lead,Neny Triana,Not Applicable
NCT05218668,2021.0,INDUSTRY,lead,Woolsey Pharmaceuticals,Phase 2
NCT05219006,2021.0,OTHER,lead,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,Not Applicable
NCT05219175,2024.0,OTHER,lead,University of New Mexico,Phase 2
NCT05219175,2024.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 2
NCT05219357,2021.0,OTHER,lead,Aarogyam UK,Not Applicable
NCT05219357,2021.0,OTHER,collaborator,NMP Medical Research Institute,Not Applicable
NCT05219357,2021.0,UNKNOWN,collaborator,Croydon Ayurveda Centre,Not Applicable
NCT05219357,2021.0,UNKNOWN,collaborator,Active Naturals Limited,Not Applicable
NCT05219357,2021.0,UNKNOWN,collaborator,AVP Research Foundation,Not Applicable
NCT05219617,2022.0,INDUSTRY,lead,"SK Life Science, Inc.",Phase 3
NCT05220072,2021.0,INDUSTRY,lead,"Bial R&D Investments, S.A.",Phase 1
NCT05220319,2022.0,OTHER,lead,Ziekenhuis Oost-Limburg,Phase 4
NCT05221892,2021.0,OTHER,lead,Fundação Educacional Serra dos Órgãos,Phase 4
NCT05222178,2022.0,INDUSTRY,lead,"Homology Medicines, Inc",Phase 1
NCT05222334,2022.0,OTHER,lead,Tanta University,Not Applicable
NCT05223010,2022.0,OTHER,lead,Menoufia University,Phase 4
NCT05223829,2023.0,OTHER,lead,Yale University,Phase 1
NCT05223829,2023.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1
NCT05223829,2023.0,INDUSTRY,collaborator,Sage Therapeutics,Phase 1
NCT05224336,2022.0,OTHER,lead,"University of California, San Diego",Phase 1
NCT05225389,2021.0,INDUSTRY,lead,Cognition Therapeutics,Phase 1
NCT05225389,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05226351,2022.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT05226546,2021.0,OTHER,lead,Centre Hospitalier Universitaire Saint Pierre,Phase 2/Phase 3
NCT05226559,2022.0,OTHER,lead,Neuromed IRCCS,Not Applicable
NCT05226637,2022.0,OTHER,lead,University of Alberta,Not Applicable
NCT05227118,2022.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT05227690,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT05227703,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT05227820,2022.0,OTHER,lead,Neurological Associates of West Los Angeles,Phase 2
NCT05227820,2022.0,INDUSTRY,collaborator,BioVie Inc.,Phase 2
NCT05229042,2022.0,INDUSTRY,lead,"Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.",Phase 1
NCT05229536,2018.0,INDUSTRY,lead,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 2
NCT05229549,2022.0,OTHER,lead,APR Applied Pharma Research s.a.,Not Applicable
NCT05229770,2022.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT05229770,2022.0,OTHER_GOV,collaborator,Helse Stavanger HF,Not Applicable
NCT05229770,2022.0,OTHER,collaborator,Helse Vest,Not Applicable
NCT05229770,2022.0,OTHER,collaborator,University of Bergen,Not Applicable
NCT05229770,2022.0,UNKNOWN,collaborator,ProLAR Nett,Not Applicable
NCT05229770,2022.0,OTHER,collaborator,University of Oslo,Not Applicable
NCT05230381,2022.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05230459,2023.0,INDUSTRY,lead,"Asklepios Biopharmaceutical, Inc.",Phase 1/Phase 2
NCT05230511,2022.0,OTHER,lead,Medstar Health Research Institute,Phase 2
NCT05231798,2021.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT05231798,2021.0,OTHER,collaborator,Vanderbilt Kennedy Center,Phase 2
NCT05232032,2024.0,OTHER,lead,Mclean Hospital,Phase 2
NCT05232032,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05232032,2024.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2
NCT05232032,2024.0,OTHER,collaborator,Massachusetts Institute of Technology,Phase 2
NCT05232032,2024.0,OTHER,collaborator,University of Washington,Phase 2
NCT05232032,2024.0,OTHER,collaborator,Brown University,Phase 2
NCT05232279,2022.0,INDUSTRY,lead,RDC Clinical Pty Ltd,Phase 3
NCT05232630,2022.0,OTHER,lead,Hospital Ruber Internacional,Phase 4
NCT05232630,2022.0,INDUSTRY,collaborator,"Zogenix, Inc.",Phase 4
NCT05232929,2022.0,INDUSTRY,lead,"Genentech, Inc.",Phase 4
NCT05233657,2020.0,INDUSTRY,lead,"Zhejiang Jingxin Pharmaceutical Co., Ltd.",Phase 1
NCT05233683,2022.0,OTHER,lead,King Saud University,Phase 3
NCT05234762,2021.0,INDUSTRY,lead,ES Therapeutics Australia Pty Ltd,Phase 2
NCT05235074,2021.0,INDUSTRY,lead,"Binhui Biopharmaceutical Co., Ltd.",Phase 1/Phase 2
NCT05235191,2019.0,OTHER,lead,University of Sao Paulo,Phase 3
NCT05235256,2022.0,OTHER,lead,Ain Shams University,Not Applicable
NCT05235893,2019.0,OTHER,lead,Marmara University,Not Applicable
NCT05236166,2017.0,OTHER,lead,University Magna Graecia,Not Applicable
NCT05236166,2017.0,OTHER_GOV,collaborator,"Ministry of Health, Italy",Not Applicable
NCT05236842,2021.0,INDUSTRY,lead,Desitin Arzneimittel GmbH,Phase 2
NCT05236907,2020.0,OTHER,lead,University of Baghdad,Not Applicable
NCT05237284,2022.0,INDUSTRY,lead,Sanofi,Phase 2
NCT05237505,2024.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05238233,2022.0,OTHER,lead,Prisma Health-Upstate,Phase 4
NCT05238324,2022.0,INDUSTRY,lead,"Homology Medicines, Inc",Phase 1
NCT05238701,2022.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT05239390,2021.0,OTHER,lead,The Israeli Medical Center for Alzheimer's,Phase 2
NCT05239702,2022.0,OTHER,lead,Zhejiang University,Early Phase 1
NCT05239702,2022.0,INDUSTRY,collaborator,Yake Biotechnology Ltd.,Early Phase 1
NCT05240976,2022.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT05240976,2022.0,OTHER,collaborator,"National Health Research Institutes, Taiwan",Phase 2
NCT05241964,2021.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT05242419,2022.0,OTHER,lead,Second Affiliated Hospital of Wenzhou Medical University,Not Applicable
NCT05242419,2022.0,UNKNOWN,collaborator,The First People's Hospital of Wenling,Not Applicable
NCT05242692,2022.0,OTHER,lead,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Early Phase 1
NCT05243017,2021.0,INDUSTRY,lead,UniQure Biopharma B.V.,Phase 1/Phase 2
NCT05243329,2022.0,INDUSTRY,lead,Halucenex Life Sciences Inc.,Phase 2
NCT05243329,2022.0,INDUSTRY,collaborator,KGK Science Inc.,Phase 2
NCT05243472,2022.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Not Applicable
NCT05243472,2022.0,UNKNOWN,collaborator,"Laurel Corporation, Taiwan",Not Applicable
NCT05243940,2022.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT05243953,2022.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05244226,2022.0,OTHER,lead,Duke University,Phase 2
NCT05245539,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT05245721,2022.0,OTHER,lead,Assiut University,Phase 1
NCT05246644,2023.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 3
NCT05246644,2023.0,OTHER,collaborator,Montreal Heart Institute,Phase 3
NCT05246644,2023.0,OTHER,collaborator,University of Manitoba,Phase 3
NCT05246644,2023.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 3
NCT05247034,2021.0,OTHER,lead,Anahuac University,Not Applicable
NCT05247034,2021.0,OTHER_GOV,collaborator,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Not Applicable
NCT05247125,2022.0,OTHER,lead,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Phase 4
NCT05248672,2022.0,INDUSTRY,lead,Cognition Therapeutics,Phase 1
NCT05249218,2019.0,OTHER,lead,Alex Pinto,Not Applicable
NCT05249985,2022.0,OTHER,lead,Loughborough University,Not Applicable
NCT05249985,2022.0,OTHER,collaborator,McMaster University,Not Applicable
NCT05249985,2022.0,INDUSTRY,collaborator,Danone Nutricia,Not Applicable
NCT05250245,2020.0,OTHER,lead,Yuzuncu Yıl University,Phase 4
NCT05251779,2022.0,OTHER,lead,Jieqiong Cui,Early Phase 1
NCT05252715,2021.0,INDUSTRY,lead,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 3
NCT05253014,2018.0,OTHER,lead,Bahaa Mohammed Refaie,Not Applicable
NCT05253287,2022.0,UNKNOWN,lead,Postgraduate Institute of Medical Education and Research,Phase 2/Phase 3
NCT05254405,2023.0,OTHER,lead,Donald Jeffrey Newport,Phase 4
NCT05254405,2023.0,INDUSTRY,collaborator,Sage Therapeutics,Phase 4
NCT05255328,2021.0,OTHER,lead,Hospital Universitario 12 de Octubre,Not Applicable
NCT05257655,2023.0,OTHER,lead,Klinikum Klagenfurt am Wörthersee,Not Applicable
NCT05257655,2023.0,OTHER,collaborator,University of Klagenfurt,Not Applicable
NCT05258071,2022.0,INDUSTRY,lead,Integrative Research Laboratories AB,Phase 2
NCT05258123,2017.0,OTHER,lead,Beijing HuiLongGuan Hospital,Not Applicable
NCT05258773,2022.0,INDUSTRY,lead,Sensorion,Phase 2
NCT05259098,2019.0,OTHER,lead,Hospital Central do Funchal,Phase 4
NCT05259527,2022.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT05259930,2022.0,OTHER,lead,"Royal College of Surgeons, Ireland",Not Applicable
NCT05259930,2022.0,UNKNOWN,collaborator,Nualtra,Not Applicable
NCT05260125,2022.0,OTHER,lead,Abant Izzet Baysal University,Phase 4
NCT05260541,2022.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 2
NCT05260593,2022.0,OTHER,lead,October 6 University,Not Applicable
NCT05261581,2022.0,OTHER,lead,Bezmialem Vakif University,Early Phase 1
NCT05261594,2022.0,OTHER,lead,Uppsala University,Not Applicable
NCT05262023,2022.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 1/Phase 2
NCT05262023,2022.0,INDUSTRY,collaborator,Takeda,Phase 1/Phase 2
NCT05263817,2021.0,OTHER,lead,Zhejiang University,Early Phase 1
NCT05263817,2021.0,INDUSTRY,collaborator,Yake Biotechnology Ltd.,Early Phase 1
NCT05264428,2021.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Not Applicable
NCT05264714,2022.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05265273,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2/Phase 3
NCT05265728,2022.0,INDUSTRY,lead,Biogen,Phase 3
NCT05266417,2022.0,INDUSTRY,lead,Gateway Institute for Brain Research,Phase 2
NCT05266560,2022.0,OTHER,lead,First Affiliated Hospital of Chongqing Medical University,Early Phase 1
NCT05267535,2022.0,INDUSTRY,lead,Neurim Pharmaceuticals Ltd.,Phase 2/Phase 3
NCT05267535,2022.0,OTHER,collaborator,Syneos Health,Phase 2/Phase 3
NCT05268497,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 1
NCT05268744,2022.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT05269004,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT05269017,2022.0,OTHER,lead,Menoufia University,Phase 2
NCT05269030,2022.0,OTHER,lead,Menoufia University,Phase 2
NCT05269173,2020.0,OTHER,lead,Capital Medical University,Phase 2
NCT05269173,2020.0,INDUSTRY,collaborator,"Xinjiang Uygur Pharmaceutical Co., Ltd.",Phase 2
NCT05269394,2021.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT05269394,2021.0,OTHER,collaborator,Alzheimer's Association,Phase 2/Phase 3
NCT05269394,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT05269394,2021.0,OTHER,collaborator,Accelerating Medicines Partnership (AMP),Phase 2/Phase 3
NCT05269394,2021.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2/Phase 3
NCT05269459,2022.0,OTHER,lead,University of Nebraska,Phase 2
NCT05269459,2022.0,UNKNOWN,collaborator,Ananda Scientific Inc,Phase 2
NCT05269459,2022.0,OTHER,collaborator,University of Texas at Austin,Phase 2
NCT05269628,2022.0,OTHER,lead,"Tiffany J. Braley, MD, MS",Phase 2
NCT05269628,2022.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Phase 2
NCT05269667,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT05269667,2022.0,UNKNOWN,collaborator,Chugai Pharmaceutical Co.,Phase 4
NCT05271552,2022.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 3
NCT05271552,2022.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 3
NCT05273320,2022.0,OTHER,lead,Hsiang-Yuan Lin,Phase 1
NCT05273372,2022.0,INDUSTRY,lead,Terra Biological LLC,Not Applicable
NCT05273372,2022.0,OTHER,collaborator,Bateman Horne Center,Not Applicable
NCT05273398,2022.0,OTHER,lead,University of Cincinnati,Phase 4
NCT05273749,2022.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 3
NCT05274568,2022.0,OTHER,lead,Invicro,Phase 1
NCT05276830,2022.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 2
NCT05276830,2022.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 2
NCT05278156,2021.0,INDUSTRY,lead,Celon Pharma SA,Phase 2
NCT05278156,2021.0,OTHER,collaborator,"National Center for Research and Development, Poland",Phase 2
NCT05278208,2022.0,OTHER,lead,Ralph Salloum,Phase 1/Phase 2
NCT05278208,2022.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 1/Phase 2
NCT05278221,2022.0,OTHER,lead,Aristotle University Of Thessaloniki,Not Applicable
NCT05278715,2022.0,OTHER,lead,Beijing Sanbo Brain Hospital,Phase 2
NCT05279118,2022.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 2/Phase 3
NCT05279586,2022.0,OTHER,lead,Madonna Magdy Fahmy,Early Phase 1
NCT05279755,2022.0,INDUSTRY,lead,ProJenX,Phase 1
NCT05279755,2022.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 1
NCT05279898,2023.0,OTHER,lead,Beth Israel Deaconess Medical Center,Not Applicable
NCT05280015,2022.0,OTHER,lead,Centre Hospitalier Universitaire de Besancon,Phase 2
NCT05280015,2022.0,OTHER,collaborator,Fondation FondaMental,Phase 2
NCT05280015,2022.0,INDUSTRY,collaborator,GYNOV,Phase 2
NCT05280223,2022.0,OTHER,lead,Assiut University,Not Applicable
NCT05280548,2022.0,INDUSTRY,lead,Sanofi,Phase 3
NCT05281120,2006.0,OTHER,lead,Istituto Auxologico Italiano,Not Applicable
NCT05281211,2022.0,OTHER,lead,"San Camillo Hospital, Rome",Not Applicable
NCT05282277,2022.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT05282277,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT05283161,2022.0,INDUSTRY,lead,FG Brasil LTDA,Phase 2/Phase 3
NCT05283161,2022.0,UNKNOWN,collaborator,3F Clinical Trials LTDA,Phase 2/Phase 3
NCT05283434,2021.0,OTHER,lead,Children's Hospitals and Clinics of Minnesota,Phase 2/Phase 3
NCT05283486,2022.0,INDUSTRY,lead,"MyMD Pharmaceuticals, Inc.",Phase 2
NCT05283551,2020.0,OTHER,lead,Queen Mary University of London,Phase 2
NCT05284019,2022.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT05284149,2022.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT05284149,2022.0,INDUSTRY,collaborator,Grape King Bio Ltd.,Not Applicable
NCT05284175,2022.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT05284175,2022.0,INDUSTRY,collaborator,"Beijing InnoCare Pharma Tech Co., Ltd.",Not Applicable
NCT05284175,2022.0,UNKNOWN,collaborator,"GCP ClinPlus Co., Ltd.",Not Applicable
NCT05284747,2022.0,INDUSTRY,lead,Amgen,Phase 4
NCT05284747,2022.0,OTHER,collaborator,Colorado Prevention Center,Phase 4
NCT05285124,2020.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT05285540,2022.0,INDUSTRY,lead,"Design Therapeutics, Inc.",Phase 1
NCT05285891,2023.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4
NCT05285891,2023.0,UNKNOWN,collaborator,Autoimmunity Centers of Excellence (ACE),Phase 4
NCT05285891,2023.0,INDUSTRY,collaborator,"Rho Federal Systems Division, Inc.",Phase 4
NCT05285891,2023.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT05286697,2022.0,OTHER,lead,Marmara University,Not Applicable
NCT05287503,2022.0,OTHER,lead,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Phase 2
NCT05287503,2022.0,OTHER,collaborator,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Phase 2
NCT05287503,2022.0,OTHER,collaborator,"University of Campania ""Luigi Vanvitelli""",Phase 2
NCT05289323,2022.0,OTHER,lead,Alexandria University,Phase 4
NCT05289323,2022.0,OTHER,collaborator,Kasr El Aini Hospital,Phase 4
NCT05289323,2022.0,OTHER,collaborator,Fayoum University,Phase 4
NCT05289947,2023.0,INDUSTRY,lead,Moleac Pte Ltd.,Phase 2
NCT05290025,2022.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT05290025,2022.0,OTHER_GOV,collaborator,Helse Stavanger HF,Not Applicable
NCT05290025,2022.0,OTHER,collaborator,Helse Vest,Not Applicable
NCT05290025,2022.0,OTHER,collaborator,University of Bergen,Not Applicable
NCT05290051,2022.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT05290285,2022.0,OTHER,lead,Villa Garda Hospital,Not Applicable
NCT05290285,2022.0,OTHER,collaborator,University of Milan,Not Applicable
NCT05290285,2022.0,OTHER,collaborator,Università degli Studi di Brescia,Not Applicable
NCT05290688,2022.0,INDUSTRY,lead,Institut Pasteur,Not Applicable
NCT05290688,2022.0,UNKNOWN,collaborator,Höpital La Pitié-Salpêtrière,Not Applicable
NCT05291455,2022.0,OTHER,lead,Sherief Abd-Elsalam,Phase 3
NCT05292222,2022.0,OTHER,lead,HealthPartners Institute,Not Applicable
NCT05293522,2022.0,INDUSTRY,lead,Neuraptive Therapeutics Inc.,Phase 2
NCT05293600,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05294263,2023.0,FED,lead,VA Office of Research and Development,Phase 2
NCT05294835,2022.0,INDUSTRY,lead,TruDiagnostic,Phase 2
NCT05294835,2022.0,UNKNOWN,collaborator,Wild Health,Phase 2
NCT05294874,2021.0,OTHER,lead,Cairo University,Not Applicable
NCT05295810,2022.0,OTHER,lead,University of Calgary,Not Applicable
NCT05296161,2022.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 4
NCT05296356,2021.0,OTHER,lead,Göteborg University,Phase 2
NCT05296356,2021.0,INDUSTRY,collaborator,Arvid Carlsson Research AB,Phase 2
NCT05296759,2021.0,OTHER,lead,Alexandria University,Phase 4
NCT05297201,2021.0,INDUSTRY,lead,Celon Pharma SA,Phase 2
NCT05297201,2021.0,OTHER,collaborator,"National Center for Research and Development, Poland",Phase 2
NCT05297448,2022.0,INDUSTRY,lead,"Bausch Health Americas, Inc.",Phase 3
NCT05297695,2022.0,OTHER,lead,Sohag University,Phase 2/Phase 3
NCT05298085,2022.0,OTHER,lead,"University Hospital, Toulouse",Phase 2/Phase 3
NCT05298670,2022.0,OTHER,lead,German University in Cairo,Phase 2
NCT05298696,2022.0,OTHER,lead,Mansoura University,Phase 1/Phase 2
NCT05299658,2021.0,INDUSTRY,lead,Clene Nanomedicine,Phase 2
NCT05300594,2022.0,INDUSTRY,lead,CEN Biotech,Not Applicable
NCT05300672,2022.0,OTHER,collaborator,"Ministero della Salute, Italy",Phase 3
NCT05300672,2022.0,OTHER_GOV,lead,Azienda Usl di Bologna,Phase 3
NCT05301361,2023.0,OTHER,lead,"University of California, Davis",Phase 1
NCT05301361,2023.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1
NCT05301660,2022.0,OTHER,lead,Sir Run Run Shaw Hospital,Early Phase 1
NCT05301712,2018.0,INDUSTRY,lead,"Samjin Pharmaceutical Co., Ltd.",Phase 4
NCT05302271,2022.0,OTHER,lead,Weill Medical College of Cornell University,Phase 1
NCT05302271,2022.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1
NCT05302999,2022.0,OTHER,lead,MetroHealth Medical Center,Phase 4
NCT05302999,2022.0,FED,collaborator,"National Institute on Disability, Independent Living, and Rehabilitation Research",Phase 4
NCT05303064,2022.0,INDUSTRY,lead,"Alkermes, Inc.",Phase 3
NCT05303259,2021.0,OTHER,lead,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2
NCT05303779,2022.0,OTHER,lead,Cairo University,Not Applicable
NCT05303935,2022.0,OTHER,lead,Flinders University,Phase 2
NCT05303987,2022.0,OTHER,lead,Erin Kirkham,Phase 2
NCT05303987,2022.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT05304767,2022.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT05304910,2022.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT05305625,2022.0,OTHER,lead,The Affiliated Hospital of Xuzhou Medical University,Not Applicable
NCT05305872,2023.0,OTHER,lead,Jun Li,Phase 4
NCT05306093,2022.0,OTHER,lead,Institut Pasteur de Lille,Not Applicable
NCT05306457,2022.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 1
NCT05306457,2022.0,OTHER,collaborator,California Institute for Regenerative Medicine (CIRM),Phase 1
NCT05306548,2022.0,OTHER,lead,Diakonhjemmet Hospital,Phase 4
NCT05306548,2022.0,OTHER,collaborator,Oslo University Hospital,Phase 4
NCT05306548,2022.0,OTHER,collaborator,Martina Hansen's Hospital,Phase 4
NCT05306548,2022.0,OTHER,collaborator,South-Eastern Norway Regional Health Authority,Phase 4
NCT05306834,2022.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT05307692,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT05307744,2022.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT05307744,2022.0,INDUSTRY,collaborator,"Bened Biomedical Co., Ltd.",Not Applicable
NCT05307770,2022.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT05308953,2021.0,INDUSTRY,lead,NervGen Pharma,Phase 1
NCT05309538,2021.0,OTHER,lead,"Neuro Counsel Hospital, Pakistan",Not Applicable
NCT05309668,2022.0,INDUSTRY,lead,AstraZeneca,Phase 1/Phase 2
NCT05309668,2022.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 1/Phase 2
NCT05310071,2022.0,INDUSTRY,lead,Biogen,Phase 3
NCT05310253,2022.0,OTHER,lead,"Charite University, Berlin, Germany",Not Applicable
NCT05312125,2022.0,OTHER,lead,Gazi University,Not Applicable
NCT05312125,2022.0,OTHER_GOV,collaborator,Gulhane Training and Research Hospital,Not Applicable
NCT05312125,2022.0,UNKNOWN,collaborator,Ankara Eğitim ve Araştırma Hastanesi,Not Applicable
NCT05312151,2022.0,INDUSTRY,lead,COMPASS Pathways,Phase 2
NCT05312632,2022.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT05313386,2021.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 2
NCT05313386,2021.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 2
NCT05313659,2022.0,OTHER,lead,Jordanian Royal Medical Services,Phase 2
NCT05314010,2022.0,INDUSTRY,lead,"Beijing Mabworks Biotech Co., Ltd.",Phase 3
NCT05315661,2022.0,OTHER,lead,Samsung Medical Center,Phase 1
NCT05316428,2022.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT05316883,2021.0,OTHER,lead,"Mental Health Services in the Capital Region, Denmark",Phase 4
NCT05317234,2023.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT05317858,2022.0,INDUSTRY,lead,InSightec,Phase 3
NCT05318040,2022.0,INDUSTRY,lead,"Virogenics, Inc.",Phase 1
NCT05318040,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05318040,2022.0,INDUSTRY,collaborator,Celerion,Phase 1
NCT05318937,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05318976,2022.0,INDUSTRY,lead,"Inmune Bio, Inc.",Phase 2
NCT05319275,2020.0,INDUSTRY,lead,"Haisco Pharmaceutical Group Co., Ltd.",Phase 3
NCT05319301,2022.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Not Applicable
NCT05319522,2023.0,FED,lead,VA Office of Research and Development,Not Applicable
NCT05321498,2023.0,INDUSTRY,lead,"Inmune Bio, Inc.",Phase 2
NCT05321602,2021.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT05321680,2021.0,OTHER,lead,"Centro Hospitalar De São João, E.P.E.",Not Applicable
NCT05322031,2022.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Phase 4
NCT05322096,2022.0,INDUSTRY,lead,Gedeon Richter Plc.,Phase 2
NCT05322603,2022.0,OTHER,lead,Petrovsky National Research Centre of Surgery,Not Applicable
NCT05322889,2020.0,OTHER,lead,Dr. Frank Behrens,Phase 2
NCT05322889,2020.0,OTHER,collaborator,Johann Wolfgang Goethe University Hospital,Phase 2
NCT05322941,2022.0,INDUSTRY,lead,Aelis Farma,Phase 2
NCT05322954,2023.0,OTHER,lead,"University of Wisconsin, Madison",Phase 1
NCT05322954,2023.0,INDUSTRY,collaborator,"Revive Therapeutics, Ltd.",Phase 1
NCT05323734,2022.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 3
NCT05323812,2023.0,INDUSTRY,lead,Treeway B.V.,Phase 2
NCT05323864,2023.0,OTHER,lead,Universitaet Innsbruck,Not Applicable
NCT05323864,2023.0,OTHER,collaborator,Medical University Innsbruck,Not Applicable
NCT05324059,2022.0,INDUSTRY,lead,Laboratorios Silanes S.A. de C.V.,Phase 3
NCT05324449,2022.0,OTHER,lead,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 4
NCT05324475,2023.0,OTHER,lead,Patrizia D'Amelio,Not Applicable
NCT05324748,2022.0,OTHER,lead,Leiden University Medical Center,Phase 3
NCT05324748,2022.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 3
NCT05324852,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT05324852,2023.0,UNKNOWN,collaborator,Lariboisière-Saint Louis clinical research unit,Phase 3
NCT05325762,2022.0,OTHER,lead,Xiangya Hospital of Central South University,Phase 4
NCT05325827,2022.0,OTHER,lead,Affiliated Hospital of Nantong University,Not Applicable
NCT05326347,2022.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 3
NCT05326867,2021.0,OTHER,lead,Indonesia University,Not Applicable
NCT05327114,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2/Phase 3
NCT05327426,2022.0,OTHER,lead,University of Vermont,Phase 1
NCT05327426,2022.0,OTHER,collaborator,World Health Organization,Phase 1
NCT05328115,2021.0,INDUSTRY,lead,Alzinova AB,Phase 1
NCT05328115,2021.0,INDUSTRY,collaborator,CRST Oy,Phase 1
NCT05328180,2022.0,OTHER,lead,Kuopio University Hospital,Not Applicable
NCT05328180,2022.0,OTHER,collaborator,University of Eastern Finland,Not Applicable
NCT05328297,2022.0,INDUSTRY,lead,"Janssen Pharmaceutica N.V., Belgium",Phase 2
NCT05329779,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT05331027,2022.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT05331105,2021.0,INDUSTRY,lead,"Shanghai Kechow Pharma, Inc.",Phase 2
NCT05332210,2022.0,INDUSTRY,lead,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 3
NCT05332340,2022.0,INDUSTRY,lead,Biozeus Biopharmaceutical S.A.,Phase 1
NCT05332340,2022.0,OTHER,collaborator,Azidus Brasil Scientific Research and Development Ltda,Phase 1
NCT05332405,2022.0,OTHER,lead,NYU Langone Health,Phase 4
NCT05332678,2023.0,INDUSTRY,lead,"Seelos Therapeutics, Inc.",Phase 2
NCT05332717,2022.0,OTHER,lead,"Hospital for Special Surgery, New York",Not Applicable
NCT05333549,2022.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT05333549,2022.0,INDUSTRY,collaborator,"Kyowa Kirin, Inc.",Phase 2
NCT05334342,2022.0,OTHER,lead,Ohio State University,Not Applicable
NCT05335278,2021.0,OTHER,lead,McGill University Health Centre/Research Institute of the McGill University Health Centre,Not Applicable
NCT05335915,2022.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT05335915,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05336695,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 1/Phase 2
NCT05336695,2022.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 1/Phase 2
NCT05337254,2021.0,INDUSTRY,lead,"Satsuma Pharmaceuticals, Inc.",Phase 1
NCT05337553,2022.0,INDUSTRY,lead,"Biohaven Pharmaceuticals, Inc.",Phase 3
NCT05338099,2022.0,INDUSTRY,lead,ENCell,Phase 1
NCT05338450,2022.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 3
NCT05339074,2022.0,OTHER,lead,"University Health Network, Toronto",Phase 2
NCT05340439,2022.0,OTHER,lead,Universita di Verona,Phase 2
NCT05340504,2022.0,OTHER,lead,Medical University of South Carolina,Phase 2
NCT05340504,2022.0,OTHER,collaborator,Milken Institute,Phase 2
NCT05340660,2022.0,OTHER,lead,Nathalie Braun,Not Applicable
NCT05340660,2022.0,OTHER,collaborator,University of Zurich,Not Applicable
NCT05340660,2022.0,OTHER,collaborator,ETH Zurich,Not Applicable
NCT05340803,2022.0,OTHER,lead,Assiut University,Phase 3
NCT05340985,2022.0,OTHER,lead,Tehran University of Medical Sciences,Phase 4
NCT05340985,2022.0,OTHER,collaborator,Boston University,Phase 4
NCT05341154,2021.0,OTHER,lead,"Huda Fahmy Mahmoud, PhD",Not Applicable
NCT05342844,2022.0,OTHER,lead,Mansoura University,Not Applicable
NCT05343507,2022.0,OTHER,lead,University of Liege,Phase 2/Phase 3
NCT05343507,2022.0,OTHER,collaborator,Centre Hospitalier Universitaire de Liege,Phase 2/Phase 3
NCT05343507,2022.0,UNKNOWN,collaborator,William Lennox Neurological Center UCLouvain,Phase 2/Phase 3
NCT05343533,2019.0,OTHER,lead,Lindenwood University,Not Applicable
NCT05343533,2019.0,UNKNOWN,collaborator,"Increnovo, LLC",Not Applicable
NCT05343611,2022.0,OTHER,lead,"Massimo Venturelli, PhD",Not Applicable
NCT05343611,2022.0,OTHER,collaborator,University Of Perugia,Not Applicable
NCT05343611,2022.0,INDUSTRY,collaborator,INCLIVA,Not Applicable
NCT05343611,2022.0,OTHER,collaborator,Molde University College,Not Applicable
NCT05343611,2022.0,OTHER,collaborator,University of Liverpool,Not Applicable
NCT05343611,2022.0,UNKNOWN,collaborator,Molecular Horizon S.r.l.,Not Applicable
NCT05343611,2022.0,UNKNOWN,collaborator,Nestlé Italiana S.p.A.,Not Applicable
NCT05343715,2021.0,INDUSTRY,lead,Bio Sidus SA,Phase 1
NCT05344313,2022.0,OTHER,lead,Sengkang General Hospital,Not Applicable
NCT05344313,2022.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT05344404,2022.0,OTHER,lead,Haukeland University Hospital,Not Applicable
NCT05344495,2022.0,OTHER,lead,Minia University,Early Phase 1
NCT05344625,2023.0,OTHER,lead,Northwell Health,Early Phase 1
NCT05344989,2022.0,INDUSTRY,lead,"APRINOIA Therapeutics, LLC",Phase 1
NCT05345171,2022.0,INDUSTRY,lead,Ultragenyx Pharmaceutical Inc,Phase 3
NCT05345509,2023.0,INDUSTRY,lead,"Inventage Lab., Inc.",Phase 1/Phase 2
NCT05345548,2019.0,OTHER,lead,"HaEmek Medical Center, Israel",Not Applicable
NCT05346354,2022.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 2/Phase 3
NCT05346588,2022.0,OTHER,lead,Washington University School of Medicine,Phase 3
NCT05346588,2022.0,OTHER,collaborator,University of Michigan,Phase 3
NCT05346588,2022.0,OTHER,collaborator,University of Pennsylvania,Phase 3
NCT05346588,2022.0,OTHER,collaborator,Stanford University,Phase 3
NCT05346588,2022.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 3
NCT05346666,2022.0,OTHER,lead,Damanhour University,Phase 3
NCT05346666,2022.0,UNKNOWN,collaborator,"Principal Investigator Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University",Phase 3
NCT05346666,2022.0,UNKNOWN,collaborator,"Principal Investigator Mohanad Omar Ahmed, Msc Pharmacy Practice Department- Horus University",Phase 3
NCT05346666,2022.0,UNKNOWN,collaborator,"Principal Investigator Sahar Hegazy, Prof Clinical pharmacy Department- Tanta University",Phase 3
NCT05347147,2022.0,INDUSTRY,lead,Invex Therapeutics Ltd.,Phase 3
NCT05347147,2022.0,INDUSTRY,collaborator,Premier Research Group plc,Phase 3
NCT05347173,2022.0,OTHER,lead,Mansoura University,Not Applicable
NCT05347329,2019.0,INDUSTRY,lead,Natural Wellness Egypt,Not Applicable
NCT05348785,2022.0,INDUSTRY,lead,Biogen,Phase 2
NCT05348785,2022.0,INDUSTRY,collaborator,Denali Therapeutics Inc.,Phase 2
NCT05349448,2022.0,OTHER,lead,Minia University,Early Phase 1
NCT05349721,2022.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT05350124,2022.0,OTHER,lead,King Abdulaziz University,Phase 3
NCT05350215,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05351021,2022.0,OTHER,lead,Mansoura University,Phase 2
NCT05351073,2022.0,OTHER,lead,Capital Medical University,Phase 2
NCT05351333,2022.0,OTHER,lead,Spaulding Rehabilitation Hospital,Not Applicable
NCT05351333,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05351736,2022.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Phase 4
NCT05352373,2008.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT05352763,2022.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 2
NCT05355025,2022.0,OTHER,lead,University of Melbourne,Not Applicable
NCT05355025,2022.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Not Applicable
NCT05355064,2022.0,OTHER,lead,Neuromed IRCCS,Phase 4
NCT05355337,2023.0,OTHER,lead,Region Skane,Phase 3
NCT05355337,2023.0,OTHER,collaborator,Lund University,Phase 3
NCT05356013,2023.0,OTHER,lead,University of Chicago,Phase 2
NCT05356013,2023.0,INDUSTRY,collaborator,"Intra-Cellular Therapies, Inc.",Phase 2
NCT05356104,2022.0,OTHER,lead,Chinese University of Hong Kong,Phase 2
NCT05356559,2022.0,OTHER,lead,University of Ulster,Not Applicable
NCT05356559,2022.0,OTHER,collaborator,University of Limerick,Not Applicable
NCT05356559,2022.0,UNKNOWN,collaborator,Bio-Marine Ingredients Ireland,Not Applicable
NCT05356858,2022.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 2
NCT05357066,2021.0,OTHER,lead,University of Chicago,Phase 2
NCT05357547,2022.0,OTHER,lead,University of Oxford,Phase 2
NCT05357612,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT05357612,2023.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 4
NCT05357677,2022.0,INDUSTRY,lead,"Shanghai SIMR Biotechnology Co., Ltd.",Phase 2
NCT05357833,2022.0,OTHER,lead,University of Utah,Early Phase 1
NCT05357859,2022.0,OTHER_GOV,lead,Taipei City Hospital,Not Applicable
NCT05357950,2022.0,INDUSTRY,lead,NeuroSense Therapeutics Ltd.,Phase 2
NCT05357989,2022.0,INDUSTRY,lead,Annovis Bio Inc.,Phase 3
NCT05357989,2022.0,INDUSTRY,collaborator,TFS Trial Form Support,Phase 3
NCT05358717,2022.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT05358821,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05358886,2022.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 3
NCT05359081,2022.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 3
NCT05359224,2022.0,OTHER,lead,Yonsei University,Phase 4
NCT05359224,2022.0,OTHER,collaborator,Severance Hospital,Phase 4
NCT05359224,2022.0,OTHER,collaborator,Gangnam Severance Hospital,Phase 4
NCT05359224,2022.0,OTHER,collaborator,Bucheon St. Mary's Hospital,Phase 4
NCT05359224,2022.0,UNKNOWN,collaborator,International St. Mary's Hospital,Phase 4
NCT05359224,2022.0,UNKNOWN,collaborator,Ewha Woman's University Seoul Hospital,Phase 4
NCT05359653,2023.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT05359653,2023.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT05359731,2022.0,OTHER,lead,University of Chile,Phase 4
NCT05360953,2022.0,OTHER,lead,"Charite University, Berlin, Germany",Phase 2
NCT05360953,2022.0,OTHER_GOV,collaborator,German Federal Ministry of Education and Research,Phase 2
NCT05361109,2022.0,OTHER,lead,University of Washington,Phase 2
NCT05361122,2023.0,OTHER,lead,University of Washington,Not Applicable
NCT05361382,2021.0,OTHER,lead,Tharick Pascoal,Phase 1
NCT05361382,2021.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05361707,2021.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 3
NCT05361824,2021.0,OTHER,lead,"National Institute of Cardiovascular Diseases, Pakistan",Phase 4
NCT05361837,2022.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT05361993,2024.0,OTHER,lead,Children's Hospital of Fudan University,Phase 4
NCT05361993,2024.0,UNKNOWN,collaborator,Shanghai Normal University,Phase 4
NCT05362994,2022.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT05362994,2022.0,INDUSTRY,collaborator,M.A. Med Alliance S.A.,Not Applicable
NCT05363228,2021.0,OTHER,lead,"Charles University, Czech Republic",Not Applicable
NCT05363228,2021.0,UNKNOWN,collaborator,University Hospital Vinohrady,Not Applicable
NCT05363228,2021.0,UNKNOWN,collaborator,Faculty of Physical Education and Sport,Not Applicable
NCT05363267,2022.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 1
NCT05363293,2022.0,INDUSTRY,lead,"Alzamend Neuro, Inc.",Phase 1/Phase 2
NCT05363410,2022.0,OTHER,lead,Franklin Health Research,Not Applicable
NCT05363410,2022.0,INDUSTRY,collaborator,"Opella Healthcare Group SAS, a Sanofi Company",Not Applicable
NCT05363514,2024.0,OTHER,lead,University of Calgary,Phase 4
NCT05363527,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT05363527,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05364021,2022.0,INDUSTRY,lead,Longboard Pharmaceuticals,Phase 1/Phase 2
NCT05364853,2024.0,OTHER,lead,Stanford University,Not Applicable
NCT05364944,2022.0,INDUSTRY,lead,Debiopharm International SA,Phase 1
NCT05365880,2022.0,OTHER,lead,University of Utah,Phase 2
NCT05366751,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2/Phase 3
NCT05366933,2022.0,FED,lead,National Aeronautics and Space Administration (NASA),Phase 1
NCT05366933,2022.0,OTHER,collaborator,Mayo Clinic,Phase 1
NCT05366933,2022.0,OTHER,collaborator,Texas A&M University,Phase 1
NCT05367492,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT05367492,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT05367960,2022.0,INDUSTRY,lead,Tetra Discovery Partners,Phase 3
NCT05368558,2022.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05368753,2022.0,OTHER,lead,"Centre Hospitalier Universitaire, Amiens",Phase 4
NCT05369533,2022.0,OTHER,lead,"University of California, Los Angeles",Phase 1/Phase 2
NCT05369793,2022.0,OTHER,lead,Tanta University,Phase 3
NCT05370911,2023.0,OTHER,lead,Yale University,Phase 1
NCT05370911,2023.0,OTHER,collaborator,Steven & Alexandra Cohen Foundation,Phase 1
NCT05371613,2022.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 2/Phase 3
NCT05371639,2022.0,OTHER,lead,"Dongzhimen Hospital, Beijing",Phase 2
NCT05372601,2022.0,INDUSTRY,lead,FrieslandCampina,Not Applicable
NCT05372887,2022.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT05374278,2021.0,OTHER,lead,David Wilson,Phase 1/Phase 2
NCT05374278,2021.0,UNKNOWN,collaborator,Rio pharmaceuticals Inc.,Phase 1/Phase 2
NCT05374681,2023.0,OTHER,lead,"University Hospital, Brest",Not Applicable
NCT05375240,2022.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2
NCT05376319,2023.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05376319,2023.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2
NCT05378061,2022.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05378074,2022.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05378256,2022.0,OTHER,lead,Centre Hospitalier Régional d'Orléans,Not Applicable
NCT05378399,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 3
NCT05378399,2022.0,INDUSTRY,collaborator,Gilead Sciences,Phase 3
NCT05378399,2022.0,OTHER,collaborator,The Fenway Institute,Phase 3
NCT05378711,2014.0,OTHER,lead,Michigan State University,Phase 2
NCT05378984,2020.0,OTHER,lead,Karolinska Institutet,Not Applicable
NCT05379634,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 2
NCT05379855,2022.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Not Applicable
NCT05379855,2022.0,OTHER,collaborator,Children's Hospital of Fudan University,Not Applicable
NCT05379855,2022.0,OTHER_GOV,collaborator,Shandong Provincial Hospital,Not Applicable
NCT05379855,2022.0,OTHER,collaborator,Shanxi Eye Hospital,Not Applicable
NCT05379855,2022.0,OTHER,collaborator,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Not Applicable
NCT05379855,2022.0,OTHER,collaborator,Tianjin Eye Hospital,Not Applicable
NCT05379855,2022.0,OTHER,collaborator,Renmin Hospital of Wuhan University,Not Applicable
NCT05379855,2022.0,UNKNOWN,collaborator,Aier Eye Affiliated Hospital of Wuhan University,Not Applicable
NCT05379855,2022.0,OTHER,collaborator,The Second Affiliated Hospital of Harbin Medical University,Not Applicable
NCT05380453,2022.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT05381090,2022.0,OTHER,lead,Swansea University,Not Applicable
NCT05381090,2022.0,OTHER,collaborator,Newcastle University,Not Applicable
NCT05381389,2018.0,OTHER,lead,Ain Shams University,Not Applicable
NCT05382026,2022.0,OTHER,lead,University of Saskatchewan,Not Applicable
NCT05382832,2022.0,OTHER,lead,Europainclinics z.ú.,Not Applicable
NCT05382832,2022.0,UNKNOWN,collaborator,"National Hospital for Neurology and Neurosurgery, London",Not Applicable
NCT05383183,2022.0,INDUSTRY,lead,Daewoong Bio Inc.,Phase 4
NCT05383300,2017.0,OTHER,lead,King's College London,Not Applicable
NCT05383300,2017.0,OTHER,collaborator,Father Flanagan's Boys' Home,Not Applicable
NCT05383742,2023.0,NIH,lead,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2
NCT05383833,2022.0,OTHER,lead,University of Kansas Medical Center,Not Applicable
NCT05383833,2022.0,OTHER,collaborator,Alzheimer's Association,Not Applicable
NCT05384210,2022.0,OTHER,lead,Mansoura University,Not Applicable
NCT05384470,2021.0,OTHER,lead,Mclean Hospital,Phase 2
NCT05384470,2021.0,UNKNOWN,collaborator,VOX BIOMEDICAL LLC,Phase 2
NCT05384951,2022.0,OTHER,lead,Gillette Children's Specialty Healthcare,Not Applicable
NCT05384951,2022.0,OTHER,collaborator,University of Minnesota,Not Applicable
NCT05384951,2022.0,UNKNOWN,collaborator,"Metabolic Technologies, LLC",Not Applicable
NCT05385744,2021.0,INDUSTRY,lead,Biocad,Phase 3
NCT05386108,2022.0,OTHER,lead,"Stemline Therapeutics, Inc.",Phase 1/Phase 2
NCT05386680,2023.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 3
NCT05386810,2020.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT05387642,2022.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 2
NCT05387798,2023.0,INDUSTRY,lead,"Radius Pharmaceuticals, Inc.",Phase 3
NCT05388825,2022.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 2
NCT05389761,2022.0,OTHER,lead,Centros de Investigación de Nutrición y Salud,Not Applicable
NCT05389761,2022.0,INDUSTRY,collaborator,AB Biotek,Not Applicable
NCT05391555,2022.0,OTHER,lead,"University of California, San Francisco",Phase 2/Phase 3
NCT05391971,2022.0,OTHER,lead,NYU Langone Health,Phase 4
NCT05394064,2022.0,INDUSTRY,lead,"SwanBio Therapeutics, Inc.",Phase 1/Phase 2
NCT05394610,2024.0,INDUSTRY,lead,Sana Health,Not Applicable
NCT05394610,2024.0,OTHER,collaborator,University of Pennsylvania,Not Applicable
NCT05395325,2022.0,OTHER,lead,Chang Gung Memorial Hospital,Not Applicable
NCT05395494,2022.0,OTHER,lead,University of Calgary,Phase 2
NCT05395845,2022.0,OTHER,lead,Aya abdelnasser hassani,Early Phase 1
NCT05395949,2019.0,OTHER,lead,Wuhan University,Not Applicable
NCT05397626,2022.0,OTHER,lead,Stony Brook University,Phase 1
NCT05397626,2022.0,UNKNOWN,collaborator,Natural Wellness Now Health Products,Phase 1
NCT05398913,2021.0,OTHER,lead,Hospital Nacional de Parapléjicos de Toledo,Phase 1/Phase 2
NCT05399459,2022.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05399485,2022.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05399498,2023.0,OTHER,lead,University of Chicago,Phase 2
NCT05399498,2023.0,OTHER,collaborator,Usona Institute,Phase 2
NCT05400330,2023.0,INDUSTRY,lead,Lexeo Therapeutics,Phase 1
NCT05401019,2022.0,OTHER,lead,Clinical Academic Center (2CA-Braga),Phase 2
NCT05401019,2022.0,OTHER,collaborator,University of Minho,Phase 2
NCT05401565,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT05402111,2022.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT05403138,2022.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2/Phase 3
NCT05404230,2022.0,OTHER,lead,Vejle Hospital,Not Applicable
NCT05405049,2022.0,OTHER,lead,Ataturk University,Not Applicable
NCT05406440,2022.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT05407324,2022.0,INDUSTRY,lead,Corcept Therapeutics,Phase 2
NCT05408780,2022.0,INDUSTRY,lead,Cerecin,Phase 1
NCT05411900,2022.0,OTHER,lead,Francesco Bono,Phase 2
NCT05411978,2022.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05412004,2022.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05412160,2023.0,OTHER,lead,University of Milan,Not Applicable
NCT05412394,2021.0,OTHER,lead,Anne M. Connolly,Phase 4
NCT05412394,2021.0,OTHER,collaborator,Ann & Robert H Lurie Children's Hospital of Chicago,Phase 4
NCT05412394,2021.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT05412394,2021.0,OTHER,collaborator,Muscular Dystrophy Association,Phase 4
NCT05412394,2021.0,OTHER,collaborator,University of Texas,Phase 4
NCT05412394,2021.0,OTHER,collaborator,Virginia Commonwealth University,Phase 4
NCT05413655,2022.0,INDUSTRY,lead,Excelsior,Phase 2
NCT05413655,2022.0,UNKNOWN,collaborator,Formosa Biomedical Technology Corp.,Phase 2
NCT05414292,2021.0,OTHER,lead,University of Nottingham,Not Applicable
NCT05414292,2021.0,OTHER,collaborator,University of Oxford,Not Applicable
NCT05416515,2022.0,OTHER,lead,"Peter C. Amadio, M.D.",Phase 2
NCT05416866,2022.0,OTHER,lead,dong zhang,Phase 4
NCT05417269,2022.0,INDUSTRY,lead,Imcyse SA,Phase 1/Phase 2
NCT05418010,2022.0,OTHER,lead,Queen Mary University of London,Phase 2
NCT05418010,2022.0,INDUSTRY,collaborator,Biogen,Phase 2
NCT05418010,2022.0,OTHER,collaborator,UCL Queen Square Institute of Neurology,Phase 2
NCT05418010,2022.0,OTHER,collaborator,Moorfields Eye Hospital NHS Foundation Trust,Phase 2
NCT05418010,2022.0,OTHER,collaborator,Barts & The London NHS Trust,Phase 2
NCT05418049,2022.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT05418049,2022.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2
NCT05418673,2022.0,INDUSTRY,lead,Biogen,Phase 3
NCT05418673,2022.0,INDUSTRY,collaborator,Denali Therapeutics Inc.,Phase 3
NCT05419193,2023.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT05420805,2022.0,OTHER,lead,Azienda Ospedaliera Universitaria Senese,Not Applicable
NCT05420805,2022.0,UNKNOWN,collaborator,Kolfarma s.r.l. - Italy,Not Applicable
NCT05420805,2022.0,OTHER,collaborator,European Institute of Oncology,Not Applicable
NCT05422352,2021.0,OTHER,lead,Beni-Suef University,Not Applicable
NCT05422482,2022.0,INDUSTRY,lead,GC Biopharma Corp,Phase 1
NCT05422612,2023.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT05422612,2023.0,INDUSTRY,collaborator,PPD,Phase 2
NCT05422612,2023.0,OTHER,collaborator,Berry Consultants,Phase 2
NCT05422612,2023.0,INDUSTRY,collaborator,Idorsia Pharmaceuticals Ltd.,Phase 2
NCT05422612,2023.0,INDUSTRY,collaborator,Cambridge Cognition Ltd,Phase 2
NCT05422612,2023.0,UNKNOWN,collaborator,Citeline,Phase 2
NCT05423028,2021.0,OTHER,lead,National Cheng-Kung University Hospital,Not Applicable
NCT05423522,2022.0,INDUSTRY,lead,Medesis Pharma SA,Phase 2
NCT05424146,2022.0,OTHER,lead,Rush University Medical Center,Not Applicable
NCT05424146,2022.0,OTHER,collaborator,Cures Within Reach,Not Applicable
NCT05424276,2023.0,INDUSTRY,lead,"Inhibikase Therapeutics, Inc.",Phase 2
NCT05425004,2022.0,OTHER,lead,Baptist Health South Florida,Phase 2
NCT05425004,2022.0,INDUSTRY,collaborator,Exelixis,Phase 2
NCT05426304,2022.0,OTHER,lead,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4
NCT05426889,2022.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT05427266,2022.0,OTHER,lead,"Royal College of Surgeons, Ireland",Not Applicable
NCT05427474,2022.0,OTHER_GOV,lead,Zagazig University,Phase 3
NCT05427500,2022.0,OTHER,lead,The Royal's Institute of Mental Health Research,Early Phase 1
NCT05427500,2022.0,OTHER,collaborator,Ottawa Hospital Research Institute,Early Phase 1
NCT05427630,2023.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05428215,2022.0,OTHER,lead,MaineHealth,Phase 4
NCT05429372,2022.0,INDUSTRY,lead,Pfizer,Phase 2
NCT05429489,2022.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT05429814,2022.0,OTHER,lead,Necmettin Erbakan University,Not Applicable
NCT05430217,2022.0,INDUSTRY,lead,Valenta Pharm JSC,Phase 3
NCT05430867,2022.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Phase 4
NCT05431413,2020.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Phase 2
NCT05431543,2022.0,OTHER,lead,Alisyn Facemire,Phase 2
NCT05431543,2022.0,INDUSTRY,collaborator,"ORA, Inc.",Phase 2
NCT05431595,2022.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT05431595,2022.0,OTHER,collaborator,Cancer Prevention Research Institute of Texas,Phase 2/Phase 3
NCT05431933,2023.0,INDUSTRY,lead,LG Chem,Phase 3
NCT05432141,2022.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 4
NCT05432362,2019.0,OTHER,lead,Medical University of Graz,Not Applicable
NCT05432713,2022.0,INDUSTRY,lead,Guangzhou Lupeng Pharmaceutical Company LTD.,Phase 1
NCT05432830,2024.0,OTHER,lead,Yale University,Not Applicable
NCT05432830,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05432934,2022.0,OTHER,lead,University of Saskatchewan,Phase 1/Phase 2
NCT05434000,2021.0,OTHER_GOV,lead,Barau Dikko Teaching Hospital,Not Applicable
NCT05434065,2023.0,OTHER,lead,National Taiwan University Hospital,Phase 2
NCT05434156,2022.0,INDUSTRY,lead,Eleusis Therapeutics,Phase 1/Phase 2
NCT05434546,2022.0,INDUSTRY,lead,Asarina Pharma,Phase 2
NCT05435729,2022.0,INDUSTRY,lead,"Sumitomo Pharma Co., Ltd.",Phase 1
NCT05435755,2022.0,OTHER,lead,Shanghai East Hospital,Early Phase 1
NCT05435755,2022.0,INDUSTRY,collaborator,"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China",Early Phase 1
NCT05435781,2022.0,OTHER,lead,Ulla Feldt-Rasmussen,Phase 4
NCT05435781,2022.0,OTHER,collaborator,Aarhus University Hospital,Phase 4
NCT05435781,2022.0,OTHER,collaborator,Odense University Hospital,Phase 4
NCT05436314,2022.0,OTHER,lead,Kutahya Health Sciences University,Not Applicable
NCT05437263,2022.0,INDUSTRY,lead,"Priovant Therapeutics, Inc.",Phase 3
NCT05437588,2022.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT05437588,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Not Applicable
NCT05439486,2022.0,OTHER,lead,Sohag University,Not Applicable
NCT05439616,2022.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05439902,2022.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT05442775,2022.0,INDUSTRY,lead,Cytokinetics,Phase 3
NCT05443724,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT05445323,2022.0,INDUSTRY,lead,Lexeo Therapeutics,Phase 1/Phase 2
NCT05445804,2022.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT05445804,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05445921,2022.0,OTHER,lead,Washington University School of Medicine,Phase 1/Phase 2
NCT05446168,2022.0,OTHER,lead,"Nicolaas Bohnen, MD, PhD",Phase 1
NCT05446493,2019.0,OTHER,lead,Aswan University,Phase 4
NCT05446857,2023.0,FED,lead,White River Junction Veterans Affairs Medical Center,Phase 2/Phase 3
NCT05447676,2022.0,OTHER,lead,Shirley Ryan AbilityLab,Early Phase 1
NCT05447676,2022.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT05448209,2022.0,OTHER,lead,Necmettin Erbakan University,Not Applicable
NCT05448469,2022.0,OTHER,lead,Ain Shams University,Phase 3
NCT05451017,2023.0,INDUSTRY,lead,Aelis Farma,Phase 1
NCT05451017,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05452239,2022.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 4
NCT05452772,2023.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT05452772,2023.0,OTHER,collaborator,University of Alabama at Birmingham,Phase 2
NCT05452772,2023.0,OTHER,collaborator,New York University,Phase 2
NCT05452772,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT05452928,2024.0,OTHER,lead,Jacob Bodilsen,Phase 4
NCT05453539,2022.0,INDUSTRY,lead,"Alzeca Biosciences, Inc.",Phase 1
NCT05453539,2022.0,UNKNOWN,collaborator,pharmtrace klinische Entwicklung GmbH,Phase 1
NCT05454085,2021.0,OTHER,lead,Sanliurfa Mehmet Akif Inan Education and Research Hospital,Not Applicable
NCT05454085,2021.0,UNKNOWN,collaborator,Bursa Yuksek Ihtisas Education and Research Hospital,Not Applicable
NCT05454683,2022.0,INDUSTRY,lead,"Laboratorios Viñas, S.A.",Not Applicable
NCT05454683,2022.0,UNKNOWN,collaborator,Laboratorio Echevarne,Not Applicable
NCT05454683,2022.0,OTHER,collaborator,Hospital Vall d'Hebron,Not Applicable
NCT05455398,2021.0,OTHER,lead,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Not Applicable
NCT05455684,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT05455996,2022.0,OTHER,lead,Willa Hall,Phase 2
NCT05456503,2022.0,OTHER,lead,University of Pennsylvania,Phase 3
NCT05456503,2022.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT05457140,2022.0,OTHER,lead,Rady Pediatric Genomics & Systems Medicine Institute,Not Applicable
NCT05457465,2023.0,OTHER,lead,Mclean Hospital,Phase 2
NCT05457946,2023.0,INDUSTRY,lead,LG Chem,Phase 2/Phase 3
NCT05458011,2022.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT05458128,2022.0,INDUSTRY,lead,"Harmony Biosciences, LLC",Phase 3
NCT05458479,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT05459272,2022.0,INDUSTRY,lead,Uriach Consumer Healthcare,Not Applicable
NCT05460351,2014.0,OTHER,lead,Wake Forest University,Not Applicable
NCT05460377,2022.0,FED,lead,Centers for Disease Control and Prevention,Phase 4
NCT05460377,2022.0,OTHER,collaborator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT05460377,2022.0,OTHER,collaborator,World Health Organization,Phase 4
NCT05460377,2022.0,OTHER_GOV,collaborator,"Centers for Disease Control and Prevention, China",Phase 4
NCT05461092,2024.0,OTHER,lead,University of Iowa,Early Phase 1
NCT05461365,2021.0,OTHER,lead,Universidad Panamericana,Phase 3
NCT05462106,2022.0,INDUSTRY,lead,AC Immune SA,Phase 1/Phase 2
NCT05462106,2022.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 1/Phase 2
NCT05462132,2022.0,INDUSTRY,lead,Synlogic,Phase 1
NCT05462340,2022.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT05462665,2020.0,OTHER,lead,Dokuz Eylul University,Not Applicable
NCT05462938,2021.0,OTHER,lead,University of Ioannina,Not Applicable
NCT05463731,2022.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05463770,2022.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT05463835,2022.0,OTHER,lead,University College Cork,Not Applicable
NCT05463835,2022.0,UNKNOWN,collaborator,South East Technological University,Not Applicable
NCT05464368,2023.0,OTHER,lead,Washington University School of Medicine,Phase 1
NCT05464368,2023.0,INDUSTRY,collaborator,Roche Pharma AG,Phase 1
NCT05466279,2021.0,OTHER,lead,Fang Jun,Not Applicable
NCT05466422,2022.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT05466604,2019.0,OTHER,lead,Hacettepe University,Phase 4
NCT05466708,2022.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Phase 4
NCT05467215,2022.0,OTHER,lead,University of Alberta,Early Phase 1
NCT05467215,2022.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Early Phase 1
NCT05467397,2021.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05467397,2021.0,OTHER,collaborator,Massachusetts General Hospital,Phase 1/Phase 2
NCT05468073,2022.0,OTHER,lead,Centre Hospitalier St Anne,Phase 2
NCT05468073,2022.0,OTHER,collaborator,For Drug Consulting,Phase 2
NCT05469360,2023.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT05469997,2023.0,OTHER,lead,University of British Columbia,Not Applicable
NCT05469997,2023.0,UNKNOWN,collaborator,Weston Family Foundation,Not Applicable
NCT05470816,2022.0,OTHER_GOV,lead,Bayside Health,Phase 3
NCT05470816,2022.0,OTHER,collaborator,Monash University,Phase 3
NCT05471063,2022.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT05471063,2022.0,UNKNOWN,collaborator,"CSPC Ouyi Pharmaceutical Group Co., Ltd.",Not Applicable
NCT05471609,2024.0,OTHER,lead,University of Minnesota,Early Phase 1
NCT05471804,2022.0,OTHER,lead,Northumbria University,Not Applicable
NCT05471804,2022.0,UNKNOWN,collaborator,HG&H Pharmaceuticals,Not Applicable
NCT05472766,2022.0,OTHER,lead,Sunnybrook Health Sciences Centre,Not Applicable
NCT05474846,2022.0,OTHER,lead,M.D. Anderson Cancer Center,Phase 2/Phase 3
NCT05475483,2022.0,INDUSTRY,lead,SOM Innovation Biotech SA,Phase 2
NCT05475808,2022.0,OTHER,lead,Abant Izzet Baysal University,Phase 4
NCT05476783,2022.0,INDUSTRY,lead,"TrueBinding, Inc.",Phase 2
NCT05476991,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT05477095,2022.0,INDUSTRY,lead,"Vaxxinity, Inc.",Phase 1
NCT05477459,2024.0,OTHER,lead,Radboud University Medical Center,Phase 2
NCT05477459,2024.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 2
NCT05477459,2024.0,OTHER,collaborator,Canisius-Wilhelmina Hospital,Phase 2
NCT05477459,2024.0,OTHER,collaborator,Leiden University Medical Center,Phase 2
NCT05477459,2024.0,OTHER,collaborator,Donders Centre for Cognitive Neuroimaging,Phase 2
NCT05477732,2021.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT05478031,2022.0,INDUSTRY,lead,reMYND,Phase 2
NCT05478720,2022.0,UNKNOWN,lead,"Douglas Postels, MD, MS",Phase 1/Phase 2
NCT05478720,2022.0,NIH,collaborator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1/Phase 2
NCT05479032,2023.0,OTHER,lead,University Hospital Tuebingen,Phase 2
NCT05479981,2022.0,INDUSTRY,lead,"Avidity Biosciences, Inc.",Phase 2
NCT05480592,2022.0,INDUSTRY,lead,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1
NCT05480826,2023.0,OTHER,lead,Fondation FondaMental,Not Applicable
NCT05481177,2023.0,FED,lead,Uniformed Services University of the Health Sciences,Phase 4
NCT05481736,2022.0,INDUSTRY,lead,COMPASS Pathways,Phase 2
NCT05481905,2022.0,INDUSTRY,lead,Engrail Therapeutics INC,Phase 2
NCT05481957,2022.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Phase 4
NCT05481957,2022.0,OTHER,collaborator,Zhejiang University,Phase 4
NCT05482334,2023.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT05482334,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05482542,2023.0,OTHER,lead,Scripps Health,Not Applicable
NCT05482672,2023.0,OTHER,lead,"Cale Andrew Jacobs, PhD",Phase 2/Phase 3
NCT05482672,2023.0,OTHER,collaborator,Massachusetts General Hospital,Phase 2/Phase 3
NCT05483647,2021.0,OTHER,lead,Lviv National Medical University,Not Applicable
NCT05484167,2023.0,OTHER,lead,University of Utah,Phase 4
NCT05484167,2023.0,INDUSTRY,collaborator,Acerus Pharmaceuticals Corporation,Phase 4
NCT05484557,2023.0,OTHER,lead,Loewenstein Hospital,Not Applicable
NCT05485012,2023.0,OTHER,lead,"Shanna Babalonis, PhD",Phase 1
NCT05485012,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05485402,2022.0,OTHER,lead,University Rovira i Virgili,Not Applicable
NCT05485480,2022.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT05485519,2022.0,OTHER,lead,King Abdullah International Medical Research Center,Phase 3
NCT05485558,2022.0,OTHER,lead,Tanta University,Phase 2
NCT05485987,2022.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT05486260,2022.0,OTHER,lead,Instituto de Investigación Hospital Universitario La Paz,Not Applicable
NCT05486260,2022.0,OTHER,collaborator,Instituto de Nutrición y Tecnología de los Alimentos,Not Applicable
NCT05486260,2022.0,UNKNOWN,collaborator,Medicinal Gardens S.L,Not Applicable
NCT05487300,2022.0,OTHER,lead,University of Utah,Phase 2/Phase 3
NCT05487378,2023.0,OTHER,lead,APR Applied Pharma Research s.a.,Not Applicable
NCT05487599,2022.0,INDUSTRY,lead,Prevail Therapeutics,Phase 1/Phase 2
NCT05487599,2022.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1/Phase 2
NCT05487807,2023.0,OTHER,lead,University of Southern California,Phase 1
NCT05487807,2023.0,NIH,collaborator,National Cancer Institute (NCI),Phase 1
NCT05487885,2022.0,OTHER,lead,Erika Forbes,Phase 4
NCT05488171,2021.0,OTHER,lead,Germans Trias i Pujol Hospital,Phase 1
NCT05488171,2021.0,UNKNOWN,collaborator,Fundació Recerca Institut Germans Trias i Pujol,Phase 1
NCT05488171,2021.0,OTHER,collaborator,Istituto Superiore di Sanità,Phase 1
NCT05488327,2022.0,OTHER,lead,Jiangxi Provincial People's Hopital,Not Applicable
NCT05490134,2023.0,OTHER,lead,Medical University of South Carolina,Early Phase 1
NCT05490563,2022.0,INDUSTRY,lead,"Seelos Therapeutics, Inc.",Phase 2/Phase 3
NCT05490680,2024.0,INDUSTRY,lead,IBSA Institut Biochimique SA,Phase 3
NCT05491122,2022.0,OTHER,lead,Liverpool John Moores University,Not Applicable
NCT05491122,2022.0,INDUSTRY,collaborator,Danone Research,Not Applicable
NCT05491356,2023.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 4
NCT05491434,2020.0,OTHER,lead,Hospital Universitari de Bellvitge,Not Applicable
NCT05491720,2020.0,OTHER,lead,The National Brain Mapping Laboratory (NBML),Phase 1
NCT05491720,2020.0,OTHER,collaborator,Ardabil University of Medical Sciences,Phase 1
NCT05491720,2020.0,UNKNOWN,collaborator,Leibniz Research Centre for Working Environment and Human Factors,Phase 1
NCT05491720,2020.0,OTHER,collaborator,University of Tehran,Phase 1
NCT05492019,2022.0,OTHER,lead,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2
NCT05492695,2022.0,OTHER,lead,Diamond Headache Clinic,Phase 4
NCT05492734,2022.0,INDUSTRY,lead,"Edgewise Therapeutics, Inc.",Phase 1
NCT05492812,2021.0,OTHER,lead,Suleyman Demirel University,Not Applicable
NCT05493462,2022.0,INDUSTRY,lead,"Zhittya Genesis Medicine, Inc.",Phase 1
NCT05493813,2022.0,OTHER_GOV,lead,"Taipei Veterans General Hospital, Taiwan",Not Applicable
NCT05494398,2022.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT05494398,2022.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT05494593,2023.0,INDUSTRY,lead,Takeda,Phase 4
NCT05494593,2023.0,INDUSTRY,collaborator,"Takeda Development Center Americas, Inc.",Phase 4
NCT05494619,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 3
NCT05494619,2022.0,UNKNOWN,collaborator,"Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)",Phase 3
NCT05495269,2022.0,INDUSTRY,lead,"Qlaris Bio, Inc.",Phase 2
NCT05495321,2022.0,OTHER,lead,Peking University People's Hospital,Phase 3
NCT05495425,2022.0,INDUSTRY,lead,Nobelpharma,Phase 3
NCT05496452,2023.0,OTHER,lead,King's College London,Not Applicable
NCT05496452,2023.0,OTHER,collaborator,University of Nottingham,Not Applicable
NCT05496530,2022.0,OTHER,lead,Benha University,Not Applicable
NCT05496764,2021.0,OTHER,lead,Assiut University,Phase 4
NCT05499689,2021.0,OTHER,lead,Diskapi Teaching and Research Hospital,Not Applicable
NCT05500599,2022.0,OTHER,lead,Alexandria University,Not Applicable
NCT05500677,2021.0,OTHER,lead,Ankara City Hospital Bilkent,Phase 4
NCT05500703,2022.0,OTHER,lead,China International Neuroscience Institution,Phase 4
NCT05501262,2022.0,OTHER,lead,Oregon Health and Science University,Not Applicable
NCT05501678,2023.0,OTHER,lead,Stanford University,Phase 2
NCT05501678,2023.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT05503082,2022.0,OTHER,lead,Chicago Headache Center & Research Institute,Phase 4
NCT05503082,2022.0,INDUSTRY,collaborator,AbbVie,Phase 4
NCT05503966,2022.0,OTHER,lead,University of Oslo,Not Applicable
NCT05503966,2022.0,OTHER,collaborator,University of Oxford,Not Applicable
NCT05504395,2022.0,INDUSTRY,lead,ConSynance Therapeutics,Phase 1
NCT05504694,2022.0,OTHER,lead,Tang-Du Hospital,Phase 1/Phase 2
NCT05504694,2022.0,OTHER,collaborator,Henan Provincial People's Hospital,Phase 1/Phase 2
NCT05505123,2022.0,OTHER,lead,Yeungnam University College of Medicine,Not Applicable
NCT05506787,2020.0,OTHER,lead,Jinling Hospital Affiliated to c University,Phase 4
NCT05506891,2023.0,OTHER,lead,Fujian Medical University Union Hospital,Phase 2
NCT05507008,2022.0,OTHER,lead,"University of California, San Diego",Not Applicable
NCT05507996,2022.0,OTHER,lead,Kunming Hope of Health Hospital,Early Phase 1
NCT05508074,2022.0,INDUSTRY,lead,InFlectis BioScience,Phase 2
NCT05508516,2022.0,OTHER,lead,China-Japan Friendship Hospital,Early Phase 1
NCT05508789,2022.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05509153,2022.0,OTHER,lead,Western Sydney Local Health District,Phase 2
NCT05509153,2022.0,OTHER,collaborator,Deakin University,Phase 2
NCT05509153,2022.0,OTHER,collaborator,Monash University,Phase 2
NCT05509153,2022.0,OTHER,collaborator,Royal Perth Hospital,Phase 2
NCT05509153,2022.0,OTHER,collaborator,The University of Queensland,Phase 2
NCT05509153,2022.0,OTHER,collaborator,University of Sydney,Phase 2
NCT05509153,2022.0,OTHER,collaborator,University of Melbourne,Phase 2
NCT05509257,2022.0,OTHER,lead,Children's Mercy Hospital Kansas City,Early Phase 1
NCT05509257,2022.0,OTHER,collaborator,University of Kansas Medical Center,Early Phase 1
NCT05509400,2022.0,INDUSTRY,lead,Pfizer,Phase 4
NCT05510141,2022.0,OTHER,lead,"Insel Gruppe AG, University Hospital Bern",Not Applicable
NCT05511766,2022.0,OTHER,lead,Tanta University,Phase 2/Phase 3
NCT05511818,2022.0,INDUSTRY,lead,Radicle Science,Not Applicable
NCT05512130,2022.0,OTHER,lead,Washington University School of Medicine,Early Phase 1
NCT05513404,2022.0,OTHER,lead,University of Aberdeen,Not Applicable
NCT05513872,2023.0,OTHER,lead,Rush University Medical Center,Phase 1/Phase 2
NCT05513872,2023.0,OTHER,collaborator,Medical University of South Carolina,Phase 1/Phase 2
NCT05514106,2023.0,OTHER,lead,Mayo Clinic,Phase 4
NCT05514249,2022.0,OTHER,lead,"Cure Rare Disease, Inc",Phase 1
NCT05514249,2022.0,OTHER,collaborator,"University of Massachusetts, Worcester",Phase 1
NCT05514977,2022.0,OTHER,lead,Cairo University,Not Applicable
NCT05515354,2022.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT05515354,2022.0,OTHER,collaborator,Canadian Cancer Society (CCS),Phase 4
NCT05515419,2024.0,OTHER,lead,The Medical Pavilion Bahamas,Early Phase 1
NCT05515536,2022.0,INDUSTRY,lead,PTC Therapeutics,Phase 3
NCT05516121,2021.0,INDUSTRY,lead,Valentech LLC,Phase 1
NCT05516407,2021.0,INDUSTRY,lead,Fenix Innovation Group,Phase 1/Phase 2
NCT05516407,2021.0,UNKNOWN,collaborator,Neurotech International,Phase 1/Phase 2
NCT05516407,2021.0,OTHER,collaborator,Monash Health,Phase 1/Phase 2
NCT05516875,2023.0,INDUSTRY,lead,Contera Pharma A/S,Phase 2
NCT05517486,2022.0,INDUSTRY,lead,Acasti Pharma Inc.,Phase 1
NCT05517603,2023.0,INDUSTRY,lead,"AnnJi Pharmaceutical Co., Ltd.",Phase 1/Phase 2
NCT05518123,2022.0,INDUSTRY,lead,Pfizer,Phase 4
NCT05518188,2023.0,OTHER,lead,University of Texas Southwestern Medical Center,Phase 1/Phase 2
NCT05518188,2023.0,UNKNOWN,collaborator,Cure SPG50,Phase 1/Phase 2
NCT05518409,2022.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT05518578,2023.0,INDUSTRY,lead,"Supernus Pharmaceuticals, Inc.",Phase 2
NCT05518877,2022.0,OTHER,lead,Summa Health System,Phase 4
NCT05519592,2022.0,OTHER,lead,Henri Mondor University Hospital,Not Applicable
NCT05519644,2023.0,OTHER,lead,Ohio State University,Not Applicable
NCT05520424,2022.0,INDUSTRY,lead,Parable,Not Applicable
NCT05520424,2022.0,INDUSTRY,collaborator,Citruslabs,Not Applicable
NCT05521048,2022.0,OTHER,lead,Massachusetts Eye and Ear Infirmary,Phase 1/Phase 2
NCT05521477,2022.0,OTHER,lead,"University Hospital, Geneva",Not Applicable
NCT05521880,2024.0,OTHER,lead,"University of Maryland, Baltimore",Phase 4
NCT05522361,2022.0,OTHER,lead,Clinic for Special Children,Phase 4
NCT05522361,2022.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 4
NCT05522387,2023.0,INDUSTRY,lead,"Inmune Bio, Inc.",Phase 2
NCT05522673,2023.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT05523115,2022.0,INDUSTRY,lead,Heights,Not Applicable
NCT05523115,2022.0,INDUSTRY,collaborator,Citruslabs,Not Applicable
NCT05523167,2022.0,INDUSTRY,lead,argenx,Phase 2/Phase 3
NCT05523570,2022.0,INDUSTRY,lead,Guangzhou Henovcom Bioscience Co. Ltd.,Phase 1
NCT05523791,2022.0,OTHER,lead,Ospedale Generale Di Zona Moriggia-Pelascini,Not Applicable
NCT05525039,2023.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT05525039,2023.0,INDUSTRY,collaborator,Abbott,Not Applicable
NCT05525611,2022.0,OTHER,lead,University of Aarhus,Not Applicable
NCT05525780,2022.0,INDUSTRY,lead,"G2GBio, Inc.",Phase 1
NCT05525819,2022.0,OTHER,lead,Tanta University,Not Applicable
NCT05526066,2022.0,INDUSTRY,lead,"Arcturus Therapeutics, Inc.",Phase 2
NCT05526391,2022.0,INDUSTRY,lead,Takeda,Phase 2
NCT05526391,2022.0,INDUSTRY,collaborator,AstraZeneca,Phase 2
NCT05526404,2022.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT05527210,2023.0,OTHER,lead,"University of Maryland, Baltimore",Not Applicable
NCT05527210,2023.0,NIH,collaborator,National Center for Complementary and Integrative Health (NCCIH),Not Applicable
NCT05527288,2021.0,INDUSTRY,lead,Sinotau Pharmaceutical Group,Not Applicable
NCT05527314,2022.0,OTHER,lead,Second Affiliated Hospital of Nanchang University,Not Applicable
NCT05527457,2022.0,OTHER,lead,Flinders University,Phase 1
NCT05527457,2022.0,INDUSTRY,collaborator,Bayer,Phase 1
NCT05528094,2022.0,OTHER,lead,JoySpring,Not Applicable
NCT05528094,2022.0,INDUSTRY,collaborator,Citruslabs,Not Applicable
NCT05528146,2022.0,OTHER,lead,Hungkuang University,Not Applicable
NCT05528224,2022.0,OTHER,lead,Shanghai Mental Health Center,Not Applicable
NCT05528575,2022.0,OTHER,lead,University of Reading,Not Applicable
NCT05528575,2022.0,FED,collaborator,United States Department of Defense,Not Applicable
NCT05529095,2022.0,OTHER,lead,"William Ondo, MD",Phase 4
NCT05529095,2022.0,INDUSTRY,collaborator,"Sumitomo Pharma America, Inc.",Phase 4
NCT05529576,2022.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT05529576,2022.0,UNKNOWN,collaborator,Qingdao Mental Health Center,Phase 4
NCT05529576,2022.0,OTHER,collaborator,Harbin Medical University,Phase 4
NCT05529992,2023.0,INDUSTRY,lead,Takeda,Phase 3
NCT05530577,2022.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT05530577,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT05531383,2021.0,OTHER,lead,Minia University,Not Applicable
NCT05531500,2022.0,OTHER,lead,Assiut University,Not Applicable
NCT05531526,2022.0,INDUSTRY,lead,"AriBio Co., Ltd.",Phase 3
NCT05531591,2019.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT05531591,2019.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT05531890,2022.0,INDUSTRY,lead,Acasti Pharma Inc.,Phase 1
NCT05532163,2023.0,INDUSTRY,lead,Biogen,Phase 4
NCT05532813,2024.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 3
NCT05532943,2023.0,INDUSTRY,lead,"Ever Supreme Bio Technology Co., Ltd.",Phase 1/Phase 2
NCT05533814,2022.0,INDUSTRY,lead,Eisai Korea Inc.,Phase 4
NCT05534230,2022.0,OTHER,lead,Wayne State University,Not Applicable
NCT05534243,2023.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT05534243,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT05534672,2023.0,OTHER,lead,Katarzyna Kotulska,Phase 3
NCT05534815,2023.0,OTHER,lead,Johns Hopkins University,Not Applicable
NCT05534815,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05535179,2019.0,OTHER,lead,Hubei Hospital of Traditional Chinese Medicine,Phase 2
NCT05536570,2022.0,INDIV,lead,"King, David, MD",Phase 4
NCT05536570,2022.0,UNKNOWN,collaborator,MERZ PHARMA,Phase 4
NCT05538130,2022.0,INDUSTRY,lead,Pfizer,Phase 1
NCT05538507,2022.0,OTHER,lead,Peking Union Medical College Hospital,Phase 2
NCT05538507,2022.0,OTHER,collaborator,Tongji University,Phase 2
NCT05538910,2023.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05539027,2022.0,OTHER,lead,Ain Shams University,Phase 4
NCT05539287,2022.0,OTHER,lead,Tanta University,Phase 2
NCT05539729,2023.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 1
NCT05539729,2023.0,OTHER,collaborator,Doris Duke Charitable Foundation,Phase 1
NCT05540262,2022.0,OTHER,lead,First Affiliated Hospital of Guangxi Medical University,Not Applicable
NCT05540574,2023.0,OTHER,lead,Stanford University,Phase 2
NCT05540574,2023.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT05540587,2022.0,OTHER,lead,Sung-Hwan Kim,Phase 2
NCT05540587,2022.0,INDUSTRY,collaborator,"Daiichi Sankyo Korea Co., Ltd.",Phase 2
NCT05540860,2022.0,INDUSTRY,lead,"Edgewise Therapeutics, Inc.",Phase 2
NCT05541003,2023.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 2
NCT05541107,2023.0,INDUSTRY,lead,"Matinas BioPharma Nanotechnologies, Inc.",Phase 3
NCT05541107,2023.0,OTHER,collaborator,University of Minnesota,Phase 3
NCT05541250,2023.0,OTHER,lead,W. Dalton Dietrich,Phase 1
NCT05541250,2023.0,FED,collaborator,United States Department of Defense,Phase 1
NCT05541276,2024.0,OTHER,lead,"Rigshospitalet, Denmark",Phase 3
NCT05541276,2024.0,OTHER,collaborator,Sygehus Lillebaelt,Phase 3
NCT05541276,2024.0,OTHER,collaborator,University of Copenhagen,Phase 3
NCT05541276,2024.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 3
NCT05541549,2023.0,INDUSTRY,lead,Cellevolve Bio Inc,Phase 2
NCT05541627,2022.0,INDUSTRY,lead,"Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)",Phase 1/Phase 2
NCT05542264,2022.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT05542576,2022.0,INDUSTRY,lead,Amydis Inc.,Phase 1/Phase 2
NCT05542953,2022.0,INDUSTRY,lead,APRINOIA Therapeutics,Phase 3
NCT05543252,2022.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 2
NCT05543681,2022.0,INDUSTRY,lead,IGC Pharma LLC,Phase 2
NCT05543694,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT05544448,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT05544721,2022.0,OTHER,lead,Mayo Clinic,Phase 4
NCT05545111,2022.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 2
NCT05545891,2023.0,OTHER,lead,University of Chicago,Phase 2
NCT05546320,2022.0,OTHER,lead,"Chinese Academy of Medical Sciences, Fuwai Hospital",Phase 4
NCT05546554,2023.0,OTHER,lead,Stanford University,Phase 2
NCT05546554,2023.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT05546658,2022.0,OTHER,lead,Johns Hopkins University,Early Phase 1
NCT05547503,2023.0,INDUSTRY,lead,Afasci Inc,Phase 1
NCT05547685,2020.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT05549024,2022.0,OTHER,lead,Peking Union Medical College Hospital,Early Phase 1
NCT05549258,2022.0,INDUSTRY,lead,Horizon Therapeutics Ireland DAC,Phase 2
NCT05550207,2022.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT05550246,2022.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05550532,2022.0,INDUSTRY,lead,"Janssen Research & Development, LLC",Phase 3
NCT05550883,2022.0,OTHER,lead,October 6 University,Not Applicable
NCT05551403,2022.0,OTHER,lead,Stichting Epilepsie Instellingen Nederland,Not Applicable
NCT05551403,2022.0,OTHER,collaborator,Erasmus Medical Center,Not Applicable
NCT05551598,2022.0,INDUSTRY,lead,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",Phase 2
NCT05551741,2023.0,INDUSTRY,lead,Immunobrain Checkpoint,Phase 1
NCT05551741,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05551741,2023.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT05551871,2022.0,OTHER,lead,Assiut University,Not Applicable
NCT05552157,2022.0,OTHER,lead,Washington University School of Medicine,Phase 2/Phase 3
NCT05552157,2022.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2/Phase 3
NCT05552157,2022.0,OTHER,collaborator,Alzheimer's Association,Phase 2/Phase 3
NCT05552157,2022.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT05552157,2022.0,INDUSTRY,collaborator,"Genentech, Inc.",Phase 2/Phase 3
NCT05554094,2023.0,OTHER,lead,Ohio State University,Phase 2
NCT05554146,2022.0,OTHER,lead,Montefiore Medical Center,Not Applicable
NCT05554146,2022.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05554146,2022.0,OTHER,collaborator,"University of Colorado, Boulder",Not Applicable
NCT05554146,2022.0,OTHER,collaborator,University of Pittsburgh,Not Applicable
NCT05554926,2022.0,INDUSTRY,lead,Aelis Farma,Phase 1
NCT05556083,2022.0,OTHER,lead,Al-Azhar University,Phase 2
NCT05557409,2022.0,INDUSTRY,lead,"Axsome Therapeutics, Inc.",Phase 3
NCT05557643,2023.0,OTHER,lead,University of Utah,Early Phase 1
NCT05557643,2023.0,OTHER,collaborator,Heffter Research Institute,Early Phase 1
NCT05557643,2023.0,OTHER,collaborator,Usona Institute,Early Phase 1
NCT05558007,2023.0,INDUSTRY,lead,Biozeus Biopharmaceutical S.A.,Phase 2
NCT05558449,2022.0,OTHER,lead,University of Liege,Phase 4
NCT05558813,2024.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT05559398,2022.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT05559931,2023.0,INDUSTRY,lead,Algernon Pharmaceuticals,Phase 1
NCT05559931,2023.0,OTHER,collaborator,"Centre for Human Drug Research, Netherlands",Phase 1
NCT05560529,2023.0,OTHER,lead,Alexandria University,Not Applicable
NCT05561205,2023.0,OTHER,lead,Sunnybrook Health Sciences Centre,Not Applicable
NCT05561257,2020.0,INDUSTRY,lead,Pascoe Pharmazeutische Praeparate GmbH,Phase 2
NCT05561660,2022.0,OTHER,lead,"Chinese Academy of Medical Sciences, Fuwai Hospital",Phase 4
NCT05562232,2022.0,OTHER,lead,"Psychiatric Research Unit, Region Zealand, Denmark",Not Applicable
NCT05562232,2022.0,OTHER,collaborator,University of Southern Denmark,Not Applicable
NCT05562349,2023.0,OTHER,lead,Temple University,Phase 2
NCT05562349,2023.0,OTHER,collaborator,University of Pennsylvania,Phase 2
NCT05562349,2023.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT05562349,2023.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT05562973,2025.0,OTHER,lead,Johns Hopkins University,Phase 1
NCT05563571,2022.0,OTHER,lead,Satasairaala,Not Applicable
NCT05563857,2022.0,INDUSTRY,lead,Viome,Not Applicable
NCT05564169,2024.0,INDUSTRY,lead,AB Science,Phase 3
NCT05565976,2020.0,OTHER,lead,Jaime Daniel Mondragon,Phase 2/Phase 3
NCT05565976,2020.0,UNKNOWN,collaborator,Hospital General León,Phase 2/Phase 3
NCT05565976,2020.0,UNKNOWN,collaborator,Hospital General de Zona IMSS N0. 21,Phase 2/Phase 3
NCT05565976,2020.0,OTHER,collaborator,University Medical Center Groningen,Phase 2/Phase 3
NCT05567653,2022.0,OTHER,lead,Poznan University of Physical Education,Not Applicable
NCT05567822,2022.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT05568498,2022.0,OTHER,lead,University of British Columbia,Phase 2
NCT05568823,2022.0,OTHER,lead,Assistance Publique Hopitaux De Marseille,Not Applicable
NCT05568953,2022.0,OTHER,lead,Singapore General Hospital,Phase 2
NCT05568953,2022.0,OTHER,collaborator,Duke-NUS Graduate Medical School,Phase 2
NCT05569122,2023.0,OTHER,lead,Children's Hospital of Philadelphia,Phase 1
NCT05569122,2023.0,FED,collaborator,United States Department of Defense,Phase 1
NCT05569720,2022.0,INDUSTRY,lead,aptaTargets S.L.,Phase 1
NCT05569720,2022.0,UNKNOWN,collaborator,Centro para el Desarrollo Tecnológico Industrial,Phase 1
NCT05569993,2022.0,OTHER,lead,Assiut University,Early Phase 1
NCT05570110,2022.0,OTHER,lead,Philipps University Marburg Medical Center,Phase 1/Phase 2
NCT05570110,2022.0,OTHER_GOV,collaborator,Slovak Academy of Sciences,Phase 1/Phase 2
NCT05571878,2021.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT05572203,2022.0,OTHER,lead,University of Nottingham,Not Applicable
NCT05573698,2022.0,INDUSTRY,lead,"Design Therapeutics, Inc.",Phase 1
NCT05573906,2023.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT05573906,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05573906,2023.0,OTHER,collaborator,Boston University,Not Applicable
NCT05574205,2022.0,OTHER,lead,University of Birmingham,Not Applicable
NCT05574205,2022.0,OTHER,collaborator,Maastricht University,Not Applicable
NCT05574400,2023.0,OTHER,lead,University of Michigan,Phase 2
NCT05574400,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05575011,2022.0,INDUSTRY,lead,Biogen,Phase 1
NCT05575076,2022.0,INDUSTRY,lead,"Cassava Sciences, Inc.",Phase 3
NCT05575700,2023.0,OTHER,lead,Naestved Hospital,Phase 4
NCT05576818,2022.0,OTHER,lead,Tanta University,Phase 3
NCT05577026,2023.0,OTHER_GOV,lead,Region Stockholm,Not Applicable
NCT05577585,2022.0,OTHER,lead,Medical University of Vienna,Not Applicable
NCT05577676,2022.0,OTHER,lead,Bangladesh College Of Physicians And Surgeons (BCPS),Not Applicable
NCT05578443,2022.0,OTHER,lead,Fujian Medical University Union Hospital,Phase 2
NCT05578521,2022.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05578521,2022.0,INDUSTRY,collaborator,"Tasly Pharmaceutical Group Co., Ltd",Phase 4
NCT05579223,2022.0,OTHER,lead,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2
NCT05579691,2022.0,INDUSTRY,lead,"Larimar Therapeutics, Inc.",Phase 2
NCT05581576,2022.0,OTHER,lead,"William Ondo, MD",Phase 4
NCT05581576,2022.0,INDUSTRY,collaborator,"Harmony Biosciences, LLC",Phase 4
NCT05581823,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT05582135,2021.0,OTHER,lead,Xuanhan County People's Hospital,Not Applicable
NCT05582161,2022.0,OTHER,lead,Chang Gung Memorial Hospital,Phase 2
NCT05583240,2021.0,OTHER,lead,Etablissement Public de Santé Barthélemy Durand,Phase 4
NCT05583266,2022.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05583266,2022.0,INDUSTRY,collaborator,"CSPC Ouyi Pharmaceutical Co., Ltd.",Phase 4
NCT05584631,2022.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 1
NCT05584826,2022.0,OTHER,lead,Sunstone Medical,Phase 2
NCT05585346,2021.0,OTHER,lead,Beijing Tongren Hospital,Not Applicable
NCT05585931,2022.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT05586581,2023.0,OTHER,lead,Yale University,Phase 1/Phase 2
NCT05586581,2023.0,NIH,collaborator,National Institutes of Health (NIH),Phase 1/Phase 2
NCT05586581,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1/Phase 2
NCT05586750,2019.0,OTHER,lead,Monash University,Phase 4
NCT05586750,2019.0,OTHER,collaborator,"National Health and Medical Research Council, Australia",Phase 4
NCT05586789,2022.0,INDUSTRY,lead,Valenta Pharm JSC,Phase 3
NCT05587361,2024.0,OTHER,lead,University of Oklahoma,Phase 4
NCT05587361,2024.0,OTHER,collaborator,Oklahoma State University Center for Health Sciences,Phase 4
NCT05587361,2024.0,OTHER,collaborator,Duke University,Phase 4
NCT05587361,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT05587361,2024.0,NIH,collaborator,National Institutes of Health (NIH),Phase 4
NCT05588141,2023.0,NIH,lead,National Cancer Institute (NCI),Phase 1/Phase 2
NCT05588934,2023.0,OTHER,lead,University of Arizona,Not Applicable
NCT05588934,2023.0,FED,collaborator,U.S. Army Medical Research Acquisition Activity,Not Applicable
NCT05588934,2023.0,UNKNOWN,collaborator,Biotechnology High Performance Computing Software Applications Institute,Not Applicable
NCT05589402,2019.0,OTHER,lead,University of Texas Rio Grande Valley,Phase 1
NCT05589753,2019.0,FED,lead,VA Office of Research and Development,Phase 1/Phase 2
NCT05589753,2019.0,FED,collaborator,John D. Dingell VA Medical Center,Phase 1/Phase 2
NCT05589766,2023.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT05589792,2023.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT05589935,2022.0,INDUSTRY,lead,Radicle Science,Not Applicable
NCT05590455,2023.0,OTHER_GOV,lead,"ANRS, Emerging Infectious Diseases",Phase 2
NCT05590468,2023.0,OTHER,lead,Eduardo N. Chini,Phase 2
NCT05590884,2022.0,INDUSTRY,lead,Guerbet,Phase 2
NCT05591027,2022.0,OTHER,lead,Oregon Health and Science University,Phase 1
NCT05591027,2022.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT05591144,2022.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Not Applicable
NCT05591417,2022.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT05591508,2022.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Not Applicable
NCT05592678,2024.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2/Phase 3
NCT05592678,2024.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2/Phase 3
NCT05594017,2019.0,OTHER,lead,University of Texas Southwestern Medical Center,Early Phase 1
NCT05594017,2019.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Early Phase 1
NCT05594407,2022.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT05594589,2022.0,INDUSTRY,lead,"Eisai Co., Ltd.",Phase 2
NCT05594667,2023.0,INDUSTRY,lead,Cybin Therapeutics Inc.,Phase 2
NCT05594992,2023.0,INDUSTRY,lead,"JCR Pharmaceuticals Co., Ltd.",Phase 3
NCT05595109,2022.0,OTHER,lead,Tanta University,Phase 2/Phase 3
NCT05595993,2022.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05596071,2016.0,OTHER,lead,Zhejiang Cancer Hospital,Not Applicable
NCT05596227,2022.0,OTHER,lead,Tanta University,Not Applicable
NCT05598138,2021.0,OTHER,lead,Centre Hospitalier Universitaire de la Réunion,Not Applicable
NCT05598307,2022.0,OTHER,lead,Aretaieion University Hospital,Not Applicable
NCT05599126,2022.0,OTHER,lead,Zhenghui YI,Phase 4
NCT05601648,2023.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT05602116,2023.0,INDUSTRY,lead,Cell2Cure ApS,Phase 1
NCT05602688,2023.0,OTHER,lead,Ayub Teaching Hospital,Not Applicable
NCT05602727,2022.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 2
NCT05603104,2024.0,OTHER,lead,Dr. Inge Winter,Phase 3
NCT05603104,2024.0,OTHER,collaborator,Universität Münster,Phase 3
NCT05603312,2022.0,INDUSTRY,lead,"MeiraGTx, LLC",Phase 1/Phase 2
NCT05603702,2023.0,OTHER,lead,Indiana University,Phase 1
NCT05603702,2023.0,NIH,collaborator,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1
NCT05603715,2022.0,OTHER,lead,University of Vermont Medical Center,Phase 2
NCT05603975,2022.0,OTHER,lead,Shenzhen Second People's Hospital,Not Applicable
NCT05604170,2022.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 3
NCT05604599,2022.0,OTHER,lead,Al-Azhar University,Phase 4
NCT05604794,2020.0,INDUSTRY,lead,Field Trip Health,Phase 4
NCT05606341,2023.0,OTHER,lead,NYU Langone Health,Phase 1
NCT05606341,2023.0,OTHER,collaborator,Alzheimer's Association,Phase 1
NCT05606614,2023.0,INDUSTRY,lead,"Taysha Gene Therapies, Inc.",Phase 1/Phase 2
NCT05607615,2022.0,INDUSTRY,lead,"Cyclo Therapeutics, Inc.",Phase 2
NCT05608070,2023.0,OTHER,lead,Beth Israel Deaconess Medical Center,Phase 4
NCT05608330,2022.0,OTHER,lead,University of Oxford,Not Applicable
NCT05608330,2022.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Not Applicable
NCT05608733,2022.0,OTHER,lead,Universidad de Antioquia,Phase 3
NCT05609890,2023.0,OTHER,lead,Carlos O Mendivil,Not Applicable
NCT05609890,2023.0,INDUSTRY,collaborator,Team Foods Colombia S.A.,Not Applicable
NCT05609916,2022.0,OTHER,lead,Baylor College of Medicine,Not Applicable
NCT05610189,2022.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 1
NCT05610878,2020.0,OTHER,lead,University of the Punjab,Phase 1
NCT05610878,2020.0,UNKNOWN,collaborator,"Centre of Excellence in Molecular Biology, University of the Punjab, Lahore",Phase 1
NCT05610878,2020.0,OTHER,collaborator,Higher Education Commission (Pakistan),Phase 1
NCT05610878,2020.0,OTHER_GOV,collaborator,"Jinnah Burn and Reconstructive Surgery Centre, Lahore",Phase 1
NCT05611372,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Beijing Tiantan Hospital,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Jiangsu Province Nanjing Brain Hospital,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,The First Affiliated Hospital of Anhui Medical University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Huashan Hospital,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Second Affiliated Hospital of Soochow University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Guizhou Medical University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,The First Affiliated Hospital of Guangzhou Medical University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,West China Hospital,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Sir Run Run Shaw Hospital,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,The Affiliated Hospital of Hangzhou Normal University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,The First Affiliated Hospital of Dalian Medical University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Qilu Hospital of Shandong University,Phase 2/Phase 3
NCT05611372,2023.0,OTHER,collaborator,Fujian Medical University Union Hospital,Phase 2/Phase 3
NCT05612594,2024.0,OTHER,lead,Yale University,Phase 4
NCT05612594,2024.0,OTHER,collaborator,Case Western Reserve University,Phase 4
NCT05613114,2020.0,OTHER,lead,European University of Lefke,Not Applicable
NCT05613166,2022.0,OTHER,lead,"National Institute on Drug Dependence, China",Phase 2
NCT05613166,2022.0,OTHER,collaborator,Peking University,Phase 2
NCT05613166,2022.0,OTHER,collaborator,Shengjing Hospital,Phase 2
NCT05615025,2023.0,OTHER,lead,Brugmann University Hospital,Phase 3
NCT05615220,2023.0,INDUSTRY,lead,Emalex Biosciences Inc.,Phase 3
NCT05615402,2022.0,OTHER,lead,Norwegian School of Sport Sciences,Not Applicable
NCT05615402,2022.0,OTHER,collaborator,Sunnaas Rehabilitation Hospital,Not Applicable
NCT05615402,2022.0,OTHER,collaborator,Norwegian University of Science and Technology,Not Applicable
NCT05615402,2022.0,OTHER,collaborator,HAN University of Applied Sciences,Not Applicable
NCT05615584,2023.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT05615623,2023.0,INDUSTRY,lead,InSightec,Phase 1/Phase 2
NCT05615948,2022.0,OTHER,lead,Maimonides Medical Center,Phase 4
NCT05616260,2022.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05616910,2024.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT05617508,2022.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT05617508,2022.0,OTHER,collaborator,Haraldsplass Deaconess Hospital,Phase 2
NCT05617664,2022.0,OTHER,lead,Benha University,Not Applicable
NCT05618470,2018.0,OTHER,lead,China Academy of Chinese Medical Sciences,Phase 2/Phase 3
NCT05619445,2023.0,OTHER,lead,University of Idaho,Not Applicable
NCT05619445,2023.0,OTHER,collaborator,"University of Nevada, Las Vegas",Not Applicable
NCT05619445,2023.0,OTHER,collaborator,University of New Mexico,Not Applicable
NCT05619692,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05619783,2022.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 3
NCT05620316,2021.0,OTHER,lead,Damascus University,Not Applicable
NCT05622201,2023.0,OTHER,lead,Region Örebro County,Phase 2
NCT05622994,2022.0,OTHER,lead,Hospital Nacional de Parapléjicos de Toledo,Phase 2
NCT05623501,2024.0,OTHER,lead,University of Southern California,Phase 1
NCT05623592,2022.0,OTHER,lead,University of Bonn,Phase 2
NCT05624151,2022.0,OTHER,lead,Ain Shams University,Phase 3
NCT05624424,2022.0,OTHER,lead,Second Affiliated Hospital of Nanchang University,Phase 4
NCT05624424,2022.0,INDUSTRY,collaborator,"Yichang Humanwell Pharmaceutical Co., Ltd., China",Phase 4
NCT05624528,2023.0,OTHER,lead,University of Chicago,Phase 2
NCT05624853,2020.0,INDUSTRY,lead,Yuhan Corporation,Phase 4
NCT05624866,2022.0,OTHER,lead,Assiut University,Not Applicable
NCT05624957,2022.0,OTHER,lead,Minia University,Not Applicable
NCT05625555,2024.0,OTHER,lead,Abraham Nunes,Phase 3
NCT05625555,2024.0,OTHER,collaborator,Nova Scotia Health Authority,Phase 3
NCT05625568,2023.0,INDUSTRY,lead,Vyant Bio,Phase 2
NCT05626140,2021.0,OTHER_GOV,lead,Pakistan Institute of Medical Sciences,Phase 3
NCT05626140,2021.0,OTHER,collaborator,Riphah International University,Phase 3
NCT05626634,2022.0,INDUSTRY,lead,Longboard Pharmaceuticals,Phase 2
NCT05626855,2023.0,INDUSTRY,lead,"Scholar Rock, Inc.",Phase 3
NCT05626959,2022.0,INDUSTRY,lead,Fenix Innovation Group,Phase 2/Phase 3
NCT05626959,2022.0,UNKNOWN,collaborator,Neurotech International,Phase 2/Phase 3
NCT05626959,2022.0,OTHER,collaborator,Monash Health,Phase 2/Phase 3
NCT05627154,2021.0,OTHER,lead,University of Oxford,Not Applicable
NCT05627154,2021.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Not Applicable
NCT05627440,2023.0,OTHER,lead,Tufts Medical Center,Not Applicable
NCT05627440,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT05627609,2022.0,OTHER,lead,University Hospital Muenster,Not Applicable
NCT05627921,2022.0,OTHER,lead,Marmara University,Not Applicable
NCT05628103,2022.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT05628636,2022.0,INDUSTRY,lead,Cerecin,Phase 1
NCT05629559,2022.0,INDUSTRY,lead,4D Molecular Therapeutics,Phase 1/Phase 2
NCT05629702,2023.0,OTHER,lead,University of Birmingham,Phase 2
NCT05629702,2023.0,OTHER,collaborator,University of Leeds,Phase 2
NCT05629702,2023.0,OTHER,collaborator,The Brain Tumour Charity,Phase 2
NCT05629702,2023.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT05630066,2023.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT05630209,2023.0,INDUSTRY,lead,InSightec,Phase 1/Phase 2
NCT05630235,2024.0,OTHER,lead,University of Miami,Phase 1/Phase 2
NCT05630235,2024.0,OTHER,collaborator,Consortium for Medical Marijuana Clinical Outcomes Research,Phase 1/Phase 2
NCT05630534,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Phase 1
NCT05630534,2023.0,OTHER,collaborator,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Phase 1
NCT05630534,2023.0,OTHER,collaborator,The Second Affiliated Hospital of Jiaxing University,Phase 1
NCT05630547,2022.0,INDUSTRY,lead,Sanofi,Phase 2
NCT05630781,2023.0,NIH,lead,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05632133,2022.0,OTHER,lead,Kafrelsheikh University,Phase 3
NCT05632627,2023.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT05632627,2023.0,OTHER,collaborator,Colorado State University,Phase 2
NCT05633407,2022.0,INDUSTRY,lead,argenx,Phase 2
NCT05633407,2022.0,INDUSTRY,collaborator,Iqvia Pty Ltd,Phase 2
NCT05633459,2022.0,INDUSTRY,lead,QurAlis Corporation,Phase 1
NCT05634148,2022.0,OTHER,lead,Security Forces Hospital,Phase 3
NCT05634876,2023.0,OTHER,lead,NYU Langone Health,Phase 1/Phase 2
NCT05635409,2022.0,OTHER,lead,Region Skane,Phase 1
NCT05635409,2022.0,OTHER,collaborator,Lund University,Phase 1
NCT05635409,2022.0,OTHER,collaborator,Cambridge University Hospitals NHS Foundation Trust,Phase 1
NCT05635409,2022.0,OTHER,collaborator,University of Cambridge,Phase 1
NCT05635461,2022.0,INDUSTRY,lead,"Cerevance Beta, Inc.",Phase 1
NCT05635604,2023.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05635851,2023.0,OTHER,lead,Simon Fraser University,Phase 2
NCT05635851,2023.0,OTHER,collaborator,University of British Columbia,Phase 2
NCT05636852,2023.0,INDUSTRY,lead,GE Healthcare,Phase 2
NCT05636852,2023.0,UNKNOWN,collaborator,"Fortrea, Inc.",Phase 2
NCT05637086,2022.0,OTHER,lead,Mostafa Bahaa,Phase 2
NCT05637086,2022.0,UNKNOWN,collaborator,"Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University",Phase 2
NCT05637086,2022.0,UNKNOWN,collaborator,"Principal Investigator Maha Ahmed Younis, PhD Pharmacy Practice Department- Horus University",Phase 2
NCT05637086,2022.0,UNKNOWN,collaborator,"Tarek Mohamed Mostafa, Prof Clinical pharmacy Department- Tanta University",Phase 2
NCT05637450,2023.0,OTHER,lead,University of Ulster,Not Applicable
NCT05637450,2023.0,OTHER,collaborator,University of Limerick,Not Applicable
NCT05637450,2023.0,UNKNOWN,collaborator,Bio-Marine Ingredients Ireland,Not Applicable
NCT05637879,2023.0,FED,lead,White River Junction Veterans Affairs Medical Center,Phase 2/Phase 3
NCT05638087,2022.0,OTHER,lead,The Hospital for Sick Children,Phase 3
NCT05638620,2023.0,OTHER,lead,"Jonathann Kuo, MD",Phase 1
NCT05639322,2023.0,OTHER,lead,Unity Health Toronto,Phase 4
NCT05639686,2023.0,OTHER,lead,Our Lady of the Lake Hospital,Not Applicable
NCT05639686,2023.0,OTHER,collaborator,Louisiana State University Health Sciences Center in New Orleans,Not Applicable
NCT05639712,2022.0,OTHER,lead,Oslo University Hospital,Phase 4
NCT05639712,2022.0,OTHER,collaborator,Vestre VikenHF Kongsberg Sykehus,Phase 4
NCT05639946,2023.0,OTHER,lead,University of Minnesota,Phase 3
NCT05640479,2022.0,OTHER,lead,Tanta University,Phase 4
NCT05641311,2019.0,INDUSTRY,lead,"Alexion Pharmaceuticals, Inc.",Phase 1
NCT05641363,2023.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 3
NCT05641363,2023.0,OTHER,collaborator,McMaster University,Phase 3
NCT05641376,2023.0,OTHER,lead,Assiut University,Not Applicable
NCT05641480,2022.0,OTHER,lead,Shaanxi Hospital of Traditional Chinese Medicine,Not Applicable
NCT05641623,2022.0,OTHER,lead,Göteborg University,Phase 2
NCT05641623,2022.0,INDUSTRY,collaborator,Arvid Carlsson Research AB,Phase 2
NCT05641649,2023.0,OTHER,lead,Kathmandu University,Phase 4
NCT05641649,2023.0,INDUSTRY,collaborator,Asian Pharmaceuticals Pvt. Ltd.,Phase 4
NCT05641688,2022.0,INDUSTRY,lead,Life Molecular Imaging Ltd,Phase 3
NCT05641909,2021.0,OTHER,lead,"Southeast University, China",Phase 3
NCT05642052,2022.0,OTHER,lead,Université de Sherbrooke,Not Applicable
NCT05642052,2022.0,INDUSTRY,collaborator,Nestlé Health Science Spain,Not Applicable
NCT05642429,2023.0,OTHER,lead,Institute for Molecular Medicine,Phase 1
NCT05642429,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05642429,2023.0,INDUSTRY,collaborator,Clinartis,Phase 1
NCT05642442,2022.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT05643170,2022.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT05643794,2022.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 2
NCT05644184,2023.0,OTHER,lead,PATH,Phase 2
NCT05644184,2023.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT05644184,2023.0,INDUSTRY,collaborator,PT Bio Farma,Phase 2
NCT05644184,2023.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 2
NCT05644184,2023.0,UNKNOWN,collaborator,DiagnoSearch Life Sciences Pvt. Ltd.,Phase 2
NCT05644262,2023.0,OTHER,lead,University of Southern California,Phase 2
NCT05644262,2023.0,OTHER,collaborator,Medical University of South Carolina,Phase 2
NCT05644262,2023.0,OTHER,collaborator,Alzheimer's Clinical Trials Consortium,Phase 2
NCT05644262,2023.0,OTHER,collaborator,Alzheimer's Therapeutic Research Institute,Phase 2
NCT05644262,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05645432,2023.0,INDUSTRY,lead,Sage Therapeutics,Phase 2
NCT05646212,2018.0,OTHER,lead,Ukrainian Institute on Public Health Policy,Not Applicable
NCT05646212,2018.0,OTHER,collaborator,Yale University,Not Applicable
NCT05646212,2018.0,UNKNOWN,collaborator,Alliance for Public Health,Not Applicable
NCT05646264,2023.0,OTHER,lead,Shanghai Mental Health Center,Phase 4
NCT05646264,2023.0,OTHER,collaborator,Tianjin Anding Hospital,Phase 4
NCT05646602,2023.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT05646784,2024.0,OTHER,lead,"St Joseph University, Beirut, Lebanon",Not Applicable
NCT05646784,2024.0,UNKNOWN,collaborator,"Lallemand Health Solutions, Canada",Not Applicable
NCT05647473,2024.0,OTHER,lead,Fujian Medical University Union Hospital,Phase 2
NCT05647681,2023.0,OTHER,lead,University of Monastir,Phase 1
NCT05648422,2023.0,OTHER,lead,Anahuac University,Not Applicable
NCT05648591,2023.0,INDUSTRY,lead,Vanda Pharmaceuticals,Phase 4
NCT05648617,2023.0,OTHER,lead,Universiti Putra Malaysia,Early Phase 1
NCT05649605,2023.0,OTHER,lead,Karolinska University Hospital,Not Applicable
NCT05650567,2023.0,INDUSTRY,lead,"EMD Serono Research & Development Institute, Inc.",Phase 2
NCT05650567,2023.0,INDUSTRY,collaborator,"Merck KGaA, Darmstadt, Germany",Phase 2
NCT05650645,2023.0,OTHER,lead,University of Minnesota,Phase 2
NCT05651126,2022.0,OTHER,lead,King's College London,Not Applicable
NCT05651126,2022.0,OTHER,collaborator,University of Cambridge,Not Applicable
NCT05654298,2022.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT05654415,2021.0,OTHER,lead,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Not Applicable
NCT05654467,2023.0,OTHER,lead,PATH,Phase 2
NCT05654467,2023.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 2
NCT05654467,2023.0,INDUSTRY,collaborator,PT Bio Farma,Phase 2
NCT05654467,2023.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 2
NCT05654467,2023.0,UNKNOWN,collaborator,"Technical Resources International, Inc. (TRI)",Phase 2
NCT05654870,2023.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 3
NCT05655520,2022.0,INDUSTRY,lead,Sage Therapeutics,Phase 3
NCT05655754,2022.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT05656027,2022.0,OTHER,lead,"LENZ Therapeutics, Inc",Phase 3
NCT05656027,2022.0,INDUSTRY,collaborator,"ORA, Inc.",Phase 3
NCT05657808,2023.0,INDUSTRY,lead,Radicle Science,Not Applicable
NCT05657860,2020.0,OTHER,lead,Maimonides Medical Center,Phase 4
NCT05658263,2023.0,OTHER,lead,University of Minnesota,Early Phase 1
NCT05658471,2023.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT05658471,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05658484,2023.0,INDUSTRY,lead,Biogen,Phase 4
NCT05658510,2022.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 3
NCT05658510,2022.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 3
NCT05659368,2024.0,OTHER,lead,Ospedale San Raffaele,Phase 2
NCT05662228,2023.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT05662228,2023.0,OTHER,collaborator,Children's Hospital Los Angeles,Phase 2
NCT05662306,2024.0,OTHER,lead,University of Miami,Phase 4
NCT05662306,2024.0,INDUSTRY,collaborator,"Alkermes, Inc.",Phase 4
NCT05663749,2022.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT05664100,2022.0,INDUSTRY,lead,Frequency Therapeutics,Phase 1
NCT05664477,2024.0,OTHER,lead,Roberta Brinton,Phase 2
NCT05664477,2024.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05664477,2024.0,OTHER,collaborator,Cornell University,Phase 2
NCT05664477,2024.0,UNKNOWN,collaborator,ADM Diagnostics,Phase 2
NCT05664711,2023.0,OTHER,lead,"Neuroversion, Inc.",Phase 1
NCT05664789,2023.0,OTHER,lead,Stanford University,Phase 2/Phase 3
NCT05664789,2023.0,NIH,collaborator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2/Phase 3
NCT05665088,2022.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 3
NCT05665088,2022.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 3
NCT05665166,2023.0,OTHER,lead,University of Manchester,Phase 1/Phase 2
NCT05665166,2023.0,INDUSTRY,collaborator,AVROBIO,Phase 1/Phase 2
NCT05665166,2023.0,OTHER,collaborator,CTI Clinical Trial and Consulting Services,Phase 1/Phase 2
NCT05665166,2023.0,OTHER,collaborator,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 1/Phase 2
NCT05665166,2023.0,OTHER_GOV,collaborator,Manchester University NHS Foundation Trust,Phase 1/Phase 2
NCT05666076,2022.0,OTHER_GOV,lead,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,Not Applicable
NCT05666310,2023.0,OTHER,lead,Nami Safai Haeri,Phase 4
NCT05666310,2023.0,OTHER,collaborator,The Claude D. Pepper Older Americans Independence Centers,Phase 4
NCT05666310,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 4
NCT05667649,2023.0,INDUSTRY,lead,"Regeneration Biomedical, Inc.",Phase 1
NCT05668208,2023.0,OTHER,lead,Konya City Hospital,Not Applicable
NCT05668754,2022.0,INDUSTRY,lead,Zevra Therapeutics,Phase 2
NCT05668754,2022.0,INDUSTRY,collaborator,"Rho, Inc.",Phase 2
NCT05669170,2024.0,FED,lead,Ralph H. Johnson VA Medical Center,Phase 2
NCT05669391,2023.0,OTHER,lead,Tongji University,Not Applicable
NCT05669885,2023.0,OTHER,lead,Danish Headache Center,Not Applicable
NCT05670158,2023.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT05670509,2019.0,OTHER,lead,Ain Shams University,Phase 4
NCT05670730,2022.0,INDUSTRY,lead,"Avidity Biosciences, Inc.",Phase 1/Phase 2
NCT05670782,2022.0,INDUSTRY,lead,FAScinate Therapeutics Inc.,Phase 2
NCT05670782,2022.0,INDUSTRY,collaborator,Parexel,Phase 2
NCT05670847,2023.0,OTHER,lead,Sohag University,Phase 2/Phase 3
NCT05670912,2022.0,OTHER,lead,Capital Medical University,Phase 2
NCT05670912,2022.0,OTHER,collaborator,China-Japan Friendship Hospital,Phase 2
NCT05670912,2022.0,OTHER,collaborator,Beijing Friendship Hospital,Phase 2
NCT05671692,2023.0,OTHER,lead,"Christine Marx, MD",Phase 2
NCT05671796,2023.0,OTHER,lead,SENAI CIMATEC,Phase 2
NCT05671796,2023.0,OTHER,collaborator,Oswaldo Cruz Foundation,Phase 2
NCT05671796,2023.0,OTHER,collaborator,Federal University of Bahia,Phase 2
NCT05671796,2023.0,UNKNOWN,collaborator,Hospital Geral do Estado,Phase 2
NCT05671796,2023.0,UNKNOWN,collaborator,Hospital da Bahia,Phase 2
NCT05673746,2020.0,OTHER,lead,IRCCS Azienda Ospedaliero-Universitaria di Bologna,Not Applicable
NCT05673746,2020.0,OTHER,collaborator,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Applicable
NCT05674552,2023.0,OTHER,lead,Sohag University,Phase 2/Phase 3
NCT05674565,2023.0,OTHER_GOV,lead,Zagazig University,Phase 2/Phase 3
NCT05675098,2023.0,OTHER,lead,Kuwait University,Early Phase 1
NCT05676034,2023.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 2
NCT05676814,2023.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT05676853,2023.0,INDUSTRY,lead,Aeglea Biotherapeutics,Phase 3
NCT05677256,2023.0,OTHER,lead,Fidec Corporation,Phase 4
NCT05677256,2023.0,OTHER,collaborator,Bill and Melinda Gates Foundation,Phase 4
NCT05678881,2023.0,INDUSTRY,lead,Receptor Life Sciences,Phase 1
NCT05678881,2023.0,OTHER,collaborator,The Epilepsy Study Consortium,Phase 1
NCT05679024,2023.0,OTHER_GOV,lead,Region Stockholm,Phase 3
NCT05679024,2023.0,OTHER,collaborator,Uppsala University,Phase 3
NCT05679375,2023.0,OTHER,lead,Assiut University,Phase 4
NCT05679453,2022.0,OTHER,lead,Kutahya Health Sciences University,Phase 4
NCT05679596,2023.0,OTHER,lead,McGill University,Not Applicable
NCT05679596,2023.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Not Applicable
NCT05680389,2020.0,OTHER,lead,Leiden University Medical Center,Phase 1/Phase 2
NCT05680532,2021.0,OTHER,lead,Chung Shan Medical University,Not Applicable
NCT05681819,2023.0,INDUSTRY,lead,"Shanghai Hengrui Pharmaceutical Co., Ltd.",Phase 1
NCT05684016,2013.0,OTHER,lead,George Washington University,Not Applicable
NCT05684523,2023.0,INDUSTRY,lead,Max Zeller Soehne AG,Phase 4
NCT05684523,2023.0,OTHER,collaborator,University of Basel,Phase 4
NCT05685225,2024.0,INDUSTRY,lead,"Allodynic Therapeutics, Inc",Phase 2
NCT05685641,2023.0,OTHER_GOV,lead,"National Institute of Respiratory Diseases, Mexico",Not Applicable
NCT05685641,2023.0,OTHER_GOV,collaborator,National Institute of Cancerology,Not Applicable
NCT05685641,2023.0,OTHER_GOV,collaborator,Hospital General Dr. Manuel Gea González,Not Applicable
NCT05685641,2023.0,OTHER,collaborator,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",Not Applicable
NCT05686044,2023.0,INDUSTRY,lead,Annovis Bio Inc.,Phase 2/Phase 3
NCT05686239,2022.0,INDUSTRY,lead,Recognify Life Sciences,Phase 2
NCT05686408,2023.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT05686408,2023.0,INDUSTRY,collaborator,"Rho, Inc.",Phase 2
NCT05686551,2023.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT05686798,2022.0,OTHER,lead,Henry Ford Health System,Phase 1
NCT05688956,2023.0,OTHER,lead,University College Dublin,Not Applicable
NCT05689164,2023.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05689359,2024.0,OTHER,lead,University of Arizona,Phase 2
NCT05690503,2023.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT05690737,2023.0,OTHER,lead,The Hong Kong Polytechnic University,Not Applicable
NCT05691114,2023.0,OTHER,lead,Shanghai East Hospital,Phase 1
NCT05691114,2023.0,INDUSTRY,collaborator,"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China",Phase 1
NCT05691244,2023.0,INDUSTRY,lead,"Pharmazz, Inc.",Phase 3
NCT05692271,2023.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 2
NCT05693142,2023.0,INDUSTRY,lead,REGENXBIO Inc.,Phase 1/Phase 2
NCT05693935,2023.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3
NCT05695339,2024.0,NIH,lead,National Institutes of Health Clinical Center (CC),Phase 1
NCT05695378,2023.0,INDUSTRY,lead,Kainos Medicine Inc.,Phase 2
NCT05695378,2023.0,INDUSTRY,collaborator,Parexel,Phase 2
NCT05695521,2023.0,INDUSTRY,lead,"Cellenkos, Inc.",Phase 1
NCT05695950,2023.0,INDUSTRY,lead,Galapagos NV,Phase 2
NCT05696483,2023.0,INDUSTRY,lead,"Oligomerix, Inc",Phase 1
NCT05696665,2022.0,OTHER_GOV,lead,Jinnah Postgraduate Medical Centre,Not Applicable
NCT05696665,2022.0,OTHER,collaborator,"Aga Khan University Hospital, Pakistan",Not Applicable
NCT05696665,2022.0,OTHER,collaborator,Liaquat National Hospital & Medical College,Not Applicable
NCT05696691,2023.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2/Phase 3
NCT05696691,2023.0,NIH,collaborator,National Center for Advancing Translational Sciences (NCATS),Phase 2/Phase 3
NCT05696912,2023.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT05697276,2022.0,OTHER,lead,Hospital Italiano de Buenos Aires,Not Applicable
NCT05697614,2023.0,OTHER,lead,Dr Cipto Mangunkusumo General Hospital,Phase 4
NCT05697887,2019.0,OTHER,lead,"Number 2 Children's Hospital, Ho Chi Minh City",Not Applicable
NCT05698017,2022.0,INDUSTRY,lead,Cytora Ltd.,Phase 1/Phase 2
NCT05698381,2023.0,OTHER,lead,Arizona State University,Not Applicable
NCT05699161,2021.0,OTHER,lead,"Samuel Vilchez, PhD",Phase 1/Phase 2
NCT05699161,2021.0,OTHER,collaborator,Wake Forest University,Phase 1/Phase 2
NCT05699161,2021.0,UNKNOWN,collaborator,"Ministerio de Salud, Nicaragua",Phase 1/Phase 2
NCT05699161,2021.0,INDUSTRY,collaborator,"GID BIO, Inc.",Phase 1/Phase 2
NCT05699161,2021.0,OTHER,collaborator,National Autonomous University of Nicaragua,Phase 1/Phase 2
NCT05699694,2023.0,OTHER,lead,Sociedad Española de Medicina Regenerativa y Terapia Celular,Not Applicable
NCT05700058,2023.0,OTHER,lead,University of Nottingham,Not Applicable
NCT05700695,2023.0,OTHER_GOV,lead,Postgraduate Institute of Medical Education and Research,Phase 1
NCT05700695,2023.0,OTHER,collaborator,Amrita Institute of Medical Sciences & Research Center,Phase 1
NCT05700695,2023.0,OTHER,collaborator,"Asian Institute of Gastroenterology, India",Phase 1
NCT05700695,2023.0,OTHER,collaborator,"All India Institute of Medical Sciences, Bhubaneswar",Phase 1
NCT05700695,2023.0,UNKNOWN,collaborator,"Kalinga Institute of Medical Sciences, Bhubaneswar",Phase 1
NCT05701111,2024.0,OTHER,lead,Stanford University,Not Applicable
NCT05701111,2024.0,UNKNOWN,collaborator,Pure Edge Inc.,Not Applicable
NCT05701111,2024.0,OTHER,collaborator,Iowa State University,Not Applicable
NCT05701111,2024.0,UNKNOWN,collaborator,Ponce Health Sciences University,Not Applicable
NCT05701189,2024.0,OTHER,lead,Chafic Karam,Phase 2
NCT05701189,2024.0,INDUSTRY,collaborator,argenx,Phase 2
NCT05701202,2021.0,OTHER,lead,University of Nottingham,Not Applicable
NCT05701774,2023.0,INDUSTRY,lead,"Soleno Therapeutics, Inc.",Phase 3
NCT05701956,2023.0,OTHER,lead,The First Affiliated Hospital of University of Science and Technology of China,Phase 3
NCT05701969,2022.0,OTHER,lead,University of Virginia,Early Phase 1
NCT05702151,2022.0,OTHER,lead,Hospital Clinic of Barcelona,Not Applicable
NCT05702359,2022.0,OTHER,lead,Agricultural University of Athens,Not Applicable
NCT05703685,2023.0,NIH,lead,National Institute of Mental Health (NIMH),Phase 1
NCT05704361,2021.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT05704374,2023.0,OTHER_GOV,lead,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,Not Applicable
NCT05704439,2024.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT05704439,2024.0,OTHER,collaborator,Olive View-UCLA Education & Research Institute,Not Applicable
NCT05705726,2023.0,OTHER,lead,Minia University,Not Applicable
NCT05705830,2022.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT05707572,2014.0,OTHER,lead,Dundee Podiatry Clinic,Not Applicable
NCT05707572,2014.0,OTHER,collaborator,Queen Margaret University,Not Applicable
NCT05707741,2023.0,OTHER,lead,Menoufia University,Not Applicable
NCT05708274,2023.0,FED,lead,Bronx VA Medical Center,Phase 1
NCT05709301,2023.0,OTHER,lead,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Phase 2
NCT05709314,2024.0,INDUSTRY,lead,Amydis Inc.,Phase 2
NCT05709314,2024.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT05709314,2024.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT05709353,2023.0,OTHER,lead,University of Sydney,Phase 2
NCT05709353,2023.0,OTHER,collaborator,Monash University,Phase 2
NCT05709353,2023.0,OTHER_GOV,collaborator,Sydney Local Health District,Phase 2
NCT05710367,2023.0,OTHER,lead,"Albina Nowak, MD",Phase 2
NCT05710692,2023.0,INDUSTRY,lead,Chiesi Farmaceutici S.p.A.,Phase 2/Phase 3
NCT05710692,2023.0,INDUSTRY,collaborator,ICON plc,Phase 2/Phase 3
NCT05711095,2023.0,OTHER,lead,Maastricht University Medical Center,Not Applicable
NCT05711095,2023.0,INDUSTRY,collaborator,Danone Nutricia,Not Applicable
NCT05711953,2021.0,INDUSTRY,lead,Contrad Swiss SA,Not Applicable
NCT05712044,2023.0,OTHER,lead,Centro Universitario de Tonalá,Not Applicable
NCT05713370,2022.0,OTHER,lead,University of Missouri-Columbia,Not Applicable
NCT05713630,2024.0,OTHER,lead,Unity Health Toronto,Phase 3
NCT05713630,2024.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 3
NCT05713630,2024.0,OTHER,collaborator,The Physicians' Services Incorporated Foundation,Phase 3
NCT05713630,2024.0,OTHER,collaborator,Applied Health Research Centre,Phase 3
NCT05713877,2023.0,OTHER,lead,Ciusss de L'Est de l'Île de Montréal,Phase 2
NCT05713877,2023.0,OTHER,collaborator,Maisonneuve-Rosemont Hospital,Phase 2
NCT05715437,2023.0,OTHER,lead,Assiut University,Phase 4
NCT05716906,2023.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT05717361,2022.0,OTHER,lead,Evangelismos Hospital,Not Applicable
NCT05717361,2022.0,OTHER,collaborator,Aretaieion University Hospital,Not Applicable
NCT05717946,2021.0,OTHER,lead,Medical University of Lodz,Phase 2
NCT05718310,2022.0,OTHER,lead,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Not Applicable
NCT05718310,2022.0,OTHER,collaborator,University of Pavia,Not Applicable
NCT05718817,2023.0,INDUSTRY,lead,Xenon Pharmaceuticals Inc.,Phase 3
NCT05718817,2023.0,OTHER,collaborator,Worldwide Clinical Trials,Phase 3
NCT05719909,2023.0,OTHER,lead,University of Pittsburgh,Not Applicable
NCT05720013,2023.0,OTHER,lead,Indiana University,Not Applicable
NCT05720416,2023.0,OTHER,lead,Central Taiwan University of Science and Technology,Not Applicable
NCT05720871,2022.0,OTHER,lead,Hospital de Mataró,Not Applicable
NCT05720871,2022.0,OTHER,collaborator,Consorci Sanitari del Maresme,Not Applicable
NCT05720871,2022.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Not Applicable
NCT05721196,2023.0,OTHER,lead,Nottingham Trent University,Not Applicable
NCT05721196,2023.0,OTHER,collaborator,University of Toronto,Not Applicable
NCT05721196,2023.0,OTHER,collaborator,Teesside University,Not Applicable
NCT05721196,2023.0,OTHER,collaborator,University of Manchester,Not Applicable
NCT05721573,2023.0,INDUSTRY,lead,"Abcuro, Inc.",Phase 2/Phase 3
NCT05721573,2023.0,OTHER,collaborator,Syneos Health,Phase 2/Phase 3
NCT05722951,2022.0,OTHER,lead,Tanta University,Phase 3
NCT05723276,2024.0,OTHER,lead,King's College London,Not Applicable
NCT05723341,2023.0,OTHER,lead,Istanbul University,Not Applicable
NCT05723588,2023.0,FED,lead,VA Office of Research and Development,Phase 2
NCT05723926,2025.0,INDUSTRY,lead,Javelin Medical,Not Applicable
NCT05723926,2025.0,OTHER,collaborator,Population Health Research Institute,Not Applicable
NCT05724485,2023.0,OTHER,lead,Mahidol University,Phase 4
NCT05724849,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT05725460,2023.0,OTHER,lead,Iraqi Board of medical specialties,Not Applicable
NCT05726786,2023.0,OTHER,lead,Centre Hospitalier Universitaire Vaudois,Phase 3
NCT05726786,2023.0,OTHER,collaborator,"Insel Gruppe AG, University Hospital Bern",Phase 3
NCT05726786,2023.0,OTHER,collaborator,"Hôpital Riviera-Chablais, Vaud-Valais",Phase 3
NCT05728229,2022.0,OTHER,lead,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Applicable
NCT05728736,2023.0,OTHER,lead,Brendan Lucey,Phase 2
NCT05728736,2023.0,INDUSTRY,collaborator,Eisai Inc.,Phase 2
NCT05728918,2023.0,INDUSTRY,lead,"Greenyn Biotechnology Co., Ltd.",Not Applicable
NCT05728944,2023.0,OTHER,lead,"LENZ Therapeutics, Inc",Phase 3
NCT05728944,2023.0,INDUSTRY,collaborator,"ORA, Inc.",Phase 3
NCT05729243,2023.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT05730062,2023.0,OTHER,lead,Leiden University Medical Center,Phase 1
NCT05730660,2022.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT05730699,2022.0,INDUSTRY,lead,Biocad,Phase 3
NCT05730738,2021.0,OTHER,lead,Ain Shams University,Not Applicable
NCT05730842,2023.0,INDUSTRY,lead,"Edgewise Therapeutics, Inc.",Phase 1
NCT05730985,2022.0,OTHER,lead,Azienda di Servizi alla Persona di Pavia,Not Applicable
NCT05732155,2023.0,OTHER,lead,"HaEmek Medical Center, Israel",Phase 2
NCT05732155,2023.0,UNKNOWN,collaborator,"MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA",Phase 2
NCT05732909,2022.0,OTHER,lead,University of Aarhus,Not Applicable
NCT05732909,2022.0,OTHER,collaborator,Danish Diabetes Academy,Not Applicable
NCT05732909,2022.0,OTHER,collaborator,AP Moeller Foundation,Not Applicable
NCT05732909,2022.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT05732909,2022.0,INDUSTRY,collaborator,Novo Nordisk A/S,Not Applicable
NCT05733390,2023.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 2
NCT05733390,2023.0,UNKNOWN,collaborator,GW Research,Phase 2
NCT05735418,2022.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT05735418,2022.0,UNKNOWN,collaborator,GI Biome,Not Applicable
NCT05735626,2021.0,OTHER,lead,Hospital de Mataró,Not Applicable
NCT05735626,2021.0,OTHER,collaborator,Consorci Sanitari del Maresme,Not Applicable
NCT05735626,2021.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Not Applicable
NCT05735717,2023.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Phase 2
NCT05737511,2023.0,OTHER,lead,Sultan Qaboos University,Phase 4
NCT05737693,2023.0,OTHER,lead,Yale University,Phase 2
NCT05737693,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05737784,2023.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 1/Phase 2
NCT05738486,2023.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05739643,2023.0,INDUSTRY,lead,"Forge Biologics, Inc",Phase 1/Phase 2
NCT05740722,2023.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT05740813,2023.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT05740813,2023.0,INDUSTRY,collaborator,Calico Life Sciences LLC,Phase 2/Phase 3
NCT05741528,2023.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 3
NCT05741710,2023.0,INDUSTRY,lead,Transcend Therapeutics,Phase 1/Phase 2
NCT05742698,2023.0,OTHER,lead,"Simon Ducharme, MD",Phase 2
NCT05742698,2023.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 2
NCT05743725,2023.0,OTHER,lead,Assiut University,Not Applicable
NCT05744401,2023.0,INDUSTRY,lead,Alector Inc.,Phase 2
NCT05744401,2023.0,INDUSTRY,collaborator,AbbVie,Phase 2
NCT05744479,2023.0,OTHER,lead,Centre for Addiction and Mental Health,Phase 4
NCT05746104,2023.0,OTHER,lead,Abramson Cancer Center at Penn Medicine,Phase 1
NCT05746273,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT05746273,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05746546,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2
NCT05746546,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05746572,2024.0,OTHER,lead,Emory University,Phase 4
NCT05747924,2023.0,INDUSTRY,lead,"Avidity Biosciences, Inc.",Phase 1/Phase 2
NCT05748236,2022.0,OTHER,lead,Dhaka Medical College,Phase 4
NCT05748249,2018.0,OTHER,lead,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Phase 1
NCT05748405,2022.0,INDUSTRY,lead,Aelis Farma,Phase 1/Phase 2
NCT05748405,2022.0,OTHER,collaborator,European Commission,Phase 1/Phase 2
NCT05748483,2023.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05748990,2023.0,OTHER,lead,Centre for Addiction and Mental Health,Not Applicable
NCT05749354,2023.0,OTHER,lead,The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Not Applicable
NCT05749393,2023.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Not Applicable
NCT05749614,2022.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT05749653,2017.0,OTHER,lead,Universiteit Antwerpen,Not Applicable
NCT05752305,2022.0,OTHER,lead,Universidad de Granada,Phase 2/Phase 3
NCT05753111,2023.0,OTHER,lead,KU Leuven,Not Applicable
NCT05753189,2023.0,OTHER,lead,"LENZ Therapeutics, Inc",Phase 3
NCT05753189,2023.0,INDUSTRY,collaborator,"ORA, Inc.",Phase 3
NCT05753462,2023.0,OTHER,lead,Sqy Therapeutics,Phase 1/Phase 2
NCT05753462,2023.0,INDUSTRY,collaborator,Biotrial,Phase 1/Phase 2
NCT05753852,2021.0,OTHER,lead,Humanitas Mirasole SpA,Phase 3
NCT05753852,2021.0,OTHER,collaborator,University of Ulm,Phase 3
NCT05753852,2021.0,OTHER,collaborator,University of Sheffield,Phase 3
NCT05753852,2021.0,OTHER,collaborator,"University Hospital, Tours",Phase 3
NCT05753852,2021.0,OTHER,collaborator,KU Leuven,Phase 3
NCT05753852,2021.0,OTHER,collaborator,UMC Utrecht,Phase 3
NCT05753852,2021.0,OTHER,collaborator,"University of Dublin, Trinity College",Phase 3
NCT05753852,2021.0,UNKNOWN,collaborator,Bruschettini S.r.l.,Phase 3
NCT05753852,2021.0,OTHER,collaborator,Istituto Superiore di Sanità,Phase 3
NCT05753852,2021.0,UNKNOWN,collaborator,Motor Neurone Disease Association,Phase 3
NCT05754073,2023.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT05754073,2023.0,FED,collaborator,United States Department of Defense,Phase 2
NCT05754593,2023.0,OTHER,lead,"University Hospital, Bordeaux",Not Applicable
NCT05754762,2023.0,OTHER,lead,Yangzhou University,Not Applicable
NCT05754996,2023.0,OTHER,lead,Cairo University,Phase 3
NCT05755737,2023.0,OTHER,lead,University of Calgary,Phase 2
NCT05757544,2023.0,INDUSTRY,lead,Marinus Pharmaceuticals,Phase 2
NCT05758090,2023.0,OTHER,lead,Khon Kaen University,Not Applicable
NCT05758831,2023.0,OTHER,lead,Rennes University Hospital,Phase 3
NCT05758922,2023.0,INDUSTRY,lead,Azafaros A.G.,Phase 2
NCT05759845,2022.0,OTHER,lead,Dr. Reaz Mahmud,Phase 4
NCT05760079,2022.0,OTHER,lead,Wake Forest University Health Sciences,Not Applicable
NCT05760976,2023.0,OTHER,lead,Yangzhou University,Not Applicable
NCT05761431,2023.0,INDUSTRY,lead,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1
NCT05761756,2023.0,OTHER,lead,Duke University,Not Applicable
NCT05763862,2023.0,OTHER,lead,National Neuroscience Institute,Not Applicable
NCT05763862,2023.0,OTHER,collaborator,Singapore General Hospital,Not Applicable
NCT05764239,2023.0,INDUSTRY,lead,Synlogic,Phase 3
NCT05764824,2023.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT05765487,2023.0,INDUSTRY,lead,"Daré Bioscience, Inc.",Phase 1
NCT05765487,2023.0,INDUSTRY,collaborator,"Strategic Science & Technologies, LLC",Phase 1
NCT05766436,2023.0,OTHER,lead,nada moahmed aboelrouse,Not Applicable
NCT05766813,2023.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 2
NCT05768126,2021.0,OTHER,lead,UMC Utrecht,Phase 4
NCT05768126,2021.0,OTHER,collaborator,ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4
NCT05768126,2021.0,OTHER,collaborator,St. Antonius Hospital,Phase 4
NCT05768126,2021.0,OTHER,collaborator,Tergooi Hospital,Phase 4
NCT05769088,2023.0,OTHER,lead,Joel Puente,Not Applicable
NCT05769088,2023.0,UNKNOWN,collaborator,Crown Sport Nutrition,Not Applicable
NCT05769088,2023.0,UNKNOWN,collaborator,Go Fit Spain,Not Applicable
NCT05769101,2022.0,OTHER,lead,Joel Puente,Not Applicable
NCT05769101,2022.0,UNKNOWN,collaborator,Crown Sport Nutrition,Not Applicable
NCT05769101,2022.0,UNKNOWN,collaborator,Go Fit Spain,Not Applicable
NCT05769478,2023.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT05770375,2024.0,OTHER,lead,"Anya Bershad, MD, PhD",Phase 1/Phase 2
NCT05770544,2024.0,OTHER,lead,Cancer Research UK,Phase 2/Phase 3
NCT05770544,2024.0,OTHER,collaborator,University of Manchester,Phase 2/Phase 3
NCT05770544,2024.0,OTHER,collaborator,University of Birmingham,Phase 2/Phase 3
NCT05770544,2024.0,OTHER,collaborator,Royal Marsden NHS Foundation Trust,Phase 2/Phase 3
NCT05770544,2024.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 2/Phase 3
NCT05771207,2023.0,OTHER,lead,Peking Union Medical College Hospital,Not Applicable
NCT05776459,2022.0,INDUSTRY,lead,AudioCure Pharma GmbH,Phase 2
NCT05776862,2023.0,OTHER,lead,University of Miami,Phase 2
NCT05776862,2023.0,OTHER,collaborator,Florida,Phase 2
NCT05776953,2023.0,OTHER,lead,Hackensack Meridian Health,Phase 4
NCT05777031,2023.0,OTHER,lead,University of Miami,Phase 4
NCT05777031,2023.0,INDUSTRY,collaborator,Endo Pharmaceuticals,Phase 4
NCT05777902,2023.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 4
NCT05778591,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT05778617,2023.0,OTHER,lead,"University College, London",Phase 3
NCT05778695,2023.0,OTHER,lead,University of Michigan,Not Applicable
NCT05778695,2023.0,UNKNOWN,collaborator,Farmer Family Foundation,Not Applicable
NCT05778903,2023.0,OTHER,lead,Oslo University Hospital,Not Applicable
NCT05779241,2023.0,INDUSTRY,lead,Lyndra Inc.,Phase 3
NCT05781399,2022.0,INDUSTRY,lead,Jnana Therapeutics,Phase 1
NCT05781711,2023.0,OTHER,lead,Tanta University,Phase 2
NCT05781711,2023.0,UNKNOWN,collaborator,"Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University",Phase 2
NCT05781711,2023.0,UNKNOWN,collaborator,"Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University",Phase 2
NCT05781711,2023.0,UNKNOWN,collaborator,"Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University",Phase 2
NCT05782244,2024.0,OTHER,lead,University of Pennsylvania,Phase 2
NCT05782244,2024.0,FED,collaborator,Walter Reed National Military Medical Center,Phase 2
NCT05783232,2023.0,INDUSTRY,lead,Radicle Science,Not Applicable
NCT05783817,2024.0,OTHER,lead,Carolyn Rodriguez,Phase 2
NCT05783830,2020.0,INDUSTRY,lead,AlzeCure Pharma,Early Phase 1
NCT05785377,2025.0,OTHER,lead,Mansoura University,Not Applicable
NCT05785689,2023.0,OTHER,lead,University of Southern Denmark,Phase 4
NCT05785689,2023.0,OTHER,collaborator,Odense Patient Data Explorative Network,Phase 4
NCT05786066,2023.0,OTHER,lead,Yale University,Phase 2
NCT05786066,2023.0,OTHER,collaborator,American Foundation for Suicide Prevention,Phase 2
NCT05786066,2023.0,FED,collaborator,National Center for PTSD,Phase 2
NCT05786066,2023.0,FED,collaborator,VA Connecticut Healthcare System,Phase 2
NCT05786378,2023.0,OTHER,lead,Assiut University,Phase 2/Phase 3
NCT05786677,2023.0,OTHER,lead,Cairo University,Not Applicable
NCT05786833,2023.0,OTHER,lead,Tanta University,Not Applicable
NCT05786859,2023.0,OTHER,lead,Sun Yat-sen University,Early Phase 1
NCT05787028,2019.0,OTHER,lead,South China Center For Innovative Pharmaceuticals,Phase 1
NCT05787028,2019.0,OTHER,collaborator,Xiangya Hospital of Central South University,Phase 1
NCT05787041,2019.0,OTHER,lead,South China Center For Innovative Pharmaceuticals,Phase 1
NCT05787041,2019.0,OTHER,collaborator,Xiangya Hospital of Central South University,Phase 1
NCT05788159,2023.0,INDUSTRY,lead,"Overseas Pharmaceuticals, Ltd.",Phase 1
NCT05788159,2023.0,UNKNOWN,collaborator,"Beijing Capton Pharmaceutical Technology Development Co., LTD",Phase 1
NCT05788393,2024.0,OTHER,lead,Assiut University,Phase 4
NCT05788627,2023.0,OTHER,lead,"Khyber Medical College, Peshawar",Phase 4
NCT05789186,2023.0,OTHER,lead,Chen Qian,Early Phase 1
NCT05790239,2023.0,FED,lead,Stephen Robert Marder,Phase 2
NCT05790382,2023.0,INDUSTRY,lead,Neuramedy Co. Ltd.,Phase 1
NCT05790382,2023.0,INDUSTRY,collaborator,Quotient Sciences,Phase 1
NCT05791604,2023.0,OTHER,lead,Children's Hospital of Fudan University,Not Applicable
NCT05792163,2023.0,INDUSTRY,lead,SciNeuro,Phase 1
NCT05792462,2023.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 1/Phase 2
NCT05792540,2023.0,OTHER,lead,Tanta University,Phase 2
NCT05792540,2023.0,UNKNOWN,collaborator,"Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University",Phase 2
NCT05792540,2023.0,UNKNOWN,collaborator,"Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University",Phase 2
NCT05792540,2023.0,UNKNOWN,collaborator,"Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University",Phase 2
NCT05792774,2023.0,OTHER,lead,University of Seville,Phase 4
NCT05793060,2024.0,OTHER_GOV,lead,Damanhour Teaching Hospital,Phase 4
NCT05793632,2023.0,OTHER,lead,Ain Shams University,Phase 2
NCT05793684,2023.0,INDUSTRY,lead,Apnimed,Phase 2
NCT05793736,2023.0,OTHER,lead,University of Cagliari,Not Applicable
NCT05793892,2023.0,INDUSTRY,lead,"Cutia Therapeutics（Wuxi）Co.,Ltd",Phase 3
NCT05794139,2023.0,INDUSTRY,lead,NMD Pharma A/S,Phase 2
NCT05796167,2024.0,OTHER,lead,State University of New York - Downstate Medical Center,Early Phase 1
NCT05796167,2024.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Early Phase 1
NCT05796401,2023.0,OTHER,lead,Centre Hospitalier St Anne,Phase 3
NCT05796791,2023.0,OTHER,lead,Medical University of South Carolina,Early Phase 1
NCT05797376,2021.0,OTHER,lead,Asan Medical Center,Phase 4
NCT05797376,2021.0,INDUSTRY,collaborator,Bayer,Phase 4
NCT05797792,2023.0,OTHER,lead,Hospital Clinic of Barcelona,Phase 3
NCT05797792,2023.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 3
NCT05797792,2023.0,OTHER,collaborator,Fundacion Clinic per a la Recerca Biomédica,Phase 3
NCT05801289,2022.0,OTHER,lead,Ain Shams University,Not Applicable
NCT05801575,2023.0,OTHER,lead,Hong Kong Baptist University,Not Applicable
NCT05803148,2023.0,OTHER_GOV,lead,China National Center for Cardiovascular Diseases,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,Beijing Chao Yang Hospital,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,RenJi Hospital,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,Yeditepe University Hospital,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,"First Affiliated Hospital, Sun Yat-Sen University",Not Applicable
NCT05803148,2023.0,OTHER,collaborator,Ningbo No. 1 Hospital,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,Fuwai Yunnan Cardiovascular Hospital,Not Applicable
NCT05803148,2023.0,OTHER,collaborator,Henan Provincial People's Hospital,Not Applicable
NCT05803434,2023.0,OTHER,lead,Meyer Children's Hospital IRCCS,Phase 2
NCT05803551,2023.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05804084,2023.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05804084,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT05804383,2023.0,INDUSTRY,lead,Allyx Therapeutics,Phase 1
NCT05804383,2023.0,OTHER,collaborator,Yale University,Phase 1
NCT05804383,2023.0,NIH,collaborator,National Institute on Aging (NIA),Phase 1
NCT05804669,2023.0,INDUSTRY,lead,Crinetics Pharmaceuticals Inc.,Phase 1/Phase 2
NCT05805683,2023.0,OTHER,lead,Tanta University,Not Applicable
NCT05805839,2023.0,OTHER,lead,Mayo Clinic,Phase 2
NCT05806177,2020.0,OTHER,lead,South China Center For Innovative Pharmaceuticals,Phase 1
NCT05806177,2020.0,OTHER,collaborator,Xiangya Hospital of Central South University,Phase 1
NCT05806697,2023.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT05808764,2024.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT05809219,2023.0,OTHER,lead,China Medical University Hospital,Not Applicable
NCT05809414,2022.0,OTHER,lead,"Hospital San Carlos, Madrid",Phase 3
NCT05809609,2022.0,OTHER,lead,University of Oxford,Not Applicable
NCT05809700,2023.0,NETWORK,lead,Dove Medical Press Ltd,Not Applicable
NCT05809908,2025.0,INDUSTRY,lead,Cerecin,Phase 3
NCT05810038,2023.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05811442,2023.0,INDUSTRY,lead,Beijing Joekai Biotechnology LLC,Phase 2
NCT05812755,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT05812755,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT05813106,2022.0,OTHER,lead,Security Forces Hospital,Phase 4
NCT05814016,2023.0,INDUSTRY,lead,Takeda,Phase 2
NCT05814601,2023.0,OTHER,lead,Yonsei University,Not Applicable
NCT05814640,2023.0,OTHER,lead,First Affiliated Hospital of Chongqing Medical University,Phase 1/Phase 2
NCT05814640,2023.0,OTHER,collaborator,The Second Affiliated Hospital of Chongqing Medical University,Phase 1/Phase 2
NCT05814640,2023.0,OTHER,collaborator,Children's Hospital of Chongqing Medical University,Phase 1/Phase 2
NCT05814640,2023.0,OTHER,collaborator,"Southwest Hospital, China",Phase 1/Phase 2
NCT05814640,2023.0,OTHER,collaborator,Central South University,Phase 1/Phase 2
NCT05817643,2023.0,INDUSTRY,lead,Allyx Therapeutics,Phase 1
NCT05817643,2023.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT05818735,2023.0,OTHER,lead,Shanghai Municipal Hospital of Traditional Chinese Medicine,Not Applicable
NCT05818735,2023.0,OTHER,collaborator,Shanghai Mental Health Center,Not Applicable
NCT05818735,2023.0,OTHER,collaborator,"Xuhui Central Hospital, Shanghai",Not Applicable
NCT05818735,2023.0,UNKNOWN,collaborator,Shanghai Huangpu District Mental Health Center,Not Applicable
NCT05818826,2023.0,OTHER,lead,Mahidol University,Phase 2
NCT05819359,2023.0,INDUSTRY,lead,"Bial R&D Investments, S.A.",Phase 2
NCT05819658,2023.0,INDUSTRY,lead,GemVax & Kael,Phase 2
NCT05820243,2023.0,OTHER,lead,University of Delaware,Not Applicable
NCT05821075,2023.0,OTHER,lead,October 6 University,Phase 1/Phase 2
NCT05821153,2019.0,OTHER,lead,The Methodist Hospital Research Institute,Phase 1
NCT05821972,2023.0,OTHER,lead,Assiut University,Phase 4
NCT05822739,2023.0,OTHER,lead,Xiangya Hospital of Central South University,Early Phase 1
NCT05822908,2023.0,INDUSTRY,lead,Vico Therapeutics B. V.,Phase 1/Phase 2
NCT05823441,2023.0,OTHER,lead,Peking University People's Hospital,Phase 4
NCT05823506,2023.0,OTHER,lead,"Saint Petersburg State University, Russia",Not Applicable
NCT05823532,2024.0,OTHER,lead,Emory University,Phase 4
NCT05823532,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT05823844,2023.0,OTHER,lead,Columbia University,Phase 4
NCT05823844,2023.0,INDUSTRY,collaborator,Merck Sharp & Dohme LLC,Phase 4
NCT05824169,2023.0,INDUSTRY,lead,GeneCradle Inc,Phase 1/Phase 2
NCT05825235,2023.0,OTHER,lead,Region Skane,Phase 3
NCT05825235,2023.0,OTHER,collaborator,Lund University,Phase 3
NCT05825365,2023.0,INDUSTRY,lead,AstraZeneca,Phase 2
NCT05825391,2023.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,"Xuanwu Hospital, Beijing",Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Chinese PLA General Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Beijing Chao Yang Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Peking University International Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Peking University First Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Hebei Medical University Third Hospital,Not Applicable
NCT05825391,2023.0,OTHER,collaborator,Tianjin Medical University General Hospital,Not Applicable
NCT05826912,2024.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT05826912,2024.0,FED,collaborator,United States Department of Defense,Phase 2
NCT05827042,2023.0,OTHER,lead,The First Affiliated Hospital of University of Science and Technology of China,Phase 3
NCT05827536,2023.0,OTHER,lead,APR Applied Pharma Research s.a.,Not Applicable
NCT05828212,2023.0,OTHER,lead,Zhejiang University,Phase 1
NCT05828225,2023.0,OTHER,lead,Zhejiang University,Phase 1
NCT05828940,2019.0,OTHER,lead,University of Oxford,Not Applicable
NCT05830396,2023.0,OTHER,lead,University Medical Center Groningen,Phase 2/Phase 3
NCT05832034,2021.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 2
NCT05832034,2021.0,OTHER,collaborator,Princess Beatrix Muscle Foundation,Phase 2
NCT05832255,2023.0,INDUSTRY,lead,Nova Mentis Life Science Corp,Phase 2
NCT05832255,2023.0,INDUSTRY,collaborator,KGK Science Inc.,Phase 2
NCT05832281,2023.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05832281,2023.0,UNKNOWN,collaborator,California Department of Cannabis Control (DCC),Phase 2
NCT05832281,2023.0,OTHER,collaborator,Center for Medicinal Cannabis Research,Phase 2
NCT05832515,2020.0,OTHER,lead,St. Petersburg State Pavlov Medical University,Phase 1
NCT05832775,2022.0,INDUSTRY,lead,4D pharma plc,Phase 1
NCT05832775,2022.0,INDUSTRY,collaborator,"Labcorp Corporation of America Holdings, Inc",Phase 1
NCT05832775,2022.0,INDUSTRY,collaborator,ICON plc,Phase 1
NCT05833711,2023.0,INDUSTRY,lead,Immunoforge Co. Ltd.,Phase 2
NCT05834010,2023.0,OTHER,lead,Hvidovre University Hospital,Early Phase 1
NCT05834010,2023.0,OTHER,collaborator,University of Copenhagen,Early Phase 1
NCT05834010,2023.0,OTHER,collaborator,Odense University Hospital,Early Phase 1
NCT05834010,2023.0,OTHER,collaborator,Psychiatric Center Ballerup,Early Phase 1
NCT05834023,2023.0,OTHER,lead,Hospital de San Carlos Dr. Benicio Arzola Medina,Phase 4
NCT05834296,2023.0,INDUSTRY,lead,"Alzamend Neuro, Inc.",Phase 1/Phase 2
NCT05834296,2023.0,INDUSTRY,collaborator,"bioRASI, LLC",Phase 1/Phase 2
NCT05834478,2024.0,OTHER,lead,Emory University,Phase 3
NCT05834478,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT05834569,2023.0,OTHER,lead,Korea University Guro Hospital,Phase 4
NCT05834569,2023.0,UNKNOWN,collaborator,"Kyongbo Pharmaceutical Co.,Ltd",Phase 4
NCT05834673,2023.0,OTHER,lead,Monash University,Phase 4
NCT05834673,2023.0,INDUSTRY,collaborator,Novartis Pharmaceuticals,Phase 4
NCT05834855,2023.0,OTHER,lead,"Amsterdam UMC, location VUmc",Phase 3
NCT05834855,2023.0,UNKNOWN,collaborator,Stichting Treatmeds,Phase 3
NCT05835687,2023.0,OTHER,lead,St. Jude Children's Research Hospital,Phase 1
NCT05837091,2024.0,OTHER,lead,Mayo Clinic,Phase 4
NCT05837130,2022.0,INDUSTRY,lead,Servier,Early Phase 1
NCT05837741,2021.0,OTHER,lead,Maimónides Biomedical Research Institute of Córdoba,Not Applicable
NCT05837845,2024.0,OTHER,lead,Patricia Suppes,Phase 2
NCT05837845,2024.0,OTHER,collaborator,Stanford University,Phase 2
NCT05837845,2024.0,FED,collaborator,VA Palo Alto Health Care System,Phase 2
NCT05837845,2024.0,OTHER,collaborator,Steven & Alexandra Cohen Foundation,Phase 2
NCT05837923,2023.0,INDUSTRY,lead,Radicle Science,Not Applicable
NCT05838560,2023.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT05838560,2023.0,OTHER,collaborator,UConn Health,Phase 2
NCT05838573,2023.0,OTHER,lead,Central South University,Phase 3
NCT05838573,2023.0,UNKNOWN,collaborator,NINGBO KANGNING HOSPITAL,Phase 3
NCT05838573,2023.0,OTHER,collaborator,Shandong Mental Health Center,Phase 3
NCT05838573,2023.0,UNKNOWN,collaborator,The Second People's Hospital of Dali Bai Autonomous Prefecture,Phase 3
NCT05840237,2023.0,INDUSTRY,lead,Terra Biological LLC,Not Applicable
NCT05840237,2023.0,OTHER,collaborator,Bateman Horne Center,Not Applicable
NCT05840315,2023.0,OTHER,lead,Horsholm Municipality,Not Applicable
NCT05841147,2023.0,OTHER,lead,Lu Hua,Phase 4
NCT05842941,2023.0,OTHER,lead,"Merit E. Cudkowicz, MD",Phase 2/Phase 3
NCT05842941,2023.0,INDUSTRY,collaborator,Denali Therapeutics Inc.,Phase 2/Phase 3
NCT05843344,2023.0,OTHER,lead,Dr Kassiani Theodoraki,Not Applicable
NCT05843344,2023.0,OTHER,collaborator,Sotiria General Hospital,Not Applicable
NCT05843916,2022.0,INDUSTRY,lead,Bio Sidus SA,Phase 3
NCT05844787,2022.0,INDUSTRY,lead,"Mthera Pharma Co., Ltd.",Phase 1
NCT05844787,2022.0,OTHER,collaborator,Amarex Clinical Research,Phase 1
NCT05848544,2021.0,OTHER,lead,Istituto Ortopedico Rizzoli,Not Applicable
NCT05848700,2023.0,INDUSTRY,lead,"Sumitomo Pharma America, Inc.",Phase 1
NCT05848830,2024.0,OTHER,lead,McMaster University,Phase 3
NCT05848960,2021.0,OTHER,lead,Maimónides Biomedical Research Institute of Córdoba,Not Applicable
NCT05849038,2023.0,OTHER,lead,Emory University,Phase 2
NCT05849038,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05849467,2023.0,NIH,lead,National Institute of Neurological Disorders and Stroke (NINDS),Phase 1
NCT05849662,2023.0,OTHER,lead,Therapeutic Advances in Childhood Leukemia Consortium,Phase 1/Phase 2
NCT05849675,2023.0,OTHER,lead,University of Oxford,Not Applicable
NCT05850364,2023.0,INDUSTRY,lead,"Sinovac Biotech Co., Ltd",Phase 3
NCT05850572,2023.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT05850585,2023.0,OTHER,lead,First Affiliated Hospital Xi'an Jiaotong University,Not Applicable
NCT05851391,2023.0,OTHER,lead,"University of California, San Francisco",Phase 2
NCT05851391,2023.0,UNKNOWN,collaborator,The ZOLL Foundation,Phase 2
NCT05851768,2023.0,OTHER,lead,"National Cancer Institute, Egypt",Not Applicable
NCT05851781,2022.0,OTHER,lead,Kafrelsheikh University,Phase 3
NCT05852496,2023.0,OTHER,lead,Assiut University,Phase 2
NCT05853263,2016.0,OTHER,lead,Erasmus Medical Center,Not Applicable
NCT05853263,2016.0,OTHER,collaborator,KU Leuven,Not Applicable
NCT05853263,2016.0,OTHER,collaborator,UMC Utrecht,Not Applicable
NCT05853263,2016.0,OTHER,collaborator,University Medical Center Groningen,Not Applicable
NCT05853471,2022.0,OTHER,lead,University Medical Center Groningen,Phase 1/Phase 2
NCT05853627,2023.0,OTHER,lead,Massachusetts General Hospital,Phase 4
NCT05853835,2023.0,INDUSTRY,lead,LAPIX Therapeutics Inc.,Phase 1
NCT05854082,2023.0,OTHER,lead,University of Alberta,Phase 4
NCT05854667,2023.0,OTHER,lead,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2
NCT05854667,2023.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT05855577,2023.0,OTHER,lead,I.R.C.C.S. Fondazione Santa Lucia,Phase 4
NCT05855577,2023.0,UNKNOWN,collaborator,Università Foro Italico Roma,Phase 4
NCT05855577,2023.0,UNKNOWN,collaborator,CNR Pisa,Phase 4
NCT05855863,2023.0,OTHER,lead,Shanghai 10th People's Hospital,Phase 4
NCT05857384,2023.0,INDUSTRY,lead,Incannex Healthcare Ltd,Phase 1
NCT05859412,2023.0,OTHER,lead,University of Oxford,Not Applicable
NCT05859412,2023.0,OTHER,collaborator,Wellcome Trust,Not Applicable
NCT05859698,2023.0,INDUSTRY,lead,Neurocrine Biosciences,Phase 4
NCT05859802,2011.0,OTHER,lead,D'Youville College,Phase 2/Phase 3
NCT05859802,2011.0,INDUSTRY,collaborator,Acorda Therapeutics,Phase 2/Phase 3
NCT05859802,2011.0,OTHER,collaborator,University at Buffalo,Phase 2/Phase 3
NCT05859997,2023.0,INDUSTRY,lead,Bioray Laboratories,Not Applicable
NCT05859997,2023.0,OTHER,collaborator,Shanghai Changzheng Hospital,Not Applicable
NCT05860088,2023.0,OTHER,lead,Indiana University,Not Applicable
NCT05860153,2023.0,OTHER,lead,Assiut University,Not Applicable
NCT05860244,2023.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT05861427,2023.0,INDUSTRY,lead,AbbVie,Phase 3
NCT05861986,2024.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT05861999,2024.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 4
NCT05862779,2023.0,OTHER,lead,Federal University of Uberlandia,Not Applicable
NCT05863416,2023.0,OTHER,lead,Tri-Service General Hospital,Phase 4
NCT05863507,2023.0,OTHER,lead,"University of California, Davis",Not Applicable
NCT05863507,2023.0,OTHER,collaborator,California Table Grape Commission,Not Applicable
NCT05863949,2023.0,OTHER,lead,Ottawa Hospital Research Institute,Not Applicable
NCT05864053,2024.0,OTHER,lead,Rush University Medical Center,Phase 1/Phase 2
NCT05864053,2024.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 1/Phase 2
NCT05864365,2023.0,INDUSTRY,lead,Alterity Therapeutics,Phase 2
NCT05864508,2023.0,OTHER,lead,"University Hospital, Toulouse",Phase 2
NCT05864677,2023.0,OTHER,lead,Medical University of Lublin,Not Applicable
NCT05865288,2023.0,OTHER,lead,Shalvata Mental Health Center,Phase 1
NCT05865470,2024.0,OTHER,lead,"University of California, Los Angeles",Phase 1
NCT05865470,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05866419,2023.0,INDUSTRY,lead,"Alcyone Therapeutics, Inc",Not Applicable
NCT05866419,2023.0,INDUSTRY,collaborator,Biogen,Not Applicable
NCT05866926,2023.0,INDUSTRY,lead,Ferrer Internacional S.A.,Phase 3
NCT05867849,2023.0,OTHER,lead,University of British Columbia,Phase 3
NCT05868798,2020.0,OTHER,lead,Jan Malecek,Phase 1
NCT05869305,2023.0,OTHER,lead,Chulalongkorn University,Not Applicable
NCT05869383,2023.0,OTHER,lead,Universitas Sriwijaya,Phase 2/Phase 3
NCT05869513,2023.0,OTHER,lead,University of Glasgow,Not Applicable
NCT05869526,2023.0,OTHER,lead,University of Glasgow,Not Applicable
NCT05869565,2023.0,OTHER,lead,Aga Khan University,Phase 2/Phase 3
NCT05869565,2023.0,OTHER,collaborator,Zeenat Qureshi Stroke Institute,Phase 2/Phase 3
NCT05869773,2023.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT05870501,2021.0,OTHER,lead,King's College London,Not Applicable
NCT05870501,2021.0,OTHER,collaborator,South London and Maudsley NHS Foundation Trust,Not Applicable
NCT05871606,2024.0,OTHER,lead,Wake Forest University Health Sciences,Phase 1
NCT05871606,2024.0,INDUSTRY,collaborator,Mallinckrodt,Phase 1
NCT05872087,2022.0,OTHER,lead,Ain Shams University,Phase 1
NCT05872360,2023.0,INDUSTRY,lead,Amway (China) R&D Center,Not Applicable
NCT05873062,2023.0,INDUSTRY,lead,Autifony Therapeutics Limited,Phase 1
NCT05874388,2023.0,OTHER_GOV,lead,"Institut National de la Santé Et de la Recherche Médicale, France",Not Applicable
NCT05875285,2023.0,OTHER,lead,Cairo University,Not Applicable
NCT05875974,2023.0,INDUSTRY,lead,Jazz Pharmaceuticals,Phase 4
NCT05876039,2023.0,OTHER,lead,Tri-Service General Hospital,Phase 4
NCT05876481,2023.0,OTHER,lead,Combat Stress,Phase 2
NCT05876481,2023.0,UNKNOWN,collaborator,The Watson Trust,Phase 2
NCT05876780,2022.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT05877040,2019.0,OTHER,lead,Istituto Clinico Humanitas,Phase 2
NCT05877846,2023.0,OTHER,lead,"University of North Carolina, Chapel Hill",Not Applicable
NCT05877846,2023.0,OTHER,collaborator,North Carolina Translational and Clinical Sciences Institute,Not Applicable
NCT05877989,2021.0,OTHER,lead,Tanta University,Phase 4
NCT05879614,2023.0,INDUSTRY,lead,Neuren Pharmaceuticals Limited,Phase 2
NCT05880563,2023.0,OTHER,lead,Markus Weber,Phase 1
NCT05880563,2023.0,OTHER,collaborator,ETH Zurich,Phase 1
NCT05880563,2023.0,OTHER,collaborator,"Insel Gruppe AG, University Hospital Bern",Phase 1
NCT05880849,2023.0,OTHER,lead,Paul E Schulz,Phase 1
NCT05880849,2023.0,OTHER,collaborator,M.D. Anderson Cancer Center,Phase 1
NCT05880849,2023.0,OTHER,collaborator,Massachusetts Institute of Technology,Phase 1
NCT05880849,2023.0,UNKNOWN,collaborator,Balchem Corporation,Phase 1
NCT05881408,2023.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT05881408,2023.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 3
NCT05881928,2023.0,OTHER,lead,Assiut University,Phase 4
NCT05882487,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Early Phase 1
NCT05882487,2023.0,OTHER,collaborator,R&D Kanglin Biotech,Early Phase 1
NCT05882695,2023.0,INDUSTRY,lead,Spinogenix,Phase 1
NCT05882695,2023.0,INDUSTRY,collaborator,Novotech (Australia) Pty Limited,Phase 1
NCT05883540,2023.0,OTHER,lead,"University Hospital, Basel, Switzerland",Phase 2
NCT05883540,2023.0,OTHER,collaborator,"University Hospital, Zürich",Phase 2
NCT05884138,2023.0,OTHER,lead,Chungnam National University Hospital,Not Applicable
NCT05884281,2023.0,OTHER,lead,Mansoura University,Phase 1/Phase 2
NCT05884957,2023.0,INDUSTRY,lead,Egymedicalpedia,Not Applicable
NCT05885360,2023.0,OTHER,lead,Georgetown University,Phase 4
NCT05885360,2023.0,INDUSTRY,collaborator,"Kyowa Kirin, Inc.",Phase 4
NCT05886582,2023.0,OTHER,lead,Virginia Commonwealth University,Phase 2
NCT05886582,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT05887466,2023.0,INDUSTRY,lead,"S.Biomedics Co., Ltd.",Phase 1/Phase 2
NCT05887466,2023.0,OTHER,collaborator,Yonsei University,Phase 1/Phase 2
NCT05887479,2023.0,OTHER,lead,Sisli Hamidiye Etfal Training and Research Hospital,Phase 4
NCT05887765,2023.0,OTHER,lead,Poznan University of Medical Sciences,Phase 4
NCT05889026,2020.0,OTHER,lead,Korea University Guro Hospital,Not Applicable
NCT05889026,2020.0,INDUSTRY,collaborator,Daewoong Pharmaceutical Co. LTD.,Not Applicable
NCT05889273,2023.0,INDUSTRY,lead,MapLight Therapeutics,Phase 2
NCT05889572,2023.0,INDUSTRY,lead,MaaT Pharma,Phase 1
NCT05889624,2023.0,OTHER,lead,"Children's Hospital Medical Center, Cincinnati",Not Applicable
NCT05889624,2023.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Not Applicable
NCT05889741,2024.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Phase 2
NCT05889741,2024.0,FED,collaborator,United States Department of Defense,Phase 2
NCT05890690,2023.0,OTHER,lead,"University Hospital, Basel, Switzerland",Not Applicable
NCT05890768,2023.0,OTHER,lead,University of New Mexico,Phase 4
NCT05890781,2023.0,OTHER,lead,"Gustave Roussy, Cancer Campus, Grand Paris",Not Applicable
NCT05891938,2023.0,OTHER,lead,Wonju Severance Christian Hospital,Not Applicable
NCT05892276,2024.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT05892510,2023.0,OTHER,lead,University of Melbourne,Phase 2/Phase 3
NCT05892887,2023.0,OTHER,lead,Kafrelsheikh University,Phase 4
NCT05893225,2023.0,OTHER,lead,"University Hospital, Antwerp",Phase 2
NCT05893225,2023.0,OTHER,collaborator,"University Hospital, Ghent",Phase 2
NCT05893225,2023.0,OTHER,collaborator,Hasselt University,Phase 2
NCT05893225,2023.0,OTHER,collaborator,AZ Sint-Jan AV,Phase 2
NCT05893225,2023.0,OTHER,collaborator,Noorderhart Pelt,Phase 2
NCT05893225,2023.0,OTHER,collaborator,National MS Center Melsbroek,Phase 2
NCT05893862,2023.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT05894343,2023.0,INDUSTRY,lead,"MeiraGTx, LLC",Phase 1/Phase 2
NCT05894902,2023.0,OTHER,lead,Advanced Integrative Medical Science Institute,Phase 1
NCT05895513,2024.0,OTHER,lead,Ohio State University,Phase 2
NCT05895513,2024.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 2
NCT05895786,2023.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05896605,2020.0,OTHER,lead,First Affiliated Hospital of Guangxi Medical University,Phase 4
NCT05897086,2021.0,OTHER,lead,Vanderbilt University Medical Center,Phase 2/Phase 3
NCT05897658,2024.0,OTHER,lead,Hamilton Health Sciences Corporation,Phase 3
NCT05897658,2024.0,OTHER,collaborator,McMaster University,Phase 3
NCT05898620,2023.0,INDUSTRY,lead,Neurogene Inc.,Phase 1/Phase 2
NCT05899764,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 1/Phase 2
NCT05900245,2023.0,OTHER,lead,Min Su,Not Applicable
NCT05901350,2019.0,OTHER,lead,Qilu Hospital of Shandong University,Not Applicable
NCT05901389,2023.0,OTHER,lead,Qilu Hospital of Shandong University,Not Applicable
NCT05901441,2022.0,OTHER,lead,Maternal and Child Health Hospital of Hubei Province,Phase 2
NCT05901818,2023.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 1
NCT05902000,2023.0,OTHER_GOV,lead,Xueli Cai,Not Applicable
NCT05902429,2021.0,OTHER,lead,Pontificia Universidade Católica do Rio Grande do Sul,Phase 4
NCT05902429,2021.0,UNKNOWN,collaborator,"Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 4
NCT05903014,2023.0,OTHER,lead,Indonesia University,Phase 4
NCT05904717,2023.0,INDUSTRY,lead,Syntara,Phase 2
NCT05905510,2023.0,OTHER,lead,Tanta University,Phase 4
NCT05905848,2023.0,OTHER,lead,West China Hospital,Phase 3
NCT05906056,2023.0,OTHER,lead,University of Ioannina,Not Applicable
NCT05906251,2023.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT05907850,2023.0,OTHER,lead,The University of Texas Health Science Center at San Antonio,Early Phase 1
NCT05907850,2023.0,UNKNOWN,collaborator,Racing the Planet,Early Phase 1
NCT05907902,2023.0,OTHER,lead,Beijing Tiantan Hospital,Phase 3
NCT05908695,2023.0,INDUSTRY,lead,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",Phase 4
NCT05911516,2023.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT05913037,2023.0,INDUSTRY,lead,Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,Phase 3
NCT05913947,2022.0,OTHER,lead,Aalborg University Hospital,Phase 4
NCT05913947,2022.0,UNKNOWN,collaborator,"Mental Health Center, Glostrup",Phase 4
NCT05913947,2022.0,UNKNOWN,collaborator,Mental Health Center North Zealand,Phase 4
NCT05913947,2022.0,UNKNOWN,collaborator,"Mental Health Department Odense, University Clinic",Phase 4
NCT05913947,2022.0,UNKNOWN,collaborator,"Psychiatric Center Copenhagen, Rigshospitalet",Phase 4
NCT05914649,2023.0,OTHER,lead,University of Calgary,Not Applicable
NCT05915013,2023.0,OTHER,lead,Yale University,Phase 1
NCT05915013,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 1
NCT05915247,2023.0,INDUSTRY,lead,Herantis Pharma Plc.,Phase 1
NCT05915247,2023.0,UNKNOWN,collaborator,Clinical Research Services Turku - CRST Oy,Phase 1
NCT05916053,2021.0,OTHER,lead,Lebanese American University,Not Applicable
NCT05916118,2022.0,OTHER,lead,Dartmouth-Hitchcock Medical Center,Not Applicable
NCT05916339,2023.0,OTHER,lead,Daniel Coury,Phase 4
NCT05916339,2023.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Phase 4
NCT05916339,2023.0,OTHER,collaborator,"University of California, Irvine",Phase 4
NCT05916339,2023.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 4
NCT05916339,2023.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 4
NCT05916339,2023.0,UNKNOWN,collaborator,University of Rochester Golisano Children's Hospital,Phase 4
NCT05916339,2023.0,OTHER,collaborator,Nationwide Children's Hospital,Phase 4
NCT05916339,2023.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 4
NCT05916339,2023.0,OTHER,collaborator,University of Pittsburgh,Phase 4
NCT05916339,2023.0,OTHER,collaborator,Children's Hospital Los Angeles,Phase 4
NCT05916339,2023.0,OTHER,collaborator,University of Virginia,Phase 4
NCT05916339,2023.0,OTHER,collaborator,University of Alberta,Phase 4
NCT05916339,2023.0,OTHER,collaborator,Massachusetts General Hospital,Phase 4
NCT05916339,2023.0,OTHER,collaborator,MaineHealth,Phase 4
NCT05916339,2023.0,OTHER,collaborator,University of Michigan,Phase 4
NCT05917340,2024.0,OTHER_GOV,lead,Indian Council of Medical Research,Phase 3
NCT05917340,2024.0,OTHER_GOV,collaborator,"All India Institute of Medical Sciences, Jodhpur",Phase 3
NCT05917340,2024.0,OTHER,collaborator,"Christian Medical College, Vellore, India",Phase 3
NCT05917340,2024.0,OTHER_GOV,collaborator,Jawaharlal Institute of Postgraduate Medical Education & Research,Phase 3
NCT05917340,2024.0,OTHER_GOV,collaborator,North Eastern Indira Gandhi Regional Institute of Health ans Medical Sciences,Phase 3
NCT05917340,2024.0,OTHER_GOV,collaborator,Madras Medical College,Phase 3
NCT05917340,2024.0,OTHER,collaborator,Rural Development Trust Hospital,Phase 3
NCT05917353,2023.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Not Applicable
NCT05917379,2023.0,OTHER,lead,Peking University Sixth Hospital,Phase 1/Phase 2
NCT05919368,2023.0,OTHER,lead,Fujian University of Traditional Chinese Medicine,Not Applicable
NCT05919407,2023.0,OTHER,lead,Leiden University Medical Center,Phase 3
NCT05919407,2023.0,INDUSTRY,collaborator,NMD Pharma A/S,Phase 3
NCT05919823,2023.0,INDUSTRY,lead,Karuna Therapeutics,Phase 3
NCT05919823,2023.0,INDUSTRY,collaborator,"Zai Lab (Shanghai) Co., Ltd.",Phase 3
NCT05919940,2023.0,OTHER,lead,Technical University of Munich,Not Applicable
NCT05919940,2023.0,INDUSTRY,collaborator,Fresenius Kabi,Not Applicable
NCT05919940,2023.0,OTHER,collaborator,University Medicine Greifswald,Not Applicable
NCT05919940,2023.0,OTHER,collaborator,Berlin Institute of Health,Not Applicable
NCT05920018,2023.0,OTHER,lead,Universität Münster,Not Applicable
NCT05920889,2023.0,OTHER,lead,Chinese University of Hong Kong,Phase 2
NCT05920889,2023.0,OTHER,collaborator,Linyi People's Hospital,Phase 2
NCT05921266,2023.0,OTHER,lead,University of Oklahoma,Not Applicable
NCT05921409,2021.0,INDUSTRY,lead,Pronacera Therapeutics SL,Not Applicable
NCT05921409,2021.0,UNKNOWN,collaborator,"Centre for the Development of Industrial Technology, Spain",Not Applicable
NCT05921929,2023.0,INDUSTRY,lead,ReST Therapeutics,Phase 1
NCT05922644,2023.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05922644,2023.0,UNKNOWN,collaborator,Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids,Not Applicable
NCT05922644,2023.0,UNKNOWN,collaborator,Shenzhen Qianhai Shekou Free Trade Zone Hospital,Not Applicable
NCT05922995,2023.0,OTHER,lead,Brigham and Women's Hospital,Early Phase 1
NCT05922995,2023.0,INDUSTRY,collaborator,Vanda Pharmaceuticals,Early Phase 1
NCT05923476,2023.0,OTHER,lead,Melbourne Health,Early Phase 1
NCT05924139,2023.0,OTHER,lead,Baylor University,Not Applicable
NCT05924243,2022.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 1
NCT05924412,2023.0,OTHER,lead,University of Chile,Phase 4
NCT05924425,2023.0,OTHER,lead,"University Hospital, Montpellier",Phase 4
NCT05924425,2023.0,INDUSTRY,collaborator,Idorsia Pharmaceuticals Ltd.,Phase 4
NCT05924646,2024.0,OTHER,lead,University of Calgary,Not Applicable
NCT05926336,2023.0,OTHER,lead,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 4
NCT05926375,2022.0,OTHER,lead,Taipei Medical University,Not Applicable
NCT05926375,2022.0,INDUSTRY,collaborator,"Taiwan Otsuka Pharm. Co., Ltd",Not Applicable
NCT05926713,2023.0,INDUSTRY,lead,"Orient Europharma Co., Ltd.",Not Applicable
NCT05927129,2022.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT05929066,2023.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05929079,2023.0,INDUSTRY,lead,Eli Lilly and Company,Phase 3
NCT05929755,2023.0,OTHER,lead,Hardeep Singh,Phase 4
NCT05929755,2023.0,OTHER,collaborator,Society for Minimally Invasive Spine Surgery,Phase 4
NCT05929924,2023.0,OTHER,lead,Auburn University,Not Applicable
NCT05930262,2020.0,OTHER,lead,The Second Hospital of Hebei Medical University,Not Applicable
NCT05931484,2024.0,INDUSTRY,lead,Forest Hills Lab,Phase 2
NCT05931965,2022.0,OTHER,lead,Riphah International University,Not Applicable
NCT05932745,2024.0,OTHER,lead,Yale University,Not Applicable
NCT05932745,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT05933057,2024.0,INDUSTRY,lead,Italfarmaco,Phase 3
NCT05933603,2023.0,OTHER,lead,University of Arizona,Phase 2
NCT05933603,2023.0,NIH,collaborator,National Institutes of Health (NIH),Phase 2
NCT05933603,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT05934422,2023.0,OTHER,lead,University of Southampton,Not Applicable
NCT05934422,2023.0,OTHER,collaborator,"National University Hospital, Singapore",Not Applicable
NCT05934422,2023.0,INDUSTRY,collaborator,Auckland UniServices Ltd.,Not Applicable
NCT05934422,2023.0,OTHER,collaborator,Singapore Institute for Clinical Sciences,Not Applicable
NCT05934422,2023.0,OTHER,collaborator,National University of Singapore,Not Applicable
NCT05934422,2023.0,OTHER,collaborator,"National University Health System, Singapore",Not Applicable
NCT05934422,2023.0,OTHER,collaborator,"University of Auckland, New Zealand",Not Applicable
NCT05934812,2023.0,OTHER,lead,Oslo University Hospital,Phase 2
NCT05934812,2023.0,OTHER,collaborator,University of Oslo,Phase 2
NCT05935631,2023.0,OTHER,lead,University of Alabama at Birmingham,Not Applicable
NCT05935787,2023.0,INDUSTRY,lead,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 3
NCT05937165,2023.0,OTHER,lead,Hebrew SeniorLife,Not Applicable
NCT05937711,2020.0,OTHER,lead,Ilker Fatih Sari,Not Applicable
NCT05938023,2023.0,INDUSTRY,lead,Percheron Therapeutics,Phase 2
NCT05938452,2022.0,INDUSTRY,lead,Forest Hills Lab,Phase 1
NCT05938452,2022.0,UNKNOWN,collaborator,Liberyx,Phase 1
NCT05939466,2021.0,OTHER,lead,Universita degli Studi della Basilicata,Phase 4
NCT05939466,2021.0,OTHER,collaborator,"San Carlo Public Hospital, Potenza, Italy",Phase 4
NCT05940324,2024.0,OTHER,lead,Stanford University,Phase 2
NCT05940324,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT05940493,2024.0,OTHER,lead,Nader Sanai,Phase 2
NCT05940493,2024.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT05940493,2024.0,OTHER,collaborator,Barrow Neurological Institute,Phase 2
NCT05940493,2024.0,OTHER,collaborator,Ivy Brain Tumor Center,Phase 2
NCT05941442,2023.0,INDUSTRY,lead,"Cerevel Therapeutics, LLC",Phase 2
NCT05941754,2022.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Not Applicable
NCT05942716,2023.0,OTHER,lead,Hospices Civils de Lyon,Phase 2
NCT05943457,2023.0,OTHER,lead,"Sola Aoun Bahous, M.D. Ph.D.",Not Applicable
NCT05943457,2023.0,INDUSTRY,collaborator,Lesaffre International,Not Applicable
NCT05943457,2023.0,INDUSTRY,collaborator,Omicron Pharmaceuticals,Not Applicable
NCT05943665,2024.0,OTHER,lead,Carolina Haass-Koffler,Phase 2
NCT05944926,2024.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 3
NCT05944926,2024.0,OTHER,collaborator,Sangath,Phase 3
NCT05944926,2024.0,UNKNOWN,collaborator,"All India Institute of Medical Sciences, Bhopal",Phase 3
NCT05944926,2024.0,OTHER,collaborator,Vanderbilt University,Phase 3
NCT05944926,2024.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 3
NCT05944926,2024.0,OTHER,collaborator,Centre for Addiction and Mental Health,Phase 3
NCT05944926,2024.0,OTHER,collaborator,Massachusetts General Hospital,Phase 3
NCT05944926,2024.0,OTHER,collaborator,Harvard School of Public Health (HSPH),Phase 3
NCT05944926,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT05945147,2024.0,OTHER,lead,Stanford University,Phase 2
NCT05945342,2023.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT05945615,2024.0,OTHER,lead,Milton S. Hershey Medical Center,Phase 3
NCT05946486,2023.0,OTHER,lead,"University Hospital, Bordeaux",Phase 3
NCT05947162,2023.0,OTHER,lead,Shenzhen Kangning Hospital,Not Applicable
NCT05947396,2023.0,OTHER,lead,Mei Han,Not Applicable
NCT05947409,2023.0,OTHER,lead,Mei Han,Not Applicable
NCT05948020,2023.0,OTHER,lead,Children's Hospital of Fudan University,Not Applicable
NCT05948020,2023.0,UNKNOWN,collaborator,"Hedu Biotechnology (Shanghai) Co., LTD",Not Applicable
NCT05948540,2023.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT05948540,2023.0,INDUSTRY,collaborator,PPD,Phase 2
NCT05948540,2023.0,OTHER,collaborator,Berry Consultants,Phase 2
NCT05948540,2023.0,INDUSTRY,collaborator,Idorsia Pharmaceuticals Ltd.,Phase 2
NCT05948540,2023.0,INDUSTRY,collaborator,Cambridge Cognition Ltd,Phase 2
NCT05948540,2023.0,UNKNOWN,collaborator,Citeline,Phase 2
NCT05948553,2023.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT05948553,2023.0,INDUSTRY,collaborator,PPD,Phase 2
NCT05948553,2023.0,OTHER,collaborator,Berry Consultants,Phase 2
NCT05948553,2023.0,INDUSTRY,collaborator,Idorsia Pharmaceuticals Ltd.,Phase 2
NCT05948553,2023.0,INDUSTRY,collaborator,Cambridge Cognition Ltd,Phase 2
NCT05948553,2023.0,UNKNOWN,collaborator,Citeline,Phase 2
NCT05948579,2024.0,FED,lead,U.S. Army Medical Research and Development Command,Phase 2
NCT05948579,2024.0,INDUSTRY,collaborator,PPD,Phase 2
NCT05948579,2024.0,OTHER,collaborator,Berry Consultants,Phase 2
NCT05948579,2024.0,INDUSTRY,collaborator,Idorsia Pharmaceuticals Ltd.,Phase 2
NCT05948579,2024.0,INDUSTRY,collaborator,Cambridge Cognition Ltd,Phase 2
NCT05948579,2024.0,UNKNOWN,collaborator,Citeline,Phase 2
NCT05948956,2023.0,OTHER,lead,University of Michigan,Not Applicable
NCT05949229,2023.0,OTHER,lead,Amira Hassan Ahmed Ali,Phase 1/Phase 2
NCT05949294,2024.0,INDUSTRY,lead,Arrowhead Pharmaceuticals,Phase 1
NCT05950906,2023.0,OTHER,lead,"Calibr, a division of Scripps Research",Phase 1
NCT05950906,2023.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Phase 1
NCT05950906,2023.0,OTHER,collaborator,Alzheimer's Drug Discovery Foundation,Phase 1
NCT05950932,2023.0,OTHER,lead,"University of Urbino ""Carlo Bo""",Phase 4
NCT05950932,2023.0,OTHER,collaborator,University of Pavia,Phase 4
NCT05951023,2023.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT05951023,2023.0,OTHER,collaborator,American Academy of Sleep Medicine,Phase 2
NCT05951439,2024.0,OTHER,lead,Universidad de Burgos,Not Applicable
NCT05951465,2023.0,OTHER,lead,The Second Hospital of Nanjing Medical University,Not Applicable
NCT05951465,2023.0,UNKNOWN,collaborator,SIR RUN RUN hospital of Nanjing Medical University,Not Applicable
NCT05951777,2024.0,INDUSTRY,lead,Hope Biosciences,Phase 2
NCT05951777,2024.0,OTHER,collaborator,"The University of Texas Health Science Center, Houston",Phase 2
NCT05952050,2023.0,INDUSTRY,lead,"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.",Not Applicable
NCT05952050,2023.0,OTHER,collaborator,Zhongshan Hospital Of Traditional Chinese Medicine,Not Applicable
NCT05952531,2023.0,OTHER,lead,The First Affiliated Hospital of Xiamen University,Early Phase 1
NCT05952596,2023.0,INDUSTRY,lead,LG Chem,Phase 1
NCT05953116,2023.0,OTHER_GOV,lead,"Food and Nutrition Research Institute, Philippines",Not Applicable
NCT05953116,2023.0,OTHER,collaborator,Wageningen University and Research,Not Applicable
NCT05953389,2023.0,OTHER,lead,Bioprojet,Phase 2
NCT05953610,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT05953610,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT05953740,2023.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT05954052,2019.0,OTHER,lead,University of Chicago,Phase 4
NCT05954598,2022.0,OTHER,lead,First Affiliated Hospital of Zhejiang University,Not Applicable
NCT05955001,2023.0,OTHER,lead,Mansoura University,Phase 2/Phase 3
NCT05957094,2023.0,OTHER,lead,University of British Columbia,Not Applicable
NCT05957913,2023.0,OTHER,lead,Massachusetts General Hospital,Phase 2
NCT05957913,2023.0,UNKNOWN,collaborator,Solving MS,Phase 2
NCT05958277,2021.0,OTHER,lead,"KRL Hospital, Islamabad",Phase 3
NCT05958303,2024.0,OTHER,lead,"University of Wisconsin, Madison",Not Applicable
NCT05958303,2024.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Not Applicable
NCT05959044,2023.0,OTHER,lead,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2
NCT05959226,2023.0,OTHER,lead,The First Hospital of Jilin University,Not Applicable
NCT05959759,2023.0,OTHER,lead,Beijing Tiantan Hospital,Phase 4
NCT05959759,2023.0,OTHER,collaborator,Beijing Neurosurgical Institute,Phase 4
NCT05959759,2023.0,OTHER,collaborator,Beijing Chao Yang Hospital,Phase 4
NCT05959759,2023.0,OTHER,collaborator,Henan Provincial People's Hospital,Phase 4
NCT05959850,2023.0,OTHER,lead,The Florey Institute of Neuroscience and Mental Health,Phase 2
NCT05959850,2023.0,INDUSTRY,collaborator,Mobius Medical Pty Ltd.,Phase 2
NCT05959850,2023.0,OTHER,collaborator,The University of Queensland,Phase 2
NCT05960942,2023.0,OTHER,lead,The Second Hospital of Nanjing Medical University,Not Applicable
NCT05960942,2023.0,UNKNOWN,collaborator,SIR RUN RUN hospital of Nanjing Medical University,Not Applicable
NCT05961501,2023.0,OTHER,lead,Wroclaw Medical University,Phase 2/Phase 3
NCT05961527,2023.0,OTHER,lead,"Portland VA Research Foundation, Inc",Phase 1/Phase 2
NCT05961527,2023.0,OTHER,collaborator,Steven & Alexandra Cohen Foundation,Phase 1/Phase 2
NCT05961644,2022.0,OTHER,lead,"Institute of Psychiatry and Neurology, Warsaw",Phase 2/Phase 3
NCT05961644,2022.0,OTHER,collaborator,"Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences",Phase 2/Phase 3
NCT05961644,2022.0,OTHER,collaborator,Mossakowski Medical Research Centre Polish Academy of Sciences,Phase 2/Phase 3
NCT05961644,2022.0,OTHER,collaborator,Poznan University of Medical Sciences,Phase 2/Phase 3
NCT05961644,2022.0,OTHER_GOV,collaborator,Military Institute of Aviation Medicine,Phase 2/Phase 3
NCT05961878,2023.0,OTHER,lead,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Not Applicable
NCT05962229,2024.0,OTHER,lead,"University of California, San Francisco",Phase 1
NCT05962229,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT05962333,2023.0,OTHER,lead,Maastricht University,Phase 2
NCT05962424,2023.0,OTHER,lead,Stanford University,Phase 1
NCT05962957,2023.0,OTHER,lead,Mostafa Bahaa,Phase 2
NCT05962957,2023.0,UNKNOWN,collaborator,"Sahar Mohamed El-Haggar clinical pharmacy department, Tanta University",Phase 2
NCT05962957,2023.0,UNKNOWN,collaborator,"Sahar Kamal Hegazi clinical pharmacy department, Tanta University",Phase 2
NCT05962957,2023.0,UNKNOWN,collaborator,"Mohanad Omar Khrieba Clinical Pharmacy Department, Faculty of Pharmacy - Horus University",Phase 2
NCT05963139,2023.0,OTHER,lead,Istanbul University,Not Applicable
NCT05963568,2024.0,OTHER,lead,Northern California Institute of Research and Education,Phase 3
NCT05963958,2021.0,OTHER,lead,Suellen Andrade,Not Applicable
NCT05963958,2021.0,OTHER,collaborator,City University of New York,Not Applicable
NCT05964231,2023.0,OTHER,lead,Mackay Memorial Hospital,Not Applicable
NCT05964790,2023.0,INDUSTRY,lead,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1/Phase 2
NCT05965414,2023.0,INDUSTRY,lead,"Artery Therapeutics, Inc.",Early Phase 1
NCT05965414,2023.0,NIH,collaborator,National Institute on Aging (NIA),Early Phase 1
NCT05965700,2023.0,INDUSTRY,lead,NervGen Pharma,Phase 1/Phase 2
NCT05967052,2023.0,NETWORK,lead,"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland",Phase 2
NCT05967052,2023.0,OTHER_GOV,collaborator,"Medical Research Agency, Poland",Phase 2
NCT05967351,2023.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 3
NCT05967351,2023.0,INDUSTRY,collaborator,Hoffmann-La Roche,Phase 3
NCT05967442,2019.0,OTHER,lead,Advocate Health Care,Phase 3
NCT05967754,2018.0,OTHER,lead,Alexandria University,Not Applicable
NCT05969054,2023.0,OTHER,lead,Xiangya Hospital of Central South University,Phase 4
NCT05969119,2023.0,OTHER,lead,Ain Shams University,Phase 4
NCT05970146,2023.0,OTHER,lead,Tanta University,Phase 4
NCT05970224,2023.0,INDUSTRY,lead,Bioxodes S.A.,Phase 2
NCT05970575,2023.0,OTHER,lead,Neurological Associates of West Los Angeles,Phase 2
NCT05970575,2023.0,INDUSTRY,collaborator,BioVie Inc.,Phase 2
NCT05971212,2021.0,OTHER,lead,Sheffield Children's NHS Foundation Trust,Not Applicable
NCT05971563,2022.0,OTHER,lead,Birmingham Women's and Children's NHS Foundation Trust,Not Applicable
NCT05971758,2024.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT05972629,2023.0,INDUSTRY,lead,Sanofi,Phase 1/Phase 2
NCT05973786,2024.0,OTHER,lead,Dr. Inge Winter,Phase 3
NCT05973786,2024.0,OTHER,collaborator,Universität Münster,Phase 3
NCT05974293,2024.0,OTHER,lead,"Michael, Levy M.D.,Ph.D.",Phase 2
NCT05974293,2024.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT05974527,2023.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT05974579,2023.0,OTHER,lead,Université de Sherbrooke,Phase 1
NCT05974579,2023.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 1
NCT05974579,2023.0,INDUSTRY,collaborator,Chorus Wellness Inc.,Phase 1
NCT05974579,2023.0,UNKNOWN,collaborator,AL-S Pharma AG,Phase 1
NCT05975684,2023.0,OTHER,lead,Nationwide Children's Hospital,Phase 3
NCT05976152,2024.0,OTHER,lead,Fudan University,Phase 3
NCT05976347,2024.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT05976503,2022.0,INDUSTRY,lead,"Yangtze River Pharmaceutical Group Co., Ltd.",Phase 1
NCT05976646,2023.0,OTHER,lead,Virginia Commonwealth University,Phase 1/Phase 2
NCT05976646,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1/Phase 2
NCT05977920,2023.0,OTHER,lead,Zurich Regional Health Center,Not Applicable
NCT05978167,2023.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Early Phase 1
NCT05978167,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Early Phase 1
NCT05978206,2023.0,NETWORK,lead,"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland",Phase 2
NCT05978206,2023.0,OTHER_GOV,collaborator,"Medical Research Agency, Poland",Phase 2
NCT05978505,2023.0,OTHER,lead,Flinders University,Phase 2
NCT05978505,2023.0,OTHER_GOV,collaborator,Flinders Medical Centre,Phase 2
NCT05979415,2023.0,INDUSTRY,lead,"Alexza Pharmaceuticals, Inc.",Phase 2
NCT05979415,2023.0,UNKNOWN,collaborator,Peachtree BioResearch Solutions,Phase 2
NCT05979415,2023.0,UNKNOWN,collaborator,DSG,Phase 2
NCT05979415,2023.0,INDUSTRY,collaborator,"ISS, Inc.",Phase 2
NCT05979441,2023.0,INDUSTRY,lead,argenx,Phase 3
NCT05979558,2020.0,OTHER_GOV,lead,"National Academy of Medical Sciences, Nepal",Not Applicable
NCT05979844,2023.0,FED,lead,Dr. Leslie Morland,Phase 3
NCT05979844,2023.0,UNKNOWN,collaborator,Healing Breakthrough,Phase 3
NCT05979844,2023.0,INDUSTRY,collaborator,Lykos Therapeutics,Phase 3
NCT05979844,2023.0,FED,collaborator,San Diego Veterans Healthcare System,Phase 3
NCT05980195,2023.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT05980520,2023.0,OTHER,lead,Guizhou Provincial People's Hospital,Not Applicable
NCT05981040,2023.0,INDUSTRY,lead,Zydus Lifesciences Limited,Phase 2
NCT05981534,2023.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT05981924,2023.0,OTHER,lead,Hao Long,Phase 2
NCT05981924,2023.0,UNKNOWN,collaborator,Sun Yat-sen University School of Art,Phase 2
NCT05981924,2023.0,UNKNOWN,collaborator,Sun Yat-sen University Department of Psychology,Phase 2
NCT05982470,2023.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT05982665,2023.0,OTHER,lead,Palacky University,Not Applicable
NCT05983939,2023.0,INDUSTRY,lead,Contineum Therapeutics,Phase 1
NCT05984771,2021.0,OTHER,lead,Aristotle University Of Thessaloniki,Not Applicable
NCT05987228,2022.0,OTHER,lead,The Hashemite University,Not Applicable
NCT05988710,2023.0,OTHER,lead,Vanderbilt University Medical Center,Phase 4
NCT05988710,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 4
NCT05989048,2023.0,INDUSTRY,lead,Pfizer,Phase 3
NCT05990790,2023.0,OTHER,lead,Medical University of Vienna,Phase 4
NCT05991232,2024.0,OTHER,lead,Jay Fournier,Phase 1/Phase 2
NCT05991453,2023.0,OTHER,lead,Washington University School of Medicine,Not Applicable
NCT05991453,2023.0,OTHER,collaborator,Patient-Centered Outcomes Research Institute,Not Applicable
NCT05991453,2023.0,OTHER,collaborator,University of Michigan,Not Applicable
NCT05993078,2023.0,OTHER,lead,Tianjin Medical University General Hospital,Phase 2
NCT05993390,2023.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT05995301,2022.0,OTHER_GOV,lead,"National Academy of Medical Sciences, Nepal",Not Applicable
NCT05995600,2023.0,OTHER,lead,Seoul National University Hospital,Phase 4
NCT05995600,2023.0,INDUSTRY,collaborator,"Samjin Pharmaceutical Co., Ltd.",Phase 4
NCT05996003,2024.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 2
NCT05996003,2024.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 2
NCT05997043,2023.0,OTHER,lead,Zhujiang Hospital,Early Phase 1
NCT05997134,2023.0,OTHER,lead,Tanta University,Phase 4
NCT05997914,2024.0,OTHER,lead,"University of Massachusetts, Worcester",Not Applicable
NCT05997914,2024.0,OTHER,collaborator,University of Michigan,Not Applicable
NCT05997914,2024.0,NIH,collaborator,National Institute on Minority Health and Health Disparities (NIMHD),Not Applicable
NCT05997979,2024.0,OTHER,lead,"University Hospital, Brest",Phase 2
NCT05998603,2021.0,OTHER,lead,Anglia Ruskin University,Not Applicable
NCT05998603,2021.0,OTHER,collaborator,University of Exeter,Not Applicable
NCT05999071,2022.0,OTHER,lead,The Hashemite University,Not Applicable
NCT05999240,2024.0,OTHER,lead,New York State Psychiatric Institute,Phase 2
NCT05999240,2024.0,INDUSTRY,collaborator,ACADIA Pharmaceuticals Inc.,Phase 2
NCT05999240,2024.0,OTHER,collaborator,University of Kansas Medical Center,Phase 2
NCT05999240,2024.0,OTHER,collaborator,"Research Foundation for Mental Hygiene, Inc.",Phase 2
NCT05999240,2024.0,OTHER,collaborator,Weill Medical College of Cornell University,Phase 2
NCT05999604,2023.0,NETWORK,lead,Fondation Ophtalmologique Adolphe de Rothschild,Phase 3
NCT05999734,2024.0,OTHER,lead,Tanta University,Not Applicable
NCT06001047,2023.0,OTHER_GOV,lead,Xi'an No.3 Hospital,Not Applicable
NCT06001372,2023.0,OTHER,lead,University of Utah,Early Phase 1
NCT06002633,2023.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT06003127,2024.0,OTHER,lead,Massachusetts General Hospital,Not Applicable
NCT06003166,2024.0,OTHER,lead,University of Arizona,Phase 3
NCT06003166,2024.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 3
NCT06004115,2023.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Phase 4
NCT06004115,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT06004115,2023.0,OTHER,collaborator,California Institute of Technology,Phase 4
NCT06004180,2023.0,INDUSTRY,lead,H. Lundbeck A/S,Phase 1
NCT06005064,2023.0,OTHER,lead,University of Glasgow,Not Applicable
NCT06006143,2024.0,OTHER,lead,Yale University,Not Applicable
NCT06006143,2024.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Not Applicable
NCT06006247,2023.0,INDUSTRY,lead,"Cerevance Beta, Inc.",Phase 2
NCT06008249,2021.0,OTHER,lead,Stichting TRICALS Foundation,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Stichting ALS Nederland,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Fight MND,Phase 3
NCT06008249,2021.0,OTHER,collaborator,Research Foundation Flanders,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,MNDA,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Thierry Latran Foundation,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Ulla-Carin Lindquist Foundation,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Luzon Foundation,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,Alan Davidson Foundation,Phase 3
NCT06008249,2021.0,UNKNOWN,collaborator,My name'5 Doddie Foundation,Phase 3
NCT06010927,2023.0,OTHER,lead,Cairo University,Phase 4
NCT06010940,2020.0,OTHER,lead,Cairo University,Not Applicable
NCT06011577,2023.0,INDUSTRY,lead,"Relmada Therapeutics, Inc.",Phase 3
NCT06012552,2023.0,OTHER,lead,Military Institute od Medicine National Research Institute,Phase 2
NCT06012552,2023.0,OTHER,collaborator,ABM Industries,Phase 2
NCT06012929,2024.0,OTHER,lead,University of Nebraska,Phase 1
NCT06012929,2024.0,INDUSTRY,collaborator,Chimerix,Phase 1
NCT06013254,2021.0,OTHER,lead,Trakya University,Not Applicable
NCT06013397,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT06013761,2023.0,OTHER,lead,University Hospital Marburg,Not Applicable
NCT06013956,2023.0,OTHER,lead,David Escobar,Phase 4
NCT06013956,2023.0,OTHER,collaborator,The Cleveland Clinic,Phase 4
NCT06014424,2023.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2
NCT06014905,2023.0,OTHER,lead,"Javier Villaneuva-Meyer, MD",Phase 1
NCT06014905,2023.0,NIH,collaborator,National Institute for Biomedical Imaging and Bioengineering (NIBIB),Phase 1
NCT06014905,2023.0,INDUSTRY,collaborator,General Electric,Phase 1
NCT06015477,2023.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Not Applicable
NCT06015841,2023.0,INDUSTRY,lead,AC Immune SA,Phase 2
NCT06015841,2023.0,INDUSTRY,collaborator,ICON Clinical Research,Phase 2
NCT06015971,2023.0,OTHER,lead,Maimónides Biomedical Research Institute of Córdoba,Not Applicable
NCT06016049,2009.0,OTHER,lead,Region Skane,Not Applicable
NCT06016465,2023.0,OTHER,lead,"Texas Tech University Health Sciences Center, El Paso",Early Phase 1
NCT06017037,2023.0,OTHER,lead,University of Oxford,Phase 1/Phase 2
NCT06017921,2023.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 4
NCT06018727,2024.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT06019000,2023.0,INDUSTRY,lead,"Cyrano Therapeutics, Inc.",Phase 2
NCT06019117,2023.0,NETWORK,lead,Deivis de Oliveira guimaraes,Not Applicable
NCT06019728,2023.0,INDUSTRY,lead,Sanofi,Phase 4
NCT06021197,2023.0,OTHER,lead,China Medical University Hospital,Phase 2
NCT06021197,2023.0,UNKNOWN,collaborator,"National Science and Technology Council, Taiwan",Phase 2
NCT06021522,2023.0,INDUSTRY,lead,Emalex Biosciences Inc.,Phase 3
NCT06021756,2019.0,OTHER,lead,University of Arizona,Phase 1
NCT06021756,2019.0,UNKNOWN,collaborator,Scott Richards,Phase 1
NCT06022068,2023.0,OTHER,lead,Karolinska Institutet,Phase 1/Phase 2
NCT06022068,2023.0,OTHER,collaborator,Karolinska University Hospital,Phase 1/Phase 2
NCT06023459,2024.0,OTHER,lead,Yih-Ing Hser,Phase 3
NCT06023459,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 3
NCT06023459,2024.0,NIH,collaborator,National Institutes of Health (NIH),Phase 3
NCT06023459,2024.0,INDUSTRY,collaborator,"The Emmes Company, LLC",Phase 3
NCT06023459,2024.0,OTHER,collaborator,"University of California, Los Angeles",Phase 3
NCT06023459,2024.0,OTHER,collaborator,RAND,Phase 3
NCT06023459,2024.0,OTHER,collaborator,Cornell University,Phase 3
NCT06023459,2024.0,OTHER,collaborator,Oregon Health and Science University,Phase 3
NCT06023459,2024.0,OTHER,collaborator,University of Illinois at Chicago,Phase 3
NCT06023459,2024.0,OTHER,collaborator,University of Washington,Phase 3
NCT06023459,2024.0,OTHER,collaborator,West Virginia University,Phase 3
NCT06023706,2023.0,OTHER,lead,Nantes University Hospital,Phase 3
NCT06024265,2023.0,INDUSTRY,lead,ExoRNA Bioscience,Early Phase 1
NCT06025097,2023.0,OTHER_GOV,lead,CMH RWP Combined Military Hospital RWP: Rawalpindi,Early Phase 1
NCT06025396,2023.0,INDUSTRY,lead,"Tempero Bio, Inc.",Phase 1
NCT06025396,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 1
NCT06027567,2022.0,OTHER,lead,Rigmor Højland Jensen,Phase 4
NCT06027567,2022.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 4
NCT06027567,2022.0,OTHER,collaborator,Odense University Hospital,Phase 4
NCT06027567,2022.0,OTHER,collaborator,University of Copenhagen,Phase 4
NCT06027723,2023.0,OTHER,lead,University of Southern California,Early Phase 1
NCT06029894,2023.0,OTHER,lead,Emory University,Not Applicable
NCT06029894,2023.0,NIH,collaborator,National Institute on Aging (NIA),Not Applicable
NCT06030297,2022.0,OTHER,lead,University of Utah,Not Applicable
NCT06030297,2022.0,OTHER,collaborator,Stanford University,Not Applicable
NCT06030297,2022.0,NIH,collaborator,National Institutes of Health (NIH),Not Applicable
NCT06030297,2022.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Not Applicable
NCT06030362,2023.0,OTHER,lead,"University of California, Los Angeles",Not Applicable
NCT06030752,2023.0,OTHER,lead,The Second Hospital of Nanjing Medical University,Phase 1
NCT06030752,2023.0,UNKNOWN,collaborator,SIR RUN RUN hospital of Nanjing Medical University,Phase 1
NCT06031259,2024.0,INDUSTRY,lead,Takeda,Phase 2/Phase 3
NCT06032026,2023.0,OTHER,lead,University of Pennsylvania,Early Phase 1
NCT06035692,2023.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Not Applicable
NCT06035692,2023.0,OTHER,collaborator,Xuzhou Central Hospital,Not Applicable
NCT06035692,2023.0,OTHER,collaborator,Huizhou Municipal Central Hospital,Not Applicable
NCT06035692,2023.0,UNKNOWN,collaborator,Nanjing Jiangbei Hospital,Not Applicable
NCT06035757,2023.0,OTHER,lead,Konkuk University Medical Center,Phase 4
NCT06036095,2023.0,OTHER,lead,Oregon Health and Science University,Phase 4
NCT06036108,2023.0,INDUSTRY,lead,"Otsuka Pharmaceutical Co., Ltd.",Phase 1
NCT06036511,2023.0,OTHER,lead,University of New Mexico,Phase 1/Phase 2
NCT06036511,2023.0,OTHER,collaborator,The Mind Research Network,Phase 1/Phase 2
NCT06036797,2023.0,OTHER,lead,Maternal and Child Health Hospital of Hubei Province,Phase 2
NCT06037460,2024.0,OTHER,lead,Centre Hospitalier Universitaire Dijon,Phase 3
NCT06037590,2023.0,INDUSTRY,lead,PureIMS B.V.,Phase 1
NCT06037590,2023.0,OTHER,collaborator,Cooperative Clinical Drug Research and Development AG (CCDRD AG),Phase 1
NCT06039007,2019.0,OTHER,lead,Ospedale Policlinico San Martino,Early Phase 1
NCT06040307,2023.0,OTHER,lead,Universitätsklinikum Hamburg-Eppendorf,Not Applicable
NCT06040840,2024.0,OTHER,lead,CMC Ambroise Paré,Not Applicable
NCT06040905,2023.0,OTHER,lead,Chung Shan Medical University,Not Applicable
NCT06040905,2023.0,FED,collaborator,National Science and Technology Council,Not Applicable
NCT06041334,2024.0,OTHER,lead,Rennes University Hospital,Not Applicable
NCT06041334,2024.0,UNKNOWN,collaborator,NeuroSphinx,Not Applicable
NCT06041451,2013.0,OTHER,lead,First Affiliated Hospital of Wenzhou Medical University,Phase 4
NCT06041646,2023.0,INDUSTRY,lead,BioXcel Therapeutics Inc,Phase 4
NCT06041646,2023.0,OTHER,collaborator,"Lotus Clinical Research, LLC",Phase 4
NCT06043440,2023.0,OTHER,lead,Brigham and Women's Hospital,Phase 2
NCT06043440,2023.0,OTHER,collaborator,"Children's Hospital Medical Center, Cincinnati",Phase 2
NCT06043440,2023.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT06043440,2023.0,OTHER,collaborator,Rainbow Babies and Children's Hospital,Phase 2
NCT06043440,2023.0,OTHER,collaborator,University of Michigan,Phase 2
NCT06043440,2023.0,OTHER,collaborator,Children's Hospital Los Angeles,Phase 2
NCT06043440,2023.0,OTHER,collaborator,Children's Hospital of The King's Daughters,Phase 2
NCT06043440,2023.0,OTHER,collaborator,Seattle Children's Hospital,Phase 2
NCT06043440,2023.0,OTHER,collaborator,University of Southern California,Phase 2
NCT06043830,2023.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT06043830,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 2
NCT06044090,2022.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT06044090,2022.0,OTHER,collaborator,Robert Wood Johnson Foundation,Phase 4
NCT06044168,2023.0,OTHER,lead,Universitaire Ziekenhuizen KU Leuven,Not Applicable
NCT06044675,2023.0,INDUSTRY,lead,Remedy,Phase 2
NCT06044675,2023.0,OTHER,collaborator,Remedy Institute,Phase 2
NCT06044740,2024.0,OTHER,lead,"Keith M. Vogt, MD, PhD",Phase 1
NCT06044740,2024.0,NIH,collaborator,National Institute of General Medical Sciences (NIGMS),Phase 1
NCT06044883,2023.0,OTHER,lead,Cairo University,Phase 1/Phase 2
NCT06045013,2023.0,OTHER,lead,General and Veteran Hospital Croatian Pride Knin,Phase 3
NCT06045013,2023.0,OTHER,collaborator,Clinical Hospital Centre Zagreb,Phase 3
NCT06045013,2023.0,UNKNOWN,collaborator,School of Public Health Andrija Štampar,Phase 3
NCT06045299,2023.0,INDUSTRY,lead,"Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.",Phase 3
NCT06045299,2023.0,OTHER,collaborator,"LENZ Therapeutics, Inc",Phase 3
NCT06045793,2023.0,INDUSTRY,lead,"Tonix Pharmaceuticals, Inc.",Phase 2
NCT06045793,2023.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Phase 2
NCT06045793,2023.0,UNKNOWN,collaborator,Premier,Phase 2
NCT06045897,2023.0,OTHER,lead,Centre Hospitalier St Anne,Not Applicable
NCT06045897,2023.0,OTHER,collaborator,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT06045936,2023.0,OTHER,lead,Mayo Clinic,Phase 4
NCT06046287,2024.0,OTHER,lead,Georgetown University,Phase 2
NCT06046287,2024.0,INDUSTRY,collaborator,"Janssen, LP",Phase 2
NCT06046638,2023.0,OTHER,lead,RenJi Hospital,Phase 4
NCT06046638,2023.0,INDUSTRY,collaborator,"Haisco Pharmaceutical Group Co., Ltd.",Phase 4
NCT06047613,2023.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT06050668,2024.0,OTHER,lead,Michael C Willey,Not Applicable
NCT06050668,2024.0,UNKNOWN,collaborator,MEND,Not Applicable
NCT06051227,2024.0,OTHER,lead,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 3
NCT06051227,2024.0,UNKNOWN,collaborator,Stichting ZiektekostenVerzekering Krijgsmacht,Phase 3
NCT06051227,2024.0,UNKNOWN,collaborator,Ambulance Amsterdam,Phase 3
NCT06051240,2023.0,OTHER_GOV,lead,Region Stockholm,Phase 2
NCT06051240,2023.0,OTHER,collaborator,"Rigshospitalet, Denmark",Phase 2
NCT06052163,2023.0,OTHER,lead,Stanford University,Phase 2
NCT06052176,2023.0,FED,lead,Hunter Holmes Mcguire Veteran Affairs Medical Center,Phase 2
NCT06052176,2023.0,INDUSTRY,collaborator,"Grifols Biologicals, LLC",Phase 2
NCT06052787,2023.0,OTHER,lead,Ain Shams University,Phase 3
NCT06053281,2024.0,OTHER,lead,DINA KEUMALA SARI,Early Phase 1
NCT06053567,2023.0,OTHER,lead,Jasper A. Smits,Phase 3
NCT06053567,2023.0,OTHER,collaborator,University of Houston,Phase 3
NCT06053567,2023.0,OTHER,collaborator,University of Oklahoma,Phase 3
NCT06053567,2023.0,NIH,collaborator,National Cancer Institute (NCI),Phase 3
NCT06053567,2023.0,OTHER,collaborator,YMCA,Phase 3
NCT06053671,2023.0,OTHER,lead,King's College Hospital NHS Trust,Not Applicable
NCT06053671,2023.0,OTHER,collaborator,King's College London,Not Applicable
NCT06053671,2023.0,UNKNOWN,collaborator,Danish Epilepsy Centre,Not Applicable
NCT06053814,2024.0,INDUSTRY,lead,"NS Pharma, Inc.",Phase 1/Phase 2
NCT06053814,2024.0,INDUSTRY,collaborator,"Nippon Shinyaku Co., Ltd.",Phase 1/Phase 2
NCT06054893,2023.0,INDUSTRY,lead,Biogen,Phase 1
NCT06055270,2024.0,OTHER,lead,Lawson Health Research Institute,Phase 3
NCT06055985,2023.0,INDUSTRY,lead,UCB Biopharma SRL,Phase 2
NCT06056921,2023.0,INDUSTRY,lead,"Chongqing Precision Biotech Co., Ltd",Phase 1
NCT06058130,2023.0,OTHER,lead,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Not Applicable
NCT06058702,2024.0,OTHER,lead,Yale University,Phase 1
NCT06058962,2019.0,INDUSTRY,lead,Paxmedica,Phase 2
NCT06059066,2023.0,OTHER,lead,The Methodist Hospital Research Institute,Not Applicable
NCT06059066,2023.0,UNKNOWN,collaborator,Collaborating for the Advancement of Interdisciplinary Research in Benign Urology,Not Applicable
NCT06059144,2024.0,OTHER,lead,"University Hospital, Bordeaux",Phase 3
NCT06059703,2023.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT06060886,2023.0,OTHER_GOV,lead,Consorcio Centro de Investigación Biomédica en Red (CIBER),Phase 4
NCT06060886,2023.0,OTHER_GOV,collaborator,Instituto de Salud Carlos III,Phase 4
NCT06061614,2023.0,OTHER,lead,First Affiliated Hospital Bengbu Medical College,Early Phase 1
NCT06061692,2023.0,OTHER,lead,Fudan University,Phase 4
NCT06062472,2023.0,OTHER,lead,Chi-Chang Huang,Not Applicable
NCT06062472,2023.0,INDUSTRY,collaborator,"Bened Biomedical Co., Ltd.",Not Applicable
NCT06062628,2024.0,OTHER,lead,University of Texas Southwestern Medical Center,Early Phase 1
NCT06062953,2023.0,OTHER,lead,Lone Baandrup,Phase 2/Phase 3
NCT06062953,2023.0,OTHER,collaborator,Danish Center for Sleep Medicine,Phase 2/Phase 3
NCT06062953,2023.0,OTHER,collaborator,Region Capital Denmark,Phase 2/Phase 3
NCT06062953,2023.0,OTHER,collaborator,"Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 2/Phase 3
NCT06062953,2023.0,OTHER,collaborator,"Mental Health Services in the Capital Region, Denmark",Phase 2/Phase 3
NCT06063369,2022.0,OTHER,lead,The Israeli Medical Center for Alzheimer's,Phase 2
NCT06064162,2023.0,OTHER,lead,Alta Bates Summit Medical Center,Early Phase 1
NCT06064175,2022.0,OTHER,lead,Ankara City Hospital Bilkent,Phase 4
NCT06064201,2023.0,OTHER,lead,KU Leuven,Not Applicable
NCT06064448,2019.0,INDUSTRY,lead,Xintian Pharmaceutical,Phase 4
NCT06064539,2020.0,INDUSTRY,lead,Sanofi,Phase 1
NCT06064838,2023.0,OTHER,lead,Guillermo Ceballos Reyes,Not Applicable
NCT06064838,2023.0,OTHER_GOV,collaborator,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Not Applicable
NCT06064890,2023.0,INDUSTRY,lead,AviadoBio Ltd,Phase 1/Phase 2
NCT06065046,2023.0,OTHER,lead,Tang-Du Hospital,Phase 2
NCT06065436,2023.0,OTHER,lead,Mayo Clinic,Not Applicable
NCT06065670,2024.0,OTHER,lead,"University of California, San Francisco",Phase 1/Phase 2
NCT06065735,2023.0,INDUSTRY,lead,GlaxoSmithKline,Phase 1
NCT06066112,2023.0,OTHER,lead,The Affiliated Hospital of Qingdao University,Phase 1
NCT06066619,2024.0,OTHER,lead,University of Florida,Not Applicable
NCT06066710,2024.0,OTHER,lead,University of Missouri-Columbia,Early Phase 1
NCT06066853,2024.0,OTHER,lead,Spaulding Rehabilitation Hospital,Early Phase 1
NCT06066853,2024.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Early Phase 1
NCT06066918,2021.0,OTHER,lead,Loewenstein Hospital,Not Applicable
NCT06067412,2022.0,OTHER,lead,Shaheed Zulfiqar Ali Bhutto Medical University,Not Applicable
NCT06069791,2024.0,OTHER,lead,Yale University,Phase 1
NCT06069791,2024.0,FED,collaborator,VA Connecticut Healthcare System,Phase 1
NCT06069791,2024.0,UNKNOWN,collaborator,National Headache Foundation,Phase 1
NCT06069843,2023.0,OTHER,lead,Icahn School of Medicine at Mount Sinai,Phase 2
NCT06070649,2024.0,OTHER,lead,Yale University,Phase 1
NCT06070649,2024.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1
NCT06070701,2023.0,OTHER,lead,Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu,Not Applicable
NCT06071936,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06071949,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06071975,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06071988,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06072001,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06072521,2023.0,OTHER,lead,Al-Azhar University,Phase 2
NCT06072573,2023.0,INDUSTRY,lead,Apurano Pharmaceuticals GmbH,Phase 3
NCT06072898,2023.0,OTHER,lead,Sunnybrook Health Sciences Centre,Phase 2
NCT06072963,2023.0,OTHER,lead,"Rutgers, The State University of New Jersey",Phase 2
NCT06072963,2023.0,OTHER,collaborator,Alzheimer's Association,Phase 2
NCT06075537,2023.0,INDUSTRY,lead,Denali Therapeutics Inc.,Phase 2/Phase 3
NCT06075771,2023.0,OTHER,lead,Emory University,Phase 4
NCT06075771,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 4
NCT06075875,2023.0,OTHER_GOV,lead,National Hepatology & Tropical Medicine Research Institute,Not Applicable
NCT06075914,2023.0,OTHER,lead,Ohio State University,Not Applicable
NCT06076122,2022.0,OTHER,lead,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Not Applicable
NCT06076434,2022.0,OTHER,lead,Kastamonu University,Not Applicable
NCT06076668,2023.0,OTHER,lead,Tanta University,Not Applicable
NCT06077240,2024.0,OTHER,lead,Yale University,Not Applicable
NCT06077240,2024.0,NIH,collaborator,National Institute on Drug Abuse (NIDA),Not Applicable
NCT06077292,2024.0,OTHER,lead,"University of California, San Francisco",Not Applicable
NCT06077292,2024.0,UNKNOWN,collaborator,Cannabis Public Policy Consulting,Not Applicable
NCT06077539,2023.0,OTHER,lead,Cairo University,Phase 1/Phase 2
NCT06077682,2023.0,OTHER,lead,"Islamic Hospital, Jordan",Phase 4
NCT06077682,2023.0,OTHER,collaborator,Jordan University of Science and Technology,Phase 4
NCT06077682,2023.0,OTHER,collaborator,Yarmouk University,Phase 4
NCT06078891,2023.0,OTHER,lead,Tamir Ben-Hur,Early Phase 1
NCT06078891,2023.0,OTHER,collaborator,Hebrew University of Jerusalem,Early Phase 1
NCT06079190,2023.0,INDUSTRY,lead,GlaxoSmithKline,Phase 2
NCT06079190,2023.0,INDUSTRY,collaborator,Alector Inc.,Phase 2
NCT06079736,2024.0,INDUSTRY,lead,PepGen Inc,Phase 2
NCT06079801,2021.0,OTHER,lead,Clínica de Intervención en Neurociencias,Not Applicable
NCT06080100,2023.0,OTHER_GOV,lead,The S.N. Fyodorov Eye Microsurgery State Institution,Early Phase 1
NCT06080932,2023.0,OTHER,lead,Ohio State University,Not Applicable
NCT06081062,2023.0,INDUSTRY,lead,"ISU Abxis Co., Ltd.",Phase 3
NCT06081283,2023.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 4
NCT06081348,2023.0,INDIV,lead,"Anagnostou, Evdokia, M.D.",Phase 2
NCT06081348,2023.0,UNKNOWN,collaborator,Azrieli Foundation,Phase 2
NCT06081348,2023.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT06081348,2023.0,OTHER,collaborator,Ontario Brain Institute,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Holland Bloorview Kids Rehabilitation Hospital,Phase 2
NCT06081348,2023.0,OTHER,collaborator,McMaster University,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Western University,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Queen's University,Phase 2
NCT06081348,2023.0,OTHER,collaborator,University of Alberta,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Alberta Health services,Phase 2
NCT06081348,2023.0,OTHER,collaborator,St. Justine's Hospital,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Dalhousie University,Phase 2
NCT06081348,2023.0,OTHER,collaborator,Unity Health Toronto,Phase 2
NCT06081348,2023.0,OTHER,collaborator,University of Toronto,Phase 2
NCT06081348,2023.0,OTHER,collaborator,The Hospital for Sick Children,Phase 2
NCT06082817,2023.0,OTHER,lead,San Diego Sexual Medicine,Phase 2
NCT06083350,2023.0,OTHER,lead,Xiaofan Xu,Not Applicable
NCT06083571,2024.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT06083571,2024.0,UNKNOWN,collaborator,"Assertio Holdings, Inc",Phase 2
NCT06083753,2023.0,INDUSTRY,lead,Contineum Therapeutics,Phase 2
NCT06084130,2023.0,OTHER,lead,Siriraj Hospital,Phase 4
NCT06085937,2023.0,OTHER,lead,University of Kansas Medical Center,Phase 1
NCT06087276,2023.0,INDUSTRY,lead,Praxis Precision Medicines,Phase 3
NCT06087471,2023.0,OTHER,lead,King's College London,Not Applicable
NCT06087757,2024.0,OTHER_GOV,lead,Sheba Medical Center,Phase 3
NCT06087757,2024.0,OTHER,collaborator,Tel Aviv University,Phase 3
NCT06087965,2023.0,OTHER,lead,Tang-Du Hospital,Phase 1/Phase 2
NCT06088550,2020.0,OTHER,lead,Cairo University,Not Applicable
NCT06088732,2024.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Phase 1/Phase 2
NCT06089356,2023.0,OTHER,lead,Tanta University,Phase 4
NCT06089603,2023.0,OTHER,lead,Hospital Universitario Ramon y Cajal,Phase 4
NCT06089811,2023.0,OTHER,lead,KU Leuven,Not Applicable
NCT06090123,2020.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT06090136,2020.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT06090422,2024.0,OTHER,lead,University Hospital of North Norway,Phase 1/Phase 2
NCT06090422,2024.0,OTHER,collaborator,University of Exeter,Phase 1/Phase 2
NCT06090474,2023.0,INDUSTRY,lead,Dr. Noah Biotech Inc.,Phase 1
NCT06090955,2023.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT06091826,2023.0,INDUSTRY,lead,NFL Biosciences SAS,Phase 2
NCT06092034,2023.0,INDUSTRY,lead,Rocket Pharmaceuticals Inc.,Phase 2
NCT06092073,2023.0,OTHER,lead,Tanta University,Not Applicable
NCT06092749,2023.0,OTHER,lead,Ain Shams University,Not Applicable
NCT06093126,2023.0,OTHER,lead,Nova Scotia Health Authority,Phase 4
NCT06093451,2023.0,OTHER,lead,Temple University,Phase 4
NCT06093451,2023.0,INDUSTRY,collaborator,BioXcel Therapeutics Inc,Phase 4
NCT06094244,2017.0,OTHER,lead,Pomeranian Medical University Szczecin,Not Applicable
NCT06094309,2024.0,OTHER,lead,Centro Hospitalar de Lisboa Central,Not Applicable
NCT06094907,2023.0,OTHER,lead,Universidade Federal do Rio Grande do Norte,Phase 2
NCT06096090,2023.0,OTHER,lead,The Methodist Hospital Research Institute,Phase 2
NCT06096389,2023.0,OTHER,lead,University of Malaya,Not Applicable
NCT06096415,2023.0,INDUSTRY,lead,"Abalonex, LLC",Phase 2
NCT06097780,2024.0,INDUSTRY,lead,Azidus Brasil,Phase 3
NCT06097780,2024.0,OTHER,collaborator,Cellavita Pesquisa Científica Ltda,Phase 3
NCT06098612,2024.0,OTHER,lead,Massachusetts General Hospital,Early Phase 1
NCT06098677,2024.0,OTHER,lead,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Not Applicable
NCT06098677,2024.0,UNKNOWN,collaborator,"Blackmores (China) CO., Ltd",Not Applicable
NCT06099886,2023.0,OTHER,lead,State University of New York at Buffalo,Phase 1
NCT06100146,2023.0,OTHER,lead,University Ghent,Not Applicable
NCT06100146,2023.0,UNKNOWN,collaborator,Arba Minch University,Not Applicable
NCT06100146,2023.0,OTHER_GOV,collaborator,"Institut de Recherche en Sciences de la Sante, Burkina Faso",Not Applicable
NCT06100146,2023.0,OTHER,collaborator,Addis Ababa University,Not Applicable
NCT06100276,2024.0,INDUSTRY,lead,UniQure Biopharma B.V.,Phase 1/Phase 2
NCT06100887,2023.0,INDUSTRY,lead,"Edgewise Therapeutics, Inc.",Phase 2
NCT06101173,2023.0,INDUSTRY,lead,CanSino Biologics Inc.,Phase 1
NCT06101173,2023.0,INDUSTRY,collaborator,Novotech (Australia) Pty Limited,Phase 1
NCT06103201,2023.0,OTHER,lead,"University of Maryland, Baltimore",Phase 1
NCT06103734,2025.0,INDUSTRY,lead,Pfizer,Phase 3
NCT06104488,2023.0,OTHER,lead,Memorial Sloan Kettering Cancer Center,Phase 1
NCT06104683,2024.0,INDUSTRY,lead,"Loxo Oncology, Inc.",Phase 2
NCT06104683,2024.0,INDUSTRY,collaborator,Eli Lilly and Company,Phase 2
NCT06105151,2023.0,INDUSTRY,lead,Vigonvita Life Sciences,Phase 1
NCT06106074,2020.0,INDUSTRY,lead,Sanofi,Phase 1
NCT06106672,2024.0,INDUSTRY,lead,"COUR Pharmaceutical Development Company, Inc.",Phase 1/Phase 2
NCT06107725,2023.0,OTHER,lead,Maimonides Medical Center,Phase 2/Phase 3
NCT06107829,2024.0,OTHER,lead,Stephen Ruedrich,Phase 4
NCT06107829,2024.0,INDUSTRY,collaborator,Neurocrine Biosciences,Phase 4
NCT06108349,2023.0,OTHER,lead,University of Virginia,Phase 2
NCT06108414,2024.0,OTHER_GOV,lead,China National Center for Cardiovascular Diseases,Phase 4
NCT06109428,2021.0,INDUSTRY,lead,Heron Therapeutics,Phase 4
NCT06111014,2023.0,INDUSTRY,lead,Alector Inc.,Phase 3
NCT06112834,2024.0,OTHER,lead,California Department of Public Health,Phase 2
NCT06113198,2023.0,INDUSTRY,lead,GlaxoSmithKline,Phase 4
NCT06113640,2023.0,OTHER,lead,Mostafa Bahaa,Phase 2/Phase 3
NCT06114056,2024.0,OTHER,lead,West China Hospital,Phase 1
NCT06114329,2023.0,INDUSTRY,lead,"AceLink Therapeutics, Inc.",Phase 2
NCT06114329,2023.0,INDUSTRY,collaborator,"Tigermed Consulting Co., Ltd",Phase 2
NCT06114810,2023.0,OTHER,lead,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4
NCT06114810,2023.0,FED,collaborator,Centers for Disease Control and Prevention,Phase 4
NCT06114810,2023.0,OTHER_GOV,collaborator,Government of Bangladesh,Phase 4
NCT06115031,2024.0,OTHER,lead,Samsung Medical Center,Not Applicable
NCT06115538,2023.0,OTHER_GOV,lead,Ankara Ataturk Sanatorium Training and Research Hospital,Phase 4
NCT06117020,2023.0,INDUSTRY,lead,Motric Bio,Phase 1
NCT06117306,2024.0,UNKNOWN,lead,Healing Breakthrough,Phase 3
NCT06117306,2024.0,INDUSTRY,collaborator,Lykos Therapeutics,Phase 3
NCT06117306,2024.0,FED,collaborator,San Diego Veterans Healthcare System,Phase 3
NCT06117306,2024.0,FED,collaborator,National Center for PTSD,Phase 3
NCT06117306,2024.0,UNKNOWN,collaborator,White River Junction VA Medical Center,Phase 3
NCT06117969,2023.0,OTHER,lead,Peking Union Medical College Hospital,Phase 4
NCT06118294,2023.0,OTHER,lead,Changhua Christian Hospital,Not Applicable
NCT06118294,2023.0,INDUSTRY,collaborator,"Bened Biomedical Co., Ltd.",Not Applicable
NCT06118567,2022.0,OTHER,lead,Ohio State University,Phase 2
NCT06118567,2022.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT06118580,2023.0,OTHER,lead,Ohio State University,Phase 2
NCT06118580,2023.0,NIH,collaborator,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2
NCT06120036,2022.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT06120036,2022.0,OTHER,collaborator,Johns Hopkins University,Phase 1
NCT06121492,2023.0,OTHER,lead,Mahidol University,Phase 3
NCT06122038,2023.0,OTHER,lead,Lindenwood University,Not Applicable
NCT06122662,2023.0,INDUSTRY,lead,Amylyx Pharmaceuticals Inc.,Phase 3
NCT06124703,2023.0,OTHER,lead,Eye & ENT Hospital of Fudan University,Not Applicable
NCT06125002,2024.0,OTHER,lead,Sergio Marques Borghi,Phase 1
NCT06125002,2024.0,OTHER,collaborator,Universidade Norte do Paraná,Phase 1
NCT06125054,2024.0,OTHER,lead,Dr. med. Marcus Herdener,Phase 2
NCT06125054,2024.0,OTHER,collaborator,University of Zurich,Phase 2
NCT06125054,2024.0,OTHER,collaborator,University of Vienna,Phase 2
NCT06125054,2024.0,OTHER,collaborator,"University of Campania ""Luigi Vanvitelli""",Phase 2
NCT06125782,2023.0,OTHER,lead,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2
NCT06125951,2024.0,INDUSTRY,lead,Actinogen Medical,Phase 2
NCT06126185,2023.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT06126315,2024.0,OTHER,lead,Mario Negri Institute for Pharmacological Research,Phase 2/Phase 3
NCT06126315,2024.0,OTHER,collaborator,University of Sydney,Phase 2/Phase 3
NCT06126315,2024.0,UNKNOWN,collaborator,FightMND,Phase 2/Phase 3
NCT06126523,2023.0,OTHER,lead,Saglik Bilimleri Universitesi,Not Applicable
NCT06126588,2024.0,OTHER,lead,"Central Hospital, Nancy, France",Phase 2
NCT06126653,2024.0,INDUSTRY,lead,"Aardvark Therapeutics, Inc.",Phase 2
NCT06126653,2024.0,INDUSTRY,collaborator,Center for Psychiatry And Behavioral Medicine Inc.,Phase 2
NCT06127368,2024.0,INDUSTRY,lead,"G2GBio, Inc.",Phase 1
NCT06128148,2022.0,INDUSTRY,lead,"Guangzhou JOYO Pharma Co., Ltd",Phase 1
NCT06128356,2023.0,OTHER,lead,NYU Langone Health,Phase 2
NCT06128564,2023.0,INDUSTRY,lead,Hoffmann-La Roche,Phase 2
NCT06128564,2023.0,INDUSTRY,collaborator,"Sarepta Therapeutics, Inc.",Phase 2
NCT06128616,2023.0,OTHER,lead,Kocaeli University,Phase 3
NCT06128954,2024.0,INDUSTRY,lead,Orphalan,Phase 1
NCT06128967,2023.0,OTHER,lead,Cardresearch,Phase 3
NCT06129032,2023.0,OTHER,lead,Ataturk University,Not Applicable
NCT06130228,2024.0,OTHER,lead,McMaster University,Phase 2
NCT06130449,2024.0,FED,lead,VA Office of Research and Development,Early Phase 1
NCT06130501,2024.0,OTHER,lead,University of Cincinnati,Not Applicable
NCT06130501,2024.0,INDUSTRY,collaborator,"Spark Biomedical, Inc.",Not Applicable
NCT06130540,2024.0,INDUSTRY,lead,Novartis Pharmaceuticals,Phase 1
NCT06131554,2024.0,INDUSTRY,lead,CanSino Biologics Inc.,Phase 3
NCT06131983,2024.0,INDUSTRY,lead,Arrowhead Pharmaceuticals,Phase 1
NCT06132165,2024.0,OTHER,lead,Massachusetts General Hospital,Phase 1
NCT06132165,2024.0,OTHER,collaborator,Johns Hopkins University,Phase 1
NCT06132178,2024.0,OTHER,lead,University of Texas at Austin,Phase 2
NCT06132685,2024.0,OTHER,lead,Emory University,Phase 2
NCT06132685,2024.0,NIH,collaborator,National Cancer Institute (NCI),Phase 2
NCT06132893,2024.0,INDUSTRY,lead,Biohaven Therapeutics Ltd.,Phase 2/Phase 3
NCT06133075,2023.0,OTHER,lead,Cedars-Sinai Medical Center,Phase 2
NCT06133309,2023.0,OTHER,lead,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Not Applicable
NCT06134401,2024.0,OTHER,lead,Imperial College London,Not Applicable
NCT06134401,2024.0,OTHER,collaborator,Nottingham University Hospitals NHS Trust,Not Applicable
NCT06134401,2024.0,OTHER,collaborator,Royal Brompton & Harefield NHS Foundation Trust,Not Applicable
NCT06134401,2024.0,INDUSTRY,collaborator,Pari Pharma GmbH,Not Applicable
NCT06136728,2024.0,OTHER,lead,MGH Institute of Health Professions,Phase 4
NCT06137664,2023.0,OTHER,lead,PATH,Phase 1/Phase 2
NCT06137664,2023.0,UNKNOWN,collaborator,"Bio Farma, Indonesia",Phase 1/Phase 2
NCT06137924,2023.0,OTHER,lead,Universidad Simón Bolívar,Phase 3
NCT06138132,2024.0,OTHER,lead,Stanford University,Phase 1
NCT06138132,2024.0,INDUSTRY,collaborator,Kyverna Therapeutics,Phase 1
NCT06138639,2024.0,INDUSTRY,lead,Solid Biosciences Inc.,Phase 1/Phase 2
NCT06138743,2024.0,INDUSTRY,lead,Arrowhead Pharmaceuticals,Phase 1
NCT06139016,2024.0,OTHER,lead,Yale University,Not Applicable
NCT06140355,2024.0,OTHER,lead,University of Minnesota,Not Applicable
NCT06141317,2023.0,OTHER,lead,ClusterXStem-Costa Rica,Phase 1/Phase 2
NCT06141317,2023.0,OTHER,collaborator,Universidad de Costa Rica,Phase 1/Phase 2
NCT06141317,2023.0,OTHER,collaborator,"University of California, Los Angeles",Phase 1/Phase 2
NCT06141473,2023.0,INDUSTRY,lead,Sanofi,Phase 3
NCT06141486,2023.0,INDUSTRY,lead,Sanofi,Phase 3
NCT06141876,2023.0,INDUSTRY,lead,Apex Labs Ltd.,Phase 2
NCT06143241,2024.0,OTHER,lead,Ege University,Not Applicable
NCT06143488,2024.0,INDUSTRY,lead,First Affiliated Hospital of Wannan Medical College,Not Applicable
NCT06144021,2023.0,OTHER,lead,Hanyang University Seoul Hospital,Not Applicable
NCT06144021,2023.0,UNKNOWN,collaborator,Ottogi Ham Taiho Foundation,Not Applicable
NCT06144021,2023.0,OTHER,collaborator,Hanyang University,Not Applicable
NCT06144099,2024.0,OTHER,lead,Konkuk University Medical Center,Phase 4
NCT06145490,2023.0,OTHER,lead,Uppsala University,Not Applicable
NCT06146062,2024.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2
NCT06146101,2024.0,INDUSTRY,lead,Incannex Healthcare Ltd,Phase 2/Phase 3
NCT06147856,2024.0,INDUSTRY,lead,"ModernaTX, Inc.",Phase 1/Phase 2
NCT06148311,2024.0,OTHER,lead,NYU Langone Health,Phase 2
NCT06150716,2024.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 1
NCT06151795,2023.0,INDUSTRY,lead,Sinotau Pharmaceutical Group,Phase 1
NCT06151808,2022.0,INDUSTRY,lead,Sinotau Pharmaceutical Group,Not Applicable
NCT06152237,2023.0,INDUSTRY,lead,"Taysha Gene Therapies, Inc.",Phase 1
NCT06153004,2023.0,OTHER,lead,Harvard Medical School (HMS and HSDM),Phase 3
NCT06153004,2023.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 3
NCT06153004,2023.0,OTHER,collaborator,Harvard School of Public Health (HSPH),Phase 3
NCT06153004,2023.0,OTHER,collaborator,Massachusetts General Hospital,Phase 3
NCT06153004,2023.0,OTHER,collaborator,Centre for Addiction and Mental Health,Phase 3
NCT06153004,2023.0,OTHER,collaborator,Brigham and Women's Hospital,Phase 3
NCT06153004,2023.0,OTHER,collaborator,Vanderbilt University,Phase 3
NCT06153004,2023.0,UNKNOWN,collaborator,"All India Institute of Medical Sciences, Bhopal",Phase 3
NCT06153004,2023.0,OTHER,collaborator,Sangath,Phase 3
NCT06153186,2019.0,OTHER,lead,University of British Columbia,Phase 2
NCT06153966,2024.0,INDUSTRY,lead,"Ionis Pharmaceuticals, Inc.",Phase 1/Phase 2
NCT06154252,2023.0,INDUSTRY,lead,Cabaletta Bio,Phase 1/Phase 2
NCT06154707,2024.0,OTHER,lead,"Wuhan Union Hospital, China",Phase 3
NCT06155487,2023.0,INDUSTRY,lead,"JMackem Co., Ltd",Phase 1
NCT06155487,2023.0,OTHER,collaborator,Seoul National University Hospital,Phase 1
NCT06155916,2022.0,OTHER,lead,Helsinki University Central Hospital,Not Applicable
NCT06155916,2022.0,OTHER,collaborator,University of Helsinki,Not Applicable
NCT06156709,2023.0,OTHER,lead,Ataturk University,Not Applicable
NCT06157385,2023.0,OTHER,lead,Texas Tech University,Not Applicable
NCT06157385,2023.0,OTHER,collaborator,National Cattlemen's Beef Association,Not Applicable
NCT06158230,2023.0,OTHER,lead,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2
NCT06158737,2023.0,OTHER,lead,"Shanghai Junshi Bioscience Co., Ltd.",Phase 1
NCT06159387,2023.0,OTHER,lead,University of Sao Paulo General Hospital,Phase 4
NCT06159712,2023.0,OTHER,lead,University of Aarhus,Not Applicable
NCT06159712,2023.0,OTHER,collaborator,Aarhus University Hospital,Not Applicable
NCT06159712,2023.0,OTHER,collaborator,Gødstrup Hospital,Not Applicable
NCT06159712,2023.0,OTHER,collaborator,"Regionshospitalet Viborg, Skive",Not Applicable
NCT06159712,2023.0,OTHER,collaborator,Sorbonne University,Not Applicable
NCT06162013,2024.0,OTHER,lead,Haukeland University Hospital,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Oslo universitetssykehus HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Akershus Universitetssykehus HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Vestre Viken HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Sykehuset Østfold HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Nevro Arendal AS,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Helse Førde HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Helse Fonna HF,Phase 2
NCT06162013,2024.0,UNKNOWN,collaborator,Universitetssykehuset Nord Norge HF,Phase 2
NCT06162013,2024.0,OTHER_GOV,collaborator,Helse Møre og Romsdal HF,Phase 2
NCT06162013,2024.0,OTHER,collaborator,Nordlandssykehuset HF,Phase 2
NCT06162819,2024.0,OTHER,lead,Shalamar Institute of Health Sciences,Not Applicable
NCT06163469,2024.0,OTHER,lead,Yale University,Not Applicable
NCT06163469,2024.0,INDUSTRY,collaborator,Irrimax Corporation,Not Applicable
NCT06164314,2024.0,OTHER,lead,Beijing Tiantan Hospital,Not Applicable
NCT06167681,2024.0,INDUSTRY,lead,"iRegene Therapeutics Co., Ltd.",Phase 1/Phase 2
NCT06168188,2020.0,OTHER,lead,Buddhist Tzu Chi General Hospital,Early Phase 1
NCT06169046,2024.0,OTHER,lead,Gianni Soraru,Phase 2
NCT06169046,2024.0,OTHER,collaborator,Mario Negri Institute for Pharmacological Research,Phase 2
NCT06169111,2024.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Not Applicable
NCT06169826,2024.0,OTHER,lead,Wake Forest University Health Sciences,Phase 4
NCT06170970,2024.0,OTHER,lead,Johns Hopkins University,Phase 2
NCT06170970,2024.0,OTHER,collaborator,National Multiple Sclerosis Society,Phase 2
NCT06170970,2024.0,INDUSTRY,collaborator,"Axsome Therapeutics, Inc.",Phase 2
NCT06171152,2024.0,OTHER,lead,University of Chicago,Early Phase 1
NCT06171295,2021.0,OTHER,lead,"University Hospital, Motol",Not Applicable
NCT06172400,2024.0,OTHER,lead,Region Skane,Not Applicable
NCT06172920,2023.0,OTHER,lead,Baskent University,Phase 4
NCT06172998,2022.0,OTHER,lead,Xu J,Early Phase 1
NCT06173271,2022.0,OTHER,lead,China Medical University Hospital,Not Applicable
NCT06173661,2024.0,OTHER,lead,Brigham and Women's Hospital,Phase 4
NCT06173661,2024.0,INDUSTRY,collaborator,Teva Pharmaceuticals USA,Phase 4
NCT06174116,2024.0,OTHER,lead,Xiaoduo Fan,Phase 4
NCT06174116,2024.0,INDUSTRY,collaborator,"Intra-Cellular Therapies, Inc.",Phase 4
NCT06175767,2024.0,INDUSTRY,lead,"Mthera Pharma Co., Ltd.",Phase 2
NCT06176144,2023.0,OTHER,lead,West China Hospital,Not Applicable
NCT06176404,2021.0,OTHER,lead,Zeng Changhao,Not Applicable
NCT06176430,2024.0,OTHER,lead,Shaheed Zulfiqar Ali Bhutto Medical University,Phase 4
NCT06177028,2024.0,OTHER,lead,"St. Joseph's Hospital and Medical Center, Phoenix",Phase 2
NCT06177028,2024.0,OTHER,collaborator,Texas Tech University,Phase 2
NCT06177431,2024.0,INDUSTRY,lead,PharmAust Ltd,Phase 1
NCT06177431,2024.0,UNKNOWN,collaborator,Calvary Health Care Bethlehem,Phase 1
NCT06177431,2024.0,OTHER,collaborator,"Macquarie University, Australia",Phase 1
NCT06178627,2023.0,OTHER,lead,Huashan Hospital,Phase 4
NCT06178835,2017.0,OTHER,lead,Yonsei University,Phase 4
NCT06179108,2023.0,INDUSTRY,lead,LB Pharmaceuticals Inc.,Phase 2
NCT06179407,2024.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT06180070,2023.0,INDUSTRY,lead,Humanis Saglık Anonim Sirketi,Phase 1
NCT06180278,2024.0,INDUSTRY,lead,Horizon Therapeutics Ireland DAC,Phase 4
NCT06181513,2022.0,OTHER,lead,University of Nicosia,Early Phase 1
NCT06181513,2022.0,OTHER,collaborator,Cyprus Institute of Neurology and Genetics,Early Phase 1
NCT06181526,2023.0,OTHER,lead,Beijing Tiantan Hospital,Phase 1
NCT06182020,2023.0,OTHER,lead,National Taiwan University Hospital,Not Applicable
NCT06182098,2023.0,OTHER,lead,Dayton Children's Hospital,Not Applicable
NCT06183008,2024.0,OTHER_GOV,lead,Sorlandet Hospital HF,Phase 4
NCT06183008,2024.0,OTHER,collaborator,Oslo University Hospital,Phase 4
NCT06183008,2024.0,OTHER,collaborator,University Hospital of North Norway,Phase 4
NCT06183008,2024.0,OTHER,collaborator,University Hospital of Saint-Etienne,Phase 4
NCT06184828,2024.0,OTHER,lead,Oregon Health and Science University,Phase 3
NCT06185361,2022.0,OTHER,lead,Fayoum University Hospital,Not Applicable
NCT06185426,2021.0,OTHER,lead,Recep Tayyip Erdogan University,Early Phase 1
NCT06185543,2023.0,INDUSTRY,lead,NeuroSense Therapeutics Ltd.,Phase 2
NCT06185673,2023.0,INDUSTRY,lead,"Benitec Biopharma, Inc.",Phase 1/Phase 2
NCT06187090,2023.0,OTHER,lead,University of Udine,Not Applicable
NCT06188221,2020.0,OTHER,lead,University of Texas at Austin,Not Applicable
NCT06188325,2018.0,INDUSTRY,lead,Sanofi,Phase 1
NCT06188390,2023.0,OTHER,lead,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",Not Applicable
NCT06188663,2024.0,OTHER,lead,University of Galway,Phase 2
NCT06188663,2024.0,OTHER,collaborator,"Health Research Board, Ireland",Phase 2
NCT06188741,2024.0,OTHER,lead,University of Alabama at Birmingham,Phase 2
NCT06188741,2024.0,OTHER,collaborator,Children's Hospital of Philadelphia,Phase 2
NCT06188741,2024.0,FED,collaborator,Congressionally Directed Medical Research Programs,Phase 2
NCT06189027,2018.0,OTHER,lead,University of Southern California,Phase 3
NCT06189027,2018.0,OTHER,collaborator,Multidisciplinary Association for Psychedelic Studies,Phase 3
NCT06189651,2021.0,OTHER_GOV,lead,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,Not Applicable
NCT06189781,2023.0,OTHER,lead,"University of California, Los Angeles",Phase 4
NCT06189781,2023.0,OTHER,collaborator,Northwestern University,Phase 4
NCT06190470,2024.0,OTHER,lead,Khon Kaen University,Phase 1
NCT06190912,2024.0,OTHER,lead,Robert Fox,Phase 1
NCT06190912,2024.0,UNKNOWN,collaborator,"Synaptogenix, Inc.",Phase 1
NCT06191289,2024.0,OTHER,lead,University of Illinois at Chicago,Early Phase 1
NCT06192615,2024.0,OTHER,lead,Massachusetts General Hospital,Phase 3
NCT06193200,2024.0,INDUSTRY,lead,Erydel,Phase 3
NCT06193200,2024.0,INDUSTRY,collaborator,Biotrial,Phase 3
NCT06193304,2014.0,INDUSTRY,lead,Sanofi,Phase 1
NCT06193421,2023.0,INDUSTRY,lead,Agyany Pharma LTD,Phase 1/Phase 2
NCT06193720,2022.0,OTHER,lead,Saint-Joseph University,Not Applicable
NCT06193759,2024.0,OTHER,lead,Children's National Research Institute,Phase 1
NCT06193889,2024.0,INDUSTRY,lead,Kyverna Therapeutics,Phase 2
NCT06194552,2022.0,INDUSTRY,lead,"NeuroTherapia, Inc.",Phase 1
NCT06194552,2022.0,UNKNOWN,collaborator,CRU Early Phase Unit Kistarcsa,Phase 1
NCT06195241,2024.0,OTHER,lead,Montefiore Medical Center,Phase 4
NCT06196606,2022.0,OTHER,lead,The First Affiliated Hospital of Zhengzhou University,Not Applicable
NCT06198699,2024.0,OTHER,lead,National Cheng Kung University,Not Applicable
NCT06198699,2024.0,OTHER,collaborator,Buddhist Tzu Chi General Hospital,Not Applicable
NCT06198699,2024.0,OTHER,collaborator,Tzu Chi University,Not Applicable
NCT06198699,2024.0,OTHER,collaborator,E-DA Hospital,Not Applicable
NCT06199011,2024.0,OTHER,lead,The Second Hospital of Anhui Medical University,Not Applicable
NCT06199037,2024.0,INDUSTRY,lead,"Shanghai Hengrui Pharmaceutical Co., Ltd.",Phase 2
NCT06199193,2024.0,OTHER,lead,Universidad Complutense de Madrid,Not Applicable
NCT06199193,2024.0,UNKNOWN,collaborator,Hospital Clínico Universitario Virgen de la Arrixaca,Not Applicable
NCT06199193,2024.0,OTHER,collaborator,Universidad Europea de Madrid,Not Applicable
NCT06199700,2023.0,OTHER,lead,Children's Hospital of Fudan University,Early Phase 1
NCT06199778,2022.0,OTHER,lead,Zeng Changhao,Not Applicable
NCT06201897,2024.0,OTHER,lead,"All India Institute of Medical Sciences, New Delhi",Phase 2/Phase 3
NCT06202664,2024.0,OTHER_GOV,lead,Muhammad Haroon Anwar,Phase 4
NCT06202664,2024.0,OTHER_GOV,collaborator,Pakistan Institute of Medical Sciences,Phase 4
NCT06204432,2023.0,OTHER,lead,"University of North Carolina, Chapel Hill",Phase 2
NCT06204809,2023.0,INDUSTRY,lead,PepGen Inc,Phase 1
NCT06205875,2024.0,OTHER,lead,Jessa Hospital,Not Applicable
NCT06206824,2024.0,INDUSTRY,lead,Perha Pharmaceuticals,Phase 1
NCT06206824,2024.0,UNKNOWN,collaborator,France 2030 program,Phase 1
NCT06206824,2024.0,UNKNOWN,collaborator,European Innovation Council,Phase 1
NCT06206824,2024.0,OTHER,collaborator,Fondation Jérôme Lejeune,Phase 1
NCT06207552,2024.0,OTHER,lead,Children's Hospital of Fudan University,Early Phase 1
NCT06207760,2023.0,OTHER,lead,IRCCS Centro San Giovanni di Dio Fatebenefratelli,Phase 2
NCT06207760,2023.0,OTHER,collaborator,Ospedale San Raffaele,Phase 2
NCT06208813,2024.0,OTHER,lead,San Diego State University,Not Applicable
NCT06209957,2017.0,OTHER,lead,Menoufia University,Phase 4
NCT06211478,2023.0,OTHER,lead,Ain Shams University,Phase 3
NCT06212089,2023.0,INDUSTRY,lead,"SNLD, Ltd.",Phase 2
NCT06212245,2024.0,INDUSTRY,lead,Hansoh BioMedical R&D Company,Phase 4
NCT06212245,2024.0,INDUSTRY,collaborator,Horizon Therapeutics Ireland DAC,Phase 4
NCT06213077,2023.0,INDUSTRY,lead,RHA Investments Ltd,Not Applicable
NCT06213116,2021.0,OTHER,lead,Universiti Sains Malaysia,Not Applicable
NCT06213298,2024.0,OTHER,lead,"Masonic Cancer Center, University of Minnesota",Early Phase 1
NCT06213415,2024.0,OTHER,lead,Assiut University,Not Applicable
NCT06213454,2024.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT06213766,2024.0,OTHER,lead,Hospices Civils de Lyon,Not Applicable
NCT06214117,2024.0,OTHER,lead,Second Affiliated Hospital of Wenzhou Medical University,Phase 4
NCT06214377,2023.0,OTHER,lead,Universidad Francisco de Vitoria,Not Applicable
NCT06214377,2023.0,OTHER,collaborator,Universidad Rey Juan Carlos,Not Applicable
NCT06214377,2023.0,OTHER,collaborator,Hospital Beata María Ana,Not Applicable
NCT06214637,2023.0,OTHER,lead,Universidade Federal do Rio de Janeiro,Phase 1
NCT06215261,2024.0,INDUSTRY,lead,Transcend Therapeutics,Phase 2
NCT06215755,2024.0,INDUSTRY,lead,Verge Genomics,Phase 1
NCT06215768,2024.0,OTHER,lead,Esraa Abdel Azez Soltan Mohamed Zayed,Early Phase 1
NCT06216054,2023.0,INDUSTRY,lead,Luye Pharma Group Ltd.,Phase 1
NCT06216886,2024.0,OTHER,lead,Stanford University,Phase 4
NCT06217146,2022.0,INDUSTRY,lead,M. H MediCane Ltd.,Not Applicable
NCT06217211,2023.0,OTHER,lead,Hospital de Mataró,Not Applicable
NCT06218056,2024.0,OTHER,lead,"University of California, Los Angeles",Phase 2
NCT06218680,2024.0,OTHER,lead,Khon Kaen University,Not Applicable
NCT06218784,2022.0,INDUSTRY,lead,"iN Therapeutics Co., Ltd.",Phase 1
NCT06218966,2024.0,OTHER,lead,Sunnybrook Health Sciences Centre,Not Applicable
NCT06218979,2023.0,OTHER,lead,Helsinki University Central Hospital,Phase 1
NCT06218979,2023.0,OTHER,collaborator,University of Helsinki,Phase 1
NCT06219590,2023.0,OTHER,lead,South Valley University,Not Applicable
NCT06219928,2024.0,OTHER,lead,Ataturk University,Not Applicable
NCT06220201,2024.0,INDUSTRY,lead,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",Phase 1
NCT06220201,2024.0,INDUSTRY,collaborator,Celgene Corporation,Phase 1
NCT06220669,2024.0,INDUSTRY,lead,Eli Lilly and Company,Phase 2
NCT06221501,2024.0,OTHER,lead,Shanghai Zhongshan Hospital,Phase 2
NCT06222255,2023.0,OTHER,lead,Seoul National University Hospital,Not Applicable
NCT06222255,2023.0,OTHER,collaborator,Seoul National University Bundang Hospital,Not Applicable
NCT06222255,2023.0,OTHER,collaborator,SMG-SNU Boramae Medical Center,Not Applicable
NCT06222255,2023.0,OTHER_GOV,collaborator,"National Cancer Center, Korea",Not Applicable
NCT06222268,2024.0,OTHER,lead,Wayne State University,Phase 1
NCT06223360,2024.0,OTHER,lead,Alzheimer's Disease Cooperative Study (ADCS),Phase 2
NCT06223360,2024.0,OTHER,collaborator,Burke Medical Research Institute,Phase 2
NCT06223360,2024.0,NIH,collaborator,National Institute on Aging (NIA),Phase 2
NCT06224127,2024.0,INDUSTRY,lead,Soovu Labs Inc.,Phase 1
NCT06224530,2024.0,OTHER,lead,King's College London,Not Applicable
NCT06225024,2022.0,OTHER_GOV,lead,Kayseri City Hospital,Not Applicable
NCT06225024,2022.0,OTHER,collaborator,Saglik Bilimleri Universitesi,Not Applicable
NCT06225037,2023.0,OTHER_GOV,lead,KK Women's and Children's Hospital,Not Applicable
NCT06225115,2023.0,INDUSTRY,lead,Kynexis B.V.,Phase 1
NCT06225115,2023.0,INDUSTRY,collaborator,Parexel,Phase 1
NCT06225895,2024.0,OTHER_GOV,lead,Zagazig University,Not Applicable
NCT06226025,2024.0,OTHER,lead,Leslie Swanson,Phase 2
NCT06226025,2024.0,OTHER,collaborator,University of Michigan,Phase 2
NCT06226025,2024.0,UNKNOWN,collaborator,Natrol,Phase 2
NCT06226025,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT06226064,2023.0,INDUSTRY,lead,Vesper Biotechnologies ApS,Phase 1
NCT06226415,2024.0,OTHER,lead,Zeng Changhao,Not Applicable
NCT06226714,2024.0,INDUSTRY,lead,CanSino Biologics Inc.,Phase 3
NCT06227676,2022.0,OTHER,lead,Cornell University,Phase 2/Phase 3
NCT06227676,2022.0,UNKNOWN,collaborator,Laidlaw Foundation,Phase 2/Phase 3
NCT06227676,2022.0,UNKNOWN,collaborator,Epperson Fund,Phase 2/Phase 3
NCT06227676,2022.0,UNKNOWN,collaborator,Beck Fellowship,Phase 2/Phase 3
NCT06227676,2022.0,UNKNOWN,collaborator,Dan Cane Fund,Phase 2/Phase 3
NCT06228391,2024.0,FED,lead,Minneapolis Veterans Affairs Medical Center,Phase 2
NCT06228742,2024.0,FED,lead,United States Army Research Institute of Environmental Medicine,Not Applicable
NCT06229210,2024.0,INDUSTRY,lead,"Intra-Cellular Therapies, Inc.",Phase 3
NCT06229483,2024.0,OTHER,lead,Stephen Lownie,Phase 3
NCT06229483,2024.0,OTHER,collaborator,Dalhousie University,Phase 3
NCT06229977,2023.0,OTHER,lead,"The University of Texas Health Science Center, Houston",Phase 2
NCT06229977,2023.0,OTHER,collaborator,Baszucki Brain Research Fund,Phase 2
NCT06230302,2023.0,OTHER,lead,Hanyang University,Not Applicable
NCT06230302,2023.0,OTHER,collaborator,Hanyang University Seoul Hospital,Not Applicable
NCT06230562,2024.0,OTHER,lead,"University Hospital, Tours",Not Applicable
NCT06230757,2024.0,OTHER,lead,"University of Colorado, Denver",Phase 2
NCT06231069,2030.0,OTHER,lead,McMaster University,Not Applicable
NCT06231355,2024.0,OTHER,lead,Peking University First Hospital,Phase 4
NCT06233825,2024.0,OTHER,lead,"Dr. Chris McGlory, PhD",Not Applicable
NCT06234436,2023.0,OTHER,lead,Oslo University Hospital,Early Phase 1
NCT06234436,2023.0,UNKNOWN,collaborator,Impetus Grants (EIN: 87-1540960),Early Phase 1
NCT06234436,2023.0,UNKNOWN,collaborator,Nasjonalforeningen for folkehelsen,Early Phase 1
NCT06234436,2023.0,OTHER,collaborator,Vestre Viken Hospital Trust,Early Phase 1
NCT06234995,2021.0,OTHER,lead,Emory University,Phase 4
NCT06234995,2021.0,NIH,collaborator,National Institute of Neurological Disorders and Stroke (NINDS),Phase 4
NCT06235177,2024.0,OTHER,lead,The Essence of Integrative Health and Medicine Practice,Early Phase 1
NCT06235411,2024.0,OTHER,lead,Centre Hospitalier Universitaire de Nīmes,Not Applicable
NCT06235476,2024.0,OTHER,lead,Radboud University Medical Center,Not Applicable
NCT06235476,2024.0,UNKNOWN,collaborator,Cosun,Not Applicable
NCT06235775,2023.0,INDUSTRY,lead,GemVax & Kael,Phase 2
NCT06236191,2023.0,OTHER_GOV,lead,KK Women's and Children's Hospital,Not Applicable
NCT06236230,2023.0,OTHER,lead,Second Affiliated Hospital of Soochow University,Phase 4
NCT06236451,2024.0,OTHER,lead,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4
NCT06236815,2024.0,OTHER,lead,"University of Wisconsin, Madison",Early Phase 1
NCT06237426,2024.0,INDUSTRY,lead,Transcend Therapeutics,Phase 2
NCT06237595,2023.0,OTHER,lead,Kasr El Aini Hospital,Not Applicable
NCT06237634,2021.0,OTHER_GOV,lead,Kayseri City Hospital,Not Applicable
NCT06238700,2024.0,OTHER,lead,Brigham and Women's Hospital,Not Applicable
NCT06241313,2024.0,INDUSTRY,lead,AbbVie,Phase 3
NCT06241677,2024.0,OTHER,lead,Chinese University of Hong Kong,Not Applicable
NCT06241677,2024.0,OTHER,collaborator,Pamela Youde Nethersole Eastern Hospital,Not Applicable
NCT06241677,2024.0,OTHER,collaborator,"Queen Mary Hospital, Hong Kong",Not Applicable
NCT06241677,2024.0,OTHER,collaborator,"Princess Margaret Hospital, Canada",Not Applicable
NCT06241677,2024.0,OTHER_GOV,collaborator,Tuen Mun Hospital,Not Applicable
NCT06241677,2024.0,OTHER,collaborator,The Queen Elizabeth Hospital,Not Applicable
NCT06241677,2024.0,OTHER,collaborator,United Christian Hospital,Not Applicable
NCT06241950,2024.0,INDUSTRY,lead,"Sarepta Therapeutics, Inc.",Phase 1
NCT06241950,2024.0,INDUSTRY,collaborator,Hansa Biopharma AB,Phase 1
NCT06242535,2023.0,INDUSTRY,lead,Hoskinson Health and Wellness Clinic,Early Phase 1
NCT06242535,2023.0,OTHER,collaborator,Buck Institute for Research on Aging,Early Phase 1
NCT06242535,2023.0,OTHER,collaborator,University of Wyoming,Early Phase 1
NCT06243133,2024.0,OTHER,lead,Sichuan Provincial People's Hospital,Phase 4
NCT06243263,2024.0,OTHER,lead,University Tunis El Manar,Phase 4
NCT06243692,2024.0,OTHER,lead,Kafrelsheikh University,Phase 3
NCT06243874,2023.0,OTHER,lead,Ankara University,Not Applicable
NCT06244082,2024.0,INDUSTRY,lead,"Avidity Biosciences, Inc.",Phase 2
NCT06244277,2023.0,OTHER,lead,The First Affiliated Hospital with Nanjing Medical University,Not Applicable
NCT06244706,2024.0,OTHER,lead,Université Catholique de Louvain,Not Applicable
NCT06244706,2024.0,OTHER,collaborator,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Not Applicable
NCT06244823,2023.0,OTHER,lead,Hospital Clínico Universitario de Valladolid,Phase 4
NCT06244823,2023.0,OTHER,collaborator,University of Valladolid,Phase 4
NCT06244823,2023.0,UNKNOWN,collaborator,Complejo Asistencial Universitario de Palencia,Phase 4
NCT06244823,2023.0,UNKNOWN,collaborator,Complejo Público Asistencial de Zamora,Phase 4
NCT06245213,2024.0,INDUSTRY,lead,Anavex Life Sciences Corp.,Phase 2
NCT06245213,2024.0,UNKNOWN,collaborator,COGNISION,Phase 2
NCT06245213,2024.0,INDUSTRY,collaborator,Cognitive Research Corporation,Phase 2
NCT06245213,2024.0,UNKNOWN,collaborator,Hassman Research Institute,Phase 2
NCT06245616,2024.0,OTHER_GOV,lead,Spanish National Research Council,Not Applicable
NCT06245642,2024.0,INDUSTRY,lead,"Heilongjiang Quanle Pharmaceutical Co., Ltd.",Phase 4
NCT06247085,2023.0,INDUSTRY,lead,"Travere Therapeutics, Inc.",Phase 3
NCT06247345,2024.0,INDUSTRY,lead,"Alzheimer's Disease Expert Lab (ADEL), Inc.",Phase 1
NCT06247345,2024.0,INDUSTRY,collaborator,Oscotec Inc.,Phase 1
NCT06247930,2024.0,OTHER,lead,Anhui Medical University,Not Applicable
NCT06248710,2024.0,OTHER,lead,Dr. Karin Hediger,Phase 2/Phase 3
NCT06248931,2024.0,OTHER,lead,Kafrelsheikh University,Phase 3
NCT06249438,2024.0,OTHER,lead,RenJi Hospital,Phase 1
NCT06249438,2024.0,UNKNOWN,collaborator,AbelZeta Pharma Inc.,Phase 1
NCT06249490,2024.0,OTHER,lead,People's Hospital of Zhengzhou University,Not Applicable
NCT06249503,2023.0,OTHER,lead,Ain Shams University,Phase 4
NCT06249802,2025.0,OTHER,lead,Jagiellonian University,Phase 4
NCT06249802,2025.0,OTHER,collaborator,University Hospital in Krakow,Phase 4
NCT06249867,2024.0,OTHER,lead,McGill University,Phase 2
NCT06249867,2024.0,OTHER,collaborator,Université de Montréal,Phase 2
NCT06250426,2023.0,OTHER,lead,Hospital de Mataró,Not Applicable
NCT06250426,2023.0,INDUSTRY,collaborator,Nutricia Research,Not Applicable
NCT06252571,2024.0,OTHER,lead,"University Hospital, Strasbourg, France",Phase 2
NCT06253546,2024.0,INDUSTRY,lead,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 1
NCT06253702,2023.0,OTHER,lead,"University of Wisconsin, Madison",Phase 4
NCT06253702,2023.0,NIH,collaborator,"National Heart, Lung, and Blood Institute (NHLBI)",Phase 4
NCT06253923,2024.0,INDUSTRY,lead,"SHINKEI Therapeutics, Inc",Phase 2
NCT06253923,2024.0,OTHER,collaborator,Duke Clinical Research Institute,Phase 2
NCT06254001,2024.0,OTHER_GOV,lead,"National Institute of Respiratory Diseases, Mexico",Phase 4
NCT06254469,2024.0,INDUSTRY,lead,"CereMark Pharma, LLC",Phase 3
NCT06254482,2023.0,INDUSTRY,lead,PTC Therapeutics,Phase 2
NCT06254534,2024.0,OTHER,lead,Haseki Training and Research Hospital,Not Applicable
NCT06255210,2024.0,OTHER,lead,Hongmeng Yu,Phase 2
NCT06255782,2024.0,INDUSTRY,lead,"iECURE, Inc.",Phase 1/Phase 2
NCT06255977,2022.0,OTHER,lead,Beijing Tiantan Hospital,Phase 2
NCT06255977,2022.0,UNKNOWN,collaborator,SDM Bio Service Inc.,Phase 2
NCT06258031,2022.0,OTHER,lead,Imperial College London,Phase 1
NCT06259526,2023.0,INDUSTRY,lead,"Tasly Pharmaceutical Group Co., Ltd",Phase 2
NCT06259630,2015.0,OTHER,lead,University of Chicago,Phase 4
NCT06261450,2024.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT06261450,2024.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT06261450,2024.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT06261450,2024.0,OTHER,collaborator,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Phase 2
NCT06261489,2024.0,OTHER,lead,University of Calgary,Phase 2
NCT06261489,2024.0,OTHER,collaborator,Multiple Sclerosis Society of Canada,Phase 2
NCT06261502,2024.0,OTHER,lead,Université de Sherbrooke,Phase 2
NCT06261502,2024.0,OTHER_GOV,collaborator,Canadian Institutes of Health Research (CIHR),Phase 2
NCT06261502,2024.0,INDUSTRY,collaborator,Jazz Pharmaceuticals,Phase 2
NCT06261502,2024.0,OTHER,collaborator,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Phase 2
NCT06262061,2024.0,OTHER,lead,London Health Sciences Centre,Early Phase 1
NCT06262594,2024.0,OTHER,lead,University of Manitoba,Phase 3
NCT06262594,2024.0,OTHER,collaborator,Duke University,Phase 3
NCT06263010,2024.0,OTHER,lead,Roberta Brinton,Phase 1
NCT06263660,2024.0,OTHER,lead,"Laureate Institute for Brain Research, Inc.",Phase 2
NCT06263673,2024.0,OTHER,lead,Mayo Clinic,Phase 4
NCT06264414,2025.0,INDUSTRY,lead,EMS,Phase 3
NCT06264427,2022.0,OTHER,lead,Steno Diabetes Center Greenland,Not Applicable
NCT06264427,2022.0,OTHER,collaborator,Zealand University Hospital,Not Applicable
NCT06264427,2022.0,OTHER,collaborator,University of Copenhagen,Not Applicable
NCT06264635,2024.0,OTHER,lead,University of Manitoba,Phase 1
NCT06266611,2024.0,OTHER,lead,"University of Colorado, Boulder",Phase 2
NCT06266715,2024.0,OTHER,lead,"Nanfang Hospital, Southern Medical University",Not Applicable
NCT06266767,2024.0,INDUSTRY,lead,Hamad Medical Corporation,Phase 4
NCT06267443,2024.0,OTHER,lead,TC Erciyes University,Not Applicable
NCT06268093,2024.0,OTHER,lead,"Xuanwu Hospital, Beijing",Phase 2
NCT06268886,2024.0,INDUSTRY,lead,Bristol-Myers Squibb,Phase 2
NCT06269146,2024.0,OTHER,lead,"University of California, San Diego",Phase 2
NCT06269146,2024.0,NIH,collaborator,National Institute of Mental Health (NIMH),Phase 2
NCT06269146,2024.0,OTHER,collaborator,New York State Psychiatric Institute,Phase 2
NCT06269614,2023.0,OTHER,lead,Nova Southeastern University,Not Applicable
NCT06270316,2024.0,INDUSTRY,lead,UniQure Biopharma B.V.,Phase 1/Phase 2
NCT06270433,2024.0,OTHER,lead,Jiangsu Province Nanjing Brain Hospital,Not Applicable
NCT06270680,2024.0,OTHER,lead,Penn State University,Early Phase 1
NCT06270680,2024.0,INDUSTRY,collaborator,MacuHealth,Early Phase 1
NCT06270680,2024.0,OTHER,collaborator,Orlando Regional Medical Center,Early Phase 1
NCT06271096,2019.0,OTHER,lead,Arooj Khan,Early Phase 1
NCT06271486,2024.0,OTHER,lead,Al-Azhar University,Phase 3
NCT06271486,2024.0,OTHER,collaborator,Benha University,Phase 3
NCT06272227,2024.0,OTHER,lead,Yonsei University,Phase 4
NCT06272682,2023.0,OTHER,lead,Hospital Italiano de Buenos Aires,Not Applicable
NCT06274021,2024.0,OTHER,lead,University of Mississippi Medical Center,Early Phase 1
NCT06274021,2024.0,OTHER,collaborator,Methodist Rehabilitation Center,Early Phase 1
NCT06274021,2024.0,OTHER,collaborator,The Craig H. Neilsen Foundation,Early Phase 1
NCT06274528,2024.0,OTHER,lead,Washington University School of Medicine,Phase 2
NCT06275633,2019.0,OTHER,lead,University Hospital Bispebjerg and Frederiksberg,Not Applicable
NCT06275698,2023.0,OTHER_GOV,lead,East and North Hertfordshire NHS Trust,Not Applicable
NCT06275698,2023.0,UNKNOWN,collaborator,Manuka Doctor UK Ltd,Not Applicable
NCT06275698,2023.0,OTHER_GOV,collaborator,"National Institute for Health Research, United Kingdom",Not Applicable
NCT06276361,2023.0,INDUSTRY,lead,Rovi Pharmaceuticals Laboratories,Phase 1
NCT06276374,2024.0,OTHER,lead,Woo-Keun Seo,Not Applicable
NCT06276504,2024.0,OTHER,lead,Assistance Publique - Hôpitaux de Paris,Phase 2/Phase 3
NCT06279312,2024.0,INDUSTRY,lead,"TCI Co., Ltd.",Not Applicable
NCT06279429,2022.0,OTHER,lead,Kuang Tien General Hospital,Not Applicable
NCT06279858,2024.0,OTHER,lead,Specila hospital for cerebral palsy and developmental neurology,Not Applicable
NCT06279858,2024.0,OTHER,collaborator,FRAXA Research Foundation,Not Applicable
NCT06280079,2024.0,OTHER,lead,University of Ulm,Not Applicable
NCT06280092,2024.0,OTHER,lead,Sanjeet S. Grewal,Early Phase 1
NCT06280209,2024.0,INDUSTRY,lead,BioMarin Pharmaceutical,Phase 1/Phase 2
NCT06280794,2018.0,OTHER,lead,Beijing Tongren Hospital,Not Applicable
NCT06281925,2024.0,OTHER,lead,NYU Langone Health,Not Applicable
NCT06281951,2024.0,OTHER,lead,"University Hospital, Rouen",Phase 1
NCT06282640,2021.0,OTHER_GOV,lead,Dr. Ayşe Güç,Phase 4
NCT06282640,2021.0,OTHER_GOV,collaborator,Kayseri City Hospital,Phase 4
NCT06282965,2024.0,OTHER,lead,University of Arizona,Phase 1/Phase 2
NCT06282965,2024.0,FED,collaborator,United States Department of Defense,Phase 1/Phase 2
NCT06284954,2024.0,INDUSTRY,lead,argenx,Phase 2
NCT06285006,2024.0,OTHER,lead,Al-Azhar University,Not Applicable
NCT06285240,2024.0,INDUSTRY,lead,Merck Sharp & Dohme LLC,Phase 1
NCT06285643,2024.0,INDUSTRY,lead,"Asklepios Biopharmaceutical, Inc.",Phase 2
NCT06285643,2024.0,INDUSTRY,collaborator,Bayer,Phase 2
NCT06286189,2024.0,OTHER,lead,Brigham and Women's Hospital,Phase 1/Phase 2
NCT06287502,2022.0,OTHER,lead,"Kowloon Hospital, Hong Kong",Not Applicable
NCT06288230,2024.0,INDUSTRY,lead,Lantu Biopharma,Phase 1/Phase 2
NCT06289192,2024.0,OTHER,lead,Johns Hopkins University,Phase 4
NCT06289192,2024.0,OTHER_GOV,collaborator,Maryland Cigarette Restitution Fund,Phase 4
NCT06289335,2020.0,OTHER,lead,"Hospital Central ""Dr. Ignacio Morones Prieto""",Phase 2
NCT06289439,2024.0,OTHER,lead,University of Valladolid,Not Applicable
NCT06289439,2024.0,OTHER,collaborator,Sanidad de Castilla y León,Not Applicable
NCT06289439,2024.0,OTHER,collaborator,Instituto de Neurociencia de Castillas y Leon,Not Applicable
NCT06289582,2024.0,OTHER,lead,University of Alabama at Birmingham,Early Phase 1
NCT06289582,2024.0,OTHER,collaborator,Michael J. Fox Foundation for Parkinson's Research,Early Phase 1
NCT06290063,2024.0,OTHER,lead,"University of Colorado, Boulder",Phase 2
NCT06290128,2024.0,INDUSTRY,lead,Sanofi,Phase 3
NCT06290713,2024.0,OTHER,lead,University of Florida,Phase 2
NCT06290713,2024.0,NIH,collaborator,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 2
NCT06291467,2024.0,OTHER,lead,"University Hospital, Montpellier",Not Applicable
NCT06291467,2024.0,UNKNOWN,collaborator,Institut de Génomique Fonctionnelle (IGF) de Montpellier,Not Applicable
NCT06292351,2023.0,INDUSTRY,lead,Bigespas LTD,Phase 2/Phase 3
NCT06292585,2024.0,OTHER,lead,Changhai Hospital,Not Applicable
NCT06293300,2024.0,OTHER,lead,University of Miami,Phase 2
NCT06293300,2024.0,FED,collaborator,United States Department of Defense,Phase 2
NCT06293586,2023.0,OTHER,lead,Cairo University,Not Applicable
NCT06293911,2024.0,OTHER,lead,University of Pavia,Not Applicable
NCT06294236,2024.0,INDUSTRY,lead,Sana Biotechnology,Phase 1
NCT06294821,2024.0,OTHER,lead,John Elfar,Phase 2/Phase 3
NCT06296082,2024.0,OTHER,lead,Universiteit Antwerpen,Phase 2
NCT06296082,2024.0,OTHER,collaborator,McGill University,Phase 2
NCT06296082,2024.0,OTHER,collaborator,Aragon Institute of Health Sciences,Phase 2
NCT06296875,2024.0,OTHER,lead,University of Glasgow,Not Applicable
